-DOCSTART- -23849147- O O

Bayesian JJ i
adaptive JJ i
trials NNS N
offer VBP N
advantages NNS N
in IN N
comparative JJ N
effectiveness NN N
trials NNS N
: : N
an DT N
example NN N
in IN N
status NN p
epilepticus NN p
. . N

OBJECTIVE IN N
We PRP N
present VBP N
a DT N
novel JJ N
Bayesian JJ i
adaptive JJ i
comparative NN N
effectiveness NN N
trial NN N
comparing VBG N
three CD N
treatments NNS N
for IN N
status NN N
epilepticus NN N
that WDT N
uses VBZ N
adaptive JJ N
randomization NN N
with IN N
potential JJ N
early JJ N
stopping NN N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
The DT N
trial NN N
will MD N
enroll VB N
720 CD p
unique JJ p
patients NNS p
in IN p
emergency NN p
departments NNS p
and CC p
uses VBZ p
a DT p
Bayesian JJ i
adaptive JJ i
design NN i
. . N

RESULTS VB N
The DT N
trial NN N
design NN N
is VBZ N
compared VBN N
to TO N
a DT N
trial NN N
without IN N
adaptive JJ N
randomization NN N
and CC N
produces VBZ N
an DT N
efficient JJ N
trial NN N
in IN N
which WDT N
a DT N
higher JJR N
proportion NN N
of IN N
patients NNS N
are VBP N
likely JJ N
to TO N
be VB N
randomized VBN N
to TO N
the DT N
most RBS N
effective JJ N
treatment NN N
arm NN N
while IN N
generally RB N
using VBG N
fewer JJR N
total JJ N
patients NNS N
and CC N
offers VBZ N
higher JJR N
power NN N
than IN N
an DT N
analogous JJ N
trial NN N
with IN N
fixed JJ N
randomization NN N
when WRB N
identifying VBG N
a DT N
superior JJ N
treatment NN N
. . N

CONCLUSION NN N
When WRB N
one CD N
treatment NN N
is VBZ N
superior JJ N
to TO N
the DT N
other JJ N
two CD N
, , N
the DT N
trial NN N
design NN N
provides VBZ N
better RBR N
patient NN o
care NN o
, , N
higher JJR N
power NN o
, , N
and CC N
a DT N
lower JJR N
expected VBN o
sample JJ o
size NN o
. . N

-DOCSTART- -20739054- O O

Eltrombopag NNP i
for IN N
management NN N
of IN N
chronic JJ p
immune NN p
thrombocytopenia NN p
( ( N
RAISE NNP N
) ) N
: : N
a DT N
6-month JJ N
, , N
randomised VBN N
, , N
phase VB N
3 CD N
study NN N
. . N

BACKGROUND NNP N
Eltrombopag NNP i
is VBZ N
an DT N
oral JJ N
thrombopoietin NN N
receptor NN N
agonist NN N
for IN N
the DT N
treatment NN N
of IN N
thrombocytopenia NN N
. . N

We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
response NN o
to TO N
once RB N
daily JJ N
eltrombopag NNS i
versus VBP N
placebo NN i
in IN N
patients NNS p
with IN p
chronic JJ p
immune JJ p
thrombocytopenia NN p
during IN N
a DT N
6-month JJ N
period NN N
. . N

METHODS NNP N
We PRP N
undertook VBD N
a DT N
phase NN N
3 CD N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
in IN N
adults NNS p
with IN p
previously RB p
treated VBN p
immune JJ p
thrombocytopenia NN p
of IN p
more JJR p
than IN p
6 CD p
months NNS p
' POS p
duration NN p
who WP p
had VBD p
baseline NN p
platelet NN p
counts VBZ p
lower JJR p
than IN p
30,000 CD p
per IN p
?L NN p
. . N

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
( ( N
in IN N
a DT N
2:1 CD N
ratio NN N
) ) N
treatment NN N
with IN N
local JJ N
standard NN N
of IN N
care NN N
plus CC N
50 CD N
mg NN N
eltrombopag NN i
or CC N
matching VBG N
placebo JJ i
once RB N
daily JJ N
for IN N
6 CD N
months NNS N
. . N

Randomisation NN N
was VBD N
done VBN N
centrally RB N
with IN N
a DT N
computer-generated JJ N
randomisation NN N
schedule NN N
and CC N
was VBD N
stratified VBN N
by IN N
baseline JJ N
platelet NN N
count NN N
( ( N
? . N
15,000 CD N
per IN N
?L NN N
) ) N
, , N
use NN N
of IN N
treatment NN N
for IN N
immune JJ N
thrombocytopenia NN N
, , N
and CC N
splenectomy JJ N
status NN N
. . N

Patients NNS N
, , N
investigators NNS N
, , N
and CC N
those DT N
assessing VBG N
data NNS N
were VBD N
masked VBN N
to TO N
allocation NN N
. . N

Dose JJ N
modifications NNS N
were VBD N
made VBN N
on IN N
the DT N
basis NN N
of IN N
platelet NN N
response NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
for IN N
response NN o
to TO o
treatment NN o
( ( o
defined VBN o
as IN o
a DT o
platelet NN o
count NN o
of IN o
50,000-400,000 CD N
per IN N
?L NN N
) ) N
weekly NN N
during IN N
the DT N
first JJ N
6 CD N
weeks NNS N
and CC N
at IN N
least JJS N
once RB N
every DT N
4 CD N
weeks NNS N
thereafter RB N
; : N
the DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
odds NNS o
of IN o
response NN o
to TO N
eltrombopag VB i
versus NN N
placebo NN i
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00370331 NNP N
. . N

FINDINGS NNP N
Between NNP p
Nov NNP p
22 CD p
, , p
2006 CD p
, , p
and CC p
July NNP p
31 CD p
, , p
2007 CD p
, , p
197 CD p
patients NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
groups NNS N
and CC N
were VBD N
included VBN N
in IN N
the DT N
intention-to-treat JJ N
analysis NN N
( ( N
135 CD N
eltrombopag NN i
, , N
62 CD N
placebo NN i
) ) N
. . N

106 CD N
( ( N
79 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
eltrombopag NN i
group NN N
responded VBD o
to TO N
treatment NN N
at IN N
least JJS N
once RB N
during IN N
the DT N
study NN N
, , N
compared VBN N
with IN N
17 CD N
( ( N
28 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
odds NNS N
of IN o
responding VBG o
were VBD N
greater JJR N
in IN N
patients NNS N
in IN N
the DT N
eltrombopag NN i
group NN N
compared VBN N
with IN N
those DT N
in IN N
the DT N
placebo NN i
group NN N
throughout IN N
the DT N
6-month JJ N
treatment NN N
period NN N
( ( N
odds NNS N
ratio VBP N
8?2 CD N
, , N
99 CD N
% NN N
CI NNP N
3?59-18?73 CD N
; : N
p CC N
< VB N
0?0001 CD N
) ) N
. . N

37 CD N
( ( N
59 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
eltrombopag NN i
reduced VBD N
concomitant JJ o
treatment NN o
versus NN N
ten NN N
( ( N
32 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
placebo NN i
( ( N
p=0?016 NN N
) ) N
. . N

24 CD N
( ( N
18 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
eltrombopag NN i
needed VBN N
rescue NN o
treatment NN o
compared VBN N
with IN N
25 CD N
( ( N
40 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
placebo NN i
( ( N
p=0?001 NN N
) ) N
. . N

Three NNP N
( ( N
2 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
eltrombopag NN i
had VBD N
thromboembolic JJ o
events NNS o
compared VBN N
with IN N
none NN N
in IN N
patients NNS N
on IN N
placebo NN i
. . N

Nine NNP N
( ( N
7 CD N
% NN N
) ) N
eltrombopag-treated JJ N
patients NNS N
and CC N
two CD N
( ( N
3 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN i
group NN N
had VBD N
mild VBN N
increases NNS N
in IN N
alanine JJ o
aminotransferase NN o
concentration NN o
, , N
and CC N
five CD N
( ( N
4 CD N
% NN N
) ) N
eltrombopag-treated JJ i
patients NNS N
( ( N
vs IN N
none NN N
allocated VBN N
to TO N
placebo VB i
) ) N
had VBD N
increases NNS N
in IN N
total JJ o
bilirubin NN o
. . N

Four CD N
( ( N
7 CD N
% NN N
) ) N
patients NNS N
taking VBG N
placebo NN i
had VBD N
serious JJ o
bleeding VBG o
events NNS o
, , N
compared VBN N
with IN N
one CD N
( ( N
< VB N
1 CD N
% NN N
) ) N
patient NN N
treated VBN N
with IN N
eltrombopag NN i
. . N

INTERPRETATION NNP N
Eltrombopag NNP i
is VBZ N
effective JJ N
for IN N
management NN N
of IN N
chronic JJ N
immune NN N
thrombocytopenia NN N
, , N
and CC N
could MD N
be VB N
particularly RB N
beneficial JJ N
for IN N
patients NNS N
who WP N
have VBP N
not RB N
responded VBN N
to TO N
splenectomy VB N
or CC N
previous JJ N
treatment NN N
. . N

These DT N
benefits NNS N
should MD N
be VB N
balanced VBN N
with IN N
the DT N
potential JJ N
risks NNS N
associated VBN N
with IN N
eltrombopag JJ i
treatment NN N
. . N

FUNDING NN N
GlaxoSmithKline NNP N
. . N

-DOCSTART- -8779382- O O

The DT N
effect NN N
of IN N
tunnelling VBG i
on IN N
epidural JJ N
catheter NN N
migration NN N
. . N

A DT N
prospective JJ N
, , N
randomised VBD N
study NN N
of IN N
82 CD p
patients NNS p
having VBG p
postoperative JJ p
epidural JJ p
analgesia NN p
was VBD N
performed VBN N
to TO N
determine VB N
whether IN N
the DT N
tunnelling NN i
of IN N
an DT N
epidural JJ N
catheter NN N
influences VBZ N
its PRP$ N
migration NN o
. . N

Tunnelling NN i
of IN N
the DT N
catheter NN N
subcutaneously RB N
for IN N
a DT N
distance NN N
of IN N
5 CD N
cm NN N
reduced VBD N
the DT N
incidence NN o
of IN o
inward JJ o
migration NN o
of IN N
1 CD N
cm NN N
or CC N
more JJR N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
compared VBN N
to TO N
a DT N
standard JJ N
method NN N
of IN N
fixation NN N
with IN N
a DT N
transparent JJ N
adhesive JJ N
dressing NN N
. . N

This DT N
effect NN N
was VBD N
more RBR N
marked JJ N
if IN N
the DT N
epidural JJ N
catheter NN N
was VBD N
sited VBN N
in IN N
the DT N
thoracic NN N
rather RB N
than IN N
the DT N
lumbar JJ N
area NN N
. . N

Sixty CD N
two CD N
percent NN N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
of IN N
tunnelled JJ i
catheters NNS i
remained VBD N
within IN N
0.5 CD N
cm NNS N
of IN N
their PRP$ N
original JJ N
position NN o
compared VBN N
to TO N
38 CD N
% NN N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
of IN N
non-tunnelled JJ i
catheters NNS i
, , N
although IN N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Outward NNP N
catheter NN o
migration NN o
was VBD N
not RB N
reduced VBN N
by IN N
subcutaneous JJ N
tunnelling NN i
. . N

-DOCSTART- -16055807- O O

Interventions NNS N
in IN N
the DT N
initial JJ p
prodromal JJ p
states NNS p
of IN p
psychosis NN p
in IN N
Germany NNP p
: : N
concept NN N
and CC N
recruitment NN N
. . N

BACKGROUND VB N
The DT N
Early JJ N
Detection NN N
and CC N
Intervention NNP N
Programme NNP N
of IN N
the DT N
German JJ N
Research NNP N
Network NNP N
on IN N
Schizophrenia NNP N
( ( N
GRNS NNP N
) ) N
investigates VBZ N
the DT N
initial JJ p
prodromal JJ p
phase NN p
of IN p
psychosis NN p
in IN N
a DT N
multidimensional JJ N
approach NN N
. . N

Two CD N
intervention NN N
strategies NNS N
are VBP N
being VBG N
studied VBN N
by IN N
two CD N
large-scale JJ N
multicentre JJ N
projects NNS N
. . N

AIMS NNP N
To TO N
present VB N
the DT N
concept NN N
of IN N
the DT N
intervention NN N
studies NNS N
, , N
and CC N
to TO N
provide VB N
an DT N
interim JJ N
report NN N
of IN N
the DT N
recruitment JJ N
procedure NN N
. . N

METHOD NNP N
Comprehensive NNP i
cognitive-behavioural JJ i
therapy NN i
has VBZ N
been VBN N
developed VBN N
for IN N
patients NNS N
in IN N
the DT N
early JJ p
initial JJ p
prodromal JJ p
state NN p
. . N

For IN N
patients NNS N
in IN N
the DT N
late JJ p
initial JJ p
prodromal JJ p
state NN p
the DT N
atypical JJ i
neuroleptic JJ i
amisulpride NN i
is VBZ N
explored VBN N
. . N

Both DT N
interventions NNS N
are VBP N
evaluated VBN N
in IN N
randomised JJ N
controlled VBN N
trials NNS N
using VBG N
clinical JJ N
management NN N
as IN N
the DT N
control NN N
condition NN N
. . N

RESULTS NNP N
Between NNP N
January NNP N
2001 CD N
and CC N
March NNP N
2003 CD N
, , N
1212 CD p
individuals NNS p
seeking VBG p
help NN p
for IN p
mental JJ p
health NN p
problems NNS p
were VBD N
screened VBN N
for IN N
putative JJ N
prodromal NN N
symptoms NNS N
at IN N
four CD N
university NN N
centres NNS N
. . N

More JJR p
than IN p
388 CD p
individuals NNS p
fulfilled VBD p
criteria NNS p
for IN p
both DT p
interventions NNS p
and CC p
188 CD p
( ( p
48.5 CD p
% NN p
) ) p
gave VBD p
informed VBN p
consent NN p
to TO p
participate VB p
in IN p
the DT p
trials NNS p
. . N

CONCLUSIONS VB N
The DT N
screening NN N
procedure NN N
appears VBZ N
to TO N
be VB N
feasible JJ N
and CC N
trial NN N
participation NN N
seems VBZ N
to TO N
be VB N
acceptable JJ N
to TO N
a DT N
relevant JJ N
proportion NN N
of IN N
people NNS N
at IN N
increased VBN N
risk NN N
of IN N
developing VBG N
psychosis NN N
. . N

-DOCSTART- -10934569- O O

Randomized VBN N
trial NN N
of IN N
intensive JJ i
early JJ i
intervention NN i
for IN N
children NNS p
with IN p
pervasive JJ p
developmental JJ p
disorder NN p
. . N

Young NNP p
children NNS p
with IN p
pervasive JJ p
developmental JJ p
disorder NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
intensive VB i
treatment NN i
or CC N
parent NN i
training NN i
. . N

The DT N
intensive JJ i
treatment NN i
group NN N
( ( N
7 CD p
with IN p
autism NN p
, , p
8 CD p
with IN p
pervasive JJ p
developmental JJ p
disorder NN p
not RB p
otherwise RB p
specified VBN p
-- : p
NOS NNP p
) ) N
averaged VBD N
24.52 CD N
hours NNS N
per IN N
week NN N
of IN N
individual JJ N
treatment NN N
for IN N
one CD N
year NN N
, , N
gradually RB N
reducing VBG N
hours NNS N
over IN N
the DT N
next JJ N
1 CD N
to TO N
2 CD N
years NNS N
. . N

The DT N
parent NN i
training NN i
group NN N
( ( N
7 CD p
with IN p
autism NN p
, , p
6 CD p
with IN p
pervasive JJ p
developmental JJ p
disorder NN p
NOS NNP p
) ) N
received VBD N
3 CD N
to TO N
9 CD N
months NNS N
of IN N
parent NN i
training NN i
. . N

The DT N
groups NNS N
appeared VBD N
similar JJ N
at IN N
intake NN N
on IN N
all DT N
measures NNS N
; : N
however RB N
, , N
at IN N
follow-up JJ N
the DT N
intensive JJ i
treatment NN i
group NN N
outperformed VBD N
the DT N
parent NN i
training VBG i
group NN N
on IN N
measures NNS N
of IN N
intelligence NN o
, , o
visual-spatial JJ o
skills NNS o
, , o
language NN o
, , o
and CC o
academics NNS o
, , N
though IN N
not RB N
adaptive JJ o
functioning NN o
or CC N
behavior NN o
problems NNS o
. . N

Children NNP p
with IN p
pervasive JJ p
developmental JJ p
disorder NN p
NOS NNP N
may MD N
have VB N
gained VBN N
more JJR N
than IN N
those DT N
with IN N
autism NN N
. . N

-DOCSTART- -15193668- O O

Combined VBN N
descriptive JJ N
and CC N
explanatory JJ N
information NN N
improves VBZ N
peers NNS o
' POS o
perceptions NNS o
of IN N
autism NN N
. . N

Authors NNS N
examined VBD N
the DT N
combined JJ N
effects NNS N
of IN N
descriptive JJ N
and CC N
explanatory JJ N
information NN N
on IN N
peers NNS o
' POS o
perceptions NNS o
and CC o
behavioral JJ o
intentions NNS o
toward IN N
an DT N
unfamiliar JJ N
child NN N
with IN N
autism NN N
. . N

Children NNP p
( ( p
N NNP p
= NNP p
576 CD p
; : p
M NNP p
age NN p
= VBD p
10.06 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
view VB N
two CD N
videotapes NNS N
of IN N
a DT N
boy NN N
engaging VBG N
in IN N
typical JJ N
and CC N
autistic JJ N
behaviors NNS N
receiving VBG N
either RB N
descriptive JJ i
( ( i
AUT-D NNP i
) ) i
or CC N
descriptive JJ i
and CC i
explanatory JJ i
information NN i
( ( i
AUT-D NNP i
+ NNP i
E NNP i
) ) i
. . N

Children NNP N
responded VBD N
to TO N
measures NNS N
of IN N
attitudes NNS N
( ( o
Adjective NNP o
Checklist NNP o
) ) o
and CC N
behavioral JJ N
intentions NNS N
( ( o
Shared NNP o
Activities NNP o
Questionnaire NNP o
) ) o
. . N

Children NNP N
rated VBD N
the DT N
typical JJ N
boy NN N
more RBR N
favorably RB N
than IN N
the DT N
boy NN N
showing VBG N
autistic JJ N
symptoms NNS N
. . N

When WRB N
compared VBN N
to TO N
descriptive VB N
information NN N
alone RB N
, , N
the DT N
combination NN N
of IN N
descriptive JJ N
and CC N
explanatory JJ N
information NN N
resulted VBD N
in IN N
improved JJ N
third- JJ N
and CC N
fourth-graders NNS N
' '' N
but CC N
not RB N
fifth-graders NNS N
' POS N
attitudes NNS N
toward IN N
the DT N
child NN N
with IN N
autism NN N
. . N

Combined VBN N
information NN N
improved VBN N
behavioral JJ N
intentions NNS N
across IN N
grades NNS N
; : N
however RB N
, , N
girls NNS N
( ( N
vs. FW N
boys NNS N
) ) N
were VBD N
more RBR N
responsive JJ N
to TO N
information NN N
as IN N
evidenced VBN N
by IN N
differences NNS N
in IN N
academic JJ N
intentions NNS N
. . N

The DT N
combination NN N
of IN N
descriptive JJ i
and CC i
explanatory JJ i
information NN i
about IN N
autism NN N
appears VBZ N
to TO N
have VB N
a DT N
positive JJ N
effect NN N
on IN N
children NNS o
's POS o
attitudes NNS o
and CC o
behavioral JJ o
intentions NNS o
. . N

Implications NNS N
of IN N
the DT N
findings NNS N
are VBP N
briefly RB N
discussed VBN N
as RB N
well RB N
as IN N
study NN N
limitations NNS N
and CC N
recommendations NNS N
for IN N
future JJ N
research NN N
. . N

-DOCSTART- -24515505- O O

Economic NNP N
burden NN N
of IN N
childhood NN p
autism NN p
spectrum NN p
disorders NNS p
. . N

OBJECTIVE NNP N
To TO N
estimate VB N
the DT N
associations NNS N
between IN N
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
diagnoses NNS N
and CC N
service NN o
use NN o
, , o
caregiver NN o
time NN o
, , o
and CC o
cost NN o
outcomes NNS o
. . N

METHODS NNP N
We PRP N
used VBD N
national JJ N
data NNS N
from IN N
the DT N
Medical NNP N
Expenditure NNP N
Panel NNP N
Survey NNP N
linked VBD N
to TO N
the DT N
National NNP N
Health NNP N
Interview NNP N
Survey NNP N
and CC N
a DT N
study-specific JJ N
survey NN N
to TO N
estimate VB N
the DT N
annual JJ o
utilization NN o
and CC o
costs NNS o
for IN N
health NN o
care NN o
, , o
school NN o
, , o
ASD-related JJ o
therapy NN o
, , o
family-coordinated JJ o
services NNS o
, , N
as RB N
well RB N
as IN N
caregiver NN o
time NN o
in IN N
children NNS p
aged VBD p
3 CD p
to TO p
17 CD p
years NNS p
, , p
with IN p
and CC p
without IN p
parent-reported JJ p
ASD NNP p
. . p

Regression NNP N
analyses VBZ N
estimated VBN N
the DT N
association NN N
between IN N
ASD NNP N
diagnosis NN N
and CC N
cost NN o
, , N
controlling VBG N
for IN N
child NN N
gender NN N
, , N
age NN N
, , N
race/ethnicity NN N
, , N
insurance NN N
status NN N
, , N
household JJ N
income NN N
, , N
country NN N
region NN N
and CC N
urban/rural JJ N
classification NN N
, , N
and CC N
non-ASD-related JJ N
illnesses NNS N
. . N

RESULTS NNP N
Children NNP p
with IN p
parent-reported JJ p
ASD NNP p
had VBD N
higher JJR N
levels NNS N
of IN N
health NN o
care NN o
office NN o
visits NNS o
and CC N
prescription NN o
drug NN o
use NN o
compared VBN N
with IN N
children NNS N
without IN N
ASD NNP N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

A DT N
greater JJR N
proportion NN N
of IN N
children NNS N
in IN N
the DT N
ASD NNP N
group NN N
used VBD N
special JJ o
educational JJ o
services NNS o
( ( N
76 CD N
% NN N
vs. FW N
7 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

After IN N
adjusting VBG N
for IN N
child JJ N
demographic JJ N
characteristics NNS N
and CC N
non-ASD-associated JJ N
illnesses NNS N
, , N
ASD NNP N
was VBD N
associated VBN N
with IN N
$ $ N
3020 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
$ $ N
1017- CD N
$ $ N
4259 CD N
) ) N
higher JJR N
health NN o
care NN o
costs NNS o
and CC N
$ $ N
14,061 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
$ $ N
4390- JJ N
$ $ N
24,302 CD N
) ) N
higher JJR N
aggregate JJ N
non-health NNS o
care NN o
costs NNS o
, , N
including VBG N
$ $ N
8610 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
$ $ N
6595- JJ N
$ $ N
10,421 CD N
) ) N
higher JJR o
school NN o
costs NNS o
. . N

In IN N
adjusted JJ N
analyses NNS N
, , N
parents NNS N
who WP N
reported VBD N
that IN N
their PRP$ N
child NN N
had VBD N
ASD NNP N
did VBD N
not RB N
have VB N
significantly RB N
higher JJR N
out-of-pocket NN o
costs NNS o
or CC N
spend VB N
more JJR N
time NN o
on IN o
caregiving VBG o
activities NNS o
compared VBN N
with IN N
control NN N
parents NNS N
. . N

CONCLUSIONS VB N
The DT N
economic JJ N
burden NN N
associated VBN N
with IN N
ASD NNP N
is VBZ N
substantial JJ N
and CC N
can MD N
be VB N
measured VBN N
across IN N
multiple JJ N
sectors NNS N
of IN N
our PRP$ N
society NN N
. . N

Previous JJ N
analyses NNS N
that WDT N
focused VBD N
on IN N
health NN N
care NN N
underestimated VBD N
this DT N
economic JJ N
burden NN N
, , N
particularly RB N
for IN N
school NN N
systems NNS N
. . N

-DOCSTART- -9816035- O O

Amonafide NN i
: : N
An DT N
active JJ N
agent NN N
in IN N
the DT N
treatment NN N
of IN N
previously RB p
untreated VBN p
advanced JJ p
breast NN p
cancer NN p
-- : N
a DT N
cancer NN N
and CC N
leukemia NN N
group NN N
B NNP N
study NN N
( ( N
CALGB NNP N
8642 CD N
) ) N
. . N

Amonafide NNP i
is VBZ N
a DT N
new JJ N
imide JJ N
derivative NN N
of IN N
naphthalic JJ N
acid NN N
. . N

The DT N
drug NN N
had VBD N
demonstrated VBN N
significant JJ N
activity NN N
in IN N
preclinical JJ N
studies NNS N
and CC N
some DT N
activity NN N
in IN N
Phase NNP N
I PRP N
trials NNS N
. . N

The DT N
drug NN N
is VBZ N
extensively RB N
metabolized VBN N
and CC N
detected VBN N
in IN N
plasma NN N
and CC N
urine NN N
. . N

Its PRP$ N
toxicity NN N
has VBZ N
previously RB N
been VBN N
correlated VBN N
to TO N
the DT N
formation NN N
of IN N
an DT N
active JJ N
metabolite NN N
, , N
N-acetyl-amonafide NNP N
. . N

Amonafide NNP i
was VBD N
chosen VBN N
for IN N
inclusion NN N
in IN N
the DT N
Cancer NNP N
and CC N
Leukemia NNP N
Group NNP N
B NNP N
( ( N
CALGB NNP N
) ) N
master NN N
metastatic JJ N
breast NN N
cancer NN N
protocol NN N
. . N

CALGB NNP N
8642 CD N
randomizes VBZ N
previously RB p
untreated VBN p
metastatic JJ p
breast NN p
cancer NN p
patients NNS p
either CC N
to TO N
one CD N
of IN N
several JJ N
Phase NNP N
II NNP N
agents NNS N
given VBN N
for IN N
up IN N
to TO N
four CD N
cycles NNS N
and CC N
then RB N
followed VBN N
by IN N
standard JJ N
cyclophosphamide-doxorubicin-5-fluorouracil NN i
, , N
or CC N
to TO N
immediate VB N
treatment NN N
with IN N
standard JJ N
cyclophosphamide-doxorubicin-5-fluorouracil NN i
. . N

The DT N
end NN N
point NN N
of IN N
CALGB NNP N
8642 CD N
is VBZ N
to TO N
assess VB N
the DT N
difference NN N
in IN N
survival NN o
, , o
toxicity NN o
, , o
and CC o
overall JJ o
response NN o
when WRB N
limited JJ N
exposure NN N
to TO N
Phase NNP N
II NNP N
agents NNS N
precedes VBZ N
standard JJ N
chemotherapy NN N
. . N

This DT N
report NN N
deals VBZ N
only RB N
with IN N
amonafide RB i
as IN N
a DT N
Phase NNP N
II NNP N
agent NN N
. . N

Comparisons NNS N
with IN N
the DT N
cyclophosphamide-doxorubicin-5-fluorouracil JJ i
arm NN N
will MD N
not RB N
be VB N
addressed VBN N
. . N

Patients NNS p
had VBD p
to TO p
have VB p
histologically RB p
documented VBN p
measurable JJ p
breast NN p
cancer NN p
and CC p
a DT p
performance NN p
status NN p
of IN p
0-1 NNP p
. . p

Patients NNS p
could MD p
not RB p
have VB p
had VBN p
prior JJ p
chemotherapy NN p
for IN p
metastatic JJ p
disease NN p
. . p

Prior NNP p
adjuvant JJ p
chemotherapy NN p
was VBD p
permitted VBN p
. . p

Patients NNS p
could MD p
not RB p
have VB p
visceral JJ p
crisis NN p
. . p

Amonafide NNP i
was VBD N
given VBN N
at IN N
300 CD N
mg/m2/day JJ N
i.v NN N
. . N

for IN N
5 CD N
days NNS N
, , N
and CC N
repeated VBD N
at IN N
21-day JJ N
intervals NNS N
for IN N
a DT N
maximum NN N
of IN N
four CD N
cycles NNS N
. . N

Escalation NN N
and CC N
reduction NN N
in IN N
dose NN N
was VBD N
mandated VBN N
dependent NN N
on IN N
hematotoxicity NN N
or CC N
lack NN N
thereof NN N
. . N

Toxicity NN o
was VBD N
primarily RB N
hematological JJ N
and CC N
bimodal NN N
: : N
32 CD N
% NN N
had VBD N
grade VBN N
3 CD N
or CC N
4 CD N
leukopenia NN o
and CC N
24 CD N
% NN N
had VBD N
grade VBN N
3 CD N
or CC N
4 CD N
thrombocytopenia NN o
; : N
22 CD N
% NN N
had VBD N
no DT N
leukopenia NN o
and CC N
44 CD N
% NN N
had VBD N
no DT N
thrombocytopenia NN o
. . N

The DT N
response NN o
rate NN o
was VBD N
18 CD N
% NN N
, , N
including VBG N
one CD N
complete JJ N
response NN N
. . N

When WRB N
response NN N
was VBD N
analyzed VBN N
by IN N
hematological JJ o
toxicity NN o
, , N
there EX N
was VBD N
a DT N
35.7 CD N
% NN N
response NN N
if IN N
patients NNS N
had VBD N
leukopenia VBN o
grade NN N
3/4 CD N
( ( N
versus IN N
8.3 CD N
% NN N
, , N
P NNP N
= NNP N
0.08 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
50 CD N
% NN N
response NN N
if IN N
patients NNS N
had VBD N
thrombocytopenia VBN o
grade NN N
3/4 CD N
( ( N
versus IN N
7.1 CD N
% NN N
, , N
P NNP N
= NNP N
< NNP N
0.01 CD N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
amonafide NN i
is VBZ N
somewhat RB N
active JJ N
in IN N
previously RB p
untreated VBN p
breast NN p
cancer NN p
patients NNS p
. . N

There EX N
may MD N
be VB N
a DT N
steep JJ N
dose-response NN N
curve NN N
, , N
based VBN N
on IN N
the DT N
significant JJ N
correlation NN N
between IN N
myelosuppression NN N
and CC N
response NN N
. . N

Rates NNS o
of IN o
responses NNS o
in IN N
patients NNS N
adequately RB N
dosed VBN N
( ( N
i.e. FW N
, , N
with IN N
significant JJ N
hematotoxicity NN N
) ) N
with IN N
amonafide NN N
ranged VBD N
from IN N
35 CD N
to TO N
50 CD N
% NN N
. . N

Further JJ N
studies NNS N
will MD N
incorporate VB N
individualized JJ N
dosing NN N
based VBN N
on IN N
pretreatment NN N
acetylator NN N
phenotyping NN N
. . N

-DOCSTART- -18544974- O O

In IN N
school-aged JJ p
children NNS p
a DT N
combination NN N
of IN N
galacto-oligosaccharides NNS i
and CC i
Lactobacillus NNP i
GG NNP i
increases VBZ N
bifidobacteria RB N
more JJR N
than IN N
Lactobacillus NNP i
GG NNP i
on IN N
its PRP$ N
own JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
a DT N
combination NN N
of IN N
Lactobacillus NNP i
GG NNP i
( ( i
LGG NNP i
) ) i
and CC i
galacto-oligosaccharides NNS i
( ( i
GOS NNP i
) ) i
with IN N
LGG NNP i
on IN N
its PRP$ N
own JJ N
, , N
and CC N
their PRP$ N
effects NNS N
on IN N
the DT N
intestinal JJ N
microbiota NN N
in IN N
school-aged JJ p
children NNS p
. . N

The DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
crossover NN N
study NN N
comprised VBD N
30 CD p
healthy JJ p
children NNS p
. . N

There EX N
were VBD N
two CD N
3-week JJ N
study NN N
periods NNS N
with IN N
a DT N
4-week JJ N
wash-out JJ N
period NN N
in IN N
between IN N
. . N

The DT N
children NNS N
ingested VBD N
daily RB N
65 CD N
ml NN N
of IN N
milk-based JJ N
fruit NN N
juice NN N
containing VBG N
either CC N
LGG NNP i
alone RB N
( ( N
6.5 CD N
x RB N
10 CD N
( ( N
9 CD N
) ) N
CFU NNP N
) ) N
or CC N
LGG NNP i
plus CC N
2 CD N
g NN N
of IN N
GOS NNP i
. . N

Symptom NNP N
diaries NNS N
were VBD N
filled VBN N
during IN N
the DT N
study NN N
periods NNS N
. . N

Fecal JJ N
samples NNS N
were VBD N
collected VBN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
both DT N
study NN N
periods NNS N
. . N

At IN N
the DT N
end NN N
of IN N
both DT N
study NN N
periods NNS N
, , N
the DT N
amount NN o
of IN o
bifidobacteria NN o
was VBD N
significantly RB N
greater JJR N
after IN N
the DT N
ingestion NN N
of IN N
LGG NNP i
+ NNP i
GOS NNP i
compared VBN N
with IN N
LGG NNP i
alone RB N
( ( N
geometric JJ N
mean VBP N
9.33 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
vs. FW N
4.28 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
CFU/g NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
the DT N
amount NN N
of IN N
lactobacilli NN o
or CC N
LGG NNP i
, , N
nor CC N
did VBD N
gastrointestinal JJ o
symptoms NNS o
, , o
defecation NN o
frequency NN o
, , o
consistency NN o
of IN o
stools NNS o
or CC o
ease NN o
of IN o
defecation NN o
differ NN N
between IN N
the DT N
two CD N
study NN N
periods NNS N
. . N

Ingestion NN N
of IN N
LGG NNP i
combined VBD N
with IN N
2 CD N
g NN N
of IN N
GOS NNP i
increased VBD N
the DT N
bifidobacteria NN o
more JJR N
than IN N
LGG NNP i
on IN N
its PRP$ N
own JJ N
and CC N
thus RB N
GOS NNP i
clearly RB N
has VBZ N
a DT N
prebiotic JJ N
effect NN N
in IN N
children NNS p
. . N

The DT N
children NNS p
tolerated VBN N
well RB N
a DT N
daily JJ N
intake NN N
of IN N
2 CD N
g NN N
of IN N
GOS NNP i
. . N

-DOCSTART- -19096921- O O

Trial JJ N
design NN N
challenges NNS N
when WRB N
combining VBG N
medication NN i
and CC N
parent NN i
training NN i
in IN N
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . N

This DT N
paper NN N
presents VBZ N
the DT N
rationale NN N
for IN N
a DT N
24-week JJ N
, , N
randomized JJ N
trial NN N
designed VBN N
to TO N
test VB N
whether IN N
risperidone NN i
plus CC N
structured JJ i
parent NN i
training NN i
would MD N
be VB N
superior JJ N
to TO N
risperidone VB i
only RB N
on IN N
measures NNS N
of IN N
noncompliance NN o
, , o
irritability NN o
and CC o
adaptive JJ o
functioning NN o
. . N

In IN N
this DT N
model NN N
, , N
medication NN N
reduces NNS N
tantrums NNS o
, , o
aggression NN o
and CC o
self-injury NN o
; : N
parent NN N
training NN N
promotes NNS N
improvement NN N
in IN N
noncompliance NN o
and CC o
adaptive JJ o
functioning NN o
. . N

Thus RB N
, , N
medication NN N
and CC N
parent NN N
training NN N
target NN N
related VBN N
, , N
but CC N
separate JJ N
, , N
outcomes RB N
. . N

At IN N
week NN N
24 CD N
, , N
the DT N
medication NN N
was VBD N
gradually RB N
withdrawn VBN N
to TO N
determine VB N
whether IN N
subjects NNS N
in IN N
the DT N
combined JJ N
treatment NN N
group NN N
could MD N
be VB N
managed VBN N
on IN N
a DT N
lower JJR N
dose NN N
or CC N
off IN N
medication NN N
without IN N
relapse NN N
. . N

Both DT N
symptom JJ o
reduction NN N
and CC N
functional JJ o
improvement NN N
are VBP N
important JJ N
clinical JJ N
treatment NN N
targets NNS N
. . N

Thus RB N
, , N
experimental JJ N
evidence NN N
on IN N
the DT N
beneficial JJ N
effects NNS N
of IN N
combining VBG N
pharmacotherapy NN N
and CC N
exportable JJ N
behavioral JJ N
interventions NNS N
is VBZ N
needed VBN N
to TO N
guide VB N
clinical JJ N
practice NN N
. . N

-DOCSTART- -2224060- O O

Randomized VBN N
controlled VBD N
study NN N
of IN N
chemoimmunotherapy NN N
with IN N
bestatin NN i
of IN N
acute JJ p
nonlymphocytic JJ p
leukemia NN p
in IN p
adults NNS p
. . N

A DT N
new JJ N
immunomodulating NN N
agent NN N
, , N
bestatin NN i
( ( N
INN NNP N
: : N
Ubenimex NNP N
has VBZ N
low JJ N
toxicity NN N
even RB N
after IN N
long-term JJ N
oral JJ N
administration NN N
and CC N
has VBZ N
significant JJ N
modifications NNS N
in IN N
immunological JJ N
response NN N
. . N

A DT N
cooperative JJ N
randomized NN N
controlled VBD N
study NN N
of IN N
bestatin NN i
immunotherapy NN N
in IN N
combination NN N
with IN N
remission NN N
maintenance NN N
chemotherapy NN N
for IN N
adult NN p
acute JJ p
nonlymphocytic JJ p
leukemia NN p
( ( p
ANLL NNP p
) ) p
was VBD N
performed VBN N
. . N

After IN N
induction NN N
of IN N
complete JJ N
remission NN N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
bestatin NN i
group NN N
( ( N
30 CD N
mg/bw NN N
per IN N
os NN N
( ( N
po NN N
) ) N
daily RB N
) ) N
and CC N
the DT N
control NN N
group NN N
. . N

The DT N
101 CD p
eligible JJ p
cases NNS p
( ( p
bestatin NN i
: : p
48 CD p
, , p
control NN p
: : p
53 CD p
) ) p
were VBD N
analyzed VBN N
; : N
the DT N
bestatin NN i
group NN N
achieved VBD N
longer JJR N
remission NN o
than IN N
the DT N
control NN N
group NN N
and CC N
a DT N
statistically RB N
significant JJ N
longer JJR N
survival NN o
. . N

Though IN N
this DT N
prolongation NN o
of IN o
remission NN o
was VBD N
not RB N
significant JJ N
in IN N
the DT N
bestatin NN i
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
in IN N
the DT N
15-49 JJ N
yr NN N
age NN N
group NN N
, , N
in IN N
the DT N
50-65 JJ N
yr NN N
age NN N
group NN N
it PRP N
was VBD N
significantly RB N
longer JJR N
. . N

Bestatin NNP i
is VBZ N
shown VBN N
to TO N
be VB N
a DT N
clinically RB N
useful JJ N
drug NN N
for IN N
immunotherapy NN N
of IN N
adult NN N
ANLL NNP N
, , N
since IN N
it PRP N
has VBZ N
prolonged VBN N
survival NN o
and CC o
remission NN o
especially RB N
in IN N
elderly JJ N
patients NNS N
, , N
with IN N
few JJ N
side-effects NNS o
. . N

-DOCSTART- -11495215- O O

Oral NNP i
contraceptive NN i
use NN N
is VBZ N
associated VBN N
with IN N
increased JJ N
cardiovascular JJ o
reactivity NN o
in IN N
nonsmokers NNS N
. . N

Women NNS N
who WP N
smoke VBD N
and CC N
take VB N
oral JJ i
contraceptives NNS i
( ( i
OCs NNP i
) ) i
have VBP N
significantly RB N
increased VBN N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
, , N
but CC N
the DT N
exact JJ N
mechanismsfor VBZ N
the DT N
increased VBN N
risk NN N
are VBP N
not RB N
known VBN N
. . N

Cardiovascular JJ N
reactivity NN N
to TO N
psychological JJ N
stress NN N
may MD N
be VB N
one CD N
mechanism NN N
for IN N
the DT N
enhanced JJ N
risk NN N
, , N
but CC N
the DT N
small JJ N
number NN N
of IN N
studies NNS N
examining VBG N
whether IN N
OC NNP N
users NNS N
who WP N
smoke VBP N
have VBP N
greater JJR N
reactivity NN N
have VBP N
produced VBN N
mixed JJ N
results NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effect NN N
of IN N
chronic JJ N
cigarette NN N
smoking NN N
, , N
acute JJ N
nicotine JJ N
administration NN N
, , N
and CC N
OC NNP N
use VBP N
on IN N
cardiovascular NN o
and CC o
lipid JJ o
reactivity NN o
. . N

Sixty NNP p
healthy JJ p
women NNS p
, , p
half NN p
of IN p
whom WP p
had VBD p
been VBN p
using VBG p
OCs NNP p
for IN p
at IN p
least JJS p
the DT p
previous JJ p
6 CD p
months NNS p
, , p
participated VBN N
in IN N
the DT N
study NN N
. . N

Approximately RB N
two CD p
thirds NNS p
were VBD p
smokers NNS p
and CC N
were VBD N
randomized VBN N
to TO N
be VB N
tested VBN N
after IN N
either DT N
a DT N
12-hr JJ N
nicotine JJ i
deprivation NN i
or CC N
administration NN N
of IN N
nicotine JJ i
gum NN N
. . N

One CD p
third WDT p
were VBD p
nonsmokers NNS p
. . N

Heart NNP o
rate NN o
, , o
blood NN o
pressure NN o
, , o
and CC o
lipid JJ o
measures NNS o
were VBD N
taken VBN N
at IN N
rest NN N
, , N
during IN N
a DT N
videotaped JJ N
speech NN N
task NN N
, , N
and CC N
during IN N
recovery NN N
from IN N
the DT N
task NN N
. . N

Results NNS N
indicated VBD N
that IN N
, , N
among IN N
OC NNP i
nonusers NNS N
, , N
there EX N
was VBD N
no DT N
effect NN N
of IN N
smoking VBG N
status NN N
or CC N
nicotine JJ i
administration NN N
on IN N
cardiovascular JJ N
reactivity NN N
. . N

However RB N
, , N
among IN N
OC NNP i
users NNS N
, , N
nonsmokers NNS N
had VBD N
significantly RB N
greater JJR N
heart NN o
rate NN o
and CC o
diastolic JJ o
blood NN o
pressure NN o
reactivity NN o
to TO N
stress VB N
. . N

These DT N
data NNS N
show VBP N
that IN N
acute JJ N
nicotine JJ i
administration NN N
, , N
in IN N
the DT N
form NN N
of IN N
nicotine JJ i
gum NN N
, , N
has VBZ N
no DT N
effect NN N
on IN N
cardiovascular NN o
or CC o
lipid JJ o
stress NN o
reactivity NN o
in IN N
women NNS N
. . N

However RB N
OC NNP i
use NN N
among IN N
nonsmoking JJ N
women NNS N
is VBZ N
associated VBN N
with IN N
greater JJR N
cardiovascular JJ o
reactivity NN o
to TO N
stress VB N
. . N

-DOCSTART- -2066441- O O

Therapeutic JJ N
effects NNS N
of IN N
combined JJ N
treatment NN N
using VBG N
tetracycline-immobilized JJ i
collagen NN i
film NN i
and CC i
root NN i
planing NN i
in IN N
periodontal JJ p
furcation NN p
pockets NNS p
. . N

46 CD p
upper JJ p
and CC p
lower JJR p
molars NNS p
with IN p
furcation NN p
grade NN p
II NNP p
involvement NN p
were VBD N
selected VBN N
from IN N
16 CD p
patients NNS p
with IN p
periodontal JJ p
disease NN p
. . N

The DT N
teeth NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
following VBG N
groups NNS N
according VBG N
to TO N
treatment NN N
; : N
( ( N
1 CD N
) ) N
4 CD N
consecutive JJ N
administrations NNS N
of IN N
tetracycline-immobilized JJ i
cross-linked JJ i
collagen NN i
film NN i
( ( i
TC NNP i
film NN i
) ) i
at IN N
intervals NNS N
of IN N
1 CD N
week NN N
( ( N
TC NNP N
group NN N
) ) N
; : N
( ( N
2 CD N
) ) N
1 CD N
root NN i
planing VBG i
treatment NN i
( ( i
RP NNP i
group NN N
) ) N
; : N
( ( N
3 CD N
) ) N
combination NN N
treatment NN N
( ( N
TC NNP i
+ NNP i
RP NNP i
group NN N
) ) N
; : N
( ( N
4 CD N
) ) N
no DT N
treatment NN N
( ( N
control VB N
group NN N
) ) N
. . N

The DT N
therapeutic JJ N
effects NNS N
of IN N
each DT N
treatment NN N
were VBD N
compared VBN N
both DT N
clinically RB N
and CC N
microbiologically RB N
. . N

Records NNS N
of IN N
plaque NN o
index NN o
, , o
gingival NN o
index NN o
, , o
bleeding VBG o
on IN o
probing VBG o
, , o
probing VBG o
depth NN o
, , o
probing VBG o
attachment JJ o
level NN o
and CC o
microscopic NN o
counts NNS o
were VBD N
obtained VBN N
at IN N
0 CD N
, , N
4 CD N
, , N
6 CD N
and CC N
8 CD N
weeks NNS N
. . N

The DT N
results NNS N
showed VBD N
marked JJ N
decreases NNS N
in IN N
probing VBG o
depth NN o
and CC o
density NN o
of IN o
micro-organisms NN o
in IN N
both CC N
the DT N
RP NNP i
and CC N
TC NNP i
+ NNP i
RP NNP i
groups NNS N
. . N

In IN N
particular JJ N
, , N
the DT N
TC NNP i
+ NNP i
RP NNP i
group NN N
was VBD N
characterized VBN N
by IN N
a DT N
decreased JJ N
rate NN o
of IN o
bleeding VBG o
on IN o
pocket NN o
probing NN o
and CC N
an DT N
increased JJ N
probing NN o
attachment NN o
gain NN o
. . N

The DT N
above JJ N
findings NNS N
demonstrated VBD N
that IN N
root NN N
planning NN N
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
furcation NN N
involvement NN N
and CC N
that IN N
the DT N
effects NNS N
are VBP N
enhanced VBN N
by IN N
the DT N
local JJ N
administration NN N
of IN N
TC NNP i
films NNS N
. . N

-DOCSTART- -23838728- O O

Teacher DT N
and CC N
child JJ N
predictors NNS N
of IN N
achieving VBG N
IEP NNP N
goals NNS N
of IN N
children NNS p
with IN p
autism NN p
. . N

It PRP N
is VBZ N
encouraging VBG N
that IN N
children NNS p
with IN p
autism NN p
show VBP N
a DT N
strong JJ N
response NN N
to TO N
early JJ N
intervention NN N
, , N
yet RB N
more JJR N
research NN N
is VBZ N
needed VBN N
for IN N
understanding VBG N
the DT N
variability NN N
in IN N
responsiveness NN N
to TO N
specialized JJ N
programs NNS N
. . N

Treatment NNP N
predictor NN N
variables NNS N
from IN N
47 CD p
teachers NNS p
and CC p
children NNS p
who WP N
were VBD N
randomized VBN N
to TO N
receive VB N
the DT N
COMPASS NNP i
intervention NN i
( ( N
Ruble JJ N
et NN N
al NN N
. . N

in IN N
The DT N
collaborative JJ N
model NN N
for IN N
promoting VBG N
competence NN N
and CC N
success NN N
for IN N
students NNS N
with IN N
ASD NNP N
. . N

Springer NNP N
, , N
New NNP N
York NNP N
, , N
2012a CD N
) ) N
were VBD N
analyzed VBN N
. . N

Predictors NNS N
evaluated VBD N
against IN N
child NN N
IEP NNP N
goal NN N
attainment NN N
included VBD N
child NN N
, , N
teacher NN N
, , N
intervention NN N
practice NN N
, , N
and CC N
implementation NN N
practice NN N
variables NNS N
based VBN N
on IN N
an DT N
implementation NN N
science NN N
framework NN N
( ( N
Dunst NNP N
and CC N
Trivette NNP N
in IN N
J NNP N
Soc NNP N
Sci NNP N
8:143-148 CD N
, , N
2012 CD N
) ) N
. . N

Findings NNS N
revealed VBD N
one CD N
child NN N
( ( N
engagement NN N
) ) N
, , N
one CD N
teacher NN N
( ( N
exhaustion NN N
) ) N
, , N
two CD N
intervention NN N
quality NN N
( ( N
IEP NNP N
quality NN N
for IN N
targeted VBN N
and CC N
not RB N
targeted JJ N
elements NNS N
) ) N
, , N
and CC N
no DT N
implementation NN N
quality NN N
variables NNS N
accounted VBD N
for IN N
variance NN N
in IN N
child NN N
outcomes NNS N
when WRB N
analyzed VBN N
separately RB N
. . N

When WRB N
the DT N
four CD N
significant JJ N
variables NNS N
were VBD N
compared VBN N
against IN N
each DT N
other JJ N
in IN N
a DT N
single JJ N
regression NN N
analysis NN N
, , N
IEP NNP N
quality NN N
accounted VBD N
for IN N
one CD N
quarter NN N
of IN N
the DT N
variance NN N
in IN N
child NN N
outcomes NNS N
. . N

-DOCSTART- -3074300- O O

Role NNP N
of IN N
angiotensin-converting JJ i
enzyme NN i
inhibitors NNS i
in IN N
early JJ N
antihypertensive JJ N
treatment NN N
in IN N
non-insulin JJ p
dependent NN p
diabetes VBZ p
mellitus NN p
. . N

The DT N
effect NN N
of IN N
captopril NN i
monotherapy NN N
on IN N
blood NN o
pressure NN o
and CC N
metabolism NN o
was VBD N
investigated VBN N
in IN N
a DT N
placebo-controlled JJ i
study NN N
in IN N
30 CD p
non-insulin JJ p
dependent NN p
( ( p
Type NNP p
II NNP p
) ) p
diabetic JJ p
subjects NNS p
during IN N
a DT N
3-week JJ N
observation NN N
period NN N
( ( N
run-in/drug JJ N
; : N
placebo/wash-out NN N
) ) N
on IN N
a DT N
metabolic JJ N
ward NN N
. . N

Captopril NNP i
significantly RB N
reduced VBD N
both DT N
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
( ( N
154/90 CD N
+/- JJ N
5/2 CD N
vs. FW N
144/86 CD N
+/- JJ N
4/3 CD N
mmHg NN N
) ) N
without IN N
major JJ N
side NN N
effects NNS N
. . N

Mean JJ N
run-in JJ N
postprandial JJ o
blood NN o
glucose JJ o
concentrations NNS o
were VBD N
also RB N
reduced VBN N
upon IN N
ACE-inhibition NNP N
( ( N
9 CD N
a.m. RB N
: : N
12.7 CD N
+/- JJ N
0.4 CD N
vs. FW N
11.1 CD N
+/- JJ N
0.4 CD N
mmol/l NN N
; : N
1 CD N
p.m. NN N
: : N
11.0 CD N
+/- JJ N
0.3 CD N
vs. FW N
8.9 CD N
+/- JJ N
0.3 CD N
mmol/l NN N
; : N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
while IN N
blood NN o
kinin NN o
concentrations NNS o
( ( N
40.0 CD N
+/- JJ N
2.5 CD N
pmol/l NN N
) ) N
were VBD N
approximately RB N
doubled VBN N
( ( N
108.8 CD N
+/- JJ N
23.5 CD N
pmol/l NN N
; : N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Body NNP o
mass NN o
index NN o
, , o
fasting VBG o
plasma JJ o
insulin NN o
, , o
serum JJ o
electrolyte NN o
pattern NN o
, , o
uric JJ o
acid NN o
, , o
white JJ o
blood NN o
count NN o
, , o
lipid JJ o
profile NN o
as RB N
well RB N
as IN N
hepatic JJ o
and CC o
renal JJ o
function NN o
parameters NNS N
remained VBD N
unaltered JJ N
throughout IN N
the DT N
observation NN N
period NN N
. . N

The DT N
data NNS N
are VBP N
in IN N
line NN N
with IN N
recent JJ N
experimental JJ N
studies NNS N
showing VBG N
a DT N
beneficial JJ N
metabolic JJ N
effect NN N
of IN N
captopril NN i
in IN N
Type NNP N
II NNP N
diabetes VBZ N
. . N

ACE NNP i
inhibitors NNS i
might MD N
therefore VB N
become JJ N
first-line JJ N
drugs NNS N
in IN N
early JJ N
antihypertensive JJ N
intervention NN N
in IN N
Type NNP p
II NNP p
diabetic JJ p
patients NNS N
. . N

-DOCSTART- -20560622- O O

Influence NN N
of IN N
diets NNS N
rich JJ N
in IN N
Maillard NNP i
reaction NN i
products NNS i
on IN N
calcium NN o
bioavailability NN o
. . N

Assays NNS N
in IN N
male JJ p
adolescents NNS p
and CC N
in IN N
Caco-2 NNP N
cells NNS N
. . N

The DT N
effects NNS N
of IN N
the DT N
high JJ N
intake NN N
of IN N
Maillard NNP i
reaction NN i
products NNS i
( ( i
MRP NNP i
) ) i
on IN N
calcium NN o
availability NN o
in IN N
adolescents NNS p
and CC N
across IN N
Caco-2 NNP N
cell NN N
monolayers NNS N
were VBD N
examined VBN N
. . N

In IN N
a DT N
2 CD N
week NN N
randomized VBN N
two-period JJ N
crossover NN N
trial NN N
, , N
18 CD p
male NN p
adolescents NNS p
consumed VBD N
two CD N
diets NNS N
, , N
named VBN N
white JJ i
diet NN i
( ( i
WD NNP i
) ) i
and CC N
brown JJ i
diet NN i
( ( i
BD NNP i
) ) i
, , N
which WDT N
were VBD N
poor JJ N
and CC N
rich JJ N
in IN N
MRP NNP i
, , N
respectively RB N
. . N

A DT N
3 CD N
day NN N
balance NN N
was VBD N
performed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
period NN N
, , N
and CC N
fasting VBG o
blood NN o
samples NNS o
were VBD N
collected VBN N
. . N

Calcium NNP o
solubility NN o
and CC o
absorption NN o
across IN o
Caco-2 NNP o
cells NNS o
were VBD N
studied VBN N
after IN N
the DT N
in IN N
vitro JJ N
digestion NN N
of IN N
the DT N
diets NNS N
. . N

The DT N
in IN N
vitro NN N
assay NN N
showed VBD N
similar JJ N
solubility NN o
after IN N
the DT N
in IN N
vitro JJ N
digestion NN N
and CC N
similar JJ N
transport NN N
across IN N
Caco-2 NNP N
cells NNS N
. . N

In IN N
accordance NN N
, , N
calcium NN o
bioavailability NN o
in IN N
adolescents NNS N
did VBD N
not RB N
vary JJ N
between IN N
the DT N
diets NNS N
( ( N
% NN N
WD NNP N
= VBZ N
40.4 CD N
+/- JJ N
5.1 CD N
, , N
% NN N
BD NNP N
= VBZ N
38.2 CD N
+/- JJ N
3.6 CD N
) ) N
. . N

Serum NNP o
and CC o
urine JJ o
biochemical JJ o
parameters NNS o
related VBN o
to TO o
calcium NN o
status NN o
and CC o
bone NN o
metabolism NN o
remained VBD N
unaltered JJ N
. . N

Only RB N
deoxypyridinoline JJ o
values NNS N
were VBD N
significantly RB N
lower JJR N
after IN N
consumption NN N
of IN N
the DT N
BD NNP N
( ( N
13.0 CD N
+/- JJ N
1.1 CD N
compared VBN N
to TO N
18.3 CD N
+/- JJ N
2.1 CD N
nM/Mm JJ N
Cr NNP N
in IN N
the DT N
WD NNP N
) ) N
, , N
possibly RB N
indicative JJ N
of IN N
less RBR N
efficient JJ N
bone NN o
turnover NN o
during IN N
this DT N
period NN N
. . N

As IN N
calcium NN N
acquired VBD N
during IN N
adolescence NN N
is VBZ N
essential JJ N
to TO N
maximize VB N
peak JJ N
bone NN N
mass NN N
and CC N
to TO N
prevent VB N
osteoporosis NN N
, , N
possible JJ N
long-term JJ N
effects NNS N
of IN N
excessive JJ N
MRP NNP i
intake NN N
during IN N
this DT N
period NN N
warrant JJ N
attention NN N
. . N

-DOCSTART- -8771302- O O

Fluoroscopic NNP N
functional JJ N
evaluation NN N
of IN N
bileaflet NN i
prostheses NNS i
: : N
effect NN N
of IN N
different JJ N
intraoperative JJ N
valve NN N
orientation NN N
. . N

Fluoroscopy NNP N
is VBZ N
a DT N
reliable JJ N
, , N
easy JJ N
, , N
and CC N
readily RB N
available JJ N
technique NN N
to TO N
follow-up JJ N
prosthesis NN N
functioning NN N
after IN N
heart NN N
valve NN N
surgery NN N
. . N

The DT N
different JJ N
orientation NN N
given VBN N
to TO N
the DT N
prosthesis NN N
may MD N
represent VB N
a DT N
limitation NN N
of IN N
the DT N
technique NN N
accounting NN N
for IN N
unsatisfactory JJ N
results NNS N
in IN N
10 CD N
% NN N
to TO N
40 CD N
% NN N
of IN N
the DT N
cases NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
and CC N
to TO N
what WP N
extent VB N
different JJ N
intraoperative JJ N
valve NN N
orientation NN N
influence NN N
feasibility NN o
and CC N
accuracy NN o
of IN N
postoperative JJ N
fluoroscopic JJ N
evaluation NN N
of IN N
bileaflet NN i
prostheses NNS i
. . N

We PRP N
prospectively RB N
evaluated VBD N
90 CD p
patients NNS p
who WP p
had VBD p
aortic JJ p
, , p
mitral JJ p
, , p
and/or JJ p
tricuspid JJ p
valve FW p
replacement NN p
with IN p
Sorin NNP i
Bicarbon NNP i
or CC i
CarboMedics NNPS i
bileaflet NN i
prostheses NNS i
. . N

Fifty NNP N
percent NN N
of IN N
the DT N
patients NNS N
in IN N
each DT N
group NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
prostheses NNS i
oriented VBN N
in IN N
a DT N
perpendicular NN N
or CC N
a DT N
parallel JJ N
position NN N
with IN N
respect NN N
to TO N
the DT N
ventricular JJ N
septum NN N
. . N

Fluoroscopic NNP N
evaluation NN N
was VBD N
considered VBN N
appropriate JJ N
when WRB N
the DT N
prosthesis NN N
' POS N
tilting VBG N
disk NN N
projection NN N
was VBD N
obtained VBN N
. . N

The DT N
valve NN N
's POS N
hemodynamic JJ o
performance NN o
was VBD N
investigated VBN N
through IN N
Doppler NNP N
study NN N
. . N

A DT N
proper JJ N
fluoroscopic NN o
evaluation NN o
was VBD N
rapidly RB N
( ( N
15 CD N
+/- JJ N
5 CD N
seconds NNS N
) ) N
achieved VBN N
in IN N
all DT N
patients NNS N
with IN N
the DT N
former JJ N
orientation NN N
, , N
whereas IN N
it PRP N
was VBD N
impossible JJ N
to TO N
obtain VB N
it PRP N
in IN N
8 CD N
of IN N
20 CD N
( ( N
40 CD N
% NN N
) ) N
, , N
19 CD N
of IN N
20 CD N
( ( N
95 CD N
% NN N
) ) N
, , N
and CC N
4 CD N
of IN N
5 CD N
( ( N
80 CD N
% NN N
) ) N
of IN N
patients NNS N
with IN N
the DT N
latter JJ N
orientation NN N
. . N

In IN N
the DT N
remaining VBG N
patients NNS N
extremely RB N
angulated VBN N
, , N
uneasy JJ N
projection NN N
was VBD N
often RB N
required VBN N
to TO N
get VB N
a DT N
correct JJ N
fluoroscopic NN N
image NN N
. . N

The DT N
Doppler NNP N
study NN N
showed VBD N
a DT N
similarly RB N
favorable JJ N
hemodynamic JJ o
performance NN o
regardless NN N
of IN N
valve JJ N
orientation NN N
. . N

Prosthesis NNP i
orientation NN N
crucially RB N
affects VBZ N
the DT N
rate NN o
of IN o
success NN o
of IN o
the DT o
fluoroscopic JJ o
evaluation NN o
. . N

The DT N
orientation NN N
perpendicular NN N
to TO N
the DT N
ventricular JJ N
septum NN N
greatly RB N
facilitates VBZ N
the DT N
postoperative JJ N
feasibility NN o
and CC o
accuracy NN o
of IN o
fluoroscopy NN o
, , N
and CC N
it PRP N
is VBZ N
not RB N
detrimental JJ N
to TO N
the DT N
valve NN o
's POS o
hemodynamic JJ o
performance NN o
. . N

This DT N
valve JJ N
orientation NN N
may MD N
provide VB N
a DT N
better JJR N
fluoroscopic NN o
window NN N
whenever WRB N
a DT N
valve NN N
dysfunction NN N
is VBZ N
suspected VBN N
. . N

-DOCSTART- -11381289- O O

Why WRB N
were VBD N
the DT N
results NNS N
of IN N
the DT N
Heart NNP N
Outcomes NNP N
Prevention NNP N
Evaluation NNP N
( ( N
HOPE NNP N
) ) N
trial NN N
so IN N
astounding VBG N
? . N
The DT N
Heart NNP N
Outcomes NNP N
Prevention NNP N
Evaluation NNP N
( ( N
HOPE NNP N
) ) N
study NN N
was VBD N
important JJ N
because IN N
it PRP N
showed VBD N
the DT N
benefits NNS N
of IN N
ramipril NN i
- : N
an DT N
angiotensin-converting JJ i
enzyme NN i
( ( i
ACE NNP i
) ) i
inhibitor NN i
- : N
in IN N
patients NNS p
at IN p
high JJ p
risk NN p
for IN p
cardiovascular JJ p
events NNS p
. . N

Treatment NN N
with IN N
ramipril NN i
significantly RB N
reduced VBD N
the DT N
rates NNS o
of IN o
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
stroke NN o
, , o
coronary JJ o
revascularization NN o
, , o
cardiac JJ o
arrest NN o
and CC o
heart NN o
failure NN o
, , o
as RB N
well RB N
as IN N
the DT N
risk NN o
of IN o
diabetes-related JJ o
complications NNS o
and CC o
of IN o
diabetes NNS o
itself PRP o
. . N

The DT N
effects NNS N
of IN N
therapy NN N
with IN N
vitamin JJ i
E NN i
were VBD N
also RB N
evaluated VBN N
, , N
but CC N
no DT N
statistical JJ N
benefits NNS N
were VBD N
shown VBN N
. . N

The DT N
benefits NNS N
of IN N
ACE NNP i
inhibitor NN i
therapy NN N
that WDT N
were VBD N
observed VBN N
were VBD N
likely JJ N
due JJ N
to TO N
a DT N
variety NN N
of IN N
mechanisms NNS N
, , N
not RB N
just RB N
a DT N
reduction NN N
in IN N
blood NN N
pressure NN N
. . N

-DOCSTART- -7814711- O O

Efficacy NN N
of IN N
intramuscular JJ N
oxytetracycline NN i
as IN N
a DT N
dry JJ N
cow NN N
treatment NN N
for IN N
Staphylococcus NNP N
aureus NN N
mastitis NN N
. . N

To TO N
determine VB N
the DT N
efficacy NN N
of IN N
intramuscular JJ N
oxytetracycline NN i
as IN N
a DT N
supplemental JJ N
dry JJ N
cow NN N
treatment NN N
for IN N
Staphylococcus NNP N
aureus NN N
mastitis NN N
, , N
37 CD p
Holstein NNP p
cows NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
treatment NN N
groups NNS N
: : N
intracisternal JJ N
infusion NN N
with IN N
a DT N
commercial JJ N
preparation NN N
of IN N
cephapirin JJ i
benzathine NN i
at IN N
drying VBG N
off RP N
( ( N
20 CD N
cows NNS N
) ) N
and CC N
infusion NN N
with IN N
cephapirin JJ i
benzathine NN i
at IN N
drying VBG N
off RP N
and CC N
intramuscular JJ N
oxytetracycline NN i
at IN N
11 CD N
mg/kg NNS N
once RB N
daily RB N
on IN N
d NN N
7 CD N
, , N
8 CD N
, , N
9 CD N
, , N
and CC N
10 CD N
after IN N
drying VBG N
off RB N
( ( N
17 CD N
cows NNS N
) ) N
. . N

Milk NN N
samples NNS N
collected VBD N
7 CD N
, , N
14 CD N
, , N
30 CD N
, , N
and CC N
60 CD N
d NN N
after IN N
calving VBG N
were VBD N
plated VBN N
for IN N
bacterial JJ N
isolation NN N
within IN N
24 CD N
h NN N
after IN N
collection NN N
and CC N
after IN N
24 CD N
to TO N
72 CD N
h NN N
of IN N
storage NN N
at IN N
-20 NNP N
degrees NNS N
C. NNP N
Quarters NNS N
were VBD N
defined VBN N
as IN N
infected JJ N
if IN N
S. NNP N
aureus NN N
was VBD N
isolated VBN N
from IN N
the DT N
fresh JJ N
and CC N
frozen JJ N
cultures NNS N
from IN N
any DT N
one CD N
sample NN N
collected VBD N
before IN N
drying VBG N
off RP N
. . N

An DT N
infected JJ N
quarter NN N
was VBD N
defined VBN N
as IN N
cured JJ N
if IN N
S. NNP N
aureus NN N
was VBD N
not RB N
isolated VBN N
from IN N
the DT N
fresh JJ N
or CC N
frozen JJ N
culture NN N
from IN N
milk NN N
samples NNS N
obtained VBD N
following VBG N
calving NN N
. . N

The DT N
rate NN o
of IN o
cure NN o
by IN N
30 CD N
d NN N
after IN N
calving VBG N
for IN N
systemic JJ N
oxytetracycline NN i
( ( N
in IN N
combination NN N
with IN N
cephapirin JJ i
treatment NN N
) ) N
was VBD N
29.4 CD N
% NN N
for IN N
infected JJ N
quarters NNS N
and CC N
29.4 CD N
% NN N
for IN N
infected JJ N
cows NNS N
, , N
compared VBN N
with IN N
27.5 CD N
and CC N
25.0 CD N
% NN N
, , N
respectively RB N
, , N
for IN N
the DT N
cephapirin NN i
treatment NN N
only RB N
. . N

Results NNS N
including VBG N
the DT N
culture NN N
at IN N
60 CD N
d NN N
after IN N
calving VBG N
were VBD N
21.2 CD N
and CC N
22.5 CD N
% NN N
, , N
respectively RB N
, , N
for IN N
combination NN N
therapy NN N
and CC N
cephapirin NN i
therapy NN N
only RB N
. . N

Systemic NNP N
oxytetracycline NN i
, , N
in IN N
combination NN N
with IN N
intramammary JJ N
dry JJ N
cow NN N
treatment NN N
, , N
did VBD N
not RB N
improve VB N
the DT N
rate NN o
of IN o
cure NN o
for IN N
S. NNP N
aureus JJ N
mastitis NN N
. . N

-DOCSTART- -10578479- O O

Effects NNS N
of IN N
soy JJ i
intake NN N
on IN N
sex NN o
hormone NN o
metabolism NN o
in IN N
premenopausal JJ p
women NNS p
. . N

Studies NNS N
suggest VBP N
that IN N
phytoestrogens NNS N
in IN N
soy JJ i
products NNS N
may MD N
impart VB N
hormonal JJ N
effects NNS N
that WDT N
protect VBP N
women NNS N
against IN N
breast NN N
cancer NN N
. . N

Limited VBN N
research NN N
suggests VBZ N
that IN N
intake NN N
of IN N
soy NN i
products NNS N
high JJ N
in IN N
isoflavonoid JJ N
phytoestrogens NNS N
affects VBZ N
sex NN o
hormone NN o
metabolism NN o
, , N
but CC N
it PRP N
is VBZ N
unknown JJ N
whether IN N
phytoestrogens NNS N
in IN N
soy NNS N
have VBP N
any DT N
effect NN N
on IN N
menstrual JJ N
function NN N
or CC N
serum VB N
sex NN N
hormones NNS N
in IN N
women NNS p
on IN N
common JJ N
hormone NN N
therapies NNS N
, , N
such JJ N
as IN N
oral JJ N
contraceptives NNS N
( ( N
OC NNP N
) ) N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
soy NN i
in IN N
36 CD p
premenopausal JJ p
women NNS p
, , p
20 CD p
of IN p
whom WP p
used VBD p
OC NNP p
. . N

Subjects NNS N
consumed VBD N
their PRP$ N
normal JJ N
diet NNS N
for IN N
two CD N
menstrual JJ N
cycles NNS N
and CC N
added VBD N
a DT N
soy JJ i
beverage NN i
containing VBG N
20 CD N
g NN N
of IN N
protein NN N
and CC N
38 CD N
mg NN N
of IN N
total JJ N
isoflavones NNS N
to TO N
their PRP$ N
usual JJ N
diet NN N
for IN N
another DT N
two CD N
menstrual JJ N
cycles NNS N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
serum NN o
estrone NN o
, , o
estradiol NN o
, , o
sex NN o
hormone-binding JJ o
globulin NN o
, , o
dehydroepiandrosterone NN o
sulfate NN o
, , o
prolactin NN o
, , o
or CC o
progesterone NN o
concentrations NNS o
with IN N
soy JJ i
feeding NN N
in IN N
the DT N
non-OC JJ N
or CC N
the DT N
OC NNP N
group NN N
. . N

No DT N
changes NNS N
in IN N
menstrual JJ o
cycle NN o
length NN o
or CC o
the DT o
urinary JJ o
estrogen NN o
metabolite NNS o
ratio NN o
of IN o
2-hydroxyestrone CD o
to TO o
16 CD o
alpha-hydroxyestrone NN o
were VBD N
seen VBN N
with IN N
soy JJ N
feeding NN N
in IN N
the DT N
non-OC JJ N
or CC N
the DT N
OC NNP N
group NN N
. . N

Levels NNP N
of IN N
urinary JJ o
estrogen NN o
metabolites NNS o
were VBD N
significantly RB N
different JJ N
between IN N
the DT N
non-OC JJ N
and CC N
the DT N
OC NNP N
group NN N
. . N

Thus RB N
soy JJ i
consumption NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
the DT N
menstrual JJ o
cycle NN o
, , o
serum JJ o
sex NN o
hormones NNS o
, , o
or CC o
urinary JJ o
estrogen NN o
metabolite NN o
ratio NN o
in IN N
premenopausal NN p
OC NNP p
or CC N
non-OC JJ p
users NNS p
. . N

-DOCSTART- -22538329- O O

Spotty JJ N
calcification NN N
as IN N
a DT N
marker NN N
of IN N
accelerated JJ N
progression NN o
of IN o
coronary JJ o
atherosclerosis NN o
: : N
insights NNS N
from IN N
serial JJ N
intravascular JJ N
ultrasound NN N
. . N

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
atheroma JJ o
progression NN o
in IN N
patients NNS p
with IN p
spotty JJ p
calcification NN p
. . N

BACKGROUND NNP N
Although IN N
extensively RB N
calcified VBN N
atherosclerotic JJ N
lesions NNS N
have VBP N
been VBN N
proposed VBN N
to TO N
be VB N
clinically RB N
quiescent JJ N
, , N
the DT N
presence NN N
of IN N
spotty JJ N
calcification NN N
within IN N
plaque NN N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
associated VBN N
with IN N
an DT N
increased JJ N
incidence NN N
of IN N
ischemic JJ N
cardiovascular JJ N
events NNS N
. . N

The DT N
relationship NN N
between IN N
spotty JJ N
calcification NN N
and CC N
disease NN o
progression NN o
has VBZ N
not RB N
been VBN N
investigated VBN N
. . N

METHODS NNP N
A NNP N
total NN p
of IN p
1,347 CD p
stable JJ p
patients NNS p
with IN p
angiographic JJ p
coronary JJ p
artery NN p
disease NN p
underwent JJ N
serial JJ N
evaluation NN N
of IN N
atheroma JJ o
burden NN o
with IN N
intravascular JJ N
ultrasound NN N
imaging NN N
. . N

Patients NNS p
with IN p
spotty JJ p
calcification NN p
were VBD p
identified VBN p
based VBN p
on IN p
the DT p
presence NN p
of IN p
lesions NNS p
( ( p
1 CD p
to TO p
4 CD p
mm NNS p
in IN p
length NN p
) ) p
containing VBG p
an DT p
arc NN p
of IN p
calcification NN p
of IN p
< $ p
90? CD p
. . N

Clinical JJ N
characteristics NNS o
and CC o
disease NN o
progression NN o
were VBD N
compared VBN N
between IN N
patients NNS N
with IN N
spotty JJ N
calcification NN N
( ( N
n JJ N
= NNP N
922 CD N
) ) N
and CC N
those DT N
with IN N
no DT N
calcification NN N
( ( N
n JJ N
= NNP N
425 CD N
) ) N
. . N

RESULTS JJ N
Patients NNS p
with IN p
spotty JJ p
calcification NN p
were VBD p
older JJR p
( ( p
age NN p
56 CD p
years NNS p
vs. IN p
54 CD N
years NNS p
; : p
p VBZ p
= $ p
0.001 CD p
) ) p
, , p
more RBR p
likely JJ p
to TO p
be VB p
male JJ p
( ( p
68 CD p
% NN p
vs. FW p
54 CD N
% NN p
; : p
p CC N
= VB N
0.01 CD N
) ) N
, , N
and CC N
have VBP N
a DT N
history NN N
of IN N
diabetes NNS N
mellitus NNS N
( ( N
30 CD N
% NN N
vs. FW N
24 CD N
% NN N
; : N
p CC N
= VB N
0.01 CD N
) ) N
and CC N
myocardial JJ N
infarction NN N
( ( N
28 CD N
% NN N
vs. FW N
20 CD N
% NN N
; : N
p CC N
= VB N
0.004 CD N
) ) N
, , N
and CC N
have VBP N
lower JJR N
on-treatment JJ N
high-density NN o
lipoprotein NN o
cholesterol NN o
levels NNS o
( ( N
48 CD N
? . N
16 CD N
mg/dl NN N
vs. FW N
51 CD N
? . N
17 CD N
mg/dl NN N
; : N
p CC N
= VB N
0.001 CD N
) ) N
. . N

Patients NNS N
with IN N
spotty JJ N
calcification NN N
demonstrated VBD N
a DT N
greater JJR N
percent JJ o
atheroma NN o
volume NN o
( ( o
PAV NNP o
) ) o
( ( N
36.0 CD N
? . N
7.6 CD N
% NN N
vs. FW N
29.0 CD N
? . N
8.5 CD N
% NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
and CC N
total JJ o
atheroma NN o
volume NN o
( ( N
174.6 CD N
? . N
71.9 CD N
mm NN N
( ( N
3 CD N
) ) N
vs. FW N
133.9 CD N
? . N
64.9 CD N
mm NN N
( ( N
3 CD N
) ) N
; : N
p CC N
< VB N
0.001 CD N
) ) N
. . N

On IN N
serial JJ N
evaluation NN N
, , N
spotty JJ N
calcification NN N
was VBD N
associated VBN N
with IN N
greater JJR N
progression NN o
of IN o
PAV NNP o
( ( N
+0.43 NNP N
? . N
0.07 CD N
% NN N
vs. FW N
+0.02 NNP N
? . N
0.11 CD N
% NN N
; : N
p CC N
= VB N
0.002 CD N
) ) N
. . N

Although IN N
intensive JJ N
low-density NN N
lipoprotein NN N
cholesterol NN N
and CC N
blood NN N
pressure NN N
lowering VBG N
therapy NN N
slowed VBD N
disease JJ N
progression NN N
, , N
these DT N
efficacies NNS N
were VBD N
attenuated VBN N
in IN N
patients NNS p
with IN p
spotty JJ p
calcification NN p
. . N

CONCLUSIONS VB N
The DT N
presence NN N
of IN N
spotty JJ N
calcification NN N
is VBZ N
associated VBN N
with IN N
more RBR N
extensive JJ N
and CC N
diffuse NN N
coronary JJ o
atherosclerosis NN o
and CC N
accelerated JJ N
disease NN N
progression NN N
despite IN N
use NN N
of IN N
medical JJ N
therapies NNS N
. . N

-DOCSTART- -11642083- O O

[ JJ N
Neoton NNP i
and CC N
thrombolytic JJ i
therapy NN i
of IN N
myocardial JJ p
infarction NN p
] NNP N
. . N

AIM NNP N
To TO N
evaluate VB N
neoton JJ i
therapy NN N
effects NNS N
in IN N
acute JJ p
myocardial JJ p
infarction NN p
( ( p
MI NNP p
) ) p
on IN N
systolic JJ o
function NN o
of IN o
the DT o
left JJ o
ventricle NN o
, , o
arrhythmia NN o
and CC o
clinical JJ o
symptoms NNS o
in IN N
patients NNS p
on IN p
thrombolytic JJ i
therapy NN i
( ( p
TLT NNP i
) ) p
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
106 CD p
males NNS p
with IN p
Q-MI NNP p
entered VBD p
the DT p
study NN p
. . N

47 CD N
received VBD N
treatment NN N
without IN N
TLT NNP i
and CC N
neoton NN i
, , N
30 CD N
patients NNS N
received VBD N
TLT NNP i
with IN N
streptokinase JJ i
preparations NNS N
, , N
29 CD N
patients NNS N
were VBD N
given VBN N
streptokinase JJ i
preparations NNS i
and CC N
neoton NN i
. . N

Left NNP o
ventricular JJ o
systolic JJ o
function NN o
was VBD N
measured VBN N
by IN N
echocardiography NN N
on IN N
day NN N
1 CD N
, , N
3 CD N
, , N
7 CD N
, , N
14 CD N
, , N
21 CD N
and CC N
28 CD N
; : N
arrhythmia NN o
was VBD N
analysed VBN N
at IN N
Holter NNP N
monitoring VBG N
in IN N
day NN N
1 CD N
and CC N
2 CD N
of IN N
MI NNP N
. . N

RESULTS NNP N
TLT NNP N
failed VBD N
to TO N
arrest VB N
progression NN N
of IN N
left JJ N
ventricular JJ N
dilation NN N
by IN N
the DT N
end NN N
of IN N
the DT N
hospital NN N
stay NN N
. . N

Patients NNS N
given VBN N
neoton NNS i
in IN N
acute JJ N
period NN N
of IN N
MI NNP N
had VBD N
no DT N
increase NN N
in IN N
the DT N
end NN N
systolic NN o
and CC o
diastolic JJ o
volumes NNS o
of IN N
the DT N
left JJ N
ventricle NN N
in IN N
the DT N
course NN N
of IN N
the DT N
first JJ N
months NNS N
after IN N
MI NNP N
onset NN N
. . N

Antiarrhythmic NNP N
action NN N
of IN N
neoton NN i
manifested VBN N
on IN N
MI NNP N
day NN N
2 CD N
. . N

CONCLUSION NNP N
Neoton NNP i
given VBN N
to TO N
MI NNP N
patients NNS N
receiving VBG N
TLT NNP N
prevents NNS N
progression NN N
of IN N
left JJ o
ventricular JJ o
systolic JJ o
dysfunction NN o
and CC N
establishment NN N
of IN N
predictors NNS N
of IN N
unfavourable JJ N
outcome NN N
. . N

-DOCSTART- -23356250- O O

Influence NN N
of IN N
lime NN i
juice NN i
on IN N
the DT N
severity NN N
of IN N
sickle NN p
cell NN p
anemia NN p
. . N

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
The DT N
pain NN N
in IN N
sickle NN N
cell NN N
anemia NN N
( ( N
SCA NNP N
) ) N
is VBZ N
often RB N
triggered VBN N
by IN N
dehydration NN N
, , N
acidosis NN N
, , N
and CC N
fever NN N
that WDT N
are VBP N
usually RB N
due JJ N
to TO N
malaria VB N
. . N

Intake NNP N
of IN N
lime JJ i
juice NN i
was VBD N
recently RB N
demonstrated VBN N
to TO N
facilitate VB N
clearance NN N
of IN N
the DT N
malaria NN N
parasite NN N
. . N

It PRP N
was VBD N
therefore RB N
sought VBN N
to TO N
determine VB N
whether IN N
regular JJ N
intake NN N
of IN N
lime JJ i
juice NN i
will MD N
ameliorate VB N
crisis NN N
, , N
especially RB N
recurrent JJ o
bone NN o
pain NN o
. . N

DESIGN NN N
In IN N
this DT N
preliminary JJ N
, , N
open-labeled JJ N
, , N
randomized JJ N
study NN N
, , N
the DT N
effects NNS N
of IN N
lime JJ i
juice NN i
on IN N
the DT N
clinical JJ N
and CC N
some DT N
laboratory JJ N
characteristics NNS N
of IN N
children NNS p
with IN p
SCA NNP p
were VBD N
tested VBN N
. . N

RESULTS NNP N
Among IN N
the DT N
113 CD p
children NNS p
with IN p
SCA NNP p
studied VBN p
in IN p
two CD p
hospitals NNS p
, , N
the DT N
58 CD N
receiving NN N
lime NN N
treatment NN N
had VBD N
lower JJR N
rates NNS N
of IN N
significant JJ o
painful JJ o
episodes NNS o
than IN N
the DT N
55 CD N
without IN i
lime NN i
( ( N
37 CD N
versus NN N
83 CD N
crises NNS N
in IN N
6 CD N
months NNS N
, , N
and CC N
0.64?0.11 CD N
versus NN N
1.51?0.34 CD N
average JJ N
rates NNS N
per IN N
child NN N
, , N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Also RB N
, , N
fewer JJR N
subjects NNS N
than IN N
the DT N
controls NNS N
had VBD N
significant JJ N
painful JJ o
episodes NNS o
( ( N
50.0 CD N
% NN N
versus IN N
92.7 CD N
% NN N
) ) N
; : N
febrile JJ o
illness NN o
( ( N
46.6 CD N
% NN N
versus IN N
87.3 CD N
% NN N
) ) N
and CC N
admission NN o
rate NN o
( ( N
3.4 CD N
% NN N
versus IN N
34.5 CD N
% NN N
) ) N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
mean JJ o
hematocrit NN o
of IN N
the DT N
subjects NNS N
( ( N
26.23?2.03 CD N
% NN N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
also RB N
higher JJR N
, , N
p JJ N
< NN N
0.001 CD N
. . N

However RB N
, , N
transfusion NN o
rate NN o
, , o
presence NN o
of IN o
hepatomegaly NN o
, , o
splenomegaly NN o
, , o
and CC o
jaundice NN o
was VBD N
similar JJ N
. . N

Treatment NN N
with IN N
lime NN i
did VBD N
not RB N
cause VB N
any DT N
significant JJ o
side-effect JJ o
. . N

CONCLUSIONS NNP N
Regular NNP N
intake NN N
of IN N
lime JJ i
juice NN i
may MD N
be VB N
of IN N
great JJ N
therapeutic JJ N
and CC N
nutritional JJ N
relevance NN N
in IN N
children NNS p
with IN p
SCA NNP p
. . N

-DOCSTART- -11891832- O O

Comparison NNP N
of IN N
weakness NN o
progression NN o
in IN N
inclusion NN p
body NN p
myositis NN p
during IN N
treatment NN N
with IN N
methotrexate NN i
or CC N
placebo NN i
. . N

We PRP N
investigated VBD N
whether IN N
5 CD N
to TO N
20mg CD N
per IN N
week NN N
oral JJ N
methotrexate NN i
could MD N
slow VB N
down RP N
disease NN o
progression NN o
in IN N
44 CD p
patients NNS p
with IN p
inclusion NN p
body NN p
myositis NN p
in IN N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
over IN N
48 CD N
weeks NNS N
. . N

Mean NNP o
change NN o
of IN o
quantitative JJ o
muscle NN o
strength NN o
testing VBG o
sum NN o
scores NNS o
was VBD N
the DT N
primary JJ N
study NN N
outcome JJ N
measure NN N
. . N

Quantitative JJ o
muscle NN o
strength NN o
testing VBG o
sum NN o
scores NNS o
declined VBD N
in IN N
both DT N
treatment NN N
groups NNS N
, , N
-0.2 CD N
% NN N
for IN N
methotrexate NN i
and CC N
-3.4 CD N
% NN N
for IN N
placebo NN i
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
= NNP N
-2.5 NNP N
% NN N
to TO N
+9.1 CD N
% NN N
for IN N
difference NN N
) ) N
. . N

There EX N
were VBD N
also RB N
no DT N
differences NNS N
in IN N
manual JJ o
muscle NN o
testing VBG o
sum JJ o
scores NNS o
, , o
activity NN o
scale NN o
scores NNS o
and CC o
patients NNS o
' POS o
own JJ o
assessments NNS o
after IN N
48 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Serum NNP o
creatine JJ o
kinase NN o
activity NN o
decreased VBN N
significantly RB N
in IN N
the DT N
methotrexate NN i
group NN N
. . N

We PRP N
conclude VBP N
that IN N
oral JJ N
methotrexate NN i
did VBD N
not RB N
slow VB N
down RP N
progression NN o
of IN o
muscle NN o
weakness NN o
but CC N
decreased VBD N
serum JJ o
creatine JJ o
kinase NN o
activity NN o
. . N

-DOCSTART- -21975269- O O

Use NNP N
of IN N
hormonal JJ i
contraceptives NNS i
and CC N
risk NN N
of IN N
HIV-1 NNP N
transmission NN N
: : N
a DT N
prospective JJ N
cohort NN N
study NN N
. . N

BACKGROUND NNP N
Hormonal NNP i
contraceptives NNS i
are VBP N
used VBN N
widely RB N
but CC N
their PRP$ N
effects NNS N
on IN N
HIV-1 NNP N
risk NN N
are VBP N
unclear JJ N
. . N

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
association NN N
between IN N
hormonal JJ i
contraceptive NN i
use NN N
and CC N
risk NN N
of IN N
HIV-1 NNP N
acquisition NN N
by IN N
women NNS N
and CC N
HIV-1 JJ N
transmission NN N
from IN N
HIV-1-infected JJ N
women NNS N
to TO N
their PRP$ N
male JJ N
partners NNS N
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
study NN N
, , N
we PRP N
followed VBD N
up RP N
3790 CD p
heterosexual JJ p
HIV-1-serodiscordant JJ p
couples NNS p
participating VBG p
in IN p
two CD p
longitudinal JJ p
studies NNS p
of IN p
HIV-1 NNP p
incidence NN p
in IN p
seven CD p
African JJ p
countries NNS p
. . N

Among IN N
injectable JJ N
and CC N
oral JJ N
hormonal JJ i
contraceptive NN i
users NNS N
and CC N
non-users NNS N
, , N
we PRP N
compared VBN N
rates NNS N
of IN N
HIV-1 NNP N
acquisition NN N
by IN N
women NNS N
and CC N
HIV-1 JJ N
transmission NN N
from IN N
women NNS N
to TO N
men NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
HIV-1 JJ N
seroconversion NN N
. . N

We PRP N
used VBD N
Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
and CC N
marginal JJ N
structural JJ N
modelling NN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
contraceptive NN N
use NN N
on IN N
HIV-1 NNP N
risk NN N
. . N

FINDINGS NNP N
Among IN N
1314 CD p
couples NNS p
in IN p
which WDT p
the DT p
HIV-1-seronegative JJ p
partner NN p
was VBD p
female JJ p
( ( N
median JJ N
follow-up NN N
18?0 CD N
[ JJ N
IQR NNP N
12?6-24?2 JJ N
] NNP N
months NNS N
) ) N
, , N
rates NNS N
of IN N
HIV-1 NNP o
acquisition NN o
were VBD N
6?61 CD N
per IN N
100 CD N
person-years NNS N
in IN N
women NNS N
who WP N
used VBD N
hormonal JJ i
contraception NN i
and CC N
3?78 CD N
per IN N
100 CD N
person-years NNS N
in IN N
those DT N
who WP N
did VBD N
not RB N
( ( N
adjusted VBN N
hazard RB N
ratio JJ N
1?98 CD N
, , N
95 CD N
% NN N
CI NNP N
1?06-3?68 CD N
, , N
p=0?03 NN N
) ) N
. . N

Among IN N
2476 CD N
couples NNS p
in IN p
which WDT p
the DT p
HIV-1-seronegative JJ p
partner NN p
was VBD p
male JJ p
( ( N
median JJ N
follow-up NN N
18?7 CD N
[ JJ N
IQR NNP N
12?8-24?2 JJ N
] NNP N
months NNS N
) ) N
, , N
rates NNS N
of IN N
HIV-1 NNP o
transmission NN o
from IN N
women NNS N
to TO N
men NNS N
were VBD N
2?61 CD N
per IN N
100 CD N
person-years NNS N
in IN N
couples NNS N
in IN N
which WDT N
women NNS N
used VBD N
hormonal JJ i
contraception NN i
and CC N
1?51 CD N
per IN N
100 CD N
person-years NNS N
in IN N
couples NNS N
in IN N
which WDT N
women NNS N
did VBD N
not RB N
use VB N
hormonal JJ i
contraception NN i
( ( N
adjusted VBN N
hazard RB N
ratio JJ N
1?97 CD N
, , N
95 CD N
% NN N
CI NNP N
1?12-3?45 CD N
, , N
p=0?02 NN N
) ) N
. . N

Marginal JJ N
structural JJ N
model NN N
analyses NNS N
generated VBD N
much RB N
the DT N
same JJ N
results NNS N
to TO N
the DT N
Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
. . N

INTERPRETATION NNP N
Women NNP N
should MD N
be VB N
counselled VBN N
about IN N
potentially RB N
increased VBN N
risk NN o
of IN o
HIV-1 NNP o
acquisition NN o
and CC o
transmission NN o
with IN N
hormonal JJ i
contraception NN i
, , N
especially RB N
injectable JJ N
methods NNS N
, , N
and CC N
about IN N
the DT N
importance NN N
of IN N
dual JJ N
protection NN N
with IN N
condoms NNS N
to TO N
decrease VB N
HIV-1 NNP N
risk NN N
. . N

Non-hormonal JJ N
or CC N
low-dose JJ N
hormonal JJ i
contraceptive NN i
methods NNS N
should MD N
be VB N
considered VBN N
for IN N
women NNS N
with IN N
or CC N
at-risk JJ N
for IN N
HIV-1 NNP N
. . N

FUNDING NNP N
US NNP N
National NNP N
Institutes NNP N
of IN N
Health NNP N
and CC N
the DT N
Bill NNP N
& CC N
Melinda NNP N
Gates NNP N
Foundation NNP N
. . N

-DOCSTART- -6989377- O O

Changes NNS N
in IN N
the DT N
fatty JJ o
acid JJ o
composition NN o
of IN o
the DT o
plasma NN o
lipid JJ o
esters NNS o
during IN N
lipid-lowering JJ N
treatment NN N
with IN N
diet JJ i
, , N
clofibrate NN i
and CC N
niceritrol NN i
. . N

Reduction NN N
of IN N
the DT N
proportion NN N
of IN N
linoleate NN o
by IN N
clofibrate NN N
but CC N
not RB N
by IN N
niceritrol NN N
. . N

The DT N
fatty JJ o
acid JJ o
composition NN o
of IN o
the DT o
plasma NN o
lipid JJ o
esters NNS o
has VBZ N
been VBN N
studied VBN N
during IN N
lipid-lowering JJ N
treatment NN N
of IN N
95 CD p
patients NNS p
with IN p
atherosclerotic JJ p
disease NN p
. . N

During IN N
the DT N
first JJ N
two CD N
months NNS N
of IN N
the DT N
trial NN N
only RB N
a DT N
diet NN N
was VBD N
prescribed VBN N
. . N

During IN N
the DT N
ensuing VBG N
two CD N
months NNS N
either CC N
clofibrate NN i
or CC N
niceritrol NN i
, , N
a DT N
nicotinic JJ N
acid NN N
ester NN N
, , N
was VBD N
added VBN N
in IN N
a DT N
randomized JJ N
order NN N
. . N

During IN N
the DT N
last JJ N
two CD N
months NNS N
the DT N
second JJ N
drug NN N
was VBD N
added VBN N
. . N

The DT N
combined JJ N
treatment NN N
with IN N
diet JJ i
, , N
clofibrate NN i
and CC N
niceritrol NN i
caused VBN N
highly RB N
significant JJ N
serum NN o
lipid JJ o
reductions NNS N
. . N

The DT N
fatty JJ o
acid JJ o
composition NN o
in IN o
the DT o
plasma NN o
lipid JJ o
esters NNS o
was VBD N
determined VBN N
in IN N
samples NNS N
from IN N
each DT N
trial NN N
period NN N
to TO N
measure VB N
the DT N
degree NN N
of IN N
dietary JJ N
adherence NN N
. . N

During IN N
dietary JJ N
treatment NN N
the DT N
relative JJ N
content NN o
of IN o
saturated JJ o
and CC o
monounsaturated VBD o
fatty JJ o
acids NNS o
secreased VBD N
and CC N
the DT N
polyunsaturated JJ o
fatty JJ o
acids NNS o
increased VBD N
with IN N
an DT N
increasing VBG N
ratio NN o
between IN o
pulyunsaturated VBN o
and CC o
saturated VBN o
fatty JJ o
acids NNS o
( ( o
P/S NNP o
ratio NN o
) ) o
in IN N
the DT N
cholesterol NN N
esters NNS N
and CC N
triglycerides NNS N
. . N

Only RB N
minor JJ N
changes NNS N
were VBD N
seen VBN N
in IN N
the DT N
phospholipids NNS o
. . N

The DT N
changes NNS N
caused VBN N
by IN N
the DT N
diet NN i
were VBD N
partly RB N
reversed VBN N
by IN N
clofibrate NN i
while IN N
niceritrol NN i
did VBD N
not RB N
cause VB N
any DT N
major JJ N
changes NNS N
of IN N
the DT N
fatty JJ o
acid JJ o
composition NN o
. . N

Clofibrate NNP i
treatment NN N
coincided VBD N
with IN N
increasing VBG N
amounts NNS N
of IN N
monounsaturated JJ o
fatty JJ o
acids NNS o
, , N
especially RB N
oleate JJ o
( ( N
18 CD N
: : N
1 CD N
) ) N
, , N
in IN N
the DT N
cholesterol NN N
esters NNS N
, , N
triglycerides NNS o
and CC o
phospholipids NNS o
while IN N
there EX N
were VBD N
significant JJ N
reductions NNS N
of IN N
the DT N
content NN o
of IN o
linoleic NN o
( ( o
18 CD o
: : o
2 CD o
) ) o
acid NN o
in IN N
both CC N
the DT N
cholesterol NN N
esters NNS N
and CC N
triglycerides NNS N
. . N

The DT N
18 CD N
: : N
2/18 CD N
: : N
1 CD N
ratio NN N
decreased VBN N
significantly RB N
in IN N
all PDT N
the DT N
lipid JJ N
esters NNS N
analyzed VBD N
. . N

However RB N
, , N
the DT N
P/S NNP o
ratio NN o
was VBD N
not RB N
significantly RB N
affected VBN N
, , N
partly RB N
because IN N
the DT N
relative JJ N
content NN N
of IN N
saturated JJ o
fatty JJ o
acids NNS o
also RB N
tended VBD N
to TO N
decrease VB N
during IN N
clofibrate JJ N
treatment NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
addition NN N
of IN N
clofibrate NN N
treatment NN N
to TO N
patients NNS N
who WP N
are VBP N
on IN N
a DT N
diet JJ N
enriched VBN N
with IN N
polyunsaturated JJ N
fats NNS N
is VBZ N
associated VBN N
with IN N
a DT N
change NN N
from IN N
polyunsaturated VBN o
to TO o
monounsaturated VBN o
fatty JJ o
acids NNS o
in IN o
the DT o
plasma NN o
lipid JJ o
esters NNS o
but CC N
does VBZ N
not RB N
significantly RB N
effect NN N
the DT N
ratio NN o
between IN o
polyunsaturated VBN o
and CC o
saturated VBN o
fatty JJ o
acids NNS o
. . N

The DT N
fatty JJ N
acid NN o
changes NNS o
caused VBN N
by IN N
clofibrate NN i
treatment NN N
and CC N
counteracted VBN N
by IN N
an DT N
increased JJ N
amount NN N
of IN N
polyunsaturated JJ N
fat NN N
in IN N
the DT N
diet NN i
. . N

-DOCSTART- -10764172- O O

Intrathecal JJ N
morphine NN i
suppresses NNS N
NK NNP o
cell NN o
activity NN o
following VBG N
abdominal JJ N
surgery NN N
. . N

PURPOSE VB N
The DT N
effects NNS N
of IN N
morphine NN i
on IN N
natural JJ o
killer NN o
( ( o
NK NNP o
) ) o
cell NN o
activity NN o
were VBD N
investigated VBN N
in IN N
patients NNS p
who WP p
underwent JJ p
hysterectomy NN p
. . N

METHODS NNP N
Forty NNP p
patients NNS p
were VBD p
divided VBN p
into IN p
four CD p
groups NNS p
of IN p
ten NN p
. . N

The DT N
groups NNS N
received VBD N
intrathecal JJ N
0.5 CD N
mg NN N
morphine NN i
( ( N
Group NNP N
IT0.5 NNP N
) ) N
, , N
intrathecal JJ N
0.1 CD N
mg NN N
morphine NN i
( ( N
Group NNP N
IT0.1 NNP N
) ) N
or CC N
10 CD N
mg NNS N
morphine JJ i
i.v NN N
. . N

( ( N
Group NNP N
IV NNP N
) ) N
. . N

The DT N
remaining VBG N
ten JJ N
patients NNS N
served VBD N
as IN N
controls NNS N
and CC N
received VBN N
inhalation NN N
anesthesia NN N
alone RB N
( ( N
Group NNP N
C NNP N
) ) N
. . N

Blood NN N
samples NNS N
were VBD N
withdrawn VBN N
before RB N
and CC N
two CD N
hours NNS N
after IN N
surgery NN N
and CC N
on IN N
postoperative JJ N
days NNS N
one CD N
and CC N
two CD N
to TO N
determine VB N
the DT N
blood NN N
NK NNP N
cell NN N
activity NN N
using VBG N
a DT N
chromium NN N
release NN N
assay VBP N
with IN N
K562 NNP N
cells NNS N
as IN N
targets NNS N
, , N
plasma JJ N
catecholamines NNS N
and CC N
cortisol NN N
levels NNS N
. . N

The DT N
postoperative JJ o
pain NN o
score NN o
and CC o
side NN o
effects NNS o
were VBD N
studied VBN N
in IN N
the DT N
four CD N
groups NNS N
. . N

RESULTS NNP N
In IN N
Group NNP N
IT0.5 NNP N
, , N
the DT N
NK NNP o
cell NN o
activity NN o
was VBD N
lower JJR N
on IN N
postoperative JJ N
day NN N
1 CD N
( ( N
23.9 CD N
+/- JJ N
8.4 CD N
% NN N
) ) N
than IN N
the DT N
baseline NN N
level NN N
( ( N
45.7 CD N
+/- JJ N
13 CD N
% NN N
) ) N
before IN N
surgery NN N
, , N
and CC N
recovered VBD N
on IN N
postoperative JJ N
day NN N
2 CD N
. . N

In IN N
Groups NNP N
IT0.1 NNP N
, , N
C NNP N
and CC N
IV NNP N
, , N
the DT N
NK NNP o
cell NN o
activities NNS o
showed VBD N
no DT N
significant JJ N
changes NNS N
. . N

In IN N
all DT N
four CD N
groups NNS N
, , N
neither CC N
plasma JJ o
adrenaline NN o
nor CC N
noradrenaline JJ o
concentrations NNS o
changed VBD N
. . N

In IN N
all DT N
four CD N
groups NNS N
, , N
the DT N
plasma NN o
cortisol NN o
levels NNS o
increased VBN N
after IN N
surgery NN N
, , N
on IN N
postoperative JJ N
days NNS N
1 CD N
and CC N
2 CD N
. . N

The DT N
pain NN o
score NN o
was VBD N
lower JJR N
two CD N
hours NNS N
after IN N
surgery NN N
and CC N
on IN N
postoperative JJ N
day NN N
1 CD N
in IN N
Group NNP N
IT0.5 NNP N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
long-lasting JJ N
analgesic JJ N
effects NNS N
of IN N
intrathecal JJ N
0.5 CD N
mg JJ N
morphine NN i
suppress NN N
the DT N
immune JJ N
response NN N
following VBG N
abdominal JJ N
surgery NN N
. . N

-DOCSTART- -9481998- O O

Effect NN N
of IN N
indomethacin JJ i
phonophoresis NN i
on IN N
the DT N
relief NN N
of IN N
temporomandibular JJ p
joint NN p
pain NN p
. . N

The DT N
pain-relieving JJ o
effect NN N
of IN N
indomethacin JJ i
phonophoresis NN i
on IN N
temporomandibular NN N
( ( N
TMJ NNP N
) ) N
joint NN N
pain NN N
was VBD N
evaluated VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
clinical JJ N
trial NN N
. . N

Twenty NNP p
subjects NNS p
, , p
who WP p
have VBP p
TMJ NNP p
pain NN p
, , N
were VBD N
included VBN N
for IN N
this DT N
study NN N
and CC N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
experimental JJ N
group NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
. . N

Each DT N
treatment NN N
consisted VBN N
of IN N
the DT N
application NN N
of IN N
ultrasound JJ N
massage NN N
( ( N
1.0 CD N
MHz NNP N
, , N
0.8 CD N
to TO N
1.5 CD N
W/cm2 NNP N
continuous JJ N
output NN N
) ) N
for IN N
15 CD N
minutes NNS N
to TO N
the DT N
painful JJ N
temporomandibular JJ N
joint NN N
. . N

As IN N
a DT N
conducting NN N
medium NN N
, , N
1 CD N
% NN N
indomethacin JJ i
cream NN N
was VBD N
used VBN N
for IN N
the DT N
experimental JJ N
group NN N
and CC N
placebo NN i
cream NN N
for IN N
the DT N
control NN N
group NN N
respectively RB N
. . N

Pre- JJ N
and CC N
post-treatment JJ N
pain NN o
levels NNS o
and CC o
pain NN o
sensitivity NN o
were VBD N
assessed VBN N
with IN N
visual JJ o
analogue NN o
scales NNS o
( ( o
VAS NNP o
) ) o
and CC N
pressure NN o
pain NN o
threshold NN o
( ( o
PPT NNP o
) ) o
. . N

Mean NNP N
data NNS N
indicated VBD N
that IN N
post-treatment JJ o
VAS NNP o
was VBD N
significantly RB N
decreased VBN N
and CC N
post-treatment JJ o
PPT NNP o
was VBD N
significantly RB N
increased VBN N
in IN N
the DT N
experimental JJ N
group NN N
, , N
not RB N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
indomethacin JJ i
phonophoresis NN i
provides VBZ N
significant JJ N
pain NN o
relieving VBG N
effect NN N
over IN N
the DT N
TMJ NNP N
pain NN N
. . N

-DOCSTART- -9573502- O O

Systemic NNP o
hemodynamic NN o
, , o
neurohormonal JJ o
, , o
and CC o
renal JJ o
effects NNS o
of IN N
a DT N
steady-state JJ N
infusion NN N
of IN N
human JJ i
brain NN i
natriuretic JJ i
peptide NN i
in IN N
patients NNS p
with IN p
hemodynamically RB p
decompensated VBN p
heart NN p
failure NN p
. . N

BACKGROUND NNP N
Human NNP i
brain NN i
natriuretic JJ i
peptide NN i
( ( i
hBNP NN i
) ) i
is VBZ N
a DT N
promising JJ N
agent NN N
for IN N
the DT N
treatment NN N
of IN N
decompensated JJ N
cardiac JJ N
failure NN N
. . N

However RB N
, , N
the DT N
systemic JJ o
hemodynamic NN o
, , o
neurohormonal JJ o
, , o
and CC o
renal JJ o
effects NNS o
of IN N
hBNP NNS i
have VBP N
been VBN N
incompletely RB N
studied VBN N
in IN N
human JJ N
heart NN N
failure NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
effects NNS N
of IN N
a DT N
continuous JJ N
4-hour JJ N
infusion NN N
of IN N
hBNP NN i
were VBD N
determined VBN N
in IN N
16 CD p
decompensated JJ p
heart NN p
failure NN p
patients NNS p
in IN N
an DT N
invasive JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
. . N

Patients NNS N
were VBD N
evaluated VBN N
during IN N
three CD N
4-hour JJ N
study NN N
periods NNS N
: : N
baseline NN N
, , N
treatment NN N
( ( N
placebo JJ i
[ NNP N
n NN N
= VBD N
4 CD N
] NNP N
versus NN N
hBNP NN i
0.025 CD N
or CC N
0.05 CD N
microgram/kg/min NNS N
[ JJ N
n JJ N
= NN N
12 CD N
] NN N
) ) N
, , N
and CC N
post-treatment NN N
. . N

Urinary JJ N
volume NN N
losses NNS N
were VBD N
replaced VBN N
hourly RB N
to TO N
separate VB N
the DT N
vasodilatory NN N
and CC N
diuretic JJ N
effects NNS N
of IN N
hBNP NN i
. . N

Two CD N
patients NNS N
in IN N
the DT N
hBNP NN i
group NN N
were VBD N
excluded VBN N
from IN N
the DT N
analysis NN N
because IN N
of IN N
adverse JJ o
events NNS o
. . N

hBNP NN i
significantly RB N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
reduced VBD N
right JJ o
atrial JJ o
pressure NN o
and CC o
pulmonary JJ o
capillary JJ o
wedge NN o
pressure NN o
by IN N
approximately RB N
30 CD N
% NN N
and CC N
40 CD N
% NN N
, , N
respectively RB N
. . N

hBNP NN i
also RB N
significantly RB N
lowered VBN N
systemic JJ o
vascular JJ o
resistance NN o
from IN N
1722 CD N
+/- JJ N
139 CD N
to TO N
1101 CD N
+/- JJ N
83 CD N
dynes.s.cm-5 NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

These DT N
unloading JJ N
effects NNS N
of IN N
hBNP NN i
produced VBD N
a DT N
28 CD N
% NN N
increase NN N
in IN N
cardiac JJ o
index NN o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
with IN N
no DT N
change NN N
in IN N
heart NN o
rate NN o
. . N

Compared VBN N
to TO N
placebo VB i
, , N
hBNP VB i
decreased VBN N
plasma JJ o
norepinephrine NN o
and CC o
aldosterone NN o
. . N

Renal JJ o
hemodynamics NNS o
were VBD N
unaffected VBN N
by IN N
hBNP NN i
; : N
however RB N
, , N
most JJS N
patients NNS N
were VBD N
resistant JJ N
to TO N
its PRP$ N
natriuretic JJ o
effect NN o
. . N

CONCLUSIONS NNP N
1 CD N
) ) N
The DT N
predominant JJ N
hemodynamic JJ o
effects NNS o
of IN N
hBNP NN i
were VBD N
a DT N
decrease NN N
in IN N
cardiac JJ o
preload NN o
and CC o
systemic JJ o
vascular JJ o
resistance NN o
. . N

2 CD N
) ) N
hBNP NN i
also RB N
improved VBD N
cardiac JJ o
output NN o
without IN N
increasing VBG N
heart NN o
rate NN o
. . N

3 CD N
) ) N
Plasma NNP o
norepinephrine NN o
and CC o
aldosterone NN o
levels NNS o
decreased VBN N
during IN N
hBNP JJ i
infusion NN N
. . N

4 CD N
) ) N
hBNP NN i
is VBZ N
pharmacologically RB N
active JJ N
and CC N
has VBZ N
potential VBN N
in IN N
the DT N
therapy NN N
for IN N
decompensated JJ N
heart NN N
failure NN N
. . N

-DOCSTART- -18337284- O O

Once-daily RB N
amoxicillin JJ i
versus IN N
twice-daily JJ N
penicillin NN i
V NNP i
in IN N
group NN N
A NNP N
beta-haemolytic JJ p
streptococcal JJ p
pharyngitis NN p
. . N

BACKGROUND NNP N
Rheumatic NNP N
fever NN N
is VBZ N
a DT N
preventable JJ N
chronic JJ N
disease NN N
preceded VBN N
by IN N
group NN p
A NNP p
beta-haemolytic JJ p
streptococcal NN p
( ( p
GABHS NNP p
) ) p
pharyngitis NN p
. . N

OBJECTIVE UH N
To TO N
test VB N
the DT N
non-inferiority NN o
of IN N
once-daily JJ N
( ( N
QD NNP N
) ) N
oral JJ N
amoxicillin NN i
to TO N
the DT N
recommended VBN N
twice-daily RB N
( ( N
BID NNP N
) ) N
oral JJ N
penicillin NN i
V NNP i
in IN N
GABHS NNP N
pharyngitis NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomised JJ N
non-inferiority JJ o
trial NN N
carried VBD N
out RP N
in IN N
a DT N
school-based JJ p
clinic NN p
in IN p
New NNP p
Zealand NNP p
. . N

Children NNP p
presenting VBG p
with IN p
GABHS NNP p
pharyngitis NN p
were VBD N
randomised VBN N
to TO N
oral JJ N
amoxicillin NN i
1500 CD N
mg NN N
QD NNP N
( ( N
or CC N
750 CD N
mg NN N
if IN N
bodyweight VBN N
was VBD N
< JJ N
or=30 JJ N
kg NN N
) ) N
or CC N
to TO N
oral JJ N
penicillin NN i
V NNP N
500 CD N
mg NN N
BID NNP N
( ( N
or CC N
250 CD N
mg NN N
if IN N
bodyweight VBN N
was VBD N
< JJ N
or=20 JJ N
kg NN N
) ) N
for IN N
10 CD N
days NNS N
. . N

Observed VBN N
medication NN N
and CC N
weekend NN N
diary JJ N
cards NNS N
were VBD N
used VBN N
to TO N
monitor VB N
adherence NN N
. . N

OUTCOME NNP N
Eradication NNP o
of IN o
GABHS NNP o
, , N
determined VBD N
with IN N
follow-up JJ N
throat NN N
cultures NNS N
on IN N
days NNS N
3-6 CD N
, , N
12-16 CD N
and CC N
26-36 JJ N
. . N

GABHS NNP N
isolates NNS N
were VBD N
serotyped VBN N
to TO N
distinguish VB N
bacteriological JJ o
treatment NN o
failures NNS o
( ( N
and CC N
relapses NNS o
) ) N
from IN N
new JJ N
acquisitions NNS N
. . N

Non-inferiority NN o
was VBD N
defined VBN N
as IN N
an DT N
upper JJ N
95 CD N
% NN N
confidence NN N
limit NN N
( ( N
CL NNP N
) ) N
for IN N
the DT N
difference NN N
in IN N
success NN N
of IN N
eradication NN N
in IN N
the DT N
amoxicillin NN i
and CC N
penicillin NN i
V NNP N
treatment NN N
groups NNS N
of IN N
< NNP N
or=10 FW N
% NN N
. . N

RESULTS CC N
353 CD p
children NNS p
with IN p
positive JJ p
throat NN p
swabs NN p
for IN p
GABHS NNP p
were VBD N
randomised VBN N
to TO N
amoxicillin VB i
( ( N
n JJ N
= NNP N
177 CD N
) ) N
or CC N
penicillin JJ i
V NNP N
( ( N
n JJ N
= NNP N
176 CD N
) ) N
. . N

The DT N
upper JJ N
95 CD N
% NN N
CL NNP N
for IN N
the DT N
differences NNS N
in IN N
positive JJ N
cultures NNS N
between IN N
the DT N
antibiotics NNS N
was VBD N
4.9 CD N
% NN N
at IN N
days NNS N
3-6 CD N
, , N
6.5 CD N
% NN N
at IN N
days NNS N
12-16 CD N
and CC N
8.5 CD N
% NN N
at IN N
days NNS N
26-36 JJ N
. . N

Treatment NN o
failures NNS o
( ( N
including VBG N
relapses NNS o
) ) N
occurred VBD N
at IN N
each DT N
visit NN N
in IN N
5.8 CD N
% NN N
, , N
12.7 CD N
% NN N
and CC N
10.7 CD N
% NN N
of IN N
amoxicillin NN i
recipients NNS N
and CC N
6.2 CD N
% NN N
, , N
11.9 CD N
% NN N
and CC N
11.3 CD N
% NN N
of IN N
penicillin NN i
V NNP N
recipients NNS N
, , N
respectively RB N
. . N

No UH N
significant JJ N
differences NNS N
in IN N
resolution NN o
of IN o
symptoms NNS o
were VBD N
noted VBN N
between IN N
treatment NN N
groups NNS N
. . N

One CD N
case NN N
of IN N
unsubstantiated JJ N
acute JJ N
rheumatic JJ N
fever NN N
occurred VBD N
after IN N
7 CD N
days NNS N
of IN N
amoxicillin NN i
. . N

CONCLUSION NN N
In IN N
this DT N
adequately RB N
powered VBN N
study NN N
, , N
once-daily JJ N
oral JJ N
amoxicillin NN i
is VBZ N
not RB N
inferior JJ N
to TO N
twice-daily JJ N
penicillin NN i
V NNP N
for IN N
the DT N
treatment NN N
and CC N
eradication NN N
of IN N
GABHS NNP p
in IN p
children NNS p
with IN p
pharyngitis NN p
. . N

-DOCSTART- -18783504- O O

Psychological JJ N
mediators NNS N
of IN N
bupropion NN i
sustained-release NN i
treatment NN N
for IN N
smoking VBG N
cessation NN N
. . N

AIM IN N
The DT N
study NN N
aimed VBN N
to TO N
test VB N
simultaneously RB N
our PRP$ N
understanding NN N
of IN N
the DT N
effects NNS N
of IN N
bupropion NN i
sustained-release NN i
( ( i
SR NNP i
) ) i
treatment NN N
on IN N
putative JJ N
mediators NNS N
and CC N
our PRP$ N
understanding NN N
of IN N
determinants NNS N
of IN N
post-quit NN N
abstinence NN N
, , N
including VBG N
withdrawal NN N
distress NN N
, , N
cigarette NN N
craving NN N
, , N
positive JJ N
affect NN N
and CC N
subjective JJ N
reactions NNS N
to TO N
cigarettes NNS N
smoked VBN N
during IN N
a DT N
lapse NN N
. . N

The DT N
specificity NN N
of IN N
bupropion NN i
SR NNP i
effects NNS N
was VBD N
also RB N
tested VBN N
in IN N
exploratory JJ N
analyses NNS N
. . N

DESIGN NNP N
Data NNP N
from IN N
a DT N
randomized VBN N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
of IN N
bupropion NN i
SR NNP i
were VBD N
submitted VBN N
to TO N
mediation NN N
analyses NNS N
. . N

SETTING NN N
Center NNP N
for IN N
Tobacco NNP N
Research NNP N
and CC N
Intervention NNP N
, , N
Madison NNP p
, , p
WI NNP p
, , p
USA NNP p
. . N

PARTICIPANTS VB N
A DT p
total NN p
of IN p
403 CD p
adult NN p
, , p
daily JJ p
smokers NNS p
without IN p
contraindications NNS p
to TO p
bupropion VB i
SR NNP i
use NN p
. . N

INTERVENTION NN N
Participants NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
a DT N
9-week JJ N
course NN N
of IN N
bupropion NN i
SR NNP i
or CC N
placebo NN i
pill NN N
and CC N
to TO N
receive VB N
eight CD N
brief JJ N
individual JJ N
counseling NN N
sessions NNS N
or CC N
no DT N
counseling NN N
. . N

MEASUREMENTS NNP N
Ecological NNP o
momentary JJ o
assessment NN o
ratings NNS o
of IN o
smoking VBG o
behavior NN o
and CC o
putative JJ o
mediators NNS o
were VBD N
collected VBN N
pre- JJ N
and CC N
post-quit NN N
. . N

FINDINGS NNP N
Results NNP N
of IN N
structural JJ N
equation NN N
and CC N
hierarchical JJ N
linear JJ N
models NNS N
did VBD N
not RB N
support VB N
the DT N
hypothesis NN N
that WDT N
bupropion NN N
SR NNP N
treatment NN N
improves VBZ N
short-term JJ o
abstinence NN o
by IN N
reducing VBG N
withdrawal NN N
distress NN N
or CC N
affecting VBG N
the DT N
subjective JJ N
effects NNS N
of IN N
a DT N
lapse NN N
cigarette NN N
, , N
but CC N
provided VBD N
partial JJ N
support NN N
for IN N
mediation NN N
by IN N
cigarette NN o
craving VBG o
reduction NN o
and CC N
enhanced VBD N
positive JJ o
affect NN o
. . N

Bupropion NNP i
SR NNP i
effects NNS N
on IN N
point-prevalence NN N
abstinence NN o
at IN N
1 CD N
month NN N
post-quit NN N
were VBD N
also RB N
mediated VBN N
partially RB N
by IN N
enhanced JJ N
motivation NN N
to TO N
quit VB N
and CC N
self-efficacy NN N
. . N

CONCLUSIONS NNP N
Results NNP N
provided VBD N
some DT N
support NN N
for IN N
models NNS N
of IN N
bupropion NN i
SR NNP i
treatment NN N
and CC N
relapse NN N
and CC N
suggested VBD N
that IN N
motivational JJ N
processes NNS N
may MD N
partially RB N
account VB N
for IN N
bupropion NN N
SR NNP N
efficacy NN N
. . N

-DOCSTART- -8519720- O O

Double-blind NNP N
randomized JJ N
evaluation NN N
of IN N
intercostal JJ i
nerve NN i
blocks NNS i
as IN N
an DT N
adjuvant NN N
to TO N
subarachnoid VB N
administered JJ N
morphine NN i
for IN N
post-thoracotomy JJ p
analgesia NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Thoracotomy NNP N
is VBZ N
associated VBN N
with IN N
pain NN N
and CC N
compromised VBD N
pulmonary JJ N
function NN N
. . N

Intercostal NNP i
nerve NN i
blocks NNS i
( ( i
INB NNP i
) ) i
and CC N
subarachnoid JJ i
morphine NN i
( ( i
SM NNP i
) ) i
act NN N
on IN N
different JJ N
portions NNS N
of IN N
the DT N
pain NN N
pathway RB N
. . N

Each DT N
is VBZ N
effective JJ N
for IN N
post-thoracotomy JJ N
pain NN o
relief NN N
. . N

The DT N
combination NN N
of IN N
these DT N
two CD N
modalities NNS N
in IN N
relieving VBG N
post-thoracotomy JJ o
pain NN o
and CC N
improving VBG N
postoperative JJ o
pulmonary JJ o
function NN o
has VBZ N
not RB N
been VBN N
investigated VBN N
. . N

METHODS NNP N
In IN N
a DT N
double-blind NN N
study NN N
, , N
20 CD p
patients NNS p
undergoing JJ p
lateral JJ p
thoracotomy NN p
for IN p
lung NN p
resection NN p
were VBD N
randomized VBN N
to TO N
receive VB N
0.5 CD N
mg NN N
SM NNP i
preoperatively RB N
and CC N
INB NNP i
with IN N
bupivacaine NN i
( ( N
INB+ NNP N
) ) N
prior RB N
to TO N
wound VB N
closure NN N
or CC N
0.5 CD N
mg NNS N
SM NNP i
with IN N
INB NNP i
using VBG N
saline NN i
( ( N
INB- NNP i
) ) N
. . N

Visual JJ o
analog NN o
scale NN o
pain NN o
scores NNS o
at IN N
rest NN N
, , N
with IN o
cough NN o
, , o
and CC o
with IN o
movement NN o
of IN o
the DT o
ipsilateral JJ o
arm NN o
, , o
forced VBD o
expiratory JJ o
volume NN o
in IN o
1 CD o
second JJ o
( ( o
FEV1 NNP o
) ) o
, , N
and CC N
forced VBD o
vital JJ o
capacity NN o
( ( o
FVC NNP o
) ) o
were VBD N
measured VBN N
at IN N
4 CD N
, , N
24 CD N
, , N
48 CD N
, , N
and CC N
72 CD N
hours NNS N
after IN N
the DT N
operation NN N
. . N

Opioid NNP o
use NN o
was VBD N
measured VBN N
during IN N
the DT N
initial JJ N
24 CD N
hours NNS N
after IN N
the DT N
operation NN N
. . N

RESULTS NNP N
At IN N
4 CD N
hours NNS N
, , N
the DT N
INB+ NNP i
group NN N
demonstrated VBD N
better JJR N
FEV1 NNP o
( ( N
56.6 CD N
% NN N
vs. FW N
40.4 CD N
% NN N
of IN N
baseline NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
FVC NNP o
values NNS N
( ( N
54.6 CD N
% NN N
vs. FW N
39.6 CD N
% NN N
of IN N
baseline NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
less RBR N
resting VBG N
and CC N
cough JJ N
pain NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

However RB N
, , N
FEV1 NNP o
continued VBD N
to TO N
decline VB N
in IN N
the DT N
INB+ NNP i
group NN N
at IN N
24 CD N
hours NNS N
to TO N
lower JJR N
than IN N
the DT N
INB- NNP i
group NN N
although IN N
pain NN o
scores NNS o
were VBD N
similar JJ N
beyond IN N
4 CD N
hours NNS N
. . N

Opioid JJ o
usage NN o
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
was VBD N
similar JJ N
( ( N
INB- NNP i
, , N
16.7 CD N
mg NN N
vs. FW N
INB+ NNP i
, , N
13.2 CD N
mg NN N
, , N
P NNP N
= NNP N
.7 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
postoperative JJ N
INB NNP i
provided VBD N
modest JJ N
improvements NNS N
in IN N
pain NN N
and CC N
pulmonary JJ N
function NN N
when WRB N
used VBN N
as IN N
an DT N
adjuvant NN N
to TO N
0.5 CD N
mg NNS N
SM NNP i
for IN N
post-thoracotomy JJ N
analgesia NN N
, , N
the DT N
benefits NNS N
were VBD N
transient JJ N
. . N

The DT N
authors NNS N
do VBP N
not RB N
recommend VB N
adding VBG N
INB NNP i
for IN N
patients NNS N
undergoing JJ N
lateral JJ N
thoracotomy NN N
who WP N
receive VBP N
0.5 CD N
mg NN N
SM NNP i
. . N

-DOCSTART- -21924760- O O

Quality NN N
of IN N
individual JJ N
INR NNP N
control NN N
and CC N
the DT N
risk NN N
of IN N
stroke NN N
and CC N
bleeding VBG N
events NNS N
in IN N
atrial JJ p
fibrillation NN p
patients NNS p
: : N
a DT N
nested JJ N
case NN N
control NN N
analysis NN N
of IN N
the DT N
ACTIVE NNP N
W NNP N
study NN N
. . N

INTRODUCTION NNP N
Time NNP o
in IN o
therapeutic JJ o
range NN o
( ( o
TTR NNP o
) ) o
for IN N
international JJ N
normalized JJ N
ratio NN N
( ( N
INR NNP N
) ) N
is VBZ N
an DT N
accepted JJ N
quality NN N
measure NN N
of IN N
anticoagulation NN N
control NN N
in IN N
patient JJ N
populations NNS N
, , N
but CC N
its PRP$ N
usefulness NN N
for IN N
predicting VBG N
stroke NN N
and CC N
bleeding NN N
in IN N
individuals NNS N
is VBZ N
not RB N
well RB N
understood RB N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
nested JJ N
case NN N
control NN N
analysis NN N
among IN N
ACTIVE NNP p
W NNP p
study NN p
patients NNS p
, , N
cases NNS p
with IN p
stroke NN p
and CC p
cases NNS p
with IN p
bleeding NN p
were VBD p
separately RB p
matched VBN p
with IN p
controls NNS p
. . N

Several JJ N
anticoagulation NN N
quality NN N
measures NNS N
were VBD N
compared VBN N
, , N
overall JJ N
and CC N
in IN N
a DT N
time-dependent JJ N
manner NN N
. . N

RESULTS CC N
32 CD p
cases NNS p
with IN p
ischemic JJ p
stroke NN p
and CC p
234 CD p
cases NNS p
with IN p
bleeding NN p
in IN p
the DT p
analysis NN p
were VBD N
matched VBN N
in IN N
a DT N
4:1 CD N
ratio NN N
to TO N
122 CD N
and CC N
865 CD N
controls NNS N
, , N
respectively RB N
. . N

Follow-up JJ N
duration NN N
was VBD N
257?154days CD N
for IN N
the DT N
stroke NN N
analysis NN N
and CC N
222?146days CD N
for IN N
the DT N
bleeding NN N
analysis NN N
. . N

Compared VBN N
with IN N
their PRP$ N
respective NN N
controls NNS N
, , N
the DT N
study NN N
mean JJ N
TTR NNP o
of IN N
both DT N
stroke NN N
cases NNS N
( ( N
53.9 CD N
% NN N
?25.1 NNP N
vs VBZ N
63.4 CD N
% NN N
?24.8 NN N
; : N
p=0.055 CC N
) ) N
and CC N
bleeding VBG N
cases NNS N
( ( N
56.2 CD N
% NN N
?25.4 NNP N
vs VBZ N
63.4 CD N
% NN N
?26.8 NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
was VBD N
lower JJR N
. . N

Time NNP o
below IN N
range NN N
for IN N
stroke NN N
and CC N
time NN o
above IN N
range NN N
for IN N
bleeding VBG N
were VBD N
only RB N
greater JJR N
in IN N
the DT N
last JJ N
month NN N
leading VBG N
up RP N
to TO N
the DT N
event NN N
, , N
not RB N
over IN N
the DT N
entire JJ N
study NN N
period NN N
. . N

Rather CC N
, , N
over IN N
the DT N
entire JJ N
study NN N
period NN N
bleeding VBG N
cases NNS N
spent VBD N
more JJR N
time NN N
below IN N
range NN N
than IN N
controls NNS N
( ( N
26.8 CD N
% NN N
?25.9 NNP N
vs VBZ N
20.8 CD N
% NN N
?24.0 NN N
; : N
p=0.001 NN N
) ) N
. . N

CONCLUSIONS NNP N
TTR NNP o
was VBD N
lower JJR N
in IN N
individual JJ p
AF NNP p
patients NNS p
with IN N
stroke NN N
or CC N
bleeding NN N
compared VBN N
with IN N
matched JJ N
controls NNS N
in IN N
ACTIVE NNP N
W. NNP N
Maintaining VBG N
a DT N
high JJ N
TTR NNP N
, , N
with IN N
equal JJ N
importance NN N
to TO N
avoid VB N
low JJ N
and CC N
high JJ N
INRs NNP N
, , N
is VBZ N
a DT N
relevant JJ N
goal NN N
of IN N
individual JJ N
patient NN N
treatment NN N
to TO N
prevent VB N
stroke NN N
and CC N
bleeding NN N
. . N

-DOCSTART- -11099086- O O

Oral JJ N
ciprofloxacin NN i
vs. FW N
intramuscular JJ N
ceftriaxone NN i
as IN N
empiric JJ N
treatment NN N
of IN N
acute JJ p
invasive JJ p
diarrhea NN p
in IN p
children NNS p
. . N

BACKGROUND NNP N
Acute NNP N
invasive JJ N
diarrhea NN N
is VBZ N
a DT N
potentially RB N
serious JJ N
condition NN N
in IN N
children NNS p
. . N

Because IN N
of IN N
the DT N
increasing VBG N
resistance NN N
of IN N
enteric JJ N
pathogens NNS N
to TO N
commonly RB N
used JJ N
oral JJ N
antibiotics NNS N
, , N
intramuscular JJ N
ceftriaxone NN i
has VBZ N
become VBN N
the DT N
routine JJ N
drug NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
invasive JJ N
diarrhea NN N
requiring VBG N
an DT N
emergency NN N
visit NN N
in IN N
southern JJ N
Israel NNP N
. . N

The DT N
inconvenience NN N
of IN N
this DT N
parenteral JJ N
regimen NNS N
created VBD N
an DT N
increased VBN N
need NN N
for IN N
oral JJ N
pediatric JJ N
formulations NNS N
for IN N
the DT N
treatment NN N
of IN N
invasive JJ N
diarrhea NN N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
a DT N
suspension NN N
formulation NN N
of IN N
ciprofloxacin NN i
in IN N
the DT N
treatment NN N
of IN N
acute JJ p
invasive JJ p
diarrhea NN p
in IN p
infants NNS p
and CC p
children NNS p
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP N
July NNP N
1996 CD N
through IN N
December NNP N
1997 CD N
, , N
201 CD p
evaluable JJ p
children NNS p
ages VBZ p
6 CD p
months NNS p
to TO p
10 CD p
years NNS p
( ( p
35 CD p
% NN p
< CC p
1 CD p
year NN p
; : p
70 CD p
% NN p
< JJ p
3 CD p
years NNS p
) ) p
presenting VBG p
with IN p
acute JJ p
invasive JJ p
diarrhea NN p
at IN p
the DT p
Pediatric NNP p
Emergency NNP p
Room NNP p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
ciprofloxacin NN i
suspension NN N
( ( N
10 CD N
mg/kg NN N
twice RB N
a DT N
day NN N
+ NNP N
im NN N
placebo NN N
; : N
n CC N
= VB N
95 CD N
) ) N
or CC N
im VB N
ceftriaxone NN i
( ( N
50 CD N
mg/kg/day NN N
+ NNP N
placebo NN N
suspension NN N
; : N
n CC N
= VB N
106 CD N
) ) N
for IN N
3 CD N
days NNS N
in IN N
a DT N
double JJ N
blind NN N
manner NN N
. . N

Stool NNP o
cultures NNS o
for IN o
Shigella NNP o
, , o
Salmonella NNP o
, , o
Campylobacter NNP o
spp NN o
. . o

and CC o
diarrheagenic JJ o
Escherichia NNP o
coli NNS o
were VBD N
obtained VBN N
on IN N
Days NNP N
1 CD N
, , N
3 CD N
, , N
4 CD N
to TO N
5 CD N
and CC N
21 CD N
+/- JJ N
5 CD N
. . N

Clinical JJ o
response NN o
and CC o
safety NN o
were VBD N
assessed VBN N
on IN N
Days NNP N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
4 CD N
to TO N
5 CD N
and CC N
21 CD N
+/- JJ N
5 CD N
. . N

RESULTS NNP N
We PRP N
isolated VBD N
127 CD N
pathogens NNS N
from IN N
121 CD N
( ( N
60 CD N
% NN N
) ) N
patients NNS N
: : N
73 CD N
( ( N
57 CD N
% NN N
) ) N
Shigella NNP N
; : N
23 CD N
( ( N
18 CD N
% NN N
) ) N
Salmonella NNP N
; : N
18 CD N
( ( N
14 CD N
% NN N
) ) N
E. NNP N
coli NNS N
; : N
and CC N
13 CD N
( ( N
10 CD N
% NN N
) ) N
Campylobacter NNP N
. . N

Overall NNP N
bacteriologic JJ N
eradication NN N
on IN N
Day NNP N
4 CD N
to TO N
5 CD N
was VBD N
99 CD N
% NN N
for IN N
Shigella NNP N
, , N
77 CD N
% NN N
for IN N
Salmonella NNP N
and CC N
77 CD N
% NN N
for IN N
Campylobacter NNP N
, , N
with IN N
no DT N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Clinical JJ o
cure NN o
or CC o
improvement NN o
was VBD N
observed VBN N
in IN N
100 CD N
and CC N
99 CD N
% NN N
of IN N
the DT N
ciprofloxacin NN i
and CC N
ceftriaxone NN i
groups NNS N
, , N
respectively RB N
. . N

Serum NNP N
ciprofloxacin NN i
values NNS N
determined VBN N
on IN N
Day NNP N
3 CD N
of IN N
the DT N
treatment NN N
were VBD N
higher JJR N
in IN N
the DT N
majority NN N
of IN N
patients NNS N
than IN N
were VBD N
the DT N
MIC50 NNP N
and CC N
MIC90 NNP N
values NNS N
for IN N
the DT N
Shigella NNP N
and CC N
Salmonella NNP N
spp NN N
. . N

isolated VBN N
. . N

Possible JJ N
drug-related JJ N
adverse JJ o
events NNS o
occurred VBD N
in IN N
13 CD N
patients NNS N
[ JJ N
ciprofloxacin NN i
, , N
8 CD N
( ( N
8 CD N
% NN N
) ) N
; : N
ceftriaxone NN i
, , N
5 CD N
( ( N
4.7 CD N
% NN N
) ) N
] NN N
and CC N
were VBD N
mild NNS N
and CC N
transient NN N
. . N

Joint JJ o
examination NN o
was VBD N
normal JJ N
during IN N
and CC N
after IN N
completion NN N
of IN N
therapy NN N
in IN N
all DT N
patients NNS N
. . N

CONCLUSION NNP N
Oral NNP N
ciprofloxacin NN i
was VBD N
as IN N
safe JJ o
and CC N
effective JJ o
as IN N
intramuscular JJ N
ceftriaxone NN i
for IN N
the DT N
empiric JJ N
treatment NN N
of IN N
acute JJ N
invasive JJ N
diarrhea NN N
in IN N
ambulatory JJ p
pediatric JJ p
patients NNS p
requiring VBG p
an DT p
emergency NN p
room NN p
visit NN p
. . p

-DOCSTART- -6421395- O O

Effects NNS N
of IN N
mild JJ i
physical JJ i
exercise NN i
on IN N
serum NN o
lipoproteins NNS o
and CC N
metabolites NNS o
of IN o
arachidonic JJ o
acid NN o
: : N
a DT N
controlled VBN N
randomised JJ N
trial NN N
in IN N
middle JJ p
aged VBN p
men NNS p
. . N

To TO N
study VB N
the DT N
effects NNS N
of IN N
physical JJ i
exercise NN i
on IN N
biochemical JJ o
risk NN o
factors NNS o
for IN o
ischaemic JJ o
heart NN o
disease NN o
31 CD p
healthy JJ p
middle NNS p
aged VBN p
men NNS p
undertook IN N
regular JJ i
physical JJ i
exercise NN i
for IN N
two CD N
months NNS N
and CC N
29 CD N
served VBD N
as IN N
controls NNS N
in IN N
a DT N
randomised JJ N
trial NN N
. . N

In IN N
the DT N
men NNS N
taking VBG N
regular JJ N
exercise NN N
serum NN o
cholesterol NN o
concentrations NNS o
increased VBD N
26 CD N
% NN N
more JJR N
in IN N
the DT N
high JJ o
density NN o
lipoprotein VBP o
subfraction NN o
two CD o
( ( o
HDL2 NNP o
) ) o
and CC N
decreased VBD N
31 CD N
% NN N
more JJR N
in IN N
the DT N
subfraction NN o
three CD o
( ( o
HDL3 NNP o
) ) o
and CC N
9 CD N
% NN N
more JJR N
in IN N
the DT N
low JJ o
density NN o
lipoprotein NN o
fraction NN o
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

A DT N
tendency NN N
towards NNS N
increased VBD N
plasma JJ o
6-keto-prostaglandin JJ o
F1 NNP o
alpha NN o
concentration NN o
and CC N
decreased VBD N
serum NN o
thromboxane NN o
B2 NNP o
concentration NN o
was VBD N
found VBN N
during IN N
the DT N
period NN N
of IN N
regular JJ N
exercise NN i
, , N
but CC N
prostaglandin VBP o
E2 NNP o
concentrations NNS o
remained VBD N
unchanged JJ N
. . N

The DT N
increase NN N
in IN N
plasma JJ o
6-keto-prostaglandin JJ o
F1 NNP o
alpha NN o
concentration NN o
was VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
serum JJ o
HDL2 NNP o
cholesterol NN o
concentration NN o
in IN N
the DT N
group NN N
taking VBG N
regular JJ N
exercise NN i
. . N

Our PRP$ N
data NNS N
suggest VBP N
that IN N
mild JJ i
regular JJ i
physical JJ i
exercise NN i
favourably RB N
influences VBZ N
cholesterol NN N
distribution NN N
in IN N
serum NN o
lipoproteins NNS o
in IN N
healthy JJ p
middle NN p
aged VBN p
men NNS p
and CC N
may MD N
have VB N
beneficial JJ N
effects NNS N
on IN N
circulating VBG o
metabolites NNS o
of IN o
arachidonic JJ o
acid NN o
. . N

-DOCSTART- -18845996- O O

Identifying VBG N
patients NNS N
at IN N
high JJ N
risk NN N
for IN N
neutropenic JJ o
complications NNS o
during IN N
chemotherapy NN N
for IN N
metastatic JJ p
breast NN p
cancer NN p
with IN N
doxorubicin NN i
or CC N
pegylated VBN i
liposomal JJ i
doxorubicin NN i
: : N
the DT N
development NN N
of IN N
a DT N
prediction NN N
model NN N
. . N

OBJECTIVE UH N
To TO N
develop VB N
a DT N
cycle-based JJ N
risk NN N
prediction NN N
model NN N
for IN N
neutropenic JJ o
complications NNS o
( ( o
NC NNP o
) ) o
during IN N
chemotherapy NN N
with IN N
doxorubicin NN i
( ( i
DOX NNP i
) ) i
or CC N
a DT N
pegylated JJ i
liposomal JJ i
formulation NN i
( ( i
PLD NNP i
) ) i
for IN N
patients NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
( ( p
MBC NNP p
) ) p
. . N

METHODS NNP N
Data NNP N
analyzed VBD N
was VBD N
from IN N
a DT N
phase NN N
III NNP N
, , N
randomized VBD N
clinical JJ N
trial NN N
of IN N
DOX NNP i
( ( N
60 CD N
mg/m NN N
( ( N
2 CD N
) ) N
every DT N
3 CD N
weeks NNS N
) ) N
or CC N
PLD NNP i
( ( N
50 CD N
mg/m NN N
( ( N
2 CD N
) ) N
every DT N
4 CD N
weeks NNS N
) ) N
for IN N
the DT N
first JJ N
line NN N
therapy NN N
for IN N
MBC NNP N
( ( N
n JJ N
= NNP N
509 CD N
) ) N
( ( N
O'Brien NNP N
et RB N
al RB N
, , N
Ann NNP N
Oncol NNP N
. . N

2004 CD N
; : N
15:440-449 JJ N
) ) N
. . N

NC NNP o
were VBD N
defined VBN N
as IN N
an DT N
absolute NN o
neutrophil NN o
count NN o
< NNP o
or CC o
=1.5 NNP o
x VBP o
10 CD o
( ( o
9 CD o
) ) o
cells/L NN o
( ( N
ie JJ N
, , N
> JJ N
or CC N
=grade JJ N
II NNP N
) ) N
before IN N
the DT N
next JJ N
cycle NN N
, , N
febrile JJ o
neutropenia NN o
or CC o
neutropenia NN o
with IN o
a DT o
documented JJ o
infection NN o
. . N

Patient NNP N
and CC N
hematologic JJ N
factors NNS N
potentially RB N
associated VBN N
with IN N
NC NNP N
were VBD N
evaluated VBN N
. . N

Factors NNS N
with IN N
a DT N
P NNP N
value NN N
of IN N
< NNP N
or CC N
=0.25 NNP N
within IN N
a DT N
cycle NN N
were VBD N
included VBN N
in IN N
a DT N
generalized JJ N
estimating NN N
equations NNS N
regression NN N
model NN N
. . N

Using VBG N
backward JJ N
elimination NN N
, , N
we PRP N
derived VBD N
a DT N
risk NN N
scoring VBG N
algorithm NN N
( ( N
range VB N
0-63 NN N
) ) N
from IN N
the DT N
final JJ N
reduced VBN N
model NN N
. . N

RESULTS NNP N
Risk NNP N
factors NNS N
retained VBD N
in IN N
the DT N
model NN N
included VBD N
poor JJ o
performance NN o
status NN o
, , o
absolute VB o
neutrophil JJ o
count NN o
< NN o
or CC o
=2.0 VB o
x JJ o
10 CD o
( ( o
9 CD o
) ) o
cells/L NN o
in IN N
the DT N
previous JJ N
cycle NN N
, , N
the DT N
first JJ N
cycle NN N
of IN N
chemotherapy NN N
, , N
DOX NNP i
versus NN N
PLD NNP i
and CC N
advanced JJ N
age NN o
. . N

A DT N
precycle NN o
risk NN o
score NN o
from IN N
> NN N
or CC N
=25 NN N
to TO N
< VB N
40 CD N
for IN N
a DT N
given VBN N
patient NN N
was VBD N
identified VBN N
as IN N
being VBG N
the DT N
optimal JJ N
threshold NN N
for IN N
sensitivity NN N
( ( N
58.0 CD N
% NN N
) ) N
and CC N
specificity NN N
( ( N
78.7 CD N
% NN N
) ) N
. . N

Patients NNS N
with IN N
a DT N
score NN N
at IN N
or CC N
beyond IN N
this DT N
threshold NN N
would MD N
be VB N
considered VBN N
at IN N
high JJ N
risk NN o
for IN N
developing VBG N
NC NNP N
in IN N
later JJ N
cycles NNS N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
this DT N
model NN N
may MD N
enhance VB N
patient NN N
care NN N
by IN N
targeting VBG N
preventative JJ N
therapies NNS N
( ( N
eg NN N
, , N
granulocyte NN N
colony NN N
stimulating VBG N
factor NN N
or CC N
PLD NNP N
) ) N
to TO N
those DT N
MBC NNP N
patients NNS p
most RBS N
likely JJ N
to TO N
experience VB N
NC NNP o
during IN N
anthracycline-based JJ N
chemotherapy NN N
. . N

-DOCSTART- -24726342- O O

Assessment NN N
of IN N
acute JJ N
bronchodilator NN N
effects NNS N
from IN N
specific JJ N
airway NN N
resistance NN N
changes NNS N
in IN N
stable JJ p
COPD NNP p
patients NNS p
. . N

BACKGROUND NNP N
In IN N
COPD NNP p
patients NNS p
, , N
reversibility NN N
is VBZ N
currently RB N
evaluated VBN N
from IN N
the DT N
changes NNS N
of IN N
forced JJ N
expiratory NN N
volume NN N
at IN N
1s CD N
( ( N
?FEV1 NN N
) ) N
and CC N
forced VBN N
vital JJ N
capacity NN N
( ( N
?FVC NNP N
) ) N
. . N

By IN N
lowering VBG N
peripheral JJ N
airway RB N
smooth JJ N
muscle NN N
tone NN N
, , N
bronchodilators NNS N
should MD N
decrease VB N
dynamic JJ N
hyperinflation NN N
, , N
gas NN N
trapping NN N
, , N
and CC N
possibly RB N
dyspnea VB N
at IN N
rest NN N
. . N

Hence NNP N
, , N
we PRP N
hypothesize VBP N
that IN N
specific JJ o
airway NN o
resistance NN o
changes NNS o
( ( o
?sRAW NN o
) ) o
should MD N
better RBR N
characterize VB N
the DT N
acute JJ N
response NN N
to TO N
bronchodilators NNS N
. . N

METHODS NNP N
On IN N
two CD N
days NNS N
, , N
60 CD p
COPD NNP p
patients NNS p
underwent JJ N
dyspnea JJ o
evaluation NN o
( ( o
VAS NNP o
score NN o
) ) o
and CC N
pulmonary JJ o
function NN o
testing VBG N
at IN N
baseline NN N
and CC N
one CD N
hour NN N
after IN N
placebo NN i
or CC N
300?g CD N
indacaterol JJ i
administration NN N
. . N

RESULTS NNP N
Spirographic NNP o
and CC o
?sRAW-based JJ o
criteria NNS o
identified VBN N
as IN N
responders NNS N
24 CD N
and CC N
45 CD N
patients NNS N
, , N
respectively RB N
. . N

?sRAW NN N
correlated VBD N
with IN N
changes NNS N
of IN N
intrathoracic NN o
gas NN o
volume NN o
( ( o
?ITGV NN o
) ) o
( ( N
r=0.61 NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
, , N
residual JJ o
volume NN o
( ( o
?RV NN o
) ) o
( ( N
r=0.60 NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
, , N
?FVC NNP o
( ( N
r=0.44 NN N
; : N
p=0.001 NN N
) ) N
, , N
and CC N
?VAS NNP N
( ( N
r=0.73 NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
, , N
while IN N
?FEV1 NN o
correlated VBD N
only RB N
with IN N
?FVC NNP o
( ( N
r=0.34 NN N
; : N
p=0.008 NN N
) ) N
. . N

Significant JJ N
differences NNS N
in IN N
terms NNS N
of IN N
?ITGV NN o
( ( N
p=0.002 NN N
) ) N
, , N
?RV NNP o
( ( N
p=0.023 NN N
) ) N
, , N
and CC N
?VAS NNP o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
occurred VBD N
only RB N
if IN N
patients NNS N
were VBD N
stratified VBN N
according VBG N
to TO N
?sRAW NNP o
. . N

CONCLUSIONS NNP N
In IN N
assessing VBG N
the DT N
acute JJ N
functional JJ N
effect NN N
of IN N
bronchodilators NNS N
, , N
?sRAW-based JJ N
criterion NN N
is VBZ N
preferable JJ N
to TO N
FEV1-FVC-based JJ N
criteria NNS N
, , N
being VBG N
more RBR N
closely RB N
related VBN N
to TO N
bronchodilator-induced JJ N
improvements NNS o
of IN o
lung NN N
mechanics NNS N
and CC N
dyspnea NN N
at IN N
rest NN N
. . N

-DOCSTART- -2223363- O O

Effect NN N
of IN N
different JJ N
rates NNS N
of IN N
infusion NN N
of IN N
propofol NN i
for IN N
induction NN N
of IN N
anaesthesia NN N
in IN N
elderly JJ p
patients NNS p
. . N

The DT N
effect NN N
of IN N
changing VBG N
the DT N
rate NN N
of IN N
infusion NN N
of IN N
propofol NN i
for IN N
induction NN N
of IN N
anaesthesia NN N
was VBD N
studied VBN N
in IN N
60 CD p
elderly JJ p
patients NNS p
. . N

Propofol NNP i
was VBD N
administered VBN N
at IN N
300 CD N
, , N
600 CD N
or CC N
1200 CD N
ml JJ N
h-1 JJ N
until IN N
loss NN o
of IN o
consciousness NN o
( ( N
as IN N
judged VBN N
by IN N
loss NN o
of IN o
verbal JJ o
contact NN o
with IN o
the DT o
patient NN o
) ) o
had VBD N
been VBN N
achieved VBN N
. . N

The DT N
duration NN o
of IN o
induction NN o
was VBD N
significantly RB N
longer JJR N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
with IN N
the DT N
slower JJR N
infusion NN N
rates NNS N
( ( N
104 CD N
, , N
68 CD N
and CC N
51 CD N
s NN N
) ) N
, , N
but CC N
the DT N
total JJ o
dose NN o
used VBN N
was VBD N
significantly RB N
less JJR N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
in IN N
these DT N
patients NNS N
( ( N
1.2 CD N
, , N
1.6 CD N
and CC N
2.5 CD N
mg NN N
kg-1 NN N
, , N
respectively RB N
) ) N
. . N

The DT N
decrease NN N
in IN N
systolic JJ o
and CC o
diastolic JJ o
arterial JJ o
pressure NN o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
300-ml JJ N
h-1 JJ N
group NN N
at IN N
the DT N
end NN N
of IN N
induction NN N
and CC N
immediately RB N
after IN N
induction NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
incidence NN o
of IN o
apnoea NN o
was VBD N
also RB N
significantly RB N
less RBR N
in IN N
the DT N
slower JJR N
infusion NN N
group NN N
. . N

-DOCSTART- -25898782- O O

Sedation NN N
during IN p
endoscopic NN p
retrograde NN p
cholangiopancreatography NN p
: : N
a DT N
randomized NN N
controlled VBN N
study NN N
of IN N
patient-controlled JJ N
propofol NN i
sedation NN N
and CC N
that IN N
given VBN N
by IN N
a DT N
nurse JJ N
anesthetist NN N
. . N

OBJECTIVE CC N
Different JJ N
regimens NNS N
are VBP N
used VBN N
for IN N
sedation NN N
during IN N
endoscopic NN N
retrograde NN N
cholangiopancreatography NN N
( ( N
ERCP NNP N
) ) N
. . N

Our PRP$ N
objectives NNS N
were VBD N
to TO N
compare VB N
safety NN o
, , o
ease NN o
of IN o
treatment NN o
, , o
recovery NN o
, , N
and CC N
patients NNS o
' POS o
experiences NNS o
using VBG N
patient-controlled JJ i
sedation NN i
( ( N
PCS NNP N
) ) N
with IN N
propofol NN i
, , N
nurse JJ N
anesthetist-controlled JJ i
sedation NN i
( ( N
ACS NNP N
) ) N
, , N
or CC N
the DT N
department NN N
's POS N
standard NN i
of IN i
care NN i
, , N
midazolam VB i
given VBN N
by IN N
the DT N
procedure NN N
team NN N
( ( N
control VB N
group NN N
) ) N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
The DT N
study NN p
included VBD p
281 CD p
adults NNS p
in IN p
301 CD p
procedures NNS p
. . N

The DT N
PCS NNP N
group NN N
( ( N
n JJ N
= NNP N
101 CD N
) ) N
delivered VBN N
bolus JJ N
doses NNS N
of IN N
5 CD N
mg NN N
of IN N
propofol NN i
according VBG N
to TO N
their PRP$ N
need NN N
for IN N
sedation NN N
. . N

The DT N
ACS NNP N
group NN N
( ( N
n JJ N
= NNP N
100 CD N
) ) N
had VBD N
2-8 JJ N
mg/kg/h NN N
of IN N
propofol NN i
infused VBN N
, , N
with IN N
the DT N
target NN N
for IN N
sedation NN N
being VBG N
level JJ N
3 CD N
of IN N
the DT N
Observer NNP N
's POS N
Assessment NNP N
of IN N
Alertness/Sedation NNP N
( ( N
OAA/S NNP N
) ) N
scale NN N
. . N

The DT N
control NN N
group NN N
was VBD N
given VBN N
2-3 JJ N
mg NN N
of IN N
midazolam NN i
for IN N
induction NN N
and CC N
additional JJ N
1 CD N
mg NN N
if IN N
required VBN N
. . N

RESULTS NNP N
PCS NNP N
and CC N
ACS NNP N
increased VBD N
the DT N
ease NN o
of IN o
the DT o
procedure NN o
and CC N
reduced VBD N
the DT N
number NN o
of IN o
sedation NN o
failures NNS o
compared VBN N
to TO N
midazolam VB i
sedation NN N
( ( N
ACS NNP N
n RB N
= VBZ N
0 CD N
; : N
PCS NNP N
n VBD N
= JJ N
4 CD N
; : N
midazolam NN i
n IN N
= $ N
20 CD N
) ) N
. . N

The DT N
ACS NNP N
group NN N
had VBD N
more RBR N
deeply RB N
sedated JJ N
patients NNS N
( ( N
OAA/S NNP N
level RB N
2 CD N
) ) N
, , N
desaturation NN N
, , N
and CC N
obstructed VBD N
airways NNS N
than IN N
the DT N
PCS NNP N
and CC N
midazolam NN i
groups NNS N
. . N

Time NN o
to TO o
full JJ o
recovery NN o
( ( o
Aldrete NNP o
score RB o
?9 VBD N
) ) N
was VBD N
shortest JJS N
following VBG N
PCS NNP N
. . N

PCS NNP N
resulted VBD N
in IN N
the DT N
least JJS N
fatigue NN o
and CC o
pain NN o
after IN N
the DT N
procedure NN N
. . N

Patients NNS N
' POS o
preference NN o
for IN N
PCS NNP N
and CC N
ACS NNP N
was VBD N
the DT N
same JJ N
. . N

CONCLUSION NNP N
PCS NNP N
with IN N
propofol NN i
is VBZ N
superior JJ N
to TO N
midazolam VB i
and CC N
comparable VB N
to TO N
ACS NNP N
. . N

PCS NNP N
resulted VBD N
in IN N
a DT N
rapid JJ N
recovery NN o
, , N
fewer JJR N
respiratory NN o
events NNS o
, , N
and CC N
was VBD N
almost RB N
as RB N
effective JJ N
as IN N
ACS NNP N
in IN N
ensuring VBG N
a DT N
successful JJ N
examination NN N
. . N

-DOCSTART- -20147856- O O

Randomized VBN N
phase NN N
II NNP N
study NN N
of IN N
two CD N
different JJ N
schedules NNS N
of IN N
gemcitabine NN i
and CC N
oral JJ N
S-1 NNP i
in IN N
chemo-na?ve JJ p
patients NNS p
with IN p
advanced JJ p
non-small JJ p
cell NN p
lung NN p
cancer NN p
. . N

INTRODUCTION NNP N
This DT N
study NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC N
safety NN o
and CC N
to TO N
compare VB N
dosing VBG N
schedules NNS N
of IN N
gemcitabine NN i
combined VBN N
with IN N
S-1 NNP i
in IN N
chemo-na?ve JJ p
non-small JJ p
cell NN p
lung NN p
cancer NN p
patients NNS p
. . N

METHODS NNP N
Patients NNPS p
with IN p
chemo-na?ve JJ p
stage NN p
IIIB/IV NNP p
non-small NN p
cell NN p
lung NN p
cancer NN p
were VBD N
randomized VBN N
into IN N
two CD N
treatment NN N
arms NNS N
. . N

Patients NNS N
were VBD N
given VBN N
oral JJ N
S-1 NNP i
( ( N
60 CD N
mg/m/d NN N
, , N
twice RB N
a DT N
day NN N
) ) N
from IN N
days NNS N
1 CD N
to TO N
14 CD N
with IN N
gemcitabine NN i
( ( N
1000 CD N
mg/m/d NN N
) ) N
on IN N
days NNS N
1 CD N
and CC N
8 CD N
( ( N
arm VB N
A NNP N
) ) N
or CC N
on IN N
days NNS N
8 CD N
and CC N
15 CD N
( ( N
arm NN N
B NNP N
) ) N
. . N

This DT N
cycle NN N
was VBD N
repeated VBN N
every DT N
21 CD N
days NNS N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
80 CD p
patients NNS p
were VBD p
entered VBN p
in IN p
this DT p
trial NN p
. . p

The DT N
primary JJ N
end NN N
point NN N
of IN N
this DT N
study NN N
was VBD N
response NN o
rate NN o
. . N

The DT N
response NN o
rates NNS o
of IN N
arm NN N
A NNP N
and CC N
arm NN N
B NNP N
were VBD N
22.0 CD N
and CC N
28.9 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.606 CD N
) ) N
. . N

Median JJ N
time NN o
to TO o
treatment NN o
failure NN o
in IN N
arm NN N
A NN N
was VBD N
3.6 CD N
months NNS N
and CC N
4.8 CD N
months NNS N
in IN N
arm NN N
B NNP N
. . N

Median JJ N
time NN o
to TO o
progression NN o
in IN N
arm NN N
A NN N
was VBD N
4.1 CD N
months NNS N
and CC N
5.5 CD N
months NNS N
in IN N
arm NN N
B NNP N
. . N

Median JJ N
survival JJ o
time NN o
in IN N
arm NN N
A NN N
and CC N
arm NN N
B NNP N
was VBD N
15.5 CD N
months NNS N
and CC N
18.8 CD N
months NNS N
, , N
respectively RB N
. . N

The DT N
toxicity NN o
profile NN o
was VBD N
relatively RB N
mild JJ N
and CC N
did VBD N
not RB N
differ VB N
very RB N
much RB N
between IN N
two CD N
arms NNS N
. . N

CONCLUSION VB N
The DT N
combination NN N
of IN N
gemcitabine NN i
and CC N
S-1 NNP i
was VBD N
determined VBN N
to TO N
be VB N
feasible JJ o
and CC N
effective JJ o
for IN N
advanced JJ N
non-small JJ N
cell NN N
lung NN N
cancer NN N
. . N

We PRP N
selected VBD N
arm NN N
B NNP N
for IN N
further JJ N
studies NNS N
because IN N
of IN N
its PRP$ N
higher JJR N
response NN o
rate NN o
and CC o
survival NN o
data NNS o
. . N

-DOCSTART- -20943715- O O

Visual JJ i
and CC i
kinesthetic JJ i
locomotor NN i
imagery NN i
training NN i
integrated VBN N
with IN N
auditory JJ i
step NN i
rhythm NN i
for IN N
walking VBG N
performance NN N
of IN N
patients NNS p
with IN p
chronic JJ p
stroke NN p
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
visual JJ i
and CC i
kinesthetic JJ i
locomotor NN i
imagery NN i
training NN i
on IN N
walking VBG o
performance NN o
and CC N
to TO N
determine VB N
the DT N
clinical JJ N
feasibility NN N
of IN N
incorporating VBG N
auditory JJ i
step NN i
rhythm NN i
into IN N
the DT N
training NN N
. . N

DESIGN NNP N
Randomized NNP N
crossover NN N
trial NN N
. . N

SETTING NNP N
Laboratory NNP N
of IN N
a DT N
Department NNP N
of IN N
Physical NNP N
Therapy NNP N
. . N

SUBJECTS NNP N
Fifteen NNP p
subjects VBZ p
with IN p
post-stroke JJ p
hemiparesis NN p
. . N

INTERVENTION NNP N
Four NNP N
locomotor NN i
imagery NN i
trainings NNS i
on IN N
walking VBG N
performance NN N
: : N
visual JJ i
locomotor NN i
imagery NN i
training NN i
, , N
kinesthetic JJ i
locomotor NN i
imagery NN i
training NN i
, , N
visual JJ i
locomotor NN i
imagery NN i
training NN i
with IN i
auditory JJ i
step NN i
rhythm NN i
and CC N
kinesthetic JJ i
locomotor NN i
imagery NN i
training NN i
with IN i
auditory JJ i
step NN i
rhythm NN i
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT o
timed JJ o
up-and-go JJ o
test NN o
and CC o
electromyographic JJ o
and CC o
kinematic JJ o
analyses NNS o
of IN o
the DT o
affected JJ o
lower JJR o
limb NN o
during IN N
one CD N
gait NN N
cycle NN N
. . N

RESULTS NNP N
After IN N
the DT N
interventions NNS N
, , N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
timed JJ o
up-and-go JJ o
test NN o
results NNS N
between IN N
the DT N
visual JJ i
locomotor NN i
imagery NN i
training NN i
( ( N
25.69 CD N
? . N
16.16 CD N
to TO N
23.97 CD N
? . N
14.30 CD N
) ) N
and CC N
the DT N
kinesthetic JJ i
locomotor NN i
imagery NN i
training NN i
with IN i
auditory JJ i
step NN i
rhythm NN i
( ( N
22.68 CD N
? . N
12.35 CD N
to TO N
15.77 CD N
? . N
8.58 CD N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

During IN N
the DT N
swing NN N
and CC N
stance NN N
phases NNS N
, , N
the DT N
kinesthetic JJ i
locomotor NN i
imagery NN i
training NN i
exhibited VBN N
significantly RB N
increased VBN N
activation NN N
in IN N
a DT N
greater JJR N
number NN N
of IN N
muscles NNS N
and CC N
increased VBD N
angular JJ o
displacement NN o
of IN o
the DT o
knee NN o
and CC o
ankle NN o
joints NNS o
compared VBN N
with IN N
the DT N
visual JJ i
locomotor NN i
imagery NN i
training NN i
, , N
and CC N
these DT N
effects NNS N
were VBD N
more RBR N
prominent JJ N
when WRB N
auditory JJ i
step NN i
rhythm NN i
was VBD N
integrated VBN N
into IN N
each DT N
form NN N
of IN N
locomotor NN i
imagery NN i
training NN i
. . N

The DT N
activation NN N
of IN N
the DT N
hamstring NN N
during IN N
the DT N
swing JJ N
phase NN N
and CC N
the DT N
gastrocnemius NN N
during IN N
the DT N
stance NN N
phase NN N
, , N
as RB N
well RB N
as IN N
kinematic JJ N
data NNS N
of IN N
the DT N
knee NN N
joint NN N
, , N
were VBD N
significantly RB N
different JJ N
for IN N
posttest JJS N
values NNS N
between IN N
the DT N
visual JJ i
locomotor NN i
imagery NN i
training NN i
and CC N
the DT N
kinesthetic JJ i
locomotor NN i
imagery NN i
training NN i
with IN i
auditory JJ i
step NN i
rhythm NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
therapeutic JJ N
effect NN N
may MD N
be VB N
further RB N
enhanced VBN N
in IN N
the DT N
kinesthetic JJ i
locomotor NN i
imagery NN i
training NN i
than IN N
in IN N
the DT N
visual JJ i
locomotor NN i
imagery NN i
training NN i
. . N

The DT N
auditory JJ i
step NN i
rhythm VBZ i
together RB N
with IN N
the DT N
locomotor NN i
imagery NN i
training NN i
produces VBZ N
a DT N
greater JJR N
positive JJ N
effect NN N
in IN N
improving VBG N
the DT N
walking VBG o
performance NN o
of IN N
patients NNS p
with IN p
post-stroke JJ p
hemiparesis NN p
. . N

-DOCSTART- -24350813- O O

An DT N
open-label JJ N
extension NN N
study NN N
of IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
risperidone NN i
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autistic JJ p
disorder NN p
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
long-term JJ N
safety NN N
and CC N
efficacy NN N
of IN N
risperidone NN i
in IN N
treating VBG N
irritability NN N
and CC N
related JJ N
behaviors NNS N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autistic JJ p
disorders NNS p
. . N

METHODS NNP N
In IN N
this DT N
6 CD N
month NN N
( ( N
26 CD N
week NN N
) ) N
open-label NN N
extension NN N
( ( N
OLE NNP N
) ) N
study NN N
, , N
patients NNS p
( ( p
5-17 JJ p
years NNS p
of IN p
age NN p
, , p
who WP p
completed VBD p
the DT p
previous JJ p
fixed-dose JJ p
, , p
6 CD p
week NN p
, , p
double-blind JJ p
[ NNP p
DB NNP p
] NNP p
phase NN p
) ) N
were VBD N
flexibly RB N
dosed VBN N
with IN N
risperidone NN i
based VBN N
on IN N
body NN N
weight NN N
. . N

The DT N
maximum JJ N
allowed VBD N
dose NN N
was VBD N
1.25 CD N
mg/day NN N
for IN N
those DT N
weighing VBG N
20 CD N
to TO N
< VB N
45 CD N
kg NN N
, , N
and CC N
1.75 CD N
mg/day NN N
for IN N
those DT N
weighing VBG N
? . N
45 CD N
kg NN N
. . N

The DT N
study NN N
primarily RB N
assessed VBD N
risperidone NN i
's POS N
safety NN o
; : N
efficacy NN o
was VBD N
assessed VBN N
as IN N
a DT N
secondary JJ N
end-point NN N
. . N

RESULTS VB N
Fifty-six NNP p
( ( p
71 CD p
% NN p
) ) p
out IN p
of IN p
79 CD p
enrolled JJ p
patients NNS p
completed VBD p
the DT p
OLE NNP p
; : N
the DT N
most RBS N
common JJ N
discontinuations NNS N
were VBD N
for IN N
insufficient JJ N
response NN N
( ( N
7 CD N
[ RB N
9 CD N
% NN N
] NN N
) ) N
or CC N
adverse JJ o
events NNS o
( ( o
AE NNP N
) ) N
( ( N
5 CD N
[ RB N
6 CD N
% NN N
] NN N
) ) N
. . N

The DT N
most RBS N
common JJ N
( ( N
? . N
5 CD N
% NN N
frequency NN N
in IN N
the DT N
total JJ N
group NN N
) ) N
AEs NNP N
were VBD N
increased VBN N
appetite RB o
( ( N
11 CD N
% NN N
[ JJ N
n=9 JJ N
] NN N
) ) N
; : N
increased VBN N
weight NN o
and CC o
vomiting NN o
( ( N
9 CD N
% NN N
[ JJ N
n=7 JJ N
] NNP N
each DT N
) ) N
; : N
sedation NN o
, , o
pyrexia NN o
, , o
and CC o
upper JJ o
respiratory NN o
tract NN o
infection NN o
( ( N
8 CD N
% NN N
[ JJ N
n=6 JJ N
] NNP N
each DT N
) ) N
; : N
nasopharyngitis NN o
( ( N
6 CD N
% NN N
[ JJ N
n=5 JJ N
] NN N
) ) N
; : N
and CC N
somnolence NN o
and CC o
fatigue NN o
( ( N
5 CD N
% NN N
[ JJ N
n=4 JJ N
] NNP N
each DT N
) ) N
. . N

Extrapyramidal JJ N
AEs NNP o
were VBD N
reported VBN N
in IN N
6 CD N
( ( N
8 CD N
% NN N
) ) N
patients NNS N
. . N

Increase NNP N
in IN o
mean JJ o
weight NN o
( ( N
11-15 CD N
% NN N
) ) N
and CC N
body NN o
mass NN o
index NN o
( ( N
5-10 CD N
% NN N
) ) N
occurred VBD N
; : N
one CD N
patient NN N
discontinued VBN N
because IN N
of IN N
weight JJ o
increase NN N
. . N

One CD N
potentially RB N
prolactin-related JJ o
AE NNP o
( ( o
irregular JJ o
menstruation NN o
) ) o
was VBD N
reported VBN N
. . N

The DT N
risperidone NN i
high-dose JJ N
group NN N
had VBD N
the DT N
greatest JJS N
mean JJ N
improvement NN N
in IN o
sleep JJ o
visual JJ o
analog NN o
scale NN o
( ( N
24.6 CD N
) ) N
. . N

All DT N
groups NNS N
showed VBD N
additional JJ N
improvement NN N
in IN N
efficacy NN o
scale JJ o
scores NNS o
during IN N
the DT N
OLE NNP N
. . N

CONCLUSIONS NNP N
During IN N
this DT N
OLE NNP N
, , N
safety NN N
findings NNS N
with IN N
risperidone NN i
treatment NN N
( ( N
maximum JJ N
weight-based JJ N
dose NN N
of IN N
1.25 CD N
mg/day NN N
or CC N
1.75 CD N
mg/day NN N
) ) N
were VBD N
consistent JJ N
with IN N
those DT N
observed VBN N
in IN N
the DT N
DB NNP N
phase NN N
, , N
and CC N
with IN N
the DT N
current JJ N
safety NN N
information NN N
for IN N
risperidone NN i
in IN N
autistic JJ N
, , N
psychiatric JJ N
, , N
and CC N
behavioral JJ N
disorders NNS N
. . N

Patients NNS N
experienced VBD N
some DT N
additional JJ N
improvement NN N
in IN N
irritability NN o
and CC o
related JJ o
behaviors NNS o
. . N

CLINICAL JJ N
TRIALS NNP N
REGISTRY NNP N
This DT N
phase-4 JJ N
study NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
( ( N
NCT00576732 NNP N
) ) N
. . N

-DOCSTART- -25950425- O O

The DT N
effects NNS N
of IN N
preoperative JJ N
oral JJ N
pregabalin NN i
and CC N
perioperative JJ N
intravenous JJ N
lidocaine NN i
infusion NN N
on IN N
postoperative JJ o
morphine NN o
requirement NN o
in IN N
patients NNS p
undergoing VBG p
laparatomy NN p
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
and CC N
compare VB N
the DT N
effects NNS N
of IN N
preoperative JJ N
oral JJ N
pregabalin NN i
and CC N
perioperative JJ N
intravenous JJ N
lidocaine NN i
infusion NN N
on IN N
postoperative JJ o
morphine NN o
requirement NN o
, , o
adverse JJ o
effects NNS o
, , o
patients NNS o
' POS o
satisfaction NN o
, , o
mobilization NN o
, , o
time NN o
to TO o
first JJ o
defecation NN o
and CC N
time NN o
to TO o
discharge VB o
in IN N
patients NNS N
undergoing VBG N
laparotomy NN N
. . N

METHODS NNP N
Eighty NNP p
patients NNS p
( ( p
18 CD p
to TO p
65 CD p
years NNS p
of IN p
age NN p
) ) p
undergoing VBG p
elective JJ p
laparotomy NN p
were VBD N
randomly RB N
divided VBN N
into IN N
four CD N
groups NNS N
( ( N
n=20 JJ N
in IN N
each DT N
group NN N
) ) N
: : N
group NN N
C NNP N
, , N
placebo NN i
capsules NNS N
and CC N
normal JJ i
saline JJ i
infusion NN i
perioperatively RB N
( ( N
control NN N
) ) N
; : N
group NN N
L NNP N
, , N
placebo NN i
capsules NNS N
and CC N
lidocaine JJ i
1 CD N
mg?kg RB N
intravenous JJ N
bolus NN N
dose NN N
followed VBN N
by IN N
2 CD N
mg?kg?h JJ N
infusion NN N
until IN N
skin JJ N
closure NN N
; : N
group NN N
P NNP N
, , N
150 CD N
mg JJ N
oral JJ N
pregabalin NN i
and CC N
normal JJ i
saline JJ i
infusion NN i
perioperatively RB N
; : N
and CC N
group NN N
PL NNP N
, , N
150 CD N
& CC N
nbsp NN N
; : N
mg CC N
oral JJ N
pregabalin NN i
and CC N
lidocaine NN i
2 CD N
mg?kg?h NN N
infusion NN N
until IN N
skin JJ N
closure NN N
. . N

Hemodynamic NNP N
parameters NNS o
, , o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
scores VBZ o
, , o
analgesic JJ o
consumption NN o
, , o
side NN o
effects NNS o
, , o
time NN o
to TO o
mobilization VB o
, , o
time NN o
to TO o
first JJ o
defecation NN o
, , o
time NN o
to TO o
discharge VB o
and CC o
patients NNS o
' POS o
satisfaction NN o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
VAS NNP N
scores NNS o
of IN N
group NN N
L NNP N
, , N
group NN N
P NNP N
and CC N
group NN N
PL NNP N
were VBD N
lower JJR N
than IN N
group NN N
C NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Morphine NNP o
consumption NN N
of IN N
group NN N
P NNP N
and CC N
group NN N
PL NNP N
was VBD N
lower JJR N
than IN N
group NN N
C NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Incidence NN o
of IN o
nausea NN o
in IN N
group NN N
C NNP N
was VBD N
higher JJR N
than IN N
group NN N
L NNP N
and CC N
group NN N
PL NNP N
. . N

Time NNP o
to TO o
first VB N
defecation NN o
and CC o
mobilization NN o
were VBD N
shorter JJR N
in IN N
group NN N
L NNP N
and CC N
group NN N
PL NNP N
compared VBN N
with IN N
group NN N
C NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Preoperative NNP N
oral JJ N
pregabalin NN i
and CC N
perioperative JJ N
intravenous JJ N
lidocaine NN i
infusion NN N
decreased VBD N
postoperative JJ o
VAS NNP o
scores NNS o
. . N

Preoperative JJ N
oral JJ N
pregabalin NN i
decreased VBD N
morphine JJ o
requirement NN o
and CC N
perioperative JJ N
intravenous JJ N
lidocaine NN i
infusion NN N
hastened VBD N
gastrointestinal JJ N
motility NN N
and CC N
mobilization NN N
, , N
and CC N
decreased VBD N
the DT N
incidence NN o
of IN o
nausea NN o
in IN N
patients NNS N
undergoing VBG N
laparotomy NN N
. . N

Therefore RB N
, , N
preoperative JJ N
pregabalin NN i
with IN N
or CC N
without IN N
lidocaine JJ i
provides VBZ N
superior JJ N
pain NN N
relief NN N
in IN N
patients NNS N
undergoing VBG N
laparatomy NN N
. . N

-DOCSTART- -21866656- O O

[ RB N
Clinical NNP N
study NN N
on IN N
treatment NN N
of IN N
endometriosis-related JJ p
infertility NN p
patients NNS p
by IN N
laparoscopic NN i
surgery NN i
in IN N
combination NN N
of IN N
quyu JJ i
jiedu NN i
recipe NN i
] NNP N
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
clinical JJ o
efficacy NN o
of IN N
the DT N
laparoscopic NN i
surgery NN i
in IN N
combination NN N
of IN N
Quyu NNP i
Jiedu NNP i
Recipe NNP i
( ( i
QYJDR NNP i
) ) i
on IN N
endometriosis NN p
( ( p
EMs NNP p
) ) p
-related VBD p
infertility NN p
patients NNS p
. . N

METHODS NNP N
130 CD p
EMs-related JJ p
infertility NN p
patients NNS p
of IN p
blood NN p
stasis NN p
and CC p
toxin NN p
accumulation NN p
syndrome NN p
diagnosed VBD p
and CC p
treated VBN p
by IN p
laparoscopic NN p
surgery NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
, , N
i.e. FW N
, , N
the DT N
test NN N
group NN N
( ( N
75 CD N
cases NNS N
) ) N
and CC N
the DT N
control NN N
group NN N
( ( N
55 CD N
cases NNS N
) ) N
. . N

All DT N
patients NNS N
received VBD N
routine JJ N
progesterone NN i
treatment NN N
after IN N
laparoscopic NN N
surgery NN N
. . N

QYJDR NNP i
was VBD N
given VBN N
to TO N
patients NNS N
in IN N
the DT N
test NN N
group NN N
after IN N
laparoscopic NN N
surgery NN N
, , N
lasting VBG N
for IN N
twelve JJ N
months NNS N
. . N

The DT N
pregnancy NN o
rate NN o
within IN N
one CD N
year NN N
after IN N
laparoscopic NN N
surgery NN N
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
Chinese JJ o
medicine NN o
syndrome NN o
integrals NNS o
, , o
serum JJ o
endometrium NN o
antibody NN o
( ( o
EMAb NNP o
) ) o
and CC o
cancer NN o
antigen NN o
125 CD o
( ( o
CA125 NNP o
) ) o
levels NNS o
were VBD N
compared VBN N
between IN N
before RB N
drug NN N
therapy NN N
and CC N
three CD N
months NNS N
after IN N
drug NN N
therapy NN N
. . N

RESULTS VB N
The DT N
pregnancy NN o
rate NN o
within IN N
one CD N
year NN N
after IN N
laparoscopic NN N
surgery NN N
was VBD N
higher RBR N
in IN N
the DT N
test NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
[ VBD N
61.33 CD N
% NN N
( ( N
46/75 CD N
) ) N
vs FW N
45.45 CD N
% NN N
( ( N
25/55 CD N
) ) N
] NN N
, , N
showing VBG N
significant JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
Chinese JJ o
medicine NN o
syndrome JJ o
integral NN o
was VBD N
( ( N
16.07 CD N
+/- JJ N
6.77 CD N
) ) N
score NN N
and CC N
( ( N
7.25 CD N
+/- JJ N
3.27 CD N
) ) N
score NN N
before IN N
and CC N
3 CD N
months NNS N
after IN N
drug NN N
therapy NN N
in IN N
the DT N
test NN N
group NN N
, , N
while IN N
it PRP N
was VBD N
( ( N
15.92 CD N
+/- JJ N
7.51 CD N
) ) N
score NN N
and CC N
( ( N
12.73 CD N
+/- JJ N
6.12 CD N
) ) N
score NN N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
Chinese JJ o
medicine NN o
syndrome JJ o
integral JJ o
after IN N
drug NN N
therapy NN N
was VBD N
lower JJR N
than IN N
that DT N
before IN N
drug NN N
therapy NN N
in IN N
the DT N
same JJ N
group NN N
. . N

Besides IN N
, , N
the DT N
integral JJ N
difference NN N
between IN N
before IN N
and CC N
after IN N
drug NN N
therapy NN N
was VBD N
higher RBR N
in IN N
the DT N
test NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
[ NNP N
( ( N
9.12 CD N
+/- JJ N
6.16 CD N
) ) N
score NN N
vs NN N
( ( N
3.48 CD N
+/- JJ N
2.06 CD N
) ) N
score NN N
) ) N
] NN N
, , N
showing VBG N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
three-month JJ N
drug NN N
therapy NN N
, , N
the DT N
serum NN o
EMAb NNP o
negative JJ N
conversion NN N
rate NN N
was VBD N
obviously RB N
higher JJR N
in IN N
the DT N
test NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
44.44 CD N
% NN N
vs JJ N
15.62 CD N
% NN N
) ) N
, , N
showing VBG N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
serum NN o
CA125 NNP o
level NN o
was VBD N
( ( N
31.88 CD N
+/- JJ N
15.78 CD N
) ) N
U/mL NNP N
before IN N
drug NN N
therapy NN N
and CC N
( ( N
18.82 CD N
+/- JJ N
10.08 CD N
) ) N
U/mL NNP N
three CD N
months NNS N
after IN N
drug NN N
therapy NN N
in IN N
the DT N
test NN N
group NN N
, , N
while IN N
it PRP N
was VBD N
( ( N
30.63 CD N
+/- JJ N
19.28 CD N
) ) N
U/mL NN N
and CC N
( ( N
18.05 CD N
+/- JJ N
11.20 CD N
) ) N
U/mL NNP N
respectively RB N
in IN N
the DT N
control NN N
group NN N
. . N

It PRP N
was VBD N
lowered VBN N
after IN N
drug NN N
therapy NN N
in IN N
the DT N
two CD N
groups NNS N
with IN N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
after IN N
drug NN N
therapy NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
laparoscopic NN i
surgery NN i
in IN N
combination NN N
of IN N
QYJDR NNP i
could MD N
effectively RB N
improve VB N
clinical JJ N
symptoms NNS N
of IN N
EMs NNP N
patients NNS N
of IN N
blood NN o
stasis NN o
and CC N
toxin NN o
accumulation NN o
syndrome NN o
, , N
promote VBP N
negative JJ o
conversion NN o
of IN o
EMAb NNP o
, , N
lower JJR N
serum NN o
CA125 NNP o
levels NNS o
, , N
and CC N
elevate VB N
the DT N
clinical JJ o
pregnancy NN o
rate NN o
. . N

QYJDR NNP i
is VBZ N
an DT N
effective JJ N
formula NN N
in IN N
treatment NN N
of IN N
EMs-related JJ N
infertility NN N
. . N

-DOCSTART- -16427787- O O

Sleep-anticipating JJ N
effects NNS o
of IN N
melatonin NN i
in IN N
the DT N
human JJ p
brain NN N
. . N

Melatonin NNP N
, , N
the DT N
hormone NN N
produced VBN N
nocturnally RB N
by IN N
the DT N
pineal NN N
gland NN N
, , N
is VBZ N
an DT N
endogenous JJ N
regulator NN N
of IN N
the DT N
sleep-wake JJ N
cycle NN N
. . N

The DT N
effects NNS N
of IN N
melatonin NN i
on IN N
brain NN N
activities NNS N
and CC N
their PRP$ N
relation NN N
to TO N
induction NN N
of IN N
sleepiness NN N
were VBD N
studied VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo NN N
controlled VBD N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
fMRI NN N
) ) N
study NN N
. . N

Melatonin NNP i
, , N
but CC N
not RB N
placebo VB i
, , N
reduced VBN N
task-related JJ o
activity NN o
in IN N
the DT N
rostro-medial JJ N
aspect NN N
of IN N
the DT N
occipital JJ N
cortex NN N
during IN N
a DT N
visual-search JJ N
task NN N
and CC N
in IN N
the DT N
auditory JJ N
cortex NN N
during IN N
a DT N
music NN N
task NN N
. . N

These DT N
effects NNS N
correlated VBD N
with IN N
subjective JJ o
measurements NNS o
of IN o
fatigue NN o
. . N

In IN N
addition NN N
, , N
melatonin NN i
enhanced VBD N
the DT N
activation NN o
in IN o
the DT o
left NN o
parahippocampus NN o
in IN N
an DT N
autobiographic JJ N
memory NN N
task NN N
. . N

Results VB N
demonstrate NN N
that IN N
melatonin NN i
modulates NNS N
brain NN o
activity NN o
in IN N
a DT N
manner NN N
resembling VBG N
actual JJ N
sleep NN N
although IN N
subjects NNS N
are VBP N
fully RB N
awake RB N
. . N

Furthermore RB N
, , N
the DT N
fatigue NN o
inducing VBG N
effect NN N
of IN N
melatonin NN i
on IN N
brain NN N
activity NN N
is VBZ N
essentially RB N
different JJ N
from IN N
that DT N
of IN N
sleep JJ N
deprivation NN N
thus RB N
revealing VBG N
differences NNS N
between IN N
fatigues NNS N
related VBN N
to TO N
the DT N
circadian JJ N
sleep NN N
regulation NN N
as IN N
opposed VBN N
to TO N
increased VBN N
homeostatic JJ N
sleep NN N
need NN N
. . N

Our PRP$ N
findings NNS N
highlight VBD N
the DT N
role NN N
of IN N
melatonin NN i
in IN N
priming VBG N
sleep-associated JJ N
brain NN N
activation NN N
patterns NNS N
in IN N
anticipation NN N
of IN N
sleep NN N
. . N

-DOCSTART- -23021296- O O

Adherence NN o
to TO N
lifestyle VB i
recommendations NNS N
by IN N
patients NNS p
with IN p
depression NN p
. . N

INTRODUCTION NNP N
There EX N
is VBZ N
an DT N
increasing VBG N
amount NN N
of IN N
evidence NN N
showing VBG N
that DT N
physical JJ N
activity NN N
and CC N
sun NN N
exposure NN N
are VBP N
effective JJ N
coadjuvant JJ N
treatments NNS N
for IN N
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
depression NN p
. . N

However RB N
, , N
there EX N
is VBZ N
a DT N
lack NN N
of IN N
information NN N
regarding VBG N
patient NN N
's POS N
adherence NN o
to TO N
these DT N
recommendations NNS N
in IN N
daily JJ N
clinical JJ N
practice NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
study NN N
including VBG N
15 CD p
depressive JJ p
patients NNS p
who WP p
had VBD p
been VBN p
under IN p
antidepressant JJ p
treatment NN p
for IN p
at IN p
least JJS p
one CD p
month NN p
. . N

They PRP N
wore VBD N
a DT N
wrist-watch-like JJ N
actimetry NN N
sensor NN N
to TO N
measure VB N
physical JJ o
activity NN o
and CC o
sun NN o
exposure NN o
24 CD N
hours NNS N
a DT N
day NN N
. . N

After IN N
one CD N
week NN N
of IN N
baseline NN N
assessment NN N
, , N
patients NNS N
were VBD N
randomised VBN N
into IN N
one CD N
of IN N
the DT N
two CD N
arms NNS N
of IN N
the DT N
study NN N
. . N

Patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
received VBD N
a DT N
brief JJ N
note NN N
in IN N
which WDT N
they PRP N
were VBD N
explicitly RB N
asked VBN N
to TO N
increase VB N
both DT N
their PRP$ N
physical JJ o
activity NN o
level NN o
and CC N
time NN o
of IN o
sun NN o
exposure NN o
, , N
while IN N
control NN i
group NN N
patients NNS N
did VBD N
not RB i
receive VB i
these DT i
explicit JJ i
recommendations NNS i
. . N

RESULTS NNP N
One CD N
week NN N
after IN N
recommendations NNS N
were VBD N
delivered VBN N
, , N
only RB N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
had VBD N
increased VBN N
time NN o
of IN o
sun NN o
exposure NN o
and CC o
physical JJ o
activity NN o
( ( N
25.8 CD N
% NN N
and CC N
14.3 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Depressive JJ p
patients NNS p
are VBP N
able JJ N
to TO N
follow VB N
prescribed JJ N
lifestyle JJ N
recommendations NNS N
in IN N
the DT N
short-term JJ N
. . N

-DOCSTART- -22744141- O O

Parent-implemented JJ N
enhanced VBD i
milieu NNS i
teaching VBG i
with IN N
preschool JJ p
children NNS p
who WP p
have VBP p
intellectual JJ p
disabilities NNS p
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
enhanced JJ i
milieu NN i
teaching NN i
( ( i
EMT NNP i
) ) i
implemented VBN N
by IN N
parents NNS N
and CC N
therapists NNS N
versus VBP N
therapists VBZ N
only RB N
on IN N
the DT N
language NN N
skills NNS N
of IN N
preschool NN p
children NNS p
with IN p
intellectual JJ p
disabilities NNS p
( ( p
IDs NNP p
) ) p
, , p
including VBG p
children NNS p
with IN p
Down NNP p
syndrome NN p
and CC p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . N

METHOD NNP N
Seventy-seven JJ p
children NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
2 CD N
treatments NNS N
( ( N
parent NN i
+ NNP i
therapist NN i
EMT NNP i
or CC N
therapist-only RB i
EMT NNP i
) ) N
and CC N
received VBD N
36 CD N
intervention NN N
sessions NNS N
. . N

Children NNP N
were VBD N
assessed VBN N
before RB N
, , N
immediately RB N
after IN N
, , N
6 CD N
months NNS N
after IN N
, , N
and CC N
12 CD N
months NNS N
after IN N
intervention NN N
. . N

Separate JJ N
linear JJ N
regressions NNS N
were VBD N
conducted VBN N
for IN N
each DT N
standardized JJ N
and CC N
observational JJ N
measure NN N
at IN N
each DT N
time NN N
point NN N
. . N

RESULTS JJ N
Parents NNS N
in IN N
the DT N
parent NN N
+ NNP N
therapist NN N
group NN N
demonstrated VBD N
greater JJR N
use NN N
of IN N
EMT NNP o
strategies NNS o
at IN N
home NN N
than IN N
untrained JJ N
parents NNS N
in IN N
the DT N
therapist-only JJ N
group NN N
, , N
and CC N
these DT N
effects NNS N
maintained VBD N
over IN N
time NN N
. . N

Effect JJ N
sizes NN N
for IN N
observational JJ o
measures NNS o
ranged VBD N
from IN N
d NN N
= $ N
0.10 CD N
to TO N
d VB N
= JJ N
1.32 CD N
favoring VBG N
the DT N
parent NN N
+ NNP N
therapist NN N
group NN N
, , N
with IN N
the DT N
largest JJS N
effect NN N
sizes VBZ N
found VBD N
12 CD N
months NNS N
after IN N
intervention NN N
. . N

CONCLUSION NNP N
Findings NNS N
from IN N
this DT N
study NN N
indicate VBP N
generally RB N
that IN N
there EX N
are VBP N
benefits NNS N
to TO N
training VBG N
parents NNS N
to TO N
implement VB N
naturalistic JJ N
language NN N
intervention NN N
strategies NNS N
with IN N
preschool JJ p
children NNS p
who WP p
have VBP p
ID NNP p
and CC p
significant JJ p
language NN p
impairments NNS p
. . N

-DOCSTART- -1286547- O O

Reduced VBN N
platelet NN o
thromboxane NN o
formation NN o
after IN N
long-term JJ N
administration NN N
of IN N
a DT N
dihydropyridine JJ i
calcium NN i
channel NN i
blocker NN i
: : N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
with IN N
nitrendipine NN i
in IN N
borderline JJ p
hypertensive JJ p
patients NNS p
with IN p
IDDM-type NNP p
diabetes NNS p
mellitus NN p
. . N

Twenty-nine JJ p
IDDM NNP p
patients NNS p
with IN p
borderline JJ p
hypertension NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
placebo VB i
or CC N
nitrendipine VB i
treatment NN N
. . N

Nitrendipine NNP i
was VBD N
given VBN N
orally RB N
at IN N
a DT N
dosage NN N
of IN N
20 CD N
mg NNS N
once RB N
daily RB N
over IN N
4 CD N
weeks NNS N
. . N

Stimulated VBN o
platelet NN o
thromboxane NN o
formation NN o
at IN N
rest NN N
and CC N
after IN N
standardized VBN N
, , N
non JJ N
exhausting VBG N
exercise NN N
was VBD N
measured VBN N
by IN N
standard JJ N
methods NNS N
. . N

In IN N
addition NN N
, , N
plasma NN o
levels NNS o
of IN o
platelet NN o
factor NN o
4 CD o
and CC o
aggregation NN o
responses NNS o
to TO o
collagen VB o
and CC o
ADP NNP o
were VBD N
determined VBN N
. . N

In IN N
the DT N
treatment NN N
group NN N
thromboxane NN o
formation NN o
after IN N
stimulation NN N
with IN N
collagen NN N
( ( N
0.3 CD N
and CC N
1.0 CD N
micrograms/ml NN N
) ) N
and CC N
1 CD N
mM NN N
arachidonic JJ N
acid NN N
( ( N
AA NNP N
) ) N
was VBD N
reduced VBN N
in IN N
the DT N
resting NN N
state NN N
. . N

Exercise NN o
induced JJ o
change NN o
of IN o
thromboxane NN o
synthesis NN o
in IN N
response NN N
to TO N
1.0 CD N
micrograms/ml NNS N
collagen NN N
was VBD N
significantly RB N
lower JJR N
as IN N
compared VBN N
to TO N
placebo VB i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
parallel JJ N
, , N
PF4 NNP o
plasma NN o
levels NNS o
were VBD N
significantly RB N
lowered VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Whole JJ o
blood NN o
aggregation NN o
after IN o
collagen NN o
stimulation NN o
( ( N
1.0 CD N
micrograms/ml NN N
) ) N
was VBD N
reduced VBN N
after IN N
4 CD N
weeks NNS N
of IN N
nitrendipine JJ i
treatment NN N
, , N
but CC N
ADP NNP N
( ( N
5 CD N
microM NN N
) ) N
induced VBD N
aggregation NN o
was VBD N
not RB N
. . N

These DT N
effects NNS N
of IN N
nitrendipine NN i
were VBD N
not RB N
seen VBN N
in IN N
platelet NN N
rich JJ N
plasma NN N
. . N

In IN N
conclusion NN N
long-term JJ N
nitrendipine JJ i
treatment NN N
may MD N
inhibit VB N
collagen NN o
dependent JJ o
platelet NN o
activation NN o
in IN N
the DT N
blood NN N
of IN N
diabetic JJ p
patients NNS p
with IN p
borderline JJ p
hypertension NN p
. . N

-DOCSTART- -21914768- O O

Cancer NNP N
information NN N
and CC N
anxiety NN o
: : N
applying VBG N
the DT N
extended JJ N
parallel NN N
process NN N
model NN N
. . N

There EX N
is VBZ N
concern NN N
that IN N
public JJ N
education NN N
about IN N
testicular JJ N
cancer NN N
( ( N
TC NNP N
) ) N
may MD N
cause VB N
unnecessary JJ N
anxiety NN N
. . N

Psychological JJ N
theory NN N
suggests VBZ N
that IN N
if IN N
threat NN N
( ( N
eg JJ N
, , N
TC NNP N
) ) N
information NN N
is VBZ N
accompanied VBN N
with IN N
threat NN N
control NN N
strategies NNS N
( ( N
eg NN N
, , N
testicular JJ i
self-examination NN i
; : i
TSE NNP N
) ) N
anxiety NN N
is VBZ N
less RBR N
likely JJ N
. . N

Male JJ p
students NNS p
( ( p
N=443 NNP p
) ) p
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
TC NNP i
or CC N
TC NNP i
+TSE NNP i
information NN N
group NN N
or CC N
a DT N
no DT N
information NN N
control NN N
group NN N
, , N
and CC N
assessed VBD N
at IN N
three CD N
time NN N
points NNS N
. . N

Anxiety NN o
levels NNS o
did VBD N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
and CC N
exposure NN N
to TO N
TC+TSE NNP N
resulted VBD N
in IN N
greater JJR N
perceived JJ o
message NN o
benefit NN o
, , N
increased VBN N
intention NN o
to TO o
self-examine NN o
and CC N
lower JJR N
message NN o
denigration NN o
. . N

This DT N
suggests VBZ N
TC NNP i
information NN N
is VBZ N
not RB N
anxiogenic JJ N
, , N
but CC N
inclusion NN N
of IN N
TSE NNP N
information NN N
may MD N
improve VB N
acceptance NN N
of IN N
disease NN N
awareness NN N
information NN N
. . N

-DOCSTART- -22154769- O O

Safety NN o
, , o
tolerability NN o
, , o
and CC o
immunogenicity NN o
after IN N
1 CD N
and CC N
2 CD N
doses NNS N
of IN N
zoster NN i
vaccine NN i
in IN N
healthy JJ p
adults NNS p
?60 CD p
years NNS p
of IN p
age NN p
. . N

BACKGROUND NNP N
Incidence NNP N
and CC N
severity NN N
of IN N
herpes NNS N
zoster NNP N
( ( N
HZ NNP N
) ) N
and CC N
postherpetic JJ N
neuralgia JJ N
increase NN N
with IN N
age NN N
, , N
associated VBN N
with IN N
age-related JJ N
decrease NN N
in IN N
immunity NN N
to TO N
varicella-zoster JJ N
virus NN N
( ( N
VZV NNP N
) ) N
. . N

One CD N
dose NN N
of IN N
zoster NN i
vaccine NN i
( ( i
ZV NNP i
) ) i
has VBZ N
demonstrated VBN N
substantial JJ N
protection NN N
against IN N
HZ NNP N
; : N
this DT N
study NN N
examined VBD N
impact NN N
of IN N
a DT N
second JJ N
dose NN N
of IN N
ZV NNP i
. . N

METHODS NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
multicenter NN N
study NN N
with IN N
210 CD p
subjects NNS p
?60 CD p
years NNS p
old JJ p
compared VBN N
immunity NN o
and CC o
safety NN o
profiles NNS o
after IN N
one CD N
and CC N
two CD N
doses NNS N
of IN N
ZV NNP i
, , N
separated VBN N
by IN N
6 CD N
weeks NNS N
, , N
vs. FW N
placebo NN N
. . N

Immunogenicity NNP N
was VBD o
evaluated VBN N
using VBG N
VZV NNP o
interferon-gamma JJ o
( ( o
IFN-? NNP o
) ) o
enzyme-linked JJ o
immunospot NN o
( ( o
ELISPOT NNP o
) ) o
assay NN o
and CC o
VZV NNP o
glycoprotein VBD o
enzyme-linked JJ o
immunosorbent NN o
antibody NN o
( ( o
gpELISA NN o
) ) o
assay NN o
. . N

Adverse JJ N
experiences NNS o
( ( o
AEs NNP o
) ) o
were VBD N
recorded VBN N
on IN N
a DT N
standardized JJ N
Vaccination NNP N
Report NNP N
Card NNP N
. . N

RESULTS NNP N
No NNP N
serious JJ N
vaccine-related JJ o
AEs NNP o
occurred VBD N
. . N

VZV NNP o
IFN-? NNP N
ELISPOT NNP o
geometric JJ o
mean NN o
count NN o
( ( o
GMC NNP o
) ) o
of IN o
spot-forming JJ o
cells NNS o
per IN o
10 CD o
( ( o
6 CD o
) ) o
peripheral JJ o
blood NN o
mononuclear JJ o
cells NNS o
increased VBN N
in IN N
the DT N
ZV NNP i
group NN N
from IN N
16.9 CD N
prevaccination NN N
to TO N
49.5 CD N
and CC N
32.8 CD N
at IN N
2 CD N
and CC N
6 CD N
weeks NNS N
postdose RB N
1 CD N
, , N
respectively RB N
. . N

Two CD N
weeks NNS N
, , N
6 CD N
weeks NNS N
and CC N
6 CD N
months NNS N
postdose RB N
2 CD N
, , N
GMC NNP N
was VBD N
44.3 CD N
, , N
42.9 CD N
, , N
and CC N
36.5 CD N
, , N
respectively RB N
. . N

GMC NNP o
in IN N
the DT N
placebo NN i
group NN N
did VBD N
not RB N
change NN N
during IN N
the DT N
study NN N
. . N

The DT N
peak JJ N
ELISPOT NNP o
response NN o
occurred VBD N
?2 NNP N
weeks NNS N
after IN N
each DT N
ZV NNP i
dose NN N
. . N

The DT N
gpELISA NN N
geometric JJ o
mean NN o
titers NNS o
( ( o
GMTs NNP o
) ) o
in IN N
the DT N
ZV NNP i
group NN N
were VBD N
higher JJR N
than IN N
in IN N
the DT N
placebo NN i
group NN N
at IN N
6 CD N
weeks NNS N
after IN N
each DT N
dose NN N
. . N

Correlation NN N
between IN N
the DT N
IFN-? NNP o
ELISPOT NNP o
and CC o
gpELISA NN o
assays NNS o
was VBD N
poor JJ N
. . N

CONCLUSIONS NNP N
ZV NNP i
was VBD N
generally RB N
well-tolerated JJ N
and CC N
immunogenic JJ N
in IN N
adults NNS N
?60 CD N
years NNS N
old JJ N
. . N

A DT N
second JJ N
dose NN N
of IN N
ZV NNP i
was VBD N
generally RB N
safe JJ o
, , N
but CC N
did VBD N
not RB N
boost VB N
VZV-specific NNP N
immunity NN o
beyond IN N
levels NNS N
achieved VBN N
postdose RB N
1 CD N
. . N

-DOCSTART- -24660757- O O

Compensation NN o
in IN N
intergroup JJ N
relations NNS N
: : N
an DT N
investigation NN N
of IN N
its PRP$ N
structural JJ N
and CC N
strategic JJ N
foundations NNS N
. . N

Recent JJ N
work NN N
in IN N
intergroup JJ N
relations NNS N
stresses VBZ N
the DT N
role NN N
of IN N
two CD N
fundamental JJ N
dimensions NNS N
, , N
competence NN N
and CC N
warmth NN N
, , N
which WDT N
organize VBP N
the DT N
perception NN N
of IN N
social JJ N
groups NNS N
. . N

A DT N
pattern NN N
often RB N
encountered VBN N
in IN N
people NNS N
's POS N
ratings NNS N
is VBZ N
one CD N
of IN N
compensation NN N
in IN N
that DT N
a DT N
group NN N
that WDT N
is VBZ N
evaluated VBN N
higher JJR N
than IN N
another DT N
group NN N
on IN N
one CD N
of IN N
the DT N
two CD N
fundamental JJ N
dimensions NNS N
is VBZ N
also RB N
judged VBN N
lower JJR N
on IN N
the DT N
other JJ N
fundamental JJ N
dimension NN N
. . N

Based VBN N
on IN N
Social NNP N
Identity NNP N
Theory NNP N
, , N
the DT N
present JJ N
work NN N
extends VBZ N
previous JJ N
research NN N
on IN N
compensation NN N
by IN N
examining VBG N
boundary JJ o
conditions NNS o
as RB N
well RB N
as IN N
underlying VBG o
psychological JJ o
processes NNS o
. . N

Two CD N
studies NNS N
involving VBG N
experimental JJ N
and CC N
correlational JJ N
evidence NN N
, , N
minimal JJ N
and CC N
real JJ N
groups NNS N
, , N
and CC N
different JJ N
kinds NNS N
of IN N
conflict NN N
, , N
reveal NN N
that IN N
compensation NN N
is VBZ N
more RBR N
likely JJ N
when WRB N
the DT N
groups NNS N
are VBP N
in IN N
asymmetrical JJ N
relation NN N
and CC N
share NN N
a DT N
cooperative JJ N
view NN N
of IN N
the DT N
intergroup NN N
setting NN N
. . N

Our PRP$ N
data NNS N
also RB N
suggest VBP N
that IN N
, , N
among IN N
members NNS N
of IN N
low JJ N
status NN N
groups NNS N
, , N
compensation NN N
is VBZ N
associated VBN N
with IN N
social JJ o
creativity NN o
. . N

In IN N
contrast NN N
, , N
and CC N
in IN N
line NN N
with IN N
the DT N
'noblesse NNP N
oblige NN N
' '' N
effect NN N
, , N
members NNS N
of IN N
the DT N
high JJ N
status NN N
group NN N
would MD N
seem VB N
to TO N
rely VB N
on IN N
compensation NN N
as IN N
a DT N
means NN N
to TO N
appear VB N
non-discriminatory JJ N
. . N

-DOCSTART- -21170734- O O

Serum NNP N
biochemical JJ N
characteristics NNS N
of IN N
Beluga NNP p
, , p
Huso NNP p
huso NN p
( ( p
L. NNP p
) ) p
, , N
in IN N
response NN N
to TO N
blood NN N
sampling NN N
after IN N
clove NN N
powder NN N
solution NN N
exposure NN N
. . N

In IN N
order NN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
anesthesia NN N
on IN N
serum NN N
parameters NNS N
, , N
Beluga NNP p
, , p
Huso NNP p
huso NN p
( ( p
L. NNP p
) ) p
were VBD N
blood-sampled JJ N
immediately RB N
without IN N
anesthesia NN i
( ( N
control NN N
) ) N
or CC N
subjected VBN N
to TO N
following VBG N
anesthesia JJ i
procedure NN N
: : N
40 CD N
, , N
120 CD N
, , N
and CC N
240 CD N
s NN N
exposure NN N
to TO N
3,000 CD N
, , N
700 CD N
, , N
and CC N
500 CD N
mg NN N
l?? NN N
clove NN i
solution NN i
, , N
respectively RB N
. . N

Blood NN N
samples NNS N
were VBD N
collected VBN N
after IN N
these DT N
periods NNS N
, , N
when WRB N
fish NN p
were VBD N
immobile JJ N
and CC N
reached VBD N
stage NN N
4 CD N
anesthesia NN N
. . N

Results NNS N
showed VBD N
that IN N
cortisol NN o
and CC o
glucose JJ o
levels NNS N
were VBD N
significantly RB N
high JJ N
in IN N
700 CD N
and CC N
500 CD N
but CC N
not RB N
3,000 CD N
mg NNS N
l?? JJ N
group NN N
compared VBN N
to TO N
control VB N
. . N

Serum NNP o
lactate NN o
levels NNS o
were VBD N
significantly RB N
high JJ N
in IN N
500 CD N
mg NNS N
l?? JJ N
group NN N
compared VBN N
to TO N
control VB N
group NN N
. . N

Lactate NNP o
levels NNS N
were VBD N
not RB N
significantly RB N
differed VBN N
between IN N
control NN N
, , N
3,000 CD N
, , N
and CC N
700 CD N
mg NN N
l?? NN N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
serum NN o
levels NNS o
of IN o
cholesterol NN o
, , o
total JJ o
protein NN o
, , o
lactate JJ o
dehydrogenase NN o
, , o
aspartate JJ o
aminotransferase NN o
, , o
alanine JJ o
aminotransferase NN o
, , o
Na? NNP o
, , o
Cl? NNP o
, , o
K? NNP o
, , o
and CC o
Ca?? NNP o
. . N

Results NNP N
suggest VBP N
that IN N
rapid JJ N
anesthesia NN N
with IN N
higher JJR N
dose NN N
is VBZ N
better JJR N
than IN N
slow JJ N
anesthesia NN N
with IN N
lower JJR N
dose NN N
for IN N
blood NN N
sampling NN N
in IN N
Beluga NNP p
. . N

-DOCSTART- -16167234- O O

[ JJ N
Effect NNP N
of IN N
branch NN N
chain NN N
amino NN i
acid NN i
enriched VBD i
formula NN i
on IN N
postoperative JJ o
fatigue NN o
and CC N
nutritional JJ o
status NN o
after IN p
digestive JJ p
surgery NN p
] NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
branch NN i
chain NN i
amino NN i
acid NN i
( ( i
BCAA NNP i
) ) i
enriched VBD i
formula NN i
on IN N
nutritional JJ o
status NN o
and CC N
postoperative JJ o
fatigue NN o
for IN N
digestive JJ p
surgery NN p
patients NNS p
. . N

METHODS NNP N
Forty NNP p
patients NNS p
who WP p
underwent VBP p
digestive JJ p
surgery NN p
were VBD N
randomly RB N
received VBN N
parenteral JJ N
nutrition NN N
with IN N
either DT N
BCAA NNP i
enriched VBD i
( ( N
study NN N
group NN N
, , N
n=20 RB N
) ) N
or CC N
routine JJ i
amino NN i
acid NN i
( ( N
control NN N
group NN N
, , N
n=20 RB N
) ) N
for IN N
seven CD N
consecutive JJ N
days NNS N
. . N

Nitrogen NNP o
balance NN o
, , o
serum JJ o
total NN o
protein NN o
, , o
albumin NN o
, , o
prealbumin NN o
, , o
transferrin NN o
, , o
retinol NN o
binding NN o
protein NN o
and CC o
postoperative JJ o
fatigue NN o
score NN o
were VBD N
monitored VBN N
during IN N
the DT N
postoperative JJ N
period NN N
. . N

RESULTS VB N
The DT N
cumulative JJ o
postoperative JJ o
fatigue NN o
scores NNS o
were VBD N
lower JJR N
in IN N
BCAA NNP i
group NN N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
at IN N
the DT N
4th CD N
, , N
5th CD N
and CC N
7th CD N
day NN N
after IN N
operation NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Patients NNS N
achieved VBD N
positive JJ N
nitrogen NN o
balance NN o
2 CD N
days NNS N
earlier RBR N
in IN N
the DT N
study NN N
group NN N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
cumulative JJ o
nitrogen NN o
balance NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
elevation NN N
of IN N
serum JJ o
total JJ o
protein NN o
, , o
albumin NN o
, , o
prealbumin NN o
, , o
transferrin NN o
at IN N
the DT N
7th CD N
day NN N
after IN N
operation NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
, , N
compared VBN N
with IN N
those DT N
at IN N
the DT N
first JJ N
day NN N
after IN N
operation NN N
. . N

The DT N
serum JJ o
level NN o
of IN o
retinol NN o
binding VBG o
protein NN o
was VBD N
higher JJR N
in IN N
BCAA-enriched NNP i
group NN N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P=0.004 NNP N
) ) N
. . N

CONCLUSION NNP N
TPN NNP N
with IN N
BCAA NNP i
enriched VBD i
formula NN i
can MD N
reduce VB N
postoperative JJ o
fatigue NN o
score NN o
and CC N
improve VB N
the DT N
nutritional JJ o
status NN o
for IN N
digestive JJ p
surgery NN p
patients NNS p
. . N

-DOCSTART- -7707420- O O

Effects NNS N
of IN N
individualized JJ i
breast NN i
cancer NN i
risk NN i
counseling NN i
: : N
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
Studies NNPS N
have VBP N
shown VBN N
that IN N
a DT N
majority NN N
of IN N
women NNS p
with IN p
a DT p
family NN p
history NN p
of IN p
breast NN p
cancer NN p
have VBP N
exaggerated VBN N
perceptions NNS N
of IN N
their PRP$ N
own JJ N
risk NN N
of IN N
this DT N
disease NN N
and CC N
experience NN N
excessive JJ N
anxiety NN N
. . N

In IN N
response NN N
to TO N
the DT N
need NN N
to TO N
communicate VB N
more JJR N
accurate JJ N
risk NN N
information NN N
to TO N
these DT N
women NNS N
, , N
specialized JJ N
programs NNS N
for IN N
breast NN N
cancer NN N
risk NN N
counseling VBG N
have VBP N
been VBN N
initiated VBN N
in IN N
medical JJ N
centers NNS N
across IN N
the DT N
United NNP N
States NNPS N
. . N

PURPOSE VB N
Our PRP$ N
purpose NN N
was VBD N
1 CD N
) ) N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
a DT N
standardized JJ N
protocol NN N
for IN N
individualized JJ i
breast NN i
cancer NN i
risk NN i
counseling VBG i
on IN N
comprehension NN N
of IN N
personal JJ N
risk NN N
among IN N
first-degree JJ p
relatives NNS p
of IN p
index NN p
breast NN p
cancer NN p
patients NNS p
and CC N
2 CD N
) ) N
to TO N
identify VB N
women NNS N
most RBS N
and CC N
least JJS N
likely JJ N
to TO N
benefit VB N
from IN N
such JJ N
counseling NN N
. . N

METHODS NNP N
This DT N
study NN N
is VBZ N
a DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
individualized VBN i
breast NN i
cancer NN i
risk NN i
counseling VBG i
to TO N
general JJ i
health NN i
counseling NN i
( ( i
control NN i
) ) i
. . N

We PRP N
studied VBD N
200 CD p
women NNS p
aged VBN p
35 CD p
years NNS p
and CC p
older JJR p
who WP p
had VBD p
a DT p
family NN p
history NN p
of IN p
breast NN p
cancer NN p
in IN p
a DT p
first-degree JJ p
relative NN p
. . N

Women NNS p
with IN p
a DT p
personal JJ p
history NN p
of IN p
cancer NN p
were VBD p
excluded VBN p
. . N

Risk NNP o
comprehension NN o
was VBD N
assessed VBN N
as IN N
the DT N
concordance NN N
between IN N
perceived VBN N
subjective JJ N
lifetime NN N
breast NN N
cancer NN N
risk NN N
and CC N
estimated VBN N
objective JJ N
lifetime NN N
risk NN N
. . N

RESULTS VB N
The DT N
results NNS N
of IN N
logistic JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
women NNS N
who WP N
received VBD N
risk NN i
counseling NN i
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
improve VB N
their PRP$ N
risk NN o
comprehension NN o
, , N
compared VBN N
with IN N
women NNS N
in IN N
the DT N
control NN N
condition NN N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
= VBZ N
3.5 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= NNP N
1.3-9.5 CD N
; : N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

However RB N
, , N
in IN N
both DT N
groups NNS N
, , N
about RB N
two CD N
thirds NNS N
of IN N
women NNS N
continued VBN N
to TO N
overestimate VB N
their PRP$ N
lifetime NN o
risks NNS o
substantially RB N
following VBG N
counseling VBG N
. . N

Examination NN N
of IN N
subjects NNS N
by IN N
treatment NN N
interaction NN N
effects NNS N
indicated VBD N
that IN N
risk NN i
counseling VBG i
did VBD N
not RB N
produce VB N
improved JJ N
comprehension NN o
among IN N
the DT N
large JJ N
proportion NN N
of IN N
women NNS N
who WP N
had VBD N
high JJ N
levels NNS N
of IN N
anxious JJ N
preoccupation NN N
with IN N
breast NN N
cancer NN N
at IN N
base NN N
line NN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

In IN N
addition NN N
, , N
white JJ N
women NNS N
were VBD N
less RBR N
likely JJ N
to TO N
benefit VB N
than IN N
African-American JJ N
women NNS N
( ( N
OR NNP N
= VBZ N
0.34 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0.11-0.99 NN N
; : N
P NNP N
= NNP N
.05 NNP N
) ) N
. . N

CONCLUSION NNP N
Efforts NNPS N
to TO N
counsel NN N
women NNS N
about IN N
their PRP$ N
breast NN N
cancer NN N
risks NNS N
are VBP N
not RB N
likely JJ N
to TO N
be VB N
effective JJ N
unless IN N
their PRP$ N
breast NN N
cancer NN N
anxieties NNS N
are VBP N
also RB N
addressed VBN N
. . N

IMPLICATIONS NNP N
Attention NNP N
to TO N
the DT N
psychological JJ N
aspects NNS N
of IN N
breast NN N
cancer NN N
risk NN N
will MD N
be VB N
critical JJ N
in IN N
the DT N
development NN N
of IN N
risk-counseling JJ i
programs NNS i
that WDT N
incorporate VBP N
testing VBG N
for IN N
the DT N
recently RB N
cloned VBN N
breast NN N
cancer NN N
susceptibility NN N
gene NN N
, , N
BRCA1 NNP N
( ( N
and CC N
BRCA2 NNP N
when WRB N
that DT N
gene NN N
has VBZ N
also RB N
been VBN N
cloned VBN N
) ) N
. . N

-DOCSTART- -10940525- O O

Efficacy NN o
and CC N
safety NN o
of IN N
selamectin NN i
against IN N
fleas NNS N
and CC N
heartworms NNS N
in IN N
dogs NNS p
and CC p
cats NNS p
presented VBD p
as IN p
veterinary JJ p
patients NNS p
in IN p
North NNP p
America NNP p
. . N

A NNP N
series NN N
of IN N
randomized VBN N
, , N
controlled VBN N
, , N
masked VBD N
field NN N
studies NNS N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
selamectin NN i
in IN N
the DT N
treatment NN N
of IN N
flea NN N
infestations NNS N
on IN N
dogs NNS p
and CC p
cats NNS p
, , N
and CC N
in IN N
the DT N
prevention NN N
of IN N
heartworm NN N
infection NN N
in IN N
dogs NNS p
. . N

In IN N
addition NN N
, , N
observations NNS N
were VBD N
made VBN N
on IN N
the DT N
beneficial JJ N
effect NN N
of IN N
selamectin NN i
treatment NN N
on IN N
dogs NNS p
and CC p
cats NNS p
showing VBG p
signs NNS p
of IN p
flea NN p
allergy NN p
dermatitis NN p
( ( p
FAD NNP p
) ) p
. . N

In IN N
all DT N
studies NNS N
selamectin VBP i
was VBD N
applied VBN N
topically RB N
, , N
once RB N
per IN N
month NN N
, , N
in IN N
unit NN N
doses NNS N
providing VBG N
a DT N
minimum JJ N
dosage NN N
of IN N
6mgkg CD N
( ( N
-1 NN N
) ) N
. . N

Dogs NNS p
and CC p
cats NNS p
with IN p
naturally RB p
occurring VBG p
flea NN p
infestations NNS p
, , p
some DT p
of IN p
which WDT p
also RB p
had VBD p
signs NNS p
associated VBN p
with IN p
FAD NNP p
, , N
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
three CD N
months NNS N
of IN N
topical JJ N
treatment NN N
with IN N
selamectin NN i
( ( N
220 CD p
dogs NNS p
, , p
189 CD p
cats NNS p
) ) p
or CC N
a DT N
positive-control JJ N
product NN N
( ( N
dogs NNS N
: : N
fenthion NN i
, , N
n=81 RB N
; : N
cats NNS N
: : N
pyrethrins NNS i
, , N
n=66 NN N
) ) N
. . N

Selamectin NNP i
was VBD N
administered VBN N
on IN N
days NNS N
0 CD N
, , N
30 CD N
, , N
and CC N
60 CD N
. . N

Day NNP N
0 CD N
was VBD N
defined VBN N
as IN N
the DT N
day NN N
that IN N
the DT N
animal NN N
first RB N
received VBD N
treatment NN N
. . N

Flea NN N
burdens NNS N
were VBD N
assessed VBN N
by IN N
flea NN o
comb NN o
counts NNS o
and CC N
clinical JJ o
evaluations NNS o
of IN o
FAD NNP o
were VBD N
performed VBN N
before IN N
treatment NN N
, , N
and CC N
on IN N
days NNS N
14 CD N
, , N
30 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
. . N

On IN N
days NNS N
30 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
, , N
mean JJ o
flea NN o
counts NNS o
in IN N
selamectin-treated JJ i
dogs NNS N
were VBD N
reduced VBN N
by IN N
92.1 CD N
, , N
99.0 CD N
, , N
and CC N
99.8 CD N
% NN N
, , N
and CC N
mean JJ o
flea NN o
counts NNS o
in IN N
fenthion-treated JJ N
dogs NNS N
were VBD N
reduced VBN N
by IN N
81.5 CD N
, , N
86.8 CD N
, , N
and CC N
86.1 CD N
% NN N
, , N
respectively RB N
, , N
compared VBN N
with IN N
day NN N
0 CD N
counts NNS N
. . N

Also RB N
, , N
on IN N
days NNS N
30 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
, , N
mean JJ o
flea NN o
counts NNS o
in IN N
selamectin-treated JJ N
cats NNS N
were VBD N
reduced VBN N
by IN N
92.5 CD N
, , N
98.3 CD N
, , N
and CC N
99.3 CD N
% NN N
, , N
and CC N
mean JJ o
flea NN o
counts NNS o
in IN N
pyrethrin-treated JJ N
cats NNS N
were VBD N
reduced VBN N
by IN N
66.4 CD N
, , N
73.9 CD N
, , N
and CC N
81.3 CD N
% NN N
, , N
respectively RB N
, , N
compared VBN N
with IN N
day NN N
0 CD N
counts NNS N
. . N

Selamectin NNP i
also RB N
was VBD N
beneficial JJ N
in IN N
alleviating VBG N
signs NNS N
in IN N
dogs NNS p
and CC p
cats NNS p
diagnosed VBD p
clinically RB p
with IN p
FAD NNP p
. . N

A NNP N
total NN N
of IN N
397 CD p
dogs NNS p
free JJ p
of IN p
adult NN p
heartworm NN p
infection NN p
from IN p
four CD p
heartworm-endemic JJ p
areas NNS p
of IN p
the DT p
USA NNP p
were VBD N
allocated VBN N
randomly RB N
to TO N
six CD N
months NNS N
of IN N
treatment NN N
with IN N
selamectin NN i
( ( N
n=298 JJ N
) ) N
or CC N
ivermectin NN i
( ( N
n=99 JJ N
) ) N
. . N

Selamectin NNP i
achieved VBD N
a DT N
heartworm JJ o
prevention NN o
rate NN o
of IN N
100 CD N
% NN N
, , N
with IN N
all DT N
dogs NNS N
testing VBG N
negative JJ N
for IN N
microfilariae NN N
and CC N
adult NN N
heartworm NN N
antigen NN N
on IN N
days NNS N
180 CD N
and CC N
300 CD N
. . N

Selamectin NNP i
was VBD N
administered VBN N
to TO N
a DT N
total NN N
of IN N
673 CD p
dogs NNS p
and CC p
347 CD p
cats NNS p
having VBG N
an DT N
age NN N
range NN N
of IN N
6 CD N
weeks NNS N
to TO N
19 CD N
years NNS N
( ( N
3954 CD N
doses NNS N
) ) N
. . N

The DT N
animals NNS p
included VBD p
19 CD p
purebred VBD p
or CC p
crossbred JJ p
Collies NNS p
( ( p
Bearded NNP p
, , p
Border NNP p
, , p
and CC p
unspecified JJ p
) ) p
. . N

There EX N
were VBD N
no DT N
serious JJ N
adverse JJ o
events NNS o
. . N

Results NNS N
of IN N
these DT N
studies NNS N
indicated VBD N
that IN N
selamectin NN i
was VBD N
highly RB N
effective JJ o
in IN N
the DT N
control NN N
of IN N
flea NN N
infestations NNS N
in IN N
dogs NNS p
and CC p
cats NNS p
without IN N
the DT N
need NN N
for IN N
simultaneous JJ N
treatment NN N
of IN N
the DT N
environment NN N
or CC N
of IN N
in-contact JJ N
animals NNS N
and CC N
also RB N
was VBD N
beneficial JJ N
in IN N
alleviating VBG N
signs NNS o
associated VBN o
with IN o
FAD NNP o
. . N

Selamectin NNP i
also RB N
was VBD N
100 CD N
% NN N
effective JJ N
in IN N
preventing VBG N
the DT N
development NN N
of IN N
canine NN N
heartworms NNS o
and CC N
was VBD N
safe JJ o
for IN N
topical JJ N
use NN N
in IN N
dogs NNS p
and CC p
cats NNS p
. . N

-DOCSTART- -14763035- O O

A DT N
selective JJ N
angiotensin NN N
receptor NN N
antagonist NN N
, , N
Valsartan NNP i
, , N
produced VBD N
regression NN N
of IN N
left JJ p
ventricular JJ p
hypertrophy NN p
associated VBN N
with IN N
a DT N
reduction NN N
of IN N
arterial JJ N
stiffness NN N
. . N

We PRP N
investigated VBD N
whether IN N
a DT N
selective JJ i
angiotensin NN i
II NNP i
receptor NN i
blocker NN i
( ( i
ARB NNP i
) ) i
would MD N
have VB N
a DT N
regressive JJ N
effect NN N
on IN N
left NN N
ventricular JJ N
hypertrophy NN N
( ( N
LVH NNP N
) ) N
in IN N
patients NNS p
on IN p
continuous JJ p
ambulatory JJ p
peritoneal JJ p
dialysis NN p
( ( p
CAPD NNP p
) ) p
. . N

In IN N
a DT N
double-blind NN N
study NN N
, , N
24 CD p
CAPD NNP p
patients NNS p
with IN p
LVH NNP p
[ NNP p
left VBD p
ventricular JJ p
mass NN p
index NN p
( ( p
LVMi NNP p
) ) p
> VBD p
110 CD p
g/m2 NN p
for IN p
women NNS p
and CC p
LVMi NNP p
> NNP p
137 CD p
g/m2 NN p
for IN p
men NNS p
] NNS p
were VBD N
randomized VBN N
to TO N
12 CD N
months NNS N
' POS N
administration NN N
of IN N
either CC N
the DT N
ARB NNP i
valsartan NN i
( ( N
n JJ N
= NNP N
14 CD N
) ) N
or CC N
a DT N
placebo NN i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
. . N

The DT N
target NN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
was VBD N
140/90 CD N
mmHg NN N
or CC N
lower JJR N
in IN N
both DT N
groups NNS N
. . N

The DT N
following JJ N
parameters NNS N
were VBD N
measured VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
: : N
aortic JJ o
and CC o
large-artery JJ o
compliance NN o
and CC N
arterial JJ o
wave NN o
reflections NNS o
[ VBP o
pulse JJ o
wave VBP o
velocity NN o
( ( o
PWV NNP o
) ) o
and CC N
augmentation NN o
index NN o
( ( o
AI NNP o
) ) o
application NN o
tonometry NN o
] NNP o
and CC N
cardiac JJ o
echocardiography NN o
. . N

Periodically RB N
recorded VBN N
were VBD N
body JJ o
weight NN o
, , o
BP NNP o
( ( o
mercury NN o
sphygmomanometer NN o
) ) o
, , o
serum JJ o
creatinine NN o
, , o
electrolytes VBZ o
, , o
complete JJ o
blood NN o
cell NN o
counts NNS o
, , o
urine JJ o
volume NN o
, , o
drainage NN o
volume NN o
, , o
and CC o
weekly JJ o
creatinine NN o
clearance NN o
. . N

Two-way JJ N
analysis NN N
of IN N
variance NN N
for IN N
repeated JJ N
measurements NNS N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

Systolic NNP o
and CC o
diastolic JJ o
BP NNP o
were VBD N
both DT N
reduced VBN N
in IN N
patients NNS N
treated VBN N
with IN N
ARB NNP i
. . N

The DT N
LVMi NNP o
was VBD N
significantly RB N
reduced VBN N
in IN N
patients NNS N
treated VBN N
with IN N
ARB NNP i
( ( N
to TO N
121 CD N
+/- JJ N
4 CD N
from IN N
145 CD N
+/- JJ N
5 CD N
) ) N
but CC N
not RB N
in IN N
those DT N
receiving VBG N
placebo NN i
( ( N
to TO N
137 CD N
+/- JJ N
3 CD N
from IN N
152 CD N
+/- JJ N
3 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
decrease NN N
in IN N
LVMi NNP o
was VBD N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
PWV NNP o
and CC N
AI NNP o
. . N

In IN N
CAPD NNP N
patients NNS N
with IN N
LVH NNP N
, , N
ARB NNP i
reduced VBD N
LVMi NNP o
in IN N
association NN N
with IN N
alterations NNS N
in IN N
arterial JJ N
hemodynamics NNS N
. . N

-DOCSTART- -18503531- O O

A DT N
multi-component JJ i
social JJ i
skills NNS i
intervention NN i
for IN N
children NNS p
with IN p
Asperger NNP p
syndrome NN p
: : N
the DT N
Junior NNP i
Detective NNP i
Training NNP i
Program NNP i
. . N

BACKGROUND NNP N
The DT N
study NN N
aimed VBN N
to TO N
investigate VB N
the DT N
effectiveness NN o
of IN N
a DT N
new JJ N
multi-component JJ i
social JJ i
skills NNS i
intervention NN i
for IN N
children NNS p
with IN p
Asperger NNP p
syndrome NN p
( ( p
AS IN p
) ) p
: : N
The DT N
Junior NNP N
Detective NNP N
Training NNP N
Program NNP N
. . N

This DT N
7-week JJ N
program NN N
included VBD N
a DT N
computer NN N
game NN N
, , N
small JJ N
group NN N
sessions NNS N
, , N
parent NN N
training NN N
sessions NNS N
and CC N
teacher NN N
handouts NNS N
. . N

METHOD NNP N
Forty-nine JJ p
children NNS p
with IN p
AS NNP p
were VBD N
recruited VBN N
to TO N
participate VB N
and CC N
randomly VB N
assigned VBN N
to TO N
intervention NN N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
or CC N
wait-list JJ N
control NN N
( ( N
n JJ N
= NNP N
23 CD N
) ) N
conditions NNS N
. . N

RESULTS NNP N
Relative NNP N
to TO N
children NNS N
in IN N
the DT N
wait-list JJ N
group NN N
, , N
program NN N
participants NNS N
showed VBD N
greater JJR N
improvements NNS o
in IN o
social JJ o
skills NNS o
over IN N
the DT N
course NN N
of IN N
the DT N
intervention NN N
, , N
as IN N
indicated VBN N
by IN N
parent-report JJ N
measures NNS N
. . N

Teacher-report NNP N
data NNS N
also RB N
confirmed VBD N
that IN N
children NNS N
receiving VBG N
the DT N
intervention NN N
made VBD N
significant JJ N
improvements NNS N
in IN N
social JJ o
functioning NN o
from IN N
pre- JJ N
to TO N
post-treatment JJ N
. . N

Treatment NNP N
group NN N
participants NNS N
were VBD N
better RBR N
able JJ N
to TO N
suggest VB N
appropriate JJ N
emotion-management JJ o
strategies NNS o
for IN N
story NN N
characters NNS N
at IN N
post-intervention NN N
than IN N
at IN N
pre-intervention NN N
, , N
whereas NNS N
control VBP N
participants NNS N
were VBD N
not RB N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
improvements NNS N
made VBN N
by IN N
children NNS N
in IN N
the DT N
intervention NN N
and CC N
control NN N
conditions NNS N
on IN N
facial JJ o
expression NN o
and CC o
body-posture NN o
recognition NN o
measures NNS o
. . N

Follow-up NNP N
data NN N
suggested VBD N
that IN N
treatment NN N
gains NNS N
were VBD N
maintained VBN N
by IN N
children NNS N
at IN N
5-months JJ N
post-intervention NN N
. . N

CONCLUSIONS VB N
The DT N
Junior NNP i
Detective NNP i
Training NNP i
Program NNP i
appeared VBD N
to TO N
be VB N
effective JJ N
in IN N
enhancing VBG N
the DT N
social JJ o
skills NNS o
and CC o
emotional JJ o
understanding NN o
of IN N
children NNS p
with IN p
AS NNP p
. . N

Limitations NNS N
and CC N
suggestions NNS N
for IN N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -12960652- O O

Gastric NNP N
dysrhythmia NN N
in IN N
infants NNS p
with IN p
gastrointestinal JJ p
diseases NNS p
measured VBN N
by IN N
epigastric JJ N
impedance NN N
. . N

BACKGROUND NNP N
Gastrointestinal NNP N
symptoms NNS N
have VBP N
been VBN N
reported VBN N
in IN N
association NN N
with IN N
myoelectrical JJ N
dysrhythmia NN N
, , N
where WRB N
different JJ N
types NNS N
of IN N
gastric JJ N
electrical JJ N
activity NN N
have VBP N
been VBN N
described VBN N
. . N

These DT N
types NNS N
of IN N
gastric JJ N
myoelectrical JJ N
activity NN N
and CC N
dysrhythmia NN N
can MD N
be VB N
measured VBN N
by IN N
electrogastrography NN N
using VBG N
cutaneous JJ N
electrodes NNS N
. . N

Epigastric JJ i
impedance NN i
is VBZ N
a DT N
non-invasive JJ N
method NN N
used VBN N
to TO N
study VB N
gastric JJ N
emptying VBG N
time NN N
and CC N
gastric JJ N
phasic JJ N
activity NN N
. . N

At IN N
present JJ N
no DT N
study NN N
of IN N
gastric JJ N
dysrhythmia NN N
, , N
measured VBN N
with IN N
epigastric JJ o
impedance NN o
, , N
has VBZ N
been VBN N
presented VBN N
, , N
and CC N
the DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
gastric JJ N
rhythms NN N
by IN N
means NNS N
of IN N
impedance NN N
gastrography NN N
in IN N
control NN N
infants NNS N
, , N
compared VBN N
to TO N
infants NNS p
with IN p
different JJ p
gastrointestinal JJ p
diseases NNS p
, , N
before IN N
and CC N
after IN N
treatment NN N
of IN N
their PRP$ N
disease NN N
. . N

METHOD NNP N
21 CD p
patients NNS p
( ( p
age NN p
0-2 CD p
months NNS p
) ) p
and CC p
40 CD p
healthy JJ p
infants NNS p
( ( p
age NN p
0-2 CD p
months NNS p
) ) p
were VBD N
investigated VBN N
. . N

The DT N
patients NNS p
suffered VBD p
from IN p
partial JJ p
or CC p
total JJ p
intestinal JJ p
obstruction NN p
, , p
necrotizing VBG p
enterocolitis NN p
or CC p
pyloric JJ p
stenosis.All NN p
infants NNS p
were VBD p
fasting VBG p
and CC N
studied VBN N
during IN N
periods NNS N
of IN N
at IN N
least JJS N
one CD N
hour NN N
. . N

The DT N
patients NNS N
were VBD N
examined VBN N
in IN N
the DT N
acute NN N
state NN N
and CC N
after IN N
treatment NN N
when WRB N
possible JJ N
. . N

RESULTS VB N
A DT N
pathologic JJ N
result NN N
was VBD N
found VBN N
in IN N
90 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

A DT N
persistent JJ N
phasic JJ o
activity NN o
pattern NN N
was VBD N
found VBN N
in IN N
19 CD N
of IN N
the DT N
21 CD N
patients NNS N
, , N
high JJ N
frequency NN o
phasic JJ o
activity NN o
in IN N
11 CD N
of IN N
the DT N
21 CD N
patients NNS N
. . N

Short-term JJ N
phasic JJ o
activity NN o
was VBD N
only RB N
found VBN N
in IN N
13 CD N
out IN N
of IN N
40 CD N
of IN N
the DT N
normal JJ N
infants NNS N
( ( N
32.5 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
Using NNP N
epigastric JJ i
impedance NN i
we PRP N
found VBD N
that IN N
infants NNS N
with IN N
partial JJ N
or CC N
total JJ N
intestinal JJ N
obstruction NN N
had VBD N
gastric JJ N
phasic JJ N
activity NN N
, , N
which WDT N
was VBD N
not RB N
found VBN N
in IN N
the DT N
control NN N
infants NNS N
. . N

The DT N
origin NN N
of IN N
the DT N
gastric JJ N
phasic JJ N
activity NN N
patterns NNS N
is VBZ N
unknown JJ N
, , N
but CC N
they PRP N
may MD N
be VB N
related VBN N
to TO N
electrical JJ N
control NN N
activity NN N
. . N

-DOCSTART- -18077611- O O

A DT N
double-blind NN N
, , N
randomized VBN N
, , N
controlled VBN N
, , N
multicenter NN N
safety NN N
and CC N
immunogenicity NN N
study NN N
of IN N
a DT N
refrigerator-stable JJ N
formulation NN N
of IN N
Zostavax NNP i
. . N

The DT N
vaccine NN N
Zostavax NNP i
has VBZ N
been VBN N
shown VBN N
to TO N
prevent VB N
herpes NNS N
zoster NNP N
( ( N
HZ NNP N
) ) N
and CC N
postherpetic JJ N
neuralgia NN N
and CC N
is VBZ N
recommended VBN N
for IN N
individuals NNS N
> CD N
or CC N
=60 CD N
years NNS N
of IN N
age NN N
. . N

This DT N
study NN N
compared VBN N
the DT N
safety NN o
and CC N
the DT N
immunogenicity NN o
of IN N
a DT N
refrigerator-stable JJ N
formulation NN N
( ( N
Zostavax NNP i
refrigerated VBD N
) ) N
with IN N
those DT N
of IN N
the DT N
current JJ N
formulation NN N
( ( N
Zostavax NNP i
frozen RB N
) ) N
in IN N
subjects NNS p
> VBP p
or CC p
=50 CD p
years NNS p
of IN p
age NN p
. . N

Subjects VBZ p
with IN p
a DT p
negative JJ p
history NN p
for IN p
HZ NNP p
were VBD N
randomized VBN N
1:1 CD N
to TO N
receive VB N
one CD N
dose NN N
of IN N
either DT N
formulation NN N
. . N

Enrollment NN p
was VBD p
stratified VBN p
1:2 CD p
by IN p
age NN p
( ( p
50 CD p
to TO p
59 CD p
years NNS p
and CC p
> NN p
or CC p
=60 CD p
years NNS p
) ) N
. . N

Safety NN o
was VBD N
evaluated VBN N
for IN N
28 CD N
days NNS N
postvaccination NN N
. . N

Varicella-zoster JJ o
virus NN o
( ( o
VZV NNP o
) ) o
antibody NN o
responses NNS o
were VBD N
measured VBN N
by IN N
a DT N
glycoprotein JJ N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( N
gpELISA NN N
) ) N
. . N

The DT N
primary JJ N
endpoints NNS N
were VBD N
the DT N
VZV NNP o
antibody NN o
geometric JJ o
mean NN o
titer NN o
( ( o
GMT NNP o
; : N
day NN N
28 CD N
) ) N
, , N
the DT N
VZV NNP o
antibody NN o
geometric JJ o
mean NN o
rise NN o
( ( o
GMR NNP o
; : N
days NNS N
1 CD N
to TO N
28 CD N
) ) N
, , N
and CC N
the DT N
incidence NN o
of IN o
vaccine-related JJ o
serious JJ o
adverse JJ o
experiences NNS o
( ( o
AEs NNP o
) ) o
over IN N
28 CD N
days NNS N
. . N

The DT N
refrigerated JJ N
( ( N
n JJ N
= NNP N
182 CD N
) ) N
and CC N
frozen JJ N
( ( N
n JJ N
= NNP N
185 CD N
) ) N
formulations NNS N
induced VBD N
similar JJ N
GMTs NNP o
( ( N
727.4 CD N
and CC N
834.4 CD N
gpELISA NN N
units/ml NN N
, , N
respectively RB N
) ) N
; : N
the DT N
estimated VBN N
GMT NNP o
ratio NN N
( ( N
refrigerated VBN N
formulation/frozen RB N
formulation NN N
) ) N
was VBD N
0.87 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.71 CD N
to TO N
1.07 CD N
) ) N
. . N

The DT N
GMRs NNPS o
were VBD N
2.6- JJ N
and CC N
2.9-fold JJ N
, , N
respectively RB N
. . N

No DT N
vaccine-related JJ o
serious JJ o
AEs NNP o
were VBD N
reported VBN N
in IN N
either DT N
group NN N
, , N
and CC N
the DT N
safety NN o
profiles NNS N
of IN N
the DT N
formulations NNS N
were VBD N
generally RB N
similar JJ N
. . N

The DT N
frequencies NNS N
of IN N
injection-site JJ o
AEs NNP o
during IN N
follow-up JJ N
were VBD N
35.6 CD N
% NN N
and CC N
46.4 CD N
% NN N
in IN N
the DT N
refrigerated JJ N
and CC N
the DT N
frozen JJ N
formulation NN N
groups NNS N
, , N
respectively RB N
, , N
and CC N
were VBD N
generally RB N
mild VBN N
. . N

The DT N
frequencies NNS N
of IN N
systemic JJ o
AEs NNP o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
, , N
and CC N
those DT N
of IN N
vaccine-related JJ o
AEs NNP o
were VBD N
approximately RB N
6 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
refrigerator-stable JJ N
formulation NN N
of IN N
Zostavax NNP i
has VBZ N
an DT N
acceptable JJ N
safety NN o
profile NN N
and CC N
is VBZ N
as RB N
immunogenic JJ o
as IN N
the DT N
frozen JJ N
formulation NN N
; : N
thus RB N
, , N
the DT N
vaccine NN N
may MD N
be VB N
used VBN N
in IN N
clinical JJ N
settings NNS N
where WRB N
freezer NN N
availability NN N
is VBZ N
limited VBN N
. . N

-DOCSTART- -25068497- O O

Safety NN o
and CC N
preliminary JJ o
immunogenicity NN o
of IN N
Cuban NNP i
pneumococcal JJ i
conjugate NN i
vaccine NN i
candidate NN N
in IN N
healthy JJ p
children NNS p
: : N
a DT N
randomized JJ N
phase NN N
I PRP N
clinical JJ N
trial NN N
. . N

A DT N
new JJ N
heptavalent NN i
conjugate NN i
vaccine NN i
( ( i
PCV7-TT NNP i
) ) i
is VBZ N
under IN N
development NN N
in IN N
Cuba NNP N
. . N

PCV7-TT NNP i
contains VBZ N
2 CD N
?g NN N
of IN N
serotypes NNS N
1 CD N
, , N
5 CD N
, , N
14 CD N
, , N
18C CD N
, , N
19F CD N
, , N
23F CD N
and CC N
4 CD N
?g NN N
of IN N
6B CD N
, , N
each DT N
one CD N
conjugated VBN N
to TO N
tetanus VB N
toxoid NN N
( ( N
TT NNP N
) ) N
. . N

This DT N
vaccine NN N
was VBD N
designed VBN N
with IN N
the DT N
serotypes NNS N
that WDT N
cause VBP N
most RBS N
invasive JJ N
pneumococcal JJ N
diseases NNS N
( ( N
IPD NNP N
) ) N
worldwide NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
investigated VBD N
the DT N
safety NN o
and CC N
explored VBD N
the DT N
immunogenicity NN o
of IN N
PCV7-TT NNP i
during IN N
a DT N
controlled VBN N
, , N
randomized VBN N
and CC N
double JJ N
blind NN N
clinical JJ N
trial NN N
phase NN N
I PRP N
in IN N
4-5-year-old JJ p
children NNS p
. . N

PCV7-TT NN N
was VBD N
well RB N
tolerated JJ o
and CC N
as RB N
safe JJ o
as IN N
Synflorix NNP i
used VBD N
as IN N
control NN N
vaccine NN N
. . N

Following VBG N
a DT N
single-dose JJ N
vaccination NN N
, , N
all DT N
individual JJ N
serotypes NNS N
included VBN N
in IN N
PCV7-TT NNP i
induced VBD N
statistically RB N
significant JJ N
increase NN N
of IN N
IgG NNP o
GMC NNP o
and CC N
OPA NNP o
GMT NNP o
. . N

These DT N
are VBP N
the DT N
first JJ N
clinical JJ N
results NNS N
of IN N
PCV7-TT NNP i
in IN N
children NNS N
and CC N
they PRP N
pave VBP N
the DT N
way NN N
toward IN N
next JJ N
clinical JJ N
trials NNS N
in IN N
children NNS N
and CC N
infants NNS N
. . N

This DT N
clinical JJ N
trial NN N
was VBD N
published VBN N
in IN N
the DT N
Cuban NNP N
Public NNP N
Register NNP N
of IN N
Clinical NNP N
Trials NNP N
with IN N
code NN N
RPCEC00000173 NNP N
. . N

-DOCSTART- -17321989- O O

The DT N
prophylactic JJ N
effect NN N
of IN N
itraconazole JJ i
capsules NNS N
and CC N
fluconazole JJ i
capsules NNS N
for IN N
systemic JJ N
fungal JJ N
infections NNS N
in IN N
patients NNS p
with IN p
acute JJ p
myeloid NN p
leukemia NN p
and CC p
myelodysplastic JJ p
syndromes NNS p
: : N
a DT N
Japanese JJ p
multicenter NN N
randomized VBN N
, , N
controlled VBN N
study NN N
. . N

We PRP N
performed VBD N
a DT N
randomized VBN N
, , N
controlled VBN N
study NN N
comparing VBG N
the DT N
prophylactic JJ N
effects NNS N
of IN N
capsule NN N
forms NNS N
of IN N
fluconazole NN i
( ( N
n JJ N
= NNP N
110 CD N
) ) N
and CC N
itraconazole JJ i
( ( N
n JJ N
= NNP N
108 CD N
) ) N
in IN N
patients NNS p
with IN p
acute JJ p
myeloid NN p
leukemia NN p
( ( p
AML NNP p
) ) p
or CC p
myelodysplastic JJ p
syndromes NNS p
( ( p
MDS NNP p
) ) p
during IN p
and CC p
after IN p
chemotherapy NN p
. . N

There EX N
were VBD N
4 CD N
cases NNS N
with IN N
possible JJ N
systemic JJ N
fungal JJ N
infection NN N
in IN N
the DT N
itraconazole NN i
group NN N
, , N
and CC N
there EX N
were VBD N
8 CD N
possible JJ N
and CC N
3 CD N
probable JJ N
cases NNS N
in IN N
the DT N
fluconazole JJ i
group NN N
. . N

Adverse JJ o
events NNS o
did VBD N
not RB N
significantly RB N
differ VB N
in IN N
the DT N
2 CD N
groups NNS N
. . N

In IN N
patients NNS N
with IN N
MDS NNP N
or CC N
in IN N
the DT N
remission-induction JJ N
phase NN N
of IN N
chemotherapy NN N
, , N
the DT N
numbers NNS N
of IN N
cases NNS N
with IN N
probable JJ o
or CC o
possible JJ o
infections NNS o
were VBD N
lower JJR N
in IN N
the DT N
itraconazole NN N
group NN N
than IN N
in IN N
the DT N
fluconazole NN N
group NN N
, , N
whereas IN N
no DT N
difference NN N
was VBD N
seen VBN N
in IN N
patients NNS N
with IN N
AML NNP N
or CC N
in IN N
the DT N
consolidation NN N
phase NN N
of IN N
therapy NN N
. . N

In IN N
patients NNS N
with IN N
neutrophil JJ N
counts NNS N
of IN N
> $ N
0.1 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
lasting VBG N
for IN N
more JJR N
than IN N
4 CD N
weeks NNS N
, , N
the DT N
frequency NN o
of IN o
infection NN o
in IN N
the DT N
fluconazole JJ N
group NN N
( ( N
5 CD N
of IN N
9 CD N
patients NNS N
) ) N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
the DT N
itraconazole JJ N
group NN N
( ( N
0 CD N
of IN N
7 CD N
patients NNS N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
both DT N
drugs NNS N
were VBD N
well RB N
tolerated VBN N
in IN N
patients NNS p
with IN p
AML NNP p
or CC p
MDS NNP p
who WP p
received VBD p
chemotherapy NN p
and CC N
that IN N
the DT N
efficacy NN N
of IN N
itraconazole NN N
for IN N
prophylaxis NN N
against IN N
systemic JJ N
fungal JJ N
disease NN N
is VBZ N
not RB N
inferior JJ N
to TO N
that DT N
of IN N
fluconazole NN N
. . N

-DOCSTART- -19108790- O O

Comparison NNP N
of IN N
propofol NN i
, , N
droperidol NN i
, , N
and CC N
metoclopramide NN i
for IN N
prophylaxis NN N
of IN N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
after IN N
breast NN p
cancer NN p
surgery NN p
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
in IN N
Japanese JJ p
patients NNS p
. . N

BACKGROUND NNP N
Breast NNP N
cancer NN N
surgery NN N
performed VBN N
with IN N
the DT N
patient NN p
under IN p
general JJ p
anesthesia NN p
has VBZ N
been VBN N
associated VBN N
with IN N
a DT N
relatively RB N
high JJ N
incidence NN N
of IN N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
( ( o
PONV NNP o
) ) o
. . N

Between $ N
60 CD N
% NN N
and CC N
80 CD N
% NN N
of IN N
patients NNS N
who WP N
undergo VBP N
mastectomy NNS N
( ( N
with IN N
axillary JJ N
dissection NN N
) ) N
experience NN N
PONV NNP o
. . N

We PRP N
previously RB N
reported VBD N
that IN N
propofol NN i
at IN N
a DT N
subhypnotic JJ N
dose NN N
of IN N
0.5 CD N
mg/kg NN N
was VBD N
more RBR N
effective JJ N
than IN N
placebo NN i
in IN N
preventing VBG N
PONV NNP o
in IN N
women NNS N
who WP N
undergo VBP N
mastectomy NN N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN o
of IN N
a DT N
subhypnotic JJ N
dose NN N
of IN N
propofol NN i
with IN N
the DT N
conventional JJ N
antiemetics NNS N
droperidol NN i
and CC N
metoclopramide NN i
for IN N
the DT N
prophylaxis NN N
of IN N
PONV NNP o
after IN N
breast NN p
cancer NN p
surgery NN p
in IN p
Japanese JJ p
patients NNS p
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
, , N
Japanese JJ p
women NNS p
were VBD N
randomized VBN N
to TO N
1 CD N
of IN N
4 CD N
groups NNS N
to TO N
receive VB N
IV NNP N
administration NN N
of IN N
propofol JJ i
0.5 CD N
mg/kg NN N
, , N
droperidol VBZ i
20 CD N
microg/kg NN N
, , N
metoclopramide RB i
0.2 CD N
mg/kg NN N
, , N
or CC N
placebo NN i
( ( i
isotonic JJ i
saline NN i
) ) i
immediately RB N
after IN N
skin JJ N
suture NN N
. . N

A DT N
standard JJ N
general JJ N
anesthetic JJ N
technique NN N
, , N
including VBG N
sevoflurane NN N
and CC N
air NN N
in IN N
oxygen NN N
, , N
was VBD N
used VBN N
. . N

All DT N
episodes NNS N
of IN N
PONV NNP o
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
after IN N
anesthesia JJ N
administration NN N
were VBD N
recorded VBN N
by IN N
an DT N
investigator NN N
who WP N
was VBD N
blinded VBN N
to TO N
treatment NN N
assignment NN N
. . N

The DT N
investigator NN N
questioned VBD N
the DT N
patients NNS N
as IN N
to TO N
whether IN N
they PRP N
experienced VBD N
extrapyramidal NN o
symptoms NNS o
. . N

To TO N
maintain VB N
the DT N
integrity NN N
of IN N
the DT N
study NN N
results NNS N
, , N
none NN N
of IN N
the DT N
patients NNS N
received VBD N
preanesthetic JJ N
medication NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
100 CD p
women NNS p
( ( p
mean JJ p
[ NNP p
SD NNP p
] NNP p
age NN p
, , p
52 CD p
[ NN p
7 CD p
] CD p
years NNS p
; : p
height VBD p
, , p
154 CD p
[ NN p
6 CD p
] NNP p
cm NN p
; : p
weight NN p
, , p
54 CD p
[ NN p
7 CD p
] NNP p
kg NN p
) ) p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Each DT N
study NN N
group NN N
comprised VBD N
25 CD N
patients NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
with IN N
regard NN N
to TO N
patient VB N
demographics NNS N
, , N
surgery NN N
type NN N
, , N
or CC N
awakening VBG N
time NN N
. . N

The DT N
prevalences NNS N
of IN N
PONV NNP o
0 CD N
to TO N
24 CD N
hours NNS N
after IN N
anesthesia NN N
were VBD N
28 CD N
% NN N
with IN N
propofol NN i
( ( N
P NNP N
= NNP N
0.005 CD N
) ) N
, , N
32 CD N
% NN N
with IN N
droperidol NN i
( ( N
P NNP N
= NNP N
0.011 CD N
) ) N
, , N
and CC N
60 CD N
% NN N
with IN N
metoclopramide NN i
( ( N
P NNP N
= NNP N
NS NNP N
) ) N
, , N
compared VBN N
with IN N
placebo NN i
( ( N
68 CD N
% NN N
) ) N
. . N

No DT N
significant JJ N
difference NN N
in IN N
the DT N
prevalence NN N
of IN N
PONV NNP o
was VBD N
found VBN N
between IN N
patients NNS N
receiving VBG N
propofol NN i
and CC N
those DT N
receiving VBG N
droperidol NN i
, , N
and CC N
propofol NN i
and CC N
droperidol NN i
were VBD N
associated VBN N
with IN N
significantly RB N
lower JJR N
prevalences NNS N
of IN N
PONV NNP o
compared VBN N
with IN N
metoclopramide NN i
( ( N
P NNP N
= NNP N
0.022 CD N
and CC N
P NNP N
= NNP N
0.043 CD N
, , N
respectively RB N
) ) N
. . N

Extrapyramidal NNP o
symptoms NNS o
were VBD N
not RB N
reported VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
. . N

CONCLUSIONS VB N
The DT N
prevalences NNS N
of IN N
PONV NNP o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
propofol NN i
0.5 CD N
mg/kg NN N
and CC N
droperidol NN i
20 CD N
microg/kg NN N
0 CD N
to TO N
24 CD N
hours NNS N
after IN N
anesthesia NN N
in IN N
this DT N
small JJ N
, , N
select JJ N
group NN N
of IN N
Japanese JJ N
women NNS N
who WP N
underwent VBP N
breast NN N
cancer NN N
surgery NN N
. . N

The DT N
prevalences NNS N
of IN N
PONV NNP o
were VBD N
significantly RB N
lower JJR N
with IN N
propofol NN i
and CC N
droperidol NN i
compared VBN N
with IN N
metoclopramide JJ i
0.2 CD N
mg/kg NN N
and CC N
placebo NN i
. . N

-DOCSTART- -3067745- O O

Levobunolol NNP i
compared VBN N
with IN N
timolol NN i
: : N
a DT N
four-year JJ N
study NN N
. . N

Fifty-one CD p
patients NNS p
with IN p
raised VBN p
intraocular JJ p
pressure NN p
( ( p
IOP NNP p
) ) p
were VBD N
treated VBN N
for IN N
up IN N
to TO N
four CD N
years NNS N
with IN N
one CD N
of IN N
three CD N
ophthalmic JJ N
solutions NNS N
: : N
0.5 CD N
% NN N
levobunolol NN i
, , N
1 CD N
% NN N
levobunolol NN i
, , N
or CC N
0.5 CD N
% NN N
timolol NN i
. . N

The DT N
study NN N
was VBD N
conducted VBN N
as IN N
a DT N
double-masked JJ N
, , N
randomised JJ N
trial NN N
in IN N
which WDT N
medications NNS N
were VBD N
administered VBN N
twice RB N
daily RB N
to TO N
both DT N
eyes NNS N
. . N

Levobunolol NNP i
and CC N
timolol NN i
were VBD N
equally RB N
effective JJ N
in IN N
reducing VBG N
overall JJ o
mean JJ o
IOP NNP o
; : N
reductions NNS N
were VBD N
greater JJR N
than IN N
8.8 CD N
mmHg NNS N
in IN N
all DT N
three CD N
treatment NN N
groups NNS N
. . N

The DT N
study NN N
showed VBD N
levobunolol NNS i
to TO N
be VB N
as IN N
safe JJ N
and CC N
effective JJ N
as IN N
timolol NN i
in IN N
the DT N
long-term JJ N
control NN N
of IN N
raised VBN N
IOP NNP N
. . N

-DOCSTART- -22271197- O O

Goal NNP o
attainment NN o
scaling NN o
as IN N
an DT N
outcome NN N
measure NN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
of IN N
psychosocial JJ i
interventions NNS i
in IN N
autism NN p
. . N

Goal NNP o
attainment JJ o
scaling NN o
( ( o
GAS NNP o
) ) o
holds VBZ N
promise NN N
as IN N
an DT N
idiographic JJ N
approach NN N
for IN N
measuring VBG N
outcomes NNS N
of IN N
psychosocial JJ i
interventions NNS i
in IN N
community NN N
settings NNS N
. . N

GAS NNP N
has VBZ N
been VBN N
criticized VBN N
for IN N
untested JJ N
assumptions NNS N
of IN N
scaling VBG N
level NN N
( ( N
i.e. JJ N
, , N
interval JJ N
or CC N
ordinal JJ N
) ) N
, , N
inter-individual JJ N
equivalence NN N
and CC N
comparability NN N
, , N
and CC N
reliability NN N
of IN N
coding VBG N
across IN N
different JJ N
behavioral JJ N
observation NN N
methods NNS N
. . N

We PRP N
tested VBD N
assumptions NNS N
of IN N
equality NN N
between IN N
GAS NNP N
descriptions NNS N
for IN N
outcome JJ N
measurement NN N
in IN N
a DT N
randomized JJ N
trial NN N
( ( N
i.e. FW N
, , N
measurability NN N
, , N
equidistance NN N
, , N
level NN N
of IN N
difficulty NN N
, , N
comparability NN N
of IN N
behavior NN N
samples NNS N
collected VBN N
from IN N
teachers NNS N
vs. FW N
researchers NNS N
and CC N
live JJ N
vs. FW N
videotape NN N
) ) N
. . N

Results NNP N
suggest VBP N
GAS NNP N
descriptions NNS N
can MD N
be VB N
evaluated VBN N
for IN N
equivalency NN N
, , N
that IN N
teacher RB N
collected VBN N
behavior NN N
samples NNS N
are VBP N
representative JJ N
, , N
and CC N
that IN N
varied JJ N
sources NNS N
of IN N
behavior NN N
samples NNS N
can MD N
be VB N
reliably RB N
coded VBN N
. . N

GAS NNP N
is VBZ N
a DT N
promising JJ N
measurement NN N
approach NN N
. . N

Recommendations NNS N
are VBP N
provided VBN N
to TO N
ensure VB N
methodological JJ N
quality NN N
. . N

-DOCSTART- -2803397- O O

[ VB N
The DT N
sympatho-adrenergic JJ N
stress NN N
reaction NN N
in IN N
ear JJ p
surgery NN p
using VBG N
various JJ N
anesthesia JJ N
technics NNS N
] VBP N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
various JJ N
anaesthetic JJ N
procedures NNS N
on IN N
the DT N
endocrine NN N
stress NN N
responses NNS N
during IN N
ear JJ p
microsurgical JJ p
operations NNS p
. . N

Simple JJ p
mastoidectomies NNS p
, , p
radical JJ p
mastoidectomies NNS p
and CC p
tympano NN p
plastics NNS p
were VBD p
carried VBN p
out IN p
in IN p
49 CD p
patients NNS p
under IN N
the DT N
following VBG N
randomised VBD N
anaesthetic JJ N
procedures NNS N
: : N
Group NNP N
1 CD N
halothane NN i
anaesthesia NN N
and CC N
retroauricular JJ N
infiltration NN N
anaesthesia NN N
with IN N
lidocaine NN i
and CC N
ornipressin NN i
( ( N
n JJ N
= NNP N
14 CD N
) ) N
, , N
Group NNP N
2 CD N
fentanyl NN i
anaesthesia NN N
and CC N
retroauricular JJ N
anaesthesia NN N
with IN N
lidocaine NN i
and CC N
ornipressin NN i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
, , N
Group NNP N
3 CD N
fentanyl NN i
anaesthesia NN N
and CC N
retroauricular JJ N
infiltration NN N
anaesthesia NN N
with IN N
lidocaine NN i
and CC N
epinephrine NN i
( ( N
n JJ N
= NNP N
14 CD N
) ) N
, , N
and CC N
Group NNP N
4 CD N
retroauricular JJ N
infiltration NN N
anaesthesia NN N
with IN N
prilocaine NN i
and CC N
epinephrine NN i
( ( N
n JJ N
= NNP N
14 CD N
) ) N
. . N

The DT N
plasma NN o
levels NNS o
of IN o
epinephrine NN o
, , o
norepinephrine NN o
, , o
glucose NN o
, , o
lactate NN o
and CC N
free JJ N
glycerol NN N
were VBD N
measured VBN N
in IN N
addition NN N
to TO N
mean VB N
arterial JJ N
pressure NN N
( ( N
MAP NNP N
) ) N
and CC N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
immediately RB N
before IN N
anaesthesia NN N
, , N
10 CD N
minutes NNS N
after IN N
skin JJ N
incision NN N
, , N
10 CD N
minutes NNS N
after IN N
having VBG N
started VBD N
bone CD N
drilling NN N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
operation NN N
and CC N
3 CD N
hours NNS N
after IN N
operation NN N
. . N

All DT N
data NNS N
were VBD N
subjected VBN N
to TO N
covariance VB N
analysis NN N
including VBG N
the DT N
age NN N
factor NN N
. . N

Plasma NNP o
catecholamine JJ o
concentrations NNS o
remained VBD N
within IN N
the DT N
normal JJ N
range NN N
during IN N
the DT N
investigation NN N
in IN N
patients NNS N
subjected VBN N
to TO N
general JJ N
anaesthesia NN N
( ( N
Groups NNP N
1-3 CD N
) ) N
. . N

Plasma NNP o
catecholamines NNS o
( ( o
epinephrine NN o
and CC o
norepinephrine NN o
) ) o
increased VBD N
significantly RB N
in IN N
Group NNP N
4 CD N
( ( N
retroauricular JJ N
infiltration NN N
anaesthesia NN N
) ) N
. . N

There EX N
were VBD N
no DT N
group NN N
variabilities VBZ N
with IN N
regard NN N
to TO N
MAP NNP o
and CC N
HR NNP o
. . N

The DT N
plasma NN o
levels NNS o
of IN o
epinephrine NN o
and CC o
norepinephrine JJ o
demonstrate NN N
a DT N
direct JJ N
response NN N
to TO N
stress NN N
followed VBN N
by IN N
a DT N
secondary JJ N
change NN N
in IN N
glucose NN o
, , o
lactate NN o
and CC o
free JJ o
glycerol NN o
. . N

The DT N
beneficial JJ N
effect NN N
of IN N
general JJ N
anaesthesia NN N
is VBZ N
documented VBN N
by IN N
normal JJ N
plasma NN N
levels NNS N
of IN N
epinephrine NN N
and CC N
norepinephrine NN N
throughout IN N
the DT N
operation NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -22881991- O O

Teaching VBG N
emotion NN i
recognition NN i
skills NNS N
to TO N
young JJ p
children NNS p
with IN p
autism NN p
: : N
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
an DT N
emotion NN i
training NN i
programme NN i
. . N

BACKGROUND NNP N
Children NNP p
with IN p
autism NN p
have VBP N
difficulties NNS N
in IN N
emotion NN N
recognition NN N
and CC N
a DT N
number NN N
of IN N
interventions NNS N
have VBP N
been VBN N
designed VBN N
to TO N
target VB N
these DT N
problems NNS N
. . N

However RB N
, , N
few JJ N
emotion NN i
training NN i
interventions NNS N
have VBP N
been VBN N
trialled VBN N
with IN N
young JJ p
children NNS p
with IN p
autism NN p
and CC p
co-morbid JJ p
ID NNP p
. . N

This DT N
study NN N
aimed VBD N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
an DT N
emotion NN i
training NN i
programme NN i
for IN N
a DT N
group NN N
of IN N
young JJ p
children NNS p
with IN p
autism NN p
with IN p
a DT p
range NN p
of IN p
intellectual JJ p
ability NN p
. . N

METHODS NNP N
Participants NNPS p
were VBD p
55 CD p
children NNS p
with IN p
autistic JJ p
disorder NN p
, , p
aged VBN p
4-7 CD p
years NNS p
( ( p
FSIQ NNP p
42-107 CD p
) ) p
. . N

Children NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
intervention NN N
( ( N
n JJ N
= NNP N
28 CD N
) ) N
or CC N
control VB N
group NN N
( ( N
n JJ N
= NNP N
27 CD N
) ) N
. . N

Participants NNS N
in IN N
the DT N
intervention NN N
group NN N
watched VBD N
a DT N
DVD NNP N
designed VBN N
to TO N
teach VB N
emotion NN i
recognition NN i
skills NNS i
to TO N
children NNS N
with IN N
autism NN N
( ( N
the DT i
Transporters NNPS i
) ) N
, , N
whereas IN N
the DT N
control NN N
group NN N
watched VBD N
a DT N
DVD NNP N
of IN N
Thomas NNP i
the DT i
Tank NNP i
Engine NNP i
. . N

Participants NNS N
were VBD N
assessed VBN N
on IN N
their PRP$ N
ability NN N
to TO N
complete VB N
basic JJ o
emotion NN o
recognition NN o
tasks NNS o
, , o
mindreading VBG o
and CC o
theory NN o
of IN o
mind NN o
( ( o
TOM NNP o
) ) o
tasks NNS o
before IN N
and CC N
after IN N
the DT N
4-week JJ N
intervention NN N
period NN N
, , N
and CC N
at IN N
3-month JJ N
follow-up NN N
. . N

RESULTS NNP N
Analyses NNP N
controlled VBD N
for IN N
the DT N
effect NN N
of IN N
chronological JJ N
age NN N
, , N
verbal JJ N
intelligence NN N
, , N
gender NN N
and CC N
DVD NNP N
viewing VBG N
time NN N
on IN N
outcomes NNS N
. . N

Children NNP N
in IN N
the DT N
intervention NN N
group NN N
showed VBD N
improved JJ N
performance NN N
in IN N
the DT N
recognition NN o
of IN o
anger NN o
compared VBN N
with IN N
the DT N
control NN N
group NN N
, , N
with IN N
few JJ N
improvements NNS N
maintained VBD N
at IN N
3-month JJ N
follow-up NN N
. . N

There EX N
was VBD N
no DT N
generalisation NN N
of IN N
skills NNS N
to TO N
TOM NNP o
or CC N
social JJ o
skills NNS o
. . N

CONCLUSIONS VB N
The DT i
Transporters NNP i
programme NN N
showed VBD N
limited JJ N
efficacy NN o
in IN N
teaching VBG N
basic JJ N
emotion NN N
recognition NN N
skills NNS N
to TO N
young JJ p
children NNS p
with IN p
autism NN p
with IN N
a DT N
lower JJR N
range NN N
of IN N
cognitive JJ N
ability NN N
. . N

Improvements NNS N
were VBD N
limited VBN N
to TO N
the DT N
recognition NN N
of IN N
expressions NNS N
of IN N
anger NN N
, , N
with IN N
poor JJ N
maintenance NN N
of IN N
these DT N
skills NNS N
at IN N
follow-up NN N
. . N

These DT N
findings NNS N
provide VBP N
limited JJ N
support NN N
for IN N
the DT N
efficacy NN N
of IN N
the DT N
Transporters NNP i
programme NN N
for IN N
young JJ p
children NNS p
with IN p
autism NN p
of IN N
a DT N
lower JJR N
cognitive JJ N
range NN N
. . N

-DOCSTART- -24317958- O O

The DT N
effect NN N
of IN N
four CD N
different JJ N
irrigation NN N
systems NNS N
in IN N
the DT N
removal NN N
of IN N
a DT N
root JJ N
canal JJ N
sealer NN N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficiency NN o
of IN N
sonic JJ i
, , i
ultrasonic JJ i
, , i
and CC i
hydrodynamic JJ i
devices NNS i
in IN N
the DT N
removal NN N
of IN N
a DT N
root JJ N
canal JJ N
sealer NN N
from IN N
the DT N
surface NN N
and CC N
from IN N
simulated JJ N
irregularities NNS N
of IN N
root NN N
canals NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Fifty-three NNP N
root NN N
canals NNS N
with IN N
two CD N
standardized JJ N
grooves NNS N
in IN N
the DT N
apical JJ N
and CC N
coronal JJ N
parts NNS N
of IN N
longitudinally RB N
split VBN N
roots NNS N
were VBD N
covered VBN N
with IN N
AH NNP N
Plus NNP N
root VBP N
canal JJ N
sealer NN N
. . N

Compared VBN N
were VBD N
the DT N
effects NNS N
of IN N
( ( N
control NN N
) ) N
syringe NN i
irrigation NN i
, , N
( ( N
1 CD N
) ) N
CanalBrush NN i
, , N
( ( N
2 CD N
) ) N
passive NN i
ultrasonic JJ i
irrigation NN i
, , N
( ( N
3 CD N
) ) N
EndoActivator NN i
, , N
and CC N
( ( N
4 CD N
) ) N
RinsEndo NN i
on IN N
the DT N
removal NN N
of IN N
the DT N
sealer NN N
. . N

The DT N
specimens NNS N
were VBD N
divided VBN N
into IN N
four CD N
groups NNS N
( ( N
N NNP N
= NNP N
12 CD N
) ) N
and CC N
one CD N
control NN N
group NN N
( ( N
N NNP N
= NNP N
5 CD N
) ) N
via IN N
randomization NN N
. . N

The DT N
amount NN N
of IN o
remaining VBG o
sealer NN o
in IN o
the DT o
root NN o
canal JJ o
irregularities NNS o
was VBD o
evaluated VBN N
under IN N
a DT N
microscope NN N
using VBG N
a DT N
4-grade JJ N
scoring NN N
system NN N
, , N
whereas IN N
the DT N
remaining VBG o
sealer NN o
on IN o
the DT o
root NN o
canal JJ o
surface NN o
was VBD N
evaluated VBN N
with IN o
a DT o
7-grade JJ o
scoring NN o
system NN o
. . N

RESULTS NNP N
Passive NNP i
ultrasonic JJ i
irrigation NN i
is VBZ N
more RBR N
effective JJ N
than IN N
the DT N
other JJ N
tested JJ N
irrigation NN i
systems NNS i
or CC N
syringe JJ i
irrigation NN i
in IN N
removing VBG o
sealer NN o
from IN o
root JJ o
canal JJ o
walls NNS o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

None NN N
of IN N
the DT N
techniques NNS N
had VBD N
a DT N
significant JJ N
effect NN N
on IN N
cleaning VBG o
the DT o
lateral JJ o
grooves NNS o
. . N

CONCLUSIONS NNP N
Within IN N
the DT N
limitations NNS N
of IN N
this DT N
study NN N
protocol VBZ N
ultrasonic JJ i
irrigation NN i
shows VBZ N
a DT N
superior JJ N
effect NN N
on IN N
sealer NN o
removal NN o
from IN o
the DT o
root NN o
canal JJ o
surface NN o
during IN N
endodontic JJ N
retreatment NN N
. . N

Cleaning NN N
of IN N
lateral JJ N
grooves NNS N
seems VBZ N
not RB N
to TO N
be VB N
possible JJ N
with IN N
one CD N
of IN N
the DT N
techniques NNS N
investigated VBN N
. . N

CLINICAL JJ N
RELEVANCE NNP N
Incomplete NNP N
removal NN o
of IN o
root JJ o
canal JJ o
sealer NN o
during IN N
re-treatment NN N
may MD N
cause VB N
treatment NN N
failure NN N
. . N

Passive NNP i
Ultrasonic NNP N
irrigation NN i
seems VBZ N
to TO N
be VB N
the DT N
most RBS N
effective JJ N
system NN N
to TO N
remove VB o
sealer NN o
from IN o
a DT o
root NN o
canal NN o
. . N

-DOCSTART- -15133359- O O

A DT N
randomized JJ N
comparison NN N
of IN N
alternative JJ N
techniques NNS N
to TO N
achieve VB N
coronary JJ p
sinus NN p
cannulation NN p
during IN p
biventricular JJ p
implantation NN p
procedures NNS N
. . N

INTRODUCTION NNP N
Biventricular NNP N
pacing VBG N
system NN N
implantation NN N
is VBZ N
a DT N
time-consuming JJ N
and CC N
challenging JJ N
procedure NN N
. . N

A DT N
critical JJ N
step NN N
in IN N
biventricular JJ N
pacemaker NN N
implantation NN N
is VBZ N
coronary JJ p
sinus NN p
( ( p
CS NNP p
) ) p
cannulation NN p
. . N

CS NNP N
cannulation NN N
can MD N
be VB N
achieved VBN N
either DT N
using VBG N
dedicated JJ N
guiding NN N
catheters NNS i
( ( N
guiding VBG i
catheter NN i
alone RB i
positioning VBG N
strategy NN N
, , N
GCA NNP N
) ) N
or CC N
with IN N
the DT N
aid NN N
of IN N
an DT N
electrophysiology NN i
catheter NN i
advanced VBD i
inside IN N
the DT N
guiding NN N
catheter NN N
( ( N
electrophysiology JJ i
catheter NN i
aided VBD i
positioning VBG N
strategy NN N
, , N
EPA NNP N
) ) N
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
evaluate VB N
whether IN N
the DT N
EPA NNP i
technique NN N
is VBZ N
useful JJ N
for IN N
reducing VBG N
CS NNP o
cannulation NN o
time NN o
compared VBN N
to TO N
a DT N
conventional JJ N
GCA NNP i
technique NN N
. . N

METHODS NNP N
Thirty-four JJ p
consecutive JJ p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
GCA NNP i
( ( N
18 CD N
patients NNS N
) ) N
or CC N
EPA NNP i
( ( N
16 CD N
patients NNS N
) ) N
CS NNP N
cannulation NN N
strategy NN N
. . N

RESULTS JJ N
Time NNP o
to TO o
successful JJ o
catheterization NN o
of IN o
CS NNP o
was VBD N
5.0 CD N
+/- JJ N
2.4 CD N
min NN N
in IN N
the DT N
EPA NNP i
group NN N
versus VBD N
10.1 CD N
+/- JJ N
5.4 CD N
min NN N
in IN N
the DT N
GCA NNP i
group NN N
p VBD N
= RB N
0.004 CD N
. . N

Fluoroscopy NN o
time NN o
was VBD N
4.6 CD N
+/- JJ N
2.3 CD N
min NN N
in IN N
the DT N
EPA NNP i
group NN N
versus VBD N
9.2 CD N
+/- JJ N
4.9 CD N
min NN N
in IN N
the DT N
GCA NNP i
group NN N
p VBD N
= RB N
0.004 CD N
. . N

Total JJ N
contrast NN o
dye NN o
volume NN o
to TO N
search NN N
and CC N
engage VB N
the DT N
CS NNP N
ostium NN N
was VBD N
0.0 CD N
ml NN N
in IN N
the DT N
EPA NNP i
group NN N
versus VBD N
14.3 CD N
+/- JJ N
3.4 CD N
ml NN N
in IN N
the DT N
GCA NNP i
group NN N
p VBD N
< RB N
0.001 CD N
. . N

CONCLUSIONS NNP N
Cannulation NNP p
of IN p
CS NNP p
with IN N
the DT N
adjunct NN N
of IN N
an DT N
electrophysiology NN N
catheter NN N
to TO N
dedicated VBN N
delivery NN N
systems NNS N
significantly RB N
reduces VBZ N
procedural JJ o
time NN o
, , o
fluoroscopy JJ o
time NN o
and CC N
contrast NN o
dye NN o
volume NN o
compared VBN N
to TO N
a DT N
conventional JJ N
strategy NN N
. . N

-DOCSTART- -8989009- O O

Prevention NN N
of IN N
spinal JJ N
anesthesia-induced JJ N
hypotension NN N
in IN N
the DT p
elderly JJ p
: : N
comparison NN N
between IN N
preanesthetic JJ N
administration NN N
of IN N
crystalloids NNS i
, , N
colloids NNS i
, , N
and CC N
no DT i
prehydration NN i
. . N

The DT N
practice NN N
of IN N
routinely RB N
prehydrating VBG N
patients NNS N
by IN N
infusing VBG N
a DT N
crystalloid NN i
or CC N
colloid JJ i
solution NN i
( ( N
up IN N
to TO N
1.0 CD N
L/70 NNP N
kg NN N
) ) N
for IN N
prevention NN N
of IN N
spinal JJ N
anesthesia-induced JJ N
hypotension NN N
has VBZ N
been VBN N
challenged VBN N
recently RB N
, , N
after IN N
several JJ N
reports NNS N
of IN N
failure NN N
to TO N
demonstrate VB N
its PRP$ N
efficacy NN N
in IN N
young JJ N
women NNS N
. . N

We PRP N
compared VBN N
the DT N
incidence NN o
and CC o
frequency NN o
of IN o
hypotension NN o
and CC o
vasopressor NN o
therapy NN o
after IN N
spinal JJ N
anesthesia NN N
and CC N
no DT i
prehydration NN i
with IN N
crystalloid NN i
and CC N
colloid JJ i
prehydration NN i
in IN p
elderly JJ p
patients NNS p
. . N

Eighty-five JJ p
ASA NNP p
grade NN p
I PRP p
or CC p
II NNP p
patients NNS p
( ( p
aged VBN p
60-89 CD p
yr NN p
) ) p
for IN p
elective JJ p
total JJ p
hip NN p
replacement NN p
were VBD N
randomized VBN N
to TO N
receive VB N
500 CD N
mL NN N
crystalloid JJ i
solution NN i
( ( N
Hartmanns NNP N
, , N
n JJ N
= NNP N
29 CD N
) ) N
, , N
500 CD N
mL NN N
colloid NN i
( ( N
Haemaccel NNP i
, , N
n JJ N
= NNP N
28 CD N
) ) N
, , N
or CC N
no DT i
prehydration NN i
( ( N
n JJ N
= NNP N
28 CD N
) ) N
over IN N
10 CD N
min NNS N
prior RB N
to TO N
spinal JJ N
anesthesia NN N
. . N

Hypotension NNP o
was VBD N
defined VBN N
as IN N
a DT N
30 CD N
% NN N
decrease NN N
from IN N
baseline JJ N
systolic JJ o
blood NN o
pressure NN o
( ( N
BP NNP N
) ) N
or CC N
systolic JJ N
< $ N
90 CD N
mm NN N
Hg NNP N
, , N
and CC N
was VBD N
treated VBN N
with IN N
ephedrine JJ N
3-mg JJ N
boluses NNS N
. . N

Although IN N
absolute JJ o
systolic JJ o
BP NNP o
readings NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
colloid NN i
group NN N
between IN N
6 CD N
and CC N
30 CD N
min NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
the DT N
incidence NN o
of IN o
hypotension NN o
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
groups NNS N
. . N

The DT N
incidence NN o
of IN o
ephedrine NN o
use NN o
, , o
incidence NN o
of IN o
nausea/vomiting NN o
, , N
and CC N
median JJ o
total NN o
dose NN o
of IN o
ephedrine NN o
were VBD N
similar JJ N
in IN N
all DT N
groups NNS N
. . N

We PRP N
conclude VBP N
that DT N
, , N
in IN N
elderly JJ p
patients NNS p
undergoing VBG p
elective JJ p
procedures NNS p
, , N
withholding VBG N
prehydration NN N
is VBZ N
not RB N
associated VBN N
with IN N
any DT N
greater JJR N
degree NN N
of IN N
hypotension NN o
or CC N
need NN o
for IN o
vasopressor NN o
therapy NN o
compared VBN N
with IN N
crystalloid NN i
or CC N
colloid JJ i
prehydration NN i
. . N

-DOCSTART- -1780092- O O

[ RB N
Clinical NNP N
study NN N
of IN N
the DT N
efficacy NN o
of IN N
and CC N
tolerance NN o
to TO N
nimesulide VB i
in IN N
suppository JJ N
formulation NN N
in IN N
pain-inflammatory JJ N
pathologies NNS N
of IN N
the DT N
ear NN N
, , N
nose RB N
, , N
and CC N
throat NN N
] NN N
. . N

The DT N
efficacy NN o
and CC N
tolerability NN o
of IN N
a DT N
new JJ N
pharmaceutical JJ N
form NN N
of IN N
the DT N
non-steroid JJ N
anti-inflammatory JJ N
drug NN N
. . N

Nimesulide NNP i
have VBP N
been VBN N
studied VBN N
in IN N
a DT N
double JJ N
blind NN N
study NN N
compared VBN N
with IN N
flurbiprofen NN i
, , N
in IN N
98 CD p
patients NNS p
aged VBN p
between IN p
18 CD p
and CC p
75 CD p
suffering VBG p
from IN p
pain-inflammatory JJ p
pathologies NNS p
of IN p
ENT NNP p
nature NN p
. . N

Both DT N
drugs NNS N
, , N
administered VBN N
in IN N
a DT N
dose NN N
of IN N
one CD N
suppository NN N
twice RB N
a DT N
day NN N
for IN N
7 CD N
days NNS N
, , N
showed VBD N
marked JJ N
anti-inflammatory JJ o
, , o
analgesic JJ o
and CC o
antipyretic JJ o
activity NN o
and CC N
produced VBD N
a DT N
significant JJ N
, , N
progressive JJ N
improvement NN N
in IN N
the DT N
typical JJ N
symptoms NNS o
of IN o
the DT o
inflammatory NN o
state NN o
up IN N
to TO N
their PRP$ N
complete JJ N
remission NN N
. . N

Nimesulide NNP i
evidenced VBD N
greater JJR N
speed NN N
and CC N
duration NN o
of IN N
therapeutic JJ N
action NN N
. . N

Assessment NN N
on IN N
the DT N
effectiveness NN o
and CC N
tolerability NN o
as IN N
expressed VBN N
separately RB N
by IN N
the DT N
physician NN N
and CC N
patient NN N
were VBD N
positive JJ N
in IN N
almost RB N
all DT N
cases NNS N
of IN N
both DT N
treatments NNS N
. . N

-DOCSTART- -21669557- O O

Intervention NN N
to TO N
lower VB N
household NN N
wood NN N
smoke NN N
exposure NN N
in IN N
Guatemala NNP N
reduces NNS N
ST-segment NNP o
depression NN o
on IN N
electrocardiograms NNS N
. . N

BACKGROUND VB N
A DT N
large JJ N
body NN N
of IN N
evidence NN N
suggests VBZ N
that IN N
fine JJ N
particulate NN N
matter NN N
( ( N
PM NNP N
) ) N
air NN N
pollution NN N
is VBZ N
a DT N
cause NN N
of IN N
cardiovascular JJ N
disease NN N
, , N
but CC N
little JJ N
is VBZ N
known VBN N
in IN N
particular JJ N
about IN N
the DT N
cardiovascular JJ N
effects NNS N
of IN N
indoor JJ N
air NN N
pollution NN N
from IN N
household NN N
use NN N
of IN N
solid JJ N
fuels NNS N
in IN N
developing VBG N
countries NNS N
. . N

RESPIRE NNP N
( ( N
Randomized NNP N
Exposure NNP N
Study NNP N
of IN N
Pollution NNP N
Indoors NNP N
and CC N
Respiratory NNP N
Effects NNP N
) ) N
was VBD N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
chimney NN i
woodstove NN i
that WDT N
reduces VBZ N
wood NN N
smoke NN N
exposure NN N
. . N

OBJECTIVES IN N
We PRP N
tested VBD N
the DT N
hypotheses NNS N
that IN N
the DT N
stove NN i
intervention NN i
, , N
compared VBN N
with IN N
open JJ i
fire NN i
use NN N
, , N
would MD N
reduce VB N
ST-segment NNP o
depression NN o
and CC N
increase VB N
heart NN o
rate NN o
variability NN o
( ( o
HRV NNP o
) ) o
. . N

METHODS NNP N
We PRP N
used VBD N
two CD N
complementary JJ N
study NN N
designs NNS N
: : N
a DT N
) ) N
between-groups NN N
comparisons NNS N
based VBN N
on IN N
randomized JJ N
stove NN i
assignment NN N
, , N
and CC N
b NN N
) ) N
before-and-after NN N
comparisons NNS N
within IN N
control NN N
subjects NNS N
who WP N
used VBD N
open JJ i
fires NNS i
during IN N
the DT N
trial NN N
and CC N
received VBD N
chimney NN i
stoves NNS i
after IN N
the DT N
trial NN N
. . N

Electrocardiogram NNP N
sessions NNS N
that WDT N
lasted VBD N
20 CD N
hr NNS N
were VBD N
repeated VBN N
up RP N
to TO N
three CD N
times NNS N
among IN N
49 CD p
intervention NN p
and CC p
70 CD p
control NN p
women NNS p
38-84 CD p
years NNS p
of IN p
age NN p
, , p
and CC p
55 CD p
control NN p
subjects NNS p
were VBD N
also RB N
assessed VBN N
after IN N
receiving VBG N
stoves NNS i
. . N

HRV NNP o
and CC o
ST-segment JJ o
values NNS o
were VBD N
assessed VBN N
for IN N
each DT N
30-min JJ N
period NN N
. . N

ST-segment JJ o
depression NN o
was VBD N
defined VBN N
as IN N
an DT N
average JJ N
value NN N
below IN N
-1.00 NNP N
mm NN N
. . N

Personal JJ o
fine JJ o
PM NNP o
[ NNP N
aerodynamic JJ N
diameter NN N
? . N
2.5 CD N
?m NN N
( ( N
PM?.? NNP N
] NNP o
exposures NNS o
were VBD N
measured VBN N
for IN N
24 CD N
hr NN N
before IN N
each DT N
electrocardiogram NN N
. . N

RESULTS NNP N
PM?.? NNP o
exposure NN o
means NNS N
were VBD N
266 CD N
and CC N
102 CD N
?g/m? NN N
during IN N
the DT N
trial NN N
period NN N
in IN N
the DT N
control NN N
and CC N
intervention NN N
groups NNS N
, , N
respectively RB N
. . N

During IN N
the DT N
trial NN N
, , N
the DT N
stove NN i
intervention NN i
was VBD N
associated VBN N
with IN N
an DT N
odds NNS N
ratio NN N
of IN N
0.26 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.08-0.90 NN N
) ) N
for IN N
ST-segment JJ o
depression NN o
. . N

We PRP N
found VBD N
similar JJ N
associations NNS N
with IN N
the DT N
before-and-after JJ N
comparison NN N
. . N

The DT N
intervention NN N
was VBD N
not RB N
significantly RB N
associated VBN N
with IN N
HRV NNP o
. . N

CONCLUSIONS NNP N
The DT N
stove NN i
intervention NN i
was VBD N
associated VBN N
with IN N
reduced JJ N
occurrence NN N
of IN N
nonspecific JJ N
ST-segment JJ o
depression NN o
, , N
suggesting VBG N
that IN N
household NN N
wood NN N
smoke NN N
exposures NNS N
affect VBP N
ventricular JJ N
repolarization NN N
and CC N
potentially RB N
cardiovascular JJ N
health NN N
. . N

-DOCSTART- -12477021- O O

Clinical JJ o
performance NN o
of IN N
the DT N
Reichert NNP i
AT550 NNP i
: : N
a DT N
new JJ N
non-contact JJ N
tonometer NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
level NN o
of IN o
accuracy NN o
for IN N
measurements NNS o
of IN N
intra-ocular JJ N
pressure NN N
( ( N
IOP NNP N
) ) N
obtained VBD N
with IN N
a DT N
new JJ N
non-contact JJ N
tonometer NN N
( ( N
NCT NNP N
) ) N
the DT N
Reichert NNP i
AT550 NNP i
. . N

Measurements NNS N
were VBD N
compared VBN N
against IN N
those DT N
obtained VBN N
with IN N
the DT N
Reichert NNP i
Xpert NNP i
Plus NNP i
, , N
Goldmann NNP i
applanation NN i
tonometer NN i
and CC N
Perkins NNP i
tonometer NN i
. . N

Thirty-five JJ p
university NN p
students NNS p
were VBD N
assessed VBN N
with IN N
the DT N
four CD N
tonometers NNS N
in IN N
a DT N
randomised JJ N
order NN N
, , N
with IN N
non-contact JJ N
tonometry NN N
performed VBD N
first RB N
. . N

Each DT N
of IN N
the DT N
four CD N
measurement NN N
devices NNS N
had VBD N
its PRP$ N
own JJ N
trained JJ N
clinical JJ N
observer NN N
. . N

Plots NNP N
of IN N
differences NNS N
of IN N
IOP NNP N
as IN N
a DT N
function NN N
of IN N
the DT N
mean NN N
for IN N
each DT N
pair NN N
of IN N
instruments NNS N
were VBD N
obtained VBN N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
when WRB N
comparing VBG N
the DT N
AT550 NNP i
NCT NNP i
with IN N
contact JJ N
applanation NN N
tonometry NN N
( ( N
AT NNP N
) ) N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
, , N
displaying VBG N
the DT N
closest JJS N
level NN N
of IN N
agreement NN N
( ( N
as IN N
represented VBN N
by IN N
the DT N
lowest JJS N
mean JJ N
difference NN N
and CC N
the DT N
narrowest JJS N
confidence NN N
interval NN N
) ) N
with IN N
the DT N
Goldmann NNP i
tonometer NN i
( ( N
limits NNS N
of IN N
agreement NN N
, , N
0.12+/-2.17 NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
readings NNS N
of IN N
IOP NNP o
with IN N
the DT N
AT550 NNP i
NCT NNP i
are VBP N
clinically RB N
comparable JJ N
with IN N
those DT N
obtained VBN N
with IN N
Goldmann NNP i
tonometry NN i
in IN N
a DT N
population NN N
with IN N
IOP NNP N
within IN N
the DT N
normal JJ N
range NN N
. . N

-DOCSTART- -22646975- O O

Effects NNS N
of IN N
guided JJ N
imagery NN N
with IN N
relaxation NN i
training NN i
on IN N
anxiety NN o
and CC N
quality NN o
of IN o
life NN o
among IN N
patients NNS p
with IN p
inflammatory JJ p
bowel NN p
disease NN p
. . N

BACKGROUND NNP N
Inflammatory NNP N
Bowel NNP N
Disease NNP N
( ( N
IBD NNP N
) ) N
impacts VBZ N
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
. . N

Psychological JJ N
factors NNS N
influence VBP N
the DT N
course NN N
of IN N
the DT N
disease NN N
and CC N
should MD N
be VB N
targeted VBN N
for IN N
intervention NN N
. . N

METHODS NNP N
Our PRP$ N
study NN N
was VBD N
a DT N
prospective JJ N
, , N
randomised VBD N
control NN N
trial NN N
. . N

Fifty-six JJ p
outpatients NNS p
were VBD N
randomly RB N
chosen VBN N
and CC N
allocated VBN N
to TO N
a DT N
treatment NN N
group NN N
or CC N
a DT N
waiting-list JJ N
control NN N
group NN N
. . N

Treatment NNP N
group NN N
patients NNS N
attended VBD N
three CD N
relaxation-training JJ i
sessions NNS i
and CC N
received VBD N
an DT N
audio JJ N
disc NN N
for IN N
home NN N
practice NN N
. . N

Evaluations NNS N
performed VBD N
pre JJ N
and CC N
post-treatment JJ N
: : N
state NN o
anxiety NN o
was VBD N
assessed VBN N
with IN N
the DT N
State-Trait NNP o
Anxiety NNP o
Inventory NNP o
, , o
QoL NNP o
with IN o
the DT o
IBD NNP o
Questionnaire NNP o
. . N

The DT N
Visual NNP o
Analogue NNP o
Scale NNP o
assessed VBD N
pain NN o
, , o
depression NN o
, , o
stress NN o
and CC N
mood NN o
. . N

Patients NNS N
completed VBD N
a DT N
symptom JJ N
monitoring NN N
diary NN N
. . N

The DT N
control NN N
group NN N
's POS N
symptoms NNS N
were VBD N
monitored VBN N
without IN N
study-related JJ N
treatment NN N
. . N

RESULTS NNP N
Thirty-nine JJ p
subjects NNS p
completed VBD p
the DT p
study NN p
and CC N
were VBD N
included VBN N
in IN N
the DT N
data NN N
analysis NN N
. . N

Following VBG N
the DT N
relaxation-training JJ i
intervention NN N
, , N
the DT N
treatment NN N
group NN N
's POS N
( ( N
n JJ N
= NNP N
18 CD N
) ) N
measured VBN N
results NNS N
showed VBD N
a DT N
statistically RB N
significant JJ N
improvement NN N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
21 CD N
) ) N
( ( N
time NN N
by IN N
treatment NN N
interaction NN N
) ) N
: : N
anxiety NN o
levels NNS o
decreased VBN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
QoL NNP o
and CC o
mood NN o
improved VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
while IN N
levels NNS N
of IN N
pain NN o
and CC o
stress NN o
decreased VBN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
Findings NNP N
indicate VBP N
IBD NNP p
patients NNS p
may MD N
benefit VB N
from IN N
relaxation NN i
training NN i
in IN N
their PRP$ N
holistic JJ N
care NN N
. . N

New NNP N
studies NNS N
as RB N
well RB N
as IN N
further JJ N
investigation NN N
of IN N
the DT N
subject NN N
are VBP N
warranted VBN N
. . N

-DOCSTART- -24960665- O O

Paternal NNP N
RHD NNP N
zygosity NN N
determination NN N
in IN N
Tunisians NNS p
: : N
evaluation NN N
of IN N
three CD N
molecular JJ N
tests NNS N
. . N

BACKGROUND IN N
The DT N
choice NN N
of IN N
a DT N
molecular JJ N
test NN N
for IN N
first JJ N
intention NN N
determination NN N
of IN N
paternal JJ N
RHD NNP N
zygosity NN N
, , N
before IN N
entering VBG N
into IN N
invasive JJ N
diagnostics NNS N
, , N
is VBZ N
important JJ N
for IN N
the DT N
management NN N
of IN N
pregnancies NNS N
at IN N
risk NN N
of IN N
haemolytic JJ N
disease NN N
of IN N
the DT N
foetus NN N
and CC N
newborn RB N
related VBN N
to TO N
anti-RhD JJ N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
RHD NNP N
zygosity NN N
was VBD N
evaluated VBN N
in IN N
370 CD p
RH:1 NNP p
Tunisian JJ p
donors NNS p
by IN N
polymerase NN N
chain NN N
reaction NN N
- : N
sequence-specific JJ N
polymorphism NN N
( ( N
PCR-SSP NNP N
) ) N
analysis NN N
and CC N
polymerase NN N
chain NN N
reaction NN N
- : N
restriction NN N
fragment NN N
length NN N
polymorphism NN N
( ( N
PCR-RFLP NNP N
) ) N
amplification NN N
of IN N
hybrid JJ N
Rhesus NNP N
box NN N
and CC N
by IN N
real JJ N
time NN N
quantitative JJ N
polymerase NN N
chain NN N
reaction NN N
( ( N
RQ-PCR NNP N
) ) N
specific NN N
for IN N
RHD NNP N
exon VBD N
5 CD N
. . N

To TO N
evaluate VB N
the DT N
accuracy NN N
of IN N
molecular JJ N
tests NNS N
in IN N
the DT N
cases NNS N
of IN N
discordant JJ N
results NNS N
, , N
the DT N
ten JJ N
exons NNS N
of IN N
RHD NNP N
and CC N
Rhesus NNP N
boxes NNS N
were VBD N
amplified VBN N
by IN N
PCR NNP N
and CC N
sequenced VBN N
. . N

RESULTS NNP N
Molecular JJ N
investigations NNS N
revealed VBD N
that IN N
our PRP$ N
370 CD p
donors NNS p
comprise VBP N
193 CD N
dizygous JJ N
and CC N
145 CD N
hemizygous JJ N
individuals NNS N
and CC N
32 CD N
subjects NNS N
whose WP$ N
zygosity NN N
remains VBZ N
unknown JJ N
. . N

Positive JJ o
predictive JJ o
values NNS o
were VBD N
higher JJR N
than IN N
99 CD N
% NN N
for IN N
all PDT N
the DT N
methods NNS N
, , N
reaching VBG N
100 CD N
% NN N
for IN N
RQ-PCR NNP N
. . N

Negative NNP o
predictive JJ o
values NNS o
were VBD N
83.24 CD N
% NN N
, , N
87.27 CD N
% NN N
and CC N
98 CD N
% NN N
for IN N
PCR-SSP NNP N
, , N
PCR-RFLP NNP N
and CC N
RQ-PCR NNP N
respectively RB N
. . N

This DT N
study NN N
also RB N
revealed VBD N
19 CD N
novel JJ N
Rhesus NNP o
box NN o
polymorphisms NN o
and CC N
three CD N
novel NN N
RHD NNP o
alleles NNS o
: : N
RHD NNP N
( ( N
Trp185Stop NNP N
) ) N
, , N
RHD NNP N
( ( N
Ala176Thr NNP N
) ) N
and CC N
RHD NNP N
( ( N
Ile342Ile NNP N
) ) N
. . N

DISCUSSION NNP N
RQ-PCR NNP N
is VBZ N
the DT N
most RBS N
convenient JJ N
method NN N
for IN N
first JJ N
intention NN N
determination NN N
of IN N
paternal JJ N
RHD NNP N
zygosity NN N
in IN N
Tunisians NNPS N
. . N

However RB N
, , N
taking VBG N
into IN N
account NN N
positive JJ N
and CC N
negative JJ N
predictive NN N
values NNS N
, , N
PCR-RFLP NNP N
could MD N
be VB N
an DT N
alternative JJ N
despite IN N
the DT N
heterogeneity NN N
of IN N
Rhesus NNP N
boxes NNS N
and CC N
the DT N
complexity NN N
of IN N
RHD NNP N
. . N

-DOCSTART- -23114870- O O

Custom-fit NNP N
minimally RB N
invasive JJ N
total JJ i
knee NN i
arthroplasty NN i
: : N
effect NN N
on IN N
blood NN o
loss NN o
and CC N
early JJ o
clinical JJ o
outcomes NNS o
. . N

PURPOSE NNP N
Recently NNP N
, , N
new JJ N
custom-fit JJ N
pin NN N
guides NNS N
in IN N
total JJ i
knee NN i
arthroplasty NN i
( ( p
TKA NNP i
) ) p
have VBP N
been VBN N
introduced VBN N
. . N

Use NN N
of IN N
these DT N
guides NNS N
may MD N
reduce VB N
operating NN N
time NN N
. . N

Use NN N
of IN N
the DT N
guides NNS N
combined VBN N
with IN N
the DT N
absence NN N
of IN N
intramedullary JJ N
alignment NN N
jigs NNS N
may MD N
lead VB N
to TO N
reduced VB N
blood NN o
loss NN o
and CC N
improved VBN N
early JJ o
outcomes NNS o
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
blood NN o
loss NN o
and CC N
early JJ o
clinical JJ o
outcomes NNS o
in IN N
patients NNS p
undergoing VBG p
minimally RB p
invasive JJ p
TKA NNP p
using VBG N
custom-fit JJ i
magnetic JJ i
resonance NN i
imaging NN i
( ( i
MRI NNP i
) ) i
-based VBD i
pin NN i
guides NNS i
. . N

METHODS NNP N
A NNP N
prospective JJ N
study NN N
in IN N
80 CD p
patients NNS p
was VBD N
carried VBN N
out RP N
. . N

Patients NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
2 CD N
equal JJ N
groups NNS N
. . N

In IN N
one CD N
group NN N
, , N
intramedullary JJ i
alignment NN i
jigs NNS i
were VBD N
used VBN N
. . N

In IN N
the DT N
second JJ N
group NN N
, , N
custom-fit JJ i
MRI-based JJ i
pin NN i
guides NNS i
were VBD N
used VBN N
. . N

All DT N
patients NNS N
received VBD N
the DT N
same JJ N
cemented VBD i
posterior-stabilized JJ i
implant NN i
through IN N
a DT N
mini-midvastus JJ N
approach NN N
. . N

The DT N
volume NN N
in IN N
the DT N
drain NN N
bottles NNS N
was VBD N
recorded VBN N
after IN N
48 CD N
h. JJ N
Hb NNP o
loss NN o
was VBD N
estimated VBN N
by IN N
subtracting VBG N
the DT N
postoperative NN N
from IN N
the DT N
preoperative JJ N
Hb NNP N
level NN N
. . N

Transfusion NN o
requirements NNS o
and CC N
surgical JJ o
time NN o
were VBD N
recorded VBN N
. . N

Outcome JJ N
measures NNS N
were VBD N
Knee NNP o
Society NNP o
Scores NNP o
( ( o
KSS NNP o
) ) o
, , o
knee JJ o
flexion NN o
, , o
knee VB o
swelling VBG o
and CC o
pain NN o
. . N

RESULTS NNP N
There EX N
was VBD N
lower JJR N
mean JJ N
drainage NN o
of IN o
blood NN o
in IN N
the DT N
custom-fit JJ i
group NN N
( ( N
391 CD N
ml NN N
vs. FW N
603 CD N
ml NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
estimated VBN N
loss NN o
of IN o
Hb NNP o
( ( N
3.6 CD N
g/dl NN N
vs. FW N
4.1 CD N
g/dl NN N
; : N
n.s CC N
. . N

) ) N
and CC N
in IN N
transfusion NN N
requirements NNS N
( ( N
7.5 CD N
% NN N
vs. FW N
10 CD N
% NN N
; : N
n.s. CC N
) ) N
. . N

Surgical JJ o
time NN o
was VBD N
reduced VBN N
in IN N
the DT N
custom-fit JJ i
group NN N
( ( N
12 CD N
min NN N
less JJR N
; : N
p NN N
= VBZ N
0.001 CD N
) ) N
. . N

KSS NNP o
measured VBD N
at IN N
week NN N
2 CD N
, , N
6 CD N
and CC N
12 CD N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
. . N

Knee NNP o
flexion NN o
measured VBN N
on IN N
days NNS N
7 CD N
, , N
10 CD N
and CC N
at IN N
week NN N
6 CD N
, , N
12 CD N
and CC N
knee VB o
swelling VBG o
and CC N
pain NN o
measured VBN N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
10 CD N
and CC N
at IN N
week NN N
6 CD N
, , N
12 CD N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
. . N

CONCLUSIONS NNP N
Using VBG N
custom-fit JJ i
pin NN i
guides NNS i
reduces NNS N
blood NN o
drainage NN o
, , N
but CC N
not RB N
the DT N
estimated VBN N
Hb NNP o
loss NN o
in IN N
minimally RB N
invasive JJ N
TKA NNP N
and CC N
does VBZ N
not RB N
affect VB N
transfusion NN o
rate NN o
. . N

Surgical JJ o
time NN o
is VBZ N
reduced VBN N
. . N

There EX N
is VBZ N
no DT N
effect NN N
on IN N
the DT N
early JJ o
clinical JJ o
outcomes NNS o
. . N

LEVEL NN N
OF IN N
EVIDENCE NNP N
Therapeutic NNP N
study NN N
, , N
Level NNP N
I PRP N
. . N

-DOCSTART- -15014018- O O

A DT N
pooled JJ N
analysis NN N
of IN N
eastern JJ N
cooperative JJ N
oncology NN N
group NN N
and CC N
intergroup NN N
trials NNS N
of IN N
adjuvant JJ N
high-dose JJ N
interferon NN i
for IN N
melanoma NN p
. . N

PURPOSE NNP N
Nearly RB p
2000 CD p
patients NNS p
with IN p
stage NN p
IIB NNP p
and CC p
III NNP p
melanoma NNS p
have VBP N
participated VBN N
in IN N
four CD N
multicenter NN N
, , N
randomized VBN N
trials NNS N
, , N
conducted VBN N
by IN N
the DT N
Eastern NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
and CC N
the DT N
Intergroup NNP N
, , N
investigating VBG N
adjuvant JJ N
high-dose JJ N
IFN-alpha JJ i
2b CD i
therapy NN N
. . N

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
update VB N
the DT N
analyses NNS N
of IN N
each DT N
individual JJ N
trial NN N
and CC N
to TO N
analyze VB N
prognostic JJ N
factors NNS N
and CC N
treatment NN N
effects NNS N
based VBN N
on IN N
pooled JJ N
data NNS N
. . N

EXPERIMENTAL NNP N
DESIGN NNP N
Survival NNP N
and CC N
disease NN N
status NN N
were VBD N
updated VBN N
to TO N
April NNP N
2001 CD N
. . N

Analysis NN N
of IN N
prognostic JJ N
factors NNS N
using VBG N
optimized JJ N
statistical JJ N
models NNS N
was VBD N
based VBN N
on IN N
data NNS N
from IN N
patients NNS N
in IN N
E1684 NNP N
, , N
E1690 NNP N
, , N
E1694 NNP N
, , N
and CC N
E2696 NNP N
. . N

Analysis NN N
of IN N
treatment NN N
effects NNS N
versus VBP N
observation NN N
( ( N
Obs NNP N
) ) N
was VBD N
based VBN N
on IN N
data NNS N
from IN N
713 CD N
patients NNS N
randomized VBN N
to TO N
high-dose JJ N
IFN-alpha JJ i
2b CD i
( ( i
HDI NNP i
) ) i
or CC N
Obs NNP i
in IN N
Trials NNP N
E1684 NNP N
and CC N
E1690 NNP N
. . N

RESULTS NNP N
Updated VBD N
analysis NN N
of IN N
E1684 NNP N
, , N
E1690 NNP N
, , N
and CC N
E1694 NNP N
confirmed VBD N
their PRP$ N
original JJ N
conclusions NNS N
, , N
now RB N
at IN N
median JJ N
follow-up JJ N
intervals NNS N
of IN N
2.1-12.6 JJ N
years NNS N
. . N

Based VBN N
on IN N
two-sided JJ N
univariate JJ N
log-rank JJ N
analysis NN N
of IN N
pooled VBN N
data NNS N
from IN N
E1684 NNP N
and CC N
E1690 NNP N
( ( N
median JJ N
follow-up NN N
, , N
7.2 CD N
years NNS N
) ) N
, , N
relapse-free JJ o
survival NN o
( ( o
RFS NNP o
) ) o
-but VBZ N
not RB N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
-was VBP N
significantly RB N
prolonged VBN N
( ( N
two-sided JJ N
log-rank NN N
P NNP N
value NN N
= NNP N
0.006 CD N
) ) N
for IN N
patients NNS N
treated VBN N
with IN N
HDI NNP i
versus NN N
Obs NNP i
. . N

Among IN N
all DT N
patients NNS N
, , N
prognostic JJ N
factors NNS N
that WDT N
significantly RB N
negatively RB N
impacted JJ N
RFS NNP N
and CC N
OS NNP N
included VBD N
ulceration NN N
, , N
recurrent JJ N
disease NN N
at IN N
entry NN N
, , N
enrollment NN N
in IN N
E1684 NNP N
, , N
and CC N
age NN N
> VBP N
49 CD N
years NNS N
. . N

Multivariate NNP N
statistical JJ N
models NNS N
adjusting VBG N
for IN N
these DT N
factors NNS N
confirmed VBD N
the DT N
statistically RB N
significant JJ N
RFS NNP o
benefit NN N
of IN N
HDI NNP i
versus NN N
Obs NNP i
but CC N
did VBD N
not RB N
demonstrate VB N
a DT N
significant JJ N
OS NNP o
benefit NN N
in IN N
the DT N
pooled JJ N
populations NNS N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
high-risk JJ p
resected JJ p
melanoma NN p
, , N
HDI NNP N
is VBZ N
effective JJ N
adjuvant JJ N
therapy NN N
with IN N
strong JJ N
evidence NN N
for IN N
improved JJ N
RFS NNP o
and CC N
evidence NN N
for IN N
moderate JJ N
improvement NN N
in IN N
OS NNP o
based VBN N
on IN N
two CD N
prospective JJ N
randomized VBN N
studies NNS N
but CC N
not RB N
the DT N
pooled JJ N
analysis NN N
. . N

Analyses NNS N
of IN N
predictors NNS N
of IN N
relapse NN N
and CC N
response NN N
are VBP N
now RB N
needed VBN N
to TO N
improve VB N
the DT N
therapeutic JJ N
value NN N
of IN N
this DT N
modality NN N
. . N

-DOCSTART- -22435114- O O

Group NNP i
cognitive JJ i
behavior NN i
therapy NN i
for IN N
children NNS p
with IN p
high-functioning JJ p
autism NN p
spectrum NN p
disorders NNS p
and CC p
anxiety NN p
: : N
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
Children NNP p
with IN N
high-functioning JJ N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
are VBP N
at IN N
high JJ N
risk NN N
for IN N
developing VBG N
significant JJ N
anxiety NN N
. . N

Anxiety NN N
can MD N
adversely RB N
impact VB N
functioning VBG N
across IN N
school NN N
, , N
home NN N
and CC N
community NN N
environments NNS N
. . N

Cognitive JJ i
behavioral JJ i
therapies NNS i
( ( i
CBT NNP i
) ) i
are VBP N
frequently RB N
used VBN N
with IN N
success NN N
for IN N
children NNS N
with IN N
anxiety NN o
symptoms NNS o
. . N

Modified NNP N
CBT NNP i
interventions NNS N
for IN N
anxiety NN p
in IN p
children NNS p
with IN p
ASD NNP p
have VBP N
also RB N
yielded VBN N
promising JJ N
results NNS N
. . N

METHODS NNP N
Fifty NNP p
children NNS p
with IN p
high-functioning JJ p
ASD NNP p
and CC p
anxiety NN p
were VBD N
randomizedto JJ N
group NN N
CBT NNP i
or CC N
treatment-as-usual JJ i
( ( i
TAU NNP i
) ) i
for IN N
12 CD N
weeks NNS N
. . N

Independent NNP N
clinical JJ N
evaluators NNS N
, , N
blind NN N
to TO N
condition NN N
, , N
completed VBN N
structured JJ N
interviews NNS N
( ( o
Anxiety NNP o
Disorders NNP o
Interview NNP o
Schedule NNP o
? . o
Parent NNP o
Version NNP o
; : o
ADIS-P NNP o
) ) o
pre- NN N
and CC N
post-intervention NN N
condition NN N
. . N

RESULTS NNP N
Forty-seven JJ p
children NNS p
completed VBN N
either CC N
the DT N
CBT NNP i
or CC N
TAU NNP i
condition NN N
. . N

Results NNS N
indicated VBD N
markedly RB N
better RBR N
outcomes NNS N
for IN N
the DT N
CBT NNP i
group NN N
. . N

Significant JJ N
differences NNS N
by IN N
group NN N
were VBD N
noted VBN N
in IN N
Clinician JJ o
Severity NNP o
Ratings NNP o
, , o
diagnostic JJ o
status NN o
, , o
and CC o
clinician JJ o
ratings NNS o
of IN o
global JJ o
improvement NN o
. . N

In IN N
the DT N
intent-to-treat JJ N
sample NN N
, , N
10 CD N
of IN N
20 CD N
children NNS N
( ( N
50 CD N
% NN N
) ) N
in IN N
the DT N
CBT NNP i
group NN N
had VBD N
a DT N
clinically RB N
meaningful JJ N
positive JJ N
treatment NN N
response NN N
, , N
compared VBN N
to TO N
2 CD N
of IN N
23 CD N
children NNS N
( ( N
8.7 CD N
% NN N
) ) N
in IN N
the DT N
TAU NNP i
group NN N
. . N

CONCLUSIONS NNP N
Initial JJ N
results NNS N
from IN N
this DT N
randomized VBN N
, , N
designed VBN N
treatment NN N
study NN N
suggest VBP N
that IN N
agroup NN N
CBT NNP i
intervention NN N
specifically RB N
developed VBD N
for IN N
children NNS N
with IN N
ASD NNP N
may MD N
be VB N
effective JJ N
in IN N
decreasing VBG N
anxiety NN N
. . N

Limitations NNS N
of IN N
this DT N
study NN N
include VBP N
small JJ N
sample JJ N
size NN N
, , N
lack NN N
of IN N
an DT N
attention NN N
control NN N
group NN N
, , N
and CC N
use NN N
of IN N
outcome NN N
measures NNS N
normed VBN N
with IN N
typically RB N
developing VBG N
children NNS N
-DOCSTART- -4919024- O O

Protection NN N
of IN N
man NN N
from IN N
natural JJ N
infection NN N
with IN N
influenza JJ N
A2 NNP N
Hong NNP N
Kong NNP N
virus NN N
by IN N
amantadine NN i
: : N
a DT N
controlled JJ N
field NN N
trial NN N
. . N

Prophylactic JJ N
administration NN N
of IN N
amantadine NN i
in IN N
doses NNS N
of IN N
100 CD N
mg. NN N
twice RB N
a DT N
day NN N
offered VBN N
statistically RB N
significant JJ N
protection NN N
against IN N
influenza JJ N
A2 NNP N
infection NN N
in IN N
a DT N
double-blind JJ N
field NN N
trial NN N
involving VBG N
391 CD p
medical JJ p
student NN p
volunteers NNS p
during IN p
the DT p
influenza JJ p
A2 NNP p
Hong NNP p
Kong NNP p
epidemic VBP p
in IN p
Helsinki NNP p
in IN p
the DT p
winter NN p
of IN p
1969 CD p
. . N

Serologically RB o
verified JJ o
influenza NN o
, , N
as IN N
measured VBN N
by IN N
complement JJ o
fixation NN o
and/or NN o
haemagglutination NN o
inhibition NN o
, , N
occurred VBD N
in IN N
27 CD N
out IN N
of IN N
192 CD N
students NNS N
in IN N
the DT N
amantadine NN i
group NN N
against IN N
57 CD N
out IN N
of IN N
199 CD N
in IN N
the DT N
placebo NN i
group NN N
, , N
giving VBG N
a DT N
protection NN N
rate NN N
of IN N
52 CD N
% NN N
. . N

-DOCSTART- -12139812- O O

[ NN N
Limbal NNP i
epithelial NN i
autograft NN i
transplantation NN i
in IN N
treatment NN N
of IN N
pterygium NN p
] NN N
. . N

OBJECTIVE UH N
To TO N
observe VB N
the DT N
therapeutic JJ N
effects NNS N
of IN N
limbal JJ i
epithelial JJ i
autograft NN i
transplantation NN i
and CC N
pterygium NN i
excision NN i
in IN N
the DT N
treatment NN N
of IN N
pterygium NN p
. . N

METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
paired-eye JJ N
trial NN N
was VBD N
studied VBN N
. . N

There EX N
were VBD N
208 CD p
patients NNS p
( ( p
229 CD p
eyes NNS p
) ) p
with IN p
initial JJ p
pterygium NN p
, , N
and CC N
they PRP N
were VBD N
allocated VBN N
to TO N
two CD N
groups NNS N
: : N
excision NN i
of IN i
pterygium NN i
with IN N
limbal JJ i
epithelial JJ i
autograft NN i
transplantation NN i
surgery NN i
( ( N
A NNP N
group NN N
, , N
106 CD N
cases NNS N
and CC N
124 CD N
eyes NNS N
) ) N
and CC N
simple JJ i
pterygium NN i
excision NN i
( ( N
B NNP N
group NN N
, , N
102 CD N
cases NNS N
and CC N
105 CD N
eyes NNS N
) ) N
. . N

The DT N
criteria NN N
for IN N
recovery NN N
were VBD N
corneal JJ N
transparency NN N
with IN N
stable JJ N
epithelial JJ o
healing NN o
and CC N
no DT N
abnormal JJ o
proliferation NN o
of IN o
pterygium-like JJ o
tissue NN o
. . N

The DT N
post-operative JJ N
follow-up JJ N
periods NNS N
ranged VBD N
from IN N
18 CD N
approximately RB N
28 CD N
( ( N
22.4 CD N
+/- JJ N
4.9 CD N
) ) N
months NNS N
. . N

RESULTS NNP N
Some DT N
of IN N
the DT N
patients NNS N
lost VBD N
follow-up JJ N
. . N

In IN N
the DT N
eyes NNS N
followed VBD N
up RB N
, , N
5 CD N
of IN N
11 CD N
2 CD N
eyes NNS N
( ( N
4.5 CD N
% NN N
) ) N
in IN N
A NNP N
group NN N
and CC N
41 CD N
of IN N
96 CD N
eyes NNS N
( ( N
42.7 CD N
% NN N
) ) N
in IN N
B NNP N
group NN N
were VBD N
recurred VBN N
, , N
the DT N
difference NN N
being VBG N
very RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
To TO N
provide VB N
a DT N
new JJ N
stem NN N
cell NN N
source NN N
, , N
limbal JJ i
epithelial JJ i
autograft NN i
transplantation NN i
, , N
for IN N
an DT N
injured JJ N
limb NN N
us PRP N
is VBZ N
a DT N
reasonable JJ N
therapeutic JJ N
method NN N
for IN N
the DT N
treatment NN N
of IN N
pterygium NN N
. . N

-DOCSTART- -18958161- O O

Neural JJ N
basis NN N
of IN N
self NN N
and CC N
other JJ N
representation NN N
in IN N
autism NN p
: : N
an DT N
FMRI NNP N
study NN N
of IN N
self-face JJ o
recognition NN o
. . N

BACKGROUND NNP N
Autism NNP N
is VBZ N
a DT N
developmental JJ N
disorder NN N
characterized VBN N
by IN N
decreased JJ N
interest NN N
and CC N
engagement NN N
in IN N
social JJ N
interactions NNS N
and CC N
by IN N
enhanced JJ N
self-focus NN N
. . N

While IN N
previous JJ N
theoretical JJ N
approaches NNS N
to TO N
understanding VBG N
autism NN N
have VBP N
emphasized VBN N
social JJ N
impairments NNS N
and CC N
altered VBD N
interpersonal JJ N
interactions NNS N
, , N
there EX N
is VBZ N
a DT N
recent JJ N
shift NN N
towards NNS N
understanding VBG N
the DT N
nature NN N
of IN N
the DT N
representation NN N
of IN N
the DT N
self NN N
in IN N
individuals NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . N

Still RB N
, , N
the DT N
neural JJ N
mechanisms NNS N
subserving VBG N
self-representations NNS N
in IN N
ASD NNP N
are VBP N
relatively RB N
unexplored JJ N
. . N

METHODOLOGY/PRINCIPAL NNP N
FINDINGS NNP N
We PRP N
used VBD N
event-related JJ N
fMRI NN N
to TO N
investigate VB N
brain NN o
responsiveness NN o
to TO N
images NNS N
of IN N
the DT N
subjects NNS N
' POS N
own JJ N
face NN N
and CC N
to TO N
faces VBZ N
of IN N
others NNS N
. . N

Children NNP p
with IN p
ASD NNP p
and CC p
typically RB p
developing VBG p
( ( p
TD NNP p
) ) p
children NNS p
viewed VBD N
randomly RB N
presented VBN N
digital JJ N
morphs NN N
between IN N
their PRP$ N
own JJ N
face NN N
and CC N
a DT N
gender-matched JJ N
other JJ N
face NN N
, , N
and CC N
made VBD N
self/other JJR N
judgments NNS N
. . N

Both DT N
groups NNS N
of IN N
children NNS N
activated VBD N
a DT N
right JJ o
premotor/prefrontal NN o
system NN o
when WRB N
identifying VBG N
images NNS N
containing VBG N
a DT N
greater JJR N
percentage NN N
of IN N
the DT N
self JJ N
face NN N
. . N

However RB N
, , N
while IN N
TD NNP N
children NNS N
showed VBD N
activation NN N
of IN N
this DT N
system NN N
during IN N
both DT N
self- JJ N
and CC N
other-processing JJ N
, , N
children NNS N
with IN N
ASD NNP N
only RB N
recruited VBD N
this DT N
system NN N
while IN N
viewing VBG N
images NNS N
containing VBG N
mostly RB N
their PRP$ N
own JJ N
face NN N
. . N

CONCLUSIONS/SIGNIFICANCE VB N
This DT N
functional JJ N
dissociation NN N
between IN N
the DT N
representation NN N
of IN N
self NN N
versus NN N
others NNS N
points NNS N
to TO N
a DT N
potential JJ N
neural JJ N
substrate NN N
for IN N
the DT N
characteristic JJ N
self-focus NN N
and CC N
decreased VBN N
social JJ N
understanding NN N
exhibited VBN N
by IN N
these DT N
individuals NNS N
, , N
and CC N
suggests VBZ N
that IN N
individuals NNS N
with IN N
ASD NNP N
lack VBP N
the DT N
shared JJ N
neural JJ N
representations NNS N
for IN N
self NN N
and CC N
others NNS N
that IN N
TD NNP N
children NNS N
and CC N
adults NNS N
possess NN N
and CC N
may MD N
use VB N
to TO N
understand VB N
others NNS N
. . N

-DOCSTART- -21718094- O O

Insulin NNP i
pump NN i
therapy NN N
started VBD N
at IN N
the DT N
time NN N
of IN N
diagnosis NN N
: : N
effects NNS N
on IN N
glycemic JJ o
control NN o
and CC N
pancreatic JJ o
?-cell NN o
function NN o
in IN N
type NN p
1 CD p
diabetes NNS p
. . N

BACKGROUND NNP N
In IN N
the DT N
interest NN N
of IN N
preserving VBG N
residual JJ N
insulin NN N
secretory NN N
capacity NN N
present NN N
at IN N
the DT N
time NN N
of IN N
diagnosis NN N
with IN N
type JJ p
1 CD p
diabetes NNS p
( ( p
T1D NNP p
) ) p
, , N
we PRP N
compared VBN N
the DT N
efficacy NN o
of IN N
starting VBG N
insulin JJ i
pump NN i
therapy NN N
at IN N
diagnosis NN N
with IN N
standard JJ N
multiple JJ N
daily JJ N
insulin NN i
injections NNS N
( ( N
MDIs NNP N
) ) N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
pilot JJ N
trial NN N
comparing VBG N
MDI NNP i
therapy NN N
with IN N
continuous JJ N
subcutaneous JJ N
insulin NN i
therapy NN i
( ( N
pump JJ i
therapy NN i
) ) N
in IN N
24 CD p
patients NNS p
, , p
8-18 CD p
years NNS p
old JJ p
, , p
with IN p
newly RB p
diagnosed VBN p
T1D NNP p
. . N

Subjects NNS N
were VBD N
evaluated VBN N
at IN N
enrollment NN N
and CC N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
initial JJ N
diagnosis NN N
of IN N
T1D NNP N
. . N

Preservation NN N
of IN o
insulin NN o
secretion NN o
, , o
measured VBN N
by IN N
mixed-meal-stimulated JJ o
C-peptide JJ o
secretion NN o
, , N
was VBD N
compared VBN N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
of IN N
treatment NN N
. . N

Between-group JJ N
differences NNS N
in IN N
glycosylated JJ o
hemoglobin NN o
( ( o
HbA1c NNP o
) ) o
, , o
continuous JJ o
glucose NN o
sensor NN o
data NNS o
, , o
insulin NN o
utilization NN o
, , o
anthropometric JJ o
measures NNS o
, , o
and CC o
patient JJ o
satisfaction NN o
with IN N
therapy NN N
were VBD N
also RB N
compared VBN N
at IN N
multiple JJ N
time NN N
points NNS N
. . N

RESULTS NNP N
Initiation NNP N
of IN N
pump NN i
therapy NN i
within IN N
1 CD N
month NN N
of IN N
diagnosis NN N
resulted VBD N
in IN N
consistently RB N
higher JJR N
mixed-meal JJ o
tolerance NN o
test-stimulated JJ o
C-peptide JJ o
values NNS o
at IN N
all DT N
time NN N
points NNS N
, , N
although IN N
these DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Nonetheless NNP N
, , N
improved JJ N
glycemic JJ o
control NN o
was VBD N
observed VBN N
in IN N
insulin JJ i
pump-treated JJ N
subjects NNS N
( ( N
more JJR N
time NN N
spent VBN N
with IN N
normoglycemia NN N
, , N
better JJR N
mean JJ N
HbA1c NNP o
) ) N
, , N
and CC N
pump-treated JJ N
subjects NNS N
reported VBN N
comparatively RB N
greater JJR N
satisfaction NN o
with IN N
route NN N
of IN N
treatment NN N
administration NN N
. . N

CONCLUSIONS NNP N
Initiation NNP N
of IN N
insulin NN i
pump NN i
therapy NN i
at IN N
diagnosis NN N
improved JJ N
glycemic JJ o
control NN o
, , N
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
contributed VBD N
to TO N
improved VBN N
patient JJ o
satisfaction NN o
with IN N
treatment NN N
. . N

This DT N
study NN N
also RB N
suggests VBZ N
that IN N
earlier JJR N
use NN N
of IN N
pump NN N
therapy NN N
might MD N
help VB N
to TO N
preserve VB N
residual JJ o
?-cell NNP o
function NN o
, , N
although IN N
a DT N
larger JJR N
clinical JJ N
trial NN N
would MD N
be VB N
required VBN N
to TO N
confirm VB N
this DT N
. . N

-DOCSTART- -18189160- O O

Feasibility NN N
of IN N
two CD N
dose-dense JJ N
FEC NNP i
regimens VBZ N
with IN N
growth NN N
factor NN N
support NN N
for IN N
adjuvant JJ N
therapy NN N
in IN N
patients NNS p
with IN p
early JJ p
breast NN p
cancer NN p
: : N
results NNS N
from IN N
a DT N
randomised JJ N
study NN N
of IN N
the DT N
Central NNP N
European NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
( ( N
CECOG NNP N
) ) N
. . N

Addition NN N
of IN N
epirubicin NN i
to TO N
adjuvant VB N
chemotherapy NN N
can MD N
provide VB N
important JJ N
benefits NNS N
for IN N
patients NNS p
with IN p
early JJ p
breast NN p
cancer NN p
, , N
but CC N
the DT N
optimal JJ N
dose NN N
remains VBZ N
unclear JJ N
. . N

Further JJ N
improvements NNS N
can MD N
be VB N
achieved VBN N
with IN N
dose-dense JJ N
regimens NNS N
, , N
but CC N
densification NN N
of IN N
fluorouracil/epirubicin/cyclophosphamide NN i
( ( i
FEC NNP i
) ) i
has VBZ N
proved VBN N
difficult JJ N
, , N
with IN N
FEC NNP N
( ( N
60 CD N
) ) N
providing VBG N
little JJ N
benefit NN N
over IN N
standard JJ N
chemotherapy NN N
and CC N
FEC NNP i
( ( N
100 CD N
) ) N
associated VBN N
with IN N
toxicity NN N
. . N

We PRP N
investigated VBD N
the DT N
feasibility NN N
of IN N
two CD N
intermediate JJ N
dose-dense JJ N
FEC NNP i
regimens NNS N
. . N

Patients NNS N
were VBD N
randomised VBN N
to TO N
six CD N
cycles NNS N
of IN N
FEC NNP i
( ( N
75 CD N
) ) N
or CC N
FEC NNP i
( ( N
90 CD N
) ) N
, , N
with IN N
all DT N
three CD N
drugs NNS N
given VBN N
on IN N
day NN N
1 CD N
of IN N
each DT N
14-day JJ N
cycle NN N
. . N

Patients NNS N
also RB N
received VBD N
pegfilgrastim JJ i
6 CD N
mg NN N
as IN N
a DT N
single JJ N
subcutaneous JJ N
injection NN N
on IN N
day NN N
2 CD N
of IN N
each DT N
cycle NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
the DT N
proportion NN o
of IN o
subjects NNS o
receiving VBG o
> NN o
or CC o
=85 CD o
% NN o
relative JJ o
dose JJ o
intensity NN o
and CC N
was VBD N
achieved VBN N
by IN N
96 CD N
% NN N
and CC N
88 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
FEC NNP N
( ( N
75 CD N
) ) N
and CC N
FEC NNP N
( ( N
90 CD N
) ) N
arms NNS N
, , N
respectively RB N
. . N

Of IN N
147 CD N
FEC NNP i
( ( N
75 CD N
) ) N
infusions NNS N
, , N
4.1 CD N
% NN N
were VBD N
delayed VBN N
, , N
while IN N
9.8 CD N
% NN N
of IN N
143 CD N
FEC NNP i
( ( N
90 CD N
) ) N
infusions NNS N
were VBD N
delayed VBN N
. . N

The DT N
most RBS N
common JJ N
reasons NNS N
for IN N
delay NN N
were VBD N
adverse JJ o
events NNS o
and CC N
personal/logistical JJ N
reasons NNS N
. . N

One CD N
dose JJ N
reduction NN N
occurred VBD N
during IN N
the DT N
study NN N
( ( N
FEC NNP i
( ( N
90 CD N
) ) N
) ) N
, , N
related VBN N
to TO N
diarrhoea VB o
. . N

Grade VB N
3-4 JJ N
haematological JJ o
toxicities NNS o
were VBD N
reported VBN N
in IN N
two CD N
patients NNS N
in IN N
the DT N
FEC NNP i
( ( N
90 CD N
) ) N
arm NN N
. . N

There EX N
were VBD N
no DT N
incidences NNS N
of IN N
febrile JJ o
neutropenia NN o
during IN N
the DT N
study NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
were VBD N
increases NNS N
in IN N
liver NN o
enzymes NNS o
and CC o
gastrointestinal JJ o
events NNS o
; : N
no DT N
event NN N
resulted VBD N
in IN N
discontinuation NN N
. . N

Only RB N
one CD N
patient NN N
( ( N
FEC NNP i
( ( N
90 CD N
) ) N
) ) N
experienced VBD N
serious JJ o
adverse JJ o
events NNS o
( ( o
vomiting VBG o
and CC o
throat VB o
oedema NN o
) ) o
. . N

In IN N
conclusion NN N
, , N
dose-dense JJ N
FEC NNP i
( ( N
75 CD N
) ) N
and CC N
FEC NNP i
( ( N
90 CD N
) ) N
are VBP N
feasible JJ N
with IN N
pegfilgrastim JJ N
support NN N
. . N

These DT N
regimens NNS N
are VBP N
associated VBN N
with IN N
a DT N
very RB N
low JJ N
risk NN N
of IN N
Grade NNP N
3-4 JJ N
toxicity NN N
. . N

-DOCSTART- -26210844- O O

A DT N
New NNP N
Interactive NNP i
Screening NNP i
Test NNP i
for IN N
Autism NNP p
Spectrum NNP p
Disorders NNP p
in IN p
Toddlers NNP p
. . N

OBJECTIVE NNP N
To TO N
develop VB N
a DT N
clinically RB N
valid JJ N
interactive JJ N
level NN N
2 CD N
screening NN N
assessment NN N
for IN N
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
in IN p
toddlers NNS p
that WDT N
is VBZ N
brief JJ N
, , N
easily RB N
administered VBN N
, , N
and CC N
scored VBN N
by IN N
clinicians NNS N
. . N

STUDY NNP N
DESIGN NNP N
We PRP N
describe VBP N
the DT N
development NN N
, , N
training NN N
, , N
standardization NN N
, , N
and CC N
validation NN N
of IN N
the DT N
Rapid NNP i
Interactive NNP i
Screening NNP i
Test NNP i
for IN N
Autism NNP N
in IN N
Toddlers NNP p
( ( N
RITA-T NNP N
) ) N
with IN N
ASD-specific NNP N
diagnostic JJ N
instruments NNS N
. . N

The DT N
RITA-T JJ i
can MD N
be VB N
administered VBN N
and CC N
scored VBN N
in IN N
10 CD N
minutes NNS N
. . N

We PRP N
studied VBD N
the DT N
validity NN N
of IN N
the DT N
RITA-T NNP i
to TO N
distinguish VB N
between IN N
toddlers NNS p
with IN p
ASD NNP p
from IN p
toddlers NNS p
with IN p
developmental JJ p
delay NN p
( ( p
DD NNP p
) ) p
/non-ASD NN p
in IN p
an DT p
early JJ p
childhood NN p
clinic NN p
. . N

We PRP N
also RB N
evaluated VBD N
the DT N
test NN N
's POS N
performance NN N
in IN N
toddlers NNS p
with IN p
no DT p
developmental JJ p
concerns NNS p
. . N

We PRP N
identified VBD N
a DT N
cutoff NN o
score NN o
based VBN N
on IN N
sensitivity NN o
, , o
specificity NN o
, , o
and CC o
positive JJ o
predictive JJ o
value NN o
of IN N
the DT N
RITA-T NNP o
that WDT N
best JJS N
differentiates NNS N
between IN N
ASD NNP N
and CC N
DD/non-ASD NNP N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
61 CD p
toddlers NNS p
were VBD N
enrolled VBN N
. . N

RITA-T JJ o
scores NNS o
were VBD N
correlated VBN N
with IN N
ASD-specific NNP N
diagnostic JJ N
tools NNS N
( ( N
r VB N
= RB N
0.79 CD N
; : N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
ASD NNP N
clinical JJ N
diagnoses NNS N
( ( N
r VB N
= RB N
0.77 CD N
; : N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Mean JJ N
scores NNS o
were VBD N
significantly RB N
different JJ N
in IN N
subjects NNS N
with IN N
ASD NNP N
, , N
those DT N
with IN N
DD/non-ASD NNP N
, , N
and CC N
those DT N
with IN N
no DT N
developmental JJ N
concerns NNS N
( ( N
20.8 CD N
vs RB N
13 CD N
vs NN N
10.6 CD N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

At IN N
a DT N
cutoff NN N
score NN N
of IN N
> $ N
14 CD N
, , N
the DT N
RITA-T NNP i
had VBD N
a DT N
sensitivity NN N
of IN N
1.00 CD N
, , N
specificity NN N
of IN N
0.84 CD N
, , N
and CC N
positive JJ N
predictive JJ N
value NN N
of IN N
0.88 CD N
for IN N
identifying VBG N
ASD NNP N
risk NN N
in IN N
a DT N
high-risk JJ N
group NN N
. . N

CONCLUSION VB N
The DT N
RITA-T NNP i
is VBZ N
a DT N
promising JJ N
new JJ N
level NN N
2 CD N
interactive JJ N
screening VBG N
tool NN N
for IN N
improving VBG N
the DT N
early JJ N
identification NN N
of IN N
ASD NNP p
in IN p
toddlers NNS p
in IN N
general JJ N
pediatric NN N
and CC N
early JJ N
intervention NN N
settings NNS N
and CC N
allowing VBG N
access NN N
to TO N
treatment NN N
. . N

-DOCSTART- -25784723- O O

Regional JJ N
ventricular JJ N
performance NN N
and CC N
exercise NN i
training NN i
in IN N
children NNS p
and CC p
young JJ p
adults NNS p
after IN p
repair NN p
of IN p
tetralogy NN p
of IN p
Fallot NN p
: : N
randomized VBN N
controlled VBD N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Public-health NNP N
guidelines NNS N
recommend VBP N
patients NNS p
with IN p
congenital JJ p
heart NN p
disease NN p
to TO N
exercise VB N
. . N

Studies NNS N
have VBP N
shown VBN N
that IN N
patients NNS N
with IN N
congenital JJ N
heart NN N
disease NN N
can MD N
improve VB N
physical JJ N
exercise NN N
capacity NN N
. . N

The DT N
effect NN N
of IN N
training VBG i
on IN N
regional JJ N
ventricular JJ N
performance NN N
has VBZ N
hardly RB N
been VBN N
studied VBN N
. . N

We PRP N
performed VBD N
a DT N
pilot NN N
study NN N
to TO N
assess VB N
whether IN N
an DT N
exercise NN i
training NN i
program NN i
would MD N
result VB N
in IN N
adverse JJ N
changes NNS N
of IN N
regional JJ N
ventricular JJ N
performance NN N
in IN N
patients NNS p
with IN p
corrected JJ p
tetralogy NN p
of IN p
Fallot NNP p
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Multicenter NNP N
prospective JJ N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
in IN N
patients NNS p
with IN p
tetralogy NN p
of IN p
Fallot NNP p
aged VBD p
10 CD p
to TO p
25 CD p
years NNS p
. . N

A DT N
12-week JJ N
standardized JJ N
aerobic JJ N
dynamic JJ N
exercise NN i
training NN i
program NN i
( ( N
3 CD N
one-hour JJ N
sessions NNS N
per IN N
week NN N
) ) N
was VBD N
used VBN N
. . N

Pre- JJ N
and CC N
post-training JJ N
cardiopulmonary JJ o
exercise NN o
tests NNS o
, , o
MRI NNP o
, , o
and CC o
echocardiography NN o
, , o
including VBG o
tissue-Doppler NN o
imaging NN o
, , N
were VBD N
performed VBN N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
exercise NN i
group NN N
( ( N
n=28 JJ N
) ) N
or CC N
control VB i
group NN N
( ( N
n=20 RB N
) ) N
. . N

One CD N
patient NN N
in IN N
the DT N
exercise NN i
group NN N
dropped VBD N
out RP N
. . N

Change VB o
in IN o
tissue-Doppler NN o
imaging NN o
parameters NNS o
was VBD N
similar JJ N
in IN N
the DT N
exercise NN i
group NN N
and CC N
control NN i
group NN N
( ( N
change NN N
in IN N
right JJ N
ventricle NN N
free JJ N
wall NN N
peak NN N
velocity NN N
E NNP N
' POS N
exercise NN N
group NN N
, , N
0.8?2.6 CD N
cm/s NN N
; : N
control NN N
group NN N
, , N
0.9?4.1 CD N
; : N
peak JJ N
velocity NN N
A NNP N
' POS N
exercise NN N
group NN N
, , N
0.4?2.4 CD N
m/s NN N
; : N
control NN N
group NN N
4.6?18.1 CD N
cm/s NN N
) ) N
. . N

CONCLUSIONS VB N
This DT N
randomized VBN N
controlled VBD N
pilot NN N
study NN N
provides VBZ N
preliminary JJ N
data NNS N
suggesting VBG N
that IN N
regional JJ N
ventricular JJ N
performance NN N
is VBZ N
well RB N
maintained VBN N
during IN N
3-month JJ N
aerobic JJ N
dynamic JJ N
exercise NN i
training NN i
in IN N
children NNS p
and CC p
young JJ p
adults NNS p
with IN p
repaired JJ p
tetralogy NN p
of IN p
Fallot NNP p
. . N

This DT N
information NN N
might MD N
help VB N
patients NNS N
adhere VB N
to TO N
current JJ N
public-health NN N
guidelines NNS N
. . N

CLINICAL JJ N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
http// NN N
: : N
www.trialregister.nl NN N
. . N

Unique NNP N
identifier NN N
: : N
NTR2731 NNP N
. . N

-DOCSTART- -7598243- O O

The DT N
efficacy NN N
of IN N
prophylactic JJ N
ondansetron NN i
, , N
droperidol NN i
, , N
perphenazine NN i
, , N
and CC N
metoclopramide RB i
in IN N
the DT N
prevention NN N
of IN N
nausea NN N
and CC N
vomiting NN N
after IN N
major JJ N
gynecologic NN N
surgery NN N
. . N

The DT N
prophylactic JJ N
antiemetic JJ N
efficacy NN N
of IN N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
ondansetron NN i
, , N
droperidol NN i
, , N
perphenazine NN i
, , N
and CC N
metoclopramide NN i
was VBD N
evaluated VBN N
in IN N
a DT N
prospective JJ N
, , N
double-blind JJ N
study NN N
of IN N
360 CD p
ASA NNP p
physical JJ p
status NN p
I-III NNP p
patients NNS p
undergoing VBG p
total JJ p
abdominal JJ p
hysterectomy NN p
( ( p
TAH NNP p
) ) p
. . N

Subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
i.v. NN N
, , N
one CD N
of IN N
ondansetron NN i
4 CD N
mg NN N
, , N
droperidol VBZ i
1.25 CD N
mg NN N
, , N
perphenazine VBP i
5 CD N
mg NN N
, , N
metoclopramide RB i
10 CD N
mg NN N
, , N
or CC N
placebo RB i
prior JJ N
to TO N
induction NN N
of IN N
anesthesia NN N
. . N

Hypotension NNP o
immediately RB N
after IN N
administration NN N
of IN N
metoclopramide NN i
was VBD N
observed VBN N
in IN N
two CD N
patients NNS N
and CC N
four CD N
patients NNS N
given VBN N
ondansetron RP N
developed JJ N
profound NN N
systolic JJ N
hypotension NN N
at IN N
induction NN N
of IN N
anesthesia NN N
. . N

Twenty-two JJ N
percent NN N
of IN N
patients NNS N
receiving VBG N
droperidol NN N
became VBD N
sedated JJ N
. . N

Postoperatively RB N
, , N
patients NNS N
developing VBG N
severe JJ o
nausea NN o
, , o
retching NN o
, , o
or CC o
vomiting NN o
, , N
defined VBD N
as IN N
severe JJ o
emetic JJ o
sequelae NN o
( ( o
SES NNP o
) ) o
, , N
were VBD N
deemed VBN N
to TO N
have VB N
failed VBN N
antiemetic JJ N
prophylaxis NN N
and CC N
received VBN N
antiemetic JJ N
rescue NN N
. . N

A DT N
significantly RB N
larger JJR N
number NN N
of IN N
patients NNS N
who WP N
received VBD N
i.v NN N
. . N

ondansetron NN N
( ( N
63 CD N
% NN N
) ) N
, , N
droperidol NN N
( ( N
76 CD N
% NN N
) ) N
, , N
and CC N
perphenazine NN N
( ( N
70 CD N
% NN N
) ) N
were VBD N
free JJ N
of IN N
SES NNP o
when WRB N
compared VBN N
to TO N
placebo VB N
( ( N
43 CD N
% NN N
) ) N
; : N
P NNP N
< VBD N
0.05 CD N
. . N

Metoclopramide NNP N
was VBD N
ineffective JJ N
. . N

Although IN N
ondansetron NN N
, , N
droperidol NN N
, , N
and CC N
perphenazine NN N
were VBD N
effective JJ o
in IN N
providing VBG N
antiemetic JJ N
prophylaxis NN N
, , N
only RB N
i.v NN N
. . N

perphenazine NN N
was VBD N
free JJ N
of IN N
side JJ o
effects NNS o
. . N

Hence NNP N
, , N
we PRP N
conclude VBP N
that DT N
perphenazine NN N
is VBZ N
the DT N
best JJS N
choice NN N
for IN N
antiemetic JJ N
prophylaxis NN N
after IN N
TAH NNP N
. . N

-DOCSTART- -11750293- O O

The DT N
course NN N
of IN N
depression NN N
in IN N
recent JJ p
onset NN p
rheumatoid NN p
arthritis NN p
: : N
the DT N
predictive JJ N
role NN N
of IN N
disability NN o
, , o
illness JJ o
perceptions NNS o
, , o
pain NN o
and CC o
coping NN o
. . N

BACKGROUND NNP N
This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
course NN N
of IN N
depression NN N
for IN N
patients NNS p
with IN p
recently RB p
diagnosed VBN p
rheumatoid NN p
arthritis NN p
( ( p
RA NNP p
) ) p
and CC N
to TO N
investigate VB N
predictors NNS N
of IN N
depression NN o
. . N

METHODS NNP N
Twenty-two JJ p
patients NNS p
with IN p
a DT p
history NN p
of IN p
recently RB p
diagnosed VBN p
RA NNP p
of IN p
less JJR p
than IN p
2 CD p
years NNS p
were VBD N
assessed VBN N
on IN N
a DT N
variety NN N
of IN N
clinical JJ o
outcome NN o
and CC o
process NN o
measures NNS o
on IN N
six CD N
assessment JJ N
occasions NNS N
over IN N
a DT N
21-month JJ N
period NN N
. . N

These DT N
22 CD p
patients NNS p
constituted VBD N
the DT N
control NN N
group NN N
of IN N
a DT N
controlled VBN N
trial NN N
and CC N
received VBN N
standard JJ i
outpatient NN i
clinic JJ i
treatment NN i
during IN N
follow-up JJ N
. . N

RESULTS JJ N
Patients NNPS N
became VBD N
significantly RB N
more RBR N
depressed JJ N
over IN N
time NN N
. . N

A DT N
set NN N
of IN N
five CD N
factors NNS N
were VBD N
found VBN N
to TO N
consistently RB N
predict VB o
depression NN o
at IN N
the DT N
following JJ N
assessment NN N
. . N

These DT N
were VBD N
initial JJ N
level NN N
of IN N
depression NN o
, , o
disability NN o
, , o
pain NN o
, , o
beliefs VB o
about IN o
the DT o
consequences NNS o
of IN o
arthritis NN o
and CC o
coping VBG o
strategies NNS o
. . N

CONCLUSIONS VB N
The DT N
results NNS N
confirm VBP N
the DT N
importance NN N
of IN N
psychological JJ N
factors NNS N
in IN N
early JJ N
RA NNP N
and CC N
their PRP$ N
relative JJ N
independence NN N
from IN N
physical JJ N
findings NNS N
. . N

This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
document VB N
the DT N
importance NN N
of IN N
illness JJ N
perceptions NNS N
in IN N
recent JJ N
onset NN N
RA NNP N
. . N

-DOCSTART- -20226474- O O

Cryoprobe NNP i
biopsy NN i
increases VBZ N
the DT N
diagnostic JJ N
yield NN N
in IN N
endobronchial JJ p
tumor NN p
lesions NNS p
. . N

OBJECTIVE NNP N
Forceps NNP N
biopsy NN N
is VBZ N
the DT N
standard JJ N
method NN N
to TO N
obtain VB N
specimens NNS N
in IN N
endoscopically RB N
visible JJ N
lesions NNS N
. . N

It PRP N
is VBZ N
common JJ N
to TO N
combine VB N
forceps NNS N
biopsy VB N
with IN N
cytology NN N
methods NNS N
to TO N
increase VB N
the DT N
diagnostic JJ N
yield NN N
. . N

Although IN N
the DT N
flexible JJ N
cryoprobe NN i
has VBZ N
been VBN N
established VBN N
for IN N
bronchoscopic NN N
interventions NNS N
in IN N
malignant JJ N
stenosis NN N
, , N
the DT N
obtained JJ N
biopsies NNS N
, , N
called VBN N
cryobiopsies NNS N
, , N
have VBP N
not RB N
been VBN N
investigated VBN N
in IN N
a DT N
large JJ N
cohort NN N
of IN N
patients NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
feasibility NN N
study NN N
was VBD N
to TO N
prospectively RB N
evaluate VB N
the DT N
diagnostic JJ N
yield NN N
and CC N
safety NN N
of IN N
cryobiopsy NN i
and CC N
forceps JJ i
biopsy NN i
. . N

METHODS NNP N
During IN N
a DT N
6-year JJ N
period NN N
, , N
296 CD p
patients NNS p
with IN p
visible JJ p
endoluminal JJ p
tumor NN p
lesions NNS p
were VBD p
included VBN p
in IN N
the DT N
study NN N
at IN N
the DT N
bronchoscopy NN N
unit NN N
of IN N
a DT N
university NN N
hospital NN N
. . N

In IN N
the DT N
first JJ N
consecutively RB N
conducted VBN N
55 CD N
cases NNS N
, , N
both DT N
techniques NNS N
, , N
forceps NNS i
biopsy NN i
and CC i
cryobiopsy NN i
, , N
were VBD N
applied VBN N
simultaneously RB N
. . N

Pathologic NNP N
and CC N
quantitative JJ N
image NN N
analyses NNS N
were VBD N
performed VBN N
to TO N
evaluate VB N
the DT N
size NN N
and CC N
quality NN N
of IN N
the DT N
obtained VBN N
specimens NNS N
. . N

We PRP N
evaluated VBD N
the DT N
safety NN o
and CC N
diagnostic JJ o
yield NN o
to TO N
describe VB N
the DT N
feasibility NN N
of IN N
cryobiopsy NN i
. . N

RESULTS NNP N
Comparative JJ N
analysis NN N
of IN N
the DT N
first JJ N
conducted VBN N
and CC N
randomly RB N
assigned VBD N
55 CD N
cases NNS N
revealed VBD N
a DT N
significantly RB N
higher RBR N
diagnostic JJ o
yield NN o
for IN N
cryobiopsy NN i
compared VBN N
with IN N
forceps NNS i
biopsy NNS i
( ( N
89.1 CD N
% NN N
vs JJ N
65.5 CD N
% NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

In IN N
this DT N
cohort NN N
, , N
quantitative JJ N
image NN N
analysis NN N
showed VBD N
significantly RB N
larger JJR N
biopsies NNS N
regarding VBG N
size NN o
and CC N
artifact-free JJ N
tissue NN N
sections NNS N
for IN N
cryobiopsy NN i
compared VBN N
with IN N
forceps NNS i
biopsy NN i
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

The DT N
overall JJ N
diagnostic JJ o
yield NN o
of IN N
cryobiopsy NN i
was VBD N
89.5 CD N
% NN N
. . N

Mild NNP N
bleeding VBG o
occurred VBD N
in IN N
11 CD N
cases NNS N
( ( N
3.7 CD N
% NN N
) ) N
, , N
moderate JJ N
bleeding NN o
occurred VBD N
in IN N
3 CD N
cases NNS N
( ( N
1.0 CD N
% NN N
) ) N
, , N
and CC N
severe JJ N
bleeding NN o
occurred VBD N
in IN N
1 CD N
case NN N
( ( N
0.3 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
Cryobiopsy NNP i
is VBZ N
safe JJ o
and CC N
increases VBZ N
the DT N
diagnostic JJ o
yield NN o
in IN N
endobronchial JJ N
tumor NN N
lesions NNS N
. . N

The DT N
method NN N
also RB N
is VBZ N
feasible JJ o
under IN N
routine JJ N
conditions NNS N
. . N

-DOCSTART- -2088233- O O

The DT N
immediate JJ o
efficacy NN o
of IN N
adjunctive JJ N
doxycycline NN i
in IN N
treatment NN N
of IN N
localized VBN p
juvenile NN p
periodontitis NN p
. . N

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
on IN N
the DT N
immediate JJ o
clinical JJ o
and CC o
microbiological JJ o
efficacy NN o
of IN N
doxycycline NN i
( ( N
100 CD N
mg NN N
for IN N
14 CD N
days NNS N
) ) N
was VBD N
carried VBN N
out IN N
to TO N
determine VB N
the DT N
benefit NN N
of IN N
adjunctive JJ N
medication NN N
in IN N
16 CD p
patients NNS p
with IN p
localized JJ p
juvenile NN p
periodontitis NN p
. . N

Measurements NNS N
of IN N
gingival NN o
fluid NN o
flow NN o
, , o
probing VBG o
depths NNS o
, , o
bleeding VBG o
on IN o
probing VBG o
and CC o
suppuration NN o
were VBD N
determined VBN N
at IN N
2 CD N
periodontal JJ N
sites NNS N
with IN N
and CC N
2 CD N
without IN N
radiographic JJ N
attachment JJ N
loss NN N
, , N
at IN N
weeks NNS N
0 CD N
, , N
1 CD N
, , N
3 CD N
and CC N
8 CD N
. . N

Subgingival JJ o
bacterial JJ o
samples NNS o
were VBD N
taken VBN N
with IN N
curettes NNS N
from IN N
the DT N
same JJ N
sites NNS N
. . N

Spirochaetes NNS o
were VBD N
searched VBN N
for IN N
by IN N
dark-field JJ o
microscopy NN o
. . N

Actinobacillus CC N
actinomycetemcomitans NNS N
, , N
pigmented VBN N
and CC N
non-pigmented JJ N
Bacteroides NNP N
spp. NN N
, , N
Capnocytophaga NNP N
, , N
Fusobacterium NNP N
and CC N
Actinomyces NNP N
spp NN N
. . N

were VBD N
cultured VBN N
on IN N
various JJ N
selective JJ N
and CC N
non-selective JJ N
media NNS N
. . N

Bacterial JJ N
species NNS N
found VBN N
at IN N
least JJS N
in IN N
50 CD N
% NN N
of IN N
the DT N
patients NNS N
and CC N
comprising VBG N
on IN N
average JJ N
5 CD N
% NN N
or CC N
more JJR N
of IN N
the DT N
cultivable JJ N
flora NNS N
were VBD N
included VBN N
in IN N
the DT N
analysis NN N
. . N

Neither CC N
short-term JJ o
clinical JJ o
nor CC o
microbiological JJ o
efficacy NN o
beyond IN N
that DT N
of IN N
a DT N
course NN N
of IN N
mechanical JJ N
debridement NN N
alone RB N
was VBD N
found VBN N
by IN N
using VBG N
systemic JJ N
medication NN N
with IN N
doxycycline NN i
in IN N
patients NNS p
with IN p
localized JJ p
juvenile NN p
periodontitis NN p
. . N

-DOCSTART- -18975051- O O

Bolus NNP N
injection NN N
of IN N
contrast NN N
agents NNS N
with IN N
various JJ N
iodine JJ N
concentrations NNS N
and CC N
delivery NN N
rates NNS N
for IN N
intracranial JJ N
three-dimensional JJ N
CT NNP N
angiography NN N
: : N
evaluation NN N
of IN N
intracranial JJ o
arteriovenous JJ o
contrast NN o
using VBG N
a DT N
multidetector-row JJ N
CT NNP N
scanner NN N
. . N

PURPOSE NNP N
We PRP N
evaluated VBD N
the DT N
difference NN o
in IN N
computed JJ N
tomography NN N
( ( N
CT NNP N
) ) N
attenuation NN N
values NNS N
of IN N
the DT N
intracranial JJ N
arterial NN N
and CC N
venous JJ N
systems NNS N
among IN N
the DT N
various JJ N
contrast NN N
injection NN N
protocols NNS N
( ( N
higher JJR N
iodine NN N
delivery NN N
rate NN N
or CC N
higher JJR N
concentration NN N
of IN N
the DT N
agent NN N
) ) N
on IN N
the DT N
source NN N
images NNS N
of IN N
intracranial JJ N
three-dimensional JJ N
CT NNP N
angiography NN N
( ( N
3D-CTA JJ N
) ) N
using VBG N
a DT N
multidetector-row JJ N
CT NNP N
( ( N
MDCT NNP N
) ) N
scanner NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
We PRP N
used VBD N
100 CD N
ml NN N
of IN N
iopamidol JJ i
300 CD N
at IN N
an DT N
injection NN N
rate NN N
of IN N
3.0 CD N
ml/s NNS N
, , N
100 CD N
ml NN N
of IN N
iopamidol JJ i
300 CD N
at IN N
an DT N
injection NN N
rate NN N
of IN N
3.7 CD N
ml/s NN N
, , N
and CC N
80 CD N
ml NN N
of IN N
iopamidol JJ i
370 CD N
at IN N
an DT N
injection NN N
rate NN N
of IN N
3.0 CD N
ml/s NN N
. . N

There EX N
were VBD N
10 CD p
patients NNS p
in IN p
each DT p
group NN p
. . N

Attenuation NNP o
values NNS o
of IN o
the DT o
bilateral JJ o
internal JJ o
carotid NN o
arteries NNS o
( ( o
ICAs NNP o
) ) o
, , o
basilar JJ o
artery NN o
trunk NN o
, , o
bilateral JJ o
cavernous JJ o
sinuses NNS o
( ( o
CSs NNP o
) ) o
, , o
and CC o
Galenic NNP o
vein NNS o
were VBD N
measured VBN N
quantitatively RB N
on IN N
the DT N
axial JJ N
CT NNP N
angiographic JJ N
source NN N
images NNS N
obtained VBN N
by IN N
four-channel JJ N
MDCT NNP N
. . N

RESULTS NNP N
Injection NNP N
of IN N
the DT N
high-concentration NN N
contrast NN N
with IN N
a DT N
higher JJR N
iodine-delivery JJ N
rate NN N
achieved VBN N
good JJ N
arteriovenous JJ o
contrast NN o
at IN N
the DT N
cavernous JJ N
portion NN N
. . N

With IN N
the DT N
same JJ N
rate NN N
of IN N
iodine NN N
delivery NN N
, , N
injection NN N
of IN N
the DT N
intermediate JJ N
concentrate NN N
agent NN N
increased VBD N
the DT N
CT NNP o
value NN o
of IN N
not RB N
only RB N
the DT N
ICAs NNP N
but CC N
also RB N
the DT N
CSs NNP N
. . N

CONCLUSION NNP N
High-concentration NNP N
contrast NN N
could MD N
increase VB N
ICA NNP o
attenuation NN o
without IN N
intracavernous JJ o
attenuation NN o
gain NN N
during IN N
the DT N
first-pass JJ N
phase NN N
. . N

-DOCSTART- -20509069- O O

Virtual JJ i
reality NN i
hypnosis NN i
for IN N
pain NN N
associated VBN N
with IN N
recovery NN N
from IN N
physical JJ p
trauma NN p
. . N

Pain VB N
following VBG N
traumatic JJ p
injuries NNS p
is VBZ N
common JJ N
, , N
can MD N
impair VB N
injury JJ N
recovery NN N
and CC N
is VBZ N
often RB N
inadequately RB N
treated VBN N
. . N

In IN N
particular JJ N
, , N
the DT N
role NN N
of IN N
adjunctive JJ N
nonpharmacologic JJ N
analgesic JJ N
techniques NNS N
is VBZ N
unclear JJ N
. . N

The DT N
authors NNS N
report VBP N
a DT N
randomized VBN N
, , N
controlled VBD N
study NN N
of IN N
21 CD p
hospitalized JJ p
trauma NN p
patients NNS p
to TO N
assess VB N
the DT N
analgesic JJ N
efficacy NN N
of IN N
virtual JJ i
reality NN i
hypnosis NN i
( ( i
VRH NNP i
) ) i
-hypnotic JJ i
induction NN i
and CC N
analgesic JJ N
suggestion NN N
delivered VBN N
by IN N
customized JJ N
virtual JJ N
reality NN N
( ( N
VR NNP N
) ) N
hardware/software NN N
. . N

Subjective JJ o
pain NN o
ratings NNS o
were VBD N
obtained VBN N
immediately RB N
and CC N
8 CD N
hours NNS N
after IN N
VRH NNP N
( ( N
used VBN N
as IN N
an DT N
adjunct NN N
to TO N
standard VB N
analgesic JJ N
care NN N
) ) N
and CC N
compared VBN N
to TO N
both DT N
adjunctive JJ N
VR NNP N
without IN N
hypnosis NN N
and CC N
standard JJ N
care NN N
alone RB N
. . N

VRH JJ N
patients NNS N
reported VBD N
less RBR N
pain JJ o
intensity NN o
and CC N
less JJR N
pain NN o
unpleasantness JJ o
compared VBN N
to TO N
control VB N
groups NNS N
. . N

These DT N
preliminary JJ N
findings NNS N
suggest VBP N
that IN N
VRH NNP i
analgesia NN N
is VBZ N
a DT N
novel JJ N
technology NN N
worthy NN N
of IN N
further JJ N
study NN N
, , N
both DT N
to TO N
improve VB N
pain NN o
management NN o
and CC N
to TO N
increase VB N
availability NN N
of IN N
hypnotic JJ N
analgesia NN N
to TO N
populations NNS N
without IN N
access NN N
to TO N
therapist-provided JJ N
hypnosis NN N
and CC N
suggestion NN N
. . N

-DOCSTART- -22341427- O O

Intermediate-term JJ N
mortality NN N
and CC N
cardiac JJ i
transplantation NN i
in IN N
infants NNS p
with IN p
single-ventricle JJ p
lesions NNS p
: : N
risk NN N
factors NNS N
and CC N
their PRP$ N
interaction NN N
with IN N
shunt NN N
type NN N
. . N

OBJECTIVE CC N
The DT N
study NN N
objective NN N
was VBD N
to TO N
identify VB N
factors NNS N
associated VBN N
with IN N
death NN N
and CC N
cardiac JJ i
transplantation NN i
in IN N
infants NNS p
undergoing VBG p
the DT p
Norwood NNP p
procedure NN p
and CC N
to TO N
determine VB N
differences NNS N
in IN N
associations NNS N
that WDT N
might MD N
favor VB N
the DT N
modified JJ N
Blalock-Taussig NNP N
shunt NN N
or CC N
a DT N
right JJ N
ventricle-to-pulmonary JJ N
artery NN N
shunt NN N
. . N

METHODS NNP N
We PRP N
used VBD N
competing VBG N
risks NNS N
methodology NN N
to TO N
analyze VB N
death NN N
without IN N
transplantation NN N
, , N
cardiac JJ N
transplantation NN N
, , N
and CC N
survival NN N
without IN N
transplantation NN N
. . N

Parametric NNP N
time-to-event JJ N
modeling NN N
and CC N
bootstrapping NN N
were VBD N
used VBN N
to TO N
identify VB N
independent JJ N
predictors NNS N
. . N

RESULTS NNP N
Data NNP N
from IN N
549 CD p
subjects NNS p
( ( p
follow-up JJ p
, , p
2.7 CD p
? . p
0.9 CD p
years NNS p
) ) N
were VBD N
analyzed VBN N
. . N

Mortality NNP N
risk NN o
was VBD N
characterized VBN N
by IN N
early JJ N
and CC N
constant JJ N
phases NNS N
; : N
transplant NN N
was VBD N
characterized VBN N
by IN N
only RB N
a DT N
constant JJ N
phase NN N
. . N

Early JJ N
phase NN N
factors NNS N
associated VBN N
with IN N
death NN o
included VBD N
lower JJR N
socioeconomic JJ N
status NN N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
, , N
obstructed VBD N
pulmonary JJ N
venous JJ N
return NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
smaller JJR N
ascending VBG N
aorta NN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
, , N
and CC N
anatomic JJ N
subtype NN N
. . N

Constant JJ N
phase NN N
factors NNS N
associated VBN N
with IN N
death NN o
included VBD N
genetic JJ N
syndrome NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
lower JJR N
gestational JJ N
age NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
right JJ N
ventricle-to-pulmonary JJ N
artery NN N
shunt NN N
demonstrated VBD N
better JJR N
survival NN o
in IN N
the DT N
51 CD N
% NN N
of IN N
subjects NNS N
who WP N
were VBD N
full JJ N
term NN N
with IN N
aortic JJ N
atresia NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
modified JJ N
Blalock-Taussig NNP N
shunt NN N
was VBD N
better RBR N
among IN N
the DT N
4 CD N
% NN N
of IN N
subjects NNS N
who WP N
were VBD N
preterm VBN N
with IN N
a DT N
patent NN N
aortic JJ N
valve NN N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
. . N

Lower JJR N
pre-Norwood NN N
right JJ N
ventricular JJ N
fractional JJ N
area NN N
change NN N
, , N
pre-Norwood NN N
surgery NN N
, , N
and CC N
anatomy VBZ N
other JJ N
than IN N
hypoplastic JJ N
left JJ N
heart NN N
syndrome NN N
were VBD N
independently RB N
associated VBN N
with IN N
transplantation NN N
( ( N
all DT N
P NNP N
< NNP N
.03 NNP N
) ) N
, , N
but CC N
shunt NN N
type NN N
was VBD N
not RB N
( ( N
P NNP N
= NNP N
.43 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Independent NNP N
risk NN N
factors NNS N
for IN N
intermediate-term JJ N
mortality NN N
include VBP N
lower JJR N
socioeconomic JJ N
status NN N
, , N
anatomy RB N
, , N
genetic JJ N
syndrome NN N
, , N
and CC N
lower JJR N
gestational JJ N
age NN N
. . N

Term JJ N
infants NNS p
with IN N
aortic JJ N
atresia NN N
benefited VBD N
from IN N
a DT N
right JJ N
ventricle-to-pulmonary JJ N
artery NN N
shunt NN N
, , N
and CC N
preterm JJ N
infants NNS p
with IN N
a DT N
patent NN N
aortic JJ N
valve NN N
benefited VBD N
from IN N
a DT N
modified VBN N
Blalock-Taussig NNP N
shunt NN N
. . N

Right NNP N
ventricular JJ N
function NN N
and CC N
anatomy NN N
, , N
but CC N
not RB N
shunt VB N
type NN N
, , N
were VBD N
associated VBN N
with IN N
transplantation NN N
. . N

-DOCSTART- -15858959- O O

Effects NNS N
of IN N
Saccharomyces NNP i
boulardii NN i
in IN N
children NNS p
with IN p
acute JJ p
diarrhoea NN p
. . N

AIM NNP N
Certain NNP N
probiotic JJ N
agents NNS N
, , N
e.g NN N
. . N

Lactobacillus CC N
GG NNP N
, , N
have VBP N
shown VBN N
efficacy NN N
in IN N
clinical JJ N
trials NNS N
for IN N
the DT N
treatment NN N
of IN N
acute JJ N
childhood NN N
diarrhoea NN N
, , N
but CC N
few JJ N
studies NNS N
have VBP N
examined VBN N
the DT N
effect NN N
of IN N
Saccharomyces NNP i
boulardii NN i
. . N

We PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
S. NNP i
boulardii NN i
in IN N
children NNS p
with IN p
acute JJ p
diarrhoea NN p
. . N

METHODS NNP N
Two CD p
hundred VBD p
children NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
S. NNP i
boulardii NN i
in IN N
a DT N
granulated JJ N
form NN N
in IN N
a DT N
daily JJ N
dose NN N
of IN N
250 CD N
mg NN N
( ( N
S. NNP i
boulardii NNP i
group NN N
) ) N
or CC N
placebo NN i
( ( N
placebo JJ i
group NN N
) ) N
for IN N
5 CD N
d. JJ N
Clinical NNP N
and CC N
demographic JJ N
characteristics NNS N
on IN N
admission NN N
were VBD N
similar JJ N
between IN N
the DT N
study NN N
groups NNS N
. . N

RESULTS VB N
The DT N
medians NNS N
of IN N
the DT N
average JJ o
stool NN o
frequency NN o
after IN N
the DT N
second JJ N
day NN N
of IN N
the DT N
treatment NN N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
S. NNP i
boulardii NN i
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

The DT N
duration NN o
of IN o
diarrhoea NN o
significantly RB N
reduced VBN N
in IN N
the DT N
S. NNP i
boulardii NN i
group NN N
compared VBN N
with IN N
the DT N
placebo NN i
group NN N
( ( N
4.7 CD N
vs RB N
5.5 CD N
d NN N
, , N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

The DT N
effect NN N
of IN N
S. NNP i
boulardii NN i
on IN N
watery NN N
diarrhoea NN N
became VBD N
apparent JJ N
after IN N
the DT N
second JJ N
day NN N
of IN N
the DT N
treatment NN N
. . N

The DT N
duration NN o
of IN o
hospital NN o
stay NN o
was VBD N
shorter JJR N
in IN N
the DT N
S. NNP i
boulardii NN i
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
2.9 CD N
vs RB N
3.9 CD N
d NN N
, , N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Four CD N
children NNS N
from IN N
the DT N
placebo NN i
group NN N
versus VBD N
only RB N
one CD N
child NN N
from IN N
the DT N
S. NNP i
boulardii NN i
group NN N
had VBD N
persisting VBG N
diarrhoea NN N
. . N

CONCLUSION VB N
The DT N
placebo-controlled JJ N
study NN N
suggested VBD N
that IN N
S. NNP i
boulardii VBP i
significantly RB N
reduced VBN N
the DT N
duration NN o
of IN o
acute JJ o
diarrhoea NN o
and CC N
the DT N
duration NN o
of IN o
hospital NN o
stay NN o
. . N

S. NNP i
boulardii NN i
seems VBZ N
to TO N
be VB N
a DT N
promising JJ N
agent NN N
for IN N
the DT N
amelioration NN N
of IN N
the DT N
course NN N
of IN N
acute JJ p
diarrhoea NN p
in IN p
children NNS p
when WRB N
used VBN N
therapeutically RB N
. . N

-DOCSTART- -1669598- O O

Local JJ N
immunotherapy NN N
by IN N
inhalation NN N
of IN N
a DT N
powder NN N
extract NN N
in IN N
asthma NN N
due JJ N
to TO N
house NN N
dust NN N
mite NN N
Dermatophagoides NNP N
pteronyssinus NN N
: : N
a DT N
double-blind JJ N
comparison NN N
with IN N
parenteral JJ N
immunotherapy NN N
. . N

To TO N
verify VB N
the DT N
efficacy NN o
and CC N
the DT N
tolerability NN o
of IN N
local JJ i
immunotherapy NN i
( ( N
LI NNP N
) ) N
by IN N
inhalation NN N
of IN N
a DT N
powder NN i
extract NN i
of IN i
house NN i
dust NN i
mite NN i
( ( i
HDM NNP i
) ) i
, , N
in IN N
comparison NN N
with IN N
parenteral JJ i
immunotherapy NN i
( ( i
PI NNP i
) ) i
by IN N
injection NN N
, , N
10 CD p
patients NNS p
with IN p
asthma NNS p
due JJ p
to TO p
HDM NNP p
were VBD N
studied VBN N
in IN N
a DT N
blind JJ N
fashion NN N
. . N

5 CD N
patients NNS N
( ( N
Group NNP N
A NNP N
) ) N
underwent NN N
LI NNP N
and CC N
subcutaneous JJ N
injections NNS N
of IN N
placebo NN i
, , N
5 CD N
patients NNS N
( ( N
Group NNP N
B NNP N
) ) N
underwent NN N
PI NNP N
and CC N
inhalation NN N
of IN N
lactose NN i
for IN N
6 CD N
months NNS N
. . N

In IN N
both DT N
groups NNS N
each DT N
inhalation NN N
was VBD N
preceded VBN N
by IN N
premedication NN N
with IN N
disodium NN i
cromoglycate NN i
( ( i
DSCG NNP i
) ) i
( ( N
40 CD N
mg NN N
) ) N
. . N

In IN N
Group NNP N
A NNP N
a DT N
significant JJ N
decrease NN N
in IN N
symptoms NNS o
score NN o
and CC N
in IN N
peak JJ o
expiratory NN o
flow NN o
( ( o
PEF NNP o
) ) o
-derived VBD o
parameters NNS o
was VBD N
observed VBN N
already RB N
after IN N
3 CD N
months NNS N
of IN N
treatment NN N
, , N
and CC N
2 CD N
patients NNS N
lost VBD N
the DT N
late JJ N
component NN N
of IN N
the DT N
bronchial JJ o
response NN o
to TO N
the DT N
challenge NN N
with IN N
HDM NNP N
. . N

No NNP N
significant JJ N
variation NN N
was VBD N
found VBN N
in IN N
bronchial JJ o
responsiveness NN o
to TO N
methacholine VB N
and CC N
ultrasonically RB N
nebulized VBN N
distilled JJ N
water NN N
( ( N
UNDW NNP N
) ) N
and CC N
in IN N
immunologic JJ o
humoral JJ o
and CC o
cellular JJ o
parameters NNS o
in IN o
peripheral JJ o
blood NN o
after IN N
treatment NN N
in IN N
either DT N
group NN N
. . N

No DT N
local JJ o
important JJ o
adverse JJ o
reactions NNS o
were VBD N
observed VBN N
in IN N
Group NNP N
A NNP N
and CC N
no DT N
systemic JJ o
side NN o
effects NNS o
were VBD N
observed VBN N
in IN N
either DT N
group NN N
. . N

We PRP N
conclude VBP N
that DT N
LI NNP N
is VBZ N
as RB N
effective JJ N
as IN N
PI NNP N
, , N
but CC N
more RBR N
rapid JJ N
in IN N
its PRP$ N
action NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
asthma NNS N
due JJ N
to TO N
HDM NNP N
. . N

Moreover RB N
, , N
LI NNP N
is VBZ N
locally RB N
well RB N
tolerated VBN N
, , N
providing VBG N
DSCG NNP N
is VBZ N
inhaled VBN N
before IN N
each DT N
therapeutic JJ N
inhalation NN N
, , N
and CC N
does VBZ N
not RB N
induce VB N
systemic JJ o
side NN o
effects NNS o
. . N

-DOCSTART- -21491990- O O

A DT N
novel JJ N
approach NN N
to TO N
the DT N
use NN N
of IN N
subgingival JJ N
controlled-release JJ N
chlorhexidine NN i
delivery NN N
in IN N
chronic JJ p
periodontitis NN p
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND IN N
We PRP N
aimed VBD N
to TO N
analyze VB N
clinical JJ o
, , o
microbiologic JJ o
, , o
and CC o
serologic JJ o
effects NNS o
of IN N
chlorhexidine NN i
( ( i
CHX NNP i
) ) i
chips NNS N
used VBN N
as IN N
a DT N
subgingival JJ N
controlled-release JJ N
delivery NN N
device NN N
before IN N
and CC N
immediately RB N
after IN N
scaling VBG N
and CC N
root NN N
planing NN N
( ( N
SRP NNP N
) ) N
. . N

METHODS NNP N
Twenty-four JJ p
patients NNS p
presenting VBG p
with IN p
?12 NNP p
teeth NNS p
with IN p
probing VBG p
depth NN p
( ( p
PD NNP p
) ) p
?5 VBP p
mm NN p
and CC p
bleeding NN p
on IN p
probing VBG p
were VBD N
assigned VBN N
in IN N
test NN N
or CC N
control NN N
groups NNS N
. . N

After IN N
prophylaxis NN N
, , N
CHX NNP i
chips NNS i
( ( N
test NN N
) ) N
or CC N
placebo JJ i
chips NNS N
( ( N
control NN N
) ) N
were VBD N
placed VBN N
in IN N
pockets NNS N
with IN N
PD NNP N
?5 NNP N
mm NN N
. . N

Ten CD N
days NNS N
later RB N
, , N
SRP NNP N
was VBD N
performed VBN N
in IN N
all DT N
teeth NNS N
with IN N
PD NNP N
?4 NNP N
mm NN N
in IN N
a DT N
single JJ N
appointment NN N
. . N

Immediately RB N
after IN N
SRP NNP N
, , N
new JJ N
chips NNS N
were VBD N
inserted VBN N
in IN N
all DT N
pockets NNS N
with IN N
PD NNP N
?5 NNP N
mm NN N
. . N

Parameters NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
; : N
beginning NN N
of IN N
SRP NNP N
; : N
and CC N
1 CD N
, , N
3 CD N
, , N
and CC N
6 CD N
months NNS N
after IN N
treatment NN N
. . N

Subgingival JJ N
samples NNS o
were VBD N
obtained VBN N
at IN N
baseline NN N
; : N
beginning NN N
of IN N
SRP NNP N
; : N
and CC N
at IN N
1 CD N
month NN N
after IN N
treatment NN N
. . N

Periodontal JJ N
pathogens NNS o
Aggregatibacter NNP o
actinomycetemcomitans NNS o
, , o
Porphyromonas NNP o
gingivalis NN o
, , o
Prevotella NNP o
intermedia NN o
, , o
Tannerella NNP o
forsythia NN o
, , o
and CC o
Treponema NNP o
denticola NN o
were VBD N
analyzed VBN N
. . N

Serum NNP o
levels NNS N
of IN o
high JJ o
sensitive JJ o
C-reactive JJ o
and CC o
lipopolysaccharide-binding JJ o
proteins NNS o
were VBD N
measured VBN N
. . N

The DT N
changes NNS N
of IN N
the DT N
parameters NNS N
between IN N
and CC N
within IN N
the DT N
groups NNS N
were VBD N
tested VBN N
by IN N
Mann-Whitney NNP o
U NNP o
test NN o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS NNP N
All NNP N
clinical JJ N
and CC N
serologic JJ N
parameters NNS N
improved VBN N
in IN N
both DT N
groups NNS N
over IN N
time NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
clinical JJ o
attachment NN o
level NN o
( ( o
CAL NNP o
) ) o
gain NN N
from IN N
baseline NN N
to TO N
6 CD N
months NNS N
between IN N
groups NNS N
( ( N
1.17 CD N
mm NN N
in IN N
the DT N
test NN N
group NN N
versus VBD N
0.79 CD N
mm NN N
in IN N
the DT N
placebo NN N
group NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
treatment NN N
with IN N
CHX NNP i
chips NNS i
showed VBD N
a DT N
greater JJR N
reduction NN N
of IN o
the DT o
microorganisms NN o
of IN o
the DT o
red JJ o
complex NN o
after IN N
1 CD N
month NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
use NN N
of IN N
CHX NNP i
chips NNS i
before IN N
and CC N
immediately RB N
after IN N
SRP NNP N
improved VBD N
CAL NNP o
and CC N
reduced VBD N
the DT N
subgingival JJ o
microorganisms NN o
of IN o
the DT o
red JJ o
complex NN o
in IN N
the DT N
treatment NN N
of IN N
chronic JJ N
periodontitis NN N
. . N

-DOCSTART- -25931290- O O

Sensory NNP i
Adapted NNP i
Dental NNP i
Environments NNP i
to TO N
Enhance VB N
Oral NNP N
Care NNP N
for IN N
Children NNP p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNPS p
: : N
A DT N
Randomized NNP N
Controlled NNP N
Pilot NNP N
Study NNP N
. . N

This DT N
pilot NN N
and CC N
feasibility NN N
study NN N
examined VBD N
the DT N
impact NN N
of IN N
a DT N
sensory JJ i
adapted JJ i
dental NN i
environment NN i
( ( i
SADE NNP i
) ) i
to TO N
reduce VB N
distress NN o
, , o
sensory JJ o
discomfort NN o
, , o
and CC o
perception NN o
of IN o
pain NN o
during IN N
oral JJ N
prophylaxis NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . N

Participants NNS p
were VBD p
44 CD p
children NNS p
ages VBZ p
6-12 NN p
( ( p
n JJ p
= $ p
22 CD p
typical JJ p
, , p
n JJ p
= FW p
22 CD p
ASD NNP p
) ) p
. . N

In IN N
an DT N
experimental JJ N
crossover NN N
design NN N
, , N
each DT N
participant JJ N
underwent JJ N
two CD N
professional JJ N
dental JJ N
cleanings NNS N
, , N
one CD N
in IN N
a DT N
regular JJ i
dental NN i
environment NN i
( ( i
RDE NNP i
) ) i
and CC N
one CD N
in IN N
a DT N
SADE NNP i
, , N
administered VBN N
in IN N
a DT N
randomized JJ N
and CC N
counterbalanced JJ N
order NN N
3-4 JJ N
months NNS N
apart RB N
. . N

Outcomes NNP N
included VBD N
measures NNS N
of IN N
physiological JJ o
anxiety NN o
, , o
behavioral JJ o
distress NN o
, , o
pain NN o
intensity NN o
, , o
and CC o
sensory JJ o
discomfort NN o
. . N

Both DT N
groups NNS N
exhibited VBD N
decreased JJ N
physiological JJ o
anxiety NN o
and CC N
reported VBD N
lower JJR N
pain NN o
and CC o
sensory JJ o
discomfort NN o
in IN N
the DT N
SADE NNP i
condition NN N
compared VBN N
to TO N
RDE NNP i
, , N
indicating VBG N
a DT N
beneficial JJ N
effect NN N
of IN N
the DT N
SADE NNP i
. . N

-DOCSTART- -1459268- O O

Prospective JJ N
study NN N
of IN N
short JJ N
and CC N
ultrashort JJ N
regimens NNS N
of IN N
gonadotropin-releasing JJ i
hormone NN i
agonist NN i
in IN N
an DT N
in IN N
vitro JJ N
fertilization NN N
program NN N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
usefulness NN o
of IN N
the DT N
ultrashort JJ N
regimen NNS N
of IN N
gonadotropin-releasing JJ i
hormone NN i
agonist NN i
( ( i
GnRH-a NNP i
) ) i
in IN N
ovulation NN N
induction NN N
in IN N
an DT N
in IN p
vitro JJ p
fertilization NN p
( ( p
IVF NNP p
) ) p
program NN N
. . N

DESIGN VB N
A DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
short JJ N
and CC N
ultrashort JJ N
regimens NNS N
of IN N
GnRH-a NNP i
. . N

SETTING NN N
Aberdeen NNP N
Assisted NNP N
Reproduction NNP N
Unit NNP N
. . N

PATIENTS NNP N
Forty-eight JJ p
patients NNS p
having VBG p
IVF NNP p
for IN p
the DT p
first JJ p
time NN p
were VBD N
randomized VBN N
between IN N
the DT N
two CD N
protocols NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Response NNP o
to TO o
ovarian JJ o
stimulation NN o
and CC o
occurrence NN o
of IN o
spontaneous JJ o
luteinizing VBG o
hormone NN o
( ( o
LH NNP o
) ) o
surges VBZ o
. . N

RESULTS NNP N
In IN N
ovulation NN o
induction NN o
, , o
fertilization NN o
, , o
and CC o
pregnancy NN o
rates NNS o
the DT N
ultrashort JJ N
regimen NNS N
produces VBZ N
results NNS N
that WDT N
were VBD N
no DT N
different JJ N
to TO N
the DT N
short JJ N
regimen NNS N
but CC N
it PRP N
did VBD N
not RB N
always RB N
prevent VB N
an DT N
LH NNP o
surge NN o
. . N

CONCLUSION VB N
The DT N
ultrashort JJ N
regimen NNS N
can MD N
be VB N
a DT N
useful JJ N
alternative NN N
for IN N
ovarian JJ N
stimulation NN N
of IN N
patients NNS p
undergoing VBG p
IVF NNP p
. . N

-DOCSTART- -25369243- O O

Atomoxetine NNP i
in IN N
autism NN p
spectrum NN p
disorder NN p
: : N
no DT N
effects NNS N
on IN N
social JJ o
functioning NN o
; : N
some DT N
beneficial JJ N
effects NNS N
on IN N
stereotyped JJ o
behaviors NNS o
, , o
inappropriate JJ o
speech NN o
, , N
and CC N
fear NN o
of IN o
change NN o
. . N

UNLABELLED NNP N
Abstract NNP N
Objective NNP N
: : N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
short-term JJ N
treatment NN N
effects NNS N
of IN N
atomoxetine NN i
on IN N
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
symptoms NNS N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
both DT p
ASD NNP p
and CC p
attention-deficit/hyperactivity JJ p
disorder NN p
( ( p
ADHD NNP p
) ) p
. . N

METHODS CC N
A DT N
total NN N
of IN N
97 CD p
patients NNS p
6-17 JJ p
years NNS p
of IN p
age NN p
, , p
with IN p
ASD NNP p
and CC p
ADHD NNP p
, , N
were VBD N
treated VBN N
with IN N
1.2 CD N
mg/kg/day NN N
of IN N
atomoxetine NN i
during IN N
an DT N
8 CD N
week NN N
double-blind JJ N
placebo-controlled JJ i
period NN N
. . N

Here RB N
, , N
we PRP N
investigated VBD N
effects NNS N
on IN N
two CD N
parent-based JJ N
secondary JJ N
outcome NN N
measures NNS N
, , N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
and CC N
the DT N
Children NNP o
's POS o
Social NNP o
Behavior NNP o
Questionnaire NNP o
( ( o
CSBQ NNP o
) ) o
. . N

RESULTS NNP N
After IN N
8 CD N
weeks NNS N
of IN N
double-blind JJ N
treatment NN N
, , N
atomoxetine JJ i
administration NN N
was VBD N
associated VBN N
with IN N
significant JJ N
treatment NN N
effects NNS N
on IN N
the DT N
ABC NNP o
subscales VBZ o
Hyperactivity NNP o
, , o
Inappropriate NNP o
Speech NNP o
, , o
and CC o
Stereotypic NNP o
Behavior NNP o
, , N
and CC N
on IN N
the DT N
CSBQ NNP o
subscale NN o
Fear NNP o
for IN o
Changes NNP o
. . N

CONCLUSIONS NNP N
Our PRP$ N
study NN N
results NNS N
indicate VBP N
no DT N
beneficial JJ N
effects NNS N
of IN N
atomoxetine NN N
on IN N
social JJ N
functioning NN N
. . N

However RB N
, , N
atomoxetine NN i
may MD N
ameliorate VB N
restricted VBN N
and CC N
stereotyped VBN o
behaviors NNS o
and CC o
communication NN o
. . N

This DT N
study NN N
has VBZ N
been VBN N
registered VBN N
in IN N
ClinicalTrials.gov NNP N
( ( N
www.clinicaltrials.gov NN N
) ) N
under IN N
registration NN N
number NN N
NCT00380692 NNP N
. . N

-DOCSTART- -19376304- O O

Rationale NNP N
and CC N
design NN N
of IN N
RE-LY NNP N
: : N
randomized JJ N
evaluation NN N
of IN N
long-term JJ N
anticoagulant JJ N
therapy NN N
, , N
warfarin NN i
, , N
compared VBN N
with IN N
dabigatran NN i
. . N

Vitamin NNP N
K NNP N
antagonists NNS N
( ( N
VKAs NNP N
) ) N
are VBP N
effective JJ N
for IN N
stroke NN N
prevention NN N
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
but CC N
are VBP N
difficult JJ N
to TO N
use VB N
. . N

Dabigatran NNP i
etexilate NN i
is VBZ N
a DT N
prodrug NN N
that WDT N
is VBZ N
rapidly RB N
converted VBN N
to TO N
the DT N
active JJ N
direct JJ N
thrombin NN N
inhibitor NN N
dabigatran NN i
. . N

It PRP N
is VBZ N
administered VBN N
in IN N
a DT N
fixed JJ N
dose NN N
without IN N
laboratory JJ N
monitoring NN N
and CC N
is VBZ N
being VBG N
compared VBN N
with IN N
warfarin NN i
( ( N
international JJ N
normalized VBN N
ratio JJ N
2-3 JJ N
) ) N
in IN N
the DT N
RE-LY JJ N
trial NN N
. . N

Two CD N
doses NNS N
of IN N
dabigatran NN i
( ( N
110 CD N
and CC N
150 CD N
mg NNS N
BID NNP N
) ) N
are VBP N
being VBG N
evaluated VBN N
. . N

RE-LY NNP N
is VBZ N
a DT N
phase NN N
3 CD N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
open-label JJ N
multinational NN N
( ( N
44 CD N
countries NNS N
) ) N
trial NN N
of IN N
patients NNS p
with IN p
nonvalvular JJ p
AF NNP p
and CC p
at IN p
least JJS p
1 CD p
risk NN p
factor NN p
for IN p
stroke NN p
. . N

Recruitment NNP N
concluded VBD N
with IN N
a DT N
total NN N
of IN N
18,113 CD p
patients NNS p
. . N

Patients NNS p
who WP p
were VBD p
VKA-naive NNP p
and CC p
experienced VBN p
are VBP p
included VBN p
in IN p
balanced JJ p
proportions NNS p
. . N

The DT N
primary JJ N
outcome NN N
is VBZ N
stroke VBN o
( ( o
including VBG o
hemorrhagic NN o
) ) o
or CC N
systemic JJ o
embolism NN o
. . N

Safety NNP N
outcomes NNS N
are VBP N
bleeding VBG o
, , o
liver JJ o
function NN o
abnormalities NNS o
, , o
and CC o
other JJ o
adverse JJ o
events NNS o
. . N

Adjudication NN N
of IN N
end NN N
points NNS N
is VBZ N
blinded VBN N
to TO N
drug NN N
assignment NN N
. . N

The DT N
trial NN N
is VBZ N
expected VBN N
to TO N
accrue VB N
a DT N
minimum NN N
of IN N
450 CD N
events NNS N
with IN N
a DT N
minimum JJ N
1-year JJ N
of IN N
follow-up JJ N
. . N

RE-LY NN N
is VBZ N
the DT N
largest JJS N
AF NNP N
stroke VBD N
prevention NN N
trial NN N
yet RB N
undertaken VBN N
. . N

It PRP N
is VBZ N
unique JJ N
because IN N
it PRP N
includes VBZ N
equal JJ N
numbers NNS N
of IN N
VKA-experienced NNP N
and CC N
naive JJ N
patients NNS N
and CC N
evaluates VBZ N
2 CD N
different JJ N
dosages NNS N
of IN N
dabigatran NN i
, , N
which WDT N
may MD N
allow VB N
tailoring NN N
of IN N
dosing VBG N
to TO N
individual JJ N
patient NN N
needs NNS N
. . N

The DT N
worldwide JJ N
site NN N
distribution NN N
and CC N
broad JJ N
range NN N
of IN N
stroke NN N
risk NN N
further RBR N
increase VB N
the DT N
general JJ N
applicability NN N
of IN N
the DT N
trial NN N
. . N

Results NNS N
are VBP N
expected VBN N
in IN N
2009 CD N
. . N

-DOCSTART- -24080592- O O

Effect NN N
of IN N
simvastatin NN i
on IN N
hemostasis NN N
in IN N
patients NNS p
with IN p
isolated JJ p
hypertriglyceridemia NN p
. . N

BACKGROUNDS/AIMS NNP N
Elevated NNP N
triglyceride NN N
levels NNS N
seem VBP N
to TO N
predispose VB N
to TO N
the DT N
earlier JJR N
development NN N
and CC N
accelerated JJ N
progression NN N
of IN N
coronary JJ N
artery NN N
disease NN N
. . N

In IN N
our PRP$ N
study NN N
, , N
we PRP N
assessed VBD N
for IN N
the DT N
first JJ N
time NN N
whether IN N
simvastatin JJ i
treatment NN N
affects NNS N
coagulation NN o
and CC o
fibrinolysis NN o
in IN N
patients NNS p
with IN p
isolated JJ p
hypertriglyceridemia NN p
. . N

METHODS NNP N
The DT N
study NN N
included VBD N
39 CD p
patients NNS p
with IN p
elevated JJ p
triglyceride NN p
levels NNS p
and CC p
peripheral JJ p
artery NN p
sclerosis NN p
, , N
treated VBD N
for IN N
90 CD N
days NNS N
with IN N
either DT N
simvastatin NN i
( ( N
40 CD N
mg NNS N
daily RB N
) ) N
or CC N
placebo NN i
. . N

Plasma NNP o
lipids NNS o
, , o
glucose JJ o
homeostasis NN o
markers NNS o
and CC N
hemostasic JJ o
variables NNS o
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
. . N

RESULTS NNP N
Simvastatin NNP i
, , N
but CC N
not RB N
placebo VB i
, , N
administered VBN N
to TO N
these DT N
patients NNS N
reduced VBD N
plasma JJ o
levels/activity NN o
of IN o
fibrinogen NN o
( ( N
from IN N
3.5 CD N
? . N
0.4 CD N
to TO N
2.8 CD N
? . N
0.3 CD N
g/l NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
, , N
factor NN o
VII NNP o
( ( N
from IN N
144.2 CD N
? . N
16.9 CD N
to TO N
112.5 CD N
? . N
14.0 CD N
% NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
and CC N
plasminogen JJ o
activator NN o
inhibitor-1 NN o
( ( N
from IN N
76.9 CD N
? . N
13.5 CD N
to TO N
50.2 CD N
? . N
9.2 CD N
ng/ml NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
without IN N
a DT N
significant JJ N
reduction NN N
in IN N
von NN o
Willebrand NNP o
factor NN o
levels NNS o
, , N
and CC N
tended VBD N
to TO N
prolong VB N
the DT N
prothrombin NN o
and CC o
partial JJ o
thromboplastin NN o
times NNS o
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
statin NN i
treatment NN N
produces VBZ N
a DT N
multidirectional JJ N
effect NN N
on IN N
coagulation NN o
and CC o
fibrinolysis NN o
in IN N
patients NNS p
with IN p
isolated JJ p
hypertriglyceridemia NN p
and CC N
that IN N
this DT N
treatment NN N
may MD N
bring VB N
some DT N
benefits NNS N
to TO N
patients NNS p
with IN p
elevated JJ p
triglyceride NN p
levels NNS p
. . N

-DOCSTART- -11737955- O O

Antioxidant JJ i
supplementation NN i
and CC N
exercise-induced JJ N
oxidative JJ N
stress NN N
in IN N
the DT p
60-year-old JJ p
as IN N
measured VBN N
by IN N
antipyrine NN i
hydroxylates NNS N
. . N

The DT N
effects NNS N
of IN N
12 CD N
weeks NNS N
of IN N
antioxidant JJ i
supplementation NN i
on IN N
exercise-induced JJ N
oxidative JJ N
stress NN N
were VBD N
investigated VBN N
in IN N
older JJR p
adults NNS p
( ( p
60 CD p
( ( p
SE NNP p
1 CD p
) ) p
years NNS p
; : p
BMI NNP p
26 CD p
( ( p
SE NNP p
1 CD p
) ) p
kg/m NN p
( ( p
2 CD p
) ) p
) ) p
. . N

Subjects NNS N
were VBD N
randomly RB N
divided VBN N
in IN N
two CD N
groups NNS N
: : N
supplementation NN N
( ( N
n JJ N
11 CD N
) ) N
with IN N
100 CD N
mg NNS N
dl-alpha-tocopheryl JJ i
acetate NN i
, , N
200 CD N
mg NN N
ascorbic JJ i
acid NN i
, , N
and CC N
2 CD N
mg NN N
beta-carotene NN i
, , N
and CC N
placebo NN i
( ( N
n JJ N
9 CD N
) ) N
. . N

Before IN N
and CC N
after IN N
the DT N
12 CD N
week NN N
supplementation NN N
period NN N
, , N
subjects NNS N
cycled VBD N
for IN N
45 CD N
min NN N
at IN N
submaximal JJ N
intensity NN N
( ( N
50 CD N
% NN N
maximal JJ N
workload NN N
capacity NN N
) ) N
. . N

Antipyrine NNP i
was VBD N
used VBN N
as IN N
marker NN N
for IN N
oxidative JJ N
stress NN N
. . N

Antipyrine NNP N
reacts VBZ N
quickly RB N
with IN N
hydroxyl JJ N
radicals NNS N
to TO N
form VB N
para- JJ N
and CC N
ortho-hydroxyantipyrine JJ N
. . N

The DT N
latter JJ N
metabolite NN N
is VBZ N
not RB N
formed VBN N
in IN N
man NN N
through IN N
the DT N
mono-oxygenase JJ N
pathway NN N
of IN N
cytochrome JJ N
P450 NNP N
. . N

Daily NNP N
supplementation NN N
significantly RB N
increased VBD N
plasma JJ N
concentrations NNS N
of IN N
alpha-tocopherol NN N
and CC N
beta-carotene NN N
in IN N
the DT N
supplemented VBN N
group NN N
( ( N
Delta NNP N
14.4 CD N
( ( N
SE NNP N
3.2 CD N
) ) N
and CC N
0.4 CD N
( ( N
se VB N
0.1 CD N
) ) N
micromol/l NN N
; : N
P NNP N
< VBZ N
0.001 CD N
and CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
, , N
within IN N
and CC N
between IN N
groups NNS N
, , N
were VBD N
observed VBN N
in IN N
the DT N
exercise-induced JJ N
increase NN N
in IN N
the DT N
ratios NNS N
para- JJ o
and CC o
ortho-hydroxyantipyrine JJ o
to TO o
antipyrine VB o
. . N

In IN N
addition NN N
, , N
supplementation NN N
did VBD N
not RB N
affect VB N
the DT N
exercise-induced JJ N
increase NN N
in IN N
thiobarbituric JJ o
acid NN o
reactive JJ o
substances NNS o
in IN o
plasma NN o
. . N

In IN N
conclusion NN N
, , N
in IN N
60-year-old JJ p
subjects NNS p
antioxidant JJ i
supplementation NN i
had VBD N
no DT N
effect NN N
on IN N
the DT N
exercise-induced JJ N
increase NN N
in IN N
oxidative JJ N
stress NN N
as IN N
measured VBN N
by IN N
free JJ o
radical JJ o
products NNS o
of IN o
antipyrine NN o
. . N

-DOCSTART- -12709693- O O

Conscious JJ N
analgesia/sedation NN N
with IN N
remifentanil NN i
and CC N
propofol NN i
versus NN N
total JJ N
intravenous JJ N
anesthesia NN N
with IN N
fentanyl NN i
, , N
midazolam NN i
, , N
and CC N
propofol NN i
for IN N
outpatient JJ p
colonoscopy NN p
. . N

BACKGROUND NNP N
This DT N
study NN N
tested VBD N
the DT N
hypothesis NN N
that WDT N
, , N
for IN N
colonoscopy NN N
, , N
analgesia/sedation NN N
with IN N
remifentanil NN i
and CC N
propofol NN i
might MD N
be VB N
more RBR N
effective JJ N
compared VBN N
with IN N
anesthesia NN N
by IN N
intravenous JJ N
administration NN N
of IN N
midazolam NN i
, , N
fentanyl NN i
, , N
and CC N
propofol NN i
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
, , N
100 CD p
adult NN p
patients NNS p
received VBD N
either RB N
conscious JJ N
analgesia/sedation NN N
( ( N
Sedation NNP N
group NN N
) ) N
or CC N
total JJ N
intravenous JJ N
anesthesia NN N
( ( N
TIVA NNP N
group NN N
) ) N
. . N

Analgesia/sedation NN N
was VBD N
achieved VBN N
by IN N
infusion NN N
of IN N
remifentanil NN i
( ( N
0.20 CD N
to TO N
0.25 CD N
microg/kg/min NN N
) ) N
and CC N
propofol NN i
in IN N
titrated JJ N
doses NNS N
. . N

TIVA NNP N
was VBD N
induced VBN N
by IN N
intravenous JJ N
administration NN N
of IN N
fentanyl NN i
( ( N
2 CD N
microg/kg NN N
) ) N
, , N
midazolam FW i
( ( N
0.05 CD N
mg/kg NN N
) ) N
and CC N
propofol NN i
( ( N
dosage NN N
titrated VBN N
) ) N
. . N

Cardiorespiratory JJ o
parameters NNS o
and CC N
bispectral JJ o
index NN o
were VBD N
monitored VBN N
and CC N
recorded VBN N
. . N

The DT N
quality NN N
of IN N
the DT N
analgesia NN N
was VBD N
assessed VBN N
with IN N
a DT N
Numerical JJ o
Pain NN o
Rating NNP o
Scale NNP o
( ( o
NRS NNP o
) ) o
; : o
recovery NN o
level NN o
and CC N
return NN o
of IN o
psychomotor NN o
efficiency NN o
were VBD N
evaluated VBN N
with IN N
, , N
respectively RB N
, , N
the DT N
Aldrete NNP o
scale NN o
and CC N
a DT N
Modified NNP o
Post NNP o
Anesthesia NNP o
Discharge NNP o
Scoring NNP o
( ( o
MPADS NNP o
) ) o
system NN o
. . N

RESULTS VB N
Both DT N
groups NNS N
of IN N
50 CD N
patients NNS N
were VBD N
comparable JJ N
with IN N
respect NN N
to TO N
demographic VB N
data NNS N
, , N
initial JJ N
parameters NNS N
, , N
and CC N
duration NN N
of IN N
colonoscopy NN p
. . N

All DT N
patients NNS N
in IN N
the DT N
TIVA NNP N
group NN N
found VBD N
the DT N
colonoscopy NN N
painless NN N
( ( N
NRS NNP N
score RB N
0 CD N
) ) N
. . N

In IN N
the DT N
Sedation NNP N
group NN N
, , N
the DT N
average JJ N
pain NN o
intensity NN o
score NN o
was VBD N
0.4 CD N
( ( N
0.8 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
marked JJ N
difference NN N
between IN N
the DT N
Sedation NNP N
and CC N
TIVA NNP N
groups NNS N
with IN N
respect NN N
to TO N
the DT N
time NN N
from IN N
the DT N
end NN N
of IN N
the DT N
procedure NN N
until IN N
the DT N
maximum JJ o
MPADS NNP o
score NN o
was VBD N
reached VBN N
: : N
respectively RB N
, , N
-6.9 NNP N
( ( N
4.0 CD N
) ) N
versus NN N
25.7 CD N
( ( N
8.4 CD N
) ) N
minutes NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
the DT N
TIVA NNP N
group NN N
, , N
changes NNS N
in IN N
mean JJ o
arterial JJ o
pressure NN o
and CC o
heart NN o
rate NN o
and CC o
signs NNS o
of IN o
respiratory NN o
depression NN o
were VBD N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Combined NNP N
administration NN N
of IN N
remifentanil NN i
and CC N
propofol NN i
for IN N
colonoscopy NN N
provides VBZ N
sufficient JJ N
analgesia NN o
, , N
satisfactory JJ N
hemodynamic JJ o
stability NN o
, , N
minor JJ N
respiratory NN o
depression NN o
, , N
and CC N
rapid JJ o
recovery NN o
, , N
and CC N
allows VBZ N
patients NNS N
to TO N
be VB N
discharged VBN N
approximately RB N
15 CD N
minutes NNS N
after IN N
the DT N
procedure NN N
. . N

-DOCSTART- -25479285- O O

Randomised VBN N
trial NN N
of IN N
text NN N
messaging NN N
on IN N
adherence NN o
to TO N
cardiovascular VB N
preventive JJ N
treatment NN N
( ( N
INTERACT NNP N
trial NN N
) ) N
. . N

BACKGROUND CC N
About IN N
one CD N
third NN N
of IN N
patients NNS p
prescribed VBN p
blood JJ p
pressure NN p
or CC p
lipid-lowering JJ p
drugs NNS p
for IN p
the DT p
prevention NN p
of IN p
coronary JJ p
heart NN p
disease NN p
and CC p
stroke NN p
do VBP N
not RB N
take VB N
their PRP$ N
medication NN N
as IN N
prescribed JJ N
. . N

We PRP N
conducted VBD N
a DT N
randomized JJ N
trial NN N
to TO N
evaluate VB N
text JJ i
messaging NN i
as IN N
a DT N
means NN N
of IN N
improving VBG N
adherence NN o
to TO N
cardiovascular VB N
disease NN N
preventive JJ N
treatment NN N
. . N

METHODS NNP N
303 CD p
patients NNS p
taking VBG p
blood NN p
pressure NN p
and/or IN p
lipid-lowering JJ p
medications NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
being VBG N
sent VBN N
text NN i
messages NNS i
( ( N
Text NNP i
group NN N
, , N
151 CD N
) ) N
or CC N
not RB i
being VBG i
sent VBN i
them PRP i
( ( N
No NNP N
text NN N
group NN N
, , N
152 CD N
) ) N
. . N

Texts NNP N
were VBD N
sent VBN N
daily RB N
for IN N
2 CD N
weeks NNS N
, , N
alternate JJ N
days NNS N
for IN N
2 CD N
weeks NNS N
and CC N
weekly JJ N
thereafter NN N
for IN N
22 CD N
weeks NNS N
( ( N
6 CD N
months NNS N
overall JJ N
) ) N
, , N
using VBG N
an DT N
automated VBN N
computer NN N
programme NN N
. . N

Patients NNS N
were VBD N
asked VBN N
to TO N
respond VB N
on IN N
whether IN N
they PRP N
had VBD N
taken VBN N
their PRP$ N
medication NN N
, , N
whether IN N
the DT N
text NN N
reminded VBD N
them PRP N
to TO N
do VB N
so RB N
if IN N
they PRP N
had VBD N
forgotten VBN N
, , N
and CC N
if IN N
they PRP N
had VBD N
not RB N
taken VBN N
their PRP$ N
medication NN N
to TO N
determine VB N
if IN N
there EX N
was VBD N
a DT N
reason NN N
for IN N
not RB N
doing VBG N
so RB N
. . N

At IN N
6 CD N
months NNS N
, , N
use NN N
of IN N
medication NN N
was VBD N
assessed VBN N
. . N

RESULTS NNP N
Two CD N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up NN N
, , N
providing VBG N
data NNS N
on IN N
301 CD N
for IN N
analysis NN N
. . N

In IN N
the DT N
No NNP N
text NN N
group NN N
38/151 CD N
( ( N
25 CD N
% NN N
) ) N
took VBD N
less JJR N
than IN N
80 CD N
% NN N
of IN N
the DT N
prescribed JJ N
regimen NNS N
( ( N
ie NN N
. . N

stopped VBD N
medication NN N
completely RB N
or CC N
took VBD N
it PRP N
on IN N
fewer JJR N
than IN N
22 CD N
of IN N
the DT N
last JJ N
28 CD N
days NNS N
of IN N
follow-up NN N
) ) N
compared VBN N
to TO N
14/150 CD N
patients NNS N
( ( N
9 CD N
% NN N
) ) N
in IN N
the DT N
Text NNP i
group NN N
- : N
an DT N
improvement NN N
in IN N
adherence NN o
affecting VBG N
16 CD N
per IN N
100 CD N
patients NNS N
( ( N
95 CD N
% NN N
CI NNP N
7 CD N
to TO N
24 CD N
) ) N
, , N
p JJ N
< NN N
0.001 CD N
. . N

The DT N
texts NN N
reminded VBD N
98/151 CD N
patients NNS N
( ( N
65 CD N
% NN N
) ) N
to TO N
take VB N
medication NN N
on IN N
at IN N
least JJS N
one CD N
occasion NN N
and CC N
lead NN N
to TO N
20/151 CD N
( ( N
13 CD N
% NN N
) ) N
who WP N
stopped VBD N
taking VBG N
medication NN N
because IN N
of IN N
concern NN N
over IN N
efficacy NN N
or CC N
side-effects NNS N
, , N
resuming VBG N
treatment NN N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
taking VBG p
blood NN p
pressure NN p
or CC p
lipid-lowering JJ p
treatment NN p
for IN p
the DT p
prevention NN p
of IN p
cardiovascular JJ p
disease NN p
, , N
text NN i
messaging NN i
improved JJ N
medication NN o
adherence NN o
compared VBN N
with IN N
no DT i
text NN i
messaging NN i
. . N

TRIAL NNP N
REGISTRATION NNP N
Controlled-Trials.com NNP N
ISRCTN74757601 NNP N
. . N

-DOCSTART- -21211686- O O

Lowering VBG N
the DT N
triglyceride/high-density NN o
lipoprotein NN o
cholesterol NN o
ratio NN o
is VBZ N
associated VBN N
with IN N
the DT N
beneficial JJ N
impact NN N
of IN N
pioglitazone NN i
on IN N
progression NN N
of IN N
coronary JJ o
atherosclerosis NN o
in IN N
diabetic JJ p
patients NNS p
: : N
insights NNS N
from IN N
the DT N
PERISCOPE NNP N
( ( N
Pioglitazone NNP N
Effect NNP N
on IN N
Regression NNP N
of IN N
Intravascular NNP N
Sonographic NNP N
Coronary NNP N
Obstruction NNP N
Prospective NNP N
Evaluation NNP N
) ) N
study NN N
. . N

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
factors NNS N
associated VBN N
with IN N
the DT N
favorable JJ N
effect NN N
of IN N
pioglitazone NN i
on IN N
atheroma JJ N
progression NN N
. . N

BACKGROUND NNP N
Diabetes NNP N
mellitus NN N
is VBZ N
associated VBN N
with IN N
accelerated JJ N
coronary JJ N
atheroma NN N
progression NN N
. . N

Pioglitazone NN i
slowed VBD N
progression NN N
compared VBN N
with IN N
glimepiride NN N
in IN N
this DT N
population NN N
. . N

METHODS NNP N
In IN N
all DT N
, , N
360 CD p
diabetic JJ p
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
were VBD N
treated VBN N
with IN N
pioglitazone NN i
or CC N
glimepiride NN i
for IN N
18 CD N
months NNS N
in IN N
the DT N
PERISCOPE NNP N
( ( N
Pioglitazone NNP N
Effect NNP N
on IN N
Regression NNP N
of IN N
Intravascular NNP N
Sonographic NNP N
Coronary NNP N
Obstruction NNP N
Prospective NNP N
Evaluation NNP N
) ) N
study NN N
. . N

Coronary NNP o
atheroma NN o
progression NN o
was VBD N
evaluated VBN N
by IN N
serial JJ N
intravascular JJ N
ultrasound NN N
. . N

The DT N
relationship NN N
between IN N
changes NNS o
in IN o
biochemical JJ o
parameters NNS o
, , o
percent JJ o
atheroma NN o
volume NN o
, , o
and CC o
total JJ o
atheroma NN o
volume NN o
was VBD N
investigated VBN N
. . N

RESULTS JJ N
Pioglitazone-treated JJ i
patients NNS N
demonstrated VBD N
greater JJR N
increases NNS N
in IN N
high-density NN o
lipoprotein NN o
cholesterol NN o
( ( o
HDL-C NNP o
) ) o
and CC N
reductions NNS N
in IN N
glycated JJ o
hemoglobin NN o
, , o
triglycerides NNS o
, , o
and CC o
C-reactive JJ o
protein NN o
. . N

Significant JJ N
correlations NNS N
were VBD N
observed VBN N
between IN N
changes NNS N
in IN N
percent NN o
atheroma NN o
volume NN o
and CC o
triglycerides NNS o
( ( N
r VB N
= RB N
0.15 CD N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
, , N
triglyceride/HDL-C JJ o
ratio NN o
( ( N
r JJ N
= NN N
0.16 CD N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
, , N
and CC N
glycated VBD o
hemoglobin NN o
( ( N
r JJ N
= NN N
0.16 CD N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
with IN N
pioglitazone NN i
, , N
and CC N
changes NNS N
in IN N
low-density NN o
lipoprotein NN o
cholesterol NN o
( ( N
r JJ N
= NNP N
-0.15 NNP N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
, , N
apolipoprotein RB o
B NNP o
( ( N
r NN N
= NNP N
-0.16 NNP N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
, , N
and CC N
apolipoprotein RB o
A-I NNP o
( ( N
r NN N
= NNP N
-0.20 NNP N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
with IN N
glimepiride NN i
. . N

Substantial JJ N
atheroma JJ N
regression NN N
, , N
compared VBN N
to TO N
progression NN N
, , N
was VBD N
associated VBN N
with IN N
greater JJR N
relative JJ N
increases NNS N
in IN N
HDL-C NNP o
( ( N
14.2 CD N
% NN N
vs. FW N
7.8 CD N
% NN N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
, , N
relative JJ N
decreases NNS N
in IN N
triglycerides NNS o
( ( N
-13.3 CD N
% NN N
vs. FW N
-1.9 CD N
% NN N
, , N
p NN N
= NNP N
0.045 CD N
) ) N
, , N
triglyceride/HDL-C JJ o
ratio NN o
( ( N
-22.5 NNP N
vs. FW N
-9.9 NNP N
% NN N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
, , N
and CC N
decrease NN N
in IN N
glycated JJ o
hemoglobin NN o
( ( N
-0.6 CD N
% NN N
vs. FW N
-0.3 CD N
% NN N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
. . N

Multivariable JJ N
analysis NN N
revealed VBD N
that IN N
pioglitazone-induced JJ i
effects NNS N
on IN N
triglyceride/HDL-C NN o
were VBD N
associated VBN N
with IN N
changes NNS N
in IN N
percent NN o
atheroma NN o
volume NN o
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
and CC N
total JJ o
atheroma NN o
volume NN o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSIONS NNP N
Favorable JJ N
effects NNS N
of IN N
pioglitazone NN i
on IN N
the DT N
triglyceride/HDL-C JJ o
ratio NN o
correlated VBN N
with IN N
delayed JJ N
atheroma NN o
progression NN o
in IN N
diabetic JJ p
patients NNS p
. . N

This DT N
finding NN N
highlights VBZ N
the DT N
potential JJ N
importance NN N
of IN N
targeting VBG N
atherogenic JJ N
dyslipidemia NN N
in IN N
diabetic JJ p
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
. . N

-DOCSTART- -23392542- O O

Plasma NNP o
AGE-peptides NNP o
and CC o
C-peptide NNP o
in IN N
early-stage JJ p
diabetic JJ p
nephropathy JJ p
patients NNS p
on IN N
thiamine NN N
and CC N
pyridoxine NN N
therapy NN N
. . N

AIM IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
circulatory JJ o
AGE-peptide JJ o
levels NNS o
in IN N
diabetic JJ N
nephropathy NN N
and CC N
to TO N
observe VB N
the DT N
effects NNS N
of IN N
thiamine NN i
( ( i
vitamin JJ i
B1 NNP i
) ) i
and CC N
pyridoxine NN i
( ( i
vitamin JJ i
B6 NNP i
) ) i
therapy NN N
. . N

METHODS NNP N
Type NNP p
2 CD p
diabetic JJ p
patients NNS p
( ( p
N.=57 NNP p
) ) p
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
as IN N
with IN N
nephropathy JJ N
( ( N
N.=27 NNP N
) ) N
and CC N
without IN N
nephropathy JJ N
( ( N
N.=30 NNP N
) ) N
. . N

Diabetic NNP p
nephropathy JJ p
patients NNS p
were VBD N
treated VBN N
with IN N
either DT N
B6 NNP i
( ( N
N.=12 NNP N
) ) N
( ( N
250 CD N
mg/day NN N
) ) N
or CC N
B1+B6 NNP i
( ( N
N.=15 NNP N
) ) N
( ( N
250 CD N
mg/day NN N
, , N
each DT N
) ) N
for IN N
five CD N
months NNS N
. . N

At IN N
the DT N
beginning NN N
and CC N
the DT N
end NN N
of IN N
the DT N
experimentation NN N
period NN N
, , N
glucose NN o
, , o
HbA1c NNP o
, , o
triglyceride NN o
, , o
cholesterol NN o
, , o
insulin NN o
, , o
C-peptide NNP o
, , o
thiamine NN o
pyrophosphate NN o
, , o
pyridoxal JJ o
phosphate NN o
and CC o
AGE- NNP o
peptides NNS o
were VBD N
measured VBN N
. . N

RESULTS JJ N
AGE-peptides NNS o
were VBD N
higher JJR N
in IN N
the DT N
diabetic JJ p
group NN N
with IN N
nephropathy JJ N
than IN N
without IN N
nephropathy JJ N
( ( N
P=0.005 NNP N
) ) N
. . N

Within IN N
five CD N
months NNS N
AGE-peptides NNS o
increased VBD N
in IN N
the DT N
diabetic JJ p
group NN N
without IN N
nephropathy JJ N
( ( N
P=0.042 NNP N
) ) N
but CC N
not RB N
in IN N
the DT N
group NN N
with IN N
nephropathy JJ N
treated VBN N
either RB N
with IN N
B1+B6 NNP i
or CC N
B6 NNP i
. . N

In IN N
B6 NNP i
treated VBD N
group NN N
a DT N
substantial JJ N
decrease NN N
was VBD N
observed VBN N
in IN N
HbA1c NNP o
( ( N
P=0.033 NNP N
) ) N
. . N

B1+B6 NNP i
or CC N
B6 NNP i
treatment NN N
both DT N
caused VBD N
an DT N
increase NN N
in IN N
C-peptide NNP o
( ( N
P=0.006 NNP N
, , N
P=0.004 NNP N
) ) N
. . N

CONCLUSION NNP N
Among IN N
the DT N
parameters NNS N
measured VBD N
, , N
plasma JJ o
AGE-peptides NNP o
was VBD N
the DT N
only JJ N
parameter NN N
found VBD N
to TO N
be VB N
higher JJR N
in IN N
type NN p
2 CD p
diabetes NNS p
mellitus JJ p
patients NNS p
with IN N
nephropathy JJ N
than IN N
without IN N
nephropathy JJ N
. . N

However RB N
, , N
patients NNS p
with IN N
nephropathy JJ N
treated VBN N
with IN N
B1+B6 NNP i
or CC N
B6 NNP i
did VBD N
not RB N
display VB N
any DT N
further JJ N
increase NN N
in IN N
AGE-peptides NNP o
within IN N
five CD N
months NNS N
. . N

Both DT N
of IN N
the DT N
treatments NNS N
caused VBD N
an DT N
increase NN N
in IN N
C-peptide NNP o
. . N

-DOCSTART- -21393467- O O

Distinct NNP N
fast RB N
and CC N
slow VB N
processes NNS N
contribute VBP N
to TO N
the DT N
selection NN N
of IN N
preferred JJ N
step NN N
frequency NN N
during IN N
human JJ p
walking VBG N
. . N

Humans NNPS N
spontaneously RB N
select VB N
a DT N
step NN N
frequency NN N
that WDT N
minimizes VBZ N
the DT N
energy NN N
expenditure NN N
of IN N
walking VBG N
. . N

This DT N
selection NN N
might MD N
be VB N
embedded VBN N
within IN N
the DT N
neural JJ N
circuits NNS N
that WDT N
generate VBP N
gait NNS N
so RB N
that IN N
the DT N
optimum NN N
is VBZ N
pre-programmed JJ N
for IN N
a DT N
given VBN N
walking VBG N
speed NN N
. . N

Or CC N
perhaps RB N
step JJ N
frequency NN N
is VBZ N
directly RB N
optimized VBN N
, , N
based VBN N
on IN N
sensed JJ N
feedback NN N
of IN N
energy NN N
expenditure NN N
. . N

Direct JJ N
optimization NN N
is VBZ N
expected VBN N
to TO N
be VB N
slow JJ N
due JJ N
to TO N
the DT N
compounded JJ N
effect NN N
of IN N
delays NNS N
and CC N
iteration NN N
, , N
whereas IN N
a DT N
pre-programmed JJ N
mechanism NN N
presumably RB N
allows VBZ N
for IN N
faster JJR N
step NN N
frequency NN N
selection NN N
, , N
albeit JJ N
dependent NN N
on IN N
prior JJ N
experience NN N
. . N

To TO N
test VB N
for IN N
both DT N
pre-programmed JJ N
selection NN N
and CC N
direct JJ N
optimization NN N
, , N
we PRP N
applied VBD N
perturbations NNS i
to TO i
treadmill VB i
walking VBG i
to TO N
elicit VB N
transient JJ N
changes NNS N
in IN N
step NN N
frequency NN N
. . N

We PRP N
found VBD N
that IN N
human JJ o
step NN o
frequency NN o
adjustments NNS o
( ( N
n JJ N
= NNP N
7 CD N
) ) N
occurred VBD N
with IN N
two CD N
components NNS N
, , N
the DT N
first JJ N
dominating VBG N
the DT N
response NN N
( ( N
66 CD N
? . N
10 CD N
% NN N
of IN N
total JJ N
amplitude JJ N
change NN N
; : N
mean VB N
? . N
SD NNP N
) ) N
and CC N
occurring VBG N
quite RB N
quickly RB N
( ( N
1.44 CD N
? . N
1.14 CD N
s NN N
to TO N
complete VB N
95 CD N
% NN N
of IN N
total JJ N
change NN N
) ) N
. . N

The DT N
other JJ N
component NN N
was VBD N
of IN N
smaller JJR N
amplitude NN o
( ( N
35 CD N
? . N
10 CD N
% NN N
of IN N
total JJ N
change NN N
) ) N
and CC N
took VBD N
tens NNS N
of IN N
seconds NNS N
( ( N
27.56 CD N
? . N
16.18 CD N
s NN N
for IN N
95 CD N
% NN N
completion NN N
) ) N
. . N

The DT N
fast JJ N
process NN N
appeared VBD N
to TO N
be VB N
too RB N
fast JJ N
for IN N
direct JJ N
optimization NN N
and CC N
more RBR N
indicative JJ N
of IN N
a DT N
pre-programmed JJ N
response NN N
. . N

It PRP N
also RB N
persisted VBD N
even RB N
with IN N
unusual JJ N
closed-loop JJ N
perturbations NNS N
that WDT N
conflicted VBD N
with IN N
prior JJ N
experience NN N
and CC N
rendered VBD N
the DT N
response NN N
energetically RB N
suboptimal JJ N
. . N

The DT N
slow JJ N
process NN N
was VBD N
more RBR N
consistent JJ N
with IN N
the DT N
timing NN N
expected VBN N
for IN N
direct JJ N
optimization NN N
. . N

Our PRP$ N
interpretation NN N
of IN N
these DT N
results NNS N
is VBZ N
that IN N
humans NNS p
may MD N
rely VB N
heavily RB N
on IN N
pre-programmed JJ N
gaits NNS N
to TO N
rapidly RB N
select VB N
their PRP$ N
preferred JJ N
step NN N
frequency NN N
and CC N
then RB N
gradually RB N
fine-tune JJ N
that IN N
selection NN N
with IN N
direct JJ N
optimization NN N
. . N

-DOCSTART- -19708562- O O

[ JJ N
Effect NNP N
of IN N
transcranial JJ i
electrostimulation NN i
on IN N
clinical JJ N
and CC N
laboratory JJ N
characteristics NNS N
in IN N
patients NNS p
with IN p
gastric JJ p
ulcer JJ p
] NN N
. . N

The DT N
study NN N
included VBD N
100 CD p
patients NNS p
with IN p
gastric JJ p
ulcer NNS p
aged VBN p
from IN p
16 CD p
to TO p
60 CD p
years NNS p
. . N

In IN N
58 CD N
patients NNS N
, , N
traditional JJ i
treatment NN i
was VBD N
supplemented VBN N
by IN N
transcranial JJ i
electrotherapy NN i
using VBG N
a DT N
TRANSAIR-02 JJ N
apparatus NN N
. . N

Laboratory NNP N
studies NNS N
included VBD N
measurements NNS N
of IN N
lactoferrin NN o
( ( o
LF NNP o
) ) o
and CC N
tumour JJ o
necrosis NN o
factor-alpha NN o
( ( o
TNF-alpha NNP o
) ) o
, , N
besides VBZ N
standard JJ N
analyses NNS N
. . N

Combined VBN N
treatment NN N
( ( i
traditional JJ i
therapy NN i
plus CC i
electrostimulation NN i
) ) N
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
duration NN o
of IN o
the DT o
main JJ o
symptoms NNS o
of IN N
the DT N
gastric JJ p
ulcer NN p
depending VBG N
on IN N
the DT N
severity NN N
of IN N
ulceration NN N
process NN N
, , N
patients NNS N
' POS N
age NN N
and CC N
sex NN N
. . N

Moreover RB N
, , N
it PRP N
facilitated VBD N
ulcer JJ o
scarring NN o
and CC N
had VBD N
beneficial JJ N
effect NN N
on IN N
dynamics NNS N
of IN N
serum NN o
LF NNP o
and CC o
TNF-alpha NNP o
levels NNS o
. . N

-DOCSTART- -19159999- O O

To TO N
compare VB N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
nifedipine NN i
sustained VBN i
release NN i
with IN N
Ginkgo NNP i
biloba NN i
extract NN i
to TO N
treat VB N
patients NNS p
with IN p
primary JJ p
Raynaud NNP p
's POS p
phenomenon NN p
in IN p
South NNP p
Korea NNP p
; : N
Korean NNP N
Raynaud NNP N
study NN N
( ( N
KOARA NNP N
study NN N
) ) N
. . N

This DT N
study NN N
examined VBD N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
nifedipine NN i
sustained VBN i
release NN i
( ( N
nifedipine JJ i
SR NNP i
) ) N
compared VBN N
with IN N
Ginkgo NNP i
biloba NN i
extract NN i
as IN N
treatment NN N
for IN N
primary JJ N
Raynaud NNP N
's POS N
phenomenon NN N
( ( N
RP NNP N
) ) N
in IN N
Korea NNP N
. . N

Primary NNP N
RP NNP N
were VBD N
screened VBN N
and CC N
assigned VBN N
to TO N
either CC N
the DT N
nifedipine JJ i
SR NNP i
group NN N
( ( N
Group NNP N
N NNP N
) ) N
or CC N
the DT N
Ginkgo NNP i
biloba NN i
extract NN i
group NN N
( ( N
Group NNP N
G NNP N
) ) N
in IN N
the DT N
ratio NN N
of IN N
2:1 CD N
. . N

After IN N
a DT N
run-in JJ N
period NN N
of IN N
2 CD N
weeks NNS N
, , N
patients NNS N
received VBD N
treatment NN N
for IN N
8 CD N
weeks NNS N
. . N

We PRP N
observed VBD N
the DT N
percent NN o
improvement NN o
of IN o
the DT o
RP NNP o
attack NN o
rate NN o
between IN N
before IN N
and CC N
after IN N
the DT N
8-week JJ N
treatment NN N
. . N

Ninety-three JJ p
subjects NNS p
were VBD N
randomly RB N
assigned VBN N
. . N

The DT N
percent NN N
improvement NN N
in IN N
Group NNP N
N NNP N
was VBD N
50.1 CD N
% NN N
at IN N
8 CD N
weeks NNS N
after IN N
treatment NN N
, , N
while IN N
it PRP N
was VBD N
31.0 CD N
% NN N
in IN N
Group NNP N
G NNP N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

No DT N
serious JJ o
adverse JJ o
events NNS o
occurred VBD N
, , N
and CC N
almost RB N
adverse JJ o
events NNS o
were VBD N
mild JJ N
and CC N
improved VBN N
without IN N
specific JJ N
treatment NN N
. . N

nifedipine JJ i
SR NNP i
was VBD N
more RBR N
effective JJ o
than IN N
Ginkgo NNP i
biloba NN i
extract NN i
for IN N
treatment NN N
of IN N
primary JJ N
RP NNP N
in IN N
Korean JJ p
patients NNS p
. . N

Both DT N
drugs NNS N
were VBD N
tolerable JJ o
with IN N
primary JJ N
RP NNP p
patients NNS p
. . N

-DOCSTART- -8911222- O O

Effects NNS N
of IN N
tryptophan JJ N
depletion NN N
in IN N
drug-free JJ p
adults NNS p
with IN p
autistic JJ p
disorder NN p
. . N

BACKGROUND IN N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
behavioral JJ N
and CC N
biochemical JJ N
responses NNS N
to TO N
acute VB N
tryptophan JJ N
depletion NN N
in IN N
drug-free JJ p
adult NN p
patients NNS p
with IN p
autistic JJ p
disorder NN p
. . N

METHODS NNP N
Twenty NNP p
drug-free JJ p
adults NNS p
with IN p
autistic JJ p
disorder NN p
( ( p
16 CD p
men NNS p
and CC p
4 CD p
women NNS p
) ) p
( ( p
mean JJ p
[ NNP p
+/- NN p
SD NNP p
] NNP p
age NN p
, , p
30.5 CD p
+/- JJ p
8.5 CD p
years NNS p
) ) p
underwent JJ N
short-term JJ N
tryptophan NN i
depletion NN i
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized JJ N
crossover NN N
design NN N
. . N

Patients NNS N
received VBD N
a DT N
24-hour JJ N
, , N
low-tryptophan JJ i
diet NN i
followed VBD N
the DT N
next JJ N
morning NN N
by IN N
an DT N
amino NN i
acid NN i
drink NN i
. . N

Behavioral JJ N
ratings NNS N
were VBD N
obtained VBN N
on IN N
the DT N
morning NN N
of IN N
the DT N
amino NN i
acid NN i
drink NN i
( ( N
baseline NN N
) ) N
and CC N
180 CD N
, , N
300 CD N
, , N
and CC N
420 CD N
minutes NNS N
after IN N
the DT N
drink NN N
. . N

Plasma NNP o
free JJ o
and CC o
total JJ o
tryptophan NN o
levels NNS o
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
5 CD N
hours NNS N
after IN N
the DT N
drink NN N
. . N

The DT N
active JJ N
and CC N
sham JJ N
testing NN N
sessions NNS N
were VBD N
separated VBN N
by IN N
7 CD N
days NNS N
. . N

RESULTS NNP N
Eleven NNP N
( ( N
65 CD N
% NN N
) ) N
of IN N
the DT N
17 CD N
patients NNS N
who WP N
completed VBD N
both DT N
test NN N
days NNS N
showed VBD N
a DT N
significant JJ N
global JJ N
worsening NN N
of IN N
behavioral JJ N
symptoms NNS N
with IN N
short-term JJ N
tryptophan NN N
depletion NN N
, , N
but CC N
none NN N
of IN N
the DT N
17 CD N
patients NNS N
showed VBD N
any DT N
significant JJ N
change NN N
in IN N
clinical JJ N
status NN N
from IN N
baseline NN N
after IN N
sham JJ N
depletion NN N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Tryptophan NNP N
depletion NN N
led VBD N
to TO N
a DT N
significant JJ N
increase NN N
in IN N
behaviors NNS N
such JJ N
as IN N
whirling NN o
, , o
flapping NN o
, , o
pacing NN o
, , o
banging NN o
and CC o
hitting VBG o
self NN o
, , o
rocking NN o
, , o
and CC o
toe NN o
walking NN o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

In IN N
addition NN N
, , N
patients NNS N
were VBD N
significantly RB N
less JJR N
calm JJ o
and CC o
happy JJ o
and CC N
more RBR N
anxious JJ o
. . N

No DT N
significant JJ N
change NN N
was VBD N
observed VBN N
in IN N
social JJ o
relatedness NN o
or CC o
repetitive JJ o
thoughts NNS o
and CC o
behavior NN o
. . N

Plasma NNP o
total JJ o
and CC o
free JJ o
tryptophan NN o
levels NNS o
were VBD N
reduced VBN N
86 CD N
% NN N
and CC N
69 CD N
% NN N
, , N
respectively RB N
, , N
5 CD N
hours NNS N
after IN N
the DT N
tryptophan-deficient JJ N
amino NN N
acid NN N
drink NN N
. . N

Patients NNS N
who WP N
had VBD N
a DT N
significant JJ N
global JJ N
exacerbation NN N
of IN N
symptoms NNS N
had VBD N
significantly RB N
higher JJR N
baseline NN N
plasma IN o
total JJ o
tryptophan NN o
levels NNS o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
Autism NNP o
Behavior NNP o
Checklist NNP o
scores NNS o
( ( N
P NNP N
= NNP N
.005 NNP N
) ) N
than IN N
did VBD N
patients NNS N
who WP N
showed VBD N
no DT N
significant JJ N
change NN N
in IN N
symptoms NNS N
after IN N
tryptophan JJ N
depletion NN N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
are VBP N
consistent JJ N
with IN N
previous JJ N
research NN N
that WDT N
has VBZ N
implicated VBN N
a DT N
dysregulation NN N
in IN N
serotonin JJ N
function NN N
in IN N
some DT N
patients NNS p
with IN p
autism NN p
. . N

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
short-term JJ N
reduction NN N
of IN N
serotonin NN N
precursor NN N
availability NN N
may MD N
exacerbate VB N
some DT N
symptoms NNS o
characteristic JJ N
of IN N
autism NN N
in IN N
some DT N
patients NNS N
. . N

Continued JJ N
investigation NN N
into IN N
the DT N
role NN N
of IN N
serotonin NN N
in IN N
the DT N
pathogenesis NN N
and CC N
treatment NN N
of IN N
autistic JJ p
disorder NN p
is VBZ N
warranted VBN N
. . N

-DOCSTART- -1963383- O O

[ JJ N
Effect NNP N
of IN N
liu NN i
wei NN i
di NN i
huang NN i
or CC N
jin NN i
gui NN i
shen NN i
qi JJ i
decoction NN N
as IN N
on IN N
adjuvant JJ N
treatment NN N
in IN N
small JJ p
cell NN p
lung NN p
cancer NN p
] NNP N
. . N

Eighty-three JJ p
patients NNS p
with IN p
small JJ p
cell NN p
lung NN p
cancer NN p
were VBD N
randomized VBN N
with IN N
or CC N
without IN N
using VBG N
a DT N
traditional JJ N
Chinese JJ N
Kidney-tonifying NNP i
decoction NN i
( ( N
Liu NNP i
Wei NNP i
Di NNP i
Huang NNP i
or CC N
Jin NNP i
Gui NNP i
Shen NNP i
Qi NNP i
medicinal JJ N
decoction NN N
) ) N
in IN N
chemotherapy NN N
or CC N
radiotherapy NN N
courses NNS N
. . N

74 CD p
patients NNS p
were VBD N
availble JJ N
to TO N
be VB N
analysis NN N
. . N

The DT N
two CD N
treatment NN N
groups NNS N
were VBD N
well-matched JJ N
in IN N
age NN N
, , N
sex NN N
, , N
stage NN N
and CC N
performance NN N
status NN N
. . N

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
response NN o
rate NN o
and CC o
the DT o
median JJ o
survival NN o
between IN N
two CD N
groups NNS N
. . N

The DT N
overall JJ o
response NN o
rate NN o
( ( N
CR+PR NNP N
) ) N
was VBD N
91.5 CD N
% NN N
for IN N
Chinese JJ i
herb NN i
group NN N
and CC N
46.9 CD N
% NN N
for IN N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
median JJ o
survival NN o
was VBD N
16 CD N
months NNS N
for IN N
the DT N
traditional JJ N
Chinese JJ N
Kidney-tonifying NNP i
decoction NN i
group NN N
, , N
and CC N
10 CD N
months NNS N
for IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Survival JJ o
curve NN o
( ( o
Kaplan-meire NNP o
's POS o
) ) o
of IN N
the DT N
Chinese NNP N
herb NN N
group NN N
was VBD N
better JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
. . N

10 CD N
patients NNS N
of IN N
Chinese JJ i
herb NN i
group NN N
was VBD N
alive JJ N
beyond IN N
more JJR N
than IN N
2 CD N
years NNS N
. . N

Until IN N
now RB N
, , N
4 CD N
patients NNS N
in IN N
the DT N
Chinese JJ i
herb NN i
group NN N
, , N
one CD N
in IN N
the DT N
control NN N
group NN N
are VBP N
still RB N
enjoying VBG N
their PRP$ N
disease-free JJ o
life NN o
for IN N
more JJR N
than IN N
7 CD N
years NNS N
. . N

Hematologic NNP o
toxicities NNS o
were VBD N
observed VBN N
much RB N
frequently RB N
in IN N
the DT N
patients NNS N
of IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.005 CD N
and CC N
0.01/WBC CD N
and CC N
BPC NNP N
) ) N
. . N

Results NNS N
of IN N
animal JJ N
experiments NNS N
with IN N
the DT N
same JJ N
traditional JJ N
medicinal JJ N
decoctions NNS N
as IN N
used VBN N
in IN N
clinic NN N
have VBP N
showed VBN N
immuno-enhancement JJ o
activities NNS o
. . N

These DT N
results NNS N
have VBP N
showed VBN N
that IN N
the DT N
traditional JJ N
Chinese JJ i
Kidney-tonifying NNP i
decoction NN i
may MD N
enhance VB N
non-specific JJ N
immunology NN N
activities NNS N
and CC N
may MD N
be VB N
much JJ N
useful JJ N
for IN N
solid JJ p
cancer NN p
patients NNS p
as IN N
an DT N
adjuvant JJ N
treatment NN N
. . N

-DOCSTART- -23103798- O O

Role NNP N
of IN N
posterior JJ i
tibial JJ i
nerve NN i
stimulation NN i
in IN N
the DT N
treatment NN N
of IN N
refractory JJ N
monosymptomatic JJ N
nocturnal JJ N
enuresis NN N
: : N
a DT N
pilot NN N
study NN N
. . N

PURPOSE NNP N
We PRP N
evaluated VBD N
the DT N
early JJ N
clinical JJ N
and CC N
urodynamic JJ N
results NNS N
of IN N
posterior JJ i
tibial JJ i
nerve NN i
stimulation NN i
in IN N
patients NNS p
with IN p
refractory JJ p
monosymptomatic JJ p
nocturnal JJ p
enuresis NN p
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
28 CD p
patients NNS p
with IN p
refractory JJ p
monosymptomatic JJ p
nocturnal JJ p
enuresis NN p
to TO N
2 CD N
equal JJ N
groups NNS N
. . N

Group NNP N
1 CD N
received VBD N
a DT N
weekly JJ N
session NN N
of IN N
posterior JJ i
tibial JJ i
nerve NN i
stimulation NN i
for IN N
12 CD N
weeks NNS N
and CC N
group NN N
2 CD N
was VBD N
the DT N
placebo NN i
group NN N
. . N

Evaluation NN N
was VBD N
performed VBN N
in IN N
each DT N
group NN N
at IN N
baseline NN N
and CC N
after IN N
posterior JJ N
tibial JJ N
nerve NN N
stimulation NN N
to TO N
compare VB N
clinical JJ N
and CC N
urodynamic JJ N
findings NNS N
. . N

Another DT N
clinical JJ N
assessment NN N
was VBD N
done VBN N
3 CD N
months NNS N
after IN N
the DT N
first JJ N
followup NN N
. . N

RESULTS VB N
The DT N
2 CD N
groups NNS N
were VBD N
comparable JJ N
in IN N
baseline JJ N
clinical JJ N
and CC N
urodynamic JJ N
data NNS N
. . N

Overall NNP N
, , N
13 CD N
patients NNS N
( ( N
46.4 CD N
% NN N
) ) N
had VBD N
detrusor VBN o
overactivity NN o
and CC N
14 CD N
( ( N
50 CD N
% NN N
) ) N
had VBD N
decreased VBN N
bladder NN o
capacity NN o
. . N

After IN N
treatment NN N
11 CD N
group NN N
1 CD N
patients NNS N
( ( N
78.6 CD N
% NN N
) ) N
had VBD N
a DT N
partial JJ N
or CC N
full JJ N
response NN o
to TO N
posterior VB N
tibial JJ N
nerve NN N
stimulation NN N
but CC N
only RB N
2 CD N
( ( N
14.3 CD N
% NN N
) ) N
in IN N
group NN N
2 CD N
had VBD N
a DT N
partial JJ N
response NN o
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

Also RB N
, , N
the DT N
average JJ N
number NN o
of IN o
wet JJ o
nights NNS o
in IN N
group NN N
1 CD N
was VBD N
significantly RB N
lower JJR N
than IN N
at IN N
baseline NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

All DT N
urodynamic JJ o
parameters NNS o
significantly RB N
improved VBN N
in IN N
group NN N
1 CD N
. . N

In IN N
contrast NN N
, , N
the DT N
number NN N
of IN N
wet JJ o
nights NNS o
and CC o
urodynamic JJ o
parameters NNS o
did VBD N
not RB N
change VB N
significantly RB N
in IN N
group NN N
2 CD N
. . N

At IN N
3-month JJ N
followup NN N
the DT N
number NN N
of IN N
patients NNS N
with IN N
a DT N
partial JJ N
or CC N
full JJ N
response NN o
in IN N
group NN N
1 CD N
had VBD N
decreased VBN N
from IN N
11 CD N
( ( N
78.6 CD N
% NN N
) ) N
to TO N
6 CD N
( ( N
42.9 CD N
% NN N
) ) N
. . N

No DT N
change NN N
was VBD N
evident JJ N
in IN N
group NN N
2 CD N
. . N

CONCLUSIONS NNP N
Posterior NNP i
tibial JJ i
nerve NN i
stimulation NN i
can MD N
be VB N
a DT N
viable JJ N
treatment NN N
option NN N
in IN N
some DT N
patients NNS p
with IN p
refractory JJ p
monosymptomatic JJ p
nocturnal JJ p
enuresis NN p
. . N

However RB N
, , N
deterioration NN N
in IN N
some DT N
responders NNS N
with IN N
time NN N
suggests VBZ N
the DT N
need NN N
for IN N
maintenance NN N
protocols NNS N
. . N

-DOCSTART- -22956006- O O

A DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
cross-over JJ N
trial NN N
of IN N
the DT N
impact NN N
on IN N
quality NN o
of IN o
life NN o
of IN N
continuing VBG N
dexamethasone JJ i
beyond IN N
24 CD N
h NN N
following VBG N
adjuvant JJ p
chemotherapy NN p
for IN p
breast NN p
cancer NN p
. . N

Uncertainty NN N
remains VBZ N
about IN N
the DT N
optimal JJ N
anti-emetic JJ N
regimen NNS N
for IN N
control NN N
of IN N
delayed JJ N
nausea NN N
and CC N
vomiting NN N
after IN N
adjuvant JJ N
chemotherapy NN N
for IN N
breast NN N
cancer NN N
. . N

Many JJ N
patients NNS N
receive VBP N
dexamethasone NN i
but CC N
complain NN N
of IN N
insomnia NN N
, , N
anxiety/agitation NN N
, , N
and CC N
indigestion NN N
. . N

The DT N
aim NN N
was VBD N
to TO N
determine VB N
if IN N
patients NNS N
receiving VBG N
chemotherapy NN N
for IN N
breast NN p
cancer NN p
prefer VBP N
treatment NN N
with IN N
dexamethasone NN i
or CC N
placebo NN i
for IN N
prophylaxis NN N
against IN N
delayed VBN N
nausea NN N
and CC N
vomiting NN N
, , N
and CC N
to TO N
compare VB N
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
between IN N
the DT N
two CD N
treatments NNS N
. . N

In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
trial NN N
, , N
we PRP N
compared VBN N
oral JJ N
dexamethasone NN i
( ( N
4 CD N
mg NN N
twice RB N
daily RB N
for IN N
2 CD N
days NNS N
) ) N
versus VBP N
placebo NN i
for IN N
chemotherapy-na?ve JJ p
patients NNS p
with IN p
breast JJ p
cancer NN p
. . N

All DT N
patients NNS N
received VBD N
intravenous JJ N
granisetron NN i
and CC N
dexamethasone NN i
pre-chemotherapy NN N
and CC N
oral JJ N
granisetron NN i
on IN N
day NN N
2 CD N
. . N

Primary JJ N
endpoints NNS N
were VBD N
: : N
( ( N
i NN N
) ) N
patient NN o
preference NN o
; : N
( ( N
ii NN N
) ) N
difference NN N
between IN N
cycles NNS N
in IN N
change NN o
of IN o
QOL NNP o
from IN N
days NNS N
1 CD N
to TO N
8 CD N
. . N

Median JJ N
age NN p
of IN p
the DT p
94 CD p
women NNS p
was VBD p
51 CD p
years NNS p
( ( p
range VB p
27-76 JJ p
) ) p
: : N
79 CD N
received VBD N
fluorouracil/epirubicin/cyclophosphamide NN i
and CC N
15 CD N
received VBD N
doxorubicin/cyclophosphamide NN i
. . N

Thirteen JJ N
withdrew VBD N
pre-cycle JJ N
2 CD N
with IN N
no DT N
differences NNS N
between IN N
arms NNS N
. . N

Of IN N
80 CD N
patients NNS N
stating VBG N
a DT N
preference NN N
, , N
31 CD N
preferred JJ N
placebo NN i
( ( N
39 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
28-50 CD N
% NN N
) ) N
and CC N
37 CD N
( ( N
46 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
35-58 CD N
% NN N
) ) N
preferred VBD N
dexamethasone NN i
; : N
12 CD N
had VBD N
no DT N
preference NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
intensity NN o
of IN o
vomiting VBG o
, , o
nausea NN o
, , o
or CC o
time NN o
to TO o
onset VB o
of IN o
vomiting VBG o
. . N

There EX N
was VBD N
greater JJR N
decrease NN N
in IN N
global JJ o
QOL NNP o
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
when WRB N
patients NNS N
received VBD N
dexamethasone NN i
. . N

No DT N
other JJ o
symptom/QOL NN N
domains NNS N
differed VBD N
significantly RB N
. . N

In IN N
conclusion NN N
, , N
no DT N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
patient JJ o
preference NN o
, , o
QOL NNP o
, , o
or CC o
symptoms NNS o
regardless RB N
of IN N
whether IN N
dexamethasone NN i
or CC N
placebo NN i
was VBD N
used VBN N
after IN N
adjuvant JJ N
chemotherapy NN N
. . N

-DOCSTART- -22865017- O O

RESPECT-PTSD JJ N
: : N
re-engineering JJ N
systems NNS N
for IN N
the DT N
primary JJ N
care NN N
treatment NN N
of IN N
PTSD NNP p
, , N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Although IN N
collaborative JJ N
care NN N
is VBZ N
effective JJ N
for IN N
treating VBG N
depression NN N
and CC N
other JJ N
mental JJ N
disorders NNS N
in IN N
primary JJ N
care NN N
, , N
there EX N
have VBP N
been VBN N
no DT N
randomized JJ N
trials NNS N
of IN N
collaborative JJ N
care NN N
specifically RB N
for IN N
patients NNS p
with IN p
Posttraumatic NNP p
stress NN p
disorder NN p
( ( p
PTSD NNP p
) ) p
. . N

OBJECTIVE UH N
To TO N
compare VB N
a DT N
collaborative JJ N
approach NN N
, , N
the DT N
Three NNP i
Component NNP i
Model NNP i
( ( i
3CM CD i
) ) i
, , N
with IN N
usual JJ i
care NN i
for IN N
treating VBG N
PTSD NNP N
in IN N
primary JJ N
care NN N
. . N

DESIGN VB N
The DT N
study NN N
was VBD N
a DT N
two-arm JJ N
, , N
parallel JJ N
randomized VBD N
clinical JJ N
trial NN N
. . N

PTSD JJ p
patients NNS p
were VBD p
recruited VBN p
from IN p
five CD p
primary JJ p
care NN p
clinics NNS p
at IN p
four CD p
Veterans NNS p
Affairs NNP p
healthcare NN p
facilities NNS p
and CC N
randomized VBN N
to TO N
receive VB N
usual JJ i
care NN i
or CC N
usual JJ i
care NN i
plus CC i
3CM CD i
. . N

Blinded VBN N
assessors NNS N
collected VBD N
data NNS N
at IN N
baseline NN N
and CC N
3-month JJ N
and CC N
6-month JJ N
follow-up NN N
. . N

PARTICIPANTS JJ N
Participants NNS p
were VBD p
195 CD p
Veterans NNPS p
. . N

Their PRP$ p
average JJ p
age NN p
was VBD p
45 CD p
years NNS p
, , p
91 CD p
% NN p
were VBD p
male JJ p
, , p
58 CD p
% NN p
were VBD p
white JJ p
, , p
40 CD p
% NN p
served VBN p
in IN p
Iraq NNP p
or CC p
Afghanistan NNP p
, , p
and CC p
42 CD p
% NN p
served VBD p
in IN p
Vietnam NNP p
. . N

INTERVENTION NNP N
All NNP N
participants NNS N
received VBD N
usual JJ N
care NN N
. . N

Participants NNS N
assigned VBD N
to TO N
3CM CD i
also RB N
received VBD N
telephone NN i
care NN i
management NN i
. . N

Care NN N
managers NNS N
received VBD N
supervision NN N
from IN N
a DT N
psychiatrist NN N
. . N

MAIN NNP N
MEASURES NNP N
PTSD NNP o
symptom NN o
severity NN o
was VBD N
the DT N
primary JJ N
outcome NN N
. . N

Depression NNP o
, , o
functioning NN o
, , o
perceived VBD o
quality NN o
of IN o
care NN o
, , o
utilization NN o
, , o
and CC o
costs NNS o
were VBD N
secondary JJ N
outcomes NNS N
. . N

KEY JJ N
RESULTS NNP N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
3CM CD N
and CC N
usual JJ N
care NN N
in IN N
symptoms NNS o
or CC N
functioning VBG o
. . N

Participants NNS N
assigned VBD N
to TO N
3CM CD i
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
a DT N
mental JJ o
health NN o
visit NN o
, , o
fill VB o
an DT o
antidepressant JJ o
prescription NN o
, , N
and CC N
have VBP N
adequate VBN o
antidepressant JJ o
refills NNS o
. . N

3CM CD i
participants NNS N
also RB N
had VBD N
more RBR N
mental JJ o
health NN o
visits NNS o
and CC N
higher JJR N
outpatient NN o
pharmacy NN o
costs NNS o
. . N

CONCLUSIONS NNP N
Results NNP N
suggest VBP N
the DT N
need NN N
for IN N
careful JJ N
examination NN N
of IN N
the DT N
way NN N
that IN N
collaborative JJ N
care NN N
models NNS N
are VBP N
implemented VBN N
for IN N
treating VBG N
PTSD NNP N
, , N
and CC N
for IN N
additional JJ N
supports NNS N
to TO N
encourage VB N
primary JJ N
care NN N
providers NNS N
to TO N
manage VB N
PTSD NNP N
. . N

-DOCSTART- -22416755- O O

Preschoolers NNS p
acquire VB N
general JJ N
knowledge NN N
by IN N
sharing VBG N
in IN N
pretense NN i
. . N

Children NNP N
acquire VB N
general JJ N
knowledge NN N
about IN N
many JJ N
kinds NNS N
of IN N
things NNS N
, , N
but CC N
there EX N
are VBP N
few JJ N
known VBN N
means NNS N
by IN N
which WDT N
this DT N
knowledge NN N
is VBZ N
acquired VBN N
. . N

In IN N
this DT N
article NN N
, , N
it PRP N
is VBZ N
proposed VBN N
that IN N
children NNS N
acquire VB N
generic JJ N
knowledge NN N
by IN N
sharing VBG N
in IN N
pretend JJ i
play NN i
. . N

In IN N
Experiment JJ N
1 CD N
, , N
twenty-two JJ p
3- JJ p
to TO p
4-year-olds NNS p
watched VBN N
pretense NN i
in IN N
which WDT N
a DT N
puppet NN N
represented VBD N
a DT N
nerp NN N
( ( N
an DT N
unfamiliar JJ N
kind NN N
of IN N
animal NN N
) ) N
. . N

For IN N
instance NN N
, , N
in IN N
one CD N
scenario NN N
, , N
the DT N
nerp JJ N
ate NN N
and CC N
disliked VBD N
a DT N
carrot NN N
. . N

When WRB N
subsequently RB N
asked VBD N
generic JJ N
questions NNS N
about IN N
real JJ N
nerps NNS N
, , N
children NNS p
's POS N
responses NNS o
suggested VBD N
that IN N
they PRP N
had VBD N
learned VBN N
general JJ N
facts NNS N
( ( N
e.g. NN N
, , N
nerps RB N
dislike JJ N
carrots NNS N
) ) N
. . N

In IN N
Experiment JJ N
2 CD N
, , N
thirty-two JJ p
4- JJ p
to TO p
5-year-olds NNS p
learned VBN N
from IN N
scenarios NNS i
lacking VBG i
pretend JJ i
speech NN i
or CC i
sound JJ i
effects NNS i
. . N

The DT N
findings NNS N
reveal VBP N
a DT N
long JJ N
overlooked JJ N
means NNS N
by IN N
which WDT N
children NNS p
can MD N
acquire VB N
generic JJ N
knowledge NN N
. . N

-DOCSTART- -17293018- O O

The DT N
safety NN N
of IN N
whey JJ i
protein NN i
concentrate NN i
derived VBN N
from IN N
the DT N
milk NN N
of IN N
cows NNS N
immunized VBN N
against IN N
Clostridium NNP N
difficile NN N
. . N

A DT N
whey JJ i
protein NN i
concentrate NN i
prepared VBN N
from IN N
the DT N
milk NN N
of IN N
cows NNS N
that WDT N
have VBP N
been VBN N
immunized VBN i
against IN i
Clostridium NNP i
difficile NN i
( ( i
C. NNP i
difficile NN i
) ) i
and CC i
its PRP$ i
toxins NNS i
, , i
toxin NN i
A NNP i
and CC i
toxin NN i
B NNP i
, , N
is VBZ N
produced VBN N
for IN N
use NN N
as IN N
a DT N
medical JJ N
food NN N
for IN N
the DT N
dietary JJ N
management NN N
of IN N
patients NNS p
with IN p
C. NNP p
difficile-associated JJ p
diarrhea NN p
( ( p
CDAD NNP p
) ) p
to TO N
prevent VB N
a DT N
relapse NN N
of IN N
the DT N
infection NN N
. . N

The DT N
safety NN N
of IN N
anti-C. JJ i
difficile NN i
whey NN i
protein VBP i
concentrate NN i
( ( i
anti-CD JJ i
WPC NNP i
) ) i
is VBZ N
supported VBN N
by IN N
analytical JJ N
data NNS N
comparing VBG N
the DT N
composition NN N
of IN N
raw JJ N
milk NN N
from IN N
immunized JJ N
cows NNS N
versus VBP N
that IN N
from IN N
non-immunized JJ N
cows NNS N
, , N
and CC N
the DT N
composition NN N
of IN N
anti-CD JJ i
WPC NNP i
versus NN N
that IN N
of IN N
regular JJ i
whey NN i
protein NN i
concentrate NN i
. . N

Additionally RB N
, , N
a DT N
prospective JJ N
clinical JJ N
study NN N
was VBD N
conducted VBN N
in IN N
77 CD p
patients NNS p
with IN p
CDAD NNP p
to TO N
demonstrate VB N
the DT N
safety NN N
of IN N
consuming VBG N
anti-CD JJ i
WPC NNP i
to TO N
prevent VB N
relapse NN N
of IN N
the DT N
infection NN N
. . N

This DT N
study NN N
, , N
which WDT N
included VBD N
adverse JJ N
event NN N
monitoring NN N
, , N
physical JJ N
examinations NNS N
, , N
and CC N
extensive JJ N
hematological NN N
and CC N
biochemical JJ N
assessments NNS N
, , N
showed VBD N
that IN N
anti-CD JJ i
WPC NNP i
is VBZ N
safe JJ o
to TO N
consume VB N
by IN N
patients NNS p
with IN p
CDAD NNP p
. . N

The DT N
available JJ N
analytical JJ N
and CC N
clinical JJ N
evidence NN N
demonstrate NN N
that IN N
anti-CD JJ i
WPC NNP i
is VBZ N
safe JJ o
for IN N
use NN N
by IN N
individuals NNS p
with IN p
CDAD NNP p
, , N
under IN N
the DT N
described JJ N
conditions NNS N
of IN N
use NN N
. . N

-DOCSTART- -8911223- O O

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
fluvoxamine NN i
in IN N
adults NNS p
with IN p
autistic JJ p
disorder NN p
. . N

BACKGROUND NNP N
Autistic NNP N
disorder NN N
is VBZ N
characterized VBN N
by IN N
a DT N
fundamental JJ N
disturbance NN N
in IN N
social JJ N
interaction NN N
, , N
impairments NNS N
in IN N
communication NN N
, , N
and CC N
a DT N
markedly RB N
restricted JJ N
repertoire NN N
of IN N
activities NNS N
and CC N
interests NNS N
. . N

Abnormalities NNS N
in IN N
the DT N
serotonin NN N
neurotransmitter NN N
system NN N
have VBP N
been VBN N
identified VBN N
in IN N
some DT N
persons NNS N
with IN N
autism NN N
. . N

No DT N
consistently RB N
effective JJ N
and CC N
safe JJ N
drugs NNS N
have VBP N
been VBN N
developed VBN N
for IN N
treating VBG N
the DT N
symptoms NNS N
of IN N
autism NN N
. . N

METHODS NNP N
Thirty NNP p
adults NNS p
with IN p
autistic JJ p
disorder NN p
completed VBD N
a DT N
12-week JJ N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
of IN N
the DT N
potent NN N
and CC N
selective JJ N
serotonin NN N
uptake JJ N
inhibitor NN N
fluvoxamine NN i
maleate NN i
. . N

Behavioral JJ o
ratings NNS o
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
after IN N
4 CD N
, , N
8 CD N
, , N
and CC N
12 CD N
weeks NNS N
of IN N
treatment NN N
. . N

RESULTS NNP N
Eight NNP N
( ( N
53 CD N
% NN N
) ) N
of IN N
15 CD N
patients NNS N
in IN N
the DT N
fluvoxamine-treated JJ i
group NN N
were VBD N
categorized VBN N
as IN N
responders NNS N
compared VBN N
with IN N
none NN N
of IN N
15 CD N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Fluvoxamine NNP i
was VBD N
superior JJ N
to TO N
placebo VB i
in IN N
reducing VBG N
repetitive JJ o
thoughts NNS o
and CC o
behavior NN o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
maladaptive JJ o
behavior NN o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
aggression NN o
( ( N
P NNP N
< NNP N
.03 NNP N
) ) N
, , N
and CC N
in IN N
improving VBG N
some DT N
aspects NNS N
of IN N
social JJ o
relatedness NN o
( ( N
P NNP N
< NNP N
.04 NNP N
) ) N
, , N
especially RB N
language NN o
usage NN o
( ( N
P NNP N
< NNP N
.008 NNP N
) ) N
. . N

Treatment JJ N
response NN N
was VBD N
not RB N
correlated VBN N
with IN N
age NN N
level NN N
of IN N
autistic JJ N
behavior NN N
, , N
or CC N
full-scale JJ N
IQ NNP N
. . N

Other JJ N
than IN N
mild JJ o
sedation NN o
and CC o
nausea NN o
in IN N
a DT N
few JJ N
patients NNS N
, , N
fluvoxamine NN i
was VBD N
well RB N
tolerated VBN N
. . N

No DT N
dyskinesias NN o
, , o
adverse JJ o
cardiovascular JJ o
events NNS o
, , o
or CC o
seizures NNS o
occurred VBD N
. . N

CONCLUSIONS NNP N
Fluvoxamine NNP i
is VBZ N
more RBR N
effective JJ N
than IN N
placebo NN i
in IN N
the DT N
short-term JJ N
treatment NN N
of IN N
the DT N
symptoms NNS N
of IN N
autistic JJ N
disorder NN N
in IN N
adults NNS N
. . N

Controlled JJ N
studies NNS N
of IN N
fluvoxamine NN i
and CC N
other JJ N
potent NN N
and CC N
selective JJ N
serotonin NN N
uptake JJ N
inhibitors NNS N
seem VBP N
warranted VBN N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
. . N

-DOCSTART- -24989854- O O

A DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
a DT N
social JJ i
skills NNS i
training VBG i
for IN N
preadolescent JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : N
generalization NN N
of IN N
skills NNS N
by IN N
training VBG N
parents NNS N
and CC N
teachers NNS N
? . N
BACKGROUND NNP N
Social NNP i
skills NNS i
training VBG i
( ( i
SST NNP i
) ) i
is VBZ N
a DT N
common JJ N
intervention NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASDs NNP p
) ) p
to TO N
improve VB N
their PRP$ N
social JJ N
and CC N
communication NN N
skills NNS N
. . N

Despite IN N
the DT N
fact NN N
that IN N
SSTs NNP i
are VBP N
often RB N
applied VBN N
in IN N
clinical JJ N
practice NN N
, , N
the DT N
evidence NN N
for IN N
the DT N
effectiveness NN N
of IN N
these DT N
trainings NNS N
for IN N
children NNS p
with IN p
ASD NNP p
is VBZ N
inconclusive JJ N
. . N

Moreover RB N
, , N
long JJ N
term NN N
outcome NN N
and CC N
generalization NN N
of IN N
learned JJ N
skills NNS N
are VBP N
little JJ N
evaluated JJ N
. . N

Additionally RB N
, , N
there EX N
is VBZ N
no DT N
research NN N
on IN N
the DT N
influence NN N
of IN N
involvement NN N
of IN N
parents NNS N
and CC N
teachers NNS N
on IN N
effectiveness NN N
of IN N
SST NNP i
and CC N
on IN N
the DT N
generalization NN N
of IN N
learned VBN N
social JJ N
skills NNS N
to TO N
daily JJ N
life NN N
. . N

We PRP N
expect VBP N
parent NN N
and CC N
teacher NN N
involvement NN N
in IN N
SST NNP i
to TO N
enhance VB N
treatment NN N
efficacy NN N
and CC N
to TO N
facilitate VB N
generalization NN N
of IN N
learned JJ N
skills NNS N
to TO N
daily JJ N
life NN N
. . N

METHOD/DESIGN NNP N
In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
with IN N
three CD N
conditions NNS N
, , N
120 CD p
participants NNS p
with IN p
ASD NNP p
at IN p
the DT p
end NN p
of IN p
primary JJ p
school NN p
( ( p
10-12 CD p
years NNS p
of IN p
calendar NN p
age NN p
) ) p
have VBP N
been VBN N
randomized VBN N
to TO N
SST NNP i
, , N
SST-PTI NNP i
( ( i
SST NNP i
with IN i
Parent NNP i
& CC i
Teacher NNP i
Involvement NNP i
) ) i
, , N
or CC N
care-as-usual JJ i
. . N

The DT N
SST NNP i
consists VBZ N
of IN N
18 CD N
group NN N
sessions NNS N
of IN N
1.5 CD N
hours NNS N
for IN N
the DT N
children NNS N
. . N

In IN N
the DT N
SST-PTI JJ i
condition NN N
, , N
parents NNS N
additionally RB N
participate VBP N
in IN N
8 CD N
parent NN N
sessions NNS N
and CC N
parents NNS N
and CC N
teachers NNS N
are VBP N
actively RB N
involved VBN N
in IN N
homework NN N
assignments NNS N
. . N

Assessment NNP N
takes VBZ N
place NN N
at IN N
three CD N
moments NNS N
: : N
before RB N
and CC N
immediately RB N
after IN N
the DT N
intervention NN N
period NN N
and CC N
at IN N
6 CD N
months NNS N
follow-up RB N
. . N

Primary JJ N
outcome NN N
is VBZ N
socialization NN o
, , N
as IN N
an DT N
aspect NN N
of IN N
adaptive JJ N
functioning NN N
. . N

Secondary JJ N
outcomes NNS N
focus VBP N
on IN N
specific JJ o
social JJ o
skills NNS o
children NNS N
learn VBP N
during IN N
SST NNP i
and CC N
on IN N
more JJR N
general JJ o
social JJ o
skills NNS o
pertaining VBG N
to TO N
home NN N
and CC N
community NN N
settings NNS N
from IN N
a DT N
multi-informant JJ N
perspective NN N
. . N

Additionally RB N
, , N
possible JJ N
predictors NNS N
of IN N
treatment NN N
outcome NN N
will MD N
be VB N
assessed VBN N
. . N

DISCUSSION VB N
The DT N
current JJ N
study NN N
is VBZ N
an DT N
RCT NNP N
study NN N
evaluating VBG N
SST NNP i
in IN N
a DT N
large JJ N
sample NN N
of IN N
Dutch NNP p
children NNS p
with IN p
ASD NNP p
in IN p
a DT p
specific JJ p
age NN p
range NN p
( ( p
10-12 CD p
years NNS p
) ) p
. . N

Strengths NNP N
of IN N
the DT N
study NN N
are VBP N
the DT N
use NN N
of IN N
one CD N
manualized VBN N
protocol NN N
, , N
application NN N
of IN N
standardized JJ N
and CC N
internationally RB N
used VBD N
rating NN N
instruments NNS N
, , N
use NN N
of IN N
multiple JJ N
raters NNS N
, , N
investigation NN N
of IN N
generalization NN N
of IN N
learned JJ N
skills NNS N
to TO N
daily JJ N
life NN N
, , N
and CC N
the DT N
evaluation NN N
of IN N
efficacy NN N
in IN N
the DT N
longer JJR N
term NN N
by IN N
follow-up JJ N
measures NNS N
at IN N
6 CD N
months NNS N
after IN N
the DT N
end NN N
of IN N
training NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NTR2405 NNP N
. . N

-DOCSTART- -24075141- O O

Data NNP N
mining NN N
the DT N
ScanBrit NNP N
study NN N
of IN N
a DT N
gluten- JJ i
and CC i
casein-free JJ i
dietary JJ i
intervention NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : N
behavioural JJ o
and CC o
psychometric JJ o
measures NNS o
of IN N
dietary JJ N
response NN N
. . N

We PRP N
previously RB N
reported VBD N
results NNS N
based VBN N
on IN N
the DT N
examination NN N
of IN N
a DT N
gluten- JJ i
and CC i
casein-free JJ i
diet NN i
as IN N
an DT N
intervention NN N
for IN N
children NNS p
diagnosed VBN p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
as IN N
part NN N
of IN N
the DT N
ScanBrit NNP N
collaboration NN N
. . N

Analysis NN N
based VBN N
on IN N
grouped JJ N
results NNS N
indicated VBD N
several JJ N
significant JJ N
differences NNS N
between IN N
dietary JJ N
and CC N
non-dietary JJ N
participants NNS N
across IN N
various JJ N
core NN N
and CC N
peripheral JJ N
areas NNS N
of IN N
functioning VBG N
. . N

Results NNP N
also RB N
indicated VBD N
some DT N
disparity NN N
in IN N
individual JJ N
responses NNS N
to TO N
dietary JJ N
modification NN N
potentially RB N
indicative JJ N
of IN N
responder NN N
and CC N
non-responder JJ N
differences NNS N
. . N

Further JJ N
examination NN N
of IN N
the DT N
behavioural JJ N
and CC N
psychometric JJ N
data NNS N
garnered VBN N
from IN N
participants NNS N
was VBD N
undertaken VBN N
, , N
with IN N
a DT N
view NN N
to TO N
determining VBG N
potential JJ N
factors NNS N
pertinent VBP N
to TO N
response NN N
to TO N
dietary JJ i
intervention NN i
. . N

Participants NNS N
with IN N
clinically RB N
significant JJ N
scores NNS N
indicative JJ N
of IN N
inattention NN o
and CC o
hyperactivity NN o
behaviours NNS o
and CC N
who WP N
had VBD N
a DT N
significant JJ N
positive JJ N
changes NNS N
to TO N
said VBD N
scores NNS N
were VBD N
defined VBN N
as IN N
responders NNS N
to TO N
the DT N
dietary JJ i
intervention NN i
. . N

Analyses NNS N
indicated VBD N
several JJ N
factors NNS N
to TO N
be VB N
potentially RB N
pertinent JJ N
to TO N
a DT N
positive JJ N
response NN o
to TO N
dietary JJ i
intervention NN i
in IN N
terms NNS N
of IN N
symptom NN N
presentation NN N
. . N

Chronological JJ N
age NN N
was VBD N
found VBN N
to TO N
be VB N
the DT N
strongest JJS N
predictor NN N
of IN N
response NN N
, , N
where WRB N
those DT N
participants NNS N
aged VBD N
between IN N
7 CD N
and CC N
9 CD N
years NNS N
seemed VBD N
to TO N
derive VB N
most JJS N
benefit NN N
from IN N
dietary JJ i
intervention NN i
. . N

Further CC N
analysis NN N
based VBN N
on IN N
the DT N
criteria NNS N
for IN N
original JJ N
study NN N
inclusion NN N
on IN N
the DT N
presence NN N
of IN N
the DT N
urine JJ N
compound NN N
, , N
trans-indolyl-3-acryloylglycine NN N
may MD N
also RB N
merit VB N
further JJ N
investigation NN N
. . N

These DT N
preliminary JJ N
observations NNS N
on IN N
potential JJ N
best JJS N
responder NN N
characteristics NNS N
to TO N
a DT N
gluten- JJ i
and CC i
casein-free JJ i
diet NN i
for IN N
children NNS N
with IN N
autism NN N
require VBP N
independent JJ N
replication NN N
. . N

-DOCSTART- -12595499- O O

Development NNP N
of IN N
renal JJ N
disease NN N
in IN N
people NNS p
at IN p
high JJ p
cardiovascular JJ p
risk NN p
: : N
results NNS N
of IN N
the DT N
HOPE NNP N
randomized VBD N
study NN N
. . N

In IN N
people NNS p
with IN p
diabetes NNS p
, , N
renal JJ N
disease NN N
tends VBZ N
to TO N
progress VB N
from IN N
microalbuminuria NN N
to TO N
clinical JJ N
proteinuria NN N
to TO N
renal JJ N
insufficiency NN N
. . N

Little JJ N
evidence NN N
has VBZ N
been VBN N
published VBN N
for IN N
the DT N
nondiabetic JJ N
population NN N
. . N

This DT N
study NN N
retrospectively RB N
analyzed VBD N
changes NNS N
of IN N
proteinuria NN N
over IN N
4.5 CD N
yr NNS N
in IN N
the DT N
HOPE NNP N
( ( N
Heart NNP N
Outcomes NNP N
and CC N
Prevention NNP N
Evaluation NNP N
) ) N
study NN N
, , N
which WDT N
compared VBN N
ramipril NN i
's POS i
effects NNS N
to TO N
placebo VB i
in IN N
9297 CD N
participants NNS N
, , N
including VBG N
3577 CD N
with IN N
diabetes NNS N
and CC N
1956 CD N
with IN N
microalbuminuria NN N
. . N

This DT N
report NN N
is VBZ N
restricted VBN N
to TO N
7674 CD p
participants NNS p
with IN p
albuminuria NNS p
data NNS p
at IN p
baseline NN p
and CC p
at IN p
follow-up JJ p
. . N

Inclusion NN N
criteria NNS N
were VBD N
known VBN N
vascular JJ N
disease NN N
or CC N
diabetes VBZ N
plus CC N
one CD N
other JJ N
cardiovascular JJ N
risk NN N
factor NN N
, , N
exclusion NN N
criteria NNS N
included VBD N
heart NN N
failure NN N
or CC N
known VBN N
impaired JJ N
left VBD N
ventricular JJ N
function NN N
, , N
dipstick-positive JJ N
proteinuria NN N
( ( N
> JJ N
1+ CD N
) ) N
, , N
and CC N
serum JJ N
creatinine NN N
> $ N
2.3 CD N
mg/dl NN N
( ( N
200 CD N
microM NN N
) ) N
. . N

Baseline NNP N
microalbuminuria NN N
predicted VBD N
subsequent JJ N
clinical JJ o
proteinuria NN o
for IN N
the DT N
study NN N
participants NNS N
overall JJ N
( ( N
adjusted VBN N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
, , N
17.5 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
12.6 CD N
to TO N
24.4 CD N
) ) N
, , N
in IN N
participants NNS N
without IN N
diabetes NNS N
( ( N
OR NNP N
, , N
16.7 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
8.6 CD N
to TO N
32.4 CD N
) ) N
, , N
and CC N
in IN N
participants NNS N
with IN N
diabetes NNS N
( ( N
OR NNP N
, , N
18.2 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
12.4 CD N
to TO N
26.7 CD N
) ) N
. . N

Any DT N
progression NN o
of IN o
albuminuria NNS o
( ( N
defined VBN N
as IN N
new JJ N
microalbuminuria NNS N
or CC N
new JJ N
clinical JJ N
proteinuria NN N
) ) N
occurred VBD N
in IN N
1859 CD N
participants NNS N
; : N
1542 CD N
developed VBD N
new JJ N
microalbuminuria NNS o
, , N
and CC N
317 CD N
participants NNS N
developed VBD N
clinical JJ o
proteinuria NN o
. . N

Ramipril NNP i
reduced VBD N
the DT N
risk NN N
for IN N
any DT N
progression NN o
( ( N
OR NNP N
, , N
0.87 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.78 CD N
to TO N
0.97 CD N
; : N
P NNP N
= NNP N
0.0146 CD N
) ) N
. . N

People NNS N
without IN N
and CC N
with IN N
diabetes NNS N
who WP N
are VBP N
at IN N
high JJ N
risk NN N
for IN N
cardiovascular JJ N
disease NN N
are VBP N
also RB N
at IN N
risk NN N
for IN N
a DT N
progressive JJ N
rise NN N
in IN N
albuminuria NN o
. . N

Microalbuminuria NNP N
itself PRP N
predicts VBZ N
clinical JJ N
proteinuria NNS N
in IN N
nondiabetic JJ p
and CC p
in IN p
diabetic JJ p
people NNS p
. . N

Ramipril JJ i
prevents NNS N
or CC N
delays VBZ N
the DT N
progression NN o
of IN o
albuminuria NN o
. . N

-DOCSTART- -23985254- O O

[ JJ N
Impact NNP N
of IN N
CCND1 NNP N
A870G NNP N
polymorphism NN N
on IN N
acute JJ o
adverse JJ o
events NNS o
in IN N
postoperative JJ p
rectal JJ p
cancer NN p
patients NNS p
treated VBN p
with IN p
adjuvant JJ p
concurrent NN p
chemoradiotherapy NN i
] NNP N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
association NN N
between IN N
single JJ N
nucleotide JJ N
polymorphism NN N
( ( N
SNP NNP N
) ) N
of IN N
CCND1 NNP N
A870G NNP N
and CC N
acute JJ o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
in IN N
postoperative JJ p
rectal JJ p
cancer NN p
patients NNS p
who WP p
received VBD p
capecitabine-based JJ i
postoperative JJ p
chemoradiotherapy NN i
( ( p
CRT NNP i
) ) p
. . N

METHODS NNP N
Four CD p
hundred VBD p
patients NNS p
with IN p
stage NN p
II NNP p
and CC p
III NNP p
rectal JJ p
cancer NN p
received VBD p
postoperative JJ p
CRT NNP p
of IN p
capecitabine NN i
with IN N
or CC N
without IN N
oxaliplatin NNS i
were VBD N
accumulated VBN N
and CC N
prostectively RB N
studied VBN N
in IN N
this DT N
study NN N
. . N

The DT N
patients NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

Two CD N
hundred CD N
and CC N
twenty-eight JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
concurrent JJ N
capecitabine NN i
and CC i
radiotherapy NN i
( ( i
Cap-CRT NNP i
) ) i
, , N
and CC N
172 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
capecitabine NN i
and CC i
oxaliplatin JJ i
plus CC i
radiotherapy JJ i
( ( i
Cap-Oxa-CRT NNP i
) ) i
. . N

Adverse JJ o
events NNS o
were VBD N
graded VBN N
according VBG N
to TO N
the DT N
Common NNP o
Terminology NNP o
Criteria NNP o
for IN o
Adverse NNP o
Events NNP o
, , o
v. NN o
3.0 CD o
( ( o
CTCAE NNP o
v3.0 NN o
) ) o
. . N

The DT N
genotype NN N
of IN N
CCND1 NNP N
A870G NNP N
in IN N
the DT N
patients NNS N
was VBD N
detected VBN N
by IN N
polymerase NN N
chain NN N
reaction-based JJ N
restriction NN N
fragment NN N
length NN N
polymorphism NN N
( ( N
PCR-RFLP NNP N
) ) N
analysis NN N
. . N

The DT N
associations NNS N
between IN N
the DT N
SNP NNP N
and CC N
acute JJ o
AEs NNP o
were VBD N
indicated VBN N
by IN N
odds NNS N
ratios NNS N
( ( N
ORs NNP N
) ) N
and CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
, , N
which WDT N
were VBD N
computed VBN N
with IN N
logistic JJ N
regression NN N
model NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
136 CD N
patients NNS N
presented VBN N
severe JJ N
AEs NNP o
. . N

Among IN N
them PRP N
the DT N
frequencies NNS N
of IN N
the DT N
three CD N
genotypes NNS N
GG NNP N
, , N
GA NNP N
and CC N
AA NNP N
were VBD N
16.9 CD N
% NN N
, , N
50.7 CD N
% NN N
and CC N
32.4 CD N
% NN N
, , N
compared VBN N
with IN N
24.6 CD N
% NN N
, , N
48.1 CD N
% NN N
and CC N
27.3 CD N
% NN N
, , N
respectively RB N
, , N
among IN N
the DT N
patients NNS N
without IN N
severe JJ N
AEs NNP o
. . N

Diarrhea NNP o
was VBD N
the DT N
most RBS N
common JJ N
AE NNP o
, , N
and CC N
severe JJ o
diarrhea NN o
occurred VBD N
in IN N
109 CD N
patients NNS N
. . N

The DT N
frequencies NNS N
of IN N
the DT N
three CD N
genotypes NNS N
GG NNP N
, , N
GA NNP N
and CC N
AA NNP N
were VBD N
15.6 CD N
% NN N
, , N
47.7 CD N
% NN N
and CC N
36.7 CD N
% NN N
among IN N
these DT N
patients NNS N
, , N
compared VBN N
with IN N
24.4 CD N
% NN N
, , N
49.5 CD N
% NN N
and CC N
26.1 CD N
% NN N
, , N
respectively RB N
, , N
among IN N
patients NNS N
without IN N
severe JJ o
diarrhea NN o
. . N

Multivariate NNP N
logistic JJ N
regression NN N
analysis NN N
showed VBD N
a DT N
1.66-fold JJ N
increased JJ N
risk NN N
for IN N
severe JJ o
diarrhea NN o
in IN N
patients NNS N
with IN N
AA NNP N
genotype NN N
( ( N
95 CD N
% NN N
CI NNP N
1.03 CD N
- : N
2.67 CD N
, , N
P NNP N
= NNP N
0.038 CD N
) ) N
compared VBN N
with IN N
the DT N
cases NNS N
with IN N
GG NNP N
or CC N
GA NNP N
genotypes NNS N
. . N

Stratified VBN N
analysis NN N
showed VBD N
that IN N
in IN N
the DT N
Cap-Oxa-CRT NNP i
group NN N
, , N
patients NNS N
with IN N
AA NNP N
genotype NN N
showed VBD N
a DT N
2.34-fold JJ N
increased JJ N
risk NN N
for IN N
severe JJ o
diarrhea NN o
( ( N
95 CD N
% NN N
CI NNP N
1.16 CD N
- : N
4.76 CD N
, , N
P NNP N
= NNP N
0.018 CD N
) ) N
compared VBN N
with IN N
those DT N
with IN N
GG NNP N
or CC N
GA NNP N
genotypes NNS N
, , N
but CC N
in IN N
the DT N
Cap-CRT NNP i
group NN N
, , N
the DT N
SNP NNP N
was VBD N
not RB N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
severe JJ o
diarrhea NN o
. . N

CONCLUSIONS VB N
The DT N
genetic JJ N
polymorphism NN N
of IN N
CCND1 NNP N
A870G NNP N
might MD N
be VB N
a DT N
potential JJ N
biomarker NN N
for IN N
predicting VBG N
acute JJ o
AEs NNP o
in IN N
postoperative JJ p
stage NN p
II NNP p
and CC p
III NNP p
rectal JJ p
cancer NN p
patients NNS p
treated VBN N
with IN N
adjuvant JJ N
concurrent JJ N
chemoradiotherapy NN i
of IN N
capecitabine NN i
and CC N
oxaliplatin NN i
. . N

-DOCSTART- -18229990- O O

Language NNP o
outcome NN o
in IN N
autism NN p
: : N
randomized JJ N
comparison NN N
of IN N
joint JJ i
attention NN i
and CC N
play NN i
interventions NNS i
. . N

This DT N
study NN N
reports VBZ N
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
aimed VBN N
at IN N
joint JJ i
attention NN i
( ( i
JA NNP i
) ) i
and CC N
symbolic JJ i
play NN i
( ( i
SP NNP i
) ) i
in IN N
preschool NN p
children NNS p
with IN p
autism NN p
, , N
with IN N
prediction NN N
to TO N
language NN o
outcome RB o
12 CD N
months NNS N
later RB N
. . N

Participants NNS p
were VBD p
58 CD p
children NNS p
( ( p
46 CD p
boys NNS p
) ) p
with IN p
autism NN p
between IN p
3 CD p
and CC p
4 CD p
years NNS p
of IN p
age NN p
. . p

Children NNP N
were VBD N
randomized VBN N
to TO N
a DT N
JA NNP i
intervention NN N
, , N
an DT N
SP NNP i
intervention NN N
, , N
or CC N
control NN N
group NN N
. . N

Interventions NNS N
were VBD N
conducted VBN N
30 CD N
min JJ N
daily JJ N
for IN N
5-6 JJ N
weeks NNS N
. . N

Assessments NNS N
of IN N
JA NNP o
skills NNS o
, , o
SP NNP o
skills NNS o
, , o
mother-child JJ o
interactions NNS o
, , o
and CC o
language NN o
development NN o
were VBD N
collected VBN N
at IN N
4 CD N
time NN N
points NNS N
: : N
pre- NN N
and CC N
postintervention NN N
and CC N
6 CD N
and CC N
12 CD N
months NNS N
postintervention NN N
by IN N
independent JJ N
testers NNS N
. . N

Results NNS N
indicate VBP N
that IN N
expressive JJ o
language NN o
gains NNS o
were VBD N
greater JJR N
for IN N
both DT N
treatment NN N
groups NNS N
compared VBN N
with IN N
the DT N
control NN N
group NN N
, , N
and CC N
results NNS N
could MD N
not RB N
be VB N
explained VBN N
by IN N
differences NNS N
in IN N
other JJ N
interventions NNS N
in IN N
which WDT N
children NNS N
participated VBD N
. . N

For IN N
children NNS N
beginning VBG N
treatment NN N
with IN N
the DT N
lowest JJS N
language NN N
levels NNS N
, , N
the DT N
JA NNP i
intervention NN N
improved VBD N
language NN o
outcome NN o
significantly RB N
more RBR N
than IN N
did VBD N
the DT N
SP NNP i
or CC N
control VB N
interventions NNS N
. . N

These DT N
findings NNS N
suggest VBP N
clinically RB N
significant JJ N
benefits NNS N
of IN N
actively RB N
treating VBG N
JA NNP i
and CC N
SP NNP i
skills NNS N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
. . N

-DOCSTART- -9229602- O O

[ JJ N
Antazoline/tetryzoline NNP i
eyedrops NNS N
in IN N
comparison NN N
with IN N
levocabastine JJ i
eyedrops NNS N
in IN N
acute JJ p
allergic JJ p
conjunctivitis NN p
] NNP N
. . N

BACKGROUND NNP N
Allergic NNP p
conjunctivitis NN p
is VBZ N
one CD N
of IN N
the DT N
most RBS N
frequent JJ N
allergic JJ N
diseases NNS N
of IN N
the DT N
anterior JJ N
eye NN N
segment NN N
. . N

METHODS NNP N
This DT N
multicentre NN N
, , N
clinical JJ N
trial NN N
was VBD N
an DT N
investigation NN N
to TO N
compare VB N
the DT N
antiallergic JJ N
efficacy NN N
, , N
local JJ N
tolerance NN N
and CC N
safety NN N
of IN N
Antazolin/Tetryzolin NNP i
eye NN N
drops NNS N
and CC N
Levocabastine NNP i
eye NN N
drops NNS N
. . N

69 CD p
patients NNS p
were VBD N
treated VBN N
over IN N
a DT N
2 CD N
weeks NNS N
course NN N
of IN N
therapy NN N
. . N

The DT N
subjective JJ o
and CC o
objective JJ o
ocular NN o
symptoms NNS o
were VBD N
documented VBN N
over IN N
the DT N
treatment NN N
period NN N
. . N

RESULTS NNP N
Both NNP N
eye NN N
drops NNS N
reduced VBD N
subjective JJ o
and CC o
objective JJ o
ocular NN o
symptoms NNS o
effective JJ N
. . N

The DT N
difference NN N
between IN N
the DT N
treatments NNS N
( ( N
p JJ N
= NNP N
0.0395 CD N
) ) N
was VBD N
the DT N
faster JJ N
onset NN o
of IN o
action NN o
of IN N
Antazolin/Tetryzolin NNP i
30 CD N
minutes NNS N
after IN N
administration NN N
of IN N
the DT N
first JJ N
drop NN N
of IN N
trial NN N
medication NN N
. . N

CONCLUSION VB N
A DT N
fast JJ N
and CC N
effective JJ N
onset NN N
of IN N
action NN N
is VBZ N
of IN N
high JJ N
clinical JJ N
relevance NN N
. . N

Therefore IN N
the DT N
benefits NNS N
of IN N
using VBG N
Antazolin/Tetryzolin NNP i
eye NN N
drops NN N
was VBD N
clearly RB N
outweigh JJ N
. . N

-DOCSTART- -15848261- O O

[ JJ N
Postural NNP N
biofeedback NN N
and CC N
locomotion NN N
reeducation NN N
in IN N
stroke NN p
patients NNS p
] VBP N
. . N

AIMS NNP N
To TO N
compare VB N
, , N
in IN N
post-acute JJ p
hemiparetic JJ p
patients NNS p
, , N
gait NN o
improvement NN o
after IN N
conventional JJ i
physical JJ i
therapy NN i
alone RB i
or CC N
with IN i
a DT i
specialised JJ i
balance NN i
retraining VBG i
program NN i
. . N

PATIENTS VB N
Twenty-six JJ p
patients NNS p
within IN p
3 CD p
months NNS p
of IN p
onset NN p
of IN p
stroke NN p
were VBD N
randomised VBN N
to TO N
receive VB N
physical JJ i
therapy NN i
( ( N
control VB N
group NN N
) ) N
or CC N
therapy NN i
and CC i
retraining NN i
( ( N
experimental JJ N
group NN N
) ) N
, , N
most JJS N
of IN N
the DT N
patients NNS N
in IN N
both DT N
groups NNS N
with IN N
left JJ N
hemiplegia NN N
. . N

The DT N
experimental JJ N
group NN N
was VBD N
significantly RB N
older JJR N
than IN N
the DT N
control NN N
group NN N
. . N

METHOD NNP N
Thirteen NNP N
patients NNS N
received VBD N
early JJ N
conventional JJ i
therapy NN i
, , N
and CC N
13 CD N
received VBD N
therapy NN i
combined VBN i
with IN i
standing VBG i
balance NN i
training NN i
by IN i
biofeedback NN i
( ( i
BPM NNP i
Monitor NNP i
) ) i
. . N

Clinical JJ N
measures NNS N
were VBD N
collected VBN N
at IN N
entry NN N
( ( N
J0 NNP N
) ) N
, , N
once RB N
when WRB N
subjects NNS N
began VBD N
to TO N
walk VB N
( ( N
JM NNP N
) ) N
and CC N
30 CD N
days NNS N
later RB N
( ( N
JM NNP N
+ NNP N
30 CD N
) ) N
. . N

Gait NNP o
spatiotemporal JJ o
parameters NNS o
were VBD N
collected VBN N
by IN N
use NN N
of IN N
the DT N
Vicon NNP N
system NN N
at IN N
JM NNP N
and CC N
JM NNP N
+ NNP N
30 CD N
. . N

RESULTS VB N
Whatever IN N
the DT N
method NN N
of IN N
rehabilitation NN N
, , N
the DT N
clinical JJ o
scores NNS o
improved VBN N
significantly RB N
between IN N
J0 NNP N
and CC N
JM NNP N
+ NNP N
30 CD N
, , N
except IN N
for IN N
spasticity NN N
. . N

The DT N
time NN o
between IN o
stroke NN o
and CC o
the DT o
beginning NN o
of IN o
walking NN o
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
both DT N
groups NNS N
. . N

Gait NNP o
velocity NN o
increased VBD N
significantly RB N
between IN N
JM NNP N
and CC N
JM NNP N
+ NNP N
30 CD N
in IN N
both DT N
groups NNS N
, , N
with IN N
no DT N
difference NN N
between IN N
groups NNS N
. . N

The DT N
walking NN o
pattern NN o
was VBD N
improved VBN N
for IN N
both DT N
groups NNS N
, , N
with IN N
a DT N
significant JJ N
increase NN N
of IN N
the DT N
duration NN o
of IN o
the DT o
paretic JJ o
limb NN o
single JJ o
stance NN o
. . N

The DT N
experimental JJ N
group NN N
significantly RB N
improved VBD N
the DT N
duration NN o
of IN o
the DT o
reception NN o
double JJ o
stance NN o
on IN o
the DT o
paretic JJ o
limb NN o
between IN N
JM NNP N
and CC N
JM NNP N
+ NNP N
30 CD N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

CONCLUSION NNP N
Both NNP N
groups NNS N
demonstrated VBD N
improvement NN N
in IN N
the DT N
rehabilitation NN N
unit NN N
. . N

The DT N
benefits NNS N
of IN N
visual JJ N
biofeedback NN N
by IN N
forceplate NN N
system NN N
training VBG N
suggest JJ N
particular JJ N
improvement NN N
of IN N
anticipation NN N
equilibrium NN N
with IN N
conventional JJ i
therapy NN i
. . N

-DOCSTART- -2908133- O O

Low JJ N
doses NNS N
of IN N
ketazolam NN i
in IN N
anxiety NN p
: : N
a DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
. . N

A DT N
multicenter NN N
, , N
double-blind JJ N
, , N
between-patient JJ N
trial NN N
comparing VBG N
two CD N
doses NNS N
of IN N
ketazolam NN i
( ( N
15 CD N
and CC N
30 CD N
mg NN N
) ) N
with IN N
placebo NN i
, , N
each DT N
given VBN N
once RB N
daily JJ N
, , N
in IN N
the DT N
evening NN N
, , N
to TO N
92 CD p
outpatients NNS p
affected VBN p
by IN p
generalized JJ p
anxiety NN p
disorders NNS p
for IN p
at IN p
least JJS p
1 CD p
month NN p
, , N
was VBD N
carried VBN N
out RP N
. . N

After IN N
1-week JJ N
washout NN N
period NN N
47 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
ketazolam VB i
15 CD N
mg NN N
, , N
and CC N
45 CD N
to TO N
placebo VB i
for IN N
15 CD N
days NNS N
( ( N
first JJ N
period NN N
) ) N
. . N

At IN N
the DT N
end NN N
of IN N
this DT N
period NN N
, , N
if IN N
the DT N
patient NN N
experienced VBD N
a DT N
decrease NN N
on IN N
the DT N
total JJ o
Hamilton NNP o
Anxiety NNP o
Rating NNP o
Scale NNP o
( ( o
HAM-A NNP o
) ) o
of IN N
at IN N
least JJS N
25 CD N
% NN N
of IN N
basal NN N
value NN N
, , N
the DT N
treatment NN N
was VBD N
kept VBN N
unchanged JJ N
for IN N
a DT N
further JJ N
15 CD N
days NNS N
, , N
otherwise RB N
15 CD N
mg NN N
of IN N
ketazolam NNS i
were VBD N
added VBN N
to TO N
the DT N
previous JJ N
treatment NN N
( ( N
second JJ N
period NN N
) ) N
. . N

Anxiety NN N
was VBD N
rated VBN N
after IN N
2 CD N
and CC N
4 CD N
weeks NNS N
with IN N
the DT N
Italian JJ o
HAM-A NNP o
scale NN o
and CC N
with IN N
a DT N
4-point JJ o
scale NN o
( ( o
patient NN o
's POS o
assessment NN o
) ) o
. . N

Seventy-eight JJ p
patients NNS p
completed VBD p
the DT p
first JJ p
period NN p
and CC p
75 CD p
the DT p
whole NN p
study NN p
. . N

During IN N
the DT N
first JJ N
period NN N
the DT N
percentage NN N
of IN N
responders NNS N
was VBD N
almost RB N
identical JJ N
in IN N
both DT N
treatment NN N
groups NNS N
, , N
but CC N
during IN N
the DT N
second JJ N
period NN N
a DT N
further JJ N
slight NN N
improvement NN N
was VBD N
observed VBN N
in IN N
the DT N
early JJ N
placebo NN i
responders NNS N
, , N
while IN N
the DT N
HAM-A NNP o
score NN o
of IN N
patients NNS N
on IN N
ketazolam NNS i
continued VBN N
to TO N
improve VB N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
throughout IN N
the DT N
study NN N
. . N

Likewise VB N
a DT N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
difference NN N
between IN N
treatments NNS N
was VBD N
observed VBN N
, , N
on IN N
the DT N
4-point JJ o
scale NN o
, , N
in IN N
the DT N
population NN N
as IN N
a DT N
whole NN N
( ( N
end NN N
of IN N
first JJ N
period NN N
) ) N
as RB N
well RB N
as IN N
in IN N
responder NN N
patients NNS N
( ( N
end JJ N
second JJ N
period NN N
) ) N
. . N

Tolerability NN N
was VBD N
good JJ N
, , N
except IN N
in IN N
1 CD N
patient NN N
on IN N
placebo NN i
, , N
who WP N
was VBD N
withdrawn VBN N
from IN N
the DT N
study NN N
because IN N
of IN N
severe JJ o
headache NN o
. . N

-DOCSTART- -7017018- O O

Bacteremia NNP N
due JJ N
to TO N
Bacteroides NNP N
fragilis NN N
after IN N
elective JJ p
appendectomy NN p
in IN p
renal JJ p
transplant NN p
recipients NNS p
. . N

Bacteremia NNP N
caused VBN N
by IN N
Bacteroides NNP N
fragilis NN N
occurred VBD N
in IN N
four CD N
of IN N
75 CD p
children NNS p
after IN p
renal JJ p
transplantation NN p
, , N
and CC N
B. NNP N
fragilis NN N
was VBD N
the DT N
most RBS N
common JJ N
cause NN N
of IN N
postoperative JJ N
bacteremia NN N
. . N

Bacteroides NNP N
bacteremia NN N
was VBD N
significantly RB N
associated VBN N
with IN N
performance NN N
of IN N
elective JJ N
appendectomy NN N
at IN N
the DT N
time NN N
of IN N
transplantation NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
with IN N
profound JJ N
lymphocytopenia NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

No DT N
patient NN N
received VBD N
antibiotics NNS N
at IN N
the DT N
time NN N
of IN N
surgery NN N
or CC N
prior RB N
to TO N
the DT N
first JJ N
positive JJ N
blood NN N
culture NN N
, , N
yet RB N
B. NNP N
fragilis NN N
was VBD N
the DT N
single JJ N
organism NN N
isolated VBN N
from IN N
blood NN N
and CC N
abscesses NNS N
in IN N
these DT N
patients NNS N
. . N

A DT N
role NN N
for IN N
lymphocytes NNS N
in IN N
containment NN N
of IN N
B. NNP N
fragilis NN N
has VBZ N
not RB N
been VBN N
suggested VBN N
previously RB N
, , N
although IN N
unexplained JJ N
occurrence NN o
of IN o
bacteroides NNS o
bacteremia VBP o
in IN N
immunocompromised JJ N
patients NNS N
has VBZ N
occasionally RB N
been VBN N
reported VBN N
. . N

Lymphocytes VBZ N
themselves PRP N
may MD N
be VB N
important JJ N
in IN N
this DT N
host-bacterium JJ N
interaction NN N
, , N
or CC N
lymphocytopenia NN o
may MD N
be VB N
the DT N
marker NN N
for IN N
a DT N
more RBR N
generalized JJ N
deficiency NN N
in IN N
host NN N
defenses NNS N
. . N

-DOCSTART- -21982657- O O

A DT N
double-blind NN N
, , N
randomized VBN N
, , N
controlled VBN N
, , N
multicenter NN N
study NN N
to TO N
assess VB N
the DT N
safety NN o
and CC N
cardiovascular JJ o
effects NNS o
of IN N
skeletal JJ i
myoblast NN i
implantation NN i
by IN N
catheter NN N
delivery NN N
in IN N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
after IN p
myocardial JJ p
infarction NN p
. . N

BACKGROUND NNP N
We PRP N
sought VBD N
to TO N
determine VB N
the DT N
safety NN o
and CC N
preliminary JJ N
efficacy NN o
of IN N
transcatheter NN N
intramyocardial JJ N
administration NN N
of IN N
myoblasts NNS i
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
( ( p
HF NNP p
) ) p
. . N

METHODS NNP N
MARVEL NNP N
is VBZ N
a DT N
randomized JJ N
placebo-controlled JJ N
trial NN N
of IN N
image-guided JJ N
, , N
catheter-based JJ N
intramyocardial JJ N
injection NN N
of IN N
placebo NN i
or CC N
myoblasts NNS i
( ( N
400 CD N
or CC N
800 CD N
million CD N
) ) N
in IN N
patients NNS p
with IN p
class NN p
II NNP p
to TO p
IV NNP p
HF NNP p
and CC p
ejection NN p
fraction NN p
< VBD p
35 CD p
% NN p
. . N

Primary JJ N
end NN N
points NNS N
were VBD N
frequency NN o
of IN o
serious JJ o
adverse JJ o
events NNS o
( ( o
safety NN o
) ) o
and CC N
changes NNS o
in IN o
6-minute JJ o
walk NN o
test NN o
and CC N
Minnesota NNP o
Living NNP o
With IN o
HF NNP o
score NN o
( ( o
efficacy NN o
) ) o
. . N

Of IN p
330 CD p
patients NNS p
intended VBN p
for IN p
enrollment NN p
, , p
23 CD p
were VBD p
randomized VBN p
( ( p
MARVEL-1 NNP p
) ) p
before IN p
stopping VBG p
the DT p
study NN p
for IN p
financial JJ p
reasons NNS p
. . N

RESULTS NNP N
At IN N
6 CD N
months NNS N
, , N
similar JJ N
numbers NNS N
of IN N
events NNS N
occurred VBN N
in IN N
each DT N
group NN N
: : N
8 CD N
( ( N
placebo NN i
) ) N
, , N
7 CD N
( ( N
low JJ N
dose NN N
) ) N
, , N
and CC N
8 CD N
( ( N
high JJ N
dose NN N
) ) N
, , N
without IN N
deaths NNS N
. . N

Ventricular JJ o
tachycardia NN o
responsive NN o
to TO N
amiodarone VB N
was VBD N
more RBR N
frequent JJ N
in IN N
myoblast-treated JJ i
patients NNS N
: : N
1 CD N
( ( N
placebo NN i
) ) N
, , N
3 CD N
( ( N
low JJ N
dose NN N
) ) N
, , N
and CC N
4 CD N
( ( N
high JJ N
dose NN N
) ) N
. . N

A DT N
trend NN N
toward IN N
improvement NN N
in IN N
functional JJ o
capacity NN o
was VBD N
noted VBN N
in IN N
myoblast-treated JJ i
groups NNS N
( ( N
?6-minute JJ N
walk NN N
test NN N
of IN N
-3.6 NNP N
vs FW N
+95.6 NNP N
vs FW N
+85.5 NNP N
m FW N
[ NNP N
placebo NN N
vs NN N
low JJ N
dose NN N
vs NN N
high JJ N
dose NN N
; : N
P NNP N
= NNP N
.50 NNP N
] NNP N
) ) N
without IN N
significant JJ N
changes NNS N
in IN N
Minnesota NNP o
Living NNP o
With IN o
HF NNP o
scores NNS o
. . N

CONCLUSIONS NNP N
In IN N
HF NNP p
patients NNS p
with IN p
chronic JJ p
postinfarction NN p
cardiomyopathy NN p
, , N
transcatheter JJ N
administration NN N
of IN N
myoblasts NNS i
in IN N
doses NNS N
of IN N
400 CD N
to TO N
800 CD N
million CD N
cells NNS N
is VBZ N
feasible JJ N
and CC N
may MD N
lead VB N
to TO N
important JJ N
clinical JJ N
benefits NNS N
. . N

Ventricular JJ N
tachycardia NN N
may MD N
be VB N
provoked VBN N
by IN N
myoblast JJ i
injection NN N
but CC N
appears VBZ N
to TO N
be VB N
a DT N
transient NN N
and CC N
treatable JJ N
problem NN N
. . N

A DT N
large-scale JJ N
outcome JJ N
trial NN N
of IN N
myoblast JJ i
administration NN N
in IN N
HF NNP p
patients NNS p
with IN p
postinfarction NN p
cardiomyopathy NN p
is VBZ N
feasible JJ N
and CC N
warranted VBD N
. . N

-DOCSTART- -15358868- O O

Superior JJ N
visual JJ N
search NN N
in IN N
adults NNS p
with IN p
autism NN p
. . N

Recent JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
children NNS N
with IN N
autism NN N
perform NN N
better RBR N
than IN N
matched VBN N
controls NNS N
on IN N
visual JJ N
search NN N
tasks NNS N
and CC N
that IN N
this DT N
stems VBZ N
from IN N
a DT N
superior JJ N
visual JJ N
discrimination NN N
ability NN N
. . N

This DT N
study NN N
assessed VBD N
whether IN N
these DT N
findings NNS N
generalize VBP N
from IN N
children NNS N
to TO N
adults NNS p
with IN p
autism NN p
. . N

Experiments NNS N
1 CD N
and CC N
2 CD N
showed VBD N
that IN N
, , N
like IN N
children NNS N
, , N
adults NNS p
with IN p
autism NN p
were VBD N
superior JJ N
to TO N
controls NNS N
at IN N
searching VBG o
for IN o
targets NNS o
. . N

Experiment NN N
3 CD N
showed VBD N
that IN N
increases NNS N
in IN N
target-distractor JJ N
similarity NN N
slowed VBD N
the DT N
visual JJ o
search NN o
performance NN o
of IN N
the DT N
control NN N
group NN N
significantly RB N
more RBR N
than IN N
that DT N
of IN N
the DT N
autism NN N
group NN N
, , N
suggesting VBG N
that IN N
the DT N
adults NNS N
with IN N
autism NN N
have VBP N
a DT N
superior JJ N
visual JJ o
discrimination NN o
ability NN o
. . N

Thus RB N
, , N
these DT N
experiments NNS N
replicate VBP N
in IN N
adults NNS N
previous JJ N
findings NNS N
in IN N
children NNS N
with IN N
autism NN N
. . N

Superior NNP N
unique JJ o
item NN o
detection NN o
in IN N
adults NNS N
with IN N
autism NN N
, , N
stemming VBG N
from IN N
enhanced VBN N
discrimination NN N
, , N
is VBZ N
discussed VBN N
in IN N
the DT N
light NN N
of IN N
the DT N
possible JJ N
role NN N
of IN N
stimulus JJ N
processing NN N
disturbances NNS N
in IN N
the DT N
disorder NN N
in IN N
general JJ N
. . N

-DOCSTART- -24451919- O O

Inverse JJ N
Effect NNP N
of IN N
Fluoxetine NNP i
on IN N
Medial NNP N
Prefrontal NNP N
Cortex NNP N
Activation NNP N
During IN N
Reward NNP N
Reversal NNP N
in IN N
ADHD NNP p
and CC p
Autism NNP p
. . N

Attention NNP p
deficit NN p
hyperactivity NN p
disorder NN p
( ( p
ADHD NNP p
) ) p
and CC p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
share NN N
brain NN N
function NN N
abnormalities NNS N
during IN N
cognitive JJ N
flexibility NN N
. . N

Serotonin NNP N
is VBZ N
involved VBN N
in IN N
both DT N
disorders NNS N
, , N
and CC N
selective JJ N
serotonin NN N
reuptake NN N
inhibitors NNS N
( ( N
SSRIs NNP N
) ) N
can MD N
modulate VB N
cognitive JJ N
flexibility NN N
and CC N
improve VB N
behavior NN N
in IN N
both DT N
disorders NNS N
. . N

Thus RB N
, , N
this DT N
study NN N
investigates VBZ N
shared VBN N
and CC N
disorder-specific JJ N
brain NN N
dysfunctions NNS N
in IN N
these DT N
2 CD N
disorders NNS N
during IN N
reward NN N
reversal NN N
, , N
and CC N
the DT N
acute JJ N
effects NNS N
of IN N
an DT N
SSRI NNP N
on IN N
these DT N
. . N

Age-matched JJ p
boys NNS p
with IN p
ADHD NNP p
( ( p
15 CD p
) ) p
, , p
ASD NNP p
( ( p
18 CD p
) ) p
, , p
and CC p
controls NNS p
( ( p
21 CD p
) ) p
were VBD N
compared VBN N
with IN N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
fMRI JJ N
) ) N
during IN N
a DT N
reversal NN N
task NN N
. . N

Patients NNS N
were VBD N
scanned VBN N
twice RB N
, , N
under IN N
either DT N
an DT N
acute NN N
dose NN N
of IN N
Fluoxetine NNP i
or CC N
placebo NN i
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
randomized JJ N
design NN N
. . N

Repeated-measures JJ N
analyses NNS N
within IN N
patients NNS N
assessed JJ N
drug NN N
effects NNS N
. . N

Patients NNS N
under IN N
each DT N
drug NN N
condition NN N
were VBD N
compared VBN N
with IN N
controls NNS N
to TO N
assess VB N
normalization NN N
effects NNS N
. . N

fMRI NN N
data NNS N
showed VBD N
that IN N
, , N
under IN N
placebo NN i
, , N
ASD NNP N
boys VBZ N
underactivated JJ N
medial JJ o
prefrontal NN o
cortex NN o
( ( o
mPFC NN o
) ) o
, , N
compared VBN N
with IN N
control NN N
and CC N
ADHD NNP N
boys NNS N
. . N

Both DT N
patient JJ N
groups NNS N
shared VBD N
decreased JJ N
precuneus NN o
activation NN o
. . N

Under IN N
Fluoxetine NNP i
, , N
mPFC JJ o
activation NN o
was VBD N
up-regulated JJ N
and CC N
normalized VBN N
in IN N
ASD NNP N
boys NNS N
relative VBP N
to TO N
controls NNS N
, , N
but CC N
down-regulated JJ N
in IN N
ADHD NNP N
boys NNS N
relative VBP N
to TO N
placebo VB i
, , N
which WDT N
was VBD N
concomitant NN N
with IN N
worse JJR N
task NN o
performance NN o
in IN N
ADHD NNP N
. . N

Fluoxetine NNP i
therefore NN N
has VBZ N
inverse JJ N
effects NNS N
on IN N
mPFC JJ o
activation NN o
in IN N
ASD NNP N
and CC N
ADHD NNP N
during IN N
reversal NN N
learning NN N
, , N
suggesting VBG N
dissociated VBN N
underlying JJ N
serotonin NN N
abnormalities NNS N
. . N

-DOCSTART- -7827398- O O

Epidemiology NN N
of IN N
stroke NN N
. . N

Importance NN N
of IN N
preventive JJ N
pharmacological JJ N
strategies NNS N
in IN N
elderly JJ p
patients NNS p
and CC N
associated JJ N
costs NNS N
. . N

Stroke NNP N
is VBZ N
a DT N
major JJ N
cause NN N
of IN N
death NN N
and CC N
disability NN N
in IN N
developed JJ N
countries NNS N
. . N

The DT N
incidence NN N
of IN N
stroke NN N
increases NNS N
exponentially RB N
with IN N
age NN N
, , N
yet RB N
, , N
traditionally RB N
, , N
many JJ N
medical JJ N
practitioners NNS N
have VBP N
been VBN N
reluctant JJ N
to TO N
treat VB N
hypertension NN N
in IN p
older JJR p
patients NNS p
. . N

Since IN N
1991 CD N
, , N
the DT N
results NNS N
of IN N
3 CD N
major JJ N
trials NNS N
-- : N
the DT N
British JJ N
Medical NNP N
Research NNP N
Council NNP N
( ( N
MRC NNP N
) ) N
trial NN N
of IN N
treatment NN N
in IN N
older JJR p
adults NNS p
, , N
the DT N
Swedish JJ N
Trial NNP N
in IN N
Old NNP p
Patients NNPS p
with IN p
Hypertension NNP p
( ( N
STOP-Hypertension NNP N
) ) N
and CC N
the DT N
Systolic NNP N
Hypertension NNP N
in IN N
the DT N
Elderly JJ N
Program NNP N
( ( N
SHEP NNP N
) ) N
-- : N
have VBP N
conclusively RB N
established VBN N
the DT N
benefits NNS N
of IN N
treating VBG N
older JJR p
patients NNS p
( ( p
> JJ p
60 CD p
years NNS p
) ) p
with IN p
both DT p
diastolic JJ p
and CC p
isolated JJ p
systolic JJ p
hypertension NN p
. . N

International NNP N
guidelines NNS N
for IN N
the DT N
management NN N
of IN N
hypertension NN N
-- : N
including VBG N
the DT N
Fifth NNP N
Report NNP N
of IN N
the DT N
Joint NNP N
National NNP N
Committee NNP N
, , N
the DT N
1993 CD N
report NN N
of IN N
the DT N
World NNP N
Health NNP N
Organization NNP N
and CC N
the DT N
International NNP N
Society NNP N
of IN N
Hypertension NNP N
and CC N
the DT N
second JJ N
report NN N
of IN N
the DT N
British JJ N
Hypertension NNP N
Society NNP N
Working NNP N
Party NNP N
-- : N
have VBP N
all DT N
been VBN N
modified VBN N
to TO N
reflect VB N
the DT N
emerging VBG N
evidence NN N
concerning VBG N
the DT N
benefits NNS N
of IN N
treating VBG N
older JJR N
patients NNS N
. . N

Cost-effectiveness JJ o
data NNS o
are VBP N
similarly RB N
in IN N
accord NN N
with IN N
giving VBG N
high JJ N
priority NN N
to TO N
the DT N
treatment NN N
of IN N
older JJR p
individuals NNS p
with IN p
hypertension NN p
. . N

-DOCSTART- -25885649- O O

Subjective JJ N
and CC N
objective JJ N
levels NNS N
of IN N
physical JJ N
activity NN N
and CC N
their PRP$ N
association NN N
with IN N
cardiorespiratory NN N
fitness NN N
in IN N
rheumatoid JJ p
arthritis NN p
patients NNS p
. . N

INTRODUCTION NNP N
The DT N
aims NNS N
of IN N
the DT N
present JJ N
study NN N
were VBD N
: : N
( ( N
a DT N
) ) N
to TO N
examine VB N
the DT N
agreement NN N
between IN N
subjective JJ N
( ( N
assessed JJ N
via IN N
the DT N
International NNP o
Physical NNP o
Activity NNP o
Questionnaire NNP o
; : o
IPAQ NNP o
) ) o
and CC N
objective JJ N
( ( N
accelerometry NN N
; : N
GT3X NNP o
) ) o
physical JJ o
activity NN o
( ( o
PA NNP o
) ) o
levels NNS N
in IN N
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
( ( p
RA NNP p
) ) p
, , N
and CC N
( ( N
b NN N
) ) N
to TO N
evaluate VB N
the DT N
associations NNS N
of IN N
RA NNP N
patients NNS N
' POS N
subjective JJ N
and CC N
objective JJ N
PA NNP N
to TO N
their PRP$ N
scores NNS N
on IN N
the DT N
maximal JJ o
oxygen NN o
uptake JJ o
test NN o
( ( o
VO2max NNP o
) ) o
. . N

METHODS PDT N
The DT N
participants NNS N
wore VBD N
the DT N
GT3X NNP N
for IN N
seven CD N
days NNS N
before IN N
completing VBG N
the DT N
IPAQ NNP o
and CC N
VO2max NNP o
test NN N
. . N

The DT N
Bland-Altman NNP N
plot NN N
was VBD N
used VBN N
to TO N
illustrate VB N
the DT N
agreement NN N
between IN N
the DT N
objective NN N
and CC N
subjective JJ N
PA NNP N
data NN N
, , N
and CC N
the DT N
Wilcoxon NNP N
test NN N
was VBD N
employed VBN N
to TO N
examine VB N
the DT N
differences NNS N
. . N

The DT N
association NN N
between IN N
the DT N
PA NNP o
measurement NN o
and CC N
VO2max NNP o
test NN N
was VBD N
examined VBN N
via IN N
the DT N
correlations NNS N
and CC N
the DT N
magnitude NN N
was VBD N
presented VBN N
by IN N
the DT N
Steiger NNP N
's POS N
Z NNP N
value NN N
. . N

RESULTS NNP N
Sixty-eight JJ p
RA NNP p
patients NNS p
( ( p
age=55?13 JJ p
years NNS p
, , p
body NN p
mass NN p
index NN p
: : p
27.8?5.4 CD p
kg/m2 NN p
, , p
median NN p
of IN p
disease NN p
duration=5 NN p
( ( p
2-8 JJ p
) ) p
yrs NN p
) ) p
were VBD N
recruited VBN N
. . N

Smaller NNP N
differences NNS N
between IN N
the DT N
subjective JJ N
and CC N
objective JJ N
measures NNS N
were VBD N
found VBN N
when WRB N
PA NNP N
was VBD N
assessed VBN N
at IN N
the DT N
moderate JJ N
level NN N
. . N

Wilcoxon NNP N
tests NNS N
revealed VBD N
that IN N
patients NNS N
reported VBD N
less JJR N
time NN N
spent VBN N
engaged VBN N
in IN N
sedentary JJ o
behaviours NNS o
( ( N
Z=-6.80 NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
light JJ o
PA NNP o
( ( N
Z=-6.89 NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
more JJR N
moderate JJ N
PA NNP N
( ( N
Z=-6.26 NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
than IN N
was VBD N
objectively RB N
indicated VBN N
. . N

Significant NNP N
positive JJ N
correlations NNS N
were VBD N
revealed VBN N
between IN N
VO2max NNP o
with IN N
all DT N
PA NNP N
levels NNS N
derived VBN N
from IN N
accelerometry NN N
( ( N
light JJ N
PA NNP N
rho=.35 NN N
, , N
P NNP N
< NNP N
.01 NNP N
; : N
moderate JJ N
PA NNP N
rho=.34 NN N
, , N
P=.01 NNP N
; : N
moderate JJ N
and CC N
vigorous JJ N
PA NNP N
, , N
( ( N
MVPA NNP N
) ) N
rho=.33 NN N
, , N
P=.01 NNP N
) ) N
, , N
and CC N
a DT N
negative JJ N
association NN N
to TO N
sedentary JJ o
time NN o
( ( o
ST NNP N
) ) N
emerged VBD N
( ( N
rho=-.27 JJ N
, , N
P=.04 NNP N
) ) N
. . N

IPAQ-reported JJ N
moderate JJ o
PA NNP o
and CC o
MVPA NNP o
positively RB N
correlated VBD N
with IN N
maxV02 NN o
( ( N
rho=.25 NN N
, , N
P=.01 NNP N
, , N
rho=.27 NN N
, , N
P=.01 NNP N
, , N
respectively RB N
) ) N
. . N

Differences NNS N
between IN N
the DT N
magnitude NN N
of IN N
correlations NNS N
between IN N
the DT N
IPAQ-VO2 NNP o
max NN o
and CC o
GT3X-VO2 NNP o
max NN o
were VBD N
only RB N
significant JJ N
for IN N
ST NNP N
( ( N
Z=3.43 NNP N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Via NNP N
responses VBZ N
to TO N
the DT N
IPAQ NNP o
, , N
RA NNP N
patients NNS N
reported VBD N
that IN N
they PRP N
were VBD N
less JJR N
sedentary JJ o
and CC N
engaged VBN N
in IN N
more RBR N
higher JJR N
intensity NN N
PA NNP o
than IN N
what WP N
was VBD N
objectively RB N
assessed VBN N
. . N

Accelerometry NNP N
data NNS N
correlated VBD N
with IN N
VO2max NNP o
at IN N
all DT N
PA NNP N
levels NNS N
. . N

Only RB N
subjective JJ N
moderate NN N
and CC N
MPVA NNP o
correlated VBD N
with IN N
VO2max NNP o
. . N

Findings NNS N
suggest VBP N
that IN N
self-reported JJ N
PA NNP o
and CC N
ST NNP o
should MD N
be VB N
interpreted VBN N
with IN N
caution NN N
in IN N
people NNS N
with IN N
RA NNP N
and CC N
complemented VBN N
with IN N
accelerometry NN N
when WRB N
possible JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
Trial NNP N
registration NN N
: : N
ClinicalTrials.gov NNP N
ISRCTN04121489 NNP N
. . N

Registered VBD N
5 CD N
September NNP N
2012 CD N
. . N

-DOCSTART- -7831628- O O

Measurement NN N
of IN N
transfer NN N
factor NN N
during IN N
constant JJ N
exhalation NN N
. . N

BACKGROUND NNP N
Transfer NNP o
factor NN o
of IN o
the DT o
lung NN o
for IN o
carbon NN o
monoxide NN o
( ( o
TLCO NNP o
) ) o
was VBD N
measured VBN N
by IN N
a DT N
new JJ N
method NN N
based VBN N
on IN N
analysis NN N
of IN N
the DT N
ratio NN N
of IN N
the DT N
concentrations NNS N
of IN N
carbon NN N
monoxide NN N
to TO N
an DT N
inert NN N
gas NN N
( ( N
methane NN N
) ) N
relative NN N
to TO N
lung NN N
volume NN N
during IN N
a DT N
constant JJ N
exhalation NN N
. . N

Since IN N
this DT N
new JJ N
technique NN N
is VBZ N
based VBN N
solely RB N
upon JJ N
exhalation NN N
, , N
anomalies NNS N
associated VBN N
with IN N
inspiration NN N
and CC N
breath NN N
holding VBG N
do VBP N
not RB N
affect VB N
results NNS N
. . N

Additionally RB N
, , N
because IN N
prolonged JJ N
breath NN N
holding NN N
is VBZ N
not RB N
required VBN N
, , N
measurements NNS N
can MD N
readily RB N
be VB N
made VBN N
in IN N
dyspnoeic JJ p
patients NNS p
. . N

METHODS NNP N
Exhalation NNP o
TLCO NNP o
( ( o
TLCO NNP o
, , o
ex NN o
) ) o
was VBD N
compared VBN N
with IN N
the DT N
standard NN o
( ( o
Jones NNP o
and CC o
Meade NNP o
) ) o
10 CD o
second JJ o
breath NN o
holding VBG o
TLCO NNP o
( ( o
TLCO NNP o
, , o
bh NN o
) ) o
in IN N
100 CD p
consecutive JJ p
patients NNS p
. . N

Patients NNS N
did VBD N
not RB N
practise VB N
the DT N
exhalation NN N
manoeuvre NN N
prior RB N
to TO N
testing VBG N
. . N

RESULTS VB N
The DT N
comparative JJ N
results NNS N
were VBD N
very RB N
close RB N
; : N
mean JJ N
difference NN N
( ( N
bias JJ N
) ) N
+/- JJ N
standard JJ N
deviation NN N
( ( N
precision NN N
) ) N
was VBD N
0.05 CD N
( ( N
0.84 CD N
) ) N
mmol/min/kPa NN N
. . N

The DT N
relation NN o
was VBD N
equally RB N
strong JJ N
in IN N
patients NNS p
with IN p
severe JJ p
pulmonary JJ p
disease NN p
; : N
for IN N
patients NNS N
with IN N
FEV1 NNP N
< $ N
1.51 CD N
the DT N
mean NN N
difference NN N
was VBD N
0.21 CD N
( ( N
0.80 CD N
) ) N
mmol/min/kPa NN N
. . N

CONCLUSIONS NNP N
Since IN N
the DT N
results NNS N
were VBD N
essentially RB N
identical JJ N
between IN N
the DT N
techniques NNS N
, , N
it PRP N
seems VBZ N
that IN N
comparable JJ N
pathophysiological JJ N
factors NNS N
affect VBP N
TLCO NNP N
during IN N
breath NN N
holding NN N
and CC N
constant JJ N
exhalation NN N
. . N

Constant JJ N
exhalation NN N
may MD N
therefore RB N
be VB N
a DT N
useful JJ N
alternative NN N
to TO N
the DT N
breath NN N
holding NN N
technique NN N
for IN N
clinical JJ N
measurement NN N
of IN N
TLCO NNP N
. . N

-DOCSTART- -19727232- O O

[ JJ N
Effects NNS N
of IN N
auditory JJ i
integrative JJ i
training NN i
on IN N
autistic JJ p
children NNS p
] VBP N
. . N

OBJECTIVE NNP N
To TO N
explore VB N
the DT N
short-term JJ N
treatment NN N
effect NN N
of IN N
the DT N
auditory JJ i
integrative JJ i
training NN i
on IN N
autistic JJ p
children NNS p
and CC N
provide VB N
them PRP N
with IN N
clinical JJ N
support NN N
for IN N
rehabilitative JJ N
treatment NN N
. . N

METHODS NNP N
A NNP p
total NN p
of IN p
81 CD p
cases NNS p
of IN p
autistic JJ p
children NNS p
were VBD N
selected VBN N
through IN N
the DT N
standard NN N
of IN N
DSM-4 NNP N
and CC N
clinical JJ N
case NN N
study NN N
was VBD N
used VBN N
. . N

They PRP N
were VBD N
divided VBN N
randomly RB N
into IN N
experimental JJ N
group NN N
and CC N
control VB N
one CD N
, , N
and CC N
respectively RB N
received VBD N
auditory JJ i
integrative JJ i
training NN i
and CC N
no DT N
training NN N
based VBN N
on IN N
the DT N
multiple JJ N
therapies NNS N
. . N

The DT N
patients NNS N
were VBD N
investigated VBN N
using VBG N
clinical JJ o
manifestation NN o
and CC N
Autism NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
and CC N
intelligence NN o
quotient NN o
( ( o
IQ NNP o
) ) o
before IN N
and CC N
after IN N
six CD N
months NNS N
of IN N
treatment NN N
. . N

The DT N
effect NN N
was VBD N
evaluated VBN N
through IN N
the DT N
changes NNS o
of IN o
clinical JJ o
manifestations NNS o
and CC N
scores NNS N
of IN N
ABC NNP o
and CC N
IQ NNP o
. . N

The DT N
changes NNS N
of IN N
scores NNS N
of IN N
IQ NNP o
were VBD N
determined VBN N
with IN N
Gesell NNP N
and CC N
WPPSI NNP N
or CC N
WISC-R NNP N
. . N

RESULTS NNP N
Compared VBD N
with IN N
40 CD N
patients NNS N
of IN N
the DT N
control NN N
group NN N
after IN N
the DT N
six CD N
months NNS N
of IN N
the DT N
auditory JJ i
integrative JJ i
training NN i
, , N
41 CD N
of IN N
the DT N
experimental JJ N
group NN N
had VBD N
greatly RB N
improved VBN N
in IN N
many JJ N
aspects NNS N
, , N
such JJ N
as IN N
the DT N
disorders NNS o
of IN o
their PRP$ o
language NN o
, , o
social JJ o
interactions NNS o
and CC o
typical JJ o
behavior NN o
symptoms NNS o
while IN N
they PRP N
had VBD N
not RB N
changed VBN N
in IN N
their PRP$ N
abnormal JJ o
behaviors NNS o
. . N

The DT N
scores NNS o
of IN o
IQ NNP o
or CC o
DQ NNP o
had VBD N
increased VBN N
and CC N
scores NNS N
of IN N
ABC NNP o
had VBD N
dropped VBN N
. . N

The DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
greatly RB N
significant JJ N
in IN N
statistics NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
decreasing VBG N
level NN N
of IN N
both DT N
ABC NNP o
scores NNS o
and CC N
the DT N
increasing VBG N
level NN N
of IN N
the DT N
IQ NNP o
scores NNS o
were VBD N
negatively RB N
correlated VBN N
with IN N
age NN N
, , N
and CC N
the DT N
decreasing VBG N
level NN N
of IN N
ABC NNP o
scores NNS o
was VBD N
in IN N
line NN N
regression NN N
( ( N
positive JJ N
correlation NN N
) ) N
with IN N
base NN N
IQ NNP N
. . N

CONCLUSION NNP N
The DT N
treatment NN N
of IN N
auditory JJ i
integrative JJ i
training NN i
( ( i
AIT NNP i
) ) i
could MD N
greatly RB N
improve VB N
on IN N
language NN o
disorders NNS o
, , N
the DT N
difficulties NNS o
of IN o
social JJ o
interactions NNS o
, , o
typical JJ o
behavior NN o
symptoms NNS o
and CC N
developmental JJ o
levels NNS o
, , N
therefore IN N
it PRP N
is VBZ N
positive JJ N
to TO N
the DT N
autistic JJ p
children NNS p
in IN N
its PRP$ N
short-term JJ N
treatment NN N
effect NN N
. . N

-DOCSTART- -21106663- O O

Time-varying JJ N
smoking NN N
abstinence NN N
predicts VBZ N
lower JJR N
depressive JJ o
symptoms NNS o
following VBG N
smoking VBG N
cessation NN N
treatment NN N
. . N

INTRODUCTION NNP N
The DT N
question NN N
of IN N
whether IN N
abstinence NN N
during IN N
the DT N
months NNS N
following VBG N
a DT N
planned VBN N
quit NN N
attempt NN N
exacerbates VBZ N
or CC N
improves VBZ N
depressive JJ o
symptoms NNS o
is VBZ N
an DT N
important JJ N
clinical JJ N
issue NN N
. . N

Extant NNP N
research NN N
has VBZ N
primarily RB N
modeled VBN N
between-person JJ N
covariation NN N
between IN N
postquit NN N
abstinence NN N
and CC N
depressive JJ N
symptom NN N
trajectories NNS N
. . N

However RB N
, , N
this DT N
approach NN N
can MD N
not RB N
account VB N
for IN N
potential JJ N
third JJ N
variables NNS N
between IN N
participants NNS N
that WDT N
may MD N
affect VB N
both DT N
smoking NN N
and CC N
depression NN N
. . N

Accordingly RB N
, , N
the DT N
current JJ N
study NN N
examined VBD N
within-person JJ N
covariation NN N
between IN N
time-varying JJ N
abstinence NN N
and CC N
depressive JJ o
symptom NN o
in IN N
a DT N
multilevel NN N
model NN N
( ( N
MLM NNP N
) ) N
, , N
which WDT N
allowed VBD N
for IN N
transitions NNS N
between IN N
smoking VBG N
statuses NNS N
within IN N
a DT N
participant NN N
. . N

METHODS JJ N
Participants NNS p
were VBD p
236 CD p
heavy JJ p
drinking NN p
smokers NNS p
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
testing VBG N
the DT N
efficacy NN N
of IN N
incorporating VBG N
brief JJ N
alcohol NN i
intervention NN i
into IN N
smoking VBG N
cessation NN N
treatment NN N
. . N

Depressive NNP o
symptoms NNS o
and CC N
biochemically RB o
verified JJ o
abstinence NN o
were VBD N
assessed VBN N
1 CD N
week NN N
prior RB N
to TO N
and CC N
2 CD N
, , N
8 CD N
, , N
16 CD N
, , N
and CC N
26 CD N
weeks NNS N
after IN N
quit NN N
date NN N
. . N

RESULTS NNP N
MLMs NNP N
indicated VBD N
a DT N
slight JJ N
increase NN N
in IN N
depressive JJ o
symptoms NNS o
over IN N
time NN N
in IN N
the DT N
sample NN N
as IN N
a DT N
whole NN N
. . N

However RB N
, , N
there EX N
was VBD N
an DT N
inverse JJ N
relation NN N
between IN N
time-varying JJ N
abstinence NN N
( ( N
vs. IN N
smoking NN N
) ) N
and CC N
concurrent JJ N
level NN o
of IN o
depressive JJ o
symptoms NNS o
, , N
indicating VBG N
that IN N
transitions NNS N
from IN N
smoking VBG N
to TO N
abstinence VB N
within IN N
individuals NNS N
were VBD N
associated VBN N
with IN N
reductions NNS N
in IN N
depressive JJ o
symptoms NNS o
. . N

CONCLUSIONS NNP N
During IN N
the DT N
first JJ N
6 CD N
months NNS N
following VBG N
a DT N
planned VBN N
quit NN N
attempt NN N
, , N
being VBG N
abstinent NN N
in IN N
a DT N
particular JJ N
week NN N
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
lower JJR N
levels NNS N
of IN N
concurrent NN N
depressive NN o
symptoms NNS o
. . N

These DT N
results NNS N
are VBP N
not RB N
concordant JJ N
with IN N
the DT N
view NN N
that IN N
intentional JJ N
smoking NN N
abstinence NN N
exacerbates VBZ N
depressive JJ o
symptoms NNS o
. . N

Efforts NNS N
to TO N
promote VB N
smoking VBG N
cessation NN N
should MD N
highlight VB N
that IN N
individuals NNS N
are VBP N
likely JJ N
to TO N
feel VB N
more RBR N
rather RB N
than IN N
less JJR N
psychologically RB N
healthy JJ N
when WRB N
they PRP N
successfully RB N
quit VBP N
smoking NN N
. . N

-DOCSTART- -9394106- O O

Effect NN N
of IN N
treatment NN N
with IN N
paromomycin NN i
on IN N
endotoxemia NN o
in IN N
patients NNS p
with IN p
alcoholic JJ p
liver NN p
disease NN p
-- : N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

The DT N
results NNS N
of IN N
experimental JJ N
and CC N
clinical JJ N
studies NNS N
support VBP N
the DT N
hypothesis NN N
that IN N
gut-derived JJ N
endotoxins NNS N
might MD N
be VB N
of IN N
relevance NN N
for IN N
the DT N
development NN N
and CC N
course NN N
of IN N
alcoholic JJ N
liver NN N
disease NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
nonabsorbable JJ N
, , N
broad-spectrum JJ N
antibiotic NN N
on IN N
endotoxemia NN o
in IN N
patients NNS p
with IN p
alcoholic JJ p
liver NN p
disease NN p
. . N

Fifty JJ p
patients NNS p
with IN p
alcoholic JJ p
liver NN p
disease NN p
( ( p
27 CD p
with IN p
cirrhosis NN p
, , p
23 CD p
without IN p
cirrhosis NN p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
paromomycin NN i
sulfate NN i
( ( N
3 CD N
x RB N
1 CD N
g/day NN N
) ) N
or CC N
placebo NN i
in IN N
a DT N
double-blind JJ N
fashion NN N
for IN N
at IN N
least JJS N
3 CD N
weeks NNS N
, , N
and CC N
if IN N
possible JJ N
4 CD N
weeks NNS N
. . N

Endotoxin NNP o
concentration NN o
, , o
liver JJ o
function NN o
tests NNS o
, , N
and CC N
other JJ N
laboratory NN N
parameters NNS N
were VBD N
determined VBN N
in IN N
weekly JJ N
intervals NNS N
. . N

Endotoxin NNP o
concentration NN o
was VBD N
also RB N
determined VBN N
in IN N
15 CD p
healthy JJ p
controls NNS p
. . N

Groups NNP N
receiving VBG N
paromomycin NN i
or CC N
placebo NN i
were VBD N
similar JJ N
for IN N
clinical JJ N
and CC N
biological JJ N
items NNS N
collected VBN N
initially RB N
. . N

Mean JJ N
initial JJ N
endotoxin NN o
concentrations NNS o
were VBD N
significantly RB N
elevated VBN N
in IN N
both DT N
groups NNS N
( ( N
mean JJ N
+/- JJ N
SEM NNP N
; : N
paromomycin NN i
, , N
16.7 CD N
+/- JJ N
5.3 CD N
pg/ml NN N
; : N
placebo NN i
, , N
17.5 CD N
+/- JJ N
6.9 CD N
pg/ml NN N
; : N
healthy JJ N
controls NNS N
, , N
2.3 CD N
+/- JJ N
0.4 CD N
pg/ml NN N
) ) N
. . N

Although IN N
the DT N
mean JJ N
endotoxin NN o
concentration NN o
was VBD N
lower JJR N
in IN N
the DT N
verum NN N
group NN N
after IN N
1 CD N
week NN N
( ( N
paromomycin NN i
, , N
8.0 CD N
+/- JJ N
1.9 CD N
pg/ml NN N
; : N
placebo NN i
, , N
14.6 CD N
+/- JJ N
3.5 CD N
pg/ml NN N
; : N
p CC N
> VB N
0.05 CD N
) ) N
, , N
paromomycin JJ i
treatment NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
endotoxin NN o
concentration NN o
or CC N
liver JJ o
function NN o
tests NNS o
during IN N
the DT N
4-week JJ N
period NN N
. . N

The DT N
beneficial JJ N
effect NN N
of IN N
paromomycin NN i
treatment NN N
on IN N
endotoxemia NN N
in IN N
cirrhotics NNS N
reported VBN N
in IN N
earlier JJR N
studies NNS N
could MD N
not RB N
be VB N
reproduced VBN N
under IN N
the DT N
conditions NNS N
of IN N
this DT N
trial NN N
in IN N
patients NNS p
with IN p
alcoholic JJ p
liver NN p
disease NN p
. . N

-DOCSTART- -11317090- O O

Economic JJ o
evaluation NN o
of IN N
aquatic JJ i
exercise NN i
for IN N
persons NNS p
with IN p
osteoarthritis NN p
. . N

OBJECTIVES NNP N
To TO N
estimate VB N
cost NN o
and CC N
outcomes NNS o
of IN N
the DT N
Arthritis NNP N
Foundation NNP N
aquatic JJ i
exercise NN i
classes NNS i
from IN N
the DT N
societal JJ N
perspective NN N
. . N

DESIGN NNP N
Randomized NNP N
trial NN N
of IN N
20-week JJ N
aquatic JJ i
classes NNS i
. . N

Cost NN o
per IN o
quality-adjusted JJ o
life NN o
year NN o
( ( o
QALY NNP o
) ) o
gained VBD N
was VBD N
estimated VBN N
using VBG N
trial NN N
data NNS N
. . N

Sample NNP N
size NN N
was VBD N
based VBN N
on IN N
80 CD N
% NN N
power NN N
to TO N
reject VB N
the DT N
null JJ N
hypothesis NN N
that IN N
the DT N
cost/QALY NN o
gained VBD N
would MD N
not RB N
exceed VB N
$ $ N
50,000 CD N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Recruited VBD N
249 CD p
adults NNS p
from IN p
Washington NNP p
State NNP p
aged VBD p
55 CD p
to TO p
75 CD p
with IN p
a DT p
doctor-confirmed JJ p
diagnosis NN p
of IN p
osteoarthritis NN p
to TO N
participate VB N
in IN N
aquatic JJ i
classes NNS i
. . N

The DT N
Quality NN o
of IN o
Well-Being NNP o
Scale NNP o
( ( o
QWB NNP o
) ) o
and CC N
Current NNP o
Health NNP o
Desirability NNP o
Rating NNP o
( ( o
CHDR NNP o
) ) o
were VBD N
used VBN N
for IN N
economic JJ N
evaluation NN N
, , N
supplemented VBN N
by IN N
the DT N
arthritis-specific JJ o
Health NNP o
Assessment NNP o
Questionnaire NNP o
( ( o
HAQ NNP o
) ) o
, , N
Center NNP o
for IN o
Epidemiologic NNP o
Studies-Depression NNP o
Scale NNP o
( ( o
CES-D NNP o
) ) o
, , N
and CC N
Perceived NNP o
Quality NNP o
of IN o
Life NNP o
Scale NNP o
( ( o
PQOL NNP o
) ) o
collected VBD N
at IN N
baseline NN N
and CC N
postclass NN N
. . N

Outcome NNP N
results NNS N
applied VBD N
to TO N
life NN N
expectancy NN N
tables NNS N
were VBD N
used VBN N
to TO N
estimate VB N
QALYs NNP o
. . N

Use NNP o
of IN o
health NN o
care NN o
facilities NNS o
was VBD N
assessed VBN N
from IN N
diaries/questionnaires NNS N
and CC N
Medicare NNP o
reimbursement NN o
rates NNS o
used VBD N
to TO N
estimate VB N
costs NNS N
. . N

Nonparametric NNP N
bootstrap NN N
sampling NN N
of IN N
costs/QALY NN o
ratios NNS o
established VBD N
the DT N
95 CD N
% NN N
CI NNP N
around IN N
the DT N
estimates NNS N
. . N

RESULTS NNP N
Aquatic JJ i
exercisers NNS i
reported VBD N
equal JJ N
( ( N
QWB NNP o
) ) N
or CC N
better JJR N
( ( N
CHDR NNP o
, , o
HAQ NNP o
, , o
PQOL NNP o
) ) N
health-related JJ N
quality NN N
of IN N
life NN N
compared VBN N
with IN N
controls NNS N
. . N

Outcomes NNS N
improved VBN N
with IN N
regular JJ N
class NN N
attendance NN N
. . N

Costs/QALY NNP o
gained VBD N
discounted VBN N
at IN N
3 CD N
% NN N
were VBD N
$ $ N
205,186 CD N
using VBG N
the DT N
QWB NNP o
and CC N
$ $ N
32,643 CD N
using VBG N
the DT N
CHRD NNP o
. . N

CONCLUSION NNP N
Aquatic NNP i
exercise NN i
exceeded VBD N
$ $ N
50,000 CD N
per IN N
QALY NN o
gained VBN N
using VBG N
the DT N
community-weighted JJ N
outcome NN N
but CC N
fell VBD N
below IN N
this DT N
arbitrary JJ N
budget NN N
constraint NN N
when WRB N
using VBG N
the DT N
participant-weighted JJ N
measure NN N
. . N

Confidence NN N
intervals NNS N
around IN N
these DT N
ratios NNS N
suggested VBD N
wide JJ N
variability NN N
of IN N
cost NN N
effectiveness NN N
of IN N
aquatic JJ i
exercise NN i
. . N

-DOCSTART- -2678230- O O

[ VB N
The DT N
effect NN N
of IN N
ionic JJ i
and CC N
nonionic JJ i
x-ray JJ i
contrast NN i
media NNS N
on IN N
myocardial JJ N
perfusion NN N
and CC N
myocardial JJ o
function NN N
] NN N
. . N

The DT N
influence NN N
of IN N
injections NNS N
of IN N
Amidotrizoate NNP i
and CC N
Iopromide NNP i
into IN N
the DT N
left JJ N
coronary JJ N
artery NN N
on IN N
global JJ o
myocardial JJ o
perfusion NN o
and CC o
function NN o
( ( N
pressures NNS N
in IN N
the DT N
left JJ N
ventricle NN N
, , N
heart NN N
rate NN N
) ) N
as RB N
well RB N
as IN N
excitation NN N
formation NN N
and CC N
transmission NN N
was VBD N
studied VBN N
in IN N
16 CD p
patients NNS p
with IN p
ischaemic JJ p
heart NN p
disease NN p
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
myocardial JJ o
perfusion NN o
measured VBN N
were VBD N
found VBN N
with IN N
xenon-133 JJ N
in IN N
this DT N
small JJ N
group NN N
between IN N
rest NN N
and CC N
dipyridamole JJ N
load NN N
for IN N
ionic JJ N
and CC N
non-ionic JJ N
contrast NN N
media NNS N
. . N

-DOCSTART- -10763172- O O

[ NN N
Improving VBG N
wound IN o
healing VBG o
after IN p
nose JJ p
surgery NN p
by IN N
combined JJ N
administration NN N
of IN N
xylometazoline NNP i
and CC N
dexpanthenol JJ i
] NNP N
. . N

BACKGROUND NNP N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
the DT N
examination NN N
of IN N
efficacy NN o
and CC N
tolerability NN o
of IN N
an DT N
application-form NN N
of IN N
the DT N
new JJ N
combination NN N
of IN N
Xylometazoline NN i
with IN N
Dexpanthenol NNP i
( ( i
Nasic NNP i
) ) i
versus FW N
Xylometazoline NNP i
alone RB i
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Randomized NNP N
verum NN N
controlled VBD N
parallel-group-comparison NN N
of IN N
two CD N
weeks NNS N
treatment NN N
of IN N
a DT N
nasal-spray JJ N
. . N

61 CD p
inpatients NNS p
with IN p
the DT p
diagnosis NN p
Rhinitis NNP p
following VBG p
nasal JJ p
operation NN p
were VBD N
included VBN N
in IN N
this DT N
study NN N
and CC N
30 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
verum NN i
and CC N
placebo NN i
each DT N
. . N

The DT N
assessment NN N
of IN N
nasal-breathing-resistance NN o
according VBG o
to TO o
scores NNS o
was VBD N
defined VBN N
as IN N
target-parameter NN N
. . N

Confirmatory NNP N
statistical JJ N
analysis NN N
was VBD N
carried VBN N
out RP N
according VBG N
to TO N
Wilcoxon-Mann-Whitney-U JJ N
two-sided JJ N
at IN N
alpha JJ N
< NN N
or CC N
= $ N
0.05 CD N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
superiority NN N
of IN N
the DT N
combination NN N
of IN N
Xylometazoline-Dexpanthenol JJ i
nasal-spray JJ N
versus NN N
Xylometazoline NNP i
nasal NN N
spray NN N
could MD N
be VB N
proven VBN N
for IN N
the DT N
target-parameter NN N
as IN N
clinically RB N
relevant JJ N
and CC N
statistically RB N
significant JJ N
. . N

The DT N
clinically RB N
proven JJ N
efficacy NN o
is VBZ N
emphasized VBN N
by IN N
good JJ N
tolerability NN o
of IN N
both DT N
treatments NNS N
. . N

Due NNP N
to TO N
easy VB N
handling NN N
of IN N
the DT N
nasal-spray JJ N
a DT N
good JJ N
compliance NN o
was VBD N
confirmed VBN N
. . N

CONCLUSION NNP N
Distinct NNP N
improvement NN o
of IN N
symptoms NNS N
in IN N
patients NNS p
following VBG p
nasal JJ p
operations NNS p
underlines VBP N
the DT N
efficacy NN o
of IN N
both DT N
medications NNS N
. . N

With IN N
respect NN N
to TO N
the DT N
tolerability NN o
therapy NN N
with IN N
the DT N
combination NN N
is VBZ N
more RBR N
beneficial JJ N
in IN N
comparison NN N
to TO N
the DT N
alternative JJ N
therapy NN N
. . N

The DT N
result NN N
of IN N
this DT N
controlled VBN N
clinical JJ N
study NN N
confirms VBZ N
that IN N
the DT N
combination NN N
Xylometazoline-Dexpanthenol NNP i
is VBZ N
an DT N
enlargement NN N
and CC N
improvement NN N
of IN N
effective JJ N
medicinal JJ N
treatment NN N
of IN N
rhinitis NN p
following VBG p
nasal JJ p
operation NN p
in IN N
comparison NN N
to TO N
therapy VB N
with IN N
Xylometazoline NNP i
alone RB N
. . N

-DOCSTART- -8726604- O O

The DT N
effects NNS N
of IN N
sevoflurane NN i
and CC N
isoflurane NN i
on IN N
recovery NN N
from IN N
outpatient JJ p
surgery NN p
. . N

This DT N
randomized JJ N
, , N
open-label JJ N
study NN N
compared VBN N
the DT N
investigational JJ N
inhalational JJ N
anesthetic JJ N
sevoflurane NN i
with IN N
isoflurane NN i
in IN N
47 CD p
healthy JJ p
women NNS p
undergoing VBG p
elective JJ p
ambulatory NN p
surgery NN p
. . N

The DT N
women NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
sevoflurane NN i
or CC N
isoflurane NN i
in IN N
60 CD N
% NN N
nitrous JJ N
oxide-oxygen NN N
. . N

Induction NN N
with IN N
thiopental JJ i
3-6 JJ N
mg/kg NN N
was VBD N
followed VBN N
by IN N
vecuronium NN i
0.1 CD N
mg/kg NN N
and CC N
fentanyl JJ i
0-200 JJ N
micrograms NNS N
. . N

Duration NN o
of IN o
anesthesia NN o
, , o
time NN o
to TO o
emergence VB o
, , o
orientation NN o
, , o
length NN o
of IN o
stay NN o
in IN o
the DT o
surgical JJ o
unit NN o
, , o
and CC o
hospital JJ o
discharge NN o
were VBD N
recorded VBN N
. . N

The DT N
emergence NN o
, , o
length NN o
of IN o
stay NN o
, , o
and CC o
discharge NN o
times NNS o
after IN N
discontinuation NN N
of IN N
sevoflurane NN i
were VBD N
9.7 CD N
+/- JJ N
0.7 CD N
, , N
120.6 CD N
+/- JJ N
8.0 CD N
, , N
and CC N
244 CD N
+/- JJ N
15 CD N
minutes NNS N
, , N
respectively RB N
, , N
and CC N
for IN N
isoflurane NN i
were VBD N
11.9 CD N
+/- JJ N
1.4 CD N
, , N
106.8 CD N
+/- JJ N
7.1 CD N
, , N
and CC N
282 CD N
+/- JJ N
24 CD N
minutes NNS N
, , N
respectively RB N
( ( N
NS NNP N
) ) N
. . N

The DT N
isoflurane NN N
group NN N
had VBD N
a DT N
higher JJR N
frequency NN N
of IN N
postoperative JJ o
cough NN o
. . N

At IN N
the DT N
end NN N
of IN N
surgery NN N
, , N
the DT N
sevoflurane NN N
group NN N
received VBD N
a DT N
deeper JJR N
level NN N
of IN N
anesthesia NN o
( ( N
minimum JJ N
alveolar JJ N
concentration NN N
1.5 CD N
vs NN N
1.3 CD N
) ) N
, , N
however RB N
, , N
these DT N
patients NNS N
were VBD N
oriented VBN N
earlier RB N
( ( N
13.6 CD N
+/- JJ N
1.1 CD N
min NN N
vs NN N
17.0 CD N
+/- JJ N
1.5 CD N
min NN N
isoflurane NN N
; : N
p CC N
= VB N
0.02 CD N
) ) N
after IN N
discontinuation NN N
of IN N
anesthesia NN N
, , N
although IN N
this DT N
difference NN N
is VBZ N
of IN N
little JJ N
clinical JJ N
significance NN N
. . N

-DOCSTART- -16505427- O O

Phase NNP N
III NNP N
study NN N
of IN N
two CD N
different JJ N
dosing VBG N
schedules NNS N
of IN N
erythropoietin NN i
in IN N
anemic JJ p
patients NNS p
with IN p
cancer NN p
. . N

PURPOSE NNP N
To TO N
compare VB N
maintenance NN N
epoetin NN i
alfa NN i
administered VBD N
once RB N
every DT N
3 CD N
weeks NNS N
with IN N
continued JJ N
weekly JJ N
epoetin NN i
alfa NN i
for IN N
patients NNS p
with IN p
cancer-associated JJ p
anemia NN p
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Eligible JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
at IN N
enrollment NN N
to TO N
receive VB N
three CD N
weekly JJ N
doses NNS N
of IN N
epoetin NN i
alfa NN i
40,000 CD N
U NNP N
subcutaneously RB N
( ( N
SC NNP N
) ) N
, , N
followed VBN N
by IN N
either DT N
standard JJ N
weekly JJ N
epoetin NN i
alfa NN i
( ( N
40K CD N
arm NN N
) ) N
or CC N
120,000 CD N
U NNP N
of IN N
epoetin NN i
alfa NN i
( ( N
120K CD N
arm NN N
) ) N
SC NNP N
every DT N
3 CD N
weeks NNS N
for IN N
18 CD N
additional JJ N
weeks NNS N
. . N

RESULTS NNP N
Three CD p
hundred VBD p
sixty-five JJ p
patients NNS p
were VBD N
enrolled VBN N
. . N

One CD N
hundred VBD N
eighty-three JJ N
patients NNS N
were VBD N
assigned VBN N
to TO N
the DT N
40K CD N
arm NN N
, , N
and CC N
182 CD N
were VBD N
assigned VBN N
to TO N
the DT N
120K CD N
arm NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
proportion NN N
of IN N
patients NNS N
requiring VBG o
transfusions NNS o
during IN N
the DT N
study NN N
( ( N
23 CD N
% NN N
in IN N
40K CD N
arm NN N
and CC N
18 CD N
% NN N
in IN N
120K CD N
arm NN N
, , N
P NNP N
= NNP N
.22 NNP N
) ) N
or CC N
specifically RB N
during IN N
the DT N
maintenance NN N
phase NN N
( ( N
13 CD N
% NN N
in IN N
40K CD N
arm NN N
v NN N
15 CD N
% NN N
in IN N
120K CD N
arm NN N
, , N
P NNP N
= NNP N
.58 NNP N
) ) N
. . N

Patients NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
40K CD N
arm NN N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
a DT N
> NN N
or CC N
= VB N
2 CD N
or CC N
> CD N
or CC N
= VB N
3 CD N
g/dL NN N
hemoglobin NN o
( ( o
Hb NNP o
) ) o
increment NN o
, , N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
a DT N
drug NN o
dose RB o
held VBD N
because IN N
of IN N
high JJ N
Hb NNP o
, , N
and CC N
had VBD N
higher JJR N
mean JJ N
end-of-study JJ N
Hb NNP o
levels NNS N
. . N

Toxicities NNS o
, , N
including VBG N
thromboembolism NN o
, , N
and CC N
overall JJ o
survival NN o
were VBD N
similar JJ N
. . N

Patients NNS N
in IN N
the DT N
40K CD N
arm NN N
had VBD N
a DT N
higher JJR N
global JJ o
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
at IN N
baseline NN N
for IN N
unclear JJ N
reasons NNS N
, , N
whereas JJ N
patients NNS N
in IN N
the DT N
120K CD N
arm NN N
had VBD N
a DT N
greater JJR N
global JJ o
QOL NNP o
improvement NN N
during IN N
the DT N
study NN N
, , N
so IN N
end-of-study JJ N
QOL NNP o
was VBD N
equivalent JJ N
. . N

CONCLUSION NN N
After IN N
three CD N
weekly JJ N
doses NNS N
of IN N
epoetin NN i
alfa NN i
40,000 CD N
U NNP N
, , N
a DT N
dose NN N
of IN N
120,000 CD N
U NNS N
can MD N
be VB N
administered VBN N
safely RB N
once RB N
every DT N
3 CD N
weeks NNS N
without IN N
increasing VBG N
transfusion NN o
needs NNS o
or CC N
sacrificing VBG N
QOL NNP o
. . N

The DT N
Hb NNP o
increment NN o
is VBZ N
somewhat RB N
greater JJR N
with IN N
continued JJ N
weekly JJ N
epoetin NN i
alfa NN i
. . N

Lack NNP N
of IN N
blinding VBG N
as IN N
a DT N
result NN N
of IN N
different JJ N
treatment NN N
schedules NNS N
may MD N
have VB N
confounded VBN N
results NNS N
. . N

-DOCSTART- -7853069- O O

Necessary NNP N
but CC N
not RB N
sufficient JJ N
: : N
the DT N
effect NN N
of IN N
screening NN N
and CC N
feedback NN N
on IN N
outcomes NNS N
of IN N
primary JJ p
care NN p
patients NNS p
with IN p
untreated JJ p
anxiety NN p
. . N

OBJECTIVE UH N
To TO N
consider VB N
the DT N
impact NN N
on IN N
primary JJ N
care NN N
patient JJ N
outcomes NNS N
of IN N
using VBG N
both DT N
a DT N
screener NN N
to TO N
determine VB N
elevated VBN N
anxiety NN N
levels NNS N
among IN N
patients NNS p
with IN p
previously RB p
undetected VBN p
anxiety NN p
and CC N
a DT N
physician JJ N
intervention NN N
to TO N
inform VB N
physicians NNS N
of IN N
their PRP$ N
patients NNS N
' POS N
conditions NNS N
. . N

DESIGN NNP N
Participating VBG N
physicians NNS N
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
demonstration NN i
or CC N
the DT N
control NN N
arm NN N
, , N
and CC N
patients NNS N
were VBD N
assigned VBN N
to TO N
a DT N
study NN N
arm NN N
based VBN N
on IN N
the DT N
randomization NN N
of IN N
their PRP$ N
physicians NNS N
. . N

The DT N
patients NNS N
were VBD N
followed VBN N
for IN N
change NN N
in IN N
outcome JJ N
measures NNS N
during IN N
the DT N
five-month JJ N
study NN N
period NN N
. . N

SETTING VB N
A DT N
mixed-model JJ N
health NN N
maintenance NN N
organization NN N
serving VBG N
approximately RB N
110,000 CD N
enrollees NNS N
in IN N
central JJ N
Colorado NNP N
. . N

PATIENTS/PARTICIPANTS NNP N
573 CD p
patients NNS p
who WP p
had VBD p
unrecognized VBN p
and CC p
untreated JJ p
anxiety NN p
identified VBN p
from IN p
the DT p
approximately RB p
8,000 CD p
patients NNS p
who WP p
completed VBD p
the DT p
waiting VBG p
room NN p
screening NN p
questionnaire NN p
. . N

INTERVENTIONS VBZ N
A DT N
physician JJ i
intervention NN i
served VBD N
the DT N
dual JJ N
function NN N
of IN N
1 CD N
) ) N
providing VBG N
an DT N
educational JJ N
demonstration NN N
of IN N
anxiety NN N
in IN N
the DT N
primary JJ N
care NN N
setting VBG N
and CC N
2 CD N
) ) N
providing VBG N
a DT N
reporting NN N
system NN N
for IN N
summarizing VBG N
the DT N
anxiety NN N
symptom NN N
levels NNS N
and CC N
functioning VBG N
status NN N
of IN N
the DT N
patients NNS N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Patient NNP N
outcomes NNS N
were VBD N
measured VBN N
as IN N
changes NNS N
in IN N
global JJ o
anxiety NN o
scores NNS o
, , o
functioning VBG o
and CC o
well-being JJ o
, , o
and CC N
patients NNS o
' POS o
reports NNS o
of IN o
global JJ o
improvements NNS o
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
indicate VBP N
that IN N
this DT N
method NN N
of IN N
reporting VBG N
symptoms NNS N
and CC N
functioning VBG N
status NN N
to TO N
primary VB N
care NN N
physicians NNS N
did VBD N
not RB N
significantly RB N
change VBP N
patient JJ N
outcomes NNS N
. . N

Improvement NN N
in IN N
outcomes NNS N
appeared VBD N
to TO N
be VB N
more RBR N
closely RB N
associated VBN N
with IN N
the DT N
patient NN N
's POS N
severity NN N
of IN N
psychological JJ N
distress NN N
. . N

-DOCSTART- -23417625- O O

Social NNP N
skills NNS N
improvement NN N
in IN N
children NNS p
with IN p
high-functioning JJ p
autism NN p
: : N
a DT N
pilot NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

High-functioning JJ N
autism NN N
( ( N
HFA NNP N
) ) N
is VBZ N
characterized VBN N
by IN N
persistent JJ N
impairment NN N
in IN N
social JJ N
interaction NN N
despite IN N
the DT N
absence NN N
of IN N
mental JJ N
retardation NN N
. . N

Although IN N
an DT N
increasing VBG N
number NN N
of IN N
group-based JJ N
programs NNS N
for IN N
the DT N
improvement NN N
of IN N
social JJ N
skills NNS N
have VBP N
been VBN N
described VBN N
, , N
randomized VBN N
controlled VBN N
trials NNS N
are VBP N
needed VBN N
to TO N
evaluate VB N
their PRP$ N
efficacy NN N
. . N

To TO N
compare VB N
the DT N
effect NN N
of IN N
a DT N
Social NNP i
Skills NNP i
Training NNP i
Group-based JJ i
Program NNP i
( ( i
SST-GP NNP i
) ) i
and CC N
a DT N
Leisure NN i
Activities VBZ i
Group-based JJ i
Program NNP i
( ( i
LA-GP NNP i
) ) i
on IN N
the DT N
perception NN N
of IN N
facial JJ N
emotions NNS N
and CC N
quality NN N
of IN N
life NN N
( ( N
QoL NNP N
) ) N
in IN N
young JJ N
people NNS N
with IN N
HFA NNP N
. . N

Eligible JJ N
patients NNS N
were VBD N
children NNS p
and CC p
adolescents NNS p
with IN p
HFA NNP p
. . N

Participants NNS N
were VBD N
randomized VBN N
to TO N
the DT N
SST NNP i
or CC N
LA NNP i
group NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
an DT N
improvement NN N
of IN N
2 CD N
points NNS N
in IN N
error NN o
rates NNS o
for IN o
facial JJ o
emotion NN o
labeling NN o
( ( o
DANVA2 NNP o
) ) o
from IN N
baseline NN N
. . N

After IN N
the DT N
6-month JJ N
training NN N
period NN N
, , N
the DT N
SST NNP i
Group NNP N
made VBD N
fewer JJR N
errors NNS N
in IN N
labeling VBG N
anger NN N
on IN N
adult NN N
faces VBZ N
, , N
whereas JJ N
error NN N
rates NNS N
in IN N
the DT N
LA NNP i
Group NNP N
remained VBD N
stable JJ N
. . N

Progress NN N
in IN N
the DT N
ability NN o
to TO o
recognize VB o
anger NN o
in IN N
the DT N
SST NNP i
Group NNP N
was VBD N
due JJ N
to TO N
better JJR N
recognition NN N
of IN N
low JJ N
intensity NN N
stimuli NN N
on IN N
adult NN N
faces VBZ N
. . N

QoL NNP o
increased VBD N
in IN N
the DT N
SST NNP i
Group NNP N
in IN N
the DT N
dimension NN N
of IN N
school NN N
environment NN N
, , N
as IN N
a DT N
marker NN N
of IN N
the DT N
transfer NN N
of IN N
skills NNS N
acquired VBN N
in IN N
the DT N
treatment NN N
setting VBG N
to TO N
their PRP$ N
use NN N
in IN N
the DT N
community NN N
. . N

The DT N
SST-GP NNP i
had VBD N
higher JJR N
efficacy NN o
than IN N
the DT N
LA-GP NNP i
. . N

Data NNP N
justify NN N
replication NN N
using VBG N
larger JJR N
samples NNS N
. . N

-DOCSTART- -21896676- O O

A DT N
physiotherapy NN i
service NN i
to TO N
an DT N
emergency NN N
extended VBD N
care NN N
unit NN N
does VBZ N
not RB N
decrease VB N
admission NN o
rates NNS o
to TO o
hospital VB o
: : N
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
One CD N
of IN N
the DT N
reasons NNS N
physiotherapy NN i
services NNS N
are VBP N
provided VBN N
to TO N
emergency NN N
departments NNS N
( ( N
EDs NNP N
) ) N
and CC N
emergency NN N
extended VBN N
care NN N
units NNS N
( ( N
EECUs NNP N
) ) N
is VBZ N
to TO N
review VB N
patients NNS N
' POS N
mobility NN N
to TO N
ensure VB N
they PRP N
are VBP N
safe JJ N
to TO N
be VB N
discharged VBN N
home NN N
. . N

AIM NNP N
To TO N
investigate VB N
whether IN N
a DT N
physiotherapy NN i
service NN i
to TO N
an DT N
EECU NNP N
altered VBD N
the DT N
rate NN o
of IN o
hospital NN o
admission NN o
, , o
rate NN o
of IN o
re-presentation NN o
to TO o
the DT o
ED NNP o
, , o
visits VBZ o
to TO o
community NN o
healthcare NN o
practitioners NNS o
, , o
return NN o
to TO o
usual JJ o
work/home/leisure NN o
activities NNS o
and CC N
patient JJ o
satisfaction NN o
. . N

METHODS NNP N
A DT N
randomised JJ N
trial NN N
with IN N
concealed JJ N
allocation NN N
, , N
assessor NN N
blinding NN N
and CC N
intention-to-treat JJ N
analysis NN N
was VBD N
undertaken VBN N
in IN N
an DT N
EECU NNP N
. . N

The DT N
sample NN N
comprised VBD N
186 CD p
patients NNS p
( ( p
mean JJ p
age NN p
70 CD p
years NNS p
, , p
123 CD p
( ( p
66 CD p
% NN p
) ) p
female NN p
patients NNS p
, , p
130 CD p
( ( p
70 CD p
% NN p
) ) p
trauma NN p
) ) p
who WP p
were VBD p
referred VBN p
for IN p
physiotherapy NN i
assessment/intervention NN i
. . N

Referral JJ N
occurred VBD N
at IN N
any DT N
stage NN N
of IN N
the DT N
patients NNS N
' POS N
EECU NNP N
admission NN N
. . N

All DT N
participants NNS N
received VBD N
medical/nursing VBG N
care NN N
as IN N
required VBN N
. . N

The DT N
physiotherapy NN i
group NN N
also RB N
received VBD N
physiotherapy JJ i
assessment/intervention NN i
. . N

RESULTS VB N
The DT N
physiotherapy NN i
group NN N
had VBD N
a DT N
4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-18 CD N
% NN N
to TO N
9 CD N
% NN N
) ) N
lower JJR N
rate NN o
of IN o
admission NN o
to TO o
hospital NN o
than IN N
the DT N
control NN N
group NN N
and CC N
a DT N
4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-6 NNP N
% NN N
to TO N
13 CD N
% NN N
) ) N
higher JJR N
rate NN o
of IN o
re-presentation NN o
to TO o
the DT o
ED NNP o
, , N
which WDT N
were VBD N
statistically RB N
non-significant JJ N
( ( N
p?0.45 NN N
) ) N
. . N

Differences NNS N
between IN N
groups NNS N
for IN N
use NN o
of IN o
community NN o
healthcare NN o
resources NNS o
, , o
return NN o
to TO o
usual JJ o
work/home/leisure NN o
activities NNS o
and CC o
satisfaction NN o
with IN o
their PRP$ o
EECU NNP o
care NN o
were VBD N
small JJ N
and CC N
not RB N
significant JJ N
. . N

CONCLUSION VB N
A NNP N
physiotherapy NN i
service NN i
for IN N
EECU NNP N
patients NNS N
, , N
as IN N
provided VBN N
in IN N
this DT N
study NN N
, , N
did VBD N
not RB N
reduce VB N
the DT N
rate NN o
of IN o
hospital NN o
admission NN o
, , o
rate NN o
of IN o
re-presentation NN o
to TO o
the DT o
ED NNP o
, , o
use NN o
of IN o
community NN o
healthcare NN o
resources NNS o
, , N
or CC N
improve VB N
the DT N
rate NN o
of IN o
return NN o
to TO o
usual JJ o
work/home/leisure NN o
activities NNS o
or CC o
patient JJ o
satisfaction NN o
. . N

Trial JJ N
registration NN N
number NN N
ANZCTRN12609000106235 NNP N
. . N

-DOCSTART- -25886492- O O

A DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
personalised JJ i
decision NN i
support NN i
delivered VBD N
via IN N
the DT N
internet NN N
for IN N
bowel NN N
cancer NN N
screening VBG N
with IN N
a DT N
faecal JJ N
occult NN N
blood NN N
test NN N
: : N
the DT N
effects NNS N
of IN N
tailoring NN N
of IN N
messages NNS N
according VBG N
to TO N
social JJ N
cognitive JJ N
variables NNS N
on IN N
participation NN N
. . N

BACKGROUND NNP N
In IN N
Australia NNP p
, , N
bowel NN N
cancer NN N
screening VBG N
participation NN N
using VBG N
faecal JJ N
occult NN N
blood NN N
testing NN N
( ( N
FOBT NNP N
) ) N
is VBZ N
low JJ N
. . N

Decision NN N
support NN N
tailored VBD N
to TO N
psychological JJ N
predictors NNS N
of IN N
participation NN N
may MD N
increase VB N
screening VBG N
. . N

The DT N
study NN N
compared VBN N
tailored VBD i
computerised JJ i
decision NN i
support NN i
to TO N
non-tailored JJ N
computer NN N
or CC N
paper NN N
information NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
FOBT NNP o
return NN o
within IN N
12 CD N
weeks NNS N
. . N

Additional JJ N
analyses NNS N
were VBD N
conducted VBN N
on IN N
movement NN o
in IN o
decision NN o
to TO o
screen NN o
and CC N
change NN N
on IN N
psychological JJ o
variables NNS o
. . N

METHODS NNP N
A NNP N
parallel NN N
, , N
randomised VBD N
controlled VBN N
, , N
trial NN N
invited VBD p
25,511 CD p
people NNS p
aged VBN p
50-74 JJ p
years NNS p
to TO N
complete VB N
an DT N
eligibility NN N
questionnaire NN N
. . N

Eligible JJ N
respondents NNS N
( ( N
n JJ p
= NNP p
3,408 CD p
) ) N
were VBD N
assigned VBN N
to TO N
Tailored NNP i
Personalised VBD i
Decision NNP i
Support NNP i
( ( i
TPDS NNP i
) ) i
, , N
Non-Tailored JJ i
PDS NNP i
( ( i
NTPDS NNP i
) ) i
, , N
or CC N
Control NNP i
( ( N
CG NNP N
) ) N
( ( N
intention-to-treat JJ N
, , N
ITT NNP N
sample NN N
) ) N
. . N

TPDS NNP i
and CC N
NTPDS NNP i
groups NNS N
completed VBD N
an DT N
on-line JJ N
baseline NN N
survey NN N
( ( N
BS NNP N
) ) N
and CC N
accessed VBN N
generic JJ N
information NN N
. . N

The DT N
TPDS NNP N
group NN N
additionally RB N
received VBD N
a DT N
tailored VBN N
intervention NN N
. . N

CG JJ N
participants NNS N
completed VBD N
a DT N
paper NN N
BS NNP N
only RB N
. . N

Those DT N
completing VBG N
the DT N
BS NNP N
( ( N
n JJ N
= NN N
2270 CD N
) ) N
were VBD N
mailed VBN N
an DT N
FOBT NNP N
and CC N
requested VBN N
to TO N
complete VB N
an DT N
endpoint NN N
survey NN N
( ( N
ES NNP N
) ) N
that IN N
re-measured JJ N
BS NNP N
variables NNS N
( ( N
per-protocol NN N
, , N
PP NNP N
sample NN N
) ) N
. . N

RESULTS NNP N
FOBT NNP N
return NN o
: : N
In IN N
the DT N
ITT NNP N
sample NN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
any DT N
group NN N
( ( N
? . N
( ( N
2 CD N
) ) N
( ( N
2 CD N
) ) N
= NN N
2.57 CD N
, , N
p NN N
= NNP N
.26 NNP N
; : N
TPDS NNP N
, , N
32.5 CD N
% NN N
; : N
NTPDS NNP N
, , N
33 CD N
% NN N
; : N
and CC N
CG NNP N
, , N
34.5 CD N
% NN N
) ) N
. . N

In IN N
the DT N
PP NNP N
sample NN N
, , N
FOBT NNP o
return NN o
in IN N
the DT N
internet NN N
groups NNS N
was VBD N
significantly RB N
higher JJR N
than IN N
the DT N
paper NN N
group NN N
( ( N
? . N
( ( N
2 CD N
) ) N
( ( N
2 CD N
) ) N
= NN N
17.01 CD N
, , N
p NN N
< NNP N
.001 NNP N
; : N
TPDS NNP N
, , N
80 CD N
% NN N
; : N
NTPDS NNP N
, , N
83 CD N
% NN N
; : N
and CC N
CG NNP N
, , N
74 CD N
% NN N
) ) N
. . N

FOBT NNP o
completion NN N
by IN N
TPDS NNP i
and CC N
NTPDS NNP i
did VBD N
not RB N
differ VB N
( ( N
? . N
( ( N
2 CD N
) ) N
( ( N
1 CD N
) ) N
= NN N
2.23 CD N
, , N
p NN N
= NNP N
.13 NNP N
) ) N
. . N

Age NNP N
was VBD N
positively RB N
associated VBN N
with IN N
kit JJ N
return NN N
. . N

Decision NN N
to TO N
screen NN N
: : N
2227/2270 CD N
of IN N
the DT N
PP NNP N
sample NN N
provided VBD N
complete JJ N
BS NNP N
data NN N
. . N

Participants NNS N
not RB N
wanting VBG N
to TO N
screen VB N
at IN N
baseline NN N
( ( N
1083/2227 CD N
) ) N
and CC N
allocated VBN N
to TO N
TPDS NNP N
and CC N
NTPDS NNP N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
decide VB N
to TO N
screen VB N
and CC N
return VB o
an DT o
FOBT NNP o
than IN N
those DT N
assigned VBN N
to TO N
the DT N
CG NNP N
. . N

FOBT NNP o
return NN o
by IN N
TPDS NNP i
and CC N
NTPDS NNP i
did VBD N
not RB N
differ VB N
from IN N
one CD N
another DT N
( ( N
OR NNP N
= VBZ N
1.16 CD N
, , N
p NN N
= NNP N
.42 NNP N
) ) N
. . N

Change NN N
on IN N
psychosocial JJ o
predictors NNS o
: : N
Analysis NN N
of IN N
change NN N
indicated VBD N
that IN N
salience NN o
and CC o
coherence NN o
of IN o
screening VBG o
and CC N
self-efficacy NN o
were VBD N
improved VBN N
and CC N
faecal JJ N
aversion NN N
decreased VBN N
by IN N
tailored JJ N
messaging NN N
. . N

CONCLUSIONS NNP N
Online NNP N
information NN N
resources NNS N
may MD N
have VB N
a DT N
role NN N
in IN N
encouraging VBG N
internet-enabled JJ N
people NNS N
who WP N
are VBP N
uncommitted VBN N
to TO N
screening VBG N
to TO N
change VB N
their PRP$ N
attitudes NNS N
, , N
perceptions NNS N
and CC N
behaviour NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Australian NNP N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
ACTRN12610000095066 NNP N
. . N

-DOCSTART- -14679127- O O

Long-term JJ N
survival NN N
in IN N
a DT N
phase NN N
III NNP N
, , N
randomised VBD N
study NN N
of IN N
topotecan JJ i
versus NN N
paclitaxel NN i
in IN N
advanced JJ p
epithelial JJ p
ovarian JJ p
carcinoma NN p
. . N

BACKGROUND IN N
We PRP N
have VBP N
continued VBN N
to TO N
monitor VB N
the DT N
survival NN N
of IN N
patients NNS N
randomised VBN N
in IN N
a DT N
previously RB N
reported VBN N
multicentre JJ N
phase NN N
III NNP N
study NN N
of IN N
topotecan JJ i
versus NN N
paclitaxel NN i
in IN N
patients NNS p
with IN p
advanced JJ p
epithelial JJ p
ovarian JJ p
cancer NN p
who WP p
had VBD p
failed VBN p
one CD p
prior JJ p
platinum-based JJ p
regimen NNS p
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
with IN p
bidimensionally RB p
measurable JJ p
disease NN p
were VBD N
randomised VBN N
to TO N
topotecan VB i
( ( N
1.5 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
for IN N
5 CD N
days NNS N
) ) N
or CC N
paclitaxel NN i
( ( N
175 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
as IN N
a DT N
3-h JJ N
infusion NN N
) ) N
every DT N
21 CD N
days NNS N
. . N

Patients NNS N
were VBD N
eligible JJ N
for IN N
treatment NN N
with IN N
the DT N
alternate NN N
therapy NN N
at IN N
third JJ N
line NN N
. . N

The DT N
European JJ o
Organisation NNP o
for IN o
Research NNP o
and CC o
Treatment NNP o
of IN o
Cancer NNP o
Quality NNP o
of IN o
Life NNP o
( ( o
EORTC NNP o
QOL NNP o
) ) o
-C30 VBP o
questionnaire NN o
was VBD N
also RB N
used VBN N
to TO N
measure VB N
eight CD N
symptoms NNS N
at IN N
baseline NN N
and CC N
during IN N
each DT N
course NN N
( ( N
pain NN o
, , o
anorexia NN o
, , o
diarrhoea NN o
, , o
fatigue NN o
, , o
nausea NN o
and CC o
vomiting NN o
, , o
dyspnea NN o
, , o
constipation NN o
and CC o
insomnia NN o
) ) N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
226 CD p
patients NNS p
were VBD N
evaluable JJ N
for IN N
response NN N
. . N

Demographic JJ N
characteristics NNS N
were VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
, , N
as IN N
were VBD N
results NNS N
of IN N
the DT N
EORTC NNP N
QOL-30 NNP N
questionnaire NN N
. . N

For IN N
the DT N
topotecan JJ i
group NN N
, , N
median JJ N
time NN N
to TO N
progression NN o
was VBD N
18.9 CD N
weeks NNS N
( ( N
range NN N
< RB N
1 CD N
to TO N
92.6+ CD N
weeks NNS N
; : N
25 CD N
% NN N
censored VBN N
) ) N
, , N
and CC N
, , N
for IN N
paclitaxel NN i
, , N
14.7 CD N
weeks NNS N
( ( N
range NN N
< RB N
1 CD N
to TO N
137.3+ CD N
weeks NNS N
; : N
12.3 CD N
% NN N
censored VBN N
) ) N
; : N
P NNP N
= VBD N
0.076 CD N
. . N

At IN N
4 CD N
years NNS N
post-randomisation NN N
, , N
median JJ o
survival NN o
in IN N
the DT N
topotecan JJ i
group NN N
was VBD N
63.0 CD N
weeks NNS N
( ( N
range NN N
< RB N
1 CD N
to TO N
238.4+ CD N
weeks NNS N
; : N
20.5 CD N
% NN N
censored VBN N
) ) N
and CC N
, , N
for IN N
paclitaxel NN i
, , N
53.0 CD N
weeks NNS N
( ( N
range NN N
< RB N
1 CD N
to TO N
226.3+ CD N
weeks NNS N
; : N
12.3 CD N
% NN N
censored VBN N
) ) N
; : N
P NNP N
= VBD N
0.44 CD N
. . N

CONCLUSION NNP N
Topotecan NNP i
continues VBZ N
to TO N
demonstrate VB N
comparable JJ N
efficacy NN o
and CC N
survival NN o
to TO N
paclitaxel VB i
with IN N
manageable JJ N
and CC N
non-cumulative JJ N
haematological JJ o
toxicity NN o
. . N

Non-haematological JJ o
toxicity NN o
was VBD N
generally RB N
mild VBN N
for IN N
both DT N
groups NNS N
. . N

The DT N
long-term JJ N
survival NN N
rate NN N
indicates VBZ N
substantial JJ N
therapeutic JJ N
benefit NN N
for IN N
this DT N
group NN N
of IN N
patients NNS N
receiving VBG N
topotecan JJ i
at IN N
relapse NN p
of IN p
ovarian JJ p
cancer NN p
. . N

-DOCSTART- -6920252- O O

Experimental JJ N
hyaline NN N
membrane NN N
disease NN N
in IN N
the DT p
premature NN p
monkey NN p
: : N
effects NNS N
of IN N
antenatal JJ N
dexamethasone NN i
. . N

A DT N
blind NN N
, , N
randomized VBN N
trial NN N
of IN N
antenatal JJ N
glucocorticoid NN i
treatment NN N
was VBD N
conducted VBN N
using VBG N
the DT N
premature NN p
monkey NN p
( ( p
Macaca NNP p
nemestrina RB p
) ) p
model NN p
of IN p
hyaline JJ p
membrane NN p
disease NN p
( ( p
HMD NNP p
) ) p
. . N

Twelve NNP p
dams VBZ p
received VBN N
dexamethasone NN i
( ( N
2 CD N
mg/dose NN N
) ) N
72 CD N
, , N
48 CD N
, , N
and CC N
24 CD N
h NN N
before IN N
abdominal JJ N
delivery NN N
at IN N
135 CD N
+/- JJ N
1 CD N
days NNS N
of IN N
gestation NN N
. . N

Twelve VB p
control NN p
animals NNS p
received VBD N
saline JJ i
. . N

Infants NNS N
of IN N
dexamethasone-treated JJ i
dams NNS N
had VBD N
significantly RB N
lower JJR N
incidence NN o
and CC o
severity NN o
of IN o
HMD NNP o
than IN N
did VBD N
infants NNS N
of IN N
control NN N
animals NNS N
( ( N
50 CD N
versus RB N
92 CD N
% NN N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Improvement JJ N
with IN N
treatment NN N
was VBD N
markedly RB N
greater JJR N
for IN N
males NNS N
than IN N
for IN N
females NNS N
. . N

Differences NNS N
in IN N
volume-pressure JJ o
behavior NN o
of IN N
the DT N
excised JJ N
lungs NNS N
included VBD N
greater JJR N
distensibility NN o
in IN N
the DT N
infants NNS N
from IN N
dexamethasone-treated JJ i
dams NNS N
( ( N
20.6 CD N
+/- JJ N
7.1 CD N
ml/g NN N
dry JJ N
lung NN N
versus IN N
14.7 CD N
+/- JJ N
6.1 CD N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
enhanced JJ N
deflation NN o
stability NN o
with IN N
treatment NN N
. . N

Accelerated JJ N
production NN o
of IN o
surface NN o
active JJ o
material NN o
( ( o
SAM NNP o
) ) o
phospholipids NNS o
in IN N
infants NNS N
from IN N
dexamethasone-treated JJ i
dams NNS N
was VBD N
indicated VBN N
by IN N
increases NNS N
in IN N
total JJ o
lung NN o
phospholipid NN o
( ( N
84.5 CD N
+/- JJ N
8.1 CD N
mg/g NN N
dry JJ N
lung NN N
versus IN N
75.1 CD N
+/- JJ N
9.9 CD N
, , N
p NN N
less JJR N
than IN N
0.025 CD N
) ) N
, , N
alveolar JJ o
lavage NN o
fluid NN o
phospholipid NN o
( ( N
5.65 CD N
+/- JJ N
3.33 CD N
mg/g NN N
dry JJ N
lung NN N
versus IN N
3.01 CD N
+/- JJ N
1.84 CD N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
and CC N
alveolar JJ o
lavage NN o
fluid NN o
disaturated VBN o
phosphatidylcholine NN o
( ( N
DPC NNP N
) ) N
( ( N
2.47 CD N
+/- JJ N
1.84 CD N
mg/g NN N
dry JJ N
lung NN N
versus IN N
1.06 CD N
+/- JJ N
1.05 CD N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Incorporation NN N
of IN N
14C-palmitate JJ o
into IN N
lung NN o
lipid NN o
was VBD N
not RB N
influenced VBN N
by IN N
dexamethasone NN i
, , N
but CC N
a DT N
significantly RB N
greater JJR N
portion NN N
of IN N
the DT N
label NN N
appeared VBD N
in IN N
the DT N
DPC NNP N
fraction NN N
with IN N
treatment NN N
. . N

Antenatal NNP N
dexamethasone NN i
treatment NN N
was VBD N
successful JJ N
in IN N
reducing VBG N
the DT N
incidence NN o
and CC o
severity NN o
of IN o
experimental JJ o
HMD NNP o
in IN N
this DT N
animal JJ N
model NN N
; : N
the DT N
beneficial JJ N
effects NNS N
of IN N
treatment NN N
were VBD N
associated VBN N
with IN N
accelerated JJ N
maturation NN N
of IN N
fetal JJ o
pulmonary JJ o
functions NNS o
, , N
including VBG N
, , N
but CC N
not RB N
limited JJ N
to TO N
, , N
synthetic JJ N
metabolism NN N
of IN N
SAM NNP N
phospholipid NN N
. . N

-DOCSTART- -22420121- O O

Training VBG N
referential JJ i
communicative JJ i
skills NNS i
to TO N
individuals NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
: : N
a DT N
pilot NN N
study NN N
. . N

The DT N
present JJ N
study NN N
reports VBZ N
the DT N
effects NNS N
of IN N
referential JJ i
communication NN i
training NN i
in IN N
individuals NNS p
formally RB p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . N

Participants NNS N
were VBD N
20 CD p
children NNS p
with IN p
ASD NNP p
( ( p
M NNP p
age NN p
= VBD p
14.3 CD p
yr. NN p
, , N
SD NNP p
= NNP p
4.2 CD p
; : p
6 CD p
girls NNS p
, , p
14 CD p
boys NNS p
) ) p
in IN p
the DT p
role NN p
of IN p
speakers NNS p
and CC p
20 CD p
control NN p
children NNS p
, , p
who WP p
acted VBD p
as IN p
listeners NNS p
. . N

They PRP N
were VBD N
all DT N
enrolled VBN N
in IN N
mainstream JJ N
compulsory NN N
education NN N
. . N

Inclusion/exclusion NNP N
criteria NNS N
were VBD N
defined VBN N
according VBG N
to TO N
the DT N
clinical JJ N
diagnosis NN N
of IN N
ASD NNP N
, , N
the DT N
presence NN N
or CC N
absence NN N
of IN N
additional JJ N
or CC N
associated JJ N
disability NN N
, , N
previous JJ N
training NN N
in IN N
referential JJ N
communication NN N
, , N
and CC N
any DT N
drug NN N
treatment NN N
. . N

Speakers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
( ( N
trained JJ N
vs NN N
untrained VBD N
) ) N
. . N

Linguistic JJ o
age NN o
, , o
cognitive JJ o
level NN o
and CC o
autistic JJ o
symptoms NNS o
were VBD N
analyzed VBN N
, , N
respectively RB N
, , N
with IN N
the DT N
Peabody NNP o
Picture NNP o
Vocabulary NNP o
Test NNP o
( ( o
PPVT NNP o
) ) o
, , o
the DT o
Wechsler NNP o
Intelligence NNP o
Scale NNP o
( ( o
WISC-R NNP o
or CC o
WAIS-III NNP o
) ) o
, , o
and CC o
the DT o
Autistic NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
. . N

Communicative JJ o
abilities NNS o
were VBD N
analyzed VBN N
through IN N
two CD N
indexes NNS N
related VBN N
to TO N
message VB N
complexity NN N
and CC N
self-regulation NN N
. . N

The DT N
trained JJ N
group NN N
was VBD N
trained VBN N
in IN N
referential JJ i
communication NN i
tasks NNS i
( ( N
task NN i
analysis NN i
, , N
role NN i
taking NN i
, , N
and CC N
task JJ i
evaluation NN i
) ) N
, , N
while IN N
the DT N
untrained JJ N
group NN N
took VBD N
part NN N
in IN N
a DT N
communicative JJ i
game NN i
but CC N
without IN N
any DT N
specific JJ N
communicative JJ N
training NN N
. . N

The DT N
results NNS N
showed VBD N
that IN N
the DT N
complexity NN o
of IN o
emitted JJ o
messages NNS o
had VBD N
improved VBN N
statistically RB N
significantly RB N
in IN N
the DT N
trained JJ N
group NN N
as IN N
an DT N
effect NN N
of IN N
training NN N
. . N

Ecological JJ N
referential JJ i
communication NN i
is VBZ N
shown VBN N
to TO N
be VB N
an DT N
appropriate JJ N
paradigm NN N
for IN N
studying VBG N
the DT N
communicative JJ N
process NN N
and CC N
its PRP$ N
products NNS N
and CC N
could MD N
be VB N
used VBN N
to TO N
develop VB N
and CC N
implement VB N
a DT N
training NN N
program NN N
focused VBN N
on IN N
those DT N
skills NNS N
in IN N
which WDT N
individuals NNS p
with IN p
ASD NNP p
are VBP N
most RBS N
deficient JJ N
. . N

-DOCSTART- -11229858- O O

Effect NN N
of IN N
antipyretic JJ i
drugs NNS i
in IN N
children NNS p
with IN p
malaria NN p
. . N

A DT N
comparison NN N
of IN N
different JJ N
antipyretics NNS i
in IN N
children NNS p
with IN p
malaria NN p
showed VBD N
a DT N
small JJ N
effect NN N
of IN N
naproxen NN i
, , N
but CC N
not RB N
of IN N
metamizol NN i
, , N
on IN N
the DT N
reduction NN o
of IN o
fever NN o
peaks NNS o
. . N

Antipyretic JJ i
treatment NN N
had VBD N
no DT N
effect NN N
on IN N
fever NN o
clearance NN o
and CC N
therefore NN N
should MD N
be VB N
used VBN N
cautiously RB N
in IN N
the DT N
treatment NN N
of IN N
malaria NN p
. . N

-DOCSTART- -11401641- O O

Additive JJ N
IOP-reducing JJ o
effect NN N
of IN N
latanoprost NN N
in IN N
patients NNS p
insufficiently RB p
controlled VBN p
on IN p
timolol NN p
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
on IN N
intraocular JJ o
pressure NN o
( ( o
IOP NNP o
) ) o
of IN N
switching VBG N
from IN N
timolol NN i
to TO N
latanoprost VB i
or CC N
adding VBG N
latanoprost NN i
to TO N
timolol VB i
in IN N
patients NNS p
with IN p
open JJ p
angle NN p
glaucoma NN p
or CC p
ocular JJ p
hypertension NN p
where WRB p
IOP NNP p
is VBZ p
not RB p
adequately RB p
controlled VBN p
with IN p
timolol NN p
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
6-week JJ N
, , N
double-masked JJ N
, , N
randomised VBD N
multi-centre NN N
study NN N
. . N

53 CD p
patients NNS p
with IN p
primary JJ p
open JJ p
angle NN p
glaucoma NN p
, , p
capsular JJ p
glaucoma NN p
, , p
or CC p
ocular JJ p
hypertension NN p
with IN p
an DT p
IOP NNP p
of IN p
at IN p
least JJS p
21 CD p
mmHg NN p
on IN p
current JJ p
therapy NN p
were VBD N
recruited VBN N
. . N

After IN N
a DT N
run-in JJ N
period NN N
of IN N
at IN N
least JJS N
2 CD N
weeks NNS N
on IN N
timolol NN i
, , N
5 CD N
mg/ml NN N
twice RB N
daily RB N
, , N
patients NNS N
were VBD N
randomised VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
. . N

One CD N
group NN N
continued VBD N
on IN N
timolol NN i
, , N
one CD N
switched VBN N
from IN N
timolol NN i
to TO N
latanoprost VB i
, , N
50 CD N
microg/ml NN N
once RB N
daily JJ N
, , N
and CC N
a DT N
third JJ N
group NN N
received VBD N
latanoprost RB i
in IN N
addition NN N
to TO N
timolol VB i
. . N

The DT N
efficacy NN N
was VBD N
evaluated VBN N
by IN N
comparing VBG N
IOP NNP o
at IN N
9 CD N
AM NNP N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
weeks NNS N
of IN N
treatment NN N
. . N

RESULTS NNP N
IOP NNP o
at IN N
baseline NN N
and CC N
after IN N
6 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
mean JJ N
+/- NNP N
SEM NNP N
) ) N
were VBD N
24.2 CD N
+/- JJ N
0.9 CD N
and CC N
23.8 CD N
+/- JJ N
1.0 CD N
mmHg NN N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
for IN N
patients NNS N
continuing VBG N
on IN N
timolol NN N
, , N
26.3 CD N
+/- JJ N
1.2 CD N
and CC N
19.6 CD N
+/- JJ N
1.1 CD N
mmHg NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
for IN N
patients NNS N
switching VBG N
to TO N
latanoprost VB N
, , N
and CC N
23.2 CD N
+/- JJ N
1.0 CD N
and CC N
17.5 CD N
+/- JJ N
0.8 CD N
mmHg NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
for IN N
patients NNS N
with IN N
combined JJ N
treatment NN N
. . N

Adding VBG N
latanoprost NN N
to TO N
timolol VB N
reduced VBN N
IOP NNP o
with IN N
5.9 CD N
+/- JJ N
0.9 CD N
mmHg NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
switching VBG N
from IN N
timolol NN N
to TO N
latanoprost VB N
reduced VBN N
IOP NNP o
with IN N
5.0 CD N
+/- JJ N
0.9 CD N
mmHg NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
which WDT N
caused VBD N
in IN N
each DT N
group NN N
a DT N
significant JJ N
IOP NNP o
reduction NN N
of IN N
about RB N
25 CD N
% NN N
. . N

CONCLUSIONS VB N
The DT N
effect NN N
of IN N
latanoprost NN N
was VBD N
additive JJ N
to TO N
that DT N
of IN N
timolol NN N
, , N
and CC N
a DT N
good JJ N
effect NN N
on IN N
IOP NNP o
reduction NN N
was VBD N
also RB N
achieved VBN N
by IN N
switching VBG N
from IN N
timolol NN N
to TO N
latanoprost VB N
, , N
suggesting VBG N
that IN N
a DT N
switch NN N
in IN N
many JJ N
patients NNS N
is VBZ N
an DT N
effective JJ N
alternative NN N
to TO N
combination NN N
treatment NN N
. . N

-DOCSTART- -2188766- O O

Chronic NNP N
vasodilator NN N
therapy NN N
with IN N
flosequinan NN i
in IN N
congestive JJ p
heart NN p
failure NN p
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
long-term JJ o
effect NN o
of IN N
flosequinan NN i
, , N
a DT N
new JJ N
orally RB N
administered VBN N
arterial JJ N
and CC N
venous JJ N
dilator NN N
, , N
on IN N
the DT N
clinical JJ N
course NN N
of IN N
patients NNS p
with IN p
moderate JJ p
to TO p
severe VB p
congestive JJ p
heart NN p
failure NN p
. . N

Seventeen JJ p
patients NNS p
on IN p
chronic JJ p
digitalis NN p
and CC p
diuretic JJ p
therapy NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
flosequinan NN i
( ( N
n JJ N
= NNP N
9 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
8 CD N
) ) N
in IN N
a DT N
double-blind JJ N
fashion NN N
. . N

Changes NNS N
in IN N
symptomatology NN o
, , o
exercise NN o
performance NN o
, , N
and CC N
left VBD o
ventricular JJ o
function NN o
were VBD N
assessed VBN N
serially RB N
during IN N
the DT N
two-month JJ N
treatment NN N
period NN N
. . N

During IN N
the DT N
course NN N
of IN N
therapy NN N
, , N
a DT N
modest JJ N
improvement NN N
in IN N
the DT N
symptom NN o
scores NNS o
and CC N
functional JJ o
classification NN o
of IN N
the DT N
flosequinan-treated JJ N
patients NNS N
was VBD N
observed VBN N
. . N

Flosequinan NNP i
evoked VBD N
a DT N
significant JJ N
increase NN N
in IN N
maximal JJ o
exercise NN o
capacity NN o
. . N

While IN N
long-term JJ N
flosequinan JJ i
administration NN N
also RB N
effected VBD N
a DT N
progressive JJ N
increase NN N
in IN N
resting VBG o
heart NN o
rate NN o
, , N
it PRP N
did VBD N
not RB N
consistently RB N
improve VB N
indices NNS N
of IN N
left JJ o
ventricular JJ o
systolic JJ o
function NN o
. . N

The DT N
addition NN N
of IN N
chronic JJ N
vasodilator NN N
therapy NN N
with IN N
flosequinan NN i
to TO N
standard VB N
digitalis-diuretic JJ N
regimens NNS N
is VBZ N
capable JJ N
of IN N
inducing VBG N
clinical JJ N
improvement NN N
in IN N
patients NNS p
with IN p
moderate JJ p
to TO p
severe VB p
chronic JJ p
heart NN p
failure NN p
. . N

Trials NNS N
involving VBG N
larger JJR N
patient JJ N
populations NNS N
will MD N
be VB N
necessary JJ N
to TO N
confirm VB N
the DT N
results NNS N
of IN N
this DT N
preliminary JJ N
study NN N
and CC N
to TO N
determine VB N
the DT N
extent NN N
of IN N
clinical JJ N
improvement NN N
, , N
subpopulations NNS N
benefited VBD N
, , N
role NN N
in IN N
heart NN N
failure NN N
therapeutics NNS N
, , N
and CC N
so RB N
forth JJ N
. . N

-DOCSTART- -3919804- O O

Rapid JJ N
tightening NN N
of IN N
blood NN N
glucose NN N
control NN N
leads VBZ N
to TO N
transient VB N
deterioration NN N
of IN N
retinopathy NN o
in IN N
insulin NN p
dependent NN p
diabetes VBZ p
mellitus NNS p
: : N
the DT N
Oslo NNP N
study NN N
. . N

In IN N
a DT N
study NN N
of IN N
retinopathy NN N
during IN N
one CD N
year NN N
of IN N
tight JJ N
blood NN N
glucose VB N
control NN N
45 CD p
type NN p
I PRP p
( ( p
insulin JJ p
dependent NN p
) ) p
diabetics NNS p
without IN p
proliferative JJ p
retinopathy NN p
were VBD N
randomised VBN N
to TO N
receive VB N
either RB N
continuous JJ N
subcutaneous JJ N
insulin NN i
infusion NN i
, , N
multiple JJ N
insulin NN i
injections NNS i
, , N
or CC N
conventional JJ N
insulin NN i
treatment NN i
( ( N
controls NNS N
) ) N
. . N

Near IN N
normoglycaemia NN N
was VBD N
achieved VBN N
with IN N
continuous JJ N
infusion NN N
and CC N
multiple JJ N
injections NNS N
but CC N
not RB N
with IN N
conventional JJ N
treatment NN N
. . N

Blind NNP N
evaluation NN N
of IN N
fluorescein JJ o
angiograms NNS o
performed VBD N
three CD N
monthly JJ N
showed VBD N
progression NN o
of IN o
retinopathy NN o
in IN N
the DT N
control NN N
group NN N
, , N
transient JJ N
deterioration NN N
in IN N
the DT N
continuous JJ N
infusion NN N
group NN N
, , N
and CC N
no DT N
change NN N
in IN N
the DT N
multiple JJ N
injection NN N
group NN N
. . N

Half PDT N
the DT N
patients NNS N
receiving VBG N
continuous JJ N
infusion NN N
and CC N
multiple JJ N
injections NNS N
developed VBD N
retinal JJ N
cotton NN N
wool NN N
spots NNS N
after IN N
three CD N
to TO N
six CD N
months NNS N
. . N

These DT N
changes NNS N
regressed VBD N
in IN N
all DT N
but CC N
four CD N
patients NNS N
after IN N
12 CD N
months NNS N
. . N

Control NNP N
patients NNS N
did VBD N
not RB N
develop VB N
cotton NN o
wool NN o
spots NNS o
. . N

Patients NNS N
who WP N
developed VBD N
cotton NN N
wool NN N
spots NNS N
are VBP N
characterised VBN N
by IN N
a DT N
larger JJR N
decrement NN N
in IN N
glycosylated JJ o
haemoglobin NN o
and CC o
blood NN o
glucose NN o
values NNS o
, , N
more RBR N
frequent JJ N
episodes NNS o
of IN o
hypoglycaemia NN o
, , N
a DT N
longer JJR N
duration NN o
of IN o
diabetes NNS o
, , N
and CC N
more RBR N
severe JJ N
retinopathy NN o
at IN N
onset NN N
. . N

A DT N
large JJ N
and CC N
rapid JJ N
fall NN N
in IN N
blood NN o
glucose JJ o
concentration NN o
may MD N
promote VB N
transient JJ N
deterioration NN N
of IN N
diabetic JJ N
retinopathy NN N
. . N

-DOCSTART- -17897478- O O

Salmeterol NNP i
plus CC N
fluticasone JJ i
propionate NN i
versus IN N
fluticasone NN i
propionate NN i
plus CC N
montelukast NN i
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
investigating VBG N
the DT N
effects NNS N
on IN N
airway JJ o
inflammation NN o
in IN N
asthma NN N
. . N

BACKGROUND NNP N
Few NNP N
studies NNS N
have VBP N
compared VBN N
treatment NN N
strategies NNS N
in IN N
patients NNS p
with IN p
asthma JJ p
poorly RB N
controlled VBN N
on IN N
low JJ N
dose NN N
inhaled JJ N
corticosteroids NNS N
, , N
and CC N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effects NNS N
of IN N
different JJ N
treatments NNS N
on IN N
airway JJ N
inflammation NN N
. . N

In IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study NN N
, , N
we PRP N
compared VBN N
the DT N
effects NNS N
of IN N
salmeterol NN i
plus CC N
fluticasone NN i
propionate NN i
( ( i
FP NNP i
) ) i
( ( i
Seretide NNP i
; : i
SFC NNP i
) ) i
and CC N
FP NNP i
plus CC N
montelukast NN i
( ( i
FP/M NNP i
) ) i
on IN N
sputum NN o
inflammatory NN o
markers NNS o
, , o
airway RB o
responsiveness NN o
, , o
lung NN o
function NN o
, , N
and CC N
symptoms NNS o
in IN N
adult NN p
asthmatics NNS p
. . N

METHODS NNP N
Sixty-six JJ p
subjects NNS p
were VBD N
randomised VBN N
to TO N
SFC NNP i
or CC N
FP/M NNP i
for IN N
12 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
changes NNS o
in IN o
neutrophil NN o
, , o
eosinophil NN o
, , o
macrophage NN o
, , o
lymphocyte NN o
, , o
and CC o
epithelial JJ o
cell NN o
levels NNS o
in IN o
induced JJ o
sputum NN o
. . N

Additional NNP N
outcomes NNS N
included VBD N
the DT N
change NN o
in IN o
other JJ o
sputum JJ o
markers NNS o
of IN o
airway JJ o
inflammation NN o
, , o
airway RB o
responsiveness NN o
, , o
symptom NN o
control NN o
, , o
and CC o
lung NN o
function NN o
. . N

RESULTS NNP N
Both NNP N
treatments NNS N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
induced JJ N
sputum NN o
inflammatory NN o
cells NNS N
, , N
although IN N
there EX N
was VBD N
a DT N
trend NN N
for IN N
a DT N
reduction NN N
in IN N
sputum NN o
eosinophils NNS o
. . N

Both DT N
treatments NNS N
significantly RB N
improved VBN N
airway RB o
responsiveness NN o
, , N
whereas WP N
SFC NNP i
generally RB N
led VBD N
to TO N
greater JJR N
improvements NNS N
in IN N
symptom JJ o
control NN o
and CC o
lung NN o
function NN o
than IN N
FP/M NNP i
. . N

FP/M NNP i
led VBD N
to TO N
significantly RB N
greater JJR N
reductions NNS N
in IN N
sputum NN o
cysteinyl NN o
leukotrienes NNS o
than IN N
SFC NNP i
( ( N
treatment NN N
ratio NN N
1.80 CD N
; : N
95 CD N
% NN N
CI NNP N
1.09 CD N
, , N
2.94 CD N
) ) N
. . N

CONCLUSION NNP N
Both DT N
treatments NNS N
led VBD N
to TO N
similar JJ N
control NN N
of IN N
eosinophilic JJ o
airway NN o
inflammation NN o
, , N
although IN N
PEF NNP N
and CC N
symptom VB N
control NN N
were VBD N
better JJR N
with IN N
SFC NNP i
. . N

STUDY NNP N
NUMBER NNP N
: : N
SAM40030 NNP N
( ( N
SOLTA NNP N
) ) N
. . N

-DOCSTART- -12576806- O O

Is VBZ N
a DT N
2-week JJ N
duration NN N
sufficient NN N
for IN N
stenting VBG i
in IN N
endopyelotomy NN N
? . N
PURPOSE NNP N
Internal NNP i
stenting NN i
is VBZ N
an DT N
integral JJ N
part NN N
of IN N
endopyelotomy NN N
. . N

Studies NNS N
in IN N
animals NNS N
show VBP N
good JJ N
healing NN N
after IN N
1 CD N
to TO N
2 CD N
weeks NNS N
of IN N
ureterotomy JJ N
. . N

Inherent JJ N
stent NN N
related VBN N
problems NNS N
warrant VBP N
a DT N
minimum JJ N
possible JJ N
duration NN N
of IN N
stenting VBG N
without IN N
compromising VBG N
the DT N
results NNS N
of IN N
endopyelotomy JJ N
. . N

We PRP N
performed VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
to TO N
evaluate VB N
the DT N
optimum JJ o
duration NN o
of IN o
stenting VBG o
after IN N
endopyelotomy NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
57 CD p
consecutive JJ p
patients NNS p
with IN p
primary JJ p
ureteropelvic JJ p
junction NN p
obstruction NN p
were VBD N
randomized VBN N
to TO N
undergo VB N
7/14Fr CD i
internal JJ i
endopyelotomy NN i
stent JJ i
placement NN i
for IN N
2 CD N
( ( N
group NN N
1 CD N
) ) N
and CC N
4 CD N
( ( N
group NN N
2 CD N
) ) N
weeks NNS N
. . N

A DT N
symptom NN N
based VBN N
questionnaire NN N
was VBD N
administered VBN N
to TO N
all DT N
patients NNS N
at IN N
stent JJ N
removal NN N
. . N

Followup NNP N
was VBD N
done VBN N
with IN N
diuretic JJ N
scanning NN N
at IN N
3 CD N
, , N
6 CD N
, , N
9 CD N
and CC N
12 CD N
months NNS N
and CC N
then RB N
yearly RB N
, , N
and CC N
thereafter RB N
with IN N
diuretic JJ N
renography NN N
. . N

RESULTS NNP N
In IN N
each DT N
group NN N
26 CD N
patients NNS N
were VBD N
available JJ N
for IN N
evaluation NN N
. . N

The DT N
2 CD N
groups NNS N
were VBD N
comparable JJ N
in IN N
terms NNS N
of IN N
age NN N
, , N
sex NN N
, , N
symptoms NNS o
and CC N
ipsilateral JJ o
glomerular JJ o
filtration NN o
rate NN o
. . N

Mean NNP N
followup NN N
was VBD N
22.3 CD N
( ( N
range NN N
12 CD N
to TO N
36 CD N
) ) N
and CC N
21.3 CD N
months NNS N
( ( N
range VB N
12 CD N
to TO N
35 CD N
) ) N
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
, , N
respectively RB N
. . N

At IN N
the DT N
end NN N
of IN N
1 CD N
year NN N
24 CD N
group NN N
1 CD N
( ( N
92.3 CD N
% NN N
) ) N
and CC N
23 CD N
group NN N
2 CD N
( ( N
90.3 CD N
% NN N
) ) N
patients NNS N
had VBD N
an DT N
improved JJ N
drainage NN o
pattern NN o
. . N

This DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

Stent NNP o
related JJ o
symptoms NNS o
were VBD N
present JJ N
in IN N
a DT N
good JJ N
proportion NN N
of IN N
patients NNS N
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
but CC N
there EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
urinary JJ o
tract NN o
infections NNS o
( ( N
11.5 CD N
% NN N
versus IN N
38.1 CD N
% NN N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
. . N

Of IN N
the DT N
group NN N
2 CD N
patients NNS N
64 CD N
% NN N
preferred JJ N
2 CD N
weeks NNS N
of IN N
stenting VBG N
. . N

CONCLUSIONS NNP N
Two CD N
weeks NNS N
seems VBZ N
to TO N
be VB N
a DT N
sufficient JJ N
duration NN o
to TO N
allow VB N
functional JJ N
restoration NN N
across IN N
the DT N
ureteropelvic JJ N
junction NN N
after IN N
endopyelotomy NN N
and CC N
decrease NN N
stent NN o
related JJ o
complications NNS o
. . N

-DOCSTART- -10070173- O O

Comparison NNP N
of IN N
budesonide JJ i
Turbuhaler NNP i
with IN N
budesonide JJ i
aqua NN i
in IN N
the DT N
treatment NN N
of IN N
seasonal JJ p
allergic JJ p
rhinitis NN p
. . N

Rhinocort NNP N
Study NNP N
Group NNP N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
effect NN N
of IN N
budesonide NN i
Turbuhaler NNP i
400 CD N
microg/day NN N
with IN N
budesonide JJ i
aqua NN i
256 CD N
microg/day NN N
in IN N
the DT N
treatment NN N
of IN N
seasonal JJ N
allergic JJ N
rhinitis NN N
( ( N
SAR NNP N
) ) N
. . N

Secondarily RB N
to TO N
ascertain VB N
patients NNS o
' POS o
preferences NNS o
for IN N
the DT N
two CD N
nasal JJ N
devices NNS N
and CC N
to TO N
assess VB N
quality NN o
of IN o
life NN o
. . N

DESIGN NNP N
Randomized NNP N
, , N
multicentre NN N
, , N
double-blind JJ N
, , N
double- JJ N
dummy NN N
, , N
parallel JJ N
groups NNS N
study NN N
. . N

SETTING NNP N
Private NNP N
practices NNS N
and CC N
hospital NN N
clinics NNS N
in IN N
Ontario NNP p
, , p
Quebec NNP p
and CC p
Manitoba NNP p
. . N

POPULATION NNP N
Two CD p
hundred VBD p
and CC p
eighty-four JJ p
out-patients NNS p
with IN p
SAR NNP p
, , p
who WP p
were VBD p
symptomatic JJ p
during IN p
the DT p
ragweed NN p
season NN p
, , p
volunteered VBD p
for IN p
enrolment NN p
( ( p
243 CD p
randomized VBN p
) ) p
. . N

RESULTS JJ N
Mean JJ o
daily JJ o
nasal NN o
symptom NN o
scores NNS o
were VBD N
significantly RB N
reduced VBN N
with IN N
treatment NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
changes NNS N
from IN N
baseline NN N
for IN N
eye NN o
symptoms NNS o
. . N

Most JJS N
patients NNS N
( ( N
more JJR N
than IN N
80 CD N
% NN N
) ) N
achieved VBN N
substantial JJ N
control NN N
of IN N
their PRP$ N
symptoms NNS N
with IN N
budesonide NN i
. . N

The DT N
most RBS N
common JJ N
nasal NN o
and CC o
non-nasal JJ o
adverse JJ o
events NNS o
for IN N
both DT N
groups NNS N
were VBD N
epistaxis JJ o
and CC N
headache NN o
. . N

Turbuhaler NNP i
was VBD N
easier JJR N
to TO N
use VB N
and CC N
more RBR N
convenient JJ N
to TO N
carry VB N
, , N
had VBD N
less JJR N
of IN N
an DT N
unpleasant JJ N
taste NN N
, , N
and CC N
caused VBD N
less JJR N
nasal JJ o
irritation NN o
than IN N
the DT N
aqua JJ N
spray NN N
. . N

More JJR N
than IN N
twice RB N
as IN N
many JJ N
patients NNS N
preferred JJ N
Turbuhaler NNP i
to TO N
the DT N
aqua NN i
spray NN i
( ( N
69 CD N
% NN N
versus IN N
31 CD N
% NN N
) ) N
. . N

Improvement NN N
in IN N
quality NN o
of IN o
life NN o
from IN N
baseline NN N
to TO N
clinic VB N
visits NNS N
was VBD N
statistically RB N
significant JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
Once RB N
daily JJ N
use NN N
of IN N
256 CD N
mg NN N
of IN N
budesonide NN i
aqua NN i
and CC N
400 CD N
mg NN N
of IN N
budesonide NN i
Turbuhaler NNP i
are VBP N
equally RB N
safe JJ o
and CC N
efficacious JJ o
in IN N
the DT N
treatment NN N
of IN N
SAR NNP p
. . N

Patients NNS N
preferred VBD N
the DT N
budesonide NN i
powder NN i
formulation NN N
delivered VBD N
via IN N
Turbuhaler NNP i
two CD N
to TO N
one CD N
over IN N
the DT N
aqua JJ i
formulation NN N
. . N

-DOCSTART- -19301724- O O

A DT N
comparison NN N
of IN N
continuous JJ i
femoral JJ i
nerve NN i
block NN i
( ( i
CFNB NNP i
) ) i
and CC N
continuous JJ i
epidural JJ i
infusion NN i
( ( i
CEI NNP i
) ) i
in IN N
postoperative JJ N
analgesia NN N
and CC N
knee NN N
rehabilitation NN N
after IN N
total JJ p
knee NN p
arthroplasty NN p
( ( p
TKA NNP p
) ) p
. . N

BACKGROUND NNP N
Postoperative NNP N
epidural JJ N
analgesia NN N
( ( N
EA NNP N
) ) N
and CC N
femoral JJ i
nerve NN i
block NN i
( ( i
FNB NNP i
) ) i
provided VBD N
effective JJ N
pain NN N
relief NN N
However RB N
, , N
EA NNP N
has VBZ N
common JJ N
side NN N
effects NNS N
such JJ N
as IN N
nausea NN N
, , N
vomiting VBG N
, , N
pruritus NN N
, , N
dizziness NN N
, , N
and CC N
hypotension NN N
. . N

Some DT N
investigations NNS N
found VBD N
that IN N
those DT N
side JJ N
effects NNS N
were VBD N
less RBR N
in IN N
FNB NNP N
than IN N
in IN N
EA NNP N
. . N

However RB N
the DT N
analgesic JJ N
equivalent NN N
of IN N
both DT N
techniques NNS N
have VBP N
not RB N
been VBN N
confirmed VBN N
. . N

OBJECTIVE IN N
The DT N
authors NNS N
compared VBN N
continuous JJ i
epidural JJ i
infusion NN i
( ( i
CEI NNP i
) ) i
with IN N
continuous JJ i
femoral JJ i
nerve NN i
block NN i
( ( i
CFNB NNP i
) ) i
regarding VBG N
the DT N
postoperative JJ o
analgesic JJ o
efficacy NN o
, , o
side NN o
effects NNS o
, , o
postoperative JJ o
knee NN o
rehabilitation NN o
, , o
and CC o
hospital JJ o
length NN o
of IN o
stay NN o
( ( o
LOS NNP o
) ) o
. . N

MATERIAL NNP N
AND NNP N
METHOD NNP N
In IN N
this DT N
prospective JJ N
, , N
randomized VBN N
controlled VBD N
study NN N
, , N
61 CD p
ASA NNP p
physical JJ p
status NN p
I-III NNP p
patients NNS p
scheduled VBN p
for IN p
elective JJ p
unilateral JJ p
total NN p
knee NN p
arthroplasty NN p
( ( p
TKA NNP p
) ) p
under IN p
spinal JJ p
anesthesia NN p
( ( p
SA NNP p
) ) p
participated VBD N
. . N

The DT N
patients NNS N
were VBD N
allocated VBN N
into IN N
two CD N
groups NNS N
. . N

In IN N
the DT N
ward NN N
, , N
patients NNS N
in IN N
Group NNP N
I PRP N
( ( N
CEI NNP i
) ) N
were VBD N
maintained VBN N
by IN N
continuous JJ N
infusion NN N
of IN N
0.125 CD N
% NN N
levobupivacaine NN i
with IN N
morphine JJ i
0.0125 CD N
mg/ml NN N
( ( N
4 CD N
ml/hr NN N
) ) N
, , N
Group NNP N
II NNP N
( ( N
CFNB NNP i
) ) N
were VBD N
maintained VBN N
by IN N
0.125 CD N
% NN N
levobupivacaine NN i
( ( N
8 CD N
ml/hr NN N
) ) N
. . N

RESULTS JJ N
Patients NNPS N
in IN N
the DT N
CFNB NNP i
group NN N
, , N
the DT N
VAS NNP o
scores NNS o
at IN N
PO6-12 NNP N
hr NN N
and CC N
tramadol NN o
IV NNP o
requirement NN o
were VBD N
significantly RB N
greater JJR N
than IN N
the DT N
CEI NNP i
group NN N
( ( N
VAS NNP N
: : N
PO6 NNP N
hr VBD N
p-value JJ N
= NN N
0.001 CD N
, , N
PO12 NNP N
hr VBD N
p-value JJ N
= NNP N
0.004 CD N
) ) N
. . N

Patients NNS N
in IN N
the DT N
CEI NNP i
group NN N
experienced VBD N
dizziness NN o
, , o
pruritus NN o
, , o
and CC o
PONV NNP o
more JJR N
than IN N
the DT N
CFNB NNP i
group NN N
significantly RB N
. . N

Patient JJ o
satisfaction NN o
was VBD N
greater JJR N
with IN N
the DT N
CFNB NNP i
group NN N
although IN N
postoperative JJ o
knee NN o
rehabilitation NN o
and CC N
the DT N
hospital NN o
LOS NNP o
were VBD N
not RB N
different JJ N
. . N

CONCLUSION NNP N
CFNB NNP i
represents VBZ N
the DT N
optimal JJ N
analgesia NN N
with IN N
fewer JJR N
side NN o
effects NNS o
and CC N
greater JJR N
patient NN o
, , o
satisfaction NN o
. . N

The DT N
rehabilitation NN o
indices NNS o
and CC N
duration NN o
of IN o
hospital NN o
stay NN o
are VBP N
comparable JJ N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -14739125- O O

Raising VBG N
high-density NN N
lipoprotein NN N
in IN N
humans NNS N
through IN N
inhibition NN N
of IN N
cholesteryl NN N
ester NN N
transfer NN N
protein NN N
: : N
an DT N
initial JJ N
multidose NN N
study NN N
of IN N
torcetrapib NN i
. . N

OBJECTIVE CC N
The DT N
ability NN N
of IN N
the DT N
potent NN N
cholesteryl NN i
ester NN i
transfer NN i
protein NN i
( ( i
CETP NNP i
) ) i
inhibitor NN i
torcetrapib NN i
( ( N
CP-529,414 NNP N
) ) N
to TO N
raise VB N
high-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
HDL-C NNP N
) ) N
levels NNS N
in IN N
healthy JJ p
young JJ p
subjects NNS p
was VBD N
tested VBN N
in IN N
this DT N
initial JJ N
phase NN N
1 CD N
multidose NN N
study NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Five NNP p
groups NNS p
of IN p
8 CD p
subjects NNS p
each DT p
were VBD N
randomized VBN N
to TO N
placebo VB i
( ( N
n=2 NN N
) ) N
or CC N
torcetrapib NN i
( ( N
n=6 JJ N
) ) N
at IN N
10 CD N
, , N
30 CD N
, , N
60 CD N
, , N
and CC N
120 CD N
mg NNS N
daily RB N
and CC N
120 CD N
mg NN N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
. . N

Torcetrapib NN i
was VBD N
well RB N
tolerated VBN N
, , N
with IN N
all DT N
treated JJ N
subjects NNS N
completing VBG N
the DT N
study NN N
. . N

The DT N
correlation NN N
of IN N
plasma JJ o
drug NN o
levels NNS o
with IN N
inhibition NN N
( ( N
EC50=43 NNP N
nM RB N
) ) N
was VBD N
as IN N
expected VBN N
based VBN N
on IN N
in IN N
vitro JJ N
potency NN N
( ( N
IC50 NNP N
approximately RB N
50 CD N
nM NNS N
) ) N
, , N
and CC N
increases VBZ N
in IN N
CETP NNP N
mass NN N
were VBD N
consistent JJ N
with IN N
the DT N
proposed VBN N
mechanism NN N
of IN N
inhibition NN N
. . N

CETP NNP N
inhibition NN N
increased VBD N
with IN N
escalating VBG N
dose NN N
, , N
leading VBG N
to TO N
elevations NNS N
of IN N
HDL-C NNP N
of IN N
16 CD N
% NN N
to TO N
91 CD N
% NN N
. . N

Total JJ o
plasma JJ o
cholesterol NN o
did VBD N
not RB N
change VB N
significantly RB N
because IN N
of IN N
a DT N
reduction NN N
in IN N
nonHDL-C JJ o
, , N
including VBG N
a DT N
21 CD N
% NN N
to TO N
42 CD N
% NN N
lowering NN N
of IN N
low-density NN o
lipoprotein NN o
cholesterol NN o
at IN N
the DT N
higher JJR N
doses NNS N
. . N

Apolipoprotein NNP o
A-I NNP o
and CC o
E NNP o
were VBD N
elevated VBN N
27 CD N
% NN N
and CC N
66 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
apoB NN o
was VBD N
reduced VBN N
26 CD N
% NN N
with IN N
120 CD N
mg NNS N
twice RB N
daily RB N
. . N

Cholesteryl NNP o
ester NN o
content NN o
decreased VBN N
and CC N
triglyceride VB o
increased VBN N
in IN N
the DT N
nonHDL JJ N
plasma NN N
fraction NN N
, , N
with IN N
contrasting VBG N
changes NNS N
occurring VBG N
in IN N
HDL NNP N
. . N

CONCLUSIONS NNP N
These DT N
effects NNS N
of IN N
CETP NNP N
inhibition NN N
resemble VBP N
those DT N
observed VBN N
in IN N
partial JJ N
CETP NNP N
deficiency NN N
. . N

This DT N
work NN N
serves VBZ N
as IN N
a DT N
prelude NN N
to TO N
further JJ N
studies NNS N
in IN N
subjects NNS N
with IN N
low JJ N
HDL NNP N
, , N
or CC N
combinations NNS N
of IN N
dyslipidemia NN N
, , N
in IN N
assessing VBG N
the DT N
role NN N
of IN N
CETP NNP N
in IN N
atherosclerosis NN N
. . N

-DOCSTART- -361799- O O

[ IN N
The DT N
chemotherapy NN i
of IN N
advanced JJ p
breast NN p
cancer NN p
. . N

A DT N
report NN N
on IN N
the DT N
first JJ N
600 CD p
cases NNS p
in IN N
a DT N
cooperative JJ N
programme NN N
to TO N
carry VB N
out RP N
a DT N
systematic JJ N
study NN N
( ( N
1974-1977 JJ N
) ) N
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

The DT N
authors NNS N
explain VBP N
the DT N
objectives NNS N
and CC N
the DT N
structure NN N
of IN N
a DT N
programme NN N
evolved VBN N
for IN N
the DT N
methodic JJ N
study NN N
of IN N
advanced JJ p
breast NN p
cancers NNS p
which WDT N
they PRP N
have VBP N
worked VBN N
out RP N
and CC N
carried VBD N
out RP N
in IN N
cooperation NN N
with IN N
the DT N
departments NNS N
of IN N
medicine NN N
in IN N
eight CD N
French JJ p
anticancer NN N
centres NNS N
. . N

They PRP N
analyse VBP N
the DT N
initial JJ N
phases NNS N
, , N
which WDT N
correspond NN N
to TO N
the DT N
three CD N
first JJ N
years NNS N
of IN N
work NN N
. . N

They PRP N
give VBP N
the DT N
state NN N
of IN N
the DT N
results NNS N
that WDT N
have VBP N
been VBN N
obtained VBN N
in IN N
603 CD p
patients NNS p
using VBG N
three CD N
protocols NNS N
for IN N
treatment NN N
. . N

These DT N
consisted VBN N
of IN N
the DT N
administration NN N
in IN N
interrupted JJ N
doses NNS N
of IN N
chemotherapy NN i
which WDT N
consisted VBD N
of IN N
vincristine NN i
associated VBN N
for IN N
the DT N
one CD N
part NN N
with IN N
cyclophosphamide NN i
and CC N
5-fluoro-uracil JJ i
and CC N
on IN N
the DT N
other JJ N
hand NN N
with IN N
doxorubicine NN i
or/and NN N
with IN N
methotrexate NN i
. . N

From IN N
this DT N
study NN N
there RB N
emerged VBD N
the DT N
value NN N
of IN N
combined JJ N
therapy NN N
using VBG N
doxorubicine NN i
as IN N
much JJ N
because IN N
of IN N
the DT N
frequency NN N
with IN N
which WDT N
results NNS o
better JJR N
than IN N
50 CD N
% NN N
were VBD N
obtained VBN N
( ( N
in IN N
a DT N
randomised JJ N
trial NN N
) ) N
as IN N
by IN N
their PRP$ N
quality NN o
, , N
which WDT N
was VBD N
made VBN N
clear JJ N
in IN N
an DT N
important JJ N
series NN N
of IN N
240 CD N
cases NNS N
. . N

They PRP N
point VBP N
out RP N
the DT N
conditions NNS N
required VBN N
to TO N
initiate VB N
the DT N
place NN N
of IN N
such PDT N
a DT N
scheme NN N
in IN N
all DT N
complex JJ N
therapy NN N
which WDT N
aims VBZ N
as RB N
much JJ N
at IN N
palliation NN N
as IN N
at IN N
cure NN N
, , N
and CC N
point VB N
out RP N
how WRB N
important JJ N
it PRP N
is VBZ N
to TO N
be VB N
methodical JJ N
in IN N
the DT N
application NN N
of IN N
chemotherapy NN i
in IN N
order NN N
to TO N
ensure VB N
its PRP$ N
development NN N
as IN N
an DT N
anticancer NN N
therapy NN N
. . N

-DOCSTART- -10475150- O O

The DT N
role NN N
of IN N
somatostatin NN i
( ( i
octreotide JJ i
) ) i
in IN N
the DT N
regulation NN N
of IN N
melatonin JJ o
secretion NN o
in IN N
healthy JJ p
volunteers NNS p
and CC p
in IN p
patients NNS p
with IN p
primary JJ p
hypothyroidism NN p
. . p

Somatostatin NNP i
has VBZ N
been VBN N
found VBN N
in IN N
the DT N
pineal JJ N
gland NN N
of IN N
several JJ N
animal JJ N
species NNS N
, , N
which WDT N
suggests VBZ N
that IN N
it PRP N
may MD N
be VB N
involved VBN N
in IN N
the DT N
regulation NN N
of IN N
melatonin JJ o
secretion NN o
. . N

Whether NNP N
somatostatin NN i
has VBZ N
regulatory JJ N
influence NN N
on IN N
melatonin NN o
secretion NN o
in IN N
man NN N
has VBZ N
never RB N
been VBN N
unequivocally RB N
shown VBN N
. . N

We PRP N
studied VBD N
the DT N
nocturnal JJ o
melatonin NN o
secretion NN o
in IN N
8 CD p
healthy JJ p
volunteers NNS p
, , p
and CC p
6 CD p
women NNS p
with IN p
untreated JJ p
primary JJ p
hypothyroidism NN p
, , N
a DT N
disease NN N
state NN N
that WDT N
is VBZ N
associated VBN N
with IN N
increased JJ N
nocturnal JJ N
secretion NN N
of IN N
melatonin NN N
. . N

The DT N
participants NNS N
were VBD N
given VBN N
subcutaneous JJ N
injections NNS N
at IN N
18:00 CD N
h NN N
and CC N
23:00 CD N
h NN N
of IN N
either DT N
saline NN i
or CC N
octreotide NN i
( ( i
Sandostatin NNP i
; : N
each DT N
injection NN N
50 CD N
microg NN N
) ) N
. . N

During IN N
the DT N
nights NNS N
when WRB N
the DT N
healthy JJ p
volunteers NNS p
were VBD N
given VBN N
octreotide RB i
, , N
melatonin JJ o
secretion NN o
was VBD N
similar JJ N
to TO N
that DT N
recorded VBN N
during IN N
administration NN N
of IN N
saline NN i
. . N

Also RB N
the DT N
urinary JJ o
excretion NN o
of IN o
melatonin NN o
was VBD N
of IN N
similar JJ N
magnitude NN N
at IN N
these DT N
two CD N
occasions NNS N
. . N

By IN N
contrast NN N
, , N
the DT N
GH NNP o
secretion NN o
was VBD N
significantly RB N
lower JJR N
the DT N
nights NNS N
the DT N
healthy JJ N
controls NNS N
were VBD N
given VBN N
octreotide RB i
( ( N
GH NNP N
AUC NNP N
22.6+/-5.4 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
octreotide JJ i
and CC N
126.6+/-21.9 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
saline NN i
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

The DT N
patients NNS p
with IN p
hypothyroidism NN p
also RB N
showed VBD N
similar JJ N
nocturnal JJ o
melatonin NN o
secretion NN o
during IN N
octreotide NN i
and CC N
saline NN i
. . N

Urinary JJ o
excretion NN o
of IN o
melatonin NN o
also RB N
remained VBD N
unchanged JJ N
, , N
as IN N
did VBD N
GH NNP N
secretion NN N
. . N

The DT N
total JJ o
nocturnal JJ o
secretion NN o
of IN o
TSH NNP o
was VBD N
, , N
however RB N
, , N
significantly RB N
reduced VBN N
by IN N
octreotide NN i
( ( N
TSH NNP N
AUC NNP N
562+/-136 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
octreotide JJ i
and CC N
851+/-185 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
saline NN i
; : N
p CC N
< VB N
0.05 CD N
) ) N
, , N
thus RB N
suggesting VBG N
that IN N
100 CD N
microg NN N
of IN N
octreotide NN i
should MD N
be VB N
sufficient JJ N
to TO N
inhibit VB N
also RB N
the DT N
pinealocytes NNS N
if IN N
their PRP$ N
function NN N
were VBD N
regulated VBN N
by IN N
somatostatin NN i
. . N

Since IN N
exogenous JJ N
somatostatin NN i
-- : N
in IN N
the DT N
form NN N
of IN N
octreotide NN i
-- : N
fails VBZ N
to TO N
influence VB N
nocturnal JJ o
secretion NN o
and CC o
urinary JJ o
excretion NN o
of IN o
melatonin NN o
in IN N
normal JJ p
subjects NNS p
and CC p
in IN p
patients NNS p
with IN p
primary JJ p
hypothyroidism NN p
, , N
it PRP N
is VBZ N
reasonable JJ N
to TO N
assume VB N
that DT N
endogenous JJ N
somatostatin NN i
may MD N
not RB N
be VB N
an DT N
important JJ N
regulator NN N
of IN N
melatonin JJ N
secretion NN N
in IN N
man NN N
. . N

-DOCSTART- -20804366- O O

Randomized VBN N
controlled JJ N
trial NN N
of IN N
acupuncture NN i
versus NN N
sham JJ i
acupuncture NN i
in IN N
autism NN p
spectrum NN p
disorder NN p
. . N

OBJECTIVE IN N
We PRP N
aim VBP N
to TO N
study VB N
the DT N
efficacy NN o
of IN N
acupuncture NN i
versus NN N
sham JJ i
acupuncture NN i
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . N

METHODS VB N
A DT N
single-blind JJ N
randomized VBN N
control NN N
trial NN N
was VBD N
conducted VBN N
in IN N
50 CD p
children NNS p
. . N

These DT N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN N
group NN N
with IN N
tongue JJ i
acupuncture NN i
( ( N
40 CD N
sessions NNS N
over IN N
8 CD N
weeks NNS N
) ) N
or CC N
the DT N
control NN N
group NN N
( ( N
sham JJ i
tongue NN i
acupuncture NN i
to TO N
nonacupoints NNS N
in IN N
the DT N
tongue NN N
) ) N
. . N

RESULTS NNP N
There EX N
was VBD N
improvement NN N
in IN N
both CC N
the DT N
treatment NN N
and CC N
control NN N
groups NNS N
in IN N
all DT N
assessed JJ N
measures NNS N
but CC N
more JJR N
so RB N
in IN N
the DT N
treatment NN N
than IN N
in IN N
the DT N
control NN N
group NN N
: : N
( ( N
1 CD N
) ) N
eye-hand NN o
coordination NN o
, , o
performance NN o
, , o
and CC o
practical JJ o
reasoning NN o
of IN o
Griffiths NNP o
Mental NNP o
Developmental NNP o
Scale NNP o
; : o
( ( o
2 CD o
) ) o
sensory-motor NN o
, , o
social JJ o
, , o
affectual JJ o
, , o
language NN o
, , o
and CC o
total JJ o
score NN o
of IN o
Ritvo-Freeman NNP o
Real NNP o
Life NNP o
Scale NNP o
; : o
( ( o
3 CD o
) ) o
Comprehension NN o
Language NNP o
age NN o
in IN o
the DT o
Reynell NNP o
Language NNP o
Developmental NNP o
Scale NNP o
; : o
and CC o
( ( o
4 CD o
) ) o
Total NN o
Score NNP o
and CC o
Mental NNP o
Age NNP o
in IN o
Symbolic NNP o
Play NNP o
Test NNP o
. . o

The DT N
only JJ N
statistically RB N
significant JJ N
improvement NN N
in IN N
the DT N
treatment NN N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
was VBD N
seen VBN N
in IN N
self-care JJ o
and CC o
cognition NN o
domains NNS o
of IN o
the DT o
Functional NNP o
Independence NNP o
Measure NN o
for IN o
children NNS o
. . N

CONCLUSIONS NNP N
We PRP N
had VBD N
demonstrated VBN N
that IN N
a DT N
short JJ N
course NN N
of IN N
acupuncture NN i
had VBD N
efficacy NN N
in IN N
improving VBG N
various JJ N
developmental JJ N
and CC N
behavioral JJ N
aspects NNS N
of IN N
children NNS p
with IN p
autism NN p
. . N

The DT N
long-term JJ N
efficacy NN N
in IN N
functional JJ N
gain NN N
needs NNS N
to TO N
be VB N
further RB N
explored VBN N
. . N

-DOCSTART- -23357440- O O

The DT N
effect NN N
of IN N
cognitive-behavioral JJ i
therapy NN i
versus NN N
treatment NN i
as IN i
usual JJ i
for IN N
anxiety NN p
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
examine VB N
the DT N
efficacy NN o
of IN N
a DT N
modular JJ N
cognitive-behavioral JJ i
therapy NN i
( ( i
CBT NNP i
) ) i
protocol VBP N
relative JJ N
to TO N
treatment NN i
as IN i
usual JJ i
( ( i
TAU NNP i
) ) i
among IN N
children NNS p
with IN p
high-functioning JJ p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
and CC p
clinically RB p
significant JJ p
anxiety NN p
. . N

METHOD NNP N
A NNP p
total NN p
of IN p
45 CD p
children NNS p
( ( p
7-11 CD p
years NNS p
of IN p
age NN p
) ) p
with IN p
high-functioning JJ p
ASD NNP p
and CC p
clinically RB p
significant JJ p
anxiety NN p
were VBD N
randomized VBN N
to TO N
receive VB N
16 CD N
sessions NNS N
of IN N
weekly JJ N
CBT NNP i
or CC N
TAU NNP i
for IN N
an DT N
equivalent JJ N
duration NN N
. . N

After IN N
screening VBG N
, , N
assessments NNS N
were VBD N
conducted VBN N
at IN N
baseline NN N
, , N
post-treatment JJ N
, , N
and CC N
3-month JJ N
follow-up NN N
. . N

Raters NNPS N
were VBD N
blind RB N
to TO N
treatment NN N
condition NN N
. . N

RESULTS NNP N
Youth NNP N
receiving VBG N
CBT NNP i
showed VBD N
substantial JJ N
improvement NN N
relative NN N
to TO N
TAU VB i
on IN N
primary JJ o
anxiety NN o
outcomes NNS o
. . N

Of IN N
24 CD N
children NNS N
randomized VBN N
to TO N
the DT N
CBT NNP i
arm NN N
, , N
18 CD N
( ( N
75 CD N
% NN N
) ) N
were VBD N
treatment NN N
responders NNS N
, , N
versus IN N
only RB N
3 CD N
of IN N
21 CD N
children NNS N
( ( N
14 CD N
% NN N
) ) N
in IN N
the DT N
TAU NNP i
arm NN N
. . N

Gains NNS N
were VBD N
generally RB N
maintained VBN N
at IN N
3-month JJ N
follow-up NN N
for IN N
CBT NNP i
responders NNS N
. . N

CONCLUSIONS NNP N
Relative NNP N
to TO N
usual JJ N
care NN N
, , N
CBT NNP i
adapted VBD N
for IN N
anxious JJ N
youth NN N
with IN N
high-functioning JJ N
ASD NNP N
demonstrates VBZ N
large JJ N
effects NNS N
in IN N
reducing VBG N
anxiety NN o
symptoms NNS o
. . N

This DT N
study NN N
contributes VBZ N
to TO N
the DT N
growing VBG N
literature NN N
supporting VBG N
adapted VBN N
CBT NNP i
approaches NNS N
for IN N
treating VBG N
anxiety NN N
in IN N
youth NN N
with IN N
ASD NNP N
. . N

-DOCSTART- -7808649- O O

[ JJ N
Double-blind NNP N
placebo-controlled JJ N
study NN N
of IN N
the DT N
effectiveness NN o
and CC N
tolerability NN o
of IN N
10 CD N
and CC N
30 CD N
mg NN N
ketorolac NN i
tromethamine NN i
suppositories NNS N
in IN N
post-cholecystectomy JJ p
pain NN p
] NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN o
and CC N
tolerability NN o
of IN N
ketorolac NN i
tromethamine NN i
10 CD N
mg NN N
and CC N
30 CD N
mg NN N
suppositories NNS N
in IN N
comparison NN N
to TO N
placebo VB i
, , N
after IN N
single JJ N
dose JJ N
administration NN N
in IN N
patients NNS p
suffering VBG p
from IN p
post-operative JJ p
pain NN p
after IN p
cholecystectomy NN p
. . N

DESIGN NNP N
Double-blind NNP N
, , N
randomized VBD N
, , N
controlled VBD N
study NN N
. . N

SETTING NNP N
Anaesthesia NNP N
Service NNP N
. . N

PATIENTS NNP N
99 CD p
patients NNS p
with IN p
severe JJ p
pain NN p
following VBG p
surgery NN p
. . N

INTERVENTIONS NNP N
Cholecystectomy NNP N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
analgesia JJ N
activity NN N
of IN N
ketorolac NN i
tromethamine NN i
10 CD N
mg NN N
and CC N
30 CD N
mg NN N
suppositories NNS N
were VBD N
evaluated VBN N
after IN N
single JJ N
dose JJ N
administration NN N
by IN N
assessing VBG N
pain NN o
intensity NN o
and CC o
pain NN o
relief NN o
using VBG N
a DT N
4 CD o
point NN o
scale NN o
( ( o
VRS NNP o
) ) N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
overall JJ N
assessment NN N
of IN N
safety NN o
and CC N
efficacy NN o
were VBD N
recorded VBN N
by IN N
physician JJ N
and CC N
patient JJ N
. . N

The DT N
results NNS N
show VBP N
that IN N
in IN N
both DT N
active JJ N
groups NNS N
after IN N
30 CD N
' POS N
and CC N
until IN N
4 CD N
hours NNS N
, , N
pain VBP o
intensity NN o
decreased VBN N
significantly RB N
with IN N
respect NN N
to TO N
the DT N
baseline NN N
. . N

However RB N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
groups NNS N
of IN N
p NN N
< NN N
0.02 CD N
, , N
p NN N
< VBD N
0.01 CD N
and CC N
p VB N
< JJ N
0.05 CD N
was VBD N
found VBN N
in IN N
favour NN N
of IN N
the DT N
30 CD N
mg NN N
dose NN N
respectively RB N
at IN N
30 CD N
' '' N
, , N
6 CD N
and CC N
8 CD N
hours NNS N
after IN N
administration NN N
. . N

All PDT N
the DT N
patients NNS N
treated VBN N
with IN N
placebo JJ i
suppositories NNS N
required VBN N
another DT N
rescue NN o
analgesic JJ o
drug NN o
and CC N
withdrew NN N
from IN N
the DT N
trial NN N
. . N

Three CD N
patients NNS N
complained VBD N
adverse JJ o
events NNS o
not RB N
related VBN N
to TO N
treatment NN N
: : N
two CD N
on IN N
placebo NN N
and CC N
one CD N
on IN N
ketorolac NN N
10 CD N
mg NN N
. . N

The DT N
systemic JJ o
and CC o
local JJ o
tolerability NN o
of IN N
the DT N
drug NN N
was VBD N
good JJ N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
ketorolac $ i
30 CD N
mg NN N
suppositories NNS N
are VBP N
effective JJ N
in IN N
clinical JJ N
conditions NNS N
, , N
such JJ N
as IN N
after IN p
surgery NN p
, , N
in IN N
which WDT N
pain NN N
control NN N
must MD N
be VB N
achieved VBN N
within IN N
the DT N
shortest JJ N
time NN N
interval NN N
and CC N
maintained VBD N
or CC N
improved VBN N
by IN N
means NNS N
of IN N
a DT N
single JJ N
route NN N
of IN N
administration NN N
. . N

-DOCSTART- -10912743- O O

Effects NNS N
of IN N
low-dose JJ N
aspirin NN i
on IN N
clinic NN o
and CC o
ambulatory JJ o
blood NN o
pressure NN o
in IN N
treated JJ p
hypertensive JJ p
patients NNS p
. . N

Collaborative NNP N
Group NNP N
of IN N
the DT N
Primary NNP N
Prevention NNP N
Project NNP N
( ( N
PPP NNP N
) ) N
-- : N
Hypertension NNP N
study NN N
. . N

Nonsteroidal NNP N
antiinflammatory JJ N
drugs NNS N
may MD N
affect VB N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
control NN o
in IN N
hypertensive JJ p
patients NNS p
receiving VBG p
drug NN p
treatment NN p
, , N
but CC N
data NNS N
on IN N
the DT N
effects NNS N
of IN N
low-dose JJ N
aspirin NNS i
are VBP N
scanty RB N
. . N

This DT N
study NN N
assessed VBD N
the DT N
effects NNS N
of IN N
chronic JJ N
treatment NN N
with IN N
low JJ N
doses NNS N
of IN N
aspirin NN i
( ( N
100 CD N
mg/day NN N
) ) N
on IN N
clinic NN o
and CC o
ambulatory JJ o
systolic NN o
( ( o
SBP NNP o
) ) o
and CC o
diastolic JJ o
( ( o
DBP NNP o
) ) o
BP NNP o
in IN N
hypertensives NNS N
on IN N
chronic NN N
, , N
stable JJ N
antihypertensive JJ N
therapy NN N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
in IN N
the DT N
framework NN N
of IN N
the DT N
Primary NNP N
Prevention NNP N
Project NNP N
( ( N
PPP NNP N
) ) N
, , N
a DT N
randomized VBN N
, , N
controlled VBN N
factorial JJ N
trial NN N
on IN N
the DT N
preventive JJ N
effect NN N
of IN N
aspirin NN i
or CC N
vitamin NN i
E NN i
in IN N
people NNS p
with IN p
one CD p
or CC p
more JJR p
cardiovascular JJ p
risk NN p
factors NNS p
. . N

Fifteen NNP p
Italian JJ p
hypertension NN p
units NNS p
studied VBD p
142 CD p
hypertensive JJ p
patients NNS p
( ( p
76 CD p
men NNS p
, , p
66 CD p
women NNS p
; : p
mean JJ p
age NN p
59 CD p
+/- JJ p
5.9 CD p
years NNS p
) ) p
treated VBD p
with IN p
different JJ p
antihypertensive JJ p
drugs NNS p
: : N
71 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
aspirin VB i
and CC N
71 CD N
served VBD N
as IN N
controls NNS N
. . N

All DT N
patients NNS N
underwent VBD N
a DT N
clinic JJ o
BP NNP o
evaluation NN N
with IN N
an DT N
automatic JJ N
sphygmomanometer NN N
and CC N
a DT N
24-h JJ o
ambulatory NN o
BP NNP o
monitoring NN o
, , N
at IN N
baseline NN N
and CC N
after IN N
3 CD N
months NNS N
of IN N
aspirin JJ i
treatment NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
the DT N
changes NNS N
in IN N
clinic JJ o
SBP NNP o
and CC o
DBP NNP o
were VBD N
not RB N
statistically RB N
different JJ N
in IN N
treated JJ N
and CC N
untreated JJ N
subjects NNS N
. . N

Ambulatory NNP o
SBP NNP o
and CC o
DBP NNP o
after IN N
3 CD N
months NNS N
of IN N
aspirin JJ i
treatment NN N
were VBD N
similar JJ N
to TO N
baseline VB N
: : N
deltaSBP NN N
-0.5 NN N
mmHg NN N
( ( N
95 CD N
% NN N
confidence NN N
intervals NNS N
[ VBP N
CI NNP N
] NN N
from IN N
-1.9 NN N
to TO N
+2.9 VB N
mm JJ N
Hg NNP N
) ) N
and CC N
deltaDBP JJ N
-1.1 NNP N
mm NN N
Hg NNP N
( ( N
95 CD N
% NN N
CI NNP N
from IN N
-2.5 NNP N
to TO N
+0.3 VB N
mm JJ N
Hg NNP N
) ) N
. . N

The DT N
pattern NN N
was VBD N
similar JJ N
in IN N
the DT N
control NN N
group NN N
. . N

No DT N
interaction NN N
was VBD N
found VBN N
between IN N
aspirin NN i
and CC N
the DT N
most RBS N
used JJ N
antihypertensive JJ N
drug NN N
classes NNS N
( ( N
angiotensin IN N
converting VBG N
enzyme JJ N
inhibitors NNS N
and CC N
calcium NN N
antagonists NNS N
) ) N
. . N

Despite IN N
the DT N
relatively RB N
small JJ N
sample NN N
size NN N
our PRP$ N
results NNS N
seem VBP N
to TO N
exclude VB N
any DT N
significant JJ N
influence NN N
of IN N
low-dose JJ N
aspirin NN i
on IN N
BP NNP o
control NN N
in IN N
hypertensives NNS N
under IN N
treatment NN N
. . N

-DOCSTART- -11829043- O O

A DT N
pilot NN N
study NN N
on IN N
the DT N
effect NN N
of IN N
progressive JJ i
muscle NN i
relaxation NN i
training NN i
of IN N
patients NNS p
after IN p
stoma NN p
surgery NN p
. . N

Eighteen JJ p
patients NNS p
who WP p
had VBD p
undergone JJ p
stoma NN p
surgery NN p
were VBD N
assessed VBN N
with IN N
respect NN N
to TO N
their PRP$ N
anxiety NN o
level NN o
and CC o
self-reported JJ o
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
on IN N
three CD N
occasions NNS N
; : N
namely RB N
, , N
immediately RB N
after IN N
surgery NN N
, , N
5 CD N
weeks NNS N
after IN N
surgery NN N
, , N
and CC N
10 CD N
weeks NNS N
after IN N
surgery NN N
. . N

The DT N
patients NNS N
were VBD N
randomised VBN N
into IN N
a DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
and CC N
an DT N
experimental JJ N
group NN N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
. . N

A DT N
20-min JJ N
set NN N
of IN N
audiotaped JJ N
instructions NNS N
on IN N
progressive JJ i
muscle NN i
relaxation NN i
training NN i
( ( i
PMRT NNP i
) ) i
was VBD N
given VBN N
to TO N
the DT N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
for IN N
home NN N
practice NN N
. . N

Assessment NNP N
instructions NNS N
included VBD N
the DT N
Chinese JJ o
State-Trait NNP o
Anxiety NNP o
Inventory NNP o
( ( o
C-STAI NNP o
) ) o
, , o
the DT o
Quality NN o
of IN o
Life NNP o
Index NNP o
for IN o
Colostomy NNP o
( ( o
QoL-Colostomy NNP o
) ) o
and CC o
the DT o
Hong NNP o
Kong NNP o
Chinese JJ o
version NN o
of IN o
the DT o
World NNP o
Health NNP o
Organisation NNP o
Quality NNP o
of IN o
Life NNP o
Scale NNP o
( ( o
WHOQoL NNP o
) ) o
. . N

Results NNS N
indicated VBD N
that IN N
there EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
both DT N
the DT N
C-STAI NNP o
score NN o
( ( N
F NNP N
= NNP N
4.66 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
the DT N
WHOQoL NNP o
score NN o
( ( N
F NNP N
= NNP N
4.74 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
experimental JJ N
group NN N
. . N

Among IN N
the DT N
domains NNS N
of IN N
WHOQoL NNP o
, , N
a DT N
significant JJ N
difference NN N
was VBD N
shown VBN N
in IN N
physical JJ N
health/independence NN N
and CC N
general JJ N
perception NN N
of IN N
QoL NNP o
, , N
with IN N
the DT N
experimental JJ N
group NN N
demonstrating VBG N
better JJR N
functioning NN N
. . N

For IN N
the DT N
QoL-Colostomy NNP o
, , N
however RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
control NN N
and CC N
experimental JJ N
groups NNS N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
the DT N
use NN N
of IN N
PMRT NNP i
could MD N
enhance VB N
quality NN o
of IN o
life NN o
and CC N
decrease NN N
state NN N
anxiety NN o
in IN N
patients NNS p
after IN p
stoma NN p
surgery NN p
. . p

-DOCSTART- -6951573- O O

A DT N
controlled VBN N
study NN N
of IN N
psychiatric JJ i
hospital NN i
versus NN N
community NN i
treatment NN i
- : N
the DT N
effect NN o
on IN o
relatives NNS o
. . N

One CD p
hundred CD p
and CC p
twenty JJ p
patients NNS p
presenting VBG p
at IN p
Macquarie NNP p
Hospital NNP p
for IN p
admission NN p
were VBD N
randomly RB N
allocated VBN N
into IN N
two CD N
groups NNS N
. . N

The DT N
control NN N
group NN N
patients NNS N
received VBD N
standard JJ i
hospital NN i
care NN i
and CC i
follow-up NN i
. . N

The DT N
project NN N
group NN N
patients NNS N
were VBD N
not RB N
admitted VBN N
if IN N
this DT N
could MD N
be VB N
avoided VBN N
; : N
instead RB N
they PRP N
were VBD N
taken VBN N
back RB i
to TO i
the DT i
community NN i
by IN N
the DT N
project NN N
team NN N
who WP N
provided VBD N
them PRP N
and CC N
their PRP$ N
relatives NNS N
with IN N
comprehensive JJ N
, , N
assertive JJ N
and CC N
prolonged JJ N
follow-up JJ i
treatment NN i
backed VBN N
by IN N
a DT N
24-hour JJ N
crisis NN N
service NN N
. . N

The DT N
majority NN N
( ( N
63 CD N
% NN N
) ) N
of IN N
the DT N
project NN N
group NN N
had VBD N
no DT N
admission NN N
during IN N
the DT N
10 CD N
month NN N
study NN N
period NN N
. . N

Initially RB N
, , N
the DT N
burden NN o
on IN o
the DT o
relatives NNS o
of IN N
the DT N
project NN N
group NN N
was VBD N
higher JJR N
, , N
but CC N
by IN N
one CD N
month NN N
it PRP N
was VBD N
somewhat RB N
lower JJR N
and CC N
by IN N
four CD N
months NNS N
it PRP N
was VBD N
significantly RB N
lower JJR N
than IN N
the DT N
burden NN N
on IN N
the DT N
control NN N
group NN N
relatives VBZ N
. . N

Relatives NNS N
of IN N
the DT N
project NN N
group NN N
patients NNS N
were VBD N
significantly RB N
more RBR N
satisfied JJ o
with IN N
the DT N
treatment NN N
than IN N
control NN N
group NN N
relatives VBZ N
. . N

It PRP N
is VBZ N
clearly RB N
feasible JJ N
to TO N
treat VB N
most JJS N
psychiatric JJ p
patients NNS p
in IN N
the DT N
community NN N
without IN N
increasing VBG N
the DT N
burden NN o
on IN o
their PRP$ o
relatives NNS o
. . N

-DOCSTART- -3081600- O O

Double-blind NNP N
comparison NN N
of IN N
doxepin NN i
versus NN N
bupropion NN i
in IN N
outpatients NNS p
with IN p
a DT p
major JJ p
depressive JJ p
disorder NN p
. . N

A DT N
double-blind NN N
controlled VBN N
study NN N
comparing VBG N
the DT N
effects NNS N
of IN N
bupropion NN i
to TO N
doxepin VB i
in IN N
outpatients NNS p
with IN p
primary JJ p
depression NN p
was VBD N
conducted VBN N
to TO N
evaluate VB N
efficacy NN o
and CC N
safety NN o
differences NNS N
between IN N
the DT N
two CD N
drugs NNS N
. . N

Following VBG N
a DT N
7-day JJ N
placebo NN i
washout NN N
period NN N
, , N
patients NNS N
could MD N
be VB N
treated VBN N
for IN N
up RB N
to TO N
13 CD N
weeks NNS N
on IN N
either DT N
treatment NN N
. . N

Antidepressant JJ o
response NN o
was VBD N
assessed VBN N
by IN N
the DT N
Hamilton NNP o
Depression NNP o
and CC o
Anxiety NNP o
Scales NNP o
, , o
Clinical NNP o
Global NNP o
Severity NNP o
and CC o
Improvement NNP o
Ratings NNP o
, , N
and CC N
the DT N
Zung NNP o
Self-Rating NNP o
Depression NNP o
Scale NNP o
. . N

Comparable JJ N
efficacy NN o
between IN N
the DT N
compounds NNS N
was VBD N
found VBN N
across IN N
the DT N
13-week JJ N
study NN N
. . N

Doxepin NNP i
differed VBD N
from IN N
bupropion NN i
mainly RB N
on IN N
the DT N
sleep JJ o
factor NN N
of IN N
the DT N
Hamilton NNP o
Depression NNP o
Scale NNP o
, , N
with IN N
doxepin NN i
improving VBG N
sleep NN o
to TO N
a DT N
greater JJR N
extent NN N
than IN N
bupropion NN i
. . N

Doxepin NNP i
produced VBD N
a DT N
greater JJR N
incidence NN N
of IN N
anticholinergic JJ o
side NN o
effects NNS o
, , N
including VBG N
dry JJ o
mouth NN o
, , o
constipation NN o
, , o
sleepiness NN o
, , o
and CC o
tiredness NN o
, , N
in IN N
comparison NN N
to TO N
bupropion NN i
. . N

Also RB N
, , N
increased VBD N
appetite NN o
and CC o
weight JJ o
gain NN o
were VBD N
consistent JJ N
side NN N
effects NNS N
of IN N
doxepin NN i
relative NN N
to TO N
bupropion NN i
. . N

-DOCSTART- -10589810- O O

Clinical JJ o
effects NNS o
of IN N
root NN N
instrumentation NN N
using VBG N
conventional JJ N
steel NN N
or CC N
non-tooth JJ N
substance NN N
removing VBG N
plastic NN N
curettes NNS N
during IN N
supportive JJ N
periodontal JJ N
therapy NN N
( ( N
SPT NNP N
) ) N
. . N

Although IN N
root NN N
instrumentation NN N
has VBZ N
been VBN N
accepted VBN N
as IN N
the DT N
most RBS N
important JJ N
cause-related JJ N
treatment NN N
of IN N
periodontal JJ N
diseases NNS N
, , N
repeated VBD N
scaling NN N
and CC N
root NN N
planing NN N
may MD N
over VB N
time NN N
result NN N
in IN N
substantive JJ N
loss NN N
of IN N
tooth JJ N
substance NN N
and CC N
increased JJ N
sensitivity NN N
of IN N
the DT N
teeth NN N
. . N

In IN N
an DT N
effort NN N
to TO N
minimize VB N
these DT N
side JJ N
effects NNS N
of IN N
therapy NN N
, , N
non-root JJ N
substance NN N
removing VBG N
curettes NNS N
have VBP N
been VBN N
developed VBN N
. . N

However RB N
, , N
the DT N
clinical JJ o
effects NNS o
of IN N
such JJ N
plastic NN N
curettes NNS N
with IN N
regard NN N
to TO N
the DT N
control NN N
of IN N
the DT N
periodontal JJ N
infection NN N
has VBZ N
not RB N
yet RB N
been VBN N
established VBN N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
, , N
therefore RB N
, , N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
root NN N
instrumentation NN N
using VBG N
plastic NN i
curettes NNS i
( ( N
Universal NNP N
Perio NNP N
Soft NNP N
Scaler NNP N
, , N
Hawe-Neos NNP N
Dental NNP N
, , N
Bioggio NNP N
, , N
TI NNP N
, , N
Switzerland NNP N
) ) N
versus VBP N
conventional JJ i
steel NN i
curettes NNS i
on IN N
the DT N
periodontal JJ N
conditions NNS N
during IN N
supportive JJ N
periodontal JJ N
therapy NN N
. . N

40 CD p
subjects NNS p
participated VBN N
in IN N
this DT N
parallel NN N
, , N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
prospective JJ N
longitudinal JJ N
clinical JJ N
study NN N
following VBG N
active JJ N
peridontal JJ N
therapy NN N
. . N

20 CD p
subjects NNS p
served VBD p
as IN p
a DT p
control NN p
group NN p
and CC N
were VBD N
treated VBN N
with IN N
conventional JJ i
steel NN i
curettes NNS i
during IN N
a DT N
supportive JJ p
periodontal NN p
care NN p
visit NN N
( ( N
SPT NNP p
) ) N
. . N

The DT N
other JJ N
20 CD p
subjects NNS p
, , N
the DT N
experimental JJ N
group NN N
, , N
were VBD N
treated VBN N
using VBG N
plastic NN i
curettes NNS i
during IN N
a DT N
similar JJ N
SPT NNP N
visit NN N
. . N

Clinical JJ N
parameters NNS N
, , N
such JJ N
as IN N
bleeding VBG o
on IN o
probing VBG o
( ( o
BOP NNP o
) ) o
and CC o
probing VBG o
pocket NN o
depth NN o
( ( o
PPD NNP o
) ) o
, , N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
3-6 JJ N
months NNS N
later RB N
at IN N
the DT N
next JJ N
regular JJ N
SPT NNP N
visit NN N
. . N

In IN N
addition NN N
, , N
the DT N
BOP NNP o
percentage NN o
was VBD N
determined VBN N
10 CD N
days NNS N
following VBG N
baseline NN N
. . N

The DT N
results NNS N
showed VBD N
that IN N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
2 CD N
treatment NN N
modalities NNS N
regarding VBG N
BOP NNP o
and CC o
PPD NNP o
at IN N
any DT N
observation NN N
time NN N
. . N

Both DT N
treatments NNS N
were VBD N
effective JJ N
in IN N
reducing VBG N
the DT N
BOP NNP o
percentage NN o
which WDT N
ranged VBD N
from IN N
17-42 CD N
% NN N
at IN N
baseline NN N
by IN N
about IN N
40 CD N
% NN N
after IN N
10 CD N
days NNS N
( ( N
mean JJ N
BOP NNP o
baseline NN N
: : N
26 CD N
% NN N
, , N
mean JJ N
BOP NNP o
after IN N
10 CD N
days NNS N
: : N
16 CD N
% NN N
) ) N
. . N

This DT N
clinical JJ N
study NN N
suggests VBZ N
that IN N
non-root JJ i
substance NN i
removing VBG i
curettes NNS i
may MD N
be VB N
valuable JJ N
instruments NNS N
for IN N
periodontally RB N
treated JJ N
patients NNS N
during IN N
maintenance NN N
care NN N
, , N
thus RB N
minimizing VBG N
trauma NN N
on IN N
the DT N
hard JJ N
structures NNS N
of IN N
the DT N
teeth NN N
. . N

-DOCSTART- -20189026- O O

Remote NNP i
ischaemic JJ i
conditioning NN i
before IN N
hospital JJ N
admission NN N
, , N
as IN N
a DT N
complement NN N
to TO N
angioplasty VB N
, , N
and CC N
effect NN N
on IN N
myocardial JJ o
salvage NN o
in IN N
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
: : N
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Remote NNP i
ischaemic JJ i
preconditioning NN i
attenuates NNS N
cardiac JJ N
injury NN N
at IN N
elective JJ N
surgery NN N
and CC N
angioplasty NN N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
remote VBP i
ischaemic JJ i
conditioning NN i
during IN N
evolving VBG N
ST-elevation NNP N
myocardial JJ N
infarction NN N
, , N
and CC N
done VBN N
before IN N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
, , N
increases VBZ N
myocardial JJ o
salvage NN o
. . N

METHODS NNP N
333 CD p
consecutive JJ p
adult NN p
patients NNS p
with IN p
a DT p
suspected VBN p
first JJ p
acute JJ p
myocardial JJ p
infarction NN p
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
1:1 CD N
ratio NN N
by IN N
computerised JJ N
block NN N
randomisation NN N
to TO N
receive VB N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
with IN N
( ( N
n=166 JJ N
patients NNS N
) ) N
versus NN N
without IN N
( ( N
n=167 NN N
) ) N
remote VBP i
conditioning VBG i
( ( N
intermittent JJ N
arm NN N
ischaemia NN N
through IN N
four CD N
cycles NNS N
of IN N
5-min JJ N
inflation NN N
and CC N
5-min JJ N
deflation NN N
of IN N
a DT N
blood-pressure JJ N
cuff NN N
) ) N
. . N

Allocation NN N
was VBD N
concealed VBN N
with IN N
opaque NN N
sealed VBN N
envelopes NNS N
. . N

Patients NNS N
received VBD N
remote JJ i
conditioning NN i
during IN N
transport NN N
to TO N
hospital NN N
, , N
and CC N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
in IN N
hospital NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
myocardial JJ o
salvage NN o
index NN o
at IN o
30 CD o
days NNS o
after IN o
primary JJ o
percutaneous JJ o
coronary JJ o
intervention NN o
, , N
measured VBN N
by IN N
myocardial JJ o
perfusion NN o
imaging NN o
as IN N
the DT N
proportion NN N
of IN N
the DT N
area NN N
at IN N
risk NN N
salvaged VBN N
by IN N
treatment NN N
; : N
analysis NN N
was VBD N
per IN N
protocol NN N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00435266 NNP N
. . N

FINDINGS NNP N
82 CD p
patients NNS p
were VBD p
excluded VBN p
on IN p
arrival NN p
at IN p
hospital NN p
because IN p
they PRP p
did VBD p
not RB p
meet VB p
inclusion NN p
criteria NNS p
, , p
32 CD p
were VBD p
lost VBN p
to TO p
follow-up NN p
, , p
and CC p
77 CD p
did VBD p
not RB p
complete VB p
the DT p
follow-up JJ p
with IN N
data NNS N
for IN N
salvage NN N
index NN N
. . N

Median JJ o
salvage NN o
index NN o
was VBD N
0.75 CD N
( ( N
IQR NNP N
0.50-0.93 CD N
, , N
n=73 NN N
) ) N
in IN N
the DT N
remote JJ i
conditioning NN i
group NN N
versus VBD N
0.55 CD N
( ( N
0.35-0.88 CD N
, , N
n=69 NN N
) ) N
in IN N
the DT N
control NN N
group NN N
, , N
with IN N
median JJ N
difference NN N
of IN N
0.10 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.01-0.22 CD N
; : N
p=0.0333 NN N
) ) N
; : N
mean JJ o
salvage NN o
index NN o
was VBD N
0.69 CD N
( ( N
SD NNP N
0.27 CD N
) ) N
versus NN N
0.57 CD N
( ( N
0.26 CD N
) ) N
, , N
with IN N
mean JJ N
difference NN N
of IN N
0.12 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.01-0.21 CD N
; : N
p=0.0333 NN N
) ) N
. . N

Major JJ o
adverse JJ o
coronary JJ o
events NNS o
were VBD N
death NN o
( ( N
n=3 JJ N
per IN N
group NN N
) ) N
, , N
reinfarction NN o
( ( N
n=1 JJ N
per IN N
group NN N
) ) N
, , N
and CC N
heart NN o
failure NN o
( ( N
n=3 JJ N
per IN N
group NN N
) ) N
. . N

INTERPRETATION NNP N
Remote NNP i
ischaemic JJ i
conditioning NN i
before IN N
hospital JJ N
admission NN N
increases VBZ N
myocardial JJ o
salvage NN o
, , N
and CC N
has VBZ N
a DT N
favourable JJ N
safety NN o
profile NN N
. . N

Our PRP$ N
findings NNS N
merit VBP N
a DT N
larger JJR N
trial NN N
to TO N
establish VB N
the DT N
effect NN N
of IN N
remote JJ i
conditioning NN i
on IN N
clinical JJ N
outcomes NNS N
. . N

FUNDING NN N
Fondation NNP N
Leducq NNP N
. . N

-DOCSTART- -18773733- O O

Vibrotactile NNP N
-- : N
auditory JJ N
interactions NNS N
are VBP N
post-perceptual JJ N
. . N

Vibrotactile NNP i
stimuli NN i
can MD N
elicit VB N
compelling VBG N
auditory JJ N
sensations NNS N
, , N
even RB N
when WRB N
sound NN N
energy NN N
levels NNS N
are VBP N
minimal JJ N
and CC N
undetectable JJ N
. . N

It PRP N
has VBZ N
previously RB N
been VBN N
shown VBN N
that IN N
subjects NNS N
judge VBP N
auditory JJ N
tones NNS N
embedded VBN N
in IN N
white JJ N
noise NN N
to TO N
be VB N
louder VBN N
when WRB N
they PRP N
are VBP N
accompanied VBN N
by IN N
a DT N
vibrotactile JJ i
stimulus NN i
of IN N
the DT N
same JJ N
frequency NN N
. . N

A DT N
first JJ N
experiment NN N
replicated VBN N
this DT N
result NN N
at IN N
four CD N
different JJ N
levels NNS N
of IN N
auditory JJ N
stimulation NN N
( ( N
no DT N
tone NN N
, , N
tone NN N
at IN N
detection NN N
threshold NN N
, , N
tone NN N
at IN N
5 CD N
dB NNS N
above IN N
threshold NN N
, , N
and CC N
tone NN N
at IN N
10 CD N
dB NNS N
above IN N
threshold NN N
) ) N
. . N

The DT N
presence NN N
of IN N
a DT N
vibrotactile JJ i
stimulus NN i
induced VBD N
an DT N
increase NN N
in IN N
the DT N
perceived JJ N
loudness NN N
of IN N
auditory NN o
tones NNS o
at IN N
three CD N
of IN N
the DT N
four CD N
values NNS N
in IN N
this DT N
range NN N
. . N

In IN N
two CD N
further JJ N
experiments NNS N
, , N
a DT N
2-interval JJ N
forced-choice JJ N
procedure NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
nature NN N
of IN N
this DT N
cross-modal JJ N
interaction NN N
. . N

Subjects NNS N
were VBD N
biased VBN N
when WRB N
vibrotaction NN i
was VBD N
applied VBN N
in IN N
one CD N
interval NN N
, , N
but CC N
applying VBG N
vibrotaction NN i
in IN N
both DT N
intervals NNS N
produced VBD N
performance NN N
comparable JJ N
to TO N
conditions NNS N
without IN N
vibrotactile NN i
stimuli NN i
. . N

This DT N
demonstrates VBZ N
that IN N
vibrotaction NN i
is VBZ N
sometimes RB N
ignored VBN N
when WRB N
judging VBG N
the DT N
presence NN N
of IN N
an DT N
auditory JJ N
tone NN N
. . N

Hence NNP N
the DT N
interaction NN N
between IN N
vibrotaction NN i
and CC N
audition NN N
does VBZ N
not RB N
appear VB N
to TO N
occur VB N
at IN N
an DT N
early JJ N
perceptual JJ N
level NN N
. . N

-DOCSTART- -8916620- O O

Analysis NN N
of IN N
prevention NN N
program NN N
effectiveness NN N
with IN N
clustered VBN N
data NNS N
using VBG N
generalized JJ N
estimating NN N
equations NNS N
. . N

Experimental JJ N
studies NNS N
of IN N
prevention NN N
programs NNS N
often RB N
randomize VBP N
clusters NNS N
of IN N
individuals NNS N
rather RB N
than IN N
individuals NNS N
to TO N
treatment NN N
conditions NNS N
. . N

When WRB N
the DT N
correlation NN N
among IN N
individuals NNS N
within IN N
clusters NNS N
is VBZ N
not RB N
accounted VBN N
for IN N
in IN N
statistical JJ N
analysis NN N
, , N
the DT N
standard JJ N
errors NNS N
are VBP N
biased VBN N
, , N
potentially RB N
resulting VBG N
in IN N
misleading VBG N
conclusions NNS N
about IN N
the DT N
significance NN N
of IN N
treatment NN N
effects NNS N
. . N

This DT N
study NN N
demonstrates VBZ N
the DT N
generalized JJ i
estimating NN i
equations NNS i
( ( i
GEE NNP i
) ) i
method NN N
, , N
focusing VBG N
specifically RB N
on IN N
the DT N
GEE-independent NNP i
method NN N
, , N
to TO N
control VB N
for IN N
within-cluster JJ N
correlation NN N
in IN N
regression NN N
models NNS N
with IN N
either DT N
continuous JJ N
or CC N
binary JJ N
outcomes NNS N
. . N

The DT N
GEE-independent JJ i
method NN N
yields NNS N
consistent JJ N
and CC N
robust JJ N
variance NN N
estimates NNS N
. . N

Data NNS N
from IN N
project NN N
DARE NNP N
, , N
a DT N
youth NN p
substance NN N
abuse NN N
prevention NN N
program NN N
, , N
are VBP N
used VBN N
for IN N
illustration NN N
. . N

-DOCSTART- -8913901- O O

Methodology NNP N
of IN N
serial JJ N
ECG NNP N
classification NN N
using VBG N
an DT N
adaptation NN N
of IN N
the DT N
NOVACODE NNP N
for IN N
Q NNP N
wave VBP N
myocardial JJ N
infarction NN N
in IN N
the DT N
Bypass NNP N
Angioplasty NNP N
Revascularization NNP N
Investigation NNP N
( ( N
BARI NNP N
) ) N
. . N

Serial JJ N
electrocardiographic JJ N
( ( N
ECG NNP N
) ) N
changes NNS N
are VBP N
a DT N
critical JJ N
component NN N
of IN N
the DT N
diagnostic JJ N
algorithm NN N
for IN N
classification NN N
of IN N
myocardial JJ N
ischemic JJ N
events NNS N
in IN N
large-scale JJ N
clinical JJ N
trials NNS N
. . N

This DT N
study NN N
describes VBZ N
a DT N
computerized JJ N
serial JJ N
ECG NNP N
classification NN N
program NN N
developed VBN N
at IN N
the DT N
St. NNP N
Louis NNP N
University NNP N
Core NNP N
ECG NNP N
Laboratory NNP N
for IN N
use NN N
in IN N
the DT N
Bypass NNP N
Angioplasty NNP N
Revascularization NNP N
Investigation NNP N
( ( N
BARI NNP N
) ) N
trial NN N
, , N
in IN N
which WDT N
patients NNS p
with IN p
multivessel JJ p
coronary JJ p
artery NN p
disease NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
coronary JJ i
artery NN i
bypass NN i
grafting NN i
or CC N
percutaneous JJ i
transluminal JJ i
coronary JJ i
angioplasty NN i
. . N

The DT N
St. NNP N
Louis NNP N
University NNP N
program NN N
detects NNS N
and CC N
codes VBZ N
serial JJ o
changes NNS o
in IN o
Q NNP o
, , o
ST NNP o
, , o
and CC o
T NNP o
wave VBP o
items NNS o
according VBG N
to TO N
Minnesota NNP N
code NN N
( ( N
MC NNP N
) ) N
criteria VBP N
using VBG N
a DT N
modified JJ N
NOVACODE NNP N
hierarchical JJ N
classification NN N
system NN N
. . N

Measurements NNS N
using VBG N
a DT N
seven-power NN N
calibrated VBN N
coding NN N
loupe NN N
are VBP N
used VBN N
to TO N
generate VB N
the DT N
MC NNP N
from IN N
a DT N
customized JJ N
software NN N
program NN N
. . N

Significant NNP N
minor VBD N
or CC N
major JJ N
changes NNS N
are VBP N
detected VBN N
by IN N
the DT N
serial JJ N
comparison NN N
program NN N
and CC N
referred VBD N
to TO N
a DT N
physician JJ N
coder NN N
for IN N
verification NN N
. . N

Serial JJ N
comparison NN N
coding NN N
rules NNS N
are VBP N
used VBN N
to TO N
adjust VB N
for IN N
weaknesses NNS N
in IN N
the DT N
standard JJ N
MC NNP N
classification NN N
system NN N
resulting VBG N
from IN N
instability NN N
at IN N
decision NN N
boundaries NNS N
. . N

Of IN N
4,244 CD p
BARI NNP p
randomized VBN p
and CC p
registry NN p
study NN p
participants NNS p
with IN p
follow-up JJ p
ECGs NNP p
received VBD p
at IN p
the DT p
Core NNP p
ECG NNP p
Laboratory NNP p
as IN p
of IN p
March NNP p
1995 CD p
, , N
a DT N
grade NN N
2 CD N
MC NNP N
Q NNP N
wave VBP N
progression NN N
was VBD N
noted VBN N
in IN N
568 CD N
participants NNS N
( ( N
13.4 CD N
% NN N
) ) N
using VBG N
MC NNP N
criteria NNS N
alone RB N
, , N
as IN N
compared VBN N
with IN N
367 CD N
( ( N
8.6 CD N
% NN N
) ) N
after IN N
the DT N
St. NNP N
Louis NNP N
University NNP N
coding NN N
rules NNS N
were VBD N
applied VBN N
. . N

The DT N
incidence NN N
of IN N
grade NN N
1 CD N
MC NNP N
Q NNP N
wave VBP N
progressions NNS N
was VBD N
16.4 CD N
% NN N
( ( N
697/4,244 CD N
) ) N
versus NN N
6.1 CD N
% NN N
( ( N
259/4,244 CD N
) ) N
when WRB N
the DT N
St. NNP N
Louis NNP N
University NNP N
program NN N
was VBD N
applied VBN N
. . N

Intraobserver NNP N
variability NN N
for IN N
grade NN N
2 CD N
Q NNP N
wave VBP N
progression NN N
codes NNS N
determined VBD N
from IN N
a DT N
sample NN N
of IN N
812 CD N
serial NN N
. . N

-DOCSTART- -9695300- O O

Salbutamol NNP i
or CC N
mist NN i
in IN N
acute JJ p
bronchiolitis NN p
. . N

BACKGROUND IN N
The DT N
role NN N
of IN N
bronchodilators NNS N
in IN N
the DT N
treatment NN N
of IN N
bronchiolitis NN N
remains VBZ N
controversial JJ N
. . N

METHODS VB N
A DT N
double-blind NN N
, , N
placebo NN N
controlled VBD N
trial NN N
was VBD N
performed VBN N
to TO N
evaluate VB N
the DT N
clinical JJ N
response NN N
to TO N
nebulized VBN N
salbutamol NN i
. . N

One CD p
hundred CD p
and CC p
fifty-six JJ p
infants NNS p
aged VBN p
between IN p
7 CD p
weeks NNS p
and CC p
24 CD p
months NNS p
who WP p
had VBD p
had VBN p
an DT p
episode NN p
of IN p
wheezing NN p
and CC p
other JJ p
signs NNS p
and CC p
symptoms NNS p
of IN p
bronchiolitis NN p
were VBD N
randomized VBN N
to TO N
three CD N
groups NNS N
as IN N
follows VBZ N
: : N
( ( N
i NN N
) ) N
nebulized VBD N
salbutamol NN i
was VBD N
administered VBN N
to TO N
52 CD N
patients NNS N
in IN N
group NN N
I PRP N
at IN N
a DT N
dose NN N
of IN N
0.15 CD N
mg/kg NNS N
in IN N
2 CD N
mL JJ N
saline NN i
; : N
( ( N
ii NN N
) ) N
saline NN i
was VBD N
nebulized VBN N
to TO N
52 CD N
patients NNS N
in IN N
group NN N
II NNP N
and CC N
( ( N
iii NN N
) ) N
in IN N
group NN N
III NNP N
52 CD N
patients NNS N
received JJ N
mist NN i
in IN N
a DT N
tent NN N
. . N

All DT N
three CD N
groups NNS N
were VBD N
administered VBN N
oxygen NN i
during IN N
the DT N
procedures NNS N
. . N

Treatment NNP N
was VBD N
repeated VBN N
with IN N
the DT N
same JJ N
agent NN N
after IN N
30 CD N
min NN N
if IN N
the DT N
respiratory NN N
score NN N
was VBD N
5 CD N
or CC N
more JJR N
. . N

Respiratory JJ o
rate NN o
, , o
heart NN o
rate NN o
, , o
oxygen NN o
saturation NN o
and CC o
presence NN o
of IN o
cyanosis NN o
, , o
wheezing VBG o
, , o
retractions NNS o
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
each DT N
treatment NN N
. . N

RESULTS VB N
The DT N
decrease NN N
in IN N
the DT N
respiratory NN o
score NN o
was VBD N
5.2 CD N
+/- JJ N
1.8 CD N
, , N
0.82 CD N
+/- JJ N
2.4 CD N
and CC N
1.7 CD N
+/- JJ N
1.3 CD N
in IN N
group NN N
I PRP N
, , N
II NNP N
and CC N
III NNP N
, , N
respectively RB N
. . N

The DT N
decrease NN N
in IN N
group NN N
I PRP N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
. . N

Heart NNP o
rate NN o
was VBD N
similar JJ N
between IN N
groups NNS N
. . N

Oxygen NNP o
saturation NN o
decreased VBD N
in IN N
group NN N
I PRP N
without IN N
reaching VBG N
statistical JJ N
significance NN N
. . N

CONCLUSIONS NNP N
Salbutamol NNP i
was VBD N
shown VBN N
to TO N
be VB N
effective JJ o
and CC N
safe JJ o
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
bronchiolitis NN N
. . N

-DOCSTART- -16295154- O O

Intervention NN i
pilot NN N
for IN N
parents NNS p
of IN p
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorder NN p
. . N

Parents NNS p
of IN p
children NNS p
who WP p
receive VBP p
the DT p
diagnosis NN p
of IN p
autistic JJ p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
experience NN N
a DT N
situational JJ N
crisis NN N
related VBN N
to TO N
receiving VBG N
the DT N
diagnosis NN N
, , N
which WDT N
causes VBZ N
feelings NNS N
of IN N
distress NN N
and CC N
urgency NN N
to TO N
access NN N
services NNS N
for IN N
the DT N
affected JJ N
child NN N
. . N

This DT N
paper NN N
describes VBZ N
a DT N
randomized JJ N
trial NN N
( ( N
n JJ p
= NNP p
31 CD p
) ) N
that WDT N
was VBD N
conducted VBN N
at IN N
a DT N
regional JJ N
diagnostic JJ N
center NN N
of IN N
a DT N
large JJ N
metropolitan JJ N
children NNS N
's POS N
hospital NN N
to TO N
( ( N
a DT N
) ) N
refine NN N
a DT N
nursing NN i
intervention NN i
designed VBN N
for IN N
parents NNS p
of IN p
children NNS p
with IN p
ASD NNP p
and CC N
( ( N
b NN N
) ) N
to TO N
identify VB N
methodological JJ N
revisions NNS N
for IN N
a DT N
larger JJR N
study NN N
. . N

A DT N
secondary JJ N
purpose NN N
was VBD N
to TO N
test VB N
the DT N
effects NNS N
of IN N
a DT N
post-diagnosis JJ i
nursing NN i
intervention NN i
on IN N
parents NNS o
' POS o
reports NNS o
of IN o
stress NN o
, , o
impact NN o
of IN o
event NN o
( ( o
diagnosis NN o
) ) o
, , N
and CC N
use NN o
of IN o
services NNS o
after IN N
a DT N
child NN N
is VBZ N
newly RB N
diagnosed VBN N
with IN N
ASD NNP N
. . N

The DT N
intervention NN N
consisted VBD N
of IN N
usual JJ i
care NN i
plus CC N
3 CD N
hours NNS N
contact NN i
with IN i
a DT i
pediatric JJ i
nurse NN i
practitioner NN i
( ( i
PNP NNP i
) ) i
for IN i
counseling NN i
, , i
instruction NN i
, , i
and CC i
assistance NN i
with IN i
implementation NN i
of IN i
the DT i
recommended VBN i
treatment NN i
plan NN i
. . N

The DT N
control NN N
group NN N
received VBD N
only RB N
the DT N
usual JJ i
care NN i
post-diagnosis NN N
, , N
which WDT N
consisted VBD N
of IN N
a DT N
1-hour JJ N
consultation NN i
session NN i
to TO i
receive VB i
the DT i
results NNS i
of IN i
diagnostic JJ i
tests NNS i
and CC i
a DT i
written VBN i
copy NN i
of IN i
the DT i
recommended VBN i
treatment NN i
plan NN i
provided VBN N
by IN N
a DT N
developmental JJ N
pediatrician JJ N
and/or NN N
PNP NNP N
. . N

Between NNP N
group NN N
differences NNS N
in IN N
measures NNS N
of IN N
impact NN o
of IN o
event NN o
and CC N
perceived VBD o
stress NN o
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

This DT N
was VBD N
attributed VBN N
to TO N
a DT N
small JJ N
sample NN N
size NN N
. . N

A NNP N
larger JJR N
study NN N
is VBZ N
feasible JJ N
and CC N
recommended VBD N
with IN N
an DT N
expanded JJ N
nursing NN N
intervention NN N
and CC N
a DT N
significantly RB N
larger JJR N
sample NN N
recruited VBD N
from IN N
an DT N
additional JJ N
recruitment NN N
site NN N
. . N

Nurses NNS N
working VBG N
with IN N
this DT N
special JJ N
population NN N
must MD N
recognize VB N
that IN N
parents NNS N
have VBP N
information NN N
and CC N
counseling NN N
needs NNS N
that WDT N
begin VBP N
after IN N
they PRP N
receive VBP N
the DT N
diagnosis NN N
of IN N
ASD NNP N
for IN N
their PRP$ N
child NN N
and CC N
can MD N
address VB N
these DT N
needs NNS N
with IN N
a DT N
standardized JJ N
nursing NN N
intervention NN N
. . N

-DOCSTART- -17616069- O O

[ RB N
Intravenous JJ N
treatment NN N
of IN N
postpartum NN p
anemia NN N
with IN N
trivalent JJ i
ferrum NN i
preparation NN i
] NNP N
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
assess VB N
the DT N
effectivity NN o
and CC N
safeness NN o
of IN N
intravenous JJ N
treatment NN N
of IN N
pospartal JJ N
anemia NN N
with IN N
trivalent JJ i
ferrum NN i
preparation NN i
. . N

TYPE NNP N
OF IN N
THE NNP N
STUDY NNP N
Prospective NNP N
randomized VBD N
study NN N
. . N

SETTING NNP N
Department NNP N
of IN N
Obstetric NNP N
and CC N
Gynecology NNP N
2nd CD N
Medical NNP N
Faculty NNP N
Charles NNP N
University NNP N
and CC N
Teaching NNP N
Hospital NNP N
Motol NNP N
, , N
Prague NNP p
, , N
and CC N
Department NNP N
of IN N
Obstetric NNP N
and CC N
Gynecology NNP N
1st CD N
Medical NNP N
Faculty NNP N
and CC N
Teaching NNP N
Hospital NNP N
Bulovka NNP N
, , N
Prague NNP p
. . N

METHODS NNP N
500 CD N
mg NN N
of IN N
sacharose JJ i
ferric JJ i
oxide NN i
( ( i
Venofer NNP i
) ) i
was VBD N
intravenously RB N
administered VBN N
in IN N
two CD N
days NNS N
regimen NNS N
to TO N
50 CD p
women NNS p
with IN p
clinical JJ p
and CC p
lab JJ p
signs NNS p
of IN p
postpartal JJ p
anemia NN p
. . p

The DT N
effect NN N
of IN N
administered JJ N
drug NN N
was VBD N
determined VBN N
by IN N
comparsion NN N
of IN N
values NNS o
of IN o
red JJ o
blood NN o
count NN o
recovered VBD N
before IN N
the DT N
treatment NN N
, , N
2nd CD N
or CC N
3rd CD N
day NN N
post NN N
administration NN N
and CC N
two CD N
weeks NNS N
later RB N
. . N

The DT N
serum NN o
values NNS o
of IN o
soluble JJ o
transferrin NN o
receptors NNS o
and CC o
ferritin NNS o
were VBD N
observed VBN N
as IN N
markers NNS N
of IN N
iron NN o
cell NN o
saturation NN o
and CC N
body NN o
iron NN o
reserves NNS o
, , N
too RB N
. . N

Integral JJ N
part NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
monitoring NN N
of IN N
adverse JJ o
events NNS o
during IN N
the DT N
treatment NN N
. . N

RESULTS NNP N
Venofer NNP i
came VBD N
in IN N
sight NN N
as IN N
effective JJ o
drug NN N
in IN N
the DT N
treatment NN N
of IN N
pospartal JJ N
anemia NN N
and CC N
could MD N
become VB N
as IN N
the DT N
alternative NN N
to TO N
blood VB N
transfusion NN N
in IN N
mid-severe JJ N
cases NNS N
. . N

It PRP N
should MD N
be VB N
emphasized VBN N
that IN N
we PRP N
have VBP N
not RB N
encountered VBN N
any DT N
serious JJ o
adverse JJ o
event NN o
with IN N
intravenous JJ N
trivalent NN i
saccharose VBD i
ferric JJ i
oxide JJ i
treatment NN N
. . N

-DOCSTART- -12586799- O O

Phase NNP N
III NNP N
study NN N
of IN N
concurrent JJ i
chemoradiotherapy NN i
versus NN N
radiotherapy NN i
alone RB N
for IN N
advanced JJ p
nasopharyngeal JJ p
carcinoma NN p
: : N
positive JJ N
effect NN N
on IN N
overall JJ o
and CC o
progression-free JJ o
survival NN o
. . N

PURPOSE NNP N
Nasopharyngeal NNP p
carcinoma NN p
( ( p
NPC NNP p
) ) p
is VBZ N
a DT N
radiosensitive JJ N
and CC N
chemosensitive JJ N
tumor NN N
. . N

This DT N
randomized JJ N
phase NN N
III NNP N
trial NN N
compared VBN N
concurrent JJ i
chemoradiotherapy NN i
( ( i
CCRT NNP i
) ) i
versus NN N
radiotherapy NN i
( ( i
RT NNP i
) ) i
alone RB N
in IN N
patients NNS p
with IN p
advanced JJ p
NPC NNP p
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP p
December NNP p
1993 CD p
to TO p
April NNP p
1999 CD p
, , p
284 CD p
patients NNS p
with IN p
1992 CD p
American NNP p
Joint NNP p
Committee NNP p
on IN p
Cancer NNP p
stage NN p
III NNP p
to TO p
IV NNP p
( ( p
M0 NNP p
) ) p
NPC NNP p
were VBD N
randomly RB N
allocated VBN N
into IN N
two CD N
arms NNS N
. . N

Similar JJ N
dosage NN N
and CC N
fractionation NN N
of IN N
RT NNP N
was VBD N
administered VBN N
in IN N
both DT N
arms NNS N
. . N

The DT N
investigational JJ N
arm NN N
received VBD N
two CD N
cycles NNS N
of IN N
concurrent JJ N
chemotherapy NN i
with IN N
cisplatin NN i
20 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
plus CC N
fluorouracil JJ i
400 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
by IN N
96-hour CD N
continuous JJ N
infusion NN N
during IN N
the DT N
weeks NNS N
1 CD N
and CC N
5 CD N
of IN N
RT NNP N
. . N

Survival NNP o
analysis NN o
was VBD N
estimated VBN N
by IN N
the DT N
Kaplan-Meier NNP N
method NN N
and CC N
compared VBN N
by IN N
the DT N
log-rank JJ N
test NN N
. . N

RESULTS NNP N
Baseline NNP N
patient JJ N
characteristics NNS N
were VBD N
comparable JJ N
in IN N
both DT N
arms NNS N
. . N

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
65 CD N
months NNS N
, , N
26.2 CD N
% NN N
( ( N
37 CD N
of IN N
141 CD N
) ) N
and CC N
46.2 CD N
% NN N
( ( N
66 CD N
of IN N
143 CD N
) ) N
of IN N
patients NNS N
developed JJ N
tumor NN o
relapse NN o
in IN N
the DT N
CCRT NNP i
and CC N
RT-alone NNP i
groups NNS N
, , N
respectively RB N
. . N

The DT N
5-year JJ o
overall JJ o
survival NN o
rates NNS o
were VBD N
72.3 CD N
% NN N
for IN N
the DT N
CCRT NNP i
arm NN N
and CC N
54.2 CD N
% NN N
for IN N
the DT N
RT-only JJ i
arm NN N
( ( N
P NNP N
=.0022 NNP N
) ) N
. . N

The DT N
5-year JJ o
progression-free JJ o
survival NN o
rates NNS o
were VBD N
71.6 CD N
% NN N
for IN N
the DT N
CCRT NNP i
group NN N
compared VBN N
with IN N
53.0 CD N
% NN N
for IN N
the DT N
RT-only JJ i
group NN N
( ( N
P NNP N
=.0012 NNP N
) ) N
. . N

Although IN N
significantly RB N
more JJR N
toxicity NN o
was VBD N
noted VBN N
in IN N
the DT N
CCRT NNP i
arm NN N
, , N
including VBG N
leukopenia NN o
and CC N
emesis NN o
, , N
compliance NN N
with IN N
the DT N
combined JJ N
treatment NN N
was VBD N
good JJ N
. . N

The DT N
second JJ N
cycle NN N
of IN N
concurrent JJ N
chemotherapy NN N
was VBD N
refused VBN N
by IN N
nine CD N
patients NNS N
and CC N
was VBD N
delayed VBN N
for IN N
> NN N
or CC N
= $ N
1 CD N
week NN N
for IN N
another DT N
nine CD N
patients NNS N
. . N

There EX N
were VBD N
no DT N
treatment-related JJ o
deaths NNS o
in IN N
either DT N
arm NN N
. . N

CONCLUSION NN N
We PRP N
conclude VBP N
that DT N
CCRT NNP i
is VBZ N
superior JJ N
to TO N
RT VB i
alone RB N
for IN N
patients NNS p
with IN p
advanced JJ p
NPC NNP p
in IN N
endemic JJ N
areas NNS N
. . N

-DOCSTART- -11454878- O O

Recurrent JJ N
epithelial JJ N
ovarian JJ N
carcinoma NN N
: : N
a DT N
randomized JJ N
phase NN N
III NNP N
study NN N
of IN N
pegylated VBN i
liposomal JJ i
doxorubicin NN i
versus NN N
topotecan JJ i
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
pegylated JJ i
liposomal JJ i
doxorubicin NN i
( ( i
PLD NNP i
) ) i
and CC N
topotecan JJ i
in IN N
patients NNS p
with IN p
epithelial JJ p
ovarian JJ p
carcinoma NN p
that WDT p
recurred VBD p
after IN p
or CC p
did VBD p
n't RB p
respond VB p
to TO p
first-line JJ p
, , p
platinum-based JJ p
chemotherapy NN p
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
with IN p
measurable JJ p
and CC p
assessable JJ p
disease NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
PLD NNP i
50 CD N
mg/m NN N
( ( N
2 CD N
) ) N
as IN N
a DT N
1-hour JJ N
infusion NN N
every DT N
4 CD N
weeks NNS N
or CC N
topotecan JJ i
1.5 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
for IN N
5 CD N
consecutive JJ N
days NNS N
every DT N
3 CD N
weeks NNS N
. . N

Patients NNS N
were VBD N
stratified VBN N
prospectively RB N
for IN N
platinum NN N
sensitivity NN N
and CC N
for IN N
the DT N
presence NN N
or CC N
absence NN N
of IN N
bulky JJ N
disease NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
474 CD p
patients NNS p
were VBD N
treated VBN N
( ( N
239 CD N
PLD NNP i
and CC N
235 CD N
topotecan JJ i
) ) N
. . N

They PRP N
comprised VBD N
the DT N
intent-to-treat JJ N
population NN N
. . N

The DT N
overall JJ o
progression-free JJ o
survival NN o
rates NNS o
were VBD N
similar JJ N
between IN N
the DT N
two CD N
arms NNS N
( ( N
P NNP N
=.095 NNP N
) ) N
. . N

The DT N
overall JJ o
response NN o
rates NNS o
for IN N
PLD NNP i
and CC N
topotecan JJ i
were VBD N
19.7 CD N
% NN N
and CC N
17.0 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
=.390 NNP N
) ) N
. . N

Median JJ o
overall JJ o
survival NN o
times NNS o
were VBD N
60 CD N
weeks NNS N
for IN N
PLD NNP i
and CC N
56.7 CD N
weeks NNS N
for IN N
topotecan JJ i
. . N

Data NNP N
analyzed VBD N
in IN N
platinum-sensitive JJ N
patients NNS N
demonstrated VBD N
a DT N
statistically RB N
significant JJ N
benefit NN N
from IN N
PLD NNP i
for IN N
progression-free JJ N
survival NN N
( ( N
P NNP N
=.037 NNP N
) ) N
, , N
with IN N
medians NNS N
of IN N
28.9 CD N
for IN N
PLD NNP i
versus FW N
23.3 CD N
weeks NNS N
for IN N
topotecan JJ i
. . N

For IN N
overall JJ o
survival NN o
, , N
PLD NNP i
was VBD N
significantly RB N
superior JJ N
to TO N
topotecan VB i
( ( N
P NNP N
=.008 NNP N
) ) N
, , N
with IN N
a DT N
median NN N
of IN N
108 CD N
weeks NNS N
versus RB N
71.1 CD N
weeks NNS N
. . N

The DT N
platinum-refractory JJ N
subgroup NN N
demonstrated VBD N
a DT N
nonstatistically RB N
significant JJ N
survival JJ N
trend NN N
in IN N
favor NN N
of IN N
topotecan JJ i
( ( N
P NNP N
=.455 NNP N
) ) N
. . N

Severe JJ o
hematologic JJ o
toxicity NN o
was VBD N
more RBR N
common JJ N
with IN N
topotecan JJ i
and CC N
was VBD N
more RBR N
likely JJ N
to TO N
be VB N
associated VBN N
with IN N
dosage NN N
modification NN N
, , N
or CC N
growth NN N
factor NN N
or CC N
blood NN N
product NN N
utilization NN N
. . N

CONCLUSION VB N
The DT N
comparable JJ N
efficacy NN o
, , N
favorable JJ N
safety NN o
profile NN N
, , N
and CC N
convenient NN N
dosing VBG N
support NN N
the DT N
role NN N
of IN N
PLD NNP i
as IN N
a DT N
valuable JJ N
treatment NN N
option NN N
in IN N
this DT N
patient JJ N
population NN N
. . N

-DOCSTART- -6418441- O O

The DT N
treatment NN N
of IN N
asthma NN p
in IN p
adults NNS p
using VBG N
sodium NN i
cromoglycate NN i
pressurized VBN N
aerosol NN N
: : N
a DT N
double-blind NN N
controlled VBN N
trial NN N
. . N

Sodium NN i
cromoglycate NN i
formulated VBN N
as IN N
a DT N
pressurized JJ N
aerosol NN N
( ( N
2 CD N
mg RB N
4-times JJ N
daily JJ N
) ) N
and CC N
placebo NN i
were VBD N
compared VBN N
in IN N
31 CD p
adult NN p
asthmatic JJ p
patients NNS p
in IN N
a DT N
double-blind JJ N
crossover NN N
trial NN N
lasting VBG N
12 CD N
weeks NNS N
. . N

Sodium NNP i
cromoglycate NN i
was VBD N
superior JJ N
to TO N
placebo VB i
in IN N
improving VBG N
breathlessness NN o
at IN o
rest NN o
( ( N
p IN N
less JJR N
than IN N
0.001 CD N
) ) N
, , N
breathlessness NN o
on IN o
exertion NN o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
the DT N
quality NN o
of IN o
sleep NN o
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
, , N
and CC N
also RB N
in IN N
improving VBG N
the DT N
morning NN o
peak NN o
expiratory NN o
flow NN o
rate NN o
value NN o
( ( N
p IN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Both CC N
the DT N
patients NNS N
' POS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
the DT N
clinicians NNS N
' POS N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
treatment NN N
opinions NNS N
, , N
and CC N
their PRP$ N
treatment NN o
preferences NNS o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
favoured VBD N
sodium NN i
cromoglycate NN i
. . N

Moreover RB N
, , N
usage NN N
of IN N
bronchodilators NNS N
( ( N
theophylline NN N
and CC N
aerosol JJ N
beta-stimulants NNS N
combined VBN N
) ) N
declined VBD N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
during IN N
sodium NN i
cromoglycate NN i
treatment NN N
compared VBN N
to TO N
placebo VB i
. . N

No DT N
side-effects NNS o
were VBD N
reported VBN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
sodium NN i
cromoglycate NN i
delivered VBN N
by IN N
pressurized JJ N
aerosol NN N
was VBD N
significantly RB N
superior JJ N
to TO N
placebo VB i
, , N
not RB N
only RB N
in IN N
improving VBG N
asthmatic JJ o
symptoms NNS o
, , N
but CC N
also RB N
in IN N
reducing VBG N
the DT N
amount NN N
of IN N
concomitant JJ N
bronchodilator NN o
therapy NN o
required VBN o
. . N

-DOCSTART- -19802506- O O

The DT N
effect NN N
of IN N
weight NN i
training NN i
on IN N
bone JJ o
mineral JJ o
density NN o
and CC N
bone NN o
turnover NN o
in IN N
postmenopausal JJ p
breast NN p
cancer NN p
survivors NNS p
with IN p
bone JJ p
loss NN p
: : N
a DT N
24-month JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

SUMMARY VB N
This DT N
study NN N
examined VBD N
whether IN N
24 CD N
months NNS N
of IN N
weight JJ i
training NN i
exercises NNS i
enhanced VBD N
the DT N
effectiveness NN N
of IN N
risedronate NN N
, , N
calcium NN N
, , N
and CC N
vitamin NN N
D NNP N
in IN N
maintaining VBG N
or CC N
improving VBG N
bone JJ o
mineral JJ o
density NN o
( ( o
BMD NNP o
) ) o
in IN N
223 CD p
postmenopausal NN p
breast NN p
cancer NN p
survivors NNS p
. . N

Subjects NNS N
who WP N
were VBD N
> NNP N
or CC N
=50 CD N
% NN N
adherent NN N
to TO N
exercise VB N
had VBN N
no DT N
improvement NN N
in IN N
BMD NNP o
but CC N
were VBD N
less RBR N
likely JJ N
to TO N
lose VB N
BMD NNP o
. . N

INTRODUCTION NNP N
This DT N
study NN N
examined VBD N
whether IN N
( ( N
1 CD N
) ) N
postmenopausal NN p
breast NN p
cancer NN p
survivors NNS p
( ( p
BCS NNP p
) ) p
with IN p
bone NN p
loss NN p
taking VBG N
24 CD N
months NNS N
of IN N
risedronate NN i
, , N
calcium NN i
, , N
and CC N
vitamin NN i
D NNP i
had VBD N
increased VBN N
bone RB o
mineral JJ o
density NN o
( ( o
BMD NNP o
) ) o
at IN N
the DT N
total JJ N
hip NN N
, , N
femoral JJ N
neck NN N
, , N
L1-L4 NNP N
spine NN N
, , N
total JJ N
radius NN N
and CC N
33 CD N
% NN N
radius NN N
, , N
and CC N
decreased VBD N
bone NN o
turnover NN o
; : N
( ( N
2 CD N
) ) N
subjects NNS N
who WP N
also RB N
participated VBD N
in IN N
strength/weight JJ i
training NN i
( ( i
ST NNP i
) ) i
exercises NNS i
had VBD N
greater JJR N
increases NNS N
in IN N
BMD NNP o
and CC N
greater JJR N
decreases NNS N
in IN N
bone NN o
turnover NN o
; : N
and CC N
( ( N
3 CD N
) ) N
subjects NNS N
who WP N
also RB N
exercised VBD N
were VBD N
more RBR N
likely JJ N
to TO N
preserve VB N
( ( N
at IN N
least JJS N
maintain NN N
) ) N
BMD NNP o
. . N

METHODS NNP N
Postmenopausal NNP p
BCS NNP p
( ( p
223 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
exercise VB i
plus JJ i
medication NN i
or CC N
medication NN i
only RB N
groups NNS N
. . N

Both DT N
groups NNS N
received VBD N
24 CD N
months NNS N
of IN N
1,200 CD N
mg NN N
of IN N
calcium NN i
and CC N
400 CD N
IU NNP N
of IN N
vitamin NNP i
D NNP i
daily RB N
and CC N
35 CD N
mg NN N
of IN N
risedronate JJ i
weekly JJ N
, , N
and CC N
the DT N
exercise NN i
group NN N
additionally RB N
had VBD N
ST NNP i
exercises NNS i
twice RB N
weekly RB N
. . N

RESULTS NNP N
After IN N
24 CD N
months NNS N
, , N
women NNS N
who WP N
took VBD N
medications NNS i
without IN N
exercising VBG i
had VBD N
significant JJ N
improvements NNS N
in IN N
BMD NNP o
at IN N
the DT N
total JJ N
hip NN N
( ( N
+1.81 CD N
% NN N
) ) N
and CC N
spine NN N
( ( N
+2.85 CD N
% NN N
) ) N
and CC N
significant JJ N
decreases NNS N
in IN N
Alkphase NNP o
B NNP o
( ( N
-8.7 NNP N
% NN N
) ) N
and CC N
serum JJ o
NTx NNP o
( ( N
-16.7 NNP N
% NN N
) ) N
. . N

Women NNS N
who WP N
also RB N
exercised VBD i
had VBD N
additional JJ N
increases NNS N
in IN N
BMD NNP o
at IN N
the DT N
femoral JJ N
neck NN N
( ( N
+0.29 CD N
% NN N
) ) N
, , N
total JJ N
hip NN N
( ( N
+0.34 CD N
% NN N
) ) N
, , N
spine NN N
( ( N
+0.23 CD N
% NN N
) ) N
, , N
total JJ N
radius NN N
( ( N
+0.30 CD N
% NN N
) ) N
, , N
and CC N
additional JJ N
decreases NNS N
in IN N
Alkphase NNP o
B NNP o
( ( N
-2.4 NNP N
% NN N
) ) N
and CC N
Serum NNP o
NTx NNP o
( ( N
-6.5 NNP N
% NN N
) ) N
. . N

Additional JJ N
changes NNS N
in IN N
BMD NNP o
and CC o
bone NN o
turnover NN o
with IN N
exercise NN N
were VBD N
not RB N
significant JJ N
. . N

Subjects NNS N
who WP N
were VBD N
> NNP N
or CC N
=50 CD N
% NN N
adherent NN N
to TO N
exercise VB i
were VBD N
less RBR N
likely JJ N
to TO N
lose VB N
BMD NNP o
at IN N
the DT N
total JJ N
hip NN N
( ( N
chi-square JJ N
[ NN N
1 CD N
] NNP N
= NNP N
4.66 CD N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
and CC N
femoral JJ N
neck NN N
( ( N
chi-square JJ N
[ NN N
1 CD N
] NNP N
= NNP N
4.63 CD N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
. . N

CONCLUSION NNP N
Strength/weight NNP i
training NN i
exercises NNS i
may MD N
prevent VB N
loss NN N
of IN N
BMD NNP o
in IN N
postmenopausal NN N
BCS NNP N
at IN N
risk NN N
for IN N
bone NN N
loss NN N
. . N

-DOCSTART- -6938020- O O

EORTC NNP N
protocols NNS N
in IN N
prostatic JJ p
cancer NN p
. . N

An DT N
interim JJ N
report NN N
. . N

Two CD N
parallel JJ N
prospective JJ N
randomized VBN N
studies NNS N
have VBP N
been VBN N
undertaken VBN N
by IN N
the DT N
EORTC NNP N
Urological NNP N
Group NNP N
in IN N
previously RB p
untreated JJ p
patients NNS p
with IN p
prostatic JJ p
cancer NN p
in IN N
order NN N
to TO N
compare VB N
low JJ N
dose JJ N
Stilboestrol NNP i
versus NN N
Cyproterone NNP i
acetate NN i
versus NN N
Medroxyprogesterone NNP i
acetate NN i
in IN N
the DT N
first JJ N
trial NN N
, , N
and CC N
Stilboestrol NNP i
versus VBP N
Estracyt NNP i
in IN N
the DT N
second JJ N
trial NN N
. . N

Although IN N
the DT N
follow JJ N
up NN N
is VBZ N
still RB N
short JJ N
, , N
no DT N
superiority NN N
of IN N
the DT N
other JJ N
drugs NNS N
over IN N
Stilboestrol NNP i
had VBD N
appeared VBN N
so RB N
far RB N
with IN N
regard NN N
to TO N
either DT N
objective JJ N
response NN N
or CC N
significant JJ N
side NN o
effects NNS o
apart RB N
from IN N
gynaecomastia NN o
. . N

In IN N
the DT N
third JJ N
trial NN N
, , N
patients NNS p
with IN p
advanced JJ p
disease NN p
no RB p
longer RBR p
responsive VB p
to TO p
hormonal JJ p
treatment NN p
were VBD N
randomized VBN N
to TO N
either DT N
Adriamycin NNP i
or CC N
Procarbazine NNP i
. . N

Toxicity NN o
and CC o
early JJ o
death NN o
were VBD N
particularly RB N
frequent JJ N
in IN N
Procarbazine NNP i
treated VBD N
patients NNS N
, , N
whereas NNS N
most JJS N
patients NNS N
progressed VBN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

-DOCSTART- -10752495- O O

Prediction NN N
of IN N
creatinine JJ o
clearance NN o
from IN o
serum JJ o
creatinine NN o
in IN N
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
: : N
comparison NN N
of IN N
six CD N
formulae NNS N
and CC N
one CD N
nomogram NN N
. . N

The DT N
estimation NN N
of IN N
glomerular JJ o
filtration NN o
rate NN o
is VBZ N
important JJ N
for IN N
the DT N
medical JJ N
treatment NN N
of IN N
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
( ( p
RA NNP p
) ) p
. . N

However RB N
, , N
the DT N
determination NN N
of IN N
endogenous JJ N
creatinine JJ N
clearance NN N
( ( N
Clcr NNP N
) ) N
from IN N
a DT N
24-h JJ N
urine JJ N
collection NN N
is VBZ N
an DT N
unreliable JJ N
and CC N
time-consuming JJ N
procedure NN N
. . N

We PRP N
therefore RB N
tested VBD N
the DT N
accuracy NN N
of IN N
six CD N
equations NNS N
and CC N
one CD N
nomogram NN N
for IN N
the DT N
prediction NN o
of IN o
Clcr NNP o
from IN o
serum JJ o
creatinine NN o
( ( o
Scr NNP o
) ) o
in IN N
38 CD p
patients NNS p
with IN p
RA NNP p
and CC p
20 CD p
controls NNS p
. . N

A DT N
positive JJ N
correlation NN o
was VBD N
found VBN N
for IN N
all DT N
methods NNS N
in IN N
the DT N
controls NNS N
( ( N
r VB N
= NNP N
0.83-0.94 NN N
) ) N
and CC N
RA NNP N
patients NNS N
( ( N
r JJ N
= NNP N
0.51-0.69 NN N
) ) N
. . N

The DT N
methods NNS N
did VBD N
not RB N
overestimate VB N
Clcr NNP N
in IN N
RA NNP N
. . N

In IN N
the DT N
RA NNP N
group NN N
the DT N
simple JJ N
formula NN N
published VBN N
by IN N
Cockcroft NNP N
[ NNP N
Clcr NNP N
= NNP N
( ( N
( ( N
140 CD N
- : N
age NN N
) ) N
x VBZ N
body NN N
weight NN N
) ) N
/ NN N
( ( N
72 CD N
x NNP N
Scr NNP N
) ) N
, , N
x $ N
0.85 CD N
for IN N
females NNS N
] VBP N
showed VBD N
the DT N
best JJS N
correlation NN N
with IN N
the DT N
measured VBN N
Clcr NNP N
. . N

In IN N
RA NNP N
the DT N
Cockroft NNP N
formula NN N
can MD N
reliably RB N
be VB N
used VBN N
to TO N
predict VB o
Clcr NNP o
from IN o
Scr NNP o
. . N

-DOCSTART- -21029638- O O

[ JJ N
Efficacy NNP N
of IN N
paliperidone NN i
extended-release JJ N
tablets NNS N
in IN N
the DT N
improvement NN N
of IN N
social JJ o
functions NNS o
in IN N
schizophrenics NNS p
: : N
a DT N
randomized NN N
and CC N
controlled VBD N
study NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
explore VB N
the DT N
efficacy NN N
of IN N
paliperidone NN i
extended-release JJ N
tablets NNS N
in IN N
the DT N
improvement NN N
of IN N
social JJ o
functions NNS o
in IN N
schizophrenics NNS p
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
81 CD p
schizophrenics NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
study NN N
group NN N
with IN N
paliperidone NN i
extended-release JJ N
tablets NNS N
and CC N
control NN N
group NN N
with IN N
risperidone NN i
for IN N
a DT N
12-week JJ N
treatment NN N
. . N

They PRP N
were VBD N
assessed VBN N
and CC N
analyzed VBN N
by IN N
positive JJ o
and CC o
negative JJ o
symptoms NNS o
scales NNS o
( ( o
PANSS NNP o
) ) o
, , o
social JJ o
disability NN o
screening VBG o
schedule NN o
( ( o
SDSS NNP o
) ) o
and CC N
treatment NN o
emergent NN o
symptom NN o
scale NN o
( ( o
TESS NNP o
) ) o
at IN N
baseline NN N
, , N
6 CD N
( ( N
th NN N
) ) N
weekend NN N
and CC N
12 CD N
( ( N
th NN N
) ) N
weekend NN N
. . N

RESULTS NNP N
In IN N
study NN N
group NN N
, , N
the DT N
factors NNS o
and CC o
total JJ o
scores NNS o
of IN o
PANSS NNP o
in IN N
the DT N
12 CD N
( ( N
th NN N
) ) N
weekend NN N
of IN N
treatment NN N
[ NNP N
( ( N
12.0 CD N
? . N
2.8 CD N
) ) N
, , N
( ( N
12.1 CD N
? . N
3.6 CD N
) ) N
, , N
( ( N
26.2 CD N
? . N
5.0 CD N
) ) N
, , N
( ( N
50.2 CD N
? . N
8.7 CD N
) ) N
] NN N
were VBD N
all DT N
significantly RB N
lower JJR N
than IN N
those DT N
at IN N
baseline JJ N
[ NNP N
( ( N
24.7 CD N
? . N
5.3 CD N
) ) N
, , N
( ( N
23.8 CD N
? . N
3.6 CD N
) ) N
, , N
( ( N
45.0 CD N
? . N
2.9 CD N
) ) N
, , N
( ( N
93.5 CD N
? . N
6.8 CD N
) ) N
] NN N
( ( N
t JJ N
= NNP N
9.60-16.78 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
study NN N
group NN N
, , N
the DT N
positive JJ o
factor NN o
, , o
negative JJ o
factor NN o
and CC o
total JJ o
scores NNS o
of IN o
PANSS NNP o
in IN N
the DT N
12 CD N
( ( N
th NN N
) ) N
weekend NN N
of IN N
treatment NN N
[ NNP N
( ( N
12.0 CD N
? . N
2.8 CD N
) ) N
, , N
( ( N
12.1 CD N
? . N
3.6 CD N
) ) N
, , N
( ( N
50.2 CD N
? . N
8.7 CD N
) ) N
] NN N
were VBD N
all DT N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
6 CD N
( ( N
th NN N
) ) N
weekend NN N
of IN N
treatment NN N
[ NNP N
( ( N
14.2 CD N
? . N
1.8 CD N
) ) N
, , N
( ( N
14.6 CD N
? . N
2.4 CD N
) ) N
, , N
( ( N
56.5 CD N
? . N
6.4 CD N
) ) N
] NN N
( ( N
t JJ N
= NNP N
2.58-4.26 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
12 CD N
( ( N
th NN N
) ) N
weekend NN N
of IN N
treatment NN N
, , N
the DT N
factors NNS o
and CC o
total JJ o
scores NNS o
of IN o
PANSS NNP o
in IN N
study NN N
group NN N
[ NNP N
( ( N
12.0 CD N
? . N
2.8 CD N
) ) N
, , N
( ( N
12.1 CD N
? . N
3.6 CD N
) ) N
, , N
( ( N
26.2 CD N
? . N
5.0 CD N
) ) N
, , N
( ( N
50.2 CD N
? . N
8.7 CD N
) ) N
] NN N
were VBD N
all DT N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
control NN N
group NN N
[ NNP N
( ( N
16.9 CD N
? . N
4.9 CD N
) ) N
, , N
( ( N
18.7 CD N
? . N
5.3 CD N
) ) N
, , N
( ( N
32.5 CD N
? . N
5.1 CD N
) ) N
, , N
( ( N
68.1 CD N
? . N
13.0 CD N
) ) N
] NN N
( ( N
t JJ N
= NNP N
-4.28 NNP N
-- : N
5.67 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
study NN N
group NN N
, , N
the DT N
total JJ N
scores NNS o
of IN o
SDSS NNP o
in IN N
the DT N
12 CD N
( ( N
th NN N
) ) N
weekend NN N
of IN N
treatment NN N
( ( N
5.93 CD N
? . N
2.78 CD N
) ) N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
at IN N
baseline NN N
( ( N
13.9 CD N
? . N
3.4 CD N
) ) N
( ( N
t JJ N
= NN N
10.83 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
study NN N
group NN N
, , N
the DT N
total JJ N
scores NNS o
of IN o
SDSS NNP o
in IN N
the DT N
12 CD N
( ( N
th NN N
) ) N
weekend NN N
of IN N
treatment NN N
( ( N
5.9 CD N
? . N
2.8 CD N
) ) N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
6 CD N
( ( N
th NN N
) ) N
weekend NN N
of IN N
treatment NN N
( ( N
7.6 CD N
? . N
2.9 CD N
) ) N
( ( N
t JJ N
= NN N
5.21 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

But CC N
there EX N
was VBD N
no DT N
significant JJ N
improvement NN N
in IN N
control NN N
group NN N
( ( N
t JJ N
= NN N
1.88 CD N
, , N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
12 CD N
( ( N
th NN N
) ) N
weekend NN N
of IN N
treatment NN N
, , N
the DT N
total JJ N
scores NNS o
of IN o
SDSS NNP o
in IN N
study NN N
group NN N
( ( N
5.9 CD N
? . N
2.8 CD N
) ) N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
control NN N
group NN N
( ( N
8.8 CD N
? . N
2.9 CD N
) ) N
( ( N
t JJ N
= NNP N
-4.49 NNP N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

No UH N
severe JJ o
adverse JJ o
effect NN o
was VBD N
reported VBN N
in IN N
either DT N
group NN N
. . N

CONCLUSION NNP N
Paliperidone NNP i
extended-release JJ N
tablets NNS N
are VBP N
effective JJ N
to TO N
improve VB N
social JJ o
functions NNS o
and CC N
psychiatric JJ o
symptoms NNS o
of IN N
schizophrenics NNS p
. . N

-DOCSTART- -24803369- O O

Youth NN p
with IN p
autism NN p
spectrum NN p
disorder NN p
comprehend NN N
lexicalized VBN i
and CC N
novel JJ N
primary JJ i
conceptual JJ i
metaphors NNS i
. . N

Individuals NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
have VBP N
difficulty NN N
comprehending VBG o
metaphors NNS o
. . N

However RB N
, , N
no DT N
study NN N
to TO N
date NN N
has VBZ N
examined VBN N
whether IN N
or CC N
not RB N
they PRP N
understand VBP N
conceptual JJ o
metaphors NNS o
( ( N
i.e NN N
. . N

mappings NNS N
between IN N
conceptual JJ N
structures NNS N
) ) N
, , N
which WDT N
could MD N
be VB N
the DT N
building NN N
blocks NNS N
of IN N
metaphoric JJ N
thinking NN N
and CC N
understanding NN N
. . N

We PRP N
investigated VBD N
whether IN N
13 CD p
participants NNS p
with IN p
ASD NNP p
( ( p
age NN p
7 CD p
; : p
03-22 CD p
; : p
03 CD p
) ) p
and CC p
13 CD p
age-matched JJ p
typically RB p
developing VBG p
( ( p
TD NNP p
) ) p
controls NNS p
could MD N
comprehend VB N
lexicalized JJ o
conceptual JJ o
metaphors NNS o
( ( N
e.g. NN N
, , N
Susan NNP N
is VBZ N
a DT N
warm JJ N
person NN N
) ) N
and CC N
novel JJ o
ones NNS o
( ( N
e.g. NN N
, , N
Susan NNP N
is VBZ N
a DT N
toasty JJ N
person NN N
) ) N
. . N

Individuals NNS p
with IN p
ASD NNP p
performed VBD N
at IN N
greater JJR N
than IN N
chance NN N
levels NNS N
on IN N
both DT N
metaphor NN o
types NNS N
, , N
although IN N
their PRP$ N
performance NN N
was VBD N
lower JJR N
than IN N
TD CD N
participants NNS N
. . N

We PRP N
discuss VBP N
the DT N
theoretical JJ N
relevance NN N
of IN N
these DT N
findings NNS N
and CC N
educational JJ N
implications NNS N
. . N

-DOCSTART- -384815- O O

Ascaris NNP N
and CC N
growth NN N
rates NNS N
: : N
a DT N
randomized JJ N
trial NN N
of IN N
treatment NN N
. . N

Three CD p
hundred VBD p
forty-one NN p
Tanzanian JJ p
preschool NN p
children NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
levamisole VB i
or CC N
placebo VB i
treatment NN N
given VBN N
at IN N
three-month JJ N
intervals NNS N
. . N

Weights NNS o
and CC o
heights NNS o
were VBD N
measured VBN N
at IN N
the DT N
tri-monthly JJ N
treatment NN N
visits NNS N
for IN N
a DT N
period NN N
of IN N
one CD N
year NN N
. . N

Among IN N
the DT N
273 CD N
children NNS N
who WP N
were VBD N
seen VBN N
and CC N
weighed VBN N
at IN N
the DT N
one-year JJ N
follow-up JJ N
visit NN N
, , N
the DT N
rate NN o
of IN o
weight NN o
gain NN o
was VBD N
8 CD N
per IN N
cent NN N
greater JJR N
for IN N
those DT N
receiving VBG N
levamisole JJR i
than IN N
for IN N
placebo-treated JJ i
controls NNS N
( ( N
p JJ N
= NNP N
.06 NNP N
) ) N
. . N

In IN N
78 CD N
children NNS p
known VBN N
to TO N
be VB N
infected VBN N
with IN N
Ascaris NNP N
at IN N
baseline NN N
, , N
the DT N
rate NN o
of IN o
weight NN o
gain NN o
was VBD N
21 CD N
per IN N
cent NN N
greater JJR N
in IN N
children NNS N
treated VBN N
with IN N
levamisole NN i
than IN N
in IN N
those DT N
receiving VBG N
placebo NN i
( ( N
p JJ N
= NNP N
.03 NNP N
) ) N
. . N

The DT N
rate NN o
of IN o
height NN o
gain NN o
was VBD N
no DT N
different JJ N
for IN N
treatment NN N
and CC N
placebo NN i
groups NNS N
. . N

-DOCSTART- -23549581- O O

Effect NN N
of IN N
duloxetine NN i
on IN N
pain NN o
, , o
function NN o
, , o
and CC o
quality NN o
of IN o
life NN o
among IN N
patients NNS p
with IN p
chemotherapy-induced JJ p
painful JJ p
peripheral JJ p
neuropathy NN p
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE NNP N
There EX N
are VBP N
no DT N
known JJ N
effective JJ N
treatments NNS N
for IN N
painful JJ N
chemotherapy-induced JJ N
peripheral JJ N
neuropathy NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
effect NN N
of IN N
duloxetine NN i
, , N
60 CD N
mg JJ N
daily RB N
, , N
on IN N
average JJ o
pain NN o
severity NN o
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
crossover NN N
trial NN N
at IN N
8 CD N
National NNP N
Cancer NNP N
Institute NNP N
( ( N
NCI NNP N
) ) N
-funded VBD N
cooperative JJ N
research NN N
networks NNS N
that WDT N
enrolled VBD N
231 CD p
patients NNS p
who WP p
were VBD p
25 CD p
years NNS p
or CC p
older JJR p
being VBG p
treated VBN p
at IN p
community NN p
and CC p
academic JJ p
settings NNS p
between IN p
April NNP p
2008 CD p
and CC p
March NNP p
2011 CD p
. . N

Study NNP N
follow-up NN N
was VBD N
completed VBN N
July NNP N
2012 CD N
. . N

Stratified VBN N
by IN N
chemotherapeutic JJ N
drug NN N
and CC N
comorbid NN N
pain NN N
risk NN N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
duloxetine NN i
followed VBN N
by IN N
placebo NN i
or CC N
placebo NN i
followed VBN N
by IN N
duloxetine NN i
. . N

Eligibility NN p
required VBD p
that IN p
patients NNS p
have VBP p
grade VBN p
1 CD p
or CC p
higher JJR p
sensory NN p
neuropathy JJ p
according VBG p
to TO p
the DT p
NCI NNP p
Common NNP p
Terminology NNP p
Criteria NNP p
for IN p
Adverse NNP p
Events NNS p
and CC p
at IN p
least JJS p
4 CD p
on IN p
a DT p
scale NN p
of IN p
0 CD p
to TO p
10 CD p
, , p
representing VBG p
average JJ p
chemotherapy-induced JJ p
pain NN p
, , p
after IN p
paclitaxel NN p
, , p
other JJ p
taxane NN p
, , p
or CC p
oxaliplatin JJ p
treatment NN p
. . N

INTERVENTIONS VBZ N
The DT N
initial JJ N
treatment NN N
consisted VBN N
of IN N
taking VBG N
1 CD N
capsule JJ N
daily RB N
of IN N
either CC N
30 CD N
mg NN N
of IN N
duloxetine NN i
or CC N
placebo NN i
for IN N
the DT N
first JJ N
week NN N
and CC N
2 CD N
capsules NNS N
of IN N
either DT N
30 CD N
mg NN N
of IN N
duloxetine NN i
or CC N
placebo JJ i
daily JJ N
for IN N
4 CD N
additional JJ N
weeks NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
hypothesis NN N
was VBD N
that IN N
duloxetine NN i
would MD N
be VB N
more RBR N
effective JJ N
than IN N
placebo NN i
in IN N
decreasing VBG N
chemotherapy-induced JJ o
peripheral JJ o
neuropathic JJ o
pain NN o
. . N

Pain NNP o
severity NN o
was VBD N
assessed VBN N
using VBG N
the DT N
Brief JJ o
Pain NNP o
Inventory-Short NNP o
Form NNP o
average NN o
pain NN o
item NN o
with IN N
0 CD N
representing VBG N
no DT N
pain NN o
and CC N
10 CD N
representing VBG N
as RB N
bad JJ N
as IN N
can MD N
be VB N
imagined VBN N
. . N

RESULTS JJ N
Individuals NNS N
receiving VBG N
duloxetine NN N
as IN N
their PRP$ N
initial JJ N
5-week JJ N
treatment NN N
reported VBD N
a DT N
mean JJ N
decrease NN N
in IN N
average JJ o
pain NN o
of IN N
1.06 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.72-1.40 NNP N
) ) N
vs VBZ N
0.34 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.01-0.66 NNP N
) ) N
among IN N
those DT N
who WP N
received VBD N
placebo NN N
( ( N
P NNP N
= NNP N
.003 NNP N
; : N
effect NN N
size NN N
, , N
0.513 CD N
) ) N
. . N

The DT N
observed JJ N
mean JJ N
difference NN N
in IN N
the DT N
average JJ o
pain NN o
score NN o
between IN N
duloxetine NN i
and CC N
placebo NN i
was VBD N
0.73 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.26-1.20 NN N
) ) N
. . N

Fifty-nine JJ N
percent NN N
of IN N
those DT N
initially RB N
receiving VBG N
duloxetine NN i
vs FW N
38 CD N
% NN N
of IN N
those DT N
initially RB N
receiving VBG N
placebo NN N
reported VBD N
decreased JJ N
pain NN o
of IN N
any DT N
amount NN N
. . N

CONCLUSION NNP N
AND CC N
RELEVANCE NNP N
Among IN N
patients NNS p
with IN p
painful JJ p
chemotherapy-induced JJ p
peripheral JJ p
neuropathy NN p
, , N
the DT N
use NN N
of IN N
duloxetine NN i
compared VBN N
with IN N
placebo NN i
for IN N
5 CD N
weeks NNS N
resulted VBD N
in IN N
a DT N
greater JJR N
reduction NN N
in IN N
pain NN o
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00489411 NN N
. . N

-DOCSTART- -20618920- O O

Effectiveness NN o
of IN N
hygienic-dietary JJ i
recommendations NNS i
as IN N
enhancers NNS N
of IN N
antidepressant JJ N
treatment NN N
in IN N
patients NNS p
with IN p
depression NN p
: : N
study NN N
protocol NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
In IN N
recent JJ N
years NNS N
some DT N
studies NNS N
have VBP N
been VBN N
published VBN N
supporting VBG N
the DT N
efficacy NN N
of IN N
light JJ N
exposure NN N
, , N
physical JJ N
activity NN N
, , N
sleep VB N
control NN N
and CC N
a DT N
Mediterranean NNP N
diet JJ N
pattern NN N
on IN N
the DT N
improvement NN N
or CC N
prevention NN N
of IN N
depression NN N
. . N

However RB N
, , N
to TO N
our PRP$ N
knowledge NN N
, , N
there EX N
have VBP N
been VBN N
no DT N
studies NNS N
using VBG N
all PDT N
these DT N
measures NNS N
together RB N
as IN N
an DT N
adjuvant JJ N
antidepressant NN N
strategy NN N
. . N

METHODS NNP N
Multicenter NNP N
, , N
randomized VBD N
, , N
controlled VBN N
, , N
two CD N
arm-parallel JJ N
, , N
clinical JJ N
trial NN N
. . N

Eighty NNP p
depressed VBD p
patients NNS p
undergoing VBG p
standard JJ p
antidepressant JJ p
treatment NN p
will MD N
be VB N
advised VBN N
to TO N
follow VB N
four CD N
additional JJ N
hygienic-dietary JJ i
recommendations NNS i
about IN N
exercise NN N
, , N
diet JJ N
, , N
sunlight JJ N
exposure NN N
and CC N
sleep NN N
. . N

Outcome NNP N
measures NNS N
will MD N
be VB N
assessed VBN N
before IN N
and CC N
after IN N
the DT N
6 CD N
month NN N
intervention NN N
period NN N
. . N

DISCUSSION NNP N
We PRP N
expect VBP N
the DT N
patients NNS N
in IN N
the DT N
active JJ N
recommendations NNS N
group NN N
to TO N
experience VB N
a DT N
greater JJR N
improvement NN N
in IN N
their PRP$ N
depressive NN o
symptoms NNS o
. . N

If IN N
so RB N
, , N
this DT N
would MD N
be VB N
a DT N
great JJ N
support NN N
for IN N
doctors NNS N
who WP N
might MD N
systematically RB N
recommend VB N
these DT N
simple JJ N
and CC N
costless JJ N
measures NNS N
, , N
especially RB N
in IN N
primary JJ N
care NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN59506583 NNP N
. . N

-DOCSTART- -7844976- O O

The DT N
effect NN N
of IN N
two CD N
types NNS N
of IN N
teacher NN i
training NN i
on IN N
implementation NN N
of IN N
Smart NNP N
Choices NNPS N
: : N
a DT N
tobacco NN N
prevention NN N
curriculum NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
implementation NN N
phase NN N
of IN N
a DT N
four-year JJ N
research NN N
project NN N
to TO N
test VB N
the DT N
effectiveness NN o
of IN N
strategies NNS N
to TO N
increase VB N
diffusion NN o
of IN o
Smart NNP o
Choices NNP o
, , N
a DT N
school-based JJ N
tobacco NN N
prevention NN N
program NN N
. . N

The DT N
impact NN N
on IN N
curriculum JJ N
implementation NN N
of IN N
two CD N
approaches NNS N
to TO N
teacher VB p
training NN N
are VBP N
compared VBN N
. . N

School JJ N
districts NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
live JJ i
workshop NN i
training NN i
or CC N
video NN i
training NN i
condition NN i
. . N

The DT N
outcome NN N
of IN N
the DT N
evaluation NN N
was VBD N
teachers NNS o
' POS o
implementation NN o
of IN o
Smart NNP o
Choices NNP o
. . N

Results NNP N
show VBP N
a DT N
lower JJR N
proportion NN N
of IN N
video-trained JJ i
teachers NNS N
implemented VBD N
the DT N
curriculum NN N
, , N
but CC N
overall JJ N
completeness NN o
and CC o
fidelity NN o
of IN o
implementation NN o
for IN N
those DT N
teachers NNS p
who WP N
did VBD N
teach VB N
the DT N
curriculum NN N
were VBD N
comparable JJ N
for IN N
the DT N
two CD N
groups NNS N
. . N

Video-trained JJ i
teachers NNS p
, , N
however RB N
, , N
were VBD N
less RBR N
likely JJ N
to TO N
use VB N
brainstorming NN N
and CC N
student NN N
presentations/role NN N
plays NNS N
, , N
two CD N
of IN N
the DT N
methods NNS N
prescribed VBN N
by IN N
the DT N
curriculum NN N
. . N

Implications NNS N
of IN N
the DT N
results NNS N
for IN N
teacher JJ p
training NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -22897461- O O

Effect NN N
of IN N
rosuvastatin NN i
monotherapy NN N
or CC N
in IN N
combination NN N
with IN N
fenofibrate NN i
or CC N
?-3 JJ i
fatty JJ i
acids NNS i
on IN N
lipoprotein JJ o
subfraction NN o
profile NN o
in IN N
patients NNS p
with IN p
mixed JJ p
dyslipidaemia NN p
and CC p
metabolic JJ p
syndrome NN p
. . N

BACKGROUND NNP N
Raised VBD N
triglycerides NNS N
( ( N
TG NNP N
) ) N
, , N
decreased VBD N
high-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
HDL-C NNP N
) ) N
levels NNS N
and CC N
a DT N
predominance NN N
of IN N
small JJ N
dense NN N
low JJ N
density NN N
lipoproteins NNS N
( ( N
sdLDL NN N
) ) N
are VBP N
characteristics NNS N
of IN N
the DT N
metabolic JJ p
syndrome NN p
( ( p
MetS NNP p
) ) p
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
high-dose JJ N
rosuvastatin NN i
monotherapy NN N
with IN N
moderate JJ N
dosing NN N
combined VBN N
with IN N
fenofibrate NN i
or CC N
?-3 JJ i
fatty JJ i
acids NNS i
on IN N
the DT N
lipoprotein JJ o
subfraction NN o
profile NN o
in IN N
patients NNS p
with IN p
mixed JJ p
dyslipidaemia NN p
and CC p
MetS NNP p
. . N

METHODS NNP N
We PRP N
previously RB N
randomised VBD N
patients NNS N
with IN N
low-density JJ N
lipoprotein NNS N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
> VBZ N
160 CD N
and CC N
TG NNP N
> NNP N
200 CD N
mg/dl NN N
to TO N
rosuvastatin VB i
monotherapy NN N
40 CD N
mg/day NN N
( ( N
R NNP N
group NN N
, , N
n RB N
= VBZ N
30 CD N
) ) N
or CC N
rosuvastatin $ i
10 CD N
mg/day NN N
combined VBN N
with IN N
fenofibrate JJ i
200 CD N
mg/day NN N
( ( N
RF NNP N
group NN N
, , N
n RB N
= VBZ N
30 CD N
) ) N
or CC N
?-3 JJ i
fatty JJ i
acids NNS i
2 CD N
g/day NN N
( ( N
R? NNP N
group NN N
, , N
n RB N
= VBZ N
30 CD N
) ) N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
only RB N
patients NNS p
with IN p
MetS NNP p
were VBD p
included VBN p
( ( N
24 CD N
, , N
23 CD N
and CC N
24 CD N
in IN N
the DT N
R NNP N
, , N
RF NNP N
and CC N
R? NNP N
groups NNS N
respectively RB N
) ) N
. . N

At IN N
baseline NN N
and CC N
after IN N
12 CD N
weeks NNS N
of IN N
treatment NN N
, , N
the DT N
lipoprotein JJ o
subfraction NN o
profile NN o
was VBD N
determined VBN N
by IN N
polyacrylamide JJ N
3 CD N
% NN N
gel JJ N
electrophoresis NN N
. . N

RESULTS VB N
The DT N
mean JJ o
LDL NNP o
size NN o
was VBD N
significantly RB N
increased VBN N
in IN N
all DT N
groups NNS N
. . N

This DT N
change NN N
was VBD N
more RBR N
prominent JJ N
with IN N
RF NNP i
than IN N
with IN N
other JJ N
treatments NNS N
in IN N
parallel JJ N
with IN N
its PRP$ N
greater JJR N
hypotriglyceridemic JJ o
capacity NN o
( ( N
p JJ N
< $ N
0.05 CD N
compared VBN N
with IN N
R NNP N
and CC N
R? NNP N
) ) N
. . N

A DT N
decrease NN N
in IN N
insulin NN o
resistance NN o
by IN N
RF NNP N
was VBD N
also RB N
noted VBN N
. . N

Only RB N
RF NNP i
significantly RB N
raised VBD N
HDL-C NNP o
levels NNS o
( ( N
by IN N
7.7 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
by IN N
increasing VBG N
the DT N
cholesterol NN N
of IN N
small JJ N
HDL NNP N
particles NNS N
. . N

The DT N
cholesterol NN N
of IN o
larger JJR o
HDL NNP o
subclasses NNS o
was VBD N
significantly RB N
increased VBN N
by IN N
R NNP i
and CC N
R? NNP i
. . N

CONCLUSIONS NNP N
All NNP N
regimens VBZ N
increased VBN N
mean JJ N
LDL NNP o
size NN o
; : N
RF NNP N
was VBD N
the DT N
most RBS N
effective JJ N
. . N

A DT N
differential JJ N
effect NN N
of IN N
treatments NNS N
was VBD N
noted VBN N
on IN N
the DT N
HDL NNP N
subfraction NN N
profile NN N
. . N

-DOCSTART- -1131298- O O

Effect NN N
of IN N
the DT N
essential JJ i
oils NNS i
of IN i
garlic NN i
and CC i
onion NN i
on IN N
alimentary JJ N
hyperlipemia NN N
. . N

SUMMARY VB N
The DT N
effect NN N
of IN N
garlic NN i
and CC i
onion NN i
on IN N
alimentary JJ N
hyperlipemia NN N
, , N
induced VBN N
by IN N
feeding VBG N
100 CD N
g JJ N
butter NN N
, , N
has VBZ N
been VBN N
studied VBN N
in IN N
10 CD p
healthy JJ p
subjects NNS p
. . N

The DT N
freshly RB N
extracted JJ N
juice NN N
of IN N
50 CD N
g NN N
of IN N
garlic NN i
or CC i
onion NN i
, , N
as RB N
well RB N
as IN N
an DT N
equivalent JJ N
amount NN N
of IN N
their PRP$ N
ether-extracted JJ N
essential JJ i
oils NNS i
, , N
was VBD N
administered VBN N
randomly RB N
on IN N
four CD N
different JJ N
days NNS N
during IN N
a DT N
one-week JJ N
period NN N
. . N

Garlic NNP i
and CC i
onion NN i
have VBP N
a DT N
significant JJ N
protective JJ N
action NN N
against IN N
fat-induced JJ N
increases NNS N
in IN N
serum NN o
cholesterol NN o
and CC o
plasma NN o
fibrinogen NN o
and CC N
decreases NNS N
in IN N
coagulation NN o
time NN o
and CC N
fibrinolytic JJ o
activity NN o
. . N

The DT N
essential JJ N
oil NN N
fraction NN N
, , N
which WDT N
contains VBZ N
all PDT N
the DT N
taste NN N
and CC N
odour NN N
, , N
exactly RB N
duplicated VBD N
the DT N
beneficial JJ N
effects NNS o
of IN N
whole JJ N
garlic NN i
and CC N
onion NN i
. . N

It PRP N
is VBZ N
, , N
therefore RB N
, , N
concluded VBD N
that IN N
the DT N
active JJ N
principle NN N
of IN N
garlic JJ i
and CC i
onion NN i
is VBZ N
the DT N
essential JJ N
oil NN N
, , N
which WDT N
chemically RB N
is VBZ N
a DT N
combination NN N
of IN N
sulphur-containing JJ N
compounds NNS N
, , N
mainly RB N
allyl VBZ N
propyl JJ N
disulphide NN N
and CC N
diallyl JJ N
disulphide NN N
. . N

-DOCSTART- -1968178- O O

Effects NNS N
of IN N
cuff NN N
inflation NN N
on IN N
self-recorded JJ o
blood NN o
pressure NN o
. . N

Changes NNS N
in IN N
continuously RB N
recorded VBN N
'Finapres NNS o
' POS o
finger NN o
blood NN o
pressure NN o
in IN N
ten JJ p
normotensive JJ p
and CC p
seven CD p
hypertensive JJ p
subjects NNS p
induced VBN N
by IN N
self-inflation NN i
of IN i
the DT i
cuff NN i
or CC N
just RB i
wearing VBG i
the DT i
inflated JJ i
cuff NN i
were VBD N
studied VBN N
. . N

Inflating VBG i
the DT i
cuff NN i
caused VBD N
an DT N
instantaneous JJ N
rise NN N
in IN N
systolic JJ o
blood NN o
pressure NN o
of IN N
13 CD N
and CC N
12 CD N
mm NN N
Hg NNP N
( ( N
hypertensive JJ N
and CC N
normotensive JJ N
subjects NNS N
, , N
respectively RB N
) ) N
. . N

Wearing VBG N
the DT N
inflated JJ i
cuff NN i
did VBD N
not RB N
change VB N
blood NN o
pressure NN o
. . N

Thus VB N
the DT N
rise NN N
in IN N
pressure NN o
was VBD N
related VBN N
to TO N
the DT N
muscular JJ N
activity NN N
required VBN N
for IN N
cuff NN i
inflation NN i
. . N

Systolic NNP o
blood NN o
pressure NN o
took VBD N
on IN N
average JJ N
7 CD N
s NN N
and CC N
at IN N
most JJS N
21 CD N
s NN N
to TO N
return VB N
to TO N
baseline VB N
level NN N
after IN N
stopping VBG N
cuff NN N
inflation NN N
. . N

Since IN N
first JJ N
Korotkoff NNP N
sounds NNS N
may MD N
already RB N
be VB N
heard VBN N
after IN N
10-15 JJ N
s NN N
when WRB N
following VBG N
recommended VBD N
procedures NNS N
, , N
self-recorded JJ o
systolic JJ o
blood NN o
pressure NN o
may MD N
be VB N
recorded VBN N
as IN N
too RB N
high JJ N
when WRB N
subjects NNS N
inflate VBP N
their PRP$ N
cuff NN N
at IN N
too RB N
low JJ N
a DT N
pressure NN N
or CC N
deflate VB N
it PRP N
too RB N
fast RB N
. . N

-DOCSTART- -9730996- O O

Inhaled VBN N
fluticasone NN i
reduces NNS N
sputum VBP o
inflammatory JJ o
indices NNS o
in IN N
severe JJ p
bronchiectasis NN p
. . N

Although IN N
corticosteroid JJ N
therapy NN N
might MD N
be VB N
clinically RB N
beneficial JJ N
for IN N
bronchiectasis NN N
, , N
very RB N
little JJ N
is VBZ N
known VBN N
of IN N
its PRP$ N
effects NNS N
on IN N
the DT N
inflammatory NN o
and CC o
infective JJ o
markers NNS o
in IN N
bronchiectasis NN N
. . N

We PRP N
have VBP N
therefore RB N
performed VBN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
4-wk JJ N
administration NN N
of IN N
inhaled JJ N
fluticasone NN i
in IN N
bronchiectasis NN N
. . N

Twenty-four CD p
patients NNS p
( ( p
12 CD p
female NN p
; : p
mean JJ p
age NN p
51 CD p
yr NN p
) ) p
were VBD N
randomized VBN N
into IN N
receiving VBG N
either CC N
inhaled JJ N
fluticasone NN i
( ( N
500 CD N
microgram NN N
twice RB N
daily RB N
) ) N
via IN N
the DT N
Accuhaler NNP N
device NN N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
or CC N
placebo NN i
. . N

At IN N
each DT N
visit NN N
, , N
spirometry NN o
, , o
24-h JJ o
sputum NN o
volume NN o
, , o
sputum NN o
leukocyte NN o
density NN o
, , o
bacterial JJ o
densities NNS o
, , N
and CC N
concentrations NNS o
of IN o
interleukin NN o
( ( o
IL NNP o
) ) o
-1beta NN o
, , o
IL-8 NNP o
, , o
tumor NN o
necrosis NN o
factor-alpha JJ o
( ( o
TNF-alpha NNP o
) ) o
, , N
and CC N
leukotriene JJ o
B4 NNP o
( ( o
LTB4 NNP o
) ) o
were VBD N
determined VBN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
decrease NN N
in IN N
sputum NN o
leukocyte NN o
density NN o
and CC N
IL-1beta NNP o
, , o
IL-8 NNP o
, , N
and CC N
LTB4 NNP o
after IN N
fluticasone NN i
treatment NN N
. . N

The DT N
fluticasone NN i
group NN N
had VBD N
one CD N
and CC N
the DT N
placebo NN i
group NN N
three CD N
episodes NNS N
of IN N
exacerbation NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
spirometry NN o
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
or CC N
any DT N
reported JJ N
adverse JJ o
reactions NNS o
in IN N
either DT N
group NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
show VB N
that IN N
high-dose JJ N
fluticasone NN N
is VBZ N
effective JJ N
in IN N
reducing VBG N
the DT N
sputum NN o
inflammatory NN o
indices NNS o
in IN N
bronchiectasis NN N
. . N

Large-scale JJ N
and CC N
long-term JJ N
studies NNS N
are VBP N
indicated VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
inhaled JJ N
steroid JJ N
therapy NN N
on IN N
the DT N
inflammatory JJ N
components NNS N
in IN N
bronchiectasis NN p
. . N

-DOCSTART- -3534803- O O

Review NN N
of IN N
the DT N
Multicenter NNP N
Trial NNP N
Committee NNP N
report NN N
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
on IN N
the DT N
prophylaxis NN N
of IN N
postoperative JJ N
deep JJ N
venous JJ N
thrombosis NN N
. . N

The DT N
etiology NN N
of IN N
postoperative JJ N
deep JJ N
venous JJ N
thrombosis NN N
( ( N
DVT NNP N
) ) N
is VBZ N
thought VBN N
to TO N
be VB N
due JJ N
to TO N
a DT N
combination NN N
of IN N
factors NNS N
including VBG N
stasis NN N
, , N
a DT N
hypercoagulable JJ N
state NN N
and CC N
venous JJ N
endothelial JJ N
damage NN N
. . N

Methods NNS N
of IN N
prophylaxis NN N
are VBP N
directed VBN N
toward IN N
correcting VBG N
one CD N
or CC N
more JJR N
of IN N
these DT N
pathologic JJ N
events NNS N
. . N

Methods NNS N
counteracting VBG N
more JJR N
than IN N
one CD N
of IN N
these DT N
factors NNS N
can MD N
be VB N
expected VBN N
to TO N
be VB N
even RB N
more RBR N
effective JJ N
. . N

The DT N
combination NN N
of IN N
dihydroergotamine NN i
( ( i
DHE NNP i
) ) i
and CC N
heparin NN i
was VBD N
anticipated VBN N
to TO N
minimize VB N
stasis NN N
and CC N
the DT N
hypercoagulable JJ N
state NN N
respectively RB N
. . N

Based VBN N
upon IN N
current JJ N
experimental JJ N
evidence NN N
and CC N
current JJ N
theory NN N
, , N
an DT N
additional JJ N
benefit NN N
might MD N
include VB N
minimizing VBG N
venous JJ N
endothelial JJ N
injury NN N
by IN N
controlling VBG N
venomotor NN N
tone NN N
. . N

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
multicenter JJ N
trial NN N
was VBD N
designed VBN N
and CC N
performed VBN N
in IN N
the DT N
United NNP p
States NNPS p
evaluating VBG N
the DT N
prophylactic JJ N
efficacy NN N
of IN N
DHE NNP i
0.5 CD N
mg NN N
plus CC N
heparin JJ i
5000 CD N
U NNP N
, , N
DHE NNP i
0.5 CD N
mg NN N
plus CC N
heparin JJ i
2500 CD N
U NNP N
, , N
heparin NN i
5000 CD N
U NNP N
, , N
and CC N
DHE NNP i
0.5 CD N
mg NN N
versus NN N
placebo NN i
. . N

General NNP p
surgical JJ p
patients NNS p
including VBG p
those DT p
undergoing JJ p
noncardiac JJ p
thoracic NN p
and CC p
pelvic JJ p
operations NNS p
who WP p
were VBD p
identified VBN p
at IN p
moderate JJ p
to TO p
high JJ p
risk NN p
for IN p
postop JJ p
DVT NNP p
were VBD p
included VBN p
. . N

Study NNP N
medications NNS N
were VBD N
injected VBN N
subcutaneously RB N
two CD N
hours NNS N
preoperatively RB N
and CC N
every DT N
12 CD N
hours NNS N
postoperatively RB N
for IN N
5-7 JJ N
days NNS N
or CC N
until IN N
the DT N
125I-fibrinogen-uptake JJ N
test NN N
( ( N
RFUT NNP N
) ) N
became VBD N
positive JJ N
. . N

Eight NNP p
hundred VBD p
and CC p
eighty JJ p
eight CD p
patients NNS p
were VBD p
entered VBN p
into IN p
this DT p
trial NN p
and CC p
744 CD p
( ( p
85 CD p
% NN p
) ) p
completed VBD p
the DT p
study NN p
. . p

Results NNP N
showed VBD N
a DT N
statistically RB N
significant JJ N
benefit NN N
from IN N
DHE/Hep NNP i
5000 CD N
compared VBN N
to TO N
placebo VB i
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
compared VBN N
to TO N
other JJ N
active JJ N
agents NNS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

None NN N
of IN N
the DT N
other JJ N
active JJ N
agents NNS N
showed VBD N
a DT N
statistically RB N
significant JJ N
prophylactic JJ N
benefit NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -26278470- O O

Inference-Based JJ i
Approach NNP i
versus NN N
Cognitive NNP i
Behavioral NNP i
Therapy NNP i
in IN N
the DT N
Treatment NNP N
of IN N
Obsessive-Compulsive NNP p
Disorder NNP p
with IN p
Poor NNP p
Insight NNP p
: : N
A DT N
24-Session JJ N
Randomized NNP N
Controlled NNP N
Trial NNP N
. . N

OBJECTIVE NNP N
Obsessive-compulsive JJ N
disorder NN N
( ( N
OCD NNP N
) ) N
with IN N
poor JJ N
insight NN N
has VBZ N
severe JJ N
consequences NNS N
for IN N
patients NNS N
; : N
nonetheless RB N
, , N
no DT N
randomized VBN N
controlled VBN N
trial NN N
has VBZ N
ever RB N
been VBN N
performed VBN N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
any DT N
treatment NN N
specifically RB N
for IN N
poor-insight JJ N
OCD NNP N
. . N

A DT N
new JJ N
psychotherapy NN N
for IN N
OCD NNP N
, , N
the DT N
inference-based JJ i
approach NN i
( ( i
IBA NNP i
) ) i
, , N
targets NNS N
insight VBP N
in IN N
OCD NNP N
by IN N
strengthening VBG N
normal JJ N
sensory-driven JJ N
reality NN N
testing VBG N
. . N

The DT N
goal NN N
of IN N
the DT N
present JJ N
study NN N
is VBZ N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
this DT N
new JJ N
treatment NN N
to TO N
the DT N
effectiveness NN N
of IN N
cognitive JJ i
behavior NN i
therapy NN i
( ( i
CBT NNP i
) ) i
for IN N
patients NNS p
with IN p
OCD NNP p
with IN p
poor JJ p
insight NN p
. . N

METHOD NNP N
A NNP N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
, , N
in IN N
which WDT N
90 CD p
patients NNS p
with IN p
OCD NNP p
with IN p
poor JJ p
insight NN p
received VBD N
either RB N
24 CD N
CBT NNP i
sessions NNS N
or CC N
24 CD N
IBA JJ i
sessions NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
Yale-Brown JJ o
Obsessive NNP o
Compulsive NNP o
Scale NNP o
( ( o
YBOCS NNP o
) ) o
. . N

Secondary JJ N
outcome NN N
measures NNS N
were VBD N
level NN o
of IN o
insight NN o
, , o
anxiety NN o
and CC o
depressive JJ o
symptoms NNS o
, , o
and CC o
quality NN o
of IN o
life NN o
. . N

Mixed-effects NNS N
models NNS N
were VBD N
used VBN N
to TO N
determine VB N
the DT N
treatment NN N
effect NN N
. . N

RESULTS NN N
In IN N
both DT N
conditions NNS N
, , N
a DT N
significant JJ N
OCD NNP o
symptom NN o
reduction NN o
was VBD N
reached VBN N
, , N
but CC N
no DT N
condition NN N
effects NNS N
were VBD N
established VBN N
. . N

Post NNP N
hoc NN N
, , N
in IN N
a DT N
small JJ N
subgroup NN N
of IN N
patients NNS N
with IN N
the DT N
worst JJS N
insight NN N
( ( N
n JJ N
= NNP N
23 CD N
) ) N
, , N
it PRP N
was VBD N
found VBN N
that IN N
the DT N
patients NNS N
treated VBN N
with IN N
the DT N
IBA NNP i
reached VBD N
a DT N
significantly RB N
higher JJR N
OCD NNP o
symptom VBZ o
reduction NN o
than IN N
the DT N
patients NNS N
treated VBN N
with IN N
CBT NNP i
[ NNP N
estimated VBD N
marginal JJ N
mean NN N
= NNP N
-7.77 NNP N
, , N
t NN N
( ( N
219.45 CD N
) ) N
= NN N
-2.4 NN N
, , N
p NN N
= VBD N
0.017 CD N
] NN N
. . N

CONCLUSION NNP N
Patients NNPS p
with IN p
OCD NNP p
with IN p
poor JJ p
insight JJ p
improve VB N
significantly RB N
after IN N
psychological JJ N
treatment NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
both DT N
CBT NNP i
and CC N
the DT N
IBA NNP i
are VBP N
effective JJ N
treatments NNS N
for IN N
OCD NNP N
with IN N
poor JJ N
insight NN N
. . N

The DT N
IBA NNP i
might MD N
be VB N
more RBR N
promising JJ N
than IN N
CBT NNP i
for IN N
patients NNS N
with IN N
more RBR N
extreme JJ N
poor JJ N
insight NN N
. . N

-DOCSTART- -10390665- O O

Anti-emetic JJ o
efficacy NN o
of IN N
prophylactic JJ N
granisetron NNS i
compared VBN N
with IN N
perphenazine NN i
for IN N
the DT N
prevention NN o
of IN N
post-operative JJ N
vomiting NN N
in IN N
children NNS p
. . N

We PRP N
have VBP N
compared VBN N
the DT N
efficacy NN o
of IN N
granisetron NN i
with IN N
perphenazine NN i
in IN N
the DT N
prevention NN N
of IN N
vomiting VBG N
after IN N
tonsillectomy NN p
with IN p
or CC p
without IN p
adenoidectomy NN p
in IN p
children NNS p
. . N

In IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
, , N
90 CD p
paediatric JJ p
patients NNS p
, , p
ASA NNP p
I PRP p
, , p
aged VBN p
4-10 CD p
years NNS p
, , N
received VBD N
granisetron NN i
40 CD N
mg JJ N
kg-1 NN N
or CC N
perphenazine VB i
70 CD N
mg JJ N
kg-1 NN N
( ( N
n JJ N
= RB N
45 CD N
each DT N
) ) N
intravenously RB N
immediately RB N
after IN N
an DT N
inhalation NN N
induction NN N
of IN N
anaesthesia NN N
. . N

A DT N
standard JJ N
general JJ N
anaesthetic JJ N
technique NN N
was VBD N
employed VBN N
throughout IN N
. . N

A DT N
complete JJ o
response NN o
, , o
defined VBD o
as IN o
no DT o
emesis NN o
with IN o
no DT o
need NN o
for IN o
another DT o
rescue NN o
antiemetic JJ o
, , N
during IN N
the DT N
first JJ N
3 CD N
h NN N
( ( N
0-3 JJ N
h NN N
) ) N
after IN N
anesthesia NN N
was VBD N
87 CD N
% NN N
with IN N
granisetron NN i
and CC N
78 CD N
% NN N
with IN N
perphenazine NN i
( ( N
P NNP N
= NNP N
0.204 CD N
) ) N
. . N

The DT N
corresponding JJ o
incidence NN o
during IN N
the DT N
next JJ N
21 CD N
h NN N
( ( N
3-24 JJ N
h NN N
) ) N
after IN N
anaesthesia NN N
was VBD N
87 CD N
% NN N
and CC N
62 CD N
% NN N
( ( N
P NNP N
= NNP N
0.007 CD N
) ) N
. . N

No UH N
clinically RB N
serious JJ N
adverse JJ o
events NNS o
were VBD N
observed VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
. . N

We PRP N
conclude VBP N
that DT N
granisetron NN i
is VBZ N
a DT N
better JJR N
anti-emetic JJ N
than IN N
perphenazine NN i
for IN N
the DT N
long-term JJ o
prevention NN o
of IN N
post-operative JJ o
vomiting NN o
in IN N
children NNS p
undergoing VBG p
general JJ p
anaesthesia NN p
for IN p
tonsillectomy NN p
. . p

-DOCSTART- -15854186- O O

Cophenylcaine NNP i
spray NN N
vs. FW N
placebo NN i
in IN N
flexible JJ p
nasendoscopy NN p
: : N
a DT N
prospective JJ N
double-blind NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

Practices NNS N
vary VBP N
across IN N
the DT N
UK NNP N
on IN N
the DT N
use NN N
of IN N
topical JJ N
preparation NN N
prior RB N
to TO N
flexible JJ N
fibreoptic JJ N
nasendoscopy NN N
. . N

In IN N
this DT N
double-blind NN N
study NN N
, , N
we PRP N
randomised VBD N
98 CD p
patients NNS p
to TO N
receive VB N
cophenylcaine NN i
or CC N
placebo NN i
nasal JJ N
spray NN N
before IN N
flexible JJ p
nasendoscopy NN p
. . N

A DT N
visual JJ N
analogue NN N
scale NN N
( ( N
1-100 JJ N
) ) N
was VBD N
used VBN N
to TO N
record VB N
pain NN o
, , o
unpleasantness NN o
of IN o
taste NN o
and CC o
overall JJ o
discomfort NN o
experienced VBD o
. . N

Overall JJ N
, , N
the DT N
procedure NN N
was VBD N
associated VBN N
with IN N
minimal JJ N
pain NN o
and CC o
discomfort NN o
in IN N
both DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
pain NN o
or CC o
overall JJ o
discomfort NN o
experienced VBD N
between IN N
the DT N
two CD N
groups NNS N
; : N
however RB N
, , N
the DT N
sensation NN o
of IN o
bad JJ o
taste NN o
was VBD N
significantly RB N
worse JJR N
in IN N
the DT N
cophenylcaine NN i
group NN N
. . N

In IN N
linear JJ N
regression NN N
, , N
factors NNS N
that WDT N
predicted VBD N
the DT N
overall JJ N
unpleasantness NN o
of IN N
the DT N
experience NN N
were VBD N
primarily RB N
pain VBN o
experienced JJ N
and CC N
secondarily JJ N
unpleasantness NN o
of IN o
taste NN o
. . N

We PRP N
conclude VBP N
that IN N
the DT N
routine JJ N
use NN N
of IN N
cophenylcaine NN i
for IN N
nasal JJ N
preparation NN N
is VBZ N
not RB N
justified VBN N
before IN N
flexible JJ p
nasendoscopy NN p
. . N

-DOCSTART- -20488452- O O

Learning VBG N
about IN N
the DT N
equal JJ N
sign NN N
: : N
does VBZ N
comparing VBG N
with IN N
inequality NN N
symbols NNS N
help VB N
? . N
This DT N
study NN N
investigated VBD N
whether IN N
instruction NN N
that WDT N
involves VBZ N
comparing VBG N
the DT N
equal JJ N
sign NN N
with IN N
other JJ N
relational JJ N
symbols NNS N
is VBZ N
more RBR N
effective JJ N
at IN N
imparting VBG N
a DT N
relational JJ N
interpretation NN N
of IN N
the DT N
equal JJ N
sign NN N
than IN N
instruction NN N
about IN N
the DT N
equal JJ N
sign NN N
alone RB N
. . N

Third- JJ N
and CC N
fourth-grade JJ N
students NNS N
in IN N
a DT N
comparing NN N
symbols NNS N
group NN N
learned VBD N
about IN N
the DT N
greater JJR N
than IN N
, , N
less JJR N
than IN N
, , N
and CC N
equal JJ N
signs NNS N
and CC N
had VBD N
the DT N
opportunity NN N
to TO N
compare VB N
the DT N
inequality NN N
symbols VBZ N
with IN N
the DT N
equal JJ N
sign NN N
. . N

Students NNS N
in IN N
an DT N
equal JJ N
sign NN N
group NN N
learned VBD N
about IN N
the DT N
equal JJ N
sign NN N
only RB N
. . N

A NNP N
third JJ N
group NN N
of IN N
students NNS N
served VBD N
as IN N
a DT N
control NN N
group NN N
. . N

Three CD N
aspects NNS N
of IN N
students NNS N
' POS N
knowledge NN N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
the DT N
lesson NN N
: : N
( ( N
a DT N
) ) N
conceptual JJ N
understanding NN N
of IN N
the DT N
equal JJ N
sign NN N
, , N
( ( N
b NN N
) ) N
equation NN N
encoding NN N
, , N
and CC N
( ( N
c NN N
) ) N
problem NN N
solving VBG N
. . N

Students NNS N
in IN N
the DT N
comparing NN N
symbols NNS N
group NN N
showed VBD N
greater JJR N
gains NNS N
in IN N
conceptual JJ N
understanding NN N
from IN N
pretest NN N
to TO N
posttest VB N
than IN N
students NNS N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
, , N
and CC N
students NNS N
in IN N
the DT N
comparing NN N
symbols NNS N
group NN N
also RB N
scored VBD N
higher JJR N
on IN N
a DT N
posttest NN N
that WDT N
assessed VBD N
knowledge NN N
about IN N
inequality NN N
symbols NNS N
and CC N
inequality NN N
problem NN N
solving VBG N
. . N

Thus RB N
, , N
they PRP N
learned VBD N
about IN N
three CD N
symbols NNS N
in IN N
the DT N
same JJ N
amount NN N
of IN N
time NN N
as IN N
other JJ N
students NNS N
learned VBD N
about IN N
the DT N
equal JJ N
sign NN N
alone RB N
or CC N
not RB N
at IN N
all DT N
. . N

Therefore NNP N
, , N
an DT N
instructional JJ N
approach NN N
involving VBG N
comparison NN N
can MD N
be VB N
an DT N
effective JJ N
tool NN N
for IN N
learning VBG N
about IN N
concepts NNS N
in IN N
mathematics NNS N
. . N

-DOCSTART- -22565161- O O

Once-daily RB N
MMX NNP N
( ( N
? . N
) ) N
mesalamine NN N
for IN N
endoscopic JJ N
maintenance NN N
of IN N
remission NN N
of IN N
ulcerative JJ N
colitis NN N
. . N

OBJECTIVES NNP N
Treatment NNP N
with IN N
mesalamine NN N
to TO N
maintain VB N
endoscopic JJ N
remission NN N
( ( N
mucosal JJ N
healing VBG N
) ) N
of IN N
ulcerative JJ N
colitis NN N
( ( N
UC NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
relapse NN N
and CC N
is VBZ N
the DT N
recommended JJ N
first-line JJ N
maintenance NN N
therapy NN N
. . N

To TO N
improve VB N
treatment NN N
adherence NN N
, , N
a DT N
mesalamine NN N
formulation NN N
that WDT N
can MD N
be VB N
administered VBN N
once-daily RB N
, , N
MMX NNP N
( ( N
? . N
) ) N
mesalamine NN N
( ( N
Lialda NNP N
; : N
Shire NNP N
Pharmaceuticals NNP N
LLC NNP N
, , N
Wayne NNP N
, , N
PA NNP N
) ) N
, , N
was VBD N
developed VBN N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
once-daily JJ N
MMX NNP N
mesalamine NN N
compared VBN N
with IN N
twice-daily JJ N
delayed-release JJ N
mesalamine NN N
( ( N
Asacol NNP N
; : N
Warner NNP N
Chilcott NNP N
, , N
Dublin NNP N
, , N
Ireland NNP N
) ) N
for IN N
maintaining VBG N
endoscopic JJ N
remission NN N
in IN N
patients NNS N
with IN N
UC NNP N
. . N

METHODS NNP N
A NNP N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
6-month JJ N
, , N
active-control JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
non-inferiority NN N
of IN N
once-daily JJ N
MMX NNP N
mesalamine NN N
2.4 CD N
g/day NN N
compared VBN N
with IN N
twice-daily JJ N
delayed-release JJ N
mesalamine NN N
at IN N
a DT N
total JJ N
daily JJ N
dose NN N
of IN N
1.6 CD N
g/day NN N
in IN N
patients NNS N
with IN N
UC NNP N
in IN N
endoscopic JJ N
remission NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
maintenance NN N
of IN N
endoscopic JJ N
remission NN N
at IN N
month NN N
6 CD N
in IN N
the DT N
per-protocol NN N
( ( N
PP NNP N
) ) N
population NN N
. . N

RESULTS NNP N
Overall NNP N
, , N
826 CD N
patients NNS N
were VBD N
randomized VBN N
and CC N
dosed VBN N
. . N

The DT N
primary JJ N
objective JJ N
( ( N
non-inferiority NN N
) ) N
was VBD N
met VBN N
. . N

At IN N
month NN N
6 CD N
, , N
83.7 CD N
and CC N
77.8 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
MMX NNP N
mesalamine NN N
in IN N
the DT N
PP NNP N
and CC N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
populations NNS N
, , N
respectively RB N
, , N
had VBD N
maintained VBN N
endoscopic JJ N
remission NN N
compared VBN N
with IN N
81.5 CD N
% NN N
( ( N
PP NNP N
) ) N
and CC N
76.9 CD N
% NN N
( ( N
ITT NNP N
) ) N
of IN N
patients NNS N
receiving VBG N
delayed-release JJ N
mesalamine NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
for IN N
difference NN N
: : N
-3.9 CD N
% NN N
, , N
8.1 CD N
% NN N
( ( N
PP NNP N
) ) N
; : N
-5.0 CD N
% NN N
, , N
6.9 CD N
% NN N
( ( N
ITT NNP N
) ) N
) ) N
. . N

Time NN N
to TO N
relapse VB N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
( ( N
log-rank JJ N
test NN N
, , N
P=0.5116 NNP N
( ( N
PP NNP N
) ) N
; : N
P=0.5455 NNP N
( ( N
ITT NNP N
) ) N
) ) N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
with IN N
adverse JJ N
events NNS N
was VBD N
37.1 CD N
and CC N
36.0 CD N
% NN N
in IN N
patients NNS N
receiving VBG N
MMX NNP N
mesalamine NN N
and CC N
delayed-release JJ N
mesalamine NN N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Once-daily JJ N
dosing NN N
of IN N
MMX NNP N
mesalamine NN N
2.4 CD N
g/day NN N
was VBD N
shown VBN N
to TO N
be VB N
well RB N
tolerated VBN N
and CC N
non-inferior JJ N
to TO N
twice-daily JJ N
dosing VBG N
with IN N
delayed-release JJ N
mesalamine NN N
1.6 CD N
g/day NN N
for IN N
maintenance NN N
of IN N
endoscopic JJ N
remission NN N
in IN N
patients NNS N
with IN N
UC NNP N
. . N

-DOCSTART- -24022375- O O

The DT N
effect NN N
of IN N
person-centred JJ N
dementia NN N
care NN N
to TO N
prevent VB N
agitation NN N
and CC N
other JJ N
neuropsychiatric JJ N
symptoms NNS N
and CC N
enhance JJ N
quality NN N
of IN N
life NN N
in IN N
nursing NN N
home NN N
patients NNS N
: : N
a DT N
10-month JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

AIMS IN N
We PRP N
examined VBD N
whether IN N
Dementia NNP N
Care NNP N
Mapping NNP N
( ( N
DCM NNP N
) ) N
or CC N
the DT N
VIPS NNP N
practice NN N
model NN N
( ( N
VPM NNP N
) ) N
is VBZ N
more RBR N
effective JJ N
than IN N
education NN N
of IN N
the DT N
nursing NN N
home NN N
staff NN N
about IN N
dementia NN N
( ( N
control VB N
group NN N
) ) N
in IN N
reducing VBG N
agitation NN N
and CC N
other JJ N
neuropsychiatric JJ N
symptoms NNS N
as RB N
well RB N
as IN N
in IN N
enhancing VBG N
the DT N
quality NN N
of IN N
life NN N
among IN N
nursing JJ N
home NN N
patients NNS N
. . N

METHODS VB N
A DT N
10-month JJ N
three-armed JJ N
cluster-randomized JJ N
controlled VBN N
trial NN N
compared VBN N
DCM NNP N
and CC N
VPM NNP N
with IN N
control NN N
. . N

Of IN N
624 CD N
nursing NN N
home NN N
patients NNS N
with IN N
dementia NN N
, , N
446 CD N
completed VBD N
follow-up JJ N
assessments NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
change NN N
on IN N
the DT N
Brief JJ N
Agitation NNP N
Rating NNP N
Scale NNP N
( ( N
BARS NNP N
) ) N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
changes NNS N
on IN N
the DT N
10-item JJ N
version NN N
of IN N
the DT N
Neuropsychiatric NNP N
Inventory NNP N
Questionnaire NNP N
( ( N
NPI-Q NNP N
) ) N
, , N
the DT N
Cornell NNP N
Scale NNP N
for IN N
Depression NNP N
in IN N
Dementia NNP N
( ( N
CSDD NNP N
) ) N
and CC N
the DT N
Quality NN N
of IN N
Life NNP N
in IN N
Late-Stage NNP N
Dementia NNP N
( ( N
QUALID NNP N
) ) N
scale NN N
. . N

RESULTS NNP N
Changes NNP N
in IN N
the DT N
BARS NNP N
score NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
DCM NNP N
and CC N
the DT N
control NN N
group NN N
or CC N
between IN N
the DT N
VPM NNP N
and CC N
the DT N
control NN N
group NN N
after IN N
10 CD N
months NNS N
. . N

Positive JJ N
differences NNS N
were VBD N
found VBN N
for IN N
changes NNS N
in IN N
the DT N
secondary JJ N
outcomes NNS N
: : N
the DT N
NPI-Q NNP N
sum NN N
score NN N
as RB N
well RB N
as IN N
the DT N
subscales NNS N
NPI-Q NNP N
agitation NN N
and CC N
NPI-Q JJ N
psychosis NN N
were VBD N
in IN N
favour NN N
of IN N
both DT N
interventions NNS N
versus VBP N
control NN N
, , N
the DT N
QUALID NNP N
score NN N
was VBD N
in IN N
favour NN N
of IN N
DCM NNP N
versus NN N
control NN N
and CC N
the DT N
CSDD NNP N
score NN N
was VBD N
in IN N
favour NN N
of IN N
VPM NNP N
versus NN N
control NN N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
failed VBD N
to TO N
find VB N
a DT N
significant JJ N
effect NN N
of IN N
both DT N
interventions NNS N
on IN N
the DT N
primary JJ N
outcome NN N
. . N

Positive JJ N
effects NNS N
on IN N
the DT N
secondary JJ N
outcomes NNS N
indicate VBP N
that IN N
the DT N
methods NNS N
merit VBP N
further JJ N
investigation NN N
. . N

-DOCSTART- -8478759- O O

Comparison NNP N
of IN N
rectal JJ N
midazolam NN N
and CC N
diazepam NN N
for IN N
premedication NN N
in IN N
pediatric JJ N
dental JJ N
patients NNS N
. . N

Rectally RB N
administered VBN N
midazolam NN N
( ( N
0.35 CD N
mg/kg NN N
) ) N
and CC N
diazepam NN N
( ( N
0.70 CD N
mg/kg NN N
) ) N
were VBD N
compared VBN N
with IN N
each DT N
other JJ N
and CC N
with IN N
placebo NN N
for IN N
preanesthetic JJ N
medication NN N
in IN N
children NNS N
undergoing VBG N
dental JJ N
extractions NNS N
. . N

All DT N
rectal JJ N
medications NNS N
were VBD N
very RB N
well RB N
accepted VBN N
, , N
but CC N
mask JJ N
acceptance NN N
, , N
improvement NN N
in IN N
anxiety NN N
, , N
and CC N
sedation NN N
were VBD N
best RBS N
in IN N
the DT N
midazolam NN N
group NN N
. . N

Improvement NNP N
in IN N
anxiety NN N
and CC N
sedation NN N
were VBD N
significantly RB N
better RBR N
in IN N
the DT N
two CD N
drug NN N
groups NNS N
than IN N
in IN N
those DT N
patients NNS N
who WP N
had VBD N
received VBN N
placebo NN N
. . N

Thirty NNP N
minutes NNS N
after IN N
rectal JJ N
administration NN N
of IN N
midazolam NNS N
, , N
patients NNS N
showed VBD N
a DT N
decrease NN N
in IN N
both DT N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
and CC N
heart NN N
rate NN N
. . N

Although IN N
these DT N
decreases NNS N
differed VBD N
significantly RB N
from IN N
the DT N
premedication NN N
values NNS N
, , N
they PRP N
were VBD N
probably RB N
of IN N
little JJ N
clinical JJ N
importance NN N
. . N

Only RB N
minor JJ N
adverse JJ N
effects NNS N
were VBD N
observed VBN N
in IN N
this DT N
study NN N
. . N

Overall NNP N
rectally RB N
administered VBD N
midazolam NNS N
appeared VBD N
to TO N
be VB N
somewhat RB N
more RBR N
efficacious JJ N
than IN N
diazepam NN N
. . N

-DOCSTART- -20633669- O O

Efficacy NN N
of IN N
patient JJ N
education NN N
and CC N
supervised VBD N
exercise NN N
vs NN N
patient JJ N
education NN N
alone RB N
in IN N
patients NNS N
with IN N
hip JJ N
osteoarthritis NN N
: : N
a DT N
single JJ N
blind NN N
randomized VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
patient JJ N
education NN N
and CC N
supervised VBD N
exercise NN N
with IN N
that DT N
of IN N
patient JJ N
education NN N
alone RB N
for IN N
the DT N
management NN N
of IN N
pain NN N
in IN N
patients NNS N
with IN N
hip NN N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
. . N

DESIGN NNP N
Single NNP N
blind IN N
randomized JJ N
clinical JJ N
trial NN N
. . N

SETTING NNP N
Recruitment NNP N
of IN N
patients NNS N
from IN N
hospitals NNS N
, , N
primary JJ N
health NN N
care NN N
and CC N
advertisement NN N
, , N
Oslo NNP N
, , N
Norway NNP N
. . N

PARTICIPANTS NNP N
109 CD N
patients NNS N
with IN N
radiographic JJ N
and CC N
symptomatic JJ N
hip NN N
OA NNP N
with IN N
mild NN N
to TO N
moderate VB N
symptoms NNS N
. . N

INTERVENTIONS NNP N
Patient NNP N
education NN N
( ( N
PE NNP N
) ) N
. . N

Patient JJ N
education NN N
and CC N
supervised VBN N
exercise NN N
( ( N
PE+SE NNP N
) ) N
. . N

PRIMARY NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
pain NN N
subscale NN N
of IN N
the DT N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
Osteoarthritis NNP N
Index NNP N
( ( N
WOMAC NNP N
pain NN N
) ) N
. . N

RESULTS NNP N
No NNP N
significant JJ N
between IN N
group NN N
differences NNS N
were VBD N
found VBN N
for IN N
WOMAC NNP N
pain NN N
over IN N
the DT N
16-month JJ N
follow-up NN N
. . N

Significant JJ N
improvements NNS N
were VBD N
found VBN N
for IN N
the DT N
secondary JJ N
outcome NN N
WOMAC NNP N
physical JJ N
function NN N
( ( N
P=0.011 NNP N
) ) N
in IN N
the DT N
group NN N
receiving VBG N
PE+SE NNP N
compared VBN N
to TO N
the DT N
group NN N
receiving VBG N
PE NNP N
only RB N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
for IN N
WOMAC NNP N
stiffness NN N
, , N
the DT N
SF-36 JJ N
subscales NNS N
or CC N
the DT N
activity NN N
scale NN N
. . N

The DT N
effect NN N
sizes VBZ N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
) ) N
for IN N
WOMAC NNP N
pain NN N
were VBD N
-0.26 NNP N
( ( N
0.11 CD N
, , N
-0.64 NN N
) ) N
, , N
-0.35 NNP N
( ( N
0.07 CD N
, , N
-0.77 NN N
) ) N
, , N
and CC N
-0.30 NNP N
( ( N
0.15 CD N
, , N
-0.75 NN N
) ) N
, , N
and CC N
for IN N
WOMAC NNP N
physical JJ N
function NN N
-0.29 NNP N
( ( N
0.09 CD N
, , N
-0.67 NN N
) ) N
, , N
-0.48 NNP N
( ( N
-0.06 NNP N
, , N
-0.91 NNP N
) ) N
, , N
and CC N
-0.47 NNP N
( ( N
-0.02 NNP N
, , N
-0.93 NNP N
) ) N
at IN N
4 CD N
, , N
10 CD N
and CC N
16 CD N
months NNS N
, , N
respectively RB N
, , N
in IN N
favor NN N
of IN N
the DT N
group NN N
receiving VBG N
both DT N
PE NNP N
and CC N
SE NNP N
. . N

All DT N
patients NNS N
attended VBD N
the DT N
three-session JJ N
PE NNP N
program NN N
, , N
and CC N
75 CD N
% NN N
performed VBN N
?16 JJ N
sessions NNS N
of IN N
the DT N
12-week JJ N
SE NNP N
program NN N
. . N

CONCLUSION NNP N
The DT N
study NN N
could MD N
not RB N
demonstrate VB N
a DT N
significant JJ N
difference NN N
in IN N
pain NN N
reduction NN N
over IN N
time NN N
between IN N
PE+SE NNP N
vs NNP N
PE NNP N
alone RB N
. . N

Adding VBG N
SE NNP N
to TO N
PE NNP N
may MD N
improve VB N
physical JJ N
function NN N
, , N
but CC N
the DT N
magnitude NN N
of IN N
possible JJ N
benefit NN N
is VBZ N
unknown JJ N
as IN N
the DT N
95 CD N
% NN N
confidence NN N
intervals NNS N
around IN N
the DT N
mean JJ N
difference NN N
were VBD N
wide JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
Trials NNP N
NCT00319423 NNP N
. . N

-DOCSTART- -16167251- O O

[ JJ N
Usage NN N
of IN N
titanoreine NN N
after IN N
procedure NN N
for IN N
prolapse NN N
and CC N
hemorrhoids NNS N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
titanoreine NN N
on IN N
early JJ N
postoperative NN N
symptoms NNS N
after IN N
procedure NN N
for IN N
prolapse NN N
and CC N
hemorrhoids NNS N
( ( N
PPH NNP N
) ) N
. . N

METHODS NNP N
From IN N
November NNP N
2002 CD N
to TO N
July NNP N
2003 CD N
, , N
80 CD N
patients NNS N
who WP N
received VBD N
PPH NNP N
were VBD N
randomly RB N
divided VBN N
in IN N
to TO N
titanoreine VB N
group NN N
( ( N
n=42 CC N
) ) N
and CC N
control VB N
group NN N
without IN N
titanoreine NN N
( ( N
n=38 JJ N
) ) N
. . N

Symptom JJ N
relief NN N
was VBD N
recorded VBN N
24 CD N
hours NNS N
, , N
6 CD N
days NNS N
and CC N
12 CD N
days NNS N
after IN N
PPH NNP N
, , N
urine JJ N
retention NN N
24h CD N
after IN N
PPH NNP N
, , N
first RB N
stool JJ N
time NN N
, , N
wound IN N
healing VBG N
time NN N
, , N
mean JJ N
hospital NN N
stay NN N
were VBD N
also RB N
recorded VBN N
. . N

RESULTS VB N
The DT N
score NN N
of IN N
symptom NN N
was VBD N
lower JJR N
in IN N
titanoreine NN N
group NN N
( ( N
4.4 CD N
) ) N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
6.1 CD N
) ) N
24 CD N
hours NNS N
after IN N
PPH NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
no DT N
significant JJ N
difference NN N
in IN N
symptom NN N
grade NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
6 CD N
days NNS N
and CC N
12 CD N
days NNS N
after IN N
PPH NNP N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Decrements NNS N
of IN N
symptom NN N
grade NN N
were VBD N
lower JJR N
in IN N
titanoreine NN N
group NN N
than IN N
those DT N
of IN N
control NN N
group NN N
at IN N
any DT N
point NN N
after IN N
PPH NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
urine JJ N
retention NN N
rate NN N
and CC N
mean JJ N
hospital NN N
stay NN N
between IN N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Titanoreine NNP N
can MD N
effectively RB N
relieve VB N
the DT N
early JJ N
postoperative NN N
symptoms NNS N
after IN N
PPH NNP N
. . N

-DOCSTART- -17156222- O O

Midazolam NNP N
vs NN N
ondansetron NN N
for IN N
preventing VBG N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

We PRP N
compared VBN N
the DT N
prophylactic JJ N
anti-emetic JJ N
efficacy NN N
of IN N
midazolam NN N
and CC N
ondansetron NN N
in IN N
90 CD N
patients NNS N
scheduled VBN N
for IN N
minor JJ N
gynaecological JJ N
( ( N
hysteroscopy NN N
) ) N
or CC N
urological JJ N
( ( N
ureteroscopy JJ N
) ) N
procedures NNS N
planned VBN N
to TO N
last JJ N
1-2 JJ N
h NN N
under IN N
sevoflurane NN N
anaesthesia NN N
with IN N
spontaneous JJ N
ventilation NN N
of IN N
the DT N
lungs NNS N
via IN N
a DT N
laryngeal JJ N
mask NN N
airway NN N
. . N

Midazolam NNP N
2 CD N
mg NN N
or CC N
ondansetron $ N
4 CD N
mg NN N
were VBD N
administered VBN N
intravenously RB N
30 CD N
min NN N
before IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

The DT N
proportions NNS N
of IN N
patients NNS N
who WP N
experienced VBD N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
in IN N
the DT N
first JJ N
24 CD N
h NN N
( ( N
30 CD N
% NN N
and CC N
27 CD N
% NN N
for IN N
the DT N
midazolam NN N
and CC N
ondansetron NN N
groups NNS N
, , N
respectively RB N
) ) N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
incidence NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
was VBD N
significantly RB N
smaller JJR N
in IN N
both DT N
groups NNS N
than IN N
predicted VBN N
according VBG N
to TO N
the DT N
patients NNS N
' POS N
underlying JJ N
risks NNS N
( ( N
midazolam JJ N
group NN N
: : N
p NN N
= VBZ N
0.018 CD N
; : N
ondansetron VBN N
group NN N
: : N
p NN N
= VBZ N
0.017 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
average JJ N
sedation NN N
scores NNS N
or CC N
pain NN N
scores NNS N
. . N

Treatment NNP N
using VBG N
ondansetron NN N
for IN N
anti-emetic JJ N
prophylaxis NN N
did VBD N
not RB N
provide VB N
a DT N
superior JJ N
benefit NN N
compared VBN N
to TO N
midazolam VB N
in IN N
the DT N
present JJ N
study NN N
. . N

-DOCSTART- -9322632- O O

A DT N
comparison NN N
of IN N
intermittent JJ N
vaginal JJ N
administration NN N
of IN N
misoprostol NN N
with IN N
continuous JJ N
dinoprostone NN N
for IN N
cervical JJ N
ripening NN N
and CC N
labor NN N
induction NN N
. . N

OBJECTIVE CC N
Our PRP$ N
purpose NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
vaginal JJ N
administration NN N
of IN N
misoprostol NN N
( ( N
Cytotec NNP N
) ) N
with IN N
that DT N
of IN N
dinoprostone NN N
( ( N
Cervidil NNP N
) ) N
on IN N
cervical JJ N
ripening NN N
and CC N
labor NN N
induction NN N
. . N

STUDY NNP N
DESIGN NNP N
Two CD N
hundred VBD N
patients NNS N
with IN N
indications NNS N
for IN N
induction NN N
of IN N
labor NN N
and CC N
unfavorable JJ N
cervical JJ N
examinations NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
vaginally RB N
administered VBN N
misoprostol NN N
( ( N
prostaglandin JJ N
E1 NNP N
) ) N
or CC N
the DT N
dinoprostone NN N
( ( N
prostaglandin JJ N
E2 NNP N
) ) N
vaginal NN N
insert NN N
. . N

Twenty-five JJ N
microgram JJ N
tablets NNS N
of IN N
misoprostol NN N
were VBD N
placed VBN N
in IN N
the DT N
posterior JJ N
vaginal JJ N
fornix NN N
every DT N
4 CD N
hours NNS N
for IN N
a DT N
maximum NN N
of IN N
six CD N
doses NNS N
. . N

Additional NNP N
misoprostol NN N
was VBD N
not RB N
given VBN N
after IN N
either DT N
spontaneous JJ N
rupture NN N
of IN N
membranes NNS N
, , N
adequate JJ N
cervical JJ N
ripening NN N
( ( N
Bishop NNP N
score NN N
of IN N
> NN N
or CC N
= VB N
8 CD N
or CC N
cervical JJ N
dilatation NN N
of IN N
> NN N
or CC N
= $ N
3 CD N
cm NN N
) ) N
, , N
or CC N
beginning NN N
of IN N
active JJ N
labor NN N
. . N

The DT N
vaginal JJ N
insert NN N
, , N
Cervidil NNP N
, , N
containing VBG N
10 CD N
mg NN N
of IN N
dinoprostone NN N
in IN N
a DT N
timed-release JJ N
preparation NN N
was VBD N
placed VBN N
in IN N
the DT N
posterior JJ N
vaginal JJ N
formix NN N
for IN N
a DT N
maximum JJ N
period NN N
of IN N
24 CD N
hours NNS N
. . N

The DT N
vaginal JJ N
insert NN N
was VBD N
removed VBN N
for IN N
spontaneous JJ N
rupture NN N
of IN N
membranes NNS N
, , N
entry NN N
into IN N
active JJ N
labor NN N
, , N
adequate JJ N
cervical JJ N
ripening NN N
, , N
or CC N
abnormality NN N
of IN N
uterine JJ N
contractile NN N
pattern NN N
or CC N
fetal JJ N
cardiac JJ N
activity NN N
. . N

RESULTS NN N
Of IN N
the DT N
200 CD N
patients NNS N
enrolled VBD N
, , N
99 CD N
were VBD N
randomized VBN N
to TO N
misoprostol VB N
and CC N
101 CD N
to TO N
dinoprostone VB N
. . N

The DT N
average JJ N
interval NN N
from IN N
start NN N
of IN N
induction NN N
to TO N
vaginal JJ N
delivery NN N
was VBD N
1 CD N
hour NN N
shorter NN N
in IN N
the DT N
misoprostol NN N
group NN N
( ( N
1296.7 CD N
+/- JJ N
722.1 CD N
minutes NNS N
) ) N
than IN N
in IN N
the DT N
dinoprostone NN N
group NN N
( ( N
1360.0 CD N
+/- JJ N
792.0 CD N
minutes NNS N
) ) N
, , N
but CC N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.97 CD N
) ) N
. . N

Oxytocin NNP N
augmentation NN N
of IN N
labor NN N
was VBD N
used VBN N
in IN N
50 CD N
( ( N
50.5 CD N
% NN N
) ) N
misoprostol-treated JJ N
patients NNS N
and CC N
43 CD N
( ( N
43.5 CD N
% NN N
) ) N
dinoprostone-treated JJ N
patients NNS N
( ( N
relative JJ N
risk NN N
1.14 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.86 CD N
to TO N
1.51 CD N
, , N
p NN N
= NNP N
0.35 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
routes NNS N
of IN N
delivery NN N
with IN N
misoprostol NN N
or CC N
dinoprostone NN N
. . N

Overall NNP N
, , N
38 CD N
patients NNS N
( ( N
19.3 CD N
% NN N
) ) N
had VBD N
cesarean JJ N
deliveries NNS N
. . N

There EX N
was VBD N
a DT N
significantly RB N
lower JJR N
prevalence NN N
of IN N
tachysystole NN N
( ( N
six CD N
or CC N
more JJR N
uterine JJ N
contractions NNS N
in IN N
a DT N
10-minute JJ N
window NN N
for IN N
two CD N
consecutive JJ N
10-minute JJ N
periods NNS N
) ) N
in IN N
the DT N
misoprostol NN N
group NN N
( ( N
7.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
dinoprostone NN N
group NN N
( ( N
18.4 CD N
% NN N
) ) N
( ( N
relative JJ N
risk NN N
0.52 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.31 CD N
to TO N
0.89 CD N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
frequency NN N
of IN N
uterine JJ N
hyperstimulation NN N
or CC N
hypertonus NN N
. . N

Abnormal NNP N
fetal JJ N
heart NN N
rate NN N
tracings NNS N
were VBD N
found VBN N
in IN N
23 CD N
( ( N
23.2 CD N
% NN N
) ) N
of IN N
misoprostol-treated JJ N
patients NNS N
and CC N
35 CD N
( ( N
35.7 CD N
% NN N
) ) N
of IN N
dinoprostone-treated JJ N
patients NNS N
( ( N
relative JJ N
risk NN N
0.73 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.52 CD N
to TO N
1.01 CD N
, , N
p NN N
= NNP N
0.0546 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
meconium NN N
passage NN N
, , N
1- JJ N
or CC N
5-minute JJ N
Apgar NNP N
scores NNS N
< VBP N
7 CD N
, , N
neonatal JJ N
resuscitations NNS N
, , N
or CC N
admissions NNS N
to TO N
the DT N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Vaginally NNP N
administered VBD N
misoprostol NN N
is VBZ N
as RB N
effective JJ N
as IN N
dinoprostone NN N
for IN N
cervical JJ N
ripening NN N
and CC N
the DT N
induction NN N
of IN N
labor NN N
. . N

Mean JJ N
time NN N
intervals NNS N
to TO N
delivery NN N
, , N
need NN N
for IN N
oxytocin JJ N
augmentation NN N
, , N
and CC N
routes NNS N
of IN N
delivery NN N
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Incidence NN N
of IN N
uterine JJ N
tachysystole NN N
with IN N
misoprostol NN N
every DT N
4 CD N
hours NNS N
was VBD N
significantly RB N
less JJR N
than IN N
with IN N
dinoprostone NN N
. . N

-DOCSTART- -15897310- O O

Efficacy NN N
of IN N
physiotherapy JJ N
management NN N
of IN N
knee NN N
joint JJ N
osteoarthritis NN N
: : N
a DT N
randomised JJ N
, , N
double JJ N
blind NN N
, , N
placebo NN N
controlled VBD N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
a DT N
multimodal JJ N
physiotherapy NN N
programme NN N
including VBG N
taping VBG N
, , N
exercises NNS N
, , N
and CC N
massage NN N
is VBZ N
effective JJ N
for IN N
knee NN N
osteoarthritis NN N
, , N
and CC N
if IN N
benefits NNS N
can MD N
be VB N
maintained VBN N
with IN N
self JJ N
management NN N
. . N

METHODS NNP N
Randomised VBD N
, , N
double JJ N
blind NN N
, , N
placebo NN N
controlled VBD N
trial NN N
; : N
140 CD N
community NN N
volunteers NNS N
with IN N
knee NN N
osteoarthritis NN N
participated VBD N
and CC N
119 CD N
completed VBD N
the DT N
trial NN N
. . N

Physiotherapy NNP N
and CC N
placebo JJ N
interventions NNS N
were VBD N
applied VBN N
by IN N
10 CD N
physiotherapists NNS N
in IN N
private JJ N
practices NNS N
for IN N
12 CD N
weeks NNS N
. . N

Physiotherapy NNP N
included VBD N
exercise NN N
, , N
massage NN N
, , N
taping VBG N
, , N
and CC N
mobilisation NN N
, , N
followed VBN N
by IN N
12 CD N
weeks NNS N
of IN N
self JJ N
management NN N
. . N

Placebo NNP N
was VBD N
sham VBN N
ultrasound JJ N
and CC N
light JJ N
application NN N
of IN N
a DT N
non-therapeutic JJ N
gel NN N
, , N
followed VBN N
by IN N
no DT N
treatment NN N
. . N

Primary JJ N
outcomes NNS N
were VBD N
pain RB N
measured VBN N
by IN N
visual JJ N
analogue NN N
scale NN N
and CC N
patient JJ N
global JJ N
change NN N
. . N

Secondary JJ N
measures NNS N
included VBD N
WOMAC NNP N
, , N
knee NN N
pain NN N
scale NN N
, , N
SF-36 NNP N
, , N
assessment NN N
of IN N
quality NN N
of IN N
life NN N
index NN N
, , N
quadriceps JJ N
strength NN N
, , N
and CC N
balance NN N
test NN N
. . N

RESULTS NNP N
Using VBG N
an DT N
intention NN N
to TO N
treat VB N
analysis NN N
, , N
physiotherapy NN N
and CC N
placebo NN N
groups NNS N
showed VBD N
similar JJ N
pain NN N
reductions NNS N
at IN N
12 CD N
weeks NNS N
: : N
-2.2 NN N
cm NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-2.6 NNP N
to TO N
-1.7 VB N
) ) N
and CC N
-2.0 $ N
cm NN N
( ( N
-2.5 UH N
to TO N
-1.5 VB N
) ) N
, , N
respectively RB N
. . N

At IN N
24 CD N
weeks NNS N
, , N
pain NN N
remained VBD N
reduced VBN N
from IN N
baseline NN N
in IN N
both DT N
groups NNS N
: : N
-2.1 NN N
( ( N
-2.6 UH N
to TO N
-1.6 VB N
) ) N
and CC N
-1.6 NNP N
( ( N
-2.2 UH N
to TO N
-1.0 VB N
) ) N
, , N
respectively RB N
. . N

Global JJ N
improvement NN N
was VBD N
reported VBN N
by IN N
70 CD N
% NN N
of IN N
physiotherapy NN N
participants NNS N
( ( N
51/73 CD N
) ) N
at IN N
12 CD N
weeks NNS N
and CC N
by IN N
59 CD N
% NN N
( ( N
43/73 CD N
) ) N
at IN N
24 CD N
weeks NNS N
. . N

Similarly RB N
, , N
global JJ N
improvement NN N
was VBD N
reported VBN N
by IN N
72 CD N
% NN N
of IN N
placebo NN N
participants NNS N
( ( N
48/67 CD N
) ) N
at IN N
12 CD N
weeks NNS N
and CC N
by IN N
49 CD N
% NN N
( ( N
33/67 CD N
) ) N
at IN N
24 CD N
weeks NNS N
( ( N
all DT N
p VBP N
> $ N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
physiotherapy NN N
programme NN N
tested VBN N
in IN N
this DT N
trial NN N
was VBD N
no DT N
more RBR N
effective JJ N
than IN N
regular JJ N
contact NN N
with IN N
a DT N
therapist NN N
at IN N
reducing VBG N
pain NN N
and CC N
disability NN N
. . N

-DOCSTART- -22020134- O O

Docosahexaenoic NNP N
acid-rich JJ N
fish JJ N
oil NN N
modulates VBZ N
the DT N
cerebral JJ N
hemodynamic JJ N
response NN N
to TO N
cognitive JJ N
tasks NNS N
in IN N
healthy JJ N
young JJ N
adults NNS N
. . N

A DT N
number NN N
of IN N
recent JJ N
studies NNS N
have VBP N
assessed VBN N
the DT N
impact NN N
of IN N
dietary JJ N
omega-3 JJ N
polyunsaturated VBN N
fatty JJ N
acids NNS N
( ( N
n-3 JJ N
PUFAs NNP N
) ) N
on IN N
behavioral JJ N
outcomes NNS N
; : N
however RB N
, , N
very RB N
little JJ N
attention NN N
has VBZ N
been VBN N
given VBN N
to TO N
their PRP$ N
impact NN N
upon IN N
brain NN N
function NN N
in IN N
physiological JJ N
terms NNS N
. . N

Sixty-five JJ N
healthy JJ N
adults NNS N
aged VBD N
18-29yrs JJ N
took VBD N
part NN N
in IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
assessing VBG N
the DT N
effects NNS N
of IN N
12 CD N
weeks NNS N
daily RB N
dietary JJ N
supplementation NN N
with IN N
docosahexaenoic JJ N
acid-rich JJ N
fish JJ N
oil NN N
( ( N
1g CD N
, , N
2g CD N
) ) N
or CC N
placebo NN N
( ( N
olive JJ N
oil NN N
) ) N
. . N

Relative JJ N
changes NNS N
in IN N
the DT N
concentration NN N
of IN N
oxyhemoglobin NN N
and CC N
deoxyhemoglobin NN N
were VBD N
assessed VBN N
in IN N
the DT N
prefrontal JJ N
cortex NN N
using VBG N
near-infrared JJ N
spectroscopy NN N
during IN N
performance NN N
of IN N
nine CD N
computerized JJ N
cognitive JJ N
tasks NNS N
. . N

Supplementation NN N
with IN N
both DT N
doses NNS N
of IN N
fish JJ N
oil NN N
, , N
in IN N
comparison NN N
with IN N
placebo NN N
, , N
resulted VBD N
in IN N
significantly RB N
increased JJ N
concentrations NNS N
of IN N
oxyhemoglobin NN N
and CC N
total JJ N
levels NNS N
of IN N
hemoglobin NN N
, , N
indicative JJ N
of IN N
increased JJ N
cerebral JJ N
blood NN N
flow NN N
, , N
during IN N
the DT N
cognitive JJ N
tasks NNS N
. . N

Changes NNS N
in IN N
hemodynamic JJ N
response NN N
to TO N
tasks NNS N
were VBD N
not RB N
accompanied VBN N
by IN N
consistent JJ N
changes NNS N
in IN N
cognitive JJ N
performance NN N
. . N

-DOCSTART- -24281134- O O

Predictors NNS N
of IN N
postdischarge NN N
outcomes NNS N
from IN N
information NN N
acquired VBN N
shortly RB N
after IN N
admission NN N
for IN N
acute JJ N
heart NN N
failure NN N
: : N
a DT N
report NN N
from IN N
the DT N
Placebo-Controlled NNP N
Randomized NNP N
Study NNP N
of IN N
the DT N
Selective NNP N
A1 NNP N
Adenosine NNP N
Receptor NNP N
Antagonist NNP N
Rolofylline NNP N
for IN N
Patients NNP N
Hospitalized NNP N
With IN N
Acute NNP N
Decompensated NNP N
Heart NNP N
Failure NNP N
and CC N
Volume NN N
Overload NNP N
to TO N
Assess NNP N
Treatment NNP N
Effect NNP N
on IN N
Congestion NNP N
and CC N
Renal NNP N
Function NNP N
( ( N
PROTECT NNP N
) ) N
Study NNP N
. . N

BACKGROUND NNP N
Acute NNP N
heart NN N
failure NN N
is VBZ N
a DT N
common JJ N
reason NN N
for IN N
admission NN N
, , N
and CC N
outcome NN N
is VBZ N
often RB N
poor JJ N
. . N

Improved VBN N
prognostic JJ N
risk NN N
stratification NN N
may MD N
assist VB N
in IN N
the DT N
design NN N
of IN N
future JJ N
trials NNS N
and CC N
in IN N
patient JJ N
management NN N
. . N

Using VBG N
data NNS N
from IN N
a DT N
large JJ N
randomized JJ N
trial NN N
, , N
we PRP N
explored VBD N
the DT N
prognostic JJ N
value NN N
of IN N
clinical JJ N
variables NNS N
, , N
measured VBN N
at IN N
hospital JJ N
admission NN N
for IN N
acute JJ N
heart NN N
failure NN N
, , N
to TO N
determine VB N
whether IN N
a DT N
few JJ N
selected VBN N
variables NNS N
were VBD N
inferior JJ N
to TO N
an DT N
extended VBN N
data NN N
set NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
prognostic JJ N
model NN N
included VBD N
37 CD N
clinical JJ N
characteristics NNS N
collected VBN N
at IN N
baseline NN N
in IN N
PROTECT NNP N
, , N
a DT N
study NN N
comparing VBG N
rolofylline NN N
and CC N
placebo NN N
in IN N
2033 CD N
patients NNS N
admitted VBN N
with IN N
acute JJ N
heart NN N
failure NN N
. . N

Prespecified VBN N
outcomes NNS N
at IN N
30 CD N
days NNS N
were VBD N
death NN N
or CC N
rehospitalization NN N
for IN N
any DT N
reason NN N
; : N
death NN N
or CC N
rehospitalization NN N
for IN N
cardiovascular NN N
or CC N
renal JJ N
reasons NNS N
; : N
and CC N
, , N
at IN N
both DT N
30 CD N
and CC N
180 CD N
days NNS N
, , N
all-cause JJ N
mortality NN N
. . N

No DT N
variable JJ N
had VBD N
a DT N
c-index NN N
> NN N
0.70 CD N
, , N
and CC N
few JJ N
had VBD N
values NNS N
> $ N
0.60 CD N
; : N
c-indices NNS N
were VBD N
lower JJR N
for IN N
composite JJ N
outcomes NNS N
than IN N
for IN N
mortality NN N
. . N

Blood NNP N
urea NN N
was VBD N
generally RB N
the DT N
strongest JJS N
single JJ N
predictor NN N
. . N

Eighteen NNP N
variables NNS N
contributed VBD N
independent JJ N
prognostic JJ N
information NN N
, , N
but CC N
a DT N
reduced JJ N
model NN N
using VBG N
only RB N
8 CD N
items NNS N
( ( N
age NN N
, , N
previous JJ N
heart NN N
failure NN N
hospitalization NN N
, , N
peripheral JJ N
edema NN N
, , N
systolic JJ N
blood NN N
pressure NN N
, , N
serum NN N
sodium NN N
, , N
urea JJ N
, , N
creatinine NN N
, , N
and CC N
albumin NN N
) ) N
performed VBD N
similarly RB N
. . N

For IN N
prediction NN N
of IN N
all-cause JJ N
mortality NN N
at IN N
180 CD N
days NNS N
, , N
the DT N
model NN N
c-index NN N
using VBG N
all DT N
variables NNS N
was VBD N
0.72 CD N
and CC N
for IN N
the DT N
simplified JJ N
model NN N
, , N
also RB N
0.72 CD N
. . N

CONCLUSIONS VB N
A NNP N
few JJ N
simple JJ N
clinical JJ N
variables NNS N
measured VBN N
on IN N
admission NN N
in IN N
patients NNS N
with IN N
acute JJ N
heart NN N
failure NN N
predict VBP N
a DT N
variety NN N
of IN N
adverse JJ N
outcomes NNS N
with IN N
accuracy NN N
similar JJ N
to TO N
more RBR N
complex JJ N
models NNS N
. . N

However RB N
, , N
predictive JJ N
models NNS N
were VBD N
of IN N
only RB N
moderate JJ N
accuracy NN N
, , N
especially RB N
for IN N
outcomes NNS N
that WDT N
included VBD N
nonfatal JJ N
events NNS N
. . N

Better NNP N
methods NNS N
of IN N
risk NN N
stratification NN N
are VBP N
required VBN N
. . N

CLINICAL JJ N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

Unique JJ N
identifiers NNS N
: : N
NCT00328692 NNP N
and CC N
NCT00354458 NNP N
. . N

-DOCSTART- -9564194- O O

The DT N
problem NN N
of IN N
measurement NN N
error NN N
in IN N
multisite JJ N
clinical JJ N
trials NNS N
. . N

The DT N
implementation NN N
of IN N
a DT N
multisite NN N
, , N
randomized VBN N
, , N
clinical JJ N
psychopharmacologic JJ N
trial NN N
involves VBZ N
a DT N
substantial JJ N
investment NN N
of IN N
time NN N
and CC N
effort NN N
on IN N
the DT N
part NN N
of IN N
all DT N
participants NNS N
. . N

Because IN N
of IN N
their PRP$ N
complexity NN N
, , N
such JJ N
clinical JJ N
trials NNS N
present JJ N
unique JJ N
methodological JJ N
and CC N
design NN N
challenges NNS N
. . N

Indeed RB N
, , N
it PRP N
is VBZ N
not RB N
uncommon JJ N
for IN N
such JJ N
studies NNS N
to TO N
conclude VB N
with IN N
uninterpretable JJ N
results NNS N
, , N
due JJ N
in IN N
part NN N
to TO N
such JJ N
methodological JJ N
pitfalls NNS N
. . N

It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
clarification NN N
of IN N
such JJ N
methodologic JJ N
dilemmas NN N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
important JJ N
challenges NNS N
facing VBG N
the DT N
future NN N
of IN N
industry-sponsored JJ N
psychopharmacologic JJ N
drug NN N
development NN N
. . N

Among IN N
the DT N
many JJ N
factors NNS N
that WDT N
may MD N
contribute VB N
to TO N
problematic JJ N
clinical JJ N
trial NN N
results NNS N
, , N
error NN N
in IN N
measuring VBG N
the DT N
phenomena NN N
being VBG N
studied VBN N
is VBZ N
of IN N
particular JJ N
concern NN N
. . N

In IN N
this DT N
article NN N
, , N
we PRP N
describe VBP N
the DT N
outcome NN N
of IN N
an DT N
intensive JJ N
series NN N
of IN N
interrater JJ N
reliability NN N
training NN N
sessions NNS N
for IN N
the DT N
17-item JJ N
Hamilton NNP N
Depression NNP N
Rating NNP N
Scale NNP N
conducted VBD N
at IN N
the DT N
start NN N
of IN N
a DT N
Phase NNP N
II NNP N
multisite RB N
clinical JJ N
drug NN N
trial NN N
. . N

The DT N
data NN N
underscore IN N
the DT N
magnitude NN N
of IN N
error NN N
present NN N
in IN N
such JJ N
a DT N
test NN N
setting NN N
and CC N
provide VB N
preliminary JJ N
evidence NN N
for IN N
the DT N
potential JJ N
effect NN N
of IN N
this DT N
problem NN N
on IN N
the DT N
detection NN N
of IN N
clinical JJ N
change NN N
. . N

-DOCSTART- -9330779- O O

Lack NN N
of IN N
effect NN N
of IN N
food NN N
on IN N
the DT N
steady JJ N
state NN N
pharmacokinetics NNS N
of IN N
BMS-181101 NNP N
, , N
an DT N
antidepressant NN N
, , N
in IN N
healthy JJ N
subjects NNS N
. . N

The DT N
effect NN N
of IN N
food NN N
on IN N
the DT N
pharmacokinetics NNS N
of IN N
BMS-181101 NNP N
, , N
a DT N
new JJ N
anti-depressant JJ N
under IN N
development NN N
, , N
was VBD N
investigated VBN N
in IN N
12 CD N
healthy JJ N
male NN N
volunteers NNS N
at IN N
steady JJ N
state NN N
. . N

Each DT N
subject NN N
received VBD N
a DT N
15 CD N
mg JJ N
oral JJ N
dose NN N
of IN N
BMS-181101 NNP N
twice NN N
a DT N
day NN N
( ( N
q JJ N
12 CD N
h NN N
) ) N
for IN N
11 CD N
days NNS N
and CC N
a DT N
morning NN N
dose NN N
of IN N
BMS-181101 NNP N
on IN N
day NN N
12 CD N
. . N

Six CD N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
BMS-181101 NNP N
under IN N
fasted VBN N
conditions NNS N
from IN N
days NNS N
1 CD N
to TO N
6 CD N
and CC N
then RB N
crossed VBD N
over IN N
to TO N
fed VB N
conditions NNS N
from IN N
days NNS N
7 CD N
to TO N
12 CD N
. . N

The DT N
other JJ N
six CD N
subjects NNS N
received VBD N
the DT N
reverse NN N
conditions NNS N
, , N
fed VBN N
for IN N
days NNS N
1-6 CD N
and CC N
fasted VBN N
for IN N
days NNS N
7-12 CD N
. . N

Serial JJ N
blood NN N
samples NNS N
were VBD N
collected VBN N
up RB N
to TO N
12 CD N
h NNS N
on IN N
days NNS N
6 CD N
and CC N
12 CD N
following VBG N
the DT N
administration NN N
of IN N
the DT N
morning NN N
dose NN N
. . N

In IN N
addition NN N
, , N
trough IN N
blood NN N
samples NNS N
were VBD N
collected VBN N
on IN N
days NNS N
4 CD N
, , N
5 CD N
, , N
10 CD N
, , N
and CC N
11 CD N
prior RB N
to TO N
the DT N
morning NN N
dose NN N
. . N

Plasma NNP N
samples NNS N
were VBD N
analyzed VBN N
for IN N
intact JJ N
BMS-181101 NNP N
using VBG N
a DT N
validated JJ N
high-performance NN N
liquid NN N
chromatography NN N
method NN N
with IN N
an DT N
electrochemical JJ N
detector NN N
. . N

BMS-181101 NNP N
was VBD N
well RB N
tolerated VBN N
both DT N
with IN N
and CC N
without IN N
ingestion NN N
of IN N
food NN N
. . N

The DT N
statistical JJ N
evaluation NN N
of IN N
the DT N
Cmin NNP N
values NNS N
indicated VBD N
that IN N
steady JJ N
state NN N
of IN N
BMS-181101 NNP N
was VBD N
achieved VBN N
by IN N
the DT N
fourth JJ N
day NN N
of IN N
dosing VBG N
regardless NN N
of IN N
whether IN N
the DT N
subject NN N
was VBD N
fasted VBN N
or CC N
fed VBN N
. . N

When WRB N
BMS-181101 NNP N
was VBD N
administered VBN N
with IN N
food NN N
, , N
Cmax NNP N
was VBD N
reduced VBN N
by IN N
about IN N
25 CD N
% NN N
and CC N
tmax NN N
was VBD N
prolonged VBN N
by IN N
1 CD N
h. NN N
However RB N
, , N
AUCtau NNP N
, , N
t1/2 NN N
, , N
and CC N
time NN N
to TO N
attain VB N
steady JJ N
state NN N
of IN N
BMS-181101 NNP N
were VBD N
not RB N
altered VBN N
by IN N
ingestion NN N
of IN N
food NN N
. . N

In IN N
summary JJ N
, , N
BMS-181101 NNP N
can MD N
be VB N
given VBN N
with IN N
food NN N
without IN N
adversely RB N
impacting VBG N
the DT N
safety NN N
or CC N
pharmacokinetic JJ N
profiles NNS N
of IN N
the DT N
drug NN N
. . N

-DOCSTART- -17617281- O O

Codeine/acetaminophen NNP N
and CC N
hydrocodone/acetaminophen JJ N
combination NN N
tablets NNS N
for IN N
the DT N
management NN N
of IN N
chronic JJ N
cancer NN N
pain NN N
in IN N
adults NNS N
: : N
a DT N
23-day JJ N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
study NN N
. . N

BACKGROUND NNP N
Analgesics NNPS N
are VBP N
an DT N
essential JJ N
component NN N
of IN N
the DT N
treatment NN N
of IN N
cancer-associated JJ N
pain NN N
. . N

Pharmacologic NNP N
treatment NN N
is VBZ N
usually RB N
begun VBN N
with IN N
nonopioid JJ N
analgesics NNS N
, , N
most JJS N
frequently RB N
acetaminophen VBP N
. . N

If IN N
pain JJ N
relief NN N
is VBZ N
not RB N
achieved VBN N
, , N
the DT N
so-called JJ N
weak JJ N
opioids NNS N
, , N
such JJ N
as IN N
codeine NN N
and CC N
hydrocodone NN N
, , N
may MD N
be VB N
used VBN N
in IN N
combination NN N
with IN N
acetaminophen NN N
. . N

Adverse JJ N
effects NNS N
( ( N
AEs NNP N
) ) N
of IN N
the DT N
opioids NNS N
include VBP N
constipation NN N
, , N
somnolence NN N
, , N
nausea NN N
, , N
and CC N
vomiting VBG N
. . N

Based VBN N
on IN N
the DT N
results NNS N
of IN N
a DT N
literature NN N
search NN N
, , N
data NNS N
comparing VBG N
the DT N
effects NNS N
of IN N
the DT N
opioids NNS N
are VBP N
lacking VBG N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
analgesic JJ N
efficacy NN N
and CC N
tolerability NN N
of IN N
codeine NN N
phosphate NN N
versus IN N
hydrocodone NN N
bitartrate NN N
in IN N
combination NN N
with IN N
acetaminophen NN N
in IN N
the DT N
relief NN N
of IN N
cancer-related JJ N
pain NN N
. . N

METHODS NNP N
This DT N
23-day JJ N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
study NN N
was VBD N
conducted VBN N
at IN N
3 CD N
Colombian JJ N
centers NNS N
: : N
University NNP N
Libre NNP N
, , N
Social NNP N
Security NNP N
Institute NNP N
, , N
and CC N
General NNP N
Hospital NNP N
of IN N
Medell?n NNP N
, , N
Cali NNP N
, , N
Colombia NNP N
. . N

Outpatients NNS N
with IN N
cancer NN N
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
if IN N
they PRP N
were VBD N
aged VBN N
> JJ N
-18 CD N
years NNS N
and CC N
had VBD N
chronic VBN N
( ( N
duration NN N
, , N
> NNP N
/= VBZ N
3 CD N
months NNS N
) ) N
moderate VBP N
to TO N
severe VB N
cancer-related JJ N
pain NN N
( ( N
score NN N
on IN N
10-cm JJ N
visual JJ N
analog NN N
scale NN N
[ NNP N
VAS NNP N
] NNP N
, , N
> VBD N
3 CD N
cm NN N
[ NN N
moderate JJ N
] NN N
; : N
score NN N
on IN N
a DT N
4-point JJ N
verbal JJ N
pain-intensity NN N
scale NN N
, , N
> VBZ N
1 CD N
[ NN N
moderate JJ N
] NN N
) ) N
. . N

Eligible JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
1 CD N
tablet NN N
of IN N
codeine/acetaminophen NN N
( ( N
C/A NNP N
) ) N
30/500 CD N
mg NN N
or CC N
hydrocodone/acetaminophen NN N
( ( N
H/A NNP N
) ) N
5/500 CD N
mg NN N
PO NNP N
q4h NN N
( ( N
total JJ N
daily JJ N
doses NNS N
, , N
150/2500 CD N
and CC N
25/2500 CD N
mg NN N
, , N
respectively RB N
) ) N
for IN N
23 CD N
days NNS N
. . N

In IN N
both DT N
groups NNS N
, , N
if IN N
pain JJ N
intensity NN N
was VBD N
rated VBN N
as IN N
> JJ N
3 CD N
on IN N
the DT N
VAS NNP N
at IN N
week NN N
1 CD N
or CC N
2 CD N
, , N
the DT N
dosage NN N
was VBD N
doubled VBN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
patients NNS N
who WP N
achieved VBD N
pain NN N
relief NN N
( ( N
defined VBN N
as IN N
a DT N
score NN N
of IN N
> $ N
1 CD N
on IN N
a DT N
5-point JJ N
verbal NN N
rating NN N
scale NN N
[ NNP N
VRS NNP N
] NNP N
( ( N
0 CD N
= NNP N
none NN N
; : N
1 CD N
= IN N
a DT N
little JJ N
; : N
2 CD N
= IN N
some DT N
; : N
3 CD N
= IN N
a DT N
lot NN N
; : N
and CC N
4 CD N
= NNP N
complete JJ N
) ) N
on IN N
study NN N
days NNS N
1 CD N
and CC N
2 CD N
and CC N
weeks NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
. . N

The DT N
secondary JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
patients NNS N
in IN N
whom WP N
pain NN N
was VBD N
decreased VBN N
( ( N
VAS NNP N
score RB N
, , N
< NNP N
- : N
3 CD N
cm NN N
) ) N
. . N

AEs $ N
were VBD N
self-reported VBN N
on IN N
a DT N
4-point JJ N
VRS NNP N
( ( N
0 CD N
= NNP N
absent NN N
; : N
1 CD N
= NNP N
mild NN N
; : N
2 CD N
= NN N
moderate NN N
; : N
and CC N
3 CD N
= NNP N
severe RB N
) ) N
. . N

RESULTS NNP N
Of IN N
the DT N
121 CD N
patients NNS N
who WP N
participated VBD N
, , N
59 CD N
received VBD N
C/A NNP N
and CC N
62 CD N
received VBD N
H/A NNP N
. . N

Of IN N
the DT N
total JJ N
number NN N
of IN N
cases NNS N
, , N
59 CD N
% NN N
were VBD N
aged VBN N
60 CD N
to TO N
89 CD N
years NNS N
, , N
and CC N
55 CD N
% NN N
were VBD N
men NNS N
. . N

At IN N
baseline NN N
, , N
88 CD N
% NN N
of IN N
the DT N
patients NNS N
described VBD N
their PRP$ N
pain NN N
intensity NN N
as IN N
moderate JJ N
; : N
12 CD N
% NN N
, , N
severe JJ N
. . N

Of IN N
the DT N
patients NNS N
who WP N
received VBD N
C/A NNP N
, , N
58 CD N
% NN N
responded VBD N
to TO N
the DT N
initial JJ N
dosage NN N
of IN N
150/2500 CD N
mg/d NN N
, , N
and CC N
8 CD N
% NN N
of IN N
the DT N
patients NNS N
responded VBD N
to TO N
the DT N
double JJ N
dosage NN N
; : N
34 CD N
% NN N
did VBD N
not RB N
experience VB N
pain NN N
relief NN N
. . N

In IN N
patients NNS N
with IN N
H/A NNP N
, , N
pain NN N
was VBD N
reported VBN N
as IN N
absent NN N
or CC N
mild NN N
in IN N
56 CD N
% NN N
of IN N
patients NNS N
at IN N
the DT N
starting VBG N
dosage NN N
of IN N
25/2500 CD N
mg/d NN N
; : N
an DT N
additional JJ N
15 CD N
% NN N
of IN N
the DT N
patients NNS N
responded VBD N
to TO N
the DT N
double JJ N
dosage NN N
; : N
the DT N
remaining VBG N
29 CD N
% NN N
of IN N
patients NNS N
did VBD N
not RB N
experience VB N
any DT N
pain NN N
relief NN N
. . N

None NN N
of IN N
the DT N
between-group JJ N
differences NNS N
in IN N
response NN N
rates NNS N
were VBD N
significant JJ N
. . N

The DT N
most RBS N
common JJ N
AEs NNP N
in IN N
the DT N
C/A NNP N
and CC N
H/A NNP N
groups NNS N
were VBD N
constipation NN N
( ( N
36 CD N
% NN N
and CC N
29 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
dizziness NN N
( ( N
24 CD N
% NN N
and CC N
19 CD N
% NN N
) ) N
, , N
vomiting VBG N
( ( N
24 CD N
% NN N
and CC N
16 CD N
% NN N
) ) N
, , N
and CC N
dry JJ N
mouth NN N
( ( N
15 CD N
% NN N
and CC N
18 CD N
% NN N
) ) N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
. . N

CONCLUSION NNP N
In IN N
this DT N
study NN N
, , N
efficacy NN N
and CC N
tolerability NN N
were VBD N
comparable JJ N
between IN N
C/A NNP N
and CC N
H/A NNP N
over IN N
23 CD N
days NNS N
of IN N
treatment NN N
in IN N
these DT N
patients NNS N
with IN N
moderate JJ N
or CC N
severe JJ N
, , N
chronic JJ N
, , N
cancer-related JJ N
pain NN N
. . N

-DOCSTART- -21183747- O O

Relationship NN N
between IN N
baseline NN N
blood NN N
pressure NN N
parameters NNS N
( ( N
including VBG N
mean JJ N
pressure NN N
, , N
pulse JJ N
pressure NN N
, , N
and CC N
variability NN N
) ) N
and CC N
early JJ N
outcome NN N
after IN N
stroke NN N
: : N
data NN N
from IN N
the DT N
Tinzaparin NNP N
in IN N
Acute NNP N
Ischaemic NNP N
Stroke NNP N
Trial NNP N
( ( N
TAIST NNP N
) ) N
. . N

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
High NNP N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
in IN N
acute JJ N
stroke NN N
is VBZ N
associated VBN N
independently RB N
with IN N
a DT N
poor JJ N
outcome NN N
. . N

Recent JJ N
evidence NN N
suggests VBZ N
that IN N
other JJ N
hemodynamic JJ N
parameters NNS N
may MD N
also RB N
be VB N
associated VBN N
with IN N
outcomes NNS N
following VBG N
stroke NN N
. . N

METHODS NNP N
The DT N
relationship NN N
between IN N
baseline NN N
BP NNP N
, , N
heart NN N
rate NN N
, , N
and CC N
other JJ N
hemodynamic JJ N
parameters NNS N
, , N
and CC N
early RB N
outcomes NNS N
were VBD N
assessed VBN N
using VBG N
data NNS N
from IN N
TAIST NNP N
trial NN N
. . N

RESULTS NNP N
Death NNP N
or CC N
neurological JJ N
deterioration NN N
at IN N
day NN N
10 CD N
was VBD N
associated VBN N
, , N
both DT N
in IN N
unadjusted JJ N
and CC N
adjusted JJ N
analyses NNS N
, , N
with IN N
systolic JJ N
BP NNP N
( ( N
adjusted VBN N
OR NNP N
, , N
1.02 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.03 JJ N
) ) N
, , N
mean JJ N
arterial JJ N
pressure NN N
( ( N
OR NNP N
, , N
1.02 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.04 JJ N
) ) N
, , N
pulse JJ N
pressure NN N
( ( N
OR NNP N
, , N
1.02 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.03 JJ N
) ) N
, , N
and CC N
BP NNP N
variability NN N
( ( N
OR NNP N
, , N
1.03 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.05 JJ N
) ) N
. . N

Similar JJ N
relationships NNS N
were VBD N
noted VBN N
for IN N
deterioration NN N
alone RB N
, , N
and CC N
recurrent JJ N
stroke NN N
. . N

CONCLUSIONS NNP N
Early JJ N
death NN N
or CC N
neurologic JJ N
deterioration NN N
, , N
deterioration NN N
, , N
and CC N
recurrent JJ N
stroke NN N
are VBP N
associated VBN N
independently RB N
with IN N
high JJ N
systolic JJ N
BP NNP N
, , N
mean JJ N
arterial JJ N
pressure NN N
, , N
pulse JJ N
pressure NN N
, , N
and CC N
BP NNP N
variability NN N
. . N

These DT N
measures NNS N
offer VBP N
potential JJ N
therapeutic JJ N
targets NNS N
for IN N
improving VBG N
early JJ N
outcome NN N
after IN N
acute JJ N
ischemic JJ N
stroke NN N
. . N

-DOCSTART- -8798245- O O

Relation NN N
of IN N
total JJ N
homocysteine NN N
and CC N
lipid JJ N
levels NNS N
in IN N
children NNS N
to TO N
premature VB N
cardiovascular JJ N
death NN N
in IN N
male JJ N
relatives NNS N
. . N

We PRP N
assessed VBD N
the DT N
relative JJ N
importance NN N
of IN N
lipid JJ N
, , N
apo JJ N
B NNP N
, , N
lipoprotein NN N
( ( N
a DT N
) ) N
[ NN N
Lp NNP N
( ( N
a DT N
) ) N
] NN N
, , N
and CC N
total JJ N
homocysteine NN N
( ( N
tHcy NN N
) ) N
levels NNS N
in IN N
children NNS N
in IN N
relation NN N
to TO N
premature VB N
cardiovascular JJ N
disease NN N
in IN N
family NN N
members NNS N
. . N

Parents NNS N
of IN N
381 CD N
girls NNS N
and CC N
375 CD N
boys NNS N
age NN N
8-12 JJ N
y NN N
completed VBN N
family NN N
history NN N
questionnaires NNS N
. . N

Nonfasting VBG N
serum JJ N
lipid JJ N
and CC N
lipoproteins NNS N
and CC N
plasma NN N
tHcy NN N
and CC N
cysteine NN N
levels NNS N
were VBD N
measured VBN N
in IN N
the DT N
children NNS N
. . N

Serum NNP N
folate NN N
and CC N
vitamin NN N
B12 NNP N
levels NNS N
were VBD N
determined VBN N
in IN N
a DT N
random JJ N
subsample NN N
of IN N
23 CD N
% NN N
of IN N
the DT N
children NNS N
, , N
who WP N
participated VBD N
in IN N
a DT N
food NN N
frequency NN N
interview NN N
. . N

Children NNP N
whose WP$ N
parents NNS N
reported VBD N
hypercholesterolemia NN N
had VBD N
higher JJR N
total JJ N
and CC N
non-HDL JJ N
cholesterol NN N
and CC N
apo NN N
B NNP N
levels NNS N
than IN N
the DT N
rest NN N
, , N
but CC N
these DT N
levels NNS N
were VBD N
not RB N
associated VBN N
with IN N
cardiovascular JJ N
disease NN N
. . N

tHcy NN N
levels NNS N
were VBD N
similar JJ N
in IN N
girls NNS N
and CC N
boys NNS N
. . N

tHcy NN N
was VBD N
higher RBR N
in IN N
children NNS N
whose WP$ N
father NN N
, , N
grandfather NN N
, , N
or CC N
uncle NN N
died VBN N
at IN N
age NN N
< NN N
or CC N
= $ N
55 CD N
y NN N
of IN N
myocardial JJ N
infarction NN N
or CC N
sudden JJ N
cardiac JJ N
arrest NN N
( ( N
n JJ N
= NNP N
42 CD N
) ) N
than IN N
in IN N
control NN N
children NNS N
[ VBP N
5.92 CD N
mumol/L NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
of IN N
5.47-6.36 NNP N
) ) N
versus NN N
5.25 CD N
mumol/L NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
5.16-5.34 JJ N
) ) N
] NN N
, , N
also RB N
after IN N
adjustment NN N
for IN N
socioeconomic JJ N
group NN N
. . N

Intake NNP N
and CC N
serum NN N
levels NNS N
of IN N
vitamin NN N
B12 NNP N
and CC N
folate NN N
were VBD N
within IN N
recommended VBN N
or CC N
reference NN N
ranges NNS N
. . N

In IN N
a DT N
stepwise NN N
multiple JJ N
regression NN N
analysis NN N
, , N
serum NN N
folate NN N
( ( N
negative JJ N
correlation NN N
) ) N
, , N
plasma JJ N
creatinine NN N
, , N
and CC N
sugar RB N
intake VB N
as IN N
percent NN N
of IN N
dietary JJ N
energy NN N
( ( N
positive JJ N
correlations NNS N
) ) N
were VBD N
significantly RB N
associated VBN N
with IN N
tHcy NN N
( ( N
multiple JJ N
r NN N
= NN N
0.44 CD N
, , N
adjusted VBN N
r2 NN N
= VBZ N
18 CD N
% NN N
; : N
95 CD N
% NN N
CI NNP N
, , N
5-30 JJ N
% NN N
) ) N
. . N

Our PRP$ N
data NNS N
show VBP N
that IN N
a DT N
modest JJ N
elevation NN N
in IN N
tHcy NN N
in IN N
children NNS N
was VBD N
related VBN N
to TO N
premature VB N
cardiovascular JJ N
death NN N
in IN N
their PRP$ N
male NN N
relatives NNS N
and CC N
may MD N
partly RB N
account VB N
for IN N
the DT N
contribution NN N
of IN N
family NN N
history NN N
to TO N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
. . N

tHcy NN N
may MD N
be VB N
modifiable JJ N
through IN N
the DT N
diet NN N
, , N
even RB N
in IN N
children NNS N
with IN N
apparently RB N
adequate JJ N
vitamin JJ N
nutriture NN N
. . N

-DOCSTART- -19081412- O O

Three-year JJ N
clinical JJ N
outcome NN N
after IN N
primary JJ N
stenting NN N
of IN N
totally RB N
occluded JJ N
native JJ N
coronary JJ N
arteries NNS N
: : N
a DT N
randomized JJ N
comparison NN N
of IN N
bare-metal JJ N
stent JJ N
implantation NN N
with IN N
sirolimus-eluting JJ N
stent NN N
implantation NN N
for IN N
the DT N
treatment NN N
of IN N
total JJ N
coronary JJ N
occlusions NNS N
( ( N
Primary JJ N
Stenting NNP N
of IN N
Totally NNP N
Occluded NNP N
Native NNP N
Coronary NNP N
Arteries NNP N
[ NNP N
PRISON NNP N
] NNP N
II NNP N
study NN N
) ) N
. . N

BACKGROUND IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
3-year JJ N
clinical JJ N
outcome NN N
in IN N
patients NNS N
enrolled VBN N
in IN N
the DT N
Primary NNP N
Stenting NNP N
of IN N
Totally NNP N
Occluded NNP N
Native NNP N
Coronary NNP N
Arteries NNP N
II NNP N
study NN N
. . N

METHODS NNP N
Patients NNPS N
with IN N
totally RB N
occluded JJ N
coronary JJ N
arteries NNS N
randomized VBN N
to TO N
either DT N
sirolimus-eluting JJ N
Cypher NNP N
stents NNS N
( ( N
SESs NNP N
) ) N
( ( N
Cordis NNP N
, , N
a DT N
Johnson NNP N
& CC N
Joshson NNP N
Company NNP N
, , N
Miami NNP N
Lakes NNP N
, , N
FL NNP N
) ) N
( ( N
100 CD N
patients NNS N
) ) N
or CC N
bare-metal JJ N
BxVelocity NNP N
stents NNS N
( ( N
BMSs NNP N
) ) N
( ( N
Cordis NNP N
) ) N
( ( N
100 CD N
patients NNS N
) ) N
were VBD N
followed VBN N
clinically RB N
for IN N
3 CD N
years NNS N
. . N

RESULTS NNP N
Between NNP N
1 CD N
and CC N
3 CD N
years NNS N
, , N
there EX N
were VBD N
infrequent JJ N
additional JJ N
clinical JJ N
events NNS N
that WDT N
were VBD N
equally RB N
distributed VBN N
between IN N
the DT N
SES NNP N
and CC N
the DT N
BMS NNP N
group NN N
. . N

After IN N
3 CD N
years NNS N
, , N
target NN N
lesion NN N
revascularization NN N
was VBD N
7 CD N
% NN N
in IN N
the DT N
SES NNP N
group NN N
versus VBD N
27 CD N
% NN N
in IN N
the DT N
BMS NNP N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
; : N
and CC N
target VB N
vessel JJ N
revascularization NN N
was VBD N
seen VBN N
in IN N
11 CD N
% NN N
in IN N
the DT N
SES NNP N
group NN N
versus VBD N
30 CD N
% NN N
in IN N
the DT N
BMS NNP N
group NN N
( ( N
P NNP N
= NNP N
.002 NNP N
) ) N
. . N

Major JJ N
adverse JJ N
cardiac NN N
events NNS N
were VBD N
noted VBN N
in IN N
10 CD N
% NN N
of IN N
the DT N
SES NNP N
group NN N
versus VBD N
34 CD N
% NN N
in IN N
the DT N
BMS NNP N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
death NN N
, , N
myocardial JJ N
infarction NN N
, , N
and CC N
stent JJ N
thrombosis NN N
according VBG N
to TO N
the DT N
Academic NNP N
Research NNP N
Consortium NNP N
criteria NNS N
between IN N
the DT N
2 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Clinical NNP N
outcome VBD N
up RB N
to TO N
3 CD N
years NNS N
after IN N
implantation NN N
of IN N
SESs NNP N
for IN N
total JJ N
coronary JJ N
occlusions NNS N
continues VBZ N
to TO N
demonstrate VB N
a DT N
significant JJ N
reduction NN N
in IN N
adverse JJ N
clinical JJ N
events NNS N
compared VBN N
with IN N
BMSs NNP N
without IN N
the DT N
evidence NN N
for IN N
either DT N
disproportionate NN N
late JJ N
restenosis NN N
or CC N
late JJ N
stent JJ N
thrombosis NN N
. . N

-DOCSTART- -22732975- O O

Lactobacillus NNP N
plantarum NN N
CECT7315 NNP N
and CC N
CECT7316 NNP N
stimulate VBP N
immunoglobulin NN N
production NN N
after IN N
influenza JJ N
vaccination NN N
in IN N
elderly JJ N
. . N

OBJECTIVE IN N
The DT N
effectiveness NN N
of IN N
influenza JJ N
vaccination NN N
in IN N
preventing VBG N
illness NN N
is VBZ N
lower RBR N
in IN N
the DT N
elderly JJ N
; : N
this DT N
is VBZ N
why WRB N
the DT N
ability NN N
of IN N
Lactobacillus NNP N
plantarum NN N
CECT NNP N
7315/7316 CD N
to TO N
stimulate VB N
the DT N
response NN N
to TO N
influenza VB N
vaccination NN N
in IN N
elderly JJ N
was VBD N
evaluated VBN N
. . N

RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
human JJ N
trial NN N
including VBG N
60 CD N
institutionalized JJ N
volunteers NNS N
aged VBN N
65-85 CD N
years NNS N
was VBD N
performed VBN N
. . N

All PDT N
the DT N
volunteers NNS N
were VBD N
vaccinated VBN N
with IN N
a DT N
trivalent JJ N
influenza NN N
vaccine NN N
( ( N
A/Wisconsin/67/2005 NNP N
NYMC NNP N
X-161B NNP N
( ( N
H3N2 NNP N
) ) N
, , N
A/Solomon NNP N
Islands/3/2006 NNP N
( ( N
H1N1 NNP N
) ) N
and CC N
B/Malaysia/2506/2004 NNP N
) ) N
for IN N
the DT N
Spanish JJ N
vaccine NN N
campaign NN N
2006/2007 CD N
. . N

The DT N
consumption NN N
of IN N
the DT N
probiotic JJ N
began VBD N
between IN N
three CD N
and CC N
four CD N
months NNS N
after IN N
the DT N
vaccination NN N
. . N

Volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
following VBG N
groups NNS N
: : N
group NN N
A NNP N
( ( N
receiving VBG N
5*10 CD N
( ( N
9 CD N
) ) N
cfu/day NN N
of IN N
L. NNP N
plantarum NN N
CECT NNP N
7315/7316 CD N
in IN N
20 CD N
g NN N
powdered VBD N
skim JJ N
milk NN N
) ) N
, , N
group NN N
B NNP N
( ( N
receiving VBG N
5*10 CD N
( ( N
8 CD N
) ) N
cfu/day NN N
of IN N
L. NNP N
plantarum NN N
CECT NNP N
7315/7316 CD N
in IN N
20 CD N
g NN N
powdered VBD N
skim JJ N
milk NN N
) ) N
and CC N
group NN N
C NNP N
or CC N
placebo NN N
( ( N
20 CD N
g NN N
powered VBN N
skim JJ N
milk NN N
) ) N
. . N

The DT N
participants NNS N
consumed VBD N
the DT N
probiotic JJ N
during IN N
3 CD N
months NNS N
. . N

RESULTS VB N
The DT N
consumption NN N
of IN N
L. NNP N
plantarum NN N
CECT NNP N
7315/7316 CD N
during IN N
3 CD N
months NNS N
after IN N
influenza JJ N
vaccination NN N
increased VBD N
the DT N
levels NNS N
of IN N
influenza-specific JJ N
IgA NNP N
and CC N
IgG NNP N
antibodies NNS N
. . N

Moreover RB N
, , N
a DT N
trend NN N
towards IN N
an DT N
increase NN N
in IN N
influenza-specific JJ N
IgM NNP N
antibodies NNS N
was VBD N
also RB N
observed VBN N
. . N

CONCLUSION NNP N
L. NNP N
plantarum NN N
CECT7315/7316 NNP N
has VBZ N
an DT N
immunostimulating JJ N
effect NN N
and CC N
could MD N
be VB N
used VBN N
to TO N
improve VB N
the DT N
response NN N
to TO N
influenza VB N
vaccination NN N
in IN N
elderly JJ N
. . N

-DOCSTART- -12394700- O O

Transurethral JJ N
prostate NN N
resection NN N
and CC N
bleeding NN N
: : N
a DT N
randomized JJ N
, , N
placebo NN N
controlled VBD N
trial NN N
of IN N
role NN N
of IN N
finasteride NN N
for IN N
decreasing VBG N
operative JJ N
blood NN N
loss NN N
. . N

PURPOSE NNP N
Bleeding NNP N
associated VBN N
with IN N
transurethral JJ N
prostate NN N
resection NN N
can MD N
often RB N
be VB N
significant JJ N
and CC N
lead JJ N
to TO N
increased VBN N
morbidity NN N
and CC N
occasionally RB N
mortality NN N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
that IN N
finasteride NN N
decreases VBZ N
bleeding VBG N
in IN N
patients NNS N
with IN N
hematuria NNS N
of IN N
prostatic JJ N
origin NN N
. . N

We PRP N
hypothesized VBD N
that IN N
bleeding VBG N
in IN N
patients NNS N
undergoing JJ N
transurethral JJ N
prostate NN N
resection NN N
could MD N
be VB N
decreased VBN N
by IN N
giving VBG N
finasteride NN N
for IN N
2 CD N
weeks NNS N
before RB N
surgery NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
total JJ N
70 CD N
patients NNS N
scheduled VBN N
to TO N
undergo VB N
elective JJ N
transurethral JJ N
prostate NN N
resection NN N
were VBD N
randomized VBN N
to TO N
receive VB N
5 CD N
mg. NNS N
finasteride JJ N
daily RB N
or CC N
placebo VB N
for IN N
2 CD N
weeks NNS N
before RB N
surgery NN N
. . N

Serum NNP N
hemoglobin NN N
was VBD N
measured VBN N
before IN N
and CC N
after IN N
surgery NN N
, , N
and CC N
the DT N
following JJ N
day NN N
. . N

The DT N
volume NN N
of IN N
irrigation NN N
fluid NN N
used VBN N
and CC N
its PRP$ N
hemoglobin JJ N
concentration NN N
as RB N
well RB N
as IN N
resected VBN N
prostate NN N
weight NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Of IN N
the DT N
68 CD N
patients NNS N
who WP N
underwent JJ N
transurethral JJ N
prostate NN N
resection NN N
2 CD N
were VBD N
withdrawn VBN N
before RB N
surgery NN N
, , N
and CC N
so RB N
32 CD N
received VBD N
finasteride NN N
and CC N
36 CD N
received VBD N
placebo NN N
. . N

There EX N
was VBD N
significantly RB N
less JJR N
mean JJ N
blood NN N
loss NN N
in IN N
irrigation NN N
fluid NN N
in IN N
the DT N
finasteride NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
43.6 CD N
versus NN N
69.3 CD N
gm NN N
. . N

hemoglobin NN N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
. . N

The DT N
mean JJ N
difference NN N
was VBD N
more RBR N
significant JJ N
when WRB N
blood NN N
loss NN N
per IN N
gm NN N
. . N

resected JJ N
prostate NN N
was VBD N
calculated VBN N
( ( N
2.65 CD N
versus NN N
4.65 CD N
gm NN N
. . N

hemoglobin NN N
per IN N
gm NN N
. . N

prostate NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
finasteride NN N
given VBN N
for IN N
2 CD N
weeks NNS N
preoperatively RB N
decreases VBZ N
bleeding VBG N
in IN N
patients NNS N
undergoing JJ N
transurethral JJ N
prostate NN N
resection NN N
. . N

Further NNP N
study NN N
is VBZ N
required VBN N
to TO N
determine VB N
the DT N
optimal JJ N
timing NN N
and CC N
dose JJ N
duration NN N
to TO N
minimize VB N
blood NN N
loss NN N
and CC N
identify VB N
how WRB N
relevant JJ N
such JJ N
a DT N
decrease NN N
in IN N
bleeding NN N
is VBZ N
in IN N
clinical JJ N
practice NN N
. . N

-DOCSTART- -23326865- O O

Effect NN N
of IN N
aliskiren NN N
on IN N
proteinuria NNS N
in IN N
non-diabetic JJ N
chronic JJ N
kidney NN N
disease NN N
: : N
a DT N
double-blind NN N
, , N
crossover NN N
, , N
randomised VBN N
, , N
controlled VBN N
trial NN N
. . N

AIM NNP N
To TO N
evaluate VB N
the DT N
proteinuria-lowering JJ N
effect NN N
of IN N
a DT N
renin NN N
inhibitor NN N
( ( N
aliskiren NN N
) ) N
, , N
compared VBN N
to TO N
placebo VB N
and CC N
to TO N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
( ( N
perindopril NN N
) ) N
, , N
in IN N
patients NNS N
with IN N
non-diabetic JJ N
chronic JJ N
kidney NN N
disease NN N
. . N

METHODS NNP N
A DT N
randomised JJ N
, , N
double-blind JJ N
, , N
crossover JJ N
trial NN N
was VBD N
performed VBN N
in IN N
14 CD N
patients NNS N
with IN N
nondiabetic JJ N
chronic JJ N
kidney NN N
disease NN N
with IN N
24-h JJ N
mean JJ N
proteinuria NN N
of IN N
2.01 CD N
g NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.36?2.66 CD N
) ) N
and CC N
estimated VBN N
creatinine JJ N
clearance NN N
of IN N
93?6.8 CD N
ml/min NN N
. . N

The DT N
study NN N
consisted VBD N
of IN N
five CD N
treatment NN N
periods NNS N
. . N

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
aliskiren NNS N
( ( N
150 CD N
mg NN N
) ) N
, , N
aliskiren RB N
( ( N
300 CD N
mg NN N
) ) N
, , N
perindopril NN N
( ( N
5 CD N
mg NN N
) ) N
, , N
perindopril NN N
( ( N
10 CD N
mg NN N
) ) N
or CC N
placebo NN N
. . N

RESULTS NNP N
Aliskiren NNP N
and CC N
perindopril NN N
reduced VBN N
proteinuria NN N
. . N

These DT N
effects NNS N
were VBD N
dose-dependent JJ N
. . N

Furthermore CD N
, , N
24-h JJ N
proteinuria NN N
was VBD N
reduced VBN N
by IN N
23 CD N
% NN N
( ( N
mean JJ N
95 CD N
% NN N
CI NNP N
; : N
2?44 CD N
) ) N
by IN N
treatment NN N
with IN N
aliskiren NNS N
( ( N
150 CD N
mg NN N
) ) N
, , N
by IN N
36 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
17?55 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
with IN N
aliskiren NN N
( ( N
300 CD N
mg NN N
) ) N
, , N
by IN N
7.1 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
11?26 CD N
) ) N
with IN N
perindopril NN N
( ( N
5 CD N
mg NN N
) ) N
and CC N
by IN N
25 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
11?39 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
perindopril NN N
( ( N
10 CD N
mg NN N
) ) N
, , N
compared VBN N
to TO N
placebo VB N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
effects NNS N
of IN N
aliskiren NNS N
and CC N
perindopril NN N
. . N

CONCLUSIONS NNP N
Aliskiren NNP N
significantly RB N
reduced VBD N
proteinuria NNS N
. . N

The DT N
antiproteinuric JJ N
effect NN N
is VBZ N
probably RB N
similar JJ N
to TO N
that DT N
of IN N
perindopril NN N
, , N
for IN N
equivalent JJ N
hypotensive JJ N
dosages NNS N
. . N

The DT N
renin JJ N
inhibitor NN N
provides VBZ N
a DT N
promising JJ N
alternative JJ N
approach NN N
for IN N
the DT N
treatment NN N
of IN N
patients NNS N
with IN N
chronic JJ N
proteinuric JJ N
non-diabetic JJ N
kidney NN N
disease NN N
. . N

-DOCSTART- -7946254- O O

Enhanced NNP N
small JJ N
group NN N
instruction NN N
using VBG N
choral JJ N
responding NN N
and CC N
student NN N
interaction NN N
for IN N
children NNS N
with IN N
autism NN N
and CC N
developmental JJ N
disabilities NNS N
. . N

The DT N
use NN N
of IN N
effective JJ N
instructional JJ N
strategies NNS N
in IN N
small JJ N
groups NNS N
was VBD N
investigated VBN N
to TO N
determine VB N
learning JJ N
effects NNS N
for IN N
24 CD N
elementary JJ N
age NN N
students NNS N
with IN N
autism NN N
and CC N
developmental JJ N
disabilities NNS N
. . N

Effective JJ N
strategies NNS N
included VBD N
( ( N
a DT N
) ) N
the DT N
use NN N
of IN N
choral JJ N
responding NN N
; : N
( ( N
b NN N
) ) N
the DT N
use NN N
of IN N
student-to-student JJ N
responding NN N
; : N
( ( N
c NN N
) ) N
the DT N
rotation NN N
of IN N
materials NNS N
every DT N
5 CD N
minutes NNS N
during IN N
the DT N
30-minute JJ N
group NN N
while IN N
teaching VBG N
2 CD N
to TO N
3 CD N
concepts NNS N
; : N
and CC N
( ( N
d NN N
) ) N
the DT N
use NN N
of IN N
random NN N
, , N
unpredictable JJ N
trials NNS N
for IN N
student NN N
responding VBG N
. . N

Thirty-minute JJ N
language NN N
groups NNS N
were VBD N
targeted VBN N
to TO N
teach VB N
receptive JJ N
and CC N
expressive JJ N
skills NNS N
using VBG N
pictures NNS N
and CC N
common JJ N
objects NNS N
across IN N
five CD N
categories NNS N
( ( N
e.g. NN N
, , N
household NN N
items NNS N
, , N
foods NNS N
) ) N
. . N

Results JJ N
showed VBD N
increased JJ N
opportunities NNS N
to TO N
respond VB N
, , N
increased JJ N
levels NNS N
of IN N
responding VBG N
and CC N
academic JJ N
engagement NN N
, , N
higher JJR N
gains NNS N
on IN N
weekly JJ N
criterion-referenced JJ N
pre- NN N
and CC N
posttests NNS N
, , N
and CC N
decreased VBD N
passive JJ N
and CC N
inappropriate JJ N
student NN N
behavior NN N
during IN N
interventions NNS N
. . N

-DOCSTART- -16253098- O O

Oral NNP N
health NN N
impacts NNS N
on IN N
daily JJ N
living NN N
related VBN N
to TO N
four CD N
different JJ N
treatment NN N
protocols NNS N
for IN N
chronic JJ N
periodontitis NN N
. . N

BACKGROUND IN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
evaluate VB N
the DT N
oral JJ N
health NN N
impacts NNS N
perceived VBN N
by IN N
patients NNS N
submitted VBN N
to TO N
different JJ N
treatments NNS N
of IN N
chronic JJ N
periodontitis NN N
and CC N
their PRP$ N
association NN N
with IN N
clinical JJ N
parameters NNS N
. . N

METHODS NNP N
Sixty NNP N
patients NNS N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
therapeutic JJ N
groups NNS N
: : N
control NN N
, , N
treated VBN N
with IN N
full-mouth JJ N
scaling NN N
and CC N
root NN N
planing NN N
( ( N
SRP NNP N
) ) N
; : N
test $ N
1 CD N
, , N
treated VBN N
with IN N
SRP NNP N
and CC N
400 CD N
mg NNS N
systemically RB N
administered VBN N
metronidazole NN N
( ( N
MET NNP N
) ) N
three CD N
times NNS N
per IN N
day NN N
for IN N
10 CD N
days NNS N
; : N
test JJS N
2 CD N
, , N
treated VBN N
with IN N
SRP NNP N
and CC N
professional JJ N
supragingival NN N
plaque NN N
removal NN N
( ( N
PP NNP N
) ) N
every DT N
week NN N
for IN N
3 CD N
months NNS N
; : N
and CC N
test VB N
3 CD N
, , N
treated VBN N
with IN N
SRP NNP N
and CC N
MET NNP N
plus CC N
PP NNP N
. . N

Clinical NNP N
periodontal JJ N
measurements NNS N
and CC N
data NNS N
regarding VBG N
patients NNS N
' POS N
oral JJ N
health NN N
impacts NNS N
( ( N
perceived VBN N
impacts NNS N
on IN N
bleeding VBG N
gums NNS N
, , N
gingival JJ N
recession NN N
, , N
sensitivity NN N
to TO N
cold VB N
, , N
packing VBG N
foods NNS N
, , N
aesthetics NNS N
, , N
bad JJ N
breath NN N
, , N
and CC N
tooth DT N
mobility NN N
) ) N
were VBD N
collected VBN N
at IN N
baseline NN N
and CC N
3 CD N
months NNS N
after IN N
therapy NN N
. . N

RESULTS NNP N
All NNP N
groups NNS N
presented VBD N
significant JJ N
improvement NN N
in IN N
oral JJ N
health NN N
perceived VBD N
impacts NNS N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
improvement NN N
of IN N
oral JJ N
health NN N
impacts NNS N
among IN N
groups NNS N
subjected VBN N
to TO N
different JJ N
treatments NNS N
. . N

The DT N
clinical JJ N
data NNS N
of IN N
percentage NN N
of IN N
deep JJ N
probing VBG N
depth NN N
, , N
deep JJ N
clinical JJ N
attachment NN N
level NN N
, , N
and CC N
bleeding VBG N
on IN N
probing VBG N
were VBD N
found VBN N
to TO N
be VB N
correlated VBN N
significantly RB N
with IN N
oral JJ N
health NN N
impacts NNS N
. . N

CONCLUSIONS NNP N
Periodontal NNP N
treatment NN N
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
of IN N
self-perceived JJ N
impacts NNS N
regardless RB N
of IN N
the DT N
non-surgical JJ N
treatment NN N
protocol NN N
employed VBN N
. . N

Most JJS N
of IN N
the DT N
clinical JJ N
data NNS N
were VBD N
associated VBN N
with IN N
oral JJ N
health NN N
impacts NNS N
. . N

-DOCSTART- -17621027- O O

Observer NNP N
variation NN N
in IN N
the DT N
assessment NN N
of IN N
outcome NN N
in IN N
traumatic JJ N
brain NN N
injury NN N
: : N
experience NN N
from IN N
a DT N
multicenter NN N
, , N
international JJ N
randomized VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE NNP N
Accurate NNP N
and CC N
consistent JJ N
outcome NN N
assessment NN N
is VBZ N
essential JJ N
to TO N
randomized VB N
clinical JJ N
trials NNS N
. . N

We PRP N
aimed VBD N
to TO N
explore VB N
observer JJ N
variation NN N
in IN N
the DT N
assessment NN N
of IN N
outcome NN N
in IN N
a DT N
recently RB N
completed VBN N
trial NN N
of IN N
dexanabinol NN N
in IN N
head JJ N
injury NN N
and CC N
to TO N
consider VB N
steps NNS N
to TO N
reduce VB N
such JJ N
variation NN N
. . N

METHODS NNP N
Eight NNP N
hundred VBD N
sixty-one JJ N
patients NNS N
with IN N
severe JJ N
traumatic JJ N
brain NN N
injury NN N
who WP N
were VBD N
admitted VBN N
to TO N
86 CD N
centers NNS N
were VBD N
included VBN N
in IN N
a DT N
multicenter NN N
, , N
placebo-controlled JJ N
, , N
Phase NNP N
III NNP N
trial NN N
. . N

Outcome NNP N
was VBD N
assessed VBN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
postinjury NN N
using VBG N
the DT N
extended JJ N
Glasgow NNP N
Outcome NNP N
Scale NNP N
; : N
standardized VBD N
assessment NN N
was VBD N
facilitated VBN N
by IN N
the DT N
use NN N
of IN N
a DT N
structured JJ N
interview NN N
. . N

Before IN N
initiation NN N
of IN N
trial NN N
centers NNS N
, , N
outcome JJ N
ratings NNS N
were VBD N
obtained VBN N
for IN N
sample JJ N
cases NNS N
to TO N
establish VB N
initial JJ N
levels NNS N
of IN N
agreement NN N
. . N

Training NN N
sessions NNS N
in IN N
outcome JJ N
assessment NN N
were VBD N
held VBN N
, , N
and CC N
problems NNS N
in IN N
assigning VBG N
outcome NN N
were VBD N
investigated VBN N
. . N

During IN N
the DT N
trial NN N
, , N
a DT N
process NN N
of IN N
central JJ N
review NN N
was VBD N
established VBN N
to TO N
monitor VB N
performance NN N
. . N

Interobserver NNP N
variation NN N
was VBD N
analyzed VBN N
using VBG N
the DT N
kappa NN N
statistic JJ N
. . N

RESULTS NNP N
Substantial NNP N
observer JJ N
variation NN N
was VBD N
found VBN N
in IN N
the DT N
rating NN N
of IN N
sample JJ N
cases NNS N
( ( N
weighted JJ N
kappa NN N
, , N
0.72 CD N
; : N
confidence NN N
interval NN N
, , N
0.68-0.75 JJ N
) ) N
and CC N
in IN N
assigning VBG N
outcome NN N
based VBN N
on IN N
completed VBN N
structured JJ N
interviews NNS N
( ( N
weighted JJ N
kappa NN N
, , N
0.61 CD N
; : N
confidence NN N
interval NN N
, , N
0.57-0.64 JJ N
) ) N
. . N

In IN N
the DT N
early JJ N
stages NNS N
of IN N
the DT N
trial NN N
, , N
a DT N
relatively RB N
large JJ N
number NN N
of IN N
discrepancies NNS N
( ( N
29-37 CD N
% NN N
) ) N
were VBD N
identified VBN N
on IN N
central JJ N
review NN N
. . N

This DT N
number NN N
declined VBD N
as IN N
the DT N
trial NN N
progressed VBD N
and CC N
coincided VBD N
with IN N
investigator NN N
training NN N
and CC N
feedback NN N
from IN N
central JJ N
review NN N
. . N

Centers NNS N
with IN N
higher JJR N
enrollment NN N
rates NNS N
showed VBD N
better JJR N
performance NN N
. . N

CONCLUSION NNP N
Observer NNP N
variation NN N
in IN N
outcome JJ N
assessment NN N
is VBZ N
a DT N
significant JJ N
problem NN N
for IN N
head NN N
injury NN N
trials NNS N
. . N

Consistency NN N
can MD N
be VB N
improved VBN N
by IN N
standardizing VBG N
procedures NNS N
, , N
training VBG N
assessors NNS N
, , N
and CC N
monitoring VBG N
the DT N
quality NN N
of IN N
assessments NNS N
and CC N
providing VBG N
feedback NN N
to TO N
interviewers NNS N
. . N

-DOCSTART- -11791023- O O

1999 CD N
WHO/ISH NNP N
Guidelines NNP N
applied VBD N
to TO N
a DT N
1999 CD N
MONICA NNP N
sample NN N
from IN N
northern JJ N
Sweden NNP N
. . N

BACKGROUND NNP N
Treating NNP N
hypertension NN N
with IN N
drugs NNS N
is VBZ N
so RB N
far RB N
the DT N
most RBS N
cost-effective JJ N
way NN N
to TO N
reduce VB N
this DT N
important JJ N
risk NN N
factor NN N
for IN N
cardiovascular JJ N
disease NN N
( ( N
CVD NNP N
) ) N
. . N

It PRP N
is VBZ N
, , N
however RB N
, , N
important JJ N
to TO N
determine VB N
absolute NN N
risk NN N
, , N
and CC N
thereby RB N
estimate VB N
indication NN N
for IN N
drug NN N
treatment NN N
, , N
in IN N
order NN N
to TO N
maintain VB N
a DT N
cost-effective JJ N
drug NN N
treatment NN N
. . N

WHO/ISH NNP N
Hypertension NNP N
Guidelines NNP N
from IN N
1999 CD N
propose NN N
a DT N
risk NN N
stratification NN N
for IN N
estimating VBG N
absolute NN N
risk NN N
for IN N
CVD NNP N
based VBN N
on IN N
blood NN N
pressure NN N
and CC N
additional JJ N
risk NN N
factors NNS N
, , N
target NN N
organ JJ N
damage NN N
( ( N
TOD NNP N
) ) N
and CC N
CVD NNP N
. . N

OBJECTIVES NNP N
We PRP N
studied VBD N
the DT N
consequences NNS N
of IN N
applying VBG N
the DT N
recent JJ N
WHO/ISH NNP N
risk NN N
stratification NN N
scheme NN N
to TO N
a DT N
MONICA NNP N
sample NN N
of IN N
6000 CD N
subjects NNS N
from IN N
a DT N
geographically RB N
defined VBN N
population NN N
in IN N
northern JJ N
Sweden NNP N
, , N
regarding VBG N
indications NNS N
for IN N
treatment NN N
, , N
target VB N
blood NN N
pressure NN N
and CC N
risk NN N
distribution NN N
. . N

METHODS NNP N
We PRP N
have VBP N
risk-classified JJ N
each DT N
of IN N
these DT N
patients NNS N
using VBG N
a DT N
computer NN N
program NN N
, , N
according VBG N
to TO N
the DT N
WHO/ISH NNP N
scheme NN N
. . N

Data NNP N
on IN N
TOD NNP N
were VBD N
not RB N
available JJ N
. . N

RESULTS NNP N
In IN N
all DT N
, , N
917 CD N
( ( N
15 CD N
% NN N
) ) N
had VBD N
drug-treated JJ N
hypertension NN N
. . N

Three-quarters NNS N
( ( N
n JJ N
= NNP N
737 CD N
) ) N
were VBD N
inadequately RB N
treated VBN N
, , N
with IN N
blood NN N
pressure NN N
levels NNS N
at IN N
or CC N
above VB N
140 CD N
or CC N
90 CD N
mmHg NN N
. . N

1773 CD N
( ( N
30 CD N
% NN N
of IN N
5997 CD N
) ) N
untreated JJ N
subjects NNS N
had VBD N
a DT N
blood NN N
pressure NN N
of IN N
140/90 CD N
or CC N
above RB N
; : N
16 CD N
% NN N
in IN N
the DT N
low- JJ N
, , N
62 CD N
% NN N
in IN N
the DT N
medium- NN N
, , N
8 CD N
% NN N
in IN N
the DT N
high- NN N
, , N
and CC N
14 CD N
% NN N
in IN N
the DT N
very-high-risk JJ N
group NN N
. . N

The DT N
corresponding JJ N
risk-group JJ N
pattern NN N
for IN N
the DT N
inadequately RB N
treated JJ N
hypertensives NNS N
( ( N
n JJ N
= NNP N
737 CD N
) ) N
was VBD N
5.5 CD N
, , N
48.3 CD N
, , N
11.1 CD N
and CC N
35.2 CD N
% NN N
, , N
respectively RB N
. . N

If IN N
we PRP N
shifted VBD N
the DT N
target NN N
blood NN N
pressure NN N
from IN N
below IN N
140/90 CD N
to TO N
below VB N
130/85 CD N
for IN N
drug-treated JJ N
subjects NNS N
under IN N
60 CD N
( ( N
n JJ N
= NNP N
278 CD N
) ) N
the DT N
number NN N
of IN N
inadequately RB N
treated JJ N
subjects NNS N
increased VBN N
by IN N
34 CD N
( ( N
12.2 CD N
% NN N
of IN N
278 CD N
) ) N
; : N
14 CD N
in IN N
the DT N
low-risk JJ N
group NN N
, , N
15 CD N
in IN N
the DT N
medium-risk JJ N
group NN N
, , N
and CC N
only RB N
five CD N
in IN N
the DT N
high- JJ N
or CC N
very-high-risk JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
Only RB N
one-fifth NN N
of IN N
the DT N
drug-treated JJ N
hypertensives NNS N
were VBD N
well RB N
controlled VBN N
. . N

Moreover RB N
, , N
the DT N
incidence NN N
of IN N
newly RB N
detected VBN N
blood NN N
pressure NN N
elevation NN N
was VBD N
high JJ N
. . N

The DT N
majority NN N
of IN N
younger JJR N
subjects NNS N
with IN N
high JJ N
blood NN N
pressure NN N
had VBD N
low JJ N
risk NN N
, , N
but CC N
in IN N
those DT N
aged VBN N
45-54 CD N
this DT N
had VBD N
already RB N
risen VBN N
to TO N
a DT N
medium NN N
risk NN N
. . N

Changing VBG N
the DT N
target NN N
blood NN N
pressure NN N
to TO N
below IN N
130/85 CD N
, , N
for IN N
subjects NNS N
aged VBN N
below IN N
60 CD N
, , N
as IN N
recommended VBN N
by IN N
WHO/ISH NNP N
, , N
affects VBZ N
predominantly RB N
low- JJ N
and CC N
medium-risk JJ N
groups NNS N
. . N

-DOCSTART- -2146389- O O

Direct JJ N
trocar NN N
insertion NN N
vs. FW N
Verres NNP N
needle FW N
use NN N
for IN N
laparoscopic JJ N
sterilization NN N
. . N

A DT N
randomized JJ N
, , N
prospective JJ N
trial NN N
was VBD N
designed VBN N
to TO N
compare VB N
direct JJ N
trocar NN N
insertion NN N
with IN N
prior JJ N
peritoneal JJ N
insufflation NN N
with IN N
a DT N
Verres NNP N
needle NN N
for IN N
laparoscopic NN N
tubal JJ N
sterilization NN N
. . N

Direct JJ N
trocar NN N
insertion NN N
resulted VBD N
in IN N
fewer JJR N
instrument NN N
insertions NNS N
( ( N
21.8 CD N
% NN N
vs. FW N
7.8 CD N
% NN N
) ) N
and CC N
use NN N
of IN N
smaller JJR N
volumes NNS N
of IN N
CO2 NNP N
( ( N
2.67 CD N
vs. FW N
2.32 CD N
L NNP N
) ) N
. . N

Direct JJ N
trocar NN N
use NN N
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
operating NN N
time NN N
from IN N
9 CD N
minutes NNS N
, , N
40 CD N
seconds NNS N
in IN N
the DT N
needle JJ N
group NN N
to TO N
7 CD N
minutes NNS N
, , N
30 CD N
seconds NNS N
in IN N
the DT N
trocar NN N
group NN N
. . N

Minor NNP N
omental JJ N
injuries NNS N
occurred VBD N
in IN N
a DT N
small JJ N
percentage NN N
of IN N
each DT N
group NN N
, , N
while IN N
serious JJ N
complications NNS N
occurred VBD N
once RB N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -16393600- O O

Pilot NNP N
study NN N
of IN N
imiquimod JJ N
5 CD N
% NN N
cream NN N
as IN N
adjunctive JJ N
therapy NN N
to TO N
curettage VB N
and CC N
electrodesiccation NN N
for IN N
nodular JJ N
basal NN N
cell NN N
carcinoma NN N
. . N

BACKGROUND NNP N
Curettage NNP N
and CC N
electrodesiccation NN N
( ( N
C NNP N
& CC N
D NNP N
) ) N
is VBZ N
a DT N
widely RB N
used VBN N
method NN N
to TO N
treat VB N
nodular JJ N
basal NN N
cell NN N
carcinoma NN N
( ( N
BCC NNP N
) ) N
. . N

However RB N
, , N
residual JJ N
tumor NN N
is VBZ N
present JJ N
immediately RB N
after IN N
the DT N
procedure NN N
in IN N
approximately RB N
20 CD N
to TO N
40 CD N
% NN N
of IN N
cases NNS N
. . N

Imiquimod NNP N
, , N
a DT N
topical JJ N
immune NN N
response NN N
modifier NN N
that WDT N
targets VBZ N
Toll-like NNP N
receptor NN N
7 CD N
, , N
is VBZ N
currently RB N
approved VBN N
for IN N
superficial JJ N
BCC NNP N
. . N

OBJECTIVE NNP N
In IN N
a DT N
double-blind JJ N
, , N
vehicle-controlled JJ N
study NN N
, , N
the DT N
administration NN N
of IN N
imiquimod NN N
after IN N
C NNP N
& CC N
D NNP N
was VBD N
investigated VBN N
to TO N
determine VB N
if IN N
the DT N
combination NN N
regimen NNS N
would MD N
reduce VB N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
compared VBN N
with IN N
C NNP N
& CC N
D NNP N
alone RB N
in IN N
patients NNS N
with IN N
nodular JJ N
BCC NNP N
. . N

METHODS NNP N
Twenty NNP N
patients NNS N
received VBD N
three CD N
cycles NNS N
of IN N
C NNP N
& CC N
D NNP N
followed VBN N
by IN N
imiquimod JJ N
5 CD N
% NN N
or CC N
vehicle NN N
cream NN N
once RB N
daily JJ N
for IN N
1 CD N
month NN N
as IN N
adjunctive JJ N
therapy NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
. . N

The DT N
secondary JJ N
end NN N
points NNS N
included VBD N
the DT N
time NN N
to TO N
heal VB N
and CC N
cosmetic JJ N
appearance NN N
. . N

RESULTS NNP N
Twenty NNP N
patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
imiquimod NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
vehicle NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
treatment NN N
group NN N
. . N

At IN N
8 CD N
weeks NNS N
, , N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
residual JJ N
tumor NN N
was VBD N
substantially RB N
decreased VBN N
with IN N
imiquimod JJ N
therapy NN N
( ( N
10 CD N
% NN N
) ) N
compared VBN N
with IN N
vehicle NN N
( ( N
40 CD N
% NN N
) ) N
. . N

Wounds VBZ N
in IN N
the DT N
vehicle NN N
group NN N
healed VBD N
more RBR N
quickly RB N
than IN N
those DT N
in IN N
the DT N
imiquimod NN N
group NN N
, , N
although IN N
by IN N
8 CD N
weeks NNS N
, , N
all DT N
excision NN N
sites NNS N
were VBD N
healed VBN N
. . N

The DT N
majority NN N
of IN N
scars NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
atrophic JJ N
and CC N
hypopigmented VBD N
, , N
whereas IN N
most JJS N
scars NNS N
in IN N
the DT N
imiquimod NN N
group NN N
were VBD N
flat JJ N
and CC N
slightly RB N
pink VBP N
. . N

CONCLUSION NNP N
Imiquimod NNP N
5 CD N
% NN N
cream NN N
once RB N
daily JJ N
for IN N
1 CD N
month NN N
as IN N
adjunctive JJ N
therapy NN N
after IN N
C NNP N
& CC N
D NNP N
substantially RB N
reduced VBD N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
and CC N
improved VBD N
the DT N
cosmetic JJ N
appearance NN N
compared VBN N
with IN N
C NNP N
& CC N
D NNP N
alone RB N
. . N

These DT N
preliminary JJ N
results NNS N
suggest VBP N
that IN N
further JJ N
studies NNS N
to TO N
investigate VB N
imiquimod JJ N
adjunctive JJ N
therapy NN N
are VBP N
warranted VBN N
. . N

-DOCSTART- -11501687- O O

Olanzapine NNP N
versus NN N
haloperidol NN N
in IN N
children NNS N
with IN N
autistic JJ N
disorder NN N
: : N
an DT N
open JJ N
pilot NN N
study NN N
. . N

OBJECTIVES NNP N
Conventional NNP N
neuroleptics NNS N
ameliorate VBP N
symptoms NNS N
in IN N
children NNS N
with IN N
autistic JJ N
disorder NN N
; : N
however RB N
, , N
they PRP N
are VBP N
known VBN N
to TO N
cause VB N
dyskinesias NN N
. . N

Atypical JJ N
neuroleptics NNS N
, , N
including VBG N
olanzapine NN N
, , N
may MD N
have VB N
less JJR N
risk NN N
for IN N
dyskinesia NN N
, , N
but CC N
their PRP$ N
efficacy NN N
in IN N
autistic JJ N
disorder NN N
is VBZ N
not RB N
established VBN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
safety NN N
and CC N
effectiveness NN N
of IN N
open-label JJ N
olanzapine NN N
as IN N
a DT N
treatment NN N
for IN N
children NNS N
with IN N
autistic JJ N
disorder NN N
by IN N
using VBG N
haloperidol NN N
as IN N
a DT N
standard JJ N
comparator NN N
treatment NN N
. . N

METHOD NNP N
In IN N
a DT N
parallel JJ N
groups NNS N
design NN N
, , N
12 CD N
children NNS N
with IN N
DSM-IV NNP N
autistic JJ N
disorder NN N
( ( N
mean JJ N
age NN N
7.8+/-2.1 CD N
years NNS N
) ) N
were VBD N
randomized VBN N
to TO N
6 CD N
weeks NNS N
of IN N
open JJ N
treatment NN N
with IN N
olanzapine NN N
or CC N
haloperidol NN N
. . N

Mean NNP N
final JJ N
dosages NNS N
were VBD N
7.9+/-2.5 JJ N
mg/day NN N
for IN N
olanzapine NN N
and CC N
1.4+/-0.7 JJ N
mg/day NN N
for IN N
haloperidol NN N
. . N

Outcome NNP N
measures NNS N
included VBD N
the DT N
Clinical NNP N
Global NNP N
Impressions NNP N
( ( N
CGI NNP N
) ) N
and CC N
the DT N
Children NNP N
's POS N
Psychiatric NNP N
Rating NNP N
Scale NNP N
( ( N
CPRS NNP N
) ) N
. . N

RESULTS NNP N
Both NNP N
groups NNS N
had VBD N
symptom VBN N
reduction NN N
. . N

Five CD N
of IN N
six CD N
in IN N
the DT N
olanzapine NN N
group NN N
and CC N
three CD N
of IN N
six CD N
in IN N
the DT N
haloperidol NN N
group NN N
were VBD N
rated VBN N
as IN N
responders NNS N
according VBG N
to TO N
the DT N
CGI NNP N
Improvement NNP N
item NN N
. . N

Subjects NNS N
showed VBD N
improvement NN N
on IN N
the DT N
CPRS NNP N
Autism NNP N
Factor NNP N
( ( N
F1,9 NNP N
= NNP N
24.4 CD N
, , N
p NN N
= NNP N
.0008 NNP N
) ) N
. . N

Side JJ N
effects NNS N
included VBD N
drowsiness NN N
and CC N
weight JJ N
gain NN N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
suggest VBP N
that IN N
olanzapine NN N
is VBZ N
a DT N
promising JJ N
treatment NN N
for IN N
children NNS N
with IN N
autistic JJ N
disorder NN N
. . N

Further JJ N
placebo-controlled JJ N
and CC N
long-term JJ N
studies NNS N
of IN N
olanzapine NN N
in IN N
autistic JJ N
disorder NN N
are VBP N
required VBN N
. . N

-DOCSTART- -24201232- O O

Double-blind NNP N
, , N
placebo-controlled JJ N
trial NN N
of IN N
risperidone NN N
plus CC N
amantadine NN N
in IN N
children NNS N
with IN N
autism NN N
: : N
a DT N
10-week JJ N
randomized NN N
study NN N
. . N

OBJECTIVE NNP N
This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
adding VBG N
amantadine NN N
to TO N
risperidone VB N
for IN N
treatment NN N
of IN N
autism NN N
. . N

METHODS NNP N
Forty NNP N
outpatients NNS N
aged VBD N
4 CD N
to12 NN N
years NNS N
, , N
who WP N
were VBD N
diagnosed VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
based VBN N
on IN N
the DT N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
, , N
Text NNP N
Revision NNP N
criteria NNS N
, , N
were VBD N
assigned VBN N
to TO N
this DT N
double-blind JJ N
clinical JJ N
trial NN N
. . N

The DT N
subjects NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
2 CD N
groups NNS N
. . N

One CD N
group NN N
received VBD N
risperidone JJ N
plus CC N
amantadine JJ N
, , N
and CC N
the DT N
other JJ N
group NN N
received VBD N
risperidone JJ N
plus CC N
placebo NN N
. . N

The DT N
dose NN N
of IN N
risperidone NN N
was VBD N
titrated VBN N
between IN N
1 CD N
and CC N
2.0 CD N
mg/d NN N
, , N
and CC N
the DT N
dose NN N
of IN N
amantadine NN N
was VBD N
100 CD N
or CC N
150 CD N
mg/d NNS N
for IN N
patients NNS N
less JJR N
than IN N
30 CD N
kg NN N
or CC N
more JJR N
than IN N
30 CD N
kg NNS N
, , N
respectively RB N
. . N

The DT N
patients NNS N
were VBD N
assessed VBN N
using VBG N
the DT N
Aberrant NNP N
Behavioral NNP N
Checklist-Community NNP N
( ( N
ABC-C NNP N
) ) N
and CC N
adverse JJ N
effects NNS N
checklist NN N
as RB N
well RB N
as IN N
clinical JJ N
global JJ N
impression-improvement NN N
( ( N
CGI-I NNP N
) ) N
at2 VBZ N
checkpoints NNS N
of IN N
5-week JJ N
intervals NNS N
after IN N
the DT N
baseline NN N
. . N

Informed NNP N
consentwas NN N
obtained VBN N
from IN N
the DT N
parents NNS N
of IN N
each DT N
participant NN N
. . N

RESULTS NNP N
Among IN N
ABC-C NNP N
subscales NNS N
, , N
Hyperactivity NNP N
and CC N
Irritability NNP N
showed VBD N
significantly RB N
greater JJR N
reduction NN N
in IN N
the DT N
amantadine NN N
group NN N
than IN N
the DT N
placebo NN N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
adverse JJ N
effects NNS N
between IN N
the DT N
2 CD N
groups NNS N
. . N

The DT N
CGI-I JJ N
scores NNS N
show VBP N
significant JJ N
improvement NN N
in IN N
the DT N
amantadine NN N
group NN N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
. . N

CONCLUSIONS VB N
The DT N
present JJ N
study NN N
suggests VBZ N
that IN N
amantadine NN N
may MD N
be VB N
a DT N
potential JJ N
adjunctive JJ N
treatment NN N
strategy NN N
for IN N
autism NN N
and CC N
it PRP N
was VBD N
generally RB N
well RB N
tolerated VBN N
. . N

-DOCSTART- -21586215- O O

Effect NN N
of IN N
a DT N
multi-faceted JJ N
intervention NN N
on IN N
gingival JJ N
health NN N
among IN N
adults NNS N
with IN N
systemic JJ N
sclerosis NN N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
adaptive JJ N
oral JJ N
hygiene NN N
devices NNS N
and CC N
orofacial JJ N
exercise NN N
to TO N
improve VB N
gingival JJ N
health NN N
among IN N
adults NNS N
with IN N
systemic JJ N
sclerosis NN N
( ( N
SSc NNP N
) ) N
. . N

METHODS NNP N
Forty-eight JJ N
patients NNS N
with IN N
SSc NNP N
were VBD N
assigned VBN N
randomly RB N
to TO N
the DT N
multifaceted VBN N
oral JJ N
health NN N
intervention NN N
or CC N
usual JJ N
dental JJ N
care NN N
control NN N
group NN N
. . N

Participants NNS N
in IN N
the DT N
intervention NN N
group NN N
received VBD N
a DT N
rechargeable JJ N
, , N
powered JJ N
Oral-B? NNP N
oscillating-rotating-pulsating NN N
toothbrush NN N
and CC N
a DT N
Reach? NNP N
Access? NNP N
Flosser NNP N
that WDT N
has VBZ N
a DT N
toothbrush-like JJ N
handle NN N
. . N

For IN N
those DT N
with IN N
an DT N
oral JJ N
aperture NN N
of IN N
less JJR N
than IN N
40 CD N
mm NN N
, , N
orofacial JJ N
exercises NNS N
were VBD N
taught VBN N
. . N

Participants NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
each DT N
given VBN N
a DT N
manual JJ N
toothbrush NN N
and CC N
dental JJ N
floss NN N
. . N

Participants NNS N
in IN N
both DT N
groups NNS N
received VBD N
instructions NNS N
and CC N
demonstration NN N
on IN N
the DT N
use NN N
of IN N
the DT N
devices NNS N
, , N
and CC N
were VBD N
requested VBN N
to TO N
perform VB N
the DT N
respective JJ N
intervention NN N
twice RB N
a DT N
day NN N
for IN N
6 CD N
months NNS N
. . N

Evaluations NNS N
were VBD N
at IN N
baseline NN N
, , N
3- JJ N
, , N
and CC N
6-months NNS N
. . N

The DT N
main JJ N
outcome NN N
was VBD N
gingival JJ N
index NN N
( ( N
GI NNP N
) ) N
, , N
an DT N
indicator NN N
of IN N
gingival JJ N
inflammation NN N
. . N

RESULTS NNP N
Both NNP N
groups NNS N
showed VBD N
significant JJ N
reduction NN N
in IN N
GI NNP N
scores NNS N
at IN N
6 CD N
months NNS N
( ( N
ps JJ N
< NNP N
0.005 CD N
) ) N
. . N

Reduction NN N
in IN N
GI NNP N
scores NNS N
of IN N
the DT N
intervention NN N
group NN N
at IN N
6 CD N
months NNS N
was VBD N
20.8 CD N
% NN N
which WDT N
is VBZ N
considered VBN N
to TO N
be VB N
clinically RB N
significant JJ N
. . N

Compared VBN N
to TO N
the DT N
control NN N
group NN N
, , N
the DT N
intervention NN N
group NN N
showed VBD N
a DT N
significant JJ N
and CC N
larger JJR N
reduction NN N
in IN N
GI NNP N
score NN N
by IN N
8 CD N
% NN N
at IN N
6 CD N
months NNS N
( ( N
p=0.0007 NN N
) ) N
. . N

CONCLUSIONS JJ N
Results NNP N
support NN N
the DT N
use NN N
of IN N
adaptive JJ N
devices NNS N
and CC N
orofacial JJ N
exercise NN N
to TO N
improve VB N
gingival NN N
health NN N
in IN N
adults NNS N
with IN N
SSc NNP N
when WRB N
compared VBN N
to TO N
use VB N
of IN N
manual JJ N
toothbrushing NN N
and CC N
finger-held JJ N
flossing NN N
. . N

Recommending VBG N
and CC N
educating VBG N
patients NNS N
with IN N
SSc NNP N
to TO N
use VB N
adaptive JJ N
devices NNS N
to TO N
clean VB N
the DT N
tooth NN N
surfaces NNS N
looks VBZ N
promising VBG N
for IN N
long-term JJ N
oral JJ N
health NN N
improvement NN N
. . N

-DOCSTART- -22972771- O O

Effects NNS N
of IN N
self-directed JJ N
stress NN N
management NN N
training NN N
and CC N
home-based JJ N
exercise NN N
on IN N
stress NN N
management NN N
skills NNS N
in IN N
cancer NN N
patients NNS N
receiving VBG N
chemotherapy NN N
. . N

Although IN N
exercise NN N
may MD N
be VB N
used VBN N
by IN N
some DT N
to TO N
decrease VB N
distress NN N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
how WRB N
it PRP N
may MD N
contribute VB N
to TO N
stress VB N
management NN N
( ( N
SM NNP N
) ) N
among IN N
patients NNS N
receiving VBG N
chemotherapy NN N
. . N

We PRP N
evaluated VBD N
whether IN N
exercise NN N
separately RB N
or CC N
in IN N
combination NN N
with IN N
SM NNP N
training NN N
is VBZ N
effective JJ N
at IN N
increasing VBG N
perceived JJ N
ability NN N
to TO N
manage VB N
stress NN N
. . N

Patients NNS N
receiving VBG N
chemotherapy NN N
( ( N
N NNP N
= NNP N
391 CD N
) ) N
were VBD N
randomized VBN N
to TO N
receive VB N
usual JJ N
care NN N
only RB N
( ( N
UCO NNP N
) ) N
, , N
SM NNP N
, , N
exercise NN N
( ( N
EX NNP N
) ) N
, , N
or CC N
stress JJ N
management NN N
and CC N
exercise NN N
( ( N
SMEX NNP N
) ) N
. . N

They PRP N
completed VBD N
the DT N
Measure NN N
of IN N
Current NNP N
Status NNP N
prior RB N
to TO N
receiving VBG N
chemotherapy NN N
and CC N
12 CD N
weeks NNS N
after IN N
the DT N
first JJ N
infusion NN N
. . N

We PRP N
hypothesized VBD N
that IN N
participants NNS N
randomized VBN N
to TO N
an DT N
intervention NN N
condition NN N
would MD N
report VB N
improvements NNS N
in IN N
relaxation NN N
, , N
awareness NN N
of IN N
tension NN N
, , N
getting VBG N
needs NNS N
met VBD N
and CC N
coping VBG N
confidence NN N
compared VBN N
with IN N
those DT N
receiving VBG N
UCO NNP N
. . N

Results NNP N
indicated VBD N
significant JJ N
group-by-time JJ N
interactions NNS N
for IN N
the DT N
following NN N
: : N
relaxation NN N
( ( N
UCO NNP N
versus NN N
SM NNP N
, , N
p NN N
= NNP N
0.008 CD N
) ) N
, , N
awareness NN N
of IN N
tension NN N
( ( N
UCO NNP N
versus NN N
SMEX NNP N
, , N
p NN N
= VBD N
0.029 CD N
and CC N
UCO NNP N
versus NN N
EX NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
getting VBG N
needs NNS N
met VBD N
( ( N
UCO NNP N
versus NN N
SMEX NNP N
, , N
p NN N
= NNP N
0.020 CD N
) ) N
and CC N
Measure NN N
of IN N
Current NNP N
Status NNP N
total NN N
score NN N
( ( N
UCO NNP N
versus NN N
SMEX NNP N
, , N
p NN N
= VBD N
0.007 CD N
and CC N
UCO NNP N
versus NN N
EX NNP N
, , N
p NN N
= NNP N
0.016 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
group-by-time JJ N
interactions NNS N
for IN N
coping VBG N
confidence NN N
( ( N
p-values JJ N
> NNP N
0.05 CD N
) ) N
. . N

This DT N
study NN N
provides VBZ N
support NN N
for IN N
including VBG N
an DT N
exercise NN N
component NN N
in IN N
SM NNP N
interventions NNS N
for IN N
cancer NN N
patients NNS N
receiving VBG N
chemotherapy NN N
( ( N
clinicaltrials.gov JJ N
identifier NN N
: : N
NCT00740038 NNP N
) ) N
. . N

-DOCSTART- -18565251- O O

Intra-articular JJ N
hyaluronic JJ N
acid NN N
compared VBN N
to TO N
exercise VB N
therapy NN N
in IN N
osteoarthritis NN N
of IN N
the DT N
ankle NN N
. . N

A DT N
prospective JJ N
randomized VBN N
trial NN N
with IN N
long-term JJ N
follow-up NN N
. . N

OBJECTIVE CC N
The DT N
goal NN N
of IN N
this DT N
study NN N
has VBZ N
been VBN N
to TO N
determine VB N
whether IN N
hyaluronic JJ N
acid NN N
( ( N
HA NNP N
) ) N
or CC N
exercise NN N
therapy NN N
can MD N
improve VB N
functional JJ N
parameters NNS N
in IN N
patients NNS N
with IN N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
of IN N
the DT N
ankle NN N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
clinical JJ N
trial NN N
, , N
43 CD N
ankles NNS N
( ( N
30 CD N
patients NNS N
) ) N
with IN N
radiographic JJ N
Kellgren NNP N
Lawrence NNP N
grade VBD N
III NNP N
OA NNP N
were VBD N
randomized VBN N
to TO N
receive VB N
three CD N
intra-articular JJ N
HA NNP N
injections NNS N
, , N
with IN N
one-week JJ N
interval NN N
of IN N
or CC N
exercise NN N
therapy NN N
for IN N
six CD N
weeks NNS N
. . N

Patients NNS N
were VBD N
evaluated VBN N
by IN N
the DT N
American JJ N
Orthopaedic NNP N
Foot NNP N
and CC N
Ankle NNP N
Society NNP N
( ( N
AOFAS NNP N
) ) N
Ankle-Hindfoot NNP N
Scale NNP N
and CC N
followed-up NN N
after IN N
12 CD N
months NNS N
. . N

RESULTS NNP N
Total JJ N
AOFAS NNP N
Ankle-Hindfoot NNP N
score NN N
of IN N
OA NNP N
patients NNS N
has VBZ N
improved VBN N
in IN N
both DT N
groups NNS N
, , N
varying VBG N
from IN N
61.6+/-16.8 JJ N
to TO N
90.1+/-9.7 JJ N
with IN N
HA NNP N
treatment NN N
and CC N
from IN N
72.1+/-16.6 JJ N
to TO N
87.5+/-17.5 JJ N
using VBG N
exercise NN N
therapy NN N
at IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
This DT N
prospective JJ N
randomized VBN N
trial NN N
confirmed VBD N
that IN N
, , N
both DT N
HA NNP N
injections NNS N
and CC N
exercise NN N
therapy NN N
provide VBP N
functional JJ N
improvement NN N
. . N

However RB N
, , N
larger JJR N
trials NNS N
with IN N
longer JJR N
follow-up NN N
are VBP N
necessary JJ N
for IN N
more RBR N
definite JJ N
conclusions NNS N
. . N

-DOCSTART- -7799030- O O

Cytokine NN N
levels NNS N
and CC N
systemic JJ N
toxicity NN N
in IN N
patients NNS N
undergoing VBG N
isolated JJ N
limb NN N
perfusion NN N
with IN N
high-dose JJ N
tumor NN N
necrosis NN N
factor NN N
, , N
interferon NN N
gamma NN N
, , N
and CC N
melphalan NN N
. . N

PURPOSE NNP N
Isolated NNP N
limb NN N
perfusion NN N
( ( N
ILP NNP N
) ) N
with IN N
tumor NN N
necrosis NN N
factor NN N
( ( N
TNF NNP N
) ) N
, , N
interferon JJ N
gamma NN N
, , N
and CC N
melphalan NN N
( ( N
M NNP N
) ) N
has VBZ N
been VBN N
reported VBN N
to TO N
result VB N
in IN N
high JJ N
response NN N
rates NNS N
for IN N
extremity NN N
melanoma NN N
and CC N
sarcoma NN N
. . N

We PRP N
have VBP N
evaluated VBN N
the DT N
relationship NN N
of IN N
systemic JJ N
TNF NNP N
exposure NN N
to TO N
induction NN N
of IN N
several JJ N
secondary JJ N
mediators NNS N
and CC N
incidence NN N
of IN N
systemic JJ N
toxicity NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Nineteen NNP N
patients NNS N
with IN N
extremity NN N
melanoma NN N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
or CC N
sarcoma NN N
( ( N
n JJ N
= NNP N
3 CD N
) ) N
, , N
underwent JJ N
90-minute JJ N
ILP NNP N
with IN N
TNF-alpha NNP N
, , N
interferon NN N
gamma NN N
( ( N
0.2 CD N
mg NN N
) ) N
, , N
and CC N
M NNP N
( ( N
10 CD N
to TO N
13 CD N
mg/L NN N
of IN N
limb NN N
volume NN N
) ) N
( ( N
TNF/IFN/M NNP N
) ) N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
, , N
or CC N
M NNP N
alone RB N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
. . N

Continuous JJ N
intraoperative JJ N
monitoring NN N
( ( N
CIM NNP N
) ) N
for IN N
systemic JJ N
leak NN N
from IN N
the DT N
perfusion NN N
circuit NN N
was VBD N
performed VBN N
using VBG N
radioactive JJ N
iodine-131 JJ N
albumin NN N
. . N

Cytokine NN N
levels NNS N
in IN N
the DT N
perfusate NN N
and CC N
systemic JJ N
circulation NN N
during IN N
and CC N
after IN N
ILP NNP N
were VBD N
measured VBN N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
. . N

RESULTS NNP N
Systemic NNP N
leaks VBZ N
> CD N
or CC N
= VB N
1 CD N
% NN N
from IN N
the DT N
perfusion NN N
circuit NN N
occurred VBD N
in IN N
six CD N
patients NNS N
who WP N
received VBD N
TNF/IFN/M NNP N
and CC N
in IN N
four CD N
who WP N
received VBD N
M NNP N
alone RB N
. . N

Hypotension NNP N
that IN N
required VBD N
vasopressor NN N
support NN N
occurred VBD N
in IN N
six CD N
of IN N
six CD N
patients NNS N
with IN N
evidence NN N
of IN N
a DT N
leak NN N
( ( N
> CD N
or CC N
= VB N
1 CD N
% NN N
) ) N
and CC N
zero CD N
of IN N
six CD N
patients NNS N
without IN N
a DT N
leak NN N
( ( N
< JJ N
1 CD N
% NN N
) ) N
. . N

These DT N
six CD N
patients NNS N
had VBD N
significantly RB N
higher JJR N
peak JJ N
systemic JJ N
TNF NNP N
levels NNS N
during IN N
and CC N
after IN N
perfusion NN N
than IN N
patients NNS N
without IN N
a DT N
leak NN N
( ( N
2.8 CD N
and CC N
8.2 CD N
ng/mL JJ N
v NN N
0.7 CD N
and CC N
2.0 CD N
ng/mL NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

All PDT N
patients NNS N
who WP N
received VBD N
TNF/IFN/M NNP N
had VBD N
significantly RB N
greater JJR N
increases NNS N
in IN N
systemic JJ N
interleukin-6 JJ N
( ( N
IL-6 NNP N
) ) N
levels NNS N
than IN N
in IN N
patients NNS N
with IN N
M NNP N
alone RB N
( ( N
12,395 CD N
+/- JJ N
10,374 CD N
pg/mL NN N
v NN N
79.4 CD N
+/- JJ N
7.2 CD N
pg/mL NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Intracellular JJ N
adhesion NN N
molecule NN N
( ( N
ICAM NNP N
) ) N
, , N
IL-8 NNP N
, , N
and CC N
TNF-R JJ N
levels NNS N
were VBD N
also RB N
increased VBN N
after IN N
ILP NNP N
with IN N
TNF/IFN/M NNP N
. . N

CONCLUSION NNP N
ILP NNP N
with IN N
TNF/IFN/M NNP N
can MD N
be VB N
safely RB N
performed VBN N
, , N
as IN N
I131 NNP N
albumin VBP N
provides VBZ N
a DT N
sensitive JJ N
measure NN N
of IN N
systemic JJ N
leakage NN N
from IN N
the DT N
perfusion NN N
circuit NN N
. . N

Patients NNS N
with IN N
a DT N
measured JJ N
leak NN N
of IN N
> NN N
or CC N
= VB N
1 CD N
% NN N
develop NN N
mild NN N
and CC N
transient JJ N
postoperative JJ N
hypotension NN N
with IN N
significantly RB N
higher JJR N
systemic JJ N
TNF NNP N
levels NNS N
and CC N
lower JJR N
perfusate NN N
TNF NNP N
levels NNS N
than IN N
in IN N
patients NNS N
without IN N
leaks NNS N
. . N

-DOCSTART- -19415409- O O

The DT N
influence NN N
of IN N
dietary JJ N
fibre NN N
source NN N
and CC N
gender NN N
on IN N
the DT N
postprandial JJ N
glucose NN N
and CC N
lipid JJ N
response NN N
in IN N
healthy JJ N
subjects NNS N
. . N

BACKGROUND NNP N
Consumption NNP N
of IN N
soluble JJ N
dietary JJ N
fibre NN N
is VBZ N
correlated VBN N
with IN N
decreased JJ N
postprandial JJ N
glucose NN N
and CC N
insulin NN N
responses NNS N
and CC N
hence NN N
has VBZ N
beneficial JJ N
effects NNS N
on IN N
the DT N
metabolic JJ N
syndrome NN N
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
investigate VB N
the DT N
effects NNS N
on IN N
postprandial JJ N
glucose NN N
, , N
insulin NN N
and CC N
triglyceride JJ N
concentrations NNS N
of IN N
meals NNS N
enriched VBN N
with IN N
soluble JJ N
dietary JJ N
fibres NNS N
from IN N
oats NNS N
, , N
rye NN N
bran NN N
, , N
sugar JJ N
beet NN N
fibre NN N
or CC N
a DT N
mixture NN N
of IN N
these DT N
three CD N
fibres NNS N
. . N

METHODS NNP N
Thirteen NNP N
healthy JJ N
human JJ N
volunteers NNS N
( ( N
6 CD N
men NNS N
and CC N
7 CD N
women NNS N
, , N
aged VBN N
20-28 CD N
years NNS N
) ) N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

The DT N
subjects NNS N
came VBD N
to TO N
the DT N
study NN N
centre NN N
once RB N
a DT N
week NN N
after IN N
an DT N
overnight JJ N
fast NN N
to TO N
ingest VB N
test NN N
meals NNS N
and CC N
a DT N
control NN N
meal NN N
in IN N
random JJ N
order NN N
. . N

The DT N
meals NNS N
contained VBD N
either CC N
oat JJ N
powder NN N
( ( N
62 CD N
g NN N
, , N
of IN N
which WDT N
2.7 CD N
soluble JJ N
fibre NN N
) ) N
, , N
rye NN N
bran NN N
( ( N
31 CD N
g NN N
, , N
of IN N
which WDT N
1.7 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
, , N
sugar JJ N
beet NN N
fibre NN N
( ( N
19 CD N
g NN N
, , N
of IN N
which WDT N
5 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
, , N
a DT N
mixture NN N
of IN N
these DT N
three CD N
fibres NNS N
( ( N
74 CD N
g NN N
, , N
of IN N
which WDT N
1.7 CD N
g NN N
soluble JJ N
fibre NN N
from IN N
each DT N
source NN N
, , N
giving VBG N
5 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
or CC N
no DT N
added JJ N
fibre NN N
( ( N
control NN N
) ) N
and CC N
were VBD N
all DT N
adjusted VBN N
to TO N
contain VB N
the DT N
same JJ N
total JJ N
amount NN N
of IN N
available JJ N
carbohydrates NNS N
. . N

Blood NN N
samples NNS N
were VBD N
drawn VBN N
before RB N
and CC N
every DT N
30 CD N
min NN N
up RB N
to TO N
180 CD N
min NN N
after IN N
the DT N
meals NNS N
. . N

RESULTS NNP N
Meals NNP N
with IN N
rye NN N
bran NN N
gave VBD N
a DT N
lower JJR N
postprandial JJ N
glucose NN N
peak NN N
when WRB N
compared VBN N
with IN N
the DT N
control NN N
meal NN N
, , N
and CC N
this DT N
effect NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
women NNS N
compared VBN N
to TO N
men NNS N
. . N

Oat NNP N
powder NN N
, , N
containing VBG N
a DT N
low JJ N
amount NN N
of IN N
total JJ N
fibre NN N
and CC N
a DT N
high JJ N
amount NN N
of IN N
carbohydrates NNS N
in IN N
liquid NN N
matrix NN N
, , N
gave VBD N
a DT N
higher JJR N
incremental JJ N
glucose JJ N
peak NN N
concentration NN N
compared VBN N
to TO N
rye VB N
bran NN N
and CC N
sugar NN N
beet NN N
fibre NN N
and CC N
higher JJR N
insulin NN N
incremental JJ N
area NN N
under IN N
curve NN N
compared VBN N
to TO N
control VB N
. . N

The DT N
oat NN N
powder NN N
also RB N
influenced VBD N
the DT N
effects NNS N
of IN N
the DT N
mixed JJ N
meal NN N
, , N
diminishing VBG N
the DT N
glucose-lowering JJ N
effects NNS N
. . N

Postprandial NNP N
triglyceride NN N
levels NNS N
tended VBD N
to TO N
be VB N
higher JJR N
after IN N
all DT N
fibre-rich JJ N
meals NNS N
, , N
but CC N
only RB N
significant JJ N
for IN N
oat NN N
powder NN N
and CC N
the DT N
mixed JJ N
meal NN N
when WRB N
compared VBN N
with IN N
the DT N
control NN N
meal NN N
. . N

CONCLUSIONS NNP N
Postprandial NNP N
glucose NN N
, , N
insulin NN N
and CC N
triglyceride JJ N
concentrations NNS N
are VBP N
influenced VBN N
by IN N
dietary JJ N
fibre-rich JJ N
meals NNS N
, , N
depending VBG N
on IN N
fibre NN N
source NN N
, , N
dose NN N
of IN N
soluble JJ N
and CC N
total JJ N
fibre NN N
and CC N
possibly RB N
gender NN N
. . N

-DOCSTART- -21272822- O O

Using VBG N
baby NN N
books NNS N
to TO N
increase VB N
new JJ N
mothers NNS N
' POS N
safety NN N
practices NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
educational JJ N
baby NN N
books NNS N
are VBP N
an DT N
effective JJ N
method NN N
for IN N
increasing VBG N
low-income JJ N
, , N
first-time JJ N
mothers NNS N
' POS N
safety NN N
practices NNS N
during IN N
their PRP$ N
child NN N
's POS N
first JJ N
18 CD N
months NNS N
. . N

METHODS NNP N
Primiparous JJ N
women NNS N
( ( N
n JJ N
= NNP N
167 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
: : N
an DT N
educational JJ N
book NN N
group NN N
, , N
a DT N
noneducational JJ N
book NN N
group NN N
, , N
or CC N
a DT N
no-book JJ N
group NN N
. . N

Home NNP N
visits NNS N
and CC N
interviews NNS N
measured VBN N
safety NN N
practices NNS N
when WRB N
women NNS N
were VBD N
in IN N
their PRP$ N
third JJ N
trimester NN N
of IN N
pregnancy NN N
( ( N
baseline NN N
) ) N
and CC N
when WRB N
their PRP$ N
children NNS N
were VBD N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
9 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
months NNS N
of IN N
age NN N
. . N

RESULTS NNP N
Women NNP N
in IN N
the DT N
educational JJ N
book NN N
group NN N
had VBD N
fewer JJR N
risks NNS N
in IN N
their PRP$ N
homes NNS N
and CC N
exercised VBD N
more JJR N
safety NN N
practices NNS N
than IN N
the DT N
no-book JJ N
group NN N
( ( N
- : N
20 CD N
% NN N
risk NN N
reduction NN N
; : N
effect NN N
size NN N
= NNP N
-.30 NNP N
) ) N
. . N

When WRB N
the DT N
safety NN N
practices NNS N
involved VBN N
little JJ N
time NN N
or CC N
expense NN N
( ( N
eg UH N
, , N
putting VBG N
away RB N
sharp JJ N
objects NNS N
) ) N
, , N
the DT N
educational JJ N
book NN N
group NN N
was VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
engage VB N
in IN N
these DT N
behaviors NNS N
than IN N
the DT N
no-book JJ N
group NN N
( ( N
40 CD N
% NN N
higher JJR N
practices NNS N
; : N
effect NN N
size NN N
= NNP N
0.19 CD N
) ) N
or CC N
noneducational JJ N
book NN N
group NN N
( ( N
27 CD N
% NN N
higher JJR N
practices NNS N
; : N
effect NN N
size NN N
= NNP N
0.13 CD N
) ) N
. . N

However RB N
, , N
no DT N
differences NNS N
were VBD N
found VBN N
between IN N
groups NNS N
for IN N
behaviors NNS N
that WDT N
required VBD N
high JJ N
effort NN N
in IN N
time NN N
, , N
money NN N
, , N
or CC N
hassle NN N
( ( N
eg JJ N
, , N
installing VBG N
latches NNS N
on IN N
cabinets NNS N
) ) N
. . N

CONCLUSIONS NNP N
Educational NNP N
baby NN N
books NNS N
appear VBP N
to TO N
be VB N
an DT N
easy JJ N
and CC N
low-cost JJ N
way NN N
to TO N
increase VB N
the DT N
safety NN N
practices NNS N
of IN N
new JJ N
mothers NNS N
, , N
especially RB N
if IN N
the DT N
practices NNS N
involve VBP N
little JJ N
to TO N
no DT N
time NN N
, , N
money NN N
, , N
or CC N
hassle NN N
. . N

-DOCSTART- -18633049- O O

The DT N
effect NN N
of IN N
acupressure NN N
at IN N
the DT N
extra JJ N
1 CD N
point NN N
on IN N
subjective JJ N
and CC N
autonomic JJ N
responses NNS N
to TO N
needle VB N
insertion NN N
. . N

BACKGROUND NNP N
Premedication NNP N
with IN N
sedatives NNS N
can MD N
decrease VB N
the DT N
discomfort NN N
associated VBN N
with IN N
invasive JJ N
anesthetic JJ N
procedures NNS N
. . N

Some DT N
researchers NNS N
have VBP N
shown VBN N
that IN N
acupressure NN N
on IN N
the DT N
acupuncture NN N
extra JJ N
1 CD N
point NN N
is VBZ N
effective JJ N
for IN N
sedation NN N
. . N

We PRP N
investigated VBD N
whether IN N
acupressure NN N
on IN N
the DT N
extra JJ N
1 CD N
point NN N
could MD N
alleviate VB N
the DT N
pain NN N
of IN N
needle JJ N
insertion NN N
. . N

METHODS NNP N
We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
acupressure NN N
at IN N
the DT N
extra JJ N
1 CD N
point NN N
or CC N
a DT N
sham JJ N
point NN N
on IN N
needle JJ N
insertion NN N
using VBG N
verbal JJ N
rating NN N
scale NN N
( ( N
VRS NNP N
) ) N
pain NN N
scores NNS N
and CC N
heart NN N
rate NN N
variability NN N
( ( N
HRV NNP N
) ) N
. . N

Twenty-two NNP N
healthy JJ N
female NN N
volunteers NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
groups NNS N
: : N
the DT N
extra JJ N
1 CD N
group NN N
received VBD N
acupressure NN N
at IN N
the DT N
extra JJ N
1 CD N
point NN N
, , N
and CC N
the DT N
sham NN N
group NN N
received VBD N
acupressure NN N
at IN N
a DT N
sham JJ N
point NN N
. . N

After IN N
starting VBG N
the DT N
electrocardiogram NN N
record NN N
, , N
a DT N
27-gauge JJ N
needle NN N
was VBD N
inserted VBN N
into IN N
the DT N
skin NN N
of IN N
a DT N
forearm NN N
. . N

Thereafter NNP N
, , N
another DT N
needle NN N
was VBD N
inserted VBN N
into IN N
the DT N
skin NN N
of IN N
the DT N
other JJ N
forearm NN N
during IN N
acupressure NN N
. . N

RESULTS JJ N
Acupressure NN N
at IN N
the DT N
extra JJ N
1 CD N
point NN N
significantly RB N
reduced VBD N
the DT N
VRS NNP N
, , N
but CC N
acupressure NN N
at IN N
the DT N
sham NN N
increased VBD N
the DT N
VRS NNP N
. . N

Acupressure NN N
at IN N
the DT N
extra JJ N
1 CD N
significantly RB N
reduced VBD N
the DT N
low JJ N
frequency/high JJ N
frequency NN N
ratio NN N
of IN N
HRV NNP N
responding VBG N
to TO N
needle DT N
insertion NN N
. . N

CONCLUSIONS JJ N
Acupressure NN N
at IN N
the DT N
extra JJ N
1 CD N
point NN N
significantly RB N
reduced VBD N
needle JJ N
insertion NN N
pain NN N
compared VBN N
with IN N
acupressure NN N
at IN N
the DT N
sham NN N
point NN N
. . N

Also RB N
, , N
acupressure NN N
at IN N
the DT N
extra JJ N
1 CD N
point NN N
significantly RB N
reduced VBD N
the DT N
low JJ N
frequency/high JJ N
frequency NN N
ratio NN N
of IN N
HRV NNP N
responding VBG N
to TO N
needle VB N
insertion NN N
, , N
which WDT N
implies VBZ N
a DT N
reduction NN N
in IN N
sympathetic JJ N
nervous JJ N
system NN N
activity NN N
. . N

-DOCSTART- -17625432- O O

Efficacy NN N
of IN N
amantadine NN N
on IN N
quality NN N
of IN N
life NN N
in IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
treated VBD N
with IN N
interferon-alpha JJ N
and CC N
ribavirin NN N
: : N
results NNS N
from IN N
a DT N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
. . N

AIM VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
amantadine JJ N
reduces NNS N
deterioration NN N
of IN N
quality NN N
of IN N
life NN N
in IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
during IN N
and CC N
after IN N
treatment NN N
with IN N
interferon-alpha JJ N
( ( N
IFN-alpha NNP N
) ) N
and CC N
ribavirin NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
randomized VBN N
, , N
prospective JJ N
, , N
placebo-controlled JJ N
, , N
multicenter JJ N
trial NN N
, , N
previously RB N
untreated JJ N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
were VBD N
treated VBN N
with IN N
IFN-alpha NNP N
plus CC N
ribavirin JJ N
[ NN N
17 CD N
] NN N
and CC N
randomized VBN N
for IN N
treatment NN N
with IN N
amantadine NN N
( ( N
200 CD N
mg/day NN N
, , N
orally RB N
, , N
n=136 NN N
) ) N
or CC N
placebo NN N
( ( N
n=131 JJ N
) ) N
. . N

Quality NN N
of IN N
life NN N
was VBD N
assessed VBN N
with IN N
the DT N
'Profile NN N
of IN N
Mood NNP N
States NNPS N
' POS N
scale NN N
and CC N
the DT N
'Everyday JJ N
Life NNP N
' POS N
questionnaire NN N
at IN N
baseline NN N
, , N
treatment NN N
week NN N
( ( N
TW NNP N
) ) N
8 CD N
, , N
TW24 NNP N
, , N
TW48 NNP N
, , N
and CC N
at IN N
follow-up JJ N
. . N

RESULTS VB N
Early JJ N
during IN N
treatment NN N
at IN N
TW8 NNP N
, , N
quality NN N
of IN N
life NN N
was VBD N
not RB N
different JJ N
between IN N
patients NNS N
in IN N
the DT N
control NN N
and CC N
the DT N
amantadine NN N
group NN N
. . N

At IN N
TW24 NNP N
, , N
the DT N
control NN N
group NN N
but CC N
not RB N
the DT N
amantadine NN N
group NN N
, , N
however RB N
, , N
showed VBD N
significant JJ N
deterioration NN N
of IN N
the DT N
modalities NNS N
depression NN N
, , N
fatigue NN N
, , N
and CC N
vigor NN N
compared VBN N
with IN N
baseline NN N
. . N

Especially RB N
, , N
nonresponders NNS N
in IN N
the DT N
amantadine NN N
group NN N
showed VBD N
significantly RB N
lower JJR N
deterioration NN N
of IN N
depression NN N
, , N
anger NN N
, , N
mind NN N
function NN N
, , N
everyday JJ N
life NN N
, , N
and CC N
zest JJS N
for IN N
life NN N
than IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
. . N

After IN N
treatment NN N
, , N
the DT N
beneficial JJ N
effects NNS N
of IN N
amantadine NN N
disappeared VBN N
. . N

CONCLUSION VB N
The DT N
addition NN N
of IN N
amantadine NN N
to TO N
IFN-alpha NNP N
plus CC N
ribavirin JJ N
combination NN N
therapy NN N
may MD N
reduce VB N
deterioration NN N
of IN N
depression NN N
, , N
fatigue NN N
, , N
and CC N
vigor NN N
during IN N
treatment NN N
but CC N
does VBZ N
not RB N
affect JJ N
quality NN N
of IN N
life NN N
after IN N
treatment NN N
. . N

-DOCSTART- -23257173- O O

Simvastatin NNP N
reduces VBZ N
sympathetic JJ N
outflow NN N
and CC N
augments NNS N
endothelium-independent JJ N
dilation NN N
in IN N
non-hyperlipidaemic JJ N
primary JJ N
hypertension NN N
. . N

OBJECTIVES NNP N
Previous JJ N
reports NNS N
, , N
involving VBG N
hypercholesterolaemic JJ N
hypertensive JJ N
subjects NNS N
, , N
that IN N
statins VBZ N
reduce VB N
muscle NN N
sympathetic JJ N
nerve NN N
activity NN N
( ( N
MSNA NNP N
) ) N
did VBD N
not RB N
investigate VB N
potential JJ N
neural JJ N
sites NNS N
of IN N
such JJ N
sympathoinhibition NN N
or CC N
determine VB N
its PRP$ N
consequences NNS N
for IN N
endothelial JJ N
function NN N
or CC N
insulin NN N
resistance NN N
. . N

This DT N
study NN N
of IN N
hypertensive JJ N
subjects NNS N
with IN N
lower JJR N
plasma NN N
cholesterol NN N
tested VBD N
the DT N
hypotheses NNS N
that WDT N
lipophilic JJ N
simvastatin NN N
would MD N
attenuate VB N
resting VBG N
sympathoexcitation NN N
and CC N
augment NN N
baroreflex JJ N
modulation NN N
of IN N
MSNA NNP N
and CC N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
, , N
flow-mediated JJ N
vasodilation NN N
and CC N
insulin NN N
sensitivity NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomised VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
. . N

SETTING NNP N
Academic NNP N
hospital-based JJ N
study NN N
. . N

PATIENTS NNP N
Fourteen JJ N
non-hyperlipidaemic JJ N
primary JJ N
hypertensive JJ N
subjects NNS N
( ( N
10 CD N
men NNS N
; : N
overall JJ N
mean?SD NN N
age NN N
58?12 CD N
years NNS N
) ) N
. . N

INTERVENTIONS NNP N
Four NNP N
weeks NNS N
of IN N
simvastatin NN N
( ( N
80 CD N
mg/day NN N
) ) N
or CC N
placebo NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Resting NNP N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
, , N
HR NNP N
, , N
MSNA NNP N
, , N
spontaneous JJ N
arterial JJ N
baroreflex NN N
MSNA NNP N
and CC N
HR NNP N
modulation NN N
, , N
endothelium-dependent JJ N
and CC N
endothelium-independent JJ N
vasodilation NN N
, , N
and CC N
the DT N
homoeostatic JJ N
model NN N
assessment NN N
of IN N
insulin NN N
resistance NN N
( ( N
HOMA-IR NNP N
) ) N
. . N

RESULTS NNP N
Simvastatin NNP N
lowered VBD N
MSNA NNP N
burst JJ N
frequency NN N
( ( N
from IN N
32?12 CD N
to TO N
25?9 CD N
bursts/min NN N
) ) N
and CC N
MSNA NNP N
burst NN N
incidence NN N
( ( N
from IN N
55?23 CD N
% NN N
to TO N
43?17 CD N
% NN N
; : N
all DT N
p VBP N
< $ N
0.01 CD N
) ) N
without IN N
affecting VBG N
BP NNP N
, , N
HR NNP N
, , N
baroreflex JJ N
modulation NN N
of IN N
either DT N
MSNA NNP N
or CC N
HR NNP N
, , N
or CC N
HR NNP N
variability NN N
( ( N
all DT N
p VBP N
> $ N
0.05 CD N
) ) N
. . N

Plasma NNP N
glucose NN N
, , N
insulin NN N
, , N
HOMA-IR NNP N
and CC N
endothelium-dependent JJ N
vasodilation NN N
( ( N
all DT N
p VBP N
> $ N
0.05 CD N
) ) N
were VBD N
unchanged JJ N
, , N
whereas JJ N
endothelium-independent JJ N
vasodilation NN N
increased VBD N
( ( N
7.1?3.8 CD N
% NN N
to TO N
9.7?3.9 CD N
% NN N
, , N
n=13 RB N
; : N
p VB N
< $ N
0.01 CD N
) ) N
. . N

The DT N
fall NN N
in IN N
MSNA NNP N
was VBD N
unrelated JJ N
to TO N
the DT N
decrease NN N
in IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
r=0.41 NN N
, , N
p=0.14 NN N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
are VBP N
consistent JJ N
with IN N
the DT N
concept NN N
that IN N
, , N
in IN N
non-hyperlipidaemic JJ N
subjects NNS N
with IN N
primary JJ N
hypertension NN N
, , N
simvastatin JJ N
causes VBZ N
a DT N
cholesterol-independent JJ N
reduction NN N
in IN N
an DT N
elevated JJ N
central JJ N
set-point NN N
for IN N
MSNA NNP N
, , N
without IN N
affecting VBG N
arterial JJ N
baroreflex JJ N
modulation NN N
of IN N
either DT N
MSNA NNP N
or CC N
HR NNP N
. . N

There EX N
may MD N
be VB N
less JJR N
neurogenic JJ N
constraint NN N
on IN N
endothelium-independent JJ N
vasodilation NN N
as IN N
a DT N
consequence NN N
. . N

-DOCSTART- -16431255- O O

Paricalcitol NNP N
capsule NN N
for IN N
the DT N
treatment NN N
of IN N
secondary JJ N
hyperparathyroidism NN N
in IN N
stages NNS N
3 CD N
and CC N
4 CD N
CKD NNP N
. . N

BACKGROUND NNP N
The DT N
safety NN N
and CC N
efficacy NN N
of IN N
paricalcitol NN N
injection NN N
have VBP N
been VBN N
well RB N
established VBN N
for IN N
the DT N
prevention NN N
and CC N
treatment NN N
of IN N
secondary JJ N
hyperparathyroidism NN N
( ( N
SHPT NNP N
) ) N
in IN N
patients NNS N
with IN N
chronic JJ N
kidney NN N
disease NN N
( ( N
CKD NNP N
) ) N
stage NN N
5 CD N
. . N

The DT N
capsule JJ N
form NN N
of IN N
paricalcitol NN N
was VBD N
developed VBN N
to TO N
provide VB N
a DT N
convenient JJ N
dosage NN N
form NN N
for IN N
patients NNS N
with IN N
stages NNS N
3 CD N
and CC N
4 CD N
CKD NNP N
. . N

METHODS NNP N
Three NNP N
randomized VBD N
, , N
placebo-controlled JJ N
, , N
phase-3 JJ N
trials NNS N
were VBD N
conducted VBN N
in IN N
patients NNS N
with IN N
stages NNS N
3 CD N
and CC N
4 CD N
CKD NNP N
with IN N
SHPT NNP N
. . N

Enrollment NNP N
criteria NNS N
included VBD N
an DT N
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
between IN N
15 CD N
and CC N
60 CD N
mL/min/1.73 NN N
m2 NN N
( ( N
0.25 CD N
and CC N
1.00 CD N
mL/s/1.73 NNS N
m2 NN N
) ) N
, , N
an DT N
average NN N
of IN N
2 CD N
consecutive JJ N
intact JJ N
parathyroid NN N
hormone NN N
( ( N
iPTH NN N
) ) N
levels NNS N
greater JJR N
than IN N
150 CD N
pg/mL NN N
( ( N
ng/L JJ N
) ) N
, , N
2 CD N
consecutive JJ N
serum NN N
calcium NN N
levels NNS N
between IN N
8.0 CD N
and CC N
10.0 CD N
mg/dL NN N
( ( N
2.00 CD N
and CC N
2.50 CD N
mmol/L NN N
) ) N
, , N
and CC N
2 CD N
consecutive JJ N
serum NN N
phosphorus NN N
levels NNS N
of IN N
5.2 CD N
mg/dL NN N
or CC N
less JJR N
( ( N
< NN N
or CC N
= $ N
1.68 CD N
mmol/L NN N
) ) N
. . N

Two CD N
studies NNS N
used VBD N
a DT N
thrice-weekly JJ N
dosing NN N
regimen NNS N
and CC N
1 CD N
study NN N
used VBD N
a DT N
once-daily JJ N
dosing NN N
regimen NNS N
for IN N
24 CD N
weeks NNS N
. . N

Dosing NNP N
was VBD N
based VBN N
on IN N
serum NN N
iPTH NN N
, , N
calcium NN N
, , N
and CC N
phosphorus NN N
levels NNS N
. . N

The DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
is VBZ N
2 CD N
consecutive JJ N
decreases NNS N
in IN N
iPTH NN N
levels NNS N
greater JJR N
than IN N
30 CD N
% NN N
from IN N
baseline NN N
. . N

RESULTS NNP N
Two CD N
hundred VBD N
twenty NN N
patients NNS N
participated VBD N
( ( N
n JJ N
= NN N
107 CD N
, , N
paricalcitol NN N
; : N
n CC N
= $ N
113 CD N
, , N
placebo NN N
) ) N
. . N

At IN N
least JJS N
2 CD N
consecutive JJ N
decreases NNS N
in IN N
iPTH JJ N
levels NNS N
of IN N
30 CD N
% NN N
or CC N
greater JJR N
from IN N
baseline NN N
occurred VBN N
in IN N
91 CD N
% NN N
of IN N
paricalcitol JJ N
versus FW N
13 CD N
% NN N
of IN N
placebo NN N
patients NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Incidences NNS N
of IN N
hypercalcemia NN N
, , N
hyperphosphatemia NN N
, , N
and CC N
elevated VBD N
calcium-phosphorus JJ N
product NN N
levels NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
. . N

Similarly RB N
, , N
no DT N
significant JJ N
differences NNS N
in IN N
urinary JJ N
calcium NN N
and CC N
phosphorus JJ N
excretion NN N
or CC N
deterioration NN N
in IN N
kidney NN N
function NN N
were VBD N
detected VBN N
in IN N
patients NNS N
administered VBN N
paricalcitol NNS N
compared VBN N
with IN N
placebo NN N
. . N

CONCLUSION NNP N
Paricalcitol NNP N
capsule NN N
was VBD N
well RB N
tolerated VBN N
and CC N
effectively RB N
decreased VBN N
iPTH NN N
levels NNS N
with IN N
minimal JJ N
or CC N
no DT N
impact NN N
on IN N
calcium NN N
levels NNS N
, , N
phosphorus NN N
balance NN N
, , N
and CC N
kidney NN N
function NN N
in IN N
patients NNS N
with IN N
stages NNS N
3 CD N
and CC N
4 CD N
CKD NNP N
. . N

-DOCSTART- -17152183- O O

Cognitive-behavioural JJ N
stress NN N
management NN N
with IN N
HIV-positive JJ N
homosexual JJ N
men NNS N
: : N
mechanisms NNS N
of IN N
sustained JJ N
reductions NNS N
in IN N
depressive JJ N
symptoms NNS N
. . N

BACKGROUND IN N
We PRP N
examined VBD N
the DT N
sustained JJ N
efficacy NN N
of IN N
a DT N
group-based JJ N
cognitive-behavioural JJ N
stress NN N
management NN N
( ( N
CBSM NNP N
) ) N
intervention NN N
in IN N
comparison NN N
to TO N
a DT N
modified VBN N
wait-list NN N
control NN N
condition NN N
on IN N
measures NNS N
of IN N
mood NN N
, , N
coping VBG N
and CC N
social JJ N
support NN N
in IN N
mildly RB N
symptomatic JJ N
HIV-positive JJ N
homosexual JJ N
and CC N
bisexual JJ N
men NNS N
. . N

Participants NNS N
were VBD N
recruited VBN N
largely RB N
during IN N
the DT N
era NN N
prior RB N
to TO N
highly RB N
active JJ N
antiretroviral JJ N
therapy NN N
( ( N
HAART NNP N
; : N
1992-1997 JJ N
) ) N
. . N

METHODS NNP N
Men NNPS N
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
10-week JJ N
, , N
group-based JJ N
CBSM NNP N
intervention NN N
( ( N
n JJ N
= NNP N
83 CD N
) ) N
or CC N
a DT N
psychoeducational JJ N
seminar NN N
group NN N
( ( N
n JJ N
= NNP N
46 CD N
) ) N
. . N

All DT N
participants NNS N
completed VBD N
a DT N
battery NN N
of IN N
psychosocial JJ N
questionnaires NNS N
administered VBN N
by IN N
a DT N
research NN N
assistant NN N
at IN N
baseline NN N
, , N
immediately RB N
following VBG N
the DT N
10-week JJ N
CBSM NNP N
intervention NN N
period NN N
, , N
and CC N
at IN N
a DT N
6-month JJ N
follow-up NN N
. . N

RESULTS NNP N
Men NNP N
in IN N
the DT N
CBSM NNP N
group NN N
maintained VBD N
previously RB N
observed VBN N
effects NNS N
on IN N
depressive NN N
symptoms NNS N
and CC N
perceived VBD N
social JJ N
support NN N
. . N

These DT N
sustained JJ N
effects NNS N
of IN N
CBSM NNP N
on IN N
depressive JJ N
symptoms NNS N
were VBD N
mediated VBN N
by IN N
10-week JJ N
increases NNS N
in IN N
cognitive JJ N
coping NN N
( ( N
i.e JJ N
. . N

positive JJ N
reframing NN N
) ) N
. . N

DISCUSSION NNP N
CBSM NNP N
appears VBZ N
to TO N
be VB N
a DT N
potentially RB N
efficacious JJ N
treatment NN N
that WDT N
reduces VBZ N
and CC N
maintains NNS N
lower JJR N
levels NNS N
of IN N
depressive NN N
symptoms NNS N
and CC N
enhances VBZ N
social JJ N
support NN N
in IN N
HIV-positive JJ N
homosexual JJ N
and CC N
bisexual JJ N
men NNS N
. . N

In IN N
particular JJ N
, , N
changes NNS N
in IN N
positive JJ N
reframing NN N
during IN N
the DT N
10-week JJ N
intervention NN N
period NN N
remain VBP N
a DT N
crucial JJ N
factor NN N
contributing VBG N
to TO N
sustained VBN N
reductions NNS N
in IN N
depressive JJ N
symptoms NNS N
. . N

-DOCSTART- -19073386- O O

Moist NN N
Exposed VBD N
Burn NNP N
Ointment NNP N
( ( N
MEBO NNP N
) ) N
in IN N
partial JJ N
thickness NN N
burns NNS N
- : N
a DT N
randomized JJ N
, , N
comparative JJ N
open JJ N
mono-center NN N
study NN N
on IN N
the DT N
efficacy NN N
of IN N
dermaheal NN N
( ( N
MEBO NNP N
) ) N
ointment NN N
on IN N
thermal JJ N
2nd CD N
degree NN N
burns NNS N
compared VBN N
to TO N
conventional JJ N
therapy NN N
. . N

OBJECTIVE NNP N
Wound NNP N
healing NN N
in IN N
burn NN N
wounds NNS N
presents VBZ N
a DT N
challenge NN N
in IN N
healthcare NN N
, , N
and CC N
there EX N
is VBZ N
still RB N
a DT N
lack NN N
of IN N
alternatives NNS N
in IN N
topical JJ N
burn NN N
wound NN N
treatments NNS N
. . N

- : N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
new JJ N
therapeutic JJ N
ointment NN N
( ( N
MEBO NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
partial JJ N
thickness NN N
burns NNS N
. . N

METHODS NNP N
40 CD N
patients NNS N
received VBD N
either RB N
topical JJ N
treatment NN N
with IN N
Moist NNP N
Exposed VBD N
Burn NNP N
Ointment NNP N
( ( N
MEBO NNP N
) ) N
or CC N
standard JJ N
Flammazine NNP N
treatment NN N
. . N

All DT N
patients NNS N
suffered VBD N
from IN N
partial-thickness JJ N
burn NN N
injuries NNS N
( ( N
< VB N
20 CD N
% NN N
TBSA NNP N
) ) N
. . N

Wounds NNS N
were VBD N
evaluated VBN N
for IN N
60 CD N
up RB N
to TO N
days NNS N
regarding VBG N
wound NN N
healing NN N
, , N
water NN N
loss NN N
, , N
inflammation NN N
, , N
and CC N
pain NN N
alleviation NN N
. . N

RESULTS NNP N
For IN N
transepidermal JJ N
water NN N
loss NN N
, , N
there EX N
was VBD N
a DT N
difference NN N
of IN N
2.3 CD N
gr/m2/h NN N
between IN N
MEBO NNP N
, , N
and CC N
Flammazine NNP N
, , N
favoring VBG N
MEBO NNP N
. . N

However RB N
, , N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
p=0.78 NN N
) ) N
. . N

For IN N
all DT N
secondary JJ N
efficacy NN N
parameter NN N
results NNS N
were VBD N
similar JJ N
. . N

- : N
CONCLUSIONS NN N
This DT N
study NN N
showed VBD N
that IN N
MEBO NNP N
ointment NN N
for IN N
topical JJ N
treatment NN N
of IN N
burn NN N
injuries NNS N
presents VBZ N
an DT N
attractive JJ N
alternative NN N
for IN N
the DT N
topical JJ N
treatment NN N
of IN N
limited JJ N
partial JJ N
thickness NN N
thermal JJ N
burns NNS N
. . N

-DOCSTART- -16304214- O O

Comparison NNP N
of IN N
antihypertensives NNS N
after IN N
coronary JJ N
artery NN N
surgery NN N
. . N

Hypertension NN N
following VBG N
coronary JJ N
artery JJ N
bypass NN N
grafting NN N
is VBZ N
a DT N
common JJ N
problem NN N
that WDT N
may MD N
result VB N
in IN N
postoperative JJ N
myocardial JJ N
infraction NN N
or CC N
bleeding NN N
, , N
Hemodynamic NNP N
effects NNS N
were VBD N
compared VBN N
in IN N
45 CD N
hypertensive JJ N
coronary JJ N
bypass NN N
patients NNS N
randomized VBN N
to TO N
receive VB N
either DT N
diltiazem NN N
, , N
nitroglycerin NN N
, , N
or CC N
sodium NN N
nitroprusside RB N
. . N

Diltiazem NNP N
was VBD N
administered VBN N
as IN N
an DT N
intravenous JJ N
bolus NN N
of IN N
0.3 CD N
mg.kg-1 NN N
within IN N
5 CD N
min NN N
, , N
followed VBN N
by IN N
infusion NN N
of IN N
0.1-0.8 JJ N
mg.kg-1.h-1 NN N
in IN N
group NN N
1 CD N
. . N

Nitroglycerin NNP N
was VBD N
infused VBN N
at IN N
a DT N
rate NN N
of IN N
1-3 JJ N
microg.kg.h-1 NN N
in IN N
group NN N
2 CD N
, , N
and CC N
sodium NN N
nitroprusside NN N
was VBD N
given VBN N
at IN N
a DT N
rate NN N
of IN N
1-3 JJ N
microg.kg-1.min-1 NN N
in IN N
group NN N
3 CD N
. . N

Hemodynamic JJ N
measurements NNS N
were VBD N
carried VBN N
out RP N
before IN N
infusion NN N
( ( N
T1 NNP N
) ) N
and CC N
at IN N
30 CD N
min NN N
( ( N
T2 NNP N
) ) N
, , N
2 CD N
h NN N
( ( N
T3 NNP N
) ) N
, , N
and CC N
12 CD N
h NN N
( ( N
T4 NNP N
) ) N
after IN N
initiation NN N
of IN N
treatment NN N
in IN N
the DT N
intensive JJ N
care NN N
unit NN N
. . N

Mean NNP N
arterial JJ N
pressure NN N
decreased VBN N
significantly RB N
in IN N
all DT N
groups NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
among IN N
groups NNS N
at IN N
T1 NNP N
and CC N
T2 NNP N
. . N

At IN N
T3 NNP N
, , N
heart NN N
rate NN N
in IN N
group NN N
2 CD N
was VBD N
significantly RB N
higher JJR N
than IN N
group NN N
1 CD N
. . N

At IN N
T3 NNP N
and CC N
T4 NNP N
, , N
the DT N
double JJ N
product NN N
was VBD N
highest JJS N
in IN N
group NN N
3 CD N
( ( N
group NN N
1 CD N
vs. NN N
3 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
hemodynamic JJ N
effects NNS N
of IN N
the DT N
3 CD N
drugs NNS N
are VBP N
similar JJ N
within IN N
the DT N
first JJ N
30 CD N
min NN N
. . N

However RB N
, , N
after IN N
30 CD N
min NN N
, , N
diltiazem NN N
affords NNS N
better RBR N
myocardial JJ N
performance NN N
and CC N
more RBR N
effective JJ N
control NN N
of IN N
hypertension NN N
. . N

-DOCSTART- -22585469- O O

Effectiveness NN N
and CC N
safety NN N
of IN N
the DT N
Levitan NNP N
FPS NNP N
Scope? NNP N
for IN N
tracheal JJ N
intubation NN N
under IN N
general JJ N
anesthesia NN N
with IN N
a DT N
simulated JJ N
difficult JJ N
airway NN N
. . N

PURPOSE NNP N
Studies NNP N
show VBP N
that IN N
the DT N
Levitan NNP N
FPS NNP N
( ( N
first JJ N
pass NN N
success NN N
) ) N
Scope? NNP N
( ( N
LFS NNP N
) ) N
is VBZ N
analogous JJ N
to TO N
a DT N
bougie NN N
in IN N
simulated JJ N
difficult JJ N
airways NNS N
with IN N
comparable JJ N
tracheal JJ N
intubation NN N
success NN N
rates NNS N
. . N

In IN N
this DT N
study NN N
, , N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
tracheal JJ N
intubation NN N
with IN N
the DT N
LFS NNP N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
the DT N
Macintosh NNP N
laryngoscope NN N
utilizing VBG N
manual JJ N
in-line JJ N
stabilization NN N
( ( N
MILS NNP N
) ) N
to TO N
simulate VB N
difficult JJ N
airways NNS N
. . N

METHODS NNP N
Ninety-four JJ N
subjects NNS N
successfully RB N
completed VBD N
the DT N
trial NN N
. . N

Manual JJ N
in-line JJ N
stabilization NN N
of IN N
the DT N
cervical JJ N
spine NN N
was VBD N
applied VBN N
and CC N
the DT N
initial JJ N
laryngoscopy NN N
was VBD N
performed VBN N
using VBG N
either CC N
the DT N
Macintosh NNP N
or CC N
the DT N
LFS NNP N
in IN N
conjunction NN N
with IN N
the DT N
Macintosh NNP N
. . N

Following VBG N
the DT N
initial JJ N
grading NN N
, , N
a DT N
second JJ N
laryngoscopy NN N
was VBD N
repeated VBN N
using VBG N
the DT N
second JJ N
randomized JJ N
technique NN N
. . N

Cormack-Lehane NNP N
grades NNS N
, , N
percentage NN N
of IN N
glottic JJ N
opening NN N
( ( N
POGO NNP N
) ) N
scores VBZ N
, , N
time NN N
to TO N
intubate VB N
, , N
number NN N
of IN N
intubation NN N
attempts NNS N
, , N
and CC N
the DT N
use NN N
of IN N
alternate NN N
techniques NNS N
were VBD N
recorded VBN N
. . N

The DT N
anesthesiologist NN N
rated VBD N
the DT N
subjective JJ N
difficulty NN N
in IN N
using VBG N
each DT N
technique NN N
with IN N
a DT N
numeric JJ N
rating NN N
scale NN N
and CC N
a DT N
visual JJ N
rating NN N
scale NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
primary JJ N
outcome NN N
good JJ N
laryngoscopic NN N
views NNS N
( ( N
Cormack-Lehane NNP N
grade VBD N
1 CD N
and CC N
2 CD N
) ) N
compared VBN N
with IN N
poor JJ N
laryngoscopic JJ N
views NNS N
( ( N
Cormack-Lehane NNP N
grade VBD N
3 CD N
and CC N
4 CD N
) ) N
between IN N
the DT N
LFS NNP N
and CC N
the DT N
Macintosh NNP N
. . N

There EX N
were VBD N
higher JJR N
POGO NNP N
scores NNS N
with IN N
the DT N
LFS NNP N
compared VBN N
with IN N
the DT N
Macintosh NNP N
( ( N
80 CD N
% NN N
vs JJ N
20 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
but CC N
this DT N
did VBD N
not RB N
translate VB N
to TO N
easier JJR N
intubations NNS N
, , N
as IN N
documented VBN N
by IN N
the DT N
need NN N
for IN N
an DT N
alternate JJ N
intubation NN N
technique NN N
or CC N
time NN N
to TO N
intubate VB N
( ( N
< JJ N
30 CD N
and CC N
< $ N
60 CD N
sec NN N
, , N
respectively RB N
) ) N
. . N

The DT N
incidence NN N
of IN N
mucosal NN N
trauma NN N
, , N
sore RB N
throat NN N
, , N
and CC N
hemodynamic JJ N
responses NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
techniques NNS N
. . N

CONCLUSION VB N
The DT N
LFS NNP N
in IN N
conjunction NN N
with IN N
the DT N
Macintosh NNP N
laryngoscope NN N
does VBZ N
not RB N
improve VB N
the DT N
efficacy NN N
or CC N
safety NN N
of IN N
tracheal JJ N
intubation NN N
in IN N
a DT N
simulated JJ N
difficult JJ N
airway NN N
. . N

-DOCSTART- -1878735- O O

Human NNP N
recombinant JJ N
GM-CSF NNP N
in IN N
allogeneic JJ N
bone NN N
marrow NN N
transplantation NN N
for IN N
leukaemia NN N
: : N
double-blind JJ N
placebo NN N
controlled VBN N
trial NN N
. . N

A DT N
double-blind NN N
randomised VBN N
trial NN N
compared VBN N
20 CD N
patients NNS N
with IN N
leukaemia JJ N
receiving VBG N
human JJ N
recombinant JJ N
granulocyte NN N
macrophage NN N
colony NN N
stimulating VBG N
factor NN N
( ( N
GM NNP N
CSF NNP N
) ) N
, , N
with IN N
20 CD N
patients NNS N
receiving VBG N
placebo NN N
for IN N
14 CD N
days NNS N
after IN N
allogeneic JJ N
matched VBD N
sibling VBG N
bone NN N
marrow NN N
transplantation NN N
. . N

The DT N
median JJ N
neutrophil NN N
count NN N
at IN N
14 CD N
days NNS N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
GM NNP N
CSF NNP N
group NN N
( ( N
1.90 CD N
vs. FW N
0.46 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/l NN N
) ) N
. . N

The DT N
duration NN N
of IN N
hospital NN N
stay NN N
, , N
the DT N
number NN N
of IN N
antibiotic JJ N
days NNS N
, , N
and CC N
the DT N
number NN N
of IN N
fever JJ N
days NNS N
was VBD N
the DT N
same JJ N
for IN N
both DT N
patient JJ N
groups NNS N
. . N

The DT N
lymphocyte NN N
count NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
GM-CSF NNP N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
between IN N
days NNS N
10 CD N
and CC N
15 CD N
after IN N
transplantation NN N
. . N

The DT N
GM-CSF NNP N
group NN N
had VBD N
lower JJR N
haemoglobin NN N
concentrations NNS N
and CC N
platelets NNS N
counts NNS N
, , N
and CC N
higher JJR N
plasma NN N
urea JJ N
creatinine NN N
and CC N
bilirubin NN N
, , N
than IN N
the DT N
placebo NN N
group NN N
. . N

There EX N
was VBD N
no DT N
evidence NN N
that IN N
GM NNP N
CSF NNP N
was VBD N
associated VBN N
with IN N
a DT N
greater JJR N
incidence NN N
of IN N
leukaemic JJ N
relapse NN N
. . N

-DOCSTART- -19462303- O O

Gamma-hydroxybutyric JJ N
acid NN N
versus NN N
clomethiazole NN N
for IN N
the DT N
treatment NN N
of IN N
alcohol NN N
withdrawal NN N
syndrome NN N
in IN N
a DT N
medical JJ N
intensive JJ N
care NN N
unit NN N
: : N
an DT N
open JJ N
, , N
single-center JJ N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
Clomethiazole NNP N
( ( N
CLO NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
treating VBG N
alcohol NN N
withdrawal NN N
syndrome NN N
( ( N
AWS NNP N
) ) N
. . N

Gamma-Hydroxybutyric JJ N
acid NN N
( ( N
GHB NNP N
) ) N
has VBZ N
also RB N
been VBN N
introduced VBN N
in IN N
the DT N
treatment NN N
of IN N
alcoholic JJ N
patients NNS N
and CC N
is VBZ N
effective JJ N
in IN N
surgical JJ N
intensive JJ N
care NN N
unit NN N
( ( N
ICU NNP N
) ) N
patients NNS N
in IN N
preventing VBG N
and CC N
treating VBG N
AWS NNP N
. . N

There EX N
are VBP N
no DT N
comparative JJ N
studies NNS N
between IN N
CLO NNP N
and CC N
GHB NNP N
in IN N
a DT N
medical JJ N
ICU NNP N
setting NN N
. . N

METHODS NNP N
Twenty-six NNP N
alcoholic JJ N
patients NNS N
with IN N
severe JJ N
AWS NNP N
and CC N
concomitant JJ N
medical JJ N
diseases NNS N
were VBD N
randomally RB N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

CLO NNP N
was VBD N
given VBN N
orally RB N
to TO N
12 CD N
patients NNS N
in IN N
a DT N
dosage NN N
of IN N
250 CD N
mg NN N
every DT N
4 CD N
hours NNS N
as IN N
a DT N
liquid NN N
; : N
GHB NNP N
( ( N
initially RB N
30 CD N
mg/kg NNS N
body NN N
weight NN N
( ( N
BW NNP N
) ) N
followed VBN N
by IN N
15 CD N
mg/kg NNS N
BW NNP N
) ) N
was VBD N
administered VBN N
intravenously RB N
to TO N
14 CD N
patients NNS N
. . N

Four CD N
major JJ N
AWS NNP N
symptoms NNS N
( ( N
tremor NN N
, , N
sweating VBG N
, , N
nausea NN N
, , N
restlessness NN N
) ) N
were VBD N
scored VBN N
, , N
and CC N
the DT N
administration NN N
of IN N
additional JJ N
medication NN N
was VBD N
registered VBN N
. . N

RESULTS NNP N
GHB NNP N
was VBD N
more RBR N
effective JJ N
in IN N
treating VBG N
AWS NNP N
symptoms NNS N
. . N

In IN N
the DT N
GHB NNP N
group NN N
, , N
AWS NNP N
score NN N
dropped VBD N
from IN N
6.6 CD N
+/- JJ N
2.6 CD N
to TO N
1.8 CD N
+/- JJ N
2.1 CD N
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
, , N
while IN N
in IN N
the DT N
CLO NNP N
group NN N
, , N
the DT N
score NN N
dropped VBD N
from IN N
6 CD N
+/- JJ N
2.5 CD N
to TO N
4.1 CD N
+/- JJ N
2.4 CD N
( ( N
n. JJ N
s. NN N
) ) N
. . N

Differences NNS N
between IN N
groups NNS N
were VBD N
significant JJ N
( ( N
p JJ N
=.021 NN N
, , N
two-way JJ N
ANOVA NNP N
) ) N
. . N

The DT N
treatment NN N
did VBD N
not RB N
alter VB N
outcome NN N
or CC N
the DT N
duration NN N
of IN N
ICU NNP N
stay NN N
. . N

No DT N
serious JJ N
side NN N
effects NNS N
were VBD N
detected VBN N
. . N

CONCLUSION NNP N
GHB NNP N
effectively RB N
controls VBZ N
AWS NNP N
symptoms NNS N
in IN N
medical JJ N
ICU NNP N
patients NNS N
. . N

The DT N
rapid JJ N
initial JJ N
treatment NN N
response NN N
of IN N
GHB NNP N
in IN N
contrast NN N
to TO N
CLO NNP N
has VBZ N
no DT N
influence NN N
on IN N
duration NN N
of IN N
patient NN N
withdrawal NN N
. . N

-DOCSTART- -20199680- O O

The DT N
development NN N
of IN N
a DT N
web- JJ N
and CC N
a DT N
print-based JJ N
decision NN N
aid NN N
for IN N
prostate NN N
cancer NN N
screening VBG N
. . N

BACKGROUND NNP N
Whether NNP N
early JJ N
detection NN N
and CC N
treatment NN N
of IN N
prostate NN N
cancer NN N
( ( N
PCa NNP N
) ) N
will MD N
reduce VB N
disease-related JJ N
mortality NN N
remains VBZ N
uncertain JJ N
. . N

As IN N
a DT N
result NN N
, , N
tools NNS N
are VBP N
needed VBN N
to TO N
facilitate VB N
informed JJ N
decision NN N
making NN N
. . N

While IN N
there EX N
have VBP N
been VBN N
several JJ N
decision NN N
aids NNS N
( ( N
DAs NNP N
) ) N
developed VBD N
and CC N
tested VBD N
, , N
very RB N
few JJ N
have VBP N
included VBN N
an DT N
exercise NN N
to TO N
help VB N
men NNS N
clarify VB N
their PRP$ N
values NNS N
and CC N
preferences NNS N
about IN N
PCa NNP N
screening NN N
. . N

Further NNP N
, , N
only RB N
one CD N
DA NNP N
has VBZ N
utilized VBN N
an DT N
interactive JJ N
web-based JJ N
format NN N
, , N
which WDT N
allows VBZ N
for IN N
an DT N
expansion NN N
and CC N
customization NN N
of IN N
the DT N
material NN N
. . N

We PRP N
describe VBP N
the DT N
development NN N
of IN N
two CD N
DAs NNP N
, , N
a DT N
booklet NN N
and CC N
an DT N
interactive JJ N
website NN N
, , N
each DT N
with IN N
a DT N
values NNS N
clarification NN N
component NN N
and CC N
designed VBN N
for IN N
use NN N
in IN N
diverse JJ N
settings NNS N
. . N

METHODS NNP N
We PRP N
conducted VBD N
two CD N
feasibility NN N
studies NNS N
to TO N
assess VB N
men NNS N
's POS N
( ( N
45-70 CD N
years NNS N
) ) N
Internet NNP N
access NN N
and CC N
their PRP$ N
willingness NN N
to TO N
use VB N
a DT N
web- JJ N
vs. FW N
a DT N
print-based JJ N
tool NN N
. . N

The DT N
booklet NN N
was VBD N
adapted VBN N
from IN N
two CD N
previous JJ N
versions NNS N
evaluated VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
( ( N
RCTs NNP N
) ) N
and CC N
the DT N
website NN N
was VBD N
created VBN N
to TO N
closely RB N
match VB N
the DT N
content NN N
of IN N
the DT N
revised JJ N
booklet NN N
. . N

Usability NNP N
testing NN N
was VBD N
conducted VBN N
to TO N
obtain VB N
feedback NN N
regarding VBG N
draft JJ N
versions NNS N
of IN N
the DT N
materials NNS N
. . N

The DT N
tools NNS N
were VBD N
also RB N
reviewed VBN N
by IN N
a DT N
plain NN N
language NN N
expert NN N
and CC N
the DT N
interdisciplinary JJ N
research NN N
team NN N
. . N

Feedback NN N
on IN N
the DT N
content NN N
and CC N
presentation NN N
led VBD N
to TO N
iterative JJ N
modifications NNS N
of IN N
the DT N
tools NNS N
. . N

RESULTS VB N
The DT N
feasibility NN N
studies NNS N
confirmed VBD N
that IN N
the DT N
Internet NNP N
was VBD N
a DT N
viable JJ N
medium NN N
, , N
as IN N
the DT N
majority NN N
of IN N
men NNS N
used VBN N
a DT N
computer NN N
, , N
had VBD N
access NN N
to TO N
the DT N
Internet NNP N
, , N
and CC N
Internet NNP N
use NN N
increased VBD N
over IN N
time NN N
. . N

Feedback NN N
from IN N
the DT N
usability NN N
testing VBG N
on IN N
the DT N
length NN N
, , N
presentation NN N
, , N
and CC N
content NN N
of IN N
the DT N
materials NNS N
was VBD N
incorporated VBN N
into IN N
the DT N
final JJ N
versions NNS N
of IN N
the DT N
booklet NN N
and CC N
website NN N
. . N

Both CC N
the DT N
feasibility NN N
studies NNS N
and CC N
the DT N
usability NN N
testing VBG N
highlighted VBD N
the DT N
need NN N
to TO N
address VB N
men NNS N
's POS N
informed VBN N
decision NN N
making VBG N
regarding VBG N
screening NN N
. . N

CONCLUSIONS NNP N
Informed NNP N
decision NN N
making VBG N
for IN N
PCa NNP N
screening NN N
is VBZ N
crucial JJ N
at IN N
present JJ N
and CC N
may MD N
be VB N
important JJ N
for IN N
some DT N
time NN N
, , N
particularly RB N
if IN N
a DT N
definitive JJ N
recommendation NN N
either DT N
for IN N
or CC N
against IN N
screening VBG N
does VBZ N
not RB N
emerge VB N
from IN N
ongoing VBG N
prostate NN N
cancer NN N
screening VBG N
trials NNS N
. . N

We PRP N
have VBP N
detailed VBN N
our PRP$ N
efforts NNS N
at IN N
developing VBG N
print- JJ N
and CC N
web-based JJ N
DAs NNP N
to TO N
assist VB N
men NNS N
in IN N
determining VBG N
how WRB N
to TO N
best VB N
meet VB N
their PRP$ N
PCa NNP N
screening NN N
preferences NNS N
. . N

Following VBG N
completion NN N
of IN N
our PRP$ N
ongoing JJ N
RCT NNP N
designed VBN N
to TO N
test VB N
these DT N
materials NNS N
, , N
our PRP$ N
goal NN N
will MD N
be VB N
to TO N
develop VB N
a DT N
dissemination NN N
project NN N
for IN N
the DT N
more RBR N
effective JJ N
tool NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NCT00623090 NNP N
. . N

-DOCSTART- -2064495- O O

Niacin NNP N
revisited VBD N
. . N

A DT N
randomized JJ N
, , N
controlled JJ N
trial NN N
of IN N
wax-matrix JJ N
sustained-release JJ N
niacin NN N
in IN N
hypercholesterolemia NN N
. . N

Two CD N
hundred VBD N
one CD N
male NN N
and CC N
female JJ N
subjects NNS N
, , N
aged VBD N
20 CD N
to TO N
70 CD N
years NNS N
, , N
with IN N
elevated VBN N
low-density NN N
lipoprotein NN N
cholesterol NN N
values NNS N
( ( N
in IN N
the DT N
75th CD N
to TO N
95th CD N
percentiles NNS N
) ) N
, , N
participated VBN N
in IN N
a DT N
randomized NN N
, , N
controlled VBN N
, , N
double-blind NN N
study NN N
using VBG N
a DT N
new JJ N
form NN N
of IN N
niacin NN N
( ( N
Enduracin NNP N
) ) N
, , N
which WDT N
employs VBZ N
a DT N
wax-matrix JJ N
vehicle NN N
for IN N
sustained JJ N
release NN N
. . N

Four CD N
niacin JJ N
treatment NN N
groups NNS N
( ( N
daily JJ N
doses NNS N
of IN N
2000 CD N
, , N
1500 CD N
, , N
1250 CD N
, , N
and CC N
1000 CD N
mg NN N
) ) N
were VBD N
compared VBN N
with IN N
placebo- JJ N
and CC N
diet-treated JJ N
controls NNS N
to TO N
determine VB N
side-effect JJ N
profile NN N
and CC N
optimal JJ N
range NN N
of IN N
efficacy NN N
. . N

The DT N
groups NNS N
given VBN N
2000 CD N
and CC N
1500 CD N
mg NN N
demonstrated VBD N
significant JJ N
reductions NNS N
in IN N
values NNS N
of IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
-26 CD N
% NN N
and CC N
-19.3 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
total JJ N
cholesterol NN N
( ( N
-18.4 CD N
% NN N
and CC N
-13.3 NNP N
% NN N
) ) N
, , N
and CC N
total JJ N
cholesterol-high-density NN N
lipoprotein NN N
cholesterol NN N
ratio NN N
( ( N
-20.4 CD N
% NN N
and CC N
-19.4 CD N
% NN N
) ) N
when WRB N
compared VBN N
with IN N
diet- JJ N
and CC N
placebo-treated JJ N
controls NNS N
. . N

Smaller NN N
improvements NNS N
were VBD N
seen VBN N
in IN N
high-density NN N
lipoprotein NN N
cholesterol NN N
and CC N
triglyceride NN N
levels NNS N
. . N

Blood NNP N
chemistry NN N
monitoring NN N
indicated VBD N
that DT N
reduction NN N
in IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
level NN N
strongly RB N
correlated VBN N
with IN N
an DT N
increase NN N
in IN N
baseline JJ N
levels NNS N
of IN N
some DT N
enzymes NNS N
for IN N
niacin-treated JJ N
subjects NNS N
. . N

The DT N
improved JJ N
side-effect JJ N
profile NN N
of IN N
the DT N
wax-matrix JJ N
form NN N
of IN N
niacin NN N
was VBD N
particularly RB N
notable JJ N
. . N

The DT N
dropout NN N
rate NN N
due JJ N
to TO N
side VB N
effects NNS N
was VBD N
only RB N
3.4 CD N
% NN N
and CC N
was VBD N
coupled VBN N
with IN N
good JJ N
medication NN N
compliance NN N
. . N

-DOCSTART- -10690697- O O

Hip NNP N
protectors NNS N
improve VBP N
falls VBZ N
self-efficacy NN N
. . N

OBJECTIVES NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
use NN N
of IN N
external JJ N
hip NN N
protectors NNS N
on IN N
subjects NNS N
' POS N
fear NN N
of IN N
falling VBG N
and CC N
falls VBZ N
self-efficacy NN N
( ( N
belief NN N
in IN N
their PRP$ N
own JJ N
ability NN N
to TO N
avoid VB N
falling VBG N
) ) N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING CC N
Aged-care JJ N
health NN N
services NNS N
in IN N
Sydney NNP N
, , N
Australia NNP N
. . N

PARTICIPANTS NNP N
131 CD N
women NNS N
aged VBN N
75 CD N
years NNS N
or CC N
older JJR N
, , N
who WP N
had VBD N
two CD N
or CC N
more JJR N
falls NNS N
or CC N
one CD N
fall NN N
requiring VBG N
hospital JJ N
admission NN N
in IN N
the DT N
previous JJ N
year NN N
and CC N
who WP N
live VBP N
at IN N
home NN N
. . N

Sixty-one JJ N
subjects NNS N
were VBD N
in IN N
the DT N
intervention NN N
group NN N
and CC N
70 CD N
in IN N
the DT N
control NN N
group NN N
. . N

INTERVENTION NNP N
Use NNP N
of IN N
external JJ N
hip NN N
protectors NNS N
and CC N
encouragement NN N
to TO N
use VB N
the DT N
protectors NNS N
by IN N
an DT N
adherence NN N
nurse NN N
. . N

MEASUREMENTS CC N
At IN N
the DT N
time NN N
of IN N
enrolment NN N
into IN N
a DT N
wider NN N
study NN N
examining VBG N
the DT N
effect NN N
of IN N
hip NN N
protectors NNS N
on IN N
hip NN N
fractures NNS N
, , N
participants NNS N
recruited VBD N
at IN N
home NN N
completed VBD N
an DT N
assessment NN N
of IN N
fear NN N
of IN N
falling VBG N
and CC N
falls VBZ N
efficacy NN N
as IN N
measured VBN N
by IN N
the DT N
Falls NNP N
Efficacy NNP N
Scale NNP N
and CC N
the DT N
Modified NNP N
Falls NNP N
Efficacy NNP N
Scale NNP N
. . N

At IN N
4-month JJ N
follow-up NN N
, , N
these DT N
scales NNS N
were VBD N
readministered VBN N
by IN N
an DT N
observer NN N
who WP N
was VBD N
not RB N
aware JJ N
of IN N
the DT N
allocation NN N
of IN N
the DT N
participant NN N
to TO N
intervention NN N
or CC N
control NN N
groups NNS N
. . N

RESULTS NNP N
Fear NNP N
of IN N
falling VBG N
and CC N
falls VBZ N
self-efficacy NN N
, , N
as IN N
measured VBN N
by IN N
the DT N
Falls NNP N
Efficacy NNP N
and CC N
Modified NNP N
Falls NNP N
Efficacy NNP N
Scales NNP N
, , N
were VBD N
similar JJ N
at IN N
baseline NN N
in IN N
both DT N
groups NNS N
. . N

Fear NN N
of IN N
falling VBG N
was VBD N
present JJ N
at IN N
follow-up NN N
in IN N
43 CD N
% NN N
of IN N
subjects NNS N
using VBG N
hip NN N
protectors NNS N
and CC N
57 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
chi2 JJ N
= NN N
2.58 CD N
, , N
P NNP N
= NNP N
0.11 CD N
) ) N
. . N

Hip NNP N
protector NN N
users NNS N
had VBD N
greater JJR N
improvement NN N
in IN N
falls VBZ N
self-efficacy NN N
at IN N
follow-up JJ N
as IN N
measured VBN N
by IN N
the DT N
Falls NNP N
Efficacy NNP N
Scale NNP N
( ( N
t JJ N
= NN N
2.44 CD N
, , N
P NNP N
= NNP N
0.016 CD N
) ) N
and CC N
the DT N
Modified NNP N
Falls NNP N
Efficacy NNP N
Scale NNP N
( ( N
t JJ N
= NN N
2.08 CD N
, , N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

CONCLUSION NNP N
Hip NNP N
protectors NNS N
improve VBP N
falls VBZ N
self-efficacy NN N
. . N

As IN N
users NNS N
of IN N
hip NN N
protectors NNS N
feel VBP N
more RBR N
confident JJ N
that IN N
they PRP N
can MD N
complete VB N
tasks NNS N
safely RB N
, , N
they PRP N
may MD N
become VB N
more RBR N
physically RB N
active JJ N
and CC N
require VB N
less JJR N
assistance NN N
with IN N
activities NNS N
of IN N
daily JJ N
living NN N
. . N

-DOCSTART- -19054718- O O

Timing VBG N
for IN N
delivering VBG N
individualized JJ N
patient JJ N
education NN N
intervention NN N
to TO N
Coronary NNP N
Artery NNP N
Bypass NNP N
Graft NNP N
patients NNS N
: : N
An DT N
RCT NNP N
. . N

BACKGROUND NNP N
The DT N
primary JJ N
focus NN N
of IN N
this DT N
study NN N
is VBZ N
on IN N
the DT N
timing NN N
of IN N
the DT N
delivery NN N
of IN N
education NN N
to TO N
patients NNS N
who WP N
had VBD N
CABG NNP N
surgery NN N
. . N

AIM NNP N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
an DT N
individualized JJ N
telephone NN N
patient JJ N
education NN N
intervention NN N
, , N
delivered VBN N
at IN N
two CD N
different JJ N
points NNS N
in IN N
time NN N
( ( N
1-2 JJ N
days NNS N
pre-discharge JJ N
versus JJ N
1-2 JJ N
days NNS N
post-discharge NN N
) ) N
in IN N
enhancing VBG N
the DT N
CABG NNP N
patient NN N
's POS N
knowledge NN N
of IN N
self-care JJ N
behaviours NNS N
, , N
performance NN N
of IN N
self-care JJ N
behaviours NNS N
, , N
and CC N
symptom JJ N
frequency NN N
. . N

METHOD NNP N
A NNP N
randomized VBD N
clinical JJ N
trial NN N
that WDT N
included VBD N
a DT N
convenience NN N
sample NN N
of IN N
first JJ N
time NN N
CABG NNP N
patients NNS N
. . N

Individuals NNS N
who WP N
received VBD N
education NN N
pre-discharge NN N
were VBD N
compared VBN N
to TO N
individuals NNS N
who WP N
received VBD N
education NN N
post-discharge NN N
on IN N
the DT N
outcomes NNS N
. . N

RESULTS NNP N
Results NNP N
indicated VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
outcomes NNS N
between IN N
the DT N
two CD N
time NN N
points NNS N
. . N

As NNP N
well RB N
, , N
anxiety NN N
levels NNS N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
higher JJR N
in IN N
the DT N
pre-discharge NN N
group NN N
than IN N
the DT N
post-discharge JJ N
group NN N
. . N

CONCLUSIONS VB N
The DT N
individualized JJ N
nature NN N
of IN N
the DT N
educational JJ N
intervention NN N
may MD N
have VB N
accounted VBN N
for IN N
non-significant JJ N
findings NNS N
reported VBN N
in IN N
outcomes NNS N
between IN N
the DT N
two CD N
time NN N
points NNS N
. . N

PRACTICE NNP N
IMPLICATIONS NNP N
Nurses NNP N
may MD N
consider VB N
assessing VBG N
anxiety NN N
levels NNS N
prior RB N
to TO N
delivery NN N
of IN N
educational JJ N
interventions NNS N
, , N
implement JJ N
interventions NNS N
aimed VBN N
at IN N
reducing VBG N
anxiety NN N
levels NNS N
, , N
and CC N
provide VB N
individualized JJ N
teaching NN N
. . N

-DOCSTART- -12886239- O O

Randomized NNP N
comparison NN N
of IN N
interferon NN N
alpha NN N
and CC N
hydroxyurea NN N
with IN N
hydroxyurea JJ N
monotherapy NN N
in IN N
chronic JJ N
myeloid NN N
leukemia NN N
( ( N
CML-study NNP N
II NNP N
) ) N
: : N
prolongation NN N
of IN N
survival NN N
by IN N
the DT N
combination NN N
of IN N
interferon NN N
alpha NN N
and CC N
hydroxyurea NN N
. . N

The DT N
optimum JJ N
treatment NN N
conditions NNS N
of IN N
interferon NN N
( ( N
IFN NNP N
) ) N
alpha VBP N
therapy NN N
in IN N
chronic JJ N
myeloid NN N
leukemia NN N
( ( N
CML NNP N
) ) N
are VBP N
still RB N
controversial JJ N
. . N

To TO N
evaluate VB N
the DT N
role NN N
of IN N
hydroxyurea NN N
( ( N
HU NNP N
) ) N
for IN N
the DT N
outcome NN N
of IN N
IFN NNP N
therapy NN N
, , N
we PRP N
conducted VBD N
a DT N
randomized JJ N
trial NN N
to TO N
compare VB N
the DT N
combination NN N
of IN N
IFN NNP N
and CC N
HU NNP N
vs VBP N
HU NNP N
monotherapy NN N
( ( N
CML-study NNP N
II NNP N
) ) N
. . N

From IN N
February NNP N
1991 CD N
to TO N
December NNP N
1994 CD N
, , N
376 CD N
patients NNS N
with IN N
newly RB N
diagnosed VBN N
CML NNP N
in IN N
chronic JJ N
phase NN N
were VBD N
randomized VBN N
. . N

In IN N
all DT N
, , N
340 CD N
patients NNS N
were VBD N
Ph/BCR-ABL NNP N
positive JJ N
and CC N
evaluable JJ N
. . N

Randomization NN N
was VBD N
unbalanced JJ N
1:2 CD N
in IN N
favor NN N
of IN N
the DT N
combination NN N
therapy NN N
, , N
since IN N
study NN N
conditions NNS N
were VBD N
identical JJ N
to TO N
the DT N
previous JJ N
CML-study NNP N
I PRP N
and CC N
it PRP N
had VBD N
been VBN N
planned VBN N
in IN N
advance NN N
to TO N
add VB N
the DT N
HU NNP N
patients NNS N
of IN N
study NN N
I PRP N
( ( N
n=194 RB N
) ) N
to TO N
the DT N
HU NNP N
control NN N
group NN N
. . N

Therefore RB N
, , N
a DT N
total NN N
of IN N
534 CD N
patients NNS N
were VBD N
evaluable JJ N
( ( N
226 CD N
patients NNS N
with IN N
IFN/HU NNP N
and CC N
308 CD N
patients NNS N
with IN N
HU NNP N
) ) N
. . N

Analyses NNS N
were VBD N
according VBG N
to TO N
intention-to-treat NN N
. . N

Median JJ N
observation NN N
time NN N
of IN N
nontransplanted JJ N
living NN N
patients NNS N
was VBD N
7.6 CD N
years NNS N
( ( N
7.9 CD N
years NNS N
for IN N
IFN/HU NNP N
and CC N
7.3 CD N
years NNS N
for IN N
HU NNP N
) ) N
. . N

The DT N
risk NN N
profile NN N
( ( N
new JJ N
CML NNP N
score NN N
) ) N
was VBD N
available JJ N
for IN N
532 CD N
patients NNS N
: : N
200 CD N
patients NNS N
( ( N
38 CD N
% NN N
) ) N
were VBD N
low JJ N
, , N
239 CD N
patients NNS N
( ( N
45 CD N
% NN N
) ) N
intermediate NN N
, , N
and CC N
93 CD N
patients NNS N
( ( N
17 CD N
% NN N
) ) N
high JJ N
risk NN N
. . N

Complete NNP N
hematologic JJ N
response NN N
rates NNS N
were VBD N
higher JJR N
in IN N
IFN/HU-treated JJ N
patients NNS N
( ( N
59 CD N
vs RB N
32 CD N
% NN N
) ) N
. . N

Of IN N
169 CD N
evaluable JJ N
IFN/HU-treated JJ N
patients NNS N
( ( N
75 CD N
% NN N
) ) N
, , N
104 CD N
patients NNS N
( ( N
62 CD N
% NN N
) ) N
achieved VBD N
a DT N
cytogenetic JJ N
response NN N
that WDT N
was VBD N
complete JJ N
in IN N
12 CD N
% NN N
( ( N
n=21 JJ N
) ) N
, , N
major JJ N
in IN N
14 CD N
% NN N
( ( N
n=24 JJ N
) ) N
, , N
and CC N
at IN N
least JJS N
minimal JJ N
in IN N
35 CD N
% NN N
( ( N
n=59 JJ N
) ) N
. . N

Of IN N
the DT N
534 CD N
patients NNS N
, , N
105 CD N
( ( N
20 CD N
% NN N
) ) N
underwent NN N
allogeneic JJ N
stem NN N
cell NN N
transplantation NN N
in IN N
first JJ N
chronic JJ N
phase NN N
. . N

In IN N
the DT N
low-risk JJ N
group NN N
, , N
65 CD N
of IN N
200 CD N
patients NNS N
were VBD N
transplanted VBN N
( ( N
33 CD N
% NN N
) ) N
, , N
30 CD N
( ( N
13 CD N
% NN N
) ) N
in IN N
the DT N
intermediate-risk JJ N
group NN N
, , N
and CC N
nine CD N
( ( N
10 CD N
% NN N
) ) N
in IN N
the DT N
high-risk JJ N
group NN N
. . N

Duration NN N
of IN N
chronic JJ N
phase NN N
was VBD N
55 CD N
months NNS N
for IN N
IFN/HU NNP N
and CC N
41 CD N
months NNS N
for IN N
HU NNP N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Median JJ N
survival NN N
was VBD N
64 CD N
months NNS N
for IN N
IFN/HU NNP N
and CC N
53 CD N
months NNS N
for IN N
HU-treated JJ N
patients NNS N
( ( N
P=0.0063 NNP N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
IFN NNP N
in IN N
combination NN N
with IN N
HU NNP N
achieves VBZ N
a DT N
significant JJ N
long-term JJ N
survival NN N
advantage NN N
over IN N
HU NNP N
monotherapy NN N
. . N

In IN N
view NN N
of IN N
the DT N
data NNS N
of IN N
CML-study NNP N
I PRP N
, , N
these DT N
results NNS N
suggest VBP N
that IN N
IFN/HU NNP N
is VBZ N
also RB N
superior JJ N
to TO N
IFN NNP N
alone RB N
. . N

HU NNP N
should MD N
be VB N
combined VBN N
with IN N
IFN NNP N
in IN N
IFN-based JJ N
therapies NNS N
and CC N
for IN N
comparisons NNS N
with IN N
new JJ N
therapies NNS N
. . N

-DOCSTART- -24330473- O O

Short- JJ N
and CC N
long-term JJ N
effects NNS N
of IN N
tactile JJ N
massage NN N
on IN N
salivary JJ N
cortisol NN N
concentrations NNS N
in IN N
Parkinson NNP N
's POS N
disease NN N
: : N
a DT N
randomised JJ N
controlled VBN N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Parkinson NNP N
's POS N
disease NN N
( ( N
PD NNP N
) ) N
is VBZ N
a DT N
chronic JJ N
neurodegenerative JJ N
disorder NN N
with IN N
limited JJ N
knowledge NN N
about IN N
the DT N
normal JJ N
function NN N
and CC N
effects NNS N
of IN N
non-pharmacological JJ N
therapies NNS N
on IN N
the DT N
hypothalamic-pituitary-adrenal JJ N
( ( N
HPA NNP N
) ) N
axis NN N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
analyse VB N
the DT N
basal NN N
diurnal JJ N
and CC N
total JJ N
secretion NN N
of IN N
salivary JJ N
cortisol NN N
in IN N
short- JJ N
and CC N
long-term JJ N
aspects NNS N
of IN N
tactile JJ N
massage NN N
( ( N
TM NNP N
) ) N
. . N

METHODS NNP N
DESIGN NNP N
Prospective NNP N
, , N
Controlled NNP N
and CC N
Randomised VBD N
Multicentre NNP N
Trial NNP N
. . N

SETTING NN N
AND JJ N
INTERVENTIONS NNP N
Forty-five NNP N
women NNS N
and CC N
men NNS N
, , N
aged VBN N
50-79 CD N
years NNS N
, , N
were VBD N
recruited VBN N
. . N

Twenty-nine NN N
of IN N
them PRP N
were VBD N
blindly RB N
randomised VBN N
to TO N
tactile VB N
massage NN N
( ( N
TM NNP N
) ) N
and CC N
16 CD N
of IN N
them PRP N
to TO N
the DT N
control NN N
group NN N
, , N
rest NN N
to TO N
music NN N
( ( N
RTM NNP N
) ) N
. . N

Ten CD N
interventions NNS N
were VBD N
given VBN N
during IN N
8 CD N
weeks NNS N
followed VBN N
by IN N
a DT N
26 CD N
weeks NNS N
of IN N
follow JJ N
up RB N
. . N

Salivary JJ N
cortisol NN N
was VBD N
collected VBN N
at IN N
8 CD N
am VBP N
, , N
1 CD N
pm NN N
, , N
8 CD N
pm NN N
, , N
and CC N
8 CD N
am VBP N
the DT N
next JJ N
day NN N
, , N
on IN N
five CD N
occasions NNS N
. . N

With IN N
the DT N
first JJ N
and CC N
eighth JJ N
interventions NNS N
, , N
it PRP N
was VBD N
collected VBN N
immediately RB N
before IN N
and CC N
after IN N
intervention NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
aim NN N
was VBD N
to TO N
assess VB N
and CC N
compare VB N
cortisol JJ N
concentrations NNS N
before IN N
and CC N
immediately RB N
after IN N
intervention NN N
and CC N
also RB N
during IN N
the DT N
follow-up JJ N
period NN N
. . N

The DT N
secondary JJ N
aim NN N
was VBD N
to TO N
assess VB N
the DT N
impact NN N
of IN N
age NN N
, , N
gender NN N
, , N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
, , N
duration NN N
and CC N
severity NN N
of IN N
PD NNP N
, , N
effects NNS N
of IN N
interventional JJ N
time-point NN N
of IN N
the DT N
day NN N
, , N
and CC N
levodopa JJ N
doses NNS N
on IN N
cortisol JJ N
concentration NN N
. . N

RESULTS VB N
The DT N
median JJ N
cortisol NN N
concentrations NNS N
for IN N
all DT N
participants NNS N
were VBD N
16.0 CD N
, , N
5.8 CD N
, , N
2.8 CD N
, , N
and CC N
14.0 CD N
nmol/L NN N
at IN N
baseline NN N
, , N
later RB N
reproduced VBD N
four CD N
times NNS N
without IN N
significant JJ N
differences NNS N
. . N

Cortisol NNP N
concentrations NNS N
decreased VBD N
significantly RB N
after IN N
TM NNP N
intervention NN N
but CC N
no DT N
change NN N
in IN N
diurnal JJ N
salivary JJ N
cortisol NN N
pattern NN N
was VBD N
found VBN N
. . N

The DT N
findings NNS N
of IN N
reduced JJ N
salivary JJ N
cortisol NN N
concentrations NNS N
immediately RB N
after IN N
the DT N
interventions NNS N
are VBP N
in IN N
agreement NN N
with IN N
previous JJ N
studies NNS N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
TM NNP N
and CC N
control NN N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
correlations NNS N
between IN N
cortisol JJ N
concentrations NNS N
and CC N
age NN N
, , N
gender NN N
, , N
BMI NNP N
, , N
time-point NN N
for IN N
intervention NN N
, , N
time NN N
interval NN N
between IN N
anti-parkinson JJ N
pharmacy NN N
intake NN N
and CC N
sampling NN N
, , N
levodopa NN N
doses NNS N
, , N
duration NN N
, , N
or CC N
severity NN N
of IN N
PD NNP N
. . N

CONCLUSIONS NNP N
Diurnal NNP N
salivary JJ N
cortisol NN N
rhythm NN N
was VBD N
normal JJ N
. . N

Salivary JJ N
cortisol NN N
concentrations NNS N
were VBD N
significantly RB N
reduced VBN N
after IN N
the DT N
TM NNP N
intervention NN N
and CC N
after IN N
RTM NNP N
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
and CC N
no DT N
sustained JJ N
long-term JJ N
effect NN N
. . N

No CC N
associations NNS N
were VBD N
seen VBN N
between IN N
salivary JJ N
cortisol NN N
concentration NN N
and CC N
clinical JJ N
and/or NN N
pharmacological JJ N
characteristics NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrial.gov NNP N
, , N
NCT01734876 NNP N
and CC N
FoU NNP N
Sweden NNP N
108881 CD N
. . N

-DOCSTART- -23773380- O O

Does VBZ N
the DT N
result NN N
of IN N
completion NN N
axillary JJ N
lymph NN N
node NN N
dissection NN N
influence NN N
the DT N
recommendation NN N
for IN N
adjuvant JJ N
treatment NN N
in IN N
sentinel JJ N
lymph JJ N
node-positive JJ N
patients NNS N
? . N
OBJECTIVE IN N
The DT N
Hungarian NNP N
National NNP N
Institute NNP N
of IN N
Oncology NNP N
has VBZ N
just RB N
closed VBN N
a DT N
single-center JJ N
randomized JJ N
clinical JJ N
study NN N
. . N

The DT N
Optimal NNP N
Treatment NNP N
of IN N
the DT N
Axilla-Surgery NNP N
or CC N
Radiotherapy NNP N
( ( N
OTOASOR NNP N
) ) N
trial NN N
compares VBZ N
completion NN N
axillary JJ N
lymph NN N
node NN N
dissection NN N
( ( N
cALND NN N
) ) N
with IN N
regional JJ N
nodal JJ N
irradiation NN N
( ( N
RNI NNP N
) ) N
in IN N
patients NNS N
with IN N
sentinel JJ N
lymph JJ N
node-positive JJ N
( ( N
SLN+ NNP N
) ) N
primary VBP N
invasive JJ N
breast NN N
cancer NN N
. . N

In IN N
the DT N
investigational JJ N
treatment NN N
arm NN N
, , N
patients NNS N
received VBD N
50 CD N
Gy NNP N
RNI NNP N
instead RB N
of IN N
cALND NN N
. . N

In IN N
these DT N
patients NNS N
we PRP N
had VBD N
information NN N
only RB N
about IN N
the DT N
sentinel NN N
lymph NN N
node NN N
( ( N
SLN NNP N
) ) N
status NN N
, , N
but CC N
the DT N
further JJ N
axillary JJ N
nodal JJ N
involvement NN N
remained VBD N
unknown JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
result NN N
of IN N
cALND NN N
influenced VBD N
the DT N
recommendation NN N
for IN N
adjuvant JJ N
treatment NN N
in IN N
patients NNS N
with IN N
SLN+ NNP N
breast NN N
cancer NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
with IN N
SLN+ NNP N
primary JJ N
breast NN N
cancer NN N
were VBD N
randomized VBN N
for IN N
cALND NN N
( ( N
arm NN N
A NNP N
, , N
standard JJ N
treatment NN N
) ) N
or CC N
RNI NNP N
( ( N
arm NN N
B NNP N
, , N
investigational JJ N
treatment NN N
) ) N
. . N

Adjuvant JJ N
systemic JJ N
treatments NNS N
were VBD N
given VBN N
according VBG N
to TO N
the DT N
standard JJ N
institutional JJ N
protocol NN N
, , N
and CC N
patients NNS N
were VBD N
followed VBN N
according VBG N
to TO N
the DT N
actual JJ N
institutional JJ N
guidelines NNS N
. . N

RESULTS NNP N
Between NNP N
August NNP N
2002 CD N
and CC N
June NNP N
2009 CD N
, , N
474 CD N
SLN+ NN N
patients NNS N
were VBD N
randomized VBN N
to TO N
cALND VB N
( ( N
arm NN N
A NNP N
, , N
standard JJ N
treatment NN N
= JJ N
244 CD N
patients NNS N
) ) N
or CC N
RNI NNP N
( ( N
arm NN N
B NNP N
, , N
investigational JJ N
treatment NN N
= VBD N
230 CD N
patients NNS N
) ) N
. . N

The DT N
2 CD N
arms NNS N
were VBD N
well RB N
balanced VBN N
according VBG N
to TO N
the DT N
majority NN N
of IN N
main JJ N
prognostic JJ N
factors NNS N
. . N

However RB N
, , N
more JJR N
patients NNS N
were VBD N
premenopausal JJ N
( ( N
34 CD N
% NN N
vs. FW N
27 CD N
% NN N
; : N
P NNP N
= NNP N
.095 NNP N
) ) N
and CC N
had VBD N
pT2-3 NN N
tumors NNS N
( ( N
57 CD N
% NN N
vs. FW N
40 CD N
% NN N
; : N
P NNP N
= NNP N
.003 NNP N
) ) N
in IN N
the DT N
completion NN N
axillary JJ N
lymph NN N
node NN N
dissection NN N
( ( N
ALND NNP N
) ) N
arm NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
there EX N
were VBD N
more JJR N
patients NNS N
with IN N
known JJ N
human JJ N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
type VBD N
2 CD N
positive JJ N
tumor NN N
( ( N
12 CD N
% NN N
vs. FW N
17 CD N
% NN N
, , N
P NNP N
= NNP N
.066 NNP N
) ) N
in IN N
the DT N
RNI NNP N
arm NN N
. . N

In IN N
the DT N
ALND NNP N
and CC N
RNI NNP N
arms NNS N
, , N
78 CD N
% NN N
( ( N
190/244 CD N
) ) N
and CC N
69 CD N
% NN N
( ( N
159/230 CD N
) ) N
, , N
respectively RB N
, , N
received VBD N
chemotherapy NN N
( ( N
P NNP N
= NNP N
.020 NNP N
) ) N
. . N

Endocrine NNP N
therapy NN N
was VBD N
administered VBN N
in IN N
87 CD N
% NN N
( ( N
213/244 CD N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
ALND NNP N
arm NN N
and CC N
89 CD N
% NN N
( ( N
204/230 CD N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
RNI NNP N
arm NN N
( ( N
P NNP N
= NNP N
.372 NNP N
) ) N
. . N

Six CD N
patients NNS N
( ( N
2.5 CD N
% NN N
) ) N
on IN N
arm NN N
A NN N
and CC N
13 CD N
patients NNS N
( ( N
5.7 CD N
% NN N
) ) N
on IN N
arm NN N
B NNP N
received VBD N
adjuvant JJ N
trastuzumab NN N
treatment NN N
( ( N
P NNP N
= NNP N
not RB N
significant JJ N
) ) N
. . N

Subgroup NNP N
analyses VBZ N
explored VBD N
that IN N
more RBR N
frequent JJ N
administration NN N
of IN N
adjuvant JJ N
chemotherapy NN N
in IN N
arm NN N
A NN N
was VBD N
associated VBN N
with IN N
the DT N
higher JJR N
percentage NN N
of IN N
premenopausal NN N
patients NNS N
and CC N
patients NNS N
with IN N
larger JJR N
( ( N
pT2-3 NN N
) ) N
tumors NNS N
. . N

CONCLUSIONS VB N
The DT N
result NN N
of IN N
cALND NN N
after IN N
positive JJ N
SLN NNP N
biopsy NN N
seems VBZ N
to TO N
have VB N
no DT N
major JJ N
impact NN N
on IN N
the DT N
administration NN N
of IN N
adjuvant JJ N
systemic JJ N
therapy NN N
. . N

-DOCSTART- -19415341- O O

Pilot NNP N
study NN N
of IN N
Panax NNP N
quinquefolius NN N
( ( N
American NNP N
ginseng NN N
) ) N
to TO N
improve VB N
cancer-related JJ N
fatigue NN N
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
dose-finding JJ N
evaluation NN N
: : N
NCCTG NNP N
trial NN N
N03CA NNP N
. . N

PURPOSE NNP N
This DT N
pilot NN N
trial NN N
sought VBD N
to TO N
investigate VB N
whether IN N
any DT N
of IN N
three CD N
doses NNS N
of IN N
American JJ N
ginseng NN N
( ( N
Panax NNP N
quinquefolius RB N
) ) N
might MD N
help VB N
cancer-related JJ N
fatigue NN N
. . N

A DT N
secondary JJ N
aim NN N
was VBD N
to TO N
evaluate VB N
toxicity NN N
. . N

METHODS NNP N
Eligible JJ N
adults NNS N
with IN N
cancer NN N
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
manner NN N
, , N
to TO N
receive VB N
American JJ N
ginseng NN N
in IN N
doses NNS N
of IN N
750 CD N
, , N
1,000 CD N
, , N
or CC N
2,000 CD N
mg/day NN N
or CC N
placebo VB N
given VBN N
in IN N
twice JJ N
daily JJ N
dosing NN N
over IN N
8 CD N
weeks NNS N
. . N

Outcome NNP N
measures NNS N
included VBD N
the DT N
Brief NNP N
Fatigue NNP N
Inventory NNP N
, , N
vitality NN N
subscale NN N
of IN N
the DT N
Medical NNP N
Outcome NNP N
Scale NNP N
Short NNP N
Form-36 NNP N
( ( N
SF-36 NNP N
) ) N
, , N
and CC N
the DT N
Global NNP N
Impression NNP N
of IN N
Benefit NNP N
Scale NNP N
at IN N
4 CD N
and CC N
8 CD N
weeks NNS N
. . N

RESULTS NNP N
Two CD N
hundred VBD N
ninety NN N
patients NNS N
were VBD N
accrued VBN N
to TO N
this DT N
trial NN N
. . N

Nonsignificant JJ N
trends NNS N
for IN N
all DT N
outcomes NNS N
were VBD N
seen VBN N
in IN N
favor NN N
of IN N
the DT N
1,000- JJ N
and CC N
2,000-mg/day JJ N
doses NNS N
of IN N
American JJ N
ginseng NN N
. . N

Area NNP N
under IN N
the DT N
curve NN N
analysis NN N
of IN N
activity NN N
interference NN N
from IN N
the DT N
Brief NNP N
Fatigue NNP N
Inventory NNP N
was VBD N
460-467 JJ N
in IN N
the DT N
placebo NN N
group NN N
and CC N
750 CD N
mg/day NN N
group NN N
versus VBD N
480-551 CD N
in IN N
the DT N
1,000- JJ N
and CC N
2,000-mg/day JJ N
arms NNS N
, , N
respectively RB N
. . N

Change NN N
from IN N
baseline NN N
in IN N
the DT N
vitality NN N
subscale NN N
of IN N
the DT N
SF-36 NNP N
was VBD N
7.3-7.8 JJ N
in IN N
the DT N
placebo NN N
and CC N
the DT N
750-mg/day JJ N
arm NN N
, , N
versus NN N
10.5-14.6 JJ N
in IN N
the DT N
1,000- JJ N
and CC N
2,000-mg/day JJ N
arms NNS N
. . N

Over NNP N
twice RB N
as RB N
many JJ N
patients NNS N
on IN N
ginseng NN N
perceived VBD N
a DT N
benefit NN N
and CC N
were VBD N
satisfied VBN N
with IN N
treatment NN N
over IN N
those DT N
on IN N
placebo NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
any DT N
measured JJ N
toxicities NNS N
between IN N
any DT N
of IN N
the DT N
arms NNS N
. . N

CONCLUSION NN N
There EX N
appears VBZ N
to TO N
be VB N
some DT N
activity NN N
and CC N
tolerable JJ N
toxicity NN N
at IN N
1,000-2,000 CD N
mg/day JJ N
doses NNS N
of IN N
American JJ N
ginseng NN N
with IN N
regard NN N
to TO N
cancer-related JJ N
fatigue NN N
. . N

Thus NNP N
, , N
further JJ N
study NN N
of IN N
American NNP N
ginseng NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -19169289- O O

Pegfilgrastim NN N
for IN N
peripheral JJ N
CD34+ NNP N
mobilization NN N
in IN N
patients NNS N
with IN N
solid JJ N
tumours NNS N
. . N

The DT N
efficacy NN N
of IN N
pegfilgrastim+/-chemotherapy NN N
for IN N
mobilizing VBG N
stem NN N
cells NNS N
in IN N
patients NNS N
with IN N
solid JJ N
tumours NN N
was VBD N
assessed VBN N
. . N

In IN N
cycle NN N
0 CD N
, , N
a DT N
14-day JJ N
prechemotherapy NN N
cycle NN N
, , N
patients NNS N
( ( N
N=61 NNP N
) ) N
were VBD N
randomized VBN N
open-label NN N
to TO N
single JJ N
doses NNS N
of IN N
pegfilgrastim NN N
( ( N
6 CD N
, , N
12 CD N
or CC N
18 CD N
mg NN N
) ) N
on IN N
day NN N
1 CD N
, , N
or CC N
daily RB N
filgrastim NNS N
( ( N
10 CD N
microg/kg NN N
) ) N
for IN N
< NN N
or CC N
=7 JJ N
days NNS N
. . N

Mean JJ N
peak JJ N
peripheral JJ N
CD34+ NNP N
cell NN N
counts NNS N
increased VBD N
with IN N
pegfilgrastim NN N
dose NN N
, , N
but CC N
were VBD N
significantly RB N
higher JJR N
than IN N
filgrastim JJR N
only RB N
at IN N
the DT N
18 CD N
mg NN N
dose NN N
( ( N
10.17 CD N
vs RB N
4.96 CD N
x JJ N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
; : N
P=0.014 NNP N
) ) N
. . N

In IN N
the DT N
clinically NN N
relevant JJ N
period NN N
of IN N
days NNS N
3-7 CD N
, , N
both DT N
12 CD N
and CC N
18 CD N
mg NN N
pegfilgrastim NN N
doses NNS N
produced VBD N
significantly RB N
higher JJR N
peak NN N
CD34+ NNP N
counts VBZ N
( ( N
8.18 CD N
and CC N
9.96 CD N
vs NN N
4.51 CD N
x NN N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
for IN N
filgrastim NN N
; : N
P=0.034 NNP N
and CC N
0.006 CD N
) ) N
. . N

In IN N
cycle NN N
1 CD N
, , N
patients NNS N
received VBD N
carboplatin/paclitaxel NNS N
on IN N
day NN N
1 CD N
, , N
followed VBD N
from IN N
day NN N
2 CD N
by IN N
pegfilgrastim JJ N
6-18 JJ N
mg NN N
or CC N
daily JJ N
filgrastim NN N
( ( N
5 CD N
microg/kg/day NN N
for IN N
< NN N
or CC N
=14 NNP N
days NNS N
) ) N
as IN N
per IN N
randomization NN N
in IN N
cycle NN N
0 CD N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
mean JJ N
peak NN N
CD34+ NNP N
count NN N
between IN N
pegfilgrastim NN N
and CC N
filgrastim NN N
, , N
but CC N
there EX N
was VBD N
an DT N
advantage NN N
for IN N
pegfilgrastim NN N
18 CD N
mg NN N
in IN N
the DT N
relevant JJ N
period NN N
of IN N
days NNS N
7-12 NNP N
( ( N
3.14 CD N
vs RB N
1.19 CD N
x JJ N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
; : N
P=0.043 NNP N
) ) N
. . N

A DT N
single JJ N
pegfilgrastim NN N
dose NN N
( ( N
> CD N
or CC N
=6 VB N
mg NN N
) ) N
could MD N
be VB N
substituted VBN N
for IN N
daily JJ N
filgrastim NN N
in IN N
cytokine-only JJ N
peripheral JJ N
CD34+ NNP N
cell NN N
mobilization NN N
. . N

-DOCSTART- -10707032- O O

Treatment NN N
with IN N
metformin NN N
of IN N
non-diabetic JJ N
men NNS N
with IN N
hypertension NN N
, , N
hypertriglyceridaemia NN N
and CC N
central JJ N
fat JJ N
distribution NN N
: : N
the DT N
BIGPRO NNP N
1.2 CD N
trial NN N
. . N

BACKGROUND NNP N
In IN N
the DT N
BIGPRO NNP N
1 CD N
trial NN N
, , N
one CD N
year NN N
of IN N
treatment NN N
with IN N
metformin NN N
in IN N
non-diabetic JJ N
obese JJ N
subjects NNS N
with IN N
a DT N
central JJ N
fat JJ N
distribution NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
fasting VBG N
plasma JJ N
triglyceride JJ N
concentration NN N
or CC N
on IN N
blood NN N
pressure NN N
despite IN N
a DT N
decrease NN N
in IN N
weight NN N
, , N
fasting VBG N
plasma JJ N
insulin NN N
and CC N
glucose JJ N
concentrations NNS N
. . N

To TO N
re-evaluate VB N
the DT N
effect NN N
of IN N
metformin NN N
on IN N
fasting VBG N
triglyceride JJ N
concentration NN N
and CC N
on IN N
blood NN N
pressure NN N
, , N
the DT N
BIGPRO NNP N
1.2 CD N
trial NN N
included VBD N
non-diabetic JJ N
men NNS N
( ( N
n=168 NN N
) ) N
with IN N
a DT N
fasting VBG N
plasma NN N
triglyceride JJ N
concentration NN N
> NN N
or CC N
=1.7 NN N
and CC N
< NN N
or CC N
=6.5 NN N
mmol/l NN N
, , N
high JJ N
blood NN N
pressure NN N
( ( N
systolic JJ N
> NN N
or CC N
=140 NN N
and CC N
< NN N
or CC N
=180 VB N
and/or JJ N
diastolic JJ N
> NN N
or CC N
=90 NN N
and CC N
< NN N
or CC N
=105 NN N
mmHg NN N
, , N
or CC N
treatment NN N
for IN N
hypertension NN N
) ) N
and CC N
a DT N
waist-to-hip JJ N
ratio NN N
> NN N
or CC N
=0.95 NN N
. . N

METHODS NNP N
A DT N
randomised JJ N
double-blind JJ N
trial NN N
comparing VBG N
metformin NN N
treatment NN N
( ( N
850 CD N
mg RB N
bid NN N
) ) N
with IN N
placebo NN N
. . N

RESULTS NNP N
Metformin NNP N
had VBD N
no DT N
significant JJ N
effect NN N
either DT N
on IN N
blood NN N
pressure NN N
or CC N
plasma NN N
triglyceride JJ N
concentration NN N
. . N

In IN N
comparison NN N
with IN N
the DT N
placebo NN N
group NN N
, , N
fasting VBG N
plasma JJ N
insulin NN N
( ( N
p JJ N
< NNP N
0.04 CD N
) ) N
, , N
total JJ N
cholesterol NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
Apo NNP N
B NNP N
( ( N
p JJ N
< NNP N
0.008 CD N
) ) N
concentrations NNS N
decreased VBD N
more RBR N
in IN N
the DT N
metformin NN N
group NN N
in IN N
the DT N
BIGPRO NNP N
1 CD N
. . N

2 CD N
trial NN N
, , N
confirming VBG N
most JJS N
of IN N
the DT N
previous JJ N
results NNS N
of IN N
the DT N
BIGPRO NNP N
1 CD N
trial NN N
. . N

Tissue NNP N
plasminogen NN N
activator NN N
antigen NN N
concentration NN N
decreased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
only RB N
in IN N
the DT N
metformin NN N
group NN N
, , N
but CC N
this DT N
was VBD N
not RB N
significantly RB N
different JJ N
from IN N
the DT N
placebo NN N
group NN N
( ( N
p JJ N
< NNP N
0.12 CD N
) ) N
; : N
further RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
change NN N
in IN N
plasminogen NN N
activator NN N
inhibitor NN N
1 CD N
. . N

CONCLUSIONS VB N
The DT N
consistency NN N
of IN N
the DT N
two CD N
BIGPRO NNP N
trials NNS N
supports VBZ N
the DT N
conclusion NN N
that IN N
metformin VBZ N
affects NNS N
several JJ N
cardiovascular JJ N
risk NN N
factors NNS N
favourably RB N
in IN N
non-diabetic JJ N
subjects NNS N
with IN N
a DT N
central JJ N
fat JJ N
distribution NN N
. . N

-DOCSTART- -16116055- O O

Impact NN N
of IN N
a DT N
single JJ N
intravenous JJ N
administration NN N
of IN N
nicorandil JJ N
before IN N
reperfusion NN N
in IN N
patients NNS N
with IN N
ST-segment-elevation NNP N
myocardial JJ N
infarction NN N
. . N

BACKGROUND NNP N
Intravenous NNP N
nicorandil NN N
, , N
a DT N
hybrid JJ N
compound NN N
of IN N
ATP-sensitive JJ N
potassium NN N
channel NN N
opener NN N
and CC N
nitric JJ N
oxide NN N
donor NN N
, , N
has VBZ N
been VBN N
reported VBN N
to TO N
ameliorate VB N
early JJ N
functional NN N
and CC N
clinical JJ N
problems NNS N
in IN N
patients NNS N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

However RB N
, , N
its PRP$ N
effects NNS N
on IN N
the DT N
late JJ N
phase NN N
remain VBP N
unclear JJ N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
This DT N
follow-up JJ N
study NN N
to TO N
5 CD N
years NNS N
of IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
trial NN N
was VBD N
conducted VBN N
among IN N
368 CD N
patients NNS N
with IN N
first JJ N
ST-segment-elevation NNP N
myocardial JJ N
infarction NN N
undergoing VBG N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
. . N

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
12 CD N
mg NN N
of IN N
nicorandil NN N
or CC N
a DT N
placebo NN N
intravenously RB N
just RB N
before IN N
reperfusion NN N
. . N

We PRP N
analyzed VBD N
incidence NN N
of IN N
cardiovascular JJ N
death NN N
or CC N
rehospitalization NN N
for IN N
congestive JJ N
heart NN N
failure NN N
after IN N
PCI NNP N
as RB N
well RB N
as IN N
various JJ N
aspects NNS N
of IN N
epicardial JJ N
flow NN N
and CC N
microvascular JJ N
function NN N
. . N

Mean JJ N
follow-up NN N
was VBD N
2.4 CD N
years NNS N
( ( N
SD NNP N
, , N
1.4 CD N
) ) N
. . N

A DT N
total NN N
of IN N
12 CD N
( ( N
6.5 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
nicorandil JJ N
and CC N
30 CD N
( ( N
16.4 CD N
% NN N
) ) N
receiving NN N
placebo NN N
had VBD N
cardiovascular JJ N
death NN N
or CC N
hospital NN N
admission NN N
for IN N
congestive JJ N
heart NN N
failure NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.39 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.20 CD N
to TO N
0.76 CD N
; : N
P=0.0058 NNP N
) ) N
. . N

Postprocedural NNP N
TIMI NNP N
3 CD N
flow NN N
was VBD N
obtained VBN N
in IN N
89.7 CD N
% NN N
of IN N
the DT N
nicorandil JJ N
group NN N
and CC N
in IN N
81.4 CD N
% NN N
of IN N
the DT N
placebo NN N
( ( N
hazard JJ N
ratio NN N
, , N
1.99 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.09 CD N
to TO N
3.65 CD N
; : N
P=0.025 NNP N
) ) N
. . N

Corrected VBN N
TIMI NNP N
frame NN N
count NN N
was VBD N
furthermore RB N
lower JJR N
in IN N
the DT N
nicorandil NN N
group NN N
( ( N
21.0+/-9.1 JJ N
versus NN N
25.1+/-14.1 CD N
; : N
P=0.0009 NNP N
) ) N
. . N

ST-segment JJ N
resolution NN N
> VBD N
50 CD N
% NN N
was VBD N
observed VBN N
in IN N
79.5 CD N
% NN N
and CC N
61.2 CD N
% NN N
of IN N
the DT N
nicorandil NN N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
( ( N
hazard JJ N
ratio NN N
, , N
2.45 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.54 CD N
to TO N
3.90 CD N
; : N
P=0.0002 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
intravenous JJ N
nicorandil NNS N
to TO N
PCI NNP N
leads VBZ N
to TO N
beneficial JJ N
clinical JJ N
outcomes NNS N
and CC N
prevents NNS N
cardiovascular JJ N
events NNS N
of IN N
long JJ N
duration NN N
and CC N
death NN N
in IN N
patients NNS N
with IN N
ST-segment-elevation NNP N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -10084579- O O

Genotyping VBG N
of IN N
CYP21 NNP N
, , N
linked VBD N
chromosome NN N
6p CD N
markers NNS N
, , N
and CC N
a DT N
sex-specific JJ N
gene NN N
in IN N
neonatal JJ N
screening NN N
for IN N
congenital JJ N
adrenal JJ N
hyperplasia NN N
. . N

We PRP N
investigated VBD N
the DT N
feasibility NN N
and CC N
diagnostic JJ N
utility NN N
of IN N
genotyping VBG N
9 CD N
CYP21 NNP N
mutations NNS N
, , N
linked VBD N
chromosome NN N
6p CD N
markers NNS N
, , N
and CC N
a DT N
dimorphic JJ N
X-Y JJ N
marker NN N
from IN N
neonatal JJ N
screening NN N
samples NNS N
. . N

Blood-impregnated JJ N
filter NN N
papers NNS N
( ( N
Guthrie NNP N
cards NNS N
) ) N
from IN N
603 CD N
randomly RB N
chosen VBN N
New NNP N
Zealand NNP N
neonates NNS N
were VBD N
genotyped VBN N
blind IN N
to TO N
17-hydroxyprogesterone CD N
( ( N
17-OHP CD N
) ) N
levels NNS N
. . N

Another DT N
50 CD N
samples NNS N
from IN N
Swiss NNP N
and CC N
North NNP N
American JJ N
infants NNS N
with IN N
correlative JJ N
hormonal JJ N
data NNS N
were VBD N
also RB N
genotyped VBN N
. . N

DNA NN N
was VBD N
extracted VBN N
, , N
and CC N
gene-specific JJ N
PCR NNP N
was VBD N
performed VBN N
. . N

CYP21 NNP N
PCR NNP N
products NNS N
were VBD N
subjected VBN N
to TO N
ligase VB N
detection NN N
reaction NN N
, , N
simultaneously RB N
analyzing VBG N
9 CD N
CYP21 NNP N
mutations NNS N
; : N
PCR NNP N
products NNS N
of IN N
other JJ N
genes NNS N
were VBD N
subjected VBN N
to TO N
direct VB N
gel JJ N
analysis NN N
. . N

CYP21 NNP N
genotyping VBG N
indicated VBD N
a DT N
heterozygote NN N
rate NN N
of IN N
2.8 CD N
% NN N
for IN N
classic JJ N
mutations NNS N
( ( N
excluding VBG N
CYP21 NNP N
deletions NNS N
) ) N
, , N
and CC N
2.0 CD N
% NN N
for IN N
nonclassic JJ N
mutations NNS N
in IN N
New NNP N
Zealanders NNP N
. . N

Ten CD N
full-term JJ N
affected JJ N
neonates NNS N
showed VBD N
a DT N
wide JJ N
range NN N
of IN N
17-OHP JJ N
levels NNS N
( ( N
15-1400 JJ N
nmol/L NN N
) ) N
. . N

Sick NNP N
or CC N
preterm JJ N
infants NNS N
or CC N
infants NNS N
screened VBN N
on IN N
the DT N
first JJ N
day NN N
of IN N
life NN N
with IN N
high JJ N
17-OHP JJ N
proved VBN N
genetically RB N
unaffected JJ N
. . N

Genetic JJ N
linkage NN N
disequilibrium NN N
was VBD N
found VBN N
between IN N
two CD N
CYP21 NNP N
mutations NNS N
and CC N
chromosome NN N
6p CD N
markers NNS N
. . N

Guthrie NNP N
cards NNS N
can MD N
be VB N
used VBN N
to TO N
accurately RB N
genotype VB N
CYP21 NNP N
and CC N
other JJ N
relevant JJ N
markers NNS N
, , N
potentially RB N
enhancing VBG N
the DT N
specificity NN N
and CC N
sensitivity NN N
of IN N
congenital JJ N
adrenal JJ N
hyperplasia NN N
screening NN N
. . N

CYP21 NNP N
heterozygote JJ N
frequency NN N
for IN N
classic JJ N
mutations NNS N
is VBZ N
higher JJR N
than IN N
expected VBN N
based VBN N
on IN N
genotype NN N
compared VBN N
with IN N
that DT N
predicted VBN N
by IN N
hormonal JJ N
newborn JJ N
screening NN N
. . N

-DOCSTART- -7053590- O O

Laser NNP N
conization NN N
versus NN N
cold JJ N
knife NN N
conization NN N
. . N

This DT N
prospective JJ N
, , N
randomized VBN N
study NN N
compares VBZ N
, , N
for IN N
the DT N
first JJ N
time NN N
, , N
measured VBN N
blood NN N
loss NN N
at IN N
conization NN N
and CC N
within IN N
24 CD N
hours NNS N
after IN N
using VBG N
either CC N
the DT N
cold JJ N
knife NN N
technique NN N
or CC N
the DT N
carbon NN N
dioxide NN N
laser NN N
scalpel NN N
. . N

One CD N
hundred CD N
and CC N
ten VB N
consecutive JJ N
patients NNS N
were VBD N
evaluated VBN N
. . N

The DT N
median JJ N
blood NN N
loss NN N
in IN N
the DT N
laser NN N
group NN N
of IN N
55 CD N
patients NNS N
was VBD N
4.6 CD N
milliliters NNS N
at IN N
, , N
and CC N
within IN N
, , N
24 CD N
hours NNS N
after IN N
operation NN N
compared VBN N
with IN N
30.1 CD N
milliliters NNS N
in IN N
the DT N
cold JJ N
knife NN N
group NN N
of IN N
55 CD N
patients NNS N
. . N

More RBR N
important JJ N
, , N
however RB N
, , N
is VBZ N
that IN N
the DT N
corresponding JJ N
figures NNS N
for IN N
the DT N
range NN N
of IN N
bleeding VBG N
were VBD N
0.4 CD N
to TO N
155.4 CD N
milliliters NNS N
and CC N
5.6 CD N
to TO N
1,570.9 CD N
milliliters NNS N
, , N
respectively RB N
. . N

The DT N
incidence NN N
rate NN N
for IN N
bleeding VBG N
complications NNS N
requiring VBG N
surgical JJ N
intervention NN N
was VBD N
1.8 CD N
per IN N
cet NN N
for IN N
the DT N
laser NN N
group NN N
and CC N
14.6 CD N
per IN N
cent NN N
for IN N
the DT N
cold JJ N
knife NN N
group NN N
. . N

This DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
, , N
p RB N
less JJR N
than IN N
0.015 CD N
-- : N
Fischer NNP N
's POS N
exact JJ N
test NN N
. . N

Conization NN N
for IN N
treatment NN N
of IN N
premalignant JJ N
changes NNS N
of IN N
the DT N
cervix NN N
uteri NN N
will MD N
probably RB N
remain VB N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
some DT N
time NN N
to TO N
come VB N
. . N

It PRP N
is VBZ N
our PRP$ N
opinion NN N
that IN N
, , N
in IN N
the DT N
future NN N
, , N
laser JJR N
conization NN N
will MD N
replace VB N
cold JJ N
knife NN N
conization NN N
. . N

-DOCSTART- -22810989- O O

Margarines NNS N
fortified VBN N
with IN N
?-linolenic JJ N
acid NN N
, , N
eicosapentaenoic JJ N
acid NN N
, , N
or CC N
docosahexaenoic JJ N
acid NN N
alter IN N
the DT N
fatty JJ N
acid JJ N
composition NN N
of IN N
erythrocytes NNS N
but CC N
do VBP N
not RB N
affect VB N
the DT N
antioxidant JJ N
status NN N
of IN N
healthy JJ N
adults NNS N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
increased JJ N
intake NN N
of IN N
?-linolenic JJ N
acid NN N
( ( N
ALA NNP N
) ) N
, , N
EPA NNP N
, , N
or CC N
DHA NNP N
incorporated VBN N
into IN N
a DT N
food NN N
matrix NN N
on IN N
the DT N
fatty JJ N
acid JJ N
composition NN N
of IN N
erythrocytes NNS N
and CC N
on IN N
biomarkers NNS N
of IN N
oxidant/antioxidant JJ N
status NN N
. . N

To TO N
this DT N
end NN N
, , N
a DT N
controlled VBN N
dietary NN N
study NN N
was VBD N
conducted VBN N
in IN N
74 CD N
healthy JJ N
men NNS N
and CC N
women NNS N
. . N

The DT N
participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
interventions NNS N
in IN N
which WDT N
margarines NNS N
fortified VBD N
with IN N
either DT N
10 CD N
weight NN N
percent NN N
ALA NNP N
, , N
EPA NNP N
, , N
or CC N
DHA NNP N
ethyl VBP N
esters NNS N
replaced VBD N
their PRP$ N
normal JJ N
spread NN N
for IN N
6 CD N
wk NN N
. . N

The DT N
total JJ N
intakes NNS N
of IN N
ALA NNP N
, , N
EPA NNP N
, , N
and CC N
DHA NNP N
were VBD N
4.4 CD N
, , N
2.2 CD N
, , N
and CC N
2.3 CD N
g/d NN N
, , N
respectively RB N
. . N

Consuming VBG N
EPA NNP N
increased VBD N
the DT N
erythrocyte JJ N
proportion NN N
of IN N
EPA NNP N
( ( N
394 CD N
% NN N
) ) N
and CC N
the DT N
omega-3 JJ N
index NN N
( ( N
sum NN N
of IN N
EPA NNP N
and CC N
DHA NNP N
, , N
38 CD N
% NN N
) ) N
. . N

Consumption NN N
of IN N
DHA NNP N
increased VBD N
erythrocyte JJ N
DHA NNP N
( ( N
91 CD N
% NN N
) ) N
, , N
the DT N
omega-3 JJ N
index NN N
( ( N
98 CD N
% NN N
) ) N
, , N
and CC N
EPA NNP N
( ( N
137 CD N
% NN N
) ) N
. . N

The DT N
omega-3 JJ N
index NN N
increased VBD N
to TO N
a DT N
significantly RB N
greater JJR N
extent NN N
in IN N
the DT N
DHA NNP N
group NN N
than IN N
in IN N
the DT N
EPA NNP N
group NN N
. . N

ALA NNP N
did VBD N
not RB N
increase VB N
erythrocyte NN N
EPA NNP N
or CC N
the DT N
omega-3 JJ N
index NN N
. . N

We PRP N
found VBD N
no DT N
change NN N
in IN N
plasma NN N
uric JJ N
acid NN N
or CC N
antioxidant JJ N
capacity NN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
. . N

Plasma NNP N
malondialdehyde NN N
( ( N
MDA NNP N
) ) N
increased VBD N
with IN N
the DT N
EPA NNP N
and CC N
DHA NNP N
interventions NNS N
. . N

All DT N
3 CD N
interventions NNS N
decreased VBD N
erythrocyte JJ N
linoleic NN N
acid NN N
hydroperoxides NNS N
but CC N
did VBD N
not RB N
affect VB N
their PRP$ N
MDA NNP N
concentrations NNS N
. . N

In IN N
conclusion NN N
, , N
the DT N
intake NN N
of IN N
both DT N
isolated JJ N
EPA NNP N
and CC N
DHA NNP N
incorporated VBD N
into IN N
margarine NN N
resulted VBN N
in IN N
an DT N
enhanced JJ N
incorporation NN N
of IN N
EPA NNP N
and CC N
DHA NNP N
into IN N
erythrocytes NNS N
. . N

Our PRP$ N
findings NNS N
indicate VBP N
that IN N
DHA NNP N
is VBZ N
quantitatively RB N
superior JJ N
to TO N
EPA NNP N
in IN N
view NN N
of IN N
the DT N
EPA+DHA NNP N
tissue NN N
incorporation NN N
and CC N
also RB N
that IN N
4 CD N
g/d NN N
ALA NNP N
is VBZ N
not RB N
sufficient JJ N
to TO N
increase VB N
the DT N
omega-3 JJ N
index NN N
over IN N
a DT N
6-wk JJ N
period NN N
. . N

-DOCSTART- -24101016- O O

Immunological JJ N
changes NNS N
after IN N
minimally RB N
invasive JJ N
or CC N
conventional JJ N
esophageal JJ N
resection NN N
for IN N
cancer NN N
: : N
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND VB N
This DT N
study NN N
was VBD N
performed VBN N
as IN N
a DT N
substudy NN N
analysis NN N
of IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
conventional JJ N
open JJ N
esophagectomy NN N
[ NNP N
open JJ N
surgical JJ N
technique NN N
( ( N
OE NNP N
) ) N
] NN N
by IN N
thoracotomy NN N
and CC N
laparotomy NN N
with IN N
minimally RB N
invasive JJ N
esophagectomy NN N
[ NNP N
minimally RB N
invasive JJ N
procedure NN N
( ( N
MIE NNP N
) ) N
] NN N
by IN N
thoracoscopy NN N
and CC N
laparoscopy NN N
. . N

This DT N
additional JJ N
analysis NN N
focuses VBZ N
on IN N
the DT N
immunological JJ N
changes NNS N
and CC N
surgical JJ N
stress NN N
response NN N
in IN N
these DT N
two CD N
randomized VBD N
groups NNS N
of IN N
a DT N
single JJ N
center NN N
. . N

METHODS NNP N
Patients NNPS N
with IN N
a DT N
resectable JJ N
esophageal NN N
cancer NN N
were VBD N
randomized VBN N
to TO N
OE NNP N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
or CC N
MIE NNP N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
. . N

All DT N
patients NNS N
received VBD N
neoadjuvant JJ N
chemoradiotherapy NN N
. . N

The DT N
immunological JJ N
response NN N
was VBD N
measured VBN N
by IN N
means NNS N
of IN N
leukocyte NN N
counts NNS N
, , N
HLA-DR NNP N
expression NN N
on IN N
monocytes NNS N
, , N
the DT N
acute-phase JJ N
response NN N
by IN N
means NNS N
of IN N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
interleukin-6 JJ N
( ( N
IL-6 NNP N
) ) N
, , N
and CC N
interleukin-8 JJ N
( ( N
IL-8 NNP N
) ) N
, , N
and CC N
the DT N
stress NN N
response NN N
was VBD N
measured VBN N
by IN N
cortisol NN N
, , N
growth NN N
hormone NN N
, , N
and CC N
prolactin NN N
. . N

All DT N
parameters NNS N
were VBD N
determined VBN N
at IN N
baseline NN N
( ( N
preoperatively RB N
) ) N
and CC N
24 CD N
, , N
72 CD N
, , N
96 CD N
, , N
and CC N
168 CD N
h NN N
postoperatively RB N
. . N

RESULTS NNP N
Significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
seen VBN N
in IN N
favor NN N
of IN N
the DT N
MIE NNP N
group NN N
with IN N
regard NN N
to TO N
leukocyte VB N
counts NNS N
, , N
IL-8 NNP N
, , N
and CC N
prolactin NN N
at IN N
168 CD N
h NN N
( ( N
1 CD N
week NN N
) ) N
postoperatively RB N
. . N

For IN N
HLA-DR NNP N
expression NN N
, , N
IL-6 NNP N
, , N
and CC N
CRP NNP N
levels NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
, , N
although IN N
there EX N
was VBD N
a DT N
clear JJ N
rise NN N
in IN N
levels NNS N
upon IN N
operation NN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
In IN N
this DT N
substudy NN N
of IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
minimally RB N
invasive JJ N
and CC N
conventional JJ N
open JJ N
esophagectomies NNS N
for IN N
cancer NN N
, , N
significantly RB N
better RBR N
preserved VBN N
leukocyte JJ N
counts NNS N
and CC N
IL-8 JJ N
levels NNS N
were VBD N
observed VBN N
in IN N
the DT N
MIE NNP N
group NN N
compared VBN N
to TO N
the DT N
open JJ N
group NN N
. . N

Both DT N
findings NNS N
can MD N
be VB N
related VBN N
to TO N
fewer JJR N
respiratory NN N
infections NNS N
found VBD N
postoperatively RB N
in IN N
the DT N
MIE NNP N
group NN N
. . N

Moreover RB N
, , N
significant JJ N
differences NNS N
in IN N
the DT N
prolactin NN N
levels NNS N
at IN N
168 CD N
h NN N
after IN N
surgery NN N
imply NN N
that IN N
the DT N
stress NN N
response NN N
is VBZ N
better RBR N
preserved VBN N
in IN N
the DT N
MIE NNP N
group NN N
. . N

These DT N
findings NNS N
indicate VBP N
that IN N
less JJR N
surgical JJ N
trauma NN N
could MD N
lead VB N
to TO N
better JJR N
preserved VBN N
acute-phase NN N
and CC N
stress NN N
responses NNS N
and CC N
fewer JJR N
clinical JJ N
manifestations NNS N
of IN N
respiratory JJ N
infections NNS N
. . N

-DOCSTART- -8986845- O O

Pedantic JJ N
speaking NN N
style NN N
differentiates VBZ N
Asperger NNP N
syndrome NN N
from IN N
high-functioning JJ N
autism NN N
. . N

Asperger NNP N
syndrome NN N
( ( N
AS IN N
) ) N
is VBZ N
a DT N
pervasive JJ N
developmental NN N
disorder NN N
recently RB N
introduced VBD N
as IN N
a DT N
new JJ N
diagnostic JJ N
category NN N
in IN N
the DT N
ICD-10 NNP N
and CC N
the DT N
DSM-IV NNP N
. . N

Along IN N
with IN N
motor NN N
clumsiness NN N
, , N
pedantic JJ N
speech NN N
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
clinical JJ N
feature NN N
of IN N
AS NNP N
. . N

However RB N
, , N
few JJ N
attempts NNS N
have VBP N
been VBN N
made VBN N
to TO N
define VB N
and CC N
measure VB N
this DT N
symptom NN N
. . N

We PRP N
studied VBD N
17 CD N
patients NNS N
with IN N
AS NNP N
( ( N
ICD-10 NNP N
; : N
14 CD N
male NN N
, , N
3 CD N
female NN N
; : N
mean JJ N
age NN N
16.4 CD N
years NNS N
, , N
mean JJ N
full-scale JJ N
IQ NNP N
97 CD N
) ) N
and CC N
compared VBN N
them PRP N
with IN N
a DT N
control NN N
group NN N
of IN N
13 CD N
patients NNS N
with IN N
normal-intelligence JJ N
autism NN N
or CC N
high-functioning JJ N
autism NN N
( ( N
HFA NNP N
) ) N
( ( N
ICD-10/DSM-III-R NNP N
; : N
12 CD N
male NN N
, , N
1 CD N
female NN N
; : N
mean JJ N
age NN N
15.5 CD N
years NNS N
, , N
mean JJ N
full-scale JJ N
IQ NNP N
81.2 CD N
) ) N
. . N

An DT N
operational JJ N
definition NN N
of IN N
pedantic JJ N
speech NN N
was VBD N
formulated VBN N
and CC N
a DT N
rating NN N
scale NN N
devised VBD N
. . N

13 CD N
( ( N
76 CD N
% NN N
) ) N
of IN N
the DT N
AS NNP N
patients NNS N
were VBD N
rated VBN N
as IN N
pedantic JJ N
compared VBN N
to TO N
4 CD N
( ( N
31 CD N
% NN N
) ) N
of IN N
the DT N
HFA NNP N
group NN N
( ( N
chi JJ N
2 CD N
= JJ N
6.3 CD N
; : N
p NN N
= NNP N
.01 NNP N
) ) N
. . N

Results VB N
suggest JJS N
that IN N
pedantic JJ N
speech NN N
is VBZ N
common JJ N
in IN N
AS NNP N
and CC N
may MD N
help VB N
differentiate VB N
AS IN N
from IN N
high-functioning JJ N
autism NN N
. . N

-DOCSTART- -12067044- O O

The DT N
effects NNS N
of IN N
physical JJ N
and CC N
emotional JJ N
status NN N
on IN N
adherence NN N
to TO N
a DT N
low-fat JJ N
dietary JJ N
pattern NN N
in IN N
the DT N
Women NNP N
's POS N
Health NNP N
Initiative NNP N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
whether IN N
the DT N
effects NNS N
of IN N
physical JJ N
and CC N
emotional JJ N
status NN N
on IN N
adherance NN N
to TO N
a DT N
low-fat JJ N
( ( N
20 CD N
% NN N
energy NN N
) ) N
dietary JJ N
pattern NN N
are VBP N
mediated VBN N
by IN N
participation NN N
in IN N
an DT N
intervention NN N
program NN N
( ( N
attending VBG N
sessions NNS N
and CC N
self-monitoring NN N
) ) N
. . N

DESIGN VB N
The DT N
Baron NNP N
and CC N
Kenny NNP N
mediator NN N
model NN N
, , N
a DT N
series NN N
of IN N
4 CD N
regression NN N
analyses NNS N
, , N
was VBD N
used VBN N
to TO N
evaluate VB N
whether IN N
: : N
a DT N
) ) N
physical JJ N
and CC N
emotional JJ N
status NN N
predicted VBD N
program NN N
participation NN N
, , N
b NN N
) ) N
program NN N
participation NN N
predicted VBD N
dietary JJ N
adherence NN N
, , N
c NN N
) ) N
physical JJ N
and CC N
emotional JJ N
status NN N
factors NNS N
predicted VBD N
dietary JJ N
adherence NN N
, , N
and CC N
, , N
ultimately RB N
d NN N
) ) N
the DT N
effects NNS N
of IN N
physical JJ N
and CC N
emotional JJ N
status NN N
on IN N
dietary JJ N
adherence NN N
were VBD N
mediated VBN N
by IN N
program NN N
participation NN N
. . N

SUBJECTS/SETTING NNP N
Data NNP N
from IN N
13,277 CD N
postmenopausal JJ N
women NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
low-fat JJ N
intervention NN N
arm NN N
of IN N
the DT N
Women NNP N
's POS N
Health NNP N
Initiative NNP N
Dietary NNP N
Modification NNP N
Trial NNP N
. . N

INTERVENTION NNP N
The DT N
nutrition NN N
goals NNS N
for IN N
women NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
low-fat JJ N
intervention NN N
were VBD N
to TO N
reduce VB N
total JJ N
fat JJ N
intake NN N
to TO N
20 CD N
% NN N
or CC N
less JJR N
of IN N
energy NN N
from IN N
fat JJ N
and CC N
to TO N
consume VB N
5 CD N
or CC N
more JJR N
fruit/vegetable JJ N
servings NNS N
daily RB N
and CC N
6 CD N
or CC N
more JJR N
grain JJ N
servings NNS N
daily RB N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Year NNP N
1 CD N
program NN N
participation NN N
( ( N
degree NN N
of IN N
attending VBG N
group NN N
sessions NNS N
and CC N
submitting VBG N
fat JJ N
scores NNS N
) ) N
and CC N
adherence NN N
to TO N
the DT N
low-fat JJ N
dietary JJ N
pattern NN N
( ( N
percent JJ N
energy NN N
from IN N
fat NN N
) ) N
as IN N
predicted VBN N
by IN N
baseline JJ N
physical JJ N
and CC N
emotional JJ N
status NN N
( ( N
eight CD N
SF-36 NNP N
Health NNP N
Survey NNP N
subscales VBZ N
) ) N
. . N

RESULTS NNP N
Participating VBG N
in IN N
the DT N
dietary JJ N
intervention NN N
program NN N
reduced VBN N
( ( N
mediated VBN N
) ) N
the DT N
negative JJ N
effect NN N
of IN N
poorer JJR N
mental JJ N
health NN N
on IN N
dietary JJ N
adherence NN N
by IN N
15 CD N
% NN N
. . N

Additional JJ N
findings NNS N
included VBD N
that IN N
a DT N
10 CD N
% NN N
increase NN N
in IN N
physical JJ N
functioning NN N
increased VBD N
session NN N
attendance NN N
by IN N
0.4 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
a DT N
10 CD N
% NN N
increase NN N
in IN N
mental JJ N
health NN N
predicted VBD N
a DT N
decrease NN N
in IN N
percent NN N
energy NN N
from IN N
fat NN N
of IN N
0.3 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Program NNP N
participation NN N
had VBD N
a DT N
marked JJ N
effect NN N
on IN N
dietary JJ N
adherence NN N
: : N
a DT N
10 CD N
% NN N
increase NN N
in IN N
session NN N
attendance NN N
predicted VBD N
a DT N
1.2 CD N
% NN N
decrease NN N
in IN N
percent NN N
energy NN N
from IN N
fat JJ N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

APPLICATIONS/CONCLUSIONS NNP N
Understanding NNP N
and CC N
using VBG N
instruments NNS N
to TO N
assess VB N
the DT N
physical JJ N
and CC N
emotional JJ N
status NN N
of IN N
a DT N
target NN N
population NN N
will MD N
help VB N
dietetic JJ N
professionals NNS N
promote VBP N
healthful JJ N
dietary JJ N
change NN N
and CC N
maintenance NN N
. . N

-DOCSTART- -8790079- O O

Warfarin NNP N
for IN N
atrial JJ N
fibrillation NN N
. . N

The DT N
patient NN N
's POS N
perspective NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
minimal JJ N
clinically RB N
important JJ N
difference NN N
( ( N
MCID NNP N
) ) N
of IN N
warfarin NN N
therapy NN N
for IN N
the DT N
treatment NN N
of IN N
nonvalvular JJ N
atrial JJ N
fibrillation NN N
from IN N
the DT N
perspective NN N
of IN N
patients NNS N
using VBG N
2 CD N
different JJ N
elicitation NN N
methods NNS N
. . N

DESIGN NNP N
All DT N
patients NNS N
completed VBD N
2 CD N
face-to-face JJ N
interviews NNS N
, , N
which WDT N
were VBD N
2 CD N
weeks NNS N
apart RB N
. . N

For IN N
each DT N
interview NN N
, , N
they PRP N
were VBD N
randomized VBN N
to TO N
receive VB N
1 CD N
of IN N
2 CD N
elicitation NN N
methods NNS N
: : N
ping-ponging NN N
or CC N
starting VBG N
at IN N
the DT N
known JJ N
efficacy NN N
. . N

SETTING CC N
The DT N
practices NNS N
of IN N
2 CD N
university-affiliated JJ N
family NN N
medicine NN N
centers NNS N
( ( N
8 CD N
physicians NNS N
each DT N
) ) N
, , N
14 CD N
community-based JJ N
family NN N
physicians NNS N
, , N
and CC N
2 CD N
cardiologists NNS N
. . N

PATIENTS VB N
Sixty-four JJ N
patients NNS N
with IN N
nonvalvular JJ N
atrial JJ N
fibrillation NN N
who WP N
were VBD N
initiated VBN N
with IN N
warfarin JJ N
therapy NN N
at IN N
least JJS N
3 CD N
months NNS N
before IN N
the DT N
study NN N
. . N

INTERVENTION NNP N
During IN N
each DT N
interview NN N
, , N
the DT N
patients NNS N
' POS N
MCIDs NNP N
were VBD N
determined VBN N
by IN N
using VBG N
( ( N
1 CD N
) ) N
a DT N
pictorial JJ N
flip NN N
chart NN N
to TO N
describe VB N
atrial JJ N
fibrillation NN N
; : N
the DT N
consequences NNS N
of IN N
a DT N
minor JJ N
stroke NN N
, , N
a DT N
major JJ N
stroke NN N
, , N
and CC N
a DT N
major JJ N
bleeding NN N
episode NN N
; : N
the DT N
chance NN N
of IN N
stroke NN N
if IN N
not RB N
taking VBG N
warfarin NN N
; : N
the DT N
chance NN N
of IN N
a DT N
major JJ N
bleeding NN N
episode NN N
if IN N
taking VBG N
warfarin NN N
; : N
examples NNS N
of IN N
the DT N
inconvenience NN N
, , N
minor JJ N
side NN N
effects NNS N
, , N
and CC N
costs NNS N
of IN N
warfarin JJ N
therapy NN N
; : N
and CC N
then RB N
( ( N
2 CD N
) ) N
1 CD N
of IN N
the DT N
2 CD N
elicitation NN N
methods NNS N
to TO N
determine VB N
their PRP$ N
MCIDs NNP N
( ( N
the DT N
smallest JJS N
reduction NN N
in IN N
stroke NN N
risk NN N
at IN N
which WDT N
the DT N
patients NNS N
were VBD N
willing JJ N
to TO N
take VB N
warfarin NN N
) ) N
. . N

Patients NNS N
' POS N
knowledge NN N
of IN N
their PRP$ N
stroke NN N
risk NN N
, , N
acceptability NN N
of IN N
the DT N
interview NN N
process NN N
, , N
and CC N
factors NNS N
determining VBG N
their PRP$ N
preferences NNS N
were VBD N
also RB N
assessed VBN N
. . N

MAIN NNP N
RESULTS NNP N
Given NNP N
a DT N
baseline NN N
risk NN N
of IN N
having VBG N
a DT N
stroke NN N
in IN N
the DT N
next JJ N
2 CD N
years NNS N
, , N
if IN N
not RB N
taking VBG N
warfarin NN N
, , N
of IN N
10 CD N
of IN N
100 CD N
, , N
the DT N
mean JJ N
MCID NNP N
was VBD N
2.01 CD N
of IN N
100 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.60-2.42 JJ N
) ) N
. . N

Fifty-two JJ N
percent NN N
of IN N
the DT N
patients NNS N
would MD N
take VB N
warfarin NN N
for IN N
an DT N
absolute JJ N
decrease NN N
in IN N
stroke NN N
risk NN N
of IN N
1 CD N
% NN N
over IN N
2 CD N
years NNS N
. . N

Before IN N
eliciting VBG N
their PRP$ N
MCIDs NNP N
, , N
patients NNS N
showed VBD N
poor JJ N
knowledge NN N
of IN N
their PRP$ N
stroke NN N
risk NN N
, , N
which WDT N
improved VBD N
afterward RB N
. . N

The DT N
interview NN N
process NN N
was VBD N
well RB N
accepted VBN N
by IN N
the DT N
patients NNS N
. . N

The DT N
MCID NNP N
using VBG N
the DT N
ping-ponging JJ N
elicitation NN N
method NN N
was VBD N
1.015 CD N
of IN N
100 CD N
smaller JJR N
compared VBN N
with IN N
use NN N
of IN N
the DT N
starting NN N
at IN N
the DT N
known JJ N
efficacy NN N
method NN N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

CONCLUSIONS NN N
We PRP N
were VBD N
able JJ N
to TO N
determine VB N
the DT N
MCID NNP N
of IN N
warfarin NN N
therapy NN N
for IN N
the DT N
prevention NN N
of IN N
stroke NN N
from IN N
the DT N
perspective NN N
of IN N
patients NNS N
with IN N
nonvalvular JJ N
atrial JJ N
fibrillation NN N
. . N

Their PRP$ N
MCIDs NNPS N
were VBD N
much RB N
smaller JJR N
than IN N
those DT N
that WDT N
have VBP N
been VBN N
implied VBN N
by IN N
some DT N
experts NNS N
and CC N
clinicians NNS N
. . N

The DT N
interview NN N
process NN N
, , N
using VBG N
the DT N
flip JJ N
chart NN N
approach NN N
, , N
appeared VBD N
to TO N
improve VB N
the DT N
patients NNS N
' POS N
knowledge NN N
of IN N
their PRP$ N
disease NN N
and CC N
its PRP$ N
consequences NNS N
and CC N
treatment NN N
. . N

The DT N
method NN N
used VBN N
to TO N
elicit VB N
the DT N
patients NNS N
' POS N
MCIDs NNP N
can MD N
have VB N
a DT N
clinically RB N
important JJ N
effect NN N
on IN N
patient NN N
responses NNS N
. . N

The DT N
method NN N
used VBN N
in IN N
our PRP$ N
study NN N
can MD N
be VB N
generalized VBN N
to TO N
other JJ N
conditions NNS N
and CC N
, , N
thus RB N
, , N
could MD N
be VB N
helpful JJ N
in IN N
3 CD N
ways NNS N
: : N
( ( N
1 CD N
) ) N
from IN N
a DT N
clinical JJ N
decision-making NN N
perspective NN N
, , N
it PRP N
could MD N
facilitate VB N
patient-physician JJ N
communication NN N
; : N
( ( N
2 CD N
) ) N
it PRP N
could MD N
clarify VB N
the DT N
patient NN N
perspective NN N
when WRB N
interpreting VBG N
the DT N
results NNS N
of IN N
previously RB N
completed VBN N
trials NNS N
; : N
and CC N
( ( N
3 CD N
) ) N
it PRP N
could MD N
be VB N
used VBN N
to TO N
derive VB N
more RBR N
clinically RB N
relevant JJ N
sample NN N
sizes NNS N
for IN N
randomized JJ N
treatment NN N
trials NNS N
. . N

-DOCSTART- -16181530- O O

[ JJ N
Effect NNP N
of IN N
Yufeining VBG N
on IN N
induced JJ N
sputum JJ N
interleukin-8 NN N
in IN N
patients NNS N
with IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
at IN N
the DT N
stable JJ N
phase NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
Yufeining NNP N
, , N
a DT N
traditional JJ N
Chinese JJ N
medicine NN N
, , N
on IN N
induced JJ N
sputum NN N
interleukin-8 JJ N
( ( N
IL-8 NNP N
) ) N
in IN N
patients NNS N
with IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
at IN N
the DT N
stable JJ N
phase NN N
. . N

METHODS NNP N
Thirty-six JJ N
patients NNS N
with IN N
COPD NNP N
were VBD N
divided VBN N
into IN N
trial NN N
group NN N
( ( N
18 CD N
cases NNS N
) ) N
and CC N
control NN N
group NN N
( ( N
18 CD N
cases NNS N
) ) N
randomly RB N
. . N

The DT N
trial NN N
group NN N
was VBD N
treated VBN N
with IN N
Yufeining VBG N
pills NNS N
taken VBN N
orally RB N
for IN N
half PDT N
a DT N
year NN N
; : N
the DT N
control NN N
group NN N
was VBD N
not RB N
given VBN N
any DT N
medicine NN N
. . N

Routine NNP N
lung NN N
function NN N
was VBD N
recorded VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

Total JJ N
cell NN N
count NN N
( ( N
TCC NNP N
) ) N
, , N
differential JJ N
cell NN N
counts NNS N
( ( N
DCCs NNP N
) ) N
and CC N
IL-8 NNP N
in IN N
induced JJ N
sputum NN N
were VBD N
determined VBN N
at IN N
the DT N
baseline NN N
and CC N
6 CD N
months NNS N
later RB N
. . N

RESULTS VB N
The DT N
indices NNS N
of IN N
lung NN N
function NN N
improved VBD N
significantly RB N
after IN N
6 CD N
months NNS N
' POS N
treatment NN N
in IN N
trial NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
; : N
TCC NNP N
and CC N
absolute JJ N
neutrophil NN N
count NN N
decreased VBD N
significantly RB N
compared VBN N
with IN N
baseline NN N
in IN N
the DT N
trial NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
; : N
Sputum NNP N
IL-8 NNP N
concentration NN N
dropped VBD N
significantly RB N
after IN N
6 CD N
months NNS N
' POS N
treatment NN N
, , N
from IN N
a DT N
mean NN N
of IN N
5.216 CD N
+/- JJ N
2.914 CD N
microg/L NN N
to TO N
4.222 CD N
+/- JJ N
2.140 CD N
microg/L NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
insignificant JJ N
changes NNS N
in IN N
the DT N
parameters NNS N
in IN N
the DT N
control NN N
group NN N
between IN N
baseline NN N
and CC N
6 CD N
months NNS N
later RB N
. . N

CONCLUSION NNP N
Yufeining NNP N
could MD N
improve VB N
lung NN N
function NN N
, , N
decrease NN N
sputum NN N
TCC NNP N
, , N
absolute JJ N
neutrophil NN N
count NN N
and CC N
IL-8 NNP N
concentration NN N
, , N
and CC N
relieve VB N
airway NN N
inflammation NN N
in IN N
patients NNS N
with IN N
COPD NNP N
in IN N
the DT N
stable JJ N
phase NN N
. . N

-DOCSTART- -16804044- O O

Psychological JJ N
well-being NN N
correlates NNS N
with IN N
free JJ N
thyroxine NN N
but CC N
not RB N
free JJ N
3,5,3'-triiodothyronine JJ N
levels NNS N
in IN N
patients NNS N
on IN N
thyroid JJ N
hormone NN N
replacement NN N
. . N

CONTEXT NNP N
AND NNP N
OBJECTIVE NNP N
An DT N
association NN N
between IN N
mood NN N
disorders NNS N
and CC N
overt JJ N
thyroid JJ N
dysfunction NN N
is VBZ N
well RB N
established VBN N
, , N
but CC N
there EX N
are VBP N
few JJ N
data NNS N
on IN N
the DT N
potential NN N
for IN N
thyroid JJ N
hormone NN N
levels NNS N
closer RBR N
to TO N
the DT N
reference NN N
range NN N
to TO N
correlate VB N
with IN N
psychological JJ N
well-being NN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
We PRP N
analyzed VBD N
the DT N
relationship NN N
between IN N
psychological JJ N
well-being NN N
and CC N
free JJ N
T NNP N
( ( N
4 CD N
) ) N
( ( N
fT4 NN N
) ) N
, , N
free JJ N
T NNP N
( ( N
3 CD N
) ) N
( ( N
fT3 NN N
) ) N
, , N
TSH NNP N
, , N
and CC N
total JJ N
rT NN N
( ( N
3 CD N
) ) N
in IN N
697 CD N
patients NNS N
on IN N
thyroid JJ N
hormone NN N
replacement NN N
therapy NN N
at IN N
entry NN N
to TO N
a DT N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
combined JJ N
T NNP N
( ( N
4 CD N
) ) N
and CC N
T NNP N
( ( N
3 CD N
) ) N
replacement NN N
therapy NN N
. . N

All DT N
patients NNS N
were VBD N
on IN N
100 CD N
mug NN N
or CC N
more JJR N
T NNP N
( ( N
4 CD N
) ) N
. . N

INTERVENTIONS NNP N
AND CC N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Psychological NNP N
well-being NN N
was VBD N
assessed VBN N
with IN N
General NNP N
Health NNP N
Questionnaire-12 NNP N
( ( N
GHQ-12 NNP N
) ) N
, , N
Thyroid NNP N
Symptom NNP N
Questionnaire NNP N
, , N
and CC N
Hospital NNP N
Anxiety NNP N
and CC N
Depression NNP N
Scale NNP N
. . N

RESULTS NNP N
fT NN N
( ( N
4 CD N
) ) N
and CC N
TSH NNP N
showed VBD N
a DT N
strong JJ N
correlation NN N
with IN N
GHQ-12 NNP N
scores NNS N
( ( N
fT4 SYM N
- : N
b NN N
: : N
-0.16 NN N
, , N
P NNP N
= NNP N
0.005 CD N
; : N
TSH NNP N
- : N
b NN N
: : N
0.663 CD N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

No UH N
correlations NNS N
were VBD N
seen VBN N
between IN N
the DT N
GHQ NNP N
scores NNS N
and CC N
fT3 NN N
( ( N
b NN N
: : N
0.318 CD N
, , N
P NNP N
= NNP N
0.275 CD N
) ) N
, , N
rT NN N
( ( N
3 CD N
) ) N
( ( N
b NN N
: : N
0.095 CD N
, , N
P NNP N
= NNP N
0.95 CD N
) ) N
, , N
rT NN N
( ( N
3 CD N
) ) N
to TO N
fT4 VB N
ratio NN N
( ( N
b NN N
: : N
71.83 CD N
, , N
P NNP N
= NNP N
0.09 CD N
) ) N
or CC N
fT3 VBN N
to TO N
rT VB N
( ( N
3 CD N
) ) N
ratio NN N
( ( N
b NN N
: : N
0.05 CD N
, , N
P NNP N
= NNP N
0.32 CD N
) ) N
. . N

The DT N
correlations NNS N
remained VBD N
when WRB N
the DT N
data NN N
set NN N
was VBD N
limited VBN N
to TO N
patients NNS N
with IN N
TSH NNP N
in IN N
the DT N
range NN N
0.3-4.0 JJ N
mIU/liter NN N
. . N

Similar JJ N
correlations NNS N
were VBD N
seen VBN N
with IN N
the DT N
Thyroid NNP N
Symptom NNP N
Questionnaire NNP N
, , N
although IN N
not RB N
with IN N
the DT N
Hospital NNP N
Anxiety NNP N
and CC N
Depression NNP N
Scale NNP N
scores NNS N
. . N

CONCLUSIONS NNP N
Differences NNPS N
in IN N
fT4 NN N
and CC N
TSH NNP N
concentration NN N
, , N
even RB N
within IN N
the DT N
reference NN N
range NN N
, , N
may MD N
be VB N
a DT N
determinant NN N
of IN N
psychological JJ N
well-being NN N
in IN N
treated JJ N
hypothyroid NN N
patients NNS N
although IN N
not RB N
necessarily RB N
with IN N
symptoms NNS N
typical JJ N
of IN N
anxiety NN N
or CC N
depression NN N
. . N

-DOCSTART- -6734073- O O

Short-term JJ N
studies NNS N
on IN N
the DT N
use NN N
of IN N
glycerol NN N
as IN N
an DT N
osmotic JJ N
agent NN N
in IN N
continuous JJ N
ambulatory JJ N
peritoneal JJ N
dialysis NN N
( ( N
CAPD NNP N
) ) N
. . N

The DT N
use NN N
of IN N
glycerol NN N
as IN N
an DT N
osmotic JJ N
agent NN N
in IN N
two CD N
different JJ N
concentrations NNS N
( ( N
92 CD N
mmol/l NN N
and CC N
272 CD N
mmol/l NN N
) ) N
in IN N
peritoneal JJ N
dialysis NN N
fluid NN N
was VBD N
investigated VBN N
over IN N
3 CD N
days NNS N
in IN N
six CD N
patients NNS N
on IN N
continuous JJ N
ambulatory JJ N
peritoneal JJ N
dialysis NN N
and CC N
compared VBN N
with IN N
two CD N
concentrations NNS N
of IN N
glucose NN N
( ( N
76 CD N
mmol/l NN N
and CC N
215 CD N
mmol/l NN N
) ) N
in IN N
the DT N
same JJ N
patients NNS N
. . N

The DT N
calorific JJ N
value NN N
of IN N
the DT N
absorbed JJ N
osmotic JJ N
agent NN N
was VBD N
lower JJR N
, , N
by IN N
19 CD N
% NN N
with IN N
isotonic JJ N
and CC N
22 CD N
% NN N
with IN N
hypertonic JJ N
solutions NNS N
, , N
when WRB N
glycerol NN N
was VBD N
used VBN N
in IN N
place NN N
of IN N
glucose NN N
. . N

However RB N
, , N
glycerol NN N
provided VBD N
significantly RB N
lower JJR N
total JJ N
ultrafiltration NN N
than IN N
glucose NN N
at IN N
each DT N
concentration NN N
, , N
despite IN N
a DT N
higher JJR N
initial JJ N
osmotic JJ N
pressure NN N
of IN N
the DT N
glycerol-based JJ N
solutions NNS N
. . N

Thus RB N
, , N
the DT N
higher JJR N
concentration NN N
of IN N
glycerol NN N
required VBN N
to TO N
provide VB N
equal JJ N
ultrafiltration NN N
may MD N
offset VB N
any DT N
calorific JJ N
advantage NN N
. . N

Equilibration NN N
of IN N
creatinine NN N
and CC N
urea NN N
was VBD N
slower JJR N
and CC N
creatinine JJ N
clearance NN N
lower RBR N
with IN N
glycerol NN N
. . N

Solutions NNS N
containing VBG N
glycerol NN N
were VBD N
initially RB N
less JJR N
acid JJ N
( ( N
pH JJ N
6.5 CD N
) ) N
than IN N
those DT N
containing VBG N
glucose NN N
( ( N
pH JJ N
5.1 CD N
) ) N
. . N

Blood NNP N
glycerol NN N
levels NNS N
, , N
which WDT N
were VBD N
in IN N
the DT N
physiological JJ N
range NN N
with IN N
glucose NN N
as IN N
the DT N
osmotic JJ N
agent NN N
, , N
reached VBD N
a DT N
peak JJ N
80-fold JJ N
greater JJR N
at IN N
4.3 CD N
+/- JJ N
0.8 CD N
mmol/l NN N
during IN N
dialysis NN N
with IN N
fluid NN N
containing VBG N
glycerol NN N
at IN N
272 CD N
mmol/l NN N
and CC N
eightfold VB N
higher JJR N
at IN N
0.42 CD N
+/- JJ N
0.09 CD N
mmol/l NN N
with IN N
glycerol NN N
at IN N
92 CD N
mmol/l NN N
. . N

There EX N
was VBD N
no DT N
evidence NN N
of IN N
haemolysis NN N
or CC N
other JJ N
toxic JJ N
effect NN N
despite IN N
these DT N
levels NNS N
. . N

The DT N
rise NN N
in IN N
blood NN N
glucose NN N
and CC N
insulin NN N
noted VBD N
during IN N
the DT N
use NN N
of IN N
glucose-based JJ N
solutions NNS N
was VBD N
not RB N
found VBN N
with IN N
glycerol NN N
. . N

Circulating NNP N
levels NNS N
of IN N
lactate NN N
, , N
pyruvate NN N
, , N
alanine NN N
, , N
non-esterified JJ N
fatty JJ N
acids NNS N
and CC N
the DT N
ketone NN N
bodies NNS N
were VBD N
similar JJ N
with IN N
the DT N
two CD N
agents NNS N
. . N

Although IN N
these DT N
short-term JJ N
studies NNS N
have VBP N
shown VBN N
no DT N
conclusive JJ N
advantage NN N
of IN N
glycerol NN N
over IN N
glucose JJ N
, , N
long-term JJ N
effects NNS N
of IN N
glycerol NN N
, , N
particularly RB N
on IN N
circulating VBG N
lipid JJ N
levels NNS N
, , N
will MD N
determine VB N
its PRP$ N
future JJ N
role NN N
as IN N
an DT N
osmotic JJ N
agent NN N
in IN N
continuous JJ N
ambulatory JJ N
peritoneal JJ N
dialysis NN N
. . N

-DOCSTART- -23511149- O O

Perioperative JJ N
myocardial JJ N
infarctions NNS N
are VBP N
common JJ N
and CC N
often RB N
unrecognized JJ N
in IN N
patients NNS N
undergoing VBG N
hip JJ N
fracture NN N
surgery NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
cohort NN N
study NN N
was VBD N
to TO N
assess VB N
the DT N
incidence NN N
and CC N
characteristics NNS N
of IN N
acute JJ N
myocardial JJ N
infarction NN N
in IN N
patients NNS N
undergoing JJ N
surgery NN N
for IN N
acute JJ N
hip NN N
fracture NN N
. . N

METHODS NNP N
A NNP N
consecutive JJ N
cohort NN N
of IN N
patients NNS N
( ( N
n JJ N
= NN N
200 CD N
, , N
68 CD N
men NNS N
) ) N
referred VBD N
to TO N
acute VB N
surgical JJ N
correction NN N
of IN N
hip NN N
fracture NN N
was VBD N
studied VBN N
. . N

Troponin NNP N
T NNP N
( ( N
TnT NNP N
) ) N
measurements NNS N
and CC N
electrocardiographic JJ N
( ( N
ECG NNP N
) ) N
recordings NNS N
were VBD N
performed VBN N
at IN N
admission NN N
, , N
before IN N
operation NN N
, , N
and CC N
on IN N
the DT N
first JJ N
and CC N
2nd CD N
postoperative JJ N
days NNS N
, , N
which WDT N
were VBD N
used VBN N
for IN N
diagnosis NN N
. . N

RESULTS VB N
The DT N
age NN N
of IN N
the DT N
patients NNS N
ranged VBD N
from IN N
32 CD N
to TO N
98 CD N
years NNS N
( ( N
mean NN N
, , N
80.8 CD N
years NNS N
) ) N
, , N
and CC N
65 CD N
patients NNS N
had VBD N
a DT N
history NN N
of IN N
coronary JJ N
artery NN N
disease NN N
. . N

A DT N
significant JJ N
rise NN N
in IN N
TnT NNP N
as IN N
a DT N
sign NN N
of IN N
myocardial JJ N
infarction NN N
was VBD N
observed VBN N
in IN N
71 CD N
patients NNS N
( ( N
35.5 CD N
% NN N
) ) N
, , N
and CC N
25 CD N
of IN N
them PRP N
had VBD N
a DT N
TnT NNP N
elevation NN N
exceeding VBG N
five CD N
times NNS N
the DT N
upper JJ N
normal JJ N
limit NN N
. . N

TnT NNP N
elevation NN N
was VBD N
observed VBN N
in IN N
36 CD N
patients NNS N
( ( N
51 CD N
% NN N
) ) N
already RB N
before RB N
surgery NN N
. . N

Seven CD N
patients NNS N
( ( N
10 CD N
% NN N
) ) N
had VBD N
ST NNP N
elevation NN N
myocardial JJ N
infarction NN N
, , N
23 CD N
patients NNS N
( ( N
32 CD N
% NN N
) ) N
had VBD N
new JJ N
ST NNP N
depressions NNS N
, , N
and CC N
21 CD N
patients NNS N
( ( N
30 CD N
% NN N
) ) N
had VBD N
no DT N
new JJ N
ST NNP N
segment NN N
changes NNS N
in IN N
the DT N
serial JJ N
electrocardiographic JJ N
recordings NNS N
. . N

In IN N
40 CD N
patients NNS N
( ( N
56 CD N
% NN N
) ) N
, , N
the DT N
perioperative JJ N
myocardial JJ N
infarction NN N
was VBD N
the DT N
first JJ N
manifestation NN N
of IN N
coronary JJ N
artery NN N
disease NN N
. . N

Multivariate NNP N
logistic JJ N
regression NN N
revealed VBD N
that IN N
old JJ N
age NN N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
, , N
1.06 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.02-1.10 JJ N
; : N
p VB N
= $ N
0.002 CD N
) ) N
, , N
earlier JJR N
revascularization NN N
( ( N
OR NNP N
, , N
3.29 CD N
; : N
95 CD N
% NN N
CI NNP N
1.12-9.73 CD N
; : N
p CC N
= VB N
0.03 CD N
) ) N
, , N
and CC N
heart NN N
failure NN N
( ( N
OR NNP N
, , N
2.42 CD N
; : N
95 CD N
% NN N
CI NNP N
1.04-5.61 CD N
; : N
p CC N
= VB N
0.04 CD N
) ) N
were VBD N
independent JJ N
predictors NNS N
of IN N
TnT NNP N
elevation NN N
. . N

Majority NNP N
of IN N
myocardial JJ N
infarctions NNS N
were VBD N
asymptomatic JJ N
or CC N
unrecognized JJ N
. . N

Evidence-based JJ N
medications NNS N
of IN N
myocardial JJ N
infarction NN N
were VBD N
seldom RB N
started VBN N
and CC N
cardiologist NN N
was VBD N
consulted VBN N
in IN N
12 CD N
patients NNS N
( ( N
16.9 CD N
% NN N
) ) N
. . N

CONCLUSION JJ N
Patients NNS N
with IN N
hip JJ N
fracture NN N
often RB N
develop VBZ N
asymptomatic JJ N
and CC N
clinically RB N
unrecognized JJ N
perioperative JJ N
myocardial JJ N
infarctions NNS N
. . N

Earlier JJR N
diagnosis NN N
and CC N
appropriate JJ N
treatment NN N
of IN N
cardiac JJ N
infarction NN N
may MD N
improve VB N
survival NN N
of IN N
hip NN N
fracture NN N
patients NNS N
. . N

LEVEL NNP N
OF IN N
EVIDENCE NNP N
Epidemiologic NNP N
study NN N
, , N
level NN N
III NNP N
. . N

-DOCSTART- -9855086- O O

Optimization NN N
of IN N
acid JJ N
suppression NN N
for IN N
patients NNS N
with IN N
peptic JJ N
ulcer NN N
bleeding NN N
: : N
an DT N
intragastric JJ N
pH-metry NN N
study NN N
with IN N
omeprazole NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
whether IN N
an DT N
intravenous JJ N
infusion NN N
dose NN N
of IN N
omeprazole NN N
( ( N
80 CD N
mg NN N
+ VBD N
8 CD N
mg/h NN N
) ) N
during IN N
24 CD N
h NNS N
can MD N
be VB N
subsequently RB N
reduced VBN N
with IN N
maintained JJ N
effect NN N
. . N

Second NNP N
, , N
to TO N
study VB N
the DT N
effect NN N
of IN N
oral JJ N
omeprazole JJ N
20 CD N
mg NN N
given VBN N
once RB N
or CC N
twice RB N
daily RB N
up IN N
to TO N
day NN N
10 CD N
, , N
after IN N
cessation NN N
of IN N
a DT N
3-day JJ N
intravenous JJ N
infusion NN N
( ( N
80 CD N
mg NN N
+ VBD N
8 CD N
mg/h NN N
) ) N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
partly RB N
blinded VBD N
study NN N
. . N

METHODS NNP N
Twelve NNP N
Helicobacter NNP N
pylori NN N
( ( N
+ NNP N
) ) N
patients NNS N
and CC N
12 CD N
H. NNP N
pylori NN N
( ( N
- : N
) ) N
subjects NNS N
were VBD N
included VBN N
. . N

In IN N
part NN N
I PRP N
the DT N
patients NNS N
received VBD N
omeprazole JJ N
, , N
80 CD N
mg NN N
+ VBD N
8 CD N
mg/h NN N
, , N
during IN N
24 CD N
h NN N
followed VBN N
by IN N
8 CD N
, , N
4 CD N
or CC N
2 CD N
mg/h NN N
. . N

In IN N
part NN N
II NNP N
the DT N
subjects NNS N
received VBD N
80 CD N
mg NNS N
+ VBD N
8 CD N
mg/h NN N
during IN N
3 CD N
days NNS N
followed VBN N
by IN N
20 CD N
mg NNS N
omeprazole JJ N
orally RB N
, , N
once RB N
or CC N
twice JJ N
daily JJ N
until IN N
day NN N
10 CD N
. . N

Intragastric NNP N
pH NN N
was VBD N
measured VBN N
. . N

RESULTS NNP N
All NNP N
H. NNP N
pylori FW N
( ( N
+ NN N
) ) N
patients NNS N
showed VBD N
a DT N
rapid JJ N
increase NN N
of IN N
intragastric JJ N
pH NN N
with IN N
a DT N
mean JJ N
intragastric JJ N
pH NN N
of IN N
6.7 CD N
during IN N
the DT N
second JJ N
half NN N
of IN N
the DT N
first JJ N
day NN N
. . N

After IN N
the DT N
subsequent JJ N
dose NN N
reduction NN N
, , N
the DT N
mean JJ N
pH NN N
decreased VBD N
to TO N
6.1-6.2 JJ N
. . N

Patients NNPS N
continuing VBG N
on IN N
8 CD N
mg/h NN N
showed VBD N
the DT N
best JJS N
results NNS N
. . N

Likewise NNP N
, , N
all DT N
H. NNP N
pylori NN N
( ( N
- : N
) ) N
subjects VBZ N
showed VBD N
a DT N
rapid JJ N
and CC N
sustained JJ N
reduction NN N
of IN N
intragastric JJ N
acidity NN N
during IN N
the DT N
infusion NN N
. . N

Subsequent NNP N
dose JJ N
reduction NN N
to TO N
20 CD N
mg NNS N
once RB N
daily RB N
led VBN N
to TO N
a DT N
stable JJ N
fraction NN N
of IN N
time NN N
with IN N
pH JJ N
> JJ N
3 CD N
of IN N
72 CD N
% NN N
. . N

CONCLUSIONS NNP N
Omeprazole NNP N
given VBN N
as IN N
a DT N
continuous JJ N
infusion NN N
of IN N
80 CD N
mg NNS N
+ VBD N
8 CD N
mg/h NN N
for IN N
72 CD N
h NN N
followed VBN N
by IN N
omeprazole JJ N
20 CD N
mg NN N
once RB N
daily RB N
raised VBD N
the DT N
intragastric JJ N
pH NN N
to TO N
and CC N
above JJ N
levels NNS N
alleged VBN N
to TO N
allow VB N
haemostasis NN N
in IN N
patients NNS N
with IN N
peptic JJ N
ulcer NN N
bleeding NN N
and CC N
subsequent JJ N
healing NN N
of IN N
the DT N
ulcer NN N
. . N

-DOCSTART- -17662102- O O

A DT N
pilot NN N
study NN N
of IN N
extended JJ N
duration NN N
peginterferon NN N
alfa-2a NN N
for IN N
patients NNS N
with IN N
hepatitis NN N
B NNP N
e VBZ N
antigen-negative JJ N
chronic JJ N
hepatitis NN N
B NNP N
. . N

OBJECTIVES NNP N
Forty-eight JJ N
weeks NNS N
of IN N
peginterferon NN N
alfa-2a NN N
is VBZ N
the DT N
approved JJ N
regimen NNS N
for IN N
chronic JJ N
hepatitis NN N
B NNP N
( ( N
CHB NNP N
) ) N
. . N

Standard NNP N
interferon NN N
is VBZ N
more RBR N
effective JJ N
for IN N
hepatitis NN N
B NNP N
e NN N
antigen NN N
( ( N
HBeAg NNP N
) ) N
-negative VBP N
CHB NNP N
when WRB N
given VBN N
for IN N
longer JJR N
than IN N
1 CD N
yr NN N
. . N

This DT N
study NN N
evaluated VBD N
peginterferon JJ N
alfa-2a NN N
for IN N
60 CD N
wk NN N
, , N
alone RB N
or CC N
in IN N
combination NN N
with IN N
lamivudine NN N
. . N

METHODS NNP N
Thirteen NNP N
patients NNS N
with IN N
HBeAg-negative JJ N
CHB NNP N
received VBD N
peginterferon JJ N
alfa-2a JJ N
( ( N
180 CD N
microg/week NN N
) ) N
for IN N
60 CD N
wk NN N
or CC N
peginterferon VB N
alfa-2a JJ N
( ( N
180 CD N
microg/week NN N
) ) N
for IN N
12 CD N
wk NN N
followed VBN N
by IN N
48 CD N
wk NN N
of IN N
peginterferon NN N
alfa-2a JJ N
plus CC N
lamivudine JJ N
. . N

The DT N
primary JJ N
end NN N
point NN N
, , N
sustained VBD N
virologic JJ N
response NN N
( ( N
SVR NNP N
) ) N
, , N
was VBD N
defined VBN N
as IN N
a DT N
reduction NN N
in IN N
hepatitis NN N
B NNP N
virus NN N
deoxyribonucleic NN N
acid NN N
( ( N
HBV NNP N
DNA NNP N
) ) N
of IN N
> NNP N
or=2 FW N
log10 NN N
copies/mL NN N
and CC N
HBV NNP N
DNA NNP N
< VBD N
20,000 CD N
copies/mL NN N
at IN N
24 CD N
wk NN N
of IN N
follow-up NN N
( ( N
week NN N
84 CD N
) ) N
. . N

Hepatitis $ N
B NNP N
surface NN N
antigen NN N
( ( N
HBsAg NNP N
) ) N
concentrations NNS N
were VBD N
analyzed VBN N
and CC N
compared VBN N
to TO N
changes NNS N
in IN N
HBV NNP N
DNA NNP N
. . N

RESULTS NNP N
SVR NNP N
was VBD N
achieved VBN N
by IN N
9/13 CD N
patients NNS N
( ( N
69 CD N
% NN N
) ) N
. . N

At IN N
week NN N
84 CD N
, , N
HBV NNP N
DNA NNP N
was VBD N
undetectable JJ N
by IN N
polymerase NN N
chain NN N
reaction NN N
in IN N
5/13 CD N
( ( N
38 CD N
% NN N
) ) N
patients NNS N
, , N
and CC N
3 CD N
additional JJ N
patients NNS N
had VBD N
a DT N
sustained VBN N
2-3 CD N
log NN N
reduction NN N
in IN N
HBV NNP N
DNA NNP N
. . N

Five CD N
patients NNS N
demonstrated VBD N
a DT N
> JJ N
90 CD N
% NN N
decrease NN N
in IN N
HBsAg NNP N
concentration NN N
at IN N
week NN N
60 CD N
, , N
including VBG N
3 CD N
with IN N
undetectable JJ N
HBV NNP N
DNA NNP N
at IN N
week NN N
84 CD N
and CC N
a DT N
fourth JJ N
who WP N
met VBD N
criteria NNS N
for IN N
SVR NNP N
. . N

CONCLUSIONS NNP N
Sixty NNP N
weeks NNS N
of IN N
peginterferon NN N
alfa-2a NN N
with IN N
or CC N
without IN N
lamivudine JJ N
resulted VBN N
in IN N
a DT N
higher JJR N
rate NN N
of IN N
SVR NNP N
compared VBN N
to TO N
historical JJ N
controls NNS N
with IN N
HBeAg-negative JJ N
CHB NNP N
treated VBD N
with IN N
48 CD N
wk NN N
of IN N
pegylated JJ N
interferon NN N
. . N

Larger JJR N
studies NNS N
are VBP N
necessary JJ N
to TO N
assess VB N
if IN N
longer JJR N
duration NN N
therapy NN N
is VBZ N
more RBR N
effective JJ N
than IN N
the DT N
standard JJ N
regimen NNS N
and CC N
results NNS N
in IN N
a DT N
greater JJR N
decline NN N
in IN N
HBsAg NNP N
concentration NN N
. . N

-DOCSTART- -18333888- O O

The DT N
dipeptidyl JJ N
peptidase-4 JJ N
inhibitor NN N
PHX1149 NNP N
improves VBZ N
blood NN N
glucose NN N
control NN N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
mellitus RB N
. . N

AIM NNP N
To TO N
determine VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
PHX1149 NNP N
, , N
a DT N
novel JJ N
dipeptidyl NN N
peptidase-4 NN N
( ( N
DPP4 NNP N
) ) N
inhibitor NN N
, , N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
multicentre NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
4-week JJ N
study NN N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
with IN N
suboptimal JJ N
metabolic JJ N
control NN N
. . N

Patients NNS N
with IN N
a DT N
baseline NN N
haemoglobin NN N
A NNP N
( ( N
1c CD N
) ) N
( ( N
HbA NNP N
( ( N
1c CD N
) ) N
) ) N
of IN N
7.3 CD N
to TO N
11.0 CD N
% NN N
were VBD N
randomized VBN N
1 CD N
: : N
1 CD N
: : N
1 CD N
: : N
1 CD N
to TO N
receive VB N
once-daily JJ N
oral JJ N
therapy NN N
with IN N
either DT N
PHX1149 NNP N
( ( N
100 CD N
, , N
200 CD N
or CC N
400 CD N
mg NN N
) ) N
or CC N
placebo NN N
; : N
patients NNS N
were VBD N
on IN N
a DT N
constant JJ N
background NN N
therapy NN N
of IN N
either DT N
metformin NN N
alone RB N
or CC N
metformin JJ N
plus CC N
a DT N
glitazone NN N
. . N

RESULTS NNP N
Treatment NNP N
with IN N
100 CD N
, , N
200 CD N
or CC N
400 CD N
mg NN N
of IN N
PHX1149 NNP N
significantly RB N
decreased VBD N
postprandial JJ N
glucose JJ N
area NN N
under IN N
the DT N
curve NN N
AUC NNP N
( ( N
0-2 JJ N
h NN N
) ) N
by IN N
approximately RB N
20 CD N
% NN N
( ( N
+0.11 JJ N
+/- JJ N
0.50 CD N
, , N
-2.08 VBD N
+/- JJ N
0.51 CD N
, , N
-1.73 VBD N
+/- JJ N
0.49 CD N
and CC N
-1.88 VB N
+/- JJ N
0.48 CD N
mmol/l NN N
x NN N
h NN N
, , N
respectively RB N
, , N
for IN N
placebo NN N
and CC N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
( ( N
p JJ N
= NN N
0.002 CD N
, , N
0.008 CD N
and CC N
0.004 CD N
vs. FW N
placebo NN N
) ) N
. . N

Postprandial JJ N
AUC NNP N
( ( N
0-2 JJ N
h NN N
) ) N
of IN N
intact JJ N
glucagon-like JJ N
peptide-1 NN N
, , N
the DT N
principal JJ N
mediator NN N
of IN N
the DT N
biological JJ N
effects NNS N
of IN N
DPP4 NNP N
inhibitors NNS N
, , N
was VBD N
increased VBN N
by IN N
3.90 CD N
+/- JJ N
2.83 CD N
, , N
11.63 CD N
+/- JJ N
2.86 CD N
, , N
16.42 CD N
+/- JJ N
2.72 CD N
and CC N
15.75 CD N
+/- JJ N
2.71 CD N
pmol/l NN N
x NN N
h NN N
, , N
respectively RB N
, , N
for IN N
placebo NN N
and CC N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
( ( N
p JJ N
= NN N
0.053 CD N
, , N
0.001 CD N
and CC N
0.002 CD N
vs. FW N
placebo NN N
) ) N
. . N

Mean JJ N
HbA NNP N
( ( N
1c CD N
) ) N
was VBD N
lower JJR N
in IN N
all DT N
dose JJ N
groups NNS N
; : N
the DT N
placebo-corrected JJ N
change NN N
in IN N
the DT N
groups NNS N
receiving VBG N
400 CD N
mg JJ N
PHX1149 NNP N
was VBD N
-0.28 VBN N
% NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

DPP4 NNP N
inhibition NN N
on IN N
day NN N
28 CD N
was VBD N
53 CD N
, , N
73 CD N
and CC N
78 CD N
% NN N
at IN N
24 CD N
h NN N
postdose NN N
in IN N
the DT N
groups NNS N
receiving VBG N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
PHX1149 NNP N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
adverse JJ N
events NNS N
between IN N
PHX1149-treated NNP N
and CC N
placebo JJ N
subjects NNS N
. . N

CONCLUSIONS NNP N
Addition NNP N
of IN N
the DT N
DPP4 NNP N
inhibitor NN N
PHX1149 NNP N
to TO N
a DT N
stable JJ N
regimen NN N
of IN N
metformin NN N
or CC N
metformin NN N
plus CC N
a DT N
glitazone NN N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
was VBD N
well RB N
tolerated VBN N
and CC N
improved VBN N
blood NN N
glucose NN N
control NN N
. . N

-DOCSTART- -21135366- O O

Mechanisms NNP N
underlying VBG N
the DT N
lack NN N
of IN N
effect NN N
of IN N
implantable JJ N
cardioverter-defibrillator JJ N
therapy NN N
on IN N
mortality NN N
in IN N
high-risk JJ N
patients NNS N
with IN N
recent JJ N
myocardial JJ N
infarction NN N
: : N
insights NNS N
from IN N
the DT N
Defibrillation NNP N
in IN N
Acute NNP N
Myocardial NNP N
Infarction NNP N
Trial NNP N
( ( N
DINAMIT NNP N
) ) N
. . N

BACKGROUND NNP N
although IN N
implantable JJ N
cardioverter-defibrillators NNS N
( ( N
ICDs NNP N
) ) N
lower JJR N
mortality NN N
in IN N
stable JJ N
patients NNS N
with IN N
low JJ N
ejection NN N
fraction NN N
late RB N
after IN N
myocardial JJ N
infarction NN N
, , N
randomized VBN N
trials NNS N
of IN N
ICD NNP N
versus FW N
control NN N
subjects NNS N
implanted VBD N
early RB N
after IN N
myocardial JJ N
infarction NN N
do VBP N
not RB N
show VB N
mortality NN N
benefit NN N
. . N

Our PRP$ N
objective NN N
was VBD N
to TO N
investigate VB N
possible JJ N
mechanisms NNS N
underlying VBG N
the DT N
lack NN N
of IN N
mortality NN N
benefit NN N
in IN N
the DT N
Defibrillation NNP N
in IN N
Acute NNP N
Myocardial NNP N
Infarction NNP N
Trial NNP N
( ( N
DINAMIT NNP N
) ) N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
this DT N
is VBZ N
a DT N
secondary JJ N
analysis NN N
of IN N
the DT N
prospective JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

Outpatients NNS N
with IN N
recent JJ N
( ( N
6 CD N
to TO N
40 CD N
days NNS N
) ) N
acute VBP N
myocardial JJ N
infarction NN N
, , N
left VBD N
ventricular JJ N
dysfunction NN N
( ( N
ejection JJ N
fraction NN N
< VBD N
35 CD N
% NN N
) ) N
, , N
and CC N
low JJ N
heart NN N
rate NN N
variability NN N
were VBD N
randomized VBN N
to TO N
ICD NNP N
( ( N
n=311 NN N
) ) N
or CC N
to TO N
standard VB N
medical JJ N
therapy NN N
( ( N
n=342 JJ N
) ) N
. . N

In IN N
a DT N
competing-risks JJ N
analysis NN N
, , N
those DT N
factors NNS N
that WDT N
increased VBD N
the DT N
risk NN N
of IN N
arrhythmic JJ N
death NN N
also RB N
increased VBD N
the DT N
risk NN N
of IN N
nonarrhythmic JJ N
deaths NNS N
. . N

After IN N
adjustment NN N
for IN N
these DT N
factors NNS N
, , N
receiving VBG N
an DT N
ICD NNP N
was VBD N
associated VBN N
with IN N
a DT N
decreased JJ N
risk NN N
of IN N
arrhythmic JJ N
death NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.33 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.15 CD N
to TO N
0.71 CD N
) ) N
but CC N
an DT N
increase NN N
in IN N
nonarrhythmic JJ N
death NN N
( ( N
hazard JJ N
ratio NN N
, , N
1.70 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.00 CD N
to TO N
2.80 CD N
) ) N
. . N

In IN N
an DT N
adjusted JJ N
time-dependent JJ N
analysis NN N
, , N
patients NNS N
receiving VBG N
an DT N
ICD NNP N
and CC N
having VBG N
appropriate JJ N
ICD NNP N
therapy NN N
had VBD N
a DT N
15.1 CD N
% NN N
yearly RB N
hazard NN N
of IN N
mortality NN N
compared VBN N
with IN N
5.2 CD N
% NN N
in IN N
ICD NNP N
patients NNS N
with IN N
no DT N
appropriate JJ N
therapy NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
reduction NN N
in IN N
sudden JJ N
death NN N
in IN N
ICD NNP N
patients NNS N
was VBD N
completely RB N
offset VBN N
by IN N
increased JJ N
nonarrhythmic JJ N
deaths NNS N
, , N
which WDT N
were VBD N
greatest JJS N
in IN N
patients NNS N
receiving VBG N
ICD NNP N
shock NN N
therapy NN N
( ( N
hazard JJ N
ratio NN N
, , N
6.0 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
2.8 CD N
to TO N
12.7 CD N
) ) N
. . N

CONCLUSIONS NNP N
in IN N
patients NNS N
receiving VBG N
ICDs NNP N
early RB N
after IN N
myocardial JJ N
infarction NN N
, , N
those DT N
factors NNS N
that WDT N
are VBP N
associated VBN N
with IN N
arrhythmia NN N
requiring VBG N
ICD NNP N
therapy NN N
are VBP N
also RB N
associated VBN N
with IN N
a DT N
high JJ N
risk NN N
of IN N
nonsudden JJ N
death NN N
, , N
negating VBG N
the DT N
benefit NN N
of IN N
ICDs NNP N
in IN N
this DT N
setting NN N
. . N

-DOCSTART- -24214189- O O

QT/QTc NNP N
study NN N
conducted VBD N
in IN N
Japanese JJ N
adult NN N
healthy JJ N
subjects NNS N
: : N
a DT N
novel JJ N
xanthine NN N
oxidase NN N
inhibitor NN N
topiroxostat NN N
was VBD N
not RB N
associated VBN N
with IN N
QT NNP N
prolongation NN N
. . N

A DT N
QT/QTc NNP N
study NN N
was VBD N
conducted VBN N
in IN N
compliance NN N
with IN N
ICH NNP N
E14 NNP N
guideline NN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
new JJ N
xanthine JJ N
oxidase NN N
inhibitor NN N
topiroxostat NN N
in IN N
Japanese JJ N
healthy JJ N
subjects NNS N
. . N

Forty-eight JJ N
Japanese JJ N
healthy JJ N
subjects NNS N
( ( N
males NNS N
24 CD N
; : N
females NNS N
24 CD N
) ) N
received VBD N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
topiroxostat NN N
( ( N
60 CD N
or CC N
180 CD N
mg NN N
) ) N
, , N
moxifloxacin FW N
( ( N
400 CD N
mg NN N
) ) N
or CC N
placebo NN N
in IN N
a DT N
single-center JJ N
, , N
double-blind JJ N
, , N
four-period JJ N
crossover NN N
design NN N
. . N

Fridericia NNP N
's POS N
formula NN N
( ( N
QTcF NNP N
= NNP N
QT/RR NNP N
( ( N
0.33 CD N
) ) N
) ) N
was VBD N
used VBN N
as IN N
a DT N
primary JJ N
method NN N
for IN N
QT-interval JJ N
correction NN N
. . N

The DT N
mean JJ N
QTcF NNP N
was VBD N
prolonged VBN N
by IN N
moxifloxacin NN N
, , N
of IN N
which WDT N
largest JJS N
time-matched JJ N
difference NN N
from IN N
placebo JJ N
administration NN N
was VBD N
13.6 CD N
milliseconds NNS N
with IN N
90 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
of IN N
11.2 CD N
and CC N
15.9 CD N
milliseconds NNS N
at IN N
4 CD N
hours NNS N
post-dose JJ N
. . N

The DT N
mean JJ N
QTcF NNP N
was VBD N
hardly RB N
affected VBN N
by IN N
either DT N
dose NN N
of IN N
topiroxostat NN N
, , N
of IN N
which WDT N
largest JJS N
time-matched JJ N
difference NN N
from IN N
placebo JJ N
administration NN N
was VBD N
2.9 CD N
milliseconds NNS N
with IN N
90 CD N
% NN N
CI NNP N
of IN N
0.6 CD N
and CC N
5.3 CD N
milliseconds NNS N
at IN N
4 CD N
hours NNS N
post-dose JJ N
for IN N
60 CD N
mg NN N
, , N
and CC N
2.3 CD N
milliseconds NNS N
with IN N
90 CD N
% NN N
CI NNP N
of IN N
0 CD N
and CC N
4.7 CD N
milliseconds NNS N
at IN N
1 CD N
hour NN N
post-dose NN N
for IN N
180 CD N
mg NN N
. . N

The DT N
results NNS N
were VBD N
essentially RB N
the DT N
same JJ N
in IN N
the DT N
sex NN N
subgroup NN N
analysis NN N
. . N

Moxifloxacin NNP N
can MD N
be VB N
used VBN N
as IN N
a DT N
positive JJ N
control NN N
for IN N
QT/QTc NNP N
studies NNS N
in IN N
Japanese JJ N
subjects NNS N
; : N
and CC N
topiroxostat VB N
may MD N
not RB N
cause VB N
QT-interval JJ N
prolongation NN N
in IN N
males NNS N
as RB N
well RB N
as IN N
females NNS N
. . N

-DOCSTART- -24641638- O O

Prophylactic JJ N
vs NN N
therapeutic JJ N
blood NN N
patch NN N
for IN N
obstetric JJ N
patients NNS N
with IN N
accidental JJ N
dural JJ N
puncture NN N
-- : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

Epidural JJ N
blood NN N
patch NN N
is VBZ N
a DT N
standard JJ N
treatment NN N
for IN N
obstetric JJ N
patients NNS N
experiencing VBG N
a DT N
severe JJ N
post-dural JJ N
puncture NN N
headache NN N
. . N

Patients NNS N
who WP N
sustained VBD N
an DT N
accidental JJ N
dural JJ N
puncture NN N
during IN N
establishment NN N
of IN N
epidural JJ N
analgesia NN N
during IN N
labour NN N
or CC N
at IN N
caesarean JJ N
delivery NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
prophylactic JJ N
epidural JJ N
blood NN N
patch NN N
or CC N
conservative JJ N
treatment NN N
with IN N
a DT N
therapeutic JJ N
epidural JJ N
blood NN N
patch NN N
if IN N
required VBN N
. . N

Eleven NNP N
of IN N
60 CD N
( ( N
18.3 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
prophylactic JJ N
epidural JJ N
blood NN N
patch NN N
group NN N
developed VBD N
a DT N
post-dural JJ N
puncture NN N
headache NN N
compared VBN N
with IN N
39 CD N
of IN N
49 CD N
( ( N
79.6 CD N
% NN N
) ) N
in IN N
the DT N
therapeutic JJ N
epidural JJ N
blood NN N
patch NN N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

A DT N
blood NN N
patch NN N
was VBD N
performed VBN N
in IN N
36 CD N
( ( N
73.4 CD N
% NN N
) ) N
of IN N
patients NNS N
in IN N
the DT N
therapeutic JJ N
group NN N
. . N

The DT N
number NN N
of IN N
patients NNS N
who WP N
needed VBD N
a DT N
second JJ N
blood NN N
patch NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
: : N
6 CD N
( ( N
10.0 CD N
% NN N
) ) N
for IN N
prophylactic JJ N
epidural JJ N
blood NN N
patch NN N
and CC N
4 CD N
( ( N
11.1 CD N
% NN N
) ) N
for IN N
therapeutic JJ N
epidural JJ N
blood NN N
patch NN N
. . N

We PRP N
conclude VBP N
that IN N
prophylactic JJ N
epidural JJ N
blood NN N
patch NN N
is VBZ N
an DT N
effective JJ N
method NN N
to TO N
reduce VB N
the DT N
development NN N
of IN N
post-dural JJ N
puncture NN N
headache NN N
in IN N
obstetric JJ N
patients NNS N
. . N

-DOCSTART- -16199793- O O

Family RB N
education NN N
for IN N
people NNS N
with IN N
schizophrenia NN N
in IN N
Beijing NNP N
, , N
China NNP N
: : N
randomised VBD N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Much NNP N
of IN N
China NNP N
lacks VBZ N
well-developed JJ N
services NNS N
for IN N
people NNS N
with IN N
schizophrenia NN N
and CC N
their PRP$ N
families NNS N
, , N
and CC N
most JJS N
of IN N
the DT N
existing VBG N
services NNS N
focus NN N
on IN N
hospitals NNS N
. . N

There EX N
is VBZ N
a DT N
need NN N
for IN N
culturally RB N
sensitive JJ N
family NN N
treatments NNS N
offered VBN N
by IN N
nurses NNS N
. . N

AIMS NNP N
To TO N
conduct VB N
a DT N
longitudinal JJ N
experimental NN N
study NN N
examining VBG N
the DT N
effect NN N
of IN N
patient NN N
and CC N
family NN N
education NN N
in IN N
a DT N
sample NN N
of IN N
Chinese JJ N
people NNS N
with IN N
schizophrenia NN N
. . N

METHOD NNP N
A NNP N
randomised VBD N
controlled VBN N
trial NN N
was VBD N
conducted VBN N
in IN N
a DT N
large JJ N
hospital NN N
with IN N
a DT N
was VBD N
conducted VBN N
in IN N
a DT N
large JJ N
hospital NN N
with IN N
a DT N
sample NN N
of IN N
101 CD N
patients NNS N
with IN N
schizophrenia NN N
and CC N
their PRP$ N
families NNS N
. . N

Data NNS N
were VBD N
collected VBN N
at IN N
admission NN N
and CC N
at IN N
discharge NN N
, , N
and CC N
then RB N
at IN N
3 CD N
and CC N
9 CD N
months NNS N
after IN N
discharge NN N
. . N

The DT N
intervention NN N
group NN N
received VBD N
family NN N
education NN N
, , N
and CC N
data NNS N
on IN N
their PRP$ N
knowledge NN N
about IN N
schizophrenia NN N
, , N
symptoms NNS N
, , N
functioning VBG N
, , N
psychosocial JJ N
behaviour NN N
, , N
relapse NN N
and CC N
medication NN N
adherence NN N
were VBD N
collected VBN N
and CC N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
knowledge NN N
about IN N
schizophrenia NN N
in IN N
the DT N
experimental JJ N
group NN N
and CC N
a DT N
significant JJ N
difference NN N
in IN N
symptom JJ N
scores NNS N
and CC N
functioning VBG N
at IN N
9 CD N
months NNS N
after IN N
discharge NN N
. . N

Patients NNS N
who WP N
were VBD N
nonadherent JJ N
to TO N
medication NN N
regimens NNS N
were VBD N
more RBR N
likely JJ N
to TO N
relapse VB N
. . N

CONCLUSIONS NNP N
Family NNP N
education NN N
on IN N
schizophrenia NN N
by IN N
nurses NNS N
in IN N
China NNP N
was VBD N
effective JJ N
in IN N
improving VBG N
knowledge NN N
and CC N
promoting VBG N
improvement NN N
in IN N
patients NNS N
' POS N
symptoms NNS N
. . N

-DOCSTART- -17934527- O O

Rehabilitation NN N
of IN N
therapy-related JJ N
cognitive JJ N
deficits NNS N
in IN N
patients NNS N
after IN N
hematopoietic JJ N
stem NN N
cell NN N
transplantation NN N
. . N

Neuropsychological JJ N
deficits NNS N
are VBP N
potential JJ N
side NN N
effects NNS N
of IN N
hematopoietic JJ N
stem NN N
cell NN N
therapy NN N
( ( N
HSCT NNP N
) ) N
. . N

Systematic JJ N
data NNS N
on IN N
the DT N
long-term JJ N
course NN N
of IN N
and CC N
therapeutic JJ N
options NNS N
for IN N
these DT N
consequences NNS N
are VBP N
limited VBN N
. . N

One CD N
hundred VBD N
fifty-seven JJ N
patients NNS N
were VBD N
screened VBN N
for IN N
cognitive JJ N
deficits NNS N
following VBG N
HSCT NNP N
for IN N
malignant JJ N
diseases NNS N
at IN N
an DT N
in-patient JJ N
oncologic NN N
rehabilitation NN N
clinic NN N
. . N

Patients NNS N
showing VBG N
evidence NN N
of IN N
impairment NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
training VBG N
groups NNS N
: : N
individualized VBN N
PC-supported JJ N
training NN N
or CC N
neuropsychological JJ N
group NN N
therapy NN N
. . N

The DT N
control NN N
group NN N
consisted VBD N
of IN N
patients NNS N
who WP N
received VBD N
no DT N
specific JJ N
training NN N
. . N

During IN N
in-patient JJ N
rehabilitation NN N
, , N
the DT N
results NNS N
of IN N
a DT N
comprehensive JJ N
neuropsychological JJ N
test NN N
battery NN N
improved VBD N
significantly RB N
in IN N
all DT N
three CD N
groups NNS N
, , N
and CC N
no DT N
specific JJ N
intervention NN N
effects NNS N
were VBD N
identified VBN N
. . N

Neuropsychological JJ N
deficits NNS N
were VBD N
still RB N
evident JJ N
in IN N
a DT N
subgroup NN N
of IN N
patients NNS N
6 CD N
months NNS N
later RB N
. . N

Correlation NN N
between IN N
neuropsychological JJ N
testing NN N
and CC N
patients NNS N
' POS N
self-evaluation NN N
of IN N
cognitive JJ N
functioning NN N
in IN N
daily JJ N
life NN N
was VBD N
generally RB N
low JJ N
. . N

Sustained VBN N
attention NN N
and CC N
verbal-semantic JJ N
memory NN N
played VBD N
the DT N
main JJ N
role NN N
for IN N
self-appraisal JJ N
and CC N
in IN N
the DT N
designation NN N
as IN N
'neuropsychologically RB N
impaired VBN N
' '' N
. . N

In IN N
conclusion NN N
, , N
a DT N
substantial JJ N
number NN N
of IN N
patients NNS N
revealed JJ N
evidence NN N
of IN N
cognitive JJ N
deficits NNS N
a DT N
long JJ N
time NN N
after IN N
HSCT NNP N
. . N

There EX N
is VBZ N
a DT N
need NN N
for IN N
more JJR N
studies NNS N
and CC N
for IN N
the DT N
development NN N
of IN N
differentiated JJ N
rehabilitative JJ N
measures NNS N
for IN N
such JJ N
therapeutic JJ N
consequences NNS N
. . N

-DOCSTART- -1302807- O O

Shorter NNP N
treatment NN N
for IN N
vaginal JJ N
candidosis NN N
: : N
comparison NN N
between IN N
single-dose JJ N
oral JJ N
fluconazole NN N
and CC N
three-day JJ N
treatment NN N
with IN N
local JJ N
miconazole NN N
. . N

Fluconazole NNP N
is VBZ N
an DT N
effective JJ N
, , N
simple JJ N
and CC N
safe JJ N
, , N
although IN N
slightly RB N
expensive JJ N
, , N
agent NN N
for IN N
the DT N
treatment NN N
of IN N
vaginal JJ N
candidosis NN N
. . N

Single-dose JJ N
fluconazole NN N
( ( N
150 CD N
mg NN N
) ) N
administered VBD N
orally RB N
in IN N
capsule NN N
form NN N
was VBD N
compared VBN N
with IN N
three-day JJ N
local JJ N
treatment NN N
with IN N
miconazole JJ N
pessaries NNS N
in IN N
the DT N
treatment NN N
of IN N
vaginal JJ N
candidosis NN N
in IN N
a DT N
randomized JJ N
study NN N
in IN N
Finland NNP N
. . N

Cure NN N
rates NNS N
were VBD N
good JJ N
( ( N
> JJ N
80 CD N
% NN N
) ) N
in IN N
randomized VBN N
patient NN N
groups NNS N
assessed VBD N
both DT N
clinically RB N
and CC N
by IN N
the DT N
results NNS N
of IN N
yeast JJ N
cultures NNS N
. . N

Oral JJ N
administration NN N
was VBD N
preferred VBN N
to TO N
local JJ N
therapy NN N
by IN N
patients NNS N
in IN N
both DT N
the DT N
miconazole NN N
and CC N
fluconazole JJ N
groups NNS N
. . N

For IN N
the DT N
time NN N
being VBG N
, , N
fluconazole NN N
is VBZ N
not RB N
recommended VBN N
for IN N
use NN N
during IN N
pregnancy NN N
or CC N
lactation NN N
. . N

-DOCSTART- -7954555- O O

Use NNP N
and CC N
limitations NNS N
of IN N
Holter NNP N
electrocardiography NN N
in IN N
assessing VBG N
drug NN N
therapy NN N
of IN N
myocardial JJ N
ischemia NN N
during IN N
the DT N
peri-PTCA JJ N
period NN N
. . N

Incidence NN N
and CC N
pattern NN N
of IN N
myocardial JJ N
ischemia NN N
during IN N
the DT N
peri-PTCA JJ N
( ( N
percutaneous JJ N
transluminal JJ N
coronary JJ N
angioplasty NN N
) ) N
period NN N
and CC N
the DT N
possible JJ N
role NN N
of IN N
continuous JJ N
intravenous JJ N
isosorbide NN N
dinitrate NN N
in IN N
its PRP$ N
prevention NN N
were VBD N
examined VBN N
prospectively RB N
in IN N
30 CD N
patients NNS N
. . N

Holter NNP N
electrocardiographic JJ N
monitoring NN N
was VBD N
performed VBN N
for IN N
21 CD N
+/- JJ N
3 CD N
h NN N
before IN N
PTCA NNP N
and CC N
continued VBN N
during IN N
and CC N
for IN N
41 CD N
+/- JJ N
8 CD N
h NN N
after IN N
the DT N
procedure NN N
. . N

Before IN N
PTCA NNP N
, , N
19 CD N
ischemic JJ N
episodes NNS N
were VBD N
present JJ N
in IN N
10 CD N
( ( N
33 CD N
% NN N
) ) N
of IN N
30 CD N
patients NNS N
. . N

PTCA NNP N
produced VBD N
an DT N
abrupt JJ N
decrease NN N
in IN N
number NN N
( ( N
p JJ N
= NNP N
0.015 CD N
) ) N
and CC N
duration NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
of IN N
spontaneous JJ N
ischemic JJ N
episodes NNS N
. . N

The DT N
rarity NN N
of IN N
recurrent JJ N
myocardial JJ N
ischemic JJ N
events NNS N
by IN N
Holter NNP N
monitoring NN N
after IN N
PTCA NNP N
negated VBD N
any DT N
attempt NN N
at IN N
assessing VBG N
the DT N
efficacy NN N
of IN N
intravenous JJ N
isosorbide JJ N
dinitrate NN N
in IN N
their PRP$ N
prevention NN N
. . N

Holter NNP N
monitoring NN N
could MD N
not RB N
be VB N
used VBN N
as IN N
an DT N
early JJ N
predictor NN N
of IN N
late JJ N
coronary JJ N
restenosis NN N
. . N

-DOCSTART- -19570717- O O

Effects NNS N
of IN N
tonabersat NN N
on IN N
migraine NN N
with IN N
aura NN N
: : N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
. . N

BACKGROUND NNP N
Migraine NNP N
with IN N
aura NN N
is VBZ N
thought VBN N
likely RB N
to TO N
be VB N
caused VBN N
by IN N
cortical JJ N
spreading VBG N
depression NN N
( ( N
CSD NNP N
) ) N
. . N

Tonabersat NNP N
inhibits VBZ N
CSD NNP N
, , N
and CC N
we PRP N
therefore RB N
investigated VBD N
whether IN N
tonabersat NN N
has VBZ N
a DT N
preventive JJ N
effect NN N
in IN N
migraine NN N
with IN N
aura NN N
. . N

METHODS NNP N
In IN N
this DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
trial NN N
, , N
40 CD N
mg NN N
tonabersat NN N
once IN N
daily JJ N
was VBD N
compared VBN N
with IN N
matched JJ N
placebo NN N
in IN N
patients NNS N
who WP N
had VBD N
at IN N
least JJS N
one CD N
aura NN N
attack NN N
per IN N
month NN N
during IN N
the DT N
past JJ N
3 CD N
months NNS N
. . N

Randomisation NN N
was VBD N
by IN N
computer-generated JJ N
list NN N
. . N

Patients NNS N
kept VBD N
a DT N
detailed JJ N
diary NN N
to TO N
enable VB N
objective JJ N
diagnosis NN N
of IN N
each DT N
attack NN N
as IN N
migraine NN N
with IN N
aura NN N
, , N
migraine NN N
without IN N
aura NN N
, , N
or CC N
other JJ N
type NN N
of IN N
headache NN N
. . N

Primary JJ N
endpoints NNS N
were VBD N
a DT N
reduction NN N
in IN N
aura NN N
attacks NNS N
with IN N
or CC N
without IN N
headache NN N
and CC N
a DT N
reduction NN N
in IN N
migraine JJ N
headache NN N
days NNS N
with IN N
or CC N
without IN N
an DT N
aura NN N
. . N

Analysis NN N
was VBD N
per IN N
protocol NN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
, , N
number NN N
NCT00332007 NNP N
. . N

FINDINGS NNP N
39 CD N
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
, , N
of IN N
whom WP N
31 CD N
were VBD N
included VBN N
in IN N
the DT N
statistical JJ N
analysis NN N
of IN N
efficacy NN N
. . N

Median JJ N
( ( N
IQR NNP N
) ) N
attacks NNS N
of IN N
aura NN N
were VBD N
reduced VBN N
from IN N
3.2 CD N
( ( N
1.0-5.0 JJ N
) ) N
per IN N
12 CD N
weeks NNS N
on IN N
placebo NN N
to TO N
1.0 CD N
( ( N
0-3.0 CD N
) ) N
on IN N
tonabersat NN N
( ( N
p=0.01 NN N
) ) N
, , N
whereas VBP N
the DT N
other JJ N
primary JJ N
outcome JJ N
measure NN N
, , N
median JJ N
migraine NN N
headache NN N
days NNS N
with IN N
or CC N
without IN N
aura NN N
, , N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
placebo NN N
and CC N
tonabersat NN N
groups NNS N
( ( N
3.0 CD N
days NNS N
in IN N
each DT N
group NN N
; : N
p=0.09 NN N
) ) N
. . N

Tonabersat NNP N
was VBD N
well RB N
tolerated VBN N
but CC N
overall JJ N
had VBD N
more RBR N
side-effects NNS N
than IN N
placebo NN N
. . N

INTERPRETATION NNP N
Tonabersat NNP N
showed VBD N
a DT N
preventive JJ N
effect NN N
on IN N
attacks NNS N
of IN N
migraine NN N
aura NN N
but CC N
no DT N
efficacy NN N
on IN N
non-aura JJ N
attacks NNS N
, , N
in IN N
keeping VBG N
with IN N
its PRP$ N
known JJ N
inhibitory JJ N
effect NN N
on IN N
CSD NNP N
. . N

The DT N
results NNS N
support VBD N
the DT N
theory NN N
that IN N
auras NNS N
are VBP N
caused VBN N
by IN N
CSD NNP N
and CC N
that IN N
this DT N
phenomenon NN N
is VBZ N
not RB N
involved VBN N
in IN N
attacks NNS N
without IN N
aura NN N
. . N

FUNDING NN N
Minster NNP N
Pharmaceuticals NNP N
; : N
Lundbeck NNP N
Foundation NNP N
. . N

-DOCSTART- -16293958- O O

Efficacy NN N
of IN N
nebulized JJ N
flunisolide NN N
combined VBN N
with IN N
salbutamol NN N
and CC N
ipratropium NN N
bromide NN N
in IN N
stable JJ N
patients NNS N
with IN N
moderate-to-severe JJ N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
. . N

BACKGROUND IN N
The DT N
efficacy NN N
of IN N
nebulized JJ N
corticosteroids NNS N
in IN N
the DT N
prevention NN N
of IN N
exacerbation NN N
of IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
has VBZ N
been VBN N
poorly RB N
studied VBN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
nebulized JJ N
flunisolide NN N
( ( N
1 CD N
mg NN N
) ) N
+ VBZ N
salbutamol/ipratropium JJ N
bromide NN N
( ( N
1,875/375 CD N
microg NN N
) ) N
b.i.d NN N
. . N

in IN N
comparison NN N
with IN N
placebo NN N
+ NNP N
salbutamol/ipratropium NN N
bromide NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
study NN N
on IN N
114 CD N
patients NNS N
with IN N
COPD NNP N
of IN N
moderate-to-severe JJ N
degree NN N
. . N

The DT N
main JJ N
outcome NN N
was VBD N
the DT N
frequency NN N
of IN N
severe JJ N
exacerbations NNS N
over IN N
a DT N
6-month JJ N
period NN N
. . N

Before IN N
and CC N
after IN N
treatment NN N
, , N
respiratory NN N
symptoms NNS N
, , N
forced VBD N
expiratory JJ N
volume NN N
in IN N
1 CD N
s NN N
( ( N
FEV NNP N
( ( N
1 CD N
) ) N
) ) N
, , N
shuttle JJ N
walking VBG N
test NN N
distance NN N
and CC N
St. NNP N
George NNP N
's POS N
Respiratory NNP N
Questionnaire NNP N
scores NNS N
were VBD N
evaluated VBN N
. . N

RESULTS VB N
The DT N
total JJ N
number NN N
of IN N
exacerbations NNS N
was VBD N
slightly RB N
lower JJR N
in IN N
the DT N
flunisolide NN N
group NN N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
( ( N
19 CD N
vs. FW N
34 CD N
, , N
p NN N
= NNP N
0.054 CD N
) ) N
; : N
the DT N
number NN N
of IN N
patients NNS N
experiencing VBG N
at IN N
least JJS N
one CD N
exacerbation NN N
during IN N
the DT N
study NN N
was VBD N
also RB N
decreased VBN N
( ( N
16 CD N
vs. FW N
26 CD N
, , N
p NN N
= NNP N
0.059 CD N
) ) N
. . N

In IN N
particular JJ N
, , N
type JJ N
3 CD N
Anthonisens NNP N
's POS N
exacerbations NNS N
were VBD N
significantly RB N
reduced VBN N
by IN N
flunisolide NN N
( ( N
p JJ N
= NNP N
0.044 CD N
) ) N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
scores NNS N
were VBD N
higher JJR N
than IN N
in IN N
the DT N
flunisolide JJ N
group NN N
but CC N
nonsignificant NN N
for IN N
dyspnea NN N
, , N
cough NN N
, , N
sputum NN N
amount NN N
and CC N
purulence NN N
. . N

FEV NNP N
( ( N
1 CD N
) ) N
was VBD N
significantly RB N
increased VBN N
compared VBN N
to TO N
baseline VB N
in IN N
both DT N
groups NNS N
, , N
and CC N
the DT N
area NN N
under IN N
the DT N
FEV NNP N
( ( N
1 CD N
) ) N
-time NN N
curve NN N
during IN N
the DT N
6-month JJ N
period NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
flunisolide NN N
group NN N
( ( N
5.2 CD N
+/- JJ N
10.6 CD N
vs. FW N
2.1 CD N
+/- JJ N
5.0 CD N
, , N
flunisolide RB N
vs. FW N
placebo NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.047 CD N
) ) N
. . N

For IN N
shuttle JJ N
walking VBG N
test NN N
distance NN N
and CC N
scores NNS N
of IN N
the DT N
St. NNP N
George NNP N
's POS N
Respiratory NNP N
Questionnaire NNP N
, , N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
baseline NN N
evaluation NN N
and CC N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
observed VBN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Nebulized NNP N
flunisolide NN N
is VBZ N
a DT N
good JJ N
alternative NN N
to TO N
other JJ N
inhaled JJ N
corticosteroids NNS N
when WRB N
added VBN N
to TO N
nebulized JJ N
salbutamol/ipratropium NN N
bromide NN N
in IN N
the DT N
long-term JJ N
treatment NN N
of IN N
moderate-to-severe JJ N
COPD NNP N
patients NNS N
. . N

-DOCSTART- -16418843- O O

The DT N
influence NN N
of IN N
rTMS NN N
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal JJ N
cortex NN N
on IN N
Stroop NNP N
task NN N
performance NN N
. . N

Several JJ N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
rTMS NN N
) ) N
can MD N
improve VB N
cognitive JJ N
processing NN N
. . N

Neuroimaging VBG N
studies NNS N
have VBP N
shown VBN N
the DT N
engagement NN N
of IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal NN N
cortex NN N
( ( N
DLPFC NNP N
) ) N
in IN N
executive NN N
functioning NN N
, , N
and CC N
more RBR N
specifically RB N
during IN N
selective JJ N
attention NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
the DT N
influence NN N
of IN N
high-frequency NN N
rTMS NN N
over IN N
the DT N
left JJ N
DLPFC NNP N
on IN N
Stroop NNP N
task NN N
performance NN N
in IN N
healthy JJ N
female NN N
volunteers NNS N
was VBD N
investigated VBN N
. . N

As IN N
expected VBN N
, , N
reaction NN N
time NN N
on IN N
both CC N
the DT N
incongruent NN N
and CC N
congruent NN N
trials NNS N
decreased VBD N
significantly RB N
after IN N
stimulation NN N
, , N
and CC N
there EX N
was VBD N
no DT N
difference NN N
with IN N
regard NN N
to TO N
the DT N
Stroop NNP N
interference NN N
effect NN N
. . N

Mood NNP N
remained VBD N
unchanged JJ N
after IN N
rTMS NN N
. . N

Such PDT N
a DT N
pattern NN N
is VBZ N
consistent JJ N
with IN N
the DT N
role NN N
of IN N
the DT N
left NN N
DLPFC NNP N
in IN N
implementing VBG N
top-down JJ N
attentional JJ N
control NN N
. . N

-DOCSTART- -393286- O O

A DT N
comparative JJ N
study NN N
of IN N
methyldopa NN N
and CC N
labetalol NN N
in IN N
the DT N
treatment NN N
of IN N
hypertension NN N
. . N

1 CD N
Twenty CD N
patients NNS N
with IN N
essential JJ N
hypertension NN N
completed VBD N
a DT N
double-blind JJ N
, , N
dose-tritrated JJ N
, , N
cross-over JJ N
comparison NN N
of IN N
methyldopa NN N
and CC N
labetalol NN N
. . N

2 CD N
Average JJ N
lying VBG N
BPs NNP N
( ( N
systolic/diastolic JJ N
) ) N
were VBD N
reduced VBN N
by IN N
28/15 CD N
mmHg NNS N
with IN N
methyldopa NN N
and CC N
by IN N
23/15 CD N
mmHg NNS N
with IN N
labetalol NN N
. . N

3 CD N
Average JJ N
standing VBG N
BPs NNP N
( ( N
systolic/diastolic JJ N
) ) N
were VBD N
reduced VBN N
by IN N
29/14 CD N
mmHg NNS N
with IN N
methyldopa NN N
and CC N
by IN N
29/15 CD N
mmHg NNS N
with IN N
labetalol NN N
. . N

4 CD N
Both DT N
lying NN N
and CC N
standing VBG N
heart NN N
rates NNS N
were VBD N
reduced VBN N
with IN N
labetalol NN N
. . N

5 CD N
It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
antihypertensive JJ N
properties NNS N
of IN N
labetalol NN N
and CC N
methyldopa NN N
are VBP N
similar JJ N
but CC N
that IN N
larger JJR N
patient NN N
populations NNS N
are VBP N
needed VBN N
to TO N
study VB N
the DT N
relative JJ N
incidence NN N
of IN N
subjective JJ N
adverse JJ N
effects NNS N
. . N

-DOCSTART- -17717526- O O

Effects NNS N
of IN N
alfuzosin NN N
10 CD N
mg NN N
once RB N
daily RB N
on IN N
sexual JJ N
function NN N
in IN N
men NNS N
treated VBN N
for IN N
symptomatic JJ N
benign NN N
prostatic JJ N
hyperplasia NN N
. . N

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
extended-release JJ N
alfuzosin NN N
HCl NNP N
10 CD N
mg NN N
once RB N
daily JJ N
( ( N
q.d JJ N
. . N

) ) N
on IN N
sexual JJ N
function NN N
in IN N
men NNS N
with IN N
lower JJR N
urinary JJ N
tract NN N
symptoms NNS N
associated VBN N
with IN N
benign JJ N
prostatic JJ N
hyperplasia NN N
( ( N
BPH NNP N
) ) N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
men NNS N
aged VBN N
> NN N
or CC N
= $ N
50 CD N
years NNS N
, , N
after IN N
a DT N
28-day JJ N
placebo NN N
run-in JJ N
period NN N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
alfuzosin NN N
10 CD N
mg NN N
q.d NN N
. . N

or CC N
matching VBG N
placebo NN N
for IN N
28 CD N
days NNS N
. . N

The DT N
mean JJ N
change NN N
from IN N
baseline NN N
( ( N
day NN N
1 CD N
) ) N
in IN N
sexual JJ N
function NN N
on IN N
day NN N
29 CD N
was VBD N
assessed VBN N
using VBG N
the DT N
Danish JJ N
Prostate NNP N
Symptom NNP N
Score NNP N
Sex NNP N
( ( N
DAN-PSSsex NNP N
) ) N
questionnaire NN N
. . N

A DT N
total NN N
of IN N
372 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
alfuzosin NN N
( ( N
n=186 JJ N
) ) N
or CC N
placebo NN N
( ( N
n=186 JJ N
) ) N
, , N
with IN N
355 CD N
completing VBG N
the DT N
study NN N
. . N

At IN N
baseline NN N
, , N
64 CD N
% NN N
of IN N
the DT N
patients NNS N
reported VBD N
erectile JJ N
dysfunction NN N
( ( N
ED NNP N
) ) N
and CC N
63 CD N
% NN N
reported VBD N
ejaculatory JJ N
dysfunction NN N
( ( N
EjD NNP N
) ) N
. . N

For IN N
the DT N
320 CD N
patients NNS N
who WP N
completed VBD N
the DT N
DAN-PSSsex NNP N
, , N
alfuzosin NN N
treatment NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
erectile JJ N
function NN N
on IN N
day NN N
29 CD N
compared VBN N
with IN N
placebo NN N
( ( N
P=0.02 NNP N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
in IN N
the DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
ejaculatory JJ N
function NN N
on IN N
day NN N
29 CD N
. . N

For IN N
patients NNS N
with IN N
ED NNP N
at IN N
baseline NN N
, , N
a DT N
marginal JJ N
improvement NN N
in IN N
erectile JJ N
function NN N
was VBD N
demonstrated VBN N
with IN N
alfuzosin NN N
treatment NN N
( ( N
P=0.09 NNP N
vs NNP N
placebo NN N
) ) N
. . N

For IN N
patients NNS N
with IN N
EjD NNP N
at IN N
baseline NN N
, , N
the DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
ejaculatory JJ N
function NN N
with IN N
alfuzosin NN N
was VBD N
comparable JJ N
to TO N
that DT N
with IN N
placebo NN N
. . N

Dizziness NNP N
was VBD N
the DT N
most RBS N
common JJ N
adverse JJ N
event NN N
with IN N
alfuzosin NN N
treatment NN N
( ( N
5 CD N
vs RB N
0 CD N
% NN N
with IN N
placebo NN N
) ) N
, , N
with IN N
other JJ N
adverse JJ N
events NNS N
reported VBN N
with IN N
comparable JJ N
frequency NN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

After IN N
1 CD N
month NN N
of IN N
treatment NN N
, , N
alfuzosin RB N
10 CD N
mg NN N
q.d NN N
. . N

significantly RB N
improved VBN N
erectile JJ N
function NN N
in IN N
men NNS N
with IN N
lower JJR N
urinary JJ N
tract NN N
symptoms/ NN N
benign JJ N
prostatic JJ N
hypertrophy NN N
and CC N
had VBD N
no DT N
adverse JJ N
effect NN N
on IN N
ejaculatory NN N
function NN N
. . N

-DOCSTART- -7733424- O O

The DT N
costs NNS N
and CC N
effects NNS N
of IN N
a DT N
nutritional JJ N
education NN N
program NN N
following VBG N
work-site JJ N
cholesterol NN N
screening NN N
. . N

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
costs NNS N
and CC N
impact NN N
of IN N
a DT N
nutrition JJ N
education NN N
program NN N
following VBG N
a DT N
cholesterol NN N
screening NN N
. . N

METHODS NNP N
Forty NNP N
work-sites NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
educational JJ N
interventions NNS N
: : N
a DT N
usual JJ N
intervention NN N
of IN N
5 CD N
minutes NNS N
of IN N
counseling NN N
, , N
or CC N
a DT N
special JJ N
intervention NN N
of IN N
2 CD N
hours NNS N
of IN N
behaviorally RB N
based VBN N
education NN N
on IN N
dietary JJ N
changes NNS N
to TO N
lower VB N
serum NN N
cholesterol NN N
. . N

Costs NNS N
were VBD N
monitored VBN N
, , N
and CC N
cholesterol NN N
levels NNS N
were VBD N
retested VBN N
6 CD N
and CC N
12 CD N
months NNS N
later RB N
. . N

RESULTS VB N
The DT N
total JJ N
per-person JJ N
cost NN N
for IN N
screening VBG N
and CC N
the DT N
educational JJ N
intervention NN N
was VBD N
about IN N
$ $ N
50 CD N
. . N

Cholesterol NN N
levels NNS N
differed VBD N
little RB N
between IN N
the DT N
two CD N
intervention NN N
groups NNS N
6 CD N
months NNS N
after IN N
screening VBG N
, , N
but CC N
after IN N
12 CD N
months NNS N
those DT N
in IN N
the DT N
special JJ N
intervention NN N
worksites NNS N
showed VBD N
a DT N
6.5 CD N
% NN N
drop NN N
in IN N
cholesterol NN N
, , N
whereas IN N
those DT N
at IN N
the DT N
usual JJ N
intervention NN N
worksites NNS N
showed VBD N
a DT N
drop NN N
of IN N
only RB N
3.0 CD N
% NN N
. . N

Hence NNP N
a DT N
3.5 CD N
% NN N
cholesterol NN N
reduction NN N
was VBD N
attributable JJ N
to TO N
the DT N
special JJ N
intervention NN N
. . N

CONCLUSIONS VB N
A NNP N
behaviorally RB N
based VBN N
nutrition JJ N
education NN N
program NN N
following VBG N
cholesterol NN N
screening VBG N
can MD N
have VB N
a DT N
meaningful JJ N
impact NN N
on IN N
long-term JJ N
cholesterol NN N
levels NNS N
at IN N
a DT N
low JJ N
cost NN N
. . N

Nutrition NNP N
education NN N
in IN N
work-sites NNS N
may MD N
therefore RB N
be VB N
a DT N
useful JJ N
way NN N
to TO N
lower VB N
the DT N
risk NN N
of IN N
heart NN N
disease NN N
in IN N
communities NNS N
. . N

-DOCSTART- -8210831- O O

How WRB N
to TO N
establish VB N
equivalence NN N
when WRB N
data NNS N
are VBP N
censored VBN N
: : N
a DT N
randomized JJ N
trial NN N
of IN N
treatments NNS N
for IN N
B NNP N
non-Hodgkin JJ N
lymphoma NN N
. . N

Interest NN N
in IN N
equivalence NN N
trials NNS N
has VBZ N
been VBN N
increasing VBG N
for IN N
many JJ N
years NNS N
, , N
though IN N
the DT N
methodology NN N
which WDT N
has VBZ N
been VBN N
developed VBN N
for IN N
such JJ N
trials NNS N
is VBZ N
mainly RB N
for IN N
uncensored JJ N
data NNS N
. . N

In IN N
cancer NN N
research NN N
we PRP N
are VBP N
more RBR N
often RB N
concerned VBN N
with IN N
survival NN N
. . N

In IN N
an DT N
efficacy NN N
trial NN N
, , N
the DT N
null JJ N
hypothesis NN N
specifies NNS N
equality NN N
of IN N
the DT N
two CD N
survival JJ N
distributions NNS N
, , N
but CC N
in IN N
an DT N
equivalence NN N
trial NN N
, , N
a DT N
null JJ N
hypothesis NN N
of IN N
inequivalence NN N
H0 NNP N
has VBZ N
to TO N
be VB N
tested VBN N
. . N

The DT N
usual JJ N
logrank NN N
test NN N
has VBZ N
to TO N
be VB N
modified VBN N
to TO N
test VB N
whether IN N
the DT N
true JJ N
value NN N
r NN N
of IN N
the DT N
ratio NN N
of IN N
hazard NN N
rates NNS N
in IN N
two CD N
treatment NN N
groups NNS N
is VBZ N
at IN N
least JJS N
equal JJ N
to TO N
a DT N
limit NN N
value NN N
r0 NN N
. . N

If IN N
prognostic JJ N
factors NNS N
have VBP N
to TO N
be VB N
taken VBN N
into IN N
account NN N
, , N
the DT N
Cox NNP N
model NN N
provides VBZ N
tests NNS N
of IN N
Ho NNP N
, , N
and CC N
a DT N
useful JJ N
confidence NN N
interval NN N
for IN N
the DT N
adjusted JJ N
relative JJ N
derived VBN N
from IN N
the DT N
regression NN N
parameter NN N
for IN N
the DT N
treatment NN N
indicator NN N
. . N

An DT N
equivalence NN N
trial NN N
of IN N
maintenance NN N
therapy NN N
was VBD N
carried VBN N
out RP N
in IN N
children NNS N
with IN N
B NNP N
non-Hodgkin JJ N
lymphoma NN N
, , N
and CC N
serves VBZ N
as IN N
an DT N
illustration NN N
. . N

-DOCSTART- -8708224- O O

The DT N
effect NN N
of IN N
body NN N
positioning VBG N
upon IN N
maximal JJ N
oxygenation NN N
of IN N
patients NNS N
with IN N
unilateral JJ N
lung NN N
pathology NN N
. . N

A DT N
quasi-experimental JJ N
, , N
repeated-measures JJ N
cross-over NN N
design NN N
study NN N
on IN N
the DT N
effect NN N
of IN N
body NN N
position NN N
on IN N
oxygenation NN N
( ( N
SaO2 NNP N
) ) N
blood NN N
pressure NN N
, , N
respiration NN N
and CC N
pulse NN N
in IN N
patients NNS N
with IN N
unilateral JJ N
lung NN N
pathology NN N
was VBD N
conducted VBN N
. . N

Previous JJ N
research NN N
strongly RB N
suggests VBZ N
that IN N
positioning VBG N
with IN N
the DT N
healthy JJ N
( ( N
unaffected JJ N
) ) N
lung NN N
in IN N
the DT N
dependent JJ N
lateral NN N
( ( N
down RP N
) ) N
position NN N
is VBZ N
related VBN N
to TO N
improved VBN N
oxygenation NN N
, , N
but CC N
knowledge VBP N
about IN N
whether IN N
this DT N
effect NN N
is VBZ N
maintained VBN N
over IN N
time NN N
is VBZ N
lacking VBG N
. . N

The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
determine VB N
: : N
( ( N
1 CD N
) ) N
Is VBZ N
positioning VBG N
with IN N
the DT N
unaffected JJ N
lung NN N
in IN N
the DT N
dependent JJ N
lateral JJ N
position NN N
related VBN N
to TO N
increased VBN N
arterial JJ N
blood NN N
saturation NN N
levels NNS N
and CC N
decreased VBD N
blood NN N
pressure NN N
, , N
pulse NN N
and CC N
respiration NN N
? . N
( ( N
2 CD N
) ) N
What WP N
is VBZ N
the DT N
relationship NN N
between IN N
the DT N
dependent JJ N
variables NNS N
-- : N
oxygenation NN N
saturation NN N
levels NNS N
, , N
blood NN N
pressure NN N
, , N
pulse NN N
and CC N
respiration NN N
-- : N
and CC N
the DT N
independent JJ N
variables NNS N
-- : N
body NN N
position NN N
and CC N
time NN N
in IN N
the DT N
position NN N
? . N
Thirty-nine JJ N
patients NNS N
with IN N
unilateral JJ N
lung NN N
pathology NN N
were VBD N
positioned VBN N
on IN N
their PRP$ N
sides NNS N
with IN N
the DT N
unaffected JJ N
lung NN N
down RP N
, , N
on IN N
their PRP$ N
sides NNS N
with IN N
the DT N
affected JJ N
lung NN N
down RB N
, , N
and CC N
also RB N
in IN N
semi-Fowler NN N
's POS N
position NN N
. . N

Arterial NNP N
( ( N
SaO2 NNP N
) ) N
blood NN N
saturation NN N
and CC N
vital JJ N
signs NNS N
were VBD N
measured VBN N
at IN N
baseline NN N
0 CD N
, , N
15 CD N
and CC N
30 CD N
minutes NNS N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
relationship NN N
between IN N
oxygenation NN N
level NN N
or CC N
systolic JJ N
blood NN N
pressure NN N
. . N

Diastolic NNP N
blood NN N
pressure NN N
, , N
respiration NN N
and CC N
pulse NN N
did VBD N
vary JJ N
significantly RB N
with IN N
position NN N
. . N

-DOCSTART- -8519722- O O

0.1 CD N
% NN N
bupivacaine NN N
does VBZ N
not RB N
reduce VB N
the DT N
requirement NN N
for IN N
epidural JJ N
fentanyl NN N
infusion NN N
after IN N
major JJ N
abdominal JJ N
surgery NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Although IN N
local JJ N
anesthesia NN N
has VBZ N
been VBN N
demonstrated VBN N
to TO N
potentiate VB N
spinal JJ N
morphine NN N
analgesia NN N
in IN N
animal JJ N
studies NNS N
, , N
results NNS N
comparing VBG N
epidural JJ N
local JJ N
anesthesia/opioid NN N
mixtures NNS N
with IN N
opioid JJ N
alone NN N
are VBP N
contradictory JJ N
in IN N
clinical JJ N
studies NNS N
. . N

The DT N
hypothesis NN N
was VBD N
that IN N
, , N
although IN N
the DT N
concentration NN N
of IN N
bupivacaine NN N
( ( N
0.1 CD N
% NN N
) ) N
was VBD N
low JJ N
to TO N
minimize VB N
its PRP$ N
adverse JJ N
effects NNS N
, , N
if IN N
the DT N
infusion NN N
rate NN N
of IN N
a DT N
fentanyl/bupivacaine JJ N
solution NN N
was VBD N
closely RB N
adjusted VBN N
according VBG N
to TO N
need NN N
, , N
the DT N
presence NN N
bupivacaine NN N
would MD N
reduce VB N
the DT N
requirement NN N
for IN N
epidural JJ N
fentanyl NN N
. . N

METHODS NNP N
Forty NNP N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
fentanyl NN N
( ( N
10 CD N
micrograms/mL NN N
) ) N
or CC N
a DT N
fentanyl/bupivacaine NN N
( ( N
0.1 CD N
% NN N
) ) N
mixture NN N
epidurally RB N
corresponding VBG N
to TO N
the DT N
dermatome NN N
of IN N
the DT N
surgical JJ N
incision NN N
in IN N
a DT N
double-blind JJ N
fashion NN N
for IN N
the DT N
first JJ N
18 CD N
hours NNS N
after IN N
major JJ N
abdominal JJ N
surgery NN N
. . N

The DT N
infusion NN N
was VBD N
titrated VBN N
for IN N
each DT N
patient NN N
to TO N
the DT N
rate NN N
required VBN N
for IN N
pain NN N
relief NN N
during IN N
forced VBN N
inspiration NN N
( ( N
pain NN N
score NN N
< NN N
or CC N
= $ N
2 CD N
, , N
maximum JJ N
10 CD N
) ) N
. . N

Pain NN N
scores NNS N
, , N
the DT N
fentanyl JJ N
doses NNS N
required VBN N
, , N
plasma JJ N
concentrations NNS N
of IN N
fentanyl NN N
at IN N
18 CD N
hours NNS N
, , N
and CC N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ N
effects NNS N
were VBD N
recorded VBN N
. . N

RESULTS JJ N
Patients NNPS N
reported VBD N
similar JJ N
median JJ N
pain NN N
scores NNS N
and CC N
were VBD N
equally RB N
satisfied VBN N
with IN N
pain NN N
relief NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
mean NN N
required VBN N
post-operative JJ N
fentanyl JJ N
infusion NN N
rate NN N
( ( N
57.7 CD N
+/- JJ N
19.5 CD N
micrograms/h NN N
) ) N
and CC N
the DT N
plasma NN N
concentrations NNS N
( ( N
0.84 CD N
+/- JJ N
0.36 CD N
ng/mL NN N
) ) N
in IN N
the DT N
fentanyl NN N
group NN N
were VBD N
comparable JJ N
to TO N
the DT N
infusion NN N
rate NN N
( ( N
54.4 CD N
+/- JJ N
19.2 CD N
micrograms/h NN N
) ) N
and CC N
the DT N
plasma NN N
concentrations NNS N
( ( N
0.86 CD N
+/- JJ N
0.36 CD N
ng/mL NN N
) ) N
in IN N
the DT N
fentanyl/bupivacaine NN N
group NN N
. . N

Respiratory NNP N
and CC N
cardiovascular JJ N
functions NNS N
were VBD N
preserved VBN N
, , N
and CC N
the DT N
incidence NN N
of IN N
nausea NN N
, , N
pruritus NN N
, , N
and CC N
periods NNS N
of IN N
drowsiness NN N
or CC N
sleep NN N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
low JJ N
concentrations NNS N
( ( N
0.1 CD N
% NN N
) ) N
, , N
bupivacaine NN N
did VBD N
not RB N
reduce VB N
the DT N
titrated JJ N
dose NN N
of IN N
epidural JJ N
fentanyl NN N
required VBN N
for IN N
adequate JJ N
pain NN N
relief NN N
during IN N
forced VBN N
inspiration NN N
after IN N
major JJ N
abdominal JJ N
surgery NN N
. . N

The DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ N
effects NNS N
were VBD N
also RB N
comparable JJ N
whether IN N
or CC N
not RB N
low-dose JJ N
bupivacaine NN N
infusion NN N
was VBD N
used VBN N
. . N

-DOCSTART- -19660462- O O

Norfloxacin NNP N
modulates VBZ N
the DT N
inflammatory JJ N
response NN N
and CC N
directly RB N
affects VBZ N
neutrophils NNS N
in IN N
patients NNS N
with IN N
decompensated JJ N
cirrhosis NN N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
Patients NNPS N
with IN N
cirrhosis NN N
undergoing VBG N
selective JJ N
intestinal JJ N
decontamination NN N
with IN N
norfloxacin JJ N
show NN N
a DT N
reduction NN N
in IN N
serum JJ N
cytokine NN N
levels NNS N
, , N
probably RB N
because IN N
of IN N
a DT N
combined JJ N
effect NN N
of IN N
norfloxacin NN N
on IN N
bowel NN N
flora NNS N
and CC N
neutrophils NNS N
. . N

METHODS NNP N
Thirty-one CD N
patients NNS N
with IN N
cirrhosis NN N
receiving VBG N
norfloxacin NN N
( ( N
400 CD N
mg/day NN N
) ) N
were VBD N
included VBN N
. . N

Blood NNP N
samples NNS N
were VBD N
collected VBN N
at IN N
0.5-4 JJ N
hours NNS N
( ( N
peak JJ N
samples NNS N
group NN N
, , N
n RB N
= VBZ N
47 CD N
) ) N
and CC N
at IN N
22-24 JJ N
hours NNS N
( ( N
trough IN N
samples NNS N
group NN N
, , N
n RB N
= VBZ N
84 CD N
) ) N
after IN N
dose NN N
. . N

Fifty-nine JJ N
ascitic JJ N
fluid NN N
samples NNS N
were VBD N
obtained VBN N
. . N

Single NNP N
doses NNS N
of IN N
norfloxacin NN N
and CC N
trimethoprim/sulfamethoxazole NN N
were VBD N
administered VBN N
to TO N
13 CD N
and CC N
5 CD N
patients NNS N
, , N
respectively RB N
, , N
( ( N
temporal JJ N
profile NN N
group NN N
) ) N
and CC N
samples NNS N
were VBD N
collected VBN N
at IN N
0 CD N
, , N
0.5 CD N
, , N
1 CD N
, , N
1.5 CD N
, , N
2 CD N
, , N
4 CD N
, , N
and CC N
24 CD N
hours NNS N
. . N

Norfloxacin NNP N
, , N
trimethoprim/sulfamethoxazole NN N
, , N
cytokines NNS N
, , N
nitric JJ N
oxide NN N
, , N
expression NN N
levels NNS N
of IN N
nuclear JJ N
factor NN N
( ( N
NF NNP N
) ) N
-kappaB NN N
and CC N
inhibitor NN N
of IN N
NF-kappaB NNP N
( ( N
IkB-alpha NNP N
) ) N
, , N
neutrophil JJ N
oxidative JJ N
burst NN N
, , N
and CC N
rate NN N
of IN N
apoptotic JJ N
events NNS N
were VBD N
determined VBN N
. . N

RESULTS NNP N
All NNP N
samples NNS N
were VBD N
bacterial JJ N
DNA NNP N
negative NN N
and CC N
had VBD N
no DT N
significant JJ N
levels NNS N
of IN N
lipopolysaccharide NN N
. . N

Serum NNP N
and CC N
ascitic JJ N
levels NNS N
of IN N
tumor NN N
necrosis NN N
factor-alpha JJ N
, , N
interferon-gamma JJ N
, , N
interleukin-12 JJ N
, , N
and CC N
nitric JJ N
oxide NN N
were VBD N
significantly RB N
lower JJR N
in IN N
peak NN N
than IN N
in IN N
trough JJ N
samples NNS N
. . N

A DT N
correlation NN N
was VBD N
present JJ N
between IN N
serum NN N
norfloxacins NNS N
concentrations NNS N
and CC N
tumor NN N
necrosis NN N
factor-alpha NN N
( ( N
r JJ N
= NNP N
-0.68 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
interferon-gamma JJ N
( ( N
r JJ N
= NNP N
-0.66 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
interleukin-12 JJ N
( ( N
r JJ N
= NNP N
-0.66 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
nitric JJ N
oxide NN N
( ( N
r JJ N
= NNP N
-0.68 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Serum NNP N
norfloxacin NN N
's POS N
highest JJS N
concentrations NNS N
( ( N
1 CD N
+/- JJ N
0.5 CD N
microg/mL NN N
) ) N
were VBD N
achieved VBN N
at IN N
1-2 JJ N
hours NNS N
and CC N
concurred VBN N
in IN N
time NN N
with IN N
the DT N
lower JJR N
levels NNS N
of IN N
cytokines NNS N
and CC N
nitric JJ N
oxide NN N
. . N

Intracellular NNP N
norfloxacin NN N
's POS N
highest JJS N
levels NNS N
( ( N
2 CD N
+/- JJ N
1 CD N
microg/mL/10 NN N
( ( N
7 CD N
) ) N
cells NNS N
) ) N
were VBD N
observed VBN N
at IN N
2 CD N
hours NNS N
and CC N
concurred VBN N
with IN N
a DT N
lower JJR N
NF-kappaB JJ N
expression NN N
, , N
a DT N
reduced JJ N
anion NN N
superoxide NN N
generation NN N
, , N
and CC N
apoptotic JJ N
rate NN N
in IN N
response NN N
to TO N
phorbol VB N
myristate JJ N
acetate NN N
. . N

Trimethoprim/sulfamethoxazole NNP N
did VBD N
not RB N
significantly RB N
modulate VB N
cytokine JJ N
expression NN N
. . N

CONCLUSIONS NNP N
Norfloxacin NNP N
but CC N
not RB N
trimethoprim/sulfamethoxazole JJ N
modulates NNS N
inflammatory JJ N
response NN N
and CC N
directly RB N
affects VBZ N
neutrophils NNS N
in IN N
patients NNS N
with IN N
cirrhosis NN N
. . N

-DOCSTART- -20043831- O O

The DT N
effectiveness NN N
of IN N
physical JJ N
activity NN N
monitoring NN N
and CC N
distance NN N
counselling NN N
in IN N
an DT N
occupational JJ N
health NN N
setting NN N
-- : N
a DT N
research NN N
protocol NN N
for IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
( ( N
CoAct NNP N
) ) N
. . N

BACKGROUND IN N
The DT N
CoAct NNP N
( ( N
Cocreating NNP N
Activity NNP N
) ) N
study NN N
is VBZ N
investigating VBG N
a DT N
novel JJ N
lifestyle JJ N
intervention NN N
, , N
aimed VBN N
at IN N
the DT N
working VBG N
population NN N
, , N
with IN N
daily JJ N
activity NN N
monitoring NN N
and CC N
distance NN N
counselling NN N
via IN N
telephone NN N
and CC N
secure NN N
web NN N
messages NNS N
. . N

The DT N
main JJ N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
lifestyle JJ N
counselling VBG N
on IN N
the DT N
level NN N
of IN N
physical JJ N
activity NN N
in IN N
an DT N
occupational JJ N
health NN N
setting NN N
. . N

The DT N
purposes NNS N
include VBP N
also RB N
analysing VBG N
the DT N
potential JJ N
effects NNS N
of IN N
changes NNS N
in IN N
physical JJ N
activity NN N
on IN N
productivity NN N
at IN N
work NN N
and CC N
sickness JJ N
absence NN N
, , N
and CC N
healthcare NN N
costs NNS N
. . N

This DT N
article NN N
describes VBZ N
the DT N
design NN N
of IN N
the DT N
study NN N
and CC N
the DT N
participant NN N
flow NN N
until IN N
and CC N
including VBG N
randomization NN N
. . N

METHODS/DESIGN NNP N
CoAct NNP N
is VBZ N
a DT N
randomised JJ N
controlled VBN N
trial NN N
with IN N
two CD N
arms NNS N
: : N
a DT N
control NN N
group NN N
and CC N
intervention NN N
group NN N
with IN N
daily JJ N
activity NN N
monitoring NN N
and CC N
distance NN N
counselling NN N
. . N

The DT N
intervention NN N
focuses VBZ N
on IN N
lifestyle JJ N
modification NN N
and CC N
takes VBZ N
12 CD N
months NNS N
. . N

The DT N
study NN N
population NN N
consists VBZ N
of IN N
volunteers NNS N
from IN N
1100 CD N
eligible JJ N
employees NNS N
of IN N
a DT N
Finnish JJ N
insurance NN N
company NN N
. . N

The DT N
primary JJ N
outcomes NNS N
of IN N
this DT N
study NN N
are VBP N
change NN N
in IN N
physical JJ N
activity NN N
measured VBN N
in IN N
MET NNP N
minutes NNS N
per IN N
week NN N
, , N
work NN N
productivity NN N
and CC N
sickness NN N
absence NN N
, , N
and CC N
healthcare JJ N
utilisation NN N
. . N

Secondary JJ N
outcomes NNS N
include VBP N
various JJ N
physiological JJ N
measures NNS N
. . N

Cost-effectiveness JJ N
analysis NN N
will MD N
also RB N
be VB N
performed VBN N
. . N

The DT N
outcomes NNS N
will MD N
be VB N
measured VBN N
by IN N
questionnaires NNS N
at IN N
baseline NN N
, , N
after IN N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
months NNS N
, , N
and CC N
sickness JJ N
absence NN N
will MD N
be VB N
obtained VBN N
from IN N
the DT N
employer NN N
's POS N
registers NNS N
. . N

DISCUSSION NNP N
No NNP N
trials NNS N
are VBP N
yet RB N
available JJ N
that WDT N
have VBP N
evaluated VBN N
the DT N
effectiveness NN N
of IN N
daily JJ N
physical JJ N
activity NN N
monitoring NN N
and CC N
distance NN N
counselling NN N
in IN N
an DT N
occupational JJ N
health NN N
setting NN N
over IN N
a DT N
12 CD N
month NN N
period NN N
and CC N
no DT N
data NN N
on IN N
cost-effectiveness NN N
of IN N
such JJ N
intervention NN N
are VBP N
available JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00994565 NNP N
. . N

-DOCSTART- -23931247- O O

Ilioinguinal-iliohypogastric JJ N
nerve NN N
block NN N
within IN N
travenous JJ N
dexketoprofen NN N
improves VBZ N
postoperative JJ N
analgesia NN N
in IN N
abdominal JJ N
hysterectomies NNS N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
In IN N
this DT N
study NN N
, , N
our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
intravenous JJ N
dexketoprofen NNS N
trometamol VBP N
with IN N
ilioinguinal JJ N
and CC N
iliohypogastric JJ N
nerve NN N
block NN N
on IN N
analgesic JJ N
quality NN N
and CC N
morphine NN N
consumption NN N
after IN N
total JJ N
abdominal JJ N
hysterectomy NN N
operations NNS N
. . N

METHODS NNP N
We PRP N
conducted VBD N
this DT N
randomized VBN N
controlled VBD N
clinical JJ N
study NN N
on IN N
61 CD N
patients NNS N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
in IN N
the DT N
operation NN N
room NN N
, , N
post-anesthesia JJ N
care NN N
unit NN N
, , N
and CC N
inpatient JJ N
clinic NN N
. . N

We PRP N
randomly RB N
grouped VBD N
the DT N
61 CD N
patients NNS N
into IN N
control NN N
group NN N
( ( N
group NN N
C NNP N
) ) N
, , N
block NN N
group NN N
( ( N
group NN N
B NNP N
) ) N
and CC N
dexketoprofen-block JJ N
group NN N
( ( N
group NN N
DB NNP N
) ) N
. . N

Before IN N
the DT N
skin NN N
incision NN N
performed VBD N
after IN N
anesthesia JJ N
induction NN N
, , N
we PRP N
performed VBD N
ilioinguinal JJ N
iliohypogastric JJ N
block NN N
( ( N
group NN N
C NNP N
given VBN N
saline NN N
and CC N
group NN N
P NNP N
and CC N
DB NNP N
given VBN N
levobupivacaine NN N
) ) N
. . N

In IN N
contrast NN N
to TO N
group NN N
C NNP N
and CC N
B NNP N
, , N
group NN N
DB NNP N
was VBD N
given VBN N
dexketoprofen RB N
. . N

We PRP N
administered VBD N
morphine JJ N
analgesia NN N
to TO N
all DT N
patients NNS N
by IN N
patient-controlled JJ N
analgesia NN N
( ( N
PCA NNP N
) ) N
during IN N
the DT N
postoperative JJ N
24 CD N
hours NNS N
. . N

We PRP N
recorded VBD N
Visual NNP N
Analogue NNP N
Scale NNP N
( ( N
VAS NNP N
) ) N
, , N
satisfaction NN N
scores NNS N
, , N
morphine NN N
consumption NN N
and CC N
side NN N
effects NNS N
during IN N
postoperative JJ N
24 CD N
hours NNS N
. . N

RESULTS NNP N
We PRP N
found VBD N
the DT N
DB NNP N
group?s NN N
VAS NNP N
scores VBZ N
to TO N
be VB N
lower JJR N
than IN N
the DT N
control NN N
group NN N
and CC N
block NN N
group?s NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
values NNS N
at IN N
postoperative JJ N
1st CD N
, , N
2nd CD N
, , N
6th CD N
and CC N
12th CD N
hours NNS N
. . N

VAS NNP N
scores NNS N
of IN N
group NN N
C NNP N
were VBD N
higher JJR N
than IN N
of IN N
group NN N
B NNP N
at IN N
postoperative JJ N
fi NN N
rst VBD N
2 CD N
hours NNS N
. . N

Time NNP N
to TO N
fi VB N
rst JJ N
PCA NNP N
demand NN N
was VBD N
longer RBR N
, , N
morphine JJ N
consumption NN N
values NNS N
were VBD N
lower JJR N
and CC N
satisfaction NN N
scores NNS N
were VBD N
higher JJR N
in IN N
group NN N
DB NNP N
than IN N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Ilioinguinal-iliohypogastric JJ N
nerve NN N
block NN N
with IN N
IV NNP N
dexketoprofen NN N
increases NNS N
patient JJ N
satisfaction NN N
by IN N
decreasing VBG N
opioid JJ N
consumption NN N
, , N
increasing VBG N
patient JJ N
satisfaction NN N
, , N
which WDT N
suggests VBZ N
that IN N
dexketoprofen NN N
trometamol NN N
is VBZ N
an DT N
effective JJ N
non-steroidal JJ N
anti-inflammatory JJ N
analgesic NN N
in IN N
postoperative JJ N
analgesia NN N
. . N

-DOCSTART- -23001240- O O

Iron NNP N
in IN N
relation NN N
to TO N
gastric JJ N
cancer NN N
in IN N
the DT N
Alpha-tocopherol NNP N
, , N
Beta-carotene NNP N
Cancer NNP N
Prevention NNP N
Study NNP N
. . N

BACKGROUND NNP N
Iron NNP N
is VBZ N
an DT N
essential JJ N
micronutrient NN N
that WDT N
can MD N
have VB N
carcinogenic JJ N
effects NNS N
when WRB N
at IN N
high JJ N
or CC N
low JJ N
concentrations NNS N
. . N

Previous JJ N
studies NNS N
of IN N
iron NN N
in IN N
relation NN N
to TO N
gastric JJ N
cancer NN N
have VBP N
not RB N
assessed VBN N
subtype-specific JJ N
relationships NNS N
. . N

We PRP N
used VBD N
the DT N
prospective JJ N
Alpha-Tocopherol NNP N
, , N
Beta-Carotene NNP N
( ( N
ATBC NNP N
) ) N
Cancer NNP N
Prevention NNP N
Study NNP N
to TO N
assess VB N
whether IN N
iron NN N
metrics NNS N
were VBD N
associated VBN N
with IN N
gastric JJ N
cardia NN N
cancer NN N
( ( N
GCC NNP N
) ) N
and CC N
gastric JJ N
noncardia NN N
cancer NN N
( ( N
GNCC NNP N
) ) N
. . N

METHODS NNP N
We PRP N
selected VBD N
341 CD N
incident JJ N
gastric JJ N
cancer NN N
cases NNS N
( ( N
86 CD N
cardia NN N
, , N
172 CD N
noncardia NN N
, , N
and CC N
83 CD N
nonspecified VBN N
) ) N
, , N
accrued VBN N
during IN N
22 CD N
years NNS N
of IN N
follow-up NN N
, , N
and CC N
341 CD N
individually RB N
matched VBN N
controls NNS N
. . N

We PRP N
measured VBD N
prediagnostic JJ N
serum NN N
iron NN N
, , N
ferritin NN N
, , N
unsaturated JJ N
iron NN N
binding NN N
capacity NN N
, , N
and CC N
C-reactive JJ N
protein NN N
. . N

Total JJ N
iron-binding JJ N
capacity NN N
( ( N
TIBC NNP N
) ) N
and CC N
transferrin JJ N
saturation NN N
were VBD N
estimated VBN N
from IN N
these DT N
metrics NNS N
. . N

Dietary NNP N
iron NN N
exposures NNS N
were VBD N
estimated VBN N
from IN N
a DT N
food NN N
frequency NN N
questionnaire NN N
. . N

Multivariable JJ N
logistic JJ N
regression NN N
was VBD N
used VBN N
for IN N
analysis NN N
. . N

RESULTS NNP N
Serum NNP N
iron NN N
metrics NNS N
were VBD N
not RB N
associated VBN N
with IN N
GCC NNP N
, , N
except IN N
for IN N
a DT N
potential JJ N
n NN N
-shaped VBD N
relationship NN N
with IN N
TIBC NNP N
( ( N
global JJ N
P NNP N
= NNP N
0.038 CD N
) ) N
. . N

GNCC NNP N
was VBD N
inversely RB N
associated VBN N
with IN N
serum NN N
ferritin NN N
( ( N
global JJ N
P NNP N
= NNP N
0.024 CD N
) ) N
, , N
serum JJ N
iron NN N
( ( N
global JJ N
P NNP N
= NNP N
0.060 CD N
) ) N
and CC N
, , N
possibly RB N
, , N
transferrin JJ N
saturation NN N
. . N

TIBC NNP N
appeared VBD N
to TO N
share NN N
a DT N
u NN N
-shaped VBD N
relationship NN N
with IN N
GNCC NNP N
( ( N
global JJ N
P NNP N
= NNP N
0.033 CD N
) ) N
. . N

Dietary NNP N
iron NN N
exposures NNS N
were VBD N
not RB N
associated VBN N
with IN N
either DT N
subsite NN N
. . N

Adjustment NN N
for IN N
Helicobacter NNP N
pylori NN N
and CC N
gastric JJ N
atrophy NN N
had VBD N
little JJ N
effect NN N
on IN N
observed JJ N
associations NNS N
. . N

CONCLUSIONS NNP N
We PRP N
found VBD N
little JJ N
evidence NN N
for IN N
the DT N
involvement NN N
of IN N
iron NN N
exposure NN N
in IN N
the DT N
pathogenesis NN N
of IN N
GCC NNP N
. . N

GNCC NNP N
was VBD N
associated VBN N
with IN N
an DT N
iron NN N
profile NN N
similar JJ N
to TO N
that DT N
of IN N
iron NN N
deficiency NN N
. . N

IMPACT NNP N
Our PRP$ N
findings NNS N
indicate VBP N
that IN N
inverse JJ N
associations NNS N
between IN N
iron NN N
metrics NNS N
and CC N
gastric JJ N
cancer NN N
are VBP N
driven VBN N
by IN N
associations NNS N
with IN N
GNCC NNP N
. . N

Further NNP N
elucidation NN N
of IN N
potential JJ N
mechanisms NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -14745744- O O

Psychoeducational NNP N
group NN N
intervention NN N
for IN N
wives NNS N
of IN N
men NNS N
with IN N
prostate NN N
cancer NN N
. . N

OBJECTIVE CC N
The DT N
effects NNS N
of IN N
a DT N
6-week JJ N
psychoeducational JJ N
group NN N
intervention NN N
on IN N
the DT N
distress NN N
, , N
coping NN N
, , N
personal JJ N
growth NN N
, , N
and CC N
marital JJ N
communication NN N
of IN N
wives NNS N
of IN N
men NNS N
diagnosed VBN N
with IN N
prostate JJ N
cancer NN N
were VBD N
evaluated VBN N
using VBG N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

METHODS NNP N
Sixty NNP N
wives NNS N
completed VBD N
measures NNS N
prior RB N
to TO N
random VB N
assignment NN N
to TO N
either VB N
the DT N
psychoeducational JJ N
group NN N
intervention NN N
or CC N
a DT N
no-treatment JJ N
control NN N
group NN N
, , N
and CC N
1 CD N
month NN N
after IN N
completion NN N
of IN N
the DT N
group NN N
. . N

RESULTS NNP N
No NNP N
differences NNS N
with IN N
regard NN N
to TO N
wives NNS N
' POS N
general JJ N
distress NN N
or CC N
cancer-specific JJ N
distress NN N
were VBD N
noted VBN N
. . N

In IN N
comparison NN N
with IN N
the DT N
control NN N
group NN N
, , N
participants NNS N
receiving VBG N
the DT N
intervention NN N
perceived VBD N
that IN N
having VBG N
a DT N
spouse NN N
with IN N
prostate NN N
cancer NN N
had VBD N
made VBN N
positive JJ N
contributions NNS N
to TO N
their PRP$ N
lives NNS N
, , N
reported VBD N
gains NNS N
in IN N
the DT N
use NN N
of IN N
positive JJ N
reappraisal NN N
coping VBG N
and CC N
reductions NNS N
in IN N
denial JJ N
coping NN N
. . N

CONCLUSION NNP N
Although IN N
the DT N
psychoeducational JJ N
intervention NN N
did VBD N
not RB N
result VB N
in IN N
changes NNS N
in IN N
psychological JJ N
distress NN N
, , N
improvements NNS N
in IN N
adaptive JJ N
coping NN N
and CC N
indicators NNS N
of IN N
psychological JJ N
growth NN N
were VBD N
found VBN N
. . N

The DT N
utility NN N
of IN N
group NN N
interventions NNS N
for IN N
spouses NNS N
of IN N
men NNS N
with IN N
prostate NN N
cancer NN N
is VBZ N
discussed VBN N
. . N

-DOCSTART- -22067237- O O

Effect NN N
of IN N
motivational JJ N
music NN N
on IN N
lactate NN N
levels NNS N
during IN N
recovery NN N
from IN N
intense JJ N
exercise NN N
. . N

The DT N
effects NNS N
of IN N
music NN N
played VBN N
during IN N
an DT N
exercise NN N
task NN N
on IN N
athletic JJ N
performance NN N
have VBP N
been VBN N
previously RB N
studied VBN N
. . N

Yet CC N
, , N
these DT N
results NNS N
are VBP N
not RB N
applicable JJ N
for IN N
competitive JJ N
athletes NNS N
, , N
who WP N
can MD N
use VB N
music NN N
only RB N
during IN N
warm-up NN N
or CC N
recovery NN N
from IN N
exercise NN N
. . N

Therefore RB N
, , N
the DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
motivational JJ N
music NN N
( ( N
music NN N
that WDT N
stimulates VBZ N
or CC N
inspires VBZ N
physical JJ N
activity NN N
) ) N
during IN N
recovery NN N
from IN N
intense JJ N
exercise NN N
, , N
on IN N
activity NN N
pattern NN N
, , N
rate NN N
of IN N
perceived VBN N
exertion NN N
( ( N
RPE NNP N
) ) N
, , N
and CC N
blood NN N
lactate NN N
concentration NN N
. . N

Twenty NNP N
young JJ N
, , N
active JJ N
men NNS N
( ( N
mean JJ N
age NN N
26.2 CD N
? . N
2.1 CD N
years NNS N
) ) N
performed VBD N
a DT N
6-minute JJ N
run NN N
at IN N
peak NN N
oxygen NN N
consumption NN N
speed NN N
( ( N
predetermined VBN N
from IN N
the DT N
VO NNP N
( ( N
2 CD N
) ) N
max FW N
test NN N
) ) N
. . N

The DT N
mean JJ N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
, , N
RPE NNP N
, , N
number NN N
of IN N
steps NNS N
( ( N
determined VBN N
by IN N
step NN N
counter NN N
) ) N
, , N
and CC N
blood NN N
lactate NN N
concentrations NNS N
were VBD N
determined VBN N
at IN N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
12 CD N
, , N
and CC N
15 CD N
minutes NNS N
during IN N
the DT N
recovery NN N
from IN N
the DT N
exercise NN N
, , N
with IN N
and CC N
without IN N
motivational JJ N
music NN N
( ( N
2 CD N
separate JJ N
sessions NNS N
, , N
at IN N
random JJ N
order NN N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
mean JJ N
HR NNP N
during IN N
the DT N
recovery NN N
with IN N
and CC N
without IN N
music NN N
. . N

Listening VBG N
to TO N
motivational JJ N
music NN N
during IN N
the DT N
recovery NN N
was VBD N
associated VBN N
with IN N
increased JJ N
voluntary JJ N
activity NN N
of IN N
the DT N
participants NNS N
, , N
determined VBN N
by IN N
increased JJ N
number NN N
of IN N
steps NNS N
( ( N
499.4 CD N
? . N
220.1 CD N
vs. IN N
413.2 CD N
? . N
150.6 CD N
steps NNS N
, , N
with IN N
and CC N
without IN N
music NN N
, , N
respectively RB N
; : N
p VB N
? . N
0.05 CD N
) ) N
. . N

The DT N
increased JJ N
number NN N
of IN N
steps NNS N
during IN N
the DT N
recovery NN N
was VBD N
accompanied VBN N
by IN N
a DT N
significantly RB N
greater JJR N
decrease NN N
in IN N
blood NN N
lactate NN N
concentration NN N
percentage NN N
( ( N
28.1 CD N
? . N
12.2 CD N
vs. IN N
22.8 CD N
? . N
10.9 CD N
% NN N
, , N
with IN N
and CC N
without IN N
music NN N
, , N
respectively RB N
, , N
p VB N
? . N
0.05 CD N
) ) N
. . N

This DT N
was VBD N
associated VBN N
with IN N
a DT N
greater JJR N
decrease NN N
in IN N
RPE NNP N
( ( N
77.7 CD N
? . N
14.4 CD N
vs. IN N
73.1 CD N
? . N
14.7 CD N
% NN N
with IN N
and CC N
without IN N
music NN N
, , N
respectively RB N
; : N
p VB N
? . N
0.05 CD N
) ) N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
listening VBG N
to TO N
motivational JJ N
music NN N
during IN N
nonstructured JJ N
recovery NN N
from IN N
intense JJ N
exercise NN N
leads VBZ N
to TO N
increased VBN N
activity NN N
, , N
faster JJR N
lactate JJ N
clearance NN N
, , N
and CC N
reduced VBD N
RPE NNP N
and CC N
therefore RB N
may MD N
be VB N
used VBN N
by IN N
athletes NNS N
in IN N
their PRP$ N
effort NN N
to TO N
enhance VB N
recovery NN N
. . N

-DOCSTART- -19324944- O O

Acute JJ N
effects NNS N
of IN N
decaffeinated JJ N
coffee NN N
and CC N
the DT N
major JJ N
coffee NN N
components NNS N
chlorogenic JJ N
acid NN N
and CC N
trigonelline NN N
on IN N
glucose JJ N
tolerance NN N
. . N

OBJECTIVE NNP N
Coffee NNP N
consumption NN N
has VBZ N
been VBN N
associated VBN N
with IN N
lower JJR N
risk NN N
of IN N
type NN N
2 CD N
diabetes NNS N
. . N

We PRP N
evaluated VBD N
the DT N
acute JJ N
effects NNS N
of IN N
decaffeinated JJ N
coffee NN N
and CC N
the DT N
major JJ N
coffee NN N
components NNS N
chlorogenic JJ N
acid NN N
and CC N
trigonelline NN N
on IN N
glucose JJ N
tolerance NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
crossover NN N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
12 CD N
g NN N
decaffeinated VBD N
coffee NN N
, , N
1 CD N
g NN N
chlorogenic JJ N
acid NN N
, , N
500 CD N
mg NN N
trigonelline NN N
, , N
and CC N
placebo NN N
( ( N
1 CD N
g NN N
mannitol NN N
) ) N
on IN N
glucose NN N
and CC N
insulin NN N
concentrations NNS N
during IN N
a DT N
2-h JJ N
oral JJ N
glucose NN N
tolerance NN N
test NN N
( ( N
OGTT NNP N
) ) N
in IN N
15 CD N
overweight JJ N
men NNS N
. . N

RESULTS NNP N
Chlorogenic NNP N
acid NN N
and CC N
trigonelline NN N
ingestion NN N
significantly RB N
reduced VBN N
glucose NN N
( ( N
-0.7 JJ N
mmol/l NN N
, , N
P NNP N
= NNP N
0.007 CD N
, , N
and CC N
-0.5 NNP N
mmol/l NN N
, , N
P NNP N
= NNP N
0.024 CD N
, , N
respectively RB N
) ) N
and CC N
insulin NN N
( ( N
-73 JJ N
pmol/l NN N
, , N
P NNP N
= NNP N
0.038 CD N
, , N
and CC N
-117 NNP N
pmol/l NN N
, , N
P NNP N
= NNP N
0.007 CD N
) ) N
concentrations NNS N
15 CD N
min NN N
following VBG N
an DT N
OGTT NNP N
compared VBN N
with IN N
placebo NN N
. . N

None NN N
of IN N
the DT N
treatments NNS N
affected VBD N
insulin NN N
or CC N
glucose JJ N
area NN N
under IN N
the DT N
curve NN N
values NNS N
during IN N
the DT N
OGTT NNP N
compared VBN N
with IN N
placebo NN N
. . N

CONCLUSIONS NNP N
Chlorogenic NNP N
acid NN N
and CC N
trigonelline NN N
reduced VBD N
early JJ N
glucose NN N
and CC N
insulin NN N
responses NNS N
during IN N
an DT N
OGTT NNP N
. . N

-DOCSTART- -16382035- O O

Albendazole JJ N
trial NN N
at IN N
15 CD N
or CC N
30 CD N
mg/kg/day NN N
for IN N
subarachnoid NN N
and CC N
intraventricular JJ N
cysticercosis NN N
. . N

Thirty-six JJ N
patients NNS N
with IN N
subarachnoid JJ N
and CC N
intraventricular JJ N
cysticercosis NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
albendazole NN N
at IN N
15 CD N
or CC N
30 CD N
mg/kg/day JJ N
plus CC N
dexamethasone NN N
for IN N
8 CD N
days NNS N
. . N

Results NNS N
favored VBD N
a DT N
higher JJR N
dose NN N
, , N
with IN N
larger JJR N
cyst NN N
reduction NN N
on IN N
MRI NNP N
at IN N
90 CD N
and CC N
180 CD N
days NNS N
and CC N
higher JJR N
albendazole JJ N
sulfoxide NN N
levels NNS N
in IN N
plasma NN N
. . N

An DT N
albendazole JJ N
course NN N
at IN N
30 CD N
mg/kg/day NN N
combined VBN N
with IN N
corticosteroids NNS N
is VBZ N
safe JJ N
and CC N
more RBR N
effective JJ N
than IN N
the DT N
usual JJ N
dose NN N
. . N

A DT N
single JJ N
treatment NN N
was VBD N
insufficient JJ N
in IN N
intraventricular JJ N
and CC N
giant JJ N
cysts NNS N
. . N

-DOCSTART- -22219012- O O

Pre-bent JJ N
instruments NNS N
used VBN N
in IN N
single-port JJ N
laparoscopic NN N
surgery NN N
versus IN N
conventional JJ N
laparoscopic NN N
surgery NN N
: : N
comparative JJ N
study NN N
of IN N
performance NN N
in IN N
a DT N
dry JJ N
lab NN N
. . N

BACKGROUND NNP N
Different NNP N
types NNS N
of IN N
single-incision NN N
laparoscopic NN N
surgery NN N
( ( N
SILS NNP N
) ) N
have VBP N
become VBN N
increasingly RB N
popular JJ N
. . N

Although IN N
SILS NNP N
is VBZ N
technically RB N
even RB N
more RBR N
challenging JJ N
than IN N
conventional JJ N
laparoscopy NN N
, , N
published VBN N
data NNS N
of IN N
first JJ N
clinical JJ N
series NN N
seem VBP N
to TO N
demonstrate VB N
the DT N
feasibility NN N
of IN N
these DT N
approaches NNS N
. . N

Various JJ N
attempts NNS N
have VBP N
been VBN N
made VBN N
to TO N
overcome VB N
restrictions NNS N
due JJ N
to TO N
loss NN N
of IN N
triangulation NN N
in IN N
SILS NNP N
by IN N
specially RB N
designed VBN N
SILS-specific JJ N
instruments NNS N
. . N

This DT N
study NN N
involving VBG N
novices NNS N
in IN N
a DT N
dry JJ N
lab NN N
compared VBN N
task NN N
performances NNS N
between IN N
conventional JJ N
laparoscopic NN N
surgery NN N
( ( N
CLS NNP N
) ) N
and CC N
single-port JJ N
laparoscopic NN N
surgery NN N
( ( N
SPLS NNP N
) ) N
using VBG N
newly RB N
designed VBN N
pre-bent JJ N
instruments NNS N
. . N

METHODS NNP N
In IN N
this DT N
study NN N
, , N
90 CD N
medical JJ N
students NNS N
without IN N
previous JJ N
experience NN N
in IN N
laparoscopic NN N
techniques NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
one CD N
of IN N
three CD N
procedures NNS N
: : N
CLS NNP N
, , N
SPLS NNP N
using VBG N
two CD N
pre-bent JJ N
instruments NNS N
( ( N
SPLS-pp NNP N
) ) N
, , N
or CC N
SPLS NNP N
using VBG N
one CD N
pre-bent NN N
and CC N
one CD N
straight NN N
laparoscopic NN N
instrument NN N
( ( N
SPLS-ps NNP N
) ) N
. . N

In IN N
the DT N
dry JJ N
lab NN N
, , N
the DT N
participants NNS N
performed VBD N
four CD N
typical JJ N
laparoscopic NN N
tasks NNS N
of IN N
increasing VBG N
difficulty NN N
. . N

Evaluation NNP N
included VBD N
performance NN N
times NNS N
or CC N
number NN N
of IN N
completed VBN N
tasks NNS N
within IN N
a DT N
given VBN N
time NN N
frame NN N
. . N

All DT N
performances NNS N
were VBD N
videotaped VBN N
and CC N
evaluated VBN N
for IN N
unsuccessful JJ N
attempts NNS N
and CC N
unwanted JJ N
interactions NNS N
of IN N
instruments NNS N
. . N

Using VBG N
subjective JJ N
questionnaires NNS N
, , N
the DT N
participants NNS N
rated VBN N
difficulties NNS N
with IN N
two-dimensional JJ N
vision NN N
and CC N
coordination NN N
of IN N
instruments NNS N
. . N

RESULTS NNP N
Task NNP N
performances NNS N
were VBD N
significantly RB N
better RBR N
in IN N
the DT N
CLS NNP N
group NN N
than IN N
in IN N
either DT N
SPLS NNP N
group NN N
. . N

The DT N
SPLS-ps NNP N
group NN N
showed VBD N
a DT N
tendency NN N
toward IN N
better JJR N
performances NNS N
than IN N
the DT N
SPLS-pp NNP N
group NN N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

Video NNP N
sequences NNS N
and CC N
participants` NN N
questionnaires NNS N
showed VBD N
instrument JJ N
interaction NN N
as IN N
the DT N
major JJ N
problem NN N
in IN N
the DT N
single-incision NN N
surgery NN N
groups NNS N
. . N

CONCLUSIONS NNP N
Although IN N
SILS NNP N
is VBZ N
feasible JJ N
, , N
as IN N
shown VBN N
in IN N
clinical JJ N
series NN N
published VBN N
by IN N
laparoscopically RB N
experienced JJ N
experts NNS N
, , N
SILS NNP N
techniques NNS N
are VBP N
demanding VBG N
due JJ N
to TO N
restrictions NNS N
that IN N
come VBP N
with IN N
the DT N
loss NN N
of IN N
triangulation NN N
. . N

These DT N
can MD N
be VB N
compensated VBN N
only RB N
partially RB N
by IN N
currently RB N
available JJ N
SILS-designed JJ N
instruments NNS N
. . N

The DT N
future NN N
of IN N
SILS NNP N
depends VBZ N
on IN N
further JJ N
improvements NNS N
in IN N
the DT N
available JJ N
equipment NN N
or CC N
the DT N
development NN N
of IN N
new JJ N
approaches NNS N
such JJ N
as IN N
needlescopically RB N
assisted VBN N
or CC N
robotically RB N
assisted JJ N
procedures NNS N
. . N

-DOCSTART- -15162076- O O

A DT N
description NN N
of IN N
the DT N
clinical JJ N
characteristics NNS N
at IN N
baseline NN N
of IN N
patients NNS N
recruited VBN N
into IN N
the DT N
Carvedilol NNP N
or CC N
Metoprolol NNP N
European JJ N
Trial NNP N
( ( N
COMET NNP N
) ) N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
The DT N
COMET NNP N
trial NN N
was VBD N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomised JJ N
trial NN N
comparing VBG N
carvedilol NN N
, , N
a DT N
comprehensive JJ N
adrenergic NN N
receptor NN N
antagonist NN N
, , N
with IN N
metoprolol NN N
, , N
a DT N
beta-1-selective JJ N
agent NN N
in IN N
patients NNS N
with IN N
heart NN N
failure NN N
and CC N
left VBD N
ventricular JJ N
systolic JJ N
dysfunction NN N
. . N

The DT N
trial NN N
showed VBD N
a DT N
reduction NN N
in IN N
mortality NN N
with IN N
carvedilol NN N
that WDT N
was VBD N
consistent JJ N
across IN N
subgroups NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
report NN N
is VBZ N
to TO N
describe VB N
in IN N
greater JJR N
detail NN N
the DT N
heterogeneity NN N
of IN N
this DT N
population NN N
at IN N
baseline NN N
with IN N
particular JJ N
reference NN N
to TO N
the DT N
impact NN N
of IN N
symptomatic JJ N
severity NN N
, , N
age NN N
and CC N
gender NN N
on IN N
patient JJ N
characteristics NNS N
. . N

METHODS NNP N
A NNP N
descriptive JJ N
report NN N
using VBG N
data NNS N
entered VBN N
in IN N
the DT N
COMET NNP N
study NN N
data-base NN N
. . N

RESULTS VB N
The DT N
characteristics NNS N
of IN N
the DT N
population NN N
studied VBN N
were VBD N
similar JJ N
to TO N
those DT N
reported VBN N
in IN N
previous JJ N
trials NNS N
of IN N
beta-blockers NNS N
. . N

Almost NNP N
all DT N
patients NNS N
were VBD N
receiving VBG N
diuretics NNS N
and CC N
ACE NNP N
inhibitors NNS N
with IN N
few JJ N
patients NNS N
taking VBG N
angiotensin JJ N
receptor NN N
blockers NNS N
. . N

As IN N
expected VBN N
, , N
older JJR N
patients NNS N
had VBD N
more RBR N
co-morbidity JJ N
. . N

Older JJR N
patients NNS N
and CC N
women NNS N
reported VBD N
worse JJR N
symptoms NNS N
and CC N
poorer JJR N
well-being JJ N
despite IN N
similar JJ N
ventricular JJ N
dimensions NNS N
and CC N
systolic JJ N
dysfunction NN N
. . N

NT-proBNP NNP N
was VBD N
higher RBR N
in IN N
patients NNS N
with IN N
more RBR N
severe JJ N
symptoms NNS N
and CC N
older JJR N
patients NNS N
but CC N
not RB N
in IN N
women NNS N
, , N
although IN N
differences NNS N
in IN N
NT-proBNP NNP N
may MD N
have VB N
been VBN N
confounded VBN N
by IN N
differences NNS N
in IN N
renal JJ N
function NN N
. . N

CONCLUSION NNP N
Age NNP N
and CC N
gender NN N
, , N
as RB N
well RB N
as IN N
the DT N
severity NN N
of IN N
cardiac JJ N
dysfunction NN N
, , N
appear VBP N
to TO N
have VB N
an DT N
important JJ N
effect NN N
on IN N
the DT N
severity NN N
of IN N
heart NN N
failure NN N
symptoms NNS N
and CC N
patient JJ N
'well-being NN N
' POS N
. . N

This DT N
could MD N
have VB N
important JJ N
implications NNS N
for IN N
the DT N
relationship NN N
between IN N
symptoms NNS N
and CC N
prognosis NN N
and CC N
therefore RB N
the DT N
way NN N
in IN N
which WDT N
patients NNS N
are VBP N
selected VBN N
for IN N
clinical JJ N
trials NNS N
and CC N
the DT N
goals NNS N
of IN N
treatment NN N
. . N

This DT N
will MD N
be VB N
the DT N
subject NN N
of IN N
further JJ N
analyses NNS N
. . N

-DOCSTART- -21385365- O O

A DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
comparing VBG N
standard NN N
wound NN N
care NN N
with IN N
adjunctive JJ N
hyperbaric JJ N
oxygen NN N
therapy NN N
( ( N
HBOT NNP N
) ) N
to TO N
standard VB N
wound NN N
care NN N
only RB N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
, , N
non-healing JJ N
ulcers NNS N
of IN N
the DT N
lower JJR N
limb NN N
in IN N
patients NNS N
with IN N
diabetes NNS N
mellitus NNS N
: : N
a DT N
study NN N
protocol NN N
. . N

BACKGROUND NNP N
It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
the DT N
use NN N
of IN N
adjunctive JJ N
hyperbaric JJ N
oxygen NN N
therapy NN N
improves VBZ N
the DT N
healing NN N
of IN N
diabetic JJ N
foot NN N
ulcers NNS N
, , N
and CC N
decreases VBZ N
the DT N
risk NN N
of IN N
lower JJR N
extremity NN N
amputations NNS N
. . N

A DT N
limited JJ N
number NN N
of IN N
studies NNS N
have VBP N
used VBN N
a DT N
double JJ N
blind NN N
approach NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
hyperbaric JJ N
oxygen NN N
therapy NN N
in IN N
the DT N
treatment NN N
of IN N
diabetic JJ N
ulcers NNS N
. . N

The DT N
primary JJ N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
hyperbaric JJ N
oxygen NN N
therapy NN N
plus CC N
standard NN N
wound NN N
care NN N
compared VBN N
with IN N
standard NN N
wound NN N
care NN N
alone RB N
in IN N
preventing VBG N
the DT N
need NN N
for IN N
major JJ N
amputation NN N
in IN N
patients NNS N
with IN N
diabetes NNS N
mellitus NNS N
and CC N
chronic JJ N
ulcers NNS N
of IN N
the DT N
lower JJR N
limb NN N
. . N

METHODS/DESIGN NNP N
One CD N
hundred CD N
and CC N
eighteen JJ N
( ( N
59 CD N
patients NNS N
per IN N
arm NN N
) ) N
patients NNS N
with IN N
non-healing JJ N
diabetic JJ N
ulcers NNS N
of IN N
the DT N
lower JJR N
limb NN N
, , N
referred VBD N
to TO N
the DT N
Judy NNP N
Dan NNP N
Research NNP N
and CC N
Treatment NNP N
Centre NNP N
are VBP N
being VBG N
recruited VBN N
if IN N
they PRP N
are VBP N
at IN N
least JJS N
18 CD N
years NNS N
of IN N
age NN N
, , N
have VBP N
either DT N
Type NNP N
1 CD N
or CC N
2 CD N
diabetes NNS N
with IN N
a DT N
Wagner NNP N
grading NN N
of IN N
foot NN N
lesions NNS N
2 CD N
, , N
3 CD N
or CC N
4 CD N
on IN N
lower JJR N
limb NN N
not RB N
healing VBG N
for IN N
at IN N
least JJS N
4 CD N
weeks NNS N
. . N

Patients NNS N
receive JJ N
hyperbaric JJ N
oxygen NN N
therapy NN N
every DT N
day NN N
for IN N
6 CD N
weeks NNS N
during IN N
the DT N
treatment NN N
phase NN N
and CC N
are VBP N
provided VBN N
ongoing VBG N
wound NN N
care NN N
and CC N
weekly JJ N
assessments NNS N
. . N

Patients NNS N
are VBP N
required VBN N
to TO N
return VB N
to TO N
the DT N
study NN N
centre NN N
every DT N
week NN N
for IN N
an DT N
additional JJ N
6 CD N
weeks NNS N
of IN N
follow-up NN N
for IN N
wound JJ N
evaluation NN N
and CC N
management NN N
. . N

The DT N
primary JJ N
outcome NN N
is VBZ N
freedom RB N
from IN N
having VBG N
, , N
or CC N
meeting VBG N
the DT N
criteria NN N
for IN N
, , N
a DT N
major JJ N
amputation NN N
( ( N
below IN N
knee NN N
amputation NN N
, , N
or CC N
metatarsal VB N
level NN N
) ) N
up RB N
to TO N
12 CD N
weeks NNS N
after IN N
randomization NN N
. . N

The DT N
decision NN N
to TO N
amputate VB N
is VBZ N
made VBN N
by IN N
a DT N
vascular JJ N
surgeon NN N
. . N

Other JJ N
outcomes NNS N
include VBP N
wound IN N
healing NN N
, , N
effectiveness NN N
, , N
safety NN N
, , N
healthcare JJ N
resource NN N
utilization NN N
, , N
quality NN N
of IN N
life NN N
, , N
and CC N
cost-effectiveness NN N
. . N

The DT N
study NN N
will MD N
run VB N
for IN N
a DT N
total NN N
of IN N
about IN N
3 CD N
years NNS N
. . N

DISCUSSION VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
will MD N
provide VB N
detailed JJ N
information NN N
on IN N
the DT N
efficacy NN N
of IN N
hyperbaric JJ N
oxygen NN N
therapy NN N
for IN N
the DT N
treatment NN N
of IN N
non-healing JJ N
ulcers NNS N
of IN N
the DT N
lower JJR N
limb NN N
. . N

This DT N
will MD N
be VB N
the DT N
first JJ N
double-blind JJ N
randomized VBN N
controlled JJ N
trial NN N
for IN N
this DT N
health NN N
technology NN N
which WDT N
evaluates VBZ N
the DT N
efficacy NN N
of IN N
hyperbaric JJ N
oxygen NN N
therapy NN N
in IN N
prevention NN N
of IN N
amputations NNS N
in IN N
diabetic JJ N
patients NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
Identifier NNP N
: : N
NCT00621608 NN N
. . N

-DOCSTART- -12058842- O O

Brief JJ N
report NN N
: : N
imitation NN N
effects NNS N
on IN N
children NNS N
with IN N
autism NN N
. . N

Twenty NNP N
children NNS N
with IN N
autism NN N
( ( N
mean JJ N
age NN N
, , N
5 CD N
years NNS N
) ) N
were VBD N
recruited VBN N
for IN N
the DT N
study NN N
from IN N
a DT N
school NN N
for IN N
children NNS N
with IN N
autism NN N
. . N

The DT N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
imitation NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
contingently RB N
responsive JJ N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
interaction NN N
group NN N
based VBN N
on IN N
a DT N
stratification NN N
table NN N
for IN N
gender NN N
and CC N
developmental NN N
and CC N
chronological JJ N
age NN N
. . N

The DT N
sessions NNS N
consisted VBD N
of IN N
four CD N
phases NNS N
, , N
with IN N
each DT N
phase NN N
lasting VBG N
3 CD N
minutes NNS N
. . N

In IN N
the DT N
first JJ N
phase NN N
, , N
the DT N
child NN N
walked VBD N
into IN N
a DT N
room NN N
that WDT N
was VBD N
furnished VBN N
with IN N
a DT N
sofa NN N
, , N
a DT N
table NN N
, , N
chairs NNS N
, , N
and CC N
two CD N
sets NNS N
of IN N
identical JJ N
toys NN N
. . N

An DT N
adult NN N
was VBD N
in IN N
the DT N
room NN N
sitting VBG N
very RB N
still RB N
like IN N
a DT N
statue NN N
( ( N
first JJ N
still-face JJ N
condition NN N
) ) N
. . N

In IN N
the DT N
second JJ N
phase NN N
, , N
the DT N
adult NN N
either RB N
imitated VBD N
the DT N
child NN N
or CC N
was VBD N
contingently RB N
responsive JJ N
to TO N
the DT N
child NN N
. . N

In IN N
the DT N
third JJ N
phase NN N
, , N
the DT N
adult NN N
sat VBD N
still RB N
again RB N
( ( N
second JJ N
still-face JJ N
condition NN N
) ) N
, , N
and CC N
in IN N
the DT N
fourth JJ N
phase NN N
, , N
the DT N
adult NN N
engaged VBN N
in IN N
a DT N
spontaneous JJ N
interaction NN N
. . N

During IN N
the DT N
third JJ N
phase NN N
( ( N
the DT N
second JJ N
still-face JJ N
condition NN N
) ) N
, , N
the DT N
children NNS N
in IN N
the DT N
imitation NN N
group NN N
spent VBD N
less JJR N
time NN N
in IN N
gross JJ N
motor NN N
activity NN N
and CC N
more JJR N
time NN N
touching VBG N
the DT N
adult NN N
, , N
as IN N
if IN N
attempting VBG N
to TO N
initiate VB N
an DT N
interaction NN N
. . N

The DT N
contingency NN N
condition NN N
appeared VBD N
to TO N
be VB N
a DT N
more RBR N
effective JJ N
way NN N
to TO N
facilitate VB N
a DT N
distal JJ N
social JJ N
behavior NN N
( ( N
attention NN N
) ) N
, , N
whereas IN N
the DT N
imitative JJ N
condition NN N
was VBD N
a DT N
more RBR N
effective JJ N
way NN N
to TO N
facilitate VB N
a DT N
proximal JJ N
social JJ N
behavior NN N
( ( N
touching VBG N
) ) N
. . N

-DOCSTART- -11837468- O O

Glibenclamide NNP N
vs NN N
gliclazide NN N
in IN N
reducing VBG N
oxidative JJ N
stress NN N
in IN N
patients NNS N
of IN N
noninsulin JJ N
dependent JJ N
diabetes VBZ N
mellitus NN N
-- : N
a DT N
double JJ N
blind NN N
randomized VBN N
study NN N
. . N

OBJECTIVE NNP N
Parameters NNPS N
of IN N
oxidative JJ N
stress NN N
were VBD N
quantitated VBN N
in IN N
50 CD N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
mellitus VBP N
in IN N
uncontrolled JJ N
state NN N
and CC N
after IN N
control NN N
using VBG N
oral JJ N
glibenclamide NN N
or CC N
gliclazide NN N
. . N

The DT N
estimates NNS N
were VBD N
further RB N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
irrespective JJ N
of IN N
drug NN N
used VBN N
to TO N
evaluate VB N
the DT N
difference NN N
, , N
if IN N
any DT N
. . N

METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
double JJ N
blind NN N
, , N
uncontrolled JJ N
, , N
noncrossover RB N
and CC N
randomized JJ N
trial NN N
. . N

Fifty JJ N
patients NNS N
of IN N
uncontrolled JJ N
type NN N
2 CD N
diabetes NNS N
were VBD N
divided VBN N
in IN N
to TO N
two CD N
groups NNS N
. . N

Group NNP N
I PRP N
( ( N
25 CD N
patients NNS N
) ) N
received VBD N
capsule NN N
A NNP N
( ( N
glibenclamide NN N
) ) N
while IN N
Group NNP N
II NNP N
( ( N
25 CD N
patients NNS N
) ) N
received VBD N
capsule NN N
B NNP N
( ( N
gliclazide NN N
) ) N
. . N

The DT N
parameters NNS N
studied VBN N
were VBD N
Superoxide NNP N
dismutase NN N
( ( N
SOD NNP N
) ) N
, , N
malonyl-dialdehyde JJ N
( ( N
MDA NNP N
) ) N
and CC N
reduced VBN N
glutathione NN N
( ( N
GSH NNP N
) ) N
. . N

They PRP N
were VBD N
done VBN N
at IN N
( ( N
a DT N
) ) N
uncontrolled JJ N
stage NN N
( ( N
FBS NNP N
-- : N
165 CD N
+/- JJ N
16.7 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
240 CD N
+/- JJ N
30.1 CD N
mg/dl NN N
and CC N
HbA1 NNP N
-- : N
10.5 CD N
+/- JJ N
0.9 CD N
% NN N
in IN N
group NN N
I PRP N
and CC N
FBS NNP N
-- : N
150 CD N
+/- JJ N
15.8 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
246 CD N
+/- JJ N
29.1 CD N
mg/dl NN N
HbA1 NNP N
10.6 CD N
+/- JJ N
0.8 CD N
% NN N
in IN N
group NN N
II NNP N
) ) N
and CC N
during IN N
controlled VBN N
stage NN N
at IN N
12 CD N
weeks NNS N
( ( N
FBS NNP N
-- : N
120 CD N
+/- JJ N
18.5 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
180 CD N
+/- JJ N
19.1 CD N
mg/dl NN N
and CC N
HbA1 NNP N
-- : N
8.4 CD N
+/- JJ N
0.29 CD N
% NN N
in IN N
group NN N
I PRP N
and CC N
FBS NNP N
-- : N
118 CD N
+/- JJ N
17.6 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
176 CD N
+/- JJ N
20.1 CD N
mg/dl NN N
and CC N
HbA1 NNP N
-- : N
8.5 CD N
+/- JJ N
0.39 CD N
% NN N
in IN N
group NN N
II NNP N
patients NNS N
) ) N
. . N

RESULTS VB N
The DT N
significantly RB N
raised VBN N
levels NNS N
of IN N
MDA NNP N
and CC N
SOD NNP N
, , N
and CC N
decreased JJ N
levels NNS N
of IN N
reduced VBN N
glutathione NN N
( ( N
GSH NNP N
) ) N
during IN N
uncontrolled JJ N
stage NN N
of IN N
diabetes NNS N
indicated VBD N
free JJ N
radical JJ N
stress NN N
induced VBD N
lipid JJ N
peroxidation NN N
. . N

The DT N
significant JJ N
fall NN N
of IN N
MDA NNP N
and CC N
SOD NNP N
and CC N
increased VBD N
levels NNS N
of IN N
GSH NNP N
in IN N
blood NN N
in IN N
both DT N
groups NNS N
after IN N
control NN N
revealed VBD N
beneficial JJ N
effects NNS N
of IN N
glycemic JJ N
control NN N
on IN N
oxidative JJ N
stress NN N
. . N

The DT N
levels NNS N
were VBD N
not RB N
normalized VBN N
and CC N
stayed VBD N
higher JJR N
than IN N
those DT N
in IN N
controls NNS N
. . N

On IN N
intergroup JJ N
comparison NN N
; : N
the DT N
control NN N
of IN N
diabetes NNS N
with IN N
gliclazide NN N
( ( N
group NN N
II NNP N
) ) N
showed VBD N
improvement NN N
in IN N
oxidative JJ N
stress NN N
( ( N
MDA NNP N
, , N
GSH NNP N
) ) N
better JJR N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
than IN N
glibenclamide NN N
( ( N
group NN N
I PRP N
) ) N
. . N

CONCLUSION NNP N
Oxidative NNP N
stress NN N
in IN N
uncontrolled JJ N
diabetes NNS N
is VBZ N
decreased VBN N
with IN N
glycemic JJ N
control NN N
. . N

The DT N
control NN N
of IN N
diabetes NNS N
with IN N
gliclazide NN N
reduced VBN N
oxidative JJ N
stress NN N
more JJR N
than IN N
glibenclamide NN N
, , N
indicating VBG N
higher JJR N
antioxidant JJ N
properties NNS N
of IN N
gliclazide NN N
. . N

Normalization NN N
of IN N
oxidative JJ N
stress NN N
was VBD N
not RB N
achieved VBN N
. . N

Further JJ N
studies NNS N
are VBP N
required VBN N
to TO N
see VB N
long-term JJ N
effect NN N
of IN N
drug NN N
therapy NN N
in IN N
combating VBG N
oxidative JJ N
stress NN N
after IN N
achieving VBG N
acceptable JJ N
control NN N
of IN N
diabetes NNS N
. . N

-DOCSTART- -1376306- O O

Induction NNP N
chemotherapy NN N
in IN N
head NN N
and CC N
neck NN N
cancer NN N
: : N
results NNS N
of IN N
a DT N
phase NN N
III NNP N
trial NN N
. . N

Between IN N
December NNP N
1982 CD N
and CC N
October NNP N
1986 CD N
, , N
131 CD N
patients NNS N
with IN N
stage JJ N
II-III-IV NNP N
squamous JJ N
cell NN N
carcinoma NN N
of IN N
the DT N
oropharynx NN N
or CC N
oral JJ N
cavity NN N
were VBD N
randomized VBN N
to TO N
induction VB N
chemotherapy NN N
, , N
consisting VBG N
of IN N
bleomycin NN N
( ( N
10 CD N
mg/m2/day NN N
in IN N
continuous JJ N
infusion NN N
from IN N
day NN N
1 CD N
to TO N
day NN N
5 CD N
) ) N
, , N
methotrexate NN N
( ( N
120 CD N
mg/m2 NN N
on IN N
day NN N
2 CD N
) ) N
followed VBN N
by IN N
folinic JJ N
acid NN N
, , N
5-fluorouracil JJ N
( ( N
5 CD N
FU NNP N
) ) N
( ( N
600 CD N
mg/m2 NN N
on IN N
day NN N
2 CD N
) ) N
, , N
and CC N
cisplatin NN N
( ( N
120 CD N
mg/m2 NN N
on IN N
day NN N
4 CD N
) ) N
every DT N
4 CD N
weeks NNS N
for IN N
a DT N
total NN N
of IN N
three CD N
cycles NNS N
followed VBN N
by IN N
definitive JJ N
locoregional JJ N
treatment NN N
versus IN N
locoregional JJ N
treatment NN N
alone RB N
. . N

The DT N
modalities NNS N
of IN N
definitive JJ N
treatment NN N
( ( N
radiotherapy JJ N
+/- JJ N
surgery NN N
) ) N
were VBD N
chosen VBN N
prior RB N
to TO N
randomization NN N
. . N

A DT N
total NN N
of IN N
116 CD N
patients NNS N
were VBD N
evaluable JJ N
. . N

Of IN N
55 CD N
patients NNS N
in IN N
the DT N
chemotherapy NN N
arm NN N
, , N
four CD N
( ( N
7 CD N
% NN N
) ) N
had VBD N
a DT N
complete JJ N
response NN N
( ( N
CR NNP N
) ) N
and CC N
23 CD N
( ( N
42 CD N
% NN N
) ) N
a DT N
partial JJ N
response NN N
( ( N
PR NNP N
) ) N
following VBG N
the DT N
induction NN N
regimen NNS N
. . N

At IN N
the DT N
completion NN N
of IN N
locoregional JJ N
treatment NN N
, , N
76 CD N
% NN N
( ( N
42 CD N
of IN N
55 CD N
) ) N
of IN N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
were VBD N
in IN N
CR NNP N
compared VBN N
to TO N
89 CD N
% NN N
( ( N
54 CD N
of IN N
61 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
survival NN N
, , N
cause-specific JJ N
survival NN N
, , N
and CC N
pattern NN N
of IN N
relapse NN N
between IN N
both DT N
groups NNS N
. . N

The DT N
median JJ N
survival NN N
was VBD N
22 CD N
months NNS N
in IN N
the DT N
chemotherapy NN N
group NN N
and CC N
29 CD N
months NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Responders NNS N
to TO N
chemotherapy VB N
did VBD N
not RB N
fare VB N
better JJR N
than IN N
nonresponders NNS N
. . N

Chemotherapy-related JJ N
toxicities NNS N
were VBD N
few JJ N
and CC N
most JJS N
of IN N
them PRP N
related VBN N
to TO N
cisplatin VB N
which WDT N
was VBD N
reduced VBN N
to TO N
100 CD N
mg/m2 NN N
for IN N
35 CD N
patients NNS N
. . N

There EX N
were VBD N
no DT N
treatment-related JJ N
deaths NNS N
and CC N
, , N
in IN N
the DT N
experimental JJ N
arm NN N
of IN N
the DT N
trial NN N
, , N
no DT N
increased VBN N
morbidity NN N
from IN N
locoregional JJ N
treatment NN N
. . N

This DT N
induction NN N
regimen NN N
does VBZ N
not RB N
offer VB N
any DT N
advantages NNS N
over IN N
standard JJ N
treatment NN N
. . N

-DOCSTART- -22585532- O O

Immunologic NNP N
response NN N
after IN N
laparoscopic NN N
colon NN N
cancer NN N
operation NN N
within IN N
an DT N
enhanced JJ N
recovery NN N
program NN N
. . N

OBJECTIVE NN N
It PRP N
has VBZ N
been VBN N
demonstrated VBN N
that IN N
colon NN N
operation NN N
combined VBN N
with IN N
fast-track NN N
( ( N
FT NNP N
) ) N
surgery NN N
and CC N
laparoscopic NN N
technique NN N
can MD N
shorten VB N
the DT N
length NN N
of IN N
hospital NN N
stay NN N
, , N
accelerate JJ N
recovery NN N
of IN N
intestinal JJ N
function NN N
, , N
and CC N
reduce VB N
the DT N
occurrence NN N
of IN N
post-operative JJ N
complications NNS N
. . N

However RB N
, , N
there EX N
are VBP N
no DT N
reports NNS N
regarding VBG N
the DT N
combined JJ N
effects NNS N
of IN N
FT NNP N
colon NN N
operation NN N
and CC N
laparoscopic NN N
technique NN N
on IN N
humoral JJ N
inflammatory NN N
cellular JJ N
immunity NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
controlled VBD N
study NN N
. . N

One CD N
hundred VBD N
sixty-three JJ N
colon NN N
cancer NN N
patients NNS N
underwent VBD N
the DT N
traditional JJ N
protocol NN N
and CC N
open JJ N
operation NN N
( ( N
traditional JJ N
open JJ N
group NN N
, , N
n=42 RB N
) ) N
, , N
the DT N
traditional JJ N
protocol NN N
and CC N
laparoscopic NN N
operation NN N
( ( N
traditional JJ N
laparoscopic NN N
group NN N
, , N
n=40 RB N
) ) N
, , N
the DT N
FT NNP N
protocol NN N
and CC N
open JJ N
operation NN N
( ( N
FT NNP N
open JJ N
group NN N
, , N
n=41 RB N
) ) N
, , N
or CC N
the DT N
FT NNP N
protocol NN N
and CC N
laparoscopic NN N
operation NN N
( ( N
FT NNP N
laparoscopic NN N
group NN N
, , N
n=40 RB N
) ) N
. . N

Blood NN N
samples NNS N
were VBD N
taken VBN N
prior RB N
to TO N
operation NN N
as RB N
well RB N
as IN N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
and CC N
5 CD N
after IN N
operation NN N
. . N

The DT N
number NN N
of IN N
lymphocyte JJ N
subpopulations NNS N
was VBD N
determined VBN N
by IN N
flow JJ N
cytometry NN N
, , N
and CC N
serum VB N
interleukin-6 JJ N
and CC N
C-reactive JJ N
protein NN N
levels NNS N
were VBD N
measured VBN N
. . N

Post-operative JJ N
hospital NN N
stay NN N
, , N
post-operative JJ N
morbidity NN N
, , N
readmission NN N
rate NN N
, , N
and CC N
in-hospital JJ N
mortality NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
open JJ N
operation NN N
, , N
laparoscopic JJ N
colon NN N
operation NN N
effectively RB N
inhibited VBD N
the DT N
release NN N
of IN N
post-operative JJ N
inflammatory JJ N
factors NNS N
and CC N
yielded VBD N
good JJ N
protection NN N
via IN N
post-operative JJ N
cell NN N
immunity NN N
. . N

FT NNP N
surgery NN N
had VBD N
a DT N
better RBR N
protective JJ N
role NN N
with IN N
respect NN N
to TO N
the DT N
post-operative JJ N
immune NN N
system NN N
compared VBN N
with IN N
traditional JJ N
peri-operative JJ N
care NN N
. . N

Inflammatory JJ N
reactions NNS N
, , N
based VBN N
on IN N
interleukin-6 JJ N
and CC N
C-reactive JJ N
protein NN N
levels NNS N
, , N
were VBD N
less JJR N
intense JJ N
following VBG N
FT NNP N
laparoscopic NN N
operation NN N
compared VBN N
to TO N
FT NNP N
open JJ N
operation NN N
; : N
however RB N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
specific JJ N
immunity NN N
( ( N
CD3+ NNP N
and CC N
CD4+ NNP N
counts NNS N
, , N
and CC N
the DT N
CD4+/CD8+ NNP N
ratio NN N
) ) N
during IN N
these DT N
two CD N
types NNS N
of IN N
surgical JJ N
procedures NNS N
. . N

Post-operative JJ N
hospital NN N
stay NN N
in IN N
patients NNS N
randomized VBN N
to TO N
the DT N
FT NNP N
laparoscopic NN N
group NN N
was VBD N
significantly RB N
shorter JJR N
than IN N
in IN N
the DT N
other JJ N
three CD N
treatment NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Post-operative JJ N
complications NNS N
in IN N
patients NNS N
who WP N
underwent VBP N
FT NNP N
laparoscopic NN N
treatment NN N
were VBD N
less JJR N
than IN N
in IN N
the DT N
other JJ N
three CD N
treatment NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
four CD N
treatment NN N
groups NNS N
regarding VBG N
readmission NN N
rate NN N
and CC N
in-hospital JJ N
mortality NN N
. . N

CONCLUSIONS VB N
The DT N
laparoscopic NN N
technique NN N
and CC N
FT NNP N
surgery NN N
rehabilitation NN N
program NN N
effectively RB N
inhibited VBD N
release NN N
of IN N
post-operative JJ N
inflammatory JJ N
factors NNS N
with IN N
a DT N
reduction NN N
in IN N
peri-operative JJ N
trauma NN N
and CC N
stress NN N
, , N
which WDT N
together RB N
played VBD N
a DT N
protective JJ N
role NN N
on IN N
the DT N
post-operative JJ N
immune NN N
system NN N
. . N

Combining VBG N
two CD N
treatment NN N
measures NNS N
during IN N
colon NN N
operation NN N
produced VBD N
better RBR N
protective JJ N
effects NNS N
via IN N
the DT N
immune JJ N
system NN N
. . N

The DT N
beneficial JJ N
clinical JJ N
effects NNS N
support NN N
that IN N
the DT N
better-preserved JJ N
post-operative JJ N
immune NN N
system NN N
may MD N
also RB N
contribute VB N
to TO N
the DT N
improvement NN N
of IN N
post-operative JJ N
results NNS N
in IN N
FT NNP N
laparoscopic NN N
patients NNS N
. . N

-DOCSTART- -20932687- O O

Late JJ N
patient-reported JJ N
toxicity NN N
after IN N
preoperative JJ N
radiotherapy NN N
or CC N
chemoradiotherapy NN N
in IN N
nonresectable JJ N
rectal JJ N
cancer NN N
: : N
results NNS N
from IN N
a DT N
randomized JJ N
Phase NNP N
III NNP N
study NN N
. . N

PURPOSE NNP N
Preoperative NNP N
chemoradiotherapy NN N
( ( N
CRT NNP N
) ) N
is VBZ N
superior JJ N
to TO N
radiotherapy VB N
( ( N
RT NNP N
) ) N
in IN N
locally RB N
advanced JJ N
rectal JJ N
cancer NN N
, , N
but CC N
the DT N
survival JJ N
gain NN N
is VBZ N
limited JJ N
. . N

Late JJ N
toxicity NN N
is VBZ N
, , N
therefore RB N
, , N
important JJ N
. . N

The DT N
aim NN N
was VBD N
to TO N
compare VB N
late JJ N
bowel NN N
, , N
urinary JJ N
, , N
and CC N
sexual JJ N
functions NNS N
after IN N
CRT NNP N
or CC N
RT NNP N
. . N

METHODS NNP N
AND CC N
MATERIALS NNP N
Patients NNP N
( ( N
N NNP N
= NNP N
207 CD N
) ) N
with IN N
nonresectable JJ N
rectal JJ N
cancer NN N
were VBD N
randomized VBN N
to TO N
preoperative VB N
CRT NNP N
or CC N
RT NNP N
( ( N
2 CD N
Gy NNP N
? . N
25 CD N
? . N
5-fluorouracil/leucovorin JJ N
) ) N
. . N

Extended VBN N
surgery NN N
was VBD N
often RB N
required VBN N
. . N

Self-reported JJ N
late JJ N
toxicity NN N
was VBD N
scored VBN N
according VBG N
to TO N
the DT N
LENT NNP N
SOMA NNP N
criteria NNS N
in IN N
a DT N
structured JJ N
telephone NN N
interview NN N
and CC N
with IN N
questionnaires NNS N
European JJ N
Organisation NNP N
for IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
( ( N
EORTC NNP N
) ) N
Quality NN N
of IN N
Life NNP N
Questionnaire NNP N
( ( N
QLQ-C30 NNP N
) ) N
, , N
International NNP N
Index NNP N
of IN N
Erectile NNP N
Function NNP N
( ( N
IIEF NNP N
) ) N
, , N
and CC N
sexual JJ N
function-vaginal JJ N
changes NNS N
questionnaire VBP N
( ( N
SVQ NNP N
) ) N
. . N

RESULTS NNP N
Of IN N
the DT N
105 CD N
patients NNS N
alive JJ N
in IN N
Norway NNP N
and CC N
Sweden NNP N
after IN N
4 CD N
to TO N
12 CD N
years NNS N
of IN N
follow-up NN N
, , N
78 CD N
( ( N
74 CD N
% NN N
) ) N
responded VBD N
. . N

More JJR N
patients NNS N
in IN N
the DT N
CRT NNP N
group NN N
had VBD N
received VBN N
a DT N
stoma NN N
( ( N
73 CD N
% NN N
vs. FW N
52 CD N
% NN N
, , N
p NN N
= NNP N
0.09 CD N
) ) N
. . N

Most JJS N
patients NNS N
without IN N
a DT N
stoma NN N
( ( N
7 CD N
of IN N
12 CD N
in IN N
CRT NNP N
group NN N
and CC N
9 CD N
of IN N
16 CD N
in IN N
RT NNP N
group NN N
) ) N
had VBD N
incontinence NN N
for IN N
liquid NN N
stools NNS N
or CC N
gas NN N
. . N

No DT N
stoma NN N
and CC N
good JJ N
anal JJ N
function NN N
were VBD N
seen VBN N
in IN N
5 CD N
patients NNS N
( ( N
11 CD N
% NN N
) ) N
in IN N
the DT N
CRT NNP N
group NN N
and CC N
in IN N
11 CD N
( ( N
30 CD N
% NN N
) ) N
in IN N
the DT N
RT NNP N
group NN N
( ( N
p JJ N
= NNP N
0.046 CD N
) ) N
. . N

Of IN N
44 CD N
patients NNS N
in IN N
the DT N
CRT NNP N
group NN N
, , N
12 CD N
( ( N
28 CD N
% NN N
) ) N
had VBD N
had VBN N
bowel VBN N
obstruction NN N
compared VBN N
with IN N
5 CD N
of IN N
33 CD N
( ( N
15 CD N
% NN N
) ) N
in IN N
the DT N
RT NNP N
group NN N
( ( N
p JJ N
= NNP N
0.27 CD N
) ) N
. . N

One-quarter NN N
of IN N
the DT N
patients NNS N
reported VBD N
urinary JJ N
incontinence NN N
. . N

The DT N
majority NN N
of IN N
men NNS N
had VBD N
severe JJ N
erectile JJ N
dysfunction NN N
. . N

Few JJ N
women NNS N
reported VBD N
sexual JJ N
activity NN N
during IN N
the DT N
previous JJ N
month NN N
. . N

However RB N
, , N
the DT N
majority NN N
did VBD N
not RB N
have VB N
concerns NNS N
about IN N
their PRP$ N
sex NN N
life NN N
. . N

CONCLUSIONS NNP N
Fecal NNP N
incontinence NN N
and CC N
erectile JJ N
dysfunction NN N
are VBP N
frequent JJ N
after IN N
combined JJ N
treatment NN N
for IN N
locally RB N
advanced JJ N
rectal JJ N
cancer NN N
. . N

There EX N
was VBD N
a DT N
clear JJ N
tendency NN N
for IN N
the DT N
problems NNS N
to TO N
be VB N
more JJR N
common JJ N
after IN N
CRT NNP N
than IN N
after IN N
RT NNP N
. . N

-DOCSTART- -11100343- O O

Somatostatin NNP N
and CC N
ranitidine NN N
in IN N
the DT N
treatment NN N
of IN N
non-variceal JJ N
upper JJ N
gastrointestinal JJ N
bleeding NN N
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind NN N
, , N
controlled VBN N
study NN N
. . N

BACKGROUND/AIMS IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
somatostatin NN N
vs. FW N
ranitidine NN N
in IN N
controlling VBG N
acute JJ N
non-variceal JJ N
gastrointestinal JJ N
bleeding NN N
. . N

METHODOLOGY NNP N
A NNP N
total NN N
of IN N
48 CD N
patients NNS N
with IN N
acute JJ N
upper JJ N
gastrointestinal NN N
bleeding NN N
due JJ N
to TO N
duodenal JJ N
or CC N
gastric JJ N
ulcer NN N
were VBD N
divided VBN N
into IN N
2 CD N
groups NNS N
. . N

Group NNP N
I PRP N
consisted VBD N
of IN N
15 CD N
patients NNS N
with IN N
Forrest NNP N
IB NNP N
and CC N
Group NNP N
II NNP N
consisted VBD N
of IN N
30 CD N
patients NNS N
with IN N
Forrest NNP N
II NNP N
. . N

Two CD N
regimens NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
all DT N
patients NNS N
within IN N
half PDT N
an DT N
hour NN N
after IN N
the DT N
endoscopic JJ N
procedure NN N
: : N
1 CD N
) ) N
somatostatin-UCB NN N
250 CD N
mcg NN N
i.v NN N
. . N

bolus CC N
followed VBN N
by IN N
continuous JJ N
i.v NN N
. . N

infusion NN N
at IN N
a DT N
rate NN N
of IN N
6 CD N
mg/d NN N
for IN N
72 CD N
h NN N
, , N
or CC N
2 CD N
) ) N
ranitidine NN N
300 CD N
mg/d NN N
by IN N
continuous JJ N
i.v NN N
. . N

infusion NN N
for IN N
72 CD N
h. JJ N
RESULTS NNP N
In IN N
Group NNP N
I PRP N
, , N
although IN N
mean JJ N
blood NN N
transfusion NN N
requirements NNS N
( ( N
no DT N
. . N

of IN N
units NNS N
) ) N
were VBD N
lower JJR N
in IN N
patients NNS N
treated VBN N
with IN N
somatostatin NN N
than IN N
in IN N
those DT N
treated VBN N
with IN N
ranitidine NN N
, , N
this DT N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
mean JJ N
+/- JJ N
SD NN N
: : N
2.56 CD N
+/- JJ N
3.05 CD N
vs. FW N
5.17 CD N
+/- JJ N
4.96 CD N
, , N
respectively RB N
; : N
P NNP N
> NNP N
0.05 CD N
) ) N
; : N
the DT N
time NN N
of IN N
bleeding VBG N
stop NN N
was VBD N
shorter RBR N
in IN N
the DT N
somatostatin NN N
group NN N
than IN N
in IN N
the DT N
ranitidine NN N
group NN N
( ( N
mean JJ N
+/- JJ N
SD NN N
: : N
3.24 CD N
+/- JJ N
2.45 CD N
vs. FW N
11.25 CD N
+/- JJ N
11.63 CD N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.0383 CD N
) ) N
. . N

The DT N
rebleeding NN N
and CC N
the DT N
mortality NN N
rates NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
treatment NN N
groups NNS N
in IN N
both DT N
Group NNP N
I PRP N
and CC N
Group NNP N
II NNP N
. . N

CONCLUSIONS NNP N
Somatostatin NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
ranitidine NN N
in IN N
controlling VBG N
acute JJ N
non-variceal JJ N
gastrointestinal JJ N
bleeding NN N
in IN N
patients NNS N
with IN N
Forrest NNP N
IB NNP N
bleeding NN N
activity NN N
. . N

Somatostatin NNP N
has VBZ N
no DT N
additional JJ N
benefit NN N
in IN N
those DT N
with IN N
Forrest NNP N
II NNP N
bleeding NN N
activity NN N
. . N

-DOCSTART- -22306962- O O

Effect NN N
of IN N
acute NN N
exercise NN N
on IN N
executive NN N
function NN N
in IN N
children NNS N
with IN N
attention NN N
deficit NN N
hyperactivity NN N
disorder NN N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
acute NN N
aerobic JJ N
exercise NN N
on IN N
executive NN N
function NN N
in IN N
children NNS N
with IN N
attention NN N
deficit NN N
hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
. . N

Forty NNP N
children NNS N
with IN N
ADHD NNP N
were VBD N
randomly RB N
assigned VBN N
into IN N
exercise NN N
or CC N
control NN N
groups NNS N
. . N

Participants NNS N
in IN N
the DT N
exercise NN N
group NN N
performed VBD N
a DT N
moderate JJ N
intensity NN N
aerobic JJ N
exercise NN N
for IN N
30 CD N
min NN N
, , N
whereas IN N
the DT N
control NN N
group NN N
watched VBD N
a DT N
running/exercise-related JJ N
video NN N
. . N

Neuropsychological JJ N
tasks NNS N
, , N
the DT N
Stroop NNP N
Test NNP N
and CC N
the DT N
Wisconsin NNP N
Card NNP N
Sorting NNP N
Test NNP N
( ( N
WCST NNP N
) ) N
, , N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
each DT N
treatment NN N
. . N

The DT N
results NNS N
indicated VBD N
that IN N
acute JJ N
exercise NN N
facilitated VBN N
performance NN N
in IN N
the DT N
Stroop NNP N
Test NNP N
, , N
particularly RB N
in IN N
the DT N
Stroop NNP N
Color-Word NNP N
condition NN N
. . N

Additionally RB N
, , N
children NNS N
in IN N
the DT N
exercise NN N
group NN N
demonstrated VBD N
improvement NN N
in IN N
specific JJ N
WCST NNP N
performances NNS N
in IN N
Non-perseverative JJ N
Errors NNS N
and CC N
Categories NNP N
Completed NNP N
, , N
whereas VBZ N
no DT N
influences NNS N
were VBD N
found VBN N
in IN N
those DT N
performances NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Tentative JJ N
explanations NNS N
for IN N
the DT N
exercise NN N
effect NN N
postulate NN N
that WDT N
exercise NN N
allocates VBZ N
attention NN N
resources NNS N
, , N
influences VBZ N
the DT N
dorsolateral JJ N
prefrontal NN N
cortex NN N
, , N
and CC N
is VBZ N
implicated VBN N
in IN N
exercise-induced JJ N
dopamine NN N
release NN N
. . N

These DT N
findings NNS N
are VBP N
promising VBG N
and CC N
additional JJ N
investigations NNS N
to TO N
explore VB N
the DT N
efficacy NN N
of IN N
exercise NN N
on IN N
executive NN N
function NN N
in IN N
children NNS N
with IN N
ADHD NNP N
are VBP N
encouraged VBN N
. . N

-DOCSTART- -17453398- O O

Similar JJ N
effects NNS N
of IN N
rofecoxib NN N
and CC N
indomethacin NN N
on IN N
the DT N
incidence NN N
of IN N
heterotopic NN N
ossification NN N
after IN N
hip NN N
arthroplasty NN N
. . N

BACKGROUND NNP N
Although IN N
indomethacin NN N
is VBZ N
effective JJ N
in IN N
preventing VBG N
heterotopic NN N
ossification NN N
( ( N
HO NNP N
) ) N
after IN N
primary JJ N
total JJ N
hip NN N
arthroplasty NN N
, , N
side NN N
effects NNS N
are VBP N
frequently RB N
observed VBN N
. . N

In IN N
the DT N
last JJ N
decade NN N
a DT N
new JJ N
class NN N
of IN N
drugs NNS N
-- : N
the DT N
COX-2 NNP N
selective JJ N
nonsteroidal JJ N
anti-inflammatory JJ N
drugs NNS N
-- : N
has VBZ N
been VBN N
developed VBN N
. . N

To TO N
investigate VB N
the DT N
effect NN N
of IN N
these DT N
COX-2 NNP N
selective NN N
NSAIDs NNP N
on IN N
heterotopic NN N
ossification NN N
( ( N
HO NNP N
) ) N
after IN N
primary JJ N
total JJ N
hip NN N
arthroplasty NN N
( ( N
THA NNP N
) ) N
, , N
we PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
using VBG N
either CC N
indomethacin NN N
or CC N
rofecoxib NN N
for IN N
7 CD N
days NNS N
. . N

METHODS NNP N
186 CD N
patients NNS N
received VBD N
either RB N
indomethacin JJ N
3 CD N
times NNS N
daily RB N
, , N
or CC N
rofecoxib VB N
twice RB N
, , N
and CC N
1 CD N
placebo NN N
, , N
daily RB N
for IN N
7 CD N
days NNS N
. . N

HO NNP N
was VBD N
graded VBN N
according VBG N
to TO N
the DT N
1-year JJ N
postoperative NN N
radiographs NN N
according VBG N
to TO N
the DT N
Brooker NNP N
classification NN N
. . N

RESULTS NNP N
12 CD N
of IN N
the DT N
186 CD N
patients NNS N
included VBD N
discontinued VBN N
their PRP$ N
medication NN N
before IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
due JJ N
to TO N
side VB N
effects NNS N
. . N

The DT N
remaining VBG N
174 CD N
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
analysis NN N
. . N

In IN N
the DT N
indomethacin NN N
group NN N
( ( N
n JJ N
= NNP N
89 CD N
) ) N
, , N
77 CD N
patients NNS N
( ( N
87 CD N
% NN N
) ) N
showed VBD N
no DT N
HO NNP N
, , N
9 CD N
showed VBD N
HO NNP N
of IN N
grade NN N
1 CD N
and CC N
3 CD N
showed VBD N
HO NNP N
of IN N
grade NN N
2 CD N
according VBG N
to TO N
the DT N
Brooker NNP N
classification NN N
. . N

In IN N
the DT N
rofecoxib NN N
group NN N
( ( N
n JJ N
= NNP N
85 CD N
) ) N
73 CD N
patients NNS N
( ( N
86 CD N
% NN N
) ) N
showed VBD N
no DT N
ossification NN N
, , N
9 CD N
showed VBD N
grade NN N
1 CD N
, , N
and CC N
3 CD N
showed VBD N
grade JJ N
2 CD N
. . N

INTERPRETATION VB N
The DT N
prophylactic JJ N
effect NN N
of IN N
rofecoxib NN N
for IN N
7 CD N
days NNS N
in IN N
preventing VBG N
heterotopic NN N
ossification NN N
after IN N
primary JJ N
total JJ N
hip NN N
arthroplasty NN N
is VBZ N
comparable JJ N
to TO N
the DT N
effect NN N
of IN N
indomethacin NN N
given VBN N
for IN N
7 CD N
days NNS N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
the DT N
development NN N
of IN N
HO NNP N
follows VBZ N
a DT N
COX-2 JJ N
pathway NN N
. . N

-DOCSTART- -22048089- O O

Arthroscopic NNP N
rotator NN N
cuff NN N
repair NN N
with IN N
and CC N
without IN N
acromioplasty NN N
in IN N
the DT N
treatment NN N
of IN N
full-thickness JJ N
rotator NN N
cuff NN N
tears NNS N
: : N
a DT N
multicenter NN N
, , N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
was VBD N
to TO N
compare VB N
functional JJ N
and CC N
quality-of-life JJ N
indices NNS N
and CC N
rates NNS N
of IN N
revision NN N
surgery NN N
in IN N
arthroscopic NN N
rotator NN N
cuff NN N
repair NN N
with IN N
and CC N
without IN N
acromioplasty JJ N
. . N

METHODS NNP N
Eighty-six JJ N
patients NNS N
consented VBN N
and CC N
were VBD N
randomly RB N
assigned VBN N
intraoperatively RB N
to TO N
one CD N
of IN N
two CD N
study NN N
groups NNS N
, , N
and CC N
sixty-eight NN N
of IN N
them PRP N
completed VBD N
the DT N
study NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
Western JJ N
Ontario NNP N
Rotator NNP N
Cuff NNP N
( ( N
WORC NNP N
) ) N
index NN N
. . N

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
the DT N
American JJ N
Shoulder NNP N
and CC N
Elbow NNP N
Surgeons NNP N
( ( N
ASES NNP N
) ) N
shoulder NN N
assessment JJ N
form NN N
and CC N
a DT N
count NN N
of IN N
revisions NNS N
required VBN N
in IN N
each DT N
group NN N
. . N

Outcome NNP N
measures NNS N
were VBD N
completed VBN N
preoperatively RB N
and CC N
at IN N
three CD N
, , N
six CD N
, , N
twelve NN N
, , N
eighteen NN N
, , N
and CC N
twenty-four JJ N
months NNS N
after IN N
surgery NN N
. . N

RESULTS NNP N
WORC NNP N
and CC N
ASES NNP N
scores VBZ N
improved VBN N
significantly RB N
in IN N
each DT N
group NN N
over IN N
time NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
WORC NNP N
or CC N
ASES NNP N
scores NNS N
between IN N
the DT N
groups NNS N
that WDT N
had VBD N
arthroscopic VBN N
cuff JJ N
repair NN N
with IN N
or CC N
without IN N
acromioplasty JJ N
at IN N
any DT N
time NN N
point NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
scores NNS N
on IN N
the DT N
basis NN N
of IN N
acromion NN N
type NN N
, , N
nor CC N
were VBD N
any DT N
interaction NN N
effects NNS N
identified VBN N
between IN N
group NN N
and CC N
acromion NN N
type NN N
. . N

Four CD N
participants NNS N
( ( N
9 CD N
% NN N
) ) N
in IN N
the DT N
group NN N
that WDT N
had VBD N
arthroscopic VBN N
cuff JJ N
repair NN N
alone RB N
, , N
one CD N
with IN N
a DT N
Type-2 JJ N
and CC N
three CD N
with IN N
a DT N
Type-3 JJ N
acromion NN N
, , N
required VBN N
additional JJ N
surgery NN N
by IN N
the DT N
twenty-four-month JJ N
time NN N
point NN N
. . N

The DT N
number NN N
of IN N
patients NNS N
who WP N
required VBD N
additional JJ N
surgery NN N
was VBD N
greater JJR N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
in IN N
the DT N
group NN N
that WDT N
had VBD N
arthroscopic VBN N
cuff JJ N
repair NN N
alone RB N
than IN N
in IN N
the DT N
group NN N
that WDT N
had VBD N
arthroscopic VBN N
cuff JJ N
repair NN N
and CC N
acromioplasty NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
are VBP N
consistent JJ N
with IN N
previous JJ N
research NN N
reports NNS N
in IN N
which WDT N
there EX N
was VBD N
no DT N
difference NN N
in IN N
functional JJ N
and CC N
quality-of-life JJ N
indices NNS N
for IN N
patients NNS N
who WP N
had VBD N
rotator NN N
cuff NN N
repair NN N
with IN N
or CC N
without IN N
acromioplasty JJ N
. . N

The DT N
higher JJR N
reoperation NN N
rate NN N
was VBD N
found VBN N
in IN N
the DT N
group NN N
without IN N
acromioplasty NN N
. . N

Further CC N
study NN N
that WDT N
includes VBZ N
follow-up JJ N
imaging NN N
and CC N
patient-reported JJ N
outcomes NNS N
over IN N
a DT N
greater JJR N
follow-up JJ N
period NN N
is VBZ N
needed VBN N
. . N

-DOCSTART- -2711711- O O

[ JJ N
Dose-reduced NNP N
antihypertensive JJ N
agents NNS N
-- : N
use NN N
in IN N
complex JJ N
nonmedicamentous JJ N
therapy NN N
of IN N
hypertension NN N
] NNP N
. . N

In IN N
order NN N
to TO N
estimate VB N
the DT N
influence NN N
of IN N
a DT N
non-medicamentous JJ N
therapy NN N
( ( N
CNT NNP N
) ) N
on IN N
the DT N
consumption NN N
of IN N
medicaments NNS N
and CC N
coronary JJ N
risk NN N
in IN N
high JJ N
blood NN N
pressure NN N
73 CD N
hypertensives NNS N
of IN N
a DT N
medicamentously RB N
stabilized VBN N
CNT-group NNP N
were VBD N
examined VBN N
in IN N
comparison NN N
to TO N
a DT N
group NN N
of IN N
the DT N
same JJ N
size NN N
of IN N
patients NNS N
with IN N
hypertension NN N
who WP N
were VBD N
managed VBN N
exclusively RB N
medicamentously RB N
for IN N
behaviour NN N
of IN N
blood NN N
pressure NN N
, , N
need NN N
of IN N
antihypertensive JJ N
drugs NNS N
and CC N
changes NNS N
of IN N
hypertension-associated JJ N
risk NN N
factors NNS N
. . N

After IN N
an DT N
exactly RB N
controlled VBN N
6-month JJ N
treatment NN N
hypertensives NNS N
with IN N
additionally RB N
recommended VBN N
far-reaching NN N
CNT NNP N
showed VBD N
an DT N
economization NN N
of IN N
medicaments NNS N
by IN N
scarcely RB N
the DT N
half NN N
in IN N
comparison NN N
to TO N
the DT N
reference NN N
group NN N
. . N

By IN N
means NNS N
of IN N
suitable JJ N
control NN N
methods VBZ N
a DT N
causal JJ N
non-medicamentously RB N
conditioned JJ N
decrease NN N
of IN N
blood NN N
pressure NN N
could MD N
be VB N
excluded VBN N
. . N

A DT N
different JJ N
need NN N
of IN N
antihypertensive JJ N
drugs NNS N
was VBD N
simulated VBN N
by IN N
the DT N
exacter JJ N
intake NN N
of IN N
medicaments NNS N
in IN N
the DT N
index-patients NNS N
. . N

Notwithstanding VBG N
the DT N
metabolic JJ N
effects NNS N
of IN N
the DT N
additional JJ N
therapy NN N
have VBP N
induced VBN N
a DT N
positive JJ N
change NN N
of IN N
atherogenic JJ N
lipids NNS N
. . N

The DT N
examinations NNS N
indicate VBP N
in IN N
general JJ N
the DT N
difficulty NN N
of IN N
the DT N
judgement NN N
of IN N
efficacy NN N
of IN N
non-medicamentous JJ N
therapeutic JJ N
measures NNS N
in IN N
connection NN N
with IN N
a DT N
rational JJ N
dose-reduced JJ N
long-term JJ N
therapy NN N
with IN N
antihypertensive JJ N
drugs NNS N
. . N

-DOCSTART- -23280086- O O

Treatment NN N
of IN N
adults NNS N
with IN N
acute JJ N
lymphoblastic JJ N
leukemia NN N
: : N
do VB N
the DT N
specifics NNS N
of IN N
the DT N
regimen NNS N
matter NN N
? . N
: : N
Results NNS N
from IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Induction NNP N
therapy NN N
for IN N
adults NNS N
with IN N
acute JJ N
lymphoblastic JJ N
leukemia NN N
( ( N
ALL DT N
) ) N
is VBZ N
similar JJ N
across IN N
essentially RB N
all DT N
regimens NNS N
, , N
comprised VBN N
of IN N
vincristine NN N
, , N
corticosteroids NNS N
, , N
and CC N
anthracyclines NNS N
intensified VBN N
with IN N
cyclophosphamide NN N
, , N
asparaginase NN N
, , N
or CC N
both DT N
. . N

Given VBN N
the DT N
lack NN N
of IN N
randomized VBN N
data NNS N
, , N
to TO N
date NN N
, , N
no DT N
regimen NN N
has VBZ N
emerged VBN N
as IN N
standard NN N
. . N

The DT N
authors NNS N
previously RB N
evaluated VBD N
cytarabine JJ N
3 CD N
g/m NN N
( ( N
2 CD N
) ) N
daily RB N
for IN N
5 CD N
days NNS N
with IN N
mitoxantrone NN N
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
( ( N
the DT N
ALL-2 NNP N
regimen NNS N
) ) N
as IN N
a DT N
novel JJ N
induction NN N
regimen NNS N
. . N

Compared VBN N
with IN N
historic JJ N
controls NNS N
, , N
the DT N
ALL-2 NNP N
regimen NN N
was VBD N
superior JJ N
in IN N
terms NNS N
of IN N
incidence NN N
of IN N
complete JJ N
remission NN N
, , N
failure NN N
with IN N
resistant JJ N
disease NN N
, , N
and CC N
activity NN N
in IN N
patients NNS N
with IN N
Philadelphia NNP N
chromosome NN N
( ( N
Ph NNP N
) ) N
-positive VBP N
ALL NNP N
. . N

METHODS NNP N
The DT N
authors NNS N
conducted VBD N
a DT N
multicenter NN N
, , N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
the DT N
ALL-2 NNP N
regimen NNS N
compared VBN N
with IN N
a DT N
standard JJ N
4-drug JJ N
induction NN N
( ( N
the DT N
L-20 NNP N
regimen NNS N
) ) N
. . N

Patients NNS N
also RB N
received VBD N
consolidation NN N
, , N
maintenance NN N
therapy NN N
, , N
and CC N
central JJ N
nervous JJ N
system NN N
prophylaxis NN N
. . N

The DT N
trial NN N
accrued VBD N
patients NNS N
from IN N
August NNP N
1996 CD N
to TO N
October NNP N
2004 CD N
. . N

RESULTS VB N
The DT N
median JJ N
follow-up NN N
for IN N
survivors NNS N
was VBD N
7 CD N
years NNS N
, , N
and CC N
the DT N
median JJ N
patient NN N
age NN N
was VBD N
43 CD N
years NNS N
. . N

Responses NNS N
were VBD N
evaluated VBN N
in IN N
164 CD N
patients NNS N
. . N

The DT N
treatment NN N
arms NNS N
were VBD N
balanced VBN N
in IN N
terms NNS N
of IN N
pretreatment NN N
characteristics NNS N
. . N

The DT N
frequency NN N
of IN N
complete JJ N
remission NN N
for IN N
the DT N
ALL-2 NNP N
regimen NNS N
versus IN N
the DT N
L-20 JJ N
regimen NN N
was VBD N
83 CD N
% NN N
versus IN N
71 CD N
% NN N
( ( N
P NNP N
= NNP N
.06 NNP N
) ) N
. . N

More JJR N
patients NNS N
on IN N
the DT N
L-20 NNP N
arm NN N
failed VBD N
with IN N
resistant JJ N
disease NN N
( ( N
21 CD N
% NN N
vs JJ N
8 CD N
% NN N
; : N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

Induction NNP N
deaths NNS N
were VBD N
comparable JJ N
at IN N
9 CD N
% NN N
( ( N
ALL-2 NNP N
) ) N
versus VBD N
7 CD N
% NN N
( ( N
L-20 NNP N
) ) N
. . N

The DT N
median JJ N
survival NN N
was VBD N
similar JJ N
; : N
and CC N
, , N
at IN N
5 CD N
years NNS N
, , N
the DT N
survival NN N
rate NN N
was VBD N
33 CD N
% NN N
alive JJ N
on IN N
the DT N
ALL-2 NNP N
arm NN N
versus NN N
27 CD N
% NN N
on IN N
the DT N
L-20 NNP N
. . N

CONCLUSIONS NNP N
Despite IN N
superior JJ N
results NNS N
of IN N
induction NN N
therapy NN N
with IN N
the DT N
ALL-2 NNP N
regimen NNS N
, , N
this DT N
treatment NN N
did VBD N
not RB N
improve VB N
long-term JJ N
outcomes NNS N
. . N

When WRB N
coupled VBN N
to TO N
the DT N
reported VBN N
experience NN N
of IN N
other JJ N
studies NNS N
in IN N
adults NNS N
with IN N
ALL NNP N
, , N
the DT N
results NNS N
of IN N
this DT N
randomized VBN N
trial NN N
raise NN N
the DT N
possibility NN N
that WDT N
ultimate JJ N
outcomes NNS N
in IN N
adult NN N
ALL NNP N
may MD N
be VB N
independent JJ N
of IN N
the DT N
specific JJ N
regimen NNS N
chosen VBN N
. . N

Cancer NN N
2013 CD N
. . N

? . N
2012 CD N
American JJ N
Cancer NNP N
Society NNP N
. . N

-DOCSTART- -24004700- O O

A DT N
randomized VBN N
controlled VBN N
trial NN N
to TO N
improve VB N
colon NN N
cancer NN N
screening VBG N
in IN N
rural JJ N
family NN N
medicine NN N
: : N
an DT N
Iowa NNP N
Research NNP N
Network NNP N
( ( N
IRENE NNP N
) ) N
study NN N
. . N

BACKGROUND NNP N
Many JJ N
adults NNS N
have VBP N
not RB N
been VBN N
screened VBN N
for IN N
colon NN N
cancer NN N
, , N
a DT N
potentially RB N
preventable JJ N
cause NN N
of IN N
death NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
conducted VBN N
between IN N
December NNP N
2008 CD N
and CC N
April NNP N
2011 CD N
to TO N
improve VB N
CRC NNP N
screening VBG N
in IN N
16 CD N
rural JJ N
family NN N
physician NN N
offices NNS N
. . N

Subjects NNS N
due JJ N
for IN N
CRC NNP N
screening VBG N
were VBD N
randomized VBN N
within IN N
each DT N
practice NN N
to TO N
1 CD N
of IN N
4 CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
usual JJ N
care NN N
; : N
( ( N
2 CD N
) ) N
physician JJ N
chart NN N
reminder NN N
; : N
( ( N
3 CD N
) ) N
physician JJ N
chart NN N
reminder NN N
, , N
mailed VBN N
education NN N
, , N
CRC NNP N
reminder NN N
magnet NN N
, , N
and CC N
fecal JJ N
immunochemical JJ N
test NN N
( ( N
FIT NNP N
) ) N
( ( N
mailed JJ N
education/FIT NN N
) ) N
; : N
or CC N
( ( N
4 CD N
) ) N
all PDT N
the DT N
preceding VBG N
plus CC N
a DT N
structured JJ N
telephone NN N
call NN N
to TO N
the DT N
patient NN N
from IN N
project JJ N
staff NN N
to TO N
provide VB N
education NN N
, , N
assess JJ N
interest NN N
in IN N
screening VBG N
, , N
explain VB N
the DT N
screening NN N
tests NNS N
, , N
and CC N
address JJ N
barriers NNS N
( ( N
mailed VBN N
education/FIT RB N
plus CC N
phone NN N
call NN N
) ) N
. . N

The DT N
main JJ N
outcome NN N
was VBD N
completion NN N
of IN N
any DT N
CRC NNP N
screening NN N
. . N

RESULTS VB N
This DT N
study NN N
enrolled VBD N
743 CD N
patients NNS N
. . N

CRC NNP N
screening NN N
was VBD N
completed VBN N
by IN N
17.8 CD N
% NN N
in IN N
the DT N
usual JJ N
care NN N
group NN N
, , N
20.5 CD N
% NN N
in IN N
the DT N
chart NN N
reminder NN N
group NN N
, , N
56.5 CD N
% NN N
in IN N
the DT N
mailed JJ N
education/FIT NN N
group NN N
, , N
and CC N
57.2 CD N
% NN N
in IN N
the DT N
mailed JJ N
education/FIT NN N
plus CC N
phone NN N
call NN N
group NN N
. . N

We PRP N
found VBD N
no DT N
effect NN N
from IN N
the DT N
chart NN N
reminder NN N
compared VBN N
with IN N
usual JJ N
care NN N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
, , N
1.2 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.7-2.0 NNP N
) ) N
; : N
and CC N
a DT N
beneficial JJ N
effect NN N
from IN N
the DT N
mailed VBN N
education/FIT NN N
( ( N
OR NNP N
, , N
6.0 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
3.7-9.6 JJ N
) ) N
and CC N
the DT N
mailed JJ N
education/FIT NN N
plus CC N
phone NN N
call NN N
( ( N
OR NNP N
, , N
6.2 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
3.8-9.9 JJ N
) ) N
. . N

Both DT N
FIT NNP N
and CC N
colonoscopy JJ N
rates NNS N
increased VBD N
significantly RB N
in IN N
both DT N
mailed JJ N
education NN N
groups NNS N
. . N

CONCLUSION NNP N
CRC NNP N
screening VBG N
rates NNS N
increased VBD N
significantly RB N
among IN N
patients NNS N
who WP N
were VBD N
overdue JJ N
for IN N
screening VBG N
after IN N
they PRP N
received VBD N
mailed VBD N
educational JJ N
materials NNS N
and CC N
a DT N
FIT NNP N
. . N

The DT N
addition NN N
of IN N
a DT N
phone NN N
call NN N
did VBD N
not RB N
further JJ N
increase NN N
screening VBG N
rates NNS N
. . N

-DOCSTART- -2015394- O O

Allogeneic NNP N
marrow NN N
transplantation NN N
in IN N
patients NNS N
with IN N
chronic JJ N
myeloid NN N
leukemia NN N
in IN N
the DT N
chronic JJ N
phase NN N
: : N
a DT N
randomized JJ N
trial NN N
of IN N
two CD N
irradiation NN N
regimens NNS N
. . N

A DT N
randomized JJ N
trial NN N
was VBD N
performed VBN N
to TO N
compare VB N
two CD N
regimens NNS N
of IN N
total JJ N
body NN N
irradiation NN N
in IN N
patients NNS N
with IN N
chronic JJ N
myeloid NN N
leukemia NN N
treated VBN N
by IN N
allogeneic JJ N
marrow NN N
transplantation NN N
while IN N
in IN N
the DT N
chronic JJ N
phase NN N
. . N

All DT N
patients NNS N
received VBD N
cyclophosphamide JJ N
120 CD N
mg/kg NN N
followed VBN N
by IN N
total JJ N
body NN N
irradiation NN N
and CC N
marrow NN N
from IN N
HLA-identical JJ N
siblings NNS N
. . N

Cyclosporine NNP N
and CC N
methotrexate NN N
were VBD N
used VBN N
for IN N
prophylaxis NN N
against IN N
acute JJ N
graft-versus-host JJ N
disease NN N
. . N

Fifty-seven JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
2.0 CD N
Gy NNP N
fractions NNS N
of IN N
irradiation NN N
daily NN N
for IN N
6 CD N
days NNS N
and CC N
59 CD N
were VBD N
randomized VBN N
to TO N
receive VB N
2.25 CD N
Gy NNP N
fractions NNS N
daily RB N
for IN N
7 CD N
days NNS N
. . N

The DT N
probabilities NNS N
of IN N
relapse NN N
at IN N
4 CD N
years NNS N
were VBD N
0.25 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.00 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.008 NNP N
) ) N
. . N

The DT N
actuarial JJ N
probabilities NNS N
of IN N
survival NN N
and CC N
relapse-free JJ N
survival NN N
at IN N
4 CD N
years NNS N
were VBD N
0.60 CD N
and CC N
0.58 CD N
among IN N
the DT N
patients NNS N
who WP N
received VBD N
12.0 CD N
Gy NNP N
compared VBN N
with IN N
0.66 CD N
and CC N
0.66 CD N
for IN N
those DT N
who WP N
received VBD N
15.75 CD N
Gy NNP N
. . N

The DT N
4-year JJ N
probabilities NNS N
of IN N
transplant-related JJ N
mortality NN N
were VBD N
0.24 CD N
and CC N
0.34 CD N
respectively RB N
( ( N
P NNP N
= NNP N
.13 NNP N
) ) N
while IN N
the DT N
probability NN N
of IN N
moderate JJ N
to TO N
severe VB N
acute JJ N
graft-versus-host JJ N
disease NN N
was VBD N
0.33 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.44 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.15 NNP N
) ) N
. . N

The DT N
lower JJR N
relapse NN N
probability NN N
in IN N
the DT N
patients NNS N
receiving VBG N
the DT N
higher JJR N
dose NN N
of IN N
total JJ N
body NN N
irradiation NN N
did VBD N
not RB N
result VB N
in IN N
improved JJ N
survival NN N
because IN N
mortality NN N
from IN N
causes VBZ N
other JJ N
than IN N
relapse NN N
was VBD N
increased VBN N
. . N

-DOCSTART- -21721430- O O

Validity NNP N
and CC N
reliability NN N
assessment NN N
of IN N
the DT N
Siriraj NNP N
Asthma NNP N
Control NNP N
Questionnaire NNP N
. . N

OBJECTIVE CC N
The DT N
present JJ N
study NN N
assessed VBD N
the DT N
validity NN N
and CC N
reliability NN N
of IN N
the DT N
Siriraj NNP N
Asthma NNP N
Control NNP N
Questionnaire NNP N
in IN N
Asthma NNP N
Clinic NNP N
, , N
Siriraj NNP N
Hospital NNP N
. . N

MATERIAL NNP N
AND CC N
METHOD NNP N
The DT N
data NN N
of IN N
the DT N
questionnaire NN N
responses NNS N
and CC N
spirometric JJ N
results NNS N
from IN N
20 CD N
randomized JJ N
asthmatic JJ N
patients NNS N
in IN N
the DT N
clinic NN N
including VBG N
the DT N
record NN N
of IN N
3 CD N
visits NNS N
for IN N
each DT N
subject NN N
. . N

The DT N
validation NN N
was VBD N
performed VBN N
by IN N
Kruskal-Wallis NNP N
test NN N
comparing VBG N
the DT N
scores NNS N
with IN N
the DT N
level NN N
of IN N
asthma NNS N
control NN N
determined VBN N
by IN N
physicians NNS N
according VBG N
to TO N
GINA NNP N
guideline NN N
. . N

Internal NNP N
consistency NN N
reliability NN N
was VBD N
analyzed VBN N
by IN N
Cronbach NNP N
's POS N
alpha NN N
. . N

RESULTS NNP N
Sixty NNP N
questionnaires VBZ N
from IN N
20 CD N
patients NNS N
with IN N
age NN N
29-73 CD N
years NNS N
were VBD N
analyzed VBN N
. . N

There EX N
were VBD N
40 CD N
controlled VBN N
, , N
7 CD N
partly RB N
controlled VBN N
and CC N
13 CD N
uncontrolled JJ N
visits NNS N
. . N

The DT N
scores NNS N
from IN N
5-items JJ N
questionnaires NNS N
and CC N
6-items JJ N
clinical JJ N
score NN N
were VBD N
significantly RB N
associated VBN N
with IN N
the DT N
physician-diagnosed JJ N
groups NNS N
( ( N
i.e. FW N
, , N
controlled VBD N
, , N
partly RB N
controlled VBN N
and CC N
uncontrolled JJ N
groups NNS N
) ) N
. . N

Median JJ N
scores NNS N
( ( N
min NN N
, , N
max NN N
) ) N
were VBD N
0 CD N
( ( N
0 CD N
, , N
5 CD N
) ) N
, , N
2 CD N
( ( N
0 CD N
, , N
6 CD N
) ) N
, , N
4 CD N
( ( N
0 CD N
, , N
12 CD N
) ) N
respectively RB N
, , N
( ( N
5-items CD N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
and CC N
2 CD N
( ( N
0 CD N
, , N
7 CD N
) ) N
, , N
3 CD N
( ( N
1 CD N
, , N
7 CD N
) ) N
, , N
6 CD N
( ( N
2,15 CD N
) ) N
respectively RB N
, , N
( ( N
6-items CD N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
. . N

Internal NNP N
consistency NN N
reliability NN N
of IN N
both DT N
5-items JJ N
questionnaire NN N
and CC N
6-items JJ N
clinical JJ N
score NN N
were VBD N
within IN N
the DT N
acceptable JJ N
range NN N
( ( N
0.829 CD N
and CC N
0.708 CD N
respectively RB N
) ) N
. . N

5-items JJ N
questionnaire NN N
is VBZ N
more RBR N
associated JJ N
with IN N
the DT N
physician NN N
diagnosed VBN N
group NN N
and CC N
more JJR N
consistent JJ N
than IN N
6-items JJ N
clinical JJ N
score NN N
. . N

Further JJ N
analysis NN N
revealed VBD N
cutoff NN N
point NN N
at IN N
2.5 CD N
to TO N
separate VB N
uncontrolled JJ N
from IN N
controlled VBN N
or CC N
partly RB N
controlled VBN N
patient NN N
with IN N
sensitivity NN N
76.9 CD N
% NN N
and CC N
specificity NN N
89.4 CD N
% NN N
and CC N
cutoff NN N
point NN N
at IN N
1.5 CD N
to TO N
separate VB N
uncontrolled JJ N
or CC N
partly RB N
controlled VBN N
from IN N
controlled VBN N
patient NN N
with IN N
sensitivity NN N
70.0 CD N
% NN N
and CC N
specificity NN N
85.0 CD N
% NN N
. . N

CONCLUSION NNP N
The DT N
validity NN N
and CC N
reliability NN N
of IN N
Siriraj NNP N
Asthma NNP N
Control NNP N
Questionnaire NNP N
is VBZ N
acceptable JJ N
and CC N
might MD N
be VB N
used VBN N
in IN N
the DT N
clinical JJ N
practice NN N
and CC N
research NN N
in IN N
Thai NNP N
asthmatic JJ N
patients NNS N
. . N

-DOCSTART- -20203546- O O

Attenuation NN N
of IN N
hemodynamic JJ N
responses NNS N
to TO N
laryngoscopy VB N
and CC N
tracheal VB N
intubation NN N
during IN N
rapid JJ N
sequence NN N
induction NN N
: : N
remifentanil NN N
vs. FW N
lidocaine NN N
with IN N
esmolol NN N
. . N

AIM NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
remifentanil NN N
vs. FW N
a DT N
lidocaine-esmolol JJ N
combination NN N
in IN N
blunting VBG N
the DT N
hemodynamic JJ N
response NN N
to TO N
laryngoscopy VB N
and CC N
intubation NN N
during IN N
rapid JJ N
sequence NN N
induction NN N
using VBG N
thiopental JJ N
and CC N
rocuronium NN N
in IN N
normotensive JJ N
patients NNS N
. . N

METHODS NNP N
Sixty-six JJ N
patients NNS N
with IN N
American JJ N
Society NNP N
of IN N
Anesthesiologists NNP N
( ( N
ASA NNP N
) ) N
physical JJ N
status NN N
class NN N
I PRP N
who WP N
required VBD N
tracheal JJ N
intubation NN N
for IN N
elective JJ N
surgery NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

Group NNP N
R NNP N
received VBD N
0.9 CD N
% NN N
saline NN N
10 CD N
ml NN N
and CC N
remifentanil VB N
1 CD N
microg/kg NN N
. . N

Group NNP N
LE NNP N
received VBD N
lidocaine JJ N
1.5 CD N
mg/kg NN N
and CC N
esmolol $ N
1.0 CD N
mg/kg NN N
. . N

Anesthesia NNP N
was VBD N
induced VBN N
with IN N
thiopental JJ N
sodium NN N
5 CD N
mg/kg NN N
, , N
followed VBN N
by IN N
rocuronium NN N
1.0 CD N
mg/kg NN N
. . N

Mean NNP N
arterial JJ N
pressure NN N
and CC N
heart NN N
rate NN N
were VBD N
recorded VBN N
at IN N
baseline NN N
, , N
after IN N
induction NN N
, , N
immediately RB N
after IN N
intubation NN N
and CC N
every DT N
minute NN N
for IN N
five CD N
minutes NNS N
after IN N
intubation NN N
. . N

RESULTS NNP N
Changes NNP N
in IN N
mean JJ N
arterial JJ N
pressure NN N
over IN N
time NN N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
significantly RB N
different JJ N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
maximum JJ N
pressor NN N
response NN N
was VBD N
observed VBN N
immediately RB N
after IN N
intubation NN N
, , N
at IN N
which WDT N
time NN N
the DT N
mean JJ N
arterial JJ N
pressure NN N
change NN N
from IN N
baseline NN N
in IN N
group NN N
LE NNP N
( ( N
29.7 CD N
% NN N
) ) N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
116.1 CD N
, , N
121.9 CD N
) ) N
was VBD N
higher JJR N
than IN N
that DT N
in IN N
group NN N
R NNP N
( ( N
4.4 CD N
% NN N
) ) N
( ( N
95 CD N
% NN N
CI NNP N
: : N
92.9 CD N
, , N
98.5 CD N
) ) N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Two CD N
patients NNS N
in IN N
group NN N
R NNP N
and CC N
15 CD N
patients NNS N
in IN N
group NN N
LE NNP N
developed VBD N
hypertension NN N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NN N
: : N
0.064 CD N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Changes NNS N
in IN N
heart NN N
rate NN N
over IN N
time NN N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
( ( N
P=0.465 NNP N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
remifentanil VBZ N
1 CD N
mg/kg NN N
is VBZ N
more RBR N
effective JJ N
than IN N
the DT N
combination NN N
of IN N
lidocaine JJ N
1.5 CD N
mg/kg NN N
and CC N
esmolol $ N
1 CD N
mg/kg NN N
for IN N
attenuating VBG N
the DT N
hemodynamic JJ N
responses NNS N
to TO N
rapid JJ N
sequence NN N
intubation NN N
. . N

-DOCSTART- -19968217- O O

Evaluation NN N
of IN N
reducing VBG N
postoperative JJ N
hip NN N
precautions NNS N
in IN N
total JJ N
hip JJ N
replacement NN N
: : N
a DT N
randomized JJ N
prospective JJ N
study NN N
. . N

Currently NNP N
, , N
many JJ N
rehabilitation NN N
protocols NNS N
for IN N
total JJ N
hip NN N
replacements NNS N
( ( N
THRs NNP N
) ) N
include VBP N
activity NN N
restrictions NNS N
to TO N
prevent VB N
postoperative JJ N
dislocation NN N
. . N

There EX N
is VBZ N
increasing VBG N
demand NN N
for IN N
more RBR N
efficient JJ N
and CC N
safe JJ N
rehabilitation NN N
protocols NNS N
. . N

This DT N
randomized JJ N
prospective JJ N
study NN N
evaluates VBZ N
the DT N
need NN N
for IN N
hip NN N
restrictions NNS N
following VBG N
a DT N
modified JJ N
anterolateral JJ N
procedure NN N
. . N

From IN N
2004 CD N
to TO N
2008 CD N
, , N
81 CD N
patients NNS N
seeking VBG N
elective JJ N
THRs NNP N
were VBD N
randomly RB N
assigned VBN N
into IN N
a DT N
standard JJ N
rehabilitation NN N
group NN N
or CC N
an DT N
early JJ N
rehabilitation NN N
group NN N
. . N

The DT N
standard JJ N
group NN N
included VBD N
restrictions NNS N
to TO N
avoid VB N
hip NN N
flexion NN N
> VBD N
90 CD N
degrees NNS N
and CC N
avoidance NN N
of IN N
riding VBG N
in IN N
a DT N
car NN N
for IN N
the DT N
first JJ N
postoperative JJ N
month NN N
. . N

The DT N
early JJ N
group NN N
had VBD N
no DT N
flexion NN N
or CC N
car NN N
riding NN N
restrictions NNS N
. . N

Forty-three JJ N
patients NNS N
were VBD N
in IN N
the DT N
standard JJ N
group NN N
and CC N
38 CD N
patients NNS N
were VBD N
in IN N
the DT N
early JJ N
group NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
demographic JJ N
differences NNS N
between IN N
the DT N
2 CD N
groups NNS N
. . N

All DT N
patients NNS N
completed VBD N
the DT N
Short JJ N
Form NNP N
12-question JJ N
Health NNP N
Survey NNP N
and CC N
Harris NNP N
Hip NNP N
Score NNP N
preoperatively RB N
and CC N
at IN N
4 CD N
weeks NNS N
, , N
1 CD N
month NN N
, , N
3 CD N
months NNS N
, , N
and CC N
1 CD N
year NN N
postoperatively RB N
. . N

The DT N
time-points NNS N
at IN N
which WDT N
the DT N
patient NN N
first RB N
drove VBD N
and CC N
ambulated VBD N
with IN N
a DT N
cane NN N
, , N
without IN N
a DT N
cane NN N
, , N
and CC N
without IN N
a DT N
limp NN N
were VBD N
also RB N
collected VBN N
. . N

No DT N
incidents NNS N
of IN N
dislocation NN N
occurred VBD N
. . N

Patients NNS N
in IN N
the DT N
early JJ N
group NN N
were VBD N
faster JJR N
to TO N
ambulate VB N
with IN N
only RB N
a DT N
cane NN N
( ( N
P=.03 NNP N
) ) N
, , N
without IN N
a DT N
cane NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
without IN N
a DT N
limp NN N
( ( N
P=.003 NNP N
) ) N
. . N

They PRP N
also RB N
drove VBD N
earlier RBR N
( ( N
P=.02 NNP N
) ) N
. . N

Pace NN N
of IN N
recovery NN N
was VBD N
the DT N
only JJ N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

The DT N
early JJ N
rehabilitation NN N
protocol NN N
increases VBZ N
the DT N
pace NN N
of IN N
recovery NN N
compared VBN N
to TO N
a DT N
pathway NN N
with IN N
hip NN N
precautions NNS N
without IN N
increasing VBG N
complications NNS N
. . N

-DOCSTART- -18684258- O O

A DT N
pilot NN N
study NN N
of IN N
a DT N
low-tilt JJ N
biphasic JJ N
waveform NN N
for IN N
transvenous JJ N
cardioversion NN N
of IN N
atrial JJ N
fibrillation NN N
: : N
improved VBN N
efficacy NN N
compared VBN N
with IN N
conventional JJ N
capacitor-based JJ N
waveforms NNS N
in IN N
patients NNS N
. . N

BACKGROUND NNP N
The DT N
optimal JJ N
waveform NN N
tilt NN N
for IN N
defibrillation NN N
is VBZ N
not RB N
known VBN N
. . N

Most JJS N
modern JJ N
defibrillators NNS N
used VBN N
for IN N
the DT N
cardioversion NN N
of IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
employ VBD N
high-tilt JJ N
, , N
capacitor-based JJ N
biphasic JJ N
waveforms NNS N
. . N

METHODS NNP N
We PRP N
have VBP N
developed VBN N
a DT N
low-tilt JJ N
biphasic JJ N
waveform NN N
for IN N
defibrillation NN N
. . N

This DT N
low-tilt JJ N
waveform NN N
was VBD N
compared VBN N
with IN N
a DT N
conventional JJ N
waveform NN N
of IN N
equivalent JJ N
duration NN N
and CC N
voltage NN N
in IN N
patients NNS N
with IN N
AF NNP N
. . N

Patients NNS N
with IN N
persistent JJ N
AF NNP N
or CC N
AF NNP N
induced VBD N
during IN N
a DT N
routine JJ N
electrophysiology NN N
study NN N
( ( N
EPS NNP N
) ) N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
the DT N
low-tilt JJ N
waveform NN N
or CC N
a DT N
conventional JJ N
waveform NN N
. . N

Defibrillation NNP N
electrodes NNS N
were VBD N
positioned VBN N
in IN N
the DT N
right JJ N
atrial JJ N
appendage NN N
and CC N
distal JJ N
coronary JJ N
sinus NN N
. . N

Phase VB N
1 CD N
peak JJ N
voltage NN N
was VBD N
increased VBN N
in IN N
a DT N
stepwise NN N
progression NN N
from IN N
50 CD N
V NNP N
to TO N
300V CD N
. . N

Shock NNP N
success NN N
was VBD N
defined VBN N
as IN N
return NN N
of IN N
sinus NN N
rhythm NN N
for IN N
> NNP N
/=30 NNP N
seconds NNS N
. . N

RESULTS VB N
The DT N
low-tilt JJ N
waveform NN N
produced VBN N
successful JJ N
termination NN N
of IN N
persistent JJ N
AF NNP N
at IN N
a DT N
mean JJ N
voltage NN N
of IN N
223 CD N
V NNP N
( ( N
8.2 CD N
J NNP N
) ) N
versus VBD N
270 CD N
V NNP N
( ( N
6.7 CD N
J NNP N
) ) N
with IN N
the DT N
conventional JJ N
waveform NN N
( ( N
P NNP N
= VBZ N
0.002 CD N
for IN N
voltage NN N
, , N
P NNP N
= NNP N
ns NN N
for IN N
energy NN N
) ) N
. . N

In IN N
patients NNS N
with IN N
induced JJ N
AF NNP N
the DT N
mean JJ N
voltage NN N
for IN N
the DT N
low-tilt JJ N
waveform NN N
was VBD N
91V CD N
( ( N
1.6 CD N
J NNP N
) ) N
and CC N
for IN N
the DT N
conventional JJ N
waveform NN N
was VBD N
158 CD N
V NNP N
( ( N
2.0 CD N
J NNP N
) ) N
( ( N
P NNP N
= VBZ N
0.005 CD N
for IN N
voltage NN N
, , N
P NNP N
= NNP N
ns NN N
for IN N
energy NN N
) ) N
. . N

The DT N
waveform NN N
was VBD N
much RB N
more RBR N
successful JJ N
at IN N
very RB N
low JJ N
voltages NNS N
( ( N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
100 CD N
V NNP N
) ) N
compared VBN N
with IN N
the DT N
conventional JJ N
waveform NN N
( ( N
Novel NNP N
: : N
82 CD N
% NN N
vs JJ N
Conventional NNP N
22 CD N
% NN N
, , N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
low-tilt JJ N
biphasic JJ N
waveform NN N
was VBD N
more RBR N
successful JJ N
for IN N
the DT N
internal JJ N
cardioversion NN N
of IN N
both DT N
persistent JJ N
and CC N
induced JJ N
AF NNP N
in IN N
patients NNS N
( ( N
in IN N
terms NNS N
of IN N
leading VBG N
edge NN N
voltage NN N
) ) N
. . N

-DOCSTART- -15701493- O O

Randomized VBN N
controlled VBD N
trial NN N
to TO N
compare VB N
the DT N
early JJ N
and CC N
mid-term JJ N
results NNS N
of IN N
stapled JJ N
versus NN N
open JJ N
hemorrhoidectomy NN N
. . N

BACKGROUND VB N
The DT N
new JJ N
technique NN N
of IN N
circular JJ N
stapler NN N
for IN N
the DT N
treatment NN N
of IN N
hemorrhoids NNS N
has VBZ N
shown VBN N
early JJ N
promise NN N
in IN N
terms NNS N
of IN N
minimal NN N
or CC N
no DT N
postoperative JJ N
pain NN N
, , N
early JJ N
discharge NN N
from IN N
hospital NN N
, , N
and CC N
quick JJ N
return NN N
to TO N
work VB N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
stapled VBN N
technique NN N
with IN N
the DT N
well-accepted JJ N
conventional JJ N
Milligan NNP N
Morgan NNP N
hemorrhoidectomy NN N
. . N

METHODS NNP N
After IN N
fulfilling VBG N
the DT N
selection NN N
criteria NNS N
, , N
84 CD N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
stapled VBN N
( ( N
n JJ N
= NNP N
42 CD N
) ) N
or CC N
open JJ N
group NN N
( ( N
n JJ N
= NNP N
42 CD N
) ) N
. . N

All DT N
patients NNS N
were VBD N
operated VBN N
on IN N
under IN N
spinal JJ N
anesthesia NN N
. . N

The DT N
2 CD N
techniques NNS N
were VBD N
evaluated VBN N
with IN N
respect NN N
to TO N
the DT N
operative JJ N
time NN N
, , N
pain NN N
scores NNS N
, , N
complications NNS N
, , N
day NN N
of IN N
discharge NN N
, , N
return NN N
to TO N
work VB N
, , N
and CC N
level NN N
of IN N
satisfaction NN N
. . N

RESULTS VB N
The DT N
mean JJ N
age NN N
of IN N
patients NNS N
was VBD N
46.02 CD N
years NNS N
( ( N
SD NNP N
, , N
12.33 CD N
) ) N
in IN N
the DT N
stapled JJ N
group NN N
and CC N
48.64 CD N
years NNS N
( ( N
14.57 CD N
) ) N
in IN N
the DT N
open JJ N
group NN N
. . N

Grade NNP N
III NNP N
or CC N
IV NNP N
hemorrhoids NNS N
were VBD N
more JJR N
common JJ N
in IN N
men NNS N
( ( N
ie NN N
, , N
80.9 CD N
% NN N
and CC N
85.7 CD N
% NN N
in IN N
the DT N
stapled JJ N
and CC N
open JJ N
group NN N
, , N
respectively RB N
) ) N
. . N

The DT N
mean JJ N
operative JJ N
time NN N
was VBD N
shorter RBR N
in IN N
the DT N
stapled JJ N
group NN N
24.28 CD N
minutes NNS N
( ( N
4.25 CD N
) ) N
versus NN N
45.21 CD N
minutes NNS N
( ( N
5.36 CD N
) ) N
in IN N
the DT N
Milligan-Morgan NNP N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
blood NN N
loss NN N
, , N
pain NN N
scores NNS N
and CC N
requirement NN N
of IN N
analgesics NNS N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
stapled JJ N
group NN N
. . N

Mean NNP N
hospital NN N
stay NN N
was VBD N
1.24 CD N
days NNS N
( ( N
0.62 CD N
) ) N
and CC N
2.76 CD N
days NNS N
( ( N
1.01 CD N
) ) N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
stapled JJ N
and CC N
open JJ N
group NN N
, , N
respectively RB N
. . N

The DT N
patients NNS N
in IN N
the DT N
stapled JJ N
group NN N
returned VBD N
to TO N
work VB N
or CC N
routine VB N
activities NNS N
earlier RBR N
( ( N
ie NN N
, , N
within IN N
8.12 CD N
days NNS N
[ RB N
2.48 CD N
] NN N
) ) N
as IN N
compared VBN N
with IN N
17.62 CD N
( ( N
5.59 CD N
) ) N
in IN N
the DT N
open JJ N
group NN N
. . N

Only RB N
88.1 CD N
% NN N
of IN N
patients NNS N
were VBD N
satisfied VBN N
by IN N
the DT N
open JJ N
method NN N
compared VBN N
with IN N
97.6 CD N
% NN N
after IN N
the DT N
stapled JJ N
technique NN N
. . N

The DT N
median JJ N
follow-up JJ N
period NN N
was VBD N
11 CD N
months NNS N
with IN N
a DT N
maximum JJ N
follow-up NN N
of IN N
19 CD N
months NNS N
( ( N
range VB N
2-19 JJ N
months NNS N
) ) N
. . N

CONCLUSIONS NNP N
Stapled NNP N
hemorrhoidectomy NN N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
day-care JJ N
procedure NN N
for IN N
the DT N
treatment NN N
of IN N
grade NN N
III NNP N
and CC N
grade VBD N
IV NNP N
hemorrhoids NNS N
. . N

It PRP N
ensures VBZ N
lesser RBR N
postoperative JJ N
pain NN N
, , N
early JJ N
discharge NN N
, , N
less JJR N
time NN N
off IN N
work NN N
, , N
complications NNS N
similar JJ N
to TO N
the DT N
open JJ N
technique NN N
, , N
and CC N
in IN N
the DT N
end NN N
a DT N
more RBR N
satisfied JJ N
patient NN N
with IN N
no DT N
perianal JJ N
wound NN N
. . N

However RB N
, , N
more RBR N
such JJ N
randomized JJ N
trials NNS N
are VBP N
essential JJ N
to TO N
deny VB N
any DT N
long-term JJ N
complication NN N
. . N

-DOCSTART- -22696144- O O

The DT N
effect NN N
of IN N
magnesium NN N
added VBN N
to TO N
levobupivacaine VB N
for IN N
femoral JJ N
nerve NN N
block NN N
on IN N
postoperative JJ N
analgesia NN N
in IN N
patients NNS N
undergoing VBG N
ACL NNP N
reconstruction NN N
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
randomised VBD N
double-blind NN N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
magnesium NN N
added VBN N
to TO N
local JJ N
anaesthetics NNS N
on IN N
postoperative JJ N
VAS NNP N
scores NNS N
, , N
total JJ N
opioid JJ N
consumption NN N
, , N
time NN N
to TO N
first JJ N
mobilisation NN N
, , N
patient JJ N
satisfaction NN N
and CC N
rescue NN N
analgesic JJ N
requirements NNS N
in IN N
arthroscopic JJ N
ACL NNP N
reconstruction NN N
surgery NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
107 CD N
American JJ N
Society NNP N
of IN N
Anaesthesiologists NNP N
physical JJ N
status NN N
grade NN N
I PRP N
and CC N
II NNP N
patients NNS N
between IN N
18 CD N
and CC N
65 CD N
years NNS N
of IN N
age NN N
who WP N
were VBD N
scheduled VBN N
to TO N
undergo VB N
elective JJ N
anterior JJ N
crucial JJ N
ligament NN N
( ( N
ACL NNP N
) ) N
reconstruction NN N
with IN N
hamstring VBG N
autografts NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

The DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
Groups NNP N
L NNP N
( ( N
n JJ N
= NNP N
51 CD N
) ) N
and CC N
LM NNP N
( ( N
n JJ N
= NNP N
56 CD N
) ) N
using VBG N
the DT N
closed-envelope NN N
method NN N
. . N

Group NNP N
LM NNP N
was VBD N
administered VBN N
19 CD N
ml NN N
of IN N
0.25 CD N
% NN N
levobupivacaine NN N
and CC N
1 CD N
ml NN N
of IN N
15 CD N
% NN N
magnesium NN N
sulphate NN N
, , N
while IN N
Group NNP N
L NNP N
was VBD N
administered VBN N
20 CD N
ml NN N
of IN N
0.25 CD N
% NN N
levobupivacaine NN N
for IN N
femoral JJ N
blockade NN N
. . N

General NNP N
anaesthesia NN N
was VBD N
administered VBN N
using VBG N
laryngeal JJ N
airway RB N
masks NNS N
following VBG N
neural JJ N
blockade NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
for IN N
heart NN N
rate NN N
and CC N
mean VB N
arterial JJ N
pressure NN N
, , N
oxygen NN N
saturation NN N
, , N
visual JJ N
analogue NN N
score NN N
( ( N
VAS NNP N
) ) N
, , N
verbal JJ N
rating NN N
scale NN N
( ( N
VRS NNP N
) ) N
, , N
rescue NN N
analgesic JJ N
requirements NNS N
, , N
total JJ N
opioid JJ N
consumption NN N
, , N
side NN N
effects NNS N
and CC N
time NN N
to TO N
first JJ N
mobilisation NN N
at IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
4th CD N
, , N
6th CD N
, , N
12th CD N
and CC N
24th CD N
hours NNS N
postoperatively RB N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
demographic JJ N
data NNS N
, , N
mean JJ N
arterial JJ N
pressure NN N
, , N
heart NN N
rate NN N
or CC N
oxygen NN N
saturation NN N
between IN N
groups NNS N
. . N

The DT N
area NN N
under IN N
the DT N
curve NN N
VAS NNP N
and CC N
VRS NNP N
scores NNS N
were VBD N
lower JJR N
at IN N
4 CD N
, , N
6 CD N
, , N
12 CD N
and CC N
24 CD N
h NN N
in IN N
Group NNP N
LM NNP N
( ( N
p JJ N
= NN N
0.001 CD N
, , N
p NN N
= VBD N
0.016 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
rescue NN N
analgesic JJ N
requirement NN N
and CC N
the DT N
total JJ N
opioid JJ N
consumption NN N
were VBD N
significantly RB N
lower JJR N
in IN N
Group NNP N
LM NNP N
( ( N
p JJ N
= NN N
0.015 CD N
, , N
p NN N
= VBD N
0.019 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
time NN N
to TO N
first JJ N
mobilisation NN N
and CC N
the DT N
Likert NNP N
score NN N
( ( N
completely RB N
comfortable JJ N
; : N
quite RB N
comfortable JJ N
; : N
slight JJ N
discomfort NN N
; : N
painful JJ N
; : N
very RB N
painful JJ N
) ) N
were VBD N
higher JJR N
, , N
and CC N
the DT N
block NN N
onset VBD N
time NN N
was VBD N
lower JJR N
in IN N
Group NNP N
LM NNP N
( ( N
p JJ N
= NN N
0.014 CD N
and CC N
p VB N
= JJ N
0.012 CD N
, , N
respectively RB N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
terms NNS N
of IN N
side NN N
effects NNS N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
magnesium NN N
to TO N
levobupivacaine VB N
prolongs NNS N
the DT N
sensory NN N
and CC N
motor NN N
block NN N
duration NN N
without IN N
increasing VBG N
side NN N
effects NNS N
, , N
enhances VBZ N
the DT N
quality NN N
of IN N
postoperative JJ N
analgesia NN N
and CC N
increases VBZ N
patient JJ N
satisfaction NN N
; : N
however RB N
, , N
the DT N
addition NN N
of IN N
magnesium NN N
delays VBZ N
the DT N
time NN N
to TO N
first JJ N
mobilisation NN N
and CC N
decreases VBZ N
rescue NN N
analgesic JJ N
requirements NNS N
. . N

-DOCSTART- -9109702- O O

Comparative JJ N
efficacy NN N
and CC N
safety NN N
of IN N
twice JJ N
daily JJ N
fluticasone NN N
propionate NN N
powder NN N
versus NN N
placebo NN N
in IN N
the DT N
treatment NN N
of IN N
moderate JJ N
asthma NN N
. . N

BACKGROUND NNP N
Fluticasone NNP N
propionate NN N
, , N
an DT N
inhaled JJ N
corticosteroid NN N
with IN N
negligible JJ N
systemic JJ N
bioavailability NN N
via IN N
the DT N
oral JJ N
route NN N
, , N
is VBZ N
efficacious JJ N
in IN N
the DT N
treatment NN N
of IN N
asthma NN N
when WRB N
administered VBN N
via IN N
metered-dose JJ N
inhaler NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
inhaled JJ N
fluticasone NN N
propionate NN N
powder NN N
in IN N
patients NNS N
with IN N
moderate JJ N
asthma NNS N
previously RB N
treated VBN N
with IN N
an DT N
inhaled JJ N
corticosteroid NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel-group JJ N
, , N
multicenter NN N
study NN N
of IN N
342 CD N
adolescent NN N
and CC N
adult NN N
patients NNS N
with IN N
moderate JJ N
asthma NNS N
[ RB N
forced VBD N
expiratory JJ N
volume NN N
in IN N
1 CD N
second JJ N
( ( N
FEV1 NNP N
) ) N
between IN N
50 CD N
% NN N
and CC N
80 CD N
% NN N
of IN N
predicted JJ N
] NNP N
treated VBD N
previously RB N
by IN N
beclomethasone NN N
dipropionate NN N
or CC N
triamcinolone NN N
acetonide RB N
. . N

Patients NNS N
received VBD N
fluticasone JJ N
propionate NN N
powder NN N
50 CD N
micrograms NNS N
, , N
100 CD N
micrograms NNS N
, , N
250 CD N
micrograms NNS N
, , N
or CC N
placebo NN N
via IN N
a DT N
breath-actuated JJ N
inhalation NN N
device NN N
, , N
the DT N
Diskhaler NNP N
, , N
twice RB N
daily RB N
for IN N
12 CD N
weeks NNS N
. . N

RESULTS JJ N
Patients NNPS N
in IN N
the DT N
fluticasone NN N
propionate NN N
groups NNS N
experienced VBD N
a DT N
mean JJ N
increase NN N
from IN N
baseline NN N
to TO N
endpoint VB N
in IN N
FEV1 NNP N
ranging VBG N
from IN N
0.43 CD N
L NNP N
to TO N
0.47 CD N
L. NNP N
Patients NNPS N
in IN N
the DT N
placebo NN N
group NN N
experienced VBD N
a DT N
mean JJ N
decrease NN N
from IN N
baseline NN N
of IN N
0.22 CD N
L NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
probability NN N
of IN N
patients NNS N
remaining VBG N
in IN N
the DT N
study NN N
over IN N
time NN N
without IN N
developing VBG N
signs NNS N
of IN N
exacerbating VBG N
asthma NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
fluticasone NN N
propionate NN N
groups NNS N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Asthma NNP N
symptom NN N
scores NNS N
, , N
supplemental JJ N
rescue NN N
albuterol NN N
use NN N
, , N
and CC N
number NN N
of IN N
nighttime JJ N
awakenings NNS N
due JJ N
to TO N
asthma VB N
requiring VBG N
treatment NN N
also RB N
improved VBN N
significantly RB N
with IN N
all DT N
fluticasone NN N
propionate NN N
treatment NN N
regimens NNS N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
at IN N
endpoint NN N
among IN N
the DT N
three CD N
fluticasone NN N
propionate NN N
groups NNS N
. . N

No DT N
serious JJ N
drug-related JJ N
adverse JJ N
events NNS N
occurred VBD N
. . N

CONCLUSIONS NNP N
Fluticasone NNP N
propionate NN N
powder NN N
( ( N
50 CD N
, , N
100 CD N
, , N
and CC N
250 CD N
micrograms NNS N
) ) N
was VBD N
well-tolerated JJ N
and CC N
significantly RB N
improved VBN N
lung NN N
function NN N
in IN N
patients NNS N
with IN N
moderate JJ N
asthma NNS N
. . N

-DOCSTART- -9806121- O O

Sunbathing VBG N
and CC N
sunbed VBN N
use NN N
related VBN N
to TO N
self-image NN N
in IN N
a DT N
randomized JJ N
sample NN N
of IN N
Swedish JJ N
adolescents NNS N
. . N

In IN N
1996 CD N
a DT N
randomized JJ N
sample NN N
of IN N
4,020 CD N
Swedish JJ N
adolescents NNS N
from IN N
three CD N
birth NN N
cohorts NNS N
were VBD N
sent VBN N
a DT N
questionnaire NN N
consisting NN N
of IN N
50 CD N
items NNS N
concerning VBG N
habitual JJ N
sun-related JJ N
behaviours NNS N
and CC N
attitudes NNS N
, , N
knowledge NN N
about IN N
melanoma NN N
, , N
risk NN N
perception NN N
and CC N
self-image NN N
. . N

A DT N
total NN N
of IN N
2,615 CD N
questionnaires NNS N
were VBD N
returned VBN N
. . N

Girls NNP N
sunbathed VBD N
and CC N
used VBD N
sunbeds NNS N
more RBR N
than IN N
boys NNS N
at IN N
all DT N
ages NNS N
. . N

Sunbathing VBG N
and CC N
sunbed VBN N
use NN N
increased VBN N
with IN N
age NN N
. . N

Boys NNS N
who WP N
were VBD N
most RBS N
satisfied JJ N
and CC N
girls NNS N
least JJS N
satisfied JJ N
with IN N
themselves PRP N
sunbathed VBD N
most JJS N
. . N

Those DT N
who WP N
were VBD N
least JJS N
satisfied JJ N
with IN N
themselves PRP N
used VBD N
sunbeds NNS N
most RBS N
frequently RB N
. . N

Girls NNP N
reported VBD N
a DT N
higher JJR N
perceived JJ N
susceptibility NN N
to TO N
melanoma VB N
than IN N
did VBD N
boys VB N
. . N

The DT N
perception NN N
of IN N
susceptibility NN N
increased VBN N
with IN N
age NN N
. . N

Those DT N
who WP N
were VBD N
least JJS N
satisfied JJ N
with IN N
themselves PRP N
reported VBD N
feeling VBG N
most RBS N
susceptible JJ N
. . N

The DT N
overall JJ N
main JJ N
reason NN N
for IN N
sunbathing NN N
was VBD N
appearance NN N
, , N
both DT N
for IN N
own JJ N
sunbathing NN N
, , N
and CC N
to TO N
an DT N
even RB N
higher JJR N
degree NN N
, , N
as IN N
a DT N
supposed JJ N
reason NN N
for IN N
other JJ N
adolescents NNS N
' POS N
behaviour NN N
, , N
and CC N
was VBD N
reported VBN N
most JJS N
frequently RB N
by IN N
girls NNS N
and CC N
the DT N
older JJR N
age NN N
groups NNS N
. . N

The DT N
second JJ N
most RBS N
'important JJ N
' POS N
reason NN N
for IN N
sunbathing NN N
was VBD N
'feeling VBG N
warm JJ N
and CC N
comfortable JJ N
' '' N
. . N

Preventive JJ N
programmes NNS N
aimed VBN N
at IN N
a DT N
change NN N
of IN N
sun NN N
related VBN N
behaviours NNS N
among IN N
Swedish JJ N
adolescents NNS N
have VBP N
to TO N
be VB N
tailored VBN N
to TO N
the DT N
climate NN N
and CC N
cultural JJ N
conditions NNS N
and CC N
must MD N
take VB N
into IN N
account NN N
that IN N
having VBG N
a DT N
tan NN N
, , N
and CC N
the DT N
warmth NN N
of IN N
the DT N
sun NN N
, , N
are VBP N
highly RB N
valued VBN N
by IN N
most JJS N
adolescents NNS N
. . N

-DOCSTART- -11517983- O O

Comparison NNP N
of IN N
thiopentone/guaifenesin NN N
, , N
ketamine/guaifenesin NN N
and CC N
ketamine/midazolam NN N
for IN N
the DT N
induction NN N
of IN N
horses NNS N
to TO N
be VB N
anaesthetised VBN N
with IN N
isoflurane NN N
. . N

Forty-eight JJ N
horses NNS N
subjected VBN N
to TO N
elective VB N
surgery NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
groups NNS N
of IN N
16 CD N
horses NNS N
. . N

After IN N
premedication NN N
with IN N
0.1 CD N
mg/kg NNS N
acepromazine VBP N
intramuscularly RB N
and CC N
0.6 CD N
mg/kg NNS N
xylazine JJ N
intravenously RB N
, , N
anaesthesia NN N
was VBD N
induced VBN N
either RB N
with IN N
2 CD N
g NNS N
thiopentone NN N
in IN N
500 CD N
ml NN N
of IN N
a DT N
10 CD N
per IN N
cent NN N
guaifenesin NN N
solution NN N
, , N
given VBN N
intravenously RB N
at IN N
a DT N
dose NN N
of IN N
1 CD N
ml/kg NNS N
( ( N
group NN N
TG NNP N
) ) N
, , N
or CC N
with IN N
100 CD N
mg/kg NNS N
guaifenesin NN N
and CC N
2.2 CD N
mg/kg NN N
ketamine NN N
given VBN N
intravenously RB N
( ( N
group NN N
KG NNP N
) ) N
, , N
or CC N
with IN N
0.06 CD N
mg/kg NNS N
midazolam NN N
, , N
and CC N
2.2 CD N
mg/kg NN N
ketamine NN N
given VBN N
intravenously RB N
( ( N
group NN N
KM NNP N
) ) N
. . N

Anaesthesia NNP N
was VBD N
maintained VBN N
with IN N
isoflurane NN N
. . N

The DT N
mean NN N
( ( N
sd NN N
) ) N
end NN N
tidal JJ N
isoflurane NN N
concentration NN N
( ( N
per IN N
cent NN N
) ) N
needed VBD N
to TO N
maintain VB N
a DT N
light JJ N
surgical JJ N
anaesthesia NN N
( ( N
stage NN N
III NNP N
, , N
plane NN N
2 CD N
) ) N
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
KM NNP N
( ( N
0.91 CD N
[ RB N
0.03 CD N
] NN N
) ) N
than IN N
in IN N
groups NNS N
TG NNP N
( ( N
1.11 CD N
[ RB N
0.03 CD N
] NN N
) ) N
and CC N
KG NNP N
( ( N
1.14 CD N
[ RB N
0.03 CD N
] NN N
) ) N
. . N

The DT N
mean NN N
( ( N
sd NN N
) ) N
arterial JJ N
pressure NN N
( ( N
mmHg NN N
) ) N
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
KG NNP N
( ( N
67.4 CD N
[ RB N
2.07 CD N
] NN N
) ) N
than IN N
in IN N
groups NNS N
TC NNP N
( ( N
75.6 CD N
[ RB N
2.23 CD N
] NN N
) ) N
and CC N
KM NNP N
( ( N
81.0 CD N
[ RB N
2.16 CD N
] NN N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
logarithm NN N
of IN N
the DT N
heart NN N
rate NN N
, , N
recovery NN N
time NN N
or CC N
quality NN N
of IN N
recovery NN N
between IN N
the DT N
three CD N
induction NN N
groups NNS N
. . N

However RB N
, , N
pronounced VBD N
ataxia NN N
was VBD N
observed VBN N
in IN N
the DT N
horses NNS N
of IN N
group NN N
KM NNP N
, , N
especially RB N
after IN N
periods NNS N
of IN N
anaesthesia NN N
lasting VBG N
less JJR N
than IN N
75 CD N
minutes NNS N
. . N

-DOCSTART- -17477785- O O

Can MD N
a DT N
home-visit JJ N
invitation NN N
increase NN N
Pap NNP N
smear JJ N
screening NN N
in IN N
Samliem NNP N
, , N
Khon NNP N
Kaen NNP N
, , N
Thailand NNP N
? . N
Our PRP$ N
objective NN N
was VBD N
to TO N
assess VB N
the DT N
efficiency NN N
of IN N
a DT N
home-visit JJ N
invitation NN N
aimed VBN N
to TO N
increase VB N
uptake NN N
of IN N
cervical JJ N
cancer NN N
screening VBG N
in IN N
women NNS N
between IN N
35 CD N
and CC N
60 CD N
years NNS N
of IN N
age NN N
. . N

From NN N
May NNP N
, , N
2006 CD N
, , N
we PRP N
conducted VBD N
a DT N
quasi-randomized JJ N
trial NN N
to TO N
determine VB N
if IN N
an DT N
in-home JJ N
education NN N
and CC N
invitation NN N
intervention NN N
would MD N
increase VB N
uptake NN N
of IN N
cervical JJ N
cancer NN N
screening VBG N
. . N

We PRP N
randomly RB N
recruited VBD N
304 CD N
women NNS N
from IN N
the DT N
Samliem NNP N
inner-city NN N
community NN N
, , N
Khon NNP N
Kaen NNP N
, , N
Northeast NNP N
Thailand NNP N
, , N
and CC N
assigned VBD N
participants NNS N
to TO N
either VB N
the DT N
intervention NN N
or CC N
control VB N
zone NN N
. . N

Baseline NNP N
screening VBG N
coverage NN N
interviews NNS N
were VBD N
then RB N
performed VBN N
: : N
58 CD N
of IN N
158 CD N
women NNS N
in IN N
the DT N
intervention NN N
zone NN N
and CC N
46 CD N
of IN N
146 CD N
in IN N
the DT N
control NN N
zone NN N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
because IN N
of IN N
having VBG N
had VBD N
a DT N
Pap NNP N
smear NN N
within IN N
5 CD N
years NNS N
, , N
but CC N
these DT N
were VBD N
included VBN N
in IN N
the DT N
final JJ N
analysis NN N
. . N

First NNP N
, , N
100 CD N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
were VBD N
visited VBN N
in IN N
their PRP$ N
homes NNS N
by IN N
one CD N
of IN N
the DT N
researchers NNS N
, , N
who WP N
provided VBD N
culturally-sensitive JJ N
health NN N
education NN N
that WDT N
emphasized VBD N
the DT N
need NN N
for IN N
screening VBG N
. . N

Four CD N
months NNS N
later RB N
, , N
post-intervention NN N
, , N
screening-coverage JJ N
interviews NNS N
were VBD N
again RB N
performed VBN N
in IN N
both DT N
groups NNS N
, , N
in IN N
combination NN N
with IN N
the DT N
same JJ N
health NN N
education NN N
for IN N
100 CD N
women NNS N
in IN N
the DT N
control NN N
group NN N
for IN N
a DT N
comparison NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
baseline NN N
Pap NNP N
smear JJ N
screening-coverage NN N
rate NN N
in IN N
the DT N
intervention NN N
vs. FW N
control NN N
zones NNS N
( ( N
36.7 CD N
vs. FW N
31.5 CD N
% NN N
, , N
p=0.339 NN N
) ) N
. . N

One CD N
hundred JJ N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
completed VBD N
the DT N
intervention NN N
interviews NNS N
and CC N
after IN N
four CD N
months NNS N
, , N
100 CD N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
and CC N
100 CD N
in IN N
the DT N
control NN N
group NN N
also RB N
completed VBD N
the DT N
post-intervention NN N
interviews NNS N
. . N

The DT N
increased JJ N
screening-coverage NN N
rate NN N
in IN N
the DT N
intervention NN N
zone NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
the DT N
control NN N
zone NN N
( ( N
43.6 CD N
vs. FW N
34.9 CD N
% NN N
, , N
p=0.119 NN N
) ) N
; : N
however RB N
, , N
there EX N
was VBD N
a DT N
borderline NN N
significant JJ N
increase NN N
in IN N
the DT N
intervention NN N
zone NN N
compared VBN N
with IN N
baseline NN N
( ( N
36.7 CD N
to TO N
43.6 CD N
% NN N
, , N
p=0.070 NN N
) ) N
. . N

Therefore NNP N
, , N
home NN N
visit NN N
education NN N
and CC N
invitation NN N
intervention NN N
produced VBD N
only RB N
a DT N
nominal JJ N
effect NN N
on IN N
increasing VBG N
Pap NNP N
smear JJ N
coverage NN N
within IN N
a DT N
4-month JJ N
study NN N
period NN N
. . N

-DOCSTART- -16095446- O O

Nitrous JJ N
oxide JJ N
diffusion NN N
into IN N
tracheal JJ N
tube JJ N
cuffs NNS N
-- : N
efficacy NN N
of IN N
a DT N
new JJ N
prototype NN N
cuff NN N
pressure NN N
release NN N
valve NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
performance NN N
of IN N
a DT N
new JJ N
cuff NN N
pressure NN N
release NN N
valve NN N
( ( N
CPRV NNP N
) ) N
, , N
in IN N
which WDT N
the DT N
release NN N
pressure NN N
can MD N
be VB N
adjusted VBN N
from IN N
10 CD N
to TO N
25 CD N
cmH2O NNS N
, , N
particularly RB N
intended VBN N
to TO N
control VB N
pressure NN N
in IN N
paediatric JJ N
cuffed NN N
tracheal NN N
tubes NNS N
and CC N
to TO N
avoid VB N
cuff NN N
hyperinflation NN N
caused VBN N
by IN N
N2O NNP N
diffusion NN N
. . N

METHODS NNP N
In IN N
vitro NN N
: : N
the DT N
PRV NNP N
was VBD N
set VBN N
to TO N
10 CD N
, , N
15 CD N
, , N
20 CD N
or CC N
25 CD N
cmH2O JJ N
release NN N
pressure NN N
and CC N
connected VBN N
to TO N
a DT N
cuffed NN N
tube NN N
placed VBD N
into IN N
a DT N
box NN N
flushed VBN N
with IN N
66 CD N
% NN N
N2O NNP N
in IN N
O2 NNP N
. . N

The DT N
cuff NN N
pressure NN N
was VBD N
monitored VBN N
with IN N
and CC N
without IN N
CPRV NNP N
for IN N
60 CD N
min NN N
. . N

Experiments NNS N
were VBD N
performed VBN N
four CD N
times NNS N
using VBG N
two CD N
different JJ N
CPRVs NNP N
. . N

In IN N
vivo NN N
: : N
with IN N
Institutional NNP N
Review NNP N
Board NNP N
approval NN N
, , N
CPRV NNP N
was VBD N
studied VBN N
in IN N
50 CD N
children NNS N
undergoing VBG N
general JJ N
anaesthesia NN N
with IN N
tracheal JJ N
intubation NN N
and CC N
standardized JJ N
anaesthesia NN N
technique NN N
( ( N
including VBG N
66 CD N
% NN N
N2O NNP N
in IN N
O2 NNP N
) ) N
and CC N
ventilator JJ N
settings NNS N
. . N

Patients NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
( ( N
with IN N
and CC N
without IN N
CPRV NNP N
) ) N
. . N

The DT N
cuff JJ N
pressure NN N
baseline NN N
was VBD N
20 CD N
cmH2O NN N
and CC N
CPRV NNP N
was VBD N
set VBN N
to TO N
25 CD N
cmH2O NN N
. . N

If IN N
the DT N
cuff NN N
pressure NN N
exceeded VBD N
25 CD N
cmH2O NN N
, , N
it PRP N
was VBD N
manually RB N
released VBN N
to TO N
20 CD N
cmH2O NN N
. . N

The DT N
numbers NNS N
of IN N
deflations NNS N
in IN N
both DT N
groups NNS N
were VBD N
noted VBN N
and CC N
compared VBN N
by IN N
Mann-Whitney NNP N
U-test NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS NNP N
In IN N
vitro NN N
: : N
the DT N
cuff NN N
pressure NN N
exceeded VBD N
50 CD N
cmH2O NN N
after IN N
60 CD N
min NN N
without IN N
CPRV NNP N
, , N
but CC N
did VBD N
not RB N
exceed VB N
the DT N
settings NNS N
with IN N
CPRV NNP N
. . N

In IN N
vivo NN N
: : N
there EX N
was VBD N
no DT N
need NN N
to TO N
manually RB N
deflate VB N
the DT N
cuff NN N
in IN N
the DT N
CPRV NNP N
group NN N
but CC N
, , N
in IN N
every DT N
patient NN N
in IN N
the DT N
control NN N
group NN N
, , N
three CD N
( ( N
two CD N
to TO N
seven CD N
) ) N
deflating VBG N
manoeuvres NNS N
were VBD N
required VBN N
within IN N
the DT N
first JJ N
hour NN N
of IN N
anaesthesia NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
CPRV NNP N
allows VBZ N
reliable JJ N
cuff NN N
pressure NN N
release NN N
at IN N
various JJ N
pressure NN N
levels NNS N
and CC N
reliably RB N
prevents NNS N
cuff JJ N
pressure NN N
increases NNS N
caused VBN N
by IN N
N2O NNP N
. . N

-DOCSTART- -18161677- O O

Effect NN N
of IN N
upper JJ N
arm NN N
brachial NN N
basilic NN N
and CC N
prosthetic JJ N
forearm NN N
arteriovenous JJ N
fistula NN N
on IN N
left JJ N
ventricular JJ N
hypertrophy NN N
. . N

BACKGROUND NNP N
Creation NNP N
of IN N
an DT N
arteriovenous JJ N
fistula NN N
( ( N
AVF NNP N
) ) N
may MD N
increase VB N
left VBD N
ventricular JJ N
hypertrophy NN N
in IN N
the DT N
hemodialysis NN N
population NN N
. . N

Aim NNP N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
a DT N
brachial-basilic JJ N
( ( N
BB NNP N
) ) N
AVF NNP N
and CC N
the DT N
prosthetic JJ N
brachial-antecubital JJ N
forearm NN N
loop NN N
access NN N
( ( N
PTFE NNP N
) ) N
on IN N
cardiac JJ N
performance NN N
. . N

METHODS JJ N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
receive VB N
BB-AVF NNP N
or CC N
prosthetic JJ N
brachial-antecubital JJ N
forearm NN N
loop NN N
access NN N
. . N

Before IN N
and CC N
three CD N
months NNS N
after IN N
AVF NNP N
creation NN N
patients NNS N
underwent VBD N
an DT N
echocardiographic JJ N
examination NN N
. . N

Mann-Whitney JJ N
U-test NNP N
was VBD N
used VBN N
to TO N
compare VB N
relative JJ N
increase NN N
between IN N
the DT N
measured JJ N
cardiac JJ N
parameters NNS N
for IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Twenty-seven JJ N
patients NNS N
participated VBN N
in IN N
the DT N
study NN N
. . N

The DT N
relative JJ N
increase NN N
in IN N
left JJ N
ventricular JJ N
parameters NNS N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Only RB N
left VBD N
ventricular JJ N
end-diastolic JJ N
diameter NN N
tended VBD N
to TO N
be VB N
of IN N
significance NN N
. . N

Mean NNP N
blood NN N
flow NN N
through IN N
the DT N
brachial JJ N
artery NN N
was VBD N
1680+/-156 JJ N
and CC N
1450+/-221 JJ N
mL/min NNS N
three CD N
months NNS N
after IN N
surgery NN N
for IN N
the DT N
PTFE NNP N
and CC N
the DT N
BB-AVF NNP N
group NN N
, , N
respectively RB N
. . N

CONCLUSION NN N
After IN N
three CD N
months NNS N
of IN N
follow-up NN N
, , N
changes NNS N
in IN N
cardiac JJ N
structure NN N
were VBD N
comparable JJ N
between IN N
patients NNS N
with IN N
BB NNP N
and CC N
PTFE NNP N
AVFs NNP N
. . N

Also RB N
access NN N
flow NN N
was VBD N
comparable JJ N
at IN N
this DT N
time NN N
. . N

In IN N
general JJ N
, , N
the DT N
effects NNS N
of IN N
creation NN N
of IN N
a DT N
fistula NN N
on IN N
LV NNP N
structure NN N
were VBD N
limited VBN N
. . N

Longer RBR N
follow VB N
up RP N
time NN N
may MD N
be VB N
needed VBN N
to TO N
explore VB N
the DT N
long JJ N
term NN N
effects NNS N
of IN N
different JJ N
vascular JJ N
accesses NNS N
on IN N
cardiac JJ N
function NN N
. . N

-DOCSTART- -23296213- O O

Contingency NNP N
management NN N
for IN N
the DT N
treatment NN N
of IN N
antipsychotic-induced JJ N
weight JJ N
gain NN N
: : N
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

OBJECTIVE NNP N
Weight NNP N
gain NN N
is VBZ N
common JJ N
for IN N
individuals NNS N
with IN N
serious JJ N
mental JJ N
illness NN N
( ( N
SMI NNP N
) ) N
receiving VBG N
antipsychotic JJ N
drug NN N
therapy NN N
. . N

Contingency NNP N
management NN N
( ( N
CM NNP N
) ) N
is VBZ N
a DT N
behavioral JJ N
intervention NN N
that IN N
rewards NNS N
positive JJ N
performance NN N
and CC N
has VBZ N
demonstrated VBN N
effectiveness NN N
in IN N
reducing VBG N
drug NN N
use NN N
in IN N
SMI NNP N
populations NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
feasibility NN N
of IN N
using VBG N
CM NNP N
to TO N
promote VB N
weight JJ N
loss NN N
in IN N
individuals NNS N
with IN N
SMI NNP N
over IN N
8 CD N
weeks NNS N
. . N

METHOD NNP N
30 CD N
individuals NNS N
( ( N
BMI NNP N
? . N
28 CD N
kg/m NN N
( ( N
2 CD N
) ) N
) ) N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
conditions NNS N
: : N
i NN N
) ) N
The DT N
combination NN N
of IN N
a DT N
standardized JJ N
lifestyle NN N
modification NN N
( ( N
LM NNP N
) ) N
program NN N
for IN N
individuals NNS N
with IN N
SMI NNP N
and CC N
payment NN N
for IN N
group NN N
attendance NN N
( ( N
CM NNP N
( ( N
attendance NN N
) ) N
) ) N
, , N
ii NN N
) ) N
The DT N
combination NN N
of IN N
LM NNP N
and CC N
payment NN N
for IN N
weight JJ N
loss NN N
( ( N
CM NNP N
( ( N
weight NN N
) ) N
) ) N
, , N
and CC N
iii NN N
) ) N
waitlist NN N
control NN N
( ( N
CON NNP N
) ) N
. . N

After IN N
the DT N
waitlist JJ N
period NN N
, , N
those DT N
participants NNS N
joined VBD N
a DT N
LM NNP N
group NN N
and CC N
received VBD N
payment NN N
for IN N
behavioral JJ N
change NN N
( ( N
CM NNP N
( ( N
behavior NN N
) ) N
) ) N
. . N

RESULTS JJ N
Subjects NNPS N
in IN N
the DT N
CM NNP N
( ( N
attendance NN N
) ) N
and CC N
in IN N
the DT N
CM NNP N
( ( N
weight NN N
) ) N
group NN N
lost VBD N
a DT N
mean NN N
of IN N
1.16 CD N
kg NNS N
and CC N
1.23 CD N
kg NN N
, , N
respectively RB N
, , N
while IN N
subjects NNS N
in IN N
the DT N
CON NNP N
gained VBD N
a DT N
mean NN N
of IN N
0.68 CD N
kg NNS N
. . N

Subjects NNS N
receiving VBG N
CM NNP N
( ( N
behavior NN N
) ) N
, , N
lost VBD N
a DT N
mean NN N
of IN N
2.54 CD N
kg NNS N
, , N
which WDT N
was VBD N
a DT N
significant JJ N
weight NN N
loss NN N
compared VBN N
to TO N
the DT N
control NN N
period NN N
. . N

CONCLUSION NNP N
LM NNP N
supplemented VBD N
with IN N
CM NNP N
may MD N
facilitate VB N
weight NN N
loss NN N
in IN N
patients NNS N
taking VBG N
antipsychotic JJ N
medications NNS N
; : N
financial JJ N
reimbursement NN N
for IN N
behavioral JJ N
change NN N
may MD N
be VB N
particularly RB N
effective JJ N
in IN N
this DT N
population NN N
. . N

-DOCSTART- -17432640- O O

[ JJ N
Clinical NNP N
observation NN N
on IN N
different JJ N
acupuncture NN N
and CC N
moxibustion NN N
therapies NNS N
for IN N
treatment NN N
of IN N
postsurgical JJ N
gastroparesis NN N
syndrome NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
optimize VB N
therapy NN N
of IN N
acupuncture NN N
and CC N
moxibustion NN N
for IN N
postsurgical JJ N
gastroparesis NN N
syndrome NN N
( ( N
PGS NNP N
) ) N
. . N

METHODS NNP N
Forty-one JJ N
cases NNS N
of IN N
PGS NNP N
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
in IN N
order NN N
of IN N
visiting VBG N
. . N

Group NNP N
A NNP N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
were VBD N
treated VBN N
by IN N
warming VBG N
needle JJ N
moxibustion NN N
, , N
group NN N
B NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
by IN N
acupuncture NN N
plus CC N
auricular JJ N
point NN N
sticking NN N
, , N
and CC N
group NN N
C NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
by IN N
routine JJ N
acupuncture NN N
. . N

Changes NNS N
of IN N
gastric JJ N
drainage NN N
volume NN N
, , N
therapeutic JJ N
times NNS N
and CC N
cured JJ N
rate NN N
were VBD N
investigated VBN N
in IN N
the DT N
3 CD N
groups NNS N
. . N

RESULTS NNP N
All PDT N
the DT N
3 CD N
therapeutic JJ N
methods NNS N
could MD N
significantly RB N
decrease VB N
gastric JJ N
drainage NN N
volume NN N
. . N

The DT N
cured JJ N
rate NN N
was VBD N
100.0 CD N
% NN N
and CC N
the DT N
therapeutic JJ N
times NNS N
was VBD N
( ( N
7.24 CD N
+/- JJ N
3.87 CD N
) ) N
in IN N
the DT N
group NN N
A NNP N
, , N
66.7 CD N
% NN N
, , N
( ( N
9.83 CD N
+/- JJ N
4.60 CD N
) ) N
times NNS N
in IN N
the DT N
group NN N
B NNP N
and CC N
75.0 CD N
% NN N
, , N
( ( N
15.25 CD N
+/- JJ N
3.81 CD N
) ) N
times NNS N
in IN N
the DT N
group NN N
C NNP N
, , N
with IN N
significant JJ N
differences NNS N
in IN N
the DT N
cured JJ N
rate NN N
and CC N
the DT N
therapeutic JJ N
times NNS N
among IN N
the DT N
3 CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
The DT N
warming VBG N
needle JJ N
moxibustion NN N
is VBZ N
the DT N
best JJS N
method NN N
for IN N
PGS NNP N
, , N
with IN N
less RBR N
therapeutic JJ N
times NNS N
, , N
high JJ N
cured VBN N
rate NN N
and CC N
rapid JJ N
effect NN N
. . N

-DOCSTART- -20875504- O O

Action NNP N
observation NN N
treatment NN N
improves VBZ N
recovery NN N
of IN N
postsurgical JJ N
orthopedic JJ N
patients NNS N
: : N
evidence NN N
for IN N
a DT N
top-down JJ N
effect NN N
? . N
OBJECTIVE UH N
To TO N
assess VB N
whether IN N
action NN N
observation NN N
treatment NN N
( ( N
AOT NNP N
) ) N
may MD N
also RB N
improve VB N
motor NN N
recovery NN N
in IN N
postsurgical JJ N
orthopedic JJ N
patients NNS N
, , N
in IN N
addition NN N
to TO N
conventional JJ N
physiotherapy NN N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Department NNP N
of IN N
rehabilitation NN N
. . N

PARTICIPANTS JJ N
Patients NNPS N
( ( N
N=60 NNP N
) ) N
admitted VBD N
to TO N
our PRP$ N
department NN N
postorthopedic NN N
surgery NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
case NN N
( ( N
n=30 NN N
) ) N
or CC N
control NN N
( ( N
n=30 JJ N
) ) N
group NN N
. . N

Exclusion NN N
criteria NNS N
were VBD N
age NN N
18 CD N
years NNS N
or CC N
younger JJR N
and CC N
90 CD N
years NNS N
or CC N
older JJR N
, , N
Mini-Mental JJ N
State NNP N
Examination NNP N
score NN N
of IN N
21 CD N
of IN N
30 CD N
or CC N
lower JJR N
, , N
no DT N
ambulating VBG N
order NN N
, , N
advanced JJ N
vision NN N
impairment NN N
, , N
malignancy NN N
, , N
pneumonia NN N
, , N
or CC N
heart NN N
failure NN N
. . N

INTERVENTIONS NNP N
All NNP N
participants NNS N
underwent JJ N
conventional JJ N
physiotherapy NN N
. . N

In IN N
addition NN N
, , N
patients NNS N
in IN N
the DT N
case NN N
group NN N
were VBD N
asked VBN N
to TO N
observe VB N
video JJ N
clips NNS N
showing VBG N
daily JJ N
actions NNS N
and CC N
to TO N
imitate VB N
them PRP N
afterward RB N
. . N

Patients NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
asked VBN N
to TO N
observe VB N
video JJ N
clips NNS N
with IN N
no DT N
motor NN N
content NN N
and CC N
to TO N
execute VB N
the DT N
same JJ N
actions NNS N
as IN N
patients NNS N
in IN N
the DT N
case NN N
group NN N
afterward RB N
. . N

Participants NNS N
were VBD N
scored VBN N
on IN N
functional JJ N
scales NNS N
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
by IN N
a DT N
physician NN N
blinded VBD N
to TO N
group NN N
assignment NN N
. . N

MAIN NNP N
OUTCOMES NNP N
MEASURES NNP N
Changes NNP N
in IN N
FIM NNP N
and CC N
Tinetti NNP N
scale NN N
scores NNS N
, , N
and CC N
dependence NN N
on IN N
walking VBG N
aids NNS N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
groups NNS N
did VBD N
not RB N
differ VB N
in IN N
clinical JJ N
and CC N
functional JJ N
scale NN N
scores NNS N
. . N

After IN N
treatment NN N
, , N
patients NNS N
in IN N
the DT N
case NN N
group NN N
scored VBD N
better JJR N
than IN N
patients NNS N
in IN N
the DT N
control NN N
group NN N
( ( N
FIM NNP N
total NN N
score NN N
, , N
P=.02 NNP N
; : N
FIM NNP N
motor NN N
subscore NN N
, , N
P=.001 NNP N
; : N
Tinetti NNP N
scale NN N
score NN N
, , N
P=.04 NNP N
) ) N
; : N
patients NNS N
in IN N
the DT N
case NN N
group NN N
were VBD N
assigned VBN N
more RBR N
frequently RB N
to TO N
1 CD N
crutch NN N
( ( N
P=.01 NNP N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
addition NN N
to TO N
conventional JJ N
physiotherapy NN N
, , N
AOT NNP N
is VBZ N
effective JJ N
in IN N
the DT N
rehabilitation NN N
of IN N
postsurgical JJ N
orthopedic JJ N
patients NNS N
. . N

The DT N
present JJ N
results NNS N
strongly RB N
support VB N
top-down JJ N
effects NNS N
of IN N
this DT N
treatment NN N
in IN N
motor NN N
recovery NN N
, , N
even RB N
in IN N
nonneurologic JJ N
patients NNS N
. . N

-DOCSTART- -17482439- O O

Fine NNP N
needle JJ N
aspiration NN N
coupled VBN N
with IN N
real-time JJ N
PCR NNP N
: : N
a DT N
painless JJ N
methodology NN N
to TO N
study VB N
adaptive JJ N
functional JJ N
changes NNS N
in IN N
skeletal JJ N
muscle NN N
. . N

BACKGROUND NNP N
AND NNP N
AIM NNP N
In IN N
this DT N
study NN N
we PRP N
developed VBD N
a DT N
new JJ N
methodology NN N
for IN N
obtaining VBG N
human JJ N
skeletal JJ N
muscle NN N
samples NNS N
to TO N
evaluate VB N
gene NN N
expression NN N
. . N

This DT N
approach NN N
is VBZ N
based VBN N
on IN N
a DT N
fine JJ N
needle JJ N
aspiration NN N
technique NN N
, , N
which WDT N
allows VBZ N
us PRP N
to TO N
extract VB N
a DT N
small JJ N
tissue NN N
sample NN N
in IN N
a DT N
significantly RB N
less RBR N
invasive JJ N
manner NN N
than IN N
with IN N
classic JJ N
biopsy NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Multiplex NNP N
tandem VBD N
RT-PCR NNP N
was VBD N
used VBN N
to TO N
determine VB N
the DT N
mRNA NN N
levels NNS N
of IN N
genes NNS N
involved VBN N
in IN N
ATP NNP N
production NN N
and CC N
mitochondrial JJ N
biogenesis NN N
in IN N
muscle NN N
tissue NN N
. . N

Samples NNS N
of IN N
vastus NN N
lateralis NNS N
muscle NN N
were VBD N
obtained VBN N
from IN N
21 CD N
healthy JJ N
subjects NNS N
with IN N
different JJ N
fitness NN N
levels NNS N
. . N

The DT N
principal JJ N
findings NNS N
in IN N
our PRP$ N
study NN N
show VB N
a DT N
strong JJ N
correlation NN N
between IN N
PGC-1alpha NNP N
and CC N
COX5B NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
between IN N
PGC-1alpha NNP N
and CC N
MT-CO2 NNP N
( ( N
p=0.017 NN N
) ) N
expression NN N
. . N

Furthermore NNP N
, , N
a DT N
significant JJ N
positive JJ N
correlation NN N
between IN N
mtDNA NN N
content NN N
and CC N
the DT N
percentage NN N
of IN N
MHCI NNP N
present NN N
in IN N
the DT N
aspired JJ N
samples NNS N
were VBD N
found VBN N
( ( N
p=0.028 NN N
) ) N
. . N

These DT N
data NNS N
are VBP N
in IN N
agreement NN N
with IN N
current JJ N
knowledge NN N
on IN N
skeletal JJ N
muscle NN N
physiology NN N
and CC N
show VB N
the DT N
reliability NN N
of IN N
the DT N
proposed VBN N
method NN N
. . N

CONCLUSION VB N
This DT N
painless JJ N
methodology NN N
can MD N
be VB N
used VBN N
to TO N
investigate VB N
, , N
in IN N
vivo NN N
, , N
human JJ N
muscle NN N
RNA NNP N
and CC N
DNA NNP N
adaptations NNS N
in IN N
response NN N
to TO N
either DT N
physiological JJ N
and/or NN N
pharmacological JJ N
stimuli NN N
. . N

This DT N
method NN N
has VBZ N
major JJ N
clinical JJ N
relevance NN N
, , N
such JJ N
as IN N
its PRP$ N
application NN N
in IN N
clarifying VBG N
the DT N
mechanisms NN N
underling VBG N
metabolic JJ N
and CC N
systemic JJ N
disorders NNS N
. . N

-DOCSTART- -22982948- O O

Take VB N
a DT N
walk NN N
in IN N
the DT N
park NN N
? . N
A DT N
cross-over NN N
pilot NN N
trial NN N
comparing VBG N
brisk JJ N
walking VBG N
in IN N
two CD N
different JJ N
environments NNS N
: : N
park NN N
and CC N
urban JJ N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
is VBZ N
to TO N
investigate VB N
whether IN N
differences NNS N
exist VBP N
between IN N
a DT N
30 CD N
minute NN N
brisk NN N
walk VBP N
taken VBN N
in IN N
two CD N
different JJ N
environments NNS N
in IN N
order NN N
to TO N
determine VB N
which WDT N
environment NN N
best JJS N
facilitates NNS N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
: : N
park NN N
or CC N
urban JJ N
. . N

METHODS NNP N
In IN N
this DT N
randomised JJ N
cross-over NN N
pilot NN N
study NN N
, , N
participants NNS N
performed VBD N
a DT N
self-timed JJ N
30 CD N
minute NN N
brisk NN N
walk VBP N
in IN N
two CD N
different JJ N
environments NNS N
, , N
park NN N
and CC N
urban JJ N
, , N
in IN N
Glasgow NNP N
, , N
Scotland NNP N
( ( N
October NNP N
2009 CD N
to TO N
January NNP N
2010 CD N
) ) N
. . N

Cadence NN N
, , N
recorded VBD N
using VBG N
the DT N
activPAL? NN N
activity NN N
monitor NN N
, , N
was VBD N
used VBN N
to TO N
measure VB N
intensity NN N
. . N

Outcome CC N
measures NNS N
were VBD N
: : N
mean JJ N
cadence NN N
; : N
moderate-to-vigorous JJ N
physical JJ N
activity NN N
time NN N
accumulated VBN N
in IN N
bouts NNS N
lasting VBG N
? . N
10 CD N
min NN N
; : N
number NN N
of IN N
walking VBG N
breaks NNS N
; : N
and CC N
duration NN N
. . N

RESULTS VB N
A DT N
convenience NN N
sample NN N
of IN N
40 CD N
healthy JJ N
adults NNS N
was VBD N
recruited VBN N
: : N
16 CD N
males NNS N
, , N
24 CD N
females NNS N
, , N
mean JJ N
age NN N
22.9 CD N
( ( N
5.5 CD N
) ) N
years NNS N
. . N

The DT N
mean JJ N
cadence NN N
for IN N
the DT N
whole JJ N
walk NN N
was VBD N
higher RBR N
in IN N
the DT N
park NN N
: : N
119.3 CD N
( ( N
8.3 CD N
) ) N
vs. FW N
110.9 CD N
( ( N
8.9 CD N
) ) N
steps/min NN N
. . N

Participants NNS N
accumulated VBD N
more RBR N
moderate-to-vigorous JJ N
physical JJ N
activity NN N
in IN N
? . N
10 CD N
minute NN N
bouts NNS N
during IN N
park JJ N
walks NNS N
: : N
25.5 CD N
( ( N
9.6 CD N
) ) N
[ NN N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
] VBZ N
vs. FW N
14.0 CD N
( ( N
20.3 CD N
) ) N
min NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
self-timed JJ N
duration NN N
between IN N
locations NNS N
. . N

CONCLUSION NNP N
Participants NNPS N
accumulated VBD N
more RBR N
moderate-to-vigorous JJ N
physical JJ N
activity NN N
in IN N
bouts NNS N
? . N
10 CD N
min NN N
in IN N
duration NN N
on IN N
park NN N
walks NNS N
due JJ N
to TO N
the DT N
lack NN N
of IN N
interruptions NNS N
in IN N
walking VBG N
. . N

Hence NNP N
the DT N
park NN N
environment NN N
better RBR N
facilitated VBD N
the DT N
achievement NN N
of IN N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
. . N

Further JJ N
research NN N
involving VBG N
a DT N
larger JJR N
, , N
more RBR N
heterogeneous JJ N
sample NN N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -23052635- O O

Computer-navigated JJ N
versus NN N
conventional JJ N
total JJ N
knee NN N
arthroplasty IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
literature NN N
lacks VBZ N
studies NNS N
that IN N
confirm VBP N
whether IN N
the DT N
improved JJ N
radiographic JJ N
alignment NN N
that WDT N
can MD N
be VB N
achieved VBN N
with IN N
computer-navigated JJ N
total JJ N
knee NN N
arthroplasty NN N
improves VBZ N
patients? JJ N
activities NNS N
of IN N
daily JJ N
living NN N
or CC N
the DT N
durability NN N
of IN N
total JJ N
knee NN N
prostheses NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
computer-navigated JJ N
total JJ N
knee NN N
arthroplasty NN N
improves VBZ N
the DT N
clinical JJ N
function NN N
, , N
alignment NN N
, , N
and CC N
survivorship NN N
of IN N
the DT N
components NNS N
. . N

METHODS NNP N
We PRP N
prospectively RB N
compared VBN N
the DT N
results NNS N
of IN N
520 CD N
patients NNS N
with IN N
osteoarthritis NN N
who WP N
underwent VBD N
computer-navigated JJ N
total JJ N
knee NN N
arthroplasty NN N
for IN N
one CD N
knee NN N
and CC N
conventional JJ N
total JJ N
knee NN N
arthroplasty NN N
for IN N
the DT N
other JJ N
. . N

The DT N
assignment NN N
of IN N
the DT N
knee NN N
to TO N
navigation NN N
or CC N
not RB N
was VBD N
done VBN N
randomly RB N
. . N

There EX N
were VBD N
452 CD N
women NNS N
( ( N
904 CD N
knees NNS N
) ) N
and CC N
sixty-eight JJ N
men NNS N
( ( N
136 CD N
knees NNS N
) ) N
with IN N
a DT N
mean JJ N
age NN N
of IN N
sixty-eight JJ N
years NNS N
( ( N
range NN N
, , N
forty-nine JJ N
to TO N
eighty-eight JJ N
years NNS N
) ) N
at IN N
the DT N
time NN N
of IN N
the DT N
index NN N
arthroplasty NN N
. . N

The DT N
mean JJ N
follow-up JJ N
period NN N
was VBD N
10.8 CD N
years NNS N
( ( N
range NN N
, , N
ten VB N
to TO N
twelve VB N
years NNS N
) ) N
. . N

The DT N
patients NNS N
were VBD N
assessed VBN N
clinically RB N
and CC N
radiographically RB N
with IN N
the DT N
rating NN N
system NN N
of IN N
the DT N
Knee NNP N
Society NNP N
and CC N
with IN N
the DT N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
Osteoarthritis NNP N
Index NNP N
( ( N
WOMAC NNP N
) ) N
score NN N
at IN N
three CD N
months NNS N
, , N
one CD N
year NN N
, , N
and CC N
annually RB N
thereafter RB N
. . N

RESULTS NNP N
Total JJ N
knee NN N
scores NNS N
, , N
knee NN N
function NN N
scores NNS N
, , N
pain NN N
scores NNS N
, , N
WOMAC NNP N
scores VBZ N
, , N
knee VB N
motion NN N
, , N
and CC N
activity NN N
scores NNS N
did VBD N
not RB N
show VB N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
preoperatively RB N
or CC N
at IN N
the DT N
time NN N
of IN N
the DT N
final JJ N
follow-up NN N
. . N

Alignment NNP N
and CC N
the DT N
survivorship NN N
of IN N
the DT N
components NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
Kaplan-Meier NNP N
survivorship NN N
with IN N
revision NN N
as IN N
the DT N
end NN N
point NN N
at IN N
10.8 CD N
years NNS N
was VBD N
98.8 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.96 CD N
to TO N
1.00 CD N
) ) N
in IN N
the DT N
computernavigated JJ N
total JJ N
knee NN N
arthroplasty NN N
group NN N
and CC N
99.2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.96 CD N
to TO N
1.00 CD N
) ) N
in IN N
the DT N
conventional JJ N
total JJ N
knee NN N
arthroplasty NN N
group NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
data NNS N
demonstrated VBD N
no DT N
difference NN N
in IN N
clinical JJ N
function NN N
or CC N
alignment NN N
and CC N
survivorship NN N
of IN N
the DT N
components NNS N
between IN N
the DT N
knees NNS N
that WDT N
underwent VBD N
computer-navigated JJ N
total JJ N
knee NN N
arthroplasty NN N
and CC N
those DT N
that WDT N
underwent JJ N
conventional JJ N
total JJ N
knee NN N
arthroplasty NN N
. . N

-DOCSTART- -16275518- O O

The DT N
evaluation NN N
of IN N
pulmonary JJ N
hypertension NN N
using VBG N
right JJ N
ventricular JJ N
myocardial JJ N
isovolumic JJ N
relaxation NN N
time NN N
. . N

Right JJ N
ventricular NN N
( ( N
RV NNP N
) ) N
blood VBD N
pool-derived JJ N
isovolumic JJ N
relaxation NN N
time NN N
( ( N
IVRT NNP N
) ) N
correlates VBZ N
well RB N
with IN N
systolic JJ N
pulmonary JJ N
arterial JJ N
pressure NN N
( ( N
PAP NNP N
) ) N
. . N

However RB N
, , N
because IN N
of IN N
complex JJ N
parameter NN N
derivation NN N
, , N
the DT N
method NN N
is VBZ N
rarely RB N
used VBN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
validate VB N
the DT N
measurement NN N
of IN N
myocardial JJ N
velocity NN N
imaging-derived JJ N
RV NNP N
IVRT NNP N
( ( N
IVRT NNP N
' POS N
) ) N
against IN N
invasively RB N
measured VBN N
PAP NNP N
. . N

Transthoracic NNP N
echocardiography NN N
with IN N
myocardial JJ N
velocity NN N
imaging NN N
and CC N
right JJ N
heart NN N
catheterization NN N
were VBD N
performed VBN N
in IN N
33 CD N
patients NNS N
with IN N
pulmonary JJ N
hypertension NN N
. . N

Blood NNP N
pool NN N
IVRT NNP N
and CC N
myocardial JJ N
IVRTs NNP N
for IN N
the DT N
tricuspid JJ N
valve NN N
annulus NN N
ring NN N
, , N
basal NN N
and CC N
apical JJ N
RV NNP N
free JJ N
wall NN N
segments NNS N
were VBD N
measured VBN N
and CC N
compared VBN N
with IN N
data NNS N
from IN N
33 CD N
age- JJ N
and CC N
sex-matched JJ N
control NN N
subjects NNS N
. . N

Measured VBN N
IVRTs NNP N
were VBD N
significantly RB N
longer RBR N
in IN N
patients NNS N
with IN N
pulmonary JJ N
hypertension NN N
than IN N
in IN N
control NN N
subjects NNS N
. . N

The DT N
strongest JJS N
correlation NN N
( ( N
R NNP N
= NNP N
0.74 CD N
, , N
P NNP N
< NNP N
.0001 NNP N
) ) N
was VBD N
found VBN N
between IN N
systolic JJ N
PAP NNP N
and CC N
the DT N
heart NN N
rate-corrected JJ N
IVRT NNP N
' POS N
derived VBN N
from IN N
the DT N
basal NN N
RV NNP N
free JJ N
wall NN N
segment NN N
. . N

The DT N
basal NN N
segment NN N
IVRT NNP N
' POS N
corrected VBN N
for IN N
heart NN N
rate NN N
correlates NNS N
well RB N
with IN N
the DT N
invasive JJ N
PAP NNP N
measurement NN N
and CC N
, , N
therefore RB N
, , N
can MD N
be VB N
used VBN N
to TO N
predict VB N
systolic JJ N
PAP NNP N
. . N

It PRP N
can MD N
even RB N
be VB N
considered VBN N
as IN N
an DT N
alternative NN N
to TO N
tricuspid VB N
regurgitation-derived JJ N
PAP NNP N
systolic NN N
when WRB N
tricuspid JJ N
regurgitation NN N
is VBZ N
nonrecordable JJ N
. . N

A DT N
proposed VBN N
method NN N
to TO N
derive VB N
systolic JJ N
PAP NNP N
should MD N
be VB N
used VBN N
while IN N
screening VBG N
the DT N
patients NNS N
at IN N
risk NN N
for IN N
pulmonary JJ N
hypertension NN N
, , N
monitoring VBG N
the DT N
disease NN N
progression NN N
and CC N
the DT N
effect NN N
of IN N
treatment NN N
. . N

-DOCSTART- -8126502- O O

Effect NN N
of IN N
entacapone NN N
, , N
a DT N
peripherally RB N
acting VBG N
catechol-O-methyltransferase NN N
inhibitor NN N
, , N
on IN N
the DT N
motor NN N
response NN N
to TO N
acute VB N
treatment NN N
with IN N
levodopa NN N
in IN N
patients NNS N
with IN N
Parkinson NNP N
's POS N
disease NN N
. . N

Catechol-O-methyltransferase NNP N
( ( N
COMT NNP N
) ) N
inhibitors NNS N
may MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
Parkinson NNP N
's POS N
disease NN N
by IN N
improving VBG N
the DT N
bioavailability NN N
of IN N
levodopa NN N
and CC N
by IN N
prolonging VBG N
its PRP$ N
effects NNS N
. . N

Entacapone NNP N
( ( N
OR-611 NNP N
) ) N
, , N
a DT N
novel JJ N
COMT NNP N
inhibitor NN N
, , N
which WDT N
does VBZ N
not RB N
cross VB N
the DT N
blood NN N
brain NN N
barrier NN N
, , N
was VBD N
assessed VBN N
in IN N
12 CD N
patients NNS N
with IN N
Parkinson NNP N
's POS N
disease NN N
and CC N
motor NN N
fluctuations NNS N
in IN N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
, , N
single JJ N
dose NN N
study NN N
. . N

The DT N
magnitude NN N
and CC N
duration NN N
of IN N
the DT N
therapeutic JJ N
response NN N
to TO N
a DT N
single JJ N
dose NN N
of IN N
200 CD N
mg NNS N
levodopa/50 JJ N
mg FW N
carbidopa NN N
was VBD N
evaluated VBN N
after IN N
concomitant JJ N
placebo NN N
, , N
or CC N
200 CD N
or CC N
800 CD N
mg NN N
entacapone NN N
. . N

A DT N
significant JJ N
increase NN N
in IN N
the DT N
duration NN N
of IN N
the DT N
motor NN N
response NN N
to TO N
levodopa NN N
was VBD N
seen VBN N
when WRB N
200 CD N
mg NN N
entacapone NN N
was VBD N
given VBN N
with IN N
levodopa/carbidopa NN N
. . N

Plasma NNP N
levodopa JJ N
concentrations NNS N
were VBD N
increased VBN N
with IN N
both DT N
doses NNS N
of IN N
the DT N
COMT NNP N
inhibitor NN N
. . N

The DT N
latency NN N
to TO N
onset VB N
of IN N
motor NN N
response NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
active JJ N
drug NN N
and CC N
placebo NN N
. . N

Entacapone NN N
may MD N
prove VB N
useful JJ N
in IN N
prolonging VBG N
the DT N
duration NN N
of IN N
the DT N
benefit NN N
obtained VBN N
from IN N
individual JJ N
doses NNS N
of IN N
levodopa NN N
. . N

-DOCSTART- -7708953- O O

The DT N
influence NN N
of IN N
breast NN N
size NN N
on IN N
late JJ N
radiation NN N
effects NNS N
and CC N
association NN N
with IN N
radiotherapy NN N
dose JJ N
inhomogeneity NN N
. . N

A DT N
prospective JJ N
assessment NN N
of IN N
late JJ N
changes NNS N
in IN N
breast NN N
appearance NN N
in IN N
559 CD N
patients NNS N
after IN N
tumour JJ N
excision NN N
and CC N
radiotherapy NN N
for IN N
early JJ N
breast NN N
cancer NN N
noted VBD N
a DT N
strong JJ N
association NN N
with IN N
breast NN N
size NN N
. . N

Only RB N
3/48 CD N
( ( N
6 CD N
% NN N
) ) N
patients NNS N
with IN N
small JJ N
breasts NNS N
developed VBD N
moderate JJ N
or CC N
severe JJ N
late JJ N
changes NNS N
compared VBN N
with IN N
94/423 CD N
( ( N
22 CD N
% NN N
) ) N
with IN N
medium NN N
sized VBN N
breasts NNS N
and CC N
34/88 CD N
( ( N
39 CD N
% NN N
) ) N
patients NNS N
with IN N
large JJ N
breasts NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

One CD N
possibility NN N
is VBZ N
that IN N
greater JJR N
radiation NN N
changes NNS N
are VBP N
related VBN N
to TO N
greater JJR N
dose JJ N
inhomogeneity NN N
in IN N
women NNS N
with IN N
large JJ N
breasts NNS N
. . N

To TO N
explore VB N
this DT N
hypothesis NN N
, , N
radiation NN N
dose JJ N
distributions NNS N
were VBD N
assessed VBN N
in IN N
a DT N
separate JJ N
group NN N
of IN N
37 CD N
women NNS N
in IN N
whom WP N
three-level JJ N
transverse NN N
computer NN N
tomographic JJ N
images NNS N
of IN N
the DT N
breast NN N
in IN N
the DT N
treatment NN N
position NN N
were VBD N
available JJ N
. . N

A DT N
significant JJ N
correlation NN N
was VBD N
found VBN N
between IN N
breast NN N
size NN N
and CC N
dose NN N
inhomogeneity NN N
which WDT N
may MD N
account VB N
for IN N
the DT N
marked JJ N
changes NNS N
in IN N
breast NN N
appearance NN N
reported VBD N
in IN N
women NNS N
with IN N
large JJ N
breasts NNS N
. . N

-DOCSTART- -16603337- O O

The DT N
effect NN N
of IN N
a DT N
parent-implemented JJ N
imitation NN N
intervention NN N
on IN N
spontaneous JJ N
imitation NN N
skills NNS N
in IN N
young JJ N
children NNS N
with IN N
autism NN N
. . N

Children NNP N
with IN N
autism NN N
exhibit NN N
significant JJ N
deficits NNS N
in IN N
their PRP$ N
ability NN N
to TO N
spontaneously RB N
imitate VB N
the DT N
play NN N
actions NNS N
and CC N
descriptive JJ N
gestures NNS N
of IN N
others NNS N
. . N

Reciprocal JJ N
imitation NN N
training NN N
( ( N
RIT NNP N
) ) N
is VBZ N
a DT N
naturalistic JJ N
imitation NN N
intervention NN N
designed VBN N
to TO N
teach VB N
spontaneous JJ N
imitation NN N
skills NNS N
during IN N
play NN N
. . N

This DT N
study NN N
assessed VBD N
the DT N
effectiveness NN N
of IN N
parent-implemented JJ N
RIT NNP N
using VBG N
a DT N
multiple-baseline JJ N
design NN N
across IN N
three CD N
young JJ N
children NNS N
with IN N
autism NN N
and CC N
their PRP$ N
mothers NNS N
. . N

After IN N
an DT N
initial JJ N
baseline NN N
, , N
mothers NNS N
were VBD N
taught VBN N
to TO N
implement VB N
RIT NNP N
techniques NNS N
with IN N
their PRP$ N
child NN N
twice RB N
a DT N
week NN N
for IN N
10 CD N
weeks NNS N
in IN N
a DT N
clinic JJ N
setting NN N
. . N

Two CD N
mothers NNS N
were VBD N
taught VBN N
to TO N
use VB N
RIT NNP N
to TO N
teach VB N
object JJ N
imitation NN N
. . N

The DT N
third JJ N
mother NN N
was VBD N
taught VBN N
to TO N
use VB N
RIT NNP N
to TO N
target VB N
both DT N
object JJ N
and CC N
gesture JJ N
imitation NN N
in IN N
a DT N
multiple-baseline JJ N
design NN N
across IN N
behaviors NNS N
. . N

Generalization NNP N
was VBD N
assessed VBN N
in IN N
the DT N
families NNS N
' POS N
homes NNS N
at IN N
the DT N
end NN N
of IN N
treatment NN N
and CC N
a DT N
1-month JJ N
follow-up NN N
. . N

Parents NNS N
learned VBD N
to TO N
use VB N
the DT N
intervention NN N
strategies NNS N
and CC N
their PRP$ N
children NNS N
exhibited VBN N
increases NNS N
in IN N
spontaneous JJ N
imitation NN N
. . N

These DT N
findings NNS N
replicate VBP N
the DT N
results NNS N
from IN N
previous JJ N
studies NNS N
, , N
indicating VBG N
that IN N
RIT NNP N
is VBZ N
effective JJ N
for IN N
teaching VBG N
imitation NN N
skills NNS N
to TO N
young JJ N
children NNS N
with IN N
autism NN N
in IN N
a DT N
naturalistic JJ N
setting NN N
and CC N
extend VB N
the DT N
findings NNS N
to TO N
parents NNS N
. . N

-DOCSTART- -4448416- O O

Coagulation NNP N
factor NN N
concentrate NN N
in IN N
the DT N
treatment NN N
of IN N
the DT N
haemorrhagic JJ N
diathesis NN N
of IN N
fulminant JJ N
hepatic JJ N
failure NN N
. . N

To TO N
assess VB N
the DT N
value NN N
of IN N
clotting VBG N
factor NN N
concentrate NN N
infusions NNS N
in IN N
fulminant JJ N
hepatic JJ N
failure NN N
, , N
a DT N
controlled JJ N
trial NN N
was VBD N
performed VBN N
in IN N
which WDT N
nine CD N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
with IN N
either DT N
concentrate NN N
alone RB N
or CC N
concentrate VB N
plus CC N
heparin VB N
. . N

The DT N
five CD N
patients NNS N
receiving VBG N
concentrate VB N
alone RB N
all DT N
died VBD N
, , N
with IN N
major JJ N
bleeding VBG N
as IN N
the DT N
direct JJ N
cause NN N
of IN N
death NN N
in IN N
three CD N
, , N
whereas NNS N
in IN N
the DT N
four CD N
receiving VBG N
heparin NN N
as RB N
well RB N
there EX N
was VBD N
only RB N
one CD N
instance NN N
of IN N
bleeding NN N
and CC N
one CD N
patient NN N
survived VBD N
. . N

Clinical JJ N
evidence NN N
of IN N
intravascular JJ N
coagulation NN N
appeared VBD N
in IN N
two CD N
patients NNS N
treated VBD N
with IN N
concentrate NN N
alone RB N
and CC N
the DT N
laboratory JJ N
evidence NN N
of IN N
this DT N
progressed VBN N
during IN N
the DT N
period NN N
of IN N
infusions NNS N
in IN N
all DT N
patients NNS N
in IN N
both DT N
treatment NN N
groups NNS N
, , N
although IN N
to TO N
a DT N
lesser JJR N
extent NN N
in IN N
those DT N
receiving VBG N
heparin NN N
. . N

Additional JJ N
evidence NN N
for IN N
intravascular JJ N
coagulation NN N
came VBD N
from IN N
the DT N
changes NNS N
observed VBN N
in IN N
factor NN N
VIII NNP N
levels NNS N
which WDT N
, , N
although IN N
initially RB N
high JJ N
in IN N
all DT N
patients NNS N
, , N
fell VBD N
subsequently RB N
, , N
particularly RB N
in IN N
those DT N
given VBN N
concentrate VBP N
alone RB N
. . N

There EX N
was VBD N
some DT N
improvement NN N
in IN N
the DT N
prothrombin NN N
ratio NN N
in IN N
both DT N
groups NNS N
of IN N
patients NNS N
but CC N
not RB N
complete JJ N
correction NN N
, , N
and CC N
serial JJ N
assays NNS N
of IN N
clotting VBG N
factors NNS N
showed VBD N
that IN N
although IN N
factor NN N
II NNP N
rose VBD N
to TO N
high JJ N
levels NNS N
during IN N
treatment NN N
, , N
factors NNS N
IX NNP N
and CC N
X NNP N
showed VBD N
little JJ N
response NN N
. . N

Thus RB N
, , N
the DT N
use NN N
of IN N
concentrate NN N
of IN N
factor NN N
IX NNP N
in IN N
this DT N
trial NN N
, , N
as RB N
well RB N
as IN N
potentiating VBG N
intravascular JJ N
coagulation NN N
, , N
was VBD N
inadequate JJ N
as IN N
replacement NN N
for IN N
the DT N
clotting NN N
factor NN N
deficiencies NNS N
. . N

-DOCSTART- -11041498- O O

An DT N
evaluation NN N
of IN N
chemical JJ N
arthrodesis NN N
of IN N
the DT N
proximal JJ N
interphalangeal NN N
joint NN N
in IN N
the DT N
horse NN N
by IN N
using VBG N
monoiodoacetate NN N
. . N

The DT N
use NN N
of IN N
monoiodoacetate NN N
( ( N
MIA NNP N
) ) N
for IN N
arthrodesis NN N
of IN N
the DT N
proximal JJ N
interphalangeal NN N
joint NN N
( ( N
PIJ NNP N
) ) N
and CC N
the DT N
effect NN N
of IN N
exercise NN N
on IN N
the DT N
degree NN N
of IN N
fusion NN N
were VBD N
investigated VBN N
. . N

Eight JJ N
horses NNS N
received VBD N
3 CD N
injections NNS N
( ( N
Weeks NNP N
0 CD N
, , N
3 CD N
, , N
6 CD N
) ) N
of IN N
MIA NNP N
( ( N
2 CD N
mL NN N
; : N
60 CD N
mg/mL NN N
) ) N
into IN N
the DT N
right NN N
or CC N
left VBD N
front JJ N
PIJ NNP N
. . N

Peri-operatively RB N
, , N
the DT N
horses NNS N
received VBD N
phenylbutazone NN N
, , N
butorphanol NN N
, , N
and CC N
abaxial JJ N
sesamoidean NN N
nerve NN N
blocks NNS N
to TO N
relieve VB N
pain NN N
. . N

During IN N
the DT N
study NN N
, , N
the DT N
horses NNS N
were VBD N
monitored VBN N
for IN N
general JJ N
health NN N
, , N
lameness NN N
, , N
and CC N
swelling VBG N
around IN N
the DT N
injection NN N
area NN N
. . N

Radiographs NNP N
were VBD N
taken VBN N
biweekly RB N
to TO N
evaluate VB N
bony NN N
fusion NN N
. . N

Horses NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
non-exercised JJ N
and CC N
exercised JJ N
groups NNS N
. . N

Exercise NNP N
consisted VBD N
of IN N
20 CD N
minutes NNS N
of IN N
trotting VBG N
on IN N
a DT N
treadmill NN N
( ( N
4 CD N
m/s NN N
) ) N
, , N
3 CD N
days NNS N
per IN N
week NN N
for IN N
13 CD N
weeks NNS N
. . N

The DT N
horses NNS N
were VBD N
euthanized VBN N
at IN N
24 CD N
weeks NNS N
. . N

Slab NNP N
sections NNS N
of IN N
the DT N
PIJ NNP N
were VBD N
evaluated VBN N
grossly RB N
and CC N
radiographically RB N
for IN N
bony NN N
fusion NN N
. . N

Histologic JJ N
examinations NNS N
were VBD N
performed VBN N
to TO N
evaluate VB N
articular JJ N
cartilage NN N
. . N

Three CD N
horses NNS N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
after IN N
developing VBG N
soft JJ N
tissue NN N
necrosis NN N
around IN N
the DT N
injection NN N
site NN N
, , N
septic JJ N
arthritis NN N
, , N
and CC N
necrotic JJ N
tendinitis NN N
. . N

The DT N
remaining VBG N
horses NNS N
remained VBD N
healthy JJ N
, , N
developed VBD N
a DT N
grade NN N
1 CD N
to TO N
4 CD N
lameness NN N
with IN N
minimal JJ N
to TO N
severe VB N
swelling VBG N
in IN N
the DT N
PIJ NNP N
region NN N
. . N

All DT N
5 CD N
horses NNS N
showed VBD N
radiographic JJ N
evidence NN N
of IN N
bony NN N
fusion NN N
, , N
however RB N
, , N
no DT N
fusion NN N
was VBD N
present JJ N
when WRB N
injected JJ N
joints NNS N
were VBD N
examined VBN N
on IN N
postmortem NN N
examination NN N
. . N

Histologic NNP N
examination NN N
revealed VBD N
thinning NN N
of IN N
the DT N
cartilage NN N
, , N
diffuse VBP N
necrosis NN N
of IN N
chondrocytes NNS N
, , N
with IN N
the DT N
calcified JJ N
zone NN N
intact JJ N
. . N

Subjectively RB N
, , N
exercise NN N
did VBD N
not RB N
influence VB N
the DT N
degree NN N
of IN N
cartilage NN N
destruction NN N
. . N

Based VBN N
on IN N
this DT N
study NN N
, , N
chemical JJ N
arthrodesis NN N
can MD N
not RB N
be VB N
advocated VBN N
in IN N
clinical JJ N
cases NNS N
because IN N
of IN N
the DT N
high JJ N
complication NN N
rate NN N
and CC N
lack NN N
of IN N
bony NN N
fusion NN N
. . N

-DOCSTART- -15798610- O O

Comparison NNP N
of IN N
intravenous JJ N
and CC N
intra-arterial JJ N
urokinase JJ N
thrombolysis NN N
for IN N
acute JJ N
ischaemic JJ N
stroke NN N
. . N

Intravenous JJ N
fibrinolysis NN N
( ( N
IVF NNP N
) ) N
with IN N
rt-PA NN N
( ( N
alteplase NN N
) ) N
provides VBZ N
significant JJ N
benefits NNS N
in IN N
acute JJ N
ischaemic JJ N
stroke NN N
when WRB N
it PRP N
is VBZ N
given VBN N
within IN N
the DT N
first JJ N
three CD N
hours NNS N
following VBG N
stroke NN N
onset VBN N
. . N

Intra-arterial JJ N
fibrinolysis NN N
( ( N
IAF NNP N
) ) N
with IN N
pro-urokinase NN N
in IN N
PROACT NNP N
II NNP N
study NN N
provides VBZ N
quite RB N
the DT N
same JJ N
benefit NN N
in IN N
the DT N
first JJ N
6 CD N
hours NNS N
. . N

IVF NNP N
and CC N
IAF NNP N
have VBP N
never RB N
been VBN N
compared VBN N
. . N

To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
IVF NNP N
and CC N
IAF NNP N
with IN N
urokinase JJ N
given VBN N
within IN N
the DT N
first JJ N
6 CD N
hours NNS N
of IN N
acute JJ N
ischaemic JJ N
stroke NN N
. . N

Patients NNS N
fulfilling VBG N
the DT N
selection NN N
criteria NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
urokinase JJ N
900,000 CD N
units NNS N
via IN N
intravenous JJ N
or CC N
intra-arterial JJ N
routes NNS N
. . N

This DT N
randomised VBD N
monocentre NN N
study NN N
was VBD N
done VBN N
between IN N
December NNP N
1995 CD N
and CC N
August NNP N
1997 CD N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
the DT N
number NN N
of IN N
patients NNS N
with IN N
a DT N
modified JJ N
Rankin NNP N
score NN N
of IN N
2 CD N
or CC N
less JJR N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
mortality NN N
, , N
frequency NN N
of IN N
symptomatic JJ N
intracranial JJ N
haemorrhage NN N
( ( N
SIH NNP N
) ) N
, , N
neurological JJ N
and CC N
functional JJ N
scores NNS N
. . N

Fourteen CD N
patients NNS N
were VBD N
given VBN N
IVF NNP N
and CC N
13 CD N
IAF NNP N
. . N

The DT N
study NN N
was VBD N
terminated VBN N
by IN N
the DT N
National NNP N
Health NNP N
Authorities NNP N
when WRB N
27 CD N
patients NNS N
had VBD N
been VBN N
included VBN N
because IN N
of IN N
the DT N
mortality NN N
rate NN N
. . N

Seven CD N
patients NNS N
( ( N
26 CD N
% NN N
) ) N
died VBD N
, , N
4 CD N
in IN N
the DT N
IV NNP N
group NN N
( ( N
oedematous JJ N
infarct NN N
in IN N
3 CD N
and CC N
recurrence NN N
in IN N
1 CD N
) ) N
, , N
3 CD N
in IN N
the DT N
IA NNP N
group NN N
( ( N
SIH NNP N
in IN N
2 CD N
, , N
and CC N
oedematous JJ N
infarct NN N
in IN N
1 CD N
) ) N
. . N

Patients NNS N
given VBN N
IVF NNP N
were VBD N
treated VBN N
significantly RB N
earlier RBR N
( ( N
4:16 CD N
h NN N
vs NN N
5:24 CD N
h NN N
; : N
p=.007 NN N
) ) N
. . N

Although IN N
IA NNP N
patients NNS N
showed VBD N
greater JJR N
and CC N
earlier RBR N
improvement NN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
. . N

Because IN N
of IN N
premature NN N
termination NN N
, , N
the DT N
trial NN N
was VBD N
too RB N
small JJ N
to TO N
provide VB N
any DT N
reliable JJ N
and CC N
conclusive JJ N
results NNS N
. . N

Intra-arterial JJ N
fibrinolysis NN N
began VBD N
significantly RB N
later RBR N
than IN N
IV NNP N
fibrinolysis NN N
but CC N
it PRP N
gave VBD N
non-significantly RB N
better JJ N
results NNS N
in IN N
this DT N
prematurely RB N
terminated VBN N
study NN N
. . N

-DOCSTART- -15810908- O O

B-domain NNP N
deleted VBD N
recombinant JJ N
factor NN N
VIII NNP N
preparations NNS N
are VBP N
bioequivalent JJ N
to TO N
a DT N
monoclonal JJ N
antibody NN N
purified VBD N
plasma-derived JJ N
factor NN N
VIII NNP N
concentrate NN N
: : N
a DT N
randomized JJ N
, , N
three-way JJ N
crossover NN N
study NN N
. . N

BACKGROUND NNP N
Deletion NNP N
of IN N
the DT N
B-domain NNP N
of IN N
recombinant JJ N
blood NN N
coagulation NN N
factor NN N
VIII NNP N
( ( N
BDDrFVIII NNP N
) ) N
increases VBZ N
the DT N
manufacturing VBG N
yield NN N
of IN N
the DT N
product NN N
but CC N
does VBZ N
not RB N
impair VB N
in IN N
vitro NN N
or CC N
in IN N
vivo JJ N
functionality NN N
. . N

BDDrFVIII NNP N
( ( N
ReFacto NNP N
) ) N
has VBZ N
been VBN N
developed VBN N
with IN N
the DT N
additional JJ N
benefit NN N
of IN N
being VBG N
formulated VBN N
without IN N
human JJ N
albumin NN N
. . N

OBJECTIVE CC N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
three-way JJ N
crossover-design NN N
study NN N
was VBD N
to TO N
compare VB N
the DT N
pharmacokinetic JJ N
( ( N
PK NNP N
) ) N
parameters NNS N
of IN N
two CD N
BDDrFVIII NNP N
formulations NNS N
( ( N
one CD N
reconstituted VBN N
with IN N
5 CD N
mL NNS N
of IN N
sterile JJ N
water NN N
, , N
the DT N
other JJ N
reconstituted VBD N
with IN N
4 CD N
mL NNS N
sodium JJ N
chloride RB N
0.9 CD N
% NN N
USP NNP N
) ) N
with IN N
those DT N
of IN N
a DT N
plasma-derived JJ N
, , N
full-length JJ N
FVIII NNP N
preparation NN N
( ( N
Hemofil NNP N
M NNP N
) ) N
in IN N
patients NNS N
with IN N
haemophilia PDT N
A DT N
to TO N
determine VB N
bioequivalence NN N
. . N

METHODS VB N
A NNP N
series NN N
of IN N
blood NN N
samples NNS N
were VBD N
collected VBN N
over IN N
a DT N
period NN N
of IN N
48 CD N
h NN N
after IN N
i.v NN N
. . N

administration NN N
of IN N
each DT N
of IN N
the DT N
FVIII NNP N
preparations NNS N
. . N

Plasma NNP N
FVIII NNP N
activity NN N
was VBD N
determined VBN N
using VBG N
a DT N
validated JJ N
chromogenic JJ N
substrate NN N
assay NN N
. . N

Plasma NNP N
FVIII NNP N
activity NN N
vs. FW N
time NN N
curves NNS N
was VBD N
characterized VBN N
for IN N
a DT N
standard JJ N
set NN N
of IN N
PK NNP N
parameter NN N
estimates NNS N
. . N

Two CD N
parameter NN N
estimates NNS N
, , N
the DT N
maximum JJ N
plasma JJ N
concentration NN N
( ( N
Cmax NNP N
) ) N
and CC N
the DT N
area NN N
under IN N
plasma JJ N
concentration NN N
vs. FW N
time NN N
curves NNS N
( ( N
AUCs NNP N
) ) N
, , N
were VBD N
used VBN N
to TO N
evaluate VB N
bioequivalence NN N
. . N

The DT N
two CD N
preparations NNS N
were VBD N
considered VBN N
bioequivalent NN N
if IN N
the DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
for IN N
the DT N
ratio NN N
of IN N
geometric JJ N
means NNS N
for IN N
Cmax NNP N
and CC N
AUCs NNP N
fell VBD N
within IN N
the DT N
bioequivalence NN N
window NN N
of IN N
80 CD N
% NN N
to TO N
125 CD N
% NN N
. . N

RESULTS/CONCLUSION NNP N
Results NNP N
show VBP N
that IN N
each DT N
BDDrFVIII NNP N
formulation NN N
is VBZ N
bioequivalent JJ N
to TO N
Hemofil NNP N
M NNP N
and CC N
the DT N
two CD N
formulations NNS N
of IN N
BDDrFVIII NNP N
are VBP N
bioequivalent JJ N
to TO N
each DT N
other JJ N
. . N

-DOCSTART- -16257339- O O

Gefitinib NNP N
plus CC N
best JJS N
supportive JJ N
care NN N
in IN N
previously RB N
treated VBN N
patients NNS N
with IN N
refractory JJ N
advanced JJ N
non-small-cell JJ N
lung NN N
cancer NN N
: : N
results NNS N
from IN N
a DT N
randomised VBN N
, , N
placebo-controlled JJ N
, , N
multicentre JJ N
study NN N
( ( N
Iressa NNP N
Survival NNP N
Evaluation NNP N
in IN N
Lung NNP N
Cancer NNP N
) ) N
. . N

BACKGROUND VB N
This DT N
placebo-controlled JJ N
phase NN N
III NNP N
study NN N
investigated VBD N
the DT N
effect NN N
on IN N
survival NN N
of IN N
gefitinib NN N
as IN N
second-line JJ N
or CC N
third-line JJ N
treatment NN N
for IN N
patients NNS N
with IN N
locally RB N
advanced JJ N
or CC N
metastatic JJ N
non-small-cell JJ N
lung NN N
cancer NN N
. . N

METHODS NNP N
1692 CD N
patients NNS N
who WP N
were VBD N
refractory JJ N
to TO N
or CC N
intolerant VB N
of IN N
their PRP$ N
latest JJS N
chemotherapy NN N
regimen NNS N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
ratio NN N
of IN N
two CD N
to TO N
one CD N
either DT N
gefitinib NN N
( ( N
250 CD N
mg/day NN N
) ) N
or CC N
placebo NN N
, , N
plus CC N
best JJS N
supportive JJ N
care NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
survival VBN N
in IN N
the DT N
overall JJ N
population NN N
of IN N
patients NNS N
and CC N
those DT N
with IN N
adenocarcinoma NN N
. . N

The DT N
primary JJ N
analysis NN N
of IN N
the DT N
population NN N
for IN N
survival NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
has VBZ N
been VBN N
submitted VBN N
for IN N
registration NN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
1839IL/709 CD N
. . N

FINDINGS JJ N
1129 CD N
patients NNS N
were VBD N
assigned VBN N
gefitinib NNS N
and CC N
563 CD N
placebo NN N
. . N

At IN N
median JJ N
follow-up NN N
of IN N
7.2 CD N
months NNS N
, , N
median JJ N
survival NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
in IN N
the DT N
overall JJ N
population NN N
( ( N
5.6 CD N
months NNS N
for IN N
gefitinib NN N
and CC N
5.1 CD N
months NNS N
for IN N
placebo NN N
; : N
hazard CC N
ratio VB N
0.89 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
0.77-1.02 CD N
] NNP N
, , N
p=0.087 NN N
) ) N
or CC N
among IN N
the DT N
812 CD N
patients NNS N
with IN N
adenocarcinoma NN N
( ( N
6.3 CD N
months NNS N
vs RB N
5.4 CD N
months NNS N
; : N
0.84 CD N
[ IN N
0.68-1.03 JJ N
] NN N
, , N
p=0.089 NN N
) ) N
. . N

Preplanned VBN N
subgroup NN N
analyses VBZ N
showed VBN N
significantly RB N
longer RBR N
survival NN N
in IN N
the DT N
gefitinib NN N
group NN N
than IN N
the DT N
placebo NN N
group NN N
for IN N
never-smokers NNS N
( ( N
n=375 NN N
; : N
0.67 CD N
[ IN N
0.49-0.92 JJ N
] NN N
, , N
p=0.012 NN N
; : N
median JJ N
survival NN N
8.9 CD N
vs NN N
6.1 CD N
months NNS N
) ) N
and CC N
patients NNS N
of IN N
Asian JJ N
origin NN N
( ( N
n=342 JJ N
; : N
0.66 CD N
[ IN N
0.48-0.91 JJ N
] NN N
, , N
p=0.01 NN N
; : N
median JJ N
survival NN N
9.5 CD N
vs NN N
5.5 CD N
months NNS N
) ) N
. . N

Gefitinib NNP N
was VBD N
well RB N
tolerated VBN N
, , N
as IN N
in IN N
previous JJ N
studies NNS N
. . N

INTERPRETATION NNP N
Treatment NNP N
with IN N
gefitinib NN N
was VBD N
not RB N
associated VBN N
with IN N
significant JJ N
improvement NN N
in IN N
survival NN N
in IN N
either DT N
coprimary JJ N
population NN N
. . N

There EX N
was VBD N
pronounced JJ N
heterogeneity NN N
in IN N
survival JJ N
outcomes NNS N
between IN N
groups NNS N
of IN N
patients NNS N
, , N
with IN N
some DT N
evidence NN N
of IN N
benefit NN N
among IN N
never-smokers NNS N
and CC N
patients NNS N
of IN N
Asian JJ N
origin NN N
. . N

-DOCSTART- -12050494- O O

Clinically RB N
relevant JJ N
improvement NN N
of IN N
recurrence-free JJ N
survival NN N
with IN N
5-aminolevulinic JJ N
acid NN N
induced VBD N
fluorescence NN N
diagnosis NN N
in IN N
patients NNS N
with IN N
superficial JJ N
bladder NN N
tumors NNS N
. . N

PURPOSES NNP N
Fluorescence NNP N
diagnosis NN N
induced VBN N
by IN N
5-aminolevulinic JJ N
acid NN N
enables VBZ N
more RBR N
thorough JJ N
transurethral JJ N
resection NN N
of IN N
superficial JJ N
bladder NN N
carcinoma NNS N
compared VBN N
with IN N
conventional JJ N
white JJ N
light NN N
. . N

We PRP N
performed VBD N
a DT N
prospective JJ N
, , N
single JJ N
institution NN N
, , N
randomized VBN N
trial NN N
to TO N
investigate VB N
whether IN N
the DT N
residual JJ N
tumor NN N
rate NN N
and CC N
long-term JJ N
tumor NN N
recurrence NN N
can MD N
be VB N
decreased VBN N
by IN N
fluorescence NN N
diagnosis NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
301 CD N
patients NNS N
underwent JJ N
transurethral JJ N
resection NN N
of IN N
bladder NN N
tumors NNS N
with IN N
white JJ N
light NN N
or CC N
fluorescence NN N
diagnosis NN N
. . N

Transurethral JJ N
resection NN N
was VBD N
repeated VBN N
5 CD N
to TO N
6 CD N
weeks NNS N
later RB N
to TO N
evaluate VB N
the DT N
residual JJ N
tumor NN N
rate NN N
. . N

To TO N
determine VB N
recurrence-free JJ N
survival JJ N
patient NN N
followup NN N
was VBD N
performed VBN N
every DT N
3 CD N
months NNS N
by IN N
white JJ N
light JJ N
cystoscopy NN N
and CC N
urine JJ N
cytology NN N
. . N

Recurrence-free JJ N
survival NN N
was VBD N
analyzed VBN N
via IN N
Kaplan-Meier NNP N
methods NNS N
and CC N
multivariable JJ N
Cox NNP N
regression NN N
analysis NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
191 CD N
patients NNS N
with IN N
superficial JJ N
bladder NN N
carcinoma NN N
were VBD N
available JJ N
for IN N
efficacy NN N
analysis NN N
. . N

The DT N
residual JJ N
tumor NN N
rate NN N
was VBD N
25.2 CD N
% NN N
in IN N
the DT N
white JJ N
light JJ N
arm NN N
versus NN N
4.5 CD N
% NN N
in IN N
the DT N
fluorescence NN N
diagnosis NN N
arm NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Median JJ N
followup NN N
in IN N
the DT N
white JJ N
light JJ N
arm NN N
in IN N
103 CD N
cases NNS N
was VBD N
21.2 CD N
months NNS N
( ( N
range VB N
4 CD N
to TO N
40 CD N
) ) N
compared VBN N
with IN N
20.5 CD N
( ( N
range NN N
3 CD N
to TO N
40 CD N
) ) N
in IN N
the DT N
88 CD N
in IN N
the DT N
fluorescence NN N
diagnosis NN N
arm NN N
. . N

Recurrence-free JJ N
survival NN N
in IN N
the DT N
fluorescence NN N
diagnosis NN N
group NN N
was VBD N
89.6 CD N
% NN N
after IN N
12 CD N
and CC N
24 CD N
months NNS N
compared VBN N
with IN N
73.8 CD N
% NN N
and CC N
65.9 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
white JJ N
light NN N
group NN N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

This DT N
superiority NN N
proved VBD N
to TO N
be VB N
independent JJ N
of IN N
risk NN N
group NN N
. . N

The DT N
adjusted JJ N
hazard NN N
ratio NN N
of IN N
fluorescence NN N
diagnosis NN N
versus IN N
white JJ N
light JJ N
transurethral JJ N
resection NN N
was VBD N
0.33 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
0.16 CD N
to TO N
0.67 CD N
) ) N
. . N

CONCLUSIONS NNP N
Fluorescence NNP N
diagnosis NN N
is VBZ N
significantly RB N
superior JJ N
to TO N
conventional JJ N
white JJ N
light JJ N
transurethral JJ N
resection NN N
with IN N
respect NN N
to TO N
the DT N
residual JJ N
tumor NN N
rate NN N
and CC N
recurrence-free JJ N
survival NN N
. . N

The DT N
differences NNS N
in IN N
recurrence-free JJ N
survival NN N
imply NN N
that WDT N
fluorescence NN N
diagnosis NN N
is VBZ N
a DT N
clinically RB N
relevant JJ N
procedure NN N
for IN N
decreasing VBG N
the DT N
number NN N
of IN N
tumor NN N
recurrences NNS N
. . N

-DOCSTART- -19144729- O O

Effect NN N
of IN N
testosterone NN N
and CC N
a DT N
nutritional JJ N
supplement NN N
, , N
alone RB N
and CC N
in IN N
combination NN N
, , N
on IN N
hospital JJ N
admissions NNS N
in IN N
undernourished JJ N
older JJR N
men NNS N
and CC N
women NNS N
. . N

BACKGROUND NNP N
In IN N
older JJR N
people NNS N
, , N
undernutrition NN N
is VBZ N
associated VBN N
with IN N
increased JJ N
hospitalization NN N
rates NNS N
and CC N
mortality NN N
. . N

Because IN N
weight JJ N
loss NN N
in IN N
older JJR N
people NNS N
often RB N
reflects VBZ N
a DT N
disproportionate JJ N
reduction NN N
of IN N
skeletal JJ N
muscle NN N
, , N
anabolic JJ N
treatments NNS N
may MD N
be VB N
beneficial JJ N
. . N

OBJECTIVE NNP N
Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
hypothesis NN N
that WDT N
testosterone NN N
treatment NN N
and CC N
a DT N
nutritional JJ N
supplement NN N
have VBP N
additive JJ N
benefits NNS N
. . N

DESIGN NNP N
Oral NNP N
testosterone NN N
undecanoate NN N
( ( N
40 CD N
mg NNS N
daily RB N
for IN N
women NNS N
, , N
80 CD N
mg NN N
twice RB N
daily RB N
for IN N
men NNS N
) ) N
and CC N
an DT N
oral JJ N
nutritional JJ N
supplement NN N
( ( N
475 CD N
kcal/d NN N
) ) N
were VBD N
administered VBN N
, , N
alone RB N
or CC N
combined VBN N
, , N
for IN N
1 CD N
y NNS N
to TO N
49 CD N
community-dwelling NN N
, , N
undernourished JJ N
people NNS N
[ VBP N
Mini NNP N
Nutritional NNP N
Assessment NNP N
score VBD N
< JJ N
24 CD N
and CC N
low JJ N
body NN N
weight NN N
( ( N
body JJ N
mass NN N
index NN N
, , N
in IN N
kg/m NN N
( ( N
2 CD N
) ) N
: : N
< $ N
22 CD N
) ) N
or CC N
recent JJ N
weight JJ N
loss NN N
( ( N
> JJ N
7.5 CD N
% NN N
over IN N
3 CD N
mo NNS N
) ) N
] VBP N
aged VBN N
> $ N
65 CD N
y NN N
( ( N
mean JJ N
age NN N
: : N
77 CD N
y NN N
; : N
26 CD N
women NNS N
and CC N
23 CD N
men NNS N
) ) N
. . N

Hospital JJ N
admissions NNS N
and CC N
other JJ N
variables NNS N
were VBD N
assessed VBN N
. . N

RESULTS NNP N
In IN N
subjects NNS N
receiving VBG N
combined VBN N
testosterone NN N
and CC N
nutritional JJ N
supplements NNS N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
, , N
there EX N
were VBD N
no DT N
hospital NN N
admissions NNS N
, , N
whereas IN N
there EX N
were VBD N
9 CD N
admissions NNS N
( ( N
2 CD N
elective NN N
) ) N
in IN N
13 CD N
subjects NNS N
in IN N
the DT N
no-treatment JJ N
group NN N
, , N
4 CD N
in IN N
the DT N
testosterone-treated JJ N
group NN N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
, , N
and CC N
5 CD N
in IN N
the DT N
supplement-treated JJ N
group NN N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
; : N
P NNP N
= VBD N
0.06 CD N
with IN N
no-treatment JJ N
compared VBN N
with IN N
combined JJ N
treatment NN N
. . N

When WRB N
compared VBN N
with IN N
the DT N
no-treatment JJ N
group NN N
, , N
the DT N
combined-treatment JJ N
group NN N
had VBD N
significantly RB N
fewer JJR N
subjects NNS N
admitted VBN N
to TO N
hospital VB N
( ( N
0 CD N
compared VBN N
with IN N
5 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
fewer JJR N
days NNS N
in IN N
hospital NN N
( ( N
0 CD N
compared VBN N
with IN N
74 CD N
, , N
P NNP N
= NNP N
0.041 CD N
) ) N
, , N
and CC N
a DT N
longer JJR N
time NN N
to TO N
hospital VB N
admission NN N
( ( N
P NNP N
= NNP N
0.017 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
undernourished JJ N
older JJR N
people NNS N
, , N
combined VBN N
treatment NN N
with IN N
testosterone NN N
and CC N
nutritional JJ N
supplementation NN N
reduced VBD N
the DT N
number NN N
of IN N
people NNS N
hospitalized VBN N
and CC N
the DT N
duration NN N
of IN N
hospital NN N
admissions NNS N
, , N
which WDT N
are VBP N
important JJ N
endpoints NNS N
in IN N
this DT N
group NN N
. . N

Larger NNP N
, , N
confirmatory NN N
studies NNS N
are VBP N
now RB N
needed VBN N
. . N

This DT N
trial NN N
was VBD N
registered VBN N
before IN N
commencement NN N
at IN N
clinical JJ N
trials.gov NN N
as IN N
NCT00117000 NNP N
. . N

-DOCSTART- -6496450- O O

Immunogenicity NN N
and CC N
safety NN N
of IN N
a DT N
plasma-derived JJ N
heat-inactivated JJ N
hepatitis NN N
B NNP N
vaccine NN N
( ( N
CLB NNP N
) ) N
. . N

Studies NNPS N
in IN N
volunteers NNS N
at IN N
a DT N
low JJ N
risk NN N
of IN N
infection NN N
with IN N
hepatitis NN N
B NNP N
virus NN N
. . N

The DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
a DT N
plasma-derived JJ N
heat-inactivated JJ N
hepatitis NN N
B NNP N
vaccine NN N
( ( N
CLB NNP N
) ) N
were VBD N
evaluated VBN N
in IN N
471 CD N
healthy JJ N
human JJ N
volunteers NNS N
, , N
who WP N
, , N
both DT N
in IN N
their PRP$ N
occupations NNS N
and CC N
in IN N
their PRP$ N
private JJ N
lives NNS N
, , N
had VBD N
been VBN N
at IN N
minimal JJ N
risk NN N
of IN N
being VBG N
infected VBN N
with IN N
hepatitis NN N
B NNP N
virus NN N
. . N

The DT N
first JJ N
202 JJ N
individuals NNS N
received VBD N
three CD N
3-micrograms JJ N
doses NNS N
of IN N
heat-inactivated JJ N
hepatitis NN N
B NNP N
surface NN N
antigen NN N
( ( N
HBsAg NNP N
) ) N
at IN N
one-month JJ N
intervals NNS N
( ( N
trial NN N
A DT N
) ) N
. . N

A DT N
total NN N
of IN N
42 CD N
% NN N
one CD N
month NN N
after IN N
the DT N
first JJ N
injection NN N
, , N
84 CD N
% NN N
after IN N
two CD N
months NNS N
, , N
and CC N
93 CD N
% NN N
after IN N
five CD N
months NNS N
had VBD N
become VBN N
anti-HBs JJ N
( ( N
antibody NN N
to TO N
hepatitis VB N
B NNP N
surface NN N
antigen NN N
) ) N
positive JJ N
. . N

In IN N
a DT N
second JJ N
randomized VBN N
study NN N
( ( N
trial NN N
B NNP N
) ) N
, , N
the DT N
immunogenicity NN N
of IN N
five CD N
different JJ N
dosages NNS N
of IN N
the DT N
vaccine NN N
was VBD N
compared VBN N
in IN N
269 CD N
volunteers NNS N
. . N

When WRB N
the DT N
dose NN N
of IN N
HBsAg NNP N
was VBD N
diminished VBN N
from IN N
3 CD N
micrograms NNS N
to TO N
1.5 CD N
, , N
0.6 CD N
, , N
and CC N
0.25 CD N
microgram NN N
, , N
no DT N
decrease NN N
of IN N
the DT N
anti-HBs JJ N
response NN N
was VBD N
observed VBN N
. . N

However RB N
, , N
when WRB N
the DT N
dose NN N
was VBD N
diminished VBN N
to TO N
0.1 CD N
microgram NN N
of IN N
HBsAg NNP N
, , N
the DT N
anti-HBs JJ N
response NN N
dropped VBD N
significantly RB N
to TO N
63 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

In IN N
the DT N
recipients NNS N
of IN N
all DT N
five CD N
vaccine NN N
dosages NNS N
, , N
no DT N
influence NN N
of IN N
sex NN N
and CC N
age NN N
was VBD N
found VBN N
on IN N
the DT N
anti-HBs JJ N
conversion NN N
rates NNS N
. . N

During IN N
the DT N
eight-month JJ N
observation NN N
period NN N
, , N
none NN N
of IN N
the DT N
vaccinees NNS N
became VBD N
HBsAg NNP N
and/or IN N
anti-HBc JJ N
( ( N
antibody NN N
to TO N
hepatitis VB N
B NNP N
core NN N
antigen NN N
) ) N
positive JJ N
, , N
and CC N
none NN N
developed VBD N
antibodies NNS N
associated VBN N
with IN N
autoimmune JJ N
liver NN N
disease NN N
. . N

No DT N
serious JJ N
side NN N
effects NNS N
were VBD N
observed VBN N
. . N

-DOCSTART- -3538985- O O

Transcutaneous JJ N
electrical JJ N
nerve NN N
stimulation NN N
following VBG N
appendicectomy NN N
: : N
the DT N
placebo NN N
effect NN N
. . N

A DT N
controlled JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
transcutaneous JJ N
electrical JJ N
nerve NN N
stimulation NN N
( ( N
TENS NNP N
) ) N
with IN N
standard JJ N
intramuscular JJ N
opiate NN N
analgesia NN N
in IN N
the DT N
management NN N
of IN N
postoperative JJ N
pain NN N
following VBG N
appendicectomy NN N
. . N

Consecutive JJ N
patients NNS N
undergoing VBG N
emergency NN N
appendicectomy NN N
were VBD N
randomised VBN N
into IN N
control NN N
, , N
sham NN N
TENS NNP N
and CC N
active JJ N
TENS NNP N
groups NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
pain NN N
severity NN N
and CC N
analgesic JJ N
intake NN N
in IN N
both DT N
active JJ N
and CC N
sham JJ N
TENS NNP N
groups NNS N
when WRB N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

No DT N
difference NN N
was VBD N
demonstrated VBN N
in IN N
pain NN N
severity NN N
between IN N
active JJ N
and CC N
sham JJ N
TENS NNP N
groups NNS N
but CC N
the DT N
active JJ N
TENS NNP N
group NN N
required VBD N
slightly RB N
less JJR N
analgesia NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
major JJ N
benefit NN N
of IN N
TENS NNP N
in IN N
the DT N
postappendicectomy NN N
patient NN N
is VBZ N
due JJ N
to TO N
its PRP$ N
'placebo JJ N
effect NN N
' POS N
and CC N
its PRP$ N
use NN N
in IN N
this DT N
situation NN N
can MD N
not RB N
be VB N
recommended VBN N
. . N

-DOCSTART- -23241003- O O

Is VBZ N
chronic JJ N
sildenafil NN N
therapy NN N
safe JJ N
and CC N
clinically RB N
beneficial JJ N
in IN N
patients NNS N
with IN N
systolic JJ N
heart NN N
failure NN N
? . N
Sildenafil NNP N
is VBZ N
a DT N
selective JJ N
phosphodiesterase-5 JJ N
inhibitor NN N
and CC N
causes VBZ N
vasodilatation NN N
, , N
particularly RB N
in IN N
pulmonary JJ N
circulation NN N
. . N

Since IN N
left JJ N
heart NN N
failure NN N
may MD N
be VB N
associated VBN N
with IN N
pulmonary JJ N
hypertension NN N
out IN N
of IN N
proportion NN N
to TO N
left VB N
heart NN N
disease NN N
, , N
sildenafil NN N
may MD N
have VB N
beneficial JJ N
effect NN N
in IN N
such JJ N
patients NNS N
. . N

The DT N
present JJ N
investigation NN N
was VBD N
designed VBN N
as IN N
a DT N
12-week JJ N
, , N
single-center JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
evaluating VBG N
the DT N
effects NNS N
of IN N
sildenafil NN N
on IN N
mean JJ N
blood NN N
pressure NN N
( ( N
primary JJ N
endpoint NN N
) ) N
in IN N
patients NNS N
with IN N
left JJ N
systolic JJ N
heart NN N
failure NN N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
exercise NN N
capacity NN N
assessed VBN N
by IN N
6-minute JJ N
walk NN N
test NN N
. . N

A DT N
total NN N
of IN N
106 CD N
patients NNS N
were VBD N
randomized VBN N
1:1 CD N
to TO N
sildenafil VB N
( ( N
n=53 NN N
) ) N
or CC N
placebo NN N
( ( N
n=53 JJ N
) ) N
. . N

Patients NNS N
received VBD N
sildenafil JJ N
25 CD N
mg NN N
twice RB N
a DT N
day NN N
or CC N
matching VBG N
placebo NN N
for IN N
the DT N
first JJ N
2 CD N
weeks NNS N
and CC N
50 CD N
mg NN N
3 CD N
times NNS N
a DT N
week NN N
for IN N
the DT N
remainder NN N
of IN N
the DT N
trial NN N
. . N

The DT N
placebo-corrected JJ N
effect NN N
on IN N
mean JJ N
blood NN N
pressure NN N
was VBD N
1.16 CD N
mm NN N
Hg NNP N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-1.6 VBP N
to TO N
5.1 CD N
, , N
P NNP N
> NNP N
.05 NNP N
) ) N
, , N
demonstrating VBG N
that IN N
sildenafil NN N
did VBD N
not RB N
decrease VB N
mean JJ N
blood NN N
pressure NN N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
sildenafil NN N
increased VBD N
the DT N
6-minute JJ N
walk NN N
test NN N
by IN N
a DT N
nonsignificant JJ N
treatment NN N
effect NN N
of IN N
14 CD N
m NN N
( ( N
P=.67 NNP N
) ) N
. . N

Adverse JJ N
effects NNS N
occurred VBD N
in IN N
a DT N
comparable JJ N
proportion NN N
of IN N
patients NNS N
taking VBG N
sildenafil JJ N
and CC N
placebo NN N
, , N
and CC N
none NN N
of IN N
the DT N
patients NNS N
needed VBN N
to TO N
discontinue VB N
therapy NN N
. . N

Sildenafil NNP N
is VBZ N
well RB N
tolerated VBN N
in IN N
left JJ N
heart NN N
failure NN N
patients NNS N
and CC N
does VBZ N
not RB N
decrease VB N
blood NN N
pressure NN N
. . N

It PRP N
can MD N
be VB N
safely RB N
added VBN N
to TO N
standard VB N
heart NN N
failure NN N
therapy NN N
. . N

-DOCSTART- -10674229- O O

Differential JJ N
effects NNS N
of IN N
amino NN N
acid NN N
and CC N
ketoacid VB N
on IN N
protein NN N
metabolism NN N
in IN N
humans NNS N
. . N

We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
insulin NN N
, , N
amino JJ N
acid NN N
( ( N
AA NNP N
) ) N
, , N
and CC N
branched-chain JJ N
ketoacid NN N
( ( N
KA NNP N
) ) N
availability NN N
on IN N
leucine JJ N
kinetics NNS N
in IN N
eight CD N
healthy JJ N
volunteers NNS N
( ( N
age NN N
= VBZ N
22 CD N
+/- JJ N
2 CD N
y NN N
, , N
body NN N
mass NN N
index NN N
= VBD N
24 CD N
+/- JJ N
1 CD N
kg NN N
) ) N
by IN N
using VBG N
the DT N
euglycemic JJ N
insulin NN N
clamp NN N
and CC N
[ JJ N
1-14C JJ N
] NNP N
leucine NN N
turnover NN N
techniques NNS N
. . N

Four CD N
experimental JJ N
conditions NNS N
were VBD N
studied VBN N
: : N
study NN N
I PRP N
, , N
hyperinsulinemia NN N
; : N
study NN N
II NNP N
, , N
hyperinsulinemia NN N
with IN N
maintenance NN N
of IN N
basal NN N
plasma NN N
AA NNP N
and CC N
branched-chain JJ N
KA NNP N
concentrations NNS N
; : N
study NN N
III NNP N
, , N
hyperinsulinemia NN N
with IN N
hyperaminoacidemia NN N
and CC N
basal NN N
plasma VBP N
branched-chain NN N
KA NNP N
concentrations NNS N
; : N
and CC N
study VB N
IV NNP N
, , N
hyperinsulinemia NN N
plus CC N
basal NN N
plasma VBP N
AA NNP N
concentrations NNS N
and CC N
elevated VBD N
branched-chain NN N
KA NNP N
levels NNS N
. . N

Basal NNP N
endogenous JJ N
leucine NN N
flux NN N
( ( N
ELF NNP N
) ) N
averaged VBD N
1.20 CD N
+/- JJ N
0.05 CD N
( ( N
mumol.kg-1.min-1 NN N
, , N
mean JJ N
+/- JJ N
SE NNP N
) ) N
; : N
basal CC N
leucine JJ N
oxidation NN N
( ( N
LOX NNP N
) ) N
was VBD N
0.25 CD N
+/- JJ N
0.01 CD N
; : N
and CC N
basal VB N
non-oxidative JJ N
leucine NN N
disposal NN N
( ( N
NOLD NNP N
) ) N
was VBD N
0.95 CD N
+/- JJ N
0.04 CD N
. . N

ELF NNP N
significantly RB N
decreased VBD N
in IN N
study NN N
I PRP N
( ( N
0.77 CD N
+/- JJ N
0.06 CD N
mumol.kg-1.min-1 NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
. . N

When WRB N
plasma NN N
AA NNP N
and CC N
branched-chain JJ N
KA NNP N
were VBD N
either RB N
maintained VBN N
at IN N
their PRP$ N
basal NN N
levels NNS N
( ( N
study VB N
II NNP N
) ) N
or CC N
increased VBN N
above IN N
baseline NN N
values NNS N
( ( N
studies NNS N
III NNP N
and CC N
IV NNP N
) ) N
, , N
ELF NNP N
declined VBD N
further RBR N
( ( N
0.64 CD N
+/- JJ N
0.05 CD N
, , N
0.66 CD N
+/- JJ N
0.02 CD N
, , N
and CC N
0.66 CD N
+/- JJ N
0.03 CD N
mumol.kg-1.min-1 NN N
, , N
respectively RB N
; : N
all DT N
Ps NNP N
< NNP N
0.01 CD N
versus NN N
basal NN N
and CC N
P NNP N
< NNP N
0.01 CD N
versus NN N
study NN N
I PRP N
) ) N
. . N

LOX NNP N
declined VBD N
in IN N
study NN N
I PRP N
( ( N
0.12 CD N
+/- JJ N
0.02 CD N
mumol.kg-1.min-1 NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
but CC N
increased VBD N
significantly RB N
in IN N
studies NNS N
II NNP N
, , N
III NNP N
, , N
and CC N
IV NNP N
( ( N
0.31 CD N
+/- JJ N
0.04 CD N
, , N
0.37 CD N
+/- JJ N
0.03 CD N
, , N
and CC N
0.40 CD N
+/- JJ N
0.03 CD N
mumol.kg-1.min-1 NN N
, , N
respectively RB N
, , N
all DT N
Ps NNP N
< NNP N
0.01 CD N
versus NN N
basal NN N
, , N
P NNP N
< NNP N
0.05 CD N
study NN N
IV NNP N
versus NN N
study NN N
II NNP N
, , N
and CC N
P NNP N
< NNP N
0.05 CD N
study NN N
III NNP N
versus NN N
study NN N
II NNP N
) ) N
. . N

NOLD NNP N
declined VBD N
in IN N
study NN N
I PRP N
( ( N
0.65 CD N
+/- JJ N
0.05 CD N
mumol/kg.min NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
, , N
whereas IN N
neither CC N
the DT N
maintenance NN N
of IN N
basal NN N
plasma IN N
AA/branched-chain NNP N
KA NNP N
levels NNS N
( ( N
study NN N
II NNP N
; : N
0.89 CD N
+/- JJ N
0.2 CD N
mumol.kg-1.min-1 NN N
) ) N
nor CC N
the DT N
elevation NN N
of IN N
plasma JJ N
branched-chain JJ N
KA NNP N
concentration NN N
( ( N
study JJ N
IV NNP N
; : N
0.96 CD N
+/- JJ N
0.1 CD N
mumol.kg-1.min-1 NN N
) ) N
increased VBD N
NOLD NNP N
above IN N
baseline NN N
level NN N
. . N

A DT N
stimulation NN N
of IN N
NOLD NNP N
was VBD N
observed VBN N
only RB N
when WRB N
plasma JJ N
AA NNP N
levels NNS N
were VBD N
increased VBN N
( ( N
study NN N
III NNP N
; : N
1.23 CD N
+/- JJ N
0.03 CD N
mumol/kg.min NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
present JJ N
data NNS N
do VBP N
not RB N
support VB N
the DT N
concept NN N
of IN N
a DT N
direct JJ N
anabolic JJ N
action NN N
of IN N
ketoanalogs NNS N
but CC N
do VBP N
provide VB N
additional JJ N
evidence NN N
for IN N
the DT N
pivotal JJ N
role NN N
of IN N
AA NNP N
availability NN N
in IN N
the DT N
stimulation NN N
of IN N
whole-body NN N
protein NN N
synthesis NN N
. . N

-DOCSTART- -16731878- O O

Outcomes NNS N
in IN N
a DT N
nursing NN N
home NN N
transition NN N
case-management JJ N
program NN N
targeting VBG N
new JJ N
admissions NNS N
. . N

PURPOSE VB N
The DT N
Providing VBG N
Assistance NNP N
to TO N
Caregivers NNPS N
in IN N
Transition NNP N
( ( N
PACT NNP N
) ) N
program NN N
offers NNS N
nursing VBG N
home NN N
discharge NN N
planning NN N
and CC N
case NN N
management NN N
for IN N
individuals NNS N
in IN N
the DT N
transitional JJ N
period NN N
following VBG N
a DT N
return NN N
to TO N
the DT N
community NN N
. . N

The DT N
PACT NNP N
program NN N
targeted VBN N
individuals NNS N
newly RB N
admitted VBN N
to TO N
nursing VBG N
homes NNS N
and CC N
worked VBD N
with IN N
a DT N
family NN N
caregiver NN N
to TO N
develop VB N
and CC N
implement VB N
a DT N
nursing NN N
home NN N
discharge NN N
plan NN N
. . N

DESIGN NNP N
AND CC N
METHOD NNP N
Reported NNP N
are VBP N
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
control NN N
design NN N
evaluating VBG N
the DT N
program NN N
's POS N
effectiveness NN N
. . N

Those DT N
individuals NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
intervention NN N
group NN N
( ( N
n JJ N
= NNP N
33 CD N
) ) N
received VBN N
PACT NNP N
case NN N
management NN N
in IN N
addition NN N
to TO N
their PRP$ N
usual JJ N
medical JJ N
and CC N
nursing NN N
home NN N
care NN N
. . N

The DT N
individuals NNS N
in IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
29 CD N
) ) N
continued VBD N
their PRP$ N
usual JJ N
care NN N
. . N

RESULT CC N
There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
in IN N
the DT N
discharge NN N
rate NN N
( ( N
84 CD N
% NN N
treatment NN N
vs RB N
76 CD N
% NN N
controls NNS N
) ) N
or CC N
in IN N
the DT N
median JJ N
length NN N
of IN N
stay NN N
( ( N
42 CD N
days NNS N
vs RB N
55 CD N
days NNS N
) ) N
between IN N
the DT N
two CD N
groups NNS N
of IN N
individuals NNS N
. . N

IMPLICATIONS NNP N
Replications NNPS N
or CC N
extensions NNS N
of IN N
a DT N
PACT-type JJ N
intervention NN N
might MD N
consider VB N
a DT N
broader JJR N
mix NN N
of IN N
nursing NN N
homes NNS N
, , N
working VBG N
directly RB N
with IN N
the DT N
nursing NN N
home NN N
's POS N
admission NN N
Minimum NNP N
Data NNP N
Set NNP N
coordinator NN N
in IN N
patient JJ N
selection NN N
, , N
or CC N
working VBG N
with IN N
Medicare NNP N
or CC N
Medicaid NNP N
HMO NNP N
plans VBZ N
. . N

-DOCSTART- -10969304- O O

Physostigmine JJ N
reverses VBZ N
propofol-induced JJ N
unconsciousness NN N
and CC N
attenuation NN N
of IN N
the DT N
auditory NN N
steady JJ N
state NN N
response NN N
and CC N
bispectral JJ N
index NN N
in IN N
human JJ N
volunteers NNS N
. . N

BACKGROUND IN N
It PRP N
is VBZ N
postulated VBN N
that IN N
alteration NN N
of IN N
central JJ N
cholinergic JJ N
transmission NN N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
the DT N
mechanism NN N
by IN N
which WDT N
anesthetics NNS N
produce VBP N
unconsciousness JJ N
. . N

The DT N
authors NNS N
investigated VBD N
the DT N
effect NN N
of IN N
altering VBG N
central JJ N
cholinergic JJ N
transmission NN N
, , N
by IN N
physostigmine NN N
and CC N
scopolamine NN N
, , N
on IN N
unconsciousness NN N
produced VBN N
by IN N
propofol NN N
. . N

METHODS NNP N
Propofol NNP N
was VBD N
administered VBN N
to TO N
American NNP N
Society NNP N
of IN N
Anesthesiologists NNP N
physical JJ N
status NN N
1 CD N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
volunteers NNS N
with IN N
use NN N
of IN N
a DT N
computer-controlled JJ N
infusion NN N
pump NN N
at IN N
increasing VBG N
concentrations NNS N
until IN N
unconsciousness JJ N
resulted VBD N
( ( N
inability NN N
to TO N
respond VB N
to TO N
verbal VB N
commands NNS N
, , N
abolition NN N
of IN N
spontaneous JJ N
movement NN N
) ) N
. . N

Central NNP N
nervous JJ N
system NN N
function NN N
was VBD N
assessed VBN N
by IN N
use NN N
of IN N
the DT N
Auditory NNP N
Steady NNP N
State NNP N
Response NNP N
( ( N
ASSR NNP N
) ) N
and CC N
Bispectral NNP N
Index NNP N
( ( N
BIS NNP N
) ) N
analysis NN N
of IN N
electrooculogram NN N
. . N

During IN N
continuous JJ N
administration NN N
of IN N
propofol NN N
, , N
reversal NN N
of IN N
unconsciousness NN N
produced VBN N
by IN N
physostigmine NN N
( ( N
28 CD N
microgram/kg NN N
) ) N
and CC N
block NN N
of IN N
this DT N
reversal NN N
by IN N
scopolamine NN N
( ( N
8.6 CD N
microgram/kg NN N
) ) N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Propofol NNP N
produced VBD N
unconsciousness JJ N
at IN N
a DT N
plasma JJ N
concentration NN N
of IN N
3.2 CD N
+/- JJ N
0.8 CD N
( ( N
+/- JJ N
SD NNP N
) ) N
microgram/ml NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
. . N

Unconsciousness NN N
was VBD N
associated VBN N
with IN N
reductions NNS N
in IN N
ASSR NNP N
( ( N
0.10 CD N
+/- JJ N
0.08 CD N
microV NN N
[ NNP N
awake VBP N
baseline JJ N
0.32 CD N
+/- JJ N
0.18 CD N
microV NN N
] NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
BIS NNP N
( ( N
55.7 CD N
+/- JJ N
8.8 CD N
[ JJ N
awake NN N
baseline NN N
92.4 CD N
+/- JJ N
3.9 CD N
] NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Physostigmine NNP N
restored VBD N
consciousness NN N
in IN N
9 CD N
of IN N
11 CD N
subjects NNS N
, , N
with IN N
concomitant JJ N
increases NNS N
in IN N
ASSR NNP N
( ( N
0.38 CD N
+/- JJ N
0.17 CD N
microV NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
BIS NNP N
( ( N
75.3 CD N
+/- JJ N
8.3 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
all DT N
subjects NNS N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
scopolamine NN N
blocked VBD N
the DT N
physostigmine-induced JJ N
reversal NN N
of IN N
unconsciousness NN N
and CC N
the DT N
increase NN N
of IN N
the DT N
ASSR NNP N
and CC N
BIS NNP N
( ( N
ASSR NNP N
and CC N
BIS NNP N
during IN N
propofol-induced JJ N
unconsciousness NN N
: : N
0.09 CD N
+/- JJ N
0.09 CD N
microV NN N
and CC N
58.2 CD N
+/- JJ N
7.5 CD N
, , N
respectively RB N
; : N
ASSR NNP N
and CC N
BIS NNP N
after IN N
physostigmine JJ N
administration NN N
: : N
0.08 CD N
+/- JJ N
0.06 CD N
microV NN N
and CC N
56.8 CD N
+/- JJ N
6.7 CD N
, , N
respectively RB N
, , N
NS NNP N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
unconsciousness NN N
produced VBN N
by IN N
propofol NN N
is VBZ N
mediated VBN N
at IN N
least JJS N
in IN N
part NN N
via IN N
interruption NN N
of IN N
central JJ N
cholinergic NN N
muscarinic JJ N
transmission NN N
. . N

-DOCSTART- -16335132- O O

Phytase NNP N
and CC N
1alpha-hydroxycholecalciferol JJ N
supplementation NN N
of IN N
broiler NN N
chickens NNS N
during IN N
the DT N
starting NN N
and CC N
growing/finishing NN N
phases NNS N
. . N

Supplemental JJ N
1alpha-hydroxycholecalciferol JJ N
( ( N
1alpha-OHD3 JJ N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
have VB N
qualitatively RB N
similar JJ N
and CC N
quantitatively RB N
additive JJ N
effects NNS N
to TO N
exogenous JJ N
phytase NN N
. . N

Two CD N
experiments NNS N
were VBD N
conducted VBN N
from IN N
0 CD N
to TO N
35 CD N
d NN N
in IN N
floor NN N
pens NNS N
to TO N
determine VB N
the DT N
additive JJ N
effect NN N
of IN N
phytase NN N
and CC N
1alpha-OHD3 JJ N
when WRB N
supplemented VBN N
to TO N
Ca- NNP N
and CC N
P-deficient NNP N
diets NNS N
. . N

In IN N
both DT N
experiments NNS N
, , N
at IN N
least JJS N
4 CD N
replicates NNS N
per IN N
treatment NN N
( ( N
50 CD N
chicks NNS N
per IN N
replicate NN N
) ) N
were VBD N
used VBN N
. . N

Corn-soybean-meal-and JJ N
soybean-oil-based JJ N
diets NNS N
were VBD N
fed VBN N
and CC N
birds NNS N
were VBD N
raised VBN N
in IN N
a DT N
house NN N
impervious JJ N
to TO N
ultraviolet VB N
light NN N
. . N

During IN N
the DT N
starter JJ N
phase NN N
( ( N
ST NNP N
) ) N
, , N
from IN N
0 CD N
to TO N
18 CD N
d NN N
, , N
chicks NNS N
were VBD N
fed VBN N
a DT N
23 CD N
% NN N
CP NNP N
diet JJ N
containing VBG N
0.60 CD N
% NN N
Ca NNP N
and CC N
0.47 CD N
% NN N
total JJ N
P NNP N
( ( N
tP NN N
) ) N
. . N

During IN N
the DT N
grower/finisher NN N
phase NN N
( ( N
GF NNP N
) ) N
, , N
from IN N
19 CD N
to TO N
35 CD N
d NN N
, , N
birds NNS N
were VBD N
fed VBN N
a DT N
19 CD N
% NN N
CP NNP N
diet JJ N
containing VBG N
0.30 CD N
% NN N
Ca NNP N
and CC N
0.37 CD N
% NN N
tP NN N
. . N

A DT N
combination NN N
of IN N
1,000 CD N
phytase NN N
units/kg NN N
of IN N
Natuphos NNP N
phytase NN N
and CC N
5 CD N
microg/kg NN N
of IN N
1alpha-OHD3 JJ N
( ( N
P+1A NNP N
) ) N
was VBD N
supplemented VBN N
to TO N
some DT N
of IN N
the DT N
feed NN N
during IN N
the DT N
ST NNP N
and CC N
GF NNP N
. . N

Diets NNS N
containing VBG N
adequate NN N
Ca NNP N
and CC N
P NNP N
were VBD N
also RB N
fed VBN N
during IN N
the DT N
ST NNP N
( ( N
0.90 CD N
% NN N
Ca NNP N
, , N
0.68 CD N
% NN N
tP NN N
) ) N
and CC N
GF NNP N
( ( N
0.80 CD N
% NN N
Ca NNP N
, , N
0.67 CD N
% NN N
tP NN N
) ) N
. . N

Performance NN N
characteristics NNS N
and CC N
the DT N
incidence NN N
of IN N
rickets NNS N
and CC N
tibial JJ N
dyschondroplasia NN N
were VBD N
measured VBN N
at IN N
18 CD N
and CC N
35 CD N
d. NN N
In IN N
experiment JJ N
1 CD N
, , N
unsupplemented JJ N
chicks NNS N
performed VBN N
well RB N
but CC N
had VBD N
considerable JJ N
leg JJ N
problems NNS N
. . N

Chicks NNP N
fed VBD N
P+1A NNP N
during IN N
the DT N
ST NNP N
or CC N
GF NNP N
did VBD N
not RB N
perform VB N
as RB N
well RB N
as IN N
birds NNS N
fed VBN N
P+1A NNP N
throughout IN N
. . N

Birds NNS N
fed VBD N
P+1A NNP N
throughout IN N
performed VBN N
as IN N
well RB N
birds NNS N
fed VBD N
the DT N
adequate JJ N
diets NNS N
without IN N
any DT N
indication NN N
of IN N
leg NN N
problems NNS N
. . N

In IN N
experiment JJ N
2 CD N
, , N
unsupplemented JJ N
birds NNS N
performed VBD N
similarly RB N
to TO N
unsupplemented JJ N
birds NNS N
in IN N
experiment JJ N
1 CD N
. . N

However RB N
, , N
chicks NNS N
fed VBP N
the DT N
supplements NNS N
or CC N
the DT N
control JJ N
diets NNS N
did VBD N
not RB N
perform VB N
as RB N
well RB N
or CC N
accumulate VB N
as IN N
much JJ N
bone NN N
ash NN N
as IN N
birds NNS N
in IN N
experiment JJ N
1 CD N
, , N
although IN N
the DT N
diets NNS N
were VBD N
formulated VBN N
identically RB N
in IN N
both DT N
experiments NNS N
. . N

Diets NNS N
with IN N
as RB N
little JJ N
as IN N
0.30 CD N
% NN N
Ca NNP N
and CC N
0.37 CD N
% NN N
tP NN N
appear VBP N
to TO N
be VB N
adequate JJ N
for IN N
broilers NNS N
older JJR N
than IN N
18 CD N
d NN N
if IN N
supplemented VBN N
with IN N
the DT N
correct JJ N
amounts NNS N
of IN N
phytase NN N
and CC N
1alpha-OHD3 JJ N
. . N

However RB N
, , N
there EX N
are VBP N
unknown JJ N
variables NNS N
that WDT N
may MD N
limit VB N
the DT N
potential NN N
of IN N
broilers NNS N
in IN N
terms NNS N
of IN N
bone NN N
mineralization NN N
and CC N
bone NN N
pathology NN N
, , N
even RB N
when WRB N
adequate JJ N
diets NNS N
are VBP N
fed VBN N
. . N

-DOCSTART- -15769967- O O

Effects NNS N
of IN N
long-term JJ N
vitamin NN N
E NNP N
supplementation NN N
on IN N
cardiovascular JJ N
events NNS N
and CC N
cancer NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

CONTEXT NNP N
Experimental NNP N
and CC N
epidemiological JJ N
data NNS N
suggest VBP N
that IN N
vitamin NN N
E NNP N
supplementation NN N
may MD N
prevent VB N
cancer NN N
and CC N
cardiovascular JJ N
events NNS N
. . N

Clinical JJ N
trials NNS N
have VBP N
generally RB N
failed VBN N
to TO N
confirm VB N
benefits NNS N
, , N
possibly RB N
due JJ N
to TO N
their PRP$ N
relatively RB N
short JJ N
duration NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
whether IN N
long-term JJ N
supplementation NN N
with IN N
vitamin JJ N
E NN N
decreases VBZ N
the DT N
risk NN N
of IN N
cancer NN N
, , N
cancer NN N
death NN N
, , N
and CC N
major JJ N
cardiovascular JJ N
events NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
international JJ N
trial NN N
( ( N
the DT N
initial JJ N
Heart NNP N
Outcomes NNP N
Prevention NNP N
Evaluation NNP N
[ NNP N
HOPE NNP N
] NNP N
trial NN N
conducted VBD N
between IN N
December NNP N
21 CD N
, , N
1993 CD N
, , N
and CC N
April NNP N
15 CD N
, , N
1999 CD N
) ) N
of IN N
patients NNS N
at IN N
least JJS N
55 CD N
years NNS N
old JJ N
with IN N
vascular JJ N
disease NN N
or CC N
diabetes VBZ N
mellitus NN N
was VBD N
extended VBN N
( ( N
HOPE-The NNP N
Ongoing NNP N
Outcomes NNP N
[ NNP N
HOPE-TOO NNP N
] NNP N
) ) N
between IN N
April NNP N
16 CD N
, , N
1999 CD N
, , N
and CC N
May NNP N
26 CD N
, , N
2003 CD N
. . N

Of IN N
the DT N
initial JJ N
267 CD N
HOPE NNP N
centers NNS N
that WDT N
had VBD N
enrolled VBN N
9541 CD N
patients NNS N
, , N
174 CD N
centers NNS N
participated VBN N
in IN N
the DT N
HOPE-TOO NNP N
trial NN N
. . N

Of IN N
7030 CD N
patients NNS N
enrolled VBN N
at IN N
these DT N
centers NNS N
, , N
916 CD N
were VBD N
deceased VBN N
at IN N
the DT N
beginning NN N
of IN N
the DT N
extension NN N
, , N
1382 CD N
refused VBD N
participation NN N
, , N
3994 CD N
continued VBD N
to TO N
take VB N
the DT N
study NN N
intervention NN N
, , N
and CC N
738 CD N
agreed VBD N
to TO N
passive VB N
follow-up NN N
. . N

Median JJ N
duration NN N
of IN N
follow-up NN N
was VBD N
7.0 CD N
years NNS N
. . N

INTERVENTION NNP N
Daily NNP N
dose NN N
of IN N
natural JJ N
source NN N
vitamin NN N
E NNP N
( ( N
400 CD N
IU NNP N
) ) N
or CC N
matching VBG N
placebo NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
outcomes NNS N
included VBD N
cancer NN N
incidence NN N
, , N
cancer NN N
deaths NNS N
, , N
and CC N
major JJ N
cardiovascular JJ N
events NNS N
( ( N
myocardial JJ N
infarction NN N
, , N
stroke NN N
, , N
and CC N
cardiovascular JJ N
death NN N
) ) N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
heart NN N
failure NN N
, , N
unstable JJ N
angina NN N
, , N
and CC N
revascularizations NNS N
. . N

RESULTS NNP N
Among IN N
all DT N
HOPE NNP N
patients NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
primary JJ N
analysis NN N
: : N
for IN N
cancer NN N
incidence NN N
, , N
there EX N
were VBD N
552 CD N
patients NNS N
( ( N
11.6 CD N
% NN N
) ) N
in IN N
the DT N
vitamin NN N
E NNP N
group NN N
vs VBD N
586 CD N
( ( N
12.3 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
0.94 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.84-1.06 NNP N
; : N
P NNP N
= NNP N
.30 NNP N
) ) N
; : N
for IN N
cancer NN N
deaths NNS N
, , N
156 CD N
( ( N
3.3 CD N
% NN N
) ) N
vs NN N
178 CD N
( ( N
3.7 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.71-1.09 NNP N
; : N
P NNP N
= NNP N
.24 NNP N
) ) N
; : N
and CC N
for IN N
major JJ N
cardiovascular JJ N
events NNS N
, , N
1022 CD N
( ( N
21.5 CD N
% NN N
) ) N
vs NN N
985 CD N
( ( N
20.6 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
1.04 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.96-1.14 NNP N
; : N
P NNP N
= NNP N
.34 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT N
vitamin NN N
E NNP N
group NN N
had VBD N
a DT N
higher JJR N
risk NN N
of IN N
heart NN N
failure NN N
( ( N
RR NNP N
, , N
1.13 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.26 JJ N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
and CC N
hospitalization NN N
for IN N
heart NN N
failure NN N
( ( N
RR NNP N
, , N
1.21 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.00-1.47 JJ N
; : N
P NNP N
= NNP N
.045 NNP N
) ) N
. . N

Similarly RB N
, , N
among IN N
patients NNS N
enrolled VBN N
at IN N
the DT N
centers NNS N
participating VBG N
in IN N
the DT N
HOPE-TOO NNP N
trial NN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
cancer NN N
incidence NN N
, , N
cancer NN N
deaths NNS N
, , N
and CC N
major JJ N
cardiovascular JJ N
events NNS N
, , N
but CC N
higher JJR N
rates NNS N
of IN N
heart NN N
failure NN N
and CC N
hospitalizations NNS N
for IN N
heart NN N
failure NN N
. . N

CONCLUSION NNP N
In IN N
patients NNS N
with IN N
vascular JJ N
disease NN N
or CC N
diabetes VBZ N
mellitus NNS N
, , N
long-term JJ N
vitamin NN N
E NNP N
supplementation NN N
does VBZ N
not RB N
prevent VB N
cancer NN N
or CC N
major JJ N
cardiovascular JJ N
events NNS N
and CC N
may MD N
increase VB N
the DT N
risk NN N
for IN N
heart NN N
failure NN N
. . N

-DOCSTART- -18067498- O O

Enhancing VBG N
attitudes NNS N
and CC N
intentions NNS N
in IN N
prospective JJ N
blood NN N
donors NNS N
: : N
evaluation NN N
of IN N
a DT N
new JJ N
donor NN N
recruitment NN N
brochure NN N
. . N

BACKGROUND NNP N
Although IN N
little JJ N
empiric JJ N
evidence NN N
has VBZ N
been VBN N
published VBN N
concerning VBG N
the DT N
efficacy NN N
of IN N
blood NN N
donor NN N
recruitment NN N
materials NNS N
, , N
research NN N
suggests VBZ N
that IN N
simple JJ N
attempts NNS N
to TO N
enhance VB N
knowledge NN N
may MD N
not RB N
be VB N
sufficient JJ N
to TO N
motivate VB N
donation NN N
. . N

In IN N
contrast NN N
, , N
recent JJ N
donor NN N
motivation NN N
studies NNS N
highlight VBD N
the DT N
importance NN N
of IN N
anxiety NN N
, , N
attitudes NNS N
, , N
and CC N
perceived VBD N
ability NN N
to TO N
cope VB N
with IN N
donation NN N
( ( N
i.e. JJ N
, , N
self-efficacy NN N
) ) N
as IN N
crucial JJ N
determinants NNS N
of IN N
donation NN N
intention NN N
. . N

Therefore RB N
, , N
recruitment JJ N
materials NNS N
that WDT N
specifically RB N
address VBP N
these DT N
constructs NNS N
have VBP N
the DT N
potential JJ N
to TO N
outperform VB N
traditional JJ N
educational JJ N
brochures NNS N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
read VB N
one CD N
of IN N
three CD N
brochures NNS N
: : N
1 CD N
) ) N
a DT N
new JJ N
brochure NN N
addressing VBG N
common JJ N
donor NN N
concerns NNS N
and CC N
suggesting VBG N
specific JJ N
coping VBG N
strategies NNS N
, , N
2 CD N
) ) N
a DT N
standard JJ N
blood NN N
center NN N
brochure NN N
, , N
or CC N
3 CD N
) ) N
a DT N
control JJ N
brochure NN N
on IN N
healthy JJ N
eating NN N
and CC N
exercise NN N
. . N

Standardized JJ N
questionnaires NNS N
were VBD N
completed VBN N
before IN N
and CC N
after IN N
the DT N
brochures NNS N
to TO N
assess VB N
change NN N
in IN N
blood NN N
donation NN N
anxiety NN N
, , N
attitude NN N
, , N
self-efficacy NN N
, , N
and CC N
intention NN N
. . N

RESULTS NNP N
Although IN N
no DT N
significant JJ N
changes NNS N
were VBD N
noted VBN N
for IN N
the DT N
control NN N
brochure NN N
, , N
after IN N
reading VBG N
the DT N
new JJ N
brochure NN N
participants NNS N
reported VBD N
significant JJ N
improvements NNS N
in IN N
attitude NN N
, , N
anxiety NN N
, , N
self-efficacy NN N
, , N
and CC N
donation NN N
intention NN N
. . N

The DT N
standard JJ N
donation NN N
brochure NN N
had VBD N
an DT N
intermediate JJ N
effect NN N
. . N

CONCLUSION NNP N
Efforts NNPS N
to TO N
address VB N
common JJ N
donor NN N
fears NNS N
and CC N
to TO N
provide VB N
useful JJ N
coping VBG N
suggestions NNS N
may MD N
improve VB N
the DT N
effectiveness NN N
of IN N
blood NN N
donation NN N
recruitment NN N
materials NNS N
. . N

-DOCSTART- -20500784- O O

Effects NNS N
of IN N
a DT N
leisure NN N
programme NN N
on IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
of IN N
individuals NNS N
with IN N
ASD NNP N
. . N

BACKGROUND NNP N
Even RB N
though IN N
there EX N
is VBZ N
research NN N
demonstrating VBG N
a DT N
positive JJ N
relationship NN N
between IN N
leisure NN N
participation NN N
and CC N
the DT N
two CD N
constructs NNS N
of IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
reduction NN N
, , N
current JJ N
conceptualisation NN N
of IN N
leisure NN N
as IN N
a DT N
contributor NN N
to TO N
quality NN N
of IN N
life NN N
is VBZ N
limited VBN N
. . N

In IN N
addition NN N
, , N
in IN N
spite NN N
of IN N
improvements NNS N
in IN N
accurate JJ N
diagnosis NN N
of IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
at IN N
increasingly RB N
earlier JJR N
ages NNS N
and CC N
proliferation NN N
of IN N
interventions NNS N
, , N
research NN N
associated VBN N
with IN N
leisure NN N
and CC N
quality NN N
of IN N
life NN N
for IN N
people NNS N
with IN N
ASD NNP N
is VBZ N
lacking VBG N
. . N

METHODS NNP N
Therefore NNP N
, , N
a DT N
study NN N
using VBG N
a DT N
repeated JJ N
measures NNS N
design NN N
was VBD N
used VBN N
to TO N
measure VB N
effects NNS N
of IN N
a DT N
1-year JJ N
group NN N
leisure NN N
programme NN N
intended VBN N
to TO N
facilitate VB N
interaction NN N
with IN N
media NNS N
, , N
engagement NN N
in IN N
exercise NN N
, , N
playing VBG N
games NNS N
and CC N
doing VBG N
crafts NNS N
, , N
attending VBG N
events NNS N
, , N
and CC N
participating VBG N
in IN N
other JJ N
recreation NN N
activities NNS N
on IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
of IN N
37 CD N
participants NNS N
( ( N
22 CD N
male NN N
, , N
15 CD N
female NN N
) ) N
, , N
ages VBZ N
17-39 JJ N
( ( N
M NNP N
= NNP N
31.49 CD N
) ) N
years NNS N
at IN N
the DT N
beginning NN N
of IN N
the DT N
programme NN N
) ) N
diagnosed VBD N
with IN N
an DT N
ASD NNP N
and CC N
a DT N
group NN N
of IN N
34 CD N
adults NNS N
with IN N
ASD NNP N
as IN N
control NN N
group NN N
( ( N
waiting VBG N
list NN N
) ) N
( ( N
19 CD N
male NN N
, , N
15 CD N
female NN N
) ) N
, , N
ages VBZ N
24-38 JJ N
( ( N
M NNP N
= VBZ N
30 CD N
at IN N
programme JJ N
initiation NN N
) ) N
years NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
overall JJ N
scores NNS N
of IN N
stress NN N
levels NNS N
for IN N
participants NNS N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
and CC N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
four CD N
factors NNS N
of IN N
quality NN N
of IN N
life NN N
that WDT N
were VBD N
measured VBN N
( ( N
satisfaction NN N
, , N
independence NN N
, , N
competence NN N
and CC N
social JJ N
interaction NN N
) ) N
as RB N
well RB N
as IN N
the DT N
total JJ N
score NN N
for IN N
quality NN N
of IN N
life NN N
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
the DT N
intervention NN N
12 CD N
months NNS N
later RB N
. . N

In IN N
contrast NN N
, , N
the DT N
control NN N
group NN N
demonstrated VBD N
no DT N
significant JJ N
improvements NNS N
related VBN N
to TO N
stress VB N
or CC N
quality NN N
of IN N
life NN N
. . N

Implications NNS N
of IN N
these DT N
findings NNS N
to TO N
leisure VB N
services NNS N
and CC N
the DT N
quality NN N
of IN N
life NN N
of IN N
individuals NNS N
with IN N
ASD NNP N
are VBP N
discussed VBN N
. . N

CONCLUSION NNP N
Findings NNP N
support NN N
the DT N
contention NN N
that WDT N
participation NN N
in IN N
recreation NN N
activities NNS N
positively RB N
influenced VBD N
the DT N
stress NN N
and CC N
quality NN N
of IN N
life NN N
of IN N
adults NNS N
with IN N
ASD NNP N
. . N

-DOCSTART- -20830241- O O

Anti-angiogenic JJ N
effects NNS N
of IN N
epigallocatechin-3-gallate NN N
in IN N
human JJ N
skin NN N
. . N

Epigallocatechin-3-gallate NNP N
( ( N
EGCG NNP N
) ) N
is VBZ N
the DT N
main JJ N
polyphenol JJ N
component NN N
of IN N
green JJ N
tea NN N
. . N

This DT N
compound NN N
exhibits VBZ N
antioxidant JJ N
, , N
immunomodulatory JJ N
, , N
photoprotective JJ N
, , N
anti-angiogenic JJ N
, , N
and CC N
anti-inflammatory JJ N
properties NNS N
. . N

We PRP N
conducted VBD N
a DT N
small JJ N
randomized NN N
, , N
double JJ N
blind NN N
, , N
split VBD N
face NN N
trial NN N
using VBG N
a DT N
cream NN N
containing VBG N
2.5 CD N
% NN N
w/w NN N
of IN N
EGCG NNP N
. . N

Four CD N
healthy JJ N
volunteers NNS N
with IN N
significant JJ N
erythema NN N
and CC N
telangiectasia NN N
on IN N
the DT N
face NN N
applied VBD N
EGCG NNP N
cream NN N
to TO N
one CD N
side NN N
of IN N
the DT N
face NN N
, , N
and CC N
vehicle NN N
control NN N
cream NN N
to TO N
the DT N
other JJ N
, , N
twice JJ N
daily RB N
for IN N
six CD N
weeks NNS N
. . N

After IN N
six CD N
weeks NNS N
, , N
biopsies NNS N
were VBD N
taken VBN N
from IN N
EGCG NNP N
and CC N
vehicle NN N
treated VBN N
sites NNS N
. . N

Immunohistochemistry NN N
was VBD N
used VBN N
to TO N
measure VB N
VEGF NNP N
and CC N
HIF-1 NNP N
?. NNP N
HIF-1 NNP N
? . N
expression NN N
was VBD N
decreased VBN N
in IN N
EGCG NNP N
treated VBD N
sites NNS N
, , N
such JJ N
that IN N
28.4 CD N
% NN N
of IN N
the DT N
epidermis NN N
showed VBD N
positive JJ N
staining NN N
in IN N
vehicle NN N
treated VBD N
vs. FW N
13.8 CD N
% NN N
in IN N
EGCG NNP N
treated VBD N
sites NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
similar JJ N
decrease NN N
in IN N
VEGF NNP N
expression NN N
was VBD N
found VBN N
( ( N
6.7 CD N
% NN N
in IN N
EGCG NNP N
vs. FW N
11.0 CD N
% NN N
in IN N
in IN N
vehicle-treated JJ N
skin NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

EGCG NNP N
topical JJ N
treatments NNS N
influence VB N
HIF-1 NNP N
? . N
induction NN N
and CC N
VEGF NNP N
expression NN N
and CC N
may MD N
serve VB N
as IN N
a DT N
potential JJ N
agent NN N
in IN N
the DT N
prevention NN N
of IN N
telangiectasias NN N
. . N

-DOCSTART- -8159300- O O

Cyclosporin NNP N
versus NN N
cyclophosphamide NN N
for IN N
patients NNS N
with IN N
steroid-dependent JJ N
and CC N
frequently RB N
relapsing VBG N
idiopathic JJ N
nephrotic JJ N
syndrome NN N
: : N
a DT N
multicentre NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
( ( N
maintenance NN N
of IN N
remission NN N
) ) N
, , N
safety NN N
and CC N
tolerability NN N
of IN N
cyclosporin NN N
( ( N
CsA NNP N
) ) N
with IN N
those DT N
of IN N
cyclophosphamide NN N
in IN N
patients NNS N
with IN N
steroid-dependent JJ N
or CC N
frequently RB N
relapsing VBG N
nephrotic JJ N
syndrome NN N
( ( N
NS NNP N
) ) N
. . N

DESIGN NNP N
Open NNP N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
multicentre FW N
, , N
controlled VBD N
study NN N
for IN N
parallel JJ N
groups NNS N
, , N
stratified VBN N
for IN N
adults NNS N
and CC N
children NNS N
. . N

The DT N
setting NN N
was VBD N
in IN N
nephrological JJ N
departments NNS N
in IN N
Italy NNP N
. . N

SUBJECTS NNP N
AND CC N
INTERVENTIONS NNP N
Seventy-three JJ N
patients NNS N
with IN N
steroid-sensitive JJ N
idiopathic JJ N
NS NNP N
admitted VBD N
to TO N
the DT N
study NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
cyclophosphamide VB N
( ( N
2.5 CD N
mg/kg/day NN N
) ) N
for IN N
8 CD N
weeks NNS N
or CC N
CsA NNP N
( ( N
5 CD N
mg/kg/day NN N
in IN N
adults NNS N
, , N
6 CD N
mg/kg/day NN N
in IN N
children NNS N
) ) N
for IN N
9 CD N
months NNS N
, , N
tapered VBD N
off RP N
by IN N
25 CD N
% NN N
every DT N
month NN N
until IN N
complete JJ N
discontinuation NN N
at IN N
month NN N
12 CD N
. . N

Seven CD N
patients NNS N
lost VBN N
to TO N
follow VB N
up RP N
were VBD N
not RB N
considered VBN N
in IN N
the DT N
analysis NN N
. . N

The DT N
remaining VBG N
66 CD N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
3-24 JJ N
months NNS N
after IN N
randomization NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Relapse-free NNP N
survival NN N
; : N
number NN N
of IN N
N.S NNP N
. . N

relapses/patient/year NN N
; : N
cumulative JJ N
dose NN N
of IN N
prednisone/patient NN N
; : N
laboratory JJ N
investigations NNS N
( ( N
kidney NN N
and CC N
liver NN N
functions NNS N
, , N
haematological JJ N
parameters NNS N
) ) N
; : N
incidence NN N
of IN N
adverse JJ N
events NNS N
. . N

RESULTS NNP N
At IN N
month NN N
9 CD N
, , N
26 CD N
of IN N
35 CD N
CsA-treated JJ N
patients NNS N
were VBD N
still RB N
in IN N
complete JJ N
remission NN N
and CC N
a DT N
further JJ N
five CD N
patients NNS N
were VBD N
in IN N
partial JJ N
remission NN N
; : N
18 CD N
of IN N
28 CD N
cyclophosphamide-treated JJ N
patients NNS N
were VBD N
in IN N
complete JJ N
remission NN N
, , N
and CC N
one CD N
in IN N
partial JJ N
remission NN N
( ( N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

No DT N
difference NN N
between IN N
adults NNS N
and CC N
children NNS N
was VBD N
seen VBN N
with IN N
either DT N
treatment NN N
. . N

The DT N
risk NN N
of IN N
relapse NN N
was VBD N
similar JJ N
between IN N
frequent JJ N
relapsers NNS N
( ( N
19 CD N
of IN N
22 CD N
) ) N
and CC N
steroid-dependent JJ N
patients NNS N
( ( N
8 CD N
of IN N
14 CD N
) ) N
given VBN N
CsA NNP N
, , N
and CC N
those DT N
given VBN N
cyclophosphamide NN N
( ( N
5 CD N
of IN N
15 CD N
and CC N
6 CD N
of IN N
15 CD N
) ) N
. . N

The DT N
mean JJ N
number NN N
of IN N
relapses NNS N
per IN N
year NN N
and CC N
the DT N
mean NN N
dose NN N
of IN N
prednisone NN N
per IN N
year NN N
were VBD N
significantly RB N
less JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
both DT N
groups NNS N
for IN N
the DT N
experimental JJ N
year NN N
than IN N
for IN N
the DT N
year NN N
before IN N
randomization NN N
. . N

At IN N
2 CD N
years NNS N
, , N
25 CD N
% NN N
of IN N
the DT N
patients NNS N
given VBN N
CsA NNP N
( ( N
50 CD N
% NN N
adults NNS N
and CC N
20 CD N
% NN N
children NNS N
) ) N
and CC N
63 CD N
% NN N
of IN N
those DT N
given VBN N
cyclophosphamide NN N
( ( N
40 CD N
% NN N
adults NNS N
and CC N
68 CD N
% NN N
children NNS N
) ) N
had VBD N
not RB N
had VBN N
any DT N
relapse NN N
of IN N
NS NNP N
. . N

Tolerance NN N
to TO N
the DT N
two CD N
drugs NNS N
was VBD N
generally RB N
good JJ N
. . N

The DT N
CsA-related JJ N
side-effects NNS N
were VBD N
mild JJ N
and CC N
disappeared VBD N
after IN N
drug NN N
discontinuation NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
both DT N
treatments NNS N
are VBP N
effective JJ N
and CC N
well RB N
tolerated VBD N
; : N
more RBR N
patients NNS N
given VBN N
cyclophosphamide JJ N
had VBD N
stable JJ N
remissions NNS N
. . N

-DOCSTART- -15302787- O O

Randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
oral JJ N
sirolimus NN N
for IN N
restenosis NN N
prevention NN N
in IN N
patients NNS N
with IN N
in-stent JJ N
restenosis NN N
: : N
the DT N
Oral NNP N
Sirolimus NNP N
to TO N
Inhibit NNP N
Recurrent NNP N
In-stent JJ N
Stenosis NNP N
( ( N
OSIRIS NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Despite IN N
recent JJ N
advances NNS N
in IN N
interventional JJ N
cardiology NN N
, , N
including VBG N
the DT N
introduction NN N
of IN N
drug-eluting JJ N
stents NNS N
for IN N
de FW N
novo FW N
coronary JJ N
lesions NNS N
, , N
the DT N
treatment NN N
of IN N
in-stent JJ N
restenosis NN N
( ( N
ISR NNP N
) ) N
remains VBZ N
a DT N
challenging JJ N
clinical JJ N
issue NN N
. . N

Given VBN N
the DT N
efficacy NN N
of IN N
systemic JJ N
sirolimus JJ N
administration NN N
to TO N
prevent VB N
neointimal JJ N
hyperplasia NN N
in IN N
animal JJ N
models NNS N
and CC N
to TO N
halt VB N
and CC N
even RB N
reverse VB N
the DT N
progression NN N
of IN N
allograft NN N
vasculopathy NN N
, , N
the DT N
aim NN N
of IN N
the DT N
present JJ N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
10-day JJ N
oral JJ N
sirolimus NN N
treatment NN N
with IN N
2 CD N
different JJ N
loading VBG N
regimens NNS N
for IN N
the DT N
prevention NN N
of IN N
recurrent JJ N
restenosis NN N
in IN N
patients NNS N
with IN N
ISR NNP N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Three NNP N
hundred VBD N
symptomatic JJ N
patients NNS N
with IN N
ISR NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
treatment NN N
arms NNS N
: : N
placebo NN N
or CC N
usual-dose JJ N
or CC N
high-dose JJ N
sirolimus NN N
. . N

Patients NNS N
received VBD N
a DT N
cumulative JJ N
loading NN N
dose NN N
of IN N
0 CD N
, , N
8 CD N
, , N
or CC N
24 CD N
mg NN N
of IN N
sirolimus JJ N
2 CD N
days NNS N
before IN N
and CC N
the DT N
day NN N
of IN N
repeat NN N
intervention NN N
followed VBN N
by IN N
maintenance NN N
therapy NN N
of IN N
2 CD N
mg/d NN N
for IN N
7 CD N
days NNS N
. . N

Angiographic JJ N
restenosis NN N
at IN N
6-month JJ N
angiography NN N
was VBD N
the DT N
primary JJ N
end NN N
point NN N
of IN N
the DT N
study NN N
. . N

Restenosis NNP N
was VBD N
significantly RB N
reduced VBN N
from IN N
42.2 CD N
% NN N
to TO N
38.6 CD N
% NN N
and CC N
to TO N
22.1 CD N
% NN N
in IN N
the DT N
placebo NN N
, , N
usual-dose JJ N
, , N
and CC N
high-dose JJ N
sirolimus NN N
groups NNS N
, , N
respectively RB N
( ( N
P=0.005 NNP N
) ) N
. . N

Similarly RB N
, , N
the DT N
need NN N
for IN N
target NN N
vessel JJ N
revascularization NN N
was VBD N
reduced VBN N
from IN N
25.5 CD N
% NN N
to TO N
24.2 CD N
% NN N
and CC N
to TO N
15.2 CD N
% NN N
in IN N
the DT N
placebo NN N
, , N
usual-dose JJ N
, , N
and CC N
high-dose JJ N
groups NNS N
, , N
respectively RB N
( ( N
P=0.08 NNP N
) ) N
. . N

The DT N
sirolimus JJ N
blood NN N
concentration NN N
on IN N
the DT N
day NN N
of IN N
the DT N
procedure NN N
correlated VBD N
significantly RB N
with IN N
the DT N
late JJ N
lumen NNS N
loss NN N
at IN N
follow-up JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS N
with IN N
ISR NNP N
, , N
an DT N
oral JJ N
adjunctive JJ N
sirolimus NN N
treatment NN N
with IN N
an DT N
intensified JJ N
loading NN N
regimen NNS N
before IN N
coronary JJ N
intervention NN N
resulted VBD N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
angiographic JJ N
parameters NNS N
of IN N
restenosis NN N
. . N

-DOCSTART- -2177746- O O

Behavioral JJ N
effects NNS N
of IN N
Org NNP N
2766 CD N
, , N
a DT N
synthetic JJ N
analog NN N
of IN N
the DT N
adrenocorticotrophic JJ N
hormone NN N
( ( N
4-9 JJ N
) ) N
, , N
in IN N
14 CD N
outpatient JJ N
autistic JJ N
children NNS N
. . N

Fourteen NNP N
children NNS N
( ( N
12 CD N
infantile NN N
autism NN N
full JJ N
syndrome NN N
present NN N
, , N
2 CD N
atypical JJ N
pervasive JJ N
developmental JJ N
disorder NN N
) ) N
between IN N
5 CD N
and CC N
13 CD N
years NNS N
of IN N
age NN N
participated VBN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
cross-over JJ N
trial NN N
. . N

Each DT N
child NN N
received VBD N
20 CD N
mg NNS N
Org JJ N
2766 CD N
( ( N
synthetic JJ N
analog NN N
of IN N
ACTH NNP N
4-9 JJ N
) ) N
/day NN N
during IN N
4 CD N
weeks NNS N
, , N
or CC N
placebo NN N
in IN N
a DT N
randomly NN N
assigned VBN N
sequence NN N
. . N

Drug JJ N
effects NNS N
were VBD N
monitored VBN N
by IN N
ethological JJ N
playroom NN N
observation NN N
and CC N
by IN N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
ratings NNS N
by IN N
parents NNS N
and CC N
teachers NNS N
. . N

Data NNP N
of IN N
the DT N
playroom NN N
observation NN N
pointed VBD N
to TO N
an DT N
activating VBG N
influence NN N
of IN N
Org NNP N
2766 CD N
, , N
as IN N
revealed VBN N
by IN N
a DT N
significant JJ N
decrease NN N
of IN N
stereotypic NN N
behavior NN N
and CC N
significant JJ N
increases NNS N
in IN N
change NN N
toys NNS N
, , N
locomote NN N
, , N
and CC N
talk NN N
. . N

Checklist JJ N
ratings NNS N
did VBD N
not RB N
show VB N
significant JJ N
changes NNS N
. . N

The DT N
clinical JJ N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -20494434- O O

Parent-mediated JJ N
communication-focused JJ N
treatment NN N
in IN N
children NNS N
with IN N
autism NN N
( ( N
PACT NNP N
) ) N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Results NNP N
of IN N
small JJ N
trials NNS N
suggest VBP N
that IN N
early JJ N
interventions NNS N
for IN N
social JJ N
communication NN N
are VBP N
effective JJ N
for IN N
the DT N
treatment NN N
of IN N
autism NN N
in IN N
children NNS N
. . N

We PRP N
therefore RB N
investigated VBD N
the DT N
efficacy NN N
of IN N
such JJ N
an DT N
intervention NN N
in IN N
a DT N
larger JJR N
trial NN N
. . N

METHODS NNP N
Children NNP N
with IN N
core NN N
autism NN N
( ( N
aged VBN N
2 CD N
years NNS N
to TO N
4 CD N
years NNS N
and CC N
11 CD N
months NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
one-to-one JJ N
ratio NN N
to TO N
a DT N
parent-mediated JJ N
communication-focused JJ N
( ( N
Preschool NNP N
Autism NNP N
Communication NNP N
Trial NNP N
[ NNP N
PACT NNP N
] NNP N
) ) N
intervention NN N
or CC N
treatment NN N
as IN N
usual JJ N
at IN N
three CD N
specialist NN N
centres NNS N
in IN N
the DT N
UK NNP N
. . N

Those DT N
assigned VBN N
to TO N
PACT NNP N
were VBD N
also RB N
given VBN N
treatment NN N
as IN N
usual JJ N
. . N

Randomisation NN N
was VBD N
by IN N
use NN N
of IN N
minimisation NN N
of IN N
probability NN N
in IN N
the DT N
marginal JJ N
distribution NN N
of IN N
treatment NN N
centre NN N
, , N
age NN N
( ( N
< JJ N
/=42 NNP N
months NNS N
or CC N
> $ N
42 CD N
months NNS N
) ) N
, , N
and CC N
autism NN N
severity NN N
( ( N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule-Generic NNP N
[ NNP N
ADOS-G NNP N
] NNP N
algorithm VBZ N
score RB N
12-17 JJ N
or CC N
18-24 JJ N
) ) N
. . N

Primary JJ N
outcome NN N
was VBD N
severity NN N
of IN N
autism NN N
symptoms NNS N
( ( N
a DT N
total NN N
score NN N
of IN N
social JJ N
communication NN N
algorithm NNS N
items NNS N
from IN N
ADOS-G NNP N
, , N
higher JJR N
score NN N
indicating VBG N
greater JJR N
severity NN N
) ) N
at IN N
13 CD N
months NNS N
. . N

Complementary NNP N
secondary JJ N
outcomes NNS N
were VBD N
measures NNS N
of IN N
parent-child JJ N
interaction NN N
, , N
child JJ N
language NN N
, , N
and CC N
adaptive JJ N
functioning NN N
in IN N
school NN N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
as IN N
an DT N
International NNP N
Standard NNP N
Randomised VBD N
Controlled NNP N
Trial NNP N
, , N
number NN N
ISRCTN58133827 NNP N
. . N

RESULTS NNP N
152 CD N
children NNS N
were VBD N
recruited VBN N
. . N

77 CD N
were VBD N
assigned VBN N
to TO N
PACT NNP N
( ( N
London NNP N
[ NNP N
n=26 MD N
] VB N
, , N
Manchester NNP N
[ NNP N
n=26 MD N
] VB N
, , N
and CC N
Newcastle NNP N
[ NNP N
n=25 FW N
] NNP N
) ) N
; : N
and CC N
75 CD N
to TO N
treatment NN N
as IN N
usual JJ N
( ( N
London NNP N
[ NNP N
n=26 MD N
] VB N
, , N
Manchester NNP N
[ NNP N
n=26 MD N
] VB N
, , N
and CC N
Newcastle NNP N
[ NNP N
n=23 FW N
] NNP N
) ) N
. . N

At IN N
the DT N
13-month JJ N
endpoint NN N
, , N
the DT N
severity NN N
of IN N
symptoms NNS N
was VBD N
reduced VBN N
by IN N
3.9 CD N
points NNS N
( ( N
SD NNP N
4.7 CD N
) ) N
on IN N
the DT N
ADOS-G NNP N
algorithm NN N
in IN N
the DT N
group NN N
assigned VBD N
to TO N
PACT NNP N
, , N
and CC N
2.9 CD N
( ( N
3.9 CD N
) ) N
in IN N
the DT N
group NN N
assigned VBD N
to TO N
treatment NN N
as IN N
usual JJ N
, , N
representing VBG N
a DT N
between-group JJ N
effect NN N
size NN N
of IN N
-0.24 NNP N
( ( N
95 CD N
% NN N
CI NNP N
-0.59 NNP N
to TO N
0.11 CD N
) ) N
, , N
after IN N
adjustment NN N
for IN N
centre NN N
, , N
sex NN N
, , N
socioeconomic JJ N
status NN N
, , N
age NN N
, , N
and CC N
verbal JJ N
and CC N
non-verbal JJ N
abilities NNS N
. . N

Treatment NNP N
effect NN N
was VBD N
positive JJ N
for IN N
parental JJ N
synchronous JJ N
response NN N
to TO N
child VB N
( ( N
1.22 CD N
, , N
0.85 CD N
to TO N
1.59 CD N
) ) N
, , N
child JJ N
initiations NNS N
with IN N
parent NN N
( ( N
0.41 CD N
, , N
0.08 CD N
to TO N
0.74 CD N
) ) N
, , N
and CC N
for IN N
parent-child JJ N
shared VBN N
attention NN N
( ( N
0.33 CD N
, , N
-0.02 NN N
to TO N
0.68 CD N
) ) N
. . N

Effects NNS N
on IN N
directly RB N
assessed VBN N
language NN N
and CC N
adaptive JJ N
functioning NN N
in IN N
school NN N
were VBD N
small JJ N
. . N

INTERPRETATION NN N
On IN N
the DT N
basis NN N
of IN N
our PRP$ N
findings NNS N
, , N
we PRP N
can MD N
not RB N
recommend VB N
the DT N
addition NN N
of IN N
the DT N
PACT NNP N
intervention NN N
to TO N
treatment NN N
as IN N
usual JJ N
for IN N
the DT N
reduction NN N
of IN N
autism NN N
symptoms NNS N
; : N
however RB N
, , N
a DT N
clear JJ N
benefit NN N
was VBD N
noted VBN N
for IN N
parent-child JJ N
dyadic JJ N
social JJ N
communication NN N
. . N

FUNDING NN N
UK NNP N
Medical NNP N
Research NNP N
Council NNP N
, , N
and CC N
UK NNP N
Department NNP N
for IN N
Children NNP N
, , N
Schools NNP N
and CC N
Families NNP N
. . N

-DOCSTART- -22395144- O O

Utility NN N
of IN N
the DT N
bladder NN N
flap NN N
at IN N
cesarean JJ N
delivery NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
test VB N
the DT N
hypothesis NN N
that IN N
omission NN N
of IN N
the DT N
bladder NN N
flap NN N
in IN N
primary JJ N
and CC N
repeat JJ N
cesarean JJ N
deliveries NNS N
shortens VBZ N
operating VBG N
time NN N
without IN N
increasing VBG N
intraoperative JJ N
and CC N
postoperative JJ N
complications NNS N
. . N

METHODS NNP N
We PRP N
randomized VBD N
258 CD N
women NNS N
undergoing VBG N
primary JJ N
and CC N
repeat JJ N
cesarean JJ N
deliveries NNS N
at IN N
32 CD N
weeks NNS N
of IN N
gestation NN N
or CC N
more JJR N
to TO N
creation NN N
( ( N
n=131 JJ N
) ) N
or CC N
omission NN N
( ( N
n=127 JJ N
) ) N
of IN N
the DT N
bladder NN N
flap NN N
. . N

Emergency NNP N
cesarean JJ N
deliveries NNS N
, , N
planned VBD N
vertical JJ N
uterine NN N
incisions NNS N
, , N
and CC N
previous JJ N
abdominal JJ N
surgeries NNS N
besides IN N
cesarean JJ N
deliveries NNS N
were VBD N
excluded VBN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
total JJ N
operating NN N
time NN N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
bladder JJ N
injury NN N
, , N
incision-to-delivery JJ N
time NN N
, , N
incision-to-fascial JJ N
closure NN N
time NN N
, , N
estimated VBN N
blood NN N
loss NN N
, , N
postoperative JJ N
microhematuria NN N
, , N
postoperative JJ N
pain NN N
, , N
hospital NN N
days NNS N
, , N
endometritis NN N
, , N
and CC N
urinary JJ N
tract NN N
infection NN N
. . N

Analysis NN N
followed VBD N
the DT N
intention-to-treat JJ N
principle NN N
. . N

RESULTS VB N
The DT N
median JJ N
skin NN N
incision NN N
to TO N
delivery NN N
interval NN N
was VBD N
shorter JJR N
with IN N
omission NN N
of IN N
the DT N
bladder NN N
flap NN N
( ( N
9 CD N
[ NN N
range NN N
1-43 JJ N
] NNS N
compared VBN N
with IN N
10 CD N
[ JJ N
range NN N
2-70 JJ N
] NNP N
minutes NNS N
; : N
P=.04 NNP N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
difference NN N
in IN N
total JJ N
operating NN N
time NN N
( ( N
51 CD N
[ NN N
range NN N
18-124 JJ N
] NNP N
minutes NNS N
compared VBN N
with IN N
51 CD N
[ JJ N
range NN N
16-178 JJ N
] NN N
; : N
P=.10 NNP N
) ) N
. . N

No DT N
bladder NN N
injuries NNS N
occurred VBD N
in IN N
either DT N
group NN N
and CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
estimated VBN N
blood NN N
loss NN N
, , N
change NN N
in IN N
hemoglobin JJ N
level NN N
, , N
postoperative JJ N
microhematuria NN N
, , N
postoperative JJ N
pain NN N
, , N
hospital NN N
days NNS N
, , N
endometritis NN N
, , N
or CC N
urinary JJ N
tract NN N
infection NN N
. . N

CONCLUSION NNP N
Omission NNP N
of IN N
the DT N
bladder NN N
flap NN N
at IN N
primary JJ N
and CC N
repeat JJ N
cesarean JJ N
deliveries NNS N
does VBZ N
not RB N
increase VB N
intraoperative JJ N
or CC N
postoperative JJ N
complications NNS N
. . N

Incision-to-delivery JJ N
time NN N
is VBZ N
shortened VBN N
but CC N
total JJ N
operating NN N
time NN N
appears VBZ N
unchanged JJ N
. . N

CLINICAL JJ N
TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
, , N
www.ClinicalTrials.gov NN N
, , N
NCT00918996 NNP N
. . N

LEVEL NNP N
OF IN N
EVIDENCE NNP N
I PRP N
. . N

-DOCSTART- -9683043- O O

White NNP N
coat NN N
effect NN N
detected VBD N
using VBG N
self-monitoring NN N
of IN N
blood NN N
pressure NN N
at IN N
home NN N
: : N
comparison NN N
with IN N
ambulatory JJ N
blood NN N
pressure NN N
. . N

The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
home NN N
blood NN N
pressure NN N
( ( N
HBP NNP N
) ) N
is VBZ N
a DT N
reliable JJ N
alternative NN N
to TO N
ambulatory VB N
blood NN N
pressure NN N
( ( N
ABP NNP N
) ) N
for IN N
the DT N
detection NN N
of IN N
the DT N
white JJ N
coat NN N
effect NN N
( ( N
WCE NNP N
) ) N
. . N

Hypertensive JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
measure VB N
HBP NNP N
for IN N
2 CD N
weeks NNS N
or CC N
ABP NNP N
for IN N
24 CD N
h. PDT N
The DT N
alternative JJ N
measurement NN N
was VBD N
then RB N
performed VBN N
. . N

Clinic NNP N
blood NN N
pressure NN N
( ( N
CBP NNP N
) ) N
was VBD N
measured VBN N
in IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
study NN N
. . N

Subjects NNS N
with IN N
a DT N
difference NN N
of IN N
> NN N
or CC N
= $ N
20 CD N
mm NN N
Hg NNP N
systolic NN N
or CC N
> NN N
or CC N
= $ N
10 CD N
mm NN N
Hg NNP N
diastolic VBZ N
BP NNP N
between IN N
CBP NNP N
and CC N
awake VB N
ABP NNP N
or CC N
CBP NNP N
and CC N
HBP NNP N
, , N
were VBD N
classified VBN N
as IN N
clinic JJ N
reactors NNS N
. . N

A DT N
total NN N
of IN N
189 CD N
patients NNS N
completed VBD N
the DT N
study NN N
( ( N
79 CD N
on IN N
stable JJ N
antihypertensive JJ N
treatment NN N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
magnitude NN N
of IN N
WCE NNP N
assessed VBD N
using VBG N
the DT N
ABP NNP N
or CC N
the DT N
HBP NNP N
method NN N
( ( N
mean JJ N
discrepancy NN N
, , N
systolic JJ N
BP NNP N
: : N
-1.5 JJ N
+/- JJ N
11.7 CD N
mm NN N
Hg NNP N
, , N
95 CD N
% NN N
CI NNP N
-3.2 NNP N
, , N
0.2 CD N
; : N
diastolic JJ N
BP NNP N
: : N
0.9 CD N
+/- JJ N
7.0 CD N
, , N
95 CD N
% NN N
CI NNP N
-0.1 NNP N
, , N
1.9 CD N
) ) N
. . N

A NNP N
strong JJ N
association NN N
existed VBD N
between IN N
WCE NNP N
calculated VBD N
using VBG N
the DT N
HBP NNP N
or CC N
the DT N
ABP NNP N
method NN N
( ( N
r VB N
= RB N
0.64/0.59 CD N
systolic/diastolic JJ N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
classified VBN N
as IN N
clinic JJ N
reactors NNS N
was VBD N
identical JJ N
using VBG N
the DT N
HBP NNP N
or CC N
the DT N
ABP NNP N
method NN N
( ( N
25.9 CD N
% NN N
) ) N
. . N

Agreement NN N
between IN N
methods NNS N
in IN N
the DT N
classification NN N
of IN N
clinic JJ N
reactors NNS N
was VBD N
found VBN N
in IN N
147 CD N
patients NNS N
( ( N
78 CD N
% NN N
) ) N
. . N

The DT N
sensitivity NN N
and CC N
specificity NN N
of IN N
the DT N
HBP NNP N
method NN N
to TO N
classify VB N
correctly RB N
clinic JJ N
reactors NNS N
( ( N
ABP NNP N
method RB N
used VBD N
as IN N
the DT N
standard NN N
) ) N
were VBD N
57 CD N
% NN N
and CC N
85 CD N
% NN N
, , N
respectively RB N
, , N
whereas VBD N
its PRP$ N
positive JJ N
and CC N
negative JJ N
predictive JJ N
value NN N
were VBD N
57 CD N
% NN N
and CC N
85 CD N
% NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
HBP NNP N
is VBZ N
not RB N
appropriate JJ N
as IN N
an DT N
alternative NN N
to TO N
ABP NNP N
diagnostic JJ N
testing NN N
in IN N
the DT N
detection NN N
of IN N
WCE NNP N
. . N

Nevertheless NNP N
, , N
HBP NNP N
appears VBZ N
useful JJ N
as IN N
a DT N
screening JJ N
test NN N
for IN N
the DT N
detection NN N
of IN N
this DT N
phenomenon NN N
. . N

-DOCSTART- -15861942- O O

Problem-based JJ N
learning NN N
: : N
is VBZ N
anatomy IN N
a DT N
casualty NN N
? . N
INTRODUCTION NNP N
The DT N
teaching NN N
of IN N
medical JJ N
anatomy NN N
is VBZ N
changing VBG N
. . N

Medical JJ N
schools NNS N
worldwide WDT N
are VBP N
moving VBG N
away RB N
from IN N
dissection NN N
and CC N
lectures VBZ N
to TO N
a DT N
more RBR N
integrated JJ N
course NN N
, , N
where WRB N
basic JJ N
science NN N
and CC N
clinical JJ N
skills NNS N
are VBP N
taught JJ N
simultaneously RB N
. . N

Medical JJ N
students NNS N
on IN N
these DT N
integrated VBN N
courses NNS N
have VBP N
reported VBN N
a DT N
lack NN N
of IN N
confidence NN N
in IN N
their PRP$ N
basic JJ N
science NN N
knowledge NN N
, , N
especially RB N
concerning VBG N
anatomy NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
perform VB N
a DT N
randomised JJ N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
to TO N
compare VB N
anatomical JJ N
knowledge NN N
of IN N
two CD N
groups NNS N
of IN N
second-year JJ N
medical JJ N
students NNS N
, , N
the DT N
first JJ N
group NN N
taught NN N
on IN N
a DT N
traditional JJ N
course NN N
, , N
the DT N
second JJ N
on IN N
an DT N
integrated JJ N
course NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Testing NNP N
was VBD N
done VBN N
using VBG N
a DT N
Questionnaire NN N
in IN N
a DT N
True/False NNP N
format NN N
. . N

There EX N
were VBD N
80 CD N
students NNS N
in IN N
each DT N
group NN N
. . N

There EX N
was VBD N
no DT N
penalty NN N
for IN N
an DT N
incorrect JJ N
answer NN N
. . N

The DT N
test NN N
was VBD N
performed VBN N
under IN N
examination NN N
conditions NNS N
. . N

Papers NNS N
were VBD N
marked VBN N
under IN N
blind JJ N
conditions NNS N
. . N

Results NNS N
were VBD N
analysed VBN N
using VBG N
a DT N
Student NN N
's POS N
t JJ N
test NN N
analysis NN N
. . N

RESULTS NNP N
Those DT N
students NNS N
taught VBP N
on IN N
a DT N
traditional JJ N
course NN N
exhibited VBD N
a DT N
significantly RB N
higher JJR N
level NN N
of IN N
basic JJ N
anatomical JJ N
knowledge NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
than IN N
those DT N
taught VBN N
on IN N
an DT N
integrated JJ N
course NN N
. . N

The DT N
students NNS N
taught VBD N
on IN N
an DT N
integrated JJ N
course NN N
showed VBD N
a DT N
much RB N
greater JJR N
range NN N
of IN N
results NNS N
. . N

CONCLUSIONS JJ N
Students NNS N
taught VBD N
on IN N
a DT N
traditional JJ N
course NN N
have VBP N
a DT N
higher JJR N
level NN N
of IN N
anatomical JJ N
knowledge NN N
than IN N
those DT N
taught VBN N
on IN N
an DT N
integrated JJ N
course NN N
. . N

Our PRP$ N
results NNS N
differ VBP N
from IN N
previous JJ N
studies NNS N
done VBN N
in IN N
Europe NNP N
which WDT N
show VBP N
no DT N
difference NN N
between IN N
the DT N
courses NNS N
. . N

-DOCSTART- -11714591- O O

Social JJ N
support NN N
and CC N
abstinence NN N
from IN N
opiates NNS N
and CC N
cocaine NN N
during IN N
opioid JJ N
maintenance NN N
treatment NN N
. . N

Social NNP N
support NN N
may MD N
play VB N
an DT N
important JJ N
role NN N
in IN N
helping VBG N
drug NN N
users NNS N
achieve VBP N
abstinence NN N
; : N
however RB N
these DT N
benefits NNS N
may MD N
depend VB N
on IN N
the DT N
type NN N
of IN N
support NN N
experienced VBN N
. . N

In IN N
this DT N
prospective JJ N
observational NN N
study NN N
, , N
we PRP N
examined VBD N
the DT N
extent NN N
to TO N
which WDT N
general JJ N
and CC N
abstinence-specific JJ N
support NN N
, , N
both DT N
structural JJ N
and CC N
functional JJ N
, , N
predicted JJ N
opiate NN N
and CC N
cocaine NN N
abstinence NN N
in IN N
128 CD N
opioid JJ N
maintenance NN N
patients NNS N
receiving VBG N
either CC N
methadone NN N
or CC N
LAAM NNP N
. . N

A DT N
new JJ N
multidimensional JJ N
self-report NN N
instrument NN N
assessing VBG N
abstinence-specific JJ N
functional JJ N
support NN N
was VBD N
developed VBN N
for IN N
the DT N
study NN N
. . N

Previously RB N
validated VBN N
measures NNS N
were VBD N
used VBN N
to TO N
assess VB N
the DT N
remaining VBG N
types NNS N
of IN N
support NN N
. . N

With IN N
baseline JJ N
abstinence NN N
and CC N
other JJ N
statistically RB N
important JJ N
covariates NNS N
adjusted VBN N
, , N
hierarchical JJ N
logistic JJ N
regression NN N
analyses NNS N
demonstrated VBD N
that IN N
the DT N
associations NNS N
between IN N
social JJ N
support NN N
at IN N
study NN N
baseline NN N
and CC N
biochemically RB N
confirmed VBN N
abstinence NN N
3 CD N
months NNS N
later RB N
varied VBN N
by IN N
type NN N
of IN N
support NN N
and CC N
by IN N
drug NN N
. . N

Greater NNP N
abstinence-specific JJ N
structural JJ N
support NN N
( ( N
operationalized VBN N
as IN N
fewer JJR N
drug NN N
users NNS N
in IN N
the DT N
social JJ N
network NN N
) ) N
and CC N
decreases VBZ N
in IN N
three CD N
types NNS N
of IN N
negative JJ N
abstinence-specific JJ N
functional JJ N
support NN N
( ( N
Complaints NNS N
about IN N
Drug NNP N
Use NNP N
, , N
Drug NNP N
Exposure NNP N
, , N
and CC N
Demoralization NNP N
) ) N
predicted VBD N
cocaine NN N
, , N
but CC N
not RB N
opiate JJ N
abstinence NN N
. . N

There EX N
were VBD N
no DT N
effects NNS N
for IN N
general JJ N
support NN N
, , N
whether IN N
structural JJ N
or CC N
functional JJ N
, , N
on IN N
abstinence NN N
from IN N
either DT N
drug NN N
. . N

Interventions NNS N
that WDT N
focus VBP N
on IN N
modifying VBG N
patients NNS N
' POS N
abstinence-specific JJ N
support NN N
may MD N
be VB N
helpful JJ N
in IN N
reducing VBG N
the DT N
high JJ N
rates NNS N
of IN N
cocaine NN N
use NN N
disorders NNS N
in IN N
this DT N
population NN N
. . N

-DOCSTART- -20486273- O O

Efficacy NN N
and CC N
safety NN N
of IN N
routine JJ N
blood NN N
pressure NN N
lowering VBG N
in IN N
older JJR N
patients NNS N
with IN N
diabetes NNS N
: : N
results NNS N
from IN N
the DT N
ADVANCE NNP N
trial NN N
. . N

OBJECTIVE CC N
The DT N
efficacy NN N
and CC N
safety NN N
of IN N
blood NN N
pressure NN N
lowering VBG N
in IN N
elderly JJ N
patients NNS N
have VBP N
not RB N
been VBN N
sufficiently RB N
investigated VBN N
in IN N
patients NNS N
with IN N
diabetes NNS N
. . N

Using VBG N
data NNS N
from IN N
the DT N
Action NNP N
in IN N
Diabetes NNP N
and CC N
Vascular NNP N
disease NN N
: : N
preterAx NN N
and CC N
diamicroN-MR NN N
Controlled NNP N
Evaluation NNP N
study NN N
, , N
we PRP N
assessed VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
routine JJ N
blood NN N
pressure NN N
lowering VBG N
to TO N
prevent VB N
major JJ N
clinical JJ N
outcomes NNS N
in IN N
elderly JJ N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
. . N

METHODS NNP N
Eleven NNP N
thousand VBP N
one CD N
hundred CD N
and CC N
forty JJ N
patients NNS N
aged VBN N
at IN N
least JJS N
55 CD N
years NNS N
with IN N
type NN N
2 CD N
diabetes NNS N
( ( N
mean JJ N
66+/-6 CD N
years NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
perindopril-indapamide JJ N
or CC N
placebo NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
a DT N
composite NN N
of IN N
major JJ N
macrovascular NN N
and CC N
microvascular JJ N
disease NN N
. . N

The DT N
effects NNS N
of IN N
active JJ N
treatment NN N
on IN N
outcomes NNS N
were VBD N
estimated VBN N
in IN N
subgroups NNS N
according VBG N
to TO N
age NN N
: : N
below IN N
65 CD N
, , N
65-74 JJ N
and CC N
at IN N
least JJS N
75 CD N
years NNS N
. . N

RESULTS NNP N
During IN N
a DT N
mean JJ N
4.3-year JJ N
follow-up NN N
, , N
1799 CD N
( ( N
16.1 CD N
% NN N
) ) N
patients NNS N
experienced VBD N
a DT N
major JJ N
event NN N
. . N

Active JJ N
treatment NN N
produced VBD N
similar JJ N
relative JJ N
risk NN N
reductions NNS N
for IN N
the DT N
primary JJ N
outcome NN N
, , N
major JJ N
macrovascular JJ N
disease NN N
, , N
death NN N
and CC N
renal JJ N
events NNS N
across IN N
age NN N
groups NNS N
( ( N
all DT N
P NNP N
heterogeneity NN N
> NNP N
0.3 CD N
) ) N
. . N

Over IN N
5 CD N
years NNS N
, , N
active JJ N
treatment NN N
was VBD N
estimated VBN N
to TO N
prevent VB N
one CD N
primary JJ N
outcome NN N
in IN N
every DT N
21 CD N
, , N
71 CD N
and CC N
118 CD N
patients NNS N
of IN N
at IN N
least JJS N
75 CD N
, , N
65-74 JJ N
and CC N
below IN N
65 CD N
years NNS N
, , N
respectively RB N
. . N

Similar JJ N
patterns NNS N
of IN N
benefits NNS N
were VBD N
observed VBN N
for IN N
secondary JJ N
outcomes NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
tolerability NN N
between IN N
randomized VBN N
allocations NNS N
across IN N
age NN N
groups NNS N
( ( N
all DT N
P NNP N
heterogeneity NN N
> NNP N
0.6 CD N
) ) N
CONCLUSION NNP N
Routine NNP N
administration NN N
of IN N
perindopril-indapamide JJ N
lowers NNS N
blood NN N
pressure NN N
safely RB N
and CC N
reduces VBZ N
the DT N
risk NN N
of IN N
major JJ N
clinical JJ N
outcomes NNS N
in IN N
patients NNS N
of IN N
at IN N
least JJS N
75 CD N
years NNS N
with IN N
type NN N
2 CD N
diabetes NNS N
. . N

The DT N
greater JJR N
absolute JJ N
benefits NNS N
in IN N
older JJR N
patients NNS N
in IN N
this DT N
age NN N
group NN N
were VBD N
not RB N
offset VBN N
by IN N
an DT N
increased VBN N
risk NN N
of IN N
side NN N
effects NNS N
. . N

-DOCSTART- -1999025- O O

Ten-year JJ N
incidence NN N
of IN N
myocardial JJ N
infarction NN N
and CC N
prognosis NN N
after IN N
infarction NN N
. . N

Department NNP N
of IN N
Veterans NNP N
Affairs NNP N
Cooperative NNP N
Study NNP N
of IN N
Coronary NNP N
Artery NNP N
Bypass NNP N
Surgery NNP N
. . N

BACKGROUND NNP N
The DT N
10-year JJ N
incidence NN N
of IN N
myocardial JJ N
infarction NN N
( ( N
fatal JJ N
and CC N
nonfatal JJ N
) ) N
and CC N
the DT N
prognosis NN N
after IN N
infarction NN N
were VBD N
evaluated VBN N
in IN N
686 CD N
patients NNS N
with IN N
stable JJ N
angina NNS N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
medical JJ N
or CC N
surgical JJ N
treatment NN N
in IN N
the DT N
Veterans NNPS N
Administration NNP N
Cooperative NNP N
Study NNP N
of IN N
Coronary NNP N
Artery NNP N
Bypass NNP N
Surgery NNP N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Myocardial NNP N
infarction NN N
was VBD N
defined VBN N
by IN N
either DT N
new JJ N
Q NNP N
wave VBP N
findings NNS N
or CC N
clinical JJ N
symptoms NNS N
compatible JJ N
with IN N
myocardial JJ N
infarction NN N
accompanied VBN N
by IN N
serum NN N
enzyme NN N
elevations NNS N
with IN N
or CC N
without IN N
electrocardiographic JJ N
findings NNS N
. . N

Treatment JJ N
comparisons NNS N
were VBD N
made VBN N
according VBG N
to TO N
original JJ N
treatment NN N
assignment NN N
; : N
35 CD N
% NN N
of IN N
the DT N
medical JJ N
cohort NN N
had VBD N
bypass NN N
surgery NN N
during IN N
the DT N
10-year JJ N
follow-up JJ N
period NN N
. . N

The DT N
overall JJ N
cumulative JJ N
infarction NN N
rate NN N
was VBD N
somewhat RB N
higher JJR N
in IN N
patients NNS N
assigned VBN N
to TO N
surgery VB N
( ( N
36 CD N
% NN N
) ) N
than IN N
in IN N
medical JJ N
patients NNS N
( ( N
31 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.13 CD N
) ) N
due JJ N
to TO N
perioperative JJ N
infarctions NNS N
( ( N
13 CD N
% NN N
) ) N
and CC N
an DT N
accelerated JJ N
infarction NN N
rate NN N
after IN N
the DT N
fifth JJ N
year NN N
of IN N
follow-up NN N
( ( N
average JJ N
, , N
2.4 CD N
% NN N
/yr NN N
in IN N
the DT N
surgical JJ N
group NN N
versus VBD N
1.4 CD N
% NN N
/yr NN N
in IN N
the DT N
medical JJ N
group NN N
) ) N
. . N

The DT N
10-year JJ N
cumulative JJ N
incidence NN N
of IN N
death NN N
or CC N
myocardial JJ N
infarction NN N
was VBD N
also RB N
higher JJR N
in IN N
surgical JJ N
( ( N
54 CD N
% NN N
) ) N
than IN N
in IN N
medical JJ N
( ( N
49 CD N
% NN N
) ) N
patients NNS N
( ( N
p JJ N
= NNP N
0.20 CD N
) ) N
. . N

According VBG N
to TO N
the DT N
Cox NNP N
model NN N
, , N
the DT N
estimated VBN N
risk NN N
of IN N
death NN N
after IN N
infarction NN N
was VBD N
59 CD N
% NN N
lower JJR N
in IN N
surgical JJ N
than IN N
in IN N
medical JJ N
patients NNS N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

The DT N
reduction NN N
in IN N
postinfarction NN N
mortality NN N
with IN N
surgery NN N
was VBD N
most RBS N
striking JJ N
in IN N
the DT N
first JJ N
month NN N
after IN N
the DT N
event NN N
: : N
99 CD N
% NN N
in IN N
the DT N
first JJ N
month NN N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
and CC N
49 CD N
% NN N
subsequently RB N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

The DT N
estimated VBN N
risk NN N
of IN N
death NN N
in IN N
the DT N
absence NN N
of IN N
infarction NN N
was VBD N
nearly RB N
identical JJ N
regardless NN N
of IN N
treatment NN N
( ( N
p JJ N
= NNP N
0.75 CD N
) ) N
. . N

Exclusion NN N
of IN N
perioperative JJ N
infarctions NNS N
did VBD N
not RB N
alter VB N
the DT N
findings NNS N
. . N

CONCLUSIONS NNP N
Although IN N
surgery NN N
does VBZ N
not RB N
reduce VB N
the DT N
incidence NN N
of IN N
myocardial JJ N
infarction NN N
overall RB N
, , N
it PRP N
does VBZ N
reduce VB N
the DT N
risk NN N
of IN N
mortality NN N
after IN N
infarction NN N
, , N
particularly RB N
in IN N
the DT N
first JJ N
30 CD N
days NNS N
after IN N
the DT N
event NN N
( ( N
fatal JJ N
infarctions NNS N
) ) N
. . N

-DOCSTART- -15466792- O O

In-hospital JJ N
costs NNS N
of IN N
self-expanding JJ N
nitinol JJ N
stent NN N
implantation NN N
versus NN N
balloon NN N
angioplasty NN N
in IN N
the DT N
femoropopliteal JJ N
artery NN N
( ( N
the DT N
VascuCoil NNP N
Trial NNP N
) ) N
. . N

PURPOSE NNP N
Although IN N
several JJ N
prospective JJ N
studies NNS N
have VBP N
examined VBN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
stent JJ N
placement NN N
for IN N
femoropopliteal JJ N
arterial JJ N
disease NN N
, , N
the DT N
current JJ N
cost NN N
of IN N
these DT N
procedures NNS N
is VBZ N
unknown JJ N
. . N

To TO N
estimate VB N
and CC N
compare VB N
hospital NN N
costs NNS N
associated VBN N
with IN N
conventional JJ N
balloon NN N
angioplasty NN N
( ( N
percutaneous JJ N
transluminal NN N
angioplasty NN N
[ NNP N
PTA NNP N
] NNP N
) ) N
and CC N
stent JJ N
placement NN N
for IN N
patients NNS N
with IN N
symptomatic JJ N
peripheral JJ N
arterial JJ N
disease NN N
, , N
the DT N
authors NNS N
performed VBD N
a DT N
prospective JJ N
economic JJ N
evaluation NN N
in IN N
conjunction NN N
with IN N
the DT N
Intracoil NNP N
Femoropopliteal NNP N
Stent NNP N
Trial NNP N
( ( N
VascuCoil NNP N
) ) N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Between NNP N
May NNP N
1997 CD N
and CC N
December NNP N
1999 CD N
, , N
266 CD N
patients NNS N
with IN N
stenotic JJ N
or CC N
occluded VBN N
superficial JJ N
femoral JJ N
or CC N
popliteal JJ N
arteries NNS N
were VBD N
prospectively RB N
randomized VBN N
to TO N
treatment NN N
with IN N
the DT N
IntraCoil NNP N
stent NN N
or CC N
PTA NNP N
. . N

Detailed NNP N
resource NN N
use NN N
and CC N
cost NN N
data NNS N
for IN N
each DT N
patient NN N
's POS N
initial JJ N
revascularization NN N
procedure NN N
and CC N
ensuing VBG N
hospitalization NN N
were VBD N
collected VBN N
and CC N
analyzed VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
conventional JJ N
balloon NN N
angioplasty NN N
, , N
stent JJ N
placement NN N
did VBD N
not RB N
improve VB N
clinical JJ N
outcomes NNS N
but CC N
increased JJ N
procedure NN N
duration NN N
, , N
equipment NN N
costs NNS N
, , N
and CC N
physician JJ N
services NNS N
. . N

As IN N
a DT N
result NN N
, , N
initial JJ N
hospital NN N
costs NNS N
were VBD N
approximately RB N
3,500 CD N
dollars NNS N
higher JJR N
for IN N
patients NNS N
randomized VBN N
to TO N
the DT N
IntraCoil NNP N
stent NN N
, , N
compared VBN N
with IN N
PTA NNP N
( ( N
8,435 CD N
dollars NNS N
vs RB N
4,980 CD N
dollars NNS N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSIONS NNP N
As IN N
performed VBN N
in IN N
the DT N
VascuCoil NNP N
trial NN N
, , N
primary JJ N
stent NN N
placement NN N
for IN N
femoropopliteal JJ N
disease NN N
did VBD N
not RB N
improve VB N
clinical JJ N
outcomes NNS N
but CC N
increased VBD N
initial JJ N
treatment NN N
costs NNS N
by IN N
more JJR N
than IN N
3,000 CD N
dollars NNS N
. . N

Because IN N
there EX N
were VBD N
no DT N
substantial JJ N
differences NNS N
in IN N
subsequent JJ N
clinical JJ N
outcomes NNS N
between IN N
the DT N
two CD N
treatments NNS N
, , N
it PRP N
is VBZ N
unlikely JJ N
that IN N
these DT N
increased VBN N
initial JJ N
costs NNS N
would MD N
be VB N
offset VBN N
by IN N
savings NNS N
in IN N
follow-up JJ N
costs NNS N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
a DT N
strategy NN N
of IN N
routine JJ N
stent NN N
implantation NN N
for IN N
patients NNS N
undergoing VBG N
femoropopliteal JJ N
PTA NNP N
is VBZ N
not RB N
optimal JJ N
on IN N
economic JJ N
grounds NNS N
and CC N
that DT N
PTA NNP N
with IN N
provisional JJ N
stent JJ N
implantation NN N
is VBZ N
preferred VBN N
. . N

-DOCSTART- -22638779- O O

Propofol NNP N
sedation NN N
with IN N
bispectral JJ N
index NN N
monitoring NN N
is VBZ N
useful JJ N
for IN N
endoscopic NN N
submucosal JJ N
dissection NN N
: : N
a DT N
randomized JJ N
prospective JJ N
phase NN N
II NNP N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIMS NNP N
Endoscopic NNP N
submucosal NN N
dissection NN N
( ( N
ESD NNP N
) ) N
has VBZ N
become VBN N
a DT N
standard JJ N
treatment NN N
. . N

However RB N
, , N
the DT N
treatment NN N
time NN N
tends VBZ N
to TO N
be VB N
relatively RB N
long JJ N
and CC N
insufflation NN N
and CC N
manipulation NN N
of IN N
the DT N
endoscope NN N
can MD N
increase VB N
pain NN N
and CC N
discomfort NN N
. . N

We PRP N
aimed VBD N
to TO N
find VB N
an DT N
optimal JJ N
method NN N
for IN N
sedation NN N
during IN N
ESD NNP N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNP N
scheduled VBD N
to TO N
undergo VB N
ESD NNP N
for IN N
early JJ N
gastric JJ N
cancer NN N
or CC N
adenoma NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
sedation NN N
with IN N
midazolam NN N
or CC N
propofol NN N
, , N
and CC N
consciousness JJ N
level NN N
was VBD N
evaluated VBN N
by IN N
bispectral JJ N
index NN N
( ( N
BIS NNP N
) ) N
monitoring NN N
. . N

Primary JJ N
end NN N
points NNS N
of IN N
effectiveness NN N
( ( N
three CD N
parameters NNS N
) ) N
and CC N
secondary JJ N
end NN N
points NNS N
of IN N
safety NN N
during IN N
ESD NNP N
and CC N
after IN N
return NN N
to TO N
the DT N
ward NN N
were VBD N
compared VBN N
between IN N
the DT N
groups NNS N
. . N

Study NNP N
registration NN N
was VBD N
in IN N
the DT N
UMIN NNP N
Clinical NNP N
Trial NNP N
Registry NNP N
( ( N
UMIN NNP N
000001497 CD N
) ) N
, , N
and CC N
the DT N
institutional JJ N
trial NN N
number NN N
was VBD N
KDOG NNP N
0801 CD N
. . N

RESULTS VBN N
From IN N
June NNP N
2008 CD N
through IN N
June NNP N
2009 CD N
, , N
we PRP N
enrolled VBD N
178 CD N
patients NNS N
( ( N
90 CD N
midazolam NN N
, , N
88 CD N
propofol NN N
) ) N
. . N

Regarding VBG N
safety NN N
after IN N
ESD NNP N
, , N
recovery NN N
was VBD N
significantly RB N
better RBR N
in IN N
the DT N
propofol NN N
group NN N
immediately RB N
after IN N
and CC N
at IN N
1 CD N
hour NN N
and CC N
2 CD N
hours NNS N
after IN N
return NN N
to TO N
the DT N
ward NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
number NN N
of IN N
patients NNS N
who WP N
required VBD N
a DT N
continuous JJ N
supply NN N
of IN N
oxygen NN N
2 CD N
hours NNS N
after IN N
returning VBG N
to TO N
the DT N
ward NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
propofol NN N
group NN N
( ( N
midazolam JJ N
18 CD N
; : N
propofol CC N
6 CD N
; : N
P NNP N
= NNP N
0.010 CD N
) ) N
. . N

Though IN N
propofol NN N
seemed VBD N
to TO N
be VB N
better JJR N
for IN N
effectiveness NN N
and CC N
safety NN N
, , N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
for IN N
all DT N
three CD N
primary JJ N
end NN N
points NNS N
and CC N
the DT N
safety NN N
parameters NNS N
( ( N
hypotension NN N
, , N
hypoxia NN N
, , N
bradycardia NN N
) ) N
. . N

CONCLUSIONS NNP N
Propofol NNP N
with IN N
BIS NNP N
monitoring VBG N
improved JJ N
recovery NN N
of IN N
patients NNS N
after IN N
ESD NNP N
, , N
though IN N
this DT N
study NN N
was VBD N
underpowered VBN N
to TO N
prove VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
propofol NN N
. . N

-DOCSTART- -23027887- O O

Multiple JJ N
courses NNS N
of IN N
rituximab NN N
produce NN N
sustained VBD N
clinical JJ N
and CC N
radiographic JJ N
efficacy NN N
and CC N
safety NN N
in IN N
patients NNS N
with IN N
rheumatoid JJ N
arthritis NN N
and CC N
an DT N
inadequate JJ N
response NN N
to TO N
1 CD N
or CC N
more JJR N
tumor JJ N
necrosis NN N
factor NN N
inhibitors NNS N
: : N
5-year JJ N
data NNS N
from IN N
the DT N
REFLEX NNP N
study NN N
. . N

OBJECTIVE VB N
This DT N
5-year JJ N
observational JJ N
posthoc NN N
analysis NN N
of IN N
the DT N
REFLEX NNP N
study NN N
and CC N
its PRP$ N
open-label JJ N
extension NN N
assessed VBD N
clinical JJ N
efficacy NN N
, , N
radiographic JJ N
response NN N
, , N
and CC N
safety NN N
of IN N
rituximab NN N
( ( N
RTX NNP N
) ) N
in IN N
patients NNS N
with IN N
rheumatoid JJ N
arthritis NN N
( ( N
RA NNP N
) ) N
who WP N
had VBD N
an DT N
inadequate JJ N
response NN N
to TO N
tumor VB N
necrosis NN N
factor NN N
( ( N
TNF NNP N
) ) N
inhibitors NNS N
. . N

METHODS NNP N
Patients NNPS N
in IN N
REFLEX NNP N
were VBD N
originally RB N
randomized VBN N
to TO N
placebo VB N
( ( N
PBO NNP N
) ) N
+ NN N
methotrexate NN N
( ( N
MTX NNP N
; : N
PBO-randomized NNP N
) ) N
or CC N
RTX NNP N
+ NNP N
MTX NNP N
( ( N
RTX-randomized NNP N
) ) N
. . N

PBO-randomized JJ N
patients NNS N
were VBD N
rescued VBN N
with IN N
RTX NNP N
as IN N
appropriate JJ N
. . N

Patients NNS N
responding VBG N
to TO N
initial JJ N
RTX NNP N
treatment NN N
could MD N
receive VB N
further JJ N
RTX NNP N
courses NNS N
. . N

For IN N
clinical JJ N
efficacy NN N
and CC N
safety NN N
analyses NNS N
, , N
PBO-randomized JJ N
patients NNS N
were VBD N
re-baselined JJ N
prior NN N
to TO N
first JJ N
RTX NNP N
treatment NN N
and CC N
the DT N
data NNS N
were VBD N
pooled VBN N
with IN N
RTX-randomized JJ N
patient NN N
data NNS N
. . N

Efficacy NNP N
outcomes RB N
24 CD N
weeks NNS N
after IN N
each DT N
course NN N
were VBD N
calculated VBN N
relative JJ N
to TO N
first JJ N
RTX NNP N
pretreatment NN N
baseline NN N
. . N

Radiographic JJ N
outcomes NNS N
were VBD N
assessed VBN N
relative JJ N
to TO N
randomization VB N
baseline NN N
for IN N
both DT N
PBO-randomized NNP N
and CC N
RTX-randomized NNP N
groups NNS N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
480 CD N
patients NNS N
received VBN N
? . N
1 CD N
RTX NNP N
course NN N
. . N

At IN N
24 CD N
weeks NNS N
, , N
American NNP N
College NNP N
of IN N
Rheumatology NNP N
20/50/70 CD N
responses NNS N
were VBD N
62.0 CD N
% NN N
, , N
30.8 CD N
% NN N
, , N
and CC N
13.0 CD N
% NN N
, , N
respectively RB N
at IN N
course NN N
1 CD N
( ( N
n JJ N
= NNP N
400 CD N
) ) N
and CC N
70.3 CD N
% NN N
, , N
41.8 CD N
% NN N
, , N
and CC N
22.0 CD N
% NN N
at IN N
course NN N
5 CD N
( ( N
n JJ N
= NNP N
91 CD N
) ) N
. . N

European JJ N
League NNP N
Against NNP N
Rheumatism NNP N
good/moderate NN N
responses NNS N
were VBD N
77.2 CD N
% NN N
and CC N
84.4 CD N
% NN N
at IN N
courses NNS N
1 CD N
( ( N
n JJ N
= NNP N
390 CD N
) ) N
and CC N
5 CD N
( ( N
n JJ N
= NNP N
90 CD N
) ) N
. . N

Rates NNS N
of IN N
adverse JJ N
events NNS N
( ( N
AE NNP N
) ) N
, , N
serious JJ N
AE NNP N
, , N
and CC N
infections NNS N
generally RB N
remained VBD N
stable JJ N
. . N

Rate NNP N
of IN N
progressive JJ N
joint JJ N
damage NN N
( ( N
PJD NNP N
; : N
change NN N
in IN N
mean JJ N
Total NNP N
Sharp NNP N
Score NNP N
) ) N
decreased VBD N
over RP N
time NN N
in IN N
both DT N
PBO-randomized NNP N
( ( N
n JJ N
= NNP N
79 CD N
) ) N
and CC N
RTX-randomized NNP N
( ( N
n JJ N
= NNP N
105 CD N
) ) N
groups NNS N
. . N

Mean JJ N
change NN N
from IN N
baseline NN N
in IN N
PJD NNP N
over IN N
5 CD N
years NNS N
was VBD N
greater JJR N
in IN N
PBO-randomized NNP N
versus NN N
RTX-randomized JJ N
patients NNS N
( ( N
5.51 CD N
vs RB N
3.21 CD N
) ) N
. . N

CONCLUSION NNP N
RTX NNP N
re-treatment NN N
over IN N
5 CD N
years NNS N
is VBZ N
associated VBN N
with IN N
maintained VBN N
or CC N
improved VBN N
efficacy NN N
, , N
continued VBD N
inhibition NN N
of IN N
PJD NNP N
, , N
and CC N
a DT N
safety NN N
profile NN N
consistent JJ N
with IN N
that DT N
previously RB N
reported VBN N
. . N

A DT N
delay NN N
in IN N
initiating VBG N
RTX NNP N
treatment NN N
may MD N
result VB N
in IN N
increased JJ N
PJD NNP N
. . N

-DOCSTART- -11378833- O O

Dose NNP N
response NN N
effect NN N
of IN N
cyclical JJ N
medroxyprogesterone NN N
on IN N
blood NN N
pressure NN N
in IN N
postmenopausal JJ N
women NNS N
. . N

OBJECTIVE VB N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
with IN N
placebo PDT N
the DT N
dose-response JJ N
effect NN N
of IN N
cyclical JJ N
doses NNS N
of IN N
the DT N
C21 NNP N
progestogen NN N
, , N
medroxyprogesterone NN N
acetate NN N
( ( N
MPA NNP N
) ) N
on IN N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
when WRB N
administered VBN N
to TO N
normotensive JJ N
postmenopausal NN N
women NNS N
receiving VBG N
a DT N
fixed JJ N
mid-range JJ N
daily JJ N
dose NN N
of IN N
conjugated JJ N
equine NN N
oestrogen NN N
( ( N
CEE NNP N
) ) N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Twenty NNP N
normotensive JJ N
postmenopausal NN N
women NNS N
( ( N
median JJ N
age NN N
53 CD N
years NNS N
) ) N
participated VBD N
in IN N
the DT N
study NN N
which WDT N
used VBD N
a DT N
double-blind JJ N
crossover NN N
design NN N
. . N

There EX N
were VBD N
four CD N
randomised VBN N
treatment NN N
phases NNS N
, , N
each DT N
of IN N
4 CD N
weeks NNS N
duration NN N
. . N

The DT N
four CD N
blinded VBD N
treatments NNS N
were VBD N
MPA NNP N
2.5 CD N
mg NN N
, , N
MPA NNP N
5 CD N
mg NN N
, , N
MPA NNP N
10 CD N
mg NN N
and CC N
matching VBG N
placebo NN N
, , N
taken VBN N
for IN N
the DT N
last JJ N
14 CD N
days NNS N
of IN N
each DT N
28 CD N
day NN N
treatment NN N
cycle NN N
. . N

CEE NNP N
0.625 CD N
mg NN N
was VBD N
also RB N
administered VBN N
once RB N
daily JJ N
as IN N
open JJ N
labelled VBD N
tablets NNS N
to TO N
all DT N
subjects NNS N
throughout IN N
the DT N
study NN N
. . N

Clinic NNP N
BP NNP N
was VBD N
measured VBN N
weekly RB N
with IN N
the DT N
mean JJ N
values NNS N
of IN N
weeks NNS N
3 CD N
and CC N
4 CD N
of IN N
each DT N
phase NN N
used VBN N
for IN N
analysis NN N
. . N

Ambulatory NNP N
BP NNP N
was VBD N
performed VBN N
in IN N
the DT N
final JJ N
week NN N
of IN N
each DT N
phase NN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
the DT N
placebo NN N
phase NN N
, , N
end NN N
of IN N
phase NN N
clinic JJ N
BP NNP N
was VBD N
unchanged JJ N
by IN N
any DT N
of IN N
the DT N
progestogen NN N
treatments NNS N
. . N

There EX N
was VBD N
a DT N
dose-dependent JJ N
decrease NN N
in IN N
ambulatory JJ N
daytime JJ N
diastolic NN N
and CC N
mean JJ N
arterial JJ N
BP NNP N
with IN N
the DT N
progestogen NN N
treatments NNS N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
In IN N
a DT N
regimen NN N
of IN N
postmenopausal NN N
hormone NN N
replacement NN N
therapy NN N
with IN N
a DT N
fixed JJ N
mid-range JJ N
daily JJ N
dose NN N
of IN N
CEE NNP N
combined VBD N
with IN N
a DT N
cyclical JJ N
regimen NN N
of IN N
a DT N
C21 NNP N
progestogen NN N
spanning VBG N
the DT N
current JJ N
clinical JJ N
dose NN N
range NN N
, , N
the DT N
progestogen NN N
has VBZ N
either CC N
no DT N
effect NN N
or CC N
a DT N
small JJ N
dose-dependent JJ N
reduction NN N
in IN N
clinic NN N
and CC N
ambulatory JJ N
BPs NNP N
over IN N
one CD N
treatment NN N
cycle NN N
. . N

-DOCSTART- -18686184- O O

Smoking VBG N
cessation NN N
with IN N
smokeless JJ N
tobacco NN N
and CC N
group NN N
therapy NN N
: : N
an DT N
open JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
. . N

Smokeless NNP N
tobacco NN N
might MD N
be VB N
effective JJ N
as IN N
an DT N
adjunct NN N
for IN N
smoking VBG N
cessation NN N
. . N

We PRP N
evaluated VBD N
the DT N
efficacy NN N
of IN N
smokeless NN N
tobacco NN N
and CC N
group NN N
support NN N
for IN N
smoking VBG N
cessation NN N
in IN N
an DT N
open JJ N
, , N
randomized VBN N
study NN N
that WDT N
compared VBN N
smokeless NN N
tobacco NN N
plus CC N
group NN N
support NN N
versus NN N
group NN N
support NN N
only RB N
. . N

The DT N
study NN N
enrolled VBD N
263 CD N
healthy JJ N
smokers NNS N
( ( N
M NNP N
( ( N
age NN N
) ) N
= VBZ N
49 CD N
years NNS N
) ) N
who WP N
smoked VBD N
a DT N
mean NN N
of IN N
24 CD N
cigarettes/day NN N
, , N
with IN N
a DT N
mean NN N
of IN N
31 CD N
pack-years NNS N
. . N

Smokeless NNP N
tobacco NN N
was VBD N
provided VBN N
for IN N
7 CD N
weeks NNS N
( ( N
or CC N
up RB N
to TO N
12 CD N
) ) N
, , N
combined VBN N
with IN N
eight CD N
group NN N
support NN N
visits NNS N
provided VBN N
by IN N
nurses NNS N
. . N

The DT N
control NN N
group NN N
received VBD N
group NN N
support NN N
only RB N
. . N

Smoking VBG N
cessation NN N
rates NNS N
were VBD N
statistically RB N
significantly RB N
better RBR N
in IN N
the DT N
smokeless NN N
tobacco NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
during IN N
the DT N
first JJ N
7 CD N
weeks NNS N
. . N

Point-prevalence NN N
abstinence NN N
rates NNS N
at IN N
7 CD N
weeks NNS N
were VBD N
36.4 CD N
% NN N
versus IN N
20.8 CD N
% NN N
( ( N
OR NNP N
= VBZ N
2.52 CD N
, , N
p NN N
= NNP N
.001 NNP N
) ) N
, , N
respectively RB N
; : N
and CC N
continuous JJ N
abstinence NN N
rates NNS N
from IN N
weeks NNS N
4 CD N
to TO N
7 CD N
were VBD N
31.5 CD N
% NN N
versus IN N
19.2 CD N
% NN N
( ( N
OR NNP N
= VBZ N
1.94 CD N
, , N
p NN N
= NNP N
.023 NNP N
) ) N
, , N
respectively RB N
. . N

The DT N
primary JJ N
outcomes NNS N
( ( N
i.e. JJ N
, , N
6-month JJ N
point NN N
prevalence NN N
) ) N
were VBD N
23.1 CD N
% NN N
versus IN N
20.8 CD N
% NN N
, , N
respectively RB N
( ( N
OR NNP N
= VBZ N
1.31 CD N
, , N
ns NN N
) ) N
. . N

Smokeless NNP N
tobacco NN N
was VBD N
relatively RB N
well RB N
tolerated VBN N
, , N
although IN N
15 CD N
subjects NNS N
( ( N
11.2 CD N
% NN N
) ) N
stopped VBD N
use NN N
due JJ N
to TO N
adverse JJ N
events NNS N
. . N

A DT N
total NN N
of IN N
25 CD N
subjects NNS N
( ( N
17.5 CD N
% NN N
) ) N
were VBD N
still RB N
using VBG N
smokeless JJ N
tobacco NN N
after IN N
6 CD N
months NNS N
. . N

This DT N
trial NN N
demonstrated VBD N
short-term JJ N
efficacy NN N
of IN N
smokeless JJ N
tobacco NN N
in IN N
combination NN N
with IN N
group NN N
support NN N
for IN N
smoking VBG N
cessation NN N
but CC N
no DT N
long-term JJ N
efficacy NN N
. . N

-DOCSTART- -20345030- O O

[ JJ N
Observation NNP N
of IN N
curative JJ N
effect NN N
on IN N
fixed-point NN N
spin NN N
reduction NN N
of IN N
spinal JJ N
manipulation NN N
therapy NN N
for IN N
cervical JJ N
vertigo NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
explore VB N
the DT N
role NN N
of IN N
fixed-point JJ N
spin JJ N
reduction NN N
of IN N
spinal JJ N
manipulation NN N
therapy NN N
in IN N
the DT N
treatment NN N
of IN N
cervical JJ N
vertigo NN N
and CC N
its PRP$ N
effect NN N
on IN N
cervical JJ N
artery NN N
spasm NN N
index NN N
( ( N
RI NNP N
) ) N
and CC N
atlantoaxial JJ N
displacement NN N
index NN N
( ( N
ADI NNP N
) ) N
. . N

METHODS NN N
From IN N
January NNP N
2002 CD N
to TO N
May NNP N
2008 CD N
, , N
168 CD N
patients NNS N
with IN N
cervical JJ N
vertigo NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
treatment NN N
group NN N
( ( N
84 CD N
cases NNS N
) ) N
and CC N
the DT N
control NN N
group NN N
( ( N
84 CD N
cases NNS N
) ) N
, , N
22 CD N
males NNS N
and CC N
62 CD N
females NNS N
in IN N
treatment NN N
group NN N
; : N
24 CD N
males NNS N
and CC N
60 CD N
females NNS N
in IN N
control NN N
group NN N
. . N

The DT N
patients NNS N
of IN N
treatment NN N
group NN N
and CC N
control NN N
group NN N
were VBD N
respectively RB N
treated VBN N
with IN N
fixed-point JJ N
spin NN N
reduction NN N
of IN N
spinal JJ N
manipulation NN N
therapy NN N
and CC N
dialectical JJ N
prescription NN N
. . N

The DT N
score NN N
of IN N
symptoms NNS N
and CC N
signs NNS N
, , N
RI NNP N
, , N
ADI NNP N
were VBD N
observed VBN N
and CC N
compared VBN N
between IN N
two CD N
groups NNS N
. . N

RESULTS VB N
The DT N
score NN N
of IN N
symptoms NNS N
and CC N
signs NNS N
markedly RB N
decreased VBD N
after IN N
treatment NN N
, , N
in IN N
treatment NN N
group NN N
: : N
vertigo NN N
had VBD N
( ( N
2.75 CD N
+/- JJ N
1.01 CD N
) ) N
scores NNS N
, , N
neck-shoulder JJ N
pain NN N
( ( N
1.58 CD N
+/- JJ N
0.36 CD N
) ) N
, , N
headache NN N
( ( N
0.39 CD N
+/- JJ N
0.09 CD N
) ) N
, , N
nausea-vomiting JJ N
( ( N
1.58 CD N
+/- JJ N
1.30 CD N
) ) N
, , N
ear JJ N
noises NNS N
( ( N
0.48 CD N
+/- JJ N
0.32 CD N
) ) N
, , N
positive JJ N
neck NN N
rotation NN N
test NN N
( ( N
0.59 CD N
+/- JJ N
0.21 CD N
) ) N
; : N
and CC N
in IN N
control NN N
group NN N
: : N
vertigo NN N
had VBD N
( ( N
5.68 CD N
+/- JJ N
2.02 CD N
) ) N
scores NNS N
, , N
neck-shoulder JJ N
pain NN N
( ( N
3.12 CD N
+/- JJ N
1.82 CD N
) ) N
, , N
headache NN N
( ( N
1.86 CD N
+/- JJ N
0.65 CD N
) ) N
, , N
nausea-vomiting JJ N
( ( N
3.25 CD N
+/- JJ N
0.69 CD N
) ) N
, , N
ear JJ N
noises NNS N
( ( N
1.64 CD N
+/- JJ N
0.61 CD N
) ) N
, , N
positive JJ N
neck NN N
rotation NN N
test NN N
( ( N
1.79 CD N
+/- JJ N
0.67 CD N
) ) N
. . N

Cervical JJ N
artery NN N
spasm NN N
index NN N
and CC N
atlantoaxial JJ N
displacement NN N
index NN N
had VBD N
been VBN N
significantly RB N
improved VBN N
, , N
cervical JJ N
artery NN N
spasm NN N
index NN N
was VBD N
respectively RB N
0.54 CD N
+/- JJ N
0.07 CD N
and CC N
0.52 CD N
+/- JJ N
0.13 CD N
, , N
atlantoaxial JJ N
displacement NN N
index NN N
was VBD N
respectively RB N
2.92 CD N
+/- JJ N
0.82 CD N
and CC N
4.50 CD N
+/- JJ N
1.32 CD N
between IN N
treatment NN N
group NN N
and CC N
control NN N
group NN N
. . N

CONCLUSION NNP N
Fixed-point NNP N
spin NN N
reduction NN N
of IN N
spinal JJ N
manipulation NN N
therapy NN N
for IN N
cervical JJ N
vertigo NN N
can MD N
accurately RB N
correct VB N
single JJ N
or CC N
multiple JJ N
vertebral JJ N
body NN N
displacement NN N
, , N
restore VB N
normal JJ N
spinal JJ N
position NN N
, , N
reduce VB N
the DT N
oppression NN N
and CC N
stimulus NN N
of IN N
the DT N
vertebral JJ N
artery NN N
, , N
release NN N
ischemia NN N
of IN N
vestibular JJ N
labyrinth NN N
, , N
eliminate VB N
symptoms NNS N
of IN N
vertigo NN N
. . N

-DOCSTART- -16791814- O O

International NNP N
Czech NNP N
and CC N
Slovak NNP N
cooperation NN N
in IN N
the DT N
treatment NN N
of IN N
patients NNS N
with IN N
differentiated JJ N
thyroid NN N
cancer NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
paper NN N
is VBZ N
to TO N
present VB N
our PRP$ N
experience NN N
concerning VBG N
cooperation NN N
in IN N
the DT N
treatment NN N
of IN N
Slovak NNP N
patients NNS N
with IN N
differentiated JJ N
thyroid NN N
cancer NN N
in IN N
Slovak NNP N
and CC N
Czech NNP N
hospitals NNS N
. . N

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
demonstrate VB N
the DT N
means NNS N
of IN N
this DT N
cooperation NN N
and CC N
the DT N
results NNS N
of IN N
therapy NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
From NNP N
September NNP N
1991 CD N
to TO N
October NNP N
2005 CD N
in IN N
the DT N
Department NNP N
of IN N
Nuclear NNP N
Medicine NNP N
in IN N
Ostrava NNP N
357 CD N
patients NNS N
from IN N
the DT N
Slovak NNP N
Republic NNP N
with IN N
differentiated VBN N
thyroid NN N
cancers NNS N
( ( N
follicular JJ N
and CC N
papillary JJ N
) ) N
underwent NN N
complex JJ N
therapy NN N
. . N

They PRP N
were VBD N
diagnosed VBN N
and CC N
operated VBN N
due JJ N
to TO N
the DT N
cancer NN N
( ( N
near-total JJ N
thyroidectomy NN N
and CC N
removal NN N
of IN N
lymph JJ N
node JJ N
metastases NNS N
) ) N
in IN N
Slovak NNP N
hospitals NNS N
. . N

Then RB N
they PRP N
were VBD N
sent VBN N
to TO N
the DT N
Department NNP N
of IN N
Nuclear NNP N
Medicine NNP N
in IN N
Ostrava NNP N
in IN N
the DT N
Czech NNP N
Republic NNP N
. . N

In IN N
this DT N
department NN N
a DT N
radioiodine JJ N
ablation NN N
of IN N
thyroid JJ N
remnants NNS N
, , N
by IN N
means NNS N
of IN N
the DT N
treatment NN N
amount NN N
of IN N
radioiodine NN N
of IN N
a DT N
standard JJ N
activity NN N
of IN N
3.7 CD N
GBq NNP N
, , N
was VBD N
performed VBN N
, , N
and CC N
then RB N
a DT N
suppression NN N
and CC N
substitution NN N
therapy NN N
of IN N
thyroid JJ N
hormones NNS N
was VBD N
started VBN N
. . N

After IN N
3-6 JJ N
months NNS N
some DT N
patients NNS N
were VBD N
examined VBN N
by IN N
means NNS N
of IN N
diagnostic JJ N
whole JJ N
body NN N
scintigraphy NN N
after IN N
application NN N
of IN N
300 CD N
MBq NNP N
131I CD N
. . N

Some DT N
patients NNS N
were VBD N
treated VBN N
by IN N
means NNS N
of IN N
a DT N
standard JJ N
activity NN N
of IN N
7.4 CD N
GBq NNP N
131I CD N
and CC N
after IN N
5 CD N
days NNS N
whole JJ N
body NN N
scintigraphy NN N
( ( N
WBS NNP N
) ) N
was VBD N
performed VBN N
. . N

In IN N
both DT N
of IN N
these DT N
groups NNS N
of IN N
patients NNS N
the DT N
diagnostic JJ N
or CC N
therapeutic JJ N
radioiodine NN N
application NN N
was VBD N
done VBN N
after IN N
withdrawal NN N
of IN N
thyroid JJ N
hormone NN N
treatment NN N
. . N

If IN N
thyroglobulin JJ N
levels NNS N
were VBD N
low JJ N
and CC N
WBSs NNP N
were VBD N
negative JJ N
, , N
patients NNS N
were VBD N
followed VBN N
up RP N
in IN N
the DT N
Department NNP N
of IN N
Nuclear NNP N
Medicine NNP N
in IN N
Martin NNP N
. . N

Patients NNS N
with IN N
radioiodine NN N
accumulated VBN N
metastases NNS N
were VBD N
again RB N
treated VBN N
with IN N
radioiodine NN N
in IN N
Ostrava NNP N
. . N

If IN N
indicated VBN N
, , N
external JJ N
radiation NN N
therapy NN N
targeted VBN N
on IN N
the DT N
neck NN N
and CC N
upper JJ N
mediastinum NN N
was VBD N
performed VBN N
in IN N
the DT N
Slovak NNP N
Republic NNP N
, , N
in IN N
the DT N
University NNP N
Hospital NNP N
in IN N
Martin NNP N
. . N

Newly RB N
formed VBN N
lymph JJ N
node NN N
metastases NNS N
were VBD N
surgically RB N
treated VBN N
in IN N
Slovakia NNP N
, , N
too RB N
. . N

Generally RB N
we PRP N
have VBP N
very RB N
good JJ N
treatment NN N
results NNS N
. . N

Also RB N
, , N
economically RB N
our PRP$ N
partnership NN N
is VBZ N
cost VBN N
effective JJ N
. . N

Our PRP$ N
collaboration NN N
also RB N
successfully RB N
continues VBZ N
after IN N
entrance NN N
of IN N
the DT N
Slovak NNP N
Republic NNP N
and CC N
the DT N
Czech NNP N
Republic NNP N
to TO N
the DT N
European NNP N
Union NNP N
in IN N
2004 CD N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
multi-centre JJ N
study NN N
show NN N
that IN N
international JJ N
Czech NNP N
and CC N
Slovak NNP N
cooperation NN N
in IN N
the DT N
complex JJ N
therapy NN N
of IN N
patients NNS N
with IN N
differentiated JJ N
thyroid NN N
cancers NNS N
is VBZ N
successful JJ N
, , N
with IN N
high JJ N
efficacy NN N
. . N

The DT N
treatment NN N
results NNS N
were VBD N
very RB N
similar JJ N
to TO N
therapeutic JJ N
results NNS N
in IN N
our PRP$ N
patients NNS N
from IN N
the DT N
Czech NNP N
Republic NNP N
. . N

-DOCSTART- -19814586- O O

Efficacy NN N
and CC N
long-term JJ N
tolerability NN N
of IN N
sublingual JJ N
fentanyl NN N
orally RB N
disintegrating VBG N
tablet NN N
in IN N
the DT N
treatment NN N
of IN N
breakthrough NN N
cancer NN N
pain NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Breakthrough NNP N
cancer NN N
pain NN N
( ( N
BTcP NNP N
) ) N
represents VBZ N
an DT N
important JJ N
clinical JJ N
challenge NN N
in IN N
the DT N
care NN N
of IN N
patients NNS N
with IN N
cancer NN N
. . N

This DT N
trial NN N
evaluated VBD N
the DT N
efficacy NN N
and CC N
long-term JJ N
tolerability NN N
of IN N
a DT N
sublingual JJ N
formulation NN N
of IN N
the DT N
fast-acting JJ N
opioid NN N
fentanyl NN N
, , N
for IN N
the DT N
treatment NN N
of IN N
BTcP NNP N
in IN N
opioid-tolerant JJ N
patients NNS N
with IN N
cancer NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
multi-center JJ N
, , N
phase JJ N
III NNP N
trial NN N
, , N
conducted VBN N
in IN N
opioid-tolerant JJ N
male NN N
and CC N
female JJ N
patients NNS N
( ( N
aged VBN N
> NN N
or CC N
=17 CD N
years NNS N
) ) N
with IN N
BTcP NNP N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
at IN N
36 CD N
centers NNS N
across IN N
the DT N
USA NNP N
. . N

The DT N
study NN N
comprised VBD N
a DT N
2-week JJ N
open-label JJ N
titration NN N
phase NN N
, , N
followed VBN N
by IN N
a DT N
double-blind JJ N
efficacy NN N
phase NN N
, , N
during IN N
which WDT N
patients NNS N
received VBD N
sublingual JJ N
fentanyl NN N
citrate NN N
orally RB N
disintegrating VBG N
tablet NN N
( ( N
sublingual JJ N
fentanyl NN N
ODT NNP N
) ) N
or CC N
placebo NN N
, , N
in IN N
a DT N
random JJ N
order NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
the DT N
sum NN N
of IN N
pain NN N
intensity NN N
difference NN N
( ( N
SPID NNP N
) ) N
over IN N
30 CD N
min JJ N
post-administration NN N
. . N

Secondary JJ N
efficacy NN N
endpoints NNS N
included VBD N
pain NN N
intensity NN N
difference NN N
( ( N
PID NNP N
) ) N
and CC N
pain NN N
relief NN N
( ( N
PR NNP N
) ) N
throughout IN N
the DT N
60-min JJ N
post-dose JJ N
assessment NN N
period NN N
. . N

Following VBG N
efficacy NN N
evaluation NN N
, , N
patients NNS N
entered VBD N
a DT N
long-term JJ N
safety NN N
phase NN N
of IN N
up IN N
to TO N
12 CD N
months NNS N
. . N

Adverse JJ N
events NNS N
were VBD N
recorded VBN N
throughout IN N
the DT N
study NN N
. . N

[ VB N
CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
NCT00262678 NNP N
] NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
131 CD N
patients NNS N
entered VBD N
the DT N
titration NN N
phase NN N
, , N
of IN N
whom WP N
61 CD N
were VBD N
included VBN N
in IN N
the DT N
primary JJ N
efficacy NN N
analysis NN N
. . N

Sublingual JJ N
fentanyl NN N
ODT NNP N
provided VBD N
significant JJ N
improvements NNS N
in IN N
SPID NNP N
relative VBP N
to TO N
placebo VB N
at IN N
30 CD N
min NN N
( ( N
49.5 CD N
vs. FW N
36.6 CD N
, , N
p NN N
= NNP N
0.0004 CD N
) ) N
and CC N
60 CD N
min NNS N
post-administration NN N
( ( N
143.0 CD N
vs. FW N
104.5 CD N
, , N
p NN N
= NNP N
0.0002 CD N
) ) N
. . N

Furthermore UH N
, , N
sublingual JJ N
fentanyl NN N
ODT NNP N
provided VBD N
significant JJ N
improvements NNS N
in IN N
PID NNP N
and CC N
PR NNP N
compared VBN N
to TO N
placebo VB N
, , N
from IN N
10 CD N
min NNS N
post-dose JJ N
( ( N
p JJ N
= NN N
0.0055 CD N
and CC N
p VB N
= $ N
0.049 CD N
for IN N
PID NNP N
and CC N
PR NNP N
, , N
respectively RB N
) ) N
. . N

Patient JJ N
recruitment NN N
was VBD N
stopped VBN N
early RB N
, , N
due JJ N
to TO N
positive JJ N
interim JJ N
analysis NN N
results NNS N
( ( N
significant JJ N
at IN N
prespecified JJ N
level NN N
, , N
p JJ N
< NN N
or CC N
= VB N
0.0414 CD N
) ) N
. . N

Overall JJ N
, , N
sublingual JJ N
fentanyl NN N
ODT NNP N
was VBD N
well-tolerated JJ N
both DT N
systemically RB N
and CC N
sublingually RB N
, , N
with IN N
41 CD N
patients NNS N
experiencing VBG N
> NN N
or CC N
=1 NN N
study NN N
drug-related JJ N
adverse JJ N
event NN N
( ( N
AE NNP N
) ) N
. . N

The DT N
most RBS N
common JJ N
AEs NNP N
included VBD N
nausea NN N
( ( N
12.2 CD N
% NN N
) ) N
, , N
vomiting VBG N
( ( N
5.3 CD N
% NN N
) ) N
and CC N
somnolence NN N
( ( N
4.6 CD N
% NN N
) ) N
. . N

One CD N
serious JJ N
AE NNP N
( ( N
mild JJ N
affect VBP N
lability NN N
) ) N
was VBD N
considered VBN N
possibly RB N
related VBN N
to TO N
study VB N
medication NN N
. . N

The DT N
observed JJ N
pattern NN N
of IN N
AEs NNP N
was VBD N
consistent JJ N
with IN N
that DT N
previously RB N
observed VBN N
with IN N
fentanyl NN N
. . N

CONCLUSIONS NNP N
Sublingual NNP N
fentanyl NN N
ODT NNP N
was VBD N
efficacious JJ N
and CC N
well-tolerated JJ N
for IN N
the DT N
treatment NN N
of IN N
BTcP NNP N
in IN N
opioid-tolerant JJ N
patients NNS N
with IN N
cancer NN N
. . N

Sublingual JJ N
fentanyl NN N
ODT NNP N
provided VBD N
significant JJ N
improvements NNS N
in IN N
pain NN N
intensity NN N
compared VBN N
to TO N
placebo VB N
, , N
from IN N
10 CD N
min JJ N
post-administration NN N
and CC N
throughout IN N
the DT N
60-min JJ N
post-dose JJ N
assessment NN N
period NN N
. . N

Sublingual JJ N
fentanyl NN N
ODT NNP N
was VBD N
well RB N
tolerated VBN N
over IN N
12 CD N
months NNS N
of IN N
treatment NN N
. . N

-DOCSTART- -1835223- O O

Intravenous JJ N
or CC N
intramuscular JJ N
teicoplanin NN N
once RB N
daily JJ N
for IN N
skin NN N
and CC N
soft-tissue JJ N
infections NNS N
. . N

Teicoplanin NNP N
is VBZ N
a DT N
new JJ N
glycopeptide NN N
antibiotic JJ N
with IN N
potent JJ N
activity NN N
against IN N
gram-positive JJ N
bacteria NNS N
and CC N
pharmacokinetics NNS N
that WDT N
allow VBP N
once RB N
daily JJ N
administration NN N
. . N

To TO N
study VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
teicoplanin NN N
for IN N
skin NN N
and CC N
soft-tissue NN N
infections NNS N
, , N
75 CD N
patients NNS N
received VBD N
teicoplanin JJ N
intravenously RB N
( ( N
38 CD N
) ) N
or CC N
intramuscularly RB N
( ( N
37 CD N
, , N
of IN N
which WDT N
16 CD N
were VBD N
outpatients NNS N
) ) N
. . N

Of IN N
62 CD N
clinically RB N
evaluable JJ N
patients NNS N
, , N
97 CD N
percent NN N
of IN N
teicoplanin NN N
iv NN N
and CC N
93 CD N
percent NN N
of IN N
teicoplanin NN N
im NN N
patients NNS N
were VBD N
cured VBN N
or CC N
improved VBN N
. . N

All DT N
teicoplanin JJ N
iv NN N
patients NNS N
and CC N
64 CD N
percent NN N
of IN N
teicoplanin NN N
im NN N
patients NNS N
were VBD N
cured VBN N
microbiologically RB N
at IN N
24-48 JJ N
hours NNS N
posttherapy NN N
. . N

Persistence NN N
of IN N
organisms NNS N
frequently RB N
was VBD N
associated VBN N
with IN N
skin JJ N
ulcers NNS N
or CC N
abscess JJ N
cavities NNS N
and CC N
usually RB N
had VBD N
no DT N
bearing NN N
on IN N
clinical JJ N
outcome NN N
. . N

Possible JJ N
adverse JJ N
clinical JJ N
and CC N
laboratory JJ N
reactions NNS N
caused VBN N
by IN N
teicoplanin NN N
occurred VBD N
in IN N
4 CD N
of IN N
38 CD N
teicoplanin JJ N
iv NN N
patients NNS N
( ( N
11 CD N
percent NN N
) ) N
and CC N
in IN N
8 CD N
of IN N
37 CD N
teicoplanin JJ N
im NN N
patients NNS N
( ( N
22 CD N
percent NN N
) ) N
. . N

Reactions NNPS N
were VBD N
mild JJ N
and CC N
resolved VBN N
with IN N
discontinuation NN N
of IN N
teicoplanin NN N
in IN N
most JJS N
cases NNS N
. . N

In IN N
this DT N
study NN N
, , N
teicoplanin NN N
appeared VBD N
to TO N
be VB N
safe JJ N
, , N
efficacious JJ N
, , N
and CC N
convenient NN N
for IN N
both DT N
hospital JJ N
staff NN N
and CC N
patients NNS N
, , N
and CC N
potentially RB N
cost-effective JJ N
for IN N
the DT N
treatment NN N
of IN N
skin NN N
and CC N
soft-tissue JJ N
infections NNS N
. . N

In IN N
particular JJ N
, , N
teicoplanin JJ N
appears VBZ N
to TO N
be VB N
appropriate JJ N
for IN N
outpatient JJ N
parenteral JJ N
therapy NN N
. . N

-DOCSTART- -16146466- O O

Hyperbaric NNP N
oxygen NN N
attenuation NN N
of IN N
lipopolysaccharide-induced JJ N
acute NN N
lung NN N
injury NN N
involves VBZ N
heme JJ N
oxygenase-1 NN N
. . N

BACKGROUND NNP N
Hyperbaric NNP N
oxygen NN N
( ( N
HBO NNP N
) ) N
attenuates VBZ N
lipopolysaccharide JJ N
( ( N
LPS NNP N
) ) N
-induced VBD N
acute JJ N
lung NN N
injury NN N
. . N

This DT N
beneficial JJ N
effect NN N
of IN N
HBO NNP N
involves VBZ N
inhibition NN N
of IN N
inducible JJ N
nitric JJ N
oxide NN N
synthase NN N
( ( N
iNOS NN N
) ) N
expression NN N
and CC N
subsequent JJ N
nitric JJ N
oxide NN N
( ( N
NO NNP N
) ) N
biosynthesis NN N
. . N

We PRP N
sought VBD N
to TO N
investigate VB N
the DT N
role NN N
of IN N
heme JJ N
oxygenase-1 JJ N
( ( N
HO-1 NNP N
) ) N
on IN N
this DT N
HBO NNP N
inhibition NN N
of IN N
iNOS JJ N
induction NN N
and CC N
acute NN N
lung NN N
injury NN N
in IN N
septic JJ N
rat NN N
lungs NNS N
. . N

METHODS NNP N
Before IN N
the DT N
experiment NN N
, , N
72 CD N
rats NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
HBO NNP N
or CC N
air NN N
treatment NN N
. . N

With IN N
or CC N
without IN N
HBO NNP N
pre-treatment NN N
, , N
the DT N
rats NNS N
were VBD N
further RB N
divided VBN N
into IN N
the DT N
following JJ N
subgroups NNS N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
: : N
( ( N
i NN N
) ) N
LPS NNP N
injection NN N
, , N
( ( N
ii NN N
) ) N
normal JJ N
saline NN N
( ( N
N/S NNP N
) ) N
injection NN N
, , N
( ( N
iii NN N
) ) N
hemin NN N
( ( N
a DT N
HO-1 NNP N
inducer NN N
) ) N
plus CC N
LPS NNP N
, , N
( ( N
iv NN N
) ) N
hemin NN N
alone RB N
, , N
( ( N
v NN N
) ) N
tin NN N
protoporphyrin NN N
( ( N
SnPP NNP N
; : N
a DT N
HO-1 NNP N
inhibitor NN N
) ) N
plus CC N
LPS NNP N
, , N
and CC N
( ( N
vi NN N
) ) N
SnPP NNP N
alone RB N
. . N

All DT N
rats NNS N
were VBD N
maintained VBN N
for IN N
6 CD N
h NN N
and CC N
then RB N
sacrificed VBD N
with IN N
a DT N
high-dose JJ N
pentobarbital JJ N
injection NN N
. . N

Lung NNP N
injuries NNS N
and CC N
relevant JJ N
enzymes NNS N
expression NN N
were VBD N
thus RB N
assayed VBN N
. . N

RESULTS NNP N
Histological NNP N
analysis NN N
, , N
PMNs/alveoli NNP N
ratio NN N
, , N
and CC N
wet/dry JJ N
weight NN N
ratio NN N
measurements NNS N
demonstrated VBD N
that IN N
LPS NNP N
caused VBD N
significant JJ N
lung JJ N
injury NN N
and CC N
HBO NNP N
and/or VBP N
hemin NN N
significantly RB N
attenuated VBD N
this DT N
LPS-induced JJ N
lung NN N
injury NN N
. . N

Increased VBD N
pulmonary JJ N
iNOS NN N
expression NN N
and CC N
NO DT N
production NN N
were VBD N
associated VBN N
with IN N
lung JJ N
injury NN N
. . N

Induction NN N
of IN N
HO-1 NNP N
, , N
by IN N
HBO NNP N
and/or NN N
hemin NN N
, , N
significantly RB N
attenuated VBD N
this DT N
LPS-induced JJ N
iNOS NN N
expression NN N
and CC N
acute NN N
lung NN N
injury NN N
. . N

SnPP NNP N
, , N
on IN N
the DT N
contrary JJ N
, , N
offset VB N
the DT N
effects NNS N
of IN N
HBO NNP N
and CC N
worsened VBD N
the DT N
LPS-induced NNP N
lung NN N
injury NN N
. . N

CONCLUSIONS NNP N
HBO NNP N
may MD N
act VB N
through IN N
inhibiting VBG N
pulmonary JJ N
iNOS NN N
expression NN N
to TO N
attenuate VB N
LPS-induced NNP N
acute NN N
lung NN N
injury NN N
in IN N
septic JJ N
rats NNS N
. . N

Furthermore RB N
, , N
this DT N
HBO NNP N
attenuation NN N
of IN N
iNOS JJ N
expression NN N
involves VBZ N
HO-1 NNP N
induction NN N
. . N

-DOCSTART- -23332872- O O

Are NNP N
tyrosine JJ N
kinase NN N
inhibitors NNS N
still RB N
active JJ N
in IN N
patients NNS N
with IN N
metastatic JJ N
renal NN N
cell NN N
carcinoma VBZ N
previously RB N
treated VBN N
with IN N
a DT N
tyrosine JJ N
kinase NN N
inhibitor NN N
and CC N
everolimus VB N
? . N
Experience NNP N
of IN N
36 CD N
patients NNS N
treated VBN N
in IN N
France NNP N
in IN N
the DT N
RECORD-1 JJ N
Trial NNP N
. . N

BACKGROUND NNP N
Because IN N
the DT N
response NN N
to TO N
treatment NN N
is VBZ N
limited JJ N
, , N
patients NNS N
with IN N
metastatic JJ N
renal NN N
cell NN N
carcinoma NN N
( ( N
mRCC NN N
) ) N
typically RB N
receive JJ N
multiple NN N
treatments NNS N
. . N

Guidelines NNS N
recommend VBP N
everolimus NN N
for IN N
patients NNS N
previously RB N
treated VBN N
with IN N
tyrosine JJ N
kinase NN N
inhibitors NNS N
( ( N
TKI NNP N
) ) N
sunitinib NN N
or CC N
sorafenib NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
TKI NNP N
re-treatment NN N
in IN N
patients NNS N
with IN N
disease JJ N
progression NN N
after IN N
a DT N
TKI-everolimus JJ N
sequence NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Data NNP N
were VBD N
reviewed VBN N
for IN N
patients NNS N
enrolled VBN N
in IN N
RECORD-1 NNP N
( ( N
Renal NNP N
Cell NNP N
Cancer NNP N
Treatment NNP N
With IN N
Oral NNP N
RAD001 NNP N
Given NNP N
Daily NNP N
) ) N
at IN N
French JJ N
sites NNS N
. . N

Response NNP N
, , N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
, , N
and CC N
overall JJ N
survival NN N
were VBD N
evaluated VBN N
in IN N
patients NNS N
treated VBN N
with IN N
a DT N
TKI-everolimus-TKI JJ N
sequence NN N
. . N

RESULTS NNP N
Thirty-six JJ N
patients NNS N
received VBD N
a DT N
TKI NNP N
after IN N
everolimus NN N
: : N
sunitinib NN N
in IN N
17 CD N
patients NNS N
, , N
sorafenib NN N
in IN N
15 CD N
, , N
and CC N
dovitinib NN N
( ( N
TKI258 NNP N
) ) N
in IN N
4 CD N
. . N

The DT N
response NN N
rate NN N
with IN N
TKI NNP N
re-treatment NN N
was VBD N
8 CD N
% NN N
, , N
and CC N
the DT N
disease-control JJ N
rate NN N
( ( N
response NN N
plus CC N
stable JJ N
disease NN N
) ) N
was VBD N
75 CD N
% NN N
. . N

The DT N
median JJ N
PFS NNP N
with IN N
each DT N
component NN N
of IN N
the DT N
TKI-everolimus-TKI NNP N
sequence NN N
was VBD N
10.7 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.8-28.5 JJ N
months NNS N
) ) N
, , N
8.9 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.7-34.6 JJ N
months NNS N
) ) N
, , N
and CC N
8.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
5.2-11.9 JJ N
months NNS N
) ) N
, , N
respectively RB N
. . N

The DT N
median JJ N
overall JJ N
survival NN N
from IN N
the DT N
start NN N
of IN N
everolimus NN N
was VBD N
29.1 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
21.1 CD N
to TO N
not RB N
reached VB N
months NNS N
) ) N
, , N
which WDT N
suggests VBZ N
a DT N
benefit NN N
in IN N
using VBG N
TKI NNP N
in IN N
this DT N
setting NN N
. . N

CONCLUSIONS NNP N
Administration NNP N
of IN N
a DT N
TKI-everolimus-TKI JJ N
sequence NN N
may MD N
be VB N
associated VBN N
with IN N
clinical JJ N
benefit NN N
and CC N
should MD N
be VB N
prospectively RB N
investigated VBN N
. . N

-DOCSTART- -18501909- O O

Penetration NN N
and CC N
accumulation NN N
of IN N
moxifloxacin NN N
in IN N
uterine JJ N
tissue NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
moxifloxacin NN N
penetrates VBZ N
the DT N
uterine JJ N
tissue NN N
and CC N
accumulates NNS N
at IN N
levels NNS N
sufficient JJ N
to TO N
eradicate VB N
the DT N
major JJ N
pathogens NNS N
causing VBG N
pelvic JJ N
inflammatory JJ N
disease NN N
( ( N
PID NNP N
) ) N
. . N

METHOD NNP N
In IN N
a DT N
prospective JJ N
, , N
multicenter NN N
, , N
open-label JJ N
, , N
parallel-group JJ N
study NN N
we PRP N
determined VBD N
the DT N
concentration NN N
of IN N
moxifloxacin NN N
in IN N
plasma NN N
and CC N
uterine JJ N
tissue NN N
after IN N
a DT N
single JJ N
, , N
400-mg JJ N
intravenous JJ N
dose NN N
of IN N
moxifloxacin NN N
. . N

Study NN N
participants NNS N
were VBD N
randomized VBN N
for IN N
time NN N
of IN N
tissue NN N
sampling NN N
, , N
which WDT N
was VBD N
performed VBN N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
7 CD N
, , N
or CC N
24 CD N
hours NNS N
following VBG N
the DT N
moxifloxacin JJ N
infusion NN N
. . N

RESULTS NNP N
Of IN N
43 CD N
participants NNS N
, , N
40 CD N
were VBD N
randomized VBN N
to TO N
tissue VB N
sampling VBG N
. . N

Moxifloxacin NNP N
accumulated VBD N
in IN N
uterine JJ N
tissue NN N
and CC N
concentrations NNS N
were VBD N
highest JJS N
1 CD N
hour NN N
after IN N
infusion NN N
in IN N
both DT N
plasma NN N
and CC N
tissue NN N
. . N

Tissue NN N
to TO N
plasma VB N
ratios NNS N
remained VBD N
between IN N
1.7 CD N
and CC N
2.1 CD N
for IN N
24 CD N
hours NNS N
. . N

Moxifloxacin NNP N
was VBD N
found VBN N
to TO N
be VB N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
known VBN N
minimum JJ N
inhibitory JJ N
concentration NN N
data NNS N
, , N
the DT N
uterine JJ N
tissue NN N
concentrations NNS N
of IN N
moxifloxacin NN N
achieved VBN N
over IN N
24 CD N
hours NNS N
would MD N
be VB N
sufficient JJ N
to TO N
eradicate VB N
the DT N
range NN N
of IN N
bacterial JJ N
pathogens NNS N
responsible JJ N
for IN N
PID NNP N
. . N

-DOCSTART- -1573044- O O

Comparative JJ N
drug NN N
effects NNS N
and CC N
abuse NN N
liability NN N
of IN N
lorazepam NN N
, , N
buspirone NN N
, , N
and CC N
secobarbital NN N
in IN N
nondependent JJ N
subjects NNS N
. . N

The DT N
pharmacologic JJ N
effects NNS N
of IN N
lorazepam NN N
( ( N
2 CD N
mg NN N
) ) N
, , N
buspirone NN N
( ( N
20 CD N
mg NN N
, , N
10 CD N
mg NN N
) ) N
, , N
secobarbital JJ N
( ( N
100 CD N
mg NN N
) ) N
, , N
and CC N
placebo NN N
were VBD N
compared VBN N
in IN N
15 CD N
male NN N
, , N
experienced VBD N
, , N
intermittent JJ N
nontherapeutic JJ N
drug NN N
users NNS N
. . N

All DT N
drugs NNS N
produced VBD N
a DT N
drug NN N
effect NN N
, , N
however RB N
, , N
buspirone RB N
20 CD N
mg NN N
was VBD N
significantly RB N
less JJR N
liked JJ N
than IN N
were VBD N
lorazepam JJ N
, , N
secobarbital JJ N
, , N
or CC N
buspirone RB N
10 CD N
mg NN N
( ( N
p NN N
less JJR N
than IN N
.05 NN N
) ) N
but CC N
not RB N
placebo VB N
. . N

Lorazepam NNP N
was VBD N
liked VBN N
better RBR N
than IN N
were VBD N
other JJ N
drugs NNS N
only RB N
at IN N
1 CD N
hour NN N
and CC N
only RB N
compared VBN N
with IN N
buspirone NN N
20 CD N
and CC N
placebo NN N
. . N

Compared VBN N
with IN N
other JJ N
drugs NNS N
, , N
lorazepam JJ N
drug NN N
effects NNS N
were VBD N
greater JJR N
and CC N
resulted VBD N
in IN N
more RBR N
prolonged JJ N
impairment NN N
of IN N
a DT N
motor NN N
tracking VBG N
task NN N
, , N
standing VBG N
steadiness NN N
, , N
and CC N
memory NN N
. . N

Buspirone CD N
20 CD N
mg NNS N
significantly RB N
impaired JJ N
memory NN N
at IN N
1 CD N
hour NN N
compared VBN N
with IN N
placebo NN N
. . N

Subjects NNS N
were VBD N
more RBR N
likely JJ N
to TO N
identify VB N
buspirone NN N
as IN N
unfamiliar JJ N
. . N

Because IN N
buspirone NN N
20 CD N
mg NN N
was VBD N
less JJR N
liked JJ N
than IN N
were VBD N
other JJ N
drugs NNS N
, , N
dose JJ N
escalation NN N
as IN N
part NN N
of IN N
drug NN N
abuse NN N
is VBZ N
not RB N
likely JJ N
to TO N
occur VB N
. . N

Lorazepam NNP N
also RB N
was VBD N
not RB N
particularly RB N
liked VBN N
and CC N
was VBD N
not RB N
different JJ N
from IN N
placebo NN N
on IN N
most JJS N
subjective JJ N
abuse-relevant JJ N
measures NNS N
. . N

-DOCSTART- -21439528- O O

Efficacy NN N
and CC N
safety NN N
of IN N
transient JJ N
ulnar JJ N
artery NN N
compression NN N
to TO N
recanalize VB N
acute JJ N
radial JJ N
artery NN N
occlusion NN N
after IN N
transradial JJ N
catheterization NN N
. . N

Radial JJ N
artery NN N
occlusion NN N
( ( N
RAO NNP N
) ) N
can MD N
result VB N
from IN N
transradial JJ N
catheterization NN N
. . N

We PRP N
compared VBN N
the DT N
incidence NN N
of IN N
RAO NNP N
with IN N
2 CD N
heparin JJ N
dosage NN N
regimens NNS N
after IN N
transradial JJ N
coronary JJ N
angiography NN N
, , N
and CC N
we PRP N
evaluated VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
transient JJ N
homolateral JJ N
ulnar JJ N
artery NN N
compression NN N
to TO N
achieve VB N
acute JJ N
radial JJ N
artery NN N
recanalization NN N
. . N

Patients NNS N
referred VBD N
for IN N
coronary JJ N
angiography NN N
were VBD N
randomized VBN N
to TO N
very-low-dose JJ N
heparin NN N
( ( N
2,000 CD N
IU NNP N
) ) N
or CC N
low-dose JJ N
heparin NN N
( ( N
5,000 CD N
IU NNP N
) ) N
. . N

On IN N
sheath NN N
removal NN N
, , N
hemostasis NN N
was VBD N
obtained VBN N
using VBG N
the DT N
TR NNP N
band NN N
with IN N
a DT N
plethysmography-guided JJ N
patent NN N
hemostasis NN N
technique NN N
. . N

In IN N
the DT N
case NN N
of IN N
RAO NNP N
as IN N
assessed VBN N
by IN N
duplex JJ N
ultrasonography NN N
3 CD N
to TO N
4 CD N
hours NNS N
after IN N
hemostasis NN N
, , N
immediate JJ N
1-hour JJ N
ulnar JJ N
artery NN N
compression NN N
was VBD N
applied VBN N
. . N

Hematomas NNP N
> VBD N
15 CD N
cm NN N
( ( N
2 CD N
) ) N
were VBD N
also RB N
assessed VBN N
. . N

We PRP N
randomized VBD N
465 CD N
patients NNS N
, , N
222 CD N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
243 CD N
in IN N
the DT N
5,000-IU JJ N
group NN N
. . N

The DT N
baseline NN N
and CC N
procedural JJ N
characteristics NNS N
were VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
incidence NN N
of IN N
initial JJ N
RAO NNP N
was VBD N
5.9 CD N
% NN N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
2.9 CD N
% NN N
in IN N
the DT N
5,000-IU JJ N
group NN N
( ( N
p JJ N
= NNP N
0.17 CD N
) ) N
, , N
with IN N
a DT N
compression NN N
time NN N
of IN N
2.10 CD N
? . N
0.78 CD N
hours NNS N
and CC N
2.25 CD N
? . N
0.82 CD N
hours NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.051 CD N
) ) N
. . N

After IN N
ulnar JJ N
artery NN N
compression NN N
, , N
the DT N
final JJ N
incidence NN N
of IN N
RAO NNP N
was VBD N
4.1 CD N
% NN N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
0.8 CD N
% NN N
in IN N
the DT N
5,000-IU JJ N
group NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
local JJ N
hematoma NN N
was VBD N
2.3 CD N
% NN N
and CC N
3.7 CD N
% NN N
in IN N
the DT N
2,000- JJ N
and CC N
5,000-IU JJ N
groups NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.42 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
acute JJ N
RAO NNP N
after IN N
transradial JJ N
catheterization NN N
can MD N
be VB N
recanalized VBN N
by IN N
early JJ N
1-hour JJ N
homolateral JJ N
ulnar JJ N
artery NN N
compression NN N
. . N

This DT N
simple JJ N
nonpharmacologic JJ N
method NN N
was VBD N
effective JJ N
and CC N
safe JJ N
in IN N
patients NNS N
with IN N
very-low- JJ N
and CC N
low-dose JJ N
heparin NN N
. . N

Nevertheless NNP N
, , N
the DT N
incidence NN N
of IN N
final JJ N
RAO NNP N
remained VBD N
significantly RB N
lower JJR N
after IN N
a DT N
higher JJR N
anticoagulation NN N
level NN N
. . N

-DOCSTART- -8437833- O O

Diode NNP N
laser NN N
photocoagulation NN N
for IN N
threshold JJ N
retinopathy NN N
of IN N
prematurity NN N
. . N

A DT N
randomized JJ N
study NN N
. . N

BACKGROUND NNP N
Although IN N
peripheral JJ N
cryotherapy NN N
decreases VBZ N
the DT N
incidence NN N
of IN N
unfavorable JJ N
anatomic JJ N
outcomes NNS N
in IN N
threshold JJ N
retinopathy NN N
of IN N
prematurity NN N
( ( N
ROP NNP N
) ) N
, , N
apnea RB N
, , N
bradycardia NN N
, , N
and CC N
lid JJ N
edema NN N
can MD N
occur VB N
. . N

Argon NNP N
laser NN N
indirect JJ N
ophthalmoscope NN N
photocoagulation NN N
has VBZ N
been VBN N
used VBN N
as IN N
an DT N
alternative NN N
to TO N
cryotherapy VB N
, , N
with IN N
fewer JJR N
adverse JJ N
effects NNS N
. . N

Retinal JJ N
lesions NNS N
placed VBN N
with IN N
diode NN N
lasers NNS N
are VBP N
deeper JJR N
than IN N
similar JJ N
argon NN N
laser NN N
lesions NNS N
, , N
and CC N
it PRP N
is VBZ N
not RB N
known VBN N
whether IN N
this DT N
difference NN N
could MD N
influence VB N
the DT N
response NN N
to TO N
ablative JJ N
therapy NN N
. . N

METHODS JJ N
Patients NNPS N
were VBD N
enrolled VBN N
under IN N
a DT N
prospective JJ N
, , N
randomized VBN N
protocol NN N
. . N

One CD N
eye NN N
of IN N
each DT N
patient NN N
with IN N
symmetric JJ N
, , N
threshold JJ N
ROP NNP N
was VBD N
treated VBN N
with IN N
an DT N
814/815 CD N
nm JJ N
diode NN N
laser NN N
, , N
while IN N
the DT N
other JJ N
eye NN N
was VBD N
treated VBN N
with IN N
cryotherapy NN N
. . N

Patients NNS N
with IN N
asymmetric JJ N
diseases NNS N
also RB N
were VBD N
randomized VBN N
for IN N
treatment NN N
in IN N
the DT N
threshold NN N
eye NN N
. . N

RESULTS NNP N
Nineteen JJ N
infants NNS N
( ( N
33 CD N
eyes NNS N
) ) N
were VBD N
treated VBN N
, , N
ranging VBG N
from IN N
485 CD N
to TO N
863 CD N
g NNS N
birth JJ N
weight NN N
( ( N
23 CD N
to TO N
27 CD N
weeks NNS N
gestational JJ N
age NN N
) ) N
; : N
18 CD N
patients NNS N
( ( N
32 CD N
eyes NNS N
) ) N
were VBD N
followed VBN N
for IN N
3 CD N
months NNS N
or CC N
longer JJR N
. . N

Four CD N
patients NNS N
( ( N
8 CD N
eyes NNS N
) ) N
had VBD N
bilateral JJ N
zone CD N
1 CD N
disease NN N
. . N

Postconceptional JJ N
age NN N
was VBD N
36 CD N
to TO N
45 CD N
weeks NNS N
at IN N
the DT N
time NN N
of IN N
treatment NN N
. . N

The DT N
diode NN N
laser NN N
treatment NN N
was VBD N
better RBR N
tolerated VBN N
than IN N
cryotherapy NN N
, , N
and CC N
the DT N
treatment NN N
apparatus NN N
was VBD N
more RBR N
easily RB N
transported VBN N
. . N

Apneic NNP N
episodes VBZ N
requiring VBG N
intubation NN N
resulted VBD N
from IN N
two CD N
cryotherapy NN N
sessions NNS N
but CC N
no DT N
diode NN N
laser NN N
sessions NNS N
. . N

Five CD N
cryotherapy-treated JJ N
eyes NNS N
required VBN N
retreatment NN N
because IN N
of IN N
persistent JJ N
disease NN N
with IN N
adjacent JJ N
skip NN N
areas NNS N
. . N

In IN N
the DT N
group NN N
followed VBD N
for IN N
3 CD N
to TO N
15 CD N
months NNS N
, , N
1 CD N
cryotherapy-treated JJ N
eye NN N
and CC N
1 CD N
diode NN N
laser-treated JJ N
eye NN N
progressed VBD N
to TO N
stage VB N
5 CD N
retinal JJ N
detachment NN N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
cryotherapy NN N
, , N
the DT N
diode NN N
laser NN N
was VBD N
more RBR N
convenient JJ N
, , N
technically RB N
easier JJR N
to TO N
administer VB N
, , N
and CC N
better RB N
tolerated VBN N
by IN N
the DT N
patient NN N
. . N

Although IN N
the DT N
number NN N
of IN N
patients NNS N
was VBD N
too RB N
small JJ N
for IN N
meaningful JJ N
statistical JJ N
analysis NN N
of IN N
outcome NN N
, , N
diode VB N
laser RBR N
peripheral JJ N
retinal JJ N
ablation NN N
appeared VBD N
to TO N
be VB N
as RB N
effective JJ N
as IN N
cryotherapy NN N
for IN N
the DT N
treatment NN N
of IN N
threshold JJ N
ROP NNP N
. . N

-DOCSTART- -18397386- O O

Clinical JJ N
trial NN N
: : N
exposure NN N
to TO N
ribavirin VB N
predicts NNS N
EVR NNP N
and CC N
SVR NNP N
in IN N
patients NNS N
with IN N
HCV NNP N
genotype NN N
1 CD N
infection NN N
treated VBN N
with IN N
peginterferon NN N
alpha-2a JJ N
plus CC N
ribavirin JJ N
. . N

BACKGROUND VB N
The DT N
impact NN N
of IN N
reduced JJ N
drug NN N
exposure NN N
on IN N
outcomes NNS N
in IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
has VBZ N
not RB N
been VBN N
determined VBN N
in IN N
routine JJ N
clinical JJ N
practice NN N
. . N

AIM NNP N
To TO N
examine VB N
the DT N
impact NN N
of IN N
exposure NN N
to TO N
peginterferon VB N
alpha-2a JJ N
and CC N
ribavirin VB N
on IN N
early JJ N
virological JJ N
response NN N
( ( N
EVR NNP N
) ) N
and CC N
sustained VBD N
virological JJ N
response NN N
( ( N
SVR NNP N
) ) N
in IN N
treatment-naive JJ N
patients NNS N
with IN N
HCV NNP N
genotype NN N
1 CD N
infection NN N
enrolled VBN N
in IN N
a DT N
large JJ N
expanded JJ N
access NN N
programme NN N
. . N

METHODS NNP N
Eight NNP N
hundred VBD N
and CC N
ninety-one JJ N
patients NNS N
treated VBD N
for IN N
48 CD N
weeks NNS N
with IN N
an DT N
initial JJ N
ribavirin NN N
dose NN N
of IN N
800 CD N
or CC N
1000/1200 CD N
mg/day NNS N
were VBD N
evaluated VBN N
. . N

Ribavirin JJ N
1000 CD N
mg/day NN N
( ( N
< JJ N
75 CD N
kg NN N
) ) N
or CC N
1200 CD N
mg/day NN N
( ( N
> JJ N
or=75 RB N
kg NN N
) ) N
and CC N
peginterferon VB N
alpha-2a JJ N
180 CD N
microg/week NN N
were VBD N
considered VBN N
optimal JJ N
. . N

The DT N
impact NN N
of IN N
reduced JJ N
drug NN N
exposure NN N
( ( N
expressed VBN N
as IN N
a DT N
percentage NN N
of IN N
optimal NN N
) ) N
on IN N
EVR NNP N
and CC N
SVR NNP N
was VBD N
evaluated VBN N
. . N

RESULTS JJ N
Mean NNP N
ribavirin NN N
exposure NN N
in IN N
week NN N
0-12 NN N
was VBD N
70 CD N
% NN N
and CC N
96 CD N
% NN N
in IN N
patients NNS N
assigned VBN N
to TO N
ribavirin VB N
800 CD N
and CC N
1000/1200 CD N
mg/day NN N
, , N
respectively RB N
. . N

EVR NNP N
and CC N
SVR NNP N
rates NNS N
were VBD N
lower JJR N
in IN N
patients NNS N
assigned VBN N
to TO N
ribavirin VB N
800 CD N
than IN N
1000/1200 CD N
mg/day NN N
( ( N
EVR NNP N
, , N
75 CD N
% NN N
vs. FW N
84 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
< NNP N
0.001 CD N
; : N
SVR NNP N
, , N
45 CD N
% NN N
vs. FW N
54 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
= NNP N
0.011 CD N
) ) N
. . N

Furthermore RB N
, , N
there EX N
was VBD N
a DT N
strong JJ N
correlation NN N
between IN N
achievement NN N
of IN N
EVR NNP N
and CC N
SVR NNP N
and CC N
ribavirin VB N
dose NN N
over IN N
the DT N
first JJ N
12 CD N
weeks NNS N
expressed VBD N
either CC N
as IN N
absolute JJ N
dose NN N
or CC N
proportion NN N
of IN N
optimal JJ N
dose NN N
received VBD N
( ( N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
) ) N
. . N

CONCLUSIONS NNP N
Ribavirin NNP N
exposure NN N
to TO N
week NN N
12 CD N
is VBZ N
significantly RB N
associated VBN N
with IN N
EVR NNP N
and CC N
SVR NNP N
in IN N
genotype JJ N
1 CD N
patients NNS N
. . N

Maintenance NNP N
of IN N
an DT N
optimal JJ N
ribavirin NN N
dose NN N
is VBZ N
the DT N
most RBS N
important JJ N
modifiable JJ N
factor NN N
during IN N
combination NN N
therapy NN N
for IN N
chronic JJ N
hepatitis NN N
C NNP N
. . N

-DOCSTART- -22692114- O O

The DT N
acute JJ N
effects NNS N
of IN N
fluid JJ N
intake NN N
on IN N
urine JJ N
specific JJ N
gravity NN N
and CC N
fluid JJ N
retention NN N
in IN N
a DT N
mildly RB N
dehydrated JJ N
state NN N
. . N

Many JJ N
athletes NNS N
arrive VBP N
at IN N
training NN N
sessions NNS N
and CC N
competitions NNS N
in IN N
a DT N
mildly RB N
hypohydrated VBN N
( ( N
HYPO NNP N
) ) N
state NN N
and CC N
are VBP N
instructed VBN N
to TO N
drink VB N
fluids NNS N
before IN N
exercise NN N
to TO N
reach VB N
a DT N
euhydrated JJ N
( ( N
HYD NNP N
) ) N
state NN N
. . N

Ten CD N
recreational JJ N
athletes NNS N
( ( N
6 CD N
women NNS N
, , N
4 CD N
men NNS N
; : N
71.9 CD N
? . N
4.6 CD N
kg NN N
, , N
25.2 CD N
? . N
0.9 CD N
years NNS N
) ) N
participated VBD N
in IN N
the DT N
studies NNS N
to TO N
examine VB N
( ( N
a DT N
) ) N
the DT N
day-to-day JJ N
variability NN N
of IN N
morning NN N
urine NN N
specific JJ N
gravity NN N
( ( N
USG NNP N
) ) N
, , N
( ( N
b NN N
) ) N
the DT N
effects NNS N
of IN N
consuming VBG N
600 CD N
ml NN N
of IN N
water NN N
on IN N
the DT N
hydration NN N
status NN N
of IN N
HYD NNP N
and CC N
HYPO NNP N
( ( N
USG NNP N
> NNP N
1.020 CD N
) ) N
subjects NNS N
, , N
and CC N
( ( N
c NN N
) ) N
the DT N
effects NNS N
of IN N
consuming VBG N
water NN N
( ( N
W NNP N
) ) N
, , N
salt-water JJ N
( ( N
SW NNP N
, , N
40 CD N
mM NN N
Na NNP N
) ) N
, , N
a DT N
carbohydrate-electrolyte JJ N
solution NN N
with IN N
3 CD N
% NN N
or CC N
light JJ N
carbohydrate NN N
( ( N
CES-L NNP N
, , N
20 CD N
mM NN N
Na NNP N
) ) N
or CC N
a DT N
CES NN N
with IN N
6 CD N
% NN N
carbohydrate NN N
( ( N
CES NNP N
, , N
20 CD N
mM NN N
Na NNP N
) ) N
on IN N
the DT N
hydration NN N
status NN N
of IN N
HYPO NNP N
subjects NNS N
. . N

The DT N
hydration NN N
status NN N
was VBD N
assessed VBN N
with IN N
USG NNP N
and CC N
body NN N
mass NN N
measures NNS N
and CC N
urine JJ N
volume NN N
collections NNS N
. . N

The DT N
day-to-day JJ N
variability NN N
in IN N
morning NN N
USG NNP N
( ( N
coefficient NN N
of IN N
variation NN N
= FW N
0.2 CD N
? . N
0.1 CD N
% NN N
) ) N
was VBD N
low JJ N
and CC N
the DT N
responses NNS N
to TO N
600 CD N
ml NN N
of IN N
W NNP N
ingestion NN N
were VBD N
repeatable JJ N
. . N

Pretrial JJ N
USG NNP N
was VBD N
1.022 CD N
? . N
0.001 CD N
in IN N
the DT N
HYPO NNP N
trial NN N
and CC N
decreased VBD N
< NNS N
1.020 CD N
by IN N
45 CD N
minutes NNS N
( ( N
1.013 CD N
? . N
0.003 CD N
) ) N
. . N

In IN N
the DT N
CES NNP N
study NN N
, , N
HYPO NNP N
subjects VBZ N
reached VBN N
HYD NNP N
status NN N
at IN N
45 CD N
minutes NNS N
in IN N
all DT N
conditions NNS N
( ( N
W NNP N
1.013 CD N
? . N
0.003 CD N
, , N
SW NNP N
1.013 CD N
? . N
0.003 CD N
, , N
CES-L NNP N
1.011 CD N
? . N
0.003 CD N
, , N
CES NNP N
1.017 CD N
? . N
0.004 CD N
) ) N
because IN N
salt NN N
or CC N
CES NNP N
ingestion NN N
did VBD N
not RB N
affect VB N
fluid NN N
retention NN N
( ( N
W NNP N
68 CD N
% NN N
, , N
SW NNP N
72 CD N
% NN N
, , N
CES-L JJ N
68 CD N
% NN N
, , N
CES NNP N
76 CD N
% NN N
) ) N
. . N

This DT N
study NN N
demonstrated VBD N
that IN N
mildly RB N
HYPO NNP N
subjects NNS N
could MD N
reach VB N
euhydration NN N
within IN N
45 CD N
minutes NNS N
of IN N
the DT N
ingestion NN N
of IN N
600 CD N
ml NN N
of IN N
W NNP N
or CC N
a DT N
combination NN N
of IN N
salt NN N
and CC N
CES NNP N
solutions NNS N
. . N

Following VBG N
this DT N
practice NN N
will MD N
minimize VB N
the DT N
incidence NN N
of IN N
starting VBG N
a DT N
practice NN N
or CC N
competition NN N
hypohydrated VBN N
. . N

-DOCSTART- -22610128- O O

Study NN N
of IN N
the DT N
therapeutic JJ N
effects NNS N
of IN N
a DT N
hippotherapy NN N
simulator NN N
in IN N
children NNS N
with IN N
cerebral JJ N
palsy NN N
: : N
a DT N
stratified JJ N
single-blind NN N
randomized VBD N
controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
whether IN N
hippotherapy NN N
( ( N
when WRB N
applied VBN N
by IN N
a DT N
simulator NN N
) ) N
improves VBZ N
postural JJ N
control NN N
and CC N
balance NN N
in IN N
children NNS N
with IN N
cerebral JJ N
palsy NN N
. . N

DESIGN NNP N
Stratified VBD N
single-blind JJ N
randomized NN N
controlled VBD N
trial NN N
with IN N
an DT N
independent JJ N
assessor NN N
. . N

Stratification NN N
was VBD N
made VBN N
by IN N
gross JJ N
motor NN N
function NN N
classification NN N
system NN N
levels NNS N
, , N
and CC N
allocation NN N
was VBD N
concealed VBN N
. . N

SUBJECTS NNP N
Children NNP N
between IN N
4 CD N
and CC N
18 CD N
years NNS N
old JJ N
with IN N
cerebral JJ N
palsy NN N
. . N

INTERVENTIONS JJ N
Participants NNS N
were VBD N
randomized VBN N
to TO N
an DT N
intervention NN N
( ( N
simulator NN N
ON NNP N
) ) N
or CC N
control NN N
( ( N
simulator VB N
OFF NNP N
) ) N
group NN N
after IN N
getting VBG N
informed JJ N
consent NN N
. . N

Treatment NNP N
was VBD N
provided VBN N
once RB N
a DT N
week NN N
( ( N
15 CD N
minutes NNS N
) ) N
for IN N
10 CD N
weeks NNS N
. . N

MAIN NNP N
MEASURES NNP N
Gross NNP N
Motor NNP N
Function NNP N
Measure NNP N
( ( N
dimension NN N
B NNP N
for IN N
balance NN N
and CC N
the DT N
Total NNP N
Score NNP N
) ) N
and CC N
Sitting VBG N
Assessment NNP N
Scale NNP N
were VBD N
carried VBN N
out RP N
at IN N
baseline NN N
( ( N
prior JJ N
to TO N
randomization NN N
) ) N
, , N
end NN N
of IN N
intervention NN N
and CC N
12 CD N
weeks NNS N
after IN N
completing VBG N
the DT N
intervention NN N
. . N

RESULTS NNP N
Thirty-eight JJ N
children NNS N
participated VBN N
. . N

The DT N
groups NNS N
were VBD N
balanced VBN N
at IN N
baseline NN N
. . N

Sitting VBG N
balance NN N
( ( N
measured VBN N
by IN N
dimension NN N
B NNP N
of IN N
the DT N
Gross NNP N
Motor NNP N
Function NNP N
Measure NNP N
) ) N
improved VBD N
significantly RB N
in IN N
the DT N
treatment NN N
group NN N
( ( N
effect NN N
size NN N
= $ N
0.36 CD N
; : N
95 CD N
% NN N
CI NNP N
0.01-0.71 NN N
) ) N
and CC N
the DT N
effect NN N
size NN N
was VBD N
greater JJR N
in IN N
the DT N
severely RB N
disabled JJ N
group NN N
( ( N
effect NN N
size NN N
= $ N
0.80 CD N
; : N
95 CD N
% NN N
CI NNP N
0.13-1.47 NN N
) ) N
. . N

The DT N
improvements NNS N
in IN N
sitting VBG N
balance NN N
were VBD N
not RB N
maintained VBN N
over IN N
the DT N
follow-up JJ N
period NN N
. . N

Changes NNS N
in IN N
the DT N
total JJ N
score NN N
of IN N
the DT N
Gross NNP N
Motor NNP N
Function NNP N
Measure NNP N
and CC N
the DT N
Sitting NNP N
Assessment NNP N
Scale NNP N
were VBD N
not RB N
significant JJ N
. . N

CONCLUSION NNP N
Hippotherapy NNP N
with IN N
a DT N
simulator NN N
can MD N
improve VB N
sitting VBG N
balance NN N
in IN N
cerebral JJ N
palsy NN N
children NNS N
who WP N
have VBP N
higher JJR N
levels NNS N
of IN N
disability NN N
. . N

However RB N
, , N
this DT N
did VBD N
not RB N
lead VB N
to TO N
a DT N
change NN N
in IN N
the DT N
overall JJ N
function NN N
of IN N
these DT N
children NNS N
( ( N
Gross NNP N
Motor NNP N
Function NNP N
Classification NNP N
System NNP N
level JJ N
V NNP N
) ) N
. . N

-DOCSTART- -23806094- O O

Randomized VBN N
trial NN N
of IN N
tailored JJ N
skin NN N
cancer NN N
prevention NN N
for IN N
children NNS N
: : N
the DT N
Project NNP N
SCAPE NNP N
family NN N
study NN N
. . N

This DT N
study NN N
evaluated VBD N
a DT N
tailored VBN N
intervention NN N
to TO N
promote VB N
sun NN N
protection NN N
in IN N
parents NNS N
and CC N
their PRP$ N
children NNS N
, , N
hypothesizing VBG N
that IN N
the DT N
tailored VBN N
intervention NN N
would MD N
lead VB N
to TO N
improved JJ N
skin NN N
cancer NN N
prevention NN N
behaviors NNS N
compared VBN N
to TO N
generic JJ N
materials NNS N
. . N

Families NNS N
were VBD N
recruited VBN N
through IN N
schools NNS N
and CC N
community NN N
centers NNS N
and CC N
were VBD N
included VBN N
if IN N
there EX N
was VBD N
1 CD N
child NN N
in IN N
Grades NNP N
1-3 JJ N
at IN N
moderate JJ N
to TO N
high JJ N
risk NN N
for IN N
skin JJ N
cancer NN N
. . N

Participants NNS N
were VBD N
randomized VBN N
into IN N
one CD N
of IN N
two CD N
intervention NN N
groups NNS N
: : N
a DT N
tailored JJ N
intervention NN N
, , N
in IN N
which WDT N
they PRP N
received VBD N
personalized JJ N
skin NN N
cancer NN N
education NN N
through IN N
the DT N
mail NN N
; : N
or CC N
a DT N
control NN N
group NN N
who WP N
received VBD N
generic JJ N
skin NN N
cancer NN N
information NN N
materials NNS N
. . N

Before IN N
and CC N
after IN N
intervention NN N
, , N
parents NNS N
completed VBD N
questionnaires NNS N
about IN N
their PRP$ N
and CC N
their PRP$ N
children NNS N
's POS N
skin NN N
cancer NN N
risk NN N
and CC N
prevention NN N
knowledge NN N
and CC N
behaviors NNS N
. . N

Parents NNS N
also RB N
completed VBD N
4-day JJ N
sun NN N
exposure NN N
and CC N
protection NN N
diaries NNS N
for IN N
their PRP$ N
child NN N
and CC N
themselves PRP N
. . N

Tailored VBN N
group NN N
participants NNS N
demonstrated VBD N
significantly RB N
greater JJR N
positive JJ N
changes NNS N
in IN N
prevention NN N
behavior NN N
after IN N
the DT N
intervention NN N
, , N
including VBG N
children NNS N
's POS N
use NN N
of IN N
sunscreen NN N
, , N
shirts NNS N
, , N
and CC N
hats NNS N
, , N
and CC N
parents NNS N
' POS N
use NN N
of IN N
shade NN N
, , N
and CC N
skin JJ N
examinations NNS N
. . N

Effect JJ N
sizes NNS N
were VBD N
small JJ N
and CC N
perceived JJ N
benefits NNS N
and CC N
social JJ N
norms NNS N
mediated VBN N
intervention NN N
effects NNS N
. . N

Findings NNS N
from IN N
this DT N
study NN N
support VBD N
the DT N
efficacy NN N
of IN N
focusing VBG N
tailored VBN N
communications NNS N
to TO N
families NNS N
in IN N
order NN N
to TO N
change VB N
skin JJ N
cancer NN N
prevention NN N
practices NNS N
in IN N
young JJ N
children NNS N
. . N

-DOCSTART- -22525955- O O

Longitudinal JJ N
follow-up NN N
of IN N
children NNS N
with IN N
autism NN N
receiving VBG N
targeted VBN N
interventions NNS N
on IN N
joint JJ N
attention NN N
and CC N
play NN N
. . N

OBJECTIVE CC N
This DT N
study NN N
examines VBZ N
the DT N
cognitive NN N
and CC N
language NN N
outcomes NNS N
of IN N
children NNS N
with IN N
an DT N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
over IN N
a DT N
5-year JJ N
period NN N
after IN N
receiving VBG N
targeted VBD N
early JJ N
interventions NNS N
that WDT N
focused VBD N
on IN N
joint JJ N
attention NN N
and CC N
play NN N
skills NNS N
. . N

METHOD NNP N
Forty NNP N
children NNS N
from IN N
the DT N
original JJ N
study NN N
( ( N
n JJ N
= NNP N
58 CD N
) ) N
had VBD N
complete JJ N
data NNS N
at IN N
the DT N
5-year JJ N
follow-up NN N
. . N

RESULTS NNP N
In IN N
all DT N
, , N
80 CD N
% NN N
of IN N
children NNS N
had VBD N
achieved VBN N
functional JJ N
use NN N
of IN N
spoken JJ N
language NN N
with IN N
baseline JJ N
play NN N
level NN N
predicting VBG N
spoken JJ N
language NN N
at IN N
the DT N
5-year JJ N
follow-up NN N
. . N

Of IN N
children NNS N
who WP N
were VBD N
using VBG N
spoken JJ N
language NN N
at IN N
age NN N
8 CD N
years NNS N
, , N
several JJ N
baseline NN N
behaviors NNS N
predicted VBD N
their PRP$ N
later JJ N
ability NN N
, , N
including VBG N
earlier JJR N
age NN N
of IN N
entry NN N
into IN N
the DT N
study NN N
, , N
initiating VBG N
joint JJ N
attention NN N
skill NN N
, , N
play VB N
level NN N
, , N
and CC N
assignment NN N
to TO N
either VB N
the DT N
joint JJ N
attention NN N
or CC N
symbolic JJ N
play NN N
intervention NN N
group NN N
. . N

Only RB N
baseline JJ N
play NN N
diversity NN N
predicted VBD N
cognitive JJ N
scores NNS N
at IN N
age NN N
8 CD N
years NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
is VBZ N
one CD N
of IN N
the DT N
only JJ N
long-term JJ N
follow-up JJ N
studies NNS N
of IN N
children NNS N
who WP N
participated VBD N
in IN N
preschool NN N
early JJ N
interventions NNS N
aimed VBN N
at IN N
targeting VBG N
core NN N
developmental NN N
difficulties NNS N
. . N

The DT N
study NN N
findings NNS N
suggest VBP N
that IN N
focusing VBG N
on IN N
joint JJ N
attention NN N
and CC N
play NN N
skills NNS N
in IN N
comprehensive JJ N
treatment NN N
models NNS N
is VBZ N
important JJ N
for IN N
long-term JJ N
spoken JJ N
language NN N
outcomes NNS N
. . N

-DOCSTART- -15564950- O O

Intranasal NNP N
nicotine NN N
for IN N
postoperative JJ N
pain NN N
treatment NN N
. . N

BACKGROUND NNP N
Despite IN N
pharmacological JJ N
treatment NN N
, , N
70-80 CD N
% NN N
of IN N
patients NNS N
report NN N
moderate VBP N
to TO N
severe VB N
pain NN N
after IN N
surgery NN N
. . N

Because IN N
nicotine NN N
has VBZ N
been VBN N
reported VBN N
to TO N
have VB N
analgesic JJ N
properties NNS N
in IN N
animal NN N
and CC N
human JJ N
volunteer NN N
studies NNS N
, , N
the DT N
authors NNS N
assessed VBD N
the DT N
analgesic JJ N
efficacy NN N
of IN N
a DT N
single JJ N
3 CD N
mg NN N
dose NN N
of IN N
nicotine JJ N
nasal NN N
spray NN N
administered VBD N
before IN N
emergence NN N
from IN N
general JJ N
anesthesia NN N
. . N

METHODS NNP N
The DT N
authors NNS N
conducted VBD N
a DT N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo NN N
controlled VBD N
trial NN N
of IN N
20 CD N
healthy JJ N
women NNS N
( ( N
mean JJ N
age NN N
45 CD N
( ( N
SD NNP N
8 CD N
) ) N
yr NN N
) ) N
who WP N
were VBD N
to TO N
undergo VB N
uterine JJ N
surgery NN N
through IN N
a DT N
low JJ N
transverse NN N
incision NN N
. . N

After IN N
the DT N
conclusion NN N
of IN N
surgery NN N
but CC N
before IN N
emergence NN N
from IN N
general JJ N
anesthesia NN N
, , N
the DT N
anesthesiologist NN N
administered VBD N
either CC N
nicotine JJ N
nasal NN N
spray NN N
or CC N
a DT N
placebo NN N
. . N

Numerical JJ N
analog NN N
pain NN N
score NN N
and CC N
morphine JJ N
utilization NN N
and CC N
hemodynamic JJ N
values NNS N
were VBD N
measured VBN N
for IN N
24 CD N
h. NN N
RESULTS NNP N
The DT N
patients NNS N
treated VBN N
with IN N
nicotine NN N
reported VBN N
lower JJR N
pain NN N
scores NNS N
during IN N
the DT N
first JJ N
hour NN N
after IN N
surgery NN N
( ( N
peak JJ N
numerical JJ N
analog NN N
score NN N
, , N
7.6 CD N
( ( N
SD NNP N
1.4 CD N
) ) N
versus NN N
5.3 CD N
( ( N
SD NNP N
1.6 CD N
) ) N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
used VBN N
half PDT N
the DT N
amount NN N
of IN N
morphine NN N
as IN N
the DT N
control NN N
group NN N
( ( N
12 CD N
( ( N
SD NNP N
6 CD N
) ) N
versus NN N
6 CD N
( ( N
SD NNP N
5 CD N
) ) N
mg NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Patients NNPS N
who WP N
received VBD N
nicotine NN N
still RB N
reported VBD N
less RBR N
pain NN N
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
24 CD N
h NN N
after IN N
surgery NN N
( ( N
1.5 CD N
( ( N
SD NNP N
0.5 CD N
) ) N
versus NN N
4.9 CD N
( ( N
SD NNP N
1.4 CD N
) ) N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Systolic JJ N
blood NN N
pressure NN N
was VBD N
lower JJR N
in IN N
the DT N
group NN N
that WDT N
received VBD N
nicotine JJ N
( ( N
105 CD N
( ( N
SD NNP N
3 CD N
) ) N
versus NN N
122 CD N
( ( N
SD NNP N
3 CD N
) ) N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
difference NN N
in IN N
diastolic JJ N
blood NN N
pressure NN N
or CC N
heart NN N
rate NN N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
a DT N
single JJ N
dose NN N
of IN N
nicotine JJ N
immediately RB N
before IN N
emergence NN N
from IN N
anesthesia NN N
was VBD N
associated VBN N
with IN N
significantly RB N
lower JJR N
reported VBD N
pain JJ N
scores NNS N
during IN N
the DT N
first JJ N
day NN N
after IN N
surgery NN N
. . N

The DT N
decreased JJ N
pain NN N
was VBD N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
morphine JJ N
utilization NN N
and CC N
the DT N
analgesic JJ N
effect NN N
of IN N
nicotine NN N
was VBD N
not RB N
associated VBN N
with IN N
hypertension NN N
or CC N
tachycardia NN N
. . N

-DOCSTART- -22548691- O O

Effectiveness NN N
of IN N
Dader NNP N
Method NNP N
for IN N
pharmaceutical JJ N
care NN N
on IN N
control NN N
of IN N
blood NN N
pressure NN N
and CC N
total JJ N
cholesterol NN N
in IN N
outpatients NNS N
with IN N
cardiovascular JJ N
disease NN N
or CC N
cardiovascular JJ N
risk NN N
: : N
EMDADER-CV JJ N
randomized NNS N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Although IN N
some DT N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
pharmacist JJ N
intervention NN N
can MD N
improve VB N
drug NN N
therapy NN N
among IN N
patients NNS N
with IN N
cardiovascular JJ N
disease NN N
( ( N
CVD NNP N
) ) N
, , N
more JJR N
evidence NN N
derived VBN N
from IN N
randomized VBN N
controlled VBN N
trials NNS N
( ( N
RCTs NNP N
) ) N
is VBZ N
needed VBN N
, , N
including VBG N
assessment NN N
of IN N
the DT N
effect NN N
of IN N
community NN N
pharmacist NN N
interventions NNS N
in IN N
patients NNS N
with IN N
CVD NNP N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
the DT N
Dader NNP N
Method NNP N
for IN N
pharmaceutical JJ N
care NN N
on IN N
achieving VBG N
therapeutic JJ N
goals NNS N
for IN N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
, , N
total JJ N
cholesterol NN N
( ( N
TC NNP N
) ) N
, , N
and CC N
both DT N
BP NNP N
and CC N
TC NNP N
( ( N
BP/TC NNP N
) ) N
in IN N
patients NNS N
with IN N
CVD NNP N
and/or VBP N
high JJ N
or CC N
intermediate JJ N
cardiovascular NN N
( ( N
CV NNP N
) ) N
risk NN N
attending VBG N
community NN N
pharmacies NNS N
in IN N
Spain NNP N
. . N

METHODS NNP N
Patients NNPS N
aged VBD N
25 CD N
to TO N
74 CD N
years NNS N
attending VBG N
community NN N
pharmacies NNS N
with IN N
a DT N
prescription NN N
for IN N
at IN N
least JJS N
1 CD N
drug NN N
indicated VBN N
for IN N
CVD NNP N
or CC N
CV NNP N
risk NN N
factors NNS N
were VBD N
randomized VBN N
to TO N
2 CD N
groups NNS N
: : N
an DT N
intervention NN N
group NN N
that WDT N
received VBD N
pharmaceutical JJ N
care NN N
, , N
which WDT N
was VBD N
provided VBN N
by IN N
specially RB N
trained JJ N
pharmacists NNS N
working VBG N
in IN N
collaboration NN N
with IN N
physicians NNS N
, , N
and CC N
a DT N
control NN N
group NN N
that WDT N
received VBD N
usual JJ N
care NN N
( ( N
routine JJ N
dispensing VBG N
counseling NN N
) ) N
and CC N
verbal JJ N
and CC N
written VBN N
counseling VBG N
regarding VBG N
CVD NNP N
prevention NN N
. . N

Patients NNS N
were VBD N
recruited VBN N
from IN N
December NNP N
2005 CD N
to TO N
September NNP N
2006 CD N
, , N
and CC N
both DT N
groups NNS N
were VBD N
followed VBN N
for IN N
8 CD N
months NNS N
. . N

Study NNP N
outcomes NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
at IN N
16 CD N
and CC N
32 CD N
weeks NNS N
after IN N
randomization NN N
. . N

The DT N
primary JJ N
outcome NN N
measures NNS N
were VBD N
the DT N
proportions NNS N
of IN N
patients NNS N
achieving VBG N
BP NNP N
, , N
TC NNP N
, , N
and CC N
BP/TC NNP N
therapeutic JJ N
goals NNS N
( ( N
BP NNP N
lower JJR N
than IN N
140/90 CD N
mm NNS N
Hg NNP N
for IN N
patients NNS N
with IN N
uncomplicated JJ N
hypertension NN N
and CC N
lower JJR N
than IN N
130/80 CD N
mm NNS N
Hg NNP N
for IN N
patients NNS N
with IN N
diabetes NNS N
, , N
chronic JJ N
kidney NN N
disease NN N
, , N
or CC N
history NN N
of IN N
myocardial JJ N
infarction NN N
or CC N
stroke NN N
; : N
TC NNP N
lower JJR N
than IN N
200 CD N
mg NNS N
per IN N
dL NN N
for IN N
patients NNS N
without IN N
CVD NNP N
and CC N
lower JJR N
than IN N
175 CD N
mg NNS N
per IN N
dL NN N
for IN N
patients NNS N
with IN N
CVD NNP N
) ) N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
mean JJ N
BP NNP N
and CC N
TC NNP N
values NNS N
. . N

BP NNP N
was VBD N
assessed VBN N
manually RB N
by IN N
the DT N
pharmacist NN N
after IN N
a DT N
10-minute JJ N
rest NN N
in IN N
the DT N
supine JJ N
position NN N
. . N

This DT N
measurement NN N
was VBD N
performed VBN N
twice RB N
for IN N
every DT N
participant NN N
, , N
and CC N
the DT N
average NN N
of IN N
the DT N
2 CD N
measurements NNS N
was VBD N
calculated VBN N
. . N

TC NNP N
was VBD N
measured VBN N
by IN N
the DT N
pharmacist NN N
during IN N
the DT N
study NN N
visit NN N
using VBG N
the DT N
enzymatic JJ N
dry JJ N
method NN N
. . N

Statistical JJ N
analyses NNS N
were VBD N
performed VBN N
using VBG N
2-tailed JJ N
McNemar NNP N
tests NNS N
, , N
Pearson NNP N
chi-square NN N
tests NNS N
, , N
and CC N
Student NNP N
's POS N
t-tests NNS N
; : N
P NNP N
< VBD N
0.05 CD N
was VBD N
considered VBN N
statistically RB N
significant JJ N
. . N

RESULTS VB N
714 CD N
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
( ( N
356 CD N
intervention NN N
, , N
358 CD N
control NN N
) ) N
, , N
and CC N
the DT N
mean JJ N
[ NNP N
SD NNP N
] NNP N
age NN N
was VBD N
62.8 CD N
[ JJ N
8.1 CD N
] JJ N
years NNS N
. . N

The DT N
2 CD N
groups NNS N
were VBD N
similar JJ N
at IN N
baseline NN N
in IN N
clinical JJ N
and CC N
demographic JJ N
characteristics NNS N
, , N
including VBG N
the DT N
proportion NN N
of IN N
patients NNS N
at IN N
therapeutic JJ N
goals NNS N
for IN N
BP NNP N
, , N
TC NNP N
, , N
and CC N
BP/TC NNP N
. . N

After IN N
8 CD N
months NNS N
of IN N
follow-up NN N
, , N
there EX N
were VBD N
statistically RB N
significant JJ N
differences NNS N
in IN N
favor NN N
of IN N
pharmaceutical JJ N
care NN N
in IN N
the DT N
proportions NNS N
of IN N
patients NNS N
who WP N
achieved VBD N
therapeutic JJ N
goals NNS N
for IN N
BP NNP N
( ( N
52.5 CD N
% NN N
vs. FW N
43.0 CD N
% NN N
, , N
P=0.017 NNP N
) ) N
, , N
TC NNP N
( ( N
56.5 CD N
% NN N
vs. FW N
44.1 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
and CC N
BP/TC NNP N
( ( N
37.1 CD N
% NN N
vs. FW N
21.8 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
usual JJ N
care NN N
plus CC N
written VBN N
education NN N
, , N
pharmaceutical JJ N
care NN N
focused VBN N
on IN N
patient JJ N
evaluation NN N
and CC N
follow-up NN N
in IN N
collaboration NN N
with IN N
physicians NNS N
improved VBN N
the DT N
achievement NN N
of IN N
BP NNP N
, , N
TC NNP N
, , N
and CC N
BP/TC NNP N
treatment NN N
goals NNS N
in IN N
patients NNS N
with IN N
CVD NNP N
and/or VBP N
high JJ N
or CC N
intermediate JJ N
CV NNP N
risk NN N
attending VBG N
community NN N
pharmacies NNS N
in IN N
Spain NNP N
. . N

-DOCSTART- -2932908- O O

Chemotherapy NN N
of IN N
large JJ N
bowel NN N
carcinoma NN N
-- : N
fluorouracil NN N
( ( N
FU NNP N
) ) N
+ VBP N
hydroxyurea NN N
( ( N
HU NNP N
) ) N
vs. FW N
methyl-CCNU NN N
, , N
oncovin NN N
, , N
fluorouracil NN N
, , N
and CC N
streptozotocin NN N
( ( N
MOF-Strep NNP N
) ) N
. . N

An DT N
Eastern JJ N
Cooperative NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

In IN N
this DT N
prospective JJ N
randomized NN N
study NN N
of IN N
initial JJ N
chemotherapy NN N
for IN N
advanced JJ N
measurable JJ N
metastatic JJ N
large JJ N
bowel NN N
carcinoma NN N
, , N
the DT N
response NN N
rate NN N
was VBD N
6/32 CD N
( ( N
19 CD N
% NN N
) ) N
for IN N
FU NNP N
+ NNP N
HU NNP N
and CC N
5/32 CD N
( ( N
16 CD N
% NN N
) ) N
for IN N
MOF-Strep NNP N
; : N
the DT N
estimated JJ N
median JJ N
survival NN N
is VBZ N
43 CD N
weeks NNS N
for IN N
both DT N
treatments NNS N
. . N

Patients NNS N
who WP N
received VBD N
MOF-Strep NNP N
experienced VBD N
substantially RB N
greater JJR N
vomiting VBG N
and CC N
hematologic JJ N
toxicity NN N
than IN N
patients NNS N
who WP N
received VBD N
FU NNP N
+ NNP N
HU NNP N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

-DOCSTART- -23609382- O O

Memantine NNP N
add-on JJ N
to TO N
risperidone VB N
for IN N
treatment NN N
of IN N
negative JJ N
symptoms NNS N
in IN N
patients NNS N
with IN N
stable JJ N
schizophrenia NN N
: : N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

We PRP N
aimed VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
memantine JJ N
add-on JJ N
in IN N
the DT N
treatment NN N
of IN N
primary JJ N
negative JJ N
symptoms NNS N
of IN N
patients NNS N
with IN N
stable JJ N
schizophrenia NN N
. . N

In IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
clinical JJ N
trial NN N
, , N
40 CD N
patients NNS N
with IN N
schizophrenia NN N
( ( N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
) ) N
who WP N
were VBD N
stabilized VBN N
on IN N
risperidone NN N
for IN N
a DT N
minimum NN N
of IN N
8 CD N
weeks NNS N
were VBD N
randomized VBN N
to TO N
either DT N
memantine NN N
( ( N
20 CD N
mg NN N
) ) N
or CC N
placebo NN N
in IN N
addition NN N
to TO N
risperidone VB N
, , N
6 CD N
mg/d NN N
, , N
for IN N
eight CD N
weeks NNS N
. . N

Assessment NNP N
was VBD N
done VBN N
using VBG N
the DT N
Positive NNP N
and CC N
Negative NNP N
Syndrome NNP N
Scale NNP N
at IN N
baseline NN N
, , N
week NN N
4 CD N
, , N
and CC N
week NN N
8 CD N
. . N

The DT N
Hamilton NNP N
Depression NNP N
Rating NNP N
Scale NNP N
and CC N
the DT N
Extrapyramidal NNP N
Symptom NNP N
Rating NNP N
Scale NNP N
at IN N
baseline NN N
and CC N
week NN N
8 CD N
were VBD N
used VBN N
to TO N
assess VB N
depression NN N
and CC N
extrapyramidal NN N
symptoms NNS N
, , N
respectively RB N
. . N

All DT N
40 CD N
patients NNS N
had VBD N
at IN N
least JJS N
one CD N
postbaseline NN N
measurement NN N
, , N
and CC N
38 CD N
patients NNS N
completed VBD N
the DT N
trial NN N
. . N

Patients NNS N
in IN N
the DT N
memantine NN N
group NN N
showed VBD N
a DT N
significantly RB N
greater JJR N
improvement NN N
on IN N
negative JJ N
subscale NN N
than IN N
the DT N
placebo NN N
group NN N
at IN N
end NN N
point NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
same JJ N
effect NN N
was VBD N
observed VBN N
for IN N
the DT N
total JJ N
score NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
the DT N
general JJ N
psychopathology NN N
subscale NN N
score NN N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
reduction NN N
of IN N
positive JJ N
symptoms NNS N
score VBP N
between IN N
the DT N
2 CD N
groups NNS N
( ( N
P NNP N
= NNP N
0.757 CD N
) ) N
. . N

Changes NNS N
in IN N
the DT N
Hamilton NNP N
Depression NNP N
Rating NNP N
Scale NNP N
and CC N
the DT N
Extrapyramidal NNP N
Symptom NNP N
Rating NNP N
Scale NNP N
scores NNS N
and CC N
frequency NN N
of IN N
adverse JJ N
effects NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Our PRP$ N
study NN N
showed VBD N
that IN N
memantine NN N
is VBZ N
a DT N
tolerable JJ N
and CC N
efficacious JJ N
add-on JJ N
treatment NN N
for IN N
primary JJ N
negative JJ N
symptoms NNS N
of IN N
schizophrenia NN N
. . N

-DOCSTART- -18795522- O O

Influence NN N
of IN N
occlusal JJ N
access NN N
on IN N
demineralized JJ N
dentin NN N
removal NN N
in IN N
the DT N
atraumatic JJ N
restorative JJ N
treatment NN N
( ( N
ART NNP N
) ) N
approach NN N
. . N

PURPOSE NNP N
To TO N
verify VB N
the DT N
influence NN N
of IN N
cavity NN N
access NN N
diameter NN N
on IN N
demineralized JJ N
dentin NN N
removal NN N
in IN N
the DT N
ART NNP N
approach NN N
. . N

METHODS $ N
40 CD N
non-carious JJ N
human JJ N
premolars NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
four CD N
groups NNS N
. . N

The DT N
occlusal JJ N
surface NN N
was VBD N
ground NN N
flat JJ N
and CC N
the DT N
teeth NNS N
were VBD N
sectioned VBN N
mesio-distally RB N
. . N

The DT N
hemi-sections NNS N
were VBD N
reassembled VBN N
and CC N
occlusal JJ N
access NN N
preparations NNS N
were VBD N
carried VBN N
out RP N
using VBG N
ball-shaped JJ N
diamonds NNS N
. . N

The DT N
resulting VBG N
size NN N
of IN N
the DT N
occlusal NN N
opening NN N
was VBD N
1.0 CD N
mm NN N
, , N
1.4 CD N
mm NN N
, , N
1.6 CD N
mm NN N
and CC N
1.8 CD N
mm NN N
for IN N
Groups NNP N
A NNP N
, , N
B NNP N
, , N
C NNP N
, , N
and CC N
D NNP N
, , N
respectively RB N
. . N

Standardized VBN N
artificial JJ N
carious JJ N
lesions NNS N
were VBD N
created VBN N
and CC N
demineralized VBN N
dentin NN N
was VBD N
excavated VBN N
. . N

After IN N
excavation NN N
, , N
the DT N
cavities NNS N
were VBD N
analyzed VBN N
using VBG N
: : N
( ( N
a DT N
) ) N
the DT N
tactile NN N
method NN N
, , N
( ( N
b NN N
) ) N
caries-detection NN N
dye NN N
to TO N
stain VB N
demineralized JJ N
dentin NN N
, , N
as IN N
proposed VBN N
by IN N
Smales NNP N
& CC N
Fang NNP N
, , N
and CC N
( ( N
c NN N
) ) N
Demineralized NNP N
Tissue NNP N
Removal NNP N
index NN N
, , N
as IN N
proposed VBN N
in IN N
this DT N
study NN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
Fisher NNP N
, , N
Spearman NNP N
correlation NN N
coefficient NN N
, , N
kappa NN N
, , N
Kruskal-Wallis NNP N
and CC N
Miller NNP N
tests NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS VB N
The DT N
three CD N
methods NNS N
of IN N
evaluation NN N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
Groups NNP N
A NNP N
vs. NN N
B NNP N
, , N
and CC N
C NNP N
vs. FW N
D NNP N
, , N
while IN N
statistically RB N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
Groups NNP N
A NNP N
vs. FW N
C NNP N
, , N
A NNP N
vs. NN N
D NNP N
, , N
B NNP N
vs. FW N
C NNP N
and CC N
B NNP N
vs. FW N
D. NNP N
Based VBD N
on IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
, , N
the DT N
size NN N
of IN N
occlusal JJ N
access NN N
significantly RB N
affected VBD N
the DT N
efficacy NN N
of IN N
demineralized JJ N
tissue NN N
removal NN N
. . N

-DOCSTART- -12017793- O O

Effect NNP N
of IN N
four CD N
intermediate JJ N
layer NN N
treatments NNS N
on IN N
microleakage NN N
of IN N
Class NNP N
II NNP N
composite JJ N
restorations NNS N
. . N

This DT N
in IN N
vitro NN N
study NN N
examines VBZ N
the DT N
marginal JJ N
sealing NN N
ability NN N
of IN N
four CD N
different JJ N
intermediate JJ N
materials NNS N
applied VBN N
before IN N
placement NN N
of IN N
a DT N
condensable JJ N
composite NN N
. . N

Class NNP N
II NNP N
preparations NNS N
were VBD N
made VBN N
with IN N
gingival JJ N
margins NNS N
placed VBD N
1.0 CD N
mm JJ N
apical JJ N
to TO N
the DT N
cementoenamel JJ N
junction NN N
of IN N
60 CD N
extracted JJ N
teeth NNS N
, , N
randomly RB N
assigned VBN N
to TO N
five CD N
groups NNS N
of IN N
12 CD N
. . N

Following VBG N
restoration NN N
, , N
teeth EX N
were VBD N
thermocycled VBN N
, , N
soaked VBN N
in IN N
0.5 CD N
% NN N
basic JJ N
fuchsin NN N
, , N
and CC N
sectioned VBD N
longitudinally RB N
. . N

The DT N
resin-modified JJ N
glass NN N
ionomer NN N
cement NN N
demonstrated VBD N
significantly RB N
less JJR N
microleakage NN N
than IN N
the DT N
use NN N
of IN N
a DT N
dentin NN N
bonding NN N
agent NN N
alone RB N
or CC N
in IN N
combination NN N
with IN N
flowable JJ N
composite JJ N
, , N
flowable JJ N
compomer NN N
, , N
or CC N
autoploymerizing VBG N
composite JJ N
( ( N
p JJ N
< NN N
0.05 CD N
, , N
Dunn NNP N
's POS N
test NN N
) ) N
. . N

This DT N
study NN N
supports VBZ N
the DT N
use NN N
of IN N
the DT N
glass NN N
ionomer NN N
open JJ N
sandwich NN N
technique NN N
in IN N
deep JJ N
Class NNP N
II NNP N
direct JJ N
composite JJ N
restorations NNS N
. . N

-DOCSTART- -18702687- O O

Long RB N
pediatric JJ N
colonoscope NN N
versus NN N
intermediate JJ N
length NN N
adult NN N
colonoscope NN N
for IN N
colonoscopy NN N
. . N

BACKGROUND NNP N
Controversy NNP N
exists VBZ N
on IN N
how WRB N
the DT N
length NN N
and CC N
diameter NN N
of IN N
colonoscopes NNS N
affect VBP N
the DT N
quality NN N
of IN N
colonoscopy NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
a DT N
long JJ N
pediatric JJ N
colonoscope NN N
with IN N
an DT N
intermediate JJ N
length NN N
adult NN N
colonoscope NN N
with IN N
regards NNS N
to TO N
completion NN N
rate NN N
and CC N
cecal JJ N
intubation NN N
time NN N
. . N

Whether CC N
either DT N
scope NN N
may MD N
be VB N
more RBR N
efficient JJ N
in IN N
any DT N
subgroups NN N
was VBD N
also RB N
investigated VBN N
. . N

METHODS NNP N
Asymptomatic JJ N
patients NNS N
admitted VBN N
to TO N
the DT N
physical JJ N
check-up JJ N
department NN N
of IN N
Buddhist NNP N
Dalin NNP N
Tzu NNP N
Chi NNP N
General NNP N
Hospital NNP N
were VBD N
included VBN N
. . N

A DT N
single JJ N
endoscopist NN N
performed VBD N
all DT N
of IN N
the DT N
colonoscopic NN N
examinations NNS N
under IN N
sedation NN N
. . N

Consecutive JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
undergo VB N
colonoscopy NN N
with IN N
either DT N
intermediate JJ N
length NN N
adult NN N
colonoscope NN N
( ( N
CF-240I NNP N
) ) N
or CC N
long JJ N
pediatric JJ N
colonoscope NN N
( ( N
PCF-240L NNP N
) ) N
. . N

The DT N
success NN N
rate NN N
and CC N
time NN N
required VBN N
to TO N
reach VB N
cecum NN N
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Between NNP N
April NNP N
2005 CD N
and CC N
February NNP N
2006 CD N
, , N
a DT N
total NN N
of IN N
918 CD N
patients NNS N
were VBD N
enrolled VBN N
. . N

Incomplete NNP N
colonoscopy NN N
occurred VBD N
in IN N
21 CD N
( ( N
2.3 CD N
% NN N
) ) N
cases NNS N
( ( N
14 CD N
in IN N
the DT N
CF-240I NNP N
group NN N
and CC N
seven CD N
in IN N
the DT N
PCF-240L NNP N
group NN N
, , N
P NNP N
> NNP N
0.1 CD N
) ) N
. . N

The DT N
overall JJ N
cecal JJ N
mean NN N
insertion NN N
time NN N
was VBD N
6.00 CD N
+/- JJ N
3.66 CD N
min NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
CF-240I NNP N
and CC N
PCF NNP N
240L CD N
groups NNS N
with IN N
regard NN N
to TO N
the DT N
cecal JJ N
intubation NN N
rate NN N
( ( N
96.9 CD N
% NN N
vs JJ N
98.5 CD N
% NN N
, , N
P NNP N
= NNP N
0.18 CD N
) ) N
, , N
the DT N
need NN N
for IN N
abdominal JJ N
pressure NN N
( ( N
71.7 CD N
% NN N
vs JJ N
73.4 CD N
% NN N
, , N
P NNP N
= NNP N
0.55 CD N
) ) N
and CC N
change NN N
of IN N
position NN N
( ( N
13.5 CD N
% NN N
vs JJ N
11.5 CD N
% NN N
, , N
P NNP N
= NNP N
0.37 CD N
) ) N
. . N

However RB N
, , N
the DT N
cecal JJ N
intubation NN N
time NN N
was VBD N
shorter RBR N
in IN N
the DT N
CF-240I NNP N
group NN N
( ( N
5.75 CD N
+/- JJ N
3.18 CD N
vs JJ N
6.26 CD N
+/- JJ N
3.30 CD N
min NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Subgroup NNP N
analysis NN N
by IN N
sex NN N
, , N
age NN N
, , N
and CC N
body NN N
mass NN N
index NN N
showed VBD N
comparable JJ N
outcomes NNS N
between IN N
the DT N
two CD N
groups NNS N
except IN N
that IN N
the DT N
cecal JJ N
intubation NN N
times NNS N
were VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
CF-240I NNP N
group NN N
when WRB N
only RB N
men NNS N
( ( N
4.78 CD N
+/- JJ N
2.57 CD N
vs JJ N
5.50 CD N
+/- JJ N
2.93 CD N
min NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
or CC N
those DT N
younger JJR N
than IN N
50 CD N
years NNS N
( ( N
5.50 CD N
+/- JJ N
2.90 CD N
vs JJ N
6.25 CD N
+/- JJ N
3.68 CD N
min NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
were VBD N
considered VBN N
. . N

CONCLUSION NNP N
Cecal NNP N
intubation NN N
time NN N
is VBZ N
shorter RBR N
in IN N
patients NNS N
examined VBN N
with IN N
an DT N
intermediate JJ N
length NN N
adult NN N
colonoscope NN N
, , N
mainly RB N
in IN N
the DT N
subgroups NNS N
of IN N
men NNS N
and CC N
those DT N
younger JJR N
than IN N
50 CD N
years NNS N
of IN N
age NN N
. . N

-DOCSTART- -2949396- O O

No DT N
effect NN N
of IN N
acetylsalicylic JJ N
acid NN N
on IN N
B-thromboglobulin NNP N
and CC N
platelet VB N
factor NN N
4 CD N
plasma NN N
levels NNS N
in IN N
patients NNS N
with IN N
transient JJ N
ischaemic JJ N
attacks NNS N
. . N

We PRP N
studied VBD N
the DT N
effect NN N
of IN N
acetylsalicylic JJ N
acid NN N
( ( N
ASA NNP N
) ) N
versus NN N
placebo NN N
on IN N
B-thromboglobulin NNP N
( ( N
B-TG NNP N
) ) N
and CC N
platelet JJ N
factor NN N
4 CD N
( ( N
PF4 NNP N
) ) N
plasma NN N
levels NNS N
and CC N
ADP-induced NNP N
platelet NN N
aggregation NN N
in IN N
25 CD N
male JJ N
patients NNS N
with IN N
transient JJ N
ischaemic JJ N
attacks NNS N
( ( N
TIA NNP N
) ) N
. . N

The DT N
patients NNS N
were VBD N
allocated VBN N
randomly RB N
to TO N
two CD N
groups NNS N
: : N
14 CD N
patients NNS N
received JJ N
oral JJ N
treatment NN N
with IN N
ASA NNP N
500 CD N
mg NN N
b.i.d NN N
. . N

for IN N
14 CD N
days NNS N
, , N
11 CD N
patients NNS N
placebo JJ N
b.i.d NN N
. . N

for IN N
the DT N
same JJ N
period NN N
. . N

B-TG NNP N
and CC N
PF4 NNP N
plasma NN N
levels NNS N
and CC N
ADP-induced NNP N
platelet NN N
aggregation NN N
were VBD N
determined VBN N
in IN N
basal NN N
conditions NNS N
, , N
and CC N
two CD N
hours NNS N
, , N
and CC N
seven CD N
and CC N
fourteen JJ N
days NNS N
after IN N
starting VBG N
with IN N
ASA NNP N
or CC N
placebo NN N
. . N

In IN N
addition NN N
, , N
the DT N
same JJ N
parameters NNS N
were VBD N
studied VBN N
in IN N
a DT N
group NN N
of IN N
20 CD N
healthy JJ N
males NNS N
of IN N
matched JJ N
age NN N
. . N

Basal NNP N
levels NNS N
of IN N
plasma JJ N
B-TG NNP N
and CC N
PF4 NNP N
and CC N
the DT N
maximal JJ N
amplitude NN N
of IN N
ADP-induced NNP N
platelet NN N
aggregation NN N
were VBD N
abnormally RB N
high JJ N
in IN N
TIA NNP N
patients NNS N
. . N

ASA NNP N
caused VBD N
a DT N
significant JJ N
reduction NN N
of IN N
B-TG NNP N
plasma NN N
levels NNS N
in IN N
TIA NNP N
patients NNS N
2 CD N
hours NNS N
after IN N
the DT N
first JJ N
administration NN N
, , N
but CC N
no DT N
effect NN N
was VBD N
observed VBN N
at IN N
the DT N
7th CD N
and CC N
14th CD N
day NN N
of IN N
treatment NN N
. . N

PF4 NNP N
plasma NN N
levels NNS N
were VBD N
unaffected VBN N
by IN N
ASA NNP N
treatment NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
ASA NNP N
, , N
at IN N
the DT N
dose NN N
conventionally RB N
used VBN N
in IN N
clinical JJ N
trials NNS N
, , N
does VBZ N
not RB N
affect VB N
the DT N
release NN N
of IN N
two CD N
alpha-granule JJ N
proteins NNS N
. . N

-DOCSTART- -6807568- O O

Treatment NN N
of IN N
stable JJ N
angina NN N
of IN N
effort NN N
with IN N
verapamil NN N
: : N
a DT N
double-blind NN N
, , N
placebo-controlled JJ N
randomized VBN N
crossover NN N
study NN N
. . N

The DT N
effects NNS N
of IN N
verapamil NN N
were VBD N
assessed VBN N
in IN N
26 CD N
patients NNS N
with IN N
stable JJ N
exertional JJ N
angina NN N
pectoris NN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized VBN N
crossover NN N
protocol NN N
using VBG N
serial JJ N
treadmill NN N
tests NNS N
. . N

Verapamil NNP N
, , N
480 CD N
mg/day NN N
, , N
reduced VBD N
anginal JJ N
frequency NN N
from IN N
5.6 CD N
+/- JJ N
7.3 CD N
to TO N
2.2 CD N
+/- JJ N
3.9 CD N
attacks NNS N
per IN N
week NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
nitroglycerin JJ N
consumption NN N
from IN N
3.4 CD N
+/- JJ N
4.9 CD N
to TO N
1.2 CD N
+/- JJ N
2.5 CD N
tablets NNS N
per IN N
week NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
compared VBN N
with IN N
placebo NN N
. . N

Treadmill NNP N
time NN N
increased VBD N
from IN N
6.4 CD N
+/- JJ N
2.1 CD N
minutes NNS N
during IN N
the DT N
placebo NN N
phase NN N
to TO N
7.5 CD N
+/- JJ N
1.8 CD N
minutes NNS N
during IN N
the DT N
verapamil JJ N
phase NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Verapamil NNP N
's POS N
beneficial JJ N
effect NN N
appeared VBD N
to TO N
be VB N
related VBN N
, , N
in IN N
part NN N
, , N
to TO N
a DT N
10 CD N
% NN N
reduction NN N
of IN N
the DT N
rate-pressure JJ N
product NN N
at IN N
rest NN N
( ( N
p IN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
a DT N
12 CD N
% NN N
reduction NN N
during IN N
submaximal JJ N
exercise NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Verapamil NNP N
also RB N
caused VBD N
less JJR N
marked JJ N
ST-segment JJ N
depressions NNS N
at IN N
peak NN N
exercise NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
at IN N
a DT N
similar JJ N
rate-pressure NN N
product NN N
, , N
suggesting VBG N
a DT N
favorable JJ N
redistribution NN N
of IN N
coronary JJ N
blood NN N
flow NN N
to TO N
the DT N
ischemic JJ N
zone NN N
. . N

Side JJ N
effects NNS N
from IN N
verapamil NN N
were VBD N
minimal JJ N
, , N
consisting VBG N
mainly RB N
of IN N
constipation NN N
( ( N
six CD N
patients NNS N
) ) N
. . N

Verapamil NNP N
appears VBZ N
to TO N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
drug NN N
for IN N
treating VBG N
angina NN N
of IN N
effort NN N
. . N

-DOCSTART- -20218011- O O

Comparison NNP N
of IN N
the DT N
in IN N
vitro NN N
and CC N
in IN N
vivo JJ N
release NN N
of IN N
digoxin NN N
from IN N
four CD N
different JJ N
soft JJ N
gelatin NN N
capsule NN N
formulations NNS N
. . N

A DT N
blinded JJ N
, , N
four-treatment JJ N
crossover NN N
study NN N
in IN N
16 CD N
normal JJ N
adult NN N
male NN N
volunteers NNS N
compared VBN N
plasma JJ N
concentrations NNS N
and CC N
urinary JJ N
excretion NN N
of IN N
digoxin NN N
, , N
measured VBN N
by IN N
radioimmunoassay NN N
, , N
after IN N
oral JJ N
administration NN N
of IN N
soft JJ N
gelatin NN N
capsule NN N
formulations NNS N
of IN N
digoxin NN N
. . N

Four CD N
0.4-mg JJ N
formulations NNS N
with IN N
different JJ N
in IN N
vitro NN N
burst NN N
times NNS N
and CC N
dissolution NN N
rates NNS N
were VBD N
administered VBN N
, , N
with IN N
2-week JJ N
intervals NNS N
between IN N
treatments NNS N
. . N

The DT N
two CD N
capsules NNS N
with IN N
lowest JJS N
in IN N
vitro NN N
burst NN N
times NNS N
( ( N
2.9 CD N
and CC N
16 CD N
min NN N
) ) N
gave VBD N
comparable JJ N
in IN N
vivo JJ N
results NNS N
. . N

The DT N
other JJ N
two CD N
capsules NNS N
, , N
with IN N
in IN N
vitro NN N
burst NN N
times NNS N
of IN N
62 CD N
and CC N
229 CD N
min NN N
, , N
produced VBD N
significant JJ N
delays NNS N
in IN N
digoxin NN N
absorption NN N
. . N

In IN N
vitro-in JJ N
vivo NN N
correlations NNS N
were VBD N
obtained VBN N
by IN N
comparing VBG N
the DT N
logarithm NN N
of IN N
the DT N
in IN N
vitro JJ N
burst NN N
time NN N
with IN N
time NN N
to TO N
peak VB N
plasma JJ N
level NN N
and CC N
the DT N
time NN N
to TO N
the DT N
first JJ N
measurable JJ N
plasma NN N
level NN N
( ( N
> CD N
or CC N
= VB N
0 CD N
. . N

05 CD N
ng/ml NN N
) ) N
. . N

Also RB N
, , N
the DT N
mean JJ N
time NN N
to TO N
peak VB N
plasma JJ N
level NN N
correlated VBN N
with IN N
the DT N
logarithm NN N
of IN N
the DT N
time NN N
required VBN N
to TO N
release VB N
either RB N
50 CD N
% NN N
or CC N
85 CD N
% NN N
of IN N
the DT N
digoxin NN N
in IN N
vitro NN N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
found VBN N
in IN N
the DT N
amount NN N
of IN N
digoxin NN N
absorbed VBN N
from IN N
each DT N
capsule NN N
as IN N
determined VBN N
by IN N
urinary JJ N
excretion NN N
or CC N
AUC0-infinity NN N
. . N

-DOCSTART- -10715372- O O

Study NN N
of IN N
the DT N
vaginal JJ N
tolerance NN N
to TO N
Acidform NNP N
, , N
an DT N
acid-buffering JJ N
, , N
bioadhesive JJ N
gel NN N
. . N

Vaginal JJ N
tolerance NN N
tests NNS N
were VBD N
performed VBN N
with IN N
a DT N
new JJ N
potential JJ N
microbicidal NN N
and CC N
spermicidal JJ N
product NN N
, , N
an DT N
acid-buffering JJ N
vaginal JJ N
gel NN N
( ( N
Acidform NNP N
) ) N
without IN N
or CC N
with IN N
nonoxynol-9 JJ N
( ( N
N-9 NNP N
) ) N
. . N

The DT N
potential JJ N
advantages NNS N
over IN N
other JJ N
vaginal JJ N
products NNS N
include VBP N
keeping VBG N
a DT N
low JJ N
pH NN N
, , N
decrease NN N
of IN N
the DT N
irritating VBG N
effect NN N
of IN N
N-9 NNP N
on IN N
the DT N
cervix NN N
or CC N
vaginal JJ N
mucosa NN N
associated VBN N
with IN N
greater JJR N
retention NN N
of IN N
the DT N
product NN N
after IN N
application NN N
, , N
and CC N
decreasing VBG N
messiness NN N
as IN N
compared VBN N
to TO N
other JJ N
vaginal JJ N
products NNS N
. . N

Three CD N
groups NNS N
of IN N
six CD N
women NNS N
were VBD N
admitted VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
use VB N
Acidform NNP N
with IN N
0 CD N
% NN N
, , N
2.5 CD N
% NN N
, , N
and CC N
5 CD N
% NN N
N-9 NNP N
. . N

Colposcopic NNP N
evaluation NN N
for IN N
vulvar NN N
, , N
vaginal JJ N
, , N
and CC N
cervical JJ N
signs NNS N
of IN N
irritation NN N
was VBD N
performed VBN N
and CC N
photographs NNS N
were VBD N
taken VBN N
, , N
following VBG N
a DT N
specific JJ N
World NNP N
Health NNP N
Organization NNP N
protocol NN N
, , N
at IN N
time NN N
0 CD N
, , N
and CC N
after IN N
24 CD N
h NN N
and CC N
6 CD N
days NNS N
of IN N
application NN N
of IN N
the DT N
gel NN N
. . N

No DT N
irritation NN N
or CC N
symptom NN N
was VBD N
reported VBN N
by IN N
users NNS N
of IN N
Acidform NNP N
without IN N
N-9 NNP N
. . N

A NNP N
generalized JJ N
and CC N
intense JJ N
erythema NN N
in IN N
cervix NN N
was VBD N
observed VBN N
in IN N
10 CD N
of IN N
12 CD N
Acidform/N-9 JJ N
users NNS N
and CC N
abrasion NN N
occurred VBD N
in IN N
nine CD N
of IN N
them PRP N
. . N

Vulvar NNP N
irritation NN N
was VBD N
seen VBN N
in IN N
seven CD N
of IN N
these DT N
10 CD N
volunteers NNS N
. . N

N-9 JJ N
concentration NN N
in IN N
the DT N
gel NN N
( ( N
2.5 CD N
% NN N
or CC N
5.0 CD N
% NN N
) ) N
was VBD N
not RB N
related VBN N
to TO N
the DT N
findings NNS N
. . N

No DT N
ulcer NN N
, , N
exulceration NN N
, , N
or CC N
de-epithelialization NN N
was VBD N
observed VBN N
. . N

Acidform VB N
without IN N
N-9 NNP N
was VBD N
well RB N
tolerated VBN N
by IN N
volunteers NNS N
, , N
but CC N
it PRP N
was VBD N
unable JJ N
to TO N
protect VB N
the DT N
cervix NN N
, , N
vagina NN N
, , N
and CC N
vulva NN N
from IN N
the DT N
N-9 JJ N
effects NNS N
. . N

-DOCSTART- -17481800- O O

Dissociation NN N
between IN N
cortical JJ N
activation NN N
and CC N
cognitive JJ N
performance NN N
under IN N
pharmacological JJ N
blood NN N
pressure NN N
elevation NN N
in IN N
chronic JJ N
hypotension NN N
. . N

The DT N
present JJ N
study NN N
explored VBD N
the DT N
impact NN N
of IN N
pharmacological JJ N
blood NN N
pressure NN N
elevation NN N
on IN N
cortical JJ N
activation NN N
and CC N
reaction NN N
time NN N
in IN N
chronic JJ N
hypotension NN N
. . N

Effects NNS N
of IN N
the DT N
sympathomimetic JJ N
etilefrine NN N
were VBD N
investigated VBN N
in IN N
50 CD N
hypotensive JJ N
persons NNS N
based VBN N
on IN N
a DT N
randomized VBN N
, , N
placebo-controlled JJ N
double JJ N
blind NN N
design NN N
. . N

As IN N
an DT N
indicator NN N
of IN N
cortical JJ N
excitability NN N
, , N
the DT N
contingent NN N
negative JJ N
variation NN N
( ( N
CNV NNP N
) ) N
, , N
induced VBN N
by IN N
a DT N
constant JJ N
foreperiod NN N
reaction NN N
time NN N
task NN N
, , N
was VBD N
assessed VBN N
at IN N
frontal JJ N
( ( N
F3 NNP N
, , N
Fz NNP N
, , N
F4 NNP N
) ) N
and CC N
central JJ N
( ( N
C3 NNP N
, , N
Cz NNP N
, , N
C4 NNP N
) ) N
scalp NN N
sites NNS N
. . N

Etilefrine NNP N
provoked VBD N
a DT N
decrease NN N
in IN N
the DT N
frontal NN N
and CC N
central JJ N
CNV NNP N
. . N

In IN N
contrast NN N
, , N
shorter JJR N
reaction NN N
times NNS N
were VBD N
observed JJ N
following JJ N
drug NN N
administration NN N
. . N

The DT N
degree NN N
of IN N
pharmacologically RB N
induced VBN N
blood NN N
pressure NN N
elevation NN N
was VBD N
correlated VBN N
to TO N
CNV NNP N
attrition NN N
as RB N
well RB N
as IN N
to TO N
performance NN N
enhancement NN N
. . N

Inhibitory JJ N
effects NNS N
of IN N
baroreceptor NN N
activation NN N
on IN N
cortical JJ N
excitability NN N
and CC N
enhanced VBD N
cerebral JJ N
blood NN N
flow NN N
are VBP N
considered VBN N
to TO N
be VB N
involved VBN N
in IN N
mediating VBG N
the DT N
effects NNS N
of IN N
blood NN N
pressure NN N
elevation NN N
on IN N
cerebral JJ N
functioning NN N
. . N

Implications NNS N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
hypotension NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -15196300- O O

The DT N
prophylactic JJ N
effect NN N
of IN N
valproate NN N
on IN N
glyceryltrinitrate NN N
induced VBN N
migraine NN N
. . N

In IN N
this DT N
study NN N
the DT N
human JJ N
glyceryltrinitrate NN N
( ( N
GTN NNP N
) ) N
model NN N
of IN N
migraine NN N
was VBD N
for IN N
the DT N
first JJ N
time NN N
used VBN N
to TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
prophylactic JJ N
drug NN N
. . N

We PRP N
chose VBD N
to TO N
test VB N
valproate NN N
due JJ N
to TO N
its PRP$ N
well RB N
documented JJ N
effect NN N
as IN N
a DT N
migraine JJ N
prophylactic JJ N
drug NN N
. . N

Efficacy NN N
of IN N
this DT N
compound NN N
would MD N
support VB N
the DT N
usefulness NN N
of IN N
the DT N
model NN N
in IN N
prophylactic JJ N
antimigraine JJ N
drug NN N
development NN N
. . N

Twelve CD N
patients NNS N
with IN N
migraine NN N
without IN N
aura NN N
were VBD N
included VBN N
in IN N
a DT N
randomized JJ N
double JJ N
blind NN N
crossover NN N
study NN N
. . N

Valproate VB N
1000 CD N
mg NN N
or CC N
placebo NN N
was VBD N
given VBN N
daily RB N
, , N
each DT N
for IN N
a DT N
minimum NN N
of IN N
13 CD N
days NNS N
. . N

On IN N
the DT N
last JJ N
treatment NN N
day NN N
of IN N
each DT N
arm NN N
a DT N
20 CD N
min NN N
intravenous JJ N
infusion NN N
of IN N
GTN NNP N
( ( N
0.25 CD N
microg/kg/min NN N
) ) N
was VBD N
given VBN N
. . N

Headache NNP N
was VBD N
registered VBN N
for IN N
12 CD N
h NN N
after IN N
the DT N
infusion NN N
and CC N
headache NN N
intensity NN N
was VBD N
scored VBN N
on IN N
a DT N
scale NN N
from IN N
0 CD N
to TO N
10 CD N
. . N

Fulfillment NN N
of IN N
IHS NNP N
criteria NNS N
was VBD N
recorded VBN N
for IN N
24 CD N
h. PDT N
The DT N
middle JJ N
cerebral JJ N
arteries NNS N
were VBD N
evaluated VBN N
by IN N
transcranial JJ N
Doppler NNP N
and CC N
the DT N
diameter NN N
of IN N
the DT N
superficial JJ N
temporal JJ N
and CC N
radial JJ N
arteries NNS N
were VBD N
measured VBN N
with IN N
high JJ N
frequency NN N
ultrasound NN N
. . N

GTN NNP N
evoked VBD N
migraine JJ N
fulfilling NN N
IHS NNP N
criteria NNS N
1.1 CD N
in IN N
6 CD N
patients NNS N
after IN N
placebo NN N
and CC N
in IN N
2 CD N
patients NNS N
after IN N
valproate NN N
( ( N
P NNP N
= NNP N
0.125 CD N
) ) N
. . N

Including VBG N
additionally RB N
3 CD N
patients NNS N
on IN N
placebo NN N
and CC N
1 CD N
patient NN N
on IN N
valproate NN N
who WP N
felt VBD N
they PRP N
had VBD N
suffered VBN N
a DT N
migraine JJ N
attack NN N
, , N
but CC N
who WP N
had VBD N
as IN N
associated VBN N
symptoms NNS N
only RB N
photophobia VBP N
or CC N
phonophobia VBP N
, , N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN N
of IN N
patients NNS N
with IN N
induced JJ N
migraine NN N
after IN N
valproate NN N
was VBD N
seen VBN N
( ( N
P NNP N
= NNP N
0.031 CD N
) ) N
. . N

Median JJ N
peak NN N
headache NN N
intensity NN N
was VBD N
1 CD N
( ( N
range VB N
0-9 NN N
) ) N
after IN N
valproate NN N
compared VBN N
to TO N
4.5 CD N
( ( N
range VB N
0-8 NN N
) ) N
after IN N
placebo NN N
( ( N
P NNP N
= NNP N
0.120 CD N
) ) N
. . N

Pretreatment NN N
with IN N
valproate NN N
as IN N
compared VBN N
to TO N
placebo VB N
reduced VBN N
the DT N
velocity NN N
in IN N
both DT N
middle JJ N
cerebral NN N
arteries NNS N
after IN N
GTN NNP N
( ( N
left VBN N
P NNP N
= NNP N
0.021 CD N
, , N
right JJ N
P NNP N
= NNP N
0.031 CD N
) ) N
. . N

No DT N
effect NN N
of IN N
valproate NN N
was VBD N
seen VBN N
in IN N
the DT N
diameter NN N
of IN N
the DT N
superficial JJ N
temporal JJ N
artery NN N
( ( N
P NNP N
= NNP N
0.781 CD N
) ) N
or CC N
the DT N
radial JJ N
artery NN N
( ( N
P NNP N
= NNP N
0.367 CD N
) ) N
before IN N
or CC N
after IN N
GTN NNP N
. . N

The DT N
study NN N
indicates VBZ N
that IN N
a DT N
prophylactic JJ N
effect NN N
of IN N
valproate NN N
may MD N
be VB N
demonstrated VBN N
using VBG N
the DT N
GTN NNP N
human JJ N
migraine NN N
model NN N
. . N

Although IN N
, , N
all DT N
headache NN N
parameters NNS N
were VBD N
reduced VBN N
after IN N
valproate NN N
compared VBN N
to TO N
placebo VB N
, , N
only RB N
one CD N
parameter NN N
was VBD N
statistically RB N
significantly RB N
reduced VBN N
probably RB N
because IN N
of IN N
the DT N
small JJ N
number NN N
of IN N
patients NNS N
. . N

The DT N
size NN N
of IN N
the DT N
effect NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
valproate NN N
in IN N
clinical JJ N
trials NNS N
. . N

The DT N
GTN NNP N
model NN N
may MD N
therefore RB N
be VB N
a DT N
valid JJ N
tool NN N
for IN N
testing VBG N
new JJ N
prophylactic JJ N
antimigraine NN N
drugs NNS N
. . N

-DOCSTART- -23404659- O O

Sex NN N
risk NN N
behavior NN N
among IN N
adolescent JJ N
and CC N
young JJ N
adult NN N
children NNS N
of IN N
opiate JJ N
addicts NNS N
: : N
outcomes NNS N
from IN N
the DT N
focus NN N
on IN N
families NNS N
prevention VBP N
trial NN N
and CC N
an DT N
examination NN N
of IN N
childhood NN N
and CC N
concurrent JJ N
predictors NNS N
of IN N
sex NN N
risk NN N
behavior NN N
. . N

This DT N
study NN N
reports VBZ N
on IN N
rates NNS N
and CC N
predictors NNS N
of IN N
sex NN N
risk NN N
behavior NN N
among IN N
a DT N
sample NN N
of IN N
adolescent NN N
and CC N
young JJ N
adult NN N
children NNS N
of IN N
parents NNS N
enrolled VBN N
in IN N
methadone NN N
treatment NN N
for IN N
opiate JJ N
addiction NN N
. . N

Data NNS N
are VBP N
from IN N
151 CD N
participants NNS N
( ( N
80 CD N
males NNS N
, , N
71 CD N
females NNS N
) ) N
in IN N
the DT N
Focus NNP N
on IN N
Families NNP N
( ( N
FOF NNP N
) ) N
project NN N
, , N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
family NN N
intervention NN N
and CC N
a DT N
study NN N
of IN N
the DT N
development NN N
of IN N
at-risk JJ N
children NNS N
. . N

The DT N
study NN N
participants NNS N
are VBP N
children NNS N
of IN N
parents NNS N
enrolled VBN N
in IN N
methadone NN N
treatment NN N
between IN N
1990 CD N
and CC N
1993 CD N
. . N

Participants NNS N
were VBD N
interviewed VBN N
in IN N
2005 CD N
when WRB N
they PRP N
ranged VBD N
in IN N
age NN N
from IN N
15 CD N
to TO N
29 CD N
years NNS N
. . N

In IN N
the DT N
year NN N
prior RB N
to TO N
the DT N
follow-up NN N
, , N
79 CD N
% NN N
of IN N
the DT N
males NNS N
and CC N
83 CD N
% NN N
of IN N
females NNS N
were VBD N
sexually RB N
active JJ N
, , N
26 CD N
% NN N
of IN N
males NNS N
and CC N
10 CD N
% NN N
of IN N
females NNS N
had VBD N
more JJR N
than IN N
one CD N
partner NN N
in IN N
the DT N
prior JJ N
year NN N
, , N
and CC N
34 CD N
% NN N
of IN N
males NNS N
and CC N
24 CD N
% NN N
of IN N
females NNS N
reported VBN N
having VBG N
sex NN N
outside IN N
of IN N
a DT N
committed JJ N
relationship NN N
. . N

Twenty-four CD N
percent NN N
of IN N
males NNS N
and CC N
17 CD N
% NN N
of IN N
females NNS N
met VBD N
criteria NNS N
for IN N
high-risk JJ N
sexual JJ N
behavior NN N
, , N
reporting VBG N
casual JJ N
or CC N
multiple JJ N
partners NNS N
in IN N
the DT N
prior JJ N
year NN N
and CC N
inconsistent NN N
condom NN N
use NN N
. . N

Participants NNS N
in IN N
the DT N
intervention NN N
and CC N
control NN N
conditions NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
terms NNS N
of IN N
any DT N
measure NN N
of IN N
sex NN N
risk NN N
behavior NN N
examined VBN N
. . N

None NN N
of IN N
the DT N
measures NNS N
of IN N
parent NN N
behavior NN N
and CC N
family NN N
processes NNS N
derived VBN N
from IN N
data NNS N
at IN N
baseline NN N
of IN N
the DT N
FOF NNP N
study NN N
predicted VBD N
whether IN N
participants NNS N
engaged VBN N
in IN N
high-risk JJ N
sex NN N
. . N

Among IN N
measures NNS N
derived VBN N
from IN N
data NNS N
collected VBN N
at IN N
long-term JJ N
follow-up NN N
, , N
however RB N
, , N
having VBG N
ever RB N
met VBN N
criteria NNS N
for IN N
substance NN N
abuse NN N
or CC N
dependence NN N
predicted VBN N
greater JJR N
likelihood NN N
of IN N
high-risk JJ N
sexual JJ N
behavior NN N
, , N
and CC N
being VBG N
married VBD N
or CC N
being VBG N
in IN N
a DT N
romantic JJ N
relationship NN N
was VBD N
associated VBN N
with IN N
lower JJR N
likelihood NN N
of IN N
high-risk JJ N
sexual JJ N
behavior NN N
. . N

The DT N
findings NNS N
point NN N
to TO N
the DT N
important JJ N
role NN N
of IN N
committed JJ N
relationships NNS N
in IN N
regulating VBG N
sex NN N
risk NN N
behavior NN N
among IN N
this DT N
population NN N
, , N
as RB N
well RB N
as IN N
heightened VBN N
levels NNS N
of IN N
sex NN N
risk NN N
behavior NN N
associated VBN N
with IN N
substance NN N
abuse NN N
or CC N
dependence NN N
. . N

-DOCSTART- -1832287- O O

Atrial NNP N
natriuretic JJ N
factor NN N
inhibits NNS N
metoclopramide RB N
stimulated VBD N
aldosterone JJ N
release NN N
in IN N
man NN N
. . N

1 CD N
. . N

Atrial NNP N
natriuretic JJ N
factor NN N
( ( N
ANF NNP N
) ) N
has VBZ N
an DT N
inhibitory JJ N
effect NN N
on IN N
angiotensin NN N
II NNP N
and CC N
ACTH NNP N
stimulated VBD N
aldosterone CD N
secretion NN N
in IN N
man NN N
. . N

The DT N
selectivity NN N
of IN N
this DT N
aldosterone NN N
suppressing VBG N
effect NN N
of IN N
ANF NNP N
is VBZ N
unclear JJ N
in IN N
man NN N
. . N

The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
ANF NNP N
on IN N
the DT N
increase NN N
in IN N
plasma JJ N
aldosterone NN N
due JJ N
to TO N
metoclopramide VB N
in IN N
man NN N
. . N

2 CD N
. . N

Eight NNP N
normal JJ N
male NN N
volunteers NNS N
were VBD N
studied VBN N
on IN N
three CD N
occasions NNS N
. . N

Metoclopramide NNP N
( ( N
10 CD N
mg RB N
slow JJ N
i.v NN N
. . N

) ) N
was VBD N
given VBN N
on IN N
all DT N
study NN N
days NNS N
and CC N
each DT N
volunteer NN N
was VBD N
randomised VBN N
to TO N
receive VB N
45 CD N
min JJ N
infusion NN N
of IN N
either DT N
5 CD N
% NN N
D-glucose NNP N
( ( N
placebo NN N
) ) N
or CC N
ANF NNP N
( ( N
99-126 CD N
) ) N
3 CD N
or CC N
15 CD N
pmol JJ N
kg-1 JJ N
min-1 NN N
. . N

3 CD N
. . N

Metoclopramide NNP N
increased VBD N
plasma RB N
aldosterone NN N
to TO N
approximately RB N
170 CD N
% NN N
of IN N
baseline NN N
levels NNS N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Concomitant JJ N
infusion NN N
of IN N
ANF NNP N
3 CD N
pmol JJ N
kg-1 JJ N
min-1 NN N
and CC N
15 CD N
pmol JJ N
kg-1 JJ N
min-1 NN N
significantly RB N
attenuated VBD N
this DT N
rise NN N
in IN N
plasma NN N
aldosterone NN N
to TO N
approximately RB N
130 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
110 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
of IN N
baseline NN N
values NNS N
respectively RB N
. . N

4 CD N
. . N

It PRP N
is VBZ N
suggested VBN N
, , N
in IN N
the DT N
light NN N
of IN N
previous JJ N
findings NNS N
, , N
that IN N
the DT N
inhibitory JJ N
effect NN N
of IN N
ANF NNP N
represents VBZ N
a DT N
non-selective JJ N
action NN N
of IN N
ANF NNP N
on IN N
aldosterone NN N
release NN N
. . N

-DOCSTART- -10928228- O O

Is VBZ N
a DT N
calculated JJ N
total JJ N
hip NN N
BMD NNP N
of IN N
clinical JJ N
use NN N
? . N
The DT N
diagnosis NN N
of IN N
osteoporosis NN N
is VBZ N
based VBN N
on IN N
bone NN N
mass NN N
measurement NN N
. . N

To TO N
avoid VB N
the DT N
errors NNS N
associated VBN N
with IN N
the DT N
measurement NN N
of IN N
spinal JJ N
bone NN N
density NN N
the DT N
total JJ N
hip NN N
has VBZ N
been VBN N
accepted VBN N
as IN N
the DT N
standard JJ N
measurement NN N
site NN N
. . N

This DT N
information NN N
is VBZ N
not RB N
available JJ N
for IN N
many JJ N
early JJ N
measurements NNS N
. . N

We PRP N
have VBP N
assessed VBN N
whether IN N
it PRP N
is VBZ N
possible JJ N
to TO N
derive VB N
clinically RB N
useful JJ N
information NN N
about IN N
total JJ N
hip NN N
bone NN N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
from IN N
measurements NNS N
at IN N
other JJ N
hip NN N
sites NNS N
. . N

The DT N
bone NN N
mass NN N
measurements NNS N
of IN N
46 CD N
patients NNS N
participating VBG N
in IN N
a DT N
current JJ N
trial NN N
of IN N
therapy NN N
for IN N
osteoporosis NN N
were VBD N
reviewed VBN N
. . N

The DT N
total JJ N
hip NN N
BMD NNP N
as IN N
directly RB N
measured VBN N
was VBD N
compared VBN N
with IN N
that DT N
obtained VBN N
from IN N
the DT N
formula NN N
: : N
Total JJ N
hip NN N
BMD NNP N
= VBZ N
0.48 CD N
x NN N
Neck NNP N
BMD NNP N
+ VBD N
0.62 CD N
x NNP N
Trochanteric NNP N
BMD NNP N
+ VBD N
0.03 CD N
. . N

In IN N
30 CD N
patients NNS N
with IN N
follow-up JJ N
data NNS N
the DT N
rate NN N
of IN N
change NN N
in IN N
hip NN N
BMD NNP N
over IN N
a DT N
year NN N
was VBD N
also RB N
determined VBN N
by IN N
both DT N
methods NNS N
. . N

In IN N
the DT N
pretreatment NN N
state NN N
there EX N
was VBD N
good JJ N
agreement NN N
between IN N
the DT N
two CD N
measures NNS N
( ( N
r2 VB N
= RB N
0.96 CD N
, , N
SEE NNP N
0.012 CD N
g/cm2 NN N
) ) N
. . N

If IN N
the DT N
formula NN N
was VBD N
used VBN N
to TO N
compute VB N
a DT N
change NN N
in IN N
total JJ N
hip NN N
BMD NNP N
, , N
the DT N
agreement NN N
between IN N
both DT N
methods NNS N
remained VBD N
good JJ N
. . N

However RB N
, , N
the DT N
standard JJ N
error NN N
of IN N
the DT N
estimate NN N
of IN N
the DT N
change NN N
represented VBD N
59 CD N
% NN N
of IN N
the DT N
observed JJ N
change NN N
. . N

This DT N
indicates VBZ N
that IN N
the DT N
error NN N
associated VBN N
with IN N
this DT N
estimate NN N
is VBZ N
too RB N
great JJ N
to TO N
allow VB N
clinically RB N
meaningful JJ N
conclusions NNS N
to TO N
be VB N
drawn VBN N
from IN N
calculated VBN N
total JJ N
hip NN N
BMD NNP N
. . N

We PRP N
conclude VBP N
that IN N
, , N
whilst VB N
it PRP N
may MD N
be VB N
possible JJ N
to TO N
obtain VB N
reasonable JJ N
point NN N
estimates NNS N
of IN N
total JJ N
hip NN N
BMD NNP N
from IN N
other JJ N
measures NNS N
in IN N
the DT N
hip NN N
, , N
these DT N
estimates NNS N
are VBP N
too RB N
imprecise JJ N
to TO N
allow VB N
conclusions NNS N
about IN N
change NN N
in IN N
BMD NNP N
to TO N
be VB N
made VBN N
. . N

-DOCSTART- -20390261- O O

Echocardiographic JJ N
evaluation NN N
of IN N
children NNS N
with IN N
systemic JJ N
ventricular JJ N
dysfunction NN N
treated VBN N
with IN N
carvedilol NN N
. . N

Echocardiography NN N
is VBZ N
used VBN N
to TO N
measure VB N
the DT N
therapeutic JJ N
effectiveness NN N
of IN N
heart NN N
failure NN N
therapy NN N
in IN N
adults NNS N
and CC N
children NNS N
. . N

The DT N
purposes NNS N
of IN N
this DT N
study NN N
were VBD N
( ( N
1 CD N
) ) N
to TO N
assess VB N
baseline JJ N
echocardiographic JJ N
predictors NNS N
of IN N
clinical JJ N
outcome NN N
, , N
( ( N
2 CD N
) ) N
to TO N
investigate VB N
changes NNS N
in IN N
echocardiographic JJ N
parameters NNS N
, , N
and CC N
( ( N
3 CD N
) ) N
to TO N
compare VB N
these DT N
echocardiographic JJ N
changes NNS N
with IN N
changes NNS N
in IN N
plasma NN N
levels NNS N
of IN N
b-type JJ N
natriuretic JJ N
peptide NN N
( ( N
BNP NNP N
) ) N
in IN N
a DT N
population NN N
of IN N
children NNS N
with IN N
systemic JJ N
ventricular JJ N
dysfunction NN N
and CC N
symptomatic JJ N
heart NN N
failure NN N
treated VBN N
with IN N
carvedilol NN N
or CC N
placebo NN N
. . N

All DT N
available JJ N
baseline NN N
and CC N
6-month JJ N
echocardiograms NNS N
from IN N
Pediatric NNP N
Carvedilol NNP N
Trial NNP N
( ( N
PCT NNP N
) ) N
participants NNS N
( ( N
carvedilol JJ N
n RB N
= JJ N
161 CD N
; : N
placebo NN N
n IN N
= $ N
55 CD N
) ) N
were VBD N
reviewed VBN N
. . N

Systolic NNP N
and CC N
diastolic JJ N
sphericity NN N
index NN N
( ( N
SI NNP N
; : N
n CC N
= VB N
110 CD N
) ) N
, , N
TEI NNP N
index NN N
( ( N
n JJ N
= NNP N
145 CD N
) ) N
, , N
and CC N
systemic JJ N
ventricular NN N
dP/dt NN N
( ( N
n JJ N
= NNP N
70 CD N
) ) N
were VBD N
measured VBN N
. . N

The DT N
PCT NNP N
composite JJ N
definition NN N
of IN N
clinical JJ N
outcome NN N
( ( N
i.e. FW N
, , N
worsened VBD N
, , N
improved VBN N
, , N
or CC N
unchanged JJ N
) ) N
was VBD N
used VBN N
. . N

For IN N
all DT N
patients NNS N
, , N
baseline VBP N
TEI NNP N
index NN N
was VBD N
a DT N
predictor NN N
of IN N
worsened JJ N
outcome NN N
. . N

Only RB N
children NNS N
treated VBD N
with IN N
carvedilol NN N
showed VBD N
a DT N
significant JJ N
decrease NN N
in IN N
systolic JJ N
SI NNP N
( ( N
P NNP N
B NNP N
0.0001 CD N
) ) N
, , N
diastolic JJ N
SI NNP N
( ( N
P NNP N
B NNP N
0.0001 CD N
) ) N
, , N
and CC N
TEI NNP N
index NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

An DT N
inverse JJ N
correlation NN N
between IN N
changes NNS N
in IN N
BNP NNP N
and CC N
changes NNS N
in IN N
dP/dt NN N
( ( N
r JJ N
= NNP N
-0.45 NNP N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
was VBD N
found VBN N
only RB N
in IN N
the DT N
carvedilol NN N
group NN N
. . N

In IN N
conclusion NN N
, , N
TEI NNP N
index NN N
predicted VBD N
outcome NN N
in IN N
children NNS N
with IN N
systemic JJ N
ventricular JJ N
dysfunction NN N
and CC N
heart NN N
failure NN N
. . N

Carvedilol NN N
may MD N
have VB N
a DT N
beneficial JJ N
effect NN N
on IN N
reversal NN N
of IN N
left JJ N
ventricular JJ N
remodeling NN N
and CC N
global JJ N
ventricular NN N
function NN N
in IN N
pediatric JJ N
heart NN N
failure NN N
. . N

-DOCSTART- -17064200- O O

Effect NN N
of IN N
patient NN N
withdrawal NN N
on IN N
a DT N
study NN N
evaluating VBG N
pharmacist JJ N
management NN N
of IN N
hypertension NN N
. . N

STUDY NNP N
OBJECTIVES NNP N
To TO N
examine VB N
potential JJ N
threats NNS N
to TO N
internal JJ N
and CC N
external JJ N
study NN N
validity NN N
caused VBN N
by IN N
differential JJ N
patient NN N
withdrawal NN N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
evaluating VBG N
pharmacist JJ N
management NN N
of IN N
hypertension NN N
, , N
to TO N
compare VB N
the DT N
characteristics NNS N
of IN N
patients NNS N
who WP N
withdrew VBP N
with IN N
those DT N
of IN N
patients NNS N
who WP N
completed VBD N
the DT N
study NN N
, , N
and CC N
to TO N
identify VB N
characteristics NNS N
that WDT N
predispose VBP N
patients NNS N
to TO N
withdraw VB N
from IN N
hypertension NN N
management NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
comparative JJ N
study NN N
. . N

SETTING NNP N
Network NNP N
of IN N
primary JJ N
care NN N
clinics NNS N
. . N

PATIENTS VB N
Four CD N
hundred JJ N
sixty-three JJ N
patients NNS N
with IN N
a DT N
diagnosis NN N
of IN N
hypertension NN N
and CC N
a DT N
last JJ N
documented JJ N
systolic JJ N
blood NN N
pressure NN N
of IN N
160 CD N
mm NNS N
Hg NNP N
or CC N
greater JJR N
and/or NNS N
diastolic JJ N
blood NN N
pressure NN N
of IN N
100 CD N
mm NNS N
Hg NNP N
or CC N
greater JJR N
. . N

INTERVENTION NN N
Patients NNPS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
pharmacist NN N
intervention NN N
or CC N
usual-care JJ N
( ( N
control NN N
) ) N
group NN N
. . N

Those DT N
in IN N
the DT N
pharmacist NN N
intervention NN N
group NN N
were VBD N
collaboratively RB N
managed VBN N
by IN N
a DT N
primary JJ N
care NN N
clinical JJ N
pharmacy NN N
specialist NN N
and CC N
their PRP$ N
primary JJ N
care NN N
provider NN N
. . N

Patients NNS N
in IN N
the DT N
control NN N
group NN N
received VBD N
usual JJ N
care NN N
from IN N
only RB N
their PRP$ N
primary JJ N
care NN N
provider NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Of IN N
the DT N
463 CD N
patients NNS N
, , N
191 CD N
( ( N
41 CD N
% NN N
) ) N
withdrew NN N
from IN N
the DT N
study NN N
after IN N
randomization NN N
and CC N
272 CD N
( ( N
59 CD N
% NN N
) ) N
completed VBD N
the DT N
study NN N
. . N

Patients NNS N
who WP N
withdrew VBP N
from IN N
the DT N
pharmacist NN N
intervention NN N
group NN N
were VBD N
similar JJ N
to TO N
patients NNS N
who WP N
withdrew VBP N
from IN N
the DT N
usual-care JJ N
group NN N
with IN N
respect NN N
to TO N
age NN N
, , N
sex NN N
, , N
insurance NN N
status NN N
, , N
and CC N
chronic JJ N
conditions NNS N
. . N

Patients NNS N
who WP N
smoked VBD N
or CC N
had VBD N
commercial JJ N
insurance NN N
were VBD N
more RBR N
likely JJ N
to TO N
withdraw VB N
from IN N
the DT N
study NN N
than IN N
the DT N
other JJ N
participants NNS N
. . N

However RB N
, , N
multivariate JJ N
analysis NN N
of IN N
all DT N
variables NNS N
, , N
when WRB N
adjusted VBN N
for IN N
the DT N
effect NN N
of IN N
the DT N
intervention NN N
, , N
revealed VBD N
that IN N
insurance NN N
status NN N
was VBD N
the DT N
only JJ N
variable NN N
associated VBN N
with IN N
a DT N
heightened JJ N
probability NN N
of IN N
withdrawal NN N
( ( N
p=0.002 NN N
) ) N
. . N

CONCLUSION NNP N
Although IN N
this DT N
study NN N
had VBD N
a DT N
high JJ N
withdrawal NN N
rate NN N
, , N
between-group JJ N
patient NN N
characteristics NNS N
remained VBD N
balanced JJ N
. . N

Therefore RB N
, , N
internal JJ N
validity NN N
was VBD N
preserved VBN N
, , N
and CC N
outcomes RB N
from IN N
the DT N
study NN N
groups NNS N
could MD N
be VB N
reliably RB N
compared VBN N
. . N

A DT N
lack NN N
of IN N
significant JJ N
differences NNS N
between IN N
patients NNS N
who WP N
withdrew VBD N
versus FW N
those DT N
who WP N
completed VBD N
, , N
with IN N
the DT N
exception NN N
of IN N
insurance NN N
status NN N
, , N
suggests VBZ N
that IN N
external JJ N
validity NN N
was VBD N
not RB N
jeopardized VBN N
. . N

-DOCSTART- -11302295- O O

Psychosocial JJ N
nursing NN N
therapy NN N
following VBG N
sudden JJ N
cardiac JJ N
arrest NN N
: : N
impact NN N
on IN N
two-year JJ N
survival NN N
. . N

BACKGROUND NNP N
Although IN N
psychosocial JJ N
therapy NN N
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
mortality NN N
after IN N
myocardial JJ N
infarction NN N
, , N
it PRP N
is VBZ N
unknown JJ N
whether IN N
the DT N
benefits NNS N
of IN N
psychosocial JJ N
therapy NN N
on IN N
mortality NN N
reduction NN N
extend VBP N
to TO N
out-of-hospital JJ N
sudden JJ N
cardiac NN N
arrest NN N
, , N
a DT N
main JJ N
cause NN N
of IN N
cardiovascular JJ N
mortality NN N
. . N

OBJECTIVE NNP N
Describe NNP N
efficacy NN N
of IN N
psychosocial JJ N
therapy NN N
on IN N
two-year JJ N
cardiovascular JJ N
mortality NN N
in IN N
sudden JJ N
cardiac JJ N
arrest NN N
survivors NNS N
. . N

METHOD NNP N
Survivors NNPS N
of IN N
out-of-hospital JJ N
ventricular JJ N
fibrillation NN N
or CC N
asystole NN N
( ( N
N NNP N
= NNP N
129 CD N
) ) N
, , N
documented VBN N
by IN N
electrocardiograms NNS N
from IN N
registries NNS N
of IN N
a DT N
citywide NN N
Medic NNP N
One NNP N
unit NN N
and CC N
two CD N
countywide NN N
emergency NN N
units NNS N
, , N
were VBD N
randomized VBN N
into IN N
a DT N
two CD N
group NN N
, , N
experimental JJ N
, , N
longitudinal JJ N
design NN N
. . N

The DT N
intervention NN N
consisted VBD N
of IN N
11 CD N
individual JJ N
sessions NNS N
, , N
implementing VBG N
three CD N
components NNS N
: : N
physiologic JJ N
relaxation NN N
with IN N
biofeedback NN N
training NN N
focused VBD N
on IN N
altering VBG N
autonomic JJ N
tone NN N
; : N
cognitive JJ N
behavioral JJ N
therapy NN N
aimed VBN N
at IN N
self-management JJ N
and CC N
coping VBG N
strategies NNS N
for IN N
depression NN N
, , N
anxiety NN N
, , N
and CC N
anger NN N
; : N
and CC N
cardiovascular JJ N
health NN N
education NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
cardiovascular JJ N
mortality NN N
. . N

RESULTS NNP N
Risk NNP N
of IN N
cardiovascular JJ N
death NN N
was VBD N
significantly RB N
reduced VBN N
86 CD N
% NN N
by IN N
psychosocial JJ N
therapy NN N
, , N
p NN N
= NNP N
.03 NNP N
. . N

Six NNP N
of IN N
the DT N
seven CD N
cardiovascular JJ N
deaths NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
caused VBN N
by IN N
ventricular JJ N
arrhythmias NN N
. . N

The DT N
cardiovascular JJ N
death NN N
in IN N
the DT N
therapy NN N
group NN N
was VBD N
due JJ N
to TO N
stroke VB N
. . N

Controlling VBG N
for IN N
depression NN N
, , N
previous JJ N
myocardial JJ N
infarction NN N
, , N
low JJ N
ejection NN N
fraction NN N
, , N
decreased JJ N
heart NN N
rate NN N
variability NN N
, , N
and CC N
ventricular JJ N
ectopic NN N
beats NNS N
had VBD N
little JJ N
impact NN N
on IN N
estimated VBN N
treatment NN N
effect NN N
. . N

The DT N
risk NN N
of IN N
all-cause JJ N
mortality NN N
was VBD N
reduced VBN N
by IN N
62 CD N
% NN N
in IN N
the DT N
therapy NN N
group NN N
, , N
p VBP N
= JJ N
.13 NNP N
. . N

There EX N
were VBD N
a DT N
total NN N
of IN N
three CD N
deaths NNS N
in IN N
the DT N
therapy NN N
group NN N
and CC N
eight CD N
deaths NNS N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSIONS NNP N
Psychosocial NNP N
therapy NN N
significantly RB N
reduced VBD N
the DT N
risk NN N
of IN N
cardiovascular JJ N
death NN N
in IN N
sudden JJ N
cardiac JJ N
arrest NN N
survivors NNS N
. . N

-DOCSTART- -20406576- O O

The DT N
ScanBrit NNP N
randomised VBD N
, , N
controlled VBD N
, , N
single-blind JJ N
study NN N
of IN N
a DT N
gluten- JJ N
and CC N
casein-free JJ N
dietary JJ N
intervention NN N
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

There EX N
is VBZ N
increasing VBG N
interest NN N
in IN N
the DT N
use NN N
of IN N
gluten- JJ N
and CC N
casein-free JJ N
diets NNS N
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP N
) ) N
. . N

We PRP N
report VBP N
results NNS N
from IN N
a DT N
two-stage NN N
, , N
24-month JJ N
, , N
randomised VBN N
, , N
controlled VBN N
trial NN N
incorporating VBG N
an DT N
adaptive JJ N
'catch-up NN N
' POS N
design NN N
and CC N
interim JJ N
analysis NN N
. . N

Stage NN N
1 CD N
of IN N
the DT N
trial NN N
saw VBD N
72 CD N
Danish JJ N
children NNS N
( ( N
aged VBN N
4 CD N
years NNS N
to TO N
10 CD N
years NNS N
11 CD N
months NNS N
) ) N
assigned VBD N
to TO N
diet VB N
( ( N
A DT N
) ) N
or CC N
non-diet JJ N
( ( N
B NNP N
) ) N
groups NNS N
by IN N
stratified JJ N
randomisation NN N
. . N

Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
( ( N
ADOS NNP N
) ) N
and CC N
the DT N
Gilliam NNP N
Autism NNP N
Rating NNP N
Scale NNP N
( ( N
GARS NNP N
) ) N
were VBD N
used VBN N
to TO N
assess VB N
core NN N
autism NN N
behaviours NNS N
, , N
Vineland NNP N
Adaptive NNP N
Behaviour NNP N
Scales NNP N
( ( N
VABS NNP N
) ) N
to TO N
ascertain VB N
developmental JJ N
level NN N
, , N
and CC N
Attention-Deficit NNP N
Hyperactivity NNP N
Disorder NNP N
- : N
IV NNP N
scale NN N
( ( N
ADHD-IV NNP N
) ) N
to TO N
determine VB N
inattention NN N
and CC N
hyperactivity NN N
. . N

Participants NNS N
were VBD N
tested VBN N
at IN N
baseline NN N
, , N
8 CD N
, , N
and CC N
12 CD N
months NNS N
. . N

Based VBN N
on IN N
per IN N
protocol NN N
repeated VBN N
measures NNS N
analysis NN N
, , N
data NNS N
for IN N
26 CD N
diet JJ N
children NNS N
and CC N
29 CD N
controls NNS N
were VBD N
available JJ N
at IN N
12 CD N
months NNS N
. . N

At IN N
this DT N
point NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
improvement NN N
to TO N
mean VB N
diet JJ N
group NN N
scores NNS N
( ( N
time*treatment JJ N
interaction NN N
) ) N
on IN N
sub-domains NNS N
of IN N
ADOS NNP N
, , N
GARS NNP N
and CC N
ADHD-IV NNP N
measures NNS N
. . N

Surpassing VBG N
of IN N
predefined JJ N
statistical JJ N
thresholds NNS N
as IN N
evidence NN N
of IN N
improvement NN N
in IN N
group NN N
A NNP N
at IN N
12 CD N
months NNS N
sanctioned VBD N
the DT N
re-assignment NN N
of IN N
group NN N
B NNP N
participants NNS N
to TO N
active JJ N
dietary JJ N
treatment NN N
. . N

Stage NN N
2 CD N
data NNS N
for IN N
18 CD N
group NN N
A NNP N
and CC N
17 CD N
group NN N
B NNP N
participants NNS N
were VBD N
available JJ N
at IN N
24 CD N
months NNS N
. . N

Multiple NNP N
scenario NN N
analysis NN N
based VBN N
on IN N
inter- JJ N
and CC N
intra-group JJ N
comparisons NNS N
showed VBD N
some DT N
evidence NN N
of IN N
sustained JJ N
clinical JJ N
group NN N
improvements NNS N
although IN N
possibly RB N
indicative JJ N
of IN N
a DT N
plateau NN N
effect NN N
for IN N
intervention NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
dietary JJ N
intervention NN N
may MD N
positively RB N
affect VB N
developmental JJ N
outcome NN N
for IN N
some DT N
children NNS N
diagnosed VBN N
with IN N
ASD NNP N
. . N

In IN N
the DT N
absence NN N
of IN N
a DT N
placebo NN N
condition NN N
to TO N
the DT N
current JJ N
investigation NN N
, , N
we PRP N
are VBP N
, , N
however RB N
, , N
unable JJ N
to TO N
disqualify VB N
potential JJ N
effects NNS N
derived VBN N
from IN N
intervention NN N
outside IN N
of IN N
dietary JJ N
changes NNS N
. . N

Further JJ N
studies NNS N
are VBP N
required VBN N
to TO N
ascertain VB N
potential JJ N
best- NN N
and CC N
non-responders NNS N
to TO N
intervention NN N
. . N

The DT N
study NN N
was VBD N
registered VBN N
with IN N
ClincialTrials.gov NNP N
, , N
number NN N
NCT00614198 NNP N
. . N

-DOCSTART- -16097539- O O

Migration NN N
of IN N
the DT N
acetabular JJ N
component NN N
: : N
effect NN N
of IN N
cement NN N
pressurization NN N
and CC N
significance NN N
of IN N
early JJ N
radiolucency NN N
: : N
a DT N
randomized JJ N
5-year JJ N
study NN N
using VBG N
radiostereometry NN N
. . N

BACKGROUND NNP N
Cementing NNP N
technique NN N
is VBZ N
a DT N
crucial JJ N
factor NN N
in IN N
prosthesis NN N
fixation NN N
. . N

No DT N
randomized JJ N
studies NNS N
have VBP N
been VBN N
published VBN N
, , N
however RB N
, , N
comparing VBG N
the DT N
outcome NN N
of IN N
conventional JJ N
fingerpacking NN N
with IN N
the DT N
outcome NN N
of IN N
pressurization NN N
of IN N
the DT N
cement NN N
prior RB N
to TO N
cup VB N
insertion NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
We PRP N
randomized VBD N
50 CD N
THAs NNP N
to TO N
either VB N
fingerpacking NN N
or CC N
sequential JJ N
pressurization NN N
( ( N
including VBG N
individual JJ N
pressurization NN N
of IN N
each DT N
anchorage NN N
hole NN N
) ) N
and CC N
followed VBD N
the DT N
patients NNS N
with IN N
RSA NNP N
for IN N
5 CD N
years NNS N
. . N

The DT N
penetration NN N
of IN N
cement NN N
into IN N
the DT N
anchorage NN N
holes NNS N
was VBD N
measured VBN N
on IN N
digital JJ N
radiographs NN N
. . N

Postoperative JJ N
radiolucent NN N
lines NNS N
around IN N
the DT N
cup NN N
were VBD N
correlated VBN N
to TO N
later RBR N
RSA NNP N
results NNS N
. . N

For IN N
clinical JJ N
evaluation NN N
, , N
we PRP N
used VBD N
SF-36 NNP N
and CC N
HHS NNP N
. . N

RESULTS VB N
The DT N
pressurized JJ N
group NN N
of IN N
THAs NNP N
was VBD N
more RBR N
stable JJ N
regarding VBG N
changes NNS N
in IN N
inclination NN N
. . N

We PRP N
found VBD N
no DT N
other JJ N
difference NN N
in IN N
the DT N
migratory NN N
behavior NN N
. . N

The DT N
cement NN N
penetration NN N
into IN N
the DT N
anchorage NN N
holes NNS N
was VBD N
deeper RBR N
with IN N
the DT N
pressurization NN N
technique NN N
than IN N
with IN N
fingerpacking NN N
. . N

For IN N
the DT N
whole JJ N
group NN N
taken VBN N
together RB N
, , N
there EX N
was VBD N
a DT N
strong JJ N
relation NN N
between IN N
the DT N
presence NN N
of IN N
radiolucent NN N
lines NNS N
as IN N
measured VBN N
on IN N
the DT N
postoperative JJ N
radiograph NN N
and CC N
later JJ N
migration NN N
observed VBN N
by IN N
RSA NNP N
at IN N
2 CD N
and CC N
5 CD N
years NNS N
. . N

INTERPRETATION NNP N
Pressurization NNP N
of IN N
the DT N
cement NN N
produced VBD N
better JJR N
cement NN N
penetration NN N
and CC N
increased VBD N
the DT N
cup NN N
stability NN N
in IN N
terms NNS N
of IN N
changes NNS N
in IN N
inclination NN N
. . N

Early JJ N
findings NNS N
of IN N
radiolucent NN N
lines NNS N
can MD N
predict VB N
later RB N
unfavorable JJ N
cup NN N
migration NN N
. . N

-DOCSTART- -19931151- O O

Tetracaine NNP N
( ( N
ametop NN N
) ) N
compared VBN N
to TO N
placebo VB N
for IN N
reducing VBG N
pain NN N
associated VBN N
with IN N
intramuscular JJ N
injection NN N
of IN N
palivizumab NN N
( ( N
synagis NN N
) ) N
. . N

Infants NNS N
receive VBP N
many JJ N
painful JJ N
immunizations NNS N
before IN N
they PRP N
are VBP N
2 CD N
years NNS N
old JJ N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
if IN N
topical JJ N
tetracaine NN N
reduces VBZ N
the DT N
pain NN N
of IN N
intramuscular JJ N
palivizumab NNS N
compared VBN N
to TO N
placebo VB N
. . N

There EX N
were VBD N
two CD N
study NN N
injections NNS N
, , N
one CD N
with IN N
tetracaine NN N
and CC N
one CD N
with IN N
placebo NN N
. . N

Pain NN N
was VBD N
scored VBN N
by IN N
their PRP$ N
parents NNS N
and CC N
a DT N
pediatric JJ N
nurse NN N
. . N

Topical JJ N
tetracaine NN N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
pain NN N
score NN N
, , N
although IN N
it PRP N
did VBD N
lead VB N
to TO N
faster VB N
recovery NN N
times NNS N
. . N

Additional JJ N
pain-reduction NN N
strategies NNS N
are VBP N
required VBN N
. . N

-DOCSTART- -12443948- O O

Reactive JJ N
balance NN N
adjustments NNS N
to TO N
unexpected JJ N
perturbations NNS N
during IN N
human JJ N
walking NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
unexpected JJ N
forward NN N
perturbations NNS N
( ( N
FP NNP N
) ) N
during IN N
gait NN N
on IN N
lower JJR N
extremity NN N
joint NN N
mechanics NNS N
and CC N
muscle NN N
Electromyographic NNP N
( ( N
EMG NNP N
) ) N
patterns VBZ N
in IN N
healthy JJ N
adults NNS N
. . N

The DT N
muscles NNS N
surrounding VBG N
the DT N
hip NN N
were VBD N
found VBN N
to TO N
be VB N
most RBS N
important JJ N
in IN N
maintaining VBG N
control NN N
of IN N
the DT N
trunk NN N
and CC N
preventing VBG N
collapse NN N
in IN N
response NN N
to TO N
the DT N
FP NNP N
. . N

Distinct NNP N
lower JJR N
extremity NN N
joint JJ N
moment NN N
and CC N
power NN N
patterns NNS N
were VBD N
observed VBN N
in IN N
response NN N
to TO N
the DT N
FP NNP N
but CC N
an DT N
overall JJ N
positive JJ N
moment NN N
of IN N
support NN N
( ( N
M NNP N
( ( N
s PRP N
) ) N
) ) N
was VBD N
maintained VBN N
. . N

Therefore RB N
, , N
reactive JJ N
balance NN N
control NN N
was VBD N
a DT N
synchronized JJ N
effort NN N
of IN N
the DT N
lower JJR N
extremity NN N
joints NNS N
to TO N
prevent VB N
collapse NN N
during IN N
the DT N
FP NNP N
. . N

-DOCSTART- -19808281- O O

Long-term JJ N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
study NN N
using VBG N
repetitive JJ N
education NN N
at IN N
six-month JJ N
intervals NNS N
and CC N
monitoring NN N
for IN N
adherence NN N
in IN N
heart NN N
failure NN N
outpatients NNS N
: : N
the DT N
REMADHE NNP N
trial NN N
. . N

BACKGROUND VB N
The DT N
effectiveness NN N
of IN N
heart NN N
failure NN N
disease NN N
management NN N
programs NNS N
in IN N
patients NNS N
under IN N
cardiologists NNS N
' POS N
care NN N
over IN N
long-term JJ N
follow-up NN N
is VBZ N
not RB N
established VBN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
a DT N
disease JJ N
management NN N
program NN N
with IN N
repetitive JJ N
education NN N
and CC N
telephone NN N
monitoring NN N
on IN N
primary JJ N
( ( N
combined VBN N
death NN N
or CC N
unplanned JJ N
first JJ N
hospitalization NN N
and CC N
quality-of-life JJ N
changes NNS N
) ) N
and CC N
secondary JJ N
end NN N
points NNS N
( ( N
hospitalization NN N
, , N
death NN N
, , N
and CC N
adherence NN N
) ) N
. . N

The DT N
REMADHE NNP N
[ NNP N
Repetitive NNP N
Education NNP N
and CC N
Monitoring NNP N
for IN N
ADherence NNP N
for IN N
Heart NNP N
Failure NNP N
] NNP N
trial NN N
is VBZ N
a DT N
long-term JJ N
randomized NN N
, , N
prospective JJ N
, , N
parallel JJ N
trial NN N
designed VBN N
to TO N
compare VB N
intervention NN N
with IN N
control NN N
. . N

One CD N
hundred VBD N
seventeen JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
usual JJ N
care NN N
, , N
and CC N
233 CD N
to TO N
additional JJ N
intervention NN N
. . N

The DT N
mean JJ N
follow-up NN N
was VBD N
2.47+/-1.75 CD N
years NNS N
, , N
with IN N
54 CD N
% NN N
adherence NN N
to TO N
the DT N
program NN N
. . N

In IN N
the DT N
intervention NN N
group NN N
, , N
the DT N
primary JJ N
end NN N
point NN N
composite NN N
of IN N
death NN N
or CC N
unplanned JJ N
hospitalization NN N
was VBD N
reduced VBN N
( ( N
hazard JJ N
ratio NN N
, , N
0.64 CD N
; : N
confidence NN N
interval NN N
, , N
0.43 CD N
to TO N
0.88 CD N
; : N
P=0.008 NNP N
) ) N
, , N
driven VBN N
by IN N
reduction NN N
in IN N
hospitalization NN N
. . N

The DT N
quality-of-life JJ N
questionnaire NN N
score NN N
improved VBD N
only RB N
in IN N
the DT N
intervention NN N
group NN N
( ( N
P NNP N
< NNP N
0.003 CD N
) ) N
. . N

Mortality NNP N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Number NNP N
of IN N
hospitalizations NNS N
( ( N
1.3+/-1.7 JJ N
versus NN N
0.8+/-1.3 NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
total JJ N
hospital NN N
days NNS N
during IN N
the DT N
follow-up JJ N
( ( N
19.9+/-51 JJ N
versus NN N
11.1+/-24 JJ N
days NNS N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
the DT N
need NN N
for IN N
emergency NN N
visits NNS N
( ( N
4.5+/-10.6 JJ N
versus NN N
1.6+/-2.4 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
were VBD N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
. . N

Beneficial JJ N
effects NNS N
were VBD N
homogeneous JJ N
for IN N
sex NN N
, , N
race NN N
, , N
diabetes NNS N
and CC N
no DT N
diabetes NN N
, , N
age NN N
, , N
functional JJ N
class NN N
, , N
and CC N
etiology NN N
. . N

CONCLUSIONS NNP N
For IN N
a DT N
longer RBR N
follow-up JJ N
period NN N
than IN N
in IN N
previous JJ N
studies NNS N
, , N
this DT N
heart NN N
failure NN N
disease JJ N
management NN N
program NN N
model NN N
of IN N
patients NNS N
under IN N
the DT N
supervision NN N
of IN N
a DT N
cardiologist NN N
is VBZ N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
unplanned JJ N
hospitalization NN N
, , N
a DT N
reduction NN N
of IN N
total JJ N
hospital NN N
days NNS N
, , N
and CC N
a DT N
reduced JJ N
need NN N
for IN N
emergency NN N
care NN N
, , N
as RB N
well RB N
as IN N
improved VBN N
quality NN N
of IN N
life NN N
, , N
despite IN N
modest JJ N
program NN N
adherence NN N
over IN N
time NN N
. . N

-DOCSTART- -15745138- O O

Online NNP N
conductivity NN N
monitoring NN N
: : N
validation NN N
and CC N
usefulness NN N
in IN N
a DT N
clinical JJ N
trial NN N
of IN N
reduced JJ N
dialysate NN N
conductivity NN N
. . N

Relatively RB N
low JJ N
dialysate NN N
conductivity NN N
( ( N
Cndi NNP N
) ) N
may MD N
improve VB N
outcomes NNS N
by IN N
reducing VBG N
the DT N
overall JJ N
sodium NN N
burden NN N
in IN N
dialysis NN N
patients NNS N
. . N

Excess NNP N
sodium NN N
removal NN N
, , N
however RB N
, , N
could MD N
lead VB N
to TO N
hemodynamic JJ N
instability NN N
. . N

We PRP N
performed VBD N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
reduction NN N
of IN N
Cndi NNP N
. . N

For IN N
the DT N
study NN N
, , N
28 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
maintenance NN N
of IN N
Cndi NNP N
at IN N
13.6 CD N
mS/cm NNS N
( ( N
equivalent JJ N
to TO N
135 CD N
mmol/L NN N
of IN N
Na+ NNP N
) ) N
or CC N
serial JJ N
reduction NN N
of IN N
Cndi NNP N
in IN N
steps NNS N
of IN N
0.2 CD N
mS/cm NNS N
, , N
guided VBN N
by IN N
symptoms NNS N
and CC N
blood NN N
pressure NN N
. . N

Sodium NNP N
removal NN N
estimated VBN N
from IN N
pre- NN N
and CC N
postplasma JJ N
concentrations NNS N
correlated VBN N
well RB N
with IN N
removal NN N
measured VBN N
by IN N
conductivity NN N
monitoring NN N
as IN N
ionic JJ N
mass NN N
balance NN N
( ( N
R2 NNP N
0.66 CD N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
. . N

Of IN N
the DT N
16 CD N
patients NNS N
randomized VBN N
to TO N
reduction NN N
of IN N
Cndi NNP N
, , N
6 CD N
achieved VBD N
Cndi NNP N
13.4 CD N
mS/cm NN N
, , N
6 CD N
achieved VBD N
13.2 CD N
mS/cm NN N
, , N
and CC N
4 CD N
achieved VBD N
13.0 CD N
mS/cm NN N
. . N

No DT N
episodes NNS N
of IN N
disequilibrium NN N
occurred VBD N
. . N

Interdialytic JJ N
weight NN N
gain NN N
was VBD N
reduced VBN N
from IN N
2.34 CD N
+/- JJ N
0.10 CD N
kg NN N
to TO N
1.57 CD N
+/- JJ N
0.11 CD N
kg NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Predialysis NNP N
systolic JJ N
blood NN N
pressure NN N
fell VBD N
from IN N
144 CD N
+/- JJ N
3 CD N
mm NN N
Hg NNP N
to TO N
137 CD N
+/- JJ N
4 CD N
mm NN N
Hg NNP N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
reduction NN N
in IN N
convective JJ N
sodium NN N
removal NN N
was VBD N
balanced VBN N
by IN N
an DT N
increase NN N
in IN N
diffusive JJ N
sodium NN N
removal NN N
( ( N
95 CD N
+/- JJ N
9 CD N
mmol NN N
cf NN N
. . N

175 CD N
+/- JJ N
14 CD N
mmol NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
. . N

Reduction NN N
in IN N
Cndi NNP N
monitored VBN N
by IN N
IMB NNP N
is VBZ N
safe JJ N
and CC N
practical JJ N
and CC N
leads VBZ N
to TO N
improved VBN N
interdialytic JJ N
weight NN N
gains NNS N
and CC N
blood NN N
pressure NN N
control NN N
, , N
while IN N
avoiding VBG N
excessive JJ N
sodium NN N
removal NN N
. . N

-DOCSTART- -17334477- O O

Comparison NNP N
of IN N
the DT N
effect NN N
of IN N
gonadotropin-releasing NN N
hormone NN N
analog NN N
( ( N
Diphereline NNP N
) ) N
and CC N
Cabergoline NNP N
( ( N
Dostinex NNP N
) ) N
treatment NN N
on IN N
uterine JJ N
myoma NN N
regression NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
cabergoline NN N
( ( N
Dostinex NNP N
, , N
a DT N
dopamine JJ N
agonist NN N
) ) N
on IN N
the DT N
myoma NN N
growth NN N
compared VBN N
to TO N
Diphereline NNP N
( ( N
a DT N
gonadotropin-releasing NN N
hormone NN N
agonist NN N
) ) N
. . N

METHODS NNP N
This DT N
study NN N
took VBD N
place NN N
in IN N
the DT N
Department NNP N
of IN N
Obstetrics NNP N
and CC N
Gynecology NNP N
of IN N
Tabriz NNP N
University NNP N
of IN N
Medical NNP N
Sciences NNPS N
, , N
Tabriz NNP N
, , N
Iran NNP N
from IN N
July NNP N
2004 CD N
to TO N
December NNP N
2005 CD N
. . N

Fifty NNP N
women NNS N
with IN N
uterine JJ N
myoma NN N
, , N
who WP N
met VBD N
the DT N
criteria NNS N
of IN N
the DT N
study NN N
thoroughly RB N
, , N
were VBD N
randomly RB N
allocated VBN N
into IN N
2 CD N
equal JJ N
groups NNS N
to TO N
take VB N
either DT N
Diphereline NNP N
or CC N
Cabergoline NNP N
. . N

The DT N
first JJ N
Group NNP N
took VBD N
3.75 CD N
mg NN N
of IN N
Diphereline NNP N
4 CD N
times NNS N
every DT N
28 CD N
days NNS N
and CC N
the DT N
second JJ N
group NN N
took VBD N
0.5 CD N
mg NN N
of IN N
Cabergoline NNP N
once RB N
a DT N
week NN N
for IN N
6 CD N
weeks NNS N
. . N

RESULTS VB N
The DT N
Cabergoline NNP N
was VBD N
well RB N
tolerated VBN N
and CC N
fewer JJR N
adverse JJ N
effects NNS N
were VBD N
noted VBN N
. . N

The DT N
tumor NN N
regressed VBD N
significantly RB N
and CC N
volume NN N
reduction NN N
rate NN N
of IN N
individual JJ N
tumor NN N
nodule NN N
varied VBD N
from IN N
46-53 CD N
% NN N
. . N

The DT N
gonadotropin NN N
releasing VBG N
hormone JJ N
agonist NN N
group NN N
all DT N
responded VBD N
to TO N
the DT N
treatment NN N
, , N
and CC N
volume NN N
reduction NN N
rate NN N
of IN N
the DT N
individual JJ N
tumor NN N
nodule NN N
varied VBD N
from IN N
21-97 CD N
% NN N
. . N

The DT N
extent NN N
of IN N
tumor NN N
shrinkage NN N
was VBD N
positively RB N
correlated VBN N
to TO N
the DT N
number NN N
of IN N
nodules NNS N
( ( N
p=0.881 NN N
, , N
p NN N
< VBD N
0.005 CD N
and CC N
0.701 CD N
, , N
p NN N
< NNP N
0.005 CD N
) ) N
. . N

CONCLUSION NNP N
In IN N
light NN N
of IN N
therapeutic JJ N
efficacy NN N
and CC N
few JJ N
adverse JJ N
effects NNS N
, , N
the DT N
dopamine NN N
agonists NNS N
may MD N
hold VB N
promise NN N
as IN N
novel JJ N
treatment NN N
modalities NNS N
for IN N
leiomyoma NN N
. . N

Further JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
optimal JJ N
strategy NN N
for IN N
the DT N
treatment NN N
of IN N
leiomyoma NN N
through IN N
these DT N
agents NNS N
. . N

-DOCSTART- -17719303- O O

Sodium NN N
bicarbonate NN N
, , N
N-acetylcysteine NNP N
, , N
and CC N
saline NN N
for IN N
prevention NN N
of IN N
radiocontrast-induced JJ N
nephropathy NN N
. . N

A DT N
comparison NN N
of IN N
3 CD N
regimens NNS N
for IN N
protecting VBG N
contrast-induced JJ N
nephropathy JJ N
in IN N
patients NNS N
undergoing VBG N
coronary JJ N
procedures NNS N
. . N

A DT N
single-center JJ N
prospective NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Several NNP N
protective JJ N
therapies NNS N
have VBP N
been VBN N
developed VBN N
to TO N
prevent VB N
contrast-induced JJ N
nephropathy JJ N
( ( N
CIN NNP N
) ) N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
efficacy NN N
of IN N
sodium NN N
bicarbonate NN N
by IN N
comparing VBG N
2 CD N
other JJ N
regimens NNS N
, , N
including VBG N
combination NN N
of IN N
N-acetylcysteine NNP N
( ( N
NAC NNP N
) ) N
plus CC N
sodium JJ N
chloride NN N
and CC N
sodium NN N
chloride NN N
alone RB N
, , N
to TO N
prevent VB N
CIN NNP N
in IN N
patients NNS N
undergoing VBG N
cardiovascular JJ N
procedures NNS N
. . N

METHODS NNP N
We PRP N
prospectively RB N
enrolled VBD N
264 CD N
patients NNS N
who WP N
were VBD N
scheduled VBN N
for IN N
cardiovascular JJ N
procedures NNS N
and CC N
had VBD N
a DT N
baseline JJ N
creatinine NN N
level NN N
> VBD N
1.2 CD N
mg/dL NN N
. . N

The DT N
patients NNS N
were VBD N
assigned VBN N
1 CD N
of IN N
3 CD N
prophylactic JJ N
regimens NNS N
: : N
infusion NN N
of IN N
sodium NN N
bicarbonate NN N
, , N
sodium NN N
chloride NN N
, , N
sodium NN N
chloride NN N
plus CC N
oral JJ N
NAC NNP N
( ( N
600 CD N
mg RB N
bid NN N
) ) N
. . N

Contrast-induced JJ N
nephropathy NN N
was VBD N
defined VBN N
as IN N
an DT N
increase NN N
in IN N
serum JJ N
creatinine NN N
level NN N
> VBD N
25 CD N
% NN N
or CC N
0.5 CD N
mg/dL NNS N
after IN N
48 CD N
hours NNS N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
among IN N
groups NNS N
regarding VBG N
baseline NN N
demographic JJ N
properties NNS N
and CC N
nephropathy JJ N
risk NN N
factors NNS N
. . N

The DT N
change NN N
in IN N
creatinine JJ N
clearance NN N
was VBD N
significantly RB N
better RBR N
in IN N
the DT N
sodium NN N
bicarbonate NN N
group NN N
than IN N
other JJ N
2 CD N
groups NNS N
( ( N
P NNP N
= NNP N
.007 NNP N
) ) N
. . N

The DT N
incidence NN N
of IN N
CIN NNP N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
sodium NN N
bicarbonate NN N
group NN N
( ( N
4.5 CD N
% NN N
) ) N
compared VBN N
with IN N
sodium JJ N
chloride NN N
alone RB N
( ( N
13.6 CD N
% NN N
, , N
P NNP N
= NNP N
.036 NNP N
) ) N
and CC N
tended VBD N
to TO N
be VB N
lower JJR N
than IN N
in IN N
the DT N
combination NN N
group NN N
( ( N
12.5 CD N
% NN N
, , N
P NNP N
= NNP N
.059 NNP N
) ) N
. . N

After IN N
adjusting VBG N
the DT N
Mehran NNP N
nephropathy NN N
risk NN N
score NN N
, , N
the DT N
risk NN N
of IN N
CIN NNP N
significantly RB N
reduced VBD N
with IN N
sodium NN N
bicarbonate NN N
compared VBN N
with IN N
sodium JJ N
chloride NN N
alone RB N
( ( N
adjusted VBN N
risk NN N
ratio NN N
0.29 CD N
, , N
P NNP N
= NNP N
.043 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Hydration NNP N
with IN N
sodium JJ N
bicarbonate NN N
provides VBZ N
better JJR N
protection NN N
against IN N
CIN NNP N
than IN N
the DT N
sodium NN N
chloride JJ N
infusion NN N
does VBZ N
alone RB N
. . N

Combination NNP N
therapy NN N
of IN N
NAC NNP N
plus CC N
sodium JJ N
chloride NN N
did VBD N
not RB N
offer VB N
additional JJ N
benefit NN N
over IN N
hydration NN N
with IN N
sodium JJ N
chloride NN N
alone RB N
. . N

-DOCSTART- -23224592- O O

Parents NNS N
' POS N
state NN N
and CC N
trait NN N
anxiety NN N
: : N
relationships NNS N
with IN N
anxiety NN N
severity NN N
and CC N
treatment NN N
response NN N
in IN N
adolescents NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Comorbid NNP N
anxiety NN N
is VBZ N
common JJ N
among IN N
children NNS N
with IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
( ( N
ASD NNP N
) ) N
, , N
and CC N
parents NNS N
of IN N
children NNS N
with IN N
ASD NNP N
are VBP N
more RBR N
likely JJ N
to TO N
have VB N
anxiety NN N
disorders NNS N
. . N

This DT N
study NN N
investigated VBD N
the DT N
relationship NN N
between IN N
parents NNS N
' POS N
state NN N
and CC N
trait NN N
anxiety NN N
and CC N
parent-reported JJ N
internalizing NN N
and CC N
externalizing VBG N
symptoms NNS N
among IN N
adolescents NNS N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
with IN N
ASD NNP N
, , N
as RB N
well RB N
as IN N
the DT N
relationship NN N
of IN N
parents NNS N
' POS N
anxiety NN N
symptoms NNS N
and CC N
adolescent JJ N
treatment NN N
response NN N
in IN N
the DT N
context NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

Parental JJ N
state NN N
anxiety NN N
correlated VBD N
with IN N
severity NN N
of IN N
adolescent JJ N
anxiety NN N
, , N
and CC N
trait NN N
anxiety NN N
in IN N
parents NNS N
correlated VBN N
with IN N
parent-reported JJ N
adolescent NN N
internalizing NN N
and CC N
externalizing NN N
symptoms NNS N
. . N

Also RB N
, , N
parents NNS N
of IN N
adolescent JJ N
treatment NN N
responders NNS N
experienced VBD N
a DT N
decrease NN N
in IN N
their PRP$ N
own JJ N
trait NN N
anxiety NN N
. . N

Findings NNS N
highlight VBD N
the DT N
importance NN N
of IN N
considering VBG N
parental JJ N
anxiety NN N
when WRB N
targeting VBG N
anxiety NN N
among IN N
youth NN N
with IN N
ASD NNP N
. . N

-DOCSTART- -8561059- O O

Effects NNS N
of IN N
interaction NN N
of IN N
RRR-alpha-tocopheryl NNP N
acetate NN N
and CC N
fish JJ N
oil NN N
on IN N
low-density-lipoprotein JJ N
oxidation NN N
in IN N
postmenopausal JJ N
women NNS N
with IN N
and CC N
without IN N
hormone-replacement JJ N
therapy NN N
. . N

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
RRR-alpha-tocpheryl NNP N
acetate NN N
( ( N
alpha-tocopheryl JJ N
acetate NN N
) ) N
and CC N
hormone-replacement JJ N
therapy NN N
( ( N
HRT NNP N
) ) N
on IN N
the DT N
oxidative JJ N
susceptibility NN N
of IN N
low-density NN N
lipoprotein NN N
( ( N
LDL NNP N
) ) N
in IN N
postmenopausal JJ N
women NNS N
consuming VBG N
a DT N
fish JJ N
oil NN N
supplement NN N
. . N

The DT N
independent JJ N
effect NN N
of IN N
fish JJ N
oil NN N
was VBD N
also RB N
assessed VBN N
. . N

Forty-eight JJ N
women NNS N
, , N
equally RB N
divided VBD N
between IN N
women NNS N
using VBG N
and CC N
not RB N
using VBG N
HRT NNP N
, , N
participated VBD N
in IN N
a DT N
double-blind JJ N
crossover NN N
trial NN N
. . N

Each DT N
of IN N
the DT N
four CD N
periods NNS N
lasted VBD N
5 CD N
wk NN N
and CC N
was VBD N
followed VBN N
by IN N
a DT N
4-wk JJ N
washout NN N
interval NN N
. . N

During IN N
each DT N
period NN N
all DT N
subjects NNS N
were VBD N
given VBN N
a DT N
15-g JJ N
supplement NN N
of IN N
fish JJ N
oil NN N
and CC N
either RB N
0 CD N
( ( N
placebo NN N
) ) N
, , N
100 CD N
, , N
200 CD N
, , N
or CC N
400 CD N
mg JJ N
alpha-tocopheryl JJ N
acetate JJ N
daily JJ N
. . N

LDL NNP N
resistance NN N
to TO N
oxidative VB N
modification NN N
was VBD N
assessed VBN N
by IN N
calculating VBG N
lag NN N
time NN N
, , N
propagation NN N
rate NN N
, , N
and CC N
maximum JJ N
production NN N
of IN N
conjugated JJ N
dienes NNS N
. . N

Supplementation NN N
with IN N
fish JJ N
oil NN N
and CC N
placebo NN N
shortened VBN N
lag JJ N
time NN N
and CC N
slowed VBN N
propagation NN N
rate NN N
in IN N
women NNS N
both DT N
using VBG N
and CC N
not RB N
using VBG N
HRT NNP N
. . N

After IN N
subjects NNS N
consumed VBD N
fish JJ N
oil NN N
, , N
supplementation NN N
with IN N
alpha-tocopheryl JJ N
acetate NN N
increased VBD N
plasma NN N
and CC N
LDL NNP N
alpha-tocopherol NN N
contents NNS N
significantly RB N
and CC N
lengthened VBD N
lag NN N
time NN N
( ( N
at IN N
even RB N
the DT N
lowest JJS N
concentration NN N
) ) N
but CC N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
propagation NN N
rate NN N
or CC N
maximum JJ N
production NN N
compared VBN N
with IN N
values NNS N
measured VBN N
after IN N
consumption NN N
of IN N
fish JJ N
oil NN N
alone RB N
. . N

Women NNP N
not RB N
using VBG N
HRT NNP N
had VBD N
faster JJR N
propagation NN N
rates NNS N
and CC N
higher JJR N
maximum NN N
production NN N
than IN N
women NNS N
using VBG N
HRT NNP N
; : N
after IN N
supplementation NN N
with IN N
fish JJ N
oil NN N
and CC N
alpha-tocopheryl JJ N
acetate NN N
these DT N
differences NNS N
prevailed VBD N
. . N

Supplements NNS N
as RB N
low JJ N
as IN N
100 CD N
mg JJ N
alpha-tocopheryl JJ N
acetate/d NN N
increase VB N
the DT N
resistance NN N
of IN N
LDL NNP N
to TO N
oxidation VB N
when WRB N
fish JJ N
oil NN N
supplements NNS N
are VBP N
used VBN N
. . N

HRT NNP N
and CC N
fish JJ N
oil NN N
supplements NNS N
may MD N
independently RB N
affect VB N
LDL NNP N
oxidative JJ N
susceptibility NN N
. . N

-DOCSTART- -15491374- O O

Effects NNS N
of IN N
bifidobacterium NN N
breve VBP N
supplementation NN N
on IN N
intestinal JJ N
flora NNS N
of IN N
low JJ N
birth NN N
weight NN N
infants NNS N
. . N

BACKGROUND IN N
It PRP N
is VBZ N
known VBN N
that IN N
the DT N
bifidobacteria NN N
flora VBP N
play NN N
important JJ N
roles NNS N
in IN N
mucosal NN N
host NN N
defense NN N
and CC N
can MD N
prevent VB N
infectious JJ N
diseases NNS N
. . N

Because IN N
bacterial JJ N
populations NNS N
develop VBP N
during IN N
the DT N
first JJ N
day NN N
of IN N
life NN N
, , N
the DT N
authors NNS N
examined VBD N
whether IN N
the DT N
early JJ N
administration NN N
of IN N
bifidobacteria NN N
has VBZ N
a DT N
positive JJ N
effect NN N
on IN N
the DT N
health NN N
of IN N
low JJ N
birth NN N
weight NN N
infants NNS N
. . N

METHODS NNP N
The DT N
effects NNS N
of IN N
oral JJ N
administration NN N
of IN N
Bifidobacterium NNP N
breve NN N
( ( N
B. NNP N
breve VBP N
) ) N
supplements NNS N
were VBD N
studied VBN N
in IN N
a DT N
controlled JJ N
trial NN N
with IN N
low JJ N
birth NN N
weight NN N
infants NNS N
( ( N
average JJ N
birth NN N
weight NN N
1489 CD N
g NN N
) ) N
. . N

The DT N
infants NNS N
were VBD N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
Group NNP N
A NNP N
and CC N
B NNP N
received VBD N
a DT N
dose NN N
of IN N
1.6 CD N
x NNS N
10 CD N
( ( N
8 CD N
) ) N
cells NNS N
of IN N
B. NNP N
breve VBP N
supplement NN N
twice RB N
a DT N
day NN N
, , N
commencing VBG N
either CC N
from IN N
several JJ N
hours NNS N
after IN N
birth NN N
( ( N
group NN N
A NNP N
) ) N
or CC N
24 CD N
h NN N
after IN N
birth NN N
( ( N
group NN N
B NNP N
) ) N
. . N

Group NNP N
C NNP N
, , N
the DT N
control NN N
group NN N
, , N
received VBD N
no DT N
supplement NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
birth NN N
weight NN N
, , N
treatment NN N
with IN N
antibiotics NNS N
, , N
and CC N
the DT N
starting JJ N
time NN N
of IN N
breast-feeding NN N
among IN N
the DT N
three CD N
groups NNS N
. . N

A DT N
Bifidobacterium-predominant JJ N
flora NN N
was VBD N
formed VBN N
at IN N
an DT N
average NN N
of IN N
2 CD N
weeks NNS N
after IN N
birth NN N
in IN N
group NN N
A NNP N
and CC N
at IN N
an DT N
average NN N
of IN N
4 CD N
weeks NNS N
after IN N
birth NN N
in IN N
group NN N
B NNP N
, , N
while IN N
no DT N
Bifidobacterium NNP N
was VBD N
isolated VBN N
in IN N
eight CD N
out IN N
of IN N
10 CD N
infants NNS N
in IN N
group NN N
C NNP N
during IN N
the DT N
observation NN N
period NN N
of IN N
7 CD N
weeks NNS N
. . N

In IN N
comparison NN N
between IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
Bifidobacterium NNP N
was VBD N
detected VBN N
significantly RB N
earlier RBR N
in IN N
group NN N
A NNP N
, , N
and CC N
the DT N
number NN N
of IN N
Enterobacteriaceae NNP N
present NN N
in IN N
the DT N
infants NNS N
at IN N
2 CD N
weeks NNS N
after IN N
birth NN N
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
A NNP N
. . N

CONCLUSION NNP N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
suggest VBP N
that IN N
very RB N
early JJ N
administration NN N
of IN N
B. NNP N
breve VBP N
to TO N
low JJ N
birth NN N
weight NN N
infants NNS N
is VBZ N
useful JJ N
in IN N
promoting VBG N
the DT N
colonization NN N
of IN N
the DT N
Bifidobacterium NNP N
and CC N
the DT N
formation NN N
of IN N
a DT N
normal JJ N
intestinal JJ N
flora NN N
. . N

-DOCSTART- -21324150- O O

Efficacy NN N
of IN N
a DT N
family NN N
practice-based JJ N
lifestyle JJ N
intervention NN N
program NN N
to TO N
increase VB N
physical JJ N
activity NN N
and CC N
reduce VB N
clinical JJ N
and CC N
physiological JJ N
markers NNS N
of IN N
vascular JJ N
health NN N
in IN N
patients NNS N
with IN N
high JJ N
normal JJ N
blood NN N
pressure NN N
and/or RB N
high JJ N
normal JJ N
blood NN N
glucose NN N
( ( N
SNAC NNP N
) ) N
: : N
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Previous JJ N
interventions NNS N
to TO N
increase VB N
physical JJ N
activity NN N
and CC N
reduce VB N
cardiovascular JJ N
risk NN N
factors NNS N
have VBP N
been VBN N
targeted VBN N
at IN N
individuals NNS N
with IN N
established VBN N
disease NN N
; : N
less CC N
attention NN N
has VBZ N
been VBN N
given VBN N
to TO N
intervention VB N
among IN N
individuals NNS N
with IN N
high JJ N
risk NN N
for IN N
disease NN N
nor CC N
has VBZ N
there RB N
been VBN N
determination NN N
of IN N
the DT N
influence NN N
of IN N
setting VBG N
in IN N
which WDT N
the DT N
intervention NN N
is VBZ N
provided VBN N
. . N

In IN N
particular JJ N
, , N
family NN N
practice NN N
represents VBZ N
an DT N
ideal JJ N
setting NN N
for IN N
the DT N
provision NN N
and CC N
long-term JJ N
maintenance NN N
of IN N
lifestyle JJ N
interventions NNS N
for IN N
patients NNS N
at IN N
risk NN N
( ( N
ie JJ N
high-normal JJ N
blood NN N
pressure NN N
or CC N
impaired JJ N
glucose JJ N
tolerance NN N
) ) N
. . N

METHODS/DESIGN PDT N
The DT N
Staged NNP N
Nutrition NNP N
and CC N
Activity NNP N
Counseling NNP N
( ( N
SNAC NNP N
) ) N
study NN N
is VBZ N
a DT N
randomized JJ N
clustered JJ N
design NN N
clinical JJ N
trial NN N
that WDT N
will MD N
investigate VB N
the DT N
effectiveness NN N
and CC N
efficacy NN N
of IN N
a DT N
multi-component JJ N
lifestyle JJ N
intervention NN N
on IN N
cardiovascular JJ N
disease NN N
risk NN N
factors NNS N
and CC N
vascular JJ N
function NN N
in IN N
patients NNS N
at IN N
risk NN N
in IN N
primary JJ N
care NN N
. . N

Patients NNS N
will MD N
be VB N
randomized VBN N
by IN N
practice NN N
to TO N
either VB N
a DT N
standard NN N
of IN N
care NN N
lifestyle JJ N
intervention NN N
or CC N
a DT N
behaviourally-based JJ N
, , N
matched VBD N
prescriptive JJ N
physical JJ N
activity NN N
and CC N
diet JJ N
change NN N
program NN N
. . N

The DT N
primary JJ N
goal NN N
is VBZ N
to TO N
increase VB N
physical JJ N
activity NN N
and CC N
improve VB N
dietary JJ N
intake NN N
according VBG N
to TO N
Canada NNP N
's POS N
Guides NNP N
to TO N
Physical NNP N
Activity NNP N
Healthy NNP N
Eating NNP N
over IN N
24 CD N
months NNS N
. . N

The DT N
primary JJ N
intention NN N
to TO N
treat VB N
analysis NN N
will MD N
compare VB N
behavioral JJ N
, , N
physiological JJ N
and CC N
metabolic JJ N
outcomes NNS N
at IN N
6 CD N
, , N
12 CD N
and CC N
24 CD N
months NNS N
post-randomization JJ N
including VBG N
estimation NN N
of IN N
incident JJ N
hypertension NN N
and/or NN N
diabetes VBZ N
. . N

DISCUSSION VB N
The DT N
design NN N
features NNS N
of IN N
our PRP$ N
trial NN N
, , N
and CC N
the DT N
practical JJ N
problems NNS N
( ( N
and CC N
solutions NNS N
) ) N
associated VBN N
with IN N
implementing VBG N
these DT N
design NN N
features NNS N
, , N
particularly RB N
those DT N
that IN N
result NN N
in IN N
potential JJ N
delay NN N
between IN N
recruitment NN N
, , N
baseline NN N
data NNS N
collection NN N
, , N
randomization NN N
, , N
intervention NN N
, , N
and CC N
assessment NN N
will MD N
be VB N
discussed VBN N
. . N

Results NNS N
of IN N
the DT N
SNAC NNP N
trial NN N
will MD N
provide VB N
scientific JJ N
rationale NN N
for IN N
the DT N
implementation NN N
of IN N
this DT N
lifestyle JJ N
intervention NN N
in IN N
primary JJ N
care NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN NNP N
: : N
ISRCTN:42921300 NNP N
. . N

-DOCSTART- -18972730- O O

[ JJ N
Effects NNS N
of IN N
small JJ N
needle-knife JJ N
comprehensive JJ N
therapy NN N
on IN N
pain NN N
and CC N
lumbar NN N
flexion NN N
range NN N
in IN N
the DT N
chronic JJ N
nonspecific NN N
low JJ N
back RB N
pain NN N
patient NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
observe VB N
therapeutic JJ N
effect NN N
of IN N
small JJ N
needle-knife JJ N
comprehensive JJ N
therapy NN N
on IN N
pain NN N
and CC N
lumbar NN N
flexion NN N
range NN N
in IN N
the DT N
chronic JJ N
nonspecific NN N
low JJ N
back RB N
pain NN N
patient NN N
. . N

METHODS NNP N
Three CD N
hundred VBD N
and CC N
five CD N
cases NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
a DT N
needle-knife JJ N
group NN N
of IN N
153 CD N
cases NNS N
and CC N
a DT N
physiotherapy NN N
group NN N
of IN N
152 CD N
cases NNS N
. . N

The DT N
needle-knife JJ N
group NN N
were VBD N
treated VBN N
with IN N
small JJ N
needle-knife JJ N
releasing NN N
therapy NN N
, , N
blocking VBG N
and CC N
functional JJ N
training NN N
. . N

The DT N
physiotherapy NN N
group NN N
were VBD N
treated VBN N
with IN N
ultra-short JJ N
wave NN N
, , N
modulated VBD N
medium NN N
frequency NN N
current JJ N
, , N
massage NN N
and CC N
functional JJ N
training NN N
. . N

Pain NN N
was VBD N
assessed VBN N
by IN N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
and CC N
the DT N
lumbar NN N
flexion NN N
range NN N
was VBD N
determined VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
pain NN N
and CC N
the DT N
lumbar NN N
flexion NN N
range NN N
were VBD N
significantly RB N
improved VBN N
in IN N
the DT N
two CD N
groups NNS N
; : N
and CC N
after IN N
treatment NN N
, , N
the DT N
VAS NNP N
score NN N
and CC N
the DT N
lumbar NN N
flexion NN N
range NN N
were VBD N
( ( N
1.60 CD N
+/- JJ N
0.38 CD N
) ) N
points NNS N
and CC N
( ( N
65.76 CD N
+/- JJ N
15.11 CD N
) ) N
cm NN N
in IN N
the DT N
needle-knife JJ N
group NN N
and CC N
( ( N
4.59 CD N
+/- JJ N
1.09 CD N
) ) N
points NNS N
and CC N
( ( N
53.74 CD N
+/- JJ N
15.13 CD N
) ) N
cm NN N
in IN N
the DT N
physiotherapy NN N
group NN N
, , N
respectively RB N
, , N
the DT N
needle-knife JJ N
group NN N
being VBG N
significantly RB N
better JJR N
than IN N
the DT N
physiotherapy NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Follow-up NNP N
survey NN N
of IN N
6-36 JJ N
months NNS N
showed VBD N
that IN N
the DT N
VAS NNP N
score NN N
and CC N
the DT N
lumbar NN N
flexion NN N
range NN N
in IN N
the DT N
needle-knife JJ N
group NN N
were VBD N
superior JJ N
to TO N
those DT N
in IN N
the DT N
physiotherapy NN N
group NN N
. . N

CONCLUSION NNP N
Small NNP N
needle-knife JJ N
comprehensive JJ N
therapy NN N
can MD N
significantly RB N
improve VB N
pain NN N
and CC N
lumbar NN N
flexion NN N
range NN N
in IN N
the DT N
chronic JJ N
nonspecific NN N
low JJ N
back RB N
pain NN N
patient NN N
, , N
with IN N
a DT N
stable JJ N
long-term JJ N
therapeutic JJ N
effect NN N
. . N

-DOCSTART- -15327617- O O

A DT N
prospective JJ N
randomised JJ N
comparison NN N
of IN N
sublingual JJ N
and CC N
vaginal JJ N
misoprostol NN N
in IN N
second JJ N
trimester NN N
termination NN N
of IN N
pregnancy NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
, , N
side NN N
effects NNS N
and CC N
acceptability NN N
of IN N
sublingual JJ N
and CC N
vaginal JJ N
misoprostol NN N
for IN N
second JJ N
trimester NN N
medical JJ N
abortion NN N
. . N

DESIGN NNP N
Prospective NNP N
randomised VBD N
controlled VBN N
trial NN N
. . N

SETTING NN N
Tertiary JJ N
referral JJ N
unit NN N
and CC N
a DT N
teaching JJ N
hospital NN N
. . N

POPULATION NNP N
Two CD N
hundred VBD N
and CC N
twenty-four JJ N
women NNS N
at IN N
12 CD N
to TO N
20 CD N
weeks NNS N
of IN N
gestation NN N
. . N

METHODS NNP N
The DT N
women NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
sublingual JJ N
or CC N
vaginal JJ N
misoprostol NN N
400 CD N
microg NN N
every DT N
3 CD N
hours NNS N
for IN N
a DT N
maximum NN N
of IN N
five CD N
doses NNS N
. . N

The DT N
course NN N
of IN N
misoprostol NN N
was VBD N
repeated VBN N
if IN N
the DT N
woman NN N
did VBD N
not RB N
abort VB N
within IN N
24 CD N
hours NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
success NN N
rate NN N
at IN N
48 CD N
hours NNS N
, , N
induction-to-abortion NN N
interval NN N
and CC N
the DT N
side NN N
effects NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
success NN N
rate NN N
at IN N
48 CD N
hours NNS N
( ( N
sublingual JJ N
: : N
91 CD N
% NN N
; : N
vaginal JJ N
: : N
95 CD N
% NN N
) ) N
. . N

However RB N
, , N
the DT N
success NN N
rate NN N
at IN N
24 CD N
hours NNS N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
vaginal JJ N
group NN N
( ( N
85 CD N
% NN N
) ) N
compared VBN N
with IN N
the DT N
sublingual JJ N
group NN N
( ( N
64 CD N
% NN N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
median JJ N
induction-to-abortion NN N
interval NN N
( ( N
sublingual JJ N
: : N
13.8 CD N
hours NNS N
; : N
vaginal JJ N
: : N
12.0 CD N
hours NNS N
) ) N
. . N

Significantly RB N
more JJR N
women NNS N
in IN N
the DT N
sublingual JJ N
group NN N
preferred VBD N
the DT N
route NN N
to TO N
which WDT N
they PRP N
were VBD N
assigned VBN N
when WRB N
compared VBN N
with IN N
the DT N
vaginal JJ N
group NN N
. . N

The DT N
incidence NN N
of IN N
fever NN N
was VBD N
also RB N
less RBR N
in IN N
the DT N
sublingual JJ N
group NN N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
vaginal JJ N
misoprostol NN N
for IN N
second JJ N
trimester NN N
medical JJ N
abortion NN N
resulted VBD N
in IN N
a DT N
higher JJR N
success NN N
rate NN N
than IN N
sublingual JJ N
misoprostol NN N
at IN N
24 CD N
hours NNS N
but CC N
the DT N
abortion NN N
rate NN N
was VBD N
similar JJ N
at IN N
48 CD N
hours NNS N
. . N

Vaginal NNP N
misoprostol NN N
should MD N
be VB N
the DT N
regimen NNS N
of IN N
choice NN N
but CC N
sublingual JJ N
misoprostol NN N
is VBZ N
also RB N
an DT N
effective JJ N
alternative NN N
. . N

-DOCSTART- -16089221- O O

Hydrogen NNP N
peroxide NN N
mouth NN N
rinse NN N
: : N
an DT N
analgesic JJ N
post-tonsillectomy NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
analgesic JJ N
efficacy NN N
of IN N
hydrogen NN N
peroxide NN N
( ( N
H2O2 NNP N
) ) N
mouth NN N
rinse NN N
with IN N
control NN N
for IN N
post-tonsillectomy JJ N
pain NN N
management NN N
. . N

DESIGN NNP N
Double-blinded NNP N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Thirty-seven JJ N
patients NNS N
from IN N
5 CD N
to TO N
14 CD N
years NNS N
old JJ N
undergoing JJ N
electrocautery NN N
tonsillectomy NN N
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
H2O2 NNP N
mouth NN N
rinse NN N
or CC N
the DT N
water NN N
rinse NN N
( ( N
control NN N
) ) N
group NN N
. . N

For IN N
14 CD N
days NNS N
, , N
patients NNS N
recorded VBD N
pain NN N
levels NNS N
twice RB N
daily RB N
using VBG N
a DT N
visual JJ N
analogue NN N
scale NN N
. . N

Analgesic JJ N
uses NNS N
, , N
as RB N
well RB N
as IN N
any DT N
complications NNS N
, , N
were VBD N
also RB N
noted VBN N
by IN N
the DT N
patients NNS N
. . N

RESULTS NNP N
Thirty-seven JJ N
patients NNS N
completed VBD N
the DT N
study NN N
, , N
21 CD N
in IN N
the DT N
treatment NN N
group NN N
and CC N
16 CD N
in IN N
the DT N
control NN N
group NN N
. . N

Mean NNP N
postoperative JJ N
days NNS N
of IN N
pain NN N
were VBD N
10.3 CD N
and CC N
8.3 CD N
, , N
respectively RB N
, , N
and CC N
differed VBD N
significantly RB N
( ( N
p JJ N
= NNP N
.008 NNP N
) ) N
. . N

Mean JJ N
postoperative JJ N
days NNS N
of IN N
analgesic JJ N
use NN N
were VBD N
9.0 CD N
and CC N
6.7 CD N
, , N
respectively RB N
, , N
and CC N
differed VBD N
significantly RB N
( ( N
p JJ N
= NNP N
.005 NNP N
) ) N
. . N

Only RB N
one CD N
incidence NN N
of IN N
postoperative JJ N
hemorrhage NN N
occurred VBD N
in IN N
the DT N
study NN N
group NN N
. . N

CONCLUSION NNP N
In IN N
our PRP$ N
study NN N
, , N
the DT N
H2O2 NNP N
mouth NN N
rinse NN N
does VBZ N
not RB N
provide VB N
a DT N
better JJR N
analgesic JJ N
effect NN N
than IN N
the DT N
water NN N
rinse NN N
for IN N
post-tonsillectomy JJ N
pain NN N
relief NN N
. . N

-DOCSTART- -24103072- O O

Long-term JJ N
exposure NN N
to TO N
belatacept VB N
in IN N
recipients NNS N
of IN N
extended JJ N
criteria NNS N
donor JJ N
kidneys NNS N
. . N

Patients NNS N
in IN N
the DT N
BENEFIT-EXT NNP N
study NN N
received VBD N
extended JJ N
criteria NNS N
donor JJ N
kidneys NNS N
and CC N
a DT N
more RBR N
intensive JJ N
( ( N
MI NNP N
) ) N
or CC N
less RBR N
intensive JJ N
( ( N
LI NNP N
) ) N
belatacept IN N
immunosuppression NN N
regimen NNS N
, , N
or CC N
cyclosporine VB N
A NNP N
( ( N
CsA NNP N
) ) N
. . N

Patients NNS N
who WP N
remained VBD N
on IN N
assigned JJ N
therapy NN N
through IN N
year NN N
3 CD N
were VBD N
eligible JJ N
to TO N
enter VB N
a DT N
long-term JJ N
extension NN N
( ( N
LTE NNP N
) ) N
study NN N
. . N

Three CD N
hundred VBD N
four CD N
patients NNS N
entered VBD N
the DT N
LTE NNP N
( ( N
n JJ N
= $ N
104 CD N
MI NNP N
; : N
n CC N
= $ N
113 CD N
LI NNP N
; : N
n CC N
= $ N
87 CD N
CsA NNP N
) ) N
, , N
and CC N
260 CD N
continued VBD N
treatment NN N
through IN N
year NN N
5 CD N
( ( N
n JJ N
= $ N
91 CD N
MI NNP N
; : N
n CC N
= $ N
100 CD N
LI NNP N
; : N
n CC N
= $ N
69 CD N
CsA NNP N
) ) N
. . N

Twenty CD N
patients NNS N
died VBD N
during IN N
the DT N
LTE NNP N
( ( N
n JJ N
= $ N
5 CD N
MI NNP N
; : N
n CC N
= $ N
9 CD N
LI NNP N
; : N
n CC N
= $ N
6 CD N
CsA NNP N
) ) N
, , N
and CC N
eight CD N
experienced VBD N
graft NN N
loss NN N
( ( N
n JJ N
= $ N
2 CD N
MI NNP N
; : N
n CC N
= $ N
1 CD N
LI NNP N
; : N
n CC N
= $ N
5 CD N
CsA NNP N
) ) N
. . N

Three CD N
patients NNS N
experienced VBD N
an DT N
acute JJ N
rejection NN N
episode NN N
( ( N
n JJ N
= $ N
2 CD N
MI NNP N
; : N
n CC N
= $ N
1 CD N
LI NNP N
) ) N
. . N

The DT N
incidence NN N
rate NN N
of IN N
serious JJ N
adverse JJ N
events NNS N
, , N
viral JJ N
infections NNS N
and CC N
fungal JJ N
infections NNS N
was VBD N
similar JJ N
across IN N
groups NNS N
during IN N
the DT N
LTE NNP N
. . N

There EX N
were VBD N
four CD N
cases NNS N
of IN N
posttransplant JJ N
lymphoproliferative JJ N
disorder NN N
( ( N
PTLD NNP N
) ) N
from IN N
the DT N
beginning NN N
of IN N
the DT N
LTE NNP N
to TO N
year NN N
5 CD N
( ( N
n JJ N
= $ N
3 CD N
LI NNP N
; : N
n CC N
= $ N
1 CD N
CsA NNP N
) ) N
; : N
two CD N
of IN N
three CD N
PTLD NNP N
cases NNS N
in IN N
the DT N
LI NNP N
group NN N
were VBD N
in IN N
patients NNS N
who WP N
were VBD N
seronegative JJ N
for IN N
Epstein-Barr NNP N
virus NN N
( ( N
EBV NNP N
( ( N
- : N
) ) N
) ) N
at IN N
transplantation NN N
. . N

Mean NNP N
? . N
SD NNP N
calculated VBD N
GFR NNP N
at IN N
year NN N
5 CD N
was VBD N
55.9 CD N
? . N
17.5 CD N
( ( N
MI NNP N
) ) N
, , N
59.0 CD N
? . N
29.1 CD N
( ( N
LI NNP N
) ) N
and CC N
44.6 CD N
? . N
16.4 CD N
( ( N
CsA NNP N
) ) N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
. . N

Continued VBN N
treatment NN N
with IN N
belatacept NN N
was VBD N
associated VBN N
with IN N
a DT N
consistent JJ N
safety NN N
profile NN N
and CC N
sustained VBD N
improvement NN N
in IN N
renal JJ N
function NN N
versus NN N
CsA NNP N
over IN N
time NN N
. . N

-DOCSTART- -20946966- O O

Clofarabine NNP N
? . N
fludarabine NN N
with IN N
once RB N
daily JJ N
i.v NN N
. . N

busulfan NN N
as IN N
pretransplant JJ N
conditioning NN N
therapy NN N
for IN N
advanced JJ N
myeloid NN N
leukemia NN N
and CC N
MDS NNP N
. . N

Although IN N
a DT N
combination NN N
of IN N
i.v NN N
. . N

busulfan NN N
( ( N
Bu NNP N
) ) N
and CC N
fludarabine NN N
( ( N
Flu NNP N
) ) N
is VBZ N
a DT N
safe JJ N
, , N
reduced-toxicity JJ N
conditioning NN N
program NN N
for IN N
acute JJ N
myelogenous JJ N
leukemia/myelodysplastic JJ N
syndromes NNS N
( ( N
AML/MDS NNP N
) ) N
, , N
recurrent JJ N
leukemia NN N
posttransplantation NN N
remains VBZ N
a DT N
problem NN N
. . N

To TO N
enhance VB N
the DT N
conditioning NN N
regimen NN N
's POS N
antileukemic JJ N
effect NN N
, , N
we PRP N
decided VBD N
to TO N
supplant VB N
Flu NNP N
with IN N
clofarabine NN N
( ( N
Clo NNP N
) ) N
, , N
and CC N
assayed VBD N
the DT N
interactions NNS N
of IN N
these DT N
nucleoside JJ N
analogs NNS N
alone RB N
and CC N
in IN N
combination NN N
with IN N
Bu NNP N
in IN N
Bu-resistant NNP N
human NN N
cell NN N
lines NNS N
in IN N
vitro NN N
. . N

We PRP N
found VBD N
pronounced VBD N
synergy NN N
between IN N
each DT N
nucleoside NN N
and CC N
the DT N
alkylator NN N
but CC N
even RB N
more RBR N
enhanced JJ N
cytotoxic NN N
synergy NN N
when WRB N
the DT N
nucleoside JJ N
analogs NNS N
were VBD N
combined VBN N
prior RB N
to TO N
exposing VBG N
the DT N
cells NNS N
to TO N
Bu NNP N
. . N

We PRP N
then RB N
designed VBD N
a DT N
4-arm JJ N
clinical JJ N
trial NN N
in IN N
patients NNS N
with IN N
myeloid JJ N
leukemia NN N
undergoing VBG N
allogeneic JJ N
stem NN N
cell NN N
transplantation NN N
( ( N
allo-SCT JJ N
) ) N
. . N

Patients NNS N
were VBD N
adaptively RB N
randomized VBN N
as IN N
follows VBZ N
: : N
Arm JJ N
I-Clo NN N
: : N
Flu CD N
10:30 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
Arm NNP N
II-20:20 NNP N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
Arm NNP N
III-30:10 NNP N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
and CC N
Arm NNP N
IV-single-agent NNP N
Clo NNP N
at IN N
40 CD N
mg/m NN N
( ( N
2 CD N
) ) N
. . N

The DT N
nucleoside JJ N
analog NN N
( ( N
s PRP N
) ) N
were/was NN N
infused VBN N
over IN N
1 CD N
hour NN N
once RB N
daily JJ N
for IN N
4 CD N
days NNS N
, , N
followed VBD N
on IN N
each DT N
day NN N
by IN N
Bu NNP N
, , N
infused VBD N
over IN N
3 CD N
hours NNS N
to TO N
a DT N
pharmacokinetically RB N
targeted VBN N
daily JJ N
area NN N
under IN N
the DT N
curve NN N
( ( N
AUC NNP N
) ) N
of IN N
6000 CD N
?Mol-min NN N
? . N
10 CD N
% NN N
. . N

Fifty-one CD N
patients NNS N
have VBP N
been VBN N
enrolled VBN N
with IN N
a DT N
minimum JJ N
follow-up JJ N
exceeding VBG N
100 CD N
days NNS N
. . N

There EX N
were VBD N
32 CD N
males NNS N
and CC N
19 CD N
females NNS N
, , N
with IN N
a DT N
median JJ N
age NN N
of IN N
45 CD N
years NNS N
( ( N
range NN N
: : N
6-59 JJ N
) ) N
. . N

Nine JJ N
patients NNS N
had VBD N
chronic JJ N
myeloid NN N
leukemia NN N
( ( N
CML NNP N
) ) N
( ( N
BC NNP N
: : N
2 CD N
, , N
second JJ N
AP NNP N
: : N
3 CD N
, , N
and CC N
tyrosine-kinase JJ N
inhibitor NN N
refractory NN N
first RB N
chronic JJ N
phase NN N
[ NNP N
CP NNP N
] NN N
: : N
4 CD N
) ) N
. . N

Forty-two JJ N
patients NNS N
had VBD N
AML NNP N
: : N
14 CD N
were VBD N
induction NN N
failures NNS N
, , N
8 CD N
in IN N
first JJ N
chemotherapy-refractory JJ N
relapse NN N
, , N
7 CD N
in IN N
untreated JJ N
relapse NN N
, , N
3 CD N
in IN N
second JJ N
or CC N
subsequent JJ N
relapse NN N
, , N
4 CD N
were VBD N
in IN N
second JJ N
complete JJ N
remission NN N
( ( N
CR NNP N
) ) N
, , N
and CC N
3 CD N
in IN N
second JJ N
CR NNP N
without IN N
platelet NN N
recovery NN N
( ( N
CRp NNP N
) ) N
, , N
2 CD N
were VBD N
in IN N
high-risk JJ N
CR1 NNP N
. . N

Finally NNP N
, , N
1 CD N
patient NN N
was VBD N
in IN N
first JJ N
CRp NNP N
. . N

Graft-versus-host NNP N
disease NN N
( ( N
GVHD NNP N
) ) N
prophylaxis NN N
was VBD N
tacrolimus JJ N
and CC N
mini-methorexate JJ N
( ( N
MTX NNP N
) ) N
, , N
and CC N
those DT N
who WP N
had VBD N
an DT N
unrelated JJ N
or CC N
1 CD N
antigen-mismatched JJ N
donor NN N
received VBD N
low-dose JJ N
rabbit-ATG NN N
( ( N
Thymoglobulin? NNP N
) ) N
. . N

All DT N
patients NNS N
engrafted VBN N
. . N

Forty-one CD N
patients NNS N
had VBD N
active JJ N
leukemia NN N
at IN N
the DT N
time NN N
of IN N
transplant NN N
, , N
and CC N
35 CD N
achieved VBN N
CR NNP N
( ( N
85 CD N
% NN N
) ) N
. . N

Twenty CD N
of IN N
the DT N
42 CD N
AML NNP N
patients NNS N
and CC N
5 CD N
of IN N
9 CD N
CML NNP N
patients NNS N
are VBP N
alive JJ N
with IN N
a DT N
projected JJ N
median JJ N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
of IN N
23 CD N
months NNS N
. . N

Marrow NNP N
and CC N
blood NN N
( ( N
T NNP N
cell NN N
) ) N
chimerism NN N
studies NNS N
at IN N
day NN N
+100 NNP N
revealed VBD N
that IN N
both DT N
in IN N
the DT N
lower-dose JJ N
Clo NNP N
groups NNS N
( ( N
groups NNS N
1+2 CD N
) ) N
and CC N
the DT N
higher-dose JJ N
Clo NNP N
groups NNS N
( ( N
groups NNS N
3+4 CD N
) ) N
, , N
the DT N
patients NNS N
had VBD N
a DT N
median NN N
of IN N
100 CD N
% NN N
donor NN N
( ( N
T NNP N
cell NN N
) ) N
-derived VBD N
DNA NNP N
. . N

There EX N
has VBZ N
been VBN N
no DT N
secondary JJ N
graft NN N
failure NN N
. . N

In IN N
the DT N
first JJ N
100 CD N
days NNS N
, , N
1 CD N
patient NN N
died VBD N
of IN N
pneumonia NN N
, , N
and CC N
1 CD N
of IN N
liver NN N
GVHD NNP N
. . N

We PRP N
conclude VBP N
that IN N
( ( N
1 CD N
) ) N
Clo NNP N
? . N
Flu NNP N
with IN N
i.v NN N
. . N

Bu NNP N
as IN N
pretransplant JJ N
conditioning NN N
is VBZ N
safe JJ N
in IN N
high-risk JJ N
myeloid JJ N
leukemia NN N
patients NNS N
; : N
( ( N
2 CD N
) ) N
clofarabine NN N
is VBZ N
sufficiently RB N
immunosuppressive JJ N
to TO N
support VB N
allo-SCT NN N
in IN N
myeloid JJ N
leukemia NN N
; : N
and CC N
( ( N
3 CD N
) ) N
the DT N
median JJ N
OS NNP N
of IN N
23 CD N
months NNS N
in IN N
this DT N
high-risk JJ N
patient NN N
population NN N
is VBZ N
encouraging VBG N
. . N

Additional JJ N
studies NNS N
to TO N
evaluate VB N
the DT N
antileukemic JJ N
efficacy NN N
of IN N
Clo NNP N
? . N
Flu NNP N
with IN N
i.v NN N
. . N

Bu NNP N
as IN N
pretransplant JJ N
conditioning NN N
therapy NN N
are VBP N
warranted VBN N
. . N

-DOCSTART- -12462350- O O

Secretin NNP N
and CC N
sleep NN N
in IN N
children NNS N
with IN N
autism NN N
. . N

The DT N
objectives NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
1 CD N
) ) N
to TO N
examine VB N
possible JJ N
effects NNS N
of IN N
secretin JJ N
infusions NNS N
on IN N
sleep-wake JJ N
state NN N
organization NN N
in IN N
children NNS N
with IN N
autism NN N
, , N
and CC N
2 CD N
) ) N
to TO N
assess VB N
the DT N
feasibility NN N
of IN N
home NN N
recordings NNS N
using VBG N
time-lapse JJ N
videosomnography NN N
in IN N
children NNS N
with IN N
autism NN N
. . N

Participants NNS N
were VBD N
a DT N
subset NN N
of IN N
subjects NNS N
from IN N
two CD N
double JJ N
blind NN N
, , N
placebo-control NN N
, , N
multi-center JJ N
clinical JJ N
trials NNS N
. . N

One CD N
trial NN N
, , N
the DT N
UC NNP N
Irvine NNP N
study NN N
, , N
assessed VBD N
the DT N
effects NNS N
of IN N
porcine NN N
secretin NN N
vs. FW N
saline NN N
infusions NNS N
on IN N
children NNS N
's POS N
behavior NN N
, , N
language NN N
and CC N
IQ NNP N
. . N

The DT N
UC NNP N
Davis NNP N
trial NN N
assessed VBD N
the DT N
effects NNS N
of IN N
synthetic JJ N
human JJ N
secretin NN N
vs. FW N
saline NN N
infusions NNS N
on IN N
behavior NN N
, , N
language NN N
and CC N
gastrointestinal JJ N
function NN N
. . N

The DT N
sleep NN N
study NN N
enrolled VBD N
some DT N
of IN N
the DT N
children NNS N
from IN N
each DT N
of IN N
the DT N
two CD N
trials NNS N
to TO N
observe VB N
possible JJ N
secretin JJ N
effects NNS N
on IN N
sleep NN N
. . N

To TO N
examine VB N
sleep NN N
, , N
the DT N
UC NNP N
Irvine NNP N
trial NN N
used VBD N
the DT N
Children NNP N
's POS N
Sleep NNP N
Habits NNP N
Questionnaire NNP N
and CC N
daily JJ N
sleep NN N
diaries NNS N
, , N
whereas IN N
the DT N
UC NNP N
Davis NNP N
study NN N
used VBD N
home-recorded JJ N
time-lapse JJ N
videosomnography NN N
. . N

Because IN N
of IN N
the DT N
small JJ N
sample NN N
size NN N
, , N
the DT N
results NNS N
from IN N
both DT N
trials NNS N
are VBP N
preliminary JJ N
. . N

They PRP N
suggest VBP N
that IN N
secretin NN N
, , N
porcine NN N
or CC N
synthetic JJ N
, , N
does VBZ N
not RB N
improve VB N
sleep-wake NN N
state NN N
organization NN N
dramatically RB N
. . N

-DOCSTART- -11956614- O O

Endometrial JJ N
cytodiagnosis NN N
using VBG N
a DT N
new JJ N
softcyte NN N
versus NN N
a DT N
conventional JJ N
endocyte NN N
. . N

A DT N
new JJ N
endometrial JJ N
cytologic NN N
sampling VBG N
device NN N
, , N
softcyte NN N
, , N
was VBD N
used VBN N
in IN N
cytological JJ N
screening NN N
for IN N
endometrial JJ N
cancer NN N
, , N
and CC N
was VBD N
compared VBN N
with IN N
the DT N
endocyte NN N
with IN N
regard NN N
to TO N
manipulability NN N
, , N
adverse JJ N
effects NNS N
( ( N
including VBG N
pain NN N
and CC N
hemorrhage NN N
) ) N
, , N
and CC N
cellular JJ N
findings NNS N
( ( N
including VBG N
the DT N
quantity NN N
of IN N
cells NNS N
collected VBN N
, , N
the DT N
success NN N
rate NN N
, , N
cell NN N
freshness NN N
, , N
and CC N
cellular JJ N
clumping NN N
) ) N
. . N

A DT N
total NN N
of IN N
315 CD N
women NNS N
( ( N
premenopause IN N
251 CD N
, , N
postmenopause RB N
64 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
who WP N
underwent VBP N
the DT N
endometrial JJ N
cytological JJ N
screening NN N
with IN N
either CC N
the DT N
softcyte NN N
or CC N
the DT N
endocyte NN N
. . N

To TO N
assess VB N
the DT N
value NN N
of IN N
the DT N
softcyte NN N
we PRP N
compared VBN N
it PRP N
with IN N
the DT N
endocyte NN N
. . N

Endometrial NNP N
cytology NN N
using VBG N
a DT N
softcyte NN N
or CC N
an DT N
endocyte NN N
achieved VBN N
high JJ N
correct JJ N
diagnosis NN N
rate NN N
for IN N
cancer NN N
, , N
and CC N
both DT N
instruments NNS N
are VBP N
valuable JJ N
as IN N
endometrial JJ N
cytologic NN N
sample NN N
devices NNS N
. . N

The DT N
softcyte NN N
causes VBZ N
only RB N
mild JJ N
pain NN N
on IN N
introduction NN N
and CC N
during IN N
collection NN N
, , N
and CC N
a DT N
large JJ N
quantity NN N
of IN N
cells NNS N
could MD N
be VB N
harvested VBN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
softcyte NN N
is VBZ N
a DT N
useful JJ N
cytologic NN N
sampling VBG N
device NN N
in IN N
screening VBG N
for IN N
endometrial JJ N
cancer NN N
. . N

-DOCSTART- -18555063- O O

Anxiety NN N
sensitivity NN N
as IN N
an DT N
incremental JJ N
predictor NN N
of IN N
later JJ N
anxiety NN N
symptoms NNS N
and CC N
syndromes NNS N
. . N

Although IN N
anxiety NN N
sensitivity NN N
( ( N
AS NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
predict VB N
anxiety NN N
symptoms NNS N
and CC N
panic NN N
, , N
this DT N
literature NN N
is VBZ N
limited VBN N
in IN N
regard NN N
to TO N
evaluating VBG N
AS NNP N
as IN N
an DT N
incremental JJ N
predictor NN N
of IN N
anxiety NN N
psychopathology NN N
relative VBP N
to TO N
other JJ N
established VBN N
risk NN N
factors NNS N
including VBG N
sex NN N
and CC N
negative JJ N
affect NN N
. . N

The DT N
present JJ N
report NN N
prospectively RB N
evaluated VBD N
whether IN N
AS NNP N
was VBD N
predictive NN N
of IN N
later JJ N
changes NNS N
in IN N
anxiety NN N
symptoms NNS N
after IN N
controlling VBG N
for IN N
potential JJ N
confounding NN N
factors NNS N
. . N

Consistent JJ N
with IN N
hypothesis NN N
, , N
AS NNP N
was VBD N
found VBN N
to TO N
be VB N
a DT N
significant JJ N
, , N
incremental JJ N
predictor NN N
of IN N
anxiety NN N
symptoms NNS N
over IN N
time NN N
, , N
even RB N
after IN N
controlling VBG N
for IN N
sex NN N
and CC N
negative JJ N
affectivity NN N
. . N

These DT N
data NNS N
provide VBP N
novel JJ N
evidence NN N
for IN N
the DT N
unique JJ N
association NN N
between IN N
AS NNP N
of IN N
the DT N
development NN N
of IN N
anxiety NN N
symptoms NNS N
. . N

-DOCSTART- -22732966- O O

Nutritional JJ N
orientation NN N
, , N
knowledge NN N
and CC N
quality NN N
of IN N
diet NN N
in IN N
heart NN N
failure NN N
: : N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Non-pharmacological JJ N
measures NNS N
are VBP N
recommended VBN N
for IN N
heart NN N
failure NN N
patients NNS N
. . N

However RB N
, , N
most JJS N
studies NNS N
evaluate VBP N
low JJ N
sodium NN N
diet NN N
, , N
while IN N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effects NNS N
of IN N
interventions NNS N
to TO N
improve VB N
adherence NN N
and CC N
knowledge NN N
of IN N
patients NNS N
about IN N
diet JJ N
content NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
if IN N
a DT N
global JJ N
nutritional JJ N
orientation NN N
could MD N
affect VB N
nutritional JJ N
knowledge NN N
, , N
adherence NN N
to TO N
food NN N
guidelines NNS N
, , N
anthropometrics NNS N
and CC N
quality NN N
of IN N
life NN N
in IN N
heart NN N
failure NN N
patients NNS N
. . N

METHODS NNP N
Forty NNP N
six CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
intervention VB N
or CC N
control VB N
group NN N
. . N

Both DT N
groups NNS N
received VBD N
usual JJ N
care NN N
with IN N
medical JJ N
and CC N
nursing JJ N
staff NN N
; : N
the DT N
intervention NN N
group NN N
received VBD N
additional JJ N
nutritional JJ N
guidance NN N
about IN N
diet JJ N
and CC N
its PRP$ N
relationship NN N
with IN N
disease NN N
, , N
sources NNS N
of IN N
nutrients NNS N
, , N
and CC N
reduction NN N
of IN N
dietary JJ N
sodium NN N
and CC N
fats NNS N
. . N

Enforcement NN N
of IN N
the DT N
nutritional JJ N
guidance NN N
was VBD N
performed VBN N
after IN N
4 CD N
weeks NNS N
. . N

Both DT N
groups NNS N
were VBD N
evaluated VBN N
at IN N
baseline NN N
, , N
and CC N
after IN N
6 CD N
weeks NNS N
and CC N
6 CD N
months NNS N
. . N

Evaluations NNS N
included VBD N
anthropometric JJ N
parameters NNS N
, , N
sodium NN N
excretion NN N
in IN N
24-hour JJ N
urine NN N
, , N
dietary JJ N
recall NN N
, , N
nutrition NN N
knowledge NN N
and CC N
quality NN N
of IN N
life NN N
questionnaires NNS N
. . N

RESULTS NNP N
Mean NNP N
age NN N
of IN N
included JJ N
patients NNS N
was VBD N
58 CD N
? . N
10 CD N
years NNS N
and CC N
70 CD N
% NN N
were VBD N
male JJ N
. . N

After IN N
6 CD N
months NNS N
of IN N
follow-up NN N
, , N
the DT N
nutritional JJ N
knowledge NN N
of IN N
intervention NN N
group NN N
increased VBD N
compared VBN N
to TO N
control VB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Caloric NNP N
, , N
fat NN N
and CC N
sodium NN N
intake NN N
decreased VBN N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
to TO N
control VB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
quality NN N
of IN N
life NN N
or CC N
anthropometric JJ N
parameters NNS N
. . N

CONCLUSIONS NNP N
Nutritional NNP N
orientation NN N
was VBD N
effective JJ N
to TO N
modify VB N
1 CD N
) ) N
knowledge NN N
about IN N
food NN N
and CC N
nutrition NN N
, , N
and CC N
2 CD N
) ) N
quality NN N
of IN N
diet NN N
in IN N
outpatients NNS N
with IN N
heart NN N
failure NN N
. . N

Further JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
evaluate VB N
the DT N
benefits NNS N
on IN N
quality NN N
of IN N
life NN N
and CC N
prognosis NN N
. . N

-DOCSTART- -22151477- O O

Effect NN N
of IN N
a DT N
vitamin/mineral JJ N
supplement NN N
on IN N
children NNS N
and CC N
adults NNS N
with IN N
autism NN N
. . N

BACKGROUND NNP N
Vitamin/mineral NNP N
supplements NNS N
are VBP N
among IN N
the DT N
most RBS N
commonly RB N
used JJ N
treatments NNS N
for IN N
autism NN N
, , N
but CC N
the DT N
research NN N
on IN N
their PRP$ N
use NN N
for IN N
treating VBG N
autism NN N
has VBZ N
been VBN N
limited VBN N
. . N

METHOD NNP N
This DT N
study NN N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
three CD N
month NN N
vitamin/mineral JJ N
treatment NN N
study NN N
. . N

The DT N
study NN N
involved VBD N
141 CD N
children NNS N
and CC N
adults NNS N
with IN N
autism NN N
, , N
and CC N
pre NN N
and CC N
post NN N
symptoms NNS N
of IN N
autism NN N
were VBD N
assessed VBN N
. . N

None NN N
of IN N
the DT N
participants NNS N
had VBD N
taken VBN N
a DT N
vitamin/mineral JJ N
supplement NN N
in IN N
the DT N
two CD N
months NNS N
prior RB N
to TO N
the DT N
start NN N
of IN N
the DT N
study NN N
. . N

For IN N
a DT N
subset NN N
of IN N
the DT N
participants NNS N
( ( N
53 CD N
children NNS N
ages VBZ N
5-16 JJ N
) ) N
pre NN N
and CC N
post NN N
measurements NNS N
of IN N
nutritional JJ N
and CC N
metabolic JJ N
status NN N
were VBD N
also RB N
conducted VBN N
. . N

RESULTS VB N
The DT N
vitamin/mineral JJ N
supplement NN N
was VBD N
generally RB N
well-tolerated JJ N
, , N
and CC N
individually RB N
titrated VBN N
to TO N
optimum JJ N
benefit NN N
. . N

Levels NNP N
of IN N
many JJ N
vitamins NNS N
, , N
minerals NNS N
, , N
and CC N
biomarkers NNS N
improved/increased VBD N
showing VBG N
good JJ N
compliance NN N
and CC N
absorption NN N
. . N

Statistically NNP N
significant JJ N
improvements NNS N
in IN N
metabolic JJ N
status NN N
were VBD N
many JJ N
including VBG N
: : N
total JJ N
sulfate NN N
( ( N
+17 CD N
% NN N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
, , N
S-adenosylmethionine NNP N
( ( N
SAM NNP N
; : N
+6 CD N
% NN N
, , N
p NN N
= NNP N
0.003 CD N
) ) N
, , N
reduced VBD N
glutathione NN N
( ( N
+17 CD N
% NN N
, , N
p NN N
= NNP N
0.0008 CD N
) ) N
, , N
ratio NN N
of IN N
oxidized JJ N
glutathione NN N
to TO N
reduced VB N
glutathione NN N
( ( N
GSSG NNP N
: : N
GSH NNP N
; : N
-27 CD N
% NN N
, , N
p NN N
= NNP N
0.002 CD N
) ) N
, , N
nitrotyrosine JJ N
( ( N
-29 CD N
% NN N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
, , N
ATP NNP N
( ( N
+25 CD N
% NN N
, , N
p NN N
= NNP N
0.000001 CD N
) ) N
, , N
NADH NNP N
( ( N
+28 CD N
% NN N
, , N
p NN N
= NNP N
0.0002 CD N
) ) N
, , N
and CC N
NADPH NNP N
( ( N
+30 CD N
% NN N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
. . N

Most JJS N
of IN N
these DT N
metabolic JJ N
biomarkers NNS N
improved VBN N
to TO N
normal JJ N
or CC N
near-normal JJ N
levels.The JJ N
supplement NN N
group NN N
had VBD N
significantly RB N
greater JJR N
improvements NNS N
than IN N
the DT N
placebo NN N
group NN N
on IN N
the DT N
Parental NNP N
Global NNP N
Impressions-Revised JJ N
( ( N
PGI-R NNP N
, , N
Average NNP N
Change NNP N
, , N
p NN N
= NNP N
0.008 CD N
) ) N
, , N
and CC N
on IN N
the DT N
subscores NNS N
for IN N
Hyperactivity NNP N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
, , N
Tantrumming NNP N
( ( N
p JJ N
= NNP N
0.009 CD N
) ) N
, , N
Overall NNP N
( ( N
p NN N
= RB N
0.02 CD N
) ) N
, , N
and CC N
Receptive JJ N
Language NNP N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

For IN N
the DT N
other JJ N
three CD N
assessment NN N
tools VBZ N
the DT N
difference NN N
between IN N
treatment NN N
group NN N
and CC N
placebo NN N
group NN N
was VBD N
not RB N
statistically RB N
significant.Regression JJ N
analysis NN N
revealed VBD N
that IN N
the DT N
degree NN N
of IN N
improvement NN N
on IN N
the DT N
Average JJ N
Change NN N
of IN N
the DT N
PGI-R NNP N
was VBD N
strongly RB N
associated VBN N
with IN N
several JJ N
biomarkers NNS N
( ( N
adj NN N
. . N

R2 NNP N
= VBD N
0.61 CD N
, , N
p NN N
< NNP N
0.0005 CD N
) ) N
with IN N
the DT N
initial JJ N
levels NNS N
of IN N
biotin NN N
and CC N
vitamin NN N
K NNP N
being VBG N
the DT N
most RBS N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
both DT N
biotin NN N
and CC N
vitamin NN N
K NNP N
are VBP N
made VBN N
by IN N
beneficial JJ N
intestinal JJ N
flora NN N
. . N

CONCLUSIONS NNP N
Oral NNP N
vitamin/mineral JJ N
supplementation NN N
is VBZ N
beneficial JJ N
in IN N
improving VBG N
the DT N
nutritional JJ N
and CC N
metabolic JJ N
status NN N
of IN N
children NNS N
with IN N
autism NN N
, , N
including VBG N
improvements NNS N
in IN N
methylation NN N
, , N
glutathione NN N
, , N
oxidative JJ N
stress NN N
, , N
sulfation NN N
, , N
ATP NNP N
, , N
NADH NNP N
, , N
and CC N
NADPH NNP N
. . N

The DT N
supplement NN N
group NN N
had VBD N
significantly RB N
greater JJR N
improvements NNS N
than IN N
did VBD N
the DT N
placebo NN N
group NN N
on IN N
the DT N
PGI-R JJ N
Average JJ N
Change NN N
. . N

This DT N
suggests VBZ N
that IN N
a DT N
vitamin/mineral JJ N
supplement NN N
is VBZ N
a DT N
reasonable JJ N
adjunct JJ N
therapy NN N
to TO N
consider VB N
for IN N
most JJS N
children NNS N
and CC N
adults NNS N
with IN N
autism NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
NCT01225198 NNP N
. . N

-DOCSTART- -20439105- O O

Small NN N
but CC N
important JJ N
errors NNS N
in IN N
cardiovascular JJ N
risk NN N
calculation NN N
by IN N
practice NN N
nurses NNS N
: : N
a DT N
cross-sectional JJ N
study NN N
in IN N
randomised JJ N
trial NN N
setting NN N
. . N

BACKGROUND NNP N
Practice NNP N
nurses NNS N
play VBP N
an DT N
increasingly RB N
important JJ N
role NN N
in IN N
the DT N
prevention NN N
of IN N
cardiovascular JJ N
diseases NNS N
but CC N
we PRP N
do VBP N
not RB N
have VB N
evidence NN N
about IN N
the DT N
accuracy NN N
of IN N
their PRP$ N
cardiovascular JJ N
risk NN N
assessments NNS N
during IN N
real JJ N
practice NN N
consultations NNS N
. . N

OBJECTIVES NNP N
To TO N
examine VB N
how WRB N
nurses NNS N
perform VBP N
with IN N
regard NN N
to TO N
absolute VB N
10-year JJ N
cardiovascular JJ N
risk NN N
assessment NN N
in IN N
actual JJ N
practice NN N
. . N

DESIGN NNP N
Cross-sectional JJ N
study NN N
. . N

SETTING NN N
This DT N
study NN N
was VBD N
nested VBN N
in IN N
the DT N
IMPALA NNP N
study NN N
, , N
a DT N
clustered VBN N
randomised VBN N
controlled VBN N
trial NN N
involving VBG N
24 CD N
general JJ N
practices NNS N
in IN N
The DT N
Netherlands NNP N
. . N

PARTICIPANTS VB N
24 CD N
practice NN N
nurses NNS N
, , N
trained VBN N
in IN N
10-year JJ N
cardiovascular JJ N
risk NN N
assessment NN N
, , N
calculated VBD N
the DT N
risk NN N
of IN N
a DT N
total NN N
of IN N
421 CD N
patients NNS N
without IN N
established VBN N
cardiovascular JJ N
diseases NNS N
but CC N
eligible JJ N
for IN N
cardiovascular JJ N
risk NN N
assessment NN N
. . N

METHODS NNP N
The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
accuracy NN N
of IN N
risk NN N
assessments NNS N
, , N
defined VBN N
as IN N
( ( N
1 CD N
) ) N
the DT N
difference NN N
between IN N
the DT N
10-year JJ N
cardiovascular JJ N
risk NN N
percentage NN N
calculated VBN N
by IN N
nurses NNS N
and CC N
an DT N
independent JJ N
assessor NN N
, , N
and CC N
( ( N
2 CD N
) ) N
the DT N
agreement NN N
between IN N
the DT N
treatment NN N
categories NNS N
assigned VBN N
by IN N
the DT N
nurses NNS N
( ( N
low JJ N
, , N
moderate JJ N
or CC N
high JJ N
risk NN N
) ) N
and CC N
those DT N
assigned VBN N
by IN N
the DT N
independent JJ N
assessor NN N
. . N

RESULTS VB N
Thirty-one NNP N
( ( N
7.4 CD N
% NN N
) ) N
of IN N
the DT N
calculated JJ N
risk NN N
percentages NNS N
differed VBN N
by IN N
more JJR N
than IN N
our PRP$ N
preset NN N
limits NNS N
, , N
25 CD N
( ( N
81 CD N
% NN N
) ) N
being VBG N
underestimations NNS N
. . N

Elderly JJ N
patients NNS N
( ( N
OR NNP N
1.1 CD N
, , N
95 CD N
% NN N
CI NNP N
1.0-1.1 CD N
) ) N
, , N
male JJ N
patients NNS N
( ( N
vs. FW N
female NN N
OR NNP N
3.1 CD N
, , N
95 CD N
% NN N
CI NNP N
1.2-7.3 CD N
) ) N
, , N
and CC N
smoking NN N
patients NNS N
( ( N
vs. IN N
non-smoking NN N
OR NNP N
3.8 CD N
, , N
95 CD N
% NN N
CI NNP N
1.7-8.9 CD N
) ) N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
their PRP$ N
cardiovascular JJ N
risk NN N
miscalculated VBD N
. . N

Ten NNP N
( ( N
28 CD N
% NN N
) ) N
of IN N
the DT N
36 CD N
patients NNS N
who WP N
should MD N
be VB N
assigned VBN N
to TO N
the DT N
high-risk JJ N
treatment NN N
category NN N
according VBG N
to TO N
the DT N
independent JJ N
calculation NN N
, , N
were VBD N
missed VBN N
as IN N
high-risk JJ N
patients NNS N
by IN N
the DT N
practice NN N
nurses NNS N
. . N

CONCLUSIONS VB N
The DT N
overall JJ N
standard NN N
of IN N
accuracy NN N
of IN N
cardiovascular JJ N
risk NN N
assessment NN N
by IN N
trained JJ N
practice NN N
nurses NNS N
in IN N
actual JJ N
practice NN N
is VBZ N
high JJ N
. . N

However RB N
, , N
a DT N
significant JJ N
number NN N
of IN N
high-risk JJ N
patients NNS N
were VBD N
misclassified VBN N
, , N
with IN N
the DT N
probability NN N
that IN N
it PRP N
led VBD N
to TO N
missed VBN N
opportunities NNS N
for IN N
risk-reducing JJ N
interventions NNS N
. . N

As IN N
cardiovascular JJ N
risk NN N
assessments NNS N
are VBP N
frequently RB N
done VBN N
by IN N
nurses NNS N
in IN N
general JJ N
practice NN N
, , N
further JJ N
specific JJ N
training NN N
should MD N
be VB N
considered VBN N
to TO N
prevent VB N
undertreatment NN N
. . N

-DOCSTART- -24215858- O O

Menopausal NNP N
quality NN N
of IN N
life NN N
: : N
RCT NNP N
of IN N
yoga NN N
, , N
exercise NN N
, , N
and CC N
omega-3 JJ N
supplements NNS N
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
3 CD N
nonhormonal JJ N
therapies NNS N
for IN N
the DT N
improvement NN N
of IN N
menopause-related JJ N
quality NN N
of IN N
life NN N
in IN N
women NNS N
with IN N
vasomotor NN N
symptoms NNS N
. . N

STUDY NNP N
DESIGN NNP N
We PRP N
conducted VBD N
a DT N
12-week JJ N
3 CD N
? . N
2 CD N
randomized VBD N
, , N
controlled VBD N
, , N
factorial JJ N
design NN N
trial NN N
. . N

Peri- NN N
and CC N
postmenopausal JJ N
women NNS N
, , N
40-62 JJ N
years NNS N
old JJ N
, , N
were VBD N
assigned VBN N
randomly RB N
to TO N
yoga VB N
( ( N
n JJ N
= NNP N
107 CD N
) ) N
, , N
exercise NN N
( ( N
n JJ N
= NNP N
106 CD N
) ) N
, , N
or CC N
usual JJ N
activity NN N
( ( N
n JJ N
= NNP N
142 CD N
) ) N
and CC N
also RB N
assigned VBD N
randomly RB N
to TO N
a DT N
double-blind JJ N
comparison NN N
of IN N
omega-3 JJ N
( ( N
n JJ N
= NNP N
177 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
178 CD N
) ) N
capsules NNS N
. . N

We PRP N
performed VBD N
the DT N
following JJ N
interventions NNS N
: : N
( ( N
1 CD N
) ) N
weekly JJ N
90-minute CD N
yoga NN N
classes NNS N
with IN N
daily JJ N
at-home JJ N
practice NN N
, , N
( ( N
2 CD N
) ) N
individualized VBN N
facility-based JJ N
aerobic JJ N
exercise NN N
training NN N
3 CD N
times/week NN N
, , N
and CC N
( ( N
3 CD N
) ) N
0.615 CD N
g JJ N
omega-3 JJ N
supplement NN N
, , N
3 CD N
times/day NN N
. . N

The DT N
outcomes NNS N
were VBD N
assessed VBN N
with IN N
the DT N
following JJ N
scores NNS N
: : N
Menopausal NNP N
Quality NNP N
of IN N
Life NNP N
Questionnaire NNP N
( ( N
MENQOL NNP N
) ) N
total NN N
and CC N
domain NN N
( ( N
vasomotor NN N
symptoms NNS N
, , N
psychosocial JJ N
, , N
physical JJ N
and CC N
sexual JJ N
) ) N
. . N

RESULTS NNP N
Among IN N
355 CD N
randomly NNS N
assigned VBN N
women NNS N
who WP N
average VBP N
age NN N
was VBD N
54.7 CD N
years NNS N
, , N
338 CD N
women NNS N
( ( N
95 CD N
% NN N
) ) N
completed VBD N
12-week JJ N
assessments NNS N
. . N

Mean NNP N
baseline NN N
vasomotor NN N
symptoms JJ N
frequency NN N
was VBD N
7.6/day CD N
, , N
and CC N
the DT N
mean JJ N
baseline NN N
total JJ N
MENQOL NNP N
score NN N
was VBD N
3.8 CD N
( ( N
range NN N
, , N
1-8 CD N
from IN N
better JJR N
to TO N
worse VB N
) ) N
with IN N
no DT N
between-group JJ N
differences NNS N
. . N

For IN N
yoga NN N
compared VBN N
to TO N
usual JJ N
activity NN N
, , N
baseline NN N
to TO N
12-week JJ N
improvements NNS N
were VBD N
seen VBN N
for IN N
MENQOL NNP N
total JJ N
-0.3 NNP N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-0.6 VBP N
to TO N
0 CD N
; : N
P NNP N
= NNP N
.02 NNP N
) ) N
, , N
vasomotor NN N
symptom NN N
domain NN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
, , N
and CC N
sexuality NN N
domain NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
scores VBZ N
. . N

For IN N
women NNS N
who WP N
underwent VBP N
exercise NN N
and CC N
omega-3 JJ N
therapy NN N
compared VBN N
with IN N
control NN N
subjects NNS N
, , N
improvements NNS N
in IN N
baseline NN N
to TO N
12-week JJ N
total JJ N
MENQOL NNP N
scores NNS N
were VBD N
not RB N
observed VBN N
. . N

Exercise NN N
showed VBD N
benefit NN N
in IN N
the DT N
MENQOL NNP N
physical JJ N
domain NN N
score NN N
at IN N
12 CD N
weeks NNS N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

CONCLUSION NNP N
All NNP N
women NNS N
become VBP N
menopausal JJ N
, , N
and CC N
many JJ N
of IN N
them PRP N
seek VBP N
medical JJ N
advice NN N
on IN N
ways NNS N
to TO N
improve VB N
quality NN N
of IN N
life NN N
; : N
little JJ N
evidence-based JJ N
information NN N
exists NNS N
. . N

We PRP N
found VBD N
that IN N
, , N
among IN N
healthy JJ N
sedentary JJ N
menopausal NN N
women NNS N
, , N
yoga NN N
appears VBZ N
to TO N
improve VB N
menopausal NN N
quality NN N
of IN N
life NN N
; : N
the DT N
clinical JJ N
significance NN N
of IN N
our PRP$ N
finding NN N
is VBZ N
uncertain JJ N
because IN N
of IN N
the DT N
modest JJ N
effect NN N
. . N

-DOCSTART- -11932879- O O

Step-down JJ N
approach NN N
using VBG N
either CC N
cyclosporin VB N
A DT N
or CC N
methotrexate NN N
as IN N
maintenance NN N
therapy NN N
in IN N
early JJ N
rheumatoid NN N
arthritis NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
feasibility NN N
and CC N
outcome NN N
of IN N
the DT N
step-down JJ N
approach NN N
using VBG N
either CC N
cyclosporin VB N
A NNP N
( ( N
CSA NNP N
) ) N
or CC N
methotrexate NN N
( ( N
MTX NNP N
) ) N
as IN N
maintenance NN N
therapy NN N
following VBG N
6 CD N
months NNS N
treatment NN N
with IN N
these DT N
2 CD N
agents NNS N
in IN N
combination NN N
in IN N
early JJ N
, , N
nonerosive JJ N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
. . N

METHODS NNP N
Fifty-seven JJ N
patients NNS N
younger JJR N
than IN N
65 CD N
years NNS N
with IN N
early JJ N
, , N
nonerosive JJ N
RA NNP N
were VBD N
first RB N
treated VBN N
with IN N
CSA NNP N
and CC N
MTX NNP N
in IN N
combination NN N
for IN N
6 CD N
months NNS N
. . N

They PRP N
were VBD N
then RB N
randomly RB N
stepped VBD N
down RB N
to TO N
single-agent JJ N
maintenance NN N
treatment NN N
for IN N
another DT N
18 CD N
months NNS N
. . N

Safety NNP N
, , N
clinical JJ N
efficacy NN N
, , N
survival NN N
on IN N
treatment NN N
, , N
and CC N
radiographic JJ N
progression NN N
were VBD N
evaluated VBN N
. . N

RESULTS VB N
When WRB N
being VBG N
treated VBN N
with IN N
combination NN N
therapy NN N
, , N
7 CD N
of IN N
the DT N
57 CD N
patients NNS N
( ( N
12.3 CD N
% NN N
) ) N
withdrew NN N
because IN N
of IN N
adverse JJ N
events NNS N
. . N

Of IN N
the DT N
remaining VBG N
50 CD N
patients NNS N
, , N
42 CD N
( ( N
84.0 CD N
% NN N
) ) N
were VBD N
American JJ N
College NNP N
of IN N
Rheumatology NNP N
( ( N
ACR NNP N
) ) N
20 CD N
% NN N
responders NNS N
, , N
30 CD N
( ( N
60.0 CD N
% NN N
) ) N
were VBD N
ACR NNP N
50 CD N
% NN N
responders NNS N
, , N
and CC N
23 CD N
( ( N
46.0 CD N
% NN N
) ) N
were VBD N
ACR NNP N
70 CD N
% NN N
responders NNS N
. . N

At IN N
month NN N
6 CD N
, , N
22 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
CSA NNP N
and CC N
27 CD N
to TO N
MTX NNP N
. . N

During IN N
this DT N
trial NN N
period NN N
, , N
the DT N
treatment NN N
was VBD N
discontinued VBN N
by IN N
16 CD N
patients NNS N
taking VBG N
CSA NNP N
( ( N
mainly RB N
because IN N
of IN N
loss NN N
of IN N
efficacy NN N
) ) N
and CC N
by IN N
4 CD N
taking VBG N
MTX NNP N
. . N

At IN N
month NN N
24 CD N
, , N
the DT N
probability NN N
( ( N
+/- JJ N
SEM NNP N
) ) N
of IN N
survival NN N
on IN N
treatment NN N
was VBD N
0.273 CD N
+/- JJ N
0.09 CD N
for IN N
CSA NNP N
and CC N
0.852 CD N
+/- JJ N
0.07 CD N
for IN N
MTX NNP N
. . N

Of IN N
the DT N
6 CD N
CSA NNP N
patients NNS N
who WP N
completed VBD N
the DT N
trial NN N
, , N
4 CD N
( ( N
66.7 CD N
% NN N
) ) N
were VBD N
ACR NNP N
20 CD N
% NN N
responders NNS N
, , N
and CC N
3 CD N
( ( N
50 CD N
% NN N
) ) N
were VBD N
both DT N
ACR NNP N
50 CD N
% NN N
and CC N
ACR NNP N
70 CD N
% NN N
responders NNS N
. . N

Of IN N
the DT N
23 CD N
completers NNS N
in IN N
the DT N
MTX NNP N
arm NN N
, , N
21 CD N
( ( N
91.3 CD N
% NN N
) ) N
were VBD N
ACR NNP N
20 CD N
% NN N
responders NNS N
, , N
18 CD N
( ( N
78.3 CD N
% NN N
) ) N
were VBD N
ACR NNP N
50 CD N
% NN N
, , N
and CC N
10 CD N
( ( N
43.5 CD N
% NN N
) ) N
were VBD N
ACR NNP N
70 CD N
% NN N
responders NNS N
. . N

The DT N
treatment NN N
was VBD N
not RB N
responsible JJ N
for IN N
severe JJ N
adverse JJ N
events NNS N
. . N

Radiography NNP N
showed VBD N
a DT N
slow JJ N
progression NN N
in IN N
the DT N
damage NN N
score NN N
and CC N
number NN N
of IN N
eroded JJ N
joints NNS N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

CONCLUSION NNP N
Stepping VBG N
down RP N
to TO N
single JJ N
agent JJ N
maintenance NN N
therapy NN N
following VBG N
6 CD N
months NNS N
of IN N
combination NN N
treatment NN N
with IN N
CSA NNP N
and CC N
MTX NNP N
in IN N
early JJ N
RA NNP N
was VBD N
only RB N
successful JJ N
with IN N
MTX NNP N
. . N

Because IN N
this DT N
treatment NN N
did VBD N
not RB N
prevent VB N
some DT N
radiographic JJ N
progression NN N
, , N
other JJ N
approaches NNS N
( ( N
e.g. NN N
, , N
step-up JJ N
approach NN N
) ) N
may MD N
be VB N
more JJR N
appropriate JJ N
in IN N
early JJ N
RA NNP N
. . N

-DOCSTART- -21998264- O O

Changes NNS N
in IN N
H NNP N
reflex NN N
and CC N
V NNP N
wave VBP N
following VBG N
short-term JJ N
endurance NN N
and CC N
strength NN N
training NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
3 CD N
wk NN N
of IN N
either DT N
endurance NN N
or CC N
strength NN N
training NN N
on IN N
plasticity NN N
of IN N
the DT N
neural JJ N
mechanisms NNS N
involved VBN N
in IN N
the DT N
soleus NN N
H NNP N
reflex NN N
and CC N
V NNP N
wave VBP N
. . N

Twenty-five JJ N
sedentary JJ N
healthy JJ N
subjects NNS N
were VBD N
randomized VBN N
into IN N
an DT N
endurance NN N
group NN N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
or CC N
strength NN N
group NN N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
. . N

Evoked VBN N
V-wave JJ N
, , N
H-reflex NNP N
, , N
and CC N
M-wave NNP N
recruitment NN N
curves NNS N
, , N
maximal JJ N
voluntary JJ N
contraction NN N
( ( N
MVC NNP N
) ) N
, , N
and CC N
time-to-task-failure NN N
( ( N
isometric JJ N
contraction NN N
at IN N
40 CD N
% NN N
MVC NNP N
) ) N
of IN N
the DT N
plantar NN N
flexors NNS N
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
training VBG N
. . N

Following VBG N
strength NN N
training NN N
, , N
MVC NNP N
of IN N
the DT N
plantar NN N
flexors NNS N
increased VBN N
by IN N
14.4 CD N
? . N
5.2 CD N
% NN N
in IN N
the DT N
strength NN N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
whereas JJ N
time-to-task-failure NN N
was VBD N
prolonged VBN N
in IN N
the DT N
endurance NN N
group NN N
( ( N
22.7 CD N
? . N
17.1 CD N
% NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
V NNP N
wave-to-maximal JJ N
M NNP N
wave NN N
( ( N
V/M NNP N
( ( N
max NN N
) ) N
) ) N
ratio NN N
increased VBN N
significantly RB N
( ( N
55.1 CD N
? . N
28.3 CD N
% NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
following VBG N
strength NN N
training NN N
, , N
but CC N
the DT N
maximal JJ N
H NNP N
wave-to-maximal JJ N
M NNP N
wave NN N
( ( N
H NNP N
( ( N
max NN N
) ) N
/M NN N
( ( N
max NN N
) ) N
) ) N
ratio NN N
remained VBD N
unchanged JJ N
. . N

Conversely RB N
, , N
in IN N
the DT N
endurance NN N
group NN N
the DT N
V/M NNP N
( ( N
max NN N
) ) N
ratio NN N
was VBD N
not RB N
altered VBN N
, , N
whereas IN N
the DT N
H NNP N
( ( N
max NN N
) ) N
/M NN N
( ( N
max NN N
) ) N
ratio NN N
increased VBN N
by IN N
30.8 CD N
? . N
21.7 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
endurance NN N
training NN N
group NN N
also RB N
displayed VBD N
a DT N
reduction NN N
in IN N
the DT N
H-reflex NNP N
excitability NN N
threshold NN N
while IN N
the DT N
H-reflex NNP N
amplitude NN N
on IN N
the DT N
ascending VBG N
limb NN N
of IN N
the DT N
recruitment NN N
curve NN N
increased VBD N
. . N

Strength NNP N
training VBG N
only RB N
elicited VBD N
a DT N
significant JJ N
decrease NN N
in IN N
H-reflex NNP N
excitability NN N
threshold NN N
, , N
while IN N
H-reflex NNP N
amplitudes NNS N
over IN N
the DT N
ascending VBG N
limb NN N
remained VBD N
unchanged JJ N
. . N

These DT N
observations NNS N
indicate VBP N
that IN N
the DT N
H-reflex NNP N
pathway NN N
is VBZ N
strongly RB N
involved VBN N
in IN N
the DT N
enhanced JJ N
endurance NN N
resistance NN N
that WDT N
occurs VBZ N
following VBG N
endurance NN N
training NN N
. . N

On IN N
the DT N
contrary JJ N
, , N
the DT N
improvements NNS N
in IN N
MVC NNP N
following VBG N
strength NN N
training NN N
are VBP N
likely JJ N
attributed VBN N
to TO N
increased VBN N
descending VBG N
drive NN N
and/or NN N
modulation NN N
in IN N
afferents NNS N
other JJ N
than IN N
Ia JJ N
afferents NNS N
. . N

-DOCSTART- -23134960- O O

[ JJ N
Effects NNS N
of IN N
transcutaneous JJ N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Shenmen NNP N
point NN N
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
and CC N
patient-controlled JJ N
epidural JJ N
analgesia NN N
in IN N
cesarean JJ N
section NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
transcutaneous JJ N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Shenmen NNP N
point NN N
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
and CC N
patient-controlled JJ N
epidural JJ N
analgesia NN N
in IN N
cesarean JJ N
section NN N
. . N

METHODS NNP N
After IN N
IRB NNP N
approval NN N
and CC N
informed JJ N
consent NN N
, , N
one CD N
hundred CD N
and CC N
eighty VB N
singleton NN N
primiparas IN N
undergoing VBG N
elective JJ N
cesarean JJ N
section NN N
, , N
in IN N
Qingdao NNP N
Municipal NNP N
Hospital NNP N
, , N
and CC N
Qingdao NNP N
Hiser NNP N
Medical NNP N
Center NNP N
, , N
from IN N
November NNP N
2011 CD N
to TO N
March NNP N
2012 CD N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
groups NNS N
: : N
transcutaneous JJ N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Shenmen NNP N
point NN N
group NN N
( ( N
group NN N
A NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
, , N
transcutaneous JJ N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Eye NNP N
point NN N
group NN N
( ( N
group NN N
B NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
and CC N
control NN N
group NN N
( ( N
group NN N
C NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
. . N

Women NNP N
of IN N
group NN N
A NNP N
received VBD N
transcutaneous JJ N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Shenmen NNP N
point NN N
( ( N
frequency NN N
1.5 CD N
HZ NNP N
) ) N
at IN N
the DT N
time NN N
of IN N
preoperation NN N
, , N
4 CD N
, , N
10 CD N
and CC N
22 CD N
hours NNS N
of IN N
postoperation NN N
for IN N
30 CD N
minutes NNS N
. . N

The DT N
strength NN N
was VBD N
controlled VBN N
by IN N
themselves PRP N
. . N

Women NNP N
of IN N
group NN N
B NNP N
received VBD N
stimulation NN N
of IN N
auricular JJ N
Eye NNP N
point NN N
as IN N
group NN N
A NNP N
. . N

Women NNP N
of IN N
group NN N
C NNP N
received VBD N
pressurization NN N
and CC N
connected VBN N
line NN N
were VBD N
the DT N
same JJ N
with IN N
group NN N
A NNP N
, , N
but CC N
without IN N
electrical JJ N
stimulation NN N
. . N

The DT N
following JJ N
indexes NNS N
was VBD N
observed VBN N
: : N
the DT N
incidence NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
for IN N
48 CD N
hours NNS N
; : N
the DT N
rate NN N
of IN N
metoclopramide NN N
; : N
the DT N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
score NN N
of IN N
rest NN N
pain NN N
, , N
uterine JJ N
contration NN N
pain NN N
and CC N
dynamic JJ N
pain NN N
at IN N
the DT N
time NN N
of IN N
postoperation NN N
for IN N
6 CD N
, , N
12 CD N
, , N
24 CD N
and CC N
48 CD N
hours NNS N
( ( N
T NNP N
( ( N
1 CD N
) ) N
-T NN N
( ( N
4 CD N
) ) N
) ) N
; : N
the DT N
total JJ N
number NN N
and CC N
effective JJ N
compressions NNS N
number NN N
of IN N
patient-controlled JJ N
epidural JJ N
analgesia NN N
( ( N
PCEA NNP N
) ) N
; : N
the DT N
dose NN N
of IN N
analgesia JJ N
mixture NN N
; : N
the DT N
anal JJ N
exhaust JJ N
time NN N
; : N
the DT N
volume NN N
of IN N
postoperative JJ N
bleeding NN N
for IN N
6 CD N
hours NNS N
of IN N
postoperation NN N
and CC N
the DT N
other JJ N
side NN N
effects NNS N
. . N

RESULTS NNP N
Compared NNP N
with IN N
group NN N
B NNP N
and CC N
group NN N
C NNP N
, , N
the DT N
incidence NN N
of IN N
PONV NNP N
, , N
the DT N
rate NN N
of IN N
metoclopramide NN N
, , N
the DT N
VAS NNP N
score NN N
at IN N
the DT N
time NN N
T NNP N
( ( N
1 CD N
) ) N
-T NN N
( ( N
4 CD N
) ) N
, , N
the DT N
total JJ N
number NN N
and CC N
effective JJ N
compressions NNS N
number NN N
of IN N
PCEA NNP N
, , N
the DT N
ratio NN N
of IN N
the DT N
total JJ N
number NN N
with IN N
effective JJ N
compressions NNS N
number NN N
and CC N
the DT N
dose NN N
of IN N
analgesia JJ N
mixture NN N
were VBD N
decreased VBN N
in IN N
group NN N
A NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
no DT N
difference NN N
compared VBN N
group NN N
B NNP N
with IN N
group NN N
C NNP N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
anal JJ N
exhaust NN N
time NN N
and CC N
the DT N
volume NN N
of IN N
postoperative JJ N
bleeding NN N
for IN N
6 CD N
hours NNS N
of IN N
postoperation NN N
were VBD N
no DT N
difference NN N
in IN N
the DT N
three CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

No UH N
other JJ N
side NN N
effects NNS N
were VBD N
observed VBN N
. . N

CONCLUSION NNP N
Transcutaneous NNP N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Shenmen NNS N
point NN N
can MD N
reduce VB N
the DT N
incidence NN N
of IN N
PONV NNP N
and CC N
improves VBZ N
analgesia JJ N
effect NN N
of IN N
PCEA NNP N
in IN N
postoperation NN N
of IN N
cesarean JJ N
section NN N
. . N

-DOCSTART- -2023746- O O

Aminocaproic NNP N
acid VBZ N
versus FW N
prednisone NN N
for IN N
the DT N
treatment NN N
of IN N
traumatic JJ N
hyphema NN N
. . N

A DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

One CD N
hundred VBD N
twelve NN N
patients NNS N
who WP N
sustained VBD N
hyphema NN N
after IN N
blunt NN N
trauma NN N
were VBD N
enrolled VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
clinical JJ N
trial NN N
to TO N
determine VB N
the DT N
relative JJ N
efficacies NNS N
of IN N
aminocaproic JJ N
acid NN N
( ( N
Amicar NNP N
) ) N
and CC N
systemic JJ N
prednisone NN N
for IN N
reducing VBG N
the DT N
rate NN N
of IN N
secondary JJ N
hemorrhage NN N
. . N

Fifty-six JJ N
patients NNS N
received VBD N
an DT N
oral JJ N
dosage NN N
of IN N
50 CD N
mg/kg NN N
of IN N
aminocaproic JJ N
acid NN N
every DT N
4 CD N
hours NNS N
for IN N
5 CD N
days NNS N
, , N
up RB N
to TO N
a DT N
maximum NN N
of IN N
30 CD N
g JJ N
daily JJ N
, , N
and CC N
56 CD N
patients NNS N
received VBD N
an DT N
oral JJ N
dosage NN N
of IN N
40 CD N
mg NN N
of IN N
prednisone JJ N
daily JJ N
( ( N
adjusted VBN N
for IN N
weight NN N
) ) N
in IN N
two CD N
divided JJ N
doses NNS N
. . N

Placebo NNP N
pills NNS N
and CC N
liquids NNS N
were VBD N
given VBN N
to TO N
each DT N
patient NN N
to TO N
mask VB N
the DT N
treatment NN N
schedules NNS N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
patient NN N
populations NNS N
for IN N
any DT N
demographic JJ N
or CC N
clinical JJ N
characteristic NN N
( ( N
e.g. JJ N
, , N
visual JJ N
acuity NN N
, , N
intraocular JJ N
pressure NN N
[ NNP N
IOP NNP N
] NNP N
, , N
initial JJ N
hyphema NN N
size NN N
) ) N
measured VBN N
in IN N
the DT N
study NN N
. . N

Blacks NNS N
comprised VBD N
53 CD N
% NN N
of IN N
the DT N
study NN N
population NN N
, , N
and CC N
the DT N
mean JJ N
age NN N
of IN N
the DT N
patients NNS N
was VBD N
23.5 CD N
years NNS N
. . N

Four CD N
patients NNS N
in IN N
each DT N
of IN N
the DT N
treatment NN N
groups NNS N
experienced VBD N
a DT N
secondary JJ N
hemorrhage NN N
; : N
the DT N
rebleed NN N
rate NN N
was VBD N
7.1 CD N
% NN N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -20058059- O O

A DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
parent-assisted JJ N
Children NNP N
's POS N
Friendship NNP N
Training NNP N
with IN N
children NNS N
having VBG N
autism NN N
spectrum NN N
disorders NNS N
. . N

This DT N
study NN N
evaluated VBD N
Children NNP N
's POS N
Friendship NNP N
Training NNP N
( ( N
CFT NNP N
) ) N
, , N
a DT N
manualized JJ N
parent-assisted JJ N
intervention NN N
to TO N
improve VB N
social JJ N
skills NNS N
among IN N
second JJ N
to TO N
fifth VB N
grade JJ N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Comparison NNP N
was VBD N
made VBN N
with IN N
a DT N
delayed JJ N
treatment NN N
control NN N
group NN N
( ( N
DTC NNP N
) ) N
. . N

Targeted VBN N
skills NNS N
included VBD N
conversational JJ N
skills NNS N
, , N
peer VBP N
entry NN N
skills NNS N
, , N
developing VBG N
friendship JJ N
networks NNS N
, , N
good JJ N
sportsmanship NN N
, , N
good JJ N
host NN N
behavior NN N
during IN N
play NN N
dates NNS N
, , N
and CC N
handling VBG N
teasing NN N
. . N

At IN N
post-testing NN N
, , N
the DT N
CFT NNP N
group NN N
was VBD N
superior JJ N
to TO N
the DT N
DTC NNP N
group NN N
on IN N
parent NN N
measures NNS N
of IN N
social JJ N
skill NN N
and CC N
play NN N
date NN N
behavior NN N
, , N
and CC N
child JJ N
measures NNS N
of IN N
popularity NN N
and CC N
loneliness NN N
, , N
At IN N
3-month JJ N
follow-up NN N
, , N
parent NN N
measures NNS N
showed VBD N
significant JJ N
improvement NN N
from IN N
baseline NN N
. . N

Post-hoc JJ N
analysis NN N
indicated VBD N
more JJR N
than IN N
87 CD N
% NN N
of IN N
children NNS N
receiving VBG N
CFT NNP N
showed VBD N
reliable JJ N
change NN N
on IN N
at IN N
least JJS N
one CD N
measure NN N
at IN N
post-test NN N
and CC N
66.7 CD N
% NN N
after IN N
3 CD N
months NNS N
follow-up RB N
. . N

-DOCSTART- -21463068- O O

Concurrent NNP N
alcohol NN N
dependence NN N
among IN N
methadone-maintained JJ N
cocaine NN N
abusers NNS N
is VBZ N
associated VBN N
with IN N
greater JJR N
abstinence NN N
. . N

Concurrent NNP N
alcohol NN N
dependence NN N
( ( N
AD NNP N
) ) N
among IN N
polysubstance NN N
abusers NNS N
has VBZ N
been VBN N
associated VBN N
with IN N
negative JJ N
consequences NNS N
, , N
although IN N
it PRP N
may MD N
not RB N
necessarily RB N
lead VB N
to TO N
poor JJ N
treatment NN N
outcomes NNS N
. . N

One CD N
of IN N
the DT N
most RBS N
efficacious JJ N
treatments NNS N
for IN N
cocaine NN N
abuse NN N
is VBZ N
contingency JJ N
management NN N
( ( N
CM NNP N
) ) N
, , N
but CC N
little JJ N
research NN N
has VBZ N
explored VBN N
the DT N
impact NN N
of IN N
AD NNP N
on IN N
abstinence NN N
outcomes NNS N
, , N
particularly RB N
among IN N
patients NNS N
in IN N
methadone JJ N
maintenance NN N
. . N

Using VBG N
data NNS N
from IN N
three CD N
trials NNS N
of IN N
CM NNP N
for IN N
cocaine NN N
use NN N
, , N
we PRP N
compared VBN N
baseline JJ N
characteristics NNS N
and CC N
posttreatment NN N
and CC N
follow-up JJ N
cocaine NN N
outcomes NNS N
between IN N
methadone-maintained JJ N
, , N
cocaine-dependent JJ N
patients NNS N
( ( N
N NNP N
= NNP N
193 CD N
) ) N
with IN N
and CC N
without IN N
concurrent JJ N
AD NNP N
, , N
randomized VBN N
to TO N
standard VB N
care NN N
( ( N
SC NNP N
) ) N
with IN N
or CC N
without IN N
CM NNP N
. . N

Patients NNS N
with IN N
and CC N
without IN N
concurrent JJ N
AD NNP N
had VBD N
similar JJ N
baseline NN N
characteristics NNS N
, , N
with IN N
the DT N
exception NN N
that WDT N
AD NNP N
patients NNS N
reported VBD N
more RBR N
alcohol NN N
use NN N
. . N

AD NN N
patients NNS N
achieved VBN N
longer JJR N
durations NNS N
of IN N
cocaine NN N
abstinence NN N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
submit VB N
a DT N
cocaine-negative JJ N
sample NN N
at IN N
follow-up JJ N
than IN N
non-AD JJ N
patients NNS N
. . N

Patients NNS N
randomized VBD N
to TO N
CM NNP N
achieved VBD N
better RBR N
outcomes NNS N
than IN N
those DT N
randomized VBN N
to TO N
SC NNP N
, , N
but CC N
there EX N
was VBD N
no DT N
interaction NN N
between IN N
treatment NN N
condition NN N
and CC N
AD NNP N
status NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
cocaine-using JJ N
methadone NN N
patients NNS N
with IN N
AD NNP N
achieve VBP N
greater JJR N
cocaine NN N
abstinence NN N
than IN N
their PRP$ N
non-AD JJ N
counterparts NNS N
and CC N
should MD N
not RB N
necessarily RB N
be VB N
viewed VBN N
as IN N
more RBR N
difficult JJ N
to TO N
treat VB N
. . N

-DOCSTART- -17941914- O O

Maternal JJ N
breast-milk NN N
and CC N
intestinal JJ N
bifidobacteria NNS N
guide VBP N
the DT N
compositional JJ N
development NN N
of IN N
the DT N
Bifidobacterium NNP N
microbiota NN N
in IN N
infants NNS N
at IN N
risk NN N
of IN N
allergic JJ N
disease NN N
. . N

BACKGROUND IN N
The DT N
sources NNS N
and CC N
the DT N
impact NN N
of IN N
maternal JJ N
bacteria NNS N
on IN N
the DT N
initial JJ N
inoculum NN N
of IN N
the DT N
intestinal JJ N
microflora NN N
of IN N
newborn JJ N
infants NNS N
remain VBP N
elusive JJ N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
association NN N
between IN N
maternal JJ N
breast-milk NN N
and CC N
fecal JJ N
bifidobacteria NN N
and CC N
infants NNS N
' POS N
fecal JJ N
bifidobacteria NN N
. . N

METHODS NNP N
Sixty-one JJ N
mother-infant JJ N
pairs NNS N
were VBD N
included VBN N
, , N
special JJ N
emphasis NN N
being VBG N
placed VBN N
on IN N
the DT N
maternal JJ N
allergic NN N
status NN N
. . N

Bifidobacteria NNP N
were VBD N
analysed VBN N
by IN N
a DT N
direct JJ N
PCR NNP N
method NN N
in IN N
fecal JJ N
samples NNS N
from IN N
mothers NNS N
at IN N
30-35 JJ N
weeks NNS N
of IN N
gestation NN N
and CC N
from IN N
infants NNS N
at IN N
1 CD N
month NN N
of IN N
age NN N
and CC N
from IN N
breast-milk JJ N
samples NNS N
1 CD N
month NN N
post-partum NN N
. . N

RESULTS NNP N
Fecal NNP N
Bifidobacterium NNP N
adolescentis NN N
and CC N
Bifidobacterium NNP N
bifidum NN N
colonization NN N
frequencies NNS N
and CC N
counts NNS N
among IN N
mother-infant JJ N
pairs NNS N
correlated VBN N
significantly RB N
( ( N
P=0.005 NNP N
and CC N
0.02 CD N
for IN N
frequencies NNS N
, , N
respectively RB N
, , N
and CC N
P=0.002 NNP N
and CC N
0.01 CD N
for IN N
counts NNS N
, , N
respectively RB N
) ) N
. . N

Only JJ N
infants NNS N
of IN N
allergic NN N
, , N
atopic NN N
mothers NNS N
were VBD N
colonized VBN N
with IN N
B. NNP N
adolescentis NN N
. . N

Each DT N
of IN N
the DT N
breast-milk NN N
samples NNS N
contained VBN N
bifidobacteria NNS N
[ NNP N
median JJ N
1.4 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
bacterial JJ N
cells/mL NN N
; : N
interquartile JJ N
range NN N
( ( N
IQR NNP N
) ) N
48.7-3.8 CD N
x $ N
10 CD N
( ( N
3 CD N
) ) N
] NN N
. . N

Bifidobacterium NNP N
longum NN N
was VBD N
the DT N
most RBS N
frequently RB N
detected VBN N
species NNS N
in IN N
breast-milk NN N
. . N

Allergic NNP N
mothers NNS N
had VBD N
significantly RB N
lower JJR N
amounts NNS N
of IN N
bifidobacteria NN N
in IN N
breast-milk NN N
compared VBN N
with IN N
non-allergic JJ N
mothers NNS N
[ VBP N
median JJ N
1.3 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
bacterial NN N
cells/mL NN N
( ( N
IQR NNP N
22.4-3.0 CD N
x NNP N
10 CD N
( ( N
3 CD N
) ) N
) ) N
vs. FW N
5.6 CD N
x $ N
10 CD N
( ( N
3 CD N
) ) N
bacterial NN N
cells/mL NN N
( ( N
1.8 CD N
x RB N
10 CD N
( ( N
3 CD N
) ) N
-1.8 NN N
x $ N
10 CD N
( ( N
4 CD N
) ) N
) ) N
, , N
respectively RB N
, , N
( ( N
P=0.004 NNP N
) ) N
] NN N
, , N
and CC N
their PRP$ N
infants NNS N
had VBD N
concurrently RB N
lower JJR N
counts NNS N
of IN N
bifidobacteria NN N
in IN N
feces NNS N
[ VBP N
3.9 CD N
x JJ N
10 CD N
( ( N
8 CD N
) ) N
bacterial NN N
cells/g NN N
( ( N
IQR NNP N
6.5 CD N
x NN N
10 CD N
( ( N
6 CD N
) ) N
-1.5 NN N
x $ N
10 CD N
( ( N
9 CD N
) ) N
) ) N
in IN N
infants NNS N
of IN N
allergic JJ N
mothers NNS N
, , N
vs. FW N
2.5 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
bacterial NN N
cells/g NN N
( ( N
6.5 CD N
x RB N
10 CD N
( ( N
8 CD N
) ) N
-3.2 NN N
x $ N
10 CD N
( ( N
10 CD N
) ) N
) ) N
in IN N
infants NNS N
of IN N
non-allergic JJ N
mothers NNS N
, , N
P=0.013 NNP N
] NNP N
. . N

CONCLUSIONS NNP N
Breast-milk NNP N
contains VBZ N
significant JJ N
numbers NNS N
of IN N
bifidobacteria NN N
and CC N
the DT N
maternal JJ N
allergic NN N
status NN N
further RBR N
deranges VBZ N
the DT N
counts NNS N
of IN N
bifidobacteria NN N
in IN N
breast-milk NN N
. . N

Maternal NNP N
fecal JJ N
and CC N
breast-milk JJ N
bifidobacterial JJ N
counts NNS N
impacted VBN N
on IN N
the DT N
infants NNS N
' POS N
fecal JJ N
Bifidobacterium NN N
levels NNS N
. . N

Breast-milk NNP N
bacteria NN N
should MD N
thus RB N
be VB N
considered VBN N
an DT N
important JJ N
source NN N
of IN N
bacteria NNS N
in IN N
the DT N
establishment NN N
of IN N
infantile JJ N
intestinal JJ N
microbiota NN N
. . N

-DOCSTART- -19502023- O O

Transdermal NNP N
scopolamine NN N
patch NN N
in IN N
addition NN N
to TO N
ondansetron VB N
for IN N
postoperative JJ N
nausea NN N
and CC N
vomiting VBG N
prophylaxis NN N
in IN N
patients NNS N
undergoing VBG N
ambulatory JJ N
cosmetic JJ N
surgery NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
transdermal JJ N
scopolamine NN N
in IN N
addition NN N
to TO N
ondansetron VB N
in IN N
decreasing VBG N
the DT N
incidence NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NN N
Academic NNP N
hospital NN N
. . N

PATIENTS CC N
126 CD N
ASA NNP N
physical JJ N
status NN N
I PRP N
and CC N
II NNP N
patients NNS N
undergoing VBG N
outpatient JJ N
plastic NN N
surgery NN N
with IN N
three CD N
or CC N
more JJR N
risk NN N
factors NNS N
for IN N
PONV NNP N
. . N

INTERVENTIONS NNP N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
to TO N
receive VB N
( ( N
Group NNP N
1 CD N
) ) N
a DT N
transdermal JJ N
scopolamine NN N
( ( N
TDS NNP N
) ) N
patch NN N
or CC N
( ( N
Group NNP N
2 CD N
) ) N
, , N
a DT N
placebo JJ N
patch NN N
two CD N
hours NNS N
before IN N
surgery NN N
. . N

MEASUREMENTS NNP N
Occurrence NNP N
of IN N
vomiting VBG N
, , N
severity NN N
of IN N
nausea NN N
using VBG N
a DT N
visual JJ N
analog NN N
scale NN N
( ( N
VAS NNP N
) ) N
, , N
rescue JJ N
medication NN N
, , N
pain VBP N
intensity NN N
and CC N
pain NN N
medications NNS N
, , N
and CC N
side JJ N
effects NNS N
were VBD N
recorded VBN N
every DT N
hour NN N
until IN N
discharge NN N
from IN N
hospital NN N
, , N
then RB N
every DT N
4 CD N
hours NNS N
thereafter RB N
for IN N
a DT N
total NN N
of IN N
24 CD N
hours NNS N
. . N

MAIN NNP N
RESULTS NNP N
A NNP N
statistically RB N
significant JJ N
reduction NN N
in IN N
postoperative JJ N
nausea NN N
between IN N
8 CD N
and CC N
24 CD N
hours NNS N
in IN N
patients NNS N
receiving VBG N
TDS NNP N
was VBD N
noted VBN N
. . N

CONCLUSIONS NNP N
Transdermal NNP N
scopolamine NN N
in IN N
addition NN N
to TO N
ondansetron VB N
benefits NNS N
patients NNS N
at IN N
high JJ N
risk NN N
for IN N
PONV NNP N
undergoing JJ N
outpatient NN N
plastic NN N
surgery NN N
for IN N
up IN N
to TO N
20 CD N
hours NNS N
after IN N
surgery NN N
. . N

-DOCSTART- -22987106- O O

Junctional NNP N
ectopic NN N
tachycardia NN N
after IN N
congenital JJ N
heart NN N
surgery NN N
in IN N
the DT N
current JJ N
surgical JJ N
era NN N
. . N

To TO N
determine VB N
the DT N
incidence NN N
of IN N
postoperative JJ N
junctional JJ N
ectopic NN N
tachycardia NN N
( ( N
JET NNP N
) ) N
in IN N
a DT N
modern JJ N
cohort NN N
of IN N
pediatric JJ N
patients NNS N
, , N
evaluate VBP N
possible JJ N
risk NN N
factors NNS N
for IN N
JET NNP N
, , N
and CC N
examine VB N
the DT N
effects NNS N
of IN N
JET NNP N
on IN N
postoperative JJ N
morbidity NN N
and CC N
mortality NN N
. . N

JET NN N
is VBZ N
common JJ N
after IN N
congenital JJ N
heart NN N
surgery NN N
. . N

JET-related JJ N
mortality NN N
has VBZ N
been VBN N
a DT N
rare JJ N
event NN N
at IN N
our PRP$ N
center NN N
, , N
which WDT N
is VBZ N
different JJ N
from IN N
previous JJ N
reports NNS N
. . N

We PRP N
reviewed VBD N
records NNS N
for IN N
pediatric JJ N
patients NNS N
who WP N
had VBD N
postoperative JJ N
arrhythmias NN N
between IN N
January NNP N
2006 CD N
and CC N
June NNP N
2010 CD N
at IN N
a DT N
large JJ N
tertiary-care JJ N
children NNS N
's POS N
hospital NN N
. . N

We PRP N
performed VBD N
a DT N
matched VBN N
case-control NN N
study NN N
to TO N
identify VB N
risk NN N
factors NNS N
for IN N
JET NNP N
and CC N
a DT N
matched-cohort NN N
study NN N
to TO N
compare VB N
outcomes NNS N
between IN N
patients NNS N
and CC N
controls NNS N
. . N

Whenever NNP N
possible JJ N
, , N
each DT N
JET NNP N
case NN N
was VBD N
randomly RB N
matched VBN N
to TO N
two CD N
controls NNS N
on IN N
the DT N
basis NN N
of IN N
lesion NN N
, , N
repair NN N
, , N
and CC N
surgical JJ N
period NN N
. . N

We PRP N
identified VBD N
54 CD N
patients NNS N
with IN N
JET NNP N
( ( N
incidence NN N
= RB N
1.4 CD N
% NN N
) ) N
. . N

After IN N
multivariate JJ N
logistic JJ N
regression NN N
analysis NN N
, , N
low JJ N
operative JJ N
weight NN N
, , N
cardiopulmonary JJ N
bypass NN N
( ( N
CPB NNP N
) ) N
duration NN N
> $ N
100 CD N
min NN N
, , N
and CC N
immediate JJ N
postoperative JJ N
serum NN N
lactic JJ N
acid NN N
level NN N
> VBD N
20 CD N
mg/dl NNS N
were VBD N
associated VBN N
with IN N
increased JJ N
odds NNS N
of IN N
developing VBG N
JET NNP N
. . N

Patients NNS N
with IN N
JET NNP N
had VBD N
longer RBR N
mechanical JJ N
ventilation NN N
time NN N
, , N
cardiac JJ N
intensive JJ N
care NN N
unit NN N
( ( N
CICU NNP N
) ) N
stay NN N
, , N
and CC N
hospital NN N
stay NN N
. . N

There EX N
was VBD N
only RB N
one CD N
death NN N
in IN N
JET NNP N
group NN N
( ( N
1.8 CD N
% NN N
) ) N
with IN N
no DT N
significant JJ N
difference NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

JET NNP N
remains VBZ N
a DT N
relatively RB N
common JJ N
postoperative JJ N
arrhythmia NN N
, , N
but CC N
it PRP N
is VBZ N
less RBR N
frequent JJ N
than IN N
previously RB N
reported VBN N
. . N

JET NNP N
occurs VBZ N
more JJR N
commonly RB N
in IN N
smaller JJR N
patients NNS N
with IN N
longer JJR N
CPB NNP N
runs NNS N
and CC N
significant JJ N
postoperative JJ N
lactic JJ N
acidosis NN N
levels NNS N
. . N

Mortality NNP N
associated VBD N
with IN N
JET NNP N
is VBZ N
lower JJR N
than IN N
historically RB N
reported VBN N
, , N
but CC N
morbidity NN N
remains VBZ N
high JJ N
. . N

-DOCSTART- -18341602- O O

A DT N
double-blind JJ N
randomized JJ N
clinical JJ N
evaluation NN N
of IN N
enamel JJ N
matrix NNS N
derivative JJ N
proteins NNS N
for IN N
the DT N
treatment NN N
of IN N
proximal JJ N
class-II JJ N
furcation NN N
involvements NNS N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
randomized VBN N
, , N
double-blind JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
clinical JJ N
response NN N
of IN N
proximal JJ N
furcations NNS N
treated VBN N
with IN N
enamel JJ N
matrix NNS N
derivative JJ N
proteins NNS N
( ( N
EMD NNP N
) ) N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
Fifteen NNP N
patients NNS N
, , N
each DT N
with IN N
a DT N
pair NN N
of IN N
contralateral JJ N
class-II JJ N
proximal JJ N
furcation NN N
involvements NNS N
, , N
presenting VBG N
probing VBG N
depths NNS N
( ( N
PDs NNP N
) ) N
> VBP N
/=5 JJ N
mm NN N
and CC N
bleeding NN N
on IN N
probing VBG N
( ( N
BOP NNP N
) ) N
were VBD N
selected VBN N
. . N

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
: : N
control NN N
group NN N
( ( N
n=15 NN N
) ) N
- : N
open JJ N
flap NN N
debridement NN N
( ( N
OFD NNP N
) ) N
+24 CD N
% NN N
ethylenediaminetetraacetic JJ N
acid NN N
( ( N
EDTA NNP N
) ) N
conditioning NN N
; : N
test CC N
group NN N
( ( N
n=15 NN N
) ) N
- : N
OFD+24 CD N
% NN N
EDTA NNP N
conditioning+EMD NN N
application NN N
. . N

Plaque NNP N
index NN N
( ( N
PI NNP N
) ) N
, , N
BOP NNP N
, , N
PD NNP N
, , N
gingival NN N
margin NN N
position NN N
( ( N
GMP NNP N
) ) N
, , N
relative JJ N
vertical NN N
and CC N
horizontal JJ N
clinical JJ N
attachment NN N
level NN N
( ( N
RVCAL NNP N
and CC N
RHCAL NNP N
) ) N
, , N
vertical JJ N
and CC N
horizontal JJ N
bone NN N
level NN N
( ( N
VBL NNP N
and CC N
HBL NNP N
) ) N
and CC N
furcation JJ N
closure NN N
were VBD N
evaluated VBN N
immediately RB N
before IN N
and CC N
2 CD N
, , N
4 CD N
and CC N
6 CD N
months NNS N
after IN N
the DT N
surgeries NNS N
. . N

RESULTS NNP N
At IN N
6 CD N
months NNS N
, , N
the DT N
RVCAL NNP N
gains NNS N
of IN N
the DT N
control NN N
and CC N
test NN N
group NN N
were VBD N
0.39 CD N
+/- JJ N
1.00 CD N
and CC N
0.54 CD N
+/- JJ N
0.95 CD N
mm NN N
, , N
while IN N
the DT N
RHCAL NNP N
gains NNS N
were VBD N
1.21 CD N
+/- JJ N
2.28 CD N
and CC N
1.36 CD N
+/- JJ N
1.26 CD N
mm NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
VBL NNP N
and CC N
HBL NNP N
gains NNS N
of IN N
the DT N
control NN N
group NN N
were VBD N
1.04 CD N
+/- JJ N
1.12 CD N
and CC N
1.00 CD N
+/- JJ N
1.79 CD N
mm NN N
, , N
and CC N
0.82 CD N
+/- JJ N
1.82 CD N
and CC N
1.17 CD N
+/- JJ N
1.38 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

In IN N
addition NN N
, , N
a DT N
statistical JJ N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
number NN N
of IN N
the DT N
remaining VBG N
class-II JJ N
furcations NNS N
between IN N
the DT N
test NN N
and CC N
control NN N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
this DT N
period NN N
. . N

CONCLUSION VB N
It PRP N
may MD N
be VB N
concluded VBN N
that IN N
the DT N
use NN N
of IN N
EMD NNP N
in IN N
proximal JJ N
furcations NNS N
did VBD N
not RB N
promote VB N
a DT N
superior JJ N
reduction NN N
in IN N
PD NNP N
or CC N
a DT N
gain NN N
in IN N
clinical JJ N
and CC N
osseous JJ N
attachment NN N
levels NNS N
, , N
but CC N
resulted VBD N
in IN N
a DT N
higher JJR N
rate NN N
of IN N
class-II NN N
to TO N
class-I JJ N
furcation NN N
conversion NN N
. . N

-DOCSTART- -16007391- O O

Effect NN N
of IN N
cigarette NN N
smoking NN N
on IN N
gastric JJ N
emptying NN N
of IN N
solids NNS N
in IN N
Japanese JJ N
smokers NNS N
: : N
a DT N
crossover NN N
study NN N
using VBG N
the DT N
13C-octanoic JJ N
acid NN N
breath NN N
test NN N
. . N

BACKGROUND NNP N
Cigarette NNP N
smoking NN N
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
peptic JJ N
ulcer NN N
and CC N
gastroesophageal NN N
reflux NN N
disease NN N
. . N

Gastric NNP N
emptying VBG N
disorders NNS N
may MD N
play VB N
a DT N
role NN N
in IN N
the DT N
development NN N
of IN N
these DT N
upper JJ N
gastrointestinal NN N
diseases NNS N
. . N

Thus RB N
, , N
studies NNS N
examining VBG N
a DT N
link NN N
between IN N
smoking VBG N
and CC N
gastric JJ N
emptying VBG N
disorders NNS N
have VBP N
clinical JJ N
relevance NN N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
smoking VBG N
on IN N
gastric JJ N
emptying NN N
of IN N
solids NNS N
in IN N
Japanese JJ N
smokers NNS N
. . N

METHODS PDT N
The DT N
( ( N
13 CD N
) ) N
C-octanoic NNP N
acid JJ N
breath NN N
test NN N
was VBD N
performed VBN N
in IN N
eight CD N
male JJ N
habitual JJ N
smokers NNS N
on IN N
two CD N
randomized JJ N
occasions NNS N
( ( N
either DT N
sham NN N
smoking NN N
or CC N
actively RB N
smoking VBG N
) ) N
. . N

The DT N
time NN N
vs NN N
( ( N
13 CD N
) ) N
CO NNP N
( ( N
2 CD N
) ) N
excretion NN N
rate NN N
curve NN N
was VBD N
mathematically RB N
fitted VBN N
to TO N
a DT N
conventional JJ N
formula NN N
of IN N
y NN N
( ( N
t NN N
) ) N
= NN N
m*k*beta*e NN N
( ( N
-k*t NNP N
) ) N
* NNP N
( ( N
1 CD N
- : N
e NN N
( ( N
-k*t NNP N
) ) N
) ) N
( ( N
beta-1 NN N
) ) N
, , N
and CC N
the DT N
parameters NNS N
of IN N
k NN N
and CC N
beta NN N
were VBD N
determined VBN N
: : N
under IN N
the DT N
crossover NN N
protocol NN N
, , N
a DT N
larger JJR N
( ( N
smaller JJR N
) ) N
beta NN N
indicates VBZ N
slower JJR N
( ( N
faster RBR N
) ) N
emptying VBG N
in IN N
the DT N
early JJ N
phase NN N
, , N
and CC N
a DT N
larger JJR N
( ( N
smaller JJR N
) ) N
k NN N
indicates VBZ N
faster RBR N
( ( N
slower JJR N
) ) N
emptying VBG N
in IN N
the DT N
later JJ N
phase NN N
. . N

The DT N
half NN N
( ( N
13 CD N
) ) N
CO NNP N
( ( N
2 CD N
) ) N
excretion NN N
time NN N
( ( N
t NN N
( ( N
1/2b CD N
) ) N
= SYM N
- : N
[ NN N
ln NN N
( ( N
1 CD N
- : N
2 CD N
( ( N
-1/beta NNP N
) ) N
) ) N
] FW N
/k NN N
) ) N
and CC N
the DT N
time NN N
of IN N
maximal NN N
( ( N
13 CD N
) ) N
CO NNP N
( ( N
2 CD N
) ) N
excretion NN N
rate NN N
( ( N
t NN N
( ( N
max NN N
) ) N
= VBZ N
[ JJ N
lnbeta NN N
] NNP N
/k NNP N
) ) N
were VBD N
also RB N
calculated VBN N
. . N

Between IN N
the DT N
two CD N
occasions NNS N
, , N
k NN N
, , N
beta NN N
, , N
t NN N
( ( N
1/2b CD N
) ) N
, , N
and CC N
t NN N
( ( N
max NN N
) ) N
were VBD N
compared VBN N
by IN N
the DT N
Wilcoxon NNP N
signed-rank JJ N
test NN N
. . N

RESULTS NNP N
After IN N
smoking VBG N
, , N
k NN N
was VBD N
significantly RB N
increased VBN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
beta NN N
, , N
t NN N
( ( N
1/2 CD N
) ) N
, , N
and CC N
t NN N
( ( N
max NN N
) ) N
between IN N
the DT N
two CD N
occasions NNS N
. . N

CONCLUSIONS VB N
The DT N
increase NN N
in IN N
k JJ N
suggests VBZ N
the DT N
acceleration NN N
of IN N
gastric JJ N
emptying VBG N
in IN N
the DT N
later JJ N
phase NN N
. . N

For IN N
the DT N
first JJ N
time NN N
, , N
this DT N
study NN N
has VBZ N
revealed VBN N
that IN N
acute JJ N
smoking NN N
speeds VBZ N
the DT N
gastric JJ N
emptying NN N
of IN N
solids NNS N
in IN N
Japanese JJ N
habitual JJ N
smokers NNS N
. . N

-DOCSTART- -7881024- O O

Gastric JJ N
ulcer NN N
treatment NN N
with IN N
intravenous JJ N
human JJ N
epidermal JJ N
growth NN N
factor NN N
: : N
a DT N
double-blind NN N
controlled VBN N
clinical JJ N
study NN N
. . N

We PRP N
introduced VBD N
a DT N
double-blind NN N
controlled VBN N
clinical JJ N
study NN N
to TO N
compare VB N
intravenous JJ N
human JJ N
epidermal JJ N
growth NN N
factor NN N
( ( N
hEGF NN N
) ) N
to TO N
cetraxate VB N
hydrochloride NN N
( ( N
CH NNP N
) ) N
, , N
an DT N
antiulcer JJ N
drug NN N
, , N
for IN N
their PRP$ N
healing NN N
effect NN N
on IN N
gastric JJ N
ulcers NNS N
. . N

We PRP N
also RB N
prospected VBD N
an DT N
oral JJ N
use NN N
of IN N
EGF NNP N
on IN N
the DT N
basis NN N
of IN N
our PRP$ N
experimental JJ N
evidence NN N
. . N

In IN N
the DT N
clinical JJ N
trial NN N
, , N
the DT N
rate NN N
of IN N
ulcer NN N
healing VBG N
within IN N
8 CD N
weeks NNS N
was VBD N
77.9 CD N
% NN N
( ( N
67/86 CD N
) ) N
in IN N
patients NNS N
receiving VBG N
6 CD N
micrograms NNS N
EGF NNP N
intravenously RB N
twice RB N
a DT N
week NN N
, , N
being VBG N
significantly RB N
greater JJR N
than IN N
51.7 CD N
% NN N
( ( N
45/87 CD N
) ) N
in IN N
those DT N
given VBN N
CH NNP N
. . N

Taking VBG N
together RB N
all DT N
aspects NNS N
assessed VBD N
including VBG N
the DT N
healing NN N
rate NN N
, , N
pain NN N
relief NN N
, , N
blood NN N
examination NN N
and CC N
adverse JJ N
reactions NNS N
, , N
we PRP N
judged VBD N
the DT N
hEGF NN N
to TO N
be VB N
a DT N
useful JJ N
and CC N
safe JJ N
anticuler NN N
drug NN N
. . N

In IN N
rats NNS N
, , N
50 CD N
micrograms/kg NN N
mouse NN N
EGF NNP N
( ( N
mEGF NN N
) ) N
and CC N
2 CD N
% NN N
hydroxypropyl NN N
cellulose NN N
( ( N
HPC NNP N
) ) N
or CC N
1.0 CD N
g/kg JJ N
sucralfate NN N
given VBN N
by IN N
gastric JJ N
intubation NN N
significantly RB N
raised VBD N
the DT N
residual JJ N
mEGF NN N
levels NNS N
in IN N
both DT N
gastric JJ N
luminal JJ N
content NN N
( ( N
HPC NNP N
: : N
x JJ N
30 CD N
; : N
sucralfate NN N
: : N
x RB N
300 CD N
as RB N
high JJ N
as IN N
those DT N
in IN N
EGF NNP N
alone RB N
) ) N
and CC N
tissue NN N
( ( N
HPC NNP N
: : N
x JJ N
60 CD N
; : N
sucralfate NN N
: : N
x JJ N
100 CD N
) ) N
. . N

In IN N
addition NN N
, , N
the DT N
combined JJ N
treatments NNS N
significantly RB N
promoted VBD N
healing NN N
of IN N
rat NN N
gastric JJ N
ulcers NNS N
whereas VBP N
each DT N
agent NN N
alone RB N
had VBD N
no DT N
significant JJ N
effect NN N
as IN N
compared VBN N
with IN N
control NN N
( ( N
saline NN N
) ) N
. . N

This DT N
indicated VBD N
the DT N
beneficial JJ N
effect NN N
on IN N
ulcers NNS N
of IN N
oral JJ N
administration NN N
of IN N
EGF NNP N
with IN N
agents NNS N
allowing VBG N
it PRP N
to TO N
remain VB N
at IN N
high JJ N
levels NNS N
in IN N
the DT N
stomach NN N
, , N
whereas IN N
most JJS N
reports NNS N
suggested VBD N
less RBR N
effect NN N
of IN N
oral JJ N
EGF NNP N
on IN N
healing NN N
of IN N
gastroduodenal JJ N
ulcers NNS N
. . N

Subsequent JJ N
to TO N
the DT N
clinical JJ N
study NN N
, , N
evaluation NN N
of IN N
oral JJ N
use NN N
of IN N
EGF NNP N
may MD N
be VB N
expected VBN N
as IN N
the DT N
next JJ N
step NN N
in IN N
the DT N
treatment NN N
of IN N
ulcers NNS N
. . N

The DT N
experimental JJ N
evidence NN N
above IN N
would MD N
possibly RB N
be VB N
a DT N
guide NN N
for IN N
such JJ N
trial NN N
. . N

-DOCSTART- -7527107- O O

Double-blind NNP N
comparison NN N
of IN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
trandolapril JJ N
2 CD N
mg NN N
and CC N
hydrochlorothiazide VB N
25 CD N
mg NNS N
in IN N
patients NNS N
with IN N
mild-to-moderate JJ N
essential JJ N
hypertension NN N
. . N

Investigator NNP N
Study NNP N
Group NNP N
. . N

This DT N
multicenter NN N
international JJ N
trial NN N
recruited VBD N
205 CD N
patients NNS N
from IN N
16 CD N
investigators NNS N
. . N

After IN N
a DT N
4-week JJ N
, , N
single-blind JJ N
placebo NN N
run-in NN N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
16 CD N
weeks NNS N
of IN N
trandolapril JJ N
2 CD N
mg/day NN N
( ( N
68 CD N
patients NNS N
) ) N
, , N
hydrochlorothiazide RB N
( ( N
HCTZ NNP N
) ) N
25 CD N
mg/day NN N
( ( N
68 CD N
patients NNS N
) ) N
, , N
or CC N
the DT N
combination NN N
( ( N
69 CD N
patients NNS N
) ) N
. . N

Morning VBG N
predosing VBG N
supine NN N
diastolic JJ N
blood NN N
pressure NN N
( ( N
DBP NNP N
) ) N
was VBD N
the DT N
primary JJ N
efficacy NN N
measurement NN N
. . N

Intention-to-treat JJ N
analysis NN N
showed VBD N
significant JJ N
decreases NNS N
in IN N
all DT N
three CD N
groups NNS N
in IN N
mean JJ N
( ( N
+/- JJ N
SEM NNP N
) ) N
supine NN N
DBP NNP N
throughout IN N
the DT N
study NN N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
at IN N
week NN N
16 CD N
between IN N
trandolapril NN N
( ( N
-10.6 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
) ) N
and CC N
HCTZ NNP N
( ( N
-10.9 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
) ) N
. . N

The DT N
combination NN N
gave VBD N
a DT N
significantly RB N
greater JJR N
reduction NN N
than IN N
either DT N
drug NN N
alone RB N
( ( N
-15.1 JJ N
+/- JJ N
1.13 CD N
mm NN N
Hg NNP N
) ) N
. . N

Blood NNP N
pressure NN N
was VBD N
normalized VBN N
in IN N
the DT N
combination NN N
group NN N
in IN N
67 CD N
% NN N
of IN N
patients NNS N
, , N
a DT N
significantly RB N
higher JJR N
proportion NN N
than IN N
either DT N
trandolapril NN N
( ( N
63 CD N
% NN N
) ) N
or CC N
HCTZ NNP N
( ( N
60 CD N
% NN N
; : N
p CC N
= VB N
0.04 CD N
) ) N
. . N

Each DT N
treatment NN N
was VBD N
well RB N
tolerated VBN N
. . N

The DT N
incidence NN N
of IN N
adverse JJ N
events NNS N
was VBD N
similar JJ N
in IN N
all DT N
three CD N
groups NNS N
. . N

Trandolapril NNP N
2 CD N
mg NN N
once RB N
daily JJ N
is VBZ N
an DT N
effective JJ N
antihypertensive JJ N
agent NN N
, , N
comparable JJ N
to TO N
HCTZ NNP N
. . N

Furthermore NNP N
, , N
the DT N
combination NN N
of IN N
the DT N
two CD N
drugs NNS N
was VBD N
shown VBN N
to TO N
enhance VB N
the DT N
antihypertensive JJ N
effect NN N
of IN N
the DT N
two CD N
compounds NNS N
alone RB N
. . N

-DOCSTART- -2228570- O O

Enhancing VBG N
the DT N
self-esteem NN N
of IN N
inpatient JJ N
alcoholics NNS N
. . N

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
pairing VBG N
inpatient JJ N
alcoholics NNS N
with IN N
nursing NN N
home NN N
residents NNS N
( ( N
NHRs NNP N
) ) N
on IN N
the DT N
alcoholics NNS N
' POS N
self-esteem NN N
. . N

In IN N
this DT N
PALS NNP N
program NN N
, , N
the DT N
alcoholic JJ N
inpatients NNS N
assumed VBD N
a DT N
helping-companion NN N
relationship NN N
with IN N
the DT N
NHRs NNP N
for IN N
2 CD N
hr NNS N
per IN N
day NN N
during IN N
their PRP$ N
last JJ N
2 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Fifty NNP N
alcoholic JJ N
inpatients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
PALS NNP N
program NN N
( ( N
n JJ N
= NNP N
25 CD N
) ) N
or CC N
to TO N
the DT N
library NN N
for IN N
free JJ N
reading NN N
time NN N
( ( N
n JJ N
= NNP N
25 CD N
) ) N
. . N

The DT N
Tennessee NNP N
Self-Concept NNP N
Scale NNP N
( ( N
TSCS NNP N
) ) N
was VBD N
administered VBN N
to TO N
all DT N
subjects NNS N
in IN N
both DT N
groups NNS N
before IN N
and CC N
after IN N
the DT N
interventions NNS N
. . N

Of IN N
the DT N
nine CD N
TSCS NNP N
scales NNS N
, , N
the DT N
improvement NN N
on IN N
the DT N
Moral-Ethical JJ N
scale NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
PALS NNP N
group NN N
. . N

Because IN N
the DT N
alcoholic JJ N
inpatients NNS N
in IN N
the DT N
PALS NNP N
group NN N
engaged VBD N
in IN N
altruistic JJ N
( ( N
moral JJ N
) ) N
behavior NN N
, , N
this DT N
study NN N
provides VBZ N
a DT N
logical JJ N
link NN N
between IN N
the DT N
intervention NN N
and CC N
the DT N
outcome NN N
, , N
which WDT N
has VBZ N
been VBN N
a DT N
prevalent JJ N
weakness NN N
in IN N
previous JJ N
studies NNS N
of IN N
self-esteem NN N
in IN N
alcoholics NNS N
. . N

-DOCSTART- -21902704- O O

Effects NNS N
of IN N
three CD N
oral JJ N
analgesics NNS N
on IN N
postoperative JJ N
pain NN N
following VBG N
root JJ N
canal JJ N
preparation NN N
: : N
a DT N
controlled JJ N
clinical JJ N
trial NN N
. . N

AIM NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
single JJ N
doses NNS N
of IN N
three CD N
oral JJ N
medications NNS N
on IN N
postoperative JJ N
pain NN N
following VBG N
instrumentation NN N
of IN N
root NN N
canals NNS N
in IN N
teeth NN N
with IN N
irreversible JJ N
pulpitis NN N
. . N

METHODOLOGY NNP N
In IN N
this DT N
double-blind JJ N
clinical JJ N
trial NN N
, , N
100 CD N
patients NNS N
who WP N
had VBD N
anterior CC N
or CC N
premolar JJ N
teeth NNS N
with IN N
irreversible JJ N
pulpitis NN N
without IN N
any DT N
signs NNS N
and CC N
symptoms NNS N
of IN N
acute NN N
or CC N
chronic JJ N
apical JJ N
periodontitis NN N
and CC N
moderate VB N
to TO N
severe VB N
pain NN N
were VBD N
divided VBN N
by IN N
balanced JJ N
block NN N
random NN N
allocation NN N
into IN N
four CD N
groups NNS N
of IN N
25 CD N
each DT N
, , N
a DT N
control NN N
group NN N
receiving VBG N
a DT N
placebo NN N
medication NN N
, , N
and CC N
three CD N
experimental JJ N
groups NNS N
receiving VBG N
a DT N
single JJ N
dose NN N
of IN N
either DT N
Tramadol NNP N
( ( N
100 CD N
mg NN N
) ) N
, , N
Novafen NNP N
( ( N
325 CD N
mg NN N
of IN N
paracetamol NN N
, , N
200 CD N
mg NN N
ibuprofen NN N
and CC N
40 CD N
mg NNS N
caffeine VBP N
anhydrous JJ N
) ) N
or CC N
Naproxen NNP N
( ( N
500 CD N
mg NN N
) ) N
immediately RB N
after IN N
the DT N
first JJ N
appointment NN N
where WRB N
the DT N
pulp NN N
was VBD N
removed VBN N
, , N
and CC N
the DT N
canals NNS N
were VBD N
fully RB N
prepared VBN N
. . N

The DT N
intensity NN N
of IN N
pain NN N
was VBD N
scored VBN N
based VBN N
on IN N
10-point JJ N
VAS NNP N
before IN N
and CC N
after IN N
treatment NN N
for IN N
up IN N
to TO N
24 CD N
h NN N
postoperatively RB N
. . N

Data NNS N
were VBD N
submitted VBN N
to TO N
repeated VBN N
analysis NN N
of IN N
variance NN N
. . N

RESULTS NNP N
At IN N
the DT N
6 CD N
, , N
12 CD N
and CC N
24 CD N
h NNS N
postoperative JJ N
intervals NNS N
after IN N
drug NN N
administration NN N
, , N
the DT N
intensity NN N
of IN N
pain NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
experimental NN N
groups NNS N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Tramadol NNP N
was VBD N
significantly RB N
less RBR N
effective JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
than IN N
Naproxen NNP N
, , N
and CC N
Novafen NNP N
that WDT N
were VBD N
similar JJ N
to TO N
each DT N
other JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
A DT N
single JJ N
oral JJ N
dose NN N
of IN N
Naproxen NNP N
, , N
Novafen NNP N
and CC N
Tramadol NNP N
taken VBN N
immediately RB N
after IN N
treatment NN N
reduced VBD N
postoperative JJ N
pain NN N
following VBG N
pulpectomy NN N
and CC N
root JJ N
canal JJ N
preparation NN N
of IN N
teeth NNS N
with IN N
irreversible JJ N
pulpitis NN N
. . N

-DOCSTART- -7856515- O O

Acute JJ N
exposure NN N
to TO N
acid VB N
fog NN N
: : N
influence NN N
of IN N
breathing VBG N
pattern NN N
on IN N
effective JJ N
dose NN N
. . N

Concern JJ N
about IN N
the DT N
possible JJ N
adverse JJ N
health NN N
effects NNS N
of IN N
acid NN N
fog NN N
has VBZ N
been VBN N
fed VBN N
by IN N
two CD N
observations NNS N
: : N
air NN N
pollution NN N
disasters NNS N
earlier RBR N
in IN N
this DT N
century NN N
were VBD N
typically RB N
associated VBN N
with IN N
fog NN N
, , N
and CC N
current JJ N
samples NNS N
of IN N
fog JJ N
water NN N
can MD N
be VB N
strongly RB N
acid JJ N
. . N

To TO N
study VB N
the DT N
acute JJ N
effects NNS N
of IN N
acid JJ N
fog NN N
on IN N
the DT N
lung NN N
, , N
the DT N
authors NNS N
generated VBD N
a DT N
monodisperse JJ N
10 CD N
microM NN N
MMAD NNP N
aerosol NN N
of IN N
H2SO4 NNP N
with IN N
a DT N
pH NN N
of IN N
2.0 CD N
and CC N
a DT N
nominal JJ N
concentration NN N
of IN N
500 CD N
micrograms/m3 NNS N
. . N

They PRP N
exposed VBD N
seven CD N
healthy JJ N
young JJ N
men NNS N
on IN N
alternate NN N
days NNS N
to TO N
acid VB N
or CC N
control VB N
equiosmolar JJ N
NaCl NNP N
aerosol NN N
during IN N
40 CD N
min NNS N
of IN N
resting VBG N
ventilation NN N
and CC N
20 CD N
min NN N
of IN N
exercise NN N
; : N
the DT N
latter NN N
was VBD N
sufficiently RB N
intense JJ N
to TO N
induce VB N
oronasal RP N
breathing VBG N
. . N

Exposure NN N
was VBD N
by IN N
means NNS N
of IN N
a DT N
head NN N
dome NN N
, , N
a DT N
head-only JJ N
exposure NN N
device NN N
that WDT N
permitted VBD N
continuous JJ N
measurement NN N
( ( N
unfettered JJ N
breathing NN N
) ) N
of IN N
Vr NNP N
, , N
f NN N
, , N
VE NNP N
, , N
and CC N
the DT N
onset NN N
and CC N
persistence NN N
of IN N
oronasal NN N
breathing NN N
. . N

In IN N
this DT N
article NN N
the DT N
authors NNS N
compare VBP N
the DT N
relative JJ N
importance NN N
of IN N
parameters NNS N
contributing VBG N
to TO N
the DT N
between-subject JJ N
variability NN N
in IN N
estimated VBN N
hydrogen NN N
ion NN N
dose NN N
to TO N
the DT N
lower JJR N
airways NNS N
( ( N
H+LAW NNP N
) ) N
, , N
based VBN N
on IN N
analysis NN N
of IN N
variance NN N
. . N

Physiologic NNP N
parameters NNS N
accounted VBD N
for IN N
70 CD N
% NN N
of IN N
the DT N
variability NN N
, , N
of IN N
which WDT N
34 CD N
% NN N
was VBD N
due JJ N
to TO N
differences NNS N
in IN N
duration NN N
of IN N
oronasal NN N
breathing NN N
( ( N
tON NN N
) ) N
and CC N
36 CD N
% NN N
to TO N
differences NNS N
in IN N
ventilation NN N
rate NN N
during IN N
oronasal NN N
breathing NN N
( ( N
VE NNP N
( ( N
ON NNP N
) ) N
) ) N
; : N
inhaled VBN N
hydrogen NN N
ion NN N
concentration NN N
[ NNP N
H+ NNP N
] NNP N
, , N
the DT N
environmental JJ N
parameter NN N
, , N
contributed VBD N
only RB N
30 CD N
% NN N
. . N

Minute JJ N
ventilation NN N
at IN N
the DT N
time NN N
of IN N
transition NN N
from IN N
nasal NN N
to TO N
oronasal VB N
breathing VBG N
varied JJ N
significantly RB N
among IN N
subjects NNS N
even RB N
if IN N
normalized VBN N
to TO N
FVC NNP N
, , N
an DT N
index NN N
of IN N
lung NN N
size NN N
. . N

-DOCSTART- -16343383- O O

Combined VBN N
typhoid JJ N
fever NN N
and CC N
hepatitis VB N
A DT N
vaccine NN N
: : N
comparison NN N
of IN N
immunogenicity NN N
and CC N
safety NN N
to TO N
concomitant VB N
monovalent JJ N
vaccine NN N
over IN N
3 CD N
years NNS N
. . N

BACKGROUND IN N
The DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
Viatim NNP N
, , N
a DT N
combined JJ N
hepatitis NN N
A NNP N
( ( N
HA NNP N
) ) N
and CC N
typhoid JJ N
fever NN N
( ( N
Vi NNP N
) ) N
vaccine NN N
, , N
were VBD N
compared VBN N
with IN N
the DT N
monovalent JJ N
component NN N
vaccines VBZ N
up IN N
to TO N
and CC N
1 CD N
month NN N
after IN N
a DT N
booster NN N
dose NN N
at IN N
3 CD N
years NNS N
. . N

METHODS NNP N
Healthy NNP N
, , N
adult NN N
volunteers NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
Viatim NNP N
( ( N
group NN N
A NNP N
, , N
n JJ N
= NNP N
179 CD N
) ) N
or CC N
separate JJ N
HA NNP N
and CC N
Vi NNP N
vaccines NNS N
( ( N
group NN N
B NNP N
, , N
n JJ N
= NNP N
181 CD N
) ) N
; : N
subgroups NNS N
were VBD N
boosted VBN N
after IN N
3 CD N
years NNS N
with IN N
Viatim NNP N
( ( N
groups NNS N
C NNP N
and CC N
D NNP N
, , N
n JJ N
= NN N
56 CD N
and CC N
46 CD N
, , N
respectively RB N
) ) N
. . N

Local JJ N
and CC N
systemic JJ N
reactions NNS N
were VBD N
recorded VBN N
for IN N
28 CD N
days NNS N
postvaccination NN N
. . N

Seroconversion NN N
and CC N
seroprotection NN N
rates NNS N
and CC N
geometric JJ N
mean NN N
antibody NN N
concentrations NNS N
were VBD N
measured VBN N
at IN N
14 CD N
and CC N
28 CD N
days NNS N
, , N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
years NNS N
postvaccination NN N
, , N
and CC N
28 CD N
days NNS N
after IN N
the DT N
booster NN N
dose NN N
. . N

RESULTS NNP N
Local NNP N
and CC N
systemic JJ N
safety NN N
profiles NNS N
were VBD N
equivalent JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Immediate NNP N
local JJ N
reactions NNS N
were VBD N
infrequent JJ N
( ( N
1 CD N
in IN N
group NN N
A NNP N
and CC N
2 CD N
in IN N
group NN N
B NNP N
) ) N
. . N

Local JJ N
reactions NNS N
, , N
consisting VBG N
mostly RB N
of IN N
mild NN N
or CC N
moderate JJ N
pain NN N
, , N
were VBD N
least JJS N
frequent JJ N
with IN N
monovalent JJ N
HA NNP N
. . N

Antibody NNP N
concentrations NNS N
to TO N
both DT N
antigens NNS N
were VBD N
similar JJ N
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
in IN N
which WDT N
HA NNP N
seroprotection NN N
rates NNS N
( ( N
> CD N
or CC N
= VB N
20 CD N
mIU/mL NN N
) ) N
were VBD N
respectively RB N
, , N
98.7 CD N
% NN N
and CC N
100 CD N
% NN N
at IN N
day NN N
28 CD N
, , N
and CC N
99.1 CD N
% NN N
and CC N
99.0 CD N
% NN N
after IN N
3 CD N
years NNS N
, , N
achieving VBG N
100 CD N
% NN N
after IN N
the DT N
booster NN N
. . N

Vi NNP N
seroprotection NN N
rates NNS N
( ( N
> CD N
or CC N
= VB N
1 CD N
microg/mL NN N
) ) N
of IN N
85.2 CD N
% NN N
and CC N
84.9 CD N
% NN N
after IN N
28 CD N
days NNS N
fell VBD N
to TO N
32.1 CD N
% NN N
and CC N
35.6 CD N
% NN N
after IN N
3 CD N
years NNS N
, , N
increasing VBG N
to TO N
67.3 CD N
% NN N
and CC N
69.8 CD N
% NN N
after IN N
the DT N
booster NN N
dose NN N
. . N

CONCLUSIONS VB N
The DT N
combined JJ N
HA/Vi NNP N
vaccine NN N
, , N
Viatim NNP N
, , N
had VBD N
equivalent JJ N
tolerability NN N
and CC N
safety NN N
and CC N
was VBD N
as IN N
rapidly RB N
immunogenic JJ N
as IN N
its PRP$ N
component NN N
monovalent NN N
vaccines NNS N
when WRB N
given VBN N
concurrently RB N
. . N

A DT N
booster NN N
dose NN N
after IN N
3 CD N
years NNS N
significantly RB N
increased VBD N
antibody NN N
levels NNS N
with IN N
some DT N
evidence NN N
of IN N
relative JJ N
hyporesponsiveness NN N
of IN N
the DT N
typhoid JJ N
response NN N
. . N

-DOCSTART- -8487324- O O

Recombinant JJ N
human JJ N
erythropoietin NN N
therapy NN N
for IN N
anemic JJ N
cancer NN N
patients NNS N
on IN N
combination NN N
chemotherapy NN N
. . N

BACKGROUND NNP N
Patients NNPS N
with IN N
advanced JJ N
cancer NN N
frequently RB N
experience VBZ N
clinically RB N
significant JJ N
anemia NN N
, , N
which WDT N
is VBZ N
often RB N
exacerbated VBN N
by IN N
myelosuppressive JJ N
chemotherapy NN N
. . N

Consistent JJ N
with IN N
the DT N
anemia NN N
of IN N
chronic JJ N
disease NN N
, , N
studies NNS N
have VBP N
documented VBN N
serum JJ N
erythropoietin NN N
levels NNS N
that WDT N
are VBP N
inappropriately RB N
low JJ N
for IN N
the DT N
degree NN N
of IN N
anemia NN N
in IN N
cancer NN N
patients NNS N
. . N

Myelosuppressive JJ N
chemotherapy NN N
impairs NNS N
erythropoiesis NN N
, , N
which WDT N
may MD N
not RB N
fully RB N
recover VB N
between IN N
treatment NN N
cycles NNS N
. . N

Recombinant NNP N
human JJ N
erythropoietin NN N
( ( N
rHuEPO NN N
) ) N
has VBZ N
been VBN N
used VBN N
safely RB N
and CC N
effectively RB N
to TO N
treat VB N
anemia NN N
in IN N
AIDS NNP N
patients NNS N
receiving VBG N
zidovudine NN N
( ( N
AZT NNP N
) ) N
and CC N
in IN N
patients NNS N
with IN N
chronic JJ N
renal JJ N
failure NN N
. . N

PURPOSE VB N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
clinical JJ N
role NN N
of IN N
rHuEPO NN N
in IN N
reducing VBG N
symptomatic JJ N
anemia NN N
in IN N
patients NNS N
with IN N
advanced JJ N
cancer NN N
who WP N
were VBD N
receiving VBG N
myelosuppressive JJ N
chemotherapy NN N
( ( N
excluding VBG N
cisplatin NN N
) ) N
. . N

METHODS NNP N
We PRP N
studied VBD N
153 CD N
anemic JJ N
cancer NN N
patients NNS N
receiving VBG N
cyclic JJ N
combination NN N
chemotherapy NN N
in IN N
a DT N
prospective JJ N
multicenter NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
rHuEPO NN N
( ( N
150 CD N
U/kg NNP N
) ) N
or CC N
placebo NN N
subcutaneously RB N
three CD N
times NNS N
a DT N
week NN N
for IN N
a DT N
maximum NN N
of IN N
12 CD N
weeks NNS N
or CC N
until IN N
the DT N
hematocrit JJ N
level NN N
increased VBD N
to TO N
38 CD N
% NN N
-40 JJ N
% NN N
. . N

If IN N
the DT N
hematocrit NN N
reached VBD N
this DT N
target NN N
level NN N
before IN N
12 CD N
weeks NNS N
, , N
the DT N
rHuEPO NN N
dose NN N
could MD N
be VB N
reduced VBN N
to TO N
maintain VB N
the DT N
hematocrit NN N
at IN N
that DT N
level NN N
for IN N
the DT N
duration NN N
of IN N
the DT N
study NN N
. . N

Response NNP N
to TO N
rHuEPO VB N
therapy NN N
was VBD N
assessed VBN N
by IN N
measuring VBG N
changes NNS N
in IN N
hematocrit NN N
level NN N
, , N
transfusion NN N
requirements NNS N
, , N
and CC N
quality NN N
of IN N
life NN N
. . N

Quality-of-life JJ N
assessment NN N
was VBD N
based VBN N
on IN N
patients NNS N
' POS N
responses NNS N
to TO N
questionnaires NNS N
before IN N
and CC N
after IN N
the DT N
courses NNS N
of IN N
therapy NN N
. . N

RESULTS VB N
The DT N
increase NN N
in IN N
hematocrit NN N
in IN N
the DT N
rHuEPO-treated JJ N
group NN N
compared VBN N
with IN N
hematocrit NN N
in IN N
the DT N
placebo-treated JJ N
group NN N
was VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
as IN N
measured VBN N
by IN N
percentage NN N
point NN N
of IN N
change NN N
from IN N
baseline NN N
to TO N
final JJ N
evaluation NN N
, , N
by IN N
an DT N
increase NN N
in IN N
hematocrit JJ N
level NN N
of IN N
six CD N
percentage NN N
points NNS N
or CC N
more JJR N
unrelated JJ N
to TO N
transfusion NN N
, , N
and CC N
by IN N
a DT N
rise NN N
in IN N
hematocrit NN N
level NN N
to TO N
38 CD N
% NN N
or CC N
more JJR N
unrelated JJ N
to TO N
transfusion NN N
. . N

There EX N
was VBD N
a DT N
trend NN N
toward IN N
the DT N
reduction NN N
in IN N
mean JJ N
units NNS N
of IN N
blood NN N
transfused VBN N
per IN N
patient NN N
during IN N
months NNS N
2 CD N
and CC N
3 CD N
of IN N
therapy NN N
combined VBN N
in IN N
rHuEPO-treated JJ N
patients NNS N
compared VBN N
with IN N
placebo-treated JJ N
patients NNS N
( ( N
0.91 CD N
U NNP N
versus NN N
1.65 CD N
U NNP N
; : N
P NNP N
= NNP N
.056 NNP N
) ) N
. . N

In IN N
addition NN N
, , N
rHuEPO-treated JJ N
patients NNS N
experienced VBD N
a DT N
statistically RB N
significant JJ N
improvement NN N
in IN N
energy NN N
level NN N
and CC N
ability NN N
to TO N
perform VB N
daily JJ N
activities NNS N
( ( N
P NNP N
< NNP N
or CC N
= NNP N
.05 NNP N
) ) N
. . N

The DT N
two CD N
treatment NN N
groups NNS N
showed VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
toxic JJ N
effects NNS N
except IN N
for IN N
increased JJ N
incidence NN N
of IN N
diaphoresis NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
diarrhea NN N
( ( N
P NNP N
= NNP N
.05 NNP N
) ) N
in IN N
the DT N
rHuEPO-treated JJ N
group NN N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that DT N
rHuEPO NN N
is VBZ N
safe JJ N
and CC N
effective JJ N
for IN N
reversing VBG N
anemia RB N
related VBN N
to TO N
advanced JJ N
cancer NN N
or CC N
to TO N
chemotherapy VB N
for IN N
cancer NN N
. . N

-DOCSTART- -20089562- O O

Epirubicin NNP N
and CC N
cyclophosphamide VB N
versus NN N
epirubicin NN N
and CC N
docetaxel NN N
as IN N
first-line JJ N
therapy NN N
for IN N
women NNS N
with IN N
metastatic JJ N
breast NN N
cancer NN N
: : N
final JJ N
results NNS N
of IN N
a DT N
randomised JJ N
phase NN N
III NNP N
trial NN N
. . N

BACKGROUND VB N
This DT N
randomised JJ N
phase NN N
III NNP N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
epirubicin NN N
and CC N
cyclophosphamide NN N
( ( N
EC NNP N
) ) N
with IN N
epirubicin NN N
and CC N
docetaxel NN N
( ( N
Taxotere NNP N
) ) N
( ( N
ED NNP N
) ) N
as IN N
first-line JJ N
chemotherapy NN N
for IN N
metastatic JJ N
breast NN N
cancer NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNP N
( ( N
n JJ N
= NNP N
240 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
ED NNP N
( ( N
epirubicin JJ N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
and CC N
docetaxel $ N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
or CC N
EC NNP N
( ( N
epirubicin VBP N
90 CD N
mg/m NN N
( ( N
2 CD N
) ) N
and CC N
cyclophosphamide $ N
600 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
objective JJ N
response NN N
rate NN N
( ( N
ORR NNP N
) ) N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
, , N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
, , N
and CC N
safety NN N
. . N

RESULTS NNP N
ORR NNP N
for IN N
patients NNS N
randomly RB N
assigned VBN N
to TO N
receive VB N
EC NNP N
and CC N
ED NNP N
were VBD N
42 CD N
% NN N
and CC N
47 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.63 CD N
) ) N
. . N

Median JJ N
PFS NNP N
[ NNP N
10.1 CD N
versus NN N
10.3 CD N
months NNS N
; : N
hazard VBN N
ratio NN N
( ( N
HR NNP N
) ) N
0.98 CD N
; : N
log-rank JJ N
P NNP N
= NNP N
0.38 CD N
] NN N
and CC N
OS NNP N
( ( N
19.9 CD N
versus NN N
30.0 CD N
months NNS N
; : N
HR NNP N
0.663 CD N
; : N
log-rank JJ N
P NNP N
= NNP N
0.21 CD N
) ) N
were VBD N
comparable JJ N
in IN N
both DT N
arms NNS N
. . N

Although IN N
grade JJ N
3/4 CD N
leucopenia NN N
occurred VBD N
more RBR N
frequently RB N
with IN N
ED NNP N
( ( N
81 CD N
% NN N
versus IN N
73 CD N
% NN N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
febrile JJ N
neutropenia NN N
and CC N
grade VBD N
3/4 CD N
infections NNS N
. . N

Grade VB N
3/4 CD N
non-haematologic JJ N
toxicity NN N
was VBD N
infrequent JJ N
in IN N
both DT N
arms NNS N
. . N

Congestive JJ N
heart NN N
failure NN N
was VBD N
observed VBN N
in IN N
one CD N
patient NN N
in IN N
each DT N
arm NN N
. . N

CONCLUSION NN N
In IN N
this DT N
randomised JJ N
trial NN N
, , N
no DT N
differences NNS N
in IN N
the DT N
efficacy NN N
study VBD N
end JJ N
points NNS N
were VBD N
observed VBN N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
. . N

-DOCSTART- -10606880- O O

Partial JJ N
depletion NN N
of IN N
tissue NN N
factor NN N
pathway NN N
inhibitor NN N
during IN N
subcutaneous JJ N
administration NN N
of IN N
unfractionated JJ N
heparin NN N
, , N
but CC N
not RB N
with IN N
two CD N
low JJ N
molecular JJ N
weight NN N
heparins NNS N
. . N

Tissue NNP N
factor NN N
pathway NN N
inhibitor NN N
( ( N
TFPI NNP N
) ) N
is VBZ N
released VBN N
to TO N
circulating VBG N
blood NN N
after IN N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
and CC N
subcutaneous JJ N
( ( N
s.c. NN N
) ) N
injections NNS N
of IN N
heparins NNS N
, , N
and CC N
may MD N
thus RB N
contribute VB N
to TO N
the DT N
antithrombotic JJ N
effect NN N
of IN N
heparins NNS N
. . N

We PRP N
have VBP N
recently RB N
shown VBN N
that IN N
total JJ N
TFPI NNP N
activity NN N
, , N
plasma VBP N
free JJ N
TFPI NNP N
antigen NN N
, , N
and CC N
heparin NN N
releasable JJ N
TFPI NNP N
were VBD N
partially RB N
depleted VBN N
during IN N
repeated VBN N
and CC N
continuous JJ N
i.v NN N
. . N

infusion NN N
of IN N
unfractionated JJ N
heparin NN N
( ( N
UFH NNP N
) ) N
, , N
but CC N
not RB N
during IN N
s.c. JJ N
treatment NN N
with IN N
a DT N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
LMWH NNP N
) ) N
. . N

The DT N
difference NN N
may MD N
be VB N
attributed VBN N
to TO N
a DT N
different JJ N
mode NN N
of IN N
action NN N
or CC N
the DT N
different JJ N
mode NN N
of IN N
administration NN N
. . N

In IN N
the DT N
present JJ N
randomized VBN N
cross-over NN N
study NN N
, , N
s.c. JJ N
administration NN N
of IN N
therapeutic JJ N
doses NNS N
of IN N
UFH NNP N
was VBD N
compared VBN N
with IN N
s.c. JJ N
administration NN N
of IN N
two CD N
LMWHs NNP N
. . N

12 CD N
healthy JJ N
male NN N
volunteers NNS N
were VBD N
treated VBN N
for IN N
3 CD N
d NN N
with IN N
UFH NNP N
, , N
250 CD N
U/kg NNP N
twice RB N
daily RB N
, , N
dalteparin NN N
, , N
200 CD N
U/kg NNP N
once RB N
daily RB N
, , N
and CC N
enoxaparin RB N
, , N
1.5 CD N
mg/kg NN N
once RB N
daily JJ N
. . N

Six CD N
participants NNS N
were VBD N
also RB N
treated VBN N
with IN N
UFH NNP N
, , N
300 CD N
U/kg NNP N
once RB N
daily RB N
. . N

On IN N
day NN N
5 CD N
a DT N
single JJ N
dose NN N
of IN N
either DT N
drug NN N
was VBD N
given VBN N
. . N

Peak NNP N
levels NNS N
of IN N
total JJ N
TFPI NNP N
activity NN N
and CC N
free JJ N
TFPI NNP N
antigen NN N
were VBD N
detected VBN N
1 CD N
h NN N
after IN N
injection NN N
, , N
whereas IN N
maximal JJ N
prolongation NN N
of IN N
activated VBN N
partial JJ N
thromboplastin NN N
time NN N
( ( N
APTT NNP N
) ) N
and CC N
peak JJ N
levels NNS N
of IN N
anti-factor JJ N
Xa NNP N
activity NN N
and CC N
anti-factor NN N
IIa NNP N
activity NN N
were VBD N
detected VBN N
after IN N
4 CD N
h. NN N
On IN N
UFH NNP N
administered VBD N
twice RB N
daily RB N
, , N
free JJ N
TFPI NNP N
antigen NN N
decreased VBN N
by IN N
44 CD N
% NN N
from IN N
baseline JJ N
level NN N
before IN N
the DT N
first JJ N
injection NN N
on IN N
day NN N
1 CD N
to TO N
pre-injection NN N
level NN N
on IN N
day NN N
5 CD N
. . N

On IN N
UFH NNP N
administered VBD N
once RB N
daily JJ N
, , N
basal JJ N
free JJ N
TFPI NNP N
antigen NN N
decreased VBN N
by IN N
50 CD N
% NN N
, , N
56 CD N
% NN N
and CC N
27 CD N
% NN N
on IN N
day NN N
2 CD N
, , N
3 CD N
and CC N
5 CD N
respectively RB N
, , N
compared VBN N
with IN N
day NN N
1 CD N
. . N

Minimal JJ N
depletion NN N
of IN N
TFPI NNP N
was VBD N
detected VBN N
during IN N
treatment NN N
with IN N
LMWHs NNP N
. . N

The DT N
study NN N
demonstrates VBZ N
the DT N
different JJ N
modes NNS N
of IN N
action NN N
of IN N
LMWHs NNP N
and CC N
UFH NNP N
and CC N
may MD N
help VB N
to TO N
explain VB N
the DT N
superior JJ N
antithrombotic JJ N
efficacy NN N
of IN N
LMWHs NNP N
. . N

-DOCSTART- -20201661- O O

Comparison NNP N
of IN N
neodymium-doped JJ N
yttrium NN N
aluminum NN N
garnet NN N
laser NN N
treatment NN N
with IN N
cold JJ N
knife NN N
endoscopic NN N
incision NN N
of IN N
urethral JJ N
strictures NNS N
in IN N
male JJ N
patients NNS N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
visual JJ N
laser NN N
ablation NN N
treatment NN N
with IN N
neodymium-doped JJ N
yttrium NN N
aluminum NN N
garnet NN N
( ( N
Nd NNP N
: : N
YAG NN N
) ) N
laser NN N
in IN N
male JJ N
patients NNS N
with IN N
urethral JJ N
strictures NNS N
and CC N
to TO N
compare VB N
the DT N
effects NNS N
with IN N
those DT N
obtained VBN N
in IN N
patients NNS N
treated VBN N
with IN N
Sachse NNP N
's POS N
optical JJ N
urethrotomy NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Fifty NNP N
patients NNS N
aged VBD N
22 CD N
to TO N
83 CD N
( ( N
mean JJ N
age NN N
61.8 CD N
) ) N
with IN N
primary JJ N
( ( N
n JJ N
= NN N
26 CD N
, , N
52 CD N
% NN N
) ) N
and CC N
recurrent NN N
( ( N
n JJ N
= NN N
24 CD N
, , N
48 CD N
% NN N
) ) N
urethral JJ N
strictures VBZ N
0.3 CD N
to TO N
2.4 CD N
cm NNS N
long RB N
qualified VBD N
for IN N
the DT N
study NN N
. . N

The DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
30 CD N
men NNS N
treated VBD N
using VBG N
visual JJ N
laser NN N
ablation NN N
of IN N
urethral JJ N
strictures NNS N
( ( N
VLASU NNP N
) ) N
with IN N
Nd NNP N
: : N
YAGlaser NN N
and CC N
20 CD N
men NNS N
treated VBN N
by IN N
correction NN N
of IN N
urethral JJ N
strictures NNS N
using VBG N
Sachse NNP N
's POS N
optical JJ N
urethrotomy NN N
. . N

RESULTS VB N
At IN N
12-month JJ N
follow-up NN N
, , N
seven CD N
( ( N
35 CD N
% NN N
) ) N
patients NNS N
who WP N
underwent JJ N
optical JJ N
urethrotomy NN N
and CC N
21 CD N
( ( N
70 CD N
% NN N
) ) N
in IN N
the DT N
VLASU NNP N
group NN N
did VBD N
not RB N
require VB N
repetition NN N
of IN N
the DT N
procedure NN N
. . N

The DT N
choice NN N
of IN N
VLASU NNP N
as IN N
a DT N
method NN N
of IN N
treatment NN N
significantly RB N
decreased VBD N
the DT N
probability NN N
of IN N
therapeutic JJ N
failure NN N
and CC N
recurrence NN N
of IN N
urethral JJ N
strictures NNS N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSION NNP N
VLASU NNP N
can MD N
be VB N
used VBN N
as IN N
a DT N
method NN N
of IN N
treatment NN N
of IN N
this DT N
disorder NN N
. . N

It PRP N
is VBZ N
an DT N
effective JJ N
, , N
modern JJ N
, , N
low-invasive JJ N
, , N
and CC N
repeatable JJ N
technique NN N
and CC N
is VBZ N
technically RB N
simple JJ N
and CC N
easy JJ N
to TO N
master NN N
. . N

It PRP N
can MD N
be VB N
used VBN N
in IN N
cases NNS N
in IN N
which WDT N
introduction NN N
of IN N
a DT N
22 CD N
Char NNP N
optical JJ N
urethrotome NN N
into IN N
the DT N
stricture NN N
site NN N
is VBZ N
impossible JJ N
, , N
as RB N
well RB N
as IN N
for IN N
treatment NN N
of IN N
multiple JJ N
strictures NNS N
during IN N
one CD N
procedure NN N
. . N

-DOCSTART- -2195532- O O

[ JJ N
Methodologic NNP N
comparison NN N
of IN N
the DT N
polyfrequency NN N
oscillation NN N
method NN N
, , N
transcutaneous JJ N
oxygen NN N
pressure NN N
measurement NN N
and CC N
body NN N
plethysmography NN N
in IN N
bronchial JJ N
provocation NN N
with IN N
methacholine JJ N
] NN N
. . N

A DT N
bronchial JJ N
provocation NN N
challenge NN N
test NN N
was VBD N
conducted VBN N
with IN N
30 CD N
subjects NNS N
using VBG N
metacholin NN N
. . N

In IN N
randomised JJ N
sequence NN N
lung NN N
function NN N
analysis NN N
tests NNS N
were VBD N
carried VBN N
out RP N
with IN N
the DT N
bodyplethysmograph NN N
( ( N
Raw NNP N
, , N
FEV1 NNP N
) ) N
and CC N
the DT N
polyfrequent JJ N
oscillation NN N
method NN N
( ( N
resistance NN N
, , N
reactance NN N
between IN N
2 CD N
and CC N
52 CD N
Hz NNP N
) ) N
, , N
whereas IN N
the DT N
transcutaneous JJ N
oxygen NN N
pressure NN N
( ( N
tc-PO2 JJ N
) ) N
was VBD N
measured VBN N
continuously RB N
. . N

Correlations NNS N
between IN N
the DT N
various JJ N
parameters NNS N
, , N
the DT N
change NN N
of IN N
the DT N
values NNS N
at IN N
PD60 NNP N
sGaw NN N
in IN N
relation NN N
to TO N
the DT N
initial JJ N
values NNS N
, , N
the DT N
interindividual JJ N
variability NN N
and CC N
the DT N
reactivity NN N
were VBD N
determined VBN N
. . N

Medium JJ N
correlations NNS N
were VBD N
found VBN N
for IN N
the DT N
oscillatory NN N
parameters NNS N
and CC N
Raw NNP N
, , N
whereas IN N
for IN N
tc-PO2 NN N
and CC N
Raw NNP N
the DT N
correlation NN N
was VBD N
markedly RB N
lower JJR N
. . N

In IN N
terms NNS N
of IN N
percentage NN N
the DT N
greatest JJS N
change NN N
was VBD N
found VBN N
in IN N
reactance NN N
, , N
in IN N
relation NN N
to TO N
the DT N
initial JJ N
value NN N
, , N
followed VBN N
by IN N
Raw NNP N
and CC N
FEV1 NNP N
. . N

The DT N
interindividual JJ N
variability NN N
resulted VBD N
in IN N
the DT N
highest JJS N
values NNS N
for IN N
the DT N
reactance NN N
, , N
followed VBN N
by IN N
Raw NNP N
and CC N
FEV1 NNP N
. . N

Interindividual NNP N
variability NN N
showed VBD N
the DT N
highest JJS N
values NNS N
for IN N
the DT N
reactance NN N
before IN N
oscillatory JJ N
resistance NN N
and CC N
Raw NNP N
. . N

In IN N
respect NN N
of IN N
reactivity NN N
, , N
reactance NN N
also RB N
had VBD N
the DT N
highest JJS N
values NNS N
. . N

Overall JJ N
evaluation NN N
showed VBD N
that IN N
bodyplethysmography NN N
and CC N
the DT N
polyfrequent JJ N
oscillation NN N
method NN N
( ( N
reactance NN N
or CC N
resonance NN N
frequency NN N
) ) N
are VBP N
comparably RB N
sensitive JJ N
. . N

-DOCSTART- -16048456- O O

Autism-Spectrum JJ N
Quotient-Japanese JJ N
version NN N
and CC N
its PRP$ N
short JJ N
forms NNS N
for IN N
screening VBG N
normally RB N
intelligent JJ N
persons NNS N
with IN N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

A DT N
Japanese JJ N
version NN N
of IN N
the DT N
Autism NNP N
Spectrum NNP N
Quotient NNP N
( ( N
AQ NNP N
) ) N
, , N
AQ-J NNP N
was VBD N
administered VBN N
to TO N
25 CD N
normally RB N
intelligent JJ N
high-functioning JJ N
pervasive JJ N
developmental NN N
disorder NN N
( ( N
HPDD NNP N
) ) N
patients NNS N
( ( N
mean JJ N
age NN N
, , N
24.2 CD N
years NNS N
; : N
24 CD N
male NN N
, , N
one CD N
female NN N
) ) N
and CC N
215 CD N
controls NNS N
( ( N
mean JJ N
age NN N
, , N
30.4 CD N
years NNS N
; : N
86 CD N
male NN N
, , N
129 CD N
female NN N
) ) N
randomly RB N
selected VBN N
from IN N
the DT N
general JJ N
population NN N
. . N

The DT N
AQ-J NNP N
had VBD N
satisfactory JJ N
internal JJ N
consistency NN N
reliability NN N
( ( N
Cronbach NNP N
's POS N
alpha NN N
> VBD N
0.70 CD N
in IN N
the DT N
two CD N
groups NNS N
) ) N
, , N
test-retest JJ N
reliability NN N
, , N
and CC N
discriminant JJ N
validity NN N
[ NNP N
i.e NN N
. . N

the DT N
AQ-J NNP N
score NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
HPDD NNP N
( ( N
mean NN N
, , N
29.6 CD N
) ) N
than IN N
controls NNS N
( ( N
mean VB N
, , N
22.2 CD N
) ) N
] NN N
. . N

At IN N
a DT N
cut-off NN N
of IN N
26 CD N
, , N
the DT N
AQ-J NNP N
had VBD N
satisfactory JJ N
sensitivity NN N
, , N
specificity NN N
, , N
and CC N
negative JJ N
predictive JJ N
value NN N
, , N
but CC N
it PRP N
had VBD N
low JJ N
positive JJ N
predictive NN N
value NN N
( ( N
0.24 CD N
) ) N
possibly RB N
due JJ N
to TO N
the DT N
facts NNS N
that IN N
the DT N
25 CD N
mild JJ N
HPDD NNP N
patients NNS N
scored VBD N
lower JJR N
and CC N
the DT N
controls NNS N
scored VBD N
higher JJR N
on IN N
the DT N
AQ-J NNP N
than IN N
British NNP N
counterparts NNS N
on IN N
the DT N
AQ NNP N
. . N

The DT N
AQ-J-21 NNP N
( ( N
consisting VBG N
of IN N
21 CD N
items NNS N
significantly RB N
associated VBN N
with IN N
HPDD NNP N
diagnosis NN N
) ) N
and CC N
the DT N
AQ-J-10 NNP N
( ( N
consisting VBG N
of IN N
10 CD N
of IN N
the DT N
21 CD N
items NNS N
with IN N
an DT N
effect NN N
size NN N
> NNP N
0.17 CD N
) ) N
had VBD N
higher JJR N
, , N
although IN N
not RB N
satisfactory JJ N
, , N
positive JJ N
predictive JJ N
values NNS N
of IN N
0.35 CD N
and CC N
0.46 CD N
at IN N
cut-offs NNS N
of IN N
12 CD N
and CC N
7 CD N
, , N
respectively RB N
, , N
than IN N
the DT N
AQ-J NNP N
. . N

The DT N
AQ-J JJ N
and CC N
two CD N
short JJ N
forms NNS N
are VBP N
useful JJ N
not RB N
to TO N
predict VB N
but CC N
to TO N
rule VB N
out RP N
mild NN N
HPDD NNP N
, , N
the DT N
most RBS N
difficult JJ N
part NN N
of IN N
HPDD NNP N
to TO N
be VB N
distinguished VBN N
from IN N
non-PDD JJ N
conditions NNS N
, , N
in IN N
persons NNS N
scoring VBG N
under IN N
the DT N
cut-offs NNS N
and CC N
to TO N
consider VB N
professionals NNS N
' POS N
examination NN N
of IN N
HPDD NNP N
in IN N
persons NNS N
scoring VBG N
over IN N
them PRP N
, , N
because IN N
their PRP$ N
negative JJ N
predictive JJ N
values NNS N
were VBD N
satisfactory JJ N
. . N

-DOCSTART- -18522171- O O

[ JJ N
Radiotherapy NNP N
of IN N
malignant JJ N
brain NN N
gliomas NN N
using VBG N
teniposide JJ N
] NNP N
. . N

Efficacy NN N
of IN N
radiochemotherapy NN N
of IN N
malignantly-converted JJ N
brain NN N
gliomas NN N
using VBG N
teniposide NN N
was VBD N
evaluated VBN N
in IN N
a DT N
randomized JJ N
prospective JJ N
study NN N
. . N

Combined VBN N
use NN N
of IN N
cytostatics NNS N
and CC N
irradiation NN N
appeared VBD N
safe JJ N
, , N
tolerable JJ N
and CC N
significantly RB N
more RBR N
effective JJ N
than IN N
radiotherapy RB N
alone RB N
as IN N
assessed VBN N
by IN N
local JJ N
control NN N
of IN N
tumor NN N
and CC N
survival NN N
. . N

-DOCSTART- -20537413- O O

Comparing VBG N
the DT N
effectiveness NN N
of IN N
peer NN N
mentoring NN N
and CC N
student NN N
mentoring NN N
in IN N
a DT N
35-week JJ N
fitness NN N
program NN N
for IN N
older JJR N
adults NNS N
. . N

To TO N
investigate VB N
the DT N
applicability NN N
and CC N
effectiveness NN N
of IN N
a DT N
peer-mentored JJ N
exercise NN N
program NN N
, , N
this DT N
study NN N
compared VBN N
the DT N
retention NN N
and CC N
participation NN N
rates NNS N
, , N
and CC N
physical JJ N
improvements NNS N
of IN N
older JJR N
adults NNS N
trained VBN N
by IN N
peer NN N
mentors NNS N
( ( N
PM NNP N
) ) N
to TO N
a DT N
group NN N
trained VBN N
by IN N
young JJ N
qualified JJ N
student NN N
mentors NNS N
( ( N
SM NNP N
) ) N
. . N

A DT N
group NN N
of IN N
older JJR N
adults NNS N
were VBD N
prepared VBN N
as IN N
peer NN N
mentors NNS N
through IN N
a DT N
30-week JJ N
preparation NN N
program NN N
. . N

Later NNP N
, , N
60 CD N
older JJR N
adults NNS N
( ( N
mean VB N
? . N
SD NNP N
age NN N
: : N
68.7 CD N
? . N
6.1 CD N
years NNS N
) ) N
were VBD N
recruited VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
PM NNP N
or CC N
SM NNP N
group NN N
. . N

Both DT N
groups NNS N
completed VBD N
an DT N
identical JJ N
35-week JJ N
fitness NN N
program NN N
. . N

Pre- NNP N
, , N
midterm- JJ N
and CC N
post-training JJ N
assessments NNS N
of IN N
fitness NN N
were VBD N
completed VBN N
and CC N
rates NNS N
of IN N
participation NN N
and CC N
retention NN N
were VBD N
documented VBN N
. . N

The DT N
same JJ N
retention NN N
rates NNS N
were VBD N
observed VBN N
in IN N
the DT N
two CD N
groups NNS N
, , N
but CC N
SM NNP N
group NN N
had VBD N
higher JJR N
participation NN N
. . N

Both DT N
groups NNS N
improved VBN N
significantly RB N
in IN N
all DT N
measures NNS N
of IN N
fitness NN N
and CC N
there EX N
were VBD N
no DT N
significant JJ N
post-test JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
the DT N
fitness NN N
measures NNS N
. . N

Findings NNS N
suggest VBP N
that IN N
the DT N
peer NN N
mentor NN N
model NN N
is VBZ N
applicable JJ N
in IN N
an DT N
older JJR N
adult NN N
exercise NN N
program NN N
and CC N
may MD N
be VB N
as RB N
effective JJ N
as IN N
a DT N
program NN N
mentored VBN N
by IN N
young JJ N
professionals NNS N
. . N

-DOCSTART- -15119720- O O

Bitewing NNP N
film NN N
quality NN N
: : N
a DT N
clinical JJ N
comparison NN N
of IN N
the DT N
loop NN N
vs. FW N
holder NN N
techniques NNS N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
in IN N
vivo JJ N
bitewing NN N
film NN N
quality NN N
using VBG N
the DT N
holder NN N
versus IN N
the DT N
paper NN N
loop NN N
technique NN N
. . N

METHOD NNP N
AND CC N
MATERIALS NNP N
Four NNP N
bitewing VBG N
films NNS N
were VBD N
taken VBN N
from IN N
the DT N
right NN N
and CC N
left VBD N
premolar JJ N
and CC N
molar JJ N
regions NNS N
of IN N
45 CD N
dental JJ N
students NNS N
using VBG N
both DT N
the DT N
bitewing NN N
holder NN N
and CC N
paper NN N
loop NN N
techniques NNS N
. . N

A DT N
total NN N
of IN N
360 CD N
films NNS N
were VBD N
taken VBN N
and CC N
assessed VBN N
by IN N
an DT N
experienced JJ N
practitioner NN N
not RB N
apprised VBN N
of IN N
the DT N
bitewing NN N
technique NN N
used VBN N
. . N

Of IN N
interest NN N
were VBD N
: : N
( ( N
1 CD N
) ) N
the DT N
number NN N
of IN N
overlaps NNS N
and CC N
the DT N
percentage NN N
of IN N
teeth NNS N
showing VBG N
the DT N
alveolar JJ N
crest NN N
; : N
( ( N
2 CD N
) ) N
proper NN N
film NN N
positioning NN N
; : N
and CC N
( ( N
3 CD N
) ) N
the DT N
percentage NN N
of IN N
cone NN N
cutting NN N
. . N

A DT N
Poisson NNP N
regression NN N
using VBG N
generalized VBN N
estimating VBG N
equations NNS N
( ( N
GEEs NNP N
) ) N
was VBD N
used VBN N
to TO N
estimate VB N
the DT N
difference NN N
in IN N
overlap NN N
between IN N
the DT N
two CD N
techniques NNS N
. . N

For IN N
proper JJ N
positioning NN N
and CC N
cone NN N
cutting NN N
, , N
logistic JJ N
regressions NNS N
using VBG N
GEEs NNP N
were VBD N
used VBN N
. . N

RESULTS VB N
The DT N
average JJ N
number NN N
of IN N
horizontal JJ N
overlaps NNS N
for IN N
the DT N
loop NN N
and CC N
holder NN N
techniques NNS N
at IN N
the DT N
right JJ N
premolar NN N
, , N
right JJ N
molar NN N
, , N
left VBD N
premolar JJ N
, , N
and CC N
left VBD N
molar NN N
were VBD N
1.64 CD N
, , N
2.11 CD N
, , N
2.16 CD N
, , N
2.78 CD N
, , N
and CC N
1.64 CD N
, , N
2.00 CD N
, , N
2.00 CD N
, , N
2.18 CD N
, , N
respectively RB N
. . N

The DT N
loop NN N
technique NN N
was VBD N
1.11 CD N
times NNS N
more RBR N
likely JJ N
to TO N
cause VB N
overlapping VBG N
than IN N
the DT N
holder NN N
technique NN N
. . N

The DT N
highest JJS N
percentage NN N
of IN N
teeth NNS N
showing VBG N
the DT N
alveolar JJ N
crest NN N
by IN N
the DT N
loop NN N
technique NN N
was VBD N
97.8 CD N
% NN N
in IN N
the DT N
mandibular JJ N
second JJ N
premolar NN N
and CC N
first JJ N
molar NN N
. . N

With IN N
respect NN N
to TO N
film NN N
positioning NN N
, , N
the DT N
loop NN N
technique NN N
was VBD N
1.12 CD N
times NNS N
more RBR N
likely JJ N
to TO N
cause VB N
improper JJ N
positioning NN N
than IN N
the DT N
holder NN N
technique NN N
. . N

Both DT N
techniques NNS N
demonstrated VBN N
minimal JJ N
cone NN N
cutting NN N
( ( N
1 CD N
in IN N
the DT N
loop NN N
versus NN N
0 CD N
in IN N
the DT N
holder NN N
) ) N
. . N

CONCLUSION VB N
The DT N
quality NN N
of IN N
bitewing VBG N
films NNS N
taken VBN N
by IN N
the DT N
loop NN N
and CC N
holder NN N
techniques NNS N
was VBD N
not RB N
significantly RB N
different JJ N
. . N

-DOCSTART- -20069077- O O

PROCLAIM NN N
: : N
pilot NN N
study NN N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
clopidogrel NN N
on IN N
inflammatory JJ N
markers NNS N
in IN N
patients NNS N
with IN N
metabolic JJ N
syndrome JJ N
receiving VBG N
low-dose JJ N
aspirin NN N
. . N

Metabolic NNP N
syndrome NN N
is VBZ N
associated VBN N
with IN N
intravascular JJ N
inflammation NN N
, , N
as IN N
determined VBN N
by IN N
increased JJ N
levels NNS N
of IN N
inflammatory NN N
biomarkers NNS N
and CC N
an DT N
increased VBN N
risk NN N
of IN N
ischemic JJ N
atherothrombotic JJ N
events NNS N
. . N

Evidence NN N
suggests VBZ N
that IN N
atherothrombosis NN N
and CC N
intravascular JJ N
inflammation NN N
share NN N
predictive JJ N
biomarkers NNS N
, , N
including VBG N
high-sensitivity JJ N
C-reactive JJ N
protein NN N
, , N
CD40 NNP N
ligand NN N
, , N
P-selectin NNP N
, , N
and CC N
N-terminal JJ N
pro-brain JJ N
natriuretic JJ N
peptide NN N
. . N

Patients NNS N
who WP N
had VBD N
metabolic JJ N
syndrome NN N
were VBD N
randomized VBN N
to TO N
receive VB N
clopidogrel NN N
75 CD N
mg/day JJ N
plus CC N
aspirin JJ N
81 CD N
mg/day NN N
( ( N
n JJ N
= NNP N
89 CD N
) ) N
or CC N
placebo JJ N
plus CC N
aspirin JJ N
81 CD N
mg/day NN N
( ( N
n JJ N
= NNP N
92 CD N
) ) N
for IN N
9 CD N
weeks NNS N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
each DT N
treatment NN N
in IN N
suppression NN N
of IN N
inflammatory JJ N
markers NNS N
. . N

Change NN N
from IN N
baseline NN N
in IN N
the DT N
levels NNS N
of IN N
high-sensitivity NN N
C-reactive JJ N
protein NN N
, , N
CD40 NNP N
ligand NN N
, , N
P-selectin NNP N
, , N
and CC N
N-terminal JJ N
pro-brain JJ N
natriuretic JJ N
peptide NN N
at IN N
6 CD N
weeks NNS N
was VBD N
assessed VBN N
to TO N
evaluate VB N
each DT N
treatment NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
at IN N
Week JJ N
6 CD N
in IN N
model-adjusted JJ N
CD40-ligand NNP N
levels NNS N
in IN N
favor NN N
of IN N
clopidogrel NN N
plus CC N
aspirin JJ N
compared VBN N
with IN N
placebo NN N
plus CC N
aspirin NN N
in IN N
both DT N
the DT N
intent-to-treat JJ N
population NN N
( ( N
difference NN N
between IN N
least-squares NNS N
means NNS N
= VBP N
-186.5 NNP N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-342.3 NN N
to TO N
-30.8 VB N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
the DT N
per-protocol JJ N
population NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
treatment NN N
arms NNS N
for IN N
high-sensitivity JJ N
C-reactive JJ N
protein NN N
, , N
P-selectin NNP N
, , N
and CC N
N-terminal JJ N
pro-brain JJ N
natriuretic JJ N
peptide NN N
. . N

There EX N
were VBD N
no DT N
deaths NNS N
or CC N
serious JJ N
adverse JJ N
events NNS N
in IN N
either DT N
treatment NN N
arm NN N
. . N

Data NNS N
from IN N
this DT N
study NN N
suggest VBP N
that IN N
clopidogrel NN N
can MD N
decrease VB N
the DT N
expression NN N
of IN N
the DT N
CD40-ligand NNP N
biomarker NN N
. . N

-DOCSTART- -20357382- O O

Effect NN N
of IN N
ranolazine NN N
on IN N
A1C NNP N
and CC N
glucose JJ N
levels NNS N
in IN N
hyperglycemic JJ N
patients NNS N
with IN N
non-ST JJ N
elevation NN N
acute NN N
coronary JJ N
syndrome NN N
. . N

OBJECTIVE IN N
We PRP N
determined VBD N
the DT N
relationships NNS N
between IN N
glycemia NN N
at IN N
randomization NN N
, , N
concurrent JJ N
antidiabetic JJ N
therapy NN N
, , N
and CC N
change NN N
in IN N
A1C NNP N
and CC N
fasting VBG N
plasma NN N
glucose NN N
( ( N
FPG NNP N
) ) N
in IN N
patients NNS N
with IN N
diabetes NNS N
receiving VBG N
standard JJ N
treatment NN N
for IN N
diabetes NNS N
and CC N
randomized VBN N
to TO N
ranolazine VB N
or CC N
placebo VB N
within IN N
the DT N
MERLIN-TIMI-36 NNP N
( ( N
MERLIN NNP N
) ) N
study NN N
. . N

Ranolazine NNP N
is VBZ N
a DT N
novel JJ N
first-in-class JJ N
drug NN N
approved VBD N
for IN N
treating VBG N
angina JJ N
pectoris NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Randomization NNP N
and CC N
4-month JJ N
glycemic NN N
and CC N
antidiabetes VBZ N
drug NN N
usage NN N
data NNS N
from IN N
MERLIN NNP N
were VBD N
analyzed VBN N
using VBG N
Spotfire NNP N
and CC N
SAS NNP N
version NN N
9.1 CD N
software NN N
. . N

RESULTS NNP N
In IN N
patients NNS N
with IN N
diabetes NNS N
and CC N
A1C NNP N
of IN N
> NNP N
or=8-10 JJ N
% NN N
at IN N
randomization NN N
( ( N
n JJ N
= NNP N
171 CD N
) ) N
, , N
there EX N
was VBD N
an DT N
absolute JJ N
A1C NNP N
reduction NN N
in IN N
the DT N
ranolazine NN N
group NN N
of IN N
1.2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-1.4 NNP N
to TO N
-1.0 VB N
) ) N
, , N
and CC N
the DT N
placebo-adjusted JJ N
( ( N
n JJ N
= NNP N
182 CD N
) ) N
decrease NN N
in IN N
A1C NNP N
by IN N
ranolazine NN N
was VBD N
0.59 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-0.99 NNP N
to TO N
-0.20 VB N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
patients NNS N
with IN N
FPG NNP N
of IN N
150-400 JJ N
mg/dl NN N
at IN N
randomization NN N
, , N
ranolazine NN N
( ( N
n JJ N
= NNP N
131 CD N
) ) N
compared VBN N
with IN N
placebo NN N
( ( N
n JJ N
= NNP N
147 CD N
) ) N
reduced VBN N
FPG NNP N
by IN N
25.7 CD N
mg/dl NNS N
( ( N
95 CD N
% NN N
CI NNP N
-43.3 NNP N
to TO N
-8.1 VB N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

When WRB N
changes NNS N
in IN N
either DT N
A1C NNP N
or CC N
FPG NNP N
were VBD N
correlated VBN N
to TO N
A1C NNP N
or CC N
FPG NNP N
at IN N
randomization NN N
, , N
the DT N
slopes NNS N
were VBD N
significantly RB N
steeper JJR N
for IN N
ranolazine NN N
than IN N
placebo NN N
( ( N
A1C NNP N
, , N
P NNP N
= NNP N
0.046 CD N
; : N
FPG NNP N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
indicating VBG N
that IN N
lowering VBG N
of IN N
A1C NNP N
and CC N
FPG NNP N
by IN N
ranolazine NN N
is VBZ N
related VBN N
to TO N
hyperglycemia VB N
at IN N
randomization NN N
. . N

Ranolazine NNP N
, , N
compared VBN N
with IN N
placebo NN N
, , N
was VBD N
not RB N
associated VBN N
with IN N
serious JJ N
hypoglycemic JJ N
events NNS N
, , N
associated VBN N
with IN N
significant JJ N
changes NNS N
in IN N
concurrent JJ N
antidiabetic JJ N
therapy NN N
, , N
or CC N
dependent NN N
on IN N
a DT N
history NN N
of IN N
angina NN N
. . N

CONCLUSIONS NNP N
Ranolazine NNP N
, , N
when WRB N
added VBN N
to TO N
concurrent VB N
antidiabetes NNS N
treatment NN N
, , N
lowers NNS N
FPG NNP N
and CC N
A1C NNP N
in IN N
patients NNS N
with IN N
cardiovascular JJ N
disease NN N
and CC N
poorly RB N
controlled VBN N
diabetes NNS N
. . N

-DOCSTART- -2474057- O O

LNH-84 JJ N
regimen NNS N
: : N
a DT N
multicenter NN N
study NN N
of IN N
intensive JJ N
chemotherapy NN N
in IN N
737 CD N
patients NNS N
with IN N
aggressive JJ N
malignant JJ N
lymphoma NN N
. . N

From IN N
July NNP N
1984 CD N
to TO N
September NNP N
1987 CD N
, , N
737 CD N
patients NNS N
with IN N
aggressive JJ N
malignant JJ N
lymphoma NN N
( ( N
ML NNP N
) ) N
were VBD N
treated VBN N
by IN N
an DT N
intensive JJ N
regimen NNS N
( ( N
LNH-84 NNP N
) ) N
comprising VBG N
three CD N
or CC N
four CD N
courses NNS N
of IN N
doxorubicin NN N
, , N
75 CD N
mg/m2 NN N
; : N
cyclophosphamide NN N
, , N
1,200 CD N
mg/m2 NN N
; : N
vindesine NN N
, , N
2 CD N
mg/m2 NN N
x NN N
2 CD N
; : N
bleomycin NN N
, , N
10 CD N
mg NN N
x NN N
2 CD N
; : N
and CC N
prednisolone NN N
, , N
60 CD N
mg/m2 NN N
x NN N
5 CD N
( ( N
ACVB NNP N
) ) N
, , N
consolidation NN N
with IN N
high-dose JJ N
methotrexate NN N
, , N
ifosfamide NN N
, , N
etoposide RB N
, , N
asparaginase NN N
, , N
and CC N
cytarabine NN N
, , N
and CC N
a DT N
randomized VBN N
late JJ N
intensification NN N
with IN N
two CD N
courses NNS N
of IN N
cytarabine NN N
, , N
cyclophosphamide NN N
, , N
teniposide NN N
, , N
bleomycin NN N
, , N
and CC N
prednisone NN N
( ( N
AraCVmB NNP N
) ) N
. . N

Four CD N
hundred VBD N
forty-two JJ N
patients NNS N
had VBD N
intermediate-grade JJ N
ML NNP N
, , N
221 CD N
highgrade NN N
ML NNP N
, , N
and CC N
74 CD N
unclassified JJ N
ML NNP N
. . N

Most JJS N
of IN N
the DT N
patients NNS N
had VBD N
advanced JJ N
disease NN N
: : N
stage NN N
IIE NNP N
( ( N
23 CD N
% NN N
) ) N
, , N
III NNP N
( ( N
13 CD N
% NN N
) ) N
, , N
or CC N
IV NNP N
( ( N
47 CD N
% NN N
) ) N
; : N
38 CD N
% NN N
disseminated JJ N
nodes NNS N
; : N
38 CD N
% NN N
two CD N
or CC N
more JJR N
extranodal JJ N
sites NNS N
; : N
and CC N
41 CD N
% NN N
a DT N
tumoral JJ N
mass NN N
greater JJR N
than IN N
10 CD N
cm NN N
. . N

Five CD N
hundred VBD N
fifty-three JJ N
patients NNS N
( ( N
75 CD N
% NN N
) ) N
went VBD N
into IN N
complete JJ N
remission NN N
( ( N
CR NNP N
) ) N
, , N
63 CD N
( ( N
9 CD N
% NN N
) ) N
into IN N
partial JJ N
remission NN N
, , N
62 CD N
( ( N
8 CD N
% NN N
) ) N
failed VBD N
to TO N
respond VB N
, , N
and CC N
59 CD N
( ( N
8 CD N
% NN N
) ) N
died VBD N
during IN N
ACVB NNP N
courses NNS N
, , N
17 CD N
of IN N
them PRP N
from IN N
progression NN N
of IN N
the DT N
disease NN N
. . N

With IN N
a DT N
median JJ N
follow-up NN N
of IN N
23 CD N
months NNS N
, , N
the DT N
estimated VBN N
2-year JJ N
overall JJ N
survival NN N
time NN N
to TO N
failure NN N
( ( N
TTF NNP N
) ) N
, , N
and CC N
time NN N
to TO N
relapse VB N
( ( N
TTR NNP N
) ) N
survival NN N
are VBP N
67 CD N
% NN N
, , N
56 CD N
% NN N
, , N
and CC N
67 CD N
% NN N
, , N
respectively RB N
. . N

Patients NNS N
receiving VBG N
a DT N
late JJ N
intensification NN N
had VBD N
the DT N
same JJ N
relapse NN N
rate NN N
as IN N
the DT N
other JJ N
patients NNS N
. . N

A DT N
persistent JJ N
fibronecrotic JJ N
mass NN N
was VBD N
found VBN N
in IN N
150 CD N
patients NNS N
( ( N
20 CD N
% NN N
) ) N
and CC N
did VBD N
not RB N
influence VB N
the DT N
relapse NN N
rate NN N
. . N

Toxicity NNP N
was VBD N
mainly RB N
neutropenia JJ N
and CC N
infection NN N
during IN N
the DT N
ACVB NNP N
courses NNS N
, , N
with IN N
40 CD N
patients NNS N
( ( N
5 CD N
% NN N
) ) N
dying VBG N
from IN N
septic JJ N
complications NNS N
while IN N
responding VBG N
to TO N
treatment NN N
. . N

Fifty-three JJ N
percent NN N
of IN N
the DT N
patients NNS N
had VBD N
a DT N
neutropenia NN N
less JJR N
than IN N
0.500 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
, , N
58 CD N
% NN N
fever NN N
( ( N
6 CD N
% NN N
grade JJ N
4 CD N
) ) N
, , N
and CC N
49 CD N
% NN N
a DT N
documented JJ N
infection NN N
( ( N
8 CD N
% NN N
grade JJ N
4 CD N
) ) N
. . N

These DT N
results NNS N
obtained VBD N
with IN N
the DT N
LNH-84 JJ N
regimen NNS N
demonstrate VBP N
that IN N
this DT N
therapeutic JJ N
scheme NN N
is VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
aggressive JJ N
ML NNP N
. . N

-DOCSTART- -8831332- O O

Clonidine NN N
increases VBZ N
the DT N
sweating NN N
threshold NN N
, , N
but CC N
does VBZ N
not RB N
reduce VB N
the DT N
gain NN N
of IN N
sweating VBG N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
clonidine NN N
produces VBZ N
a DT N
dose-dependent JJ N
increase NN N
in IN N
the DT N
sweating NN N
threshold NN N
but CC N
does VBZ N
not RB N
reduce VB N
the DT N
gain NN N
of IN N
sweating VBG N
. . N

Six NNP N
healthy JJ N
male NN N
volunteers NNS N
were VBD N
evaluated VBN N
, , N
each DT N
on IN N
three CD N
separate JJ N
days NNS N
in IN N
random JJ N
order NN N
. . N

In IN N
one CD N
, , N
saline NN N
was VBD N
administered VBN N
; : N
in IN N
another DT N
, , N
a DT N
2-micrograms/kg JJ N
bolus NN N
of IN N
clonidine NN N
was VBD N
followed VBN N
by IN N
an DT N
infusion NN N
at IN N
2 CD N
micrograms.kg-1.h-1 NN N
, , N
and CC N
on IN N
a DT N
third JJ N
day NN N
, , N
a DT N
4-micrograms/kg JJ N
bolus NN N
was VBD N
followed VBN N
by IN N
an DT N
infusion NN N
at IN N
4 CD N
micrograms.kg-1.h-1 JJ N
. . N

Core NN N
temperature NN N
was VBD N
measured VBN N
at IN N
the DT N
tympanic JJ N
membrane NN N
and CC N
mean JJ N
skin NN N
temperature NN N
was VBD N
determined VBN N
from IN N
four CD N
sites NNS N
. . N

A DT N
chest JJ N
sweating NN N
rate NN N
of IN N
40 CD N
g.m-2.h-1 NN N
was VBD N
considered VBN N
significant JJ N
. . N

The DT N
core NN N
temperature NN N
triggering VBG N
sweating NN N
, , N
adjusted VBN N
to TO N
a DT N
designated VBN N
mean NN N
skin JJ N
temperature NN N
of IN N
34 CD N
degrees NNS N
C NNP N
, , N
identified VBD N
the DT N
threshold NN N
for IN N
this DT N
response NN N
. . N

Gain NNP N
was VBD N
defined VBN N
by IN N
the DT N
adjusted VBN N
core NN N
temperature NN N
increase NN N
required VBN N
to TO N
augment VB N
sweating VBG N
from IN N
100 CD N
to TO N
300 CD N
g.m-2.h-1 NN N
. . N

degree JJ N
C-1 NNP N
. . N

Plasma NNP N
clonidine JJ N
concentrations NNS N
were VBD N
0.8 CD N
+/- JJ N
0.1 CD N
and CC N
1.6 CD N
+/- JJ N
0.2 CD N
ng/mL NN N
on IN N
the DT N
small- JJ N
and CC N
large-dose JJ N
days NNS N
, , N
respectively RB N
. . N

Clonidine NNP N
administration NN N
increased VBD N
the DT N
sweating NN N
threshold VBD N
approximately RB N
0.4 CD N
degree JJ N
C NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
the DT N
increase NN N
was VBD N
comparable JJ N
at IN N
each DT N
dose NN N
. . N

The DT N
gain NN N
of IN N
sweating NN N
was VBD N
approximately RB N
0.2 CD N
degree JJ N
C NNP N
and CC N
was VBD N
not RB N
influenced VBN N
by IN N
clonidine JJ N
administration NN N
. . N

The DT N
thermoregulatory JJ N
effects NNS N
of IN N
clonidine NN N
thus RB N
resemble JJ N
those DT N
of IN N
volatile JJ N
anesthetics NNS N
, , N
opioids NNS N
, , N
and CC N
propofol NN N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
antishivering VBG N
effect NN N
of IN N
clonidine NN N
results NNS N
from IN N
central JJ N
thermoregulatory JJ N
inhibition NN N
rather RB N
than IN N
a DT N
specific JJ N
peripheral JJ N
action NN N
on IN N
thermogenic JJ N
muscular JJ N
activity NN N
. . N

Unlike IN N
other JJ N
sedatives NNS N
and CC N
anesthetics NNS N
, , N
the DT N
concentration-dependence NN N
of IN N
clonidine NN N
demonstrates VBZ N
a DT N
ceiling NN N
beyond IN N
which WDT N
the DT N
administration NN N
of IN N
an DT N
additional JJ N
drug NN N
fails NNS N
to TO N
enhance VB N
the DT N
effect NN N
, , N
suggesting VBG N
that IN N
the DT N
thermoregulatory JJ N
effect NN N
of IN N
clonidine NN N
may MD N
be VB N
limited VBN N
, , N
even RB N
at IN N
high JJ N
plasma NN N
concentrations NNS N
. . N

The DT N
gain NN N
of IN N
sweating NN N
was VBD N
well RB N
preserved JJ N
indicating VBG N
that IN N
this DT N
response NN N
remains VBZ N
effective JJ N
in IN N
the DT N
presence NN N
of IN N
sedatives NNS N
and CC N
anesthetics NNS N
. . N

-DOCSTART- -9935021- O O

Morphological JJ N
onset NN N
and CC N
early JJ N
diagnosis NN N
in IN N
apical JJ N
hypertrophic JJ N
cardiomyopathy NN N
: : N
a DT N
long JJ N
term NN N
analysis NN N
with IN N
nuclear JJ N
magnetic JJ N
resonance NN N
imaging NN N
. . N

OBJECTIVES VB N
A DT N
long-term JJ N
follow-up NN N
study NN N
with IN N
nuclear JJ N
magnetic JJ N
resonance NN N
( ( N
NMR NNP N
) ) N
imaging NN N
was VBD N
undertaken VBN N
to TO N
detect VB N
the DT N
morphological JJ N
onset NN N
and CC N
to TO N
establish VB N
the DT N
early JJ N
diagnosis NN N
in IN N
apical JJ N
hypertrophic JJ N
cardiomyopathy NN N
( ( N
HCM NNP N
) ) N
. . N

BACKGROUND VB N
A DT N
spadelike JJ N
configuration NN N
on IN N
left JJ N
ventriculogram NN N
( ( N
LVG NNP N
) ) N
is VBZ N
regarded VBN N
as IN N
a DT N
diagnostic JJ N
criterion NN N
for IN N
the DT N
classical JJ N
apical JJ N
HCM NNP N
. . N

There EX N
also RB N
exists VBZ N
a DT N
segmented JJ N
hypertrophy NN N
at IN N
the DT N
apical JJ N
level NN N
without IN N
indicating VBG N
the DT N
spadelike NN N
features NNS N
( ( N
a DT N
nonspade NN N
configuration NN N
) ) N
. . N

To TO N
detect VB N
the DT N
hypertrophied JJ N
myocardium NN N
of IN N
the DT N
nonspade JJ N
configuration NN N
, , N
circumferential JJ N
scrutiny NN N
of IN N
the DT N
apex NN N
is VBZ N
required VBN N
. . N

Although IN N
both DT N
configurations NNS N
can MD N
be VB N
underlying JJ N
causes NNS N
of IN N
giant JJ N
negative JJ N
T NNP N
waves NNS N
, , N
etiological JJ N
relationship NN N
between IN N
the DT N
two CD N
is VBZ N
not RB N
clarified VBN N
. . N

METHODS NNP N
The DT N
criteria NN N
for IN N
the DT N
spadelike NN N
configuration NN N
defined VBN N
on IN N
left JJ N
ventricular JJ N
short-axis JJ N
NMR NNP N
images NNS N
were VBD N
as IN N
follows VBZ N
: : N
( ( N
apical JJ N
maximal NN N
thickness NN N
> NN N
or CC N
= $ N
15 CD N
mm NN N
) ) N
, , N
( ( N
apical JJ N
anterior NN N
thickness NN N
over IN N
basal JJ N
anterior JJ N
thickness NN N
> NN N
or CC N
= VB N
1.3 CD N
) ) N
and CC N
( ( N
apical JJ N
posterior NN N
thickness NN N
over IN N
basal JJ N
posterior JJ N
thickness NN N
> NN N
or CC N
=1.3 NN N
) ) N
. . N

Thirteen JJ N
patients NNS N
who WP N
had VBD N
predominant JJ N
hypertrophy NN N
( ( N
> CD N
or CC N
= VB N
15 CD N
mm NN N
) ) N
at IN N
the DT N
apical JJ N
level NN N
without IN N
the DT N
spadelike NN N
configuration NN N
underwent JJ N
NMR NNP N
imaging VBG N
twice RB N
before RB N
and CC N
after IN N
54+/-10 JJ N
months NNS N
' POS N
follow-up NN N
. . N

RESULTS NNP N
Apical NNP N
hypertrophy NN N
that WDT N
had VBD N
been VBN N
confined VBN N
to TO N
the DT N
lateral JJ N
wall NN N
in IN N
four CD N
, , N
the DT N
anterior-lateral JJ N
wall NN N
in IN N
two CD N
, , N
and CC N
the DT N
septal-anterior JJ N
wall NN N
in IN N
one CD N
developed NN N
to TO N
become VB N
circumferential JJ N
hypertrophy NN N
that WDT N
fulfilled VBD N
the DT N
criteria NNS N
for IN N
the DT N
spadelike NN N
configuration NN N
after IN N
the DT N
follow-up JJ N
period NN N
. . N

CONCLUSIONS VB N
The DT N
spadelike NN N
configuration NN N
can MD N
begin VB N
with IN N
the DT N
nonspade JJ N
configuration NN N
and CC N
therefore NN N
, , N
both DT N
can MD N
constitute VB N
a DT N
single JJ N
disease NN N
entity NN N
of IN N
apical JJ N
HCM NNP N
. . N

The DT N
early JJ N
diagnosis NN N
of IN N
apical JJ N
HCM NNP N
can MD N
be VB N
achieved VBN N
by IN N
identifying VBG N
the DT N
hypertrophy NN N
frequently RB N
confined VBN N
to TO N
the DT N
lateral JJ N
wall NN N
at IN N
the DT N
apical JJ N
level NN N
. . N

-DOCSTART- -24092940- O O

18F-FDG JJ N
PET/CT NNP N
for IN N
early JJ N
prediction NN N
of IN N
response NN N
to TO N
neoadjuvant JJ N
lapatinib NN N
, , N
trastuzumab NN N
, , N
and CC N
their PRP$ N
combination NN N
in IN N
HER2-positive JJ N
breast NN N
cancer NN N
: : N
results NNS N
from IN N
Neo-ALTTO NNP N
. . N

UNLABELLED NNP N
Molecular NNP N
imaging VBG N
receives NNS N
increased VBD N
attention NN N
for IN N
selecting VBG N
patients NNS N
who WP N
will MD N
benefit VB N
from IN N
targeted JJ N
anticancer NN N
therapies NNS N
. . N

Neo-ALTTO NNP N
( ( N
Neoadjuvant NNP N
Lapatinib NNP N
and/or VBZ N
Trastuzumab NNP N
Treatment NNP N
Optimisation NNP N
) ) N
enrolled VBD N
455 CD N
women NNS N
with IN N
invasive JJ N
human JJ N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
2 CD N
( ( N
HER2 NNP N
) ) N
-positive VBP N
breast NN N
cancer NN N
and CC N
compared VBN N
rates NNS N
of IN N
pathologic JJ N
complete JJ N
response NN N
( ( N
pCR NN N
) ) N
to TO N
neoadjuvant JJ N
lapatinib NN N
, , N
trastuzumab NN N
, , N
and CC N
their PRP$ N
combination NN N
. . N

Each DT N
anti-HER2 JJ N
therapy NN N
was VBD N
given VBN N
alone RB N
for IN N
6 CD N
wk NN N
, , N
followed VBN N
by IN N
12 CD N
wk NN N
of IN N
the DT N
same JJ N
therapy NN N
plus CC N
weekly JJ N
paclitaxel NN N
. . N

The DT N
early JJ N
metabolic JJ N
effects NNS N
of IN N
the DT N
anti-HER2 JJ N
therapies NNS N
on IN N
the DT N
primary JJ N
tumors NNS N
and CC N
their PRP$ N
predictive JJ N
values NNS N
for IN N
pCR NN N
were VBD N
assessed VBN N
in IN N
a DT N
subset NN N
of IN N
patients NNS N
. . N

METHODS NNP N
Eighty-six JJ N
patients NNS N
underwent JJ N
( ( N
18 CD N
) ) N
F-FDG CD N
PET/CT NNP N
at IN N
baseline NN N
and CC N
weeks NNS N
2 CD N
and CC N
6 CD N
of IN N
anti-HER2 JJ N
treatment NN N
. . N

An DT N
imaging VBG N
core NN N
laboratory NN N
provided VBD N
central JJ N
validation NN N
, , N
and CC N
2 CD N
independent JJ N
reviewers NNS N
, , N
masked VBD N
to TO N
assigned VB N
treatment NN N
arm NN N
and CC N
clinical JJ N
outcomes NNS N
, , N
performed VBN N
consensus NN N
( ( N
18 CD N
) ) N
F-FDG NNP N
PET/CT NNP N
readings NNS N
. . N

Maximum NNP N
standardized VBD N
uptake JJ N
value NN N
( ( N
SUVmax NNP N
) ) N
reductions NNS N
from IN N
baseline NN N
were VBD N
used VBN N
to TO N
measure VB N
metabolic JJ N
response NN N
. . N

RESULTS NNP N
Seventy-seven NNP N
of IN N
the DT N
86 CD N
enrolled VBD N
patients NNS N
presented VBD N
an DT N
evaluable JJ N
baseline NN N
( ( N
18 CD N
) ) N
F-FDG NNP N
PET/CT NNP N
scan JJ N
; : N
of IN N
these DT N
, , N
68 CD N
and CC N
66 CD N
were VBD N
evaluable JJ N
at IN N
weeks NNS N
2 CD N
and CC N
6 CD N
, , N
respectively RB N
. . N

Metabolic JJ N
responses NNS N
in IN N
the DT N
primary JJ N
tumors NNS N
were VBD N
evident JJ N
after IN N
2 CD N
wk NN N
of IN N
targeted JJ N
therapy NN N
and CC N
correlated VBN N
highly RB N
with IN N
metabolic JJ N
responses NNS N
at IN N
week NN N
6 CD N
( ( N
R NNP N
( ( N
2 CD N
) ) N
= FW N
0.81 CD N
) ) N
. . N

pCRs NN N
were VBD N
associated VBN N
with IN N
greater JJR N
SUVmax NNP N
reductions NNS N
at IN N
both DT N
time NN N
points NNS N
. . N

Mean NNP N
SUVmax NNP N
reductions NNS N
for IN N
pCR NN N
and CC N
non-pCR JJ N
, , N
respectively RB N
, , N
were VBD N
54.3 CD N
% NN N
versus IN N
32.8 CD N
% NN N
at IN N
week NN N
2 CD N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
61.5 CD N
% NN N
versus IN N
34.1 CD N
% NN N
at IN N
week NN N
6 CD N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

( ( N
18 CD N
) ) N
F-FDG NNP N
PET/CT NNP N
metabolic JJ N
response NN N
rates NNS N
at IN N
weeks NNS N
2 CD N
and CC N
6 CD N
were VBD N
71.6 CD N
% NN N
and CC N
60 CD N
% NN N
, , N
respectively RB N
using VBG N
European JJ N
Organization NNP N
for IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
criteria NNS N
; : N
pCR VBN N
rates NNS N
were VBD N
twice RB N
as RB N
high JJ N
for IN N
( ( N
18 CD N
) ) N
F-FDG NNP N
PET/CT NNP N
responders NNS N
than IN N
nonresponders NNS N
( ( N
week NN N
2 CD N
: : N
42 CD N
% NN N
vs. FW N
21 CD N
% NN N
, , N
P NNP N
= NNP N
0.12 CD N
; : N
week NN N
6 CD N
: : N
44 CD N
% NN N
vs. FW N
19 CD N
% NN N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Early NNP N
metabolic JJ N
assessment NN N
using VBG N
( ( N
18 CD N
) ) N
F-FDG CD N
PET/CT NNP N
can MD N
identify VB N
patients NNS N
with IN N
an DT N
increased VBN N
likelihood NN N
of IN N
pCR NN N
after IN N
neoadjuvant JJ N
trastuzumab NN N
, , N
lapatinib NN N
, , N
or CC N
their PRP$ N
combination NN N
when WRB N
given VBN N
with IN N
chemotherapy NN N
. . N

-DOCSTART- -22151475- O O

Motion NNP N
style NN N
acupuncture NN N
treatment NN N
( ( N
MSAT NNP N
) ) N
for IN N
acute NN N
low JJ N
back RB N
pain NN N
with IN N
severe JJ N
disability NN N
: : N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
protocol NN N
. . N

BACKGROUND NNP N
Acupuncture NNP N
is VBZ N
widely-used JJ N
to TO N
treat VB N
patients NNS N
with IN N
low JJ N
back RB N
pain NN N
, , N
despite IN N
insufficient JJ N
evidence NN N
of IN N
the DT N
technique NN N
's POS N
efficacy NN N
for IN N
acute NN N
back RB N
pain NN N
. . N

Motion NNP N
style NN N
acupuncture NN N
treatment NN N
( ( N
MSAT NNP N
) ) N
is VBZ N
a DT N
non-traditional JJ N
acupuncture NN N
treatment NN N
requiring VBG N
a DT N
patient NN N
to TO N
exercise VB N
while IN N
receiving VBG N
acupuncture NN N
. . N

In IN N
Korea NNP N
, , N
MSAT NNP N
is VBZ N
used VBN N
to TO N
reduce VB N
musculoskeletal JJ N
pain NN N
and CC N
improve VB N
functional JJ N
status NN N
. . N

The DT N
study NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
MSAT NNP N
on IN N
acute NN N
low JJ N
back RB N
pain NN N
with IN N
severe JJ N
disability NN N
. . N

METHODS/DESIGN NNP N
This DT N
study NN N
is VBZ N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
active-controlled JJ N
trial NN N
with IN N
two CD N
parallel JJ N
arms NNS N
. . N

Participants NNS N
with IN N
acute NN N
low JJ N
back RB N
pain NN N
and CC N
severe JJ N
functional JJ N
disability NN N
, , N
defined VBD N
as IN N
an DT N
Oswestry NNP N
Disability NNP N
Index NNP N
( ( N
ODI NNP N
) ) N
value NN N
> $ N
60 CD N
% NN N
, , N
will MD N
be VB N
randomly RB N
allocated VBN N
to TO N
the DT N
acupuncture NN N
group NN N
and CC N
the DT N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
( ( N
NSAID NNP N
) ) N
injection NN N
group NN N
. . N

The DT N
acupuncture NN N
group NN N
will MD N
receive VB N
MSAT NNP N
and CC N
the DT N
NSAID NNP N
injection NN N
group NN N
will MD N
receive VB N
an DT N
intramuscular JJ N
injection NN N
of IN N
diclofenac NN N
. . N

All DT N
procedures NNS N
will MD N
be VB N
limited VBN N
to TO N
one CD N
session NN N
and CC N
the DT N
symptoms NNS N
before IN N
and CC N
after IN N
treatment NN N
will MD N
be VB N
measured VBN N
by IN N
assessors NNS N
blinded VBD N
to TO N
treatment NN N
allocation NN N
. . N

The DT N
primary JJ N
outcome NN N
will MD N
be VB N
measured VBN N
at IN N
30 CD N
minutes NNS N
after IN N
treatment NN N
using VBG N
the DT N
numerical JJ N
rating NN N
scale NN N
( ( N
NRS NNP N
) ) N
of IN N
low JJ N
back RB N
pain NN N
while IN N
the DT N
patient NN N
is VBZ N
moving VBG N
. . N

Secondary JJ N
outcomes NNS N
will MD N
be VB N
measured VBN N
at IN N
30 CD N
minutes NNS N
after IN N
treatment NN N
using VBG N
the DT N
NRS NNP N
of IN N
leg NN N
pain NN N
, , N
ODI NNP N
, , N
patient NN N
global JJ N
impression NN N
of IN N
change NN N
, , N
range NN N
of IN N
motion NN N
( ( N
ROM NNP N
) ) N
of IN N
the DT N
lumbar NN N
spine NN N
, , N
and CC N
degrees NNS N
of IN N
straight JJ N
leg NN N
raising VBG N
( ( N
SLR NNP N
) ) N
. . N

Post-treatment JJ N
follow-up NN N
will MD N
be VB N
performed VBN N
to TO N
measure VB N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
with IN N
the DT N
exception NN N
of IN N
ROM NNP N
and CC N
SLR NNP N
at IN N
2 CD N
, , N
4 CD N
, , N
and CC N
24 CD N
weeks NNS N
after IN N
treatment NN N
. . N

DISCUSSION NNP N
The DT N
results NNS N
of IN N
this DT N
trial NN N
will MD N
be VB N
discussed VBN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrial.gov NNP N
NCT01315561 NNP N
. . N

-DOCSTART- -15193471- O O

An DT N
open JJ N
and CC N
randomized JJ N
study NN N
comparing VBG N
the DT N
efficacy NN N
of IN N
standard JJ N
danazol NN N
and CC N
modified VBD N
triptorelin NN N
regimens NNS N
for IN N
postoperative JJ N
disease NN N
management NN N
of IN N
moderate JJ N
to TO N
severe JJ N
endometriosis NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
danazol NN N
and CC N
triptorelin NN N
( ( N
Decapeptyl NNP N
CR NNP N
, , N
Ferring NNP N
, , N
Kiel NNP N
, , N
Germany NNP N
) ) N
in IN N
the DT N
management NN N
of IN N
moderate JJ N
and CC N
severe JJ N
endometriosis NN N
in IN N
terms NNS N
of IN N
symptom NN N
control NN N
and CC N
revised VBN N
American JJ N
Fertility NNP N
Society NNP N
( ( N
AFS NNP N
) ) N
score NN N
reduction NN N
, , N
and CC N
to TO N
evaluate VB N
the DT N
hormonal JJ N
profile NN N
of IN N
patients NNS N
treated VBN N
with IN N
triptorelin NN N
every DT N
6 CD N
weeks NNS N
. . N

DESIGN NNP N
Open NNP N
and CC N
randomized VBN N
trial NN N
. . N

SETTING NN N
Kwong NNP N
Wah NNP N
Hospital NNP N
, , N
a DT N
large JJ N
public JJ N
hospital NN N
in IN N
an DT N
urban JJ N
location NN N
( ( N
Hong NNP N
Kong NNP N
) ) N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
Forty NNP N
patients NNS N
after IN N
their PRP$ N
first JJ N
conservative JJ N
operation NN N
for IN N
endometriosis NN N
, , N
with IN N
surgical JJ N
confirmation NN N
of IN N
revised VBN N
AFS NNP N
stage NN N
III NNP N
or CC N
IV NNP N
endometriosis NN N
. . N

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Postoperative VBP N
6 CD N
months NNS N
' POS N
therapy NN N
of IN N
danazol NN N
or CC N
triptorelin NN N
every DT N
6 CD N
weeks NNS N
, , N
postmedical JJ N
therapy NN N
second-look NN N
laparoscopy NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Symptom NNP N
control NN N
and CC N
patients NNS N
' POS N
tolerance NN N
during IN N
medical JJ N
therapy NN N
, , N
posttherapy NN N
revised VBD N
AFS NNP N
score NN N
, , N
hormonal JJ N
profile NN N
during IN N
triptorelin JJ N
therapy NN N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Pain NNP N
control NN N
was VBD N
similar JJ N
between IN N
danazol NN N
and CC N
triptorelin NN N
therapy NN N
. . N

There EX N
was VBD N
less JJR N
breakthrough IN N
bleeding NN N
with IN N
triptorelin NN N
. . N

More JJR N
patients NNS N
failed VBD N
to TO N
complete VB N
the DT N
whole JJ N
course NN N
of IN N
danazol NN N
because IN N
of IN N
its PRP$ N
side NN N
effects NNS N
. . N

The DT N
revised JJ N
AFS NNP N
score NN N
at IN N
second-look JJ N
laparoscopy NN N
did VBD N
not RB N
show VB N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
medications NNS N
. . N

Adequate NNP N
pituitary JJ N
suppression NN N
was VBD N
observed VBN N
with IN N
injection NN N
of IN N
triptorelin NN N
every DT N
6 CD N
weeks NNS N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Lengthening NNP N
of IN N
triptorelin JJ N
administration NN N
intervals NNS N
from IN N
4 CD N
weeks NNS N
to TO N
6 CD N
weeks NNS N
is VBZ N
effective JJ N
in IN N
maintaining VBG N
a DT N
hypoestrogenic JJ N
state NN N
. . N

Patients NNS N
were VBD N
more RBR N
compliant JJ N
with IN N
triptorelin NN N
than IN N
danazol NN N
. . N

Thus RB N
, , N
triptorelin JJ N
injection NN N
every DT N
6 CD N
weeks NNS N
is VBZ N
more JJR N
cost-effective JJ N
than IN N
conventional JJ N
regimens NNS N
. . N

-DOCSTART- -10649829- O O

The DT N
relationship NN N
between IN N
repetitive JJ N
behaviors NNS N
and CC N
growth NN N
hormone NN N
response NN N
to TO N
sumatriptan VB N
challenge NN N
in IN N
adult NN N
autistic JJ N
disorder NN N
. . N

Autism NNP N
is VBZ N
heterogeneous JJ N
with IN N
respect NN N
to TO N
clinical JJ N
symptoms NNS N
and CC N
etiology NN N
. . N

To TO N
sort VB N
out RP N
this DT N
heterogeneity NN N
in IN N
autism NN N
, , N
we PRP N
investigated VBD N
whether IN N
specific JJ N
neurobiological JJ N
markers NNS N
vary VBP N
in IN N
parallel NN N
to TO N
core VB N
symptomatology NN N
. . N

Specifically RB N
, , N
we PRP N
assessed VBD N
growth NN N
hormone NN N
response NN N
to TO N
the DT N
5-HT JJ N
1d CD N
agonist NN N
, , N
sumatriptan NN N
, , N
and CC N
linked VBD N
this DT N
measure NN N
of IN N
serotonergic JJ N
function NN N
to TO N
the DT N
severity NN N
of IN N
repetitive JJ N
behaviors NNS N
in IN N
adult NN N
autistic JJ N
patients NNS N
. . N

Eleven NNP N
adult NN N
patients NNS N
with IN N
autism NN N
or CC N
Asperger NNP N
's POS N
disorder NN N
were VBD N
randomized VBN N
to TO N
single JJ N
dose JJ N
sumatriptan NN N
( ( N
6 CD N
mg RB N
SQ NNP N
) ) N
and CC N
placebo NN N
challenges NNS N
, , N
separated VBN N
by IN N
a DT N
one-week JJ N
interval NN N
. . N

In IN N
adult JJ N
autistic JJ N
disorders NNS N
, , N
severity NN N
of IN N
repetitive JJ N
behaviors NNS N
at IN N
baseline NN N
, , N
as IN N
measured VBN N
by IN N
YBOCS-compulsion NNP N
score NN N
, , N
significantly RB N
positively RB N
correlated VBN N
with IN N
both DT N
peak JJ N
delta NN N
growth NN N
hormone NN N
response NN N
and CC N
area NN N
under IN N
the DT N
curve NN N
growth NN N
hormone NN N
response NN N
to TO N
sumatriptan VB N
. . N

Thus RB N
, , N
the DT N
severity NN N
of IN N
a DT N
specific JJ N
behavioral JJ N
dimension NN N
in IN N
autism NN N
( ( N
repetitive JJ N
behaviors NNS N
) ) N
parallels VBP N
the DT N
sensitivity NN N
of IN N
the DT N
5-HT JJ N
1d CD N
receptor NN N
, , N
as IN N
manifest NN N
by IN N
sumatriptan NN N
elicited VBN N
GH NNP N
response NN N
. . N

-DOCSTART- -24387919- O O

Whole-body JJ N
CT NNP N
screening NN N
: : N
scan JJ N
delay NN N
and CC N
contrast NN N
injection NN N
duration NN N
for IN N
optimal JJ N
enhancement NN N
of IN N
abdominal JJ N
organs NNS N
and CC N
deep JJ N
vessels NNS N
. . N

PURPOSE NNP N
To TO N
assess VB N
the DT N
optimal JJ N
scan JJ N
delays NNS N
and CC N
contrast NN N
injection NN N
durations NNS N
for IN N
contrast-enhanced JJ N
whole-body NN N
computed VBN N
tomography NN N
( ( N
CT NNP N
) ) N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
One CD N
hundred VBD N
forty-two JJ N
patients NNS N
were VBD N
randomized VBN N
into IN N
three CD N
groups NNS N
: : N
protocol NN N
A-scan JJ N
delay NN N
of IN N
65 CD N
s NNS N
after IN N
starting VBG N
contrast NN N
injection NN N
over IN N
30 CD N
s NNS N
; : N
protocol CC N
B-105 NNP N
and CC N
70 CD N
s NN N
; : N
and CC N
protocol VB N
C-145 NNP N
and CC N
110 CD N
s NN N
, , N
respectively RB N
. . N

Contrast NNP N
enhancement NN N
and CC N
diagnostic JJ N
acceptability NN N
were VBD N
assessed VBN N
. . N

RESULTS NNP N
Qualitative JJ N
assessment NN N
was VBD N
subtle JJ N
among IN N
the DT N
three CD N
protocols NNS N
. . N

Homogenous JJ N
enhancement NN N
of IN N
deep JJ N
veins NNS N
was VBD N
more RBR N
assuredly RB N
achieved VBN N
with IN N
protocol NN N
C. NNP N
CONCLUSION NNP N
With IN N
protocol NN N
C NNP N
, , N
qualitatively RB N
acceptable JJ N
enhancement NN N
can MD N
be VB N
obtained VBN N
in IN N
whole-body JJ N
CT NNP N
. . N

-DOCSTART- -7826791- O O

Co-administration NN N
of IN N
pethidine NN N
and CC N
clonidine NN N
: : N
a DT N
spinal JJ N
anaesthetic JJ N
technique NN N
for IN N
total JJ N
hip NN N
replacement NN N
. . N

Co-administration NN N
of IN N
pethidine NN N
0.75 CD N
mg NN N
kg-1 NN N
and CC N
clonidine NN N
75 CD N
micrograms NNS N
intrathecally RB N
provided VBD N
good JJ N
intraoperative JJ N
anaesthesia NN N
for IN N
total JJ N
hip NN N
replacement NN N
, , N
similar JJ N
to TO N
that DT N
obtained VBN N
using VBG N
0.5 CD N
% NN N
isobaric JJ N
bupivacaine NN N
. . N

Sensory NNP N
and CC N
motor NN N
block NN N
were VBD N
of IN N
shorter JJR N
duration NN N
than IN N
that DT N
after IN N
0.5 CD N
% NN N
isobaric JJ N
bupivacaine NN N
and CC N
0.5 CD N
% NN N
isobaric JJ N
bupivacaine NN N
with IN N
morphine JJ N
0.5 CD N
mg NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
sensory JJ N
block NN N
, , N
P NNP N
< VBZ N
0.001 CD N
motor NN N
block NN N
) ) N
. . N

Postoperative JJ N
morphine NN N
consumption NN N
, , N
measured VBN N
using VBG N
a DT N
patient-controlled JJ N
system NN N
, , N
was VBD N
similar JJ N
to TO N
that DT N
in IN N
patients NNS N
in IN N
the DT N
bupivacaine NN N
only RB N
group NN N
( ( N
pethidine-clonidine JJ N
: : N
median JJ N
39 CD N
mg/24 NN N
h NN N
; : N
bupivacaine NN N
: : N
median JJ N
34 CD N
mg/24 NN N
h NN N
) ) N
but CC N
greater JJR N
than IN N
that DT N
in IN N
the DT N
bupivacaine-morphine JJ N
group NN N
( ( N
median JJ N
8 CD N
mg/24 NN N
h NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Visual JJ N
analogue NN N
pain NN N
scores NNS N
after IN N
operation NN N
were VBD N
similar JJ N
to TO N
those DT N
with IN N
bupivacaine JJ N
alone NN N
at IN N
all DT N
but CC N
one CD N
of IN N
the DT N
recording NN N
times NNS N
but CC N
were VBD N
greater JJR N
than IN N
those DT N
in IN N
patients NNS N
who WP N
received VBD N
bupivacaine NN N
and CC N
morphine NN N
at IN N
4 CD N
, , N
6 CD N
and CC N
10 CD N
h NN N
after IN N
operation NN N
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
P NNP N
< NNP N
0.04 CD N
, , N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

The DT N
combination NN N
did VBD N
not RB N
offer VB N
any DT N
major JJ N
advantage NN N
over IN N
conventional JJ N
agents NNS N
. . N

-DOCSTART- -19404150- O O

Perioperative JJ N
fever NN N
and CC N
outcome NN N
in IN N
surgical JJ N
patients NNS N
with IN N
aneurysmal JJ N
subarachnoid JJ N
hemorrhage NN N
. . N

OBJECTIVE IN N
We PRP N
examined VBD N
the DT N
incidence NN N
of IN N
perioperative JJ N
fever NN N
and CC N
its PRP$ N
relationship NN N
to TO N
outcome VB N
among IN N
patients NNS N
enrolled VBN N
in IN N
the DT N
Intraoperative NNP N
Hypothermia NNP N
for IN N
Aneurysm NNP N
Surgery NNP N
Trial NNP N
. . N

METHODS NNP N
One CD N
thousand NN N
patients NNS N
with IN N
initial JJ N
World NNP N
Federation NNP N
of IN N
Neurological NNP N
Surgeons NNP N
grades NNS N
of IN N
I PRP N
to TO N
III NNP N
undergoing VBG N
clipping NN N
of IN N
intracranial JJ N
aneurysms NNS N
after IN N
subarachnoid JJ N
hemorrhage NN N
were VBD N
randomized VBN N
to TO N
intraoperative VB N
normothermia NN N
( ( N
36 CD N
degrees NNS N
C-37 JJ N
degrees NNS N
C NNP N
) ) N
or CC N
hypothermia NN N
( ( N
32.5 CD N
degrees NNS N
C-33.5 JJ N
degrees NNS N
C NNP N
) ) N
. . N

Fever NNP N
( ( N
> CD N
or CC N
=38.5 VB N
degrees NNS N
C NNP N
) ) N
and CC N
other JJ N
complications NNS N
( ( N
including VBG N
infections NNS N
) ) N
occurring VBG N
between IN N
admission NN N
and CC N
discharge NN N
( ( N
or CC N
death NN N
) ) N
were VBD N
recorded VBN N
. . N

Functional NNP N
and CC N
neuropsychologic JJ N
outcomes NNS N
were VBD N
assessed VBN N
3 CD N
months NNS N
postoperatively RB N
. . N

The DT N
primary JJ N
outcome NN N
variable NN N
for IN N
the DT N
trial NN N
was VBD N
dichotomized VBN N
Glasgow NNP N
Outcome NNP N
Scale NNP N
( ( N
good JJ N
outcome NN N
versus IN N
all DT N
others NNS N
) ) N
. . N

RESULTS NNP N
Fever NNP N
was VBD N
reported VBN N
in IN N
41 CD N
% NN N
of IN N
patients NNS N
. . N

In IN N
97 CD N
% NN N
of IN N
these DT N
, , N
fever RB N
occurred VBD N
in IN N
the DT N
postoperative JJ N
period NN N
. . N

The DT N
median JJ N
time NN N
from IN N
surgery NN N
to TO N
first VB N
fever NN N
was VBD N
3 CD N
days NNS N
. . N

All DT N
measures NNS N
of IN N
outcome NN N
were VBD N
worse JJR N
in IN N
patients NNS N
who WP N
developed VBD N
fever NN N
, , N
even RB N
in IN N
those DT N
without IN N
infections NNS N
or CC N
who WP N
were VBD N
World NNP N
Federation NNP N
of IN N
Neurological NNP N
Surgeons NNP N
grade VBD N
I. NNP N
Logistic NNP N
regression NN N
analyses NNS N
were VBD N
performed VBN N
to TO N
adjust VB N
for IN N
differences NNS N
in IN N
preoperative JJ N
factors NNS N
( ( N
e.g. NN N
, , N
age NN N
, , N
Fisher NNP N
grade NN N
, , N
initial JJ N
neurological JJ N
status NN N
) ) N
. . N

This DT N
demonstrated VBD N
that IN N
fever NN N
continued VBD N
to TO N
be VB N
significantly RB N
associated VBN N
with IN N
most JJS N
outcome JJ N
measures NNS N
, , N
even RB N
when WRB N
infection NN N
was VBD N
added VBN N
to TO N
the DT N
model NN N
. . N

An DT N
alternative JJ N
stepwise NN N
model NN N
selection NN N
process NN N
including VBG N
all DT N
fever-related JJ N
measures NNS N
from IN N
the DT N
preoperative NN N
and CC N
intraoperative JJ N
period NN N
( ( N
e.g. JJ N
, , N
hydrocephalus JJ N
, , N
duration NN N
of IN N
surgery NN N
, , N
intraoperative JJ N
blood NN N
loss NN N
) ) N
resulted VBD N
in IN N
the DT N
loss NN N
of IN N
significance NN N
for IN N
dichotomized JJ N
Glasgow NNP N
Outcome NNP N
Scale NNP N
, , N
but CC N
significant JJ N
associations NNS N
between IN N
fever NN N
and CC N
several JJ N
other JJ N
outcome JJ N
measures NNS N
remained VBD N
. . N

After IN N
adding VBG N
postoperative JJ N
delayed VBN N
ischemic JJ N
neurological JJ N
deficits NNS N
to TO N
the DT N
model NN N
, , N
only RB N
worsened VBD N
National NNP N
Institutes NNPS N
of IN N
Health NNP N
Stroke NNP N
Scale NNP N
score NN N
, , N
Barthel NNP N
Activities NNP N
of IN N
Daily NNP N
Living NNP N
index NN N
, , N
and CC N
discharge NN N
destination NN N
( ( N
home NN N
versus IN N
other JJ N
) ) N
remained VBD N
independently RB N
associated VBN N
with IN N
fever NN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
fever NN N
is VBZ N
associated VBN N
with IN N
worsened JJ N
outcome NN N
in IN N
surgical JJ N
subarachnoid JJ N
hemorrhage NN N
patients NNS N
, , N
although IN N
, , N
because IN N
the DT N
association NN N
between IN N
fever NN N
and CC N
the DT N
primary JJ N
outcome NN N
measure NN N
for IN N
the DT N
trial NN N
is VBZ N
dependent JJ N
on IN N
the DT N
covariates NNS N
used VBN N
in IN N
the DT N
analysis NN N
( ( N
particularly RB N
operative JJ N
events NNS N
and CC N
delayed VBN N
ischemic JJ N
neurological JJ N
deficits NNS N
) ) N
, , N
we PRP N
can MD N
not RB N
rule VB N
out IN N
the DT N
possibility NN N
that IN N
fever NN N
is VBZ N
a DT N
marker NN N
for IN N
other JJ N
events NNS N
. . N

Only RB N
a DT N
formal JJ N
trial NN N
of IN N
fever NN N
treatment NN N
or CC N
prevention NN N
can MD N
address VB N
this DT N
issue NN N
. . N

-DOCSTART- -15769918- O O

Controlled VBN N
clinical JJ N
trial NN N
of IN N
IV NNP N
cyclophosphamide NN N
versus NN N
IV NNP N
methylprednisolone NN N
in IN N
severe JJ N
neurological JJ N
manifestations NNS N
in IN N
systemic JJ N
lupus NN N
erythematosus NN N
. . N

BACKGROUND NNP N
Severe NNP N
neurological JJ N
involvement NN N
in IN N
systemic JJ N
lupus NN N
erythematosus NN N
( ( N
NPSLE NNP N
) ) N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
dreadful JJ N
complications NNS N
of IN N
the DT N
disease NN N
. . N

OBJECTIVE UH N
To TO N
identify VB N
the DT N
best JJS N
drug NN N
, , N
dose NN N
, , N
and CC N
treatment NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
controlled JJ N
clinical JJ N
trial NN N
at IN N
two CD N
tertiary JJ N
care NN N
centres NNS N
of IN N
patients NNS N
with IN N
SLE NNP N
according VBG N
to TO N
the DT N
ACR NNP N
criteria NNS N
, , N
with IN N
incident NN N
( ( N
no DT N
more JJR N
than IN N
15 CD N
days NNS N
) ) N
onset NN N
of IN N
severe JJ N
NP NNP N
manifestations NNS N
such JJ N
as IN N
seizures NNS N
, , N
optic JJ N
neuritis NN N
, , N
peripheral JJ N
or CC N
cranial JJ N
neuropathy NN N
, , N
coma NN N
, , N
brainstem NN N
disease NN N
, , N
or CC N
transverse JJ N
myelitis NN N
. . N

Induction NNP N
treatment NN N
with IN N
3 CD N
g NN N
of IN N
IV NNP N
methylprednisolone NN N
( ( N
MP NNP N
) ) N
followed VBN N
by IN N
either DT N
IV NNP N
monthly JJ N
cyclophosphamide NN N
( ( N
Cy NNP N
) ) N
versus NN N
IV NNP N
MP NNP N
bimonthly RB N
every DT N
4 CD N
months NNS N
for IN N
1 CD N
year NN N
and CC N
then RB N
IV NNP N
Cy NNP N
or CC N
IV NNP N
MP NNP N
every DT N
3 CD N
months NNS N
for IN N
another DT N
year NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
response NN N
to TO N
treatment NN N
: : N
at IN N
least JJS N
20 CD N
% NN N
improvement NN N
from IN N
basal JJ N
conditions NNS N
on IN N
clinical JJ N
, , N
laboratory NN N
, , N
or CC N
specific JJ N
neurological JJ N
testing NN N
variables NNS N
. . N

RESULTS NNP N
Overall NNP N
, , N
a DT N
response NN N
rate NN N
of IN N
75 CD N
% NN N
was VBD N
observed VBN N
. . N

Of IN N
the DT N
32 CD N
patients NNS N
studied VBN N
, , N
18/19 CD N
receiving VBG N
Cy NNP N
and CC N
7/13 CD N
receiving VBG N
MP NNP N
responded VBD N
to TO N
treatment NN N
( ( N
p JJ N
< NNP N
0.03 CD N
) ) N
. . N

CONCLUSIONS NNP N
Cy NNP N
seems VBZ N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
MP NNP N
in IN N
the DT N
treatment NN N
of IN N
acute NN N
, , N
severe JJ N
NPSLE NNP N
. . N

-DOCSTART- -21266651- O O

Factors NNS N
predictive VBP N
of IN N
severe JJ N
hypoglycemia NN N
in IN N
type NN N
1 CD N
diabetes NNS N
: : N
analysis NN N
from IN N
the DT N
Juvenile NNP N
Diabetes NNP N
Research NNP N
Foundation NNP N
continuous JJ N
glucose JJ N
monitoring VBG N
randomized VBN N
control NN N
trial NN N
dataset NN N
. . N

OBJECTIVE NNP N
Identify NNP N
factors NNS N
predictive VBP N
of IN N
severe JJ N
hypoglycemia NN N
( ( N
SH NNP N
) ) N
and CC N
assess VB N
the DT N
clinical JJ N
utility NN N
of IN N
continuous JJ N
glucose JJ N
monitoring NN N
( ( N
CGM NNP N
) ) N
to TO N
warn VB N
of IN N
impending VBG N
SH NNP N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
multicenter NN N
randomized VBN N
clinical JJ N
trial NN N
, , N
436 CD N
children NNS N
and CC N
adults NNS N
with IN N
type JJ N
1 CD N
diabetes NNS N
were VBD N
randomized VBN N
to TO N
a DT N
treatment NN N
group NN N
that WDT N
used VBD N
CGM NNP N
( ( N
N NNP N
= NNP N
224 CD N
) ) N
, , N
or CC N
a DT N
control NN N
group NN N
that WDT N
used VBD N
standard JJ N
home NN N
blood NN N
glucose JJ N
monitoring NN N
( ( N
N NNP N
= NNP N
212 CD N
) ) N
and CC N
completed VBD N
12 CD N
months NNS N
of IN N
follow-up NN N
. . N

After IN N
6 CD N
months NNS N
, , N
the DT N
original JJ N
control NN N
group NN N
initiated VBD N
CGM NNP N
while IN N
the DT N
treatment NN N
group NN N
continued VBD N
use NN N
of IN N
CGM NNP N
for IN N
6 CD N
months NNS N
. . N

Baseline NNP N
risk NN N
factors NNS N
for IN N
SH NNP N
were VBD N
evaluated VBN N
over IN N
12 CD N
months NNS N
of IN N
follow-up JJ N
using VBG N
proportional JJ N
hazards NNS N
regression NN N
. . N

CGM-derived JJ N
indices NNS N
of IN N
hypoglycemia NN N
were VBD N
used VBN N
to TO N
predict VB N
episodes NNS N
of IN N
SH NNP N
over IN N
a DT N
24-h JJ N
time NN N
horizon NN N
. . N

RESULTS VB N
The DT N
SH NNP N
rate NN N
was VBD N
17.9 CD N
per IN N
100 CD N
person-years NNS N
, , N
and CC N
a DT N
higher JJR N
rate NN N
was VBD N
associated VBN N
with IN N
the DT N
occurrence NN N
of IN N
SH NNP N
in IN N
the DT N
prior JJ N
6 CD N
months NNS N
and CC N
female JJ N
sex NN N
. . N

SH NNP N
frequency NN N
increased VBD N
eightfold RB N
when WRB N
30 CD N
% NN N
of IN N
CGM NNP N
values NNS N
were VBD N
? . N
70 CD N
mg/dL NN N
on IN N
the DT N
prior JJ N
day NN N
( ( N
4.5 CD N
vs. FW N
0.5 CD N
% NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
the DT N
positive JJ N
predictive JJ N
value NN N
( ( N
PPV NNP N
) ) N
was VBD N
low JJ N
( ( N
< JJ N
5 CD N
% NN N
) ) N
. . N

Results NNS N
were VBD N
similar JJ N
for IN N
hypoglycemic JJ N
area NN N
under IN N
the DT N
curve NN N
and CC N
the DT N
low JJ N
blood NN N
glucose NN N
index NN N
calculated VBN N
by IN N
CGM NNP N
. . N

CONCLUSIONS NNP N
SH NNP N
in IN N
the DT N
6 CD N
months NNS N
prior RB N
to TO N
the DT N
study NN N
was VBD N
the DT N
strongest JJS N
predictor NN N
of IN N
SH NNP N
during IN N
the DT N
study NN N
. . N

CGM-measured JJ N
hypoglycemia NN N
over IN N
a DT N
24-h JJ N
span NN N
is VBZ N
highly RB N
associated VBN N
with IN N
SH NNP N
the DT N
following JJ N
day NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
the DT N
PPV NNP N
is VBZ N
low JJ N
. . N

-DOCSTART- -15463829- O O

Creon NNP N
10,000 CD N
Minimicrospheres NNP N
vs. FW N
Creon NNP N
8,000 CD N
microspheres NNS N
-- : N
an DT N
open JJ N
randomised VBN N
crossover NN N
preference NN N
study NN N
. . N

Creon NNP N
10,000 CD N
Minimicrospherestrade NNP N
mark NN N
( ( N
Creon NNP N
) ) N
10,000 CD N
MMS NNP N
) ) N
is VBZ N
a DT N
pancreatic JJ N
enzyme NN N
formulation NN N
that IN N
contains VBZ N
smaller JJR N
spheres NNS N
of IN N
pancreatin NN N
in IN N
a DT N
50 CD N
% NN N
smaller JJR N
capsule NN N
than IN N
conventional JJ N
microspheres NNS N
( ( N
Creon NNP N
) ) N
8,000 CD N
) ) N
. . N

This DT N
three-centre JJ N
study NN N
investigated VBD N
the DT N
preference NN N
of IN N
cystic JJ N
fibrosis NN N
( ( N
CF NNP N
) ) N
patients NNS N
for IN N
these DT N
products NNS N
. . N

In IN N
one CD N
centre NN N
, , N
72 CD N
h NN N
stool NN N
fat JJ N
excretion NN N
and CC N
coefficient NN N
of IN N
fat JJ N
absorption NN N
( ( N
CFA NNP N
) ) N
were VBD N
also RB N
compared VBN N
. . N

Fifty-nine JJ N
patients NNS N
with IN N
a DT N
mean JJ N
age NN N
10 CD N
years NNS N
( ( N
range VB N
3-17 NNP N
) ) N
took VBD N
Creon NNP N
8,000 CD N
ms NN N
for IN N
14 CD N
days NNS N
and CC N
were VBD N
then RB N
randomised VBN N
to TO N
28 CD N
days NNS N
of IN N
Creon NNP N
8,000 CD N
ms NN N
followed VBN N
by IN N
28 CD N
days NNS N
of IN N
Creon NNP N
10,000 CD N
MMS NNP N
, , N
or CC N
vice NN N
versa NN N
. . N

Dosing NNP N
was VBD N
lipase NN N
for IN N
lipase NN N
according VBG N
to TO N
the DT N
labelled VBN N
declaration NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
second JJ N
treatment NN N
period NN N
, , N
51 CD N
of IN N
54 CD N
patients NNS N
who WP N
completed VBD N
the DT N
study NN N
expressed VBD N
a DT N
preference NN N
, , N
with IN N
a DT N
statistically RB N
significant JJ N
preference NN N
in IN N
favour NN N
of IN N
Creon NNP N
10,000 CD N
MMS NNP N
( ( N
47/51 CD N
; : N
87 CD N
% NN N
) ) N
vs. FW N
Creon NNP N
8,000 CD N
ms NN N
( ( N
4/51 CD N
; : N
7.4 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Stool NNP N
fat NN N
( ( N
g/day NN N
) ) N
and CC N
CFA NNP N
( ( N
% NN N
) ) N
were VBD N
measured VBN N
in IN N
24 CD N
patients NNS N
at IN N
the DT N
end NN N
of IN N
each DT N
treatment NN N
period NN N
: : N
the DT N
products NNS N
were VBD N
therapeutically RB N
equivalent JJ N
( ( N
Creon JJ N
10,000 CD N
: : N
8.4 CD N
g/day NN N
, , N
91.3 CD N
% NN N
CFA NNP N
; : N
Creon NNP N
8,000 CD N
: : N
6.7 CD N
g/day NN N
, , N
93.5 CD N
% NN N
CFA NNP N
) ) N
. . N

Both DT N
products NNS N
were VBD N
well RB N
tolerated VBN N
. . N

In IN N
conclusion NN N
, , N
in IN N
CF NNP N
children NNS N
we PRP N
found VBD N
a DT N
clear JJ N
preference NN N
for IN N
Creon NNP N
10,000 CD N
MMS NNP N
compared VBN N
with IN N
Creon NNP N
8,000 CD N
ms NN N
with IN N
no DT N
difference NN N
in IN N
fat JJ N
absorption NN N
between IN N
the DT N
two CD N
products NNS N
. . N

Creon NNP N
10,000s CD N
smaller JJR N
capsules NNS N
are VBP N
easier JJR N
to TO N
take VB N
and CC N
should MD N
aid VB N
patient NN N
compliance NN N
. . N

-DOCSTART- -20152559- O O

A DT N
randomized JJ N
comparison NN N
of IN N
the DT N
Endeavor NNP N
zotarolimus-eluting JJ N
stent NN N
versus IN N
the DT N
TAXUS NNP N
paclitaxel-eluting JJ N
stent NN N
in IN N
de FW N
novo FW N
native JJ N
coronary JJ N
lesions NNS N
12-month JJ N
outcomes NNS N
from IN N
the DT N
ENDEAVOR NNP N
IV NNP N
trial NN N
. . N

OBJECTIVES CC N
The DT N
ENDEAVOR NNP N
IV NNP N
( ( N
Randomized NNP N
Comparison NNP N
of IN N
Zotarolimus-Eluting NNP N
and CC N
Paclitaxel-Eluting NNP N
Stents NNP N
in IN N
Patients NNP N
with IN N
Coronary NNP N
Artery NNP N
Disease NNP N
) ) N
trial NN N
evaluated VBD N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
zotarolimus-eluting JJ N
stent NN N
( ( N
ZES NNP N
) ) N
compared VBN N
with IN N
the DT N
paclitaxel-eluting JJ N
stent NN N
( ( N
PES NNP N
) ) N
. . N

BACKGROUND NNP N
First-generation NNP N
drug-eluting NN N
stents NNS N
have VBP N
reduced VBN N
angiographic JJ N
and CC N
clinical JJ N
restenosis NN N
, , N
but CC N
long-term JJ N
safety NN N
remains VBZ N
controversial JJ N
. . N

A DT N
second-generation JJ N
drug-eluting JJ N
stent NN N
, , N
which WDT N
delivers VBZ N
zotarolimus NN N
, , N
a DT N
potent JJ N
antiproliferative JJ N
agent NN N
, , N
via IN N
a DT N
biocompatible JJ N
phosphorylcholine NN N
polymer NN N
on IN N
a DT N
cobalt JJ N
alloy NN N
thin-strut JJ N
stent NN N
has VBZ N
shown VBN N
promising JJ N
experimental JJ N
and CC N
early JJ N
clinical JJ N
results NNS N
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
( ( N
1:1 CD N
) ) N
, , N
single-blind JJ N
, , N
controlled JJ N
trial NN N
comparing VBG N
outcomes NNS N
of IN N
patients NNS N
with IN N
single JJ N
de FW N
novo FW N
coronary JJ N
lesions NNS N
treated VBN N
with IN N
ZES NNP N
or CC N
PES NNP N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
noninferiority NN N
of IN N
9-month JJ N
target NN N
vessel JJ N
failure NN N
defined VBD N
as IN N
cardiac JJ N
death NN N
, , N
myocardial JJ N
infarction NN N
, , N
or CC N
target VB N
vessel JJ N
revascularization NN N
. . N

RESULTS NNP N
Among IN N
a DT N
total NN N
of IN N
1,548 CD N
patients NNS N
assigned VBN N
to TO N
ZES NNP N
( ( N
n JJ N
= NNP N
773 CD N
) ) N
or CC N
PES NNP N
( ( N
n JJ N
= NNP N
775 CD N
) ) N
, , N
at IN N
9 CD N
months NNS N
, , N
ZES NNP N
was VBD N
noninferior JJ N
to TO N
PES VB N
with IN N
rates NNS N
of IN N
target NN N
vessel JJ N
failure NN N
6.6 CD N
% NN N
versus IN N
7.1 CD N
% NN N
, , N
respectively RB N
( ( N
p NN N
( ( N
noninferiority NN N
) ) N
< NN N
or CC N
= VB N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
fewer JJR N
periprocedural JJ N
myocardial JJ N
infarctions NNS N
with IN N
ZES NNP N
( ( N
0.5 CD N
% NN N
vs. FW N
2.2 CD N
% NN N
; : N
p CC N
= VB N
0.007 CD N
) ) N
, , N
whereas VBP N
at IN N
12 CD N
months NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
rates NNS N
of IN N
cardiac JJ N
death NN N
, , N
myocardial JJ N
infarction NN N
, , N
target NN N
vessel NN N
revascularization NN N
, , N
or CC N
stent JJ N
thrombosis NN N
. . N

Although IN N
incidence NN N
of IN N
8-month JJ N
binary JJ N
angiographic JJ N
in-segment JJ N
restenosis NN N
was VBD N
higher RBR N
in IN N
patients NNS N
treated VBN N
with IN N
ZES NNP N
versus NN N
PES NNP N
( ( N
15.3 CD N
% NN N
vs. FW N
10.4 CD N
% NN N
; : N
p CC N
= VB N
0.284 CD N
) ) N
, , N
rates NNS N
of IN N
12-month JJ N
target NN N
lesion NN N
revascularization NN N
were VBD N
similar JJ N
( ( N
4.5 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
; : N
p CC N
= VB N
0.228 CD N
) ) N
, , N
especially RB N
in IN N
patients NNS N
without IN N
planned JJ N
angiographic JJ N
follow-up NN N
( ( N
3.6 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
; : N
p CC N
= VB N
0.756 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
demonstrate VBP N
that IN N
ZES NNP N
has VBZ N
similar JJ N
clinical JJ N
safety NN N
and CC N
efficacy NN N
compared VBN N
with IN N
PES NNP N
in IN N
simple JJ N
and CC N
medium JJ N
complexity NN N
single JJ N
de FW N
novo FW N
coronary JJ N
lesions NNS N
. . N

( ( N
ENDEAVOR NNP N
IV NNP N
Clinical NNP N
Trial NNP N
; : N
NCT00217269 NNP N
) ) N
. . N

-DOCSTART- -8888660- O O

Effect NN N
of IN N
hydrochlorothiazide NN N
therapy NN N
on IN N
cardiac JJ N
arrhythmias NN N
in IN N
African-American JJ N
men NNS N
with IN N
systemic JJ N
hypertension NN N
and CC N
moderate VB N
to TO N
severe VB N
left JJ N
ventricular JJ N
hypertrophy NN N
. . N

The DT N
effect NN N
of IN N
hydrochlorothiazide NN N
therapy NN N
on IN N
ventricular JJ N
arrhythmias NN N
was VBD N
studied VBN N
in IN N
45 CD N
hypertensive JJ N
African-American JJ N
men NNS N
with IN N
moderate JJ N
to TO N
severe VB N
left VBN N
ventricular JJ N
( ( N
LV NNP N
) ) N
hypertrophy NN N
. . N

After IN N
medication NN N
washout NN N
, , N
patients NNS N
were VBD N
treated VBN N
with IN N
placebo NN N
followed VBN N
by IN N
hydrochlorothiazide NN N
. . N

Clinical NNP N
, , N
biochemical JJ N
, , N
and CC N
48-hour JJ N
ambulatory NN N
electrocardiographic JJ N
data NN N
was VBD N
collected VBN N
after IN N
each DT N
treatment NN N
phase NN N
. . N

Signal-averaged JJ N
electrocardiograms NNS N
were VBD N
recorded VBN N
in IN N
a DT N
subgroup NN N
of IN N
24 CD N
patients NNS N
. . N

Average JJ N
LV NNP N
posterior NN N
wall NN N
thickness NN N
was VBD N
15 CD N
+/- JJ N
1.1 CD N
mm NN N
, , N
septum VBD N
16 CD N
+/- JJ N
2 CD N
mm NN N
, , N
LV NNP N
mass VBD N
420 CD N
+/- JJ N
90 CD N
g NN N
, , N
and CC N
LV NNP N
mass NNP N
index NN N
212 CD N
= NN N
51 CD N
g/m2 NN N
. . N

Systolic NNP N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
was VBD N
168 CD N
+/- JJ N
18 CD N
mm NN N
Hg NNP N
after IN N
the DT N
placebo NN N
phase NN N
and CC N
146 CD N
+/- JJ N
15 CD N
mm NN N
Hg NNP N
after IN N
hydrochlorothiazide NN N
; : N
diastolic JJ N
BP NNP N
was VBD N
103 CD N
+/- JJ N
6 CD N
mm NN N
Hg NNP N
and CC N
89 CD N
+/- JJ N
9 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
. . N

Serum NNP N
potassium NN N
decreased VBD N
significantly RB N
from IN N
4.2 CD N
+/- JJ N
0.4 CD N
mmol/L NN N
to TO N
3.7 CD N
+/- JJ N
0.6 CD N
mmol/L NN N
after IN N
hydrochlorothiazide JJ N
therapy NN N
. . N

The DT N
average JJ N
hourly JJ N
incidence NN N
of IN N
ventricular JJ N
premature NN N
contractions NNS N
was VBD N
22 CD N
with IN N
placebo NN N
and CC N
25 CD N
with IN N
hydrochlorothiazide NN N
. . N

There EX N
were VBD N
3 CD N
and CC N
1 CD N
couplets NNS N
and CC N
0.2 CD N
and CC N
0.2 CD N
runs NNS N
of IN N
ventricular JJ N
tachycardia NN N
per IN N
patient NN N
per IN N
hour NN N
, , N
respectively RB N
. . N

Variables NNS N
of IN N
signal-averaged JJ N
electrocardiography NN N
did VBD N
not RB N
differ VB N
between IN N
the DT N
2 CD N
treatments NNS N
. . N

Thus RB N
, , N
in IN N
hypertensive JJ N
African-American JJ N
men NNS N
with IN N
moderate JJ N
to TO N
severe VB N
LV NNP N
hypertrophy NN N
, , N
hydrochlorothiazide NN N
does VBZ N
not RB N
worsen VB N
ventricular JJ N
arrhythmias NNS N
or CC N
signal-averaged JJ N
electrocardiographic JJ N
variables NNS N
. . N

-DOCSTART- -12116339- O O

Monitoring VBG N
tumour NN N
cells NNS N
in IN N
the DT N
peripheral JJ N
blood NN N
of IN N
small JJ N
cell NN N
lung NN N
cancer NN N
patients NNS N
. . N

BACKGROUND NNP N
Flow NNP N
cytometry NN N
was VBD N
used VBN N
to TO N
enumerate VB N
tumour JJ N
cells NNS N
in IN N
longitudinal JJ N
studies NNS N
of IN N
peripheral JJ N
blood NN N
from IN N
small JJ N
cell NN N
lung NN N
cancer NN N
( ( N
SCLC NNP N
) ) N
patients NNS N
, , N
together RB N
with IN N
magnetic JJ N
bead NN N
selection NN N
to TO N
isolate VB N
and CC N
identify VB N
these DT N
cells NNS N
. . N

As IN N
part NN N
of IN N
a DT N
trial NN N
, , N
11 CD N
patients NNS N
received VBD N
either RB N
standard JJ N
( ( N
four CD N
weekly RB N
) ) N
chemotherapy NN N
with IN N
ifosfamide NN N
, , N
carboplatin NN N
, , N
and CC N
etoposide RB N
( ( N
ICE NNP N
) ) N
or CC N
accelerated VBN N
( ( N
two CD N
weekly RB N
) ) N
ICE NNP N
with IN N
filgrastim NN N
( ( N
granulocyte JJ N
colony-stimulating NN N
factor NN N
[ IN N
G-CSF NNP N
] NNP N
) ) N
and CC N
autologous JJ N
stem NN N
cell NN N
support NN N
. . N

METHODS NNP N
Fresh NNP N
venous JJ N
blood NN N
was VBD N
taken VBN N
throughout IN N
treatment NN N
and CC N
follow-up NN N
. . N

Aliquots NNS N
were VBD N
stained VBN N
with IN N
a DT N
tumour-specific JJ N
antibody NN N
against IN N
epithelial JJ N
tissue NN N
( ( N
Ber NNP N
EP4 NNP N
) ) N
, , N
verified VBD N
as IN N
a DT N
good JJ N
marker NN N
of IN N
SCLC NNP N
cells NNS N
by IN N
immunohistochemistry NN N
. . N

Matched NNP N
samples NNS N
labelled VBD N
with IN N
Ber NNP N
EP4 NNP N
were VBD N
separated VBN N
magnetically RB N
by IN N
adding VBG N
a DT N
secondary JJ N
bead-antibody NN N
conjugate NN N
for IN N
confirmation NN N
of IN N
tumour NN N
cell NN N
identity NN N
. . N

RESULTS NNP N
Circulating NNP N
tumour JJ N
cells NNS N
were VBD N
detected VBN N
and CC N
monitored VBN N
throughout IN N
treatment NN N
periods NNS N
. . N

An DT N
initial JJ N
rise NN N
in IN N
circulating VBG N
cells NNS N
after IN N
the DT N
first JJ N
cycle NN N
was VBD N
followed VBN N
by IN N
a DT N
fall NN N
in IN N
both DT N
treatment NN N
arms NNS N
to TO N
baseline NN N
levels NNS N
set VBN N
by IN N
normal JJ N
controls NNS N
. . N

This DT N
was VBD N
achieved VBN N
by IN N
week NN N
12 CD N
in IN N
the DT N
accelerated JJ N
treatment NN N
arm NN N
and CC N
by IN N
week NN N
24 CD N
in IN N
the DT N
standard JJ N
arm NN N
. . N

CONCLUSIONS NNP N
Flow NNP N
cytometry NN N
and CC N
magnetic JJ N
bead NN N
isolation NN N
can MD N
be VB N
used VBN N
to TO N
identify VB N
changes NNS N
in IN N
numbers NNS N
of IN N
circulating VBG N
tumour JJ N
cells NNS N
in IN N
patients NNS N
undergoing JJ N
chemotherapy NN N
for IN N
SCLC NNP N
and CC N
thereafter RB N
during IN N
follow-up JJ N
periods NNS N
. . N

Absence NN N
of IN N
tumour JJ N
cells NNS N
may MD N
indicate VB N
a DT N
more RBR N
favourable JJ N
patient NN N
group NN N
who WP N
would MD N
benefit VB N
from IN N
a DT N
more RBR N
intense JJ N
course NN N
of IN N
treatment NN N
. . N

-DOCSTART- -14655885- O O

Extracorporeal NNP N
shock NN N
wave NN N
therapy NN N
( ( N
ESWT NNP N
) ) N
in IN N
patients NNS N
with IN N
chronic JJ N
proximal JJ N
plantar NN N
fasciitis NN N
: : N
a DT N
2-year JJ N
follow-up NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
extracorporeal NN N
shock NN N
wave VBP N
therapy NN N
( ( N
ESWT NNP N
) ) N
in IN N
patients NNS N
with IN N
chronically RB N
painful JJ N
proximal JJ N
plantar NN N
fasciitis NN N
with IN N
a DT N
further JJ N
conventional JJ N
conservative JJ N
treatment NN N
. . N

Forty-seven JJ N
patients NNS N
( ( N
49 CD N
feet NNS N
) ) N
with IN N
a DT N
previously RB N
unsuccessful JJ N
nonsurgical JJ N
treatment NN N
of IN N
at IN N
least JJS N
6 CD N
months NNS N
were VBD N
randomized VBN N
to TO N
two CD N
groups NNS N
. . N

Heel NNP N
cups NNS N
had VBD N
to TO N
be VB N
worn VBN N
throughout IN N
the DT N
study NN N
. . N

Group NNP N
1 CD N
( ( N
25 CD N
heels NNS N
) ) N
was VBD N
treated VBN N
immediately RB N
with IN N
three CD N
sessions NNS N
of IN N
ESWT NNP N
( ( N
3000 CD N
shock NN N
waves/session NN N
of IN N
0.2 CD N
mJ/mm2 NN N
) ) N
at IN N
weekly JJ N
intervals NNS N
. . N

The DT N
patients NNS N
of IN N
group NN N
2 CD N
( ( N
24 CD N
heels NNS N
) ) N
continued VBD N
nonsurgical JJ N
treatment NN N
( ( N
iontophoresis NN N
with IN N
diclofenac NN N
and CC N
an DT N
oral JJ N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
) ) N
for IN N
12 CD N
weeks NNS N
. . N

After IN N
this DT N
period NN N
they PRP N
were VBD N
treated VBN N
using VBG N
the DT N
protocol NN N
of IN N
group NN N
1 CD N
. . N

No DT N
significant JJ N
difference NN N
of IN N
pain NN N
and CC N
walking NN N
time NN N
after IN N
further JJ N
nonsurgical JJ N
treatment NN N
( ( N
3 CD N
months NNS N
) ) N
was VBD N
seen VBN N
in IN N
group NN N
2 CD N
. . N

At IN N
12 CD N
weeks NNS N
after IN N
ESWT NNP N
, , N
the DT N
pain NN N
estimation NN N
on IN N
the DT N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
for IN N
activities NNS N
of IN N
daily JJ N
living NN N
diminished VBN N
significantly RB N
by IN N
62.9 CD N
% NN N
in IN N
group NN N
1 CD N
and CC N
by IN N
63.0 CD N
% NN N
in IN N
group NN N
2 CD N
. . N

The DT N
comfortable JJ N
walking NN N
time NN N
had VBD N
increased VBN N
significantly RB N
in IN N
both DT N
groups NNS N
. . N

Two CD N
years NNS N
after IN N
ESWT NNP N
, , N
pain NN N
during IN N
activities NNS N
of IN N
daily JJ N
living NN N
decreased VBN N
by IN N
94 CD N
% NN N
in IN N
group NN N
1 CD N
and CC N
by IN N
90 CD N
% NN N
in IN N
group NN N
2 CD N
on IN N
the DT N
VAS NNP N
and CC N
the DT N
comfortable JJ N
walking NN N
time NN N
had VBD N
increased VBN N
significantly RB N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -12839657- O O

[ RB N
Long NNP N
term NN N
observation NN N
in IN N
effects NNS N
of IN N
potassium NN N
and CC N
calcium NN N
supplementation NN N
on IN N
arterial JJ N
blood NN N
pressure NN N
and CC N
sodium NN N
metabolism NN N
in IN N
adolescents NNS N
with IN N
higher JJR N
blood NN N
pressure NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
potassium NN N
and CC N
calcium NN N
supplementation NN N
in IN N
table JJ N
salt NN N
on IN N
reduction NN N
of IN N
arterial JJ N
blood NN N
pressure NN N
and CC N
sodium NN N
metabolism NN N
in IN N
adolescents NNS N
with IN N
higher JJR N
blood NN N
pressure NN N
. . N

METHODS CC N
A DT N
single JJ N
blind NN N
placebo-controlled JJ N
trial NN N
was VBD N
carried VBN N
out RP N
for IN N
two CD N
years NNS N
in IN N
220 CD N
adolescents NNS N
with IN N
higher JJR N
blood NN N
pressure NN N
, , N
aged VBD N
18 CD N
- : N
22 CD N
years NNS N
, , N
who WP N
were VBD N
randomly RB N
divided VBN N
into IN N
supplementary JJ N
group NN N
( ( N
n JJ N
= NNP N
110 CD N
) ) N
and CC N
control NN N
group NN N
( ( N
n JJ N
= NNP N
110 CD N
) ) N
. . N

Each DT N
of IN N
the DT N
subjects NNS N
in IN N
the DT N
supplementary JJ N
group NN N
and CC N
their PRP$ N
family NN N
members NNS N
was VBD N
given VBN N
10 CD N
mmol NN N
of IN N
potassium NN N
and CC N
10 CD N
mmol NN N
of IN N
calcium NN N
mixed VBN N
in IN N
their PRP$ N
table JJ N
salt JJ N
daily RB N
for IN N
24 CD N
months NNS N
. . N

RESULTS NNP N
Night NNP N
urinary JJ N
sodium NN N
and CC N
potassium JJ N
excretion NN N
increased VBD N
( ( N
urinary JJ N
Na NNP N
( ( N
+ NNP N
) ) N
, , N
P NNP N
< NNP N
0.05 CD N
; : N
urinary JJ N
K NNP N
( ( N
+ NNP N
) ) N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
blood NN N
pressure NN N
lowered VBN N
by IN N
5.3 CD N
mm NNS N
Hg/1.8 NNP N
mm NN N
Hg NNP N
in IN N
average NN N
from IN N
the DT N
baseline NN N
in IN N
the DT N
supplementary JJ N
group NN N
two CD N
years NNS N
after IN N
potassium NN N
and CC N
calcium NN N
supplementation NN N
, , N
as IN N
compared VBN N
with IN N
that DT N
in IN N
the DT N
control NN N
group NN N
increased VBN N
by IN N
( ( N
1.3/1.7 CD N
) ) N
mm NN N
Hg NNP N
. . N

CONCLUSIONS NNP N
Adequate NNP N
supplement NN N
of IN N
potassium NN N
and CC N
calcium NN N
in IN N
daily JJ N
table JJ N
salt NN N
intake NN N
was VBD N
an DT N
effective JJ N
way NN N
to TO N
prevent VB N
form NN N
hypertension NN N
and CC N
could MD N
promote VB N
their PRP$ N
urinary JJ N
sodium NN N
excretion NN N
and CC N
reduction NN N
of IN N
arterial JJ N
blood NN N
pressure NN N
in IN N
adolescents NNS N
with IN N
higher JJR N
blood NN N
pressure NN N
. . N

-DOCSTART- -17521473- O O

Pilot NNP N
comparison NN N
between IN N
potassium NN N
titanyl NN N
phosphate NN N
laser NN N
and CC N
bipolar JJ N
radiofrequency NN N
in IN N
paediatric JJ N
tonsillectomy NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
advantages NNS N
and CC N
disadvantages NNS N
of IN N
potassium NN N
titanyl NN N
phosphate NN N
laser NN N
with IN N
those DT N
of IN N
bipolar JJ N
radiofrequency NN N
techniques NNS N
, , N
in IN N
paediatric JJ N
tonsillectomy NN N
. . N

STUDY NNP N
DESIGN NNP N
Prospective NNP N
, , N
randomised VBD N
, , N
clinical JJ N
study NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP N
July NNP N
2004 CD N
to TO N
April NNP N
2006 CD N
, , N
80 CD N
patients NNS N
aged VBN N
between IN N
10 CD N
and CC N
15 CD N
years NNS N
, , N
with IN N
tonsillectomy NN N
planned VBN N
for IN N
chronic JJ N
tonsillitis NN N
, , N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Children NNP N
were VBD N
prospectively RB N
randomised VBN N
into IN N
two CD N
equal JJ N
groups NNS N
: : N
potassium NN N
titanyl NN N
phosphate NN N
laser NN N
tonsillectomy NN N
and CC N
bipolar JJ N
radiofrequency NN N
tonsillectomy NN N
. . N

Operative JJ N
time NN N
and CC N
intra-operative JJ N
blood NN N
loss NN N
were VBD N
recorded VBN N
. . N

Patients NNS N
were VBD N
scheduled VBN N
for IN N
follow VB N
up RP N
during IN N
the DT N
first JJ N
, , N
second JJ N
and CC N
fourth JJ N
post-operative JJ N
weeks NNS N
. . N

They PRP N
were VBD N
asked VBN N
to TO N
record VB N
their PRP$ N
pain NN N
and CC N
discomfort NN N
on IN N
a DT N
standardised JJ N
visual JJ N
analogue NN N
scale NN N
, , N
from IN N
zero CD N
( ( N
no DT N
pain NN N
) ) N
to TO N
10 CD N
( ( N
severe JJ N
pain NN N
) ) N
. . N

Post-operative JJ N
complications NNS N
were VBD N
also RB N
recorded VBN N
and CC N
managed VBN N
. . N

RESULTS VB N
The DT N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
group NN N
showed VBD N
a DT N
slightly RB N
longer RBR N
operative JJ N
time NN N
( ( N
mean JJ N
12 CD N
minutes NNS N
) ) N
than IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
( ( N
mean JJ N
10 CD N
minutes NNS N
) ) N
. . N

Intra-operative JJ N
blood NN N
loss NN N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
group NN N
( ( N
mean JJ N
21 CD N
cm3 NN N
) ) N
than IN N
in IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
( ( N
mean JJ N
30 CD N
cm3 NN N
) ) N
. . N

In IN N
the DT N
first JJ N
week NN N
, , N
post-operative JJ N
pain NN N
scores NNS N
were VBD N
less RBR N
in IN N
the DT N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
group NN N
than IN N
in IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
( ( N
means VBZ N
7.5 CD N
and CC N
8.5 CD N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
in IN N
the DT N
second JJ N
week NN N
pain NN N
scores NNS N
increased VBD N
more RBR N
in IN N
the DT N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
group NN N
than IN N
in IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
( ( N
means VBZ N
8.5 CD N
and CC N
6 CD N
, , N
respectively RB N
) ) N
. . N

In IN N
the DT N
fourth JJ N
week NN N
, , N
both DT N
groups NNS N
showed VBD N
equal JJ N
and CC N
nearly RB N
normal JJ N
pain NN N
scores NNS N
. . N

No DT N
case NN N
of IN N
reactionary JJ N
post-tonsillectomy JJ N
haemorrhage NN N
was VBD N
recorded VBN N
in IN N
either DT N
group NN N
. . N

Only RB N
one CD N
case NN N
of IN N
secondary JJ N
post-tonsillectomy JJ N
haemorrhage NN N
was VBD N
recorded VBN N
, , N
in IN N
the DT N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
group NN N
( ( N
2.5 CD N
per IN N
cent NN N
) ) N
, , N
managed VBD N
conservatively RB N
. . N

CONCLUSION NNP N
Both NNP N
the DT N
potassium NN N
titanyl NN N
phosphate NN N
and CC N
the DT N
bipolar JJ N
radiofrequency NN N
techniques NNS N
were VBD N
safe JJ N
and CC N
easy JJ N
to TO N
use VB N
for IN N
tonsillectomy NN N
, , N
with IN N
reduced VBN N
operative JJ N
time NN N
, , N
blood NN N
loss NN N
and CC N
complication NN N
rates NNS N
and CC N
better JJR N
post-operative JJ N
general JJ N
patient NN N
condition NN N
. . N

Potassium NNP N
titanyl JJ N
phosphate NN N
laser NN N
resulted VBD N
in IN N
reduced JJ N
operative JJ N
bleeding NN N
and CC N
immediate JJ N
post-operative JJ N
pain NN N
, , N
compared VBN N
with IN N
the DT N
bipolar JJ N
radiofrequency NN N
technique NN N
. . N

However RB N
, , N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
required VBN N
slightly RB N
more RBR N
operative JJ N
time NN N
and CC N
caused VBD N
more JJR N
late JJ N
post-operative JJ N
pain NN N
than IN N
the DT N
bipolar JJ N
radiofrequency NN N
technique NN N
. . N

The DT N
low JJ N
rate NN N
of IN N
recorded VBN N
complications NNS N
showed VBD N
that IN N
both DT N
techniques NNS N
cause VBP N
little JJ N
damage NN N
to TO N
the DT N
tonsillar JJ N
bed NN N
during IN N
dissection NN N
, , N
thus RB N
minimising VBG N
complications NNS N
. . N

-DOCSTART- -14699228- O O

The DT N
effect NN N
of IN N
use NN N
of IN N
pyridostigmine NN N
and CC N
requirement NN N
of IN N
vecuronium NN N
in IN N
patients NNS N
with IN N
myasthenia JJ N
gravis NN N
. . N

CONTEXT NNP N
Patients NNPS N
with IN N
myasthenia NNP N
gravis FW N
receive JJ N
pyridostigmine NN N
, , N
an DT N
anticholinesterase NN N
agent NN N
, , N
as IN N
a DT N
part NN N
of IN N
therapy NN N
. . N

These DT N
patients NNS N
demonstrate VBP N
a DT N
heightened JJ N
sensitivity NN N
towards IN N
non-depolarising JJ N
muscle NN N
relaxants NNS N
. . N

Continuing VBG N
pyridostigmine NN N
till IN N
the DT N
day NN N
of IN N
the DT N
surgery NN N
or CC N
omitting VBG N
it PRP N
on IN N
the DT N
night NN N
before IN N
surgery NN N
could MD N
provide VB N
variable JJ N
results NNS N
with IN N
regards NNS N
to TO N
the DT N
effect NN N
of IN N
vecuronium NN N
. . N

AIMS NNP N
Myographic NNP N
evaluation NN N
of IN N
a DT N
dose NN N
of IN N
vecuronium NN N
in IN N
patients NNS N
with IN N
myasthenia JJ N
gravis NN N
on IN N
pyridostigmine NN N
therapy NN N
. . N

SETTING NN N
AND CC N
DESIGN NNP N
A NNP N
randomised JJ N
, , N
double-blind JJ N
, , N
clinical JJ N
study NN N
conducted VBN N
in IN N
a DT N
teaching JJ N
hospital NN N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Medically NNP N
( ( N
oral JJ N
pyridostigmine NN N
) ) N
well-controlled JJ N
adult NN N
patients NNS N
with IN N
myasthenia JJ N
gravis NNS N
who WP N
were VBD N
posted VBN N
for IN N
thymectomy NN N
, , N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

Patients NNS N
in IN N
Group NNP N
1 CD N
received VBD N
their PRP$ N
last JJ N
dose NN N
of IN N
pyridostigmine NN N
on IN N
the DT N
night NN N
before IN N
surgery NN N
while IN N
those DT N
in IN N
Group NNP N
2 CD N
received VBD N
even RB N
the DT N
morning NN N
dose NN N
of IN N
the DT N
drug NN N
on IN N
the DT N
day NN N
of IN N
surgery NN N
. . N

Neostigmine NNP N
( ( N
1-2 JJ N
mg NN N
) ) N
intravenously RB N
was VBD N
used VBN N
as IN N
rescue JJ N
medication NN N
. . N

Vecuronium NNP N
( ( N
0.01 CD N
mg/kg NN N
) ) N
was VBD N
used VBN N
for IN N
intubation NN N
and CC N
muscle NN N
relaxation NN N
during IN N
trans-sternal JJ N
thymectomy NN N
and CC N
its PRP$ N
effect NN N
was VBD N
reversed VBN N
using VBG N
neostigmine NN N
and CC N
atropine NN N
. . N

RESULTS NNP N
Fourteen JJ N
patients NNS N
( ( N
7 CD N
in IN N
each DT N
group NN N
) ) N
belonging NN N
to TO N
both DT N
sexes NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

The DT N
intubating VBG N
dose NN N
of IN N
vecuronium NN N
showed VBD N
quicker JJR N
onset JJ N
time NN N
( ( N
155 CD N
sec NN N
or CC N
2.7 CD N
min NN N
approx NN N
. . N

) ) N
and CC N
peak JJ N
effect NN N
( ( N
99 CD N
% NN N
T1 NNP N
suppression NN N
) ) N
in IN N
patients NNS N
belonging VBG N
to TO N
Group NNP N
1 CD N
, , N
and CC N
3/7 CD N
( ( N
43 CD N
% NN N
) ) N
complained VBD N
of IN N
respiratory JJ N
discomfort NN N
while IN N
waiting VBG N
for IN N
surgery NN N
. . N

By IN N
giving VBG N
the DT N
morning NN N
dose NN N
of IN N
pyridostigmine NN N
( ( N
Group NNP N
2 CD N
) ) N
, , N
an DT N
identical JJ N
intubating NN N
dose NN N
of IN N
vecuronium NN N
showed VBD N
relative JJ N
resistance NN N
( ( N
peak JJ N
effect-97 NN N
% NN N
T1 NNP N
suppression NN N
) ) N
and CC N
delayed VBN N
onset NN N
time NN N
( ( N
198 CD N
sec NN N
approx. NN N
) ) N
. . N

However RB N
, , N
the DT N
reversal NN N
was VBD N
complete JJ N
at IN N
the DT N
end NN N
of IN N
surgery NN N
in IN N
both CC N
the DT N
regimens NNS N
. . N

CONCLUSIONS NNP N
Omission NNP N
of IN N
the DT N
pyridostigmine NN N
dose NN N
on IN N
the DT N
day NN N
of IN N
surgery NN N
predisposed VBN N
patients NNS N
with IN N
myasthenia JJ N
gravis NN N
to TO N
the DT N
possibility NN N
of IN N
respiratory JJ N
discomfort NN N
and CC N
sensitivity NN N
to TO N
vecuronium NN N
. . N

Continued VBN N
administration NN N
significantly RB N
prolonged VBD N
the DT N
onset JJ N
time NN N
of IN N
vecuronium NN N
and CC N
the DT N
patients NNS N
required VBD N
a DT N
higher JJR N
dose NN N
of IN N
vecuronium NN N
. . N

-DOCSTART- -8331682- O O

Low-dose JJ N
aspirin NN N
and CC N
incidence NN N
of IN N
colorectal JJ N
tumors NNS N
in IN N
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
Laboratory NNP N
, , N
clinical JJ N
, , N
and CC N
epidemiologic JJ N
studies NNS N
have VBP N
recently RB N
suggested VBN N
that IN N
regular JJ N
use NN N
of IN N
aspirin NN N
can MD N
reduce VB N
colorectal JJ N
cancer NN N
incidence NN N
or CC N
mortality NN N
. . N

However RB N
, , N
observational JJ N
epidemiologic NN N
analyses NNS N
have VBP N
had VBN N
limited VBN N
opportunity NN N
to TO N
control VB N
for IN N
confounding VBG N
bias NN N
or CC N
to TO N
specify VB N
aspirin JJ N
doses NNS N
used VBN N
. . N

PURPOSE VB N
Our PRP$ N
purpose NN N
was VBD N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
regular JJ N
use NN N
of IN N
low-dose JJ N
aspirin NN N
and CC N
incidence NN N
of IN N
invasive JJ N
and CC N
noninvasive JJ N
colorectal NN N
tumors NNS N
by IN N
utilizing VBG N
data NNS N
from IN N
the DT N
Physicians NNPS N
' POS N
Health NNP N
Study NNP N
, , N
a DT N
randomized VBN N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
aspirin NN N
and CC N
beta NN N
carotene NN N
. . N

We PRP N
also RB N
attempted VBD N
to TO N
determine VB N
whether IN N
invasive JJ N
cancers NNS N
among IN N
aspirin JJ N
users NNS N
were VBD N
associated VBN N
with IN N
rectal JJ N
bleeding NN N
and CC N
early JJ N
stage NN N
at IN N
diagnosis NN N
. . N

METHODS NNP N
The DT N
Physicians NNPS N
' POS N
Health NNP N
Study NNP N
includes VBZ N
22071 CD N
U.S. NNP N
male JJ N
physicians NNS N
. . N

The DT N
aspirin JJ N
arm NN N
was VBD N
terminated VBN N
in IN N
1988 CD N
after IN N
a DT N
mean JJ N
follow-up NN N
of IN N
5 CD N
years NNS N
. . N

Stage NN N
at IN N
diagnosis NN N
and CC N
signs NNS N
and/or VBP N
symptoms NNS N
during IN N
presentation NN N
were VBD N
abstracted VBN N
from IN N
medical JJ N
records NNS N
. . N

Cox NNP N
proportional JJ N
hazards NNS N
models NNS N
were VBD N
used VBN N
to TO N
estimate VB N
relative JJ N
risk NN N
( ( N
RR NNP N
) ) N
, , N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
, , N
and CC N
the DT N
association NN N
between IN N
aspirin NN N
and CC N
bleeding NN N
. . N

Differences NNS N
between IN N
aspirin NN N
and CC N
placebo NN N
groups NNS N
in IN N
tumor NN N
risk NN N
over IN N
time NN N
were VBD N
visualized VBN N
with IN N
Kaplan-Meier NNP N
curves NNS N
. . N

We PRP N
assessed VBD N
the DT N
association NN N
between IN N
aspirin NN N
and CC N
stage NN N
at IN N
diagnosis NN N
with IN N
a DT N
Mann-Whitney NNP N
rank NN N
sum NN N
statistic NN N
for IN N
non-parametric JJ N
comparison NN N
of IN N
two CD N
ordinal JJ N
distributions NNS N
. . N

RESULTS VB N
The DT N
RR NNP N
of IN N
developing VBG N
colorectal JJ N
cancer NN N
for IN N
aspirin NNS N
compared VBN N
with IN N
placebo NN N
was VBD N
1.15 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
0.80-1.65 NN N
) ) N
. . N

For IN N
in IN N
situ NN N
cancers NNS N
and CC N
polyps NNS N
, , N
the DT N
RR NNP N
was VBD N
0.86 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
0.68-1.10 NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
trend NN N
for IN N
decreasing VBG N
RR NNP N
by IN N
year NN N
of IN N
follow-up NN N
for IN N
invasive JJ N
cancers NNS N
( ( N
P NNP N
= NNP N
.09 NNP N
) ) N
or CC N
noninvasive JJ N
tumors NNS N
( ( N
P NNP N
= NNP N
.96 NNP N
) ) N
. . N

Aspirin NNP N
and CC N
placebo NN N
groups NNS N
did VBD N
not RB N
differ VB N
in IN N
stage NN N
or CC N
prevalence NN N
of IN N
rectal JJ N
bleeding NN N
at IN N
diagnosis NN N
. . N

CONCLUSIONS NNP N
Regular NNP N
aspirin NN N
use NN N
, , N
at IN N
a DT N
dose JJ N
adequate NN N
for IN N
preventing VBG N
myocardial JJ N
infarction NN N
, , N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
substantial JJ N
reduction NN N
in IN N
the DT N
incidence NN N
of IN N
colorectal JJ N
cancer NN N
during IN N
5 CD N
years NNS N
of IN N
randomized JJ N
treatment NN N
and CC N
follow-up NN N
. . N

A DT N
small JJ N
decrease NN N
in IN N
polyps NNS N
in IN N
the DT N
aspirin NN N
group NN N
could MD N
not RB N
be VB N
reliably RB N
distinguished VBN N
from IN N
a DT N
chance NN N
association NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
among IN N
low-dose JJ N
aspirin NN N
users NNS N
, , N
( ( N
a DT N
) ) N
colorectal NN N
cancer NN N
mortality NN N
is VBZ N
not RB N
likely JJ N
to TO N
be VB N
reduced VBN N
by IN N
earlier JJR N
detection NN N
and CC N
( ( N
b NN N
) ) N
incidence NN N
is VBZ N
not RB N
likely JJ N
to TO N
be VB N
increased VBN N
due JJ N
to TO N
aspirin-induced JJ N
gastrointestinal JJ N
bleeding NN N
. . N

IMPLICATIONS VBZ N
The DT N
potential NN N
for IN N
a DT N
benefit NN N
from IN N
higher JJR N
doses NNS N
of IN N
aspirin NN N
or CC N
longer JJR N
duration NN N
of IN N
use NN N
should MD N
be VB N
addressed VBN N
by IN N
more JJR N
detailed JJ N
observational JJ N
epidemiologic NN N
studies NNS N
and CC N
prevention NN N
trials NNS N
with IN N
longer JJR N
follow-up NN N
of IN N
randomized JJ N
participants NNS N
. . N

-DOCSTART- -22550938- O O

B-type JJ N
natriuretic JJ N
peptide NN N
in IN N
the DT N
evaluation NN N
and CC N
management NN N
of IN N
dyspnoea NN N
in IN N
primary JJ N
care NN N
. . N

OBJECTIVES IN N
The DT N
rapid JJ N
and CC N
accurate JJ N
diagnosis NN N
of IN N
heart NN N
failure NN N
in IN N
primary JJ N
care NN N
is VBZ N
a DT N
major JJ N
unmet JJ N
clinical JJ N
need NN N
. . N

We PRP N
evaluated VBD N
the DT N
additional JJ N
use NN N
of IN N
B-type NNP N
natriuretic JJ N
peptide NN N
( ( N
BNP NNP N
) ) N
levels NNS N
. . N

DESIGN VB N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

SETTING CC N
Twenty-nine JJ N
primary JJ N
care NN N
physicians NNS N
in IN N
Switzerland NNP N
and CC N
Germany NNP N
coordinated VBN N
by IN N
the DT N
University NNP N
Hospital NNP N
Basel NNP N
, , N
Switzerland NNP N
. . N

SUBJECTS NNP N
A NNP N
total NN N
of IN N
323 CD N
consecutive JJ N
patients NNS N
presenting VBG N
with IN N
dyspnoea NN N
. . N

INTERVENTIONS NNP N
Assignment NNP N
in IN N
a DT N
1 CD N
: : N
1 CD N
ratio NN N
to TO N
a DT N
diagnostic JJ N
strategy NN N
including VBG N
point-of-care JJ N
measurement NN N
of IN N
BNP NNP N
( ( N
n JJ N
= NNP N
163 CD N
) ) N
or CC N
standard JJ N
assessment NN N
without IN N
BNP NNP N
( ( N
n JJ N
= NNP N
160 CD N
) ) N
. . N

The DT N
total JJ N
medical JJ N
cost NN N
at IN N
3 CD N
months NNS N
was VBD N
the DT N
primary JJ N
end-point NN N
. . N

Secondary JJ N
end-points NNS N
were VBD N
diagnostic JJ N
certainty NN N
, , N
time NN N
to TO N
appropriate VB N
therapy NN N
, , N
functional JJ N
capacity NN N
, , N
hospitalization NN N
and CC N
mortality NN N
. . N

The DT N
final JJ N
diagnosis NN N
was VBD N
adjudicated VBN N
by IN N
a DT N
physician NN N
blinded VBN N
to TO N
the DT N
BNP NNP N
levels NNS N
. . N

RESULTS NNP N
Heart NNP N
failure NN N
was VBD N
the DT N
final JJ N
diagnosis NN N
in IN N
34 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
number NN N
of IN N
hospitalizations NNS N
, , N
functional JJ N
status NN N
and CC N
total JJ N
medical JJ N
cost NN N
at IN N
3 CD N
months NNS N
[ JJ N
median JJ N
$ $ N
1655 CD N
, , N
interquartile JJ N
range NN N
( ( N
IQR NNP N
) ) N
, , N
850-3331 JJ N
vs. IN N
$ $ N
1541 CD N
, , N
IQR NNP N
859-2827 CD N
; : N
P NNP N
= VBD N
0.68 CD N
] NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

BNP NNP N
increased VBD N
diagnostic JJ N
certainty NN N
as IN N
defined VBN N
by IN N
the DT N
need NN N
for IN N
further JJ N
diagnostic JJ N
work-up NN N
( ( N
33 CD N
% NN N
vs. FW N
45 CD N
% NN N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
accelerated VBD N
the DT N
initiation NN N
of IN N
the DT N
appropriate JJ N
treatment NN N
( ( N
13 CD N
days NNS N
vs. FW N
25 CD N
days NNS N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

The DT N
area NN N
under IN N
the DT N
receiver-operating JJ N
characteristics NNS N
curve NN N
for IN N
BNP NNP N
to TO N
identify VB N
heart NN N
failure NN N
was VBD N
0.87 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.81-0.93 JJ N
) ) N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
BNP NNP N
levels NNS N
in IN N
primary JJ N
care NN N
did VBD N
not RB N
reduce VB N
total JJ N
medical JJ N
cost NN N
, , N
but CC N
improved VBD N
some DT N
of IN N
the DT N
secondary JJ N
end-points NNS N
including VBG N
diagnostic JJ N
certainty NN N
and CC N
time NN N
to TO N
initiation NN N
of IN N
appropriate JJ N
treatment NN N
. . N

-DOCSTART- -3342655- O O

The DT N
effects NNS N
of IN N
hypoxemia NN N
on IN N
cardiac JJ N
output NN N
. . N

A DT N
dose-response JJ N
curve NN N
. . N

To TO N
establish VB N
a DT N
dose-response JJ N
curve NN N
for IN N
the DT N
effects NNS N
of IN N
isocapnic JJ N
hypoxemia NN N
on IN N
cardiac JJ N
output NN N
( ( N
CO NNP N
) ) N
, , N
we PRP N
studied VBD N
20 CD N
healthy JJ N
men NNS N
, , N
aged VBD N
20 CD N
to TO N
34 CD N
years NNS N
, , N
using VBG N
a DT N
tight-fitting JJ N
face NN N
mask NN N
and CC N
an DT N
isocapnic JJ N
partial NN N
rebreathing NN N
system NN N
( ( N
a DT N
modified VBN N
anesthesia NN N
machine NN N
) ) N
. . N

We PRP N
blended VBD N
oxygen NN N
and CC N
hypoxic NN N
gas NN N
to TO N
achieve VB N
arterial JJ N
oxygen NN N
saturations NNS N
( ( N
SaO2 NNP N
) ) N
of IN N
80 CD N
, , N
85 CD N
, , N
and CC N
90 CD N
percent NN N
; : N
subjects NNS N
also RB N
breathed VBD N
100 CD N
percent NN N
oxygen NN N
and CC N
room NN N
air NN N
( ( N
RA NNP N
) ) N
. . N

Target NNP N
SaO2 NNP N
and CC N
end-tidal JJ N
carbon NN N
dioxide NN N
were VBD N
continuously RB N
monitored VBN N
using VBG N
an DT N
ear JJ N
oximeter NN N
and CC N
CO2 NNP N
gas NN N
analyzer NN N
. . N

Subjects NNS N
experienced VBD N
the DT N
five CD N
SaO2 NNP N
measurements NNS N
in IN N
random JJ N
order NN N
. . N

CO NNP N
was VBD N
measured VBN N
noninvasively RB N
at IN N
approximately RB N
two-minute JJ N
intervals NNS N
, , N
using VBG N
continuous-wave JJ N
Doppler NNP N
echocardiography NN N
. . N

Mean NNP N
cardiac JJ N
output NN N
increased VBD N
with IN N
increasing VBG N
hypoxemia NN N
from IN N
6.84 CD N
L/min NNP N
at IN N
FIo2 NNP N
1.0 CD N
to TO N
8.44 CD N
L/min NNP N
at IN N
SaO2 NNP N
80 CD N
percent NN N
( ( N
p NN N
less JJR N
than IN N
0.0005 CD N
) ) N
; : N
the DT N
increase NN N
was VBD N
entirely RB N
due JJ N
to TO N
increased JJ N
heart NN N
rate NN N
. . N

We PRP N
concluded VBD N
that IN N
cardiac JJ N
output NN N
increases NNS N
significantly RB N
in IN N
a DT N
dose-response JJ N
manner NN N
in IN N
response NN N
to TO N
acute VB N
isocapnic JJ N
hypoxemia NN N
in IN N
normal JJ N
persons NNS N
. . N

-DOCSTART- -19480863- O O

Effects NNS N
of IN N
weight-bearing JJ N
versus NN N
nonweight-bearing JJ N
exercise NN N
on IN N
function NN N
, , N
walking VBG N
speed NN N
, , N
and CC N
position NN N
sense NN N
in IN N
participants NNS N
with IN N
knee NN N
osteoarthritis NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
whether IN N
weight-bearing NN N
( ( N
WB NNP N
) ) N
exercise NN N
enhances VBZ N
functional JJ N
capacity NN N
to TO N
a DT N
greater JJR N
extent NN N
than IN N
nonweight-bearing JJ N
( ( N
NWB NNP N
) ) N
exercise NN N
in IN N
participants NNS N
with IN N
knee NN N
osteoarthritis NN N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Kinesiology NNP N
laboratory NN N
. . N

PARTICIPANTS JJ N
Participants NNS N
( ( N
N=106 NNP N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
WB NNP N
exercise NN N
, , N
NWB NNP N
exercise NN N
, , N
or CC N
a DT N
control NN N
group NN N
( ( N
no DT N
exercise NN N
) ) N
. . N

INTERVENTION NNP N
WB NNP N
exercise NN N
and CC N
NWB NNP N
exercise NN N
groups NNS N
underwent VBD N
an DT N
8-week JJ N
knee NN N
extension-flexion NN N
exercise NN N
program NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
Osteoarthritis NNP N
Index NNP N
( ( N
WOMAC NNP N
) ) N
function NN N
scale NN N
, , N
walking VBG N
speed NN N
, , N
muscle NN N
torque NN N
, , N
and CC N
knee VB N
reposition NN N
error NN N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
intervention NN N
. . N

RESULTS NNP N
Equally NNP N
significant JJ N
improvements NNS N
were VBD N
apparent JJ N
for IN N
all DT N
outcomes NNS N
after IN N
WB NNP N
exercise NN N
and CC N
NWB NNP N
exercise NN N
, , N
except IN N
for IN N
reposition NN N
error NN N
, , N
for IN N
which WDT N
improvement NN N
was VBD N
greater JJR N
in IN N
the DT N
WB NNP N
exercise NN N
group NN N
. . N

In IN N
contrast NN N
, , N
there EX N
were VBD N
no DT N
improvements NNS N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSIONS NNP N
Simple NNP N
knee NNP N
flexion NN N
and CC N
extension NN N
exercises NNS N
( ( N
WB NNP N
and CC N
NWB NNP N
) ) N
performed VBD N
over IN N
8 CD N
weeks NNS N
resulted VBD N
in IN N
significant JJ N
improvement NN N
in IN N
the DT N
WOMAC NNP N
function NN N
scale NN N
and CC N
knee NN N
strength NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

NWB NNP N
exercise NN N
alone RB N
may MD N
be VB N
sufficient JJ N
enough RB N
to TO N
improve VB N
function NN N
and CC N
muscle NN N
strength NN N
. . N

The DT N
additional JJ N
benefit NN N
of IN N
WB NNP N
exercise NN N
was VBD N
improved VBN N
position NN N
sense NN N
, , N
which WDT N
may MD N
enhance VB N
complex JJ N
walking NN N
tasks NNS N
( ( N
walking VBG N
on IN N
figure NN N
of IN N
8 CD N
route NN N
and CC N
spongy JJ N
surface NN N
) ) N
. . N

-DOCSTART- -8454478- O O

A DT N
randomized JJ N
trial NN N
of IN N
radiation NN N
therapy NN N
compared VBN N
to TO N
split VB N
course NN N
radiation NN N
therapy NN N
combined VBN N
with IN N
mitomycin JJ N
C NNP N
and CC N
5 CD N
fluorouracil NN N
as IN N
initial JJ N
treatment NN N
for IN N
advanced JJ N
laryngeal NN N
and CC N
hypopharyngeal NN N
squamous JJ N
carcinoma NN N
. . N

Two CD N
hundred VBD N
and CC N
twelve JJ N
patients NNS N
with IN N
previously RB N
untreated VBN N
advanced JJ N
squamous JJ N
carcinoma NN N
of IN N
the DT N
larynx NN N
or CC N
hypopharynx NN N
were VBD N
randomized VBN N
to TO N
receive VB N
initial JJ N
treatment NN N
with IN N
radiotherapy NN N
, , N
50 CD N
Gy NNP N
in IN N
20 CD N
fractions NNS N
in IN N
28 CD N
days NNS N
or CC N
split JJ N
course NN N
radiotherapy NN N
and CC N
concurrent NN N
chemotherapy NN N
, , N
25 CD N
Gy NNP N
in IN N
10 CD N
fractions NNS N
in IN N
14 CD N
days NNS N
followed VBN N
by IN N
a DT N
4 CD N
week NN N
rest NN N
and CC N
a DT N
further JJ N
25 CD N
Gy NNP N
in IN N
10 CD N
fractions NNS N
in IN N
14 CD N
days NNS N
starting VBG N
on IN N
day NN N
43 CD N
; : N
Mitomycin NNP N
C NNP N
was VBD N
given VBN N
on IN N
day NN N
1 CD N
and CC N
day NN N
43 CD N
and CC N
5FU CD N
continuous JJ N
infusions NNS N
on IN N
days NNS N
1 CD N
-- : N
4 CD N
and CC N
days NNS N
43 CD N
-- : N
46 CD N
. . N

Surgery NN N
was VBD N
reserved VBN N
for IN N
persistent NN N
or CC N
recurrent JJ N
disease NN N
. . N

Two CD N
hundred VBD N
and CC N
nine CD N
of IN N
the DT N
212 CD N
patients NNS N
randomized VBN N
were VBD N
included VBN N
in IN N
the DT N
analyses NNS N
. . N

Outcome NN N
analyses NNS N
were VBD N
performed VBN N
at IN N
a DT N
median JJ N
follow-up JJ N
interval NN N
of IN N
4.4 CD N
years NNS N
. . N

No DT N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
arms NNS N
for IN N
the DT N
end NN N
points NNS N
of IN N
local JJ N
relapse-free JJ N
rate NN N
( ( N
p JJ N
= NNP N
0.91 CD N
) ) N
, , N
regional JJ N
relapse-free JJ N
rate NN N
( ( N
p JJ N
= NN N
0.17 CD N
, , N
adjusted VBN N
) ) N
or CC N
overall JJ N
survival NN N
( ( N
p JJ N
= NNP N
0.86 CD N
) ) N
. . N

Eight-eight JJ N
patients NNS N
had VBD N
attempted VBN N
surgical JJ N
resection NN N
following VBG N
radiotherapy JJ N
failure NN N
. . N

The DT N
contribution NN N
of IN N
salvage NN N
surgery NN N
to TO N
overall JJ N
survival NN N
was VBD N
similar JJ N
for IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
as IN N
was VBD N
the DT N
surgical JJ N
complication NN N
rate NN N
. . N

Serious JJ N
late JJ N
radiation NN N
toxicity NN N
was VBD N
minimal JJ N
( ( N
3 CD N
% NN N
in IN N
the DT N
RT NNP N
group NN N
, , N
0 CD N
% NN N
in IN N
the DT N
radiation NN N
therapy NN N
plus CC N
chemotherapy NN N
group NN N
) ) N
. . N

The DT N
result NN N
of IN N
the DT N
trial NN N
shows VBZ N
no DT N
advantage NN N
in IN N
terms NNS N
of IN N
local JJ N
control NN N
or CC N
survival NN N
for IN N
the DT N
experimental JJ N
treatment NN N
arm NN N
of IN N
split NN N
course NN N
radiotherapy NN N
and CC N
concurrent JJ N
chemotherapy NN N
with IN N
Mitomycin NNP N
C NNP N
and CC N
5 CD N
Fluorouracil NNP N
compared VBN N
to TO N
radiotherapy VB N
alone RB N
. . N

-DOCSTART- -18077065- O O

Mechanical JJ N
efficiency NN N
and CC N
propulsion NN N
technique NN N
after IN N
7 CD N
weeks NNS N
of IN N
low-intensity JJ N
wheelchair NN N
training NN N
. . N

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
7-week JJ N
low-intensity NN N
hand NN N
rim VBZ N
wheelchair JJ N
training VBG N
on IN N
the DT N
submaximal JJ N
metabolic NN N
cost NN N
, , N
mechanical JJ N
efficiency NN N
and CC N
propulsion NN N
technique NN N
in IN N
able-bodied JJ N
participants NNS N
. . N

METHODS JJ N
Participants NNS N
were VBD N
randomly RB N
divided VBN N
over RP N
an DT N
experimental JJ N
group NN N
( ( N
n=14 CC N
) ) N
and CC N
a DT N
control NN N
group NN N
( ( N
n=7 RB N
) ) N
. . N

The DT N
experimental JJ N
group NN N
received VBD N
7 CD N
weeks NNS N
wheelchair JJ N
training NN N
( ( N
3 CD N
week NN N
( ( N
-1 NN N
) ) N
, , N
70 CD N
min NN N
) ) N
at IN N
a DT N
low JJ N
intensity NN N
( ( N
30 CD N
% NN N
of IN N
the DT N
heart NN N
rate NN N
reserve NN N
) ) N
, , N
whereas IN N
the DT N
control NN N
group NN N
did VBD N
not RB N
receive VB N
training NN N
. . N

During IN N
pre- JJ N
and CC N
post-tests NNS N
, , N
submaximal JJ N
exercise NN N
was VBD N
performed VBN N
on IN N
a DT N
stationary JJ N
wheelchair NN N
ergometer NN N
at IN N
fixed JJ N
levels NNS N
of IN N
power NN N
output NN N
. . N

Mechanical JJ N
efficiency NN N
, , N
oxygen NN N
uptake NN N
, , N
heart NN N
rate NN N
, , N
timing VBG N
parameters NNS N
and CC N
stroke NN N
angles NNS N
were VBD N
measured VBN N
. . N

Video NNP N
recordings NNS N
were VBD N
made VBN N
to TO N
determine VB N
the DT N
stroke NN N
pattern NN N
. . N

FINDINGS NNP N
Mechanical NNP N
efficiency NN N
increased VBD N
and CC N
metabolic JJ N
cost NN N
decreased VBN N
significantly RB N
in IN N
the DT N
experimental JJ N
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Push NNP N
time NN N
increased VBD N
and CC N
cycle NN N
frequency NN N
decreased VBD N
as IN N
a DT N
result NN N
of IN N
training NN N
. . N

The DT N
stroke NN N
angle NN N
increased VBD N
in IN N
the DT N
experimental JJ N
group NN N
during IN N
the DT N
training NN N
period NN N
. . N

The DT N
experimental JJ N
group NN N
preferred VBD N
double-looping NN N
over IN N
propulsion NN N
, , N
while IN N
the DT N
control NN N
group NN N
mainly RB N
used VBD N
single-looping NN N
over IN N
propulsion NN N
patterns NNS N
during IN N
the DT N
post-test JJ N
. . N

INTERPRETATION VB N
A DT N
low-intensity NN N
, , N
7-week JJ N
training NN N
protocol NN N
has VBZ N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
mechanical JJ N
efficiency NN N
and CC N
metabolic JJ N
cost NN N
of IN N
wheelchair NN N
propulsion NN N
in IN N
able-bodied JJ N
participants NNS N
. . N

The DT N
improved JJ N
mechanical JJ N
efficiency NN N
seems VBZ N
to TO N
be VB N
the DT N
result NN N
of IN N
changes NNS N
in IN N
propulsion NN N
technique NN N
that WDT N
were VBD N
found VBN N
. . N

-DOCSTART- -11034934- O O

VLDL NNP N
, , N
apolipoproteins VBZ N
B NNP N
, , N
CIII NNP N
, , N
and CC N
E NNP N
, , N
and CC N
risk NN N
of IN N
recurrent JJ N
coronary JJ N
events NNS N
in IN N
the DT N
Cholesterol NNP N
and CC N
Recurrent NNP N
Events NNP N
( ( N
CARE NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Plasma NNP N
triglyceride NN N
concentration NN N
has VBZ N
been VBN N
an DT N
inconsistent JJ N
independent JJ N
risk NN N
factor NN N
for IN N
coronary JJ N
heart NN N
disease NN N
, , N
perhaps RB N
because IN N
of IN N
the DT N
metabolic JJ N
heterogeneity NN N
among IN N
VLDL NNP N
particles NNS N
, , N
the DT N
main JJ N
carriers NNS N
of IN N
triglycerides NNS N
in IN N
plasma NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
nested JJ N
case-control NN N
study NN N
in IN N
the DT N
Cholesterol NNP N
and CC N
Recurrent NNP N
Events NNP N
( ( N
CARE NNP N
) ) N
trial NN N
, , N
a DT N
randomized JJ N
placebo-controlled JJ N
trial NN N
of IN N
pravastatin NN N
in IN N
4159 CD N
patients NNS N
with IN N
myocardial JJ N
infarction NN N
and CC N
average JJ N
LDL NNP N
concentrations NNS N
at IN N
baseline NN N
( ( N
115 CD N
to TO N
174 CD N
mg/dL NNS N
, , N
mean VBP N
139 CD N
mg/dL NN N
) ) N
. . N

Baseline NNP N
concentrations NNS N
of IN N
VLDL-apolipoprotein NNP N
( ( N
apo NN N
) ) N
B NNP N
( ( N
the DT N
VLDL NNP N
particle NN N
concentration NN N
) ) N
, , N
VLDL NNP N
lipids NNS N
, , N
and CC N
apoCIII NN N
and CC N
apoE NN N
in IN N
VLDL+LDL NNP N
and CC N
in IN N
HDL NNP N
were VBD N
compared VBN N
in IN N
patients NNS N
who WP N
had VBD N
either CC N
a DT N
myocardial JJ N
infarction NN N
or CC N
coronary JJ N
death NN N
( ( N
cases NNS N
, , N
n=418 NN N
) ) N
with IN N
those DT N
in IN N
patients NNS N
who WP N
did VBD N
not RB N
have VB N
a DT N
cardiovascular JJ N
event NN N
( ( N
control NN N
subjects VBZ N
, , N
n=370 NN N
) ) N
in IN N
5 CD N
years NNS N
of IN N
follow-up JJ N
. . N

VLDL-cholesterol NN N
, , N
VLDL-triglyceride NNP N
, , N
VLDL-apoB NNP N
, , N
apoCIII NN N
and CC N
apoE NN N
in IN N
VLDL+LDL NNP N
and CC N
apoE NN N
in IN N
HDL NNP N
were VBD N
all DT N
interrelated VBN N
, , N
and CC N
each DT N
was VBD N
a DT N
univariate JJ N
predictor NN N
of IN N
subsequent JJ N
coronary JJ N
events NNS N
. . N

The DT N
significant JJ N
independent JJ N
predictors NNS N
were VBD N
VLDL-apoB NNP N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] VBZ N
3.2 CD N
for IN N
highest JJS N
to TO N
lowest JJS N
quintiles NNS N
, , N
P NNP N
: : N
=0.04 NN N
) ) N
, , N
apoCIII RB N
in IN N
VLDL+LDL NNP N
( ( N
RR NNP N
2.3 CD N
, , N
P NNP N
: : N
=0.04 NN N
) ) N
, , N
and CC N
apoE NN N
in IN N
HDL NNP N
( ( N
RR NNP N
1.8 CD N
, , N
P NNP N
: : N
=0.02 NN N
) ) N
. . N

Plasma NNP N
triglycerides NNS N
, , N
a DT N
univariate JJ N
predictor NN N
of IN N
coronary JJ N
events NNS N
( ( N
RR NNP N
1.6 CD N
, , N
P NNP N
: : N
=0.03 NN N
) ) N
, , N
was VBD N
not RB N
related VBN N
to TO N
coronary JJ N
events NNS N
( ( N
RR NNP N
1.3 CD N
, , N
P NNP N
: : N
=0.6 NN N
) ) N
when WRB N
apoCIII NN N
in IN N
VLDL+LDL NNP N
was VBD N
included VBN N
in IN N
the DT N
model NN N
, , N
whereas JJ N
apoCIII NN N
remained VBD N
significant JJ N
. . N

Adjustment NN N
for IN N
LDL- NNP N
and CC N
HDL-cholesterol NNP N
did VBD N
not RB N
affect VB N
these DT N
results NNS N
. . N

CONCLUSIONS NNP N
The DT N
plasma JJ N
concentrations NNS N
of IN N
VLDL NNP N
particles NNS N
and CC N
apoCIII NN N
in IN N
VLDL NNP N
and CC N
LDL NNP N
are VBP N
more RBR N
specific JJ N
measures NNS N
of IN N
coronary JJ N
heart NN N
disease NN N
risk NN N
than IN N
plasma JJ N
triglycerides NNS N
perhaps RB N
because IN N
their PRP$ N
known VBN N
metabolic NN N
properties NNS N
link VBP N
them PRP N
more RBR N
closely RB N
to TO N
atherosclerosis NN N
. . N

-DOCSTART- -17178774- O O

The DT N
additional JJ N
value NN N
of IN N
a DT N
night NN N
splint NN N
to TO N
eccentric VB N
exercises NNS N
in IN N
chronic JJ N
midportion NN N
Achilles NNP N
tendinopathy NN N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

AIM NNP N
To TO N
assess VB N
whether IN N
the DT N
use NN N
of IN N
a DT N
night NN N
splint NN N
is VBZ N
of IN N
added JJ N
benefit NN N
on IN N
functional JJ N
outcome NN N
in IN N
treating VBG N
chronic JJ N
midportion NN N
Achilles NNP N
tendinopathy NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
single-blind JJ N
, , N
prospective JJ N
, , N
single JJ N
centre NN N
, , N
randomised VBD N
controlled VBN N
trial NN N
set NN N
in IN N
the DT N
Sports NNP N
Medical NNP N
Department NNP N
, , N
The DT N
Hague NNP N
Medical NNP N
Centre NNP N
, , N
The DT N
Netherlands NNP N
. . N

Inclusion NNP N
criteria NNS N
were VBD N
: : N
age NN N
18-70 CD N
years NNS N
, , N
active JJ N
participation NN N
in IN N
sports NNS N
, , N
and CC N
tendon VB N
pain NN N
localised VBN N
at IN N
2-7 JJ N
cm NN N
from IN N
distal JJ N
insertion NN N
. . N

Exclusion NN N
criteria NNS N
were VBD N
: : N
insertional JJ N
disorders NNS N
, , N
partial JJ N
or CC N
complete JJ N
ruptures NNS N
, , N
or CC N
systemic JJ N
illness NN N
. . N

70 CD N
tendons NNS N
were VBD N
included VBN N
and CC N
randomised VBN N
into IN N
one CD N
of IN N
two CD N
treatment NN N
groups NNS N
: : N
eccentric JJ N
exercises NNS N
with IN N
a DT N
night NN N
splint NN N
( ( N
night NN N
splint NN N
group NN N
, , N
n RB N
= VBZ N
36 CD N
) ) N
or CC N
eccentric JJ N
exercises NNS N
only RB N
( ( N
eccentric JJ N
group NN N
, , N
n RB N
= VBZ N
34 CD N
) ) N
. . N

INTERVENTIONS NNP N
Both DT N
groups NNS N
completed VBD N
a DT N
12-week JJ N
heavy-load NN N
eccentric JJ N
training NN N
programme NN N
. . N

One CD N
group NN N
received VBD N
a DT N
night NN N
splint NN N
in IN N
addition NN N
to TO N
eccentric JJ N
exercises NNS N
. . N

At IN N
baseline NN N
and CC N
follow-up NN N
at IN N
12 CD N
weeks NNS N
, , N
patient JJ N
satisfaction NN N
, , N
Victorian NNP N
Institute NNP N
of IN N
Sport NNP N
Assessment-Achilles NNP N
questionnaire NN N
( ( N
VISA-A NNP N
) ) N
score NN N
and CC N
reported VBD N
compliance NN N
were VBD N
recorded VBN N
by IN N
a DT N
single-blind NN N
trained JJ N
researcher NN N
who WP N
was VBD N
blinded VBN N
to TO N
the DT N
treatment NN N
. . N

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
, , N
patient JJ N
satisfaction NN N
in IN N
the DT N
eccentric JJ N
group NN N
was VBD N
63 CD N
% NN N
compared VBN N
with IN N
48 CD N
% NN N
in IN N
the DT N
night NN N
splint NN N
group NN N
. . N

The DT N
VISA-A NNP N
score NN N
significantly RB N
improved VBN N
in IN N
both DT N
groups NNS N
; : N
in IN N
the DT N
eccentric JJ N
group NN N
from IN N
50.1 CD N
to TO N
68.8 CD N
( ( N
p NN N
= RB N
0.001 CD N
) ) N
and CC N
in IN N
the DT N
night NN N
splint NN N
group NN N
from IN N
49.4 CD N
to TO N
67.0 CD N
( ( N
p NN N
< RB N
0.001 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
VISA-A NNP N
score NN N
( ( N
p JJ N
= NNP N
0.815 CD N
) ) N
and CC N
patient JJ N
satisfaction NN N
( ( N
p JJ N
= NNP N
0.261 CD N
) ) N
. . N

CONCLUSION VB N
A DT N
night NN N
splint NN N
is VBZ N
not RB N
beneficial JJ N
in IN N
addition NN N
to TO N
eccentric VB N
exercises NNS N
in IN N
the DT N
treatment NN N
of IN N
chronic JJ N
midportion NN N
Achilles NNP N
tendinopathy NN N
. . N

-DOCSTART- -17276969- O O

Effects NNS N
of IN N
sibutramine NN N
on IN N
thermogenesis NN N
in IN N
obese JJ N
patients NNS N
assessed VBD N
via IN N
immersion NN N
calorimetry NN N
. . N

Glucose NNP N
utilization JJ N
studies NNS N
show VBP N
that IN N
sibutramine-induced JJ N
thermogenesis NN N
is VBZ N
mediated VBN N
via IN N
selective JJ N
sympathetic JJ N
activation NN N
of IN N
brown JJ N
adipose JJ N
tissue NN N
. . N

The DT N
goal NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
use VB N
a DT N
new JJ N
calorimetry NN N
method NN N
in IN N
which WDT N
resting VBG N
metabolic JJ N
rate NN N
is VBZ N
enhanced VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
sibutramine JJ N
treatment NN N
on IN N
thermogenesis NN N
. . N

Sixty NNP N
obese JJ N
women NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Subjects NNS N
were VBD N
divided VBN N
into IN N
2 CD N
equal JJ N
groups-the JJ N
placebo NN N
and CC N
sibutramine JJ N
treatment NN N
groups NNS N
. . N

The DT N
sibutramine NN N
group NN N
was VBD N
given VBN N
sibutramine JJ N
10 CD N
mg JJ N
daily RB N
for IN N
12 CD N
wk NN N
. . N

At IN N
baseline NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
12-wk JJ N
treatment NN N
period NN N
, , N
thermogenic JJ N
measurements NNS N
were VBD N
taken VBN N
with IN N
the DT N
use NN N
of IN N
water NN N
immersion NN N
calorimetry NN N
. . N

Subjects NNS N
were VBD N
examined VBN N
at IN N
weeks NNS N
4 CD N
, , N
8 CD N
, , N
and CC N
12 CD N
of IN N
treatment NN N
to TO N
identify VB N
adverse JJ N
effects NNS N
. . N

Body NNP N
mass NN N
index NN N
, , N
measured VBN N
at IN N
31.5+/-2.05 JJ N
kg/m2 NN N
in IN N
the DT N
placebo NN N
group NN N
, , N
decreased VBN N
to TO N
30.4+/-2.94 JJ N
kg/m NN N
( ( N
2 CD N
) ) N
after IN N
12 CD N
wk NN N
( ( N
P=.07 NNP N
) ) N
. . N

In IN N
the DT N
sibutramine NN N
group NN N
, , N
it PRP N
decreased VBD N
from IN N
33.5+/-4.1 JJ N
kg/m NN N
( ( N
2 CD N
) ) N
to TO N
30.9+/-4.8 JJ N
kg/m NN N
( ( N
2 CD N
) ) N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

In IN N
the DT N
sibutramine NN N
group NN N
, , N
mean VBP N
thermogenic JJ N
response NN N
changed VBD N
from IN N
a DT N
baseline NN N
value NN N
of IN N
1.27+/-0.29 JJ N
kcal/kg/h NN N
to TO N
1.44+/-0.13 JJ N
kcal/kg/h NN N
after IN N
12 CD N
wk NN N
of IN N
treatment NN N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
the DT N
baseline NN N
value NN N
was VBD N
1.56+/-0.27 JJ N
kcal/kg/h NN N
; : N
it PRP N
changed VBD N
to TO N
1.33+/-0.36 JJ N
kcal/kg/h NN N
at IN N
the DT N
end NN N
of IN N
12 CD N
wk NN N
. . N

The DT N
findings NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
sibutramine NN N
treatment NN N
promotes VBZ N
thermogenesis NN N
, , N
thus RB N
facilitating VBG N
weight JJ N
loss NN N
. . N

Calorimetry NNP N
enhances VBZ N
resting VBG N
metabolism NN N
through IN N
more RBR N
efficient JJ N
heat NN N
transfer NN N
from IN N
the DT N
body NN N
. . N

-DOCSTART- -2474103- O O

Moderate NNP N
sodium NN N
restriction NN N
, , N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibition NN N
, , N
and CC N
thiazide RB N
diuretic JJ N
in IN N
the DT N
management NN N
of IN N
essential JJ N
hypertension NN N
. . N

Dietary NNP N
sodium JJ N
restriction NN N
alone RB N
is VBZ N
effective JJ N
in IN N
lowering VBG N
blood NN N
pressure NN N
in IN N
some DT N
, , N
but CC N
not RB N
all DT N
, , N
patients NNS N
with IN N
essential JJ N
hypertension NN N
. . N

Homeostatic JJ N
mechanisms NNS N
, , N
including VBG N
activation NN N
of IN N
the DT N
renin-aldosterone NN N
system NN N
, , N
may MD N
counteract VB N
the DT N
effects NNS N
of IN N
sodium JJ N
restriction NN N
. . N

Angiotensin NNP N
converting VBG N
enzyme NN N
( ( N
ACE NNP N
) ) N
inhibitors NNS N
are VBP N
also RB N
effective JJ N
as IN N
sole JJ N
therapy NN N
in IN N
many JJ N
patients NNS N
with IN N
essential JJ N
hypertension NN N
, , N
but CC N
may MD N
be VB N
less RBR N
effective JJ N
in IN N
those DT N
with IN N
low-renin JJ N
hypertension NN N
. . N

The DT N
combination NN N
of IN N
dietary JJ N
sodium NN N
restriction NN N
with IN N
blockade NN N
of IN N
the DT N
renin NN N
system NN N
by IN N
an DT N
ACE NNP N
inhibitor NN N
is VBZ N
a DT N
particularly RB N
effective JJ N
way NN N
to TO N
improve VB N
blood NN N
pressure NN N
control NN N
. . N

Addition NNP N
of IN N
a DT N
thiazide JJ N
diuretic NN N
will MD N
reduce VB N
pressure NN N
further RBR N
. . N

-DOCSTART- -11706697- O O

Does NNP N
temporary JJ N
clamping NN N
of IN N
drains NNS N
following VBG N
knee NN N
arthroplasty JJ N
reduce VB N
blood NN N
loss NN N
? . N
A DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

In IN N
a DT N
randomised JJ N
, , N
blinded VBD N
study NN N
76 CD N
patients NNS N
undergoing JJ N
primary JJ N
total JJ N
knee NN N
arthroplasty NN N
were VBD N
assigned VBN N
to TO N
either DT N
immediate JJ N
drain NN N
opening NN N
( ( N
n JJ N
= NNP N
45 CD N
) ) N
or CC N
drains NNS N
opened VBN N
at IN N
2 CD N
h NN N
( ( N
n JJ N
= NNP N
31 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
for IN N
the DT N
volume NN N
of IN N
drained JJ N
blood NN N
, , N
transfusion NN N
requirements NNS N
, , N
knee JJ N
motion NN N
or CC N
wound NN N
status NN N
. . N

The DT N
authors NNS N
conclude VBP N
that IN N
the DT N
practice NN N
of IN N
clamping VBG N
drains NNS N
has VBZ N
no DT N
benefit NN N
in IN N
routine JJ N
knee NN N
arthroplasty NN N
. . N

However RB N
, , N
when WRB N
faced VBN N
with IN N
immediate JJ N
brisk JJ N
blood NN N
loss NN N
, , N
the DT N
results NNS N
suggest VBP N
that IN N
drains NNS N
can MD N
be VB N
clamped VBN N
without IN N
any DT N
excess JJ N
morbidity NN N
. . N

-DOCSTART- -15622265- O O

A DT N
randomized JJ N
, , N
evaluator-blind JJ N
, , N
multicenter JJ N
comparison NN N
of IN N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
Perlane NNP N
versus NN N
Zyplast NNP N
in IN N
the DT N
correction NN N
of IN N
nasolabial JJ N
folds NNS N
. . N

Bovine NNP N
collagen NN N
is VBZ N
widely RB N
used VBN N
as IN N
a DT N
dermal JJ N
filler NN N
for IN N
facial JJ N
soft-tissue JJ N
augmentation NN N
, , N
but CC N
it PRP N
provides VBZ N
only RB N
temporary JJ N
cosmetic JJ N
improvement NN N
. . N

Nonanimal NNP N
stabilized VBD N
hyaluronic JJ N
acid NN N
has VBZ N
reduced VBN N
potential JJ N
for IN N
immunogenicity NN N
and CC N
hypersensitivity NN N
and CC N
may MD N
provide VB N
a DT N
more RBR N
durable JJ N
aesthetic JJ N
result NN N
. . N

Sixty-eight JJ N
patients NNS N
with IN N
prominent JJ N
nasolabial JJ N
folds NNS N
were VBD N
randomized VBN N
to TO N
intradermal VB N
treatment NN N
with IN N
nonanimal JJ N
stabilized VBN N
hyaluronic JJ N
acid NN N
gel NN N
( ( N
Perlane NNP N
) ) N
and CC N
bovine JJ N
collagen NN N
( ( N
Zyplast NNP N
) ) N
on IN N
contralateral JJ N
sides NNS N
of IN N
the DT N
face NN N
. . N

On IN N
achievement NN N
of IN N
optimal JJ N
cosmetic JJ N
result NN N
( ( N
baseline NN N
) ) N
, , N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
6 CD N
months NNS N
; : N
bilateral JJ N
retreatment NN N
with IN N
Perlane NNP N
was VBD N
offered VBN N
at IN N
6 CD N
or CC N
9 CD N
months NNS N
after IN N
baseline NN N
. . N

Responses NNS N
were VBD N
evaluated VBN N
at IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
baseline NN N
. . N

Investigator-based JJ N
and CC N
patient-based JJ N
ratings NNS N
indicated VBD N
that IN N
Perlane NNP N
was VBD N
more RBR N
effective JJ N
than IN N
Zyplast NNP N
in IN N
maintaining VBG N
cosmetic JJ N
correction NN N
. . N

According VBG N
to TO N
investigator-based JJ N
Wrinkle NNP N
Severity NNP N
Rating NNP N
Scale NNP N
assessments NNS N
at IN N
6 CD N
and CC N
9 CD N
months NNS N
after IN N
baseline NN N
, , N
Perlane NNP N
was VBD N
superior JJ N
in IN N
50.0 CD N
percent NN N
and CC N
48.8 CD N
percent NN N
of IN N
patients NNS N
, , N
respectively RB N
, , N
whereas IN N
Zyplast NNP N
was VBD N
superior JJ N
in IN N
10.3 CD N
percent NN N
and CC N
14.0 CD N
percent NN N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
p JJ N
< NNP N
0.0004 CD N
) ) N
. . N

Investigator-based JJ N
Global NNP N
Aesthetic NNP N
Improvement NNP N
Scale NNP N
assessment NN N
at IN N
9 CD N
months NNS N
after IN N
baseline NN N
indicated VBD N
that IN N
Perlane NNP N
was VBD N
superior JJ N
in IN N
48.8 CD N
percent NN N
of IN N
patients NNS N
, , N
whereas IN N
Zyplast NNP N
was VBD N
superior JJ N
in IN N
14.0 CD N
percent NN N
of IN N
patients NNS N
( ( N
p JJ N
= NNP N
0.0025 CD N
) ) N
. . N

Optimal NNP N
cosmetic JJ N
result NN N
was VBD N
achieved VBN N
with IN N
a DT N
smaller JJR N
volume NN N
of IN N
Perlane NNP N
than IN N
Zyplast NNP N
( ( N
mean NN N
, , N
1.2 CD N
ml NN N
versus NN N
2.1 CD N
ml NN N
) ) N
. . N

Local JJ N
injection-site JJ N
reactions NNS N
( ( N
redness NN N
, , N
swelling VBG N
, , N
pruritus NN N
, , N
and CC N
induration NN N
) ) N
were VBD N
less RBR N
frequent JJ N
with IN N
Perlane NNP N
than IN N
with IN N
Zyplast NNP N
. . N

Delayed-onset JJ N
reactions NNS N
were VBD N
rare JJ N
and CC N
did VBD N
not RB N
reoccur VB N
after IN N
Perlane NNP N
retreatment NN N
. . N

Perlane NNP N
has VBZ N
acceptable JJ N
long-term JJ N
safety NN N
and CC N
offers VBZ N
a DT N
longer-lasting JJ N
aesthetic JJ N
improvement NN N
than IN N
Zyplast NNP N
. . N

-DOCSTART- -17244294- O O

How WRB N
does VBZ N
Cash NNP N
and CC N
Counseling NNP N
affect NN N
costs NNS N
? . N
OBJECTIVE NNP N
To TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
consumer-directed JJ N
model NN N
( ( N
Cash NNP N
and CC N
Counseling NNP N
) ) N
of IN N
Medicaid NNP N
personal JJ N
care NN N
services NNS N
( ( N
PCS NNPS N
) ) N
or CC N
home- JJ N
and CC N
community-based JJ N
waiver NN N
services NNS N
( ( N
HCBS NNP N
) ) N
on IN N
the DT N
cost NN N
of IN N
Medicaid NNP N
services NNS N
. . N

DATA NNP N
SOURCES/STUDY NNP N
SETTING NNP N
Medicaid NNP N
claims NNS N
data NNS N
were VBD N
collected VBN N
for IN N
all DT N
enrollees NNS N
in IN N
the DT N
Cash NNP N
and CC N
Counseling NNP N
demonstration NN N
. . N

Demonstration NNP N
enrollees NNS N
included VBD N
those DT N
eligible JJ N
for IN N
PCS NNP N
( ( N
in IN N
Arkansas NNP N
) ) N
, , N
those DT N
assessed VBN N
to TO N
receive VB N
such JJ N
services NNS N
( ( N
in IN N
New NNP N
Jersey NNP N
) ) N
, , N
and CC N
recipients NNS N
of IN N
Medicaid NNP N
HCBS NNP N
( ( N
in IN N
Florida NNP N
) ) N
. . N

Enrollment NN N
occurred VBD N
from IN N
December NNP N
1998 CD N
through IN N
April NNP N
2001 CD N
. . N

The DT N
follow-up JJ N
period NN N
covered VBD N
up RB N
to TO N
24 CD N
months NNS N
after IN N
enrollment NN N
. . N

STUDY NNP N
DESIGN NNP N
Demonstration NNP N
volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
have VB N
the DT N
option NN N
to TO N
participate VB N
in IN N
Cash NNP N
and CC N
Counseling NNP N
( ( N
the DT N
treatment NN N
group NN N
) ) N
, , N
or CC N
to TO N
receive VB N
Medicaid NNP N
services NNS N
as RB N
usual JJ N
from IN N
an DT N
agency NN N
( ( N
the DT N
control NN N
group NN N
) ) N
. . N

Ordinary JJ N
least JJS N
squares NNS N
regressions NNS N
were VBD N
used VBN N
to TO N
estimate VB N
the DT N
effect NN N
of IN N
the DT N
program NN N
on IN N
costs NNS N
for IN N
Medicaid NNP N
PCS/waiver NNP N
services NNS N
and CC N
other JJ N
Medicaid NNP N
services NNS N
, , N
while IN N
controlling VBG N
for IN N
consumers NNS N
' POS N
preenrollment NN N
characteristics NNS N
and CC N
preenrollment NN N
Medicaid NNP N
spending NN N
. . N

Models NNS N
were VBD N
estimated VBN N
separately RB N
for IN N
nonelderly RB N
and CC N
elderly JJ N
adults NNS N
in IN N
each DT N
state NN N
and CC N
for IN N
children NNS N
in IN N
Florida NNP N
. . N

DATA NNP N
EXTRACTION NNP N
METHODS NNP N
Each DT N
state NN N
supplied VBD N
claims NNS N
data NNS N
for IN N
demonstration NN N
enrollees NNS N
. . N

PRINCIPAL NNP N
FINDINGS NNP N
Largely NNP N
because IN N
the DT N
program NN N
increased VBD N
consumers NNS N
' POS N
ability NN N
to TO N
get VB N
the DT N
authorized JJ N
amount NN N
of IN N
paid VBN N
care NN N
, , N
expenditures VBZ N
for IN N
personal JJ N
care/waiver NN N
services NNS N
were VBD N
higher JJR N
for IN N
the DT N
treatment NN N
group NN N
than IN N
for IN N
the DT N
control NN N
group NN N
in IN N
each DT N
state NN N
and CC N
age NN N
group NN N
, , N
except IN N
among IN N
the DT N
elderly JJ N
in IN N
Florida NNP N
. . N

Higher JJR N
costs NNS N
for IN N
personal JJ N
care/waiver NN N
services NNS N
were VBD N
partially RB N
offset VBN N
by IN N
savings NNS N
in IN N
other JJ N
Medicaid NNP N
services NNS N
, , N
particularly RB N
those DT N
related VBN N
to TO N
long-term JJ N
care NN N
. . N

During IN N
year NN N
1 CD N
, , N
total JJ N
Medicaid NNP N
costs NNS N
were VBD N
generally RB N
higher JJR N
for IN N
the DT N
treatment NN N
group NN N
than IN N
for IN N
the DT N
control NN N
group NN N
, , N
with IN N
treatment-control JJ N
cost NN N
differences NNS N
ranging VBG N
from IN N
1 CD N
percent NN N
( ( N
and CC N
statistically RB N
insignificant JJ N
) ) N
for IN N
the DT N
elderly JJ N
in IN N
Florida NNP N
to TO N
17 CD N
percent NN N
for IN N
the DT N
elderly JJ N
in IN N
Arkansas NNP N
. . N

In IN N
year NN N
2 CD N
, , N
these DT N
cost NN N
differences NNS N
were VBD N
generally RB N
greater JJR N
than IN N
in IN N
year NN N
1 CD N
. . N

Only RB N
in IN N
Arkansas NNP N
did VBD N
the DT N
treatment-control NN N
difference NN N
in IN N
total JJ N
cost NN N
shrink NN N
over IN N
time-to JJ N
less JJR N
than IN N
5 CD N
percent NN N
( ( N
and CC N
statistically RB N
insignificant JJ N
) ) N
in IN N
year NN N
2 CD N
. . N

CONCLUSIONS NNP N
Medicaid NNP N
costs NNS N
were VBD N
generally RB N
higher JJR N
under IN N
Cash NNP N
and CC N
Counseling NNP N
because IN N
those DT N
in IN N
the DT N
traditional JJ N
system NN N
did VBD N
not RB N
get VB N
the DT N
services NNS N
they PRP N
were VBD N
entitled VBN N
to TO N
. . N

Compared VBN N
with IN N
the DT N
treatment NN N
group NN N
, , N
( ( N
1 CD N
) ) N
control NN N
group NN N
members NNS N
were VBD N
less RBR N
likely JJ N
to TO N
receive VB N
any DT N
services NNS N
at IN N
all DT N
( ( N
despite IN N
being VBG N
authorized VBN N
for IN N
them PRP N
) ) N
, , N
and CC N
( ( N
2 CD N
) ) N
service NN N
recipients NNS N
received VBD N
a DT N
lower JJR N
proportion NN N
of IN N
the DT N
amount NN N
of IN N
care NN N
that WDT N
was VBD N
authorized VBN N
. . N

In IN N
addition NN N
, , N
a DT N
flaw NN N
in IN N
Florida NNP N
's POS N
reassessment NN N
procedures NNS N
led VBD N
to TO N
treatment NN N
group NN N
members NNS N
receiving VBG N
more RBR N
generous JJ N
benefit NN N
amounts NNS N
than IN N
control NN N
group NN N
members NNS N
. . N

To TO N
keep VB N
total JJ N
Medicaid NNP N
costs NNS N
per IN N
recipient NN N
at IN N
the DT N
level NN N
incurred VBN N
under IN N
the DT N
traditional JJ N
system NN N
, , N
consumer-directed JJ N
programs NNS N
need VBP N
to TO N
be VB N
carefully RB N
designed VBN N
and CC N
closely RB N
monitored VBN N
. . N

-DOCSTART- -23699515- O O

The DT N
aging VBG N
motor NN N
system NN N
as IN N
a DT N
model NN N
for IN N
plastic JJ N
changes NNS N
of IN N
GABA-mediated NNP N
intracortical JJ N
inhibition NN N
and CC N
their PRP$ N
behavioral JJ N
relevance NN N
. . N

Since IN N
GABAA-mediated JJ N
intracortical JJ N
inhibition NN N
has VBZ N
been VBN N
shown VBN N
to TO N
underlie VB N
plastic NN N
changes NNS N
throughout IN N
the DT N
lifespan NN N
from IN N
development NN N
to TO N
aging VBG N
, , N
here RB N
, , N
the DT N
aging VBG N
motor NN N
system NN N
was VBD N
used VBN N
as IN N
a DT N
model NN N
to TO N
analyze VB N
the DT N
interdependence NN N
of IN N
plastic JJ N
alterations NNS N
within IN N
the DT N
inhibitory JJ N
motorcortical JJ N
network NN N
and CC N
level NN N
of IN N
behavioral JJ N
performance NN N
. . N

Double-pulse JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
dpTMS NN N
) ) N
was VBD N
used VBN N
to TO N
examine VB N
inhibition NN N
by IN N
means NNS N
of IN N
short-interval JJ N
intracortical JJ N
inhibition NN N
( ( N
SICI NNP N
) ) N
of IN N
the DT N
contralateral JJ N
primary JJ N
motor NN N
cortex NN N
in IN N
a DT N
sample NN N
of IN N
64 CD N
healthy JJ N
right-handed JJ N
human JJ N
subjects NNS N
covering VBG N
a DT N
wide JJ N
range NN N
of IN N
the DT N
adult NN N
lifespan NN N
( ( N
age NN N
range NN N
20-88 CD N
years NNS N
, , N
mean VB N
47.6 CD N
? . N
20.7 CD N
, , N
34 CD N
female NN N
) ) N
. . N

SICI NNP N
was VBD N
evaluated VBN N
during IN N
resting VBG N
state NN N
and CC N
in IN N
an DT N
event-related JJ N
condition NN N
during IN N
movement NN N
preparation NN N
in IN N
a DT N
visually RB N
triggered VBN N
simple JJ N
reaction NN N
time NN N
task NN N
. . N

In IN N
a DT N
subgroup NN N
( ( N
N NNP N
= NNP N
23 CD N
) ) N
, , N
manual JJ N
motor NN N
performance NN N
was VBD N
tested VBN N
with IN N
tasks NNS N
of IN N
graded VBN N
dexterous JJ N
demand NN N
. . N

Weak JJ N
resting-state JJ N
inhibition NN N
was VBD N
associated VBN N
with IN N
an DT N
overall JJ N
lower JJR N
manual JJ N
motor NN N
performance NN N
. . N

Better RBR N
event-related JJ N
modulation NN N
of IN N
inhibition NN N
correlated VBN N
with IN N
better JJR N
performance NN N
in IN N
more RBR N
demanding JJ N
tasks NNS N
, , N
in IN N
which WDT N
fast RB N
alternating VBG N
activation NN N
of IN N
cortical JJ N
representations NNS N
are VBP N
necessary JJ N
. . N

Declining VBG N
resting-state JJ N
inhibition NN N
was VBD N
associated VBN N
with IN N
weakened JJ N
event-related JJ N
modulation NN N
of IN N
inhibition NN N
. . N

Therefore NN N
, , N
reduced VBD N
resting-state JJ N
inhibition NN N
might MD N
lead VB N
to TO N
a DT N
subsequent JJ N
loss NN N
of IN N
modulatory JJ N
capacity NN N
, , N
possibly RB N
reflecting VBG N
malfunctioning VBG N
precision NN N
in IN N
GABAAergic NNP N
neurotransmission NN N
; : N
the DT N
consequence NN N
is VBZ N
an DT N
inevitable JJ N
decline NN N
in IN N
motor NN N
function NN N
. . N

-DOCSTART- -18415946- O O

Comparison NNP N
of IN N
the DT N
time NN N
required VBN N
to TO N
administer VB N
three CD N
different JJ N
fluke NNS N
and CC N
worm VB N
combination NN N
products NNS N
to TO N
commercial JJ N
beef NN N
cattle NNS N
at IN N
housing NN N
. . N

Larger NNP N
livestock VBD N
units NNS N
, , N
a DT N
decline NN N
in IN N
the DT N
farm NN N
labor NN N
force NN N
, , N
animal JJ N
welfare NN N
concerns NNS N
, , N
and CC N
a DT N
trend NN N
toward IN N
more RBR N
selective JJ N
use NN N
of IN N
drugs NNS N
have VBP N
increased VBN N
the DT N
focus NN N
on IN N
animal NN N
handling NN N
, , N
time NN N
management NN N
, , N
convenience NN N
, , N
and CC N
compliance NN N
in IN N
administering VBG N
veterinary JJ N
therapeutics NNS N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
quantify VB N
and CC N
compare VB N
the DT N
time NN N
needed VBN N
to TO N
treat VB N
commercial JJ N
beef NN N
cattle NNS N
with IN N
three CD N
fluke NNS N
and CC N
worm VB N
combination NN N
products NNS N
with IN N
different JJ N
administration NN N
profiles NNS N
. . N

Young NNP N
beef NN N
cattle NNS N
( ( N
n JJ N
= NNP N
270 CD N
) ) N
weighing VBG N
approximately RB N
400 CD N
kg NNS N
were VBD N
allocated VBN N
to TO N
batches NNS N
of IN N
five CD N
, , N
which WDT N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
ivermectin NN N
+ NNP N
clorsulon NN N
injection NN N
, , N
ivermectin JJ N
+ JJ N
closantel NN N
injection NN N
, , N
or CC N
levamisole JJ N
+ JJ N
triclabendazole JJ N
oral JJ N
drench NN N
. . N

The DT N
mean JJ N
time NN N
needed VBN N
to TO N
administer VB N
ivermectin JJ N
+ NN N
clorsulon NN N
( ( N
single JJ N
injection NN N
) ) N
to TO N
five CD N
cattle NNS N
was VBD N
31 CD N
seconds NNS N
, , N
which WDT N
was VBD N
significantly RB N
less JJR N
than IN N
the DT N
100 CD N
seconds NNS N
needed VBN N
for IN N
ivermectin JJ N
+ JJ N
closantel NN N
( ( N
two CD N
injections NNS N
) ) N
and CC N
the DT N
126 CD N
seconds NNS N
needed VBN N
for IN N
levamisole JJ N
+ JJ N
triclabendazole NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Such JJ N
quantitative JJ N
data NNS N
can MD N
allow VB N
for IN N
better JJR N
planning NN N
and CC N
selection NN N
of IN N
parasiticide JJ N
treatment NN N
approaches NNS N
at IN N
the DT N
farm NN N
level NN N
. . N

-DOCSTART- -17391914- O O

Information NNP N
source NN N
affects VBZ N
peers NNS N
' POS N
initial JJ N
attitudes NNS N
toward IN N
autism NN N
. . N

Authors NNS N
examined VBD N
the DT N
effects NNS N
of IN N
information NN N
source NN N
on IN N
peers NNS N
' POS N
cognitive NN N
and CC N
behavioral JJ N
attitudes NNS N
toward IN N
an DT N
unfamiliar JJ N
child NN N
with IN N
autism NN N
. . N

Children NNP N
( ( N
N=296 NNP N
; : N
M NNP N
age=10.21 IN N
years NNS N
) ) N
received VBD N
information NN N
about IN N
an DT N
unfamiliar JJ N
child NN N
with IN N
autism NN N
from IN N
one CD N
of IN N
the DT N
following JJ N
sources NNS N
: : N
( ( N
a DT N
) ) N
videotape NN N
, , N
( ( N
b NN N
) ) N
teacher NN N
, , N
( ( N
c NN N
) ) N
hypothetical JJ N
mother NN N
, , N
( ( N
d NN N
) ) N
hypothetical JJ N
father NN N
, , N
or CC N
( ( N
e NN N
) ) N
hypothetical JJ N
doctor NN N
. . N

Interactive JJ N
effects NNS N
between IN N
source NN N
, , N
and CC N
sex NN N
and CC N
grade NN N
were VBD N
found VBN N
for IN N
cognitive JJ N
and CC N
behavioral JJ N
attitudes NNS N
. . N

Fifth-graders NNS N
reported VBD N
more RBR N
favorable JJ N
cognitive JJ N
and CC N
behavioral JJ N
attitudes NNS N
when WRB N
information NN N
was VBD N
provided VBN N
by IN N
extra-familial JJ N
sources NNS N
( ( N
i.e. NN N
, , N
doctor NN N
) ) N
versus NN N
parent NN N
sources NNS N
. . N

Mother NNP N
yielded VBD N
more RBR N
persuasive JJ N
effects NNS N
on IN N
behavioral JJ N
attitudes NNS N
for IN N
third-graders NNS N
versus JJ N
fifth-graders NNS N
. . N

Attitudes NNS N
toward IN N
autism NN N
differ VBP N
depending VBG N
on IN N
who WP N
provides VBZ N
information NN N
about IN N
the DT N
disability NN N
. . N

Persuasion NNP N
theory NN N
appears VBZ N
useful JJ N
to TO N
guide VB N
evaluation NN N
of IN N
educational JJ N
interventions NNS N
to TO N
improve VB N
attitudes NNS N
towards IN N
autism NN N
. . N

Implications NNS N
of IN N
the DT N
findings NNS N
, , N
study NN N
limitations NNS N
, , N
and CC N
recommendations NNS N
for IN N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -7654128- O O

Failure NN N
of IN N
naltrexone NN N
hydrochloride NN N
to TO N
reduce VB N
self-injurious JJ N
and CC N
autistic JJ N
behavior NN N
in IN N
mentally RB N
retarded JJ N
adults NNS N
. . N

Double-blind JJ N
placebo-controlled JJ N
studies NNS N
. . N

BACKGROUND IN N
It PRP N
is VBZ N
hypothesized VBN N
that IN N
self-injurious JJ N
behavior NN N
( ( N
SIB NNP N
) ) N
and CC N
symptoms NNS N
of IN N
autism NN N
may MD N
be VB N
due JJ N
to TO N
overactivity NN N
in IN N
some DT N
opioid JJ N
systems NNS N
in IN N
the DT N
brain NN N
. . N

We PRP N
examined VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
naltrexone JJ N
hydrochloride NN N
, , N
an DT N
opioid JJ N
antagonist NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
SIB NNP N
and CC N
autism NN N
in IN N
mentally RB N
retarded JJ N
adults NNS N
. . N

METHOD NNP N
Thirty-three NNP N
mentally RB N
retarded VBD N
adults NNS N
with IN N
autism NN N
and/or NN N
SIB NNP N
participated VBD N
in IN N
double-blind NN N
, , N
placebo-controlled JJ N
crossover NN N
studies NNS N
. . N

Active JJ N
treatment NN N
was VBD N
first RB N
a DT N
single JJ N
100-mg JJ N
dose NN N
of IN N
naltrexone JJ N
hydrochloride NN N
. . N

Subsequently NNP N
, , N
19 CD N
subjects NNS N
were VBD N
treated VBN N
with IN N
50 CD N
mg/d NNS N
and CC N
14 CD N
with IN N
150 CD N
mg/d NNS N
of IN N
naltrexone NN N
hydrochloride NN N
for IN N
4 CD N
weeks NNS N
. . N

The DT N
outcome NN N
was VBD N
assessed VBN N
by IN N
means NNS N
of IN N
direct JJ N
observations NNS N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
and CC N
on IN N
the DT N
basis NN N
of IN N
scores NNS N
on IN N
a DT N
list NN N
of IN N
target NN N
behaviors NNS N
, , N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
, , N
and CC N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
Scale NNP N
. . N

RESULTS NNP N
Thirty-two JJ N
subjects NNS N
( ( N
seven CD N
with IN N
autism NN N
, , N
16 CD N
with IN N
autism NN N
and CC N
SIB NNP N
, , N
and CC N
nine CD N
with IN N
SIB NNP N
) ) N
completed VBD N
the DT N
trial NN N
. . N

Naltrexone CD N
treatment NN N
failed VBD N
to TO N
have VB N
therapeutic JJ N
effects NNS N
on IN N
SIB NNP N
and CC N
autism NN N
. . N

On IN N
the DT N
contrary JJ N
, , N
naltrexone RB N
increased VBD N
the DT N
incidence NN N
of IN N
stereotypic JJ N
behavior NN N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
, , N
and CC N
the DT N
care NN N
staff NN N
evaluated VBD N
the DT N
effect NN N
of IN N
the DT N
50-mg/d JJ N
treatment NN N
as IN N
being VBG N
significantly RB N
worse JJR N
than IN N
that DT N
of IN N
the DT N
placebo NN N
treatment NN N
as IN N
measured VBN N
by IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
Scale NNP N
. . N

CONCLUSION NNP N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
naltrexone NN N
has VBZ N
no DT N
clinical JJ N
value NN N
for IN N
a DT N
broad JJ N
group NN N
of IN N
mentally RB N
retarded JJ N
subjects NNS N
with IN N
SIB NNP N
and/or JJ N
autism NN N
. . N

-DOCSTART- -18535816- O O

Effects NNS N
of IN N
20 CD N
mg NNS N
rosuvastatin NN N
on IN N
VLDL1- NNP N
, , N
VLDL2- NNP N
, , N
IDL- NNP N
and CC N
LDL-ApoB NNP N
kinetics NNS N
in IN N
type NN N
2 CD N
diabetes NNS N
. . N

AIMS/HYPOTHESIS NNP N
In IN N
addition NN N
to TO N
its PRP$ N
efficacy NN N
in IN N
reducing VBG N
LDL-cholesterol NNP N
, , N
rosuvastatin NN N
has VBZ N
been VBN N
shown VBN N
to TO N
significantly RB N
decrease VB N
plasma NN N
triacylglycerol NN N
. . N

The DT N
use NN N
of IN N
rosuvastatin NN N
may MD N
be VB N
beneficial JJ N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
, , N
who WP N
usually RB N
have VBP N
increased VBN N
triacylglycerol NN N
levels NNS N
. . N

However RB N
, , N
its PRP$ N
effects NNS N
on IN N
the DT N
metabolism NN N
of IN N
triacylglycerol-rich JJ N
lipoproteins NNS N
in IN N
type NN N
2 CD N
diabetic JJ N
patients NNS N
remains VBZ N
unknown JJ N
. . N

METHODS NNP N
We PRP N
performed VBD N
a DT N
randomised JJ N
double-blind NN N
crossover NN N
trial NN N
of IN N
6-week JJ N
treatment NN N
with IN N
placebo NN N
or CC N
rosuvastatin VB N
20 CD N
mg NN N
in IN N
eight CD N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
who WP N
were VBD N
being VBG N
treated VBN N
with IN N
oral JJ N
glucose-lowering JJ N
agents NNS N
. . N

In IN N
each DT N
patient NN N
, , N
an DT N
in IN N
vivo NN N
kinetic JJ N
study NN N
of IN N
apolipoprotein NN N
B NNP N
( ( N
ApoB NNP N
) ) N
-containing VBG N
lipoproteins NNS N
with IN N
[ JJ N
13C CD N
] JJ N
leucine NN N
was VBD N
performed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
treatment NN N
period NN N
. . N

A DT N
central JJ N
randomisation NN N
centre NN N
used VBN N
computer-generated JJ N
tables NNS N
to TO N
allocate VB N
treatments NNS N
. . N

Participants NNS N
, , N
caregivers NNS N
and CC N
those DT N
assessing VBG N
the DT N
outcomes NNS N
were VBD N
blinded VBN N
to TO N
group NN N
assignment NN N
. . N

RESULTS NNP N
Rosuvastatin NNP N
20 CD N
mg NN N
significantly RB N
reduced VBN N
plasma JJ N
LDL-cholesterol NNP N
, , N
triacylglycerol NN N
and CC N
total JJ N
ApoB NNP N
. . N

It PRP N
also RB N
significantly RB N
reduced VBN N
ApoB NNP N
pool NN N
sizes NNS N
of IN N
larger JJR N
triacylglycerol-rich JJ N
VLDL NNP N
particles NNS N
( ( N
VLDL1 NNP N
; : N
p VBZ N
= $ N
0.011 CD N
) ) N
, , N
smaller JJR N
VLDL NNP N
particles NNS N
( ( N
VLDL2 NNP N
; : N
p VBZ N
= $ N
0.011 CD N
) ) N
, , N
intermediate JJ N
density NN N
lipoprotein NN N
( ( N
IDL NNP N
; : N
p VBZ N
= $ N
0.011 CD N
) ) N
and CC N
LDL NNP N
( ( N
p JJ N
= NNP N
0.011 CD N
) ) N
. . N

This DT N
reduction NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
total JJ N
fractional JJ N
catabolic NN N
rate NN N
of IN N
VLDL1-ApoB NNP N
( ( N
6.70 CD N
+/- JJ N
3.24 CD N
vs JJ N
4.52 CD N
+/- JJ N
2.34 CD N
pool/day NN N
, , N
p NN N
= NNP N
0.049 CD N
) ) N
, , N
VLDL2-ApoB NNP N
( ( N
8.72 CD N
+/- JJ N
3.37 CD N
vs JJ N
5.36 CD N
+/- JJ N
2.64 CD N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
, , N
IDL-ApoB NNP N
( ( N
7.06 CD N
+/- JJ N
1.68 CD N
vs JJ N
4.21 CD N
+/- JJ N
1.51 CD N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
and CC N
LDL-ApoB NNP N
( ( N
1.02 CD N
+/- JJ N
0.27 CD N
vs JJ N
0.59 CD N
+/- JJ N
0.13 CD N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
. . N

Rosuvastatin NNPS N
did VBD N
not RB N
change VB N
the DT N
production NN N
rates NNS N
of IN N
VLDL2- NNP N
, , N
IDL- NNP N
or CC N
LDL- NNP N
, , N
but CC N
did VBD N
reduce VB N
VLDL1-ApoB NNP N
production NN N
rate NN N
( ( N
12.4 CD N
+/- JJ N
4.5 CD N
vs JJ N
19.5 CD N
+/- JJ N
8.4 CD N
mg NN N
kg NN N
( ( N
-1 JJ N
) ) N
day NN N
( ( N
-1 NNP N
) ) N
, , N
p JJ N
= NNP N
0.035 CD N
) ) N
. . N

No DT N
side NN N
effects NNS N
of IN N
rosuvastatin NN N
were VBD N
observed VBN N
during IN N
the DT N
study NN N
. . N

CONCLUSIONS/INTERPRETATION NNP N
In IN N
type NN N
2 CD N
diabetic JJ N
patients NNS N
rosuvastatin VBP N
20 CD N
mg NN N
not RB N
only RB N
induces VBZ N
a DT N
significant JJ N
increase NN N
of IN N
LDL-ApoB JJ N
catabolism NN N
( ( N
73 CD N
% NN N
) ) N
, , N
but CC N
also RB N
has VBZ N
favourable JJ N
effects NNS N
on IN N
the DT N
catabolism NN N
of IN N
triacylglycerol-rich JJ N
lipoproteins NNS N
, , N
e.g NN N
. . N

a DT N
significant JJ N
increase NN N
in IN N
the DT N
catabolism NN N
of IN N
VLDL1-ApoB NNP N
( ( N
48 CD N
% NN N
) ) N
, , N
VLDL2-ApoB NNP N
( ( N
63 CD N
% NN N
) ) N
and CC N
IDL-ApoB NNP N
( ( N
68 CD N
% NN N
) ) N
, , N
and CC N
a DT N
reduction NN N
in IN N
the DT N
production NN N
rate NN N
of IN N
VLDL1-ApoB NNP N
( ( N
-36 CD N
% NN N
) ) N
. . N

The DT N
effects NNS N
of IN N
rosuvastatin NN N
on IN N
the DT N
metabolism NN N
of IN N
triacylglycerol-rich JJ N
lipoproteins NNS N
may MD N
be VB N
beneficial JJ N
for IN N
prevention NN N
of IN N
atherosclerosis NN N
in IN N
type NN N
2 CD N
diabetic JJ N
patients NNS N
. . N

-DOCSTART- -9609624- O O

Long-term JJ N
evaluation NN N
of IN N
tamsulosin NN N
in IN N
benign JJ N
prostatic JJ N
hyperplasia NN N
: : N
placebo-controlled JJ N
, , N
double-blind JJ N
extension NN N
of IN N
phase NN N
III NNP N
trial NN N
. . N

Tamsulosin NNP N
Investigator NNP N
Group NNP N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
long-term JJ N
efficacy NN N
and CC N
safety NN N
of IN N
once-daily JJ N
tamsulosin NN N
( ( N
0.4 CD N
and CC N
0.8 CD N
mg NN N
) ) N
, , N
a DT N
unique JJ N
selective JJ N
alpha1A-adrenoceptor NN N
antagonist NN N
in IN N
patients NNS N
with IN N
benign JJ N
prostatic JJ N
hyperplasia NN N
( ( N
BPH NNP N
) ) N
. . N

METHODS NNP N
This DT N
trial NN N
extended VBD N
a DT N
13-week JJ N
, , N
Phase NNP N
III NNP N
multicenter NN N
placebo-controlled JJ N
, , N
double-blind JJ N
outpatient JJ N
trial NN N
for IN N
an DT N
additional JJ N
40 CD N
weeks NNS N
. . N

Of IN N
618 CD N
patients NNS N
, , N
418 CD N
( ( N
68 CD N
% NN N
) ) N
continued VBD N
into IN N
the DT N
extension NN N
phase NN N
on IN N
the DT N
same JJ N
double-blind JJ N
medication NN N
and CC N
dose NN N
. . N

The DT N
primary JJ N
efficacy NN N
parameters NNS N
were VBD N
total JJ N
American NNP N
Urological NNP N
Association NNP N
( ( N
AUA NNP N
) ) N
symptom NN N
score NN N
and CC N
maximum JJ N
urinary JJ N
flow NN N
( ( N
Qmax NNP N
) ) N
. . N

RESULTS VB N
The DT N
mean JJ N
changes NNS N
in IN N
AUA NNP N
symptom NN N
score NN N
from IN N
baseline NN N
to TO N
end VB N
point NN N
were VBD N
statistically RB N
significant JJ N
in IN N
all DT N
groups NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
Qmax NNP N
for IN N
both DT N
tamsulosin JJ N
groups NNS N
but CC N
not RB N
for IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
statistically RB N
significant JJ N
improvements NNS N
from IN N
baseline NN N
in IN N
efficacy NN N
parameters NNS N
observed VBD N
for IN N
each DT N
tamsulosin NN N
group NN N
at IN N
the DT N
end NN N
of IN N
the DT N
13-week JJ N
Phase NNP N
III NNP N
trial NN N
were VBD N
maintained VBN N
during IN N
the DT N
long-term JJ N
extension NN N
phase NN N
. . N

Tamsulosin NN N
at IN N
both DT N
dosages NNS N
was VBD N
well RB N
tolerated VBN N
as IN N
maintenance NN N
therapy NN N
. . N

Clinically NNP N
significant JJ N
orthostatic JJ N
hypotension NN N
was VBD N
not RB N
observed VBN N
. . N

Vital JJ N
sign NN N
changes NNS N
in IN N
either DT N
hypertensive JJ N
or CC N
normotensive JJ N
patients NNS N
were VBD N
not RB N
clinically RB N
significantly RB N
different JJ N
across IN N
the DT N
three CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Tamsulosin NNP N
once-daily RB N
at IN N
0.4 CD N
or CC N
0.8 CD N
mg NN N
was VBD N
shown VBN N
to TO N
be VB N
effective JJ N
, , N
safe JJ N
, , N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
target NN N
BPH NNP N
population NN N
during IN N
long-term JJ N
use NN N
. . N

-DOCSTART- -10148879- O O

Comparison NNP N
of IN N
patient-controlled JJ N
and CC N
nurse-administered JJ N
analgesia NN N
using VBG N
intravenous JJ N
fentanyl NN N
during IN N
labor NN N
. . N

Preliminary JJ N
observations NNS N
have VBP N
shown VBN N
that IN N
fentanyl NN N
citrate NN N
, , N
a DT N
potent JJ N
narcotic JJ N
, , N
is VBZ N
helpful JJ N
during IN N
labor NN N
without IN N
undue JJ N
side NN N
effects NNS N
. . N

This DT N
randomized JJ N
prospective JJ N
investigation NN N
compared VBN N
the DT N
patient-controlled JJ N
administration NN N
of IN N
fentanyl NN N
with IN N
that DT N
of IN N
administration NN N
by IN N
nurses NNS N
on IN N
request NN N
. . N

Eighty NNP N
healthy JJ N
women NNS N
beginning VBG N
active JJ N
labor NN N
( ( N
cervical JJ N
dilation NN N
4 CD N
cm NN N
) ) N
at IN N
term NN N
were VBD N
assigned VBN N
to TO N
receive VB N
fentanyl NN N
intravenously RB N
by IN N
either CC N
patient-controlled JJ N
administration NN N
( ( N
n=37 JJ N
) ) N
or CC N
nurse JJ N
administration NN N
on IN N
demand NN N
( ( N
n=43 JJ N
) ) N
. . N

Pain NNP N
intensity NN N
measurements NNS N
during IN N
early JJ N
and CC N
late JJ N
labor NN N
revealed VBD N
the DT N
degree NN N
of IN N
analgesia NN N
to TO N
be VB N
the DT N
same JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
delay NN N
in IN N
setting VBG N
up RP N
the DT N
infusion NN N
system NN N
and CC N
the DT N
short JJ N
time NN N
between IN N
requesting VBG N
analgesia NN N
and CC N
vaginal JJ N
delivery NN N
were VBD N
limitations NNS N
with IN N
self-administration NN N
. . N

Maternal JJ N
oversedation NN N
and CC N
vomiting VBG N
did VBD N
not RB N
occur VB N
. . N

Neonatal NNP N
naloxone NN N
therapy NN N
was VBD N
used VBN N
infrequently RB N
, , N
umbilical JJ N
serum NN N
levels NNS N
of IN N
fentanyl NN N
were VBD N
the DT N
same JJ N
in IN N
both DT N
groups NNS N
, , N
and CC N
postnatal JJ N
neuroadaptive JJ N
testing NN N
revealed VBD N
comparable JJ N
results NNS N
in IN N
both DT N
groups NNS N
. . N

Despite IN N
the DT N
usefulness NN N
of IN N
fentanyl NN N
during IN N
labor NN N
, , N
administration NN N
by IN N
the DT N
patient NN N
had VBD N
no DT N
advantages NNS N
over IN N
administration NN N
by IN N
the DT N
nurses NNS N
in IN N
significantly RB N
reducing VBG N
drug NN N
use NN N
, , N
improving VBG N
pain NN N
relief NN N
, , N
or CC N
avoiding VBG N
drowsiness NN N
. . N

-DOCSTART- -11045790- O O

Randomized VBN N
trial NN N
of IN N
fenretinide NN N
in IN N
superficial JJ N
bladder NN N
cancer NN N
using VBG N
DNA NNP N
flow JJ N
cytometry NN N
as IN N
an DT N
intermediate JJ N
end NN N
point NN N
. . N

Retinoids NNS N
have VBP N
shown VBN N
a DT N
potential JJ N
activity NN N
in IN N
preventing VBG N
tumor NN N
recurrence NN N
in IN N
superficial JJ N
bladder NN N
cancer NN N
. . N

We PRP N
assessed VBD N
the DT N
activity NN N
of IN N
the DT N
synthetic JJ N
retinoid NN N
fenretinide NN N
in IN N
superficial JJ N
bladder NN N
cancer NN N
using VBG N
DNA NNP N
flow JJ N
cytometry NN N
and CC N
conventional JJ N
cytology NN N
as IN N
surrogate JJ N
biomarkers NNS N
. . N

A DT N
total NN N
of IN N
99 CD N
subjects NNS N
with IN N
resected JJ N
superficial JJ N
bladder NN N
cancer NN N
( ( N
pTa NN N
, , N
pT1 NN N
) ) N
were VBD N
randomized VBN N
to TO N
either DT N
fenretinide NN N
( ( N
200 CD N
mg NNS N
day NN N
p.o NN N
. . N

for IN N
24 CD N
months NNS N
) ) N
or CC N
no DT N
intervention NN N
. . N

Cystoscopy NNP N
and CC N
bladder NN N
washing NN N
for IN N
DNA NNP N
flow NN N
cytometry NN N
end NN N
points NNS N
( ( N
proportion NN N
of IN N
DNA NNP N
aneuploid JJ N
histograms NN N
, , N
hyperdiploid JJ N
fraction NN N
, , N
and CC N
percentage NN N
of IN N
apoptotic JJ N
cells NNS N
) ) N
and CC N
proportion NN N
of IN N
abnormal JJ N
cytological JJ N
examinations NNS N
were VBD N
repeated VBN N
every DT N
4 CD N
months NNS N
for IN N
up IN N
to TO N
36 CD N
months NNS N
. . N

The DT N
primary JJ N
study NN N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
DNA NNP N
aneuploid JJ N
histograms NNS N
after IN N
12 CD N
months NNS N
. . N

This DT N
figure NN N
was VBD N
48.9 CD N
% NN N
in IN N
the DT N
fenretinide JJ N
arm NN N
and CC N
41.9 CD N
% NN N
in IN N
the DT N
control NN N
arm NN N
( ( N
odds NNS N
ratio NN N
, , N
1.16 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.44-3.07 JJ N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
any DT N
other JJ N
response NN N
biomarker NN N
between IN N
the DT N
two CD N
groups NNS N
up RB N
to TO N
36 CD N
months NNS N
, , N
nor CC N
was VBD N
any DT N
biomarker NN N
able JJ N
to TO N
predict VB N
recurrence NN N
risk NN N
. . N

Recurrence-free JJ N
survival NN N
was VBD N
comparable JJ N
between IN N
the DT N
arms NNS N
( ( N
27 CD N
events NNS N
in IN N
the DT N
fenretinide JJ N
arm NN N
versus NN N
21 CD N
in IN N
the DT N
control NN N
arm NN N
; : N
P NNP N
= NNP N
0.36 CD N
) ) N
. . N

Twelve NNP N
subjects VBZ N
in IN N
the DT N
fenretinide JJ N
arm NN N
complained VBD N
of IN N
diminished JJ N
dark NN N
adaptability NN N
, , N
and CC N
nine CD N
subjects NNS N
in IN N
the DT N
fenretinide JJ N
arm NN N
versus IN N
one CD N
control NN N
subject NN N
had VBD N
mild JJ N
dermatological JJ N
alterations NNS N
. . N

We PRP N
conclude VBP N
that DT N
fenretinide NN N
showed VBD N
a DT N
lack NN N
of IN N
effect NN N
on IN N
the DT N
DNA NNP N
content NN N
distribution NN N
and CC N
the DT N
morphology NN N
of IN N
urothelial JJ N
cells NNS N
obtained VBN N
in IN N
serial JJ N
bladder NN N
washings NNS N
. . N

Recurrence-free JJ N
survival NN N
was VBD N
comparable JJ N
between IN N
groups NNS N
. . N

Because IN N
our PRP$ N
data NNS N
are VBP N
hampered VBN N
by IN N
the DT N
lack NN N
of IN N
predictivity NN N
of IN N
the DT N
selected VBN N
biomarkers NNS N
, , N
additional JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
assess VB N
the DT N
activity NN N
of IN N
fenretinide NN N
in IN N
preventing VBG N
bladder NN N
cancer NN N
. . N

